<!DOCTYPE html>
<html xmlns="http://www.w3.org/1999/xhtml" lang="" xml:lang="">
<head>
<title>guidelines-adult-adolescent-oi_sample</title>
<meta http-equiv="Content-Type" content="text/html; charset=UTF-8"/>
<meta name="generator" content="pdftohtml 0.36"/>
<meta name="date" content="2025-07-24T22:56:21+00:00"/>
<style type="text/css">
<!--
.xflip {
    -moz-transform: scaleX(-1);
    -webkit-transform: scaleX(-1);
    -o-transform: scaleX(-1);
    transform: scaleX(-1);
    filter: fliph;
}
.yflip {
    -moz-transform: scaleY(-1);
    -webkit-transform: scaleY(-1);
    -o-transform: scaleY(-1);
    transform: scaleY(-1);
    filter: flipv;
}
.xyflip {
    -moz-transform: scaleX(-1) scaleY(-1);
    -webkit-transform: scaleX(-1) scaleY(-1);
    -o-transform: scaleX(-1) scaleY(-1);
    transform: scaleX(-1) scaleY(-1);
    filter: fliph + flipv;
}
-->
</style>
</head>
<body bgcolor="#A0A0A0" vlink="blue" link="blue">
<!-- Page 1 -->
<a name="1"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}	.ft00{font-size:30px;font-family:AWWRYA+Arimo;color:#2e5395;}
	.ft01{font-size:30px;font-family:MLWKWG+Arial,Bold;color:#2e5395;}
	.ft02{font-size:17px;font-family:BGKYCV+LiberationSansNarrow;color:#000000;}
	.ft03{font-size:17px;font-family:RAJFOH+LiberationSansNarrow;color:#000000;}
	.ft04{font-size:17px;font-family:WOSUCG+ArialNarrow;color:#000000;}
	.ft05{font-size:17px;font-family:RAJFOH+LiberationSansNarrow;color:#005299;}
	.ft06{font-size:16px;font-family:RAJFOH+LiberationSansNarrow;color:#000000;}
	.ft07{font-size:16px;font-family:WOSUCG+ArialNarrow;color:#000000;}
	.ft08{font-size:17px;line-height:19px;font-family:RAJFOH+LiberationSansNarrow;color:#000000;}
-->
</style>
<div id="page1-div" style="position:relative;width:917px;height:1187px;">
<p style="position:absolute;top:313px;left:124px;white-space:nowrap" class="ft00"><b>Guidelines for&#160;the Prevention and&#160;Treatment of&#160;</b></p>
<p style="position:absolute;top:348px;left:268px;white-space:nowrap" class="ft00"><b>Opportunistic Infections&#160;in &#160;</b></p>
<p style="position:absolute;top:382px;left:222px;white-space:nowrap" class="ft00"><b>Adults and&#160;Adolescents&#160;</b></p>
<p style="position:absolute;top:382px;left:572px;white-space:nowrap" class="ft01"><b>W</b></p>
<p style="position:absolute;top:382px;left:600px;white-space:nowrap" class="ft00"><b>ith HIV&#160;</b></p>
<p style="position:absolute;top:880px;left:108px;white-space:nowrap" class="ft02"><b>How to Cite&#160;the&#160;Adult and&#160;Adolescent Opportunistic&#160;Infection Guidelines:&#160;</b></p>
<p style="position:absolute;top:917px;left:108px;white-space:nowrap" class="ft03">Panel&#160;on&#160;Guidelines&#160;for the&#160;Prevention&#160;and&#160;Treatment&#160;of&#160;Opportunistic&#160;Infections&#160;in&#160;Adults&#160;and&#160;Adolescents&#160;</p>
<p style="position:absolute;top:937px;left:108px;white-space:nowrap" class="ft04">W</p>
<p style="position:absolute;top:937px;left:121px;white-space:nowrap" class="ft03">ith&#160;HIV.&#160;</p>
<p style="position:absolute;top:937px;left:172px;white-space:nowrap" class="ft04">Guidelines&#160;for&#160;the&#160;Prevention&#160;and&#160;Treatment&#160;of&#160;Opportunistic&#160;Infections&#160;in&#160;Adults&#160;and&#160;Adolescents&#160;</p>
<p style="position:absolute;top:956px;left:108px;white-space:nowrap" class="ft04">With&#160;HIV.&#160;National&#160;Institutes&#160;of&#160;Health,&#160;HIV&#160;Medicine Association, and&#160;Infectious&#160;Diseases&#160;Society&#160;of&#160;</p>
<p style="position:absolute;top:976px;left:108px;white-space:nowrap" class="ft04">America.&#160;</p>
<p style="position:absolute;top:976px;left:168px;white-space:nowrap" class="ft03">Available&#160;at&#160;</p>
<p style="position:absolute;top:976px;left:245px;white-space:nowrap" class="ft05">https://clinicalinfo.hiv.gov/en/guidelines/adult-and-adolescent-opportunistic-infection</p>
<p style="position:absolute;top:976px;left:770px;white-space:nowrap" class="ft03">.&#160;</p>
<p style="position:absolute;top:996px;left:108px;white-space:nowrap" class="ft03">Accessed&#160;(insert&#160;date) [include&#160;page&#160;numbers, table&#160;number, etc.,&#160;if&#160;applicable].&#160;</p>
<p style="position:absolute;top:1033px;left:108px;white-space:nowrap" class="ft08">It&#160;is&#160;emphasized&#160;that concepts relevant&#160;to&#160;HIV&#160;management&#160;evolve&#160;rapidly.&#160;The&#160;Panels&#160;have&#160;a&#160;mechanism&#160;<br/>to&#160;update&#160;recommendations&#160;on&#160;a&#160;regular basis,&#160;and&#160;the&#160;most&#160;recent&#160;information&#160;is&#160;available&#160;on&#160;the&#160;<br/>Clinicalinfo&#160;website&#160;(</p>
<p style="position:absolute;top:1072px;left:236px;white-space:nowrap" class="ft05">https://clinicalinfo.hiv.gov/</p>
<p style="position:absolute;top:1072px;left:398px;white-space:nowrap" class="ft03">).&#160;</p>
<p style="position:absolute;top:463px;left:323px;white-space:nowrap" class="ft06">Developed&#160;by&#160;the&#160;National&#160;Institutes&#160;of Health, the&#160;HIV&#160;Medicine Association</p>
<p style="position:absolute;top:463px;left:782px;white-space:nowrap" class="ft07">,&#160;</p>
<p style="position:absolute;top:482px;left:328px;white-space:nowrap" class="ft07">and</p>
<p style="position:absolute;top:482px;left:351px;white-space:nowrap" class="ft06">&#160;the Infectious&#160;Diseases&#160;Society&#160;of America Panel&#160;on&#160;Guidelines&#160;for the&#160;</p>
<p style="position:absolute;top:501px;left:354px;white-space:nowrap" class="ft06">Prevention&#160;and&#160;Treatment&#160;of Opportunistic&#160;Infections&#160;in&#160;Adults&#160;and&#160;</p>
<p style="position:absolute;top:520px;left:321px;white-space:nowrap" class="ft06">Adolescents&#160;</p>
<p style="position:absolute;top:520px;left:400px;white-space:nowrap" class="ft07">W</p>
<p style="position:absolute;top:520px;left:413px;white-space:nowrap" class="ft06">ith&#160;HIV—A Working&#160;Group&#160;of&#160;the NIH&#160;Office of&#160;AIDS&#160;Research&#160;</p>
<p style="position:absolute;top:539px;left:473px;white-space:nowrap" class="ft06">Advisory&#160;Council&#160;(OARAC)&#160;</p>
</div>
<!-- Page 2 -->
<a name="2"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}	.ft09{font-size:13px;font-family:QZSKMX+LiberationSansNarrow;color:#000000;}
	.ft010{font-size:13px;font-family:WOSUCG+ArialNarrow;color:#000000;}
	.ft011{font-size:23px;font-family:LKZECW+DejaVuSans;color:#234a91;}
	.ft012{font-size:17px;font-family:BTLIFY+Tinos;color:#000000;}
	.ft013{font-size:17px;font-family:TURBHP+Tinos;color:#000000;}
	.ft014{font-size:17px;font-family:MQTIBR+TimesNewRomanPS;color:#000000;}
	.ft015{font-size:17px;font-family:UXKBCS+TimesNewRoman,Bold;color:#000000;}
	.ft016{font-size:17px;font-family:PKKETS+TimesNewRomanPSMT;color:#000000;}
	.ft017{font-size:17px;font-family:QZPFRO+Tinos;color:#000000;}
-->
</style>
<div id="page2-div" style="position:relative;width:917px;height:1187px;">
<p style="position:absolute;top:1118px;left:54px;white-space:nowrap" class="ft09"><i>Guidelines&#160;for&#160;the&#160;Prevention&#160;and&#160;Treatment&#160;of&#160;Opportunistic&#160;Infections&#160;in&#160;Adults&#160;and&#160;Adolescents&#160;</i></p>
<p style="position:absolute;top:1118px;left:534px;white-space:nowrap" class="ft010">W</p>
<p style="position:absolute;top:1118px;left:544px;white-space:nowrap" class="ft09"><i>ith&#160;HIV&#160;</i></p>
<p style="position:absolute;top:1118px;left:861px;white-space:nowrap" class="ft09"><i>i</i></p>
<p style="position:absolute;top:58px;left:54px;white-space:nowrap" class="ft011"><b>Table&#160;of&#160;Contents&#160;</b></p>
<p style="position:absolute;top:106px;left:54px;white-space:nowrap" class="ft012"><b>What’s&#160;New&#160;in&#160;the&#160;Guidelines</b></p>
<p style="position:absolute;top:106px;left:273px;white-space:nowrap" class="ft013">&#160;....................................................................................................................................&#160;iii</p>
<p style="position:absolute;top:143px;left:54px;white-space:nowrap" class="ft012"><b>Introduction</b></p>
<p style="position:absolute;top:143px;left:148px;white-space:nowrap" class="ft013">&#160;&#160;.............................................................................................................................................................&#160;A-1&#160;</p>
<p style="position:absolute;top:180px;left:54px;white-space:nowrap" class="ft012"><b>Bacterial</b></p>
<p style="position:absolute;top:180px;left:121px;white-space:nowrap" class="ft014"><b>&#160;Enteric</b></p>
<p style="position:absolute;top:180px;left:180px;white-space:nowrap" class="ft013">&#160;</p>
<p style="position:absolute;top:180px;left:184px;white-space:nowrap" class="ft012"><b>Infections</b></p>
<p style="position:absolute;top:180px;left:257px;white-space:nowrap" class="ft013">&#160;.......................................................................................................................................B-1&#160;</p>
<p style="position:absolute;top:217px;left:54px;white-space:nowrap" class="ft012"><b>Bartonellosis</b></p>
<p style="position:absolute;top:217px;left:150px;white-space:nowrap" class="ft013">&#160;...............................................................................................................................................................C-1&#160;</p>
<p style="position:absolute;top:254px;left:54px;white-space:nowrap" class="ft012"><b>Candidiasis&#160;(Mucocutaneous)</b></p>
<p style="position:absolute;top:254px;left:272px;white-space:nowrap" class="ft013">..................................................................................................................................&#160;D-1&#160;</p>
<p style="position:absolute;top:291px;left:54px;white-space:nowrap" class="ft012"><b>Chagas</b></p>
<p style="position:absolute;top:291px;left:109px;white-space:nowrap" class="ft013">&#160;</p>
<p style="position:absolute;top:291px;left:113px;white-space:nowrap" class="ft012"><b>Disease</b></p>
<p style="position:absolute;top:291px;left:168px;white-space:nowrap" class="ft013">&#160;...........................................................................................................................................................&#160;E-1&#160;</p>
<p style="position:absolute;top:328px;left:54px;white-space:nowrap" class="ft012"><b>Coccidiodomycosis</b></p>
<p style="position:absolute;top:328px;left:194px;white-space:nowrap" class="ft013">&#160;.....................................................................................................................................................&#160;F-1&#160;</p>
<p style="position:absolute;top:365px;left:54px;white-space:nowrap" class="ft012"><b>Community-Acquired&#160;Pneumonia</b></p>
<p style="position:absolute;top:365px;left:305px;white-space:nowrap" class="ft013">&#160;..........................................................................................................................&#160;G-1&#160;</p>
<p style="position:absolute;top:402px;left:54px;white-space:nowrap" class="ft012"><b>Cryptococcosis</b></p>
<p style="position:absolute;top:402px;left:165px;white-space:nowrap" class="ft013">&#160;..........................................................................................................................................................&#160;H-1&#160;</p>
<p style="position:absolute;top:439px;left:54px;white-space:nowrap" class="ft012"><b>Cryptosporidiosis</b></p>
<p style="position:absolute;top:439px;left:185px;white-space:nowrap" class="ft013">&#160;........................................................................................................................................................&#160;I-1&#160;</p>
<p style="position:absolute;top:477px;left:54px;white-space:nowrap" class="ft012"><b>Cystoisosporiasis</b></p>
<p style="position:absolute;top:477px;left:180px;white-space:nowrap" class="ft013">&#160;.........................................................................................................................................................&#160;J-1&#160;</p>
<p style="position:absolute;top:514px;left:54px;white-space:nowrap" class="ft012"><b>Cytomegalovirus</b></p>
<p style="position:absolute;top:514px;left:180px;white-space:nowrap" class="ft013">&#160;</p>
<p style="position:absolute;top:514px;left:184px;white-space:nowrap" class="ft012"><b>Disease</b></p>
<p style="position:absolute;top:514px;left:242px;white-space:nowrap" class="ft013">.........................................................................................................................................&#160;K-1&#160;</p>
<p style="position:absolute;top:551px;left:54px;white-space:nowrap" class="ft012"><b>Hepatitis&#160;B Virus&#160;Infection</b></p>
<p style="position:absolute;top:551px;left:253px;white-space:nowrap" class="ft013">&#160;.......................................................................................................................................&#160;L-1&#160;</p>
<p style="position:absolute;top:588px;left:54px;white-space:nowrap" class="ft012"><b>Hepatitis&#160;C&#160;Virus Infection</b></p>
<p style="position:absolute;top:588px;left:254px;white-space:nowrap" class="ft013">&#160;......................................................................................................................................&#160;M-1&#160;</p>
<p style="position:absolute;top:625px;left:54px;white-space:nowrap" class="ft012"><b>Herpes&#160;Simplex Virus&#160;Disease</b></p>
<p style="position:absolute;top:625px;left:275px;white-space:nowrap" class="ft013">&#160;.................................................................................................................................&#160;N-1&#160;</p>
<p style="position:absolute;top:662px;left:54px;white-space:nowrap" class="ft012"><b>Histoplasmosis</b></p>
<p style="position:absolute;top:662px;left:164px;white-space:nowrap" class="ft013">...........................................................................................................................................................&#160;O-1&#160;</p>
<p style="position:absolute;top:699px;left:54px;white-space:nowrap" class="ft012"><b>Human&#160;Herpesvirus&#160;8</b></p>
<p style="position:absolute;top:699px;left:217px;white-space:nowrap" class="ft013">&#160;</p>
<p style="position:absolute;top:699px;left:221px;white-space:nowrap" class="ft012"><b>Disease</b></p>
<p style="position:absolute;top:699px;left:276px;white-space:nowrap" class="ft013">&#160;..................................................................................................................................&#160;P-1&#160;</p>
<p style="position:absolute;top:736px;left:54px;white-space:nowrap" class="ft012"><b>Human&#160;Papillomavirus&#160;Disease</b></p>
<p style="position:absolute;top:736px;left:285px;white-space:nowrap" class="ft013">&#160;...............................................................................................................................&#160;Q-1&#160;</p>
<p style="position:absolute;top:773px;left:54px;white-space:nowrap" class="ft012"><b>Immunizations&#160;for&#160;Preventable&#160;Diseases&#160;in&#160;Adults&#160;and&#160;Adolescents</b></p>
<p style="position:absolute;top:773px;left:542px;white-space:nowrap" class="ft015"><b>&#160;W</b></p>
<p style="position:absolute;top:773px;left:564px;white-space:nowrap" class="ft012"><b>ith&#160;HIV</b></p>
<p style="position:absolute;top:773px;left:620px;white-space:nowrap" class="ft013">&#160;.......................................</p>
<p style="position:absolute;top:773px;left:792px;white-space:nowrap" class="ft016">............</p>
<p style="position:absolute;top:773px;left:844px;white-space:nowrap" class="ft013">R-1&#160;</p>
<p style="position:absolute;top:810px;left:54px;white-space:nowrap" class="ft012"><b>Leishmaniasis</b></p>
<p style="position:absolute;top:810px;left:158px;white-space:nowrap" class="ft013">&#160;.............................................................................................................................................................&#160;S-1&#160;</p>
<p style="position:absolute;top:848px;left:54px;white-space:nowrap" class="ft012"><b>Malaria</b></p>
<p style="position:absolute;top:848px;left:113px;white-space:nowrap" class="ft013">&#160;.......................................................................................................................................................................&#160;T-1&#160;</p>
<p style="position:absolute;top:885px;left:54px;white-space:nowrap" class="ft012"><b>Microsporidiosis</b></p>
<p style="position:absolute;top:885px;left:178px;white-space:nowrap" class="ft013">&#160;.......................................................................................................................................................&#160;U-1&#160;</p>
<p style="position:absolute;top:922px;left:54px;white-space:nowrap" class="ft012"><b>Mpox</b></p>
<p style="position:absolute;top:922px;left:97px;white-space:nowrap" class="ft013">&#160;..........................................................................................................................................................................&#160;V-1&#160;</p>
<p style="position:absolute;top:959px;left:54px;white-space:nowrap" class="ft017"><i><b>Mycobacterium&#160;avium</b></i></p>
<p style="position:absolute;top:959px;left:214px;white-space:nowrap" class="ft012"><b>&#160;Complex Disease</b></p>
<p style="position:absolute;top:959px;left:343px;white-space:nowrap" class="ft013">&#160;................................................................................................................&#160;W-1&#160;</p>
<p style="position:absolute;top:996px;left:54px;white-space:nowrap" class="ft017"><i><b>Mycobacterium&#160;tuberculosis</b></i></p>
<p style="position:absolute;top:996px;left:256px;white-space:nowrap" class="ft012"><b>&#160;Infection&#160;and&#160;Disease</b></p>
<p style="position:absolute;top:996px;left:417px;white-space:nowrap" class="ft013">&#160;................................................................................................&#160;X-1&#160;</p>
<p style="position:absolute;top:1033px;left:54px;white-space:nowrap" class="ft017"><i><b>Pneumocystis</b></i></p>
<p style="position:absolute;top:1033px;left:152px;white-space:nowrap" class="ft013">&#160;</p>
<p style="position:absolute;top:1033px;left:156px;white-space:nowrap" class="ft012"><b>Pneumonia</b></p>
<p style="position:absolute;top:1033px;left:239px;white-space:nowrap" class="ft013">&#160;.........................................................................................................................................&#160;Y-1&#160;</p>
<p style="position:absolute;top:1070px;left:54px;white-space:nowrap" class="ft012"><b>Progressive&#160;Multifocal&#160;Leukoencephalopathy/JC&#160;Virus&#160;Infection</b></p>
<p style="position:absolute;top:1070px;left:529px;white-space:nowrap" class="ft013">&#160;.......................................................................&#160;Z-1&#160;</p>
</div>
<!-- Page 3 -->
<a name="3"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}	.ft018{font-size:17px;font-family:AWFWWM+TimesNewRomanPSMT;color:#000000;}
	.ft019{font-size:17px;font-family:KPYRPS+Tinos;color:#000000;}
	.ft020{font-size:17px;font-family:AHWKTD+TimesNewRoman,Italic;color:#000000;}
	.ft021{font-size:17px;font-family:RPCIIG+TimesNewRomanPS;color:#000000;}
	.ft022{font-size:17px;font-family:YOUJEO+TimesNewRoman;color:#000000;}
	.ft023{font-size:17px;line-height:19px;font-family:KPYRPS+Tinos;color:#000000;}
-->
</style>
<div id="page3-div" style="position:relative;width:917px;height:1187px;">
<p style="position:absolute;top:1118px;left:54px;white-space:nowrap" class="ft09"><i>Guidelines&#160;for&#160;the&#160;Prevention&#160;and&#160;Treatment&#160;of&#160;Opportunistic&#160;Infections&#160;in&#160;Adults&#160;and&#160;Adolescents&#160;</i></p>
<p style="position:absolute;top:1118px;left:534px;white-space:nowrap" class="ft010">W</p>
<p style="position:absolute;top:1118px;left:544px;white-space:nowrap" class="ft09"><i>ith&#160;HIV&#160;</i></p>
<p style="position:absolute;top:1118px;left:859px;white-space:nowrap" class="ft09"><i>ii</i></p>
<p style="position:absolute;top:55px;left:54px;white-space:nowrap" class="ft012"><b>Syphilis</b></p>
<p style="position:absolute;top:55px;left:112px;white-space:nowrap" class="ft013">&#160;...................................................................................................................................................................&#160;AA-1&#160;</p>
<p style="position:absolute;top:92px;left:54px;white-space:nowrap" class="ft012"><b>Talaromycosis&#160;(Penicilliosis)</b></p>
<p style="position:absolute;top:92px;left:263px;white-space:nowrap" class="ft013">&#160;..................................................................................................................................&#160;BB-1&#160;</p>
<p style="position:absolute;top:129px;left:54px;white-space:nowrap" class="ft014"><b>Toxoplasmosis</b></p>
<p style="position:absolute;top:129px;left:162px;white-space:nowrap" class="ft013">&#160;.</p>
<p style="position:absolute;top:129px;left:169px;white-space:nowrap" class="ft018">.............................</p>
<p style="position:absolute;top:129px;left:295px;white-space:nowrap" class="ft013">...........................................................................................................................&#160;CC-1&#160;</p>
<p style="position:absolute;top:166px;left:54px;white-space:nowrap" class="ft012"><b>Varicella-Zoster&#160;Virus&#160;Diseases</b></p>
<p style="position:absolute;top:166px;left:286px;white-space:nowrap" class="ft013">&#160;...........................................................................................................................&#160;DD-1&#160;</p>
<p style="position:absolute;top:203px;left:54px;white-space:nowrap" class="ft012"><b>Tables&#160;</b></p>
<p style="position:absolute;top:240px;left:101px;white-space:nowrap" class="ft019"><i>Table&#160;1. Prophylaxis&#160;to&#160;Prevent&#160;First&#160;Episode&#160;of&#160;Opportunistic&#160;Disease</i></p>
<p style="position:absolute;top:240px;left:596px;white-space:nowrap" class="ft013">&#160;.....................................................&#160;EE-1&#160;</p>
<p style="position:absolute;top:277px;left:101px;white-space:nowrap" class="ft019"><i>Table&#160;2. Treatment&#160;of&#160;</i></p>
<p style="position:absolute;top:277px;left:255px;white-space:nowrap" class="ft020"><i>HIV</i></p>
<p style="position:absolute;top:277px;left:284px;white-space:nowrap" class="ft019"><i>-Associated Opportunistic&#160;Infections&#160;(Includes&#160;Recommendations&#160;for&#160;Acute&#160;</i></p>
<p style="position:absolute;top:297px;left:101px;white-space:nowrap" class="ft019"><i>Treatment&#160;and Chronic&#160;Suppressive/Maintenance&#160;Therapy)</i></p>
<p style="position:absolute;top:297px;left:512px;white-space:nowrap" class="ft013">&#160;.........................................................................&#160;FF-1&#160;</p>
<p style="position:absolute;top:334px;left:101px;white-space:nowrap" class="ft019"><i>Table&#160;3. Indications&#160;for&#160;Discontinuing&#160;and&#160;Restarting Opportunistic&#160;Infection&#160;Prophylaxis&#160;in&#160;</i></p>
<p style="position:absolute;top:354px;left:101px;white-space:nowrap" class="ft020"><i>Adults and&#160;</i></p>
<p style="position:absolute;top:354px;left:180px;white-space:nowrap" class="ft019"><i>Adolescents&#160;</i></p>
<p style="position:absolute;top:354px;left:267px;white-space:nowrap" class="ft020"><i>W</i></p>
<p style="position:absolute;top:354px;left:281px;white-space:nowrap" class="ft021"><i>ith&#160;HIV&#160;&#160;..</i></p>
<p style="position:absolute;top:354px;left:349px;white-space:nowrap" class="ft016">....</p>
<p style="position:absolute;top:354px;left:367px;white-space:nowrap" class="ft022">..............</p>
<p style="position:absolute;top:354px;left:427px;white-space:nowrap" class="ft013">...........................................................................................&#160;GG-1&#160;</p>
<p style="position:absolute;top:391px;left:101px;white-space:nowrap" class="ft023"><i>Table&#160;4. Significant&#160;Pharmacokinetic&#160;Interactions&#160;for&#160;Drugs&#160;Used to Treat&#160;or&#160;Prevent&#160;Opportunistic&#160;<br/>Infections</i></p>
<p style="position:absolute;top:411px;left:169px;white-space:nowrap" class="ft013">&#160;......................................................................................................................................................&#160;HH-1&#160;</p>
<p style="position:absolute;top:448px;left:101px;white-space:nowrap" class="ft019"><i>Table&#160;5. Common or&#160;Serious&#160;Adverse&#160;Reactions&#160;Associated&#160;</i></p>
<p style="position:absolute;top:448px;left:516px;white-space:nowrap" class="ft020"><i>W</i></p>
<p style="position:absolute;top:448px;left:530px;white-space:nowrap" class="ft019"><i>ith Drugs&#160;Used&#160;for Preventing&#160;or Treating&#160;</i></p>
<p style="position:absolute;top:468px;left:101px;white-space:nowrap" class="ft019"><i>Opportunistic&#160;Infections</i></p>
<p style="position:absolute;top:468px;left:269px;white-space:nowrap" class="ft013">&#160;...................................................................................................................................II-1&#160;</p>
<p style="position:absolute;top:505px;left:101px;white-space:nowrap" class="ft023"><i>Table&#160;6. Dosing Recommendations&#160;for&#160;Drugs&#160;Used in Treating or&#160;Preventing&#160;Opportunistic&#160;Infections&#160;Where&#160;<br/>Dosage&#160;Adjustment&#160;is&#160;Needed&#160;in&#160;Patients&#160;</i></p>
<p style="position:absolute;top:525px;left:391px;white-space:nowrap" class="ft020"><i>W</i></p>
<p style="position:absolute;top:525px;left:405px;white-space:nowrap" class="ft019"><i>ith Renal&#160;Insufficiency</i></p>
<p style="position:absolute;top:525px;left:560px;white-space:nowrap" class="ft013">&#160;...............................................................&#160;JJ-1&#160;</p>
<p style="position:absolute;top:565px;left:54px;white-space:nowrap" class="ft012"><b>Appendix&#160;A. List of Abbreviations</b></p>
<p style="position:absolute;top:565px;left:307px;white-space:nowrap" class="ft013">&#160;......................................................................................................................&#160;</p>
<p style="position:absolute;top:565px;left:824px;white-space:nowrap" class="ft022">KK</p>
<p style="position:absolute;top:565px;left:849px;white-space:nowrap" class="ft013">-1&#160;</p>
<p style="position:absolute;top:602px;left:54px;white-space:nowrap" class="ft012"><b>Appendix&#160;B. Panel&#160;Roster&#160;and&#160;Financial&#160;Disclosures</b></p>
<p style="position:absolute;top:602px;left:438px;white-space:nowrap" class="ft013">&#160;.......................................................................................</p>
<p style="position:absolute;top:602px;left:817px;white-space:nowrap" class="ft022">..</p>
<p style="position:absolute;top:602px;left:825px;white-space:nowrap" class="ft013">&#160;</p>
<p style="position:absolute;top:602px;left:828px;white-space:nowrap" class="ft022">LL</p>
<p style="position:absolute;top:602px;left:849px;white-space:nowrap" class="ft013">-1&#160;</p>
</div>
<!-- Page 4 -->
<a name="4"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}	.ft024{font-size:15px;font-family:QZSKMX+LiberationSansNarrow;color:#000000;}
	.ft025{font-size:24px;font-family:LKZECW+DejaVuSans;color:#005299;}
	.ft026{font-size:20px;font-family:BGKYCV+LiberationSansNarrow;color:#005299;}
	.ft027{font-size:20px;font-family:WOSUCG+ArialNarrow;color:#005299;}
	.ft028{font-size:20px;font-family:QZPFRO+Tinos;color:#005299;}
	.ft029{font-size:20px;font-family:QZPFRO+Tinos;color:#000000;}
	.ft030{font-size:15px;font-family:VSNPHD+SymbolMT;color:#000000;}
	.ft031{font-size:16px;font-family:VWQSJC+Aptos;color:#000000;}
	.ft032{font-size:17px;line-height:19px;font-family:TURBHP+Tinos;color:#000000;}
	.ft033{font-size:20px;line-height:24px;font-family:QZPFRO+Tinos;color:#005299;}
-->
</style>
<div id="page4-div" style="position:relative;width:917px;height:1187px;">
<p style="position:absolute;top:1117px;left:108px;white-space:nowrap" class="ft024"><i>Guidelines for the Prevention and Treatment&#160;of&#160;Opportunistic&#160;Infections in Adults&#160;and Adolescents&#160;With HIV&#160;</i></p>
<p style="position:absolute;top:1117px;left:802px;white-space:nowrap" class="ft024"><i>iii&#160;</i></p>
<p style="position:absolute;top:112px;left:108px;white-space:nowrap" class="ft025"><b>What’s&#160;New&#160;in&#160;the&#160;Guidelines&#160;</b></p>
<p style="position:absolute;top:160px;left:108px;white-space:nowrap" class="ft013">The&#160;</p>
<p style="position:absolute;top:160px;left:139px;white-space:nowrap" class="ft019"><i>Guidelines for the Prevention and Treatment of Opportunistic Infections in Adults and&#160;</i></p>
<p style="position:absolute;top:180px;left:108px;white-space:nowrap" class="ft019"><i>Adolescents&#160;With HIV</i></p>
<p style="position:absolute;top:180px;left:260px;white-space:nowrap" class="ft013">&#160;document&#160;is published in an&#160;electronic&#160;format and updated as relevant changes&#160;</p>
<p style="position:absolute;top:200px;left:108px;white-space:nowrap" class="ft013">in prevention and treatment recommendations occur.&#160;</p>
<p style="position:absolute;top:237px;left:108px;white-space:nowrap" class="ft032">All changes&#160;are&#160;developed by the&#160;subject-matter groups listed in&#160;the&#160;document. (Changes&#160;in group&#160;<br/>composition also are&#160;posted promptly.) These changes are&#160;reviewed by the editors and relevant&#160;<br/>outside&#160;reviewers before the document&#160;is altered. Major revisions within the last 6 months&#160;are&#160;<br/>as follows:&#160;</p>
<p style="position:absolute;top:333px;left:108px;white-space:nowrap" class="ft026"><b>July&#160;1</b></p>
<p style="position:absolute;top:333px;left:157px;white-space:nowrap" class="ft027">4</p>
<p style="position:absolute;top:333px;left:166px;white-space:nowrap" class="ft026"><b>,&#160;2025&#160;</b></p>
<p style="position:absolute;top:375px;left:108px;white-space:nowrap" class="ft028"><i><b>Cytomegalovirus&#160;Disease</b></i></p>
<p style="position:absolute;top:375px;left:326px;white-space:nowrap" class="ft029"><i><b>&#160;</b></i></p>
<p style="position:absolute;top:416px;left:108px;white-space:nowrap" class="ft030">•</p>
<p style="position:absolute;top:416px;left:135px;white-space:nowrap" class="ft032">Expanded the discussion&#160;on the&#160;diagnosis and treatment of non-ocular cytomegalovirus end-<br/>organ disease.</p>
<p style="position:absolute;top:465px;left:108px;white-space:nowrap" class="ft030">•</p>
<p style="position:absolute;top:465px;left:135px;white-space:nowrap" class="ft013">Updated guidance on monitoring response to therapy and drug&#160;adverse effects.</p>
<p style="position:absolute;top:502px;left:108px;white-space:nowrap" class="ft028"><i><b>Herpes Simplex Virus&#160;</b></i></p>
<p style="position:absolute;top:543px;left:108px;white-space:nowrap" class="ft030">•</p>
<p style="position:absolute;top:543px;left:135px;white-space:nowrap" class="ft032">Provided more detailed information on&#160;diagnosing&#160;diseases associated with human herpes<br/>simplex virus type 1 (HSV-1) and&#160;type 2 (HSV-2).</p>
<p style="position:absolute;top:592px;left:108px;white-space:nowrap" class="ft030">•</p>
<p style="position:absolute;top:592px;left:135px;white-space:nowrap" class="ft013">Added recommendations on the management&#160;of HSV epithelial&#160;keratitis and stromal keratitis.</p>
<p style="position:absolute;top:621px;left:108px;white-space:nowrap" class="ft030">•</p>
<p style="position:absolute;top:621px;left:135px;white-space:nowrap" class="ft032">Added treatment recommendations for central&#160;nervous system,&#160;visceral, and&#160;disseminated HSV-1<br/>and HSV-2&#160;disease.</p>
<p style="position:absolute;top:678px;left:108px;white-space:nowrap" class="ft028"><i><b>Immunizations for Preventable Diseases in Adults&#160;and Adolescents With&#160;HIV&#160;</b></i></p>
<p style="position:absolute;top:719px;left:108px;white-space:nowrap" class="ft030">•</p>
<p style="position:absolute;top:719px;left:135px;white-space:nowrap" class="ft032">Updated pneumococcal vaccine recommendations to include the use of 21-pneumococcal<br/>conjugate&#160;vaccine (PCV21).</p>
<p style="position:absolute;top:768px;left:108px;white-space:nowrap" class="ft030">•</p>
<p style="position:absolute;top:768px;left:135px;white-space:nowrap" class="ft013">Updated mpox vaccine recommendations with new&#160;information on data&#160;supporting their use.</p>
<p style="position:absolute;top:797px;left:108px;white-space:nowrap" class="ft030">•</p>
<p style="position:absolute;top:796px;left:135px;white-space:nowrap" class="ft032">Added a&#160;second pentavalent meningococcal&#160;conjugate&#160;vaccine&#160;(MenABCWY) recommendation<br/>and updated&#160;the&#160;dosing intervals for meningococcal&#160;group B vaccines</p>
<p style="position:absolute;top:816px;left:615px;white-space:nowrap" class="ft031">.</p>
<p style="position:absolute;top:854px;left:108px;white-space:nowrap" class="ft028"><i><b>Mpox&#160;</b></i></p>
<p style="position:absolute;top:896px;left:108px;white-space:nowrap" class="ft030">•</p>
<p style="position:absolute;top:896px;left:135px;white-space:nowrap" class="ft032">Updated treatment&#160;recommendations to reflect&#160;new&#160;trial&#160;data suggesting limited benefit of<br/>tecovirimat&#160;monotherapy; clarified eligibility for use under an expanded-access investigational<br/>new drug&#160;protocol.</p>
<p style="position:absolute;top:973px;left:108px;white-space:nowrap" class="ft033"><i><b>Table 4: Significant Pharmacokinetic&#160;Interactions Between&#160;Drugs Used to&#160;Treat&#160;<br/>or&#160;Prevent&#160;Opportunistic Infections&#160;</b></i></p>
<p style="position:absolute;top:1038px;left:108px;white-space:nowrap" class="ft030">•</p>
<p style="position:absolute;top:1038px;left:135px;white-space:nowrap" class="ft032">Expanded the discussion&#160;on rifamycin- and azole-related interactions, as well&#160;as therapeutic&#160;drug<br/>monitoring.</p>
</div>
<!-- Page 5 -->
<a name="5"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}	.ft034{font-size:17px;font-family:TURBHP+Tinos;color:#005299;}
-->
</style>
<div id="page5-div" style="position:relative;width:917px;height:1187px;">
<p style="position:absolute;top:1117px;left:108px;white-space:nowrap" class="ft024"><i>Guidelines for the Prevention and Treatment&#160;of&#160;Opportunistic&#160;Infections in Adults&#160;and Adolescents&#160;With HIV&#160;</i></p>
<p style="position:absolute;top:1117px;left:801px;white-space:nowrap" class="ft024"><i>iv&#160;</i></p>
<p style="position:absolute;top:109px;left:108px;white-space:nowrap" class="ft028"><i><b>Talaromycosis (Formerly&#160;Penicilliosis)</b></i></p>
<p style="position:absolute;top:109px;left:445px;white-space:nowrap" class="ft029"><i><b>&#160;</b></i></p>
<p style="position:absolute;top:150px;left:108px;white-space:nowrap" class="ft030">•</p>
<p style="position:absolute;top:150px;left:135px;white-space:nowrap" class="ft013">Updated and&#160;expanded the&#160;Diagnosis&#160;section, with a focus on&#160;non–culture-based diagnostics.</p>
<p style="position:absolute;top:179px;left:108px;white-space:nowrap" class="ft030">•</p>
<p style="position:absolute;top:179px;left:135px;white-space:nowrap" class="ft013">Provided more detailed recommendations regarding the&#160;use of&#160;primary prophylaxis.</p>
<p style="position:absolute;top:215px;left:108px;white-space:nowrap" class="ft026"><b>April 23,&#160;2025&#160;</b></p>
<p style="position:absolute;top:258px;left:108px;white-space:nowrap" class="ft028"><i><b>Cystoisosporiasis&#160;(Formerly&#160;Isosporiasis)</b></i></p>
<p style="position:absolute;top:258px;left:465px;white-space:nowrap" class="ft029"><i><b>&#160;</b></i></p>
<p style="position:absolute;top:299px;left:108px;white-space:nowrap" class="ft030">•</p>
<p style="position:absolute;top:299px;left:135px;white-space:nowrap" class="ft013">Updated the&#160;epidemiology information, including adding new regions endemic for</p>
<p style="position:absolute;top:319px;left:135px;white-space:nowrap" class="ft019"><i>Cystoisospora belli</i></p>
<p style="position:absolute;top:319px;left:269px;white-space:nowrap" class="ft013">.</p>
<p style="position:absolute;top:348px;left:108px;white-space:nowrap" class="ft030">•</p>
<p style="position:absolute;top:347px;left:135px;white-space:nowrap" class="ft032">Updated the&#160;Diagnosis&#160;section, including new information on the&#160;use of polymerase chain<br/>reaction, or PCR, for&#160;diagnosing cystoisosporiasis.</p>
<p style="position:absolute;top:396px;left:108px;white-space:nowrap" class="ft030">•</p>
<p style="position:absolute;top:396px;left:135px;white-space:nowrap" class="ft013">Provided more detailed recommendations regarding the&#160;use of&#160;primary prophylaxis.</p>
<p style="position:absolute;top:425px;left:108px;white-space:nowrap" class="ft030">•</p>
<p style="position:absolute;top:425px;left:135px;white-space:nowrap" class="ft013">Updated preferred and alternative&#160;regimens for treatment&#160;and chronic maintenance therapy.</p>
<p style="position:absolute;top:462px;left:108px;white-space:nowrap" class="ft028"><i><b>Human&#160;Herpesvirus-8&#160;Disease</b></i></p>
<p style="position:absolute;top:462px;left:374px;white-space:nowrap" class="ft029"><i><b>&#160;</b></i></p>
<p style="position:absolute;top:504px;left:108px;white-space:nowrap" class="ft030">•</p>
<p style="position:absolute;top:503px;left:135px;white-space:nowrap" class="ft032">Provided more detailed information on&#160;diagnosing&#160;diseases associated with human<br/>herpesvirus-8 (HHV-8).</p>
<p style="position:absolute;top:552px;left:108px;white-space:nowrap" class="ft030">•</p>
<p style="position:absolute;top:552px;left:135px;white-space:nowrap" class="ft032">Updated recommended treatment regimens for&#160;Kaposi sarcoma&#160;(KS), multicentric&#160;Castleman’s<br/>disease, primary effusion lymphoma, and HHV-8 diffuse large&#160;B-cell lymphoma.</p>
<p style="position:absolute;top:601px;left:108px;white-space:nowrap" class="ft030">•</p>
<p style="position:absolute;top:601px;left:135px;white-space:nowrap" class="ft013">Added information on the&#160;treatment&#160;of KS&#160;inflammatory cytokine syndrome.</p>
<p style="position:absolute;top:638px;left:108px;white-space:nowrap" class="ft028"><i><b>Table 6</b></i></p>
<p style="position:absolute;top:638px;left:173px;white-space:nowrap" class="ft029"><i><b>&#160;</b></i></p>
<p style="position:absolute;top:680px;left:108px;white-space:nowrap" class="ft030">•</p>
<p style="position:absolute;top:679px;left:135px;white-space:nowrap" class="ft032">Updated to incorporate clinical&#160;discretion when adjusting doses&#160;of lamivudine&#160;and emtricitabine<br/>for renal&#160;insufficiency, now aligning with dosing recommendations found in&#160;the&#160;</p>
<p style="position:absolute;top:699px;left:692px;white-space:nowrap" class="ft034">Adult and</p>
<p style="position:absolute;top:719px;left:135px;white-space:nowrap" class="ft034">Adolescent&#160;Antiretroviral&#160;Guidelines</p>
<p style="position:absolute;top:719px;left:391px;white-space:nowrap" class="ft013">&#160;from the U.S. Department&#160;of Health and Human&#160;Services.</p>
</div>
<!-- Page 6 -->
<a name="6"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}	.ft035{font-size:18px;font-family:BGKYCV+LiberationSansNarrow;color:#000000;}
	.ft036{font-size:18px;font-family:RAJFOH+LiberationSansNarrow;color:#000000;}
	.ft037{font-size:18px;font-family:WOSUCG+ArialNarrow;color:#000000;}
	.ft038{font-size:11px;font-family:TURBHP+Tinos;color:#000000;}
	.ft039{font-size:17px;font-family:TURBHP+Tinos;color:#ff0000;}
	.ft040{font-size:17px;font-family:VSNPHD+SymbolMT;color:#000000;}
-->
</style>
<div id="page6-div" style="position:relative;width:917px;height:1187px;">
<p style="position:absolute;top:1117px;left:108px;white-space:nowrap" class="ft024"><i>Guidelines for the Prevention and Treatment&#160;of&#160;Opportunistic&#160;Infections in Adults&#160;and Adolescents&#160;With HIV&#160;</i></p>
<p style="position:absolute;top:1117px;left:791px;white-space:nowrap" class="ft024"><i>A-1</i></p>
<p style="position:absolute;top:112px;left:108px;white-space:nowrap" class="ft025"><b>Introduction&#160;</b></p>
<p style="position:absolute;top:159px;left:108px;white-space:nowrap" class="ft035"><b>Updated:&#160;</b></p>
<p style="position:absolute;top:159px;left:176px;white-space:nowrap" class="ft036">December&#160;16,&#160;2024&#160;</p>
<p style="position:absolute;top:180px;left:108px;white-space:nowrap" class="ft035"><b>Reviewed:&#160;</b></p>
<p style="position:absolute;top:180px;left:185px;white-space:nowrap" class="ft037">January</p>
<p style="position:absolute;top:180px;left:237px;white-space:nowrap" class="ft036">&#160;</p>
<p style="position:absolute;top:180px;left:242px;white-space:nowrap" class="ft037">8</p>
<p style="position:absolute;top:180px;left:250px;white-space:nowrap" class="ft036">, 202</p>
<p style="position:absolute;top:180px;left:283px;white-space:nowrap" class="ft037">5</p>
<p style="position:absolute;top:180px;left:291px;white-space:nowrap" class="ft036">&#160;</p>
<p style="position:absolute;top:218px;left:108px;white-space:nowrap" class="ft032">Opportunistic&#160;infections (OIs),&#160;which in the&#160;context&#160;of HIV have&#160;been defined as infections that are&#160;<br/>more&#160;frequent or more severe&#160;because&#160;of HIV-mediated immunosuppression,</p>
<p style="position:absolute;top:237px;left:641px;white-space:nowrap" class="ft038">1</p>
<p style="position:absolute;top:238px;left:647px;white-space:nowrap" class="ft013">&#160;were the&#160;first clinical&#160;</p>
<p style="position:absolute;top:258px;left:108px;white-space:nowrap" class="ft013">manifestations that alerted clinicians to the occurrence of AIDS.&#160;</p>
<p style="position:absolute;top:258px;left:555px;white-space:nowrap" class="ft019"><i>Pneumocystis&#160;</i></p>
<p style="position:absolute;top:258px;left:654px;white-space:nowrap" class="ft013">pneumonia (PCP),&#160;</p>
<p style="position:absolute;top:278px;left:108px;white-space:nowrap" class="ft019"><i>Toxoplasma</i></p>
<p style="position:absolute;top:278px;left:192px;white-space:nowrap" class="ft013">&#160;encephalitis, cytomegalovirus retinitis, cryptococcal&#160;meningitis, tuberculosis,&#160;</p>
<p style="position:absolute;top:298px;left:108px;white-space:nowrap" class="ft013">disseminated&#160;</p>
<p style="position:absolute;top:298px;left:202px;white-space:nowrap" class="ft019"><i>Mycobacterium avium</i></p>
<p style="position:absolute;top:298px;left:357px;white-space:nowrap" class="ft013">&#160;complex (MAC) disease, and pneumococcal&#160;respiratory disease,&#160;</p>
<p style="position:absolute;top:318px;left:108px;white-space:nowrap" class="ft032">as well as&#160;Kaposi&#160;sarcoma&#160;and central&#160;nervous&#160;system&#160;lymphoma cancers, have been hallmarks of&#160;<br/>AIDS. These&#160;OIs occurred,&#160;on&#160;average, 7 to 10 years after infection with HIV.</p>
<p style="position:absolute;top:336px;left:649px;white-space:nowrap" class="ft038">2,3</p>
<p style="position:absolute;top:337px;left:663px;white-space:nowrap" class="ft039">&#160;</p>
<p style="position:absolute;top:337px;left:667px;white-space:nowrap" class="ft013">Until&#160;effective&#160;</p>
<p style="position:absolute;top:357px;left:108px;white-space:nowrap" class="ft032">antiretroviral&#160;therapy (ART) was developed, patients generally survived only&#160;1 to 2 years after the&#160;<br/>initial&#160;clinical manifestation of AIDS.</p>
<p style="position:absolute;top:376px;left:369px;white-space:nowrap" class="ft038">4</p>
<p style="position:absolute;top:377px;left:375px;white-space:nowrap" class="ft013">&#160;</p>
<p style="position:absolute;top:414px;left:108px;white-space:nowrap" class="ft032">Since the&#160;late&#160;1980s, the&#160;use of chemoprophylaxis,&#160;immunization, and better strategies for&#160;managing&#160;<br/>OIs&#160;have improved the quality of life and lengthened the survival&#160;of people with HIV.</p>
<p style="position:absolute;top:433px;left:702px;white-space:nowrap" class="ft038">5</p>
<p style="position:absolute;top:434px;left:707px;white-space:nowrap" class="ft013">&#160;Profound&#160;</p>
<p style="position:absolute;top:454px;left:108px;white-space:nowrap" class="ft032">reduction in OI-related morbidity and&#160;mortality in&#160;people with&#160;HIV resulted&#160;from the introduction of&#160;<br/>highly effective&#160;combination ART in the mid-1990s.</p>
<p style="position:absolute;top:472px;left:472px;white-space:nowrap" class="ft038">6-12</p>
<p style="position:absolute;top:474px;left:492px;white-space:nowrap" class="ft013">&#160;</p>
<p style="position:absolute;top:511px;left:108px;white-space:nowrap" class="ft032">Despite&#160;the availability&#160;and wide use&#160;of safe, effective, and simple&#160;ART regimens that have led&#160;to&#160;<br/>corresponding population-level&#160;declines&#160;in the incidence of OIs,</p>
<p style="position:absolute;top:529px;left:551px;white-space:nowrap" class="ft038">10,13,14</p>
<p style="position:absolute;top:531px;left:590px;white-space:nowrap" class="ft013">&#160;the Centers for&#160;Disease&#160;</p>
<p style="position:absolute;top:550px;left:108px;white-space:nowrap" class="ft032">Control&#160;and&#160;Prevention (CDC) estimates that in 2022, 13% of people with HIV&#160;in&#160;the United&#160;States&#160;<br/>were unaware of their positive HIV&#160;status&#160;and 43%&#160;of Americans with HIV&#160;who&#160;were aware&#160;of their&#160;<br/>positive HIV&#160;status&#160;were&#160;not effectively virally suppressed (see&#160;</p>
<p style="position:absolute;top:590px;left:549px;white-space:nowrap" class="ft034">Figure 14 and Table 5&#160;in the CDC&#160;</p>
<p style="position:absolute;top:610px;left:108px;white-space:nowrap" class="ft034">HIV Surveillance report</p>
<p style="position:absolute;top:610px;left:275px;white-space:nowrap" class="ft013">).</p>
<p style="position:absolute;top:609px;left:285px;white-space:nowrap" class="ft038">15,16</p>
<p style="position:absolute;top:610px;left:310px;white-space:nowrap" class="ft013">&#160;As a result, OIs continue to cause&#160;preventable morbidity and mortality&#160;</p>
<p style="position:absolute;top:630px;left:108px;white-space:nowrap" class="ft013">in&#160;the United&#160;States.&#160;</p>
<p style="position:absolute;top:667px;left:108px;white-space:nowrap" class="ft032">Achieving and maintaining durable&#160;viral&#160;suppression in all&#160;people with HIV&#160;and preventing or&#160;<br/>substantially reducing the&#160;incidence of HIV-related OIs remains&#160;challenging for three main reasons:&#160;</p>
<p style="position:absolute;top:723px;left:108px;white-space:nowrap" class="ft040">•</p>
<p style="position:absolute;top:725px;left:135px;white-space:nowrap" class="ft023"><i>Not all HIV infections have been diagnosed, and&#160;once&#160;HIV is diagnosed,&#160;many people have<br/>already&#160;experienced substantial immunosuppression.</i></p>
<p style="position:absolute;top:745px;left:502px;white-space:nowrap" class="ft013">&#160;The&#160;CDC estimates that in 2022, among</p>
<p style="position:absolute;top:765px;left:135px;white-space:nowrap" class="ft032">those with diagnosed&#160;HIV, approximately 21% had&#160;a CD4 T lymphocyte (CD4) cell count<br/>&lt;200 cells/mm</p>
<p style="position:absolute;top:783px;left:238px;white-space:nowrap" class="ft038">3</p>
<p style="position:absolute;top:785px;left:244px;white-space:nowrap" class="ft013">&#160;(or &lt;14%) at the time&#160;of diagnosis&#160;(see&#160;</p>
<p style="position:absolute;top:785px;left:521px;white-space:nowrap" class="ft034">Figure 2&#160;and Table 1a in the&#160;CDC&#160;HIV</p>
<p style="position:absolute;top:804px;left:135px;white-space:nowrap" class="ft034">Surveillance report</p>
<p style="position:absolute;top:804px;left:267px;white-space:nowrap" class="ft013">).</p>
<p style="position:absolute;top:803px;left:277px;white-space:nowrap" class="ft038">15</p>
<p style="position:absolute;top:833px;left:108px;white-space:nowrap" class="ft040">•</p>
<p style="position:absolute;top:834px;left:135px;white-space:nowrap" class="ft019"><i>Not all people with diagnosed HIV receive timely, continuous&#160;HIV care or are prescribed&#160;ART.</i></p>
<p style="position:absolute;top:854px;left:135px;white-space:nowrap" class="ft013">The</p>
<p style="position:absolute;top:854px;left:162px;white-space:nowrap" class="ft019"><i>&#160;</i></p>
<p style="position:absolute;top:854px;left:166px;white-space:nowrap" class="ft013">CDC estimates that in 2022, 82%&#160;of people with newly diagnosed&#160;HIV&#160;had been linked to</p>
<p style="position:absolute;top:874px;left:135px;white-space:nowrap" class="ft013">care&#160;within 1 month (see&#160;</p>
<p style="position:absolute;top:874px;left:310px;white-space:nowrap" class="ft034">Figure 3 and&#160;Table&#160;2a in the&#160;CDC&#160;HIV&#160;Surveillance report</p>
<p style="position:absolute;top:874px;left:715px;white-space:nowrap" class="ft013">). However,</p>
<p style="position:absolute;top:894px;left:135px;white-space:nowrap" class="ft013">only 47% of&#160;people with&#160;HIV&#160;were adequately engaged in continuous care (see&#160;</p>
<p style="position:absolute;top:894px;left:686px;white-space:nowrap" class="ft034">Figure 14&#160;in the</p>
<p style="position:absolute;top:914px;left:135px;white-space:nowrap" class="ft034">CDC&#160;HIV&#160;Surveillance report</p>
<p style="position:absolute;top:914px;left:341px;white-space:nowrap" class="ft013">).</p>
<p style="position:absolute;top:912px;left:352px;white-space:nowrap" class="ft038">15</p>
<p style="position:absolute;top:942px;left:108px;white-space:nowrap" class="ft040">•</p>
<p style="position:absolute;top:944px;left:135px;white-space:nowrap" class="ft019"><i>Not all people&#160;who are treated for HIV&#160;achieve&#160;durable&#160;viral suppression.&#160;</i></p>
<p style="position:absolute;top:944px;left:651px;white-space:nowrap" class="ft013">The</p>
<p style="position:absolute;top:944px;left:677px;white-space:nowrap" class="ft019"><i>&#160;</i></p>
<p style="position:absolute;top:944px;left:682px;white-space:nowrap" class="ft013">CDC estimates</p>
<p style="position:absolute;top:964px;left:135px;white-space:nowrap" class="ft032">that in 2022,&#160;only 65% of&#160;people were&#160;both engaged in care and&#160;had durable&#160;viral suppression<br/>within 6 months of HIV diagnosis (see&#160;</p>
<p style="position:absolute;top:984px;left:407px;white-space:nowrap" class="ft034">Figure 11 in&#160;the&#160;CDC&#160;HIV Surveillance&#160;report</p>
<p style="position:absolute;top:984px;left:727px;white-space:nowrap" class="ft013">).</p>
<p style="position:absolute;top:982px;left:737px;white-space:nowrap" class="ft038">15</p>
<p style="position:absolute;top:984px;left:748px;white-space:nowrap" class="ft019"><i>&#160;</i></p>
<p style="position:absolute;top:984px;left:753px;white-space:nowrap" class="ft013">Causes</p>
<p style="position:absolute;top:1003px;left:135px;white-space:nowrap" class="ft032">for the&#160;suboptimal&#160;response to treatment include challenges with adherence, unfavorable<br/>pharmacokinetics, or unexplained biologic&#160;factors.</p>
<p style="position:absolute;top:1022px;left:485px;white-space:nowrap" class="ft038">17</p>
</div>
<!-- Page 7 -->
<a name="7"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}	.ft041{font-size:15px;font-family:RAJFOH+LiberationSansNarrow;color:#000000;}
-->
</style>
<div id="page7-div" style="position:relative;width:917px;height:1187px;">
<p style="position:absolute;top:1117px;left:108px;white-space:nowrap" class="ft024"><i>Guidelines for the Prevention and Treatment&#160;of&#160;Opportunistic&#160;Infections in Adults&#160;and Adolescents&#160;With HIV&#160;</i></p>
<p style="position:absolute;top:1117px;left:791px;white-space:nowrap" class="ft024"><i>A-2</i></p>
<p style="position:absolute;top:1117px;left:810px;white-space:nowrap" class="ft041">&#160;</p>
<p style="position:absolute;top:109px;left:108px;white-space:nowrap" class="ft032">Thus, some&#160;people with&#160;HIV&#160;will&#160;continue to present&#160;with an OI as the&#160;sentinel&#160;event (leading to a&#160;<br/>diagnosis of&#160;HIV) or present&#160;with an OI as a complication of unsuccessful viral&#160;suppression.</p>
<p style="position:absolute;top:127px;left:746px;white-space:nowrap" class="ft038">15</p>
<p style="position:absolute;top:129px;left:757px;white-space:nowrap" class="ft013">&#160;</p>
<p style="position:absolute;top:166px;left:108px;white-space:nowrap" class="ft032">Durable viral&#160;suppression&#160;eliminates most but&#160;not all&#160;OIs. Tuberculosis, pneumococcal disease, and&#160;<br/>dermatomal zoster are examples of infectious diseases that occur at&#160;higher incidence in people&#160;with&#160;<br/>HIV&#160;regardless&#160;of&#160;CD4 count. The likelihood of each of these&#160;OIs occurring does vary inversely with&#160;<br/>the&#160;CD4 count, however.</p>
<p style="position:absolute;top:224px;left:281px;white-space:nowrap" class="ft038">18-24</p>
<p style="position:absolute;top:225px;left:307px;white-space:nowrap" class="ft013">&#160;Certain&#160;OIs—most notably tuberculosis and&#160;syphilis—can increase&#160;</p>
<p style="position:absolute;top:245px;left:108px;white-space:nowrap" class="ft013">plasma viral&#160;load,</p>
<p style="position:absolute;top:244px;left:231px;white-space:nowrap" class="ft038">25-29</p>
<p style="position:absolute;top:245px;left:257px;white-space:nowrap" class="ft039">&#160;</p>
<p style="position:absolute;top:245px;left:262px;white-space:nowrap" class="ft013">which both accelerates HIV progression and increases&#160;the&#160;risk of&#160;HIV&#160;</p>
<p style="position:absolute;top:265px;left:108px;white-space:nowrap" class="ft013">transmission&#160;if patients are not&#160;virally suppressed by ART.&#160;</p>
<p style="position:absolute;top:302px;left:108px;white-space:nowrap" class="ft032">Therefore, clinicians continue&#160;to need to be&#160;knowledgeable about the prevention and management&#160;of&#160;<br/>HIV-related OIs.&#160;</p>
<p style="position:absolute;top:358px;left:108px;white-space:nowrap" class="ft026"><b>History of&#160;These Guidelines&#160;</b></p>
<p style="position:absolute;top:400px;left:108px;white-space:nowrap" class="ft013">In 1989, the&#160;Guidelines for Prophylaxis Against&#160;</p>
<p style="position:absolute;top:400px;left:443px;white-space:nowrap" class="ft019"><i>Pneumocystis&#160;carinii</i></p>
<p style="position:absolute;top:400px;left:588px;white-space:nowrap" class="ft013">&#160;Pneumonia for Persons&#160;</p>
<p style="position:absolute;top:420px;left:108px;white-space:nowrap" class="ft032">Infected with&#160;the&#160;Human Immunodeficiency Virus&#160;became&#160;the&#160;first HIV-related treatment guideline&#160;<br/>published by&#160;the&#160;U.S. government.</p>
<p style="position:absolute;top:438px;left:348px;white-space:nowrap" class="ft038">30</p>
<p style="position:absolute;top:440px;left:359px;white-space:nowrap" class="ft013">&#160;This guideline was published in the&#160;</p>
<p style="position:absolute;top:440px;left:613px;white-space:nowrap" class="ft019"><i>Morbidity and&#160;Mortality&#160;</i></p>
<p style="position:absolute;top:460px;left:108px;white-space:nowrap" class="ft019"><i>Weekly&#160;Report (MMWR)</i></p>
<p style="position:absolute;top:460px;left:278px;white-space:nowrap" class="ft013">,&#160;which was the most rapid&#160;mode&#160;of publication at&#160;the time. It&#160;was&#160;followed&#160;</p>
<p style="position:absolute;top:480px;left:108px;white-space:nowrap" class="ft013">by a guideline&#160;on prevention of MAC&#160;disease in 1993.</p>
<p style="position:absolute;top:478px;left:483px;white-space:nowrap" class="ft038">31</p>
<p style="position:absolute;top:480px;left:494px;white-space:nowrap" class="ft013">&#160;In 1995, these guidelines were&#160;expanded to&#160;</p>
<p style="position:absolute;top:499px;left:108px;white-space:nowrap" class="ft032">include&#160;the&#160;treatment of 18 HIV-related OIs. In 2004, information about&#160;the&#160;prevention of&#160;HIV-<br/>related OIs&#160;was incorporated into the guidelines. The National&#160;Institutes of&#160;Health (NIH), the&#160;HIV&#160;<br/>Medicine&#160;Association (HIVMA), and the Infectious&#160;Diseases&#160;Society of America (IDSA) jointly co-<br/>sponsor these guidelines,</p>
<p style="position:absolute;top:558px;left:281px;white-space:nowrap" class="ft038">1,32,33</p>
<p style="position:absolute;top:559px;left:315px;white-space:nowrap" class="ft039">&#160;</p>
<p style="position:absolute;top:559px;left:319px;white-space:nowrap" class="ft013">which&#160;have&#160;been published in peer-reviewed journals and/or the&#160;</p>
<p style="position:absolute;top:579px;left:108px;white-space:nowrap" class="ft019"><i>MMWR</i></p>
<p style="position:absolute;top:579px;left:162px;white-space:nowrap" class="ft013">&#160;in 1997, 1999,&#160;2002, 2004,&#160;and 2009.</p>
<p style="position:absolute;top:577px;left:424px;white-space:nowrap" class="ft038">33-44</p>
<p style="position:absolute;top:579px;left:451px;white-space:nowrap" class="ft039">&#160;</p>
<p style="position:absolute;top:579px;left:455px;white-space:nowrap" class="ft013">Since&#160;2009, these OI&#160;guidelines have been&#160;</p>
<p style="position:absolute;top:598px;left:108px;white-space:nowrap" class="ft032">managed as&#160;a living document on the web, with each chapter reviewed quarterly by the&#160;guidelines&#160;<br/>committee.&#160;Updates are&#160;published as&#160;often and as&#160;promptly as&#160;deemed appropriate&#160;by the&#160;guidelines&#160;<br/>committee.&#160;&#160;</p>
<p style="position:absolute;top:675px;left:108px;white-space:nowrap" class="ft032">In 2023, there were nearly 566,000&#160;online page views&#160;and approximately 17,400 PDF&#160;downloads,&#160;<br/>which demonstrate that&#160;the&#160;Adult and&#160;Adolescent&#160;OI Guidelines continue&#160;to&#160;be a valuable resource to&#160;<br/>clinicians, other health care&#160;providers,&#160;people with&#160;HIV,&#160;and policymakers in the United States.&#160;<br/>Guidelines pertinent&#160;to other regions of the&#160;world, especially resource-limited countries,&#160;may differ&#160;<br/>with respect&#160;to the spectrum of relevant OIs and the diagnostic and therapeutic options that are&#160;<br/>available&#160;to clinicians.&#160;</p>
<p style="position:absolute;top:812px;left:108px;white-space:nowrap" class="ft032">All guideline recommendations related to prevention or treatment are rated based on rigorous criteria&#160;<br/>that include&#160;the quality of supporting evidence. These ratings allow readers to assess the relative&#160;<br/>importance of each recommendation.&#160;</p>
<p style="position:absolute;top:888px;left:108px;white-space:nowrap" class="ft032">These guidelines address&#160;the&#160;prevention and treatment of HIV-related OIs&#160;in&#160;adults and adolescents.&#160;<br/>Guidelines addressing the&#160;prevention and treatment of HIV-related OIs&#160;in&#160;pediatric populations can&#160;<br/>be found on&#160;the&#160;</p>
<p style="position:absolute;top:928px;left:220px;white-space:nowrap" class="ft034">Clinicalinfo</p>
<p style="position:absolute;top:928px;left:303px;white-space:nowrap" class="ft013">&#160;website.&#160;</p>
<p style="position:absolute;top:964px;left:108px;white-space:nowrap" class="ft026"><b>Snapshot&#160;of Guidelines&#160;Development&#160;Process&#160;</b></p>
<p style="position:absolute;top:1006px;left:108px;white-space:nowrap" class="ft032">These guidelines were prepared by the&#160;Panel&#160;on Guidelines for the Prevention&#160;and Treatment of&#160;<br/>Opportunistic&#160;Infections in Adults and&#160;Adolescents&#160;With HIV&#160;(the&#160;Panel) under the auspices of the&#160;<br/>Office of&#160;AIDS Research&#160;Advisory Council (OARAC), an authorized Federal&#160;Advisory&#160;Committee&#160;</p>
</div>
<!-- Page 8 -->
<a name="8"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page8-div" style="position:relative;width:917px;height:1187px;">
<p style="position:absolute;top:1117px;left:108px;white-space:nowrap" class="ft024"><i>Guidelines for the Prevention and Treatment&#160;of&#160;Opportunistic&#160;Infections in Adults&#160;and Adolescents&#160;With HIV&#160;</i></p>
<p style="position:absolute;top:1117px;left:791px;white-space:nowrap" class="ft024"><i>A-3</i></p>
<p style="position:absolute;top:1117px;left:810px;white-space:nowrap" class="ft041">&#160;</p>
<p style="position:absolute;top:109px;left:108px;white-space:nowrap" class="ft032">to the U.S.&#160;Department&#160;of Health and Human Services established in 1994. Co-chairs who&#160;are&#160;<br/>selected and appointed by&#160;their respective agencies or organizations (i.e.,&#160;NIH, IDSA, HIVMA)</p>
<p style="position:absolute;top:129px;left:769px;white-space:nowrap" class="ft039">&#160;</p>
<p style="position:absolute;top:148px;left:108px;white-space:nowrap" class="ft032">convene&#160;OI-specific working groups&#160;of clinicians and scientists with subject&#160;matter expertise in&#160;<br/>specific OIs.&#160;&#160;</p>
<p style="position:absolute;top:205px;left:108px;white-space:nowrap" class="ft032">The&#160;working&#160;groups&#160;review in real time the relevant literature published since the&#160;last review, with&#160;<br/>the&#160;help of quarterly literature searches for articles&#160;relevant&#160;to their section that are provided by&#160;<br/>guidelines support staff. The working&#160;groups propose revisions to&#160;their section as appropriate. The&#160;<br/>co-chairs, representatives from HIVMA and IDSA,&#160;and other Panel&#160;working&#160;groups&#160;with&#160;special&#160;<br/>expertise (e.g., pharmacology, pregnancy) review&#160;proposed&#160;revisions.&#160;&#160;</p>
<p style="position:absolute;top:322px;left:108px;white-space:nowrap" class="ft032">The co-chairs and working group leaders have quarterly teleconferences to discuss&#160;section&#160;updates.&#160;<br/>In addition, the&#160;co-chairs&#160;convene&#160;an annual&#160;meeting with members of the&#160;Panel&#160;to discuss guidelines&#160;<br/>content and strategic&#160;planning.&#160;</p>
<p style="position:absolute;top:399px;left:108px;white-space:nowrap" class="ft013">The&#160;names and affiliations of all&#160;contributors, as&#160;well&#160;as their financial&#160;disclosures, are&#160;provided in&#160;</p>
<p style="position:absolute;top:418px;left:108px;white-space:nowrap" class="ft034">Appendix B:&#160;Panel&#160;Roster&#160;and Financial&#160;Disclosures</p>
<p style="position:absolute;top:418px;left:471px;white-space:nowrap" class="ft013">.&#160;</p>
<p style="position:absolute;top:418px;left:691px;white-space:nowrap" class="ft013">&#160;</p>
</div>
<!-- Page 9 -->
<a name="9"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}	.ft042{font-size:15px;font-family:BGKYCV+LiberationSansNarrow;color:#000000;}
	.ft043{font-size:15px;font-family:RAJFOH+LiberationSansNarrow;color:#005299;}
	.ft044{font-size:15px;line-height:17px;font-family:RAJFOH+LiberationSansNarrow;color:#000000;}
	.ft045{font-size:15px;line-height:17px;font-family:BGKYCV+LiberationSansNarrow;color:#000000;}
-->
</style>
<div id="page9-div" style="position:relative;width:917px;height:1187px;">
<p style="position:absolute;top:1117px;left:108px;white-space:nowrap" class="ft024"><i>Guidelines for the Prevention and Treatment&#160;of&#160;Opportunistic&#160;Infections in Adults&#160;and Adolescents&#160;With HIV&#160;</i></p>
<p style="position:absolute;top:1117px;left:791px;white-space:nowrap" class="ft024"><i>A-4</i></p>
<p style="position:absolute;top:1117px;left:810px;white-space:nowrap" class="ft041">&#160;</p>
<p style="position:absolute;top:119px;left:347px;white-space:nowrap" class="ft02"><b>Guidelines Development Process&#160;</b></p>
<p style="position:absolute;top:162px;left:170px;white-space:nowrap" class="ft02"><b>Topic&#160;</b></p>
<p style="position:absolute;top:162px;left:507px;white-space:nowrap" class="ft02"><b>Comment&#160;</b></p>
<p style="position:absolute;top:195px;left:115px;white-space:nowrap" class="ft042"><b>Goal&#160;of&#160;the&#160;guidelines&#160;</b></p>
<p style="position:absolute;top:196px;left:276px;white-space:nowrap" class="ft041">Provide&#160;guidance to HIV&#160;care practitioners&#160;and others&#160;on&#160;the&#160;optimal&#160;prevention and&#160;</p>
<p style="position:absolute;top:213px;left:276px;white-space:nowrap" class="ft041">management&#160;of HIV-related opportunistic&#160;infections (OIs)&#160;for&#160;adults&#160;and&#160;adolescents&#160;in the&#160;</p>
<p style="position:absolute;top:230px;left:276px;white-space:nowrap" class="ft041">United States.&#160;</p>
<p style="position:absolute;top:261px;left:115px;white-space:nowrap" class="ft042"><b>Panel members&#160;</b></p>
<p style="position:absolute;top:261px;left:276px;white-space:nowrap" class="ft041">The Panel on Guidelines for the Prevention and&#160;Treatment&#160;of&#160;Opportunistic&#160;Infections in&#160;Adults&#160;</p>
<p style="position:absolute;top:278px;left:276px;white-space:nowrap" class="ft044">and&#160;Adolescents&#160;With HIV&#160;(the Panel) is composed&#160;of co-chairs&#160;who represent&#160;the National&#160;<br/>Institutes&#160;of Health (NIH), the HIV&#160;Medicine Association (HIVMA),&#160;and&#160;the&#160;Infectious&#160;Diseases&#160;</p>
<p style="position:absolute;top:313px;left:276px;white-space:nowrap" class="ft041">Society of America (IDSA), plus&#160;Panel&#160;members&#160;with&#160;expertise in&#160;HIV clinical&#160;care,&#160;infectious&#160;</p>
<p style="position:absolute;top:330px;left:276px;white-space:nowrap" class="ft041">disease management, and research.&#160;Co-chairs&#160;are selected&#160;by&#160;their&#160;respective agencies&#160;or&#160;</p>
<p style="position:absolute;top:347px;left:276px;white-space:nowrap" class="ft044">organizations. Each working group&#160;is led by a Panel&#160;member selected&#160;by the&#160;co-chairs. Panel&#160;<br/>members&#160;are&#160;selected from government,&#160;academia, and the health care&#160;community&#160;by the&#160;</p>
<p style="position:absolute;top:382px;left:276px;white-space:nowrap" class="ft041">co-chairs&#160;and working group leaders&#160;based&#160;on&#160;the member’s&#160;area of subject matter expertise.&#160;</p>
<p style="position:absolute;top:399px;left:276px;white-space:nowrap" class="ft041">Members&#160;serve&#160;on the Panel&#160;for a 4-year&#160;term,&#160;with&#160;an&#160;option to be&#160;reappointed for additional&#160;</p>
<p style="position:absolute;top:416px;left:276px;white-space:nowrap" class="ft044">terms. Prospective Panel&#160;members&#160;may&#160;self-nominate at any&#160;time.&#160;When specific or unique&#160;<br/>subject matter expertise is&#160;required,&#160;the&#160;co-chairs, together with&#160;working group leaders, may&#160;</p>
<p style="position:absolute;top:451px;left:276px;white-space:nowrap" class="ft041">solicit advice from individuals&#160;with&#160;such&#160;specialized knowledge. The&#160;list of&#160;the&#160;current&#160;Panel&#160;</p>
<p style="position:absolute;top:468px;left:276px;white-space:nowrap" class="ft041">members&#160;can be&#160;found&#160;in&#160;</p>
<p style="position:absolute;top:468px;left:419px;white-space:nowrap" class="ft043">Appendix&#160;B:&#160;Panel&#160;Roster and Financial&#160;Disclosures</p>
<p style="position:absolute;top:468px;left:703px;white-space:nowrap" class="ft041">.&#160;</p>
<p style="position:absolute;top:499px;left:115px;white-space:nowrap" class="ft042"><b>Financial disclosure&#160;and&#160;</b></p>
<p style="position:absolute;top:516px;left:115px;white-space:nowrap" class="ft045"><b>management&#160;of conflicts&#160;<br/>of&#160;interest&#160;</b></p>
<p style="position:absolute;top:499px;left:276px;white-space:nowrap" class="ft041">All&#160;members&#160;of&#160;the&#160;Panel&#160;submit&#160;a written financial&#160;disclosure annually&#160;reporting&#160;any</p>
<p style="position:absolute;top:516px;left:276px;white-space:nowrap" class="ft044">associations&#160;with manufacturers of drugs,&#160;vaccines, medical&#160;devices, or diagnostics&#160;used to&#160;<br/>manage&#160;HIV-related OIs. A&#160;list of these disclosures and their&#160;last&#160;update&#160;is&#160;available in&#160;</p>
<p style="position:absolute;top:551px;left:276px;white-space:nowrap" class="ft043">Appendix&#160;B:&#160;Panel&#160;Roster&#160;and&#160;Financial&#160;Disclosures</p>
<p style="position:absolute;top:551px;left:561px;white-space:nowrap" class="ft041">.&#160;The co-chairs&#160;review each reported&#160;</p>
<p style="position:absolute;top:568px;left:276px;white-space:nowrap" class="ft041">association&#160;for potential&#160;conflicts&#160;of interest and determine&#160;the&#160;appropriate action:&#160;</p>
<p style="position:absolute;top:585px;left:276px;white-space:nowrap" class="ft044">disqualification&#160;from the&#160;Panel, disqualification or&#160;recusal&#160;from topic&#160;review and&#160;discussion, or&#160;<br/>no&#160;disqualification needed. A&#160;conflict of interest&#160;is&#160;defined&#160;as any direct financial&#160;interest&#160;related&#160;</p>
<p style="position:absolute;top:619px;left:276px;white-space:nowrap" class="ft041">to a&#160;product addressed&#160;in&#160;the&#160;section&#160;of the guideline to&#160;which a&#160;Panel&#160;member contributes&#160;</p>
<p style="position:absolute;top:637px;left:276px;white-space:nowrap" class="ft041">content. Financial&#160;interests include direct receipt&#160;by the Panel&#160;member of payments, gratuities,&#160;</p>
<p style="position:absolute;top:654px;left:276px;white-space:nowrap" class="ft044">consultancies, honoraria, employment, grants,&#160;support for&#160;travel&#160;or accommodation, or&#160;gifts&#160;<br/>from an&#160;entity&#160;having a&#160;commercial&#160;interest in that product.&#160;Financial&#160;interests also include&#160;</p>
<p style="position:absolute;top:688px;left:276px;white-space:nowrap" class="ft041">direct compensation&#160;for membership on&#160;an&#160;advisory&#160;board, data&#160;safety&#160;monitoring board,&#160;or&#160;</p>
<p style="position:absolute;top:706px;left:276px;white-space:nowrap" class="ft041">speakers’ bureau. Compensation and support provided&#160;to&#160;a Panel&#160;member’s university&#160;or&#160;</p>
<p style="position:absolute;top:723px;left:276px;white-space:nowrap" class="ft041">institution (e.g., grants,&#160;research&#160;funding) is not&#160;considered a financial&#160;conflict of interest.&#160;The&#160;</p>
<p style="position:absolute;top:740px;left:276px;white-space:nowrap" class="ft044">co-chairs&#160;strive to ensure that&#160;50% or more of the&#160;members&#160;of each working group&#160;have no&#160;<br/>conflicts&#160;of&#160;interest.&#160;</p>
<p style="position:absolute;top:788px;left:115px;white-space:nowrap" class="ft042"><b>Primary&#160;users&#160;of&#160;the&#160;</b></p>
<p style="position:absolute;top:805px;left:115px;white-space:nowrap" class="ft042"><b>guidelines&#160;</b></p>
<p style="position:absolute;top:788px;left:276px;white-space:nowrap" class="ft041">HIV&#160;treatment providers&#160;</p>
<p style="position:absolute;top:837px;left:115px;white-space:nowrap" class="ft042"><b>Developer&#160;</b></p>
<p style="position:absolute;top:837px;left:276px;white-space:nowrap" class="ft041">Panel&#160;on&#160;Guidelines for the Prevention and Treatment&#160;of Opportunistic&#160;Infections&#160;in Adults and&#160;</p>
<p style="position:absolute;top:854px;left:276px;white-space:nowrap" class="ft044">Adolescents With HIV, a working group of&#160;the&#160;Office of AIDS Research Advisory&#160;<br/>Council&#160;(OARAC). See&#160;</p>
<p style="position:absolute;top:871px;left:405px;white-space:nowrap" class="ft043">Appendix&#160;B:&#160;Panel&#160;Roster&#160;and&#160;Financial&#160;Disclosures</p>
<p style="position:absolute;top:871px;left:689px;white-space:nowrap" class="ft041">.&#160;</p>
<p style="position:absolute;top:902px;left:115px;white-space:nowrap" class="ft042"><b>Funding&#160;source&#160;</b></p>
<p style="position:absolute;top:903px;left:276px;white-space:nowrap" class="ft043">Office of&#160;AIDS Research (OAR)</p>
<p style="position:absolute;top:903px;left:449px;white-space:nowrap" class="ft041">,&#160;NIH&#160;</p>
<p style="position:absolute;top:934px;left:115px;white-space:nowrap" class="ft042"><b>Evidence&#160;collection&#160;</b></p>
<p style="position:absolute;top:934px;left:276px;white-space:nowrap" class="ft041">The recommendations in the guidelines are based on studies published&#160;in peer-reviewed&#160;</p>
<p style="position:absolute;top:951px;left:276px;white-space:nowrap" class="ft041">journals. On&#160;some occasions, particularly&#160;when&#160;new information may affect patient safety,&#160;</p>
<p style="position:absolute;top:968px;left:276px;white-space:nowrap" class="ft041">unpublished data presented at&#160;major conferences or&#160;information&#160;prepared by&#160;the&#160;U.S. Food&#160;and&#160;</p>
<p style="position:absolute;top:985px;left:276px;white-space:nowrap" class="ft044">Drug&#160;Administration or&#160;manufacturers&#160;(e.g.,&#160;warnings to the public) may be used as&#160;evidence to&#160;<br/>revise the guidelines. Members&#160;of each working group&#160;are responsible for&#160;identifying&#160;relevant&#160;</p>
<p style="position:absolute;top:1020px;left:276px;white-space:nowrap" class="ft041">literature and&#160;conducting a&#160;systematic comprehensive review of literature that&#160;is provided to&#160;</p>
<p style="position:absolute;top:1037px;left:276px;white-space:nowrap" class="ft041">them on&#160;a quarterly basis.&#160;</p>
</div>
<!-- Page 10 -->
<a name="10"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}	.ft046{font-size:17px;font-family:LLANCQ+Arimo;color:#000000;}
-->
</style>
<div id="page10-div" style="position:relative;width:917px;height:1187px;">
<p style="position:absolute;top:1117px;left:108px;white-space:nowrap" class="ft024"><i>Guidelines for the Prevention and Treatment&#160;of&#160;Opportunistic&#160;Infections in Adults&#160;and Adolescents&#160;With HIV&#160;</i></p>
<p style="position:absolute;top:1117px;left:791px;white-space:nowrap" class="ft024"><i>A-5</i></p>
<p style="position:absolute;top:1117px;left:810px;white-space:nowrap" class="ft041">&#160;</p>
<p style="position:absolute;top:119px;left:347px;white-space:nowrap" class="ft02"><b>Guidelines Development Process&#160;</b></p>
<p style="position:absolute;top:162px;left:170px;white-space:nowrap" class="ft02"><b>Topic&#160;</b></p>
<p style="position:absolute;top:162px;left:507px;white-space:nowrap" class="ft02"><b>Comment&#160;</b></p>
<p style="position:absolute;top:195px;left:115px;white-space:nowrap" class="ft042"><b>Method&#160;of&#160;synthesizing&#160;</b></p>
<p style="position:absolute;top:213px;left:115px;white-space:nowrap" class="ft042"><b>data and&#160;formulating&#160;</b></p>
<p style="position:absolute;top:230px;left:115px;white-space:nowrap" class="ft042"><b>recommendations&#160;</b></p>
<p style="position:absolute;top:196px;left:276px;white-space:nowrap" class="ft041">Each section&#160;of the guidelines is assigned to&#160;a working group&#160;of&#160;Panel&#160;members&#160;with&#160;expertise&#160;</p>
<p style="position:absolute;top:213px;left:276px;white-space:nowrap" class="ft041">in the area of interest.&#160;The members&#160;of the&#160;working group synthesize the&#160;available data.&#160;</p>
<p style="position:absolute;top:230px;left:276px;white-space:nowrap" class="ft041">Recommendations are&#160;reviewed&#160;and&#160;updated by&#160;each working group&#160;after an assessment of&#160;</p>
<p style="position:absolute;top:247px;left:276px;white-space:nowrap" class="ft041">the&#160;quality and impact of the&#160;existing and&#160;any new data. Types&#160;of&#160;evidence that&#160;are considered&#160;</p>
<p style="position:absolute;top:264px;left:276px;white-space:nowrap" class="ft044">include&#160;but are not necessarily&#160;limited&#160;to case&#160;series, prospective&#160;cohort trials, and randomized&#160;<br/>controlled trials,&#160;with consideration of&#160;the&#160;quality&#160;and&#160;appropriateness&#160;of&#160;the&#160;methods, and&#160;the&#160;</p>
<p style="position:absolute;top:299px;left:276px;white-space:nowrap" class="ft041">number of participants and effect&#160;sizes&#160;observed.&#160;Finally, all&#160;proposed recommendations&#160;and&#160;</p>
<p style="position:absolute;top:316px;left:276px;white-space:nowrap" class="ft041">supporting evidence are&#160;reviewed by the&#160;co-chairs&#160;before final&#160;approval and&#160;publication.&#160;OAR&#160;</p>
<p style="position:absolute;top:333px;left:276px;white-space:nowrap" class="ft041">reviews&#160;all proposed recommendations and&#160;gives&#160;final&#160;approval.&#160;</p>
<p style="position:absolute;top:364px;left:115px;white-space:nowrap" class="ft042"><b>Recommendation&#160;rating&#160;</b></p>
<p style="position:absolute;top:364px;left:276px;white-space:nowrap" class="ft041">Recommendations are&#160;rated according to the information in the table below, “Rating System for&#160;</p>
<p style="position:absolute;top:382px;left:276px;white-space:nowrap" class="ft041">Prevention and&#160;Treatment&#160;Recommendations,”&#160;and&#160;accompanied, as needed, by&#160;explanatory&#160;</p>
<p style="position:absolute;top:399px;left:276px;white-space:nowrap" class="ft041">text that reviews the evidence and the working group’s assessment. All proposed changes&#160;are&#160;</p>
<p style="position:absolute;top:416px;left:276px;white-space:nowrap" class="ft044">discussed&#160;during teleconferences&#160;and&#160;by email&#160;and then&#160;assessed by&#160;the&#160;Panel’s co-chairs&#160;and&#160;<br/>reviewed&#160;by&#160;OAR, HIVMA, and&#160;IDSA&#160;before being&#160;endorsed as&#160;official&#160;recommendations.&#160;</p>
<p style="position:absolute;top:464px;left:115px;white-space:nowrap" class="ft042"><b>Other guidelines&#160;</b></p>
<p style="position:absolute;top:465px;left:276px;white-space:nowrap" class="ft041">These guidelines focus&#160;on&#160;prevention and treatment of&#160;HIV-related OIs&#160;for adults&#160;and&#160;</p>
<p style="position:absolute;top:482px;left:276px;white-space:nowrap" class="ft041">adolescents. A&#160;separate&#160;guideline outlines similar recommendations for&#160;children who&#160;have HIV.&#160;</p>
<p style="position:absolute;top:499px;left:276px;white-space:nowrap" class="ft041">These guidelines are also available on&#160;the&#160;</p>
<p style="position:absolute;top:499px;left:510px;white-space:nowrap" class="ft043">Clinicalinfo</p>
<p style="position:absolute;top:499px;left:572px;white-space:nowrap" class="ft041">website.</p>
<p style="position:absolute;top:530px;left:115px;white-space:nowrap" class="ft042"><b>Update plan&#160;</b></p>
<p style="position:absolute;top:530px;left:276px;white-space:nowrap" class="ft041">Each working group&#160;leader&#160;and the co-chairs&#160;meet every&#160;3 months by&#160;teleconference to review&#160;</p>
<p style="position:absolute;top:547px;left:276px;white-space:nowrap" class="ft044">interim&#160;data that may&#160;warrant&#160;modification of the&#160;guidelines. Updates&#160;may be prompted by&#160;<br/>approvals&#160;of&#160;new drugs, vaccines, medical&#160;devices, or&#160;diagnostics; new information regarding&#160;</p>
<p style="position:absolute;top:582px;left:277px;white-space:nowrap" class="ft041">indications or&#160;dosing;&#160;new safety&#160;or efficacy&#160;data;&#160;or other information that&#160;may affect&#160;</p>
<p style="position:absolute;top:599px;left:277px;white-space:nowrap" class="ft041">prevention and treatment of&#160;HIV-related&#160;OIs.&#160;</p>
<p style="position:absolute;top:647px;left:108px;white-space:nowrap" class="ft026"><b>How to Use&#160;the Information&#160;in These&#160;Guidelines&#160;</b></p>
<p style="position:absolute;top:689px;left:108px;white-space:nowrap" class="ft013">Recommendations in this report&#160;address—&#160;</p>
<p style="position:absolute;top:726px;left:108px;white-space:nowrap" class="ft040">•</p>
<p style="position:absolute;top:727px;left:116px;white-space:nowrap" class="ft046">&#160;</p>
<p style="position:absolute;top:728px;left:135px;white-space:nowrap" class="ft013">Preventing exposure to opportunistic&#160;pathogens;&#160;</p>
<p style="position:absolute;top:756px;left:108px;white-space:nowrap" class="ft040">•</p>
<p style="position:absolute;top:757px;left:116px;white-space:nowrap" class="ft046">&#160;</p>
<p style="position:absolute;top:758px;left:135px;white-space:nowrap" class="ft013">Preventing disease;&#160;</p>
<p style="position:absolute;top:786px;left:108px;white-space:nowrap" class="ft040">•</p>
<p style="position:absolute;top:787px;left:116px;white-space:nowrap" class="ft046">&#160;</p>
<p style="position:absolute;top:788px;left:135px;white-space:nowrap" class="ft013">Discontinuing primary prophylaxis after immune reconstitution;&#160;</p>
<p style="position:absolute;top:816px;left:108px;white-space:nowrap" class="ft040">•</p>
<p style="position:absolute;top:818px;left:116px;white-space:nowrap" class="ft046">&#160;</p>
<p style="position:absolute;top:818px;left:135px;white-space:nowrap" class="ft013">Treating disease;&#160;</p>
<p style="position:absolute;top:846px;left:108px;white-space:nowrap" class="ft040">•</p>
<p style="position:absolute;top:848px;left:116px;white-space:nowrap" class="ft046">&#160;</p>
<p style="position:absolute;top:848px;left:135px;white-space:nowrap" class="ft013">When to start ART in the&#160;setting of an&#160;acute OI;&#160;</p>
<p style="position:absolute;top:876px;left:108px;white-space:nowrap" class="ft040">•</p>
<p style="position:absolute;top:878px;left:116px;white-space:nowrap" class="ft046">&#160;</p>
<p style="position:absolute;top:878px;left:135px;white-space:nowrap" class="ft013">Monitoring for adverse effects (including immune&#160;reconstitution inflammatory syndrome);&#160;</p>
<p style="position:absolute;top:906px;left:108px;white-space:nowrap" class="ft040">•</p>
<p style="position:absolute;top:908px;left:116px;white-space:nowrap" class="ft046">&#160;</p>
<p style="position:absolute;top:908px;left:135px;white-space:nowrap" class="ft013">Managing treatment failure;&#160;</p>
<p style="position:absolute;top:936px;left:108px;white-space:nowrap" class="ft040">•</p>
<p style="position:absolute;top:938px;left:116px;white-space:nowrap" class="ft046">&#160;</p>
<p style="position:absolute;top:938px;left:135px;white-space:nowrap" class="ft013">Preventing disease recurrence&#160;(secondary prophylaxis or chronic maintenance&#160;therapy);&#160;</p>
<p style="position:absolute;top:966px;left:108px;white-space:nowrap" class="ft040">•</p>
<p style="position:absolute;top:968px;left:116px;white-space:nowrap" class="ft046">&#160;</p>
<p style="position:absolute;top:968px;left:135px;white-space:nowrap" class="ft032">Discontinuing secondary&#160;prophylaxis&#160;or chronic maintenance&#160;therapy after immune&#160;<br/>reconstitution;&#160;</p>
<p style="position:absolute;top:988px;left:239px;white-space:nowrap" class="ft019"><i>and</i></p>
<p style="position:absolute;top:988px;left:265px;white-space:nowrap" class="ft013">&#160;</p>
<p style="position:absolute;top:1016px;left:108px;white-space:nowrap" class="ft040">•</p>
<p style="position:absolute;top:1018px;left:116px;white-space:nowrap" class="ft046">&#160;</p>
<p style="position:absolute;top:1018px;left:135px;white-space:nowrap" class="ft013">Special&#160;considerations during pregnancy.&#160;</p>
</div>
<!-- Page 11 -->
<a name="11"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page11-div" style="position:relative;width:917px;height:1187px;">
<p style="position:absolute;top:1117px;left:108px;white-space:nowrap" class="ft024"><i>Guidelines for the Prevention and Treatment&#160;of&#160;Opportunistic&#160;Infections in Adults&#160;and Adolescents&#160;With HIV&#160;</i></p>
<p style="position:absolute;top:1117px;left:791px;white-space:nowrap" class="ft024"><i>A-6</i></p>
<p style="position:absolute;top:1117px;left:810px;white-space:nowrap" class="ft041">&#160;</p>
<p style="position:absolute;top:109px;left:108px;white-space:nowrap" class="ft032">Recommendations are&#160;rated according&#160;to the criteria&#160;in the table below and accompanied, as needed,&#160;<br/>by explanatory text that&#160;reviews the evidence and the&#160;working&#160;group’s assessment. In this&#160;system, the&#160;<br/>letters A, B,&#160;or C signify the strength of the&#160;recommendation for&#160;or against a&#160;preventive&#160;or&#160;<br/>therapeutic&#160;measure, and&#160;the&#160;Roman numerals I, II, or III indicate the quality of the evidence&#160;<br/>supporting the recommendation. &#160;</p>
<p style="position:absolute;top:234px;left:244px;white-space:nowrap" class="ft02"><b>Rating&#160;System for&#160;Prevention and Treatment Recommendations&#160;</b></p>
<p style="position:absolute;top:273px;left:171px;white-space:nowrap" class="ft02"><b>Strength&#160;of Recommendation&#160;</b></p>
<p style="position:absolute;top:273px;left:470px;white-space:nowrap" class="ft02"><b>Quality of&#160;Evidence for the&#160;Recommendation&#160;&#160;</b></p>
<p style="position:absolute;top:302px;left:115px;white-space:nowrap" class="ft042"><b>A:</b></p>
<p style="position:absolute;top:302px;left:128px;white-space:nowrap" class="ft041">&#160;&#160;Strong&#160;recommendation&#160;for the statement</p>
<p style="position:absolute;top:302px;left:367px;white-space:nowrap" class="ft042"><b>&#160;</b></p>
<p style="position:absolute;top:335px;left:115px;white-space:nowrap" class="ft042"><b>B:</b></p>
<p style="position:absolute;top:335px;left:128px;white-space:nowrap" class="ft041">&#160;&#160;Moderate recommendation for the statement&#160;</p>
<p style="position:absolute;top:367px;left:115px;white-space:nowrap" class="ft042"><b>C:</b></p>
<p style="position:absolute;top:367px;left:128px;white-space:nowrap" class="ft041">&#160;&#160;Weak&#160;recommendation&#160;for the statement&#160;</p>
<p style="position:absolute;top:302px;left:438px;white-space:nowrap" class="ft042"><b>I:</b></p>
<p style="position:absolute;top:302px;left:446px;white-space:nowrap" class="ft041">&#160;&#160;One or more randomized trials&#160;with clinical&#160;outcomes&#160;and/or&#160;</p>
<p style="position:absolute;top:320px;left:464px;white-space:nowrap" class="ft041">validated laboratory endpoints</p>
<p style="position:absolute;top:320px;left:628px;white-space:nowrap" class="ft042"><b>&#160;</b></p>
<p style="position:absolute;top:352px;left:438px;white-space:nowrap" class="ft042"><b>II:</b></p>
<p style="position:absolute;top:352px;left:449px;white-space:nowrap" class="ft041">&#160;&#160;One or more well-designed, non-randomized trials&#160;or&#160;</p>
<p style="position:absolute;top:369px;left:464px;white-space:nowrap" class="ft041">observational&#160;cohort studies&#160;with&#160;long-term clinical&#160;outcomes*&#160;</p>
<p style="position:absolute;top:401px;left:438px;white-space:nowrap" class="ft042"><b>III:</b></p>
<p style="position:absolute;top:401px;left:453px;white-space:nowrap" class="ft041">&#160;&#160;Expert opinion*&#160;</p>
<p style="position:absolute;top:428px;left:108px;white-space:nowrap" class="ft041">* In cases&#160;where&#160;there are no data for&#160;the&#160;prevention or&#160;treatment&#160;of an opportunistic&#160;infection&#160;based on&#160;studies&#160;conducted in&#160;</p>
<p style="position:absolute;top:446px;left:108px;white-space:nowrap" class="ft044">people with HIV&#160;but&#160;there are data derived&#160;from&#160;studies in&#160;people without HIV&#160;that could&#160;plausibly guide management&#160;of patients&#160;<br/>with&#160;HIV, the&#160;recommendation is&#160;rated II&#160;or III but&#160;is&#160;assigned A, B, or C depending on the strength&#160;of the recommendation.&#160;</p>
<p style="position:absolute;top:498px;left:108px;white-space:nowrap" class="ft032">This document also includes tables in&#160;each section pertinent to the&#160;prevention and treatment of the&#160;<br/>OI(s) in that section, as well&#160;as six summary tables at&#160;the end of the&#160;document&#160;(Tables 1–6).&#160;</p>
</div>
<!-- Page 12 -->
<a name="12"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}	.ft047{font-size:16px;font-family:TURBHP+Tinos;color:#000000;}
	.ft048{font-size:16px;font-family:LLANCQ+Arimo;color:#000000;}
	.ft049{font-size:16px;font-family:KPYRPS+Tinos;color:#000000;}
	.ft050{font-size:16px;font-family:TURBHP+Tinos;color:#005299;}
	.ft051{font-size:16px;line-height:18px;font-family:TURBHP+Tinos;color:#000000;}
-->
</style>
<div id="page12-div" style="position:relative;width:917px;height:1187px;">
<p style="position:absolute;top:1117px;left:108px;white-space:nowrap" class="ft024"><i>Guidelines for the Prevention and Treatment&#160;of&#160;Opportunistic&#160;Infections in Adults&#160;and Adolescents&#160;With HIV&#160;</i></p>
<p style="position:absolute;top:1117px;left:791px;white-space:nowrap" class="ft024"><i>A-7</i></p>
<p style="position:absolute;top:1117px;left:810px;white-space:nowrap" class="ft041">&#160;</p>
<p style="position:absolute;top:108px;left:108px;white-space:nowrap" class="ft026"><b>References&#160;</b></p>
<p style="position:absolute;top:150px;left:108px;white-space:nowrap" class="ft047">1.</p>
<p style="position:absolute;top:150px;left:120px;white-space:nowrap" class="ft048">&#160;</p>
<p style="position:absolute;top:150px;left:162px;white-space:nowrap" class="ft051">Kaplan&#160;JE,&#160;Masur&#160;H, Holmes KK, et&#160;al.&#160;USPHS/IDSA guidelines for&#160;the prevention&#160;of&#160;<br/>opportunistic&#160;infections in&#160;persons infected with&#160;human&#160;immunodeficiency&#160;virus: an&#160;overview.&#160;<br/>USPHS/IDSA Prevention&#160;of Opportunistic Infections Working&#160;Group.&#160;</p>
<p style="position:absolute;top:188px;left:632px;white-space:nowrap" class="ft049"><i>Clin&#160;Infect Dis</i></p>
<p style="position:absolute;top:188px;left:729px;white-space:nowrap" class="ft047">.&#160;1995;21&#160;</p>
<p style="position:absolute;top:207px;left:162px;white-space:nowrap" class="ft047">Suppl&#160;1:S12-31. Available at:&#160;</p>
<p style="position:absolute;top:207px;left:362px;white-space:nowrap" class="ft050">https://www.ncbi.nlm.nih.gov/pubmed/8547500</p>
<p style="position:absolute;top:207px;left:680px;white-space:nowrap" class="ft047">.&#160;</p>
<p style="position:absolute;top:243px;left:108px;white-space:nowrap" class="ft047">2.</p>
<p style="position:absolute;top:243px;left:120px;white-space:nowrap" class="ft048">&#160;</p>
<p style="position:absolute;top:243px;left:162px;white-space:nowrap" class="ft047">Bacchetti&#160;P,&#160;Moss&#160;AR. Incubation&#160;period&#160;of AIDS in&#160;San&#160;Francisco.&#160;</p>
<p style="position:absolute;top:243px;left:616px;white-space:nowrap" class="ft049"><i>Nature</i></p>
<p style="position:absolute;top:243px;left:662px;white-space:nowrap" class="ft047">.&#160;</p>
<p style="position:absolute;top:262px;left:162px;white-space:nowrap" class="ft047">1989;338(6212):251-253.&#160;Available&#160;at:&#160;</p>
<p style="position:absolute;top:262px;left:425px;white-space:nowrap" class="ft050">https://www.ncbi.nlm.nih.gov/pubmed/2922052</p>
<p style="position:absolute;top:262px;left:743px;white-space:nowrap" class="ft047">.&#160;</p>
<p style="position:absolute;top:298px;left:108px;white-space:nowrap" class="ft047">3.</p>
<p style="position:absolute;top:298px;left:120px;white-space:nowrap" class="ft048">&#160;</p>
<p style="position:absolute;top:298px;left:162px;white-space:nowrap" class="ft051">Alcabes P,&#160;Munoz A, Vlahov&#160;D, Friedland&#160;GH. Incubation&#160;period&#160;of human&#160;immunodeficiency&#160;<br/>virus.&#160;</p>
<p style="position:absolute;top:317px;left:203px;white-space:nowrap" class="ft049"><i>Epidemiol Rev</i></p>
<p style="position:absolute;top:317px;left:300px;white-space:nowrap" class="ft047">.&#160;1993;15(2):303-318. Available at:&#160;</p>
<p style="position:absolute;top:336px;left:162px;white-space:nowrap" class="ft050">https://www.ncbi.nlm.nih.gov/pubmed/8174659</p>
<p style="position:absolute;top:336px;left:480px;white-space:nowrap" class="ft047">.</p>
<p style="position:absolute;top:373px;left:108px;white-space:nowrap" class="ft047">4.</p>
<p style="position:absolute;top:372px;left:120px;white-space:nowrap" class="ft048">&#160;</p>
<p style="position:absolute;top:373px;left:162px;white-space:nowrap" class="ft051">Bacchetti P,&#160;Osmond&#160;D, Chaisson&#160;RE,&#160;et al.&#160;Survival&#160;patterns of the first 500&#160;patients with&#160;AIDS&#160;<br/>in&#160;San&#160;Francisco.&#160;</p>
<p style="position:absolute;top:392px;left:280px;white-space:nowrap" class="ft049"><i>J Infect Dis</i></p>
<p style="position:absolute;top:392px;left:356px;white-space:nowrap" class="ft047">. 1988;157(5):1044-1047.&#160;Available at:&#160;</p>
<p style="position:absolute;top:410px;left:162px;white-space:nowrap" class="ft050">https://www.ncbi.nlm.nih.gov/pubmed/3258900</p>
<p style="position:absolute;top:410px;left:480px;white-space:nowrap" class="ft047">.&#160;</p>
<p style="position:absolute;top:447px;left:108px;white-space:nowrap" class="ft047">5.</p>
<p style="position:absolute;top:447px;left:120px;white-space:nowrap" class="ft048">&#160;</p>
<p style="position:absolute;top:447px;left:162px;white-space:nowrap" class="ft051">Detels R, Munoz A, McFarlane G, et al.&#160;Effectiveness&#160;of potent&#160;antiretroviral therapy&#160;on&#160;time&#160;to&#160;<br/>AIDS and&#160;death&#160;in&#160;men with&#160;known&#160;HIV infection&#160;duration. Multicenter AIDS&#160;Cohort&#160;Study&#160;<br/>Investigators.&#160;</p>
<p style="position:absolute;top:485px;left:255px;white-space:nowrap" class="ft049"><i>JAMA</i></p>
<p style="position:absolute;top:485px;left:297px;white-space:nowrap" class="ft047">. 1998;280(17):1497-1503.&#160;Available at:&#160;</p>
<p style="position:absolute;top:504px;left:162px;white-space:nowrap" class="ft050">https://www.ncbi.nlm.nih.gov/pubmed/9809730</p>
<p style="position:absolute;top:504px;left:480px;white-space:nowrap" class="ft047">.&#160;</p>
<p style="position:absolute;top:540px;left:108px;white-space:nowrap" class="ft047">6.</p>
<p style="position:absolute;top:540px;left:120px;white-space:nowrap" class="ft048">&#160;</p>
<p style="position:absolute;top:540px;left:162px;white-space:nowrap" class="ft051">Mocroft A,&#160;Vella S,&#160;Benfield&#160;TL, et&#160;al.&#160;Changing&#160;patterns of&#160;mortality&#160;across Europe in&#160;patients&#160;<br/>infected with&#160;HIV-1.&#160;EuroSIDA Study&#160;Group.&#160;</p>
<p style="position:absolute;top:559px;left:472px;white-space:nowrap" class="ft049"><i>Lancet</i></p>
<p style="position:absolute;top:559px;left:517px;white-space:nowrap" class="ft047">. 1998;352(9142):1725-1730. Available at:&#160;</p>
<p style="position:absolute;top:578px;left:162px;white-space:nowrap" class="ft050">https://www.ncbi.nlm.nih.gov/pubmed/9848347</p>
<p style="position:absolute;top:578px;left:480px;white-space:nowrap" class="ft047">.&#160;</p>
<p style="position:absolute;top:614px;left:108px;white-space:nowrap" class="ft047">7.</p>
<p style="position:absolute;top:614px;left:120px;white-space:nowrap" class="ft048">&#160;</p>
<p style="position:absolute;top:614px;left:162px;white-space:nowrap" class="ft051">McNaghten&#160;AD, Hanson&#160;DL,&#160;Jones JL, Dworkin&#160;MS, Ward&#160;JW.&#160;Effects of antiretroviral therapy&#160;<br/>and&#160;opportunistic illness&#160;primary chemoprophylaxis&#160;on&#160;survival after AIDS diagnosis.&#160;<br/>Adult/Adolescent Spectrum of Disease&#160;Group.&#160;</p>
<p style="position:absolute;top:652px;left:473px;white-space:nowrap" class="ft049"><i>AIDS</i></p>
<p style="position:absolute;top:652px;left:509px;white-space:nowrap" class="ft047">. 1999;13(13):1687-1695. Available at:&#160;</p>
<p style="position:absolute;top:671px;left:162px;white-space:nowrap" class="ft050">https://www.ncbi.nlm.nih.gov/pubmed/10509570</p>
<p style="position:absolute;top:671px;left:488px;white-space:nowrap" class="ft047">.&#160;</p>
<p style="position:absolute;top:707px;left:108px;white-space:nowrap" class="ft047">8.</p>
<p style="position:absolute;top:707px;left:120px;white-space:nowrap" class="ft048">&#160;</p>
<p style="position:absolute;top:707px;left:162px;white-space:nowrap" class="ft051">Miller V,&#160;Mocroft&#160;A, Reiss&#160;P,&#160;et al.&#160;Relations among&#160;CD4 lymphocyte count&#160;nadir, antiretroviral&#160;<br/>therapy, and&#160;HIV-1&#160;disease progression: results from the EuroSIDA study.&#160;</p>
<p style="position:absolute;top:726px;left:658px;white-space:nowrap" class="ft049"><i>Ann&#160;Intern&#160;Med</i></p>
<p style="position:absolute;top:726px;left:763px;white-space:nowrap" class="ft047">.&#160;</p>
<p style="position:absolute;top:745px;left:162px;white-space:nowrap" class="ft047">1999;130(7):570-577. Available at:&#160;</p>
<p style="position:absolute;top:745px;left:400px;white-space:nowrap" class="ft050">https://www.ncbi.nlm.nih.gov/pubmed/10189326</p>
<p style="position:absolute;top:745px;left:727px;white-space:nowrap" class="ft047">.&#160;</p>
<p style="position:absolute;top:781px;left:108px;white-space:nowrap" class="ft047">9.</p>
<p style="position:absolute;top:781px;left:120px;white-space:nowrap" class="ft048">&#160;</p>
<p style="position:absolute;top:781px;left:162px;white-space:nowrap" class="ft051">Mocroft A,&#160;Ledergerber B,&#160;Katlama C, et al.&#160;Decline&#160;in&#160;the AIDS and&#160;death&#160;rates in&#160;the&#160;<br/>EuroSIDA study: an&#160;observational study.&#160;</p>
<p style="position:absolute;top:800px;left:438px;white-space:nowrap" class="ft049"><i>Lancet</i></p>
<p style="position:absolute;top:800px;left:483px;white-space:nowrap" class="ft047">.&#160;2003;362(9377):22-29. Available at:&#160;</p>
<p style="position:absolute;top:819px;left:162px;white-space:nowrap" class="ft050">https://www.ncbi.nlm.nih.gov/pubmed/12853195</p>
<p style="position:absolute;top:819px;left:488px;white-space:nowrap" class="ft047">.&#160;</p>
<p style="position:absolute;top:856px;left:108px;white-space:nowrap" class="ft047">10.</p>
<p style="position:absolute;top:855px;left:129px;white-space:nowrap" class="ft048">&#160;</p>
<p style="position:absolute;top:856px;left:162px;white-space:nowrap" class="ft051">Buchacz K, Lau&#160;B, Jing&#160;Y,&#160;et al.&#160;Incidence of&#160;AIDS-defining&#160;opportunistic infections in&#160;a&#160;<br/>multicohort analysis of&#160;HIV-infected&#160;persons in&#160;the&#160;United&#160;States&#160;and&#160;Canada, 2000–2010.&#160;</p>
<p style="position:absolute;top:875px;left:767px;white-space:nowrap" class="ft049"><i>J&#160;</i></p>
<p style="position:absolute;top:894px;left:162px;white-space:nowrap" class="ft049"><i>Infect Dis</i></p>
<p style="position:absolute;top:894px;left:226px;white-space:nowrap" class="ft047">. 2016;214(6):862-872. Available at:&#160;</p>
<p style="position:absolute;top:894px;left:473px;white-space:nowrap" class="ft050">https://www.ncbi.nlm.nih.gov/pubmed/27559122</p>
<p style="position:absolute;top:894px;left:799px;white-space:nowrap" class="ft047">.&#160;</p>
<p style="position:absolute;top:930px;left:108px;white-space:nowrap" class="ft047">11.</p>
<p style="position:absolute;top:929px;left:129px;white-space:nowrap" class="ft048">&#160;</p>
<p style="position:absolute;top:930px;left:162px;white-space:nowrap" class="ft051">Gardner EM,&#160;McLees MP,&#160;Steiner JF, Del Rio&#160;C,&#160;Burman&#160;WJ.&#160;The&#160;spectrum of&#160;engagement&#160;in&#160;<br/>HIV care and&#160;its relevance&#160;to&#160;test-and-treat strategies for prevention of&#160;HIV infection.&#160;</p>
<p style="position:absolute;top:949px;left:732px;white-space:nowrap" class="ft049"><i>Clin Infect&#160;</i></p>
<p style="position:absolute;top:968px;left:162px;white-space:nowrap" class="ft049"><i>Dis</i></p>
<p style="position:absolute;top:968px;left:185px;white-space:nowrap" class="ft047">. 2011;52(6):793-800.&#160;Available&#160;at:&#160;</p>
<p style="position:absolute;top:968px;left:423px;white-space:nowrap" class="ft050">https://www.ncbi.nlm.nih.gov/pubmed/21367734</p>
<p style="position:absolute;top:968px;left:750px;white-space:nowrap" class="ft047">.&#160;</p>
<p style="position:absolute;top:1004px;left:108px;white-space:nowrap" class="ft047">12.</p>
<p style="position:absolute;top:1004px;left:129px;white-space:nowrap" class="ft048">&#160;</p>
<p style="position:absolute;top:1004px;left:162px;white-space:nowrap" class="ft051">Ives NJ, Gazzard&#160;BG, Easterbrook&#160;PJ.&#160;The changing&#160;pattern&#160;of AIDS-defining&#160;illnesses with&#160;the&#160;<br/>introduction&#160;of highly&#160;active antiretroviral therapy&#160;(HAART) in&#160;a&#160;London&#160;clinic.&#160;</p>
<p style="position:absolute;top:1023px;left:699px;white-space:nowrap" class="ft049"><i>J Infect</i></p>
<p style="position:absolute;top:1023px;left:747px;white-space:nowrap" class="ft047">.&#160;</p>
<p style="position:absolute;top:1042px;left:162px;white-space:nowrap" class="ft047">2001;42(2):134-139.&#160;Available at:&#160;</p>
<p style="position:absolute;top:1042px;left:392px;white-space:nowrap" class="ft050">https://www.ncbi.nlm.nih.gov/pubmed/11531320</p>
<p style="position:absolute;top:1042px;left:718px;white-space:nowrap" class="ft047">.&#160;</p>
</div>
<!-- Page 13 -->
<a name="13"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page13-div" style="position:relative;width:917px;height:1187px;">
<p style="position:absolute;top:1117px;left:108px;white-space:nowrap" class="ft024"><i>Guidelines for the Prevention and Treatment&#160;of&#160;Opportunistic&#160;Infections in Adults&#160;and Adolescents&#160;With HIV&#160;</i></p>
<p style="position:absolute;top:1117px;left:791px;white-space:nowrap" class="ft024"><i>A-8</i></p>
<p style="position:absolute;top:1117px;left:810px;white-space:nowrap" class="ft041">&#160;</p>
<p style="position:absolute;top:109px;left:108px;white-space:nowrap" class="ft047">13.</p>
<p style="position:absolute;top:108px;left:129px;white-space:nowrap" class="ft048">&#160;</p>
<p style="position:absolute;top:109px;left:162px;white-space:nowrap" class="ft047">Coelho&#160;L,&#160;Veloso VG,&#160;Grinsztejn&#160;B, Luz PM.&#160;Trends in&#160;overall&#160;opportunistic illnesses,&#160;</p>
<p style="position:absolute;top:128px;left:162px;white-space:nowrap" class="ft049"><i>Pneumocystis&#160;carinii</i></p>
<p style="position:absolute;top:128px;left:301px;white-space:nowrap" class="ft047">&#160;pneumonia, cerebral toxoplasmosis and&#160;</p>
<p style="position:absolute;top:128px;left:570px;white-space:nowrap" class="ft049"><i>Mycobacterium avium&#160;</i></p>
<p style="position:absolute;top:128px;left:722px;white-space:nowrap" class="ft047">complex&#160;</p>
<p style="position:absolute;top:147px;left:162px;white-space:nowrap" class="ft047">incidence rates over&#160;the 30 years of&#160;the HIV epidemic: a systematic review.&#160;</p>
<p style="position:absolute;top:147px;left:665px;white-space:nowrap" class="ft049"><i>Braz J Infect Dis</i></p>
<p style="position:absolute;top:147px;left:776px;white-space:nowrap" class="ft047">.&#160;</p>
<p style="position:absolute;top:166px;left:162px;white-space:nowrap" class="ft047">2014;18(2):196-210.&#160;Available at:&#160;</p>
<p style="position:absolute;top:166px;left:392px;white-space:nowrap" class="ft050">https://www.ncbi.nlm.nih.gov/pubmed/24275372</p>
<p style="position:absolute;top:166px;left:718px;white-space:nowrap" class="ft047">.&#160;</p>
<p style="position:absolute;top:202px;left:108px;white-space:nowrap" class="ft047">14.</p>
<p style="position:absolute;top:202px;left:129px;white-space:nowrap" class="ft048">&#160;</p>
<p style="position:absolute;top:202px;left:162px;white-space:nowrap" class="ft051">Rubaihayo&#160;J,&#160;Tumwesigye&#160;NM,&#160;Konde-Lule J. Trends in&#160;prevalence of&#160;selected&#160;opportunistic&#160;<br/>infections associated&#160;with&#160;HIV/AIDS in&#160;Uganda.&#160;</p>
<p style="position:absolute;top:221px;left:489px;white-space:nowrap" class="ft049"><i>BMC Infect Dis</i></p>
<p style="position:absolute;top:221px;left:593px;white-space:nowrap" class="ft047">.&#160;2015;15:187.&#160;Available&#160;at:&#160;</p>
<p style="position:absolute;top:240px;left:162px;white-space:nowrap" class="ft050">https://www.ncbi.nlm.nih.gov/pubmed/25879621</p>
<p style="position:absolute;top:240px;left:488px;white-space:nowrap" class="ft047">.&#160;</p>
<p style="position:absolute;top:276px;left:108px;white-space:nowrap" class="ft047">15.</p>
<p style="position:absolute;top:276px;left:129px;white-space:nowrap" class="ft048">&#160;</p>
<p style="position:absolute;top:276px;left:162px;white-space:nowrap" class="ft051">Centers for Disease Control and&#160;Prevention. Monitoring&#160;selected&#160;national HIV prevention&#160;and&#160;<br/>care objectives by&#160;using&#160;HIV surveillance data—United&#160;States and&#160;6 territories and&#160;freely&#160;<br/>associated&#160;states, 2022.&#160;</p>
<p style="position:absolute;top:314px;left:320px;white-space:nowrap" class="ft049"><i>HIV Surveillance&#160;Supplemental Report</i></p>
<p style="position:absolute;top:314px;left:577px;white-space:nowrap" class="ft047">. 2024;29(2). Available at:&#160;</p>
<p style="position:absolute;top:333px;left:162px;white-space:nowrap" class="ft050">https://www.cdc.gov/hiv-data/nhss/national-hiv-prevention-and-care-outcomes.html</p>
<p style="position:absolute;top:333px;left:718px;white-space:nowrap" class="ft047">.&#160;</p>
<p style="position:absolute;top:369px;left:108px;white-space:nowrap" class="ft047">16.</p>
<p style="position:absolute;top:369px;left:129px;white-space:nowrap" class="ft048">&#160;</p>
<p style="position:absolute;top:369px;left:162px;white-space:nowrap" class="ft051">Centers for&#160;Disease Control and&#160;Prevention. Estimated&#160;HIV incidence and&#160;prevalence in&#160;the&#160;<br/>United&#160;States, 2018–2022.&#160;</p>
<p style="position:absolute;top:388px;left:341px;white-space:nowrap" class="ft049"><i>HIV Surveillance Supplemental Report</i></p>
<p style="position:absolute;top:388px;left:598px;white-space:nowrap" class="ft047">.&#160;2024;29(1). Available at:&#160;</p>
<p style="position:absolute;top:407px;left:162px;white-space:nowrap" class="ft050">https://www.cdc.gov/hiv-data/nhss/estimated-hiv-incidence-and-prevalence.html</p>
<p style="position:absolute;top:407px;left:696px;white-space:nowrap" class="ft047">.&#160;</p>
<p style="position:absolute;top:443px;left:108px;white-space:nowrap" class="ft047">17.</p>
<p style="position:absolute;top:443px;left:129px;white-space:nowrap" class="ft048">&#160;</p>
<p style="position:absolute;top:443px;left:162px;white-space:nowrap" class="ft051">Kelly&#160;C,&#160;Gaskell KM,&#160;Richardson&#160;M,&#160;Klein&#160;N, Garner P, MacPherson&#160;P.&#160;Discordant&#160;immune&#160;<br/>response with&#160;antiretroviral therapy&#160;in&#160;HIV-1:&#160;a systematic review of&#160;clinical outcomes.</p>
<p style="position:absolute;top:462px;left:746px;white-space:nowrap" class="ft049"><i>PLoS</i></p>
<p style="position:absolute;top:481px;left:162px;white-space:nowrap" class="ft049"><i>One</i></p>
<p style="position:absolute;top:481px;left:189px;white-space:nowrap" class="ft047">.&#160;2016;11(6):e0156099.&#160;Available at:&#160;</p>
<p style="position:absolute;top:481px;left:438px;white-space:nowrap" class="ft050">https://www.ncbi.nlm.nih.gov/pubmed/27284683</p>
<p style="position:absolute;top:481px;left:764px;white-space:nowrap" class="ft047">.&#160;</p>
<p style="position:absolute;top:517px;left:108px;white-space:nowrap" class="ft047">18.</p>
<p style="position:absolute;top:517px;left:129px;white-space:nowrap" class="ft048">&#160;</p>
<p style="position:absolute;top:517px;left:162px;white-space:nowrap" class="ft051">Sonnenberg P, Glynn&#160;JR,&#160;Fielding&#160;K,&#160;Murray&#160;J, Godfrey-Faussett P,&#160;Shearer S. How soon&#160;after&#160;<br/>infection&#160;with HIV&#160;does the&#160;risk&#160;of tuberculosis start to&#160;increase? A retrospective cohort study&#160;in&#160;<br/>South&#160;African&#160;gold&#160;miners.&#160;</p>
<p style="position:absolute;top:555px;left:346px;white-space:nowrap" class="ft049"><i>J Infect Dis</i></p>
<p style="position:absolute;top:555px;left:422px;white-space:nowrap" class="ft047">.&#160;2005;191(2):150-158. Available at:&#160;</p>
<p style="position:absolute;top:574px;left:162px;white-space:nowrap" class="ft050">https://www.ncbi.nlm.nih.gov/pubmed/15609223</p>
<p style="position:absolute;top:574px;left:488px;white-space:nowrap" class="ft047">.&#160;</p>
<p style="position:absolute;top:611px;left:108px;white-space:nowrap" class="ft047">19.</p>
<p style="position:absolute;top:610px;left:129px;white-space:nowrap" class="ft048">&#160;</p>
<p style="position:absolute;top:611px;left:162px;white-space:nowrap" class="ft051">Wood&#160;R,&#160;Maartens G,&#160;Lombard&#160;CJ. Risk factors for developing tuberculosis in&#160;HIV-1-infected&#160;<br/>adults from communities&#160;with&#160;a low or&#160;very&#160;high incidence of tuberculosis.&#160;</p>
<p style="position:absolute;top:630px;left:662px;white-space:nowrap" class="ft049"><i>J Acquir Immune&#160;</i></p>
<p style="position:absolute;top:649px;left:162px;white-space:nowrap" class="ft049"><i>Defic Syndr</i></p>
<p style="position:absolute;top:649px;left:240px;white-space:nowrap" class="ft047">. 2000;23(1):75-80.&#160;Available at:&#160;</p>
<p style="position:absolute;top:649px;left:462px;white-space:nowrap" class="ft050">https://www.ncbi.nlm.nih.gov/pubmed/10708059</p>
<p style="position:absolute;top:649px;left:788px;white-space:nowrap" class="ft047">.&#160;</p>
<p style="position:absolute;top:685px;left:108px;white-space:nowrap" class="ft047">20.</p>
<p style="position:absolute;top:685px;left:129px;white-space:nowrap" class="ft048">&#160;</p>
<p style="position:absolute;top:685px;left:162px;white-space:nowrap" class="ft051">Wallace&#160;JM,&#160;Hansen NI,&#160;Lavange L,&#160;et al.&#160;Respiratory&#160;disease trends in&#160;the Pulmonary&#160;<br/>Complications of&#160;HIV Infection&#160;Study&#160;cohort.&#160;Pulmonary&#160;Complications of HIV Infection&#160;Study&#160;<br/>Group.&#160;</p>
<p style="position:absolute;top:723px;left:212px;white-space:nowrap" class="ft049"><i>Am J Respir Crit Care Med</i></p>
<p style="position:absolute;top:723px;left:394px;white-space:nowrap" class="ft047">.&#160;1997;155(1):72-80. Available at:&#160;</p>
<p style="position:absolute;top:742px;left:162px;white-space:nowrap" class="ft050">https://www.ncbi.nlm.nih.gov/pubmed/9001292</p>
<p style="position:absolute;top:742px;left:480px;white-space:nowrap" class="ft047">.&#160;</p>
<p style="position:absolute;top:778px;left:108px;white-space:nowrap" class="ft047">21.</p>
<p style="position:absolute;top:778px;left:129px;white-space:nowrap" class="ft048">&#160;</p>
<p style="position:absolute;top:778px;left:162px;white-space:nowrap" class="ft051">Hirschtick&#160;RE,&#160;Glassroth&#160;J, Jordan&#160;MC,&#160;et al.&#160;Bacterial pneumonia in&#160;persons infected&#160;with&#160;the&#160;<br/>human&#160;immunodeficiency&#160;virus. Pulmonary&#160;Complications of HIV Infection&#160;Study&#160;Group.&#160;</p>
<p style="position:absolute;top:797px;left:765px;white-space:nowrap" class="ft049"><i>N&#160;</i></p>
<p style="position:absolute;top:816px;left:162px;white-space:nowrap" class="ft049"><i>Engl J Med</i></p>
<p style="position:absolute;top:816px;left:238px;white-space:nowrap" class="ft047">.&#160;1995;333(13):845-851. Available at:&#160;</p>
<p style="position:absolute;top:835px;left:162px;white-space:nowrap" class="ft050">https://www.ncbi.nlm.nih.gov/pubmed/7651475</p>
<p style="position:absolute;top:835px;left:480px;white-space:nowrap" class="ft047">.&#160;</p>
<p style="position:absolute;top:871px;left:108px;white-space:nowrap" class="ft047">22.</p>
<p style="position:absolute;top:871px;left:129px;white-space:nowrap" class="ft048">&#160;</p>
<p style="position:absolute;top:871px;left:162px;white-space:nowrap" class="ft051">Engels EA, Rosenberg&#160;PS,&#160;Biggar RJ. Zoster incidence in&#160;human&#160;immunodeficiency&#160;virus-<br/>infected&#160;hemophiliacs and&#160;homosexual men,&#160;1984–1997. District&#160;of Columbia&#160;Gay Cohort Study.&#160;<br/>Multicenter Hemophilia Cohort Study.&#160;</p>
<p style="position:absolute;top:909px;left:422px;white-space:nowrap" class="ft049"><i>J Infect Dis</i></p>
<p style="position:absolute;top:909px;left:497px;white-space:nowrap" class="ft047">.&#160;1999;180(6):1784-1789.&#160;Available at:&#160;</p>
<p style="position:absolute;top:928px;left:162px;white-space:nowrap" class="ft050">https://www.ncbi.nlm.nih.gov/pubmed/10558932</p>
<p style="position:absolute;top:928px;left:488px;white-space:nowrap" class="ft047">.&#160;</p>
<p style="position:absolute;top:964px;left:108px;white-space:nowrap" class="ft047">23.</p>
<p style="position:absolute;top:964px;left:129px;white-space:nowrap" class="ft048">&#160;</p>
<p style="position:absolute;top:964px;left:162px;white-space:nowrap" class="ft051">Gebo&#160;KA, Kalyani&#160;R,&#160;Moore&#160;RD, Polydefkis MJ. The incidence of,&#160;risk&#160;factors for, and&#160;sequelae&#160;<br/>of herpes zoster among&#160;HIV patients in&#160;the highly active antiretroviral therapy&#160;era.&#160;</p>
<p style="position:absolute;top:983px;left:711px;white-space:nowrap" class="ft049"><i>J Acquir&#160;</i></p>
<p style="position:absolute;top:1002px;left:162px;white-space:nowrap" class="ft049"><i>Immune Defic Syndr</i></p>
<p style="position:absolute;top:1002px;left:298px;white-space:nowrap" class="ft047">. 2005;40(2):169-174. Available at:&#160;</p>
<p style="position:absolute;top:1021px;left:162px;white-space:nowrap" class="ft050">https://www.ncbi.nlm.nih.gov/pubmed/16186734</p>
<p style="position:absolute;top:1021px;left:488px;white-space:nowrap" class="ft047">.&#160;</p>
</div>
<!-- Page 14 -->
<a name="14"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page14-div" style="position:relative;width:917px;height:1187px;">
<p style="position:absolute;top:1117px;left:108px;white-space:nowrap" class="ft024"><i>Guidelines for the Prevention and Treatment&#160;of&#160;Opportunistic&#160;Infections in Adults&#160;and Adolescents&#160;With HIV&#160;</i></p>
<p style="position:absolute;top:1117px;left:791px;white-space:nowrap" class="ft024"><i>A-9</i></p>
<p style="position:absolute;top:1117px;left:810px;white-space:nowrap" class="ft041">&#160;</p>
<p style="position:absolute;top:109px;left:108px;white-space:nowrap" class="ft047">24.</p>
<p style="position:absolute;top:108px;left:129px;white-space:nowrap" class="ft048">&#160;</p>
<p style="position:absolute;top:109px;left:162px;white-space:nowrap" class="ft051">Vanhems P,&#160;Voisin&#160;L,&#160;Gayet-Ageron&#160;A, et&#160;al.&#160;The incidence of herpes zoster is&#160;less&#160;likely&#160;than&#160;<br/>other opportunistic infections to&#160;be reduced by&#160;highly&#160;active antiretroviral therapy.&#160;</p>
<p style="position:absolute;top:128px;left:711px;white-space:nowrap" class="ft049"><i>J Acquir&#160;</i></p>
<p style="position:absolute;top:147px;left:162px;white-space:nowrap" class="ft049"><i>Immune Defic Syndr</i></p>
<p style="position:absolute;top:147px;left:298px;white-space:nowrap" class="ft047">. 2005;38(1):111-113. Available at:&#160;</p>
<p style="position:absolute;top:166px;left:162px;white-space:nowrap" class="ft050">https://www.ncbi.nlm.nih.gov/pubmed/15608535</p>
<p style="position:absolute;top:166px;left:488px;white-space:nowrap" class="ft047">.&#160;</p>
<p style="position:absolute;top:202px;left:108px;white-space:nowrap" class="ft047">25.</p>
<p style="position:absolute;top:202px;left:129px;white-space:nowrap" class="ft048">&#160;</p>
<p style="position:absolute;top:202px;left:162px;white-space:nowrap" class="ft051">Toossi&#160;Z,&#160;Mayanja-Kizza&#160;H, Hirsch&#160;CS,&#160;et al.&#160;Impact&#160;of tuberculosis (TB) on&#160;HIV-1&#160;activity&#160;in&#160;<br/>dually&#160;infected patients.&#160;</p>
<p style="position:absolute;top:221px;left:324px;white-space:nowrap" class="ft049"><i>Clin&#160;Exp&#160;Immunol</i></p>
<p style="position:absolute;top:221px;left:445px;white-space:nowrap" class="ft047">. 2001;123(2):233-238.&#160;Available at:&#160;</p>
<p style="position:absolute;top:240px;left:162px;white-space:nowrap" class="ft050">https://www.ncbi.nlm.nih.gov/pubmed/11207653</p>
<p style="position:absolute;top:240px;left:488px;white-space:nowrap" class="ft047">.&#160;</p>
<p style="position:absolute;top:276px;left:108px;white-space:nowrap" class="ft047">26.</p>
<p style="position:absolute;top:276px;left:129px;white-space:nowrap" class="ft048">&#160;</p>
<p style="position:absolute;top:276px;left:162px;white-space:nowrap" class="ft051">Sadiq&#160;ST,&#160;McSorley&#160;J, Copas AJ,&#160;et al.&#160;The effects&#160;of&#160;early&#160;syphilis on&#160;CD4&#160;counts and&#160;HIV-1&#160;<br/>RNA viral loads in&#160;blood&#160;and&#160;semen.&#160;</p>
<p style="position:absolute;top:295px;left:411px;white-space:nowrap" class="ft049"><i>Sex Transm Infect</i></p>
<p style="position:absolute;top:295px;left:530px;white-space:nowrap" class="ft047">. 2005;81(5):380-385. Available at:&#160;</p>
<p style="position:absolute;top:314px;left:162px;white-space:nowrap" class="ft050">https://www.ncbi.nlm.nih.gov/pubmed/16199736</p>
<p style="position:absolute;top:314px;left:488px;white-space:nowrap" class="ft047">.&#160;</p>
<p style="position:absolute;top:350px;left:108px;white-space:nowrap" class="ft047">27.</p>
<p style="position:absolute;top:350px;left:129px;white-space:nowrap" class="ft048">&#160;</p>
<p style="position:absolute;top:350px;left:162px;white-space:nowrap" class="ft047">Bentwich Z.&#160;Concurrent infections that rise the HIV viral load.&#160;</p>
<p style="position:absolute;top:350px;left:580px;white-space:nowrap" class="ft049"><i>J HIV Ther</i></p>
<p style="position:absolute;top:350px;left:655px;white-space:nowrap" class="ft047">. 2003;8(3):72-75.&#160;</p>
<p style="position:absolute;top:369px;left:162px;white-space:nowrap" class="ft047">Available at:&#160;</p>
<p style="position:absolute;top:369px;left:251px;white-space:nowrap" class="ft050">https://www.ncbi.nlm.nih.gov/pubmed/12951545</p>
<p style="position:absolute;top:369px;left:577px;white-space:nowrap" class="ft047">.&#160;</p>
<p style="position:absolute;top:405px;left:108px;white-space:nowrap" class="ft047">28.</p>
<p style="position:absolute;top:405px;left:129px;white-space:nowrap" class="ft048">&#160;</p>
<p style="position:absolute;top:405px;left:162px;white-space:nowrap" class="ft047">Kublin&#160;JG, Patnaik&#160;P,&#160;Jere&#160;CS,&#160;et al.&#160;Effect of&#160;</p>
<p style="position:absolute;top:405px;left:467px;white-space:nowrap" class="ft049"><i>Plasmodium falciparum</i></p>
<p style="position:absolute;top:405px;left:626px;white-space:nowrap" class="ft047">&#160;malaria on&#160;concentration&#160;</p>
<p style="position:absolute;top:424px;left:162px;white-space:nowrap" class="ft047">of HIV-1-RNA in&#160;the blood&#160;of adults in&#160;rural Malawi:&#160;a prospective cohort study.&#160;</p>
<p style="position:absolute;top:424px;left:705px;white-space:nowrap" class="ft049"><i>Lancet</i></p>
<p style="position:absolute;top:424px;left:749px;white-space:nowrap" class="ft047">.&#160;</p>
<p style="position:absolute;top:443px;left:162px;white-space:nowrap" class="ft047">2005;365(9455):233-240.&#160;Available&#160;at:&#160;</p>
<p style="position:absolute;top:443px;left:425px;white-space:nowrap" class="ft050">https://www.ncbi.nlm.nih.gov/pubmed/15652606</p>
<p style="position:absolute;top:443px;left:751px;white-space:nowrap" class="ft047">.&#160;</p>
<p style="position:absolute;top:480px;left:108px;white-space:nowrap" class="ft047">29.</p>
<p style="position:absolute;top:479px;left:129px;white-space:nowrap" class="ft048">&#160;</p>
<p style="position:absolute;top:480px;left:162px;white-space:nowrap" class="ft051">Abu-Raddad&#160;LJ,&#160;Patnaik&#160;P, Kublin&#160;JG.&#160;Dual&#160;infection&#160;with&#160;HIV and&#160;malaria fuels the spread&#160;of&#160;<br/>both&#160;diseases&#160;in&#160;sub-Saharan&#160;Africa.&#160;</p>
<p style="position:absolute;top:499px;left:406px;white-space:nowrap" class="ft049"><i>Science</i></p>
<p style="position:absolute;top:499px;left:457px;white-space:nowrap" class="ft047">. 2006;314(5805):1603-1606.&#160;Available at:&#160;</p>
<p style="position:absolute;top:517px;left:162px;white-space:nowrap" class="ft050">https://www.ncbi.nlm.nih.gov/pubmed/17158329</p>
<p style="position:absolute;top:517px;left:488px;white-space:nowrap" class="ft047">.&#160;</p>
<p style="position:absolute;top:554px;left:108px;white-space:nowrap" class="ft047">30.</p>
<p style="position:absolute;top:553px;left:129px;white-space:nowrap" class="ft048">&#160;</p>
<p style="position:absolute;top:554px;left:162px;white-space:nowrap" class="ft047">Centers for Disease Control and&#160;Prevention. Guidelines for prophylaxis against&#160;</p>
<p style="position:absolute;top:554px;left:689px;white-space:nowrap" class="ft049"><i>Pneumocystis&#160;</i></p>
<p style="position:absolute;top:573px;left:162px;white-space:nowrap" class="ft049"><i>carinii</i></p>
<p style="position:absolute;top:573px;left:206px;white-space:nowrap" class="ft047">&#160;pneumonia for persons infected&#160;with&#160;human&#160;immunodeficiency&#160;virus.&#160;</p>
<p style="position:absolute;top:573px;left:674px;white-space:nowrap" class="ft049"><i>MMWR Suppl</i></p>
<p style="position:absolute;top:573px;left:767px;white-space:nowrap" class="ft047">.&#160;</p>
<p style="position:absolute;top:592px;left:162px;white-space:nowrap" class="ft047">1989;38(5):1-9. Available at:&#160;</p>
<p style="position:absolute;top:592px;left:359px;white-space:nowrap" class="ft050">https://www.ncbi.nlm.nih.gov/pubmed/2524643</p>
<p style="position:absolute;top:592px;left:677px;white-space:nowrap" class="ft047">.&#160;</p>
<p style="position:absolute;top:628px;left:108px;white-space:nowrap" class="ft047">31.</p>
<p style="position:absolute;top:628px;left:129px;white-space:nowrap" class="ft048">&#160;</p>
<p style="position:absolute;top:628px;left:162px;white-space:nowrap" class="ft047">Masur&#160;H. Recommendations on&#160;prophylaxis and&#160;therapy&#160;for&#160;disseminated&#160;</p>
<p style="position:absolute;top:628px;left:653px;white-space:nowrap" class="ft049"><i>Mycobacterium avium</i></p>
<p style="position:absolute;top:628px;left:801px;white-space:nowrap" class="ft047">&#160;</p>
<p style="position:absolute;top:647px;left:162px;white-space:nowrap" class="ft051">complex&#160;disease in&#160;patients infected&#160;with&#160;the human&#160;immunodeficiency&#160;virus. Public Health&#160;<br/>Service Task&#160;Force&#160;on&#160;Prophylaxis and&#160;Therapy&#160;for&#160;</p>
<p style="position:absolute;top:666px;left:507px;white-space:nowrap" class="ft049"><i>Mycobacterium avium</i></p>
<p style="position:absolute;top:666px;left:655px;white-space:nowrap" class="ft047">&#160;Complex.&#160;</p>
<p style="position:absolute;top:666px;left:728px;white-space:nowrap" class="ft049"><i>N Engl J&#160;</i></p>
<p style="position:absolute;top:685px;left:162px;white-space:nowrap" class="ft049"><i>Med</i></p>
<p style="position:absolute;top:685px;left:191px;white-space:nowrap" class="ft047">.&#160;1993;329(12):898-904. Available at:&#160;</p>
<p style="position:absolute;top:685px;left:446px;white-space:nowrap" class="ft050">https://www.ncbi.nlm.nih.gov/pubmed/8395019</p>
<p style="position:absolute;top:685px;left:764px;white-space:nowrap" class="ft047">.&#160;</p>
<p style="position:absolute;top:721px;left:108px;white-space:nowrap" class="ft047">32.</p>
<p style="position:absolute;top:721px;left:129px;white-space:nowrap" class="ft048">&#160;</p>
<p style="position:absolute;top:721px;left:162px;white-space:nowrap" class="ft051">USPHS/IDSA guidelines&#160;for the prevention&#160;of opportunistic infections in&#160;persons infected with&#160;<br/>human&#160;immunodeficiency&#160;virus: a summary.&#160;</p>
<p style="position:absolute;top:740px;left:461px;white-space:nowrap" class="ft049"><i>MMWR&#160;Recomm&#160;Rep</i></p>
<p style="position:absolute;top:740px;left:603px;white-space:nowrap" class="ft047">.&#160;1995;44(RR-8):1-34.&#160;</p>
<p style="position:absolute;top:759px;left:162px;white-space:nowrap" class="ft047">Available at:&#160;</p>
<p style="position:absolute;top:759px;left:251px;white-space:nowrap" class="ft050">https://www.ncbi.nlm.nih.gov/pubmed/7565547</p>
<p style="position:absolute;top:759px;left:569px;white-space:nowrap" class="ft047">.&#160;</p>
<p style="position:absolute;top:795px;left:108px;white-space:nowrap" class="ft047">33.</p>
<p style="position:absolute;top:795px;left:129px;white-space:nowrap" class="ft048">&#160;</p>
<p style="position:absolute;top:795px;left:162px;white-space:nowrap" class="ft051">USPHS/IDSA guidelines&#160;for the prevention&#160;of opportunistic infections in&#160;persons infected with&#160;<br/>human&#160;immunodeficiency&#160;virus: disease-specific recommendations. USPHS/IDSA Prevention of&#160;<br/>Opportunistic&#160;Infections Working Group.&#160;</p>
<p style="position:absolute;top:833px;left:440px;white-space:nowrap" class="ft049"><i>Clin&#160;Infect&#160;Dis</i></p>
<p style="position:absolute;top:833px;left:537px;white-space:nowrap" class="ft047">.&#160;1995;21&#160;Suppl&#160;1:S32-43.&#160;Available at:&#160;</p>
<p style="position:absolute;top:852px;left:162px;white-space:nowrap" class="ft050">https://www.ncbi.nlm.nih.gov/pubmed/8547510</p>
<p style="position:absolute;top:852px;left:480px;white-space:nowrap" class="ft047">.&#160;</p>
<p style="position:absolute;top:888px;left:108px;white-space:nowrap" class="ft047">34.</p>
<p style="position:absolute;top:888px;left:129px;white-space:nowrap" class="ft048">&#160;</p>
<p style="position:absolute;top:888px;left:162px;white-space:nowrap" class="ft051">1997&#160;USPHS/IDSA guidelines for&#160;the prevention&#160;of&#160;opportunistic infections in&#160;persons infected&#160;<br/>with&#160;HIV: part I.&#160;prevention&#160;of exposure.&#160;U.S.&#160;Department&#160;of Health&#160;and&#160;Human&#160;Services, Public&#160;<br/>Health&#160;Service, Centers for&#160;Disease Control and&#160;Prevention.&#160;</p>
<p style="position:absolute;top:926px;left:563px;white-space:nowrap" class="ft049"><i>Am Fam Physician</i></p>
<p style="position:absolute;top:926px;left:688px;white-space:nowrap" class="ft047">. 1997;56(3):823-</p>
<p style="position:absolute;top:945px;left:162px;white-space:nowrap" class="ft047">834.&#160;Available at:&#160;</p>
<p style="position:absolute;top:945px;left:284px;white-space:nowrap" class="ft050">https://www.ncbi.nlm.nih.gov/pubmed/9301575</p>
<p style="position:absolute;top:945px;left:602px;white-space:nowrap" class="ft047">.&#160;</p>
<p style="position:absolute;top:982px;left:108px;white-space:nowrap" class="ft047">35.</p>
<p style="position:absolute;top:981px;left:129px;white-space:nowrap" class="ft048">&#160;</p>
<p style="position:absolute;top:982px;left:162px;white-space:nowrap" class="ft051">1999&#160;USPHS/IDSA guidelines for&#160;the prevention&#160;of&#160;opportunistic infections in&#160;persons infected&#160;<br/>with&#160;human&#160;immunodeficiency&#160;virus. U.S.&#160;Public Health&#160;Service (USPHS)&#160;and&#160;Infectious&#160;<br/>Diseases Society&#160;of America (IDSA).&#160;</p>
<p style="position:absolute;top:1019px;left:414px;white-space:nowrap" class="ft049"><i>MMWR Recomm Rep</i></p>
<p style="position:absolute;top:1019px;left:556px;white-space:nowrap" class="ft047">.&#160;1999;48(RR-10):1-59,&#160;61-56.&#160;</p>
<p style="position:absolute;top:1038px;left:162px;white-space:nowrap" class="ft047">Available at:&#160;</p>
<p style="position:absolute;top:1038px;left:251px;white-space:nowrap" class="ft050">https://www.ncbi.nlm.nih.gov/pubmed/10499670</p>
<p style="position:absolute;top:1038px;left:577px;white-space:nowrap" class="ft047">.&#160;</p>
</div>
<!-- Page 15 -->
<a name="15"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page15-div" style="position:relative;width:917px;height:1187px;">
<p style="position:absolute;top:1117px;left:108px;white-space:nowrap" class="ft024"><i>Guidelines for the Prevention and Treatment&#160;of&#160;Opportunistic&#160;Infections in Adults&#160;and Adolescents&#160;With HIV&#160;</i></p>
<p style="position:absolute;top:1117px;left:784px;white-space:nowrap" class="ft024"><i>A-10</i></p>
<p style="position:absolute;top:1117px;left:810px;white-space:nowrap" class="ft041">&#160;</p>
<p style="position:absolute;top:109px;left:108px;white-space:nowrap" class="ft047">36.</p>
<p style="position:absolute;top:108px;left:129px;white-space:nowrap" class="ft048">&#160;</p>
<p style="position:absolute;top:109px;left:162px;white-space:nowrap" class="ft051">Kaplan&#160;JE,&#160;Masur&#160;H, Holmes KK, U.S.&#160;Public Health&#160;Service, Infectious Disease Society&#160;of&#160;<br/>America.&#160;Guidelines&#160;for preventing&#160;opportunistic infections among&#160;HIV-infected&#160;persons—2002.&#160;<br/>Recommendations of&#160;the U.S. Public Health&#160;Service and&#160;the Infectious Diseases&#160;Society&#160;of&#160;<br/>America.&#160;</p>
<p style="position:absolute;top:166px;left:227px;white-space:nowrap" class="ft049"><i>MMWR Recomm Rep</i></p>
<p style="position:absolute;top:166px;left:369px;white-space:nowrap" class="ft047">. 2002;51(RR-8):1-52. Available at:&#160;</p>
<p style="position:absolute;top:185px;left:162px;white-space:nowrap" class="ft050">https://www.ncbi.nlm.nih.gov/pubmed/12081007</p>
<p style="position:absolute;top:185px;left:488px;white-space:nowrap" class="ft047">.&#160;</p>
<p style="position:absolute;top:221px;left:108px;white-space:nowrap" class="ft047">37.</p>
<p style="position:absolute;top:221px;left:129px;white-space:nowrap" class="ft048">&#160;</p>
<p style="position:absolute;top:221px;left:162px;white-space:nowrap" class="ft051">Kaplan&#160;JE,&#160;Masur&#160;H, Jaffe&#160;HW,&#160;Holmes&#160;KK.&#160;Preventing&#160;opportunistic infections in&#160;persons&#160;<br/>infected with&#160;HIV: 1997&#160;guidelines.&#160;</p>
<p style="position:absolute;top:240px;left:404px;white-space:nowrap" class="ft049"><i>JAMA</i></p>
<p style="position:absolute;top:240px;left:445px;white-space:nowrap" class="ft047">.&#160;1997;278(4):337-338.&#160;Available at:&#160;</p>
<p style="position:absolute;top:259px;left:162px;white-space:nowrap" class="ft050">https://www.ncbi.nlm.nih.gov/pubmed/9228443</p>
<p style="position:absolute;top:259px;left:480px;white-space:nowrap" class="ft047">.&#160;</p>
<p style="position:absolute;top:295px;left:108px;white-space:nowrap" class="ft047">38.</p>
<p style="position:absolute;top:295px;left:129px;white-space:nowrap" class="ft048">&#160;</p>
<p style="position:absolute;top:295px;left:162px;white-space:nowrap" class="ft051">1999&#160;USPHS/IDSA guidelines for&#160;the prevention&#160;of&#160;opportunistic infections in&#160;persons infected&#160;<br/>with&#160;human&#160;immunodeficiency&#160;virus.&#160;</p>
<p style="position:absolute;top:314px;left:413px;white-space:nowrap" class="ft049"><i>Clin&#160;Infect Dis</i></p>
<p style="position:absolute;top:314px;left:510px;white-space:nowrap" class="ft047">. 2000;30&#160;Suppl 1:S29-65.&#160;Available at:&#160;</p>
<p style="position:absolute;top:333px;left:162px;white-space:nowrap" class="ft050">https://www.ncbi.nlm.nih.gov/pubmed/10770913</p>
<p style="position:absolute;top:333px;left:488px;white-space:nowrap" class="ft047">.&#160;</p>
<p style="position:absolute;top:369px;left:108px;white-space:nowrap" class="ft047">39.</p>
<p style="position:absolute;top:369px;left:129px;white-space:nowrap" class="ft048">&#160;</p>
<p style="position:absolute;top:369px;left:162px;white-space:nowrap" class="ft051">USPHS/IDSA guidelines&#160;for the prevention&#160;of opportunistic infections in&#160;persons infected with&#160;<br/>human&#160;immunodeficiency&#160;virus: a summary.&#160;</p>
<p style="position:absolute;top:388px;left:461px;white-space:nowrap" class="ft049"><i>Ann&#160;Intern Med</i></p>
<p style="position:absolute;top:388px;left:566px;white-space:nowrap" class="ft047">.&#160;1996;124(3):349-368.&#160;Available at:&#160;</p>
<p style="position:absolute;top:407px;left:162px;white-space:nowrap" class="ft050">https://www.ncbi.nlm.nih.gov/pubmed/8554235</p>
<p style="position:absolute;top:407px;left:480px;white-space:nowrap" class="ft047">.&#160;</p>
<p style="position:absolute;top:443px;left:108px;white-space:nowrap" class="ft047">40.</p>
<p style="position:absolute;top:443px;left:129px;white-space:nowrap" class="ft048">&#160;</p>
<p style="position:absolute;top:443px;left:162px;white-space:nowrap" class="ft051">1997&#160;USPHS/IDSA guidelines for&#160;the prevention&#160;of&#160;opportunistic infections in&#160;persons infected&#160;<br/>with&#160;human&#160;immunodeficiency&#160;virus.</p>
<p style="position:absolute;top:462px;left:413px;white-space:nowrap" class="ft049"><i>Ann&#160;Intern&#160;Med</i></p>
<p style="position:absolute;top:462px;left:518px;white-space:nowrap" class="ft047">.&#160;1997;127(10):922-946.&#160;Available&#160;at:&#160;</p>
<p style="position:absolute;top:481px;left:162px;white-space:nowrap" class="ft050">https://www.ncbi.nlm.nih.gov/pubmed/9382373</p>
<p style="position:absolute;top:481px;left:480px;white-space:nowrap" class="ft047">.&#160;</p>
<p style="position:absolute;top:517px;left:108px;white-space:nowrap" class="ft047">41.</p>
<p style="position:absolute;top:517px;left:129px;white-space:nowrap" class="ft048">&#160;</p>
<p style="position:absolute;top:517px;left:162px;white-space:nowrap" class="ft051">1999&#160;USPHS/IDSA guidelines for&#160;the prevention&#160;of&#160;opportunistic infections in&#160;persons infected&#160;<br/>with&#160;HIV: part I.&#160;prevention&#160;of exposure.&#160;</p>
<p style="position:absolute;top:536px;left:437px;white-space:nowrap" class="ft049"><i>Am Fam Physician</i></p>
<p style="position:absolute;top:536px;left:563px;white-space:nowrap" class="ft047">. 2000;61(1):163-174. Available at:&#160;</p>
<p style="position:absolute;top:555px;left:162px;white-space:nowrap" class="ft050">https://www.ncbi.nlm.nih.gov/pubmed/10643957</p>
<p style="position:absolute;top:555px;left:488px;white-space:nowrap" class="ft047">.&#160;</p>
<p style="position:absolute;top:592px;left:108px;white-space:nowrap" class="ft047">42.</p>
<p style="position:absolute;top:591px;left:129px;white-space:nowrap" class="ft048">&#160;</p>
<p style="position:absolute;top:592px;left:162px;white-space:nowrap" class="ft051">Benson&#160;CA, Kaplan&#160;JE,&#160;Masur&#160;H, et&#160;al. Treating&#160;opportunistic infections among&#160;HIV-infected&#160;<br/>adults and&#160;adolescents: recommendations from CDC,&#160;the National Institutes of Health, and&#160;the&#160;<br/>HIV Medicine Association/Infectious Diseases Society&#160;of America.&#160;</p>
<p style="position:absolute;top:630px;left:612px;white-space:nowrap" class="ft049"><i>MMWR Recomm Rep</i></p>
<p style="position:absolute;top:630px;left:754px;white-space:nowrap" class="ft047">.&#160;</p>
<p style="position:absolute;top:649px;left:162px;white-space:nowrap" class="ft047">2004;53(RR-15):1-112. Available at:&#160;</p>
<p style="position:absolute;top:649px;left:411px;white-space:nowrap" class="ft050">https://www.ncbi.nlm.nih.gov/pubmed/15841069</p>
<p style="position:absolute;top:649px;left:738px;white-space:nowrap" class="ft047">.&#160;</p>
<p style="position:absolute;top:685px;left:108px;white-space:nowrap" class="ft047">43.</p>
<p style="position:absolute;top:685px;left:129px;white-space:nowrap" class="ft048">&#160;</p>
<p style="position:absolute;top:685px;left:162px;white-space:nowrap" class="ft051">Kaplan&#160;JE,&#160;Benson&#160;C,&#160;Holmes&#160;KK, et al.&#160;Guidelines for&#160;prevention and&#160;treatment of opportunistic&#160;<br/>infections in&#160;HIV-infected&#160;adults and&#160;adolescents: recommendations from CDC,&#160;the National&#160;<br/>Institutes of Health, and&#160;the HIV Medicine Association&#160;of the Infectious Diseases&#160;Society&#160;of&#160;<br/>America.&#160;</p>
<p style="position:absolute;top:742px;left:227px;white-space:nowrap" class="ft049"><i>MMWR Recomm Rep</i></p>
<p style="position:absolute;top:742px;left:369px;white-space:nowrap" class="ft047">. 2009;58(RR-4):1-207; quiz CE201-204.&#160;Available at:&#160;</p>
<p style="position:absolute;top:761px;left:162px;white-space:nowrap" class="ft050">https://www.ncbi.nlm.nih.gov/pubmed/19357635</p>
<p style="position:absolute;top:761px;left:488px;white-space:nowrap" class="ft047">.&#160;</p>
<p style="position:absolute;top:797px;left:108px;white-space:nowrap" class="ft047">44.</p>
<p style="position:absolute;top:797px;left:129px;white-space:nowrap" class="ft048">&#160;</p>
<p style="position:absolute;top:797px;left:162px;white-space:nowrap" class="ft051">Mofenson&#160;LM,&#160;Brady&#160;MT, Danner SP,&#160;et al.&#160;Guidelines&#160;for the Prevention&#160;and&#160;Treatment&#160;of&#160;<br/>Opportunistic&#160;Infections among&#160;HIV-exposed&#160;and&#160;HIV-infected children:&#160;recommendations from&#160;<br/>CDC, the National Institutes of Health, the HIV Medicine Association&#160;of the Infectious Diseases&#160;<br/>Society&#160;of America, the Pediatric Infectious Diseases&#160;Society, and&#160;the American&#160;Academy of&#160;<br/>Pediatrics.&#160;</p>
<p style="position:absolute;top:873px;left:235px;white-space:nowrap" class="ft049"><i>MMWR Recomm Rep</i></p>
<p style="position:absolute;top:873px;left:377px;white-space:nowrap" class="ft047">.&#160;2009;58(RR-11):1-166. Available&#160;at:&#160;</p>
<p style="position:absolute;top:892px;left:162px;white-space:nowrap" class="ft050">https://www.ncbi.nlm.nih.gov/pubmed/19730409</p>
<p style="position:absolute;top:892px;left:488px;white-space:nowrap" class="ft047">.&#160;</p>
</div>
<!-- Page 16 -->
<a name="16"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}	.ft052{font-size:17px;font-family:RHXCLC+Cambria;color:#000000;}
	.ft053{font-size:17px;font-family:ADVVUY+Calibri-Light;color:#000000;}
-->
</style>
<div id="page16-div" style="position:relative;width:917px;height:1187px;">
<p style="position:absolute;top:1114px;left:108px;white-space:nowrap" class="ft024"><i>Guidelines for the Prevention and Treatment&#160;of&#160;Opportunistic&#160;Infections in Adults&#160;and Adolescents&#160;With HIV&#160;</i></p>
<p style="position:absolute;top:1114px;left:791px;white-space:nowrap" class="ft024"><i>B-1&#160;</i></p>
<p style="position:absolute;top:90px;left:108px;white-space:nowrap" class="ft025"><b>Bacterial&#160;Enteric&#160;Infections&#160;</b></p>
<p style="position:absolute;top:138px;left:108px;white-space:nowrap" class="ft035"><b>Updated:</b></p>
<p style="position:absolute;top:138px;left:172px;white-space:nowrap" class="ft036">&#160;October&#160;8,&#160;2024&#160;</p>
<p style="position:absolute;top:158px;left:108px;white-space:nowrap" class="ft035"><b>Reviewed:</b></p>
<p style="position:absolute;top:158px;left:181px;white-space:nowrap" class="ft036">&#160;January 8,&#160;2025&#160;</p>
<p style="position:absolute;top:196px;left:108px;white-space:nowrap" class="ft026"><b>Epidemiology&#160;</b></p>
<p style="position:absolute;top:238px;left:108px;white-space:nowrap" class="ft032">HIV-associated alterations in mucosal&#160;immunity or intestinal integrity and treatment with acid-<br/>suppressive&#160;agents may increase the&#160;risk of enteric&#160;bacterial infections. Rates&#160;of Gram-negative&#160;<br/>bacterial&#160;enteric infections are at&#160;least 10 times higher among adults with HIV than in the&#160;general&#160;<br/>population, but these rates are lower among people&#160;with HIV who are treated with antiretroviral&#160;<br/>therapy (ART).</p>
<p style="position:absolute;top:316px;left:214px;white-space:nowrap" class="ft038">1</p>
<p style="position:absolute;top:317px;left:220px;white-space:nowrap" class="ft013">&#160;The&#160;risk&#160;of bacterial&#160;diarrhea varies according to CD4 T lymphocyte (CD4) cell&#160;</p>
<p style="position:absolute;top:337px;left:108px;white-space:nowrap" class="ft013">count&#160;and is&#160;greatest in individuals with clinical&#160;AIDS or&#160;CD4&#160;counts &lt;200 cells/mm</p>
<p style="position:absolute;top:336px;left:695px;white-space:nowrap" class="ft038">3</p>
<p style="position:absolute;top:337px;left:701px;white-space:nowrap" class="ft013">. &#160;</p>
<p style="position:absolute;top:374px;left:108px;white-space:nowrap" class="ft013">The&#160;bacteria most frequently isolated by culture&#160;from adults with HIV in the&#160;United States are&#160;</p>
<p style="position:absolute;top:394px;left:108px;white-space:nowrap" class="ft019"><i>Shigella</i></p>
<p style="position:absolute;top:394px;left:164px;white-space:nowrap" class="ft013">,&#160;</p>
<p style="position:absolute;top:394px;left:173px;white-space:nowrap" class="ft019"><i>Campylobacter</i></p>
<p style="position:absolute;top:394px;left:279px;white-space:nowrap" class="ft013">,&#160;and nontyphoidal&#160;</p>
<p style="position:absolute;top:394px;left:413px;white-space:nowrap" class="ft019"><i>Salmonella</i></p>
<p style="position:absolute;top:394px;left:490px;white-space:nowrap" class="ft013">&#160;spp. (particularly&#160;</p>
<p style="position:absolute;top:394px;left:616px;white-space:nowrap" class="ft019"><i>Salmonella enterica&#160;</i></p>
<p style="position:absolute;top:414px;left:108px;white-space:nowrap" class="ft013">serotypes Typhimurium&#160;and Enteritidis).</p>
<p style="position:absolute;top:413px;left:389px;white-space:nowrap" class="ft038">1-6</p>
<p style="position:absolute;top:414px;left:404px;white-space:nowrap" class="ft013">&#160;Diarrheagenic&#160;</p>
<p style="position:absolute;top:414px;left:510px;white-space:nowrap" class="ft019"><i>Escherichia coli</i></p>
<p style="position:absolute;top:414px;left:622px;white-space:nowrap" class="ft013">, particularly&#160;</p>
<p style="position:absolute;top:434px;left:108px;white-space:nowrap" class="ft013">enteroaggregative&#160;</p>
<p style="position:absolute;top:434px;left:236px;white-space:nowrap" class="ft019"><i>E. coli</i></p>
<p style="position:absolute;top:434px;left:281px;white-space:nowrap" class="ft013">,&#160;may contribute to the&#160;burden of diarrheal&#160;disease,</p>
<p style="position:absolute;top:433px;left:632px;white-space:nowrap" class="ft038">7</p>
<p style="position:absolute;top:434px;left:637px;white-space:nowrap" class="ft013">&#160;but their role is&#160;</p>
<p style="position:absolute;top:454px;left:108px;white-space:nowrap" class="ft013">understood&#160;poorly because reporting to public health systems is&#160;not required. Data on&#160;</p>
<p style="position:absolute;top:454px;left:702px;white-space:nowrap" class="ft019"><i>Helicobacter&#160;</i></p>
<p style="position:absolute;top:474px;left:108px;white-space:nowrap" class="ft019"><i>pylori</i></p>
<p style="position:absolute;top:474px;left:149px;white-space:nowrap" class="ft013">&#160;infection in HIV infection are&#160;limited and do not&#160;suggest excess&#160;risk in people with HIV.</p>
<p style="position:absolute;top:472px;left:767px;white-space:nowrap" class="ft038">8</p>
<p style="position:absolute;top:474px;left:772px;white-space:nowrap" class="ft013">&#160;&#160;</p>
<p style="position:absolute;top:511px;left:108px;white-space:nowrap" class="ft019"><i>Clostridioides difficile</i></p>
<p style="position:absolute;top:511px;left:263px;white-space:nowrap" class="ft013">–associated infection (CDI) is common in&#160;people with&#160;HIV</p>
<p style="position:absolute;top:509px;left:672px;white-space:nowrap" class="ft038">9</p>
<p style="position:absolute;top:511px;left:678px;white-space:nowrap" class="ft013">; in addition to&#160;</p>
<p style="position:absolute;top:530px;left:108px;white-space:nowrap" class="ft013">traditional risk factors,&#160;such as exposure to a health care&#160;facility&#160;or to antibiotics, data</p>
<p style="position:absolute;top:529px;left:698px;white-space:nowrap" class="ft038">10</p>
<p style="position:absolute;top:530px;left:709px;white-space:nowrap" class="ft013">&#160;suggest that&#160;</p>
<p style="position:absolute;top:550px;left:108px;white-space:nowrap" class="ft013">low CD4 count (&lt;50 cells/mm</p>
<p style="position:absolute;top:549px;left:318px;white-space:nowrap" class="ft038">3</p>
<p style="position:absolute;top:550px;left:324px;white-space:nowrap" class="ft013">) is an independent&#160;risk factor. Incidence&#160;of community-onset&#160;CDI is&#160;</p>
<p style="position:absolute;top:570px;left:108px;white-space:nowrap" class="ft032">increasing, and clinicians also should consider CDI&#160;in the evaluation of outpatient&#160;diarrheal&#160;illnesses&#160;<br/>in people with HIV.&#160;&#160;</p>
<p style="position:absolute;top:627px;left:108px;white-space:nowrap" class="ft013">Other enteric infections that may cause diarrhea—such as&#160;</p>
<p style="position:absolute;top:627px;left:510px;white-space:nowrap" class="ft019"><i>Mycobacterium avium&#160;</i></p>
<p style="position:absolute;top:627px;left:669px;white-space:nowrap" class="ft013">complex&#160;(MAC),&#160;</p>
<p style="position:absolute;top:647px;left:108px;white-space:nowrap" class="ft013">cytomegalovirus, and various protozoa—are discussed elsewhere in these guidelines.&#160;</p>
<p style="position:absolute;top:684px;left:108px;white-space:nowrap" class="ft032">As&#160;with bacterial&#160;enteric&#160;infections in&#160;people without HIV,&#160;the&#160;probable source for most bacterial&#160;<br/>enteric infections in people with HIV is ingestion of contaminated food or&#160;water.</p>
<p style="position:absolute;top:702px;left:666px;white-space:nowrap" class="ft038">11</p>
<p style="position:absolute;top:704px;left:677px;white-space:nowrap" class="ft013">&#160;Sexual activity&#160;</p>
<p style="position:absolute;top:724px;left:108px;white-space:nowrap" class="ft032">with the potential&#160;for direct&#160;or indirect fecal-oral exposure also increases risk&#160;of infections, especially&#160;<br/>with&#160;</p>
<p style="position:absolute;top:743px;left:143px;white-space:nowrap" class="ft019"><i>Shigella</i></p>
<p style="position:absolute;top:742px;left:200px;white-space:nowrap" class="ft038">12</p>
<p style="position:absolute;top:743px;left:211px;white-space:nowrap" class="ft019"><i>&#160;</i></p>
<p style="position:absolute;top:743px;left:215px;white-space:nowrap" class="ft013">and&#160;</p>
<p style="position:absolute;top:743px;left:244px;white-space:nowrap" class="ft019"><i>Campylobacter</i></p>
<p style="position:absolute;top:743px;left:350px;white-space:nowrap" class="ft013">.</p>
<p style="position:absolute;top:742px;left:355px;white-space:nowrap" class="ft038">3,13-16</p>
<p style="position:absolute;top:743px;left:390px;white-space:nowrap" class="ft013">&#160;&#160;</p>
<p style="position:absolute;top:780px;left:108px;white-space:nowrap" class="ft026"><b>Clinical Manifestations&#160;</b></p>
<p style="position:absolute;top:822px;left:108px;white-space:nowrap" class="ft032">Three major clinical syndromes of infection are associated with Gram-negative enteric&#160;bacteria&#160;<br/>among people with HIV:&#160;</p>
<p style="position:absolute;top:878px;left:108px;white-space:nowrap" class="ft052">•</p>
<p style="position:absolute;top:879px;left:116px;white-space:nowrap" class="ft046">&#160;</p>
<p style="position:absolute;top:879px;left:135px;white-space:nowrap" class="ft013">Self-limited gastroenteritis;&#160;</p>
<p style="position:absolute;top:907px;left:108px;white-space:nowrap" class="ft052">•</p>
<p style="position:absolute;top:908px;left:116px;white-space:nowrap" class="ft046">&#160;</p>
<p style="position:absolute;top:908px;left:135px;white-space:nowrap" class="ft032">Severe and prolonged diarrheal&#160;disease, potentially&#160;associated with fever, bloody diarrhea,&#160;and&#160;<br/>weight&#160;loss;&#160;</p>
<p style="position:absolute;top:928px;left:222px;white-space:nowrap" class="ft019"><i>and</i></p>
<p style="position:absolute;top:928px;left:248px;white-space:nowrap" class="ft013">&#160;</p>
<p style="position:absolute;top:956px;left:108px;white-space:nowrap" class="ft052">•</p>
<p style="position:absolute;top:956px;left:116px;white-space:nowrap" class="ft046">&#160;</p>
<p style="position:absolute;top:956px;left:135px;white-space:nowrap" class="ft032">Bacteremia&#160;associated with extra-intestinal&#160;involvement, with or without concurrent&#160;or preceding&#160;<br/>gastrointestinal (GI) illness.</p>
<p style="position:absolute;top:976px;left:327px;white-space:nowrap" class="ft038">6,17,18</p>
<p style="position:absolute;top:976px;left:361px;white-space:nowrap" class="ft013">&#160;</p>
<p style="position:absolute;top:1013px;left:108px;white-space:nowrap" class="ft013">Severe community-associated diarrhea often is defined as six or&#160;more&#160;loose stools</p>
<p style="position:absolute;top:1016px;left:673px;white-space:nowrap" class="ft053">&#160;</p>
<p style="position:absolute;top:1013px;left:677px;white-space:nowrap" class="ft013">(loose stool&#160;is&#160;</p>
<p style="position:absolute;top:1033px;left:108px;white-space:nowrap" class="ft032">defined as defecated material that&#160;takes the shape of a container) per day with&#160;or without&#160;other signs&#160;<br/>of systemic illness, such as fecal&#160;blood, orthostatic hypotension,&#160;or fever. In&#160;people with&#160;HIV,&#160;the&#160;<br/>risk of more&#160;profound illness increases&#160;with the degree of immunosuppression but risk diminishes&#160;</p>
</div>
<!-- Page 17 -->
<a name="17"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}	.ft054{font-size:17px;font-family:GGOOQY+Cambria;color:#000000;}
	.ft055{font-size:20px;font-family:TURBHP+Tinos;color:#000000;}
-->
</style>
<div id="page17-div" style="position:relative;width:917px;height:1187px;">
<p style="position:absolute;top:1114px;left:108px;white-space:nowrap" class="ft024"><i>Guidelines for the Prevention and Treatment&#160;of&#160;Opportunistic&#160;Infections in Adults&#160;and Adolescents&#160;With HIV&#160;</i></p>
<p style="position:absolute;top:1114px;left:791px;white-space:nowrap" class="ft024"><i>B-2&#160;</i></p>
<p style="position:absolute;top:87px;left:108px;white-space:nowrap" class="ft013">with ART therapy.</p>
<p style="position:absolute;top:86px;left:238px;white-space:nowrap" class="ft038">1,4,5,11,18,19</p>
<p style="position:absolute;top:87px;left:303px;white-space:nowrap" class="ft013">&#160;Relapses&#160;in infection with&#160;</p>
<p style="position:absolute;top:87px;left:491px;white-space:nowrap" class="ft019"><i>Salmonella</i></p>
<p style="position:absolute;top:86px;left:568px;white-space:nowrap" class="ft054"><i>&#160;</i></p>
<p style="position:absolute;top:87px;left:572px;white-space:nowrap" class="ft013">and other Gram-negative bacterial&#160;</p>
<p style="position:absolute;top:107px;left:108px;white-space:nowrap" class="ft013">enteric pathogens after appropriate&#160;treatment have been well&#160;documented in people with&#160;HIV.</p>
<p style="position:absolute;top:106px;left:756px;white-space:nowrap" class="ft038">11,20,21</p>
<p style="position:absolute;top:107px;left:795px;white-space:nowrap" class="ft013">&#160;</p>
<p style="position:absolute;top:127px;left:108px;white-space:nowrap" class="ft032">As&#160;in other&#160;populations, CDI can cause&#160;a variety of&#160;syndromes, from watery diarrhea&#160;to toxic&#160;<br/>megacolon.</p>
<p style="position:absolute;top:145px;left:188px;white-space:nowrap" class="ft038">10</p>
<p style="position:absolute;top:184px;left:108px;white-space:nowrap" class="ft032">Although enteric pathogens can be&#160;associated with clinical&#160;proctitis (e.g., pain with defecation,&#160;<br/>tenesmus, bloody discharge),</p>
<p style="position:absolute;top:202px;left:309px;white-space:nowrap" class="ft038">22</p>
<p style="position:absolute;top:204px;left:321px;white-space:nowrap" class="ft013">&#160;other infections that&#160;may be transmitted during intimate contact&#160;</p>
<p style="position:absolute;top:223px;left:108px;white-space:nowrap" class="ft013">(e.g.,&#160;</p>
<p style="position:absolute;top:223px;left:147px;white-space:nowrap" class="ft019"><i>Chlamydia trachomatis</i></p>
<p style="position:absolute;top:223px;left:310px;white-space:nowrap" class="ft013">&#160;including lymphogranuloma venereum,&#160;</p>
<p style="position:absolute;top:223px;left:591px;white-space:nowrap" class="ft019"><i>Neisseria gonorrhoeae,&#160;</i></p>
<p style="position:absolute;top:223px;left:758px;white-space:nowrap" class="ft013">herpes&#160;</p>
<p style="position:absolute;top:243px;left:108px;white-space:nowrap" class="ft013">simplex virus,&#160;</p>
<p style="position:absolute;top:243px;left:210px;white-space:nowrap" class="ft019"><i>Treponema pallidum,&#160;</i></p>
<p style="position:absolute;top:243px;left:363px;white-space:nowrap" class="ft013">and mpox) more commonly cause this syndrome, especially in&#160;</p>
<p style="position:absolute;top:263px;left:108px;white-space:nowrap" class="ft013">those with relevant exposures (e.g., condomless receptive&#160;anal&#160;intercourse).</p>
<p style="position:absolute;top:262px;left:629px;white-space:nowrap" class="ft038">23</p>
<p style="position:absolute;top:263px;left:640px;white-space:nowrap" class="ft013">&#160;Proctocolitis with&#160;</p>
<p style="position:absolute;top:283px;left:108px;white-space:nowrap" class="ft013">diarrhea caused by STIs is&#160;less&#160;common but may occur;&#160;relevant&#160;exposures should be&#160;queried.</p>
<p style="position:absolute;top:281px;left:757px;white-space:nowrap" class="ft038">24</p>
<p style="position:absolute;top:283px;left:768px;white-space:nowrap" class="ft013">&#160;</p>
<p style="position:absolute;top:319px;left:108px;white-space:nowrap" class="ft026"><b>Diagnosis&#160;</b></p>
<p style="position:absolute;top:361px;left:108px;white-space:nowrap" class="ft032">Assessment&#160;of patients with diarrhea should include a complete exposure history (i.e., ingestion of&#160;<br/>contaminated food or&#160;water, including through recreational exposure to&#160;water, sexual history or other&#160;<br/>fecal-oral&#160;exposures, animal/pet&#160;exposures, travel-related exposures, exposure to antibiotics or&#160;<br/>chemotherapies, use of acid-suppressing medications, recent&#160;hospitalization); a medication review,&#160;<br/>because diarrhea is a common side effect&#160;of some&#160;ART&#160;and antibiotics; quantification of the diarrheal&#160;<br/>illness&#160;by stool frequency,&#160;consistency,&#160;volume, duration, and presence&#160;of blood; and associated signs&#160;<br/>and symptoms, such as presence&#160;and&#160;duration of fever. Physical examination should include&#160;<br/>measurement of temperature&#160;and assessment of intravascular volume&#160;and nutritional status.</p>
<p style="position:absolute;top:497px;left:737px;white-space:nowrap" class="ft055">&#160;</p>
<p style="position:absolute;top:537px;left:108px;white-space:nowrap" class="ft032">The&#160;diagnosis of&#160;Gram-negative&#160;bacterial enteric infection is established through cultures of stool&#160;<br/>and blood or&#160;stool molecular methods (i.e., culture-independent&#160;diagnostic&#160;tests [CIDTs]),&#160;ideally&#160;<br/>before antibiotics are given. Although&#160;stool molecular methods rapidly diagnose enteric infections,&#160;<br/>stool cultures are required to obtain phenotypic antibiotic&#160;sensitivity testing&#160;for isolated enteric&#160;<br/>pathogens and may also be helpful during outbreak&#160;investigations to identify the&#160;source. Thus, the&#160;<br/>Centers for&#160;Disease Control&#160;and Prevention (CDC)&#160;recommends&#160;reflex stool&#160;cultures and&#160;antibiotic&#160;<br/>sensitivity testing for specimens with&#160;positive CIDT reports given increasing&#160;resistance detected in&#160;<br/>enteric bacterial infections.</p>
<p style="position:absolute;top:675px;left:295px;white-space:nowrap" class="ft038">25</p>
<p style="position:absolute;top:676px;left:307px;white-space:nowrap" class="ft013">&#160;Because&#160;incidence of bacteremia associated with&#160;</p>
<p style="position:absolute;top:676px;left:651px;white-space:nowrap" class="ft019"><i>Salmonella</i></p>
<p style="position:absolute;top:676px;left:729px;white-space:nowrap" class="ft013">&#160;</p>
<p style="position:absolute;top:696px;left:108px;white-space:nowrap" class="ft032">gastroenteritis is high in people with HIV—particularly those with advanced&#160;disease—blood cultures&#160;<br/>should be obtained from any patient&#160;who has diarrhea&#160;and fever.&#160;For shigellosis, blood cultures may&#160;<br/>be helpful but are less likely to be positive&#160;than in salmonellosis.</p>
<p style="position:absolute;top:734px;left:555px;white-space:nowrap" class="ft038">18</p>
<p style="position:absolute;top:736px;left:566px;white-space:nowrap" class="ft013">&#160;</p>
<p style="position:absolute;top:773px;left:108px;white-space:nowrap" class="ft013">Other infections for&#160;which people with HIV are at&#160;risk, albeit&#160;at&#160;a lower rate,&#160;are non-</p>
<p style="position:absolute;top:773px;left:698px;white-space:nowrap" class="ft019"><i>jejuni,</i></p>
<p style="position:absolute;top:773px;left:741px;white-space:nowrap" class="ft013">&#160;non-</p>
<p style="position:absolute;top:773px;left:777px;white-space:nowrap" class="ft019"><i>coli&#160;</i></p>
<p style="position:absolute;top:793px;left:108px;white-space:nowrap" class="ft019"><i>Campylobacter</i></p>
<p style="position:absolute;top:793px;left:214px;white-space:nowrap" class="ft013">&#160;spp.—such as&#160;</p>
<p style="position:absolute;top:793px;left:319px;white-space:nowrap" class="ft019"><i>C. fetus,&#160;C. upsaliensis,&#160;</i></p>
<p style="position:absolute;top:793px;left:485px;white-space:nowrap" class="ft013">and&#160;</p>
<p style="position:absolute;top:793px;left:515px;white-space:nowrap" class="ft019"><i>C. lari—</i></p>
<p style="position:absolute;top:793px;left:575px;white-space:nowrap" class="ft013">and the enterohepatic</p>
<p style="position:absolute;top:793px;left:722px;white-space:nowrap" class="ft019"><i>&#160;</i></p>
<p style="position:absolute;top:812px;left:108px;white-space:nowrap" class="ft019"><i>Helicobacter&#160;</i></p>
<p style="position:absolute;top:812px;left:202px;white-space:nowrap" class="ft013">spp. (</p>
<p style="position:absolute;top:812px;left:241px;white-space:nowrap" class="ft019"><i>H. cineadi&#160;</i></p>
<p style="position:absolute;top:812px;left:317px;white-space:nowrap" class="ft013">and</p>
<p style="position:absolute;top:812px;left:342px;white-space:nowrap" class="ft019"><i>&#160;H. fennelliae)</i></p>
<p style="position:absolute;top:812px;left:441px;white-space:nowrap" class="ft013">, which were described originally as</p>
<p style="position:absolute;top:812px;left:694px;white-space:nowrap" class="ft019"><i>Campylobacter</i></p>
<p style="position:absolute;top:812px;left:800px;white-space:nowrap" class="ft013">&#160;</p>
<p style="position:absolute;top:832px;left:108px;white-space:nowrap" class="ft032">spp. Blood culture systems typically will&#160;grow these bacteria, but&#160;they are unlikely to be identified on&#160;<br/>routine stool&#160;cultures performed by most laboratories because growing these&#160;fastidious organisms&#160;<br/>requires special stool&#160;culture conditions.&#160;</p>
<p style="position:absolute;top:909px;left:108px;white-space:nowrap" class="ft032">The&#160;diagnosis of CDI can&#160;be made only through careful&#160;selection of the&#160;correct&#160;population for testing&#160;<br/>and a correlation of clinical&#160;and laboratory findings. Populations&#160;at&#160;risk for&#160;</p>
<p style="position:absolute;top:929px;left:628px;white-space:nowrap" class="ft019"><i>C.&#160;difficile</i></p>
<p style="position:absolute;top:929px;left:701px;white-space:nowrap" class="ft013">&#160;diarrhea&#160;</p>
<p style="position:absolute;top:949px;left:108px;white-space:nowrap" class="ft032">include&#160;individuals who recently received or currently are receiving antibiotics (including&#160;<br/>antimicrobial prophylaxis)&#160;or cancer chemotherapy; those who&#160;have been hospitalized in the past&#160;4 to&#160;<br/>6 weeks&#160;(or&#160;currently are hospitalized);&#160;those who&#160;reside&#160;in a long-term care facility;&#160;those&#160;with CD4&#160;<br/>counts &lt;200&#160;cells/mm</p>
<p style="position:absolute;top:1007px;left:260px;white-space:nowrap" class="ft038">3</p>
<p style="position:absolute;top:1008px;left:266px;white-space:nowrap" class="ft013">; those taking acid-suppressive medications; and those&#160;with moderate-to-</p>
<p style="position:absolute;top:1028px;left:108px;white-space:nowrap" class="ft013">severe community-acquired diarrhea.</p>
<p style="position:absolute;top:1027px;left:365px;white-space:nowrap" class="ft038">26</p>
<p style="position:absolute;top:1028px;left:376px;white-space:nowrap" class="ft013">&#160;Only people&#160;with diarrhea&#160;(defined as three&#160;or more&#160;loose&#160;</p>
<p style="position:absolute;top:1048px;left:108px;white-space:nowrap" class="ft032">stools in 24&#160;hours)&#160;should be tested for CDI to limit detection&#160;of asymptomatic colonization, and only&#160;<br/>stool samples that&#160;take the shape of the container (i.e., diarrheal) should be tested.</p>
<p style="position:absolute;top:1066px;left:673px;white-space:nowrap" class="ft038">27</p>
<p style="position:absolute;top:1068px;left:684px;white-space:nowrap" class="ft013">&#160;Detection of&#160;</p>
</div>
<!-- Page 18 -->
<a name="18"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page18-div" style="position:relative;width:917px;height:1187px;">
<p style="position:absolute;top:1114px;left:108px;white-space:nowrap" class="ft024"><i>Guidelines for the Prevention and Treatment&#160;of&#160;Opportunistic&#160;Infections in Adults&#160;and Adolescents&#160;With HIV&#160;</i></p>
<p style="position:absolute;top:1114px;left:791px;white-space:nowrap" class="ft024"><i>B-3&#160;</i></p>
<p style="position:absolute;top:87px;left:108px;white-space:nowrap" class="ft013">either the&#160;</p>
<p style="position:absolute;top:87px;left:177px;white-space:nowrap" class="ft019"><i>C. difficile</i></p>
<p style="position:absolute;top:87px;left:249px;white-space:nowrap" class="ft013">&#160;toxin B gene (using nucleic acid amplification testing [NAAT]) or&#160;the&#160;</p>
<p style="position:absolute;top:87px;left:741px;white-space:nowrap" class="ft019"><i>C.&#160;</i></p>
<p style="position:absolute;top:107px;left:108px;white-space:nowrap" class="ft019"><i>difficile</i></p>
<p style="position:absolute;top:107px;left:160px;white-space:nowrap" class="ft013">&#160;toxin B protein (using an enzyme&#160;immunoassay [EIA])&#160;is required for diagnosis. Current&#160;</p>
<p style="position:absolute;top:127px;left:108px;white-space:nowrap" class="ft032">EIAs&#160;suffer from low sensitivity, whereas polymerase chain reaction (or PCR)&#160;assays&#160;have&#160;high&#160;<br/>sensitivity and can detect&#160;asymptomatic carriers. Glutamate&#160;dehydrogenase&#160;(GDH) antigen enzyme&#160;<br/>immunoassays, which detect&#160;an antigen common to&#160;</p>
<p style="position:absolute;top:166px;left:468px;white-space:nowrap" class="ft019"><i>C. difficile</i></p>
<p style="position:absolute;top:166px;left:540px;white-space:nowrap" class="ft013">&#160;strains, whether or not&#160;toxigenic,&#160;</p>
<p style="position:absolute;top:186px;left:108px;white-space:nowrap" class="ft013">must be&#160;combined with a&#160;second confirmatory test for stool&#160;</p>
<p style="position:absolute;top:186px;left:523px;white-space:nowrap" class="ft019"><i>C. difficile</i></p>
<p style="position:absolute;top:186px;left:595px;white-space:nowrap" class="ft013">&#160;toxin B.</p>
<p style="position:absolute;top:185px;left:656px;white-space:nowrap" class="ft038">28,29</p>
<p style="position:absolute;top:186px;left:681px;white-space:nowrap" class="ft013">&#160;Based&#160;on the&#160;</p>
<p style="position:absolute;top:206px;left:108px;white-space:nowrap" class="ft032">criteria&#160;above (i.e., person meets the definition of diarrhea&#160;and the stool&#160;sample&#160;is diarrhea, taking the&#160;<br/>shape of the&#160;container), Infectious Diseases Society of America&#160;(IDSA) and&#160;Society for&#160;Healthcare&#160;<br/>Epidemiology of America&#160;(or SHEA)&#160;guidelines for CDI&#160;support using an NAAT alone or a&#160;<br/>multiple-step algorithm&#160;(e.g., GDH&#160;plus toxin B assay) versus an&#160;EIA alone for&#160;</p>
<p style="position:absolute;top:266px;left:659px;white-space:nowrap" class="ft019"><i>C. difficile</i></p>
<p style="position:absolute;top:266px;left:732px;white-space:nowrap" class="ft013">&#160;testing.</p>
<p style="position:absolute;top:264px;left:787px;white-space:nowrap" class="ft038">29</p>
<p style="position:absolute;top:266px;left:799px;white-space:nowrap" class="ft013">&#160;</p>
<p style="position:absolute;top:303px;left:108px;white-space:nowrap" class="ft013">Endoscopy&#160;generally should be reserved for patients in whom&#160;stool culture, microscopy,&#160;</p>
<p style="position:absolute;top:303px;left:722px;white-space:nowrap" class="ft019"><i>C. difficile</i></p>
<p style="position:absolute;top:303px;left:794px;white-space:nowrap" class="ft013">&#160;</p>
<p style="position:absolute;top:323px;left:108px;white-space:nowrap" class="ft032">toxin B assay, and blood&#160;culture&#160;fail to reveal&#160;an etiology or in whom treatment for an established&#160;<br/>diagnosis fails. Endoscopy with biopsy may be required for diagnosing etiologies other than bacterial&#160;<br/>enteric infections—including cryptosporidiosis, microsporidiosis, cytomegalovirus, or&#160;MAC&#160;<br/>gastroenteritis—and noninfectious causes of&#160;GI&#160;symptoms.&#160;</p>
<p style="position:absolute;top:419px;left:108px;white-space:nowrap" class="ft032">Clinicians should remain alert&#160;to the possibility of&#160;sexually transmitted infections (STIs).&#160;In patients&#160;<br/>with relevant&#160;exposures and symptoms of proctitis&#160;or proctocolitis, diagnostic&#160;evaluation and&#160;<br/>treatment for STIs</p>
<p style="position:absolute;top:459px;left:235px;white-space:nowrap" class="ft034">&#160;</p>
<p style="position:absolute;top:459px;left:239px;white-space:nowrap" class="ft013">should&#160;are recommended.</p>
<p style="position:absolute;top:457px;left:417px;white-space:nowrap" class="ft038">30</p>
<p style="position:absolute;top:459px;left:428px;white-space:nowrap" class="ft013">&#160;&#160;</p>
<p style="position:absolute;top:495px;left:108px;white-space:nowrap" class="ft026"><b>Preventing&#160;Exposure &#160;</b></p>
<p style="position:absolute;top:537px;left:108px;white-space:nowrap" class="ft032">Multiple&#160;epidemiologic&#160;exposures can&#160;place people&#160;at&#160;risk for enteric&#160;illnesses. The&#160;most common&#160;<br/>are ingestion of contaminated food or&#160;water and fecal-oral exposures.&#160;Providing advice&#160;and education&#160;<br/>about&#160;such exposures is the responsibility of the&#160;health care provider. The clinical&#160;condition and CD4&#160;<br/>count&#160;of a person&#160;with HIV can help the provider determine&#160;what prevention recommendations are&#160;<br/>most appropriate. People with HIV with CD4 counts &lt;200 cells/mm</p>
<p style="position:absolute;top:615px;left:579px;white-space:nowrap" class="ft038">3</p>
<p style="position:absolute;top:617px;left:584px;white-space:nowrap" class="ft013">&#160;or a history of AIDS-defining&#160;</p>
<p style="position:absolute;top:636px;left:108px;white-space:nowrap" class="ft013">illness</p>
<p style="position:absolute;top:635px;left:152px;white-space:nowrap" class="ft038">31</p>
<p style="position:absolute;top:636px;left:163px;white-space:nowrap" class="ft013">&#160;are&#160;at the greatest risk of enteric illnesses;&#160;however, excess risk&#160;of undetermined magnitude&#160;</p>
<p style="position:absolute;top:656px;left:108px;white-space:nowrap" class="ft032">or duration&#160;may persist in those with&#160;lesser degrees of immune&#160;impairment, including individuals&#160;<br/>treated with ART.&#160;</p>
<p style="position:absolute;top:713px;left:108px;white-space:nowrap" class="ft032">Individuals in the community should be advised to&#160;wash their hands regularly&#160;with soap and water or&#160;<br/>alcohol-based cleansers to reduce&#160;the&#160;risk of enteric infection&#160;</p>
<p style="position:absolute;top:733px;left:534px;white-space:nowrap" class="ft012"><b>(AIII).</b></p>
<p style="position:absolute;top:733px;left:583px;white-space:nowrap" class="ft013">&#160;To&#160;prevent&#160;enteric infections,&#160;</p>
<p style="position:absolute;top:753px;left:108px;white-space:nowrap" class="ft013">soap and&#160;water are preferred over alcohol-based cleansers,&#160;which do not kill&#160;</p>
<p style="position:absolute;top:753px;left:637px;white-space:nowrap" class="ft019"><i>C. difficile</i></p>
<p style="position:absolute;top:753px;left:709px;white-space:nowrap" class="ft013">&#160;spores and&#160;</p>
<p style="position:absolute;top:773px;left:108px;white-space:nowrap" class="ft013">are active only partially against norovirus and&#160;</p>
<p style="position:absolute;top:773px;left:428px;white-space:nowrap" class="ft019"><i>Cryptosporidium</i></p>
<p style="position:absolute;top:773px;left:546px;white-space:nowrap" class="ft013">&#160;</p>
<p style="position:absolute;top:773px;left:550px;white-space:nowrap" class="ft012"><b>(AIII).</b></p>
<p style="position:absolute;top:773px;left:599px;white-space:nowrap" class="ft013">&#160;People with HIV should be&#160;</p>
<p style="position:absolute;top:793px;left:108px;white-space:nowrap" class="ft032">advised to wash their hands with soap&#160;and water after potential&#160;contact&#160;with human feces&#160;<br/>(e.g., through defecation, sexual exposures, cleaning feces from infants, contact&#160;with a person&#160;who&#160;<br/>has diarrhea), after handling&#160;pets&#160;or&#160;other&#160;animals,&#160;after&#160;gardening&#160;or&#160;other&#160;contact&#160;with&#160;soil,&#160;and&#160;before&#160;<br/>preparing&#160;food&#160;and&#160;eating&#160;</p>
<p style="position:absolute;top:852px;left:286px;white-space:nowrap" class="ft012"><b>(AIII).</b></p>
<p style="position:absolute;top:852px;left:334px;white-space:nowrap" class="ft013">&#160;In addition to handwashing,&#160;use of barriers&#160;(e.g., condoms, dental&#160;</p>
<p style="position:absolute;top:872px;left:108px;white-space:nowrap" class="ft032">dams, and gloves) can reduce exposure&#160;to feces when engaging in sex practices such as anal&#160;sex and&#160;<br/>oral-anal&#160;contact&#160;</p>
<p style="position:absolute;top:892px;left:228px;white-space:nowrap" class="ft012"><b>(AIII).</b></p>
<p style="position:absolute;top:890px;left:276px;white-space:nowrap" class="ft038">22,30,32</p>
<p style="position:absolute;top:892px;left:314px;white-space:nowrap" class="ft013">&#160;Avoiding&#160;sex&#160;while&#160;any&#160;partner&#160;has&#160;diarrhea&#160;may&#160;further&#160;reduce&#160;risk&#160;of&#160;</p>
<p style="position:absolute;top:912px;left:108px;white-space:nowrap" class="ft013">transmission.&#160;Travelers&#160;to&#160;relevant&#160;locations&#160;may&#160;be&#160;counseled&#160;on&#160;food&#160;and&#160;water&#160;hygiene&#160;(see&#160;the&#160;</p>
<p style="position:absolute;top:912px;left:769px;white-space:nowrap" class="ft034">CDC&#160;</p>
<p style="position:absolute;top:931px;left:108px;white-space:nowrap" class="ft034">Travelers’&#160;Health&#160;webpage</p>
<p style="position:absolute;top:931px;left:289px;white-space:nowrap" class="ft013">).</p>
<p style="position:absolute;top:930px;left:299px;white-space:nowrap" class="ft038">33</p>
<p style="position:absolute;top:931px;left:310px;white-space:nowrap" class="ft013">&#160;</p>
</div>
<!-- Page 19 -->
<a name="19"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}	.ft056{font-size:16px;font-family:BGKYCV+LiberationSansNarrow;color:#000000;}
	.ft057{font-size:15px;font-family:LLANCQ+Arimo;color:#000000;}
-->
</style>
<div id="page19-div" style="position:relative;width:917px;height:1187px;">
<p style="position:absolute;top:1114px;left:108px;white-space:nowrap" class="ft024"><i>Guidelines for the Prevention and Treatment&#160;of&#160;Opportunistic&#160;Infections in Adults&#160;and Adolescents&#160;With HIV&#160;</i></p>
<p style="position:absolute;top:1114px;left:791px;white-space:nowrap" class="ft024"><i>B-4&#160;</i></p>
<p style="position:absolute;top:87px;left:108px;white-space:nowrap" class="ft026"><b>Preventing&#160;Disease&#160;&#160;</b></p>
<p style="position:absolute;top:137px;left:253px;white-space:nowrap" class="ft02"><b>Recommendations for Preventing&#160;Bacterial Enteric&#160;Infections&#160;</b></p>
<p style="position:absolute;top:172px;left:116px;white-space:nowrap" class="ft056"><b>Preventing&#160;Bacterial Enteric&#160;Illness&#160;</b></p>
<p style="position:absolute;top:196px;left:116px;white-space:nowrap" class="ft030">•</p>
<p style="position:absolute;top:197px;left:123px;white-space:nowrap" class="ft057">&#160;</p>
<p style="position:absolute;top:197px;left:132px;white-space:nowrap" class="ft041">Immunizations (e.g., against&#160;</p>
<p style="position:absolute;top:197px;left:290px;white-space:nowrap" class="ft024"><i>Salmonella serotype&#160;</i></p>
<p style="position:absolute;top:197px;left:404px;white-space:nowrap" class="ft041">Typhi)&#160;should&#160;be&#160;recommended in advance of travel to relevant&#160;locations&#160;</p>
<p style="position:absolute;top:214px;left:132px;white-space:nowrap" class="ft041">(see&#160;</p>
<p style="position:absolute;top:214px;left:160px;white-space:nowrap" class="ft043">Immunizations for Preventable Diseases&#160;in Adults&#160;and Adolescents&#160;With HIV&#160;in&#160;the&#160;Adult and Adolescent&#160;</p>
<p style="position:absolute;top:231px;left:132px;white-space:nowrap" class="ft043">Opportunistic&#160;Infection&#160;Guidelines</p>
<p style="position:absolute;top:231px;left:316px;white-space:nowrap" class="ft041">)&#160;</p>
<p style="position:absolute;top:231px;left:324px;white-space:nowrap" class="ft042"><b>(AIII).&#160;</b></p>
<p style="position:absolute;top:257px;left:116px;white-space:nowrap" class="ft030">•</p>
<p style="position:absolute;top:259px;left:123px;white-space:nowrap" class="ft057">&#160;</p>
<p style="position:absolute;top:258px;left:132px;white-space:nowrap" class="ft041">Antimicrobial&#160;prophylaxis to prevent&#160;bacterial&#160;enteric illness&#160;</p>
<p style="position:absolute;top:258px;left:458px;white-space:nowrap" class="ft042"><b>is not routinely recommended,</b></p>
<p style="position:absolute;top:258px;left:637px;white-space:nowrap" class="ft041">&#160;including for travelers&#160;</p>
<p style="position:absolute;top:258px;left:760px;white-space:nowrap" class="ft042"><b>(AIII).&#160;</b></p>
<p style="position:absolute;top:285px;left:116px;white-space:nowrap" class="ft030">•</p>
<p style="position:absolute;top:286px;left:123px;white-space:nowrap" class="ft057">&#160;</p>
<p style="position:absolute;top:286px;left:132px;white-space:nowrap" class="ft041">In rare&#160;cases—such as for&#160;immunosuppressed&#160;travelers&#160;(depending&#160;on&#160;their level&#160;of&#160;immunosuppression,&#160;the&#160;region of&#160;</p>
<p style="position:absolute;top:303px;left:132px;white-space:nowrap" class="ft041">travel, and the trip’s&#160;duration)—antimicrobial&#160;prophylaxis&#160;with&#160;rifaximin&#160;or&#160;azithromycin&#160;should be&#160;offered&#160;</p>
<p style="position:absolute;top:303px;left:702px;white-space:nowrap" class="ft042"><b>(CIII).&#160;&#160;</b></p>
<p style="position:absolute;top:329px;left:116px;white-space:nowrap" class="ft030">•</p>
<p style="position:absolute;top:331px;left:123px;white-space:nowrap" class="ft057">&#160;</p>
<p style="position:absolute;top:330px;left:132px;white-space:nowrap" class="ft041">Because of toxicity&#160;associated with fluoroquinolone use (e.g.,&#160;CDI,&#160;tendinitis)&#160;and&#160;increasing rates&#160;of antimicrobial&#160;</p>
<p style="position:absolute;top:347px;left:132px;white-space:nowrap" class="ft041">resistance among enteric&#160;bacterial&#160;pathogens&#160;outside of the United&#160;States,&#160;routine&#160;use of fluoroquinolones&#160;for prophylaxis&#160;</p>
<p style="position:absolute;top:364px;left:132px;white-space:nowrap" class="ft041">is&#160;discouraged&#160;</p>
<p style="position:absolute;top:364px;left:215px;white-space:nowrap" class="ft042"><b>(AIII).</b></p>
<p style="position:absolute;top:364px;left:246px;white-space:nowrap" class="ft041">&#160;</p>
<p style="position:absolute;top:391px;left:116px;white-space:nowrap" class="ft030">•</p>
<p style="position:absolute;top:392px;left:123px;white-space:nowrap" class="ft057">&#160;</p>
<p style="position:absolute;top:392px;left:132px;white-space:nowrap" class="ft041">During pregnancy, azithromycin is&#160;the&#160;preferred agent for prophylaxis&#160;</p>
<p style="position:absolute;top:392px;left:512px;white-space:nowrap" class="ft042"><b>(BIII).</b></p>
<p style="position:absolute;top:392px;left:543px;white-space:nowrap" class="ft041">&#160;</p>
<p style="position:absolute;top:419px;left:108px;white-space:nowrap" class="ft042"><b>Key:&#160;</b></p>
<p style="position:absolute;top:419px;left:138px;white-space:nowrap" class="ft041">CDI =&#160;</p>
<p style="position:absolute;top:419px;left:173px;white-space:nowrap" class="ft024"><i>Clostridioides difficile</i></p>
<p style="position:absolute;top:419px;left:288px;white-space:nowrap" class="ft041">–associated&#160;infection&#160;</p>
<p style="position:absolute;top:454px;left:108px;white-space:nowrap" class="ft013">Antimicrobial prophylaxis&#160;to prevent&#160;bacterial&#160;enteric&#160;illness&#160;</p>
<p style="position:absolute;top:454px;left:531px;white-space:nowrap" class="ft012"><b>is not routinely&#160;recommended,</b></p>
<p style="position:absolute;top:454px;left:756px;white-space:nowrap" class="ft013">&#160;</p>
<p style="position:absolute;top:474px;left:108px;white-space:nowrap" class="ft013">including for&#160;travelers&#160;</p>
<p style="position:absolute;top:474px;left:265px;white-space:nowrap" class="ft012"><b>(AIII).</b></p>
<p style="position:absolute;top:474px;left:314px;white-space:nowrap" class="ft013">&#160;Prophylactic antimicrobial treatment can elicit adverse reactions,&#160;</p>
<p style="position:absolute;top:494px;left:108px;white-space:nowrap" class="ft032">promote the&#160;emergence of resistant&#160;organisms, and&#160;increase the risk of CDI.&#160;In rare cases,&#160;however,&#160;<br/>antimicrobial prophylaxis&#160;(e.g., with rifaximin or azithromycin) should be considered—such as for&#160;<br/>immunosuppressed travelers, depending on their level&#160;of immunosuppression, the&#160;region of travel,&#160;<br/>and the trip’s&#160;duration&#160;</p>
<p style="position:absolute;top:553px;left:265px;white-space:nowrap" class="ft012"><b>(CIII).</b></p>
<p style="position:absolute;top:552px;left:313px;white-space:nowrap" class="ft038">34,35</p>
<p style="position:absolute;top:553px;left:339px;white-space:nowrap" class="ft013">&#160;In addition, immunizations, (e.g., against&#160;</p>
<p style="position:absolute;top:553px;left:630px;white-space:nowrap" class="ft019"><i>Salmonella</i></p>
<p style="position:absolute;top:553px;left:708px;white-space:nowrap" class="ft013">&#160;serotype&#160;</p>
<p style="position:absolute;top:573px;left:108px;white-space:nowrap" class="ft032">Typhi), should be&#160;recommended in advance&#160;of travel&#160;to relevant&#160;locations (see Immunizations for&#160;<br/>Travel in the&#160;</p>
<p style="position:absolute;top:593px;left:200px;white-space:nowrap" class="ft034">Immunizations section of the&#160;Adult and Adolescent Opportunistic&#160;Infection Guidelines</p>
<p style="position:absolute;top:593px;left:801px;white-space:nowrap" class="ft013">)&#160;</p>
<p style="position:absolute;top:613px;left:108px;white-space:nowrap" class="ft012"><b>(AIII).&#160;</b></p>
<p style="position:absolute;top:650px;left:108px;white-space:nowrap" class="ft013">For people&#160;with&#160;HIV&#160;already&#160;taking&#160;trimethoprim-sulfamethoxazole&#160;(TMP-SMX)&#160;(e.g., for&#160;</p>
<p style="position:absolute;top:670px;left:108px;white-space:nowrap" class="ft019"><i>Pneumocystis jirovecii</i></p>
<p style="position:absolute;top:670px;left:264px;white-space:nowrap" class="ft013">&#160;pneumonia prophylaxis), TMP-SMX may offer limited protection against&#160;</p>
<p style="position:absolute;top:689px;left:108px;white-space:nowrap" class="ft013">traveler’s diarrhea.</p>
<p style="position:absolute;top:688px;left:238px;white-space:nowrap" class="ft038">36</p>
<p style="position:absolute;top:689px;left:250px;white-space:nowrap" class="ft013">&#160;During pregnancy, azithromycin would be&#160;the&#160;preferred agent for prophylaxis&#160;</p>
<p style="position:absolute;top:709px;left:108px;white-space:nowrap" class="ft012"><b>(BIII).</b></p>
<p style="position:absolute;top:709px;left:155px;white-space:nowrap" class="ft013">&#160;Clinicians&#160;should&#160;be&#160;aware&#160;of&#160;concerns&#160;about&#160;fluoroquinolone&#160;safety.&#160;Given&#160;increased&#160;</p>
<p style="position:absolute;top:729px;left:108px;white-space:nowrap" class="ft032">recognition&#160;of&#160;fluoroquinolone&#160;toxicities,&#160;as&#160;well&#160;as&#160;increasing&#160;rates&#160;of&#160;antimicrobial resistance among&#160;<br/>enteric bacterial&#160;pathogens outside&#160;the&#160;United States,&#160;routine&#160;use&#160;of&#160;fluoroquinolones&#160;for&#160;prophylaxis&#160;is&#160;<br/>discouraged&#160;</p>
<p style="position:absolute;top:769px;left:193px;white-space:nowrap" class="ft012"><b>(AIII).</b></p>
<p style="position:absolute;top:767px;left:240px;white-space:nowrap" class="ft038">37</p>
<p style="position:absolute;top:769px;left:251px;white-space:nowrap" class="ft013">&#160;</p>
<p style="position:absolute;top:805px;left:108px;white-space:nowrap" class="ft026"><b>Treating Disease&#160;&#160;</b></p>
<p style="position:absolute;top:856px;left:261px;white-space:nowrap" class="ft02"><b>Recommendations for Treating Bacterial&#160;Enteric&#160;Infections&#160;</b></p>
<p style="position:absolute;top:890px;left:116px;white-space:nowrap" class="ft056"><b>General&#160;Considerations When&#160;Managing&#160;Patients&#160;With&#160;Bacterial Enteric&#160;Infections&#160;</b></p>
<p style="position:absolute;top:915px;left:116px;white-space:nowrap" class="ft030">•</p>
<p style="position:absolute;top:916px;left:123px;white-space:nowrap" class="ft057">&#160;</p>
<p style="position:absolute;top:916px;left:132px;white-space:nowrap" class="ft041">Oral or&#160;IV&#160;rehydration therapy (if&#160;indicated) should&#160;be&#160;given to patients&#160;with diarrhea&#160;</p>
<p style="position:absolute;top:916px;left:592px;white-space:nowrap" class="ft042"><b>(AIII).</b></p>
<p style="position:absolute;top:916px;left:622px;white-space:nowrap" class="ft041">&#160;</p>
<p style="position:absolute;top:942px;left:116px;white-space:nowrap" class="ft030">•</p>
<p style="position:absolute;top:943px;left:123px;white-space:nowrap" class="ft057">&#160;</p>
<p style="position:absolute;top:943px;left:132px;white-space:nowrap" class="ft041">Antimotility&#160;agents&#160;should be&#160;avoided&#160;if concern about inflammatory&#160;diarrhea, including&#160;CDI, exists&#160;</p>
<p style="position:absolute;top:943px;left:670px;white-space:nowrap" class="ft042"><b>(BIII).</b></p>
<p style="position:absolute;top:943px;left:701px;white-space:nowrap" class="ft041">&#160;</p>
<p style="position:absolute;top:969px;left:116px;white-space:nowrap" class="ft030">•</p>
<p style="position:absolute;top:971px;left:123px;white-space:nowrap" class="ft057">&#160;</p>
<p style="position:absolute;top:970px;left:132px;white-space:nowrap" class="ft041">Diagnostic fecal&#160;specimens&#160;should be obtained&#160;before initiation of&#160;empiric antimicrobial&#160;therapy.&#160;</p>
<p style="position:absolute;top:996px;left:116px;white-space:nowrap" class="ft030">•</p>
<p style="position:absolute;top:998px;left:123px;white-space:nowrap" class="ft057">&#160;</p>
<p style="position:absolute;top:997px;left:132px;white-space:nowrap" class="ft041">If a&#160;pathogen is&#160;identified in stool, antibiotic&#160;susceptibilities should&#160;be&#160;performed to&#160;confirm and&#160;inform antibiotic&#160;choice&#160;</p>
<p style="position:absolute;top:1014px;left:132px;white-space:nowrap" class="ft041">given increased&#160;reports&#160;of antibiotic&#160;resistance.&#160;Reflexively&#160;culturing the stool&#160;of patients&#160;diagnosed using PCR-based&#160;</p>
<p style="position:absolute;top:1032px;left:132px;white-space:nowrap" class="ft041">methods can facilitate antibiotic&#160;susceptibility&#160;testing among these&#160;patients.&#160;</p>
</div>
<!-- Page 20 -->
<a name="20"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}	.ft058{font-size:9px;font-family:RAJFOH+LiberationSansNarrow;color:#000000;}
	.ft059{font-size:9px;font-family:BGKYCV+LiberationSansNarrow;color:#000000;}
	.ft060{font-size:15px;font-family:PZCZYN+ArialNarrow;color:#000000;}
	.ft061{font-size:15px;font-family:LLJGTQ+ArialNarrow;color:#000000;}
	.ft062{font-size:15px;font-family:TJEAIW+Cousine;color:#000000;}
	.ft063{font-size:16px;line-height:18px;font-family:BGKYCV+LiberationSansNarrow;color:#000000;}
-->
</style>
<div id="page20-div" style="position:relative;width:917px;height:1187px;">
<p style="position:absolute;top:1114px;left:108px;white-space:nowrap" class="ft024"><i>Guidelines for the Prevention and Treatment&#160;of&#160;Opportunistic&#160;Infections in Adults&#160;and Adolescents&#160;With HIV&#160;</i></p>
<p style="position:absolute;top:1114px;left:791px;white-space:nowrap" class="ft024"><i>B-5&#160;</i></p>
<p style="position:absolute;top:87px;left:116px;white-space:nowrap" class="ft030">•</p>
<p style="position:absolute;top:89px;left:123px;white-space:nowrap" class="ft057">&#160;</p>
<p style="position:absolute;top:88px;left:132px;white-space:nowrap" class="ft041">Risk&#160;of&#160;a bacterial&#160;enteric infection&#160;increases&#160;as&#160;CD4 count declines, with&#160;the&#160;greatest risk&#160;in people with CD4 counts&#160;</p>
<p style="position:absolute;top:105px;left:132px;white-space:nowrap" class="ft041">&lt;200&#160;cells/mm</p>
<p style="position:absolute;top:107px;left:212px;white-space:nowrap" class="ft058">3</p>
<p style="position:absolute;top:105px;left:217px;white-space:nowrap" class="ft041">.&#160;Risk&#160;of bacteremia also increases with decreasing&#160;CD4 count. If&#160;no&#160;clinical&#160;response occurs&#160;after&#160;3 to&#160;</p>
<p style="position:absolute;top:123px;left:132px;white-space:nowrap" class="ft041">4 days&#160;of&#160;therapy, consider follow-up&#160;stool&#160;culture with antibiotic&#160;susceptibility&#160;testing and other methods to detect&#160;enteric&#160;</p>
<p style="position:absolute;top:140px;left:132px;white-space:nowrap" class="ft041">pathogens (e.g.,&#160;toxin&#160;assays, molecular&#160;methods), alternative diagnosis, antibiotic&#160;resistance, or&#160;drug–drug interactions&#160;</p>
<p style="position:absolute;top:157px;left:132px;white-space:nowrap" class="ft042"><b>(BIII).</b></p>
<p style="position:absolute;top:157px;left:163px;white-space:nowrap" class="ft041">&#160;&#160;</p>
<p style="position:absolute;top:183px;left:116px;white-space:nowrap" class="ft030">•</p>
<p style="position:absolute;top:185px;left:123px;white-space:nowrap" class="ft057">&#160;</p>
<p style="position:absolute;top:184px;left:132px;white-space:nowrap" class="ft041">Effective ART may reduce the frequency,&#160;severity, and recurrence of&#160;bacterial&#160;enteric&#160;infections.</p>
<p style="position:absolute;top:184px;left:655px;white-space:nowrap" class="ft042"><b>&#160;</b></p>
<p style="position:absolute;top:216px;left:116px;white-space:nowrap" class="ft063"><b>Empiric Treatment&#160;of&#160;Bacterial&#160;Enteric Infections&#160;&#160;<br/>(Pending&#160;Diagnostic&#160;Studies&#160;and&#160;Antimicrobial&#160;Resistance&#160;Testing)&#160;</b></p>
<p style="position:absolute;top:259px;left:116px;white-space:nowrap" class="ft042"><b>For People With HIV&#160;and CD4&#160;&gt;500&#160;cells/mm</b></p>
<p style="position:absolute;top:260px;left:374px;white-space:nowrap" class="ft059"><b>3</b></p>
<p style="position:absolute;top:259px;left:379px;white-space:nowrap" class="ft042"><b>,&#160;With 1–2 Days&#160;of&#160;Loose Stools Without&#160;Fever or Blood&#160;</b></p>
<p style="position:absolute;top:285px;left:116px;white-space:nowrap" class="ft030">•</p>
<p style="position:absolute;top:287px;left:123px;white-space:nowrap" class="ft057">&#160;</p>
<p style="position:absolute;top:286px;left:132px;white-space:nowrap" class="ft041">Oral hydration; no further work-up and no treatment&#160;is&#160;needed.</p>
<p style="position:absolute;top:286px;left:473px;white-space:nowrap" class="ft024"><i>&#160;</i></p>
<p style="position:absolute;top:318px;left:116px;white-space:nowrap" class="ft042"><b>For People With HIV&#160;and CD4&#160;Count&#160;200–500&#160;cells/mm</b></p>
<p style="position:absolute;top:319px;left:434px;white-space:nowrap" class="ft059"><b>3</b></p>
<p style="position:absolute;top:318px;left:438px;white-space:nowrap" class="ft042"><b>, With&#160;Diarrhea Severe Enough&#160;to&#160;Compromise&#160;&#160;</b></p>
<p style="position:absolute;top:336px;left:116px;white-space:nowrap" class="ft042"><b>Quality of Life&#160;or Ability to Work &#160;</b></p>
<p style="position:absolute;top:362px;left:116px;white-space:nowrap" class="ft030">•</p>
<p style="position:absolute;top:363px;left:123px;white-space:nowrap" class="ft057">&#160;</p>
<p style="position:absolute;top:363px;left:132px;white-space:nowrap" class="ft041">Azithromycin&#160;500 mg PO&#160;daily for&#160;5 days&#160;</p>
<p style="position:absolute;top:363px;left:358px;white-space:nowrap" class="ft042"><b>(BIII)</b></p>
<p style="position:absolute;top:363px;left:385px;white-space:nowrap" class="ft041">,</p>
<p style="position:absolute;top:363px;left:389px;white-space:nowrap" class="ft042"><b>&#160;</b></p>
<p style="position:absolute;top:363px;left:392px;white-space:nowrap" class="ft024"><i>or</i></p>
<p style="position:absolute;top:363px;left:403px;white-space:nowrap" class="ft041">&#160;</p>
<p style="position:absolute;top:389px;left:116px;white-space:nowrap" class="ft030">•</p>
<p style="position:absolute;top:390px;left:123px;white-space:nowrap" class="ft057">&#160;</p>
<p style="position:absolute;top:390px;left:133px;white-space:nowrap" class="ft041">Ciprofloxacin&#160;500–750&#160;mg PO every&#160;12 hours&#160;for 5 days&#160;</p>
<p style="position:absolute;top:390px;left:442px;white-space:nowrap" class="ft042"><b>(BIII)&#160;&#160;</b></p>
<p style="position:absolute;top:422px;left:116px;white-space:nowrap" class="ft042"><b>For People With HIV&#160;and Severe&#160;Disease&#160;(e.g., people with&#160;CD4 count&#160;&lt;200&#160;cells/mm</b></p>
<p style="position:absolute;top:423px;left:608px;white-space:nowrap" class="ft059"><b>3</b></p>
<p style="position:absolute;top:422px;left:613px;white-space:nowrap" class="ft042"><b>&#160;or concomitant&#160;AIDS-defining&#160;</b></p>
<p style="position:absolute;top:439px;left:116px;white-space:nowrap" class="ft042"><b>illnesses), With&#160;Clinically Severe&#160;Diarrhea (</b></p>
<p style="position:absolute;top:439px;left:368px;white-space:nowrap" class="ft060"><b>≥</b></p>
<p style="position:absolute;top:439px;left:376px;white-space:nowrap" class="ft061"><b>6&#160;liquid stools/day or bloody stool and/or accompanying fever&#160;or chills)</b></p>
<p style="position:absolute;top:439px;left:793px;white-space:nowrap" class="ft042"><b>&#160;</b></p>
<p style="position:absolute;top:466px;left:116px;white-space:nowrap" class="ft030">•</p>
<p style="position:absolute;top:467px;left:123px;white-space:nowrap" class="ft057">&#160;</p>
<p style="position:absolute;top:467px;left:132px;white-space:nowrap" class="ft041">Hospitalization for inpatient diagnostic evaluation and IV&#160;antibiotics&#160;</p>
<p style="position:absolute;top:493px;left:116px;white-space:nowrap" class="ft030">•</p>
<p style="position:absolute;top:494px;left:123px;white-space:nowrap" class="ft057">&#160;</p>
<p style="position:absolute;top:494px;left:132px;white-space:nowrap" class="ft041">Ceftriaxone&#160;1–2&#160;g IV every&#160;24&#160;hours&#160;</p>
<p style="position:absolute;top:494px;left:333px;white-space:nowrap" class="ft042"><b>(BIII)</b></p>
<p style="position:absolute;top:495px;left:360px;white-space:nowrap" class="ft058">a</p>
<p style="position:absolute;top:494px;left:365px;white-space:nowrap" class="ft041">&#160;until&#160;antimicrobial&#160;susceptibility&#160;is&#160;available, then treatment can be&#160;changed&#160;</p>
<p style="position:absolute;top:511px;left:132px;white-space:nowrap" class="ft041">based on sensitivity&#160;results.&#160;</p>
<p style="position:absolute;top:539px;left:132px;white-space:nowrap" class="ft062">o</p>
<p style="position:absolute;top:538px;left:141px;white-space:nowrap" class="ft057">&#160;</p>
<p style="position:absolute;top:537px;left:149px;white-space:nowrap" class="ft041">If&#160;</p>
<p style="position:absolute;top:537px;left:159px;white-space:nowrap" class="ft024"><i>Campylobacter</i></p>
<p style="position:absolute;top:537px;left:242px;white-space:nowrap" class="ft041">&#160;or&#160;</p>
<p style="position:absolute;top:537px;left:260px;white-space:nowrap" class="ft024"><i>Shigella</i></p>
<p style="position:absolute;top:537px;left:303px;white-space:nowrap" class="ft041">&#160;bacteremia is&#160;suspected,&#160;a carbapenem is&#160;preferred for empiric&#160;therapy&#160;</p>
<p style="position:absolute;top:537px;left:699px;white-space:nowrap" class="ft042"><b>(BIII).</b></p>
<p style="position:absolute;top:537px;left:730px;white-space:nowrap" class="ft041">&#160;</p>
<p style="position:absolute;top:570px;left:116px;white-space:nowrap" class="ft042"><b>Duration&#160;of&#160;Therapy&#160;</b></p>
<p style="position:absolute;top:596px;left:116px;white-space:nowrap" class="ft030">•</p>
<p style="position:absolute;top:597px;left:123px;white-space:nowrap" class="ft057">&#160;</p>
<p style="position:absolute;top:597px;left:132px;white-space:nowrap" class="ft041">Therapy&#160;and its&#160;duration&#160;should be&#160;adjusted depending&#160;on stool&#160;microbiology results and antibiotic&#160;sensitivity testing.&#160;See&#160;</p>
<p style="position:absolute;top:614px;left:133px;white-space:nowrap" class="ft041">recommendations&#160;for&#160;specific&#160;bacteria&#160;below. If&#160;no pathogen is&#160;identified and&#160;the&#160;patient&#160;recovers&#160;quickly, 5 days&#160;of&#160;</p>
<p style="position:absolute;top:631px;left:133px;white-space:nowrap" class="ft041">therapy&#160;is&#160;recommended.&#160;</p>
<p style="position:absolute;top:663px;left:116px;white-space:nowrap" class="ft042"><b>Other Considerations&#160;</b></p>
<p style="position:absolute;top:690px;left:116px;white-space:nowrap" class="ft030">•</p>
<p style="position:absolute;top:691px;left:123px;white-space:nowrap" class="ft057">&#160;</p>
<p style="position:absolute;top:691px;left:132px;white-space:nowrap" class="ft041">MSM&#160;may be at&#160;increased&#160;risk&#160;for&#160;antibiotic-resistant&#160;enteric&#160;infections. &#160;</p>
<p style="position:absolute;top:717px;left:116px;white-space:nowrap" class="ft030">•</p>
<p style="position:absolute;top:718px;left:123px;white-space:nowrap" class="ft057">&#160;</p>
<p style="position:absolute;top:718px;left:132px;white-space:nowrap" class="ft041">Diarrhea&#160;is&#160;a&#160;common&#160;illness&#160;of international&#160;travelers. Antimicrobial&#160;resistance among enteric bacterial&#160;pathogens&#160;outside&#160;</p>
<p style="position:absolute;top:735px;left:133px;white-space:nowrap" class="ft044">the&#160;United&#160;States&#160;is&#160;common. Clinicians should consider the possibility&#160;of&#160;resistant&#160;infections when&#160;prescribing&#160;empiric&#160;<br/>antibiotic&#160;therapy&#160;for travelers&#160;with HIV&#160;while&#160;traveling or upon return to&#160;the&#160;United States, particularly&#160;among travelers&#160;to&#160;</p>
<p style="position:absolute;top:770px;left:133px;white-space:nowrap" class="ft041">South&#160;and&#160;Southeast Asia&#160;or Africa.&#160;&#160;</p>
<p style="position:absolute;top:796px;left:116px;white-space:nowrap" class="ft030">•</p>
<p style="position:absolute;top:797px;left:123px;white-space:nowrap" class="ft057">&#160;</p>
<p style="position:absolute;top:797px;left:133px;white-space:nowrap" class="ft041">For&#160;patients&#160;with&#160;persistent&#160;diarrhea (&gt;14 days)&#160;but no other&#160;severe clinical&#160;signs&#160;(e.g., dehydration, blood&#160;in stool),&#160;</p>
<p style="position:absolute;top:814px;left:133px;white-space:nowrap" class="ft041">antibiotic&#160;therapy&#160;can be&#160;withheld until&#160;a diagnosis is&#160;confirmed. Noninfectious&#160;etiologies&#160;of&#160;persistent&#160;diarrhea&#160;</p>
<p style="position:absolute;top:831px;left:133px;white-space:nowrap" class="ft041">(e.g., inflammatory&#160;bowel&#160;disease) also can&#160;be&#160;considered in the differential&#160;diagnosis&#160;</p>
<p style="position:absolute;top:831px;left:602px;white-space:nowrap" class="ft042"><b>(BIII).</b></p>
<p style="position:absolute;top:831px;left:633px;white-space:nowrap" class="ft041">&#160;</p>
<p style="position:absolute;top:857px;left:116px;white-space:nowrap" class="ft030">•</p>
<p style="position:absolute;top:859px;left:123px;white-space:nowrap" class="ft057">&#160;</p>
<p style="position:absolute;top:858px;left:133px;white-space:nowrap" class="ft041">Azithromycin&#160;should not be used to&#160;treat bacteremia.&#160;</p>
<p style="position:absolute;top:885px;left:116px;white-space:nowrap" class="ft030">•</p>
<p style="position:absolute;top:886px;left:123px;white-space:nowrap" class="ft057">&#160;</p>
<p style="position:absolute;top:886px;left:133px;white-space:nowrap" class="ft041">Before susceptibilities are known,&#160;empiric IV ceftriaxone is&#160;recommended, although given the rise&#160;of antimicrobial&#160;</p>
<p style="position:absolute;top:903px;left:133px;white-space:nowrap" class="ft041">resistance in enteric pathogens,&#160;updated outbreak information,&#160;local&#160;susceptibility&#160;patterns, and&#160;travel history&#160;should&#160;</p>
<p style="position:absolute;top:920px;left:133px;white-space:nowrap" class="ft041">always be&#160;considered.&#160;</p>
<p style="position:absolute;top:920px;left:258px;white-space:nowrap" class="ft042"><b>&#160;</b></p>
<p style="position:absolute;top:951px;left:116px;white-space:nowrap" class="ft056"><b>Treating&#160;Nontyphoidal&#160;Salmonellosis&#160;</b></p>
<p style="position:absolute;top:976px;left:116px;white-space:nowrap" class="ft041">All&#160;people with HIV&#160;and&#160;salmonellosis&#160;should&#160;receive antibiotic&#160;treatment due to&#160;the&#160;increased&#160;risk&#160;of bacteremia (by&#160;20- to&#160;</p>
<p style="position:absolute;top:993px;left:116px;white-space:nowrap" class="ft041">100-fold) and mortality&#160;(by&#160;as much as&#160;sevenfold) compared with people without HIV&#160;</p>
<p style="position:absolute;top:993px;left:579px;white-space:nowrap" class="ft042"><b>(AIII).</b></p>
<p style="position:absolute;top:993px;left:610px;white-space:nowrap" class="ft041">&#160;</p>
<p style="position:absolute;top:1025px;left:116px;white-space:nowrap" class="ft042"><b>For Invasive&#160;Disease (Suspected or Confirmed)&#160;Pending Susceptibilities&#160;</b></p>
<p style="position:absolute;top:1051px;left:116px;white-space:nowrap" class="ft030">•</p>
<p style="position:absolute;top:1052px;left:123px;white-space:nowrap" class="ft057">&#160;</p>
<p style="position:absolute;top:1052px;left:135px;white-space:nowrap" class="ft041">Ceftriaxone 1–2&#160;g IV&#160;every&#160;24&#160;hours&#160;pending susceptibilities&#160;</p>
<p style="position:absolute;top:1052px;left:465px;white-space:nowrap" class="ft042"><b>(BIII)</b></p>
<p style="position:absolute;top:1052px;left:492px;white-space:nowrap" class="ft041">&#160;</p>
</div>
<!-- Page 21 -->
<a name="21"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}	.ft064{font-size:15px;font-family:IFTYHD+ArialNarrow;color:#000000;}
-->
</style>
<div id="page21-div" style="position:relative;width:917px;height:1187px;">
<p style="position:absolute;top:1114px;left:108px;white-space:nowrap" class="ft024"><i>Guidelines for the Prevention and Treatment&#160;of&#160;Opportunistic&#160;Infections in Adults&#160;and Adolescents&#160;With HIV&#160;</i></p>
<p style="position:absolute;top:1114px;left:791px;white-space:nowrap" class="ft024"><i>B-6&#160;</i></p>
<p style="position:absolute;top:87px;left:116px;white-space:nowrap" class="ft042"><b>Preferred Therapy for Nontyphoidal Salmonella Gastroenteritis With&#160;or Without&#160;Bacteremia&#160;(If Susceptible)&#160;</b></p>
<p style="position:absolute;top:113px;left:116px;white-space:nowrap" class="ft030">•</p>
<p style="position:absolute;top:115px;left:123px;white-space:nowrap" class="ft057">&#160;</p>
<p style="position:absolute;top:114px;left:132px;white-space:nowrap" class="ft041">Ciprofloxacin&#160;500–750&#160;mg PO (or&#160;400&#160;mg&#160;IV) every&#160;12&#160;hours</p>
<p style="position:absolute;top:114px;left:467px;white-space:nowrap" class="ft042"><b>(AIII)</b></p>
<p style="position:absolute;top:114px;left:494px;white-space:nowrap" class="ft041">&#160;</p>
<p style="position:absolute;top:147px;left:116px;white-space:nowrap" class="ft042"><b>Alternative Therapy (If&#160;Susceptible)&#160;</b></p>
<p style="position:absolute;top:173px;left:116px;white-space:nowrap" class="ft030">•</p>
<p style="position:absolute;top:174px;left:123px;white-space:nowrap" class="ft057">&#160;</p>
<p style="position:absolute;top:174px;left:132px;white-space:nowrap" class="ft041">Levofloxacin 750 mg&#160;(PO or&#160;IV)&#160;every&#160;24&#160;hours&#160;</p>
<p style="position:absolute;top:174px;left:392px;white-space:nowrap" class="ft042"><b>(BIII),&#160;</b></p>
<p style="position:absolute;top:174px;left:426px;white-space:nowrap" class="ft024"><i>or</i></p>
<p style="position:absolute;top:174px;left:437px;white-space:nowrap" class="ft041">&#160;</p>
<p style="position:absolute;top:200px;left:116px;white-space:nowrap" class="ft030">•</p>
<p style="position:absolute;top:202px;left:123px;white-space:nowrap" class="ft057">&#160;</p>
<p style="position:absolute;top:201px;left:132px;white-space:nowrap" class="ft041">Moxifloxacin 400mg (PO or IV) every&#160;24&#160;hours&#160;</p>
<p style="position:absolute;top:201px;left:388px;white-space:nowrap" class="ft042"><b>(BIII),&#160;</b></p>
<p style="position:absolute;top:201px;left:422px;white-space:nowrap" class="ft024"><i>or</i></p>
<p style="position:absolute;top:201px;left:433px;white-space:nowrap" class="ft041">&#160;</p>
<p style="position:absolute;top:227px;left:116px;white-space:nowrap" class="ft030">•</p>
<p style="position:absolute;top:229px;left:123px;white-space:nowrap" class="ft057">&#160;</p>
<p style="position:absolute;top:228px;left:132px;white-space:nowrap" class="ft041">Trimethoprim 160 mg/sulfamethoxazole&#160;800 mg&#160;(PO or IV) every&#160;12&#160;hours&#160;</p>
<p style="position:absolute;top:228px;left:540px;white-space:nowrap" class="ft042"><b>(BIII),</b></p>
<p style="position:absolute;top:228px;left:571px;white-space:nowrap" class="ft041">&#160;</p>
<p style="position:absolute;top:228px;left:574px;white-space:nowrap" class="ft024"><i>or</i></p>
<p style="position:absolute;top:228px;left:585px;white-space:nowrap" class="ft041">&#160;</p>
<p style="position:absolute;top:255px;left:116px;white-space:nowrap" class="ft030">•</p>
<p style="position:absolute;top:256px;left:123px;white-space:nowrap" class="ft057">&#160;</p>
<p style="position:absolute;top:256px;left:132px;white-space:nowrap" class="ft041">Ceftriaxone&#160;1–2&#160;g IV every&#160;24&#160;hours&#160;</p>
<p style="position:absolute;top:256px;left:333px;white-space:nowrap" class="ft042"><b>(BIII)</b></p>
<p style="position:absolute;top:256px;left:360px;white-space:nowrap" class="ft041">&#160;</p>
<p style="position:absolute;top:288px;left:116px;white-space:nowrap" class="ft042"><b>Duration&#160;of&#160;Therapy for&#160;Gastroenteritis Without&#160;Bacteremia&#160;</b></p>
<p style="position:absolute;top:314px;left:116px;white-space:nowrap" class="ft030">•</p>
<p style="position:absolute;top:316px;left:123px;white-space:nowrap" class="ft057">&#160;</p>
<p style="position:absolute;top:315px;left:132px;white-space:nowrap" class="ft041">If CD4 count&#160;</p>
<p style="position:absolute;top:315px;left:204px;white-space:nowrap" class="ft064">≥</p>
<p style="position:absolute;top:315px;left:212px;white-space:nowrap" class="ft041">200 cells/mm</p>
<p style="position:absolute;top:316px;left:285px;white-space:nowrap" class="ft058">3</p>
<p style="position:absolute;top:315px;left:289px;white-space:nowrap" class="ft041">: 7–14&#160;days&#160;</p>
<p style="position:absolute;top:315px;left:356px;white-space:nowrap" class="ft042"><b>(BIII)</b></p>
<p style="position:absolute;top:315px;left:384px;white-space:nowrap" class="ft041">&#160;</p>
<p style="position:absolute;top:341px;left:116px;white-space:nowrap" class="ft030">•</p>
<p style="position:absolute;top:343px;left:123px;white-space:nowrap" class="ft057">&#160;</p>
<p style="position:absolute;top:342px;left:132px;white-space:nowrap" class="ft041">If CD4 count&#160;&lt;200 cells/mm</p>
<p style="position:absolute;top:343px;left:284px;white-space:nowrap" class="ft058">3</p>
<p style="position:absolute;top:342px;left:288px;white-space:nowrap" class="ft041">, minimum of 2&#160;weeks&#160;(may&#160;extend&#160;to up to&#160;6 weeks&#160;if&#160;with&#160;severe disease or bacteremia)&#160;</p>
<p style="position:absolute;top:359px;left:132px;white-space:nowrap" class="ft042"><b>(BIII)&#160;</b></p>
<p style="position:absolute;top:392px;left:116px;white-space:nowrap" class="ft042"><b>Duration&#160;of&#160;Therapy for&#160;Gastroenteritis With&#160;Bacteremia&#160;</b></p>
<p style="position:absolute;top:418px;left:116px;white-space:nowrap" class="ft030">•</p>
<p style="position:absolute;top:419px;left:123px;white-space:nowrap" class="ft057">&#160;</p>
<p style="position:absolute;top:419px;left:132px;white-space:nowrap" class="ft041">If CD4 count</p>
<p style="position:absolute;top:419px;left:201px;white-space:nowrap" class="ft042"><b>&#160;</b></p>
<p style="position:absolute;top:419px;left:204px;white-space:nowrap" class="ft064">≥</p>
<p style="position:absolute;top:419px;left:213px;white-space:nowrap" class="ft041">200 cells/mm</p>
<p style="position:absolute;top:420px;left:285px;white-space:nowrap" class="ft058">3</p>
<p style="position:absolute;top:419px;left:289px;white-space:nowrap" class="ft041">: 14&#160;days; longer duration&#160;if&#160;bacteremia persists&#160;or if&#160;the infection&#160;is complicated&#160;</p>
<p style="position:absolute;top:436px;left:132px;white-space:nowrap" class="ft041">(e.g., metastatic&#160;foci of infection&#160;are present)&#160;</p>
<p style="position:absolute;top:436px;left:379px;white-space:nowrap" class="ft042"><b>(BIII)&#160;</b></p>
<p style="position:absolute;top:462px;left:116px;white-space:nowrap" class="ft030">•</p>
<p style="position:absolute;top:464px;left:123px;white-space:nowrap" class="ft057">&#160;</p>
<p style="position:absolute;top:463px;left:132px;white-space:nowrap" class="ft041">If CD4 count&#160;&lt;200 cells/mm</p>
<p style="position:absolute;top:465px;left:284px;white-space:nowrap" class="ft058">3</p>
<p style="position:absolute;top:463px;left:288px;white-space:nowrap" class="ft041">: 2–6 weeks&#160;</p>
<p style="position:absolute;top:463px;left:357px;white-space:nowrap" class="ft042"><b>(BIII)&#160;&#160;</b></p>
<p style="position:absolute;top:496px;left:116px;white-space:nowrap" class="ft042"><b>Secondary Prophylaxis&#160;</b></p>
<p style="position:absolute;top:522px;left:116px;white-space:nowrap" class="ft030">•</p>
<p style="position:absolute;top:523px;left:123px;white-space:nowrap" class="ft057">&#160;</p>
<p style="position:absolute;top:523px;left:132px;white-space:nowrap" class="ft041">The role&#160;of long-term, secondary&#160;prophylaxis&#160;for patients&#160;with&#160;recurrent bacteremia&#160;or gastroenteritis is not well&#160;</p>
<p style="position:absolute;top:540px;left:132px;white-space:nowrap" class="ft041">established.&#160;Clinicians must&#160;weigh the benefit against the risks&#160;of&#160;long-term antibiotic&#160;exposure&#160;</p>
<p style="position:absolute;top:540px;left:651px;white-space:nowrap" class="ft042"><b>(BIII).</b></p>
<p style="position:absolute;top:540px;left:682px;white-space:nowrap" class="ft041">&#160;Antibiotic&#160;choices for&#160;</p>
<p style="position:absolute;top:557px;left:132px;white-space:nowrap" class="ft041">secondary&#160;prophylaxis&#160;are the same as&#160;for primary&#160;treatment and&#160;are dependent&#160;on&#160;the&#160;sensitivity&#160;of the&#160;</p>
<p style="position:absolute;top:557px;left:703px;white-space:nowrap" class="ft024"><i>Salmonella</i></p>
<p style="position:absolute;top:557px;left:764px;white-space:nowrap" class="ft041">&#160;</p>
<p style="position:absolute;top:574px;left:132px;white-space:nowrap" class="ft041">isolate.&#160;</p>
<p style="position:absolute;top:601px;left:116px;white-space:nowrap" class="ft030">•</p>
<p style="position:absolute;top:602px;left:123px;white-space:nowrap" class="ft057">&#160;</p>
<p style="position:absolute;top:602px;left:132px;white-space:nowrap" class="ft041">HIV suppression with ART&#160;is expected to&#160;decrease the risk&#160;of&#160;recurrent&#160;illnesses.&#160;</p>
<p style="position:absolute;top:628px;left:116px;white-space:nowrap" class="ft030">•</p>
<p style="position:absolute;top:629px;left:123px;white-space:nowrap" class="ft057">&#160;</p>
<p style="position:absolute;top:629px;left:132px;white-space:nowrap" class="ft041">Clinicians should be&#160;aware that&#160;recurrence may&#160;represent&#160;development of antimicrobial&#160;resistance&#160;during therapy. &#160;</p>
<p style="position:absolute;top:661px;left:116px;white-space:nowrap" class="ft024"><i>Indication</i></p>
<p style="position:absolute;top:661px;left:169px;white-space:nowrap" class="ft041">&#160;</p>
<p style="position:absolute;top:687px;left:116px;white-space:nowrap" class="ft030">•</p>
<p style="position:absolute;top:689px;left:123px;white-space:nowrap" class="ft057">&#160;</p>
<p style="position:absolute;top:688px;left:132px;white-space:nowrap" class="ft041">Patients with&#160;recurrent bacteremia&#160;</p>
<p style="position:absolute;top:688px;left:322px;white-space:nowrap" class="ft042"><b>(BIII),</b></p>
<p style="position:absolute;top:688px;left:353px;white-space:nowrap" class="ft041">&#160;</p>
<p style="position:absolute;top:688px;left:357px;white-space:nowrap" class="ft024"><i>or</i></p>
<p style="position:absolute;top:688px;left:368px;white-space:nowrap" class="ft041">&#160;&#160;</p>
<p style="position:absolute;top:715px;left:116px;white-space:nowrap" class="ft030">•</p>
<p style="position:absolute;top:716px;left:123px;white-space:nowrap" class="ft057">&#160;</p>
<p style="position:absolute;top:716px;left:132px;white-space:nowrap" class="ft041">Patients with&#160;recurrent gastroenteritis&#160;(with or&#160;without bacteremia) with CD4&#160;count&#160;&lt;200&#160;cells/mm</p>
<p style="position:absolute;top:717px;left:660px;white-space:nowrap" class="ft058">3</p>
<p style="position:absolute;top:716px;left:664px;white-space:nowrap" class="ft041">&#160;and&#160;&#160;</p>
<p style="position:absolute;top:733px;left:132px;white-space:nowrap" class="ft041">severe diarrhea&#160;</p>
<p style="position:absolute;top:733px;left:221px;white-space:nowrap" class="ft042"><b>(BIII)&#160;</b></p>
<p style="position:absolute;top:765px;left:116px;white-space:nowrap" class="ft024"><i>Discontinuing Secondary&#160;Prophylaxis&#160;</i></p>
<p style="position:absolute;top:791px;left:116px;white-space:nowrap" class="ft030">•</p>
<p style="position:absolute;top:793px;left:123px;white-space:nowrap" class="ft057">&#160;</p>
<p style="position:absolute;top:792px;left:132px;white-space:nowrap" class="ft041">After resolution&#160;of&#160;</p>
<p style="position:absolute;top:792px;left:232px;white-space:nowrap" class="ft024"><i>Salmonella</i></p>
<p style="position:absolute;top:792px;left:293px;white-space:nowrap" class="ft041">&#160;infection and response to ART&#160;with sustained&#160;viral&#160;suppression and&#160;CD4 count&#160;</p>
<p style="position:absolute;top:809px;left:132px;white-space:nowrap" class="ft041">&gt;200&#160;cells/mm</p>
<p style="position:absolute;top:811px;left:212px;white-space:nowrap" class="ft058">3</p>
<p style="position:absolute;top:809px;left:217px;white-space:nowrap" class="ft041">,&#160;secondary&#160;prophylaxis&#160;likely&#160;can&#160;be&#160;discontinued&#160;</p>
<p style="position:absolute;top:809px;left:493px;white-space:nowrap" class="ft042"><b>(CII).</b></p>
<p style="position:absolute;top:841px;left:116px;white-space:nowrap" class="ft056"><b>Treating&#160;Shigellosis&#160;</b></p>
<p style="position:absolute;top:865px;left:116px;white-space:nowrap" class="ft044">Therapy&#160;should&#160;be&#160;considered because it may&#160;slightly shorten the&#160;duration&#160;of illness&#160;and&#160;help prevent&#160;spread of the infection&#160;<br/>to others&#160;</p>
<p style="position:absolute;top:882px;left:168px;white-space:nowrap" class="ft042"><b>(AIII);</b></p>
<p style="position:absolute;top:882px;left:199px;white-space:nowrap" class="ft041">&#160;however, antibiotic&#160;selection should be guided&#160;by the results&#160;of&#160;antibiotic&#160;susceptibility&#160;testing.&#160;Because&#160;</p>
<p style="position:absolute;top:900px;left:116px;white-space:nowrap" class="ft041">antimicrobial&#160;resistance of&#160;</p>
<p style="position:absolute;top:900px;left:262px;white-space:nowrap" class="ft024"><i>Shigella&#160;</i></p>
<p style="position:absolute;top:900px;left:309px;white-space:nowrap" class="ft041">spp. is&#160;increasing and limited data&#160;demonstrate&#160;that antibiotic&#160;therapy limits&#160;transmission,&#160;</p>
<p style="position:absolute;top:917px;left:116px;white-space:nowrap" class="ft041">antibiotic&#160;treatment&#160;may be withheld in people with HIV&#160;and&#160;CD4&#160;&gt;500&#160;cells/mm</p>
<p style="position:absolute;top:918px;left:550px;white-space:nowrap" class="ft058">3</p>
<p style="position:absolute;top:917px;left:555px;white-space:nowrap" class="ft041">&#160;whose diarrhea&#160;resolves&#160;before&#160;culture&#160;</p>
<p style="position:absolute;top:934px;left:116px;white-space:nowrap" class="ft041">confirmation of&#160;</p>
<p style="position:absolute;top:934px;left:200px;white-space:nowrap" class="ft024"><i>Shigella</i></p>
<p style="position:absolute;top:934px;left:244px;white-space:nowrap" class="ft041">&#160;infection&#160;</p>
<p style="position:absolute;top:934px;left:297px;white-space:nowrap" class="ft042"><b>(CIII).</b></p>
<p style="position:absolute;top:934px;left:327px;white-space:nowrap" class="ft041">&#160;</p>
<p style="position:absolute;top:966px;left:116px;white-space:nowrap" class="ft042"><b>In Severely&#160;Ill Patients R</b></p>
<p style="position:absolute;top:966px;left:258px;white-space:nowrap" class="ft061"><b>equiring&#160;</b></p>
<p style="position:absolute;top:966px;left:310px;white-space:nowrap" class="ft042"><b>Empiric&#160;Parenteral Therapy&#160;While Awaiting Susceptibility&#160;</b></p>
<p style="position:absolute;top:993px;left:116px;white-space:nowrap" class="ft030">•</p>
<p style="position:absolute;top:994px;left:123px;white-space:nowrap" class="ft057">&#160;</p>
<p style="position:absolute;top:994px;left:132px;white-space:nowrap" class="ft041">Initiate a&#160;carbapenem until&#160;antimicrobial&#160;susceptibilities are available&#160;</p>
<p style="position:absolute;top:994px;left:508px;white-space:nowrap" class="ft042"><b>(BIII).</b></p>
<p style="position:absolute;top:994px;left:539px;white-space:nowrap" class="ft024"><i>&#160;</i></p>
<p style="position:absolute;top:1026px;left:116px;white-space:nowrap" class="ft042"><b>Preferred Therapy (If Susceptible)&#160;</b></p>
<p style="position:absolute;top:1052px;left:116px;white-space:nowrap" class="ft030">•</p>
<p style="position:absolute;top:1054px;left:123px;white-space:nowrap" class="ft057">&#160;</p>
<p style="position:absolute;top:1053px;left:132px;white-space:nowrap" class="ft041">Ciprofloxacin&#160;500–750&#160;mg PO (or&#160;400&#160;mg&#160;IV) every&#160;12&#160;hours&#160;if&#160;MIC &lt;0.12&#160;µ&#160;g/mL&#160;for 5 to 10 days&#160;</p>
<p style="position:absolute;top:1053px;left:664px;white-space:nowrap" class="ft042"><b>(AIII)&#160;</b></p>
</div>
<!-- Page 22 -->
<a name="22"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}	.ft065{font-size:15px;font-family:WOSUCG+ArialNarrow;color:#000000;}
	.ft066{font-size:18px;font-family:GGOOQY+Cambria;color:#000000;}
-->
</style>
<div id="page22-div" style="position:relative;width:917px;height:1187px;">
<p style="position:absolute;top:1114px;left:108px;white-space:nowrap" class="ft024"><i>Guidelines for the Prevention and Treatment&#160;of&#160;Opportunistic&#160;Infections in Adults&#160;and Adolescents&#160;With HIV&#160;</i></p>
<p style="position:absolute;top:1114px;left:791px;white-space:nowrap" class="ft024"><i>B-7&#160;</i></p>
<p style="position:absolute;top:87px;left:116px;white-space:nowrap" class="ft042"><b>Alternative Therapy (If&#160;Susceptible)&#160;</b></p>
<p style="position:absolute;top:113px;left:116px;white-space:nowrap" class="ft030">•</p>
<p style="position:absolute;top:115px;left:123px;white-space:nowrap" class="ft057">&#160;</p>
<p style="position:absolute;top:114px;left:132px;white-space:nowrap" class="ft041">Levofloxacin 750 mg (PO or IV)&#160;every 24 hours&#160;if&#160;MIC &lt;0.12 ug/mL for 5 to 10&#160;days&#160;</p>
<p style="position:absolute;top:114px;left:588px;white-space:nowrap" class="ft042"><b>(BIII),</b></p>
<p style="position:absolute;top:114px;left:619px;white-space:nowrap" class="ft041">&#160;</p>
<p style="position:absolute;top:114px;left:622px;white-space:nowrap" class="ft024"><i>or&#160;</i></p>
<p style="position:absolute;top:114px;left:636px;white-space:nowrap" class="ft041">&#160;</p>
<p style="position:absolute;top:141px;left:116px;white-space:nowrap" class="ft030">•</p>
<p style="position:absolute;top:142px;left:123px;white-space:nowrap" class="ft057">&#160;</p>
<p style="position:absolute;top:142px;left:132px;white-space:nowrap" class="ft041">Trimethoprim&#160;160 mg/sulfamethoxazole&#160;800&#160;mg&#160;PO or&#160;IV&#160;every&#160;12&#160;hours&#160;for 5 to 7&#160;days&#160;</p>
<p style="position:absolute;top:142px;left:613px;white-space:nowrap" class="ft042"><b>(BIII),</b></p>
<p style="position:absolute;top:142px;left:644px;white-space:nowrap" class="ft041">&#160;</p>
<p style="position:absolute;top:142px;left:647px;white-space:nowrap" class="ft024"><i>or</i></p>
<p style="position:absolute;top:142px;left:658px;white-space:nowrap" class="ft041">&#160;&#160;</p>
<p style="position:absolute;top:169px;left:133px;white-space:nowrap" class="ft062">o</p>
<p style="position:absolute;top:168px;left:142px;white-space:nowrap" class="ft057">&#160;</p>
<p style="position:absolute;top:168px;left:149px;white-space:nowrap" class="ft041">Note: TMP-SMX&#160;</p>
<p style="position:absolute;top:168px;left:242px;white-space:nowrap" class="ft042"><b>is not recommended</b></p>
<p style="position:absolute;top:168px;left:362px;white-space:nowrap" class="ft041">&#160;for&#160;bacteremia.&#160;</p>
<p style="position:absolute;top:194px;left:116px;white-space:nowrap" class="ft030">•</p>
<p style="position:absolute;top:196px;left:123px;white-space:nowrap" class="ft057">&#160;</p>
<p style="position:absolute;top:195px;left:133px;white-space:nowrap" class="ft041">Azithromycin&#160;500 mg PO daily&#160;for&#160;5 days&#160;</p>
<p style="position:absolute;top:195px;left:358px;white-space:nowrap" class="ft042"><b>(BIII)&#160;</b></p>
<p style="position:absolute;top:195px;left:389px;white-space:nowrap" class="ft041">&#160;</p>
<p style="position:absolute;top:223px;left:133px;white-space:nowrap" class="ft062">o</p>
<p style="position:absolute;top:222px;left:142px;white-space:nowrap" class="ft057">&#160;</p>
<p style="position:absolute;top:221px;left:149px;white-space:nowrap" class="ft041">Note:&#160;Azithromycin&#160;</p>
<p style="position:absolute;top:221px;left:255px;white-space:nowrap" class="ft042"><b>is not recommended</b></p>
<p style="position:absolute;top:221px;left:376px;white-space:nowrap" class="ft041">&#160;for&#160;bacteremia&#160;</p>
<p style="position:absolute;top:221px;left:461px;white-space:nowrap" class="ft042"><b>(AIII)</b></p>
<p style="position:absolute;top:221px;left:488px;white-space:nowrap" class="ft041">&#160;</p>
<p style="position:absolute;top:248px;left:116px;white-space:nowrap" class="ft030">•</p>
<p style="position:absolute;top:249px;left:123px;white-space:nowrap" class="ft057">&#160;</p>
<p style="position:absolute;top:249px;left:133px;white-space:nowrap" class="ft041">Ceftriaxone&#160;1–2&#160;g IV&#160;every&#160;24&#160;hours&#160;</p>
<p style="position:absolute;top:249px;left:333px;white-space:nowrap" class="ft042"><b>(BIII)</b></p>
<p style="position:absolute;top:249px;left:360px;white-space:nowrap" class="ft041">&#160;</p>
<p style="position:absolute;top:281px;left:116px;white-space:nowrap" class="ft042"><b>Duration&#160;of&#160;Therapy&#160;</b></p>
<p style="position:absolute;top:307px;left:116px;white-space:nowrap" class="ft030">•</p>
<p style="position:absolute;top:309px;left:123px;white-space:nowrap" class="ft057">&#160;</p>
<p style="position:absolute;top:308px;left:133px;white-space:nowrap" class="ft041">Gastroenteritis:&#160;5–7&#160;days&#160;</p>
<p style="position:absolute;top:308px;left:273px;white-space:nowrap" class="ft042"><b>(AIII)&#160;</b></p>
<p style="position:absolute;top:308px;left:303px;white-space:nowrap" class="ft041">(except&#160;ciprofloxacin [5 to&#160;10&#160;days] and azithromycin [5 days])&#160;</p>
<p style="position:absolute;top:336px;left:133px;white-space:nowrap" class="ft062">o</p>
<p style="position:absolute;top:335px;left:142px;white-space:nowrap" class="ft057">&#160;</p>
<p style="position:absolute;top:334px;left:149px;white-space:nowrap" class="ft041">7–10 days&#160;of therapy may&#160;be reasonable in patients&#160;who are&#160;severely immunosuppressed&#160;with&#160;poor&#160;clinical&#160;response to&#160;</p>
<p style="position:absolute;top:351px;left:149px;white-space:nowrap" class="ft041">antibiotics.&#160;</p>
<p style="position:absolute;top:378px;left:116px;white-space:nowrap" class="ft030">•</p>
<p style="position:absolute;top:379px;left:123px;white-space:nowrap" class="ft057">&#160;</p>
<p style="position:absolute;top:379px;left:133px;white-space:nowrap" class="ft041">Bacteremia:&#160;</p>
<p style="position:absolute;top:379px;left:202px;white-space:nowrap" class="ft064">≥</p>
<p style="position:absolute;top:379px;left:210px;white-space:nowrap" class="ft065">14&#160;days&#160;</p>
<p style="position:absolute;top:379px;left:256px;white-space:nowrap" class="ft042"><b>(BIII)&#160;</b></p>
<p style="position:absolute;top:405px;left:116px;white-space:nowrap" class="ft030">•</p>
<p style="position:absolute;top:406px;left:123px;white-space:nowrap" class="ft057">&#160;</p>
<p style="position:absolute;top:406px;left:133px;white-space:nowrap" class="ft041">Recurrent infections: up&#160;to 6&#160;weeks&#160;</p>
<p style="position:absolute;top:406px;left:328px;white-space:nowrap" class="ft042"><b>(BIII)&#160;&#160;</b></p>
<p style="position:absolute;top:438px;left:116px;white-space:nowrap" class="ft042"><b>Chronic Maintenance or Suppressive&#160;Therapy&#160;</b></p>
<p style="position:absolute;top:464px;left:116px;white-space:nowrap" class="ft030">•</p>
<p style="position:absolute;top:466px;left:123px;white-space:nowrap" class="ft057">&#160;</p>
<p style="position:absolute;top:465px;left:133px;white-space:nowrap" class="ft042"><b>Not&#160;recommended</b></p>
<p style="position:absolute;top:465px;left:241px;white-space:nowrap" class="ft041">&#160;for&#160;first-time&#160;</p>
<p style="position:absolute;top:465px;left:312px;white-space:nowrap" class="ft024"><i>Shigella</i></p>
<p style="position:absolute;top:465px;left:356px;white-space:nowrap" class="ft041">&#160;infections&#160;</p>
<p style="position:absolute;top:465px;left:415px;white-space:nowrap" class="ft042"><b>(BIII)&#160;</b></p>
<p style="position:absolute;top:497px;left:116px;white-space:nowrap" class="ft056"><b>Treating&#160;Campylobacteriosis&#160;</b></p>
<p style="position:absolute;top:521px;left:116px;white-space:nowrap" class="ft030">•</p>
<p style="position:absolute;top:523px;left:123px;white-space:nowrap" class="ft057">&#160;</p>
<p style="position:absolute;top:522px;left:132px;white-space:nowrap" class="ft041">Optimal&#160;treatment is&#160;poorly defined and multidrug resistance may&#160;occur.</p>
<p style="position:absolute;top:522px;left:524px;white-space:nowrap" class="ft042"><b>&#160;</b></p>
<p style="position:absolute;top:548px;left:116px;white-space:nowrap" class="ft030">•</p>
<p style="position:absolute;top:550px;left:123px;white-space:nowrap" class="ft057">&#160;</p>
<p style="position:absolute;top:549px;left:132px;white-space:nowrap" class="ft041">Antimicrobial&#160;therapy&#160;should&#160;be&#160;modified&#160;based on susceptibility&#160;reports.&#160;</p>
<p style="position:absolute;top:581px;left:116px;white-space:nowrap" class="ft042"><b>Mild Disease If&#160;CD4 Count &gt;200 cells/mm</b></p>
<p style="position:absolute;top:582px;left:356px;white-space:nowrap" class="ft059"><b>3</b></p>
<p style="position:absolute;top:581px;left:360px;white-space:nowrap" class="ft042"><b>&#160;</b></p>
<p style="position:absolute;top:608px;left:116px;white-space:nowrap" class="ft030">•</p>
<p style="position:absolute;top:609px;left:123px;white-space:nowrap" class="ft057">&#160;</p>
<p style="position:absolute;top:609px;left:132px;white-space:nowrap" class="ft041">If</p>
<p style="position:absolute;top:609px;left:139px;white-space:nowrap" class="ft042"><b>&#160;</b></p>
<p style="position:absolute;top:609px;left:143px;white-space:nowrap" class="ft041">diarrhea resolves before&#160;culture&#160;confirmation of&#160;</p>
<p style="position:absolute;top:609px;left:403px;white-space:nowrap" class="ft024"><i>Campylobacter</i></p>
<p style="position:absolute;top:609px;left:486px;white-space:nowrap" class="ft041">&#160;infection,&#160;antibiotic&#160;treatment&#160;can&#160;be&#160;withheld&#160;</p>
<p style="position:absolute;top:609px;left:738px;white-space:nowrap" class="ft042"><b>(CIII).</b></p>
<p style="position:absolute;top:609px;left:769px;white-space:nowrap" class="ft041">&#160;If&#160;</p>
<p style="position:absolute;top:626px;left:132px;white-space:nowrap" class="ft041">symptoms persist for more than&#160;several days, consider antibiotic&#160;therapy&#160;</p>
<p style="position:absolute;top:626px;left:530px;white-space:nowrap" class="ft042"><b>(CIII).</b></p>
<p style="position:absolute;top:626px;left:561px;white-space:nowrap" class="ft041">&#160;</p>
<p style="position:absolute;top:658px;left:116px;white-space:nowrap" class="ft042"><b>Mild-to-Moderate Disease&#160;</b></p>
<p style="position:absolute;top:684px;left:116px;white-space:nowrap" class="ft030">•</p>
<p style="position:absolute;top:686px;left:123px;white-space:nowrap" class="ft057">&#160;</p>
<p style="position:absolute;top:685px;left:132px;white-space:nowrap" class="ft024"><i>Preferred&#160;Therapy (If Susceptible)&#160;</i></p>
<p style="position:absolute;top:713px;left:133px;white-space:nowrap" class="ft062">o</p>
<p style="position:absolute;top:712px;left:142px;white-space:nowrap" class="ft057">&#160;</p>
<p style="position:absolute;top:712px;left:149px;white-space:nowrap" class="ft041">Azithromycin&#160;500 mg&#160;PO daily for 5 days&#160;</p>
<p style="position:absolute;top:712px;left:374px;white-space:nowrap" class="ft042"><b>(BIII)&#160;</b></p>
<p style="position:absolute;top:712px;left:405px;white-space:nowrap" class="ft041">(</p>
<p style="position:absolute;top:712px;left:409px;white-space:nowrap" class="ft042"><b>not recommended</b></p>
<p style="position:absolute;top:712px;left:515px;white-space:nowrap" class="ft041">&#160;for&#160;bacteremia&#160;</p>
<p style="position:absolute;top:712px;left:601px;white-space:nowrap" class="ft042"><b>[AIII]</b></p>
<p style="position:absolute;top:712px;left:628px;white-space:nowrap" class="ft041">),&#160;</p>
<p style="position:absolute;top:712px;left:639px;white-space:nowrap" class="ft024"><i>or</i></p>
<p style="position:absolute;top:712px;left:650px;white-space:nowrap" class="ft041">&#160;</p>
<p style="position:absolute;top:739px;left:133px;white-space:nowrap" class="ft062">o</p>
<p style="position:absolute;top:738px;left:142px;white-space:nowrap" class="ft057">&#160;</p>
<p style="position:absolute;top:738px;left:149px;white-space:nowrap" class="ft041">Ciprofloxacin</p>
<p style="position:absolute;top:739px;left:220px;white-space:nowrap" class="ft058">b</p>
<p style="position:absolute;top:738px;left:224px;white-space:nowrap" class="ft041">&#160;500–750&#160;mg&#160;PO (or 400&#160;mg IV) every&#160;12&#160;hours&#160;for&#160;7–10&#160;days&#160;</p>
<p style="position:absolute;top:738px;left:565px;white-space:nowrap" class="ft042"><b>(BIII)&#160;</b></p>
<p style="position:absolute;top:738px;left:596px;white-space:nowrap" class="ft041">(if susceptible)&#160;</p>
<p style="position:absolute;top:770px;left:116px;white-space:nowrap" class="ft030">•</p>
<p style="position:absolute;top:771px;left:123px;white-space:nowrap" class="ft057">&#160;</p>
<p style="position:absolute;top:771px;left:132px;white-space:nowrap" class="ft024"><i>Alternative Therapy (If Susceptible)</i></p>
<p style="position:absolute;top:768px;left:325px;white-space:nowrap" class="ft066"><i>&#160;</i></p>
<p style="position:absolute;top:799px;left:132px;white-space:nowrap" class="ft062">o</p>
<p style="position:absolute;top:798px;left:141px;white-space:nowrap" class="ft057">&#160;</p>
<p style="position:absolute;top:797px;left:149px;white-space:nowrap" class="ft041">Levofloxacin</p>
<p style="position:absolute;top:798px;left:217px;white-space:nowrap" class="ft058">c</p>
<p style="position:absolute;top:797px;left:221px;white-space:nowrap" class="ft041">&#160;750&#160;mg&#160;PO or IV every&#160;24&#160;hours&#160;</p>
<p style="position:absolute;top:797px;left:404px;white-space:nowrap" class="ft042"><b>(BIII),</b></p>
<p style="position:absolute;top:797px;left:435px;white-space:nowrap" class="ft041">&#160;</p>
<p style="position:absolute;top:797px;left:438px;white-space:nowrap" class="ft024"><i>or</i></p>
<p style="position:absolute;top:797px;left:449px;white-space:nowrap" class="ft041">&#160;</p>
<p style="position:absolute;top:829px;left:116px;white-space:nowrap" class="ft042"><b>Bacteremia&#160;</b></p>
<p style="position:absolute;top:856px;left:116px;white-space:nowrap" class="ft030">•</p>
<p style="position:absolute;top:857px;left:123px;white-space:nowrap" class="ft057">&#160;</p>
<p style="position:absolute;top:857px;left:132px;white-space:nowrap" class="ft041">Ciprofloxacin</p>
<p style="position:absolute;top:858px;left:204px;white-space:nowrap" class="ft058">b</p>
<p style="position:absolute;top:857px;left:208px;white-space:nowrap" class="ft041">&#160;500–750&#160;mg&#160;PO (or 400&#160;mg IV) every&#160;12&#160;hours&#160;</p>
<p style="position:absolute;top:857px;left:471px;white-space:nowrap" class="ft065">for&#160;</p>
<p style="position:absolute;top:857px;left:489px;white-space:nowrap" class="ft064">≥</p>
<p style="position:absolute;top:857px;left:497px;white-space:nowrap" class="ft065">14 days</p>
<p style="position:absolute;top:857px;left:540px;white-space:nowrap" class="ft041">&#160;</p>
<p style="position:absolute;top:857px;left:544px;white-space:nowrap" class="ft042"><b>(BIII)&#160;</b></p>
<p style="position:absolute;top:857px;left:574px;white-space:nowrap" class="ft041">(if&#160;susceptible)&#160;plus an aminoglycoside&#160;</p>
<p style="position:absolute;top:874px;left:133px;white-space:nowrap" class="ft042"><b>(BIII)&#160;</b></p>
<p style="position:absolute;top:874px;left:163px;white-space:nowrap" class="ft041">to limit the emergence of antibiotic&#160;resistance</p>
<p style="position:absolute;top:874px;left:409px;white-space:nowrap" class="ft042"><b>&#160;</b></p>
<p style="position:absolute;top:906px;left:116px;white-space:nowrap" class="ft042"><b>Duration&#160;of&#160;Therapy&#160;</b></p>
<p style="position:absolute;top:932px;left:116px;white-space:nowrap" class="ft030">•</p>
<p style="position:absolute;top:934px;left:123px;white-space:nowrap" class="ft057">&#160;</p>
<p style="position:absolute;top:933px;left:132px;white-space:nowrap" class="ft041">Gastroenteritis:&#160;7–10&#160;days&#160;(except&#160;azithromycin,&#160;which is&#160;5 days)&#160;</p>
<p style="position:absolute;top:933px;left:490px;white-space:nowrap" class="ft042"><b>(BIII)&#160;</b></p>
<p style="position:absolute;top:933px;left:521px;white-space:nowrap" class="ft041">&#160;</p>
<p style="position:absolute;top:960px;left:116px;white-space:nowrap" class="ft030">•</p>
<p style="position:absolute;top:961px;left:123px;white-space:nowrap" class="ft057">&#160;</p>
<p style="position:absolute;top:961px;left:132px;white-space:nowrap" class="ft065">Bacteremia:&#160;</p>
<p style="position:absolute;top:961px;left:202px;white-space:nowrap" class="ft064">≥</p>
<p style="position:absolute;top:961px;left:210px;white-space:nowrap" class="ft065">14&#160;days&#160;</p>
<p style="position:absolute;top:961px;left:256px;white-space:nowrap" class="ft042"><b>(BIII)</b></p>
<p style="position:absolute;top:961px;left:284px;white-space:nowrap" class="ft041">&#160;</p>
<p style="position:absolute;top:987px;left:116px;white-space:nowrap" class="ft030">•</p>
<p style="position:absolute;top:988px;left:123px;white-space:nowrap" class="ft057">&#160;</p>
<p style="position:absolute;top:988px;left:132px;white-space:nowrap" class="ft041">Recurrent disease: 2–6 weeks&#160;</p>
<p style="position:absolute;top:988px;left:301px;white-space:nowrap" class="ft042"><b>(BIII)</b></p>
<p style="position:absolute;top:988px;left:329px;white-space:nowrap" class="ft041">&#160;</p>
</div>
<!-- Page 23 -->
<a name="23"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}	.ft067{font-size:15px;font-family:JJWKPC+Cambria;color:#000000;}
	.ft068{font-size:16px;font-family:TMWRTT+LiberationSansNarrow;color:#000000;}
-->
</style>
<div id="page23-div" style="position:relative;width:917px;height:1187px;">
<p style="position:absolute;top:1114px;left:108px;white-space:nowrap" class="ft024"><i>Guidelines for the Prevention and Treatment&#160;of&#160;Opportunistic&#160;Infections in Adults&#160;and Adolescents&#160;With HIV&#160;</i></p>
<p style="position:absolute;top:1114px;left:791px;white-space:nowrap" class="ft024"><i>B-8&#160;</i></p>
<p style="position:absolute;top:87px;left:116px;white-space:nowrap" class="ft042"><b>Chronic Maintenance or Suppressive&#160;Therapy&#160;</b></p>
<p style="position:absolute;top:113px;left:116px;white-space:nowrap" class="ft030">•</p>
<p style="position:absolute;top:115px;left:123px;white-space:nowrap" class="ft057">&#160;</p>
<p style="position:absolute;top:114px;left:132px;white-space:nowrap" class="ft041">Not recommended for first-time&#160;</p>
<p style="position:absolute;top:114px;left:305px;white-space:nowrap" class="ft024"><i>Campylobacter&#160;</i></p>
<p style="position:absolute;top:114px;left:391px;white-space:nowrap" class="ft041">infections&#160;</p>
<p style="position:absolute;top:114px;left:447px;white-space:nowrap" class="ft042"><b>(BIII)</b></p>
<p style="position:absolute;top:114px;left:474px;white-space:nowrap" class="ft067"><b>&#160;</b></p>
<p style="position:absolute;top:148px;left:116px;white-space:nowrap" class="ft058">b</p>
<p style="position:absolute;top:147px;left:121px;white-space:nowrap" class="ft041">&#160;The rate of&#160;fluoroquinolone&#160;resistance in the United&#160;States is increasing (29%&#160;resistance in 2018&#160;among&#160;</p>
<p style="position:absolute;top:147px;left:693px;white-space:nowrap" class="ft024"><i>C. jejuni</i></p>
<p style="position:absolute;top:147px;left:737px;white-space:nowrap" class="ft041">&#160;isolates).&#160;</p>
<p style="position:absolute;top:164px;left:116px;white-space:nowrap" class="ft041">Third generation&#160;cephalosporins&#160;are not&#160;reliably&#160;active and use of&#160;alternative cell-wall active agents&#160;such as&#160;carbapenems&#160;</p>
<p style="position:absolute;top:181px;left:116px;white-space:nowrap" class="ft041">may be necessary&#160;in&#160;severely&#160;ill&#160;people requiring&#160;empiric&#160;parenteral&#160;therapy&#160;until&#160;antimicrobial&#160;susceptibilities&#160;return.</p>
<p style="position:absolute;top:181px;left:748px;white-space:nowrap" class="ft067"><b>&#160;</b></p>
<p style="position:absolute;top:212px;left:116px;white-space:nowrap" class="ft056"><b>Treating&#160;</b></p>
<p style="position:absolute;top:212px;left:173px;white-space:nowrap" class="ft068"><i><b>Clostridioides&#160;difficile</b></i></p>
<p style="position:absolute;top:212px;left:314px;white-space:nowrap" class="ft056"><b>–Associated Infection&#160;</b></p>
<p style="position:absolute;top:237px;left:116px;white-space:nowrap" class="ft042"><b>Preferred Therapy (Severe or Nonsevere&#160;CDI</b></p>
<p style="position:absolute;top:238px;left:377px;white-space:nowrap" class="ft059"><b>c</b></p>
<p style="position:absolute;top:237px;left:381px;white-space:nowrap" class="ft042"><b>)&#160;</b></p>
<p style="position:absolute;top:263px;left:116px;white-space:nowrap" class="ft030">•</p>
<p style="position:absolute;top:264px;left:123px;white-space:nowrap" class="ft057">&#160;</p>
<p style="position:absolute;top:264px;left:132px;white-space:nowrap" class="ft041">Fidaxomicin 200&#160;mg PO two times&#160;per day&#160;for 10&#160;days&#160;</p>
<p style="position:absolute;top:264px;left:431px;white-space:nowrap" class="ft042"><b>(AI)</b></p>
<p style="position:absolute;top:264px;left:452px;white-space:nowrap" class="ft041">&#160;</p>
<p style="position:absolute;top:296px;left:116px;white-space:nowrap" class="ft042"><b>Alternative Therapy&#160;</b></p>
<p style="position:absolute;top:322px;left:116px;white-space:nowrap" class="ft030">•</p>
<p style="position:absolute;top:323px;left:132px;white-space:nowrap" class="ft041">Vancomycin 125&#160;mg PO&#160;four&#160;times per day&#160;for&#160;10 days</p>
<p style="position:absolute;top:323px;left:435px;white-space:nowrap" class="ft042"><b>(AI)</b></p>
<p style="position:absolute;top:350px;left:116px;white-space:nowrap" class="ft030">•</p>
<p style="position:absolute;top:351px;left:123px;white-space:nowrap" class="ft057">&#160;</p>
<p style="position:absolute;top:351px;left:132px;white-space:nowrap" class="ft041">For&#160;severe, life-threatening CDI,&#160;see&#160;</p>
<p style="position:absolute;top:351px;left:334px;white-space:nowrap" class="ft024"><i>C.&#160;difficile</i></p>
<p style="position:absolute;top:351px;left:387px;white-space:nowrap" class="ft041">&#160;and references for additional&#160;information.&#160;</p>
<p style="position:absolute;top:383px;left:116px;white-space:nowrap" class="ft042"><b>Alternative Therapy for&#160;Nonsevere CDI</b></p>
<p style="position:absolute;top:384px;left:342px;white-space:nowrap" class="ft059"><b>c</b></p>
<p style="position:absolute;top:383px;left:346px;white-space:nowrap" class="ft042"><b>&#160;</b></p>
<p style="position:absolute;top:409px;left:116px;white-space:nowrap" class="ft030">•</p>
<p style="position:absolute;top:411px;left:123px;white-space:nowrap" class="ft057">&#160;</p>
<p style="position:absolute;top:410px;left:132px;white-space:nowrap" class="ft041">If neither fidaxomicin nor vancomycin&#160;is&#160;available:&#160;metronidazole&#160;500&#160;mg PO three times per day&#160;for 10 days&#160;</p>
<p style="position:absolute;top:410px;left:725px;white-space:nowrap" class="ft042"><b>(CI).</b></p>
<p style="position:absolute;top:410px;left:749px;white-space:nowrap" class="ft041">&#160;</p>
<p style="position:absolute;top:442px;left:116px;white-space:nowrap" class="ft042"><b>Note:</b></p>
<p style="position:absolute;top:442px;left:148px;white-space:nowrap" class="ft041">&#160;Based on&#160;clinical&#160;trials, vancomycin&#160;is&#160;superior to metronidazole&#160;for therapy&#160;of CDI (discussed in text).&#160;</p>
<p style="position:absolute;top:475px;left:116px;white-space:nowrap" class="ft042"><b>Recurrent CDI&#160;</b></p>
<p style="position:absolute;top:501px;left:116px;white-space:nowrap" class="ft030">•</p>
<p style="position:absolute;top:502px;left:123px;white-space:nowrap" class="ft057">&#160;</p>
<p style="position:absolute;top:502px;left:132px;white-space:nowrap" class="ft041">Use of&#160;fidaxomicin over&#160;oral&#160;vancomycin&#160;is&#160;recommended, in agreement with the 2021&#160;IDSA&#160;CDI Guidelines,&#160;as it has a&#160;</p>
<p style="position:absolute;top:519px;left:133px;white-space:nowrap" class="ft041">greater likelihood&#160;for a sustained&#160;clinical&#160;response at&#160;30&#160;days&#160;</p>
<p style="position:absolute;top:519px;left:468px;white-space:nowrap" class="ft042"><b>(AI).&#160;</b></p>
<p style="position:absolute;top:545px;left:116px;white-space:nowrap" class="ft030">•</p>
<p style="position:absolute;top:547px;left:123px;white-space:nowrap" class="ft057">&#160;</p>
<p style="position:absolute;top:546px;left:132px;white-space:nowrap" class="ft041">Vancomycin&#160;is an acceptable option (see&#160;</p>
<p style="position:absolute;top:546px;left:360px;white-space:nowrap" class="ft043">IDSA&#160;Guideline</p>
<p style="position:absolute;top:546px;left:444px;white-space:nowrap" class="ft041">&#160;for tapered and&#160;pulsed regimens)&#160;</p>
<p style="position:absolute;top:546px;left:632px;white-space:nowrap" class="ft042"><b>(AI).&#160;</b></p>
<p style="position:absolute;top:573px;left:116px;white-space:nowrap" class="ft030">•</p>
<p style="position:absolute;top:574px;left:123px;white-space:nowrap" class="ft057">&#160;</p>
<p style="position:absolute;top:574px;left:132px;white-space:nowrap" class="ft041">FMT&#160;may&#160;be&#160;considered&#160;after&#160;three CDI episodes&#160;(i.e., an initial&#160;and&#160;two recurrent episodes)&#160;</p>
<p style="position:absolute;top:574px;left:637px;white-space:nowrap" class="ft042"><b>(CIII).&#160;</b></p>
<p style="position:absolute;top:607px;left:116px;white-space:nowrap" class="ft058">c</p>
<p style="position:absolute;top:606px;left:120px;white-space:nowrap" class="ft041">&#160;Severe CDI:&#160;white blood&#160;cell count&#160;</p>
<p style="position:absolute;top:606px;left:315px;white-space:nowrap" class="ft064">≥</p>
<p style="position:absolute;top:606px;left:323px;white-space:nowrap" class="ft041">15,000&#160;cells/mL or&#160;serum creatinine&#160;concentrations &gt;1.5 mg/dL;&#160;nonsevere CDI: white&#160;</p>
<p style="position:absolute;top:623px;left:116px;white-space:nowrap" class="ft041">blood&#160;cell&#160;count &lt;15,000 cells/mL and serum&#160;creatinine concentrations &lt;1.5 mg/dL&#160;</p>
<p style="position:absolute;top:654px;left:116px;white-space:nowrap" class="ft056"><b>Treating&#160;Bacterial Enteric Infections&#160;During&#160;Pregnancy</b></p>
<p style="position:absolute;top:654px;left:468px;white-space:nowrap" class="ft068"><i><b>&#160;</b></i></p>
<p style="position:absolute;top:679px;left:116px;white-space:nowrap" class="ft030">•</p>
<p style="position:absolute;top:680px;left:123px;white-space:nowrap" class="ft057">&#160;</p>
<p style="position:absolute;top:680px;left:132px;white-space:nowrap" class="ft041">Based&#160;on their safety profile, expanded-spectrum&#160;cephalosporins&#160;(such as&#160;ceftriaxone&#160;and cefotaxime)&#160;or azithromycin&#160;</p>
<p style="position:absolute;top:697px;left:132px;white-space:nowrap" class="ft044">should be&#160;the&#160;first-line&#160;therapy&#160;for&#160;bacterial&#160;enteric infections&#160;during&#160;pregnancy&#160;if antimicrobials&#160;are required, depending&#160;on&#160;<br/>the&#160;organism and the results of&#160;susceptibility&#160;testing&#160;</p>
<p style="position:absolute;top:714px;left:418px;white-space:nowrap" class="ft042"><b>(BIII).&#160;</b></p>
<p style="position:absolute;top:714px;left:452px;white-space:nowrap" class="ft041">&#160;</p>
<p style="position:absolute;top:740px;left:116px;white-space:nowrap" class="ft030">•</p>
<p style="position:absolute;top:742px;left:123px;white-space:nowrap" class="ft057">&#160;</p>
<p style="position:absolute;top:741px;left:132px;white-space:nowrap" class="ft041">Other&#160;commonly&#160;prescribed&#160;antimicrobials&#160;during pregnancy&#160;include&#160;vancomycin&#160;and metronidazole. Fidaxomicin,&#160;</p>
<p style="position:absolute;top:758px;left:132px;white-space:nowrap" class="ft041">quinolones, and TMP-SMX&#160;should&#160;be prescribed&#160;using&#160;shared decision-making.&#160;&#160;</p>
<p style="position:absolute;top:785px;left:116px;white-space:nowrap" class="ft030">•</p>
<p style="position:absolute;top:786px;left:123px;white-space:nowrap" class="ft057">&#160;</p>
<p style="position:absolute;top:786px;left:132px;white-space:nowrap" class="ft041">Quinolones can&#160;be used for bacterial&#160;enteric infections during pregnancy&#160;if indicated&#160;by susceptibility&#160;testing or failure of&#160;</p>
<p style="position:absolute;top:803px;left:132px;white-space:nowrap" class="ft041">first-line&#160;therapy&#160;</p>
<p style="position:absolute;top:803px;left:223px;white-space:nowrap" class="ft042"><b>(BIII).</b></p>
<p style="position:absolute;top:803px;left:254px;white-space:nowrap" class="ft041">&#160;</p>
<p style="position:absolute;top:829px;left:116px;white-space:nowrap" class="ft030">•</p>
<p style="position:absolute;top:831px;left:123px;white-space:nowrap" class="ft057">&#160;</p>
<p style="position:absolute;top:830px;left:132px;white-space:nowrap" class="ft041">TMP-SMX&#160;use in the first trimester should&#160;be&#160;avoided,&#160;if possible, because of&#160;an association&#160;with&#160;an&#160;increased&#160;risk&#160;of birth&#160;</p>
<p style="position:absolute;top:847px;left:132px;white-space:nowrap" class="ft041">defects,&#160;specifically&#160;neural tube,&#160;cardiovascular,&#160;and&#160;urinary&#160;tract&#160;defects&#160;</p>
<p style="position:absolute;top:847px;left:532px;white-space:nowrap" class="ft042"><b>(BIII).&#160;</b></p>
<p style="position:absolute;top:847px;left:566px;white-space:nowrap" class="ft041">As&#160;soon&#160;as&#160;possible&#160;during the first&#160;</p>
<p style="position:absolute;top:865px;left:132px;white-space:nowrap" class="ft044">trimester of pregnancy, or&#160;when&#160;anticipating or attempting&#160;conception, any administration of TMP-SMX&#160;should be&#160;<br/>supplemented&#160;with</p>
<p style="position:absolute;top:882px;left:235px;white-space:nowrap" class="ft042"><b>&#160;</b></p>
<p style="position:absolute;top:882px;left:238px;white-space:nowrap" class="ft041">4 mg/day of folic acid</p>
<p style="position:absolute;top:882px;left:354px;white-space:nowrap" class="ft042"><b>&#160;(BIII).</b></p>
<p style="position:absolute;top:880px;left:388px;white-space:nowrap" class="ft06">&#160;</p>
<p style="position:absolute;top:909px;left:108px;white-space:nowrap" class="ft042"><b>Key:&#160;</b></p>
<p style="position:absolute;top:909px;left:138px;white-space:nowrap" class="ft041">ART =</p>
<p style="position:absolute;top:909px;left:173px;white-space:nowrap" class="ft042"><b>&#160;</b></p>
<p style="position:absolute;top:909px;left:177px;white-space:nowrap" class="ft041">antiretroviral therapy;</p>
<p style="position:absolute;top:909px;left:292px;white-space:nowrap" class="ft042"><b>&#160;</b></p>
<p style="position:absolute;top:909px;left:296px;white-space:nowrap" class="ft041">CD4&#160;= CD4&#160;T&#160;lymphocyte;&#160;CDI&#160;=&#160;</p>
<p style="position:absolute;top:909px;left:477px;white-space:nowrap" class="ft024"><i>Clostridioides&#160;difficile</i></p>
<p style="position:absolute;top:909px;left:592px;white-space:nowrap" class="ft041">–associated infection;&#160;FMT = fecal&#160;</p>
<p style="position:absolute;top:926px;left:108px;white-space:nowrap" class="ft041">microbiota therapy; IDSA = Infectious&#160;Diseases Society&#160;of&#160;America; IV = intravenously; MIC&#160;= minimum inhibitory&#160;concentration;&#160;</p>
<p style="position:absolute;top:943px;left:108px;white-space:nowrap" class="ft044">MSM&#160;= men&#160;who have sex&#160;with&#160;men;&#160;PCR = polymerase&#160;chain reaction; PO = orally; TMP-SMX&#160;= trimethoprim-<br/>sulfamethoxazole&#160;</p>
<p style="position:absolute;top:988px;left:108px;white-space:nowrap" class="ft029"><i><b>Empiric&#160;Therapy&#160;</b></i></p>
<p style="position:absolute;top:1029px;left:108px;white-space:nowrap" class="ft032">In most situations, treatment&#160;of diarrheal disease in people with&#160;HIV&#160;does not differ significantly&#160;<br/>from that&#160;in immunocompetent&#160;individuals. Decisions on therapy are based on an assessment&#160;of&#160;<br/>diarrhea severity and hydration status. Patients should be&#160;informed of the importance of maintaining&#160;</p>
</div>
<!-- Page 24 -->
<a name="24"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}	.ft069{font-size:17px;font-family:ICIUHX+TimesNewRomanPSMT;color:#000000;}
	.ft070{font-size:18px;font-family:BTLIFY+Tinos;color:#000000;}
	.ft071{font-size:18px;font-family:QZPFRO+Tinos;color:#000000;}
-->
</style>
<div id="page24-div" style="position:relative;width:917px;height:1187px;">
<p style="position:absolute;top:1114px;left:108px;white-space:nowrap" class="ft024"><i>Guidelines for the Prevention and Treatment&#160;of&#160;Opportunistic&#160;Infections in Adults&#160;and Adolescents&#160;With HIV&#160;</i></p>
<p style="position:absolute;top:1114px;left:791px;white-space:nowrap" class="ft024"><i>B-9&#160;</i></p>
<p style="position:absolute;top:87px;left:108px;white-space:nowrap" class="ft013">hydration and be given oral&#160;or intravenous (IV) rehydration, if indicated&#160;</p>
<p style="position:absolute;top:87px;left:610px;white-space:nowrap" class="ft012"><b>(AIII).</b></p>
<p style="position:absolute;top:87px;left:658px;white-space:nowrap" class="ft013">&#160;Because&#160;diarrheal&#160;</p>
<p style="position:absolute;top:107px;left:108px;white-space:nowrap" class="ft032">disease can produce temporary malabsorption or lactose intolerance, consuming a bland diet&#160;and&#160;<br/>avoiding fat, dairy, and complex carbohydrates are&#160;likely to be&#160;useful and are&#160;therefore&#160;<br/>recommended&#160;</p>
<p style="position:absolute;top:147px;left:210px;white-space:nowrap" class="ft012"><b>(BIII).</b></p>
<p style="position:absolute;top:147px;left:257px;white-space:nowrap" class="ft013">&#160;The&#160;effectiveness&#160;and safety&#160;of probiotics&#160;or antimotility agents have not&#160;been&#160;</p>
<p style="position:absolute;top:166px;left:108px;white-space:nowrap" class="ft013">studied adequately in people with HIV&#160;who have&#160;diarrheal&#160;illnesses.</p>
<p style="position:absolute;top:165px;left:578px;white-space:nowrap" class="ft038">38</p>
<p style="position:absolute;top:166px;left:590px;white-space:nowrap" class="ft013">&#160;Antimotility agents should be&#160;</p>
<p style="position:absolute;top:186px;left:108px;white-space:nowrap" class="ft013">avoided if concern about&#160;inflammatory diarrhea, including CDI,&#160;exists&#160;</p>
<p style="position:absolute;top:186px;left:598px;white-space:nowrap" class="ft012"><b>(BIII).</b></p>
<p style="position:absolute;top:186px;left:645px;white-space:nowrap" class="ft013">&#160;</p>
<p style="position:absolute;top:223px;left:108px;white-space:nowrap" class="ft032">After obtaining stool&#160;samples for diagnostic&#160;evaluation, the initiation and duration of empiric&#160;<br/>antimicrobial therapy depend on the patient’s CD4&#160;count&#160;and clinical&#160;appearance. If stool&#160;samples are&#160;<br/>obtained, antibiotic susceptibility testing should&#160;be performed to confirm and inform&#160;antibiotic&#160;<br/>choice. For example, in patients with CD4 counts&#160;&gt;500 cells/mm</p>
<p style="position:absolute;top:281px;left:557px;white-space:nowrap" class="ft038">3</p>
<p style="position:absolute;top:283px;left:563px;white-space:nowrap" class="ft013">&#160;who&#160;have&#160;had 1 to 2 days of loose&#160;</p>
<p style="position:absolute;top:303px;left:108px;white-space:nowrap" class="ft032">stools without fever or blood, no further work-up and no treatment other than oral&#160;rehydration may&#160;<br/>be required.&#160;However, a short course of antibiotics (e.g., ciprofloxacin for 5 days&#160;</p>
<p style="position:absolute;top:323px;left:670px;white-space:nowrap" class="ft012"><b>[BIII]</b></p>
<p style="position:absolute;top:323px;left:713px;white-space:nowrap" class="ft013">)&#160;may be&#160;</p>
<p style="position:absolute;top:342px;left:108px;white-space:nowrap" class="ft013">indicated in people with&#160;HIV&#160;and CD4 counts of&#160;200 to 500 cells/mm</p>
<p style="position:absolute;top:341px;left:589px;white-space:nowrap" class="ft038">3</p>
<p style="position:absolute;top:342px;left:594px;white-space:nowrap" class="ft013">&#160;who&#160;have&#160;diarrhea severe&#160;</p>
<p style="position:absolute;top:362px;left:108px;white-space:nowrap" class="ft032">enough to compromise quality of life&#160;or ability to work. Patients&#160;with severe&#160;disease (advanced HIV&#160;<br/>disease [i.e.,&#160;CD4 counts&#160;&lt;200 cells/mm</p>
<p style="position:absolute;top:381px;left:387px;white-space:nowrap" class="ft038">3</p>
<p style="position:absolute;top:382px;left:393px;white-space:nowrap" class="ft013">&#160;or concomitant AIDS-defining illness] and clinically severe&#160;</p>
<p style="position:absolute;top:402px;left:108px;white-space:nowrap" class="ft013">diarrhea [i.e.,&#160;</p>
<p style="position:absolute;top:402px;left:204px;white-space:nowrap" class="ft069">≥</p>
<p style="position:absolute;top:402px;left:214px;white-space:nowrap" class="ft018">6</p>
<p style="position:absolute;top:402px;left:222px;white-space:nowrap" class="ft013">&#160;liquid stools per day or bloody stools or a lower&#160;number of liquid stools per day but&#160;</p>
<p style="position:absolute;top:422px;left:108px;white-space:nowrap" class="ft032">accompanied by fever or chills concerning for invasive bacterial&#160;disease]) should undergo inpatient&#160;<br/>diagnostic&#160;evaluation to determine&#160;the etiology of the diarrheal illness and receive parenteral&#160;<br/>antimicrobial treatment&#160;</p>
<p style="position:absolute;top:461px;left:274px;white-space:nowrap" class="ft012"><b>(AIII).</b></p>
<p style="position:absolute;top:461px;left:322px;white-space:nowrap" class="ft013">&#160;In stable patients, empiric&#160;therapy with oral&#160;ciprofloxacin&#160;</p>
<p style="position:absolute;top:461px;left:727px;white-space:nowrap" class="ft012"><b>(BIII)</b></p>
<p style="position:absolute;top:461px;left:770px;white-space:nowrap" class="ft013">&#160;or&#160;</p>
<p style="position:absolute;top:481px;left:108px;white-space:nowrap" class="ft013">azithromycin&#160;</p>
<p style="position:absolute;top:481px;left:203px;white-space:nowrap" class="ft012"><b>(BIII)</b></p>
<p style="position:absolute;top:481px;left:246px;white-space:nowrap" class="ft013">&#160;is recommended,&#160;particularly if the&#160;infection is not associated with international&#160;</p>
<p style="position:absolute;top:501px;left:108px;white-space:nowrap" class="ft032">travel. However, even in the United States, all&#160;patients should&#160;have&#160;careful follow-up&#160;since rates of&#160;<br/>resistance to ciprofloxacin and (to a lesser extent) azithromycin in common enteric&#160;pathogens are&#160;<br/>substantial, and therefore&#160;treatment&#160;failure may occur. In patients with severe&#160;disease, treatment&#160;with&#160;<br/>empiric IV ceftriaxone&#160;is recommended until antimicrobial susceptibility results are&#160;available&#160;</p>
<p style="position:absolute;top:561px;left:756px;white-space:nowrap" class="ft012"><b>(BIII).</b></p>
<p style="position:absolute;top:561px;left:804px;white-space:nowrap" class="ft013">&#160;</p>
<p style="position:absolute;top:580px;left:108px;white-space:nowrap" class="ft032">Given the rise of antimicrobial resistance in enteric pathogens, however, updated outbreak&#160;<br/>information, local susceptibility patterns and travel&#160;history always should be&#160;considered.&#160;For&#160;<br/>example, if&#160;</p>
<p style="position:absolute;top:620px;left:190px;white-space:nowrap" class="ft019"><i>Campylobacter&#160;</i></p>
<p style="position:absolute;top:620px;left:300px;white-space:nowrap" class="ft013">or</p>
<p style="position:absolute;top:620px;left:315px;white-space:nowrap" class="ft019"><i>&#160;Shigella</i></p>
<p style="position:absolute;top:620px;left:376px;white-space:nowrap" class="ft013">&#160;bacteremia&#160;is suspected, a carbapenem&#160;is preferred for&#160;</p>
<p style="position:absolute;top:640px;left:108px;white-space:nowrap" class="ft013">empiric therapy&#160;</p>
<p style="position:absolute;top:640px;left:221px;white-space:nowrap" class="ft012"><b>(BIII).</b></p>
<p style="position:absolute;top:642px;left:268px;white-space:nowrap" class="ft053">&#160;</p>
<p style="position:absolute;top:677px;left:108px;white-space:nowrap" class="ft032">Therapy should be adjusted based on the results of&#160;the&#160;diagnostic&#160;work-up. For diarrhea that&#160;is&#160;<br/>persistent (i.e., lasting &gt;14 days) in the absence of&#160;other clinical signs of&#160;severity—such&#160;as bloody&#160;<br/>stool or dehydration—antibiotic therapy can be&#160;withheld and directed therapy initiated once a&#160;<br/>diagnosis is&#160;confirmed. Noninfectious&#160;etiologies of persistent&#160;diarrhea (e.g., inflammatory bowel&#160;<br/>disease) also&#160;should be considered in the differential diagnosis&#160;</p>
<p style="position:absolute;top:756px;left:543px;white-space:nowrap" class="ft012"><b>(BIII).</b></p>
<p style="position:absolute;top:756px;left:590px;white-space:nowrap" class="ft013">&#160;</p>
<p style="position:absolute;top:793px;left:108px;white-space:nowrap" class="ft019"><i>International&#160;travel</i></p>
<p style="position:absolute;top:793px;left:243px;white-space:nowrap" class="ft013">:&#160;Diarrhea&#160;is one of&#160;the&#160;most common illnesses affecting&#160;international&#160;travelers.&#160;</p>
<p style="position:absolute;top:813px;left:108px;white-space:nowrap" class="ft032">Antimicrobial resistance&#160;among enteric bacterial pathogens outside the United States is an&#160;important&#160;<br/>public health problem. For example, traveler’s diarrhea caused by fluoroquinolone-resistant&#160;</p>
<p style="position:absolute;top:833px;left:745px;white-space:nowrap" class="ft019"><i>C. jejuni</i></p>
<p style="position:absolute;top:833px;left:804px;white-space:nowrap" class="ft013">&#160;</p>
<p style="position:absolute;top:853px;left:108px;white-space:nowrap" class="ft013">in South and&#160;Southeast Asia&#160;or Africa is common.</p>
<p style="position:absolute;top:852px;left:454px;white-space:nowrap" class="ft038">39,40</p>
<p style="position:absolute;top:853px;left:480px;white-space:nowrap" class="ft013">&#160;Clinicians&#160;should consider the possibility of a&#160;</p>
<p style="position:absolute;top:873px;left:108px;white-space:nowrap" class="ft032">resistant infection when prescribing empiric&#160;therapy for travelers with&#160;HIV who experience&#160;diarrhea&#160;<br/>or a syndrome consistent&#160;with a&#160;systemic infection&#160;while&#160;traveling or upon returning to the&#160;<br/>United States, given reports of multidrug-resistant&#160;</p>
<p style="position:absolute;top:913px;left:458px;white-space:nowrap" class="ft019"><i>Enterobacteriaceae</i></p>
<p style="position:absolute;top:913px;left:594px;white-space:nowrap" class="ft013">&#160;acquisition during&#160;travel.</p>
<p style="position:absolute;top:911px;left:771px;white-space:nowrap" class="ft038">41-45</p>
<p style="position:absolute;top:913px;left:798px;white-space:nowrap" class="ft013">&#160;&#160;</p>
<p style="position:absolute;top:950px;left:108px;white-space:nowrap" class="ft029"><i><b>Pathogen-Specific Therapy&#160;</b></i></p>
<p style="position:absolute;top:991px;left:108px;white-space:nowrap" class="ft070"><b>Nontyphoidal</b></p>
<p style="position:absolute;top:991px;left:213px;white-space:nowrap" class="ft071"><i><b>&#160;Salmonella&#160;</b></i></p>
<p style="position:absolute;top:991px;left:306px;white-space:nowrap" class="ft070"><b>Species&#160;</b></p>
<p style="position:absolute;top:1029px;left:108px;white-space:nowrap" class="ft013">Immunocompetent&#160;hosts&#160;who do&#160;not have HIV&#160;often do not require antibiotic&#160;treatment for&#160;</p>
<p style="position:absolute;top:1049px;left:108px;white-space:nowrap" class="ft019"><i>Salmonella</i></p>
<p style="position:absolute;top:1049px;left:186px;white-space:nowrap" class="ft013">&#160;gastroenteritis (typically caused by nontyphoidal&#160;</p>
<p style="position:absolute;top:1049px;left:530px;white-space:nowrap" class="ft019"><i>Salmonella&#160;</i></p>
<p style="position:absolute;top:1049px;left:612px;white-space:nowrap" class="ft013">spp.) because the&#160;condition&#160;</p>
<p style="position:absolute;top:1069px;left:108px;white-space:nowrap" class="ft013">is usually self-limited, and treatment&#160;may prolong&#160;the&#160;carrier state. In contrast, all people&#160;with HIV&#160;</p>
</div>
<!-- Page 25 -->
<a name="25"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page25-div" style="position:relative;width:917px;height:1187px;">
<p style="position:absolute;top:1114px;left:108px;white-space:nowrap" class="ft024"><i>Guidelines for the Prevention and Treatment&#160;of&#160;Opportunistic&#160;Infections in Adults&#160;and Adolescents&#160;With HIV&#160;</i></p>
<p style="position:absolute;top:1114px;left:784px;white-space:nowrap" class="ft024"><i>B-10&#160;</i></p>
<p style="position:absolute;top:87px;left:108px;white-space:nowrap" class="ft013">and salmonellosis should&#160;be treated&#160;</p>
<p style="position:absolute;top:87px;left:357px;white-space:nowrap" class="ft012"><b>(AIII),</b></p>
<p style="position:absolute;top:87px;left:406px;white-space:nowrap" class="ft013">&#160;even though no clinical&#160;trials have&#160;compared&#160;</p>
<p style="position:absolute;top:107px;left:108px;white-space:nowrap" class="ft013">antimicrobial therapy with&#160;placebo. Notably, HIV infection increases the risk&#160;of&#160;</p>
<p style="position:absolute;top:107px;left:664px;white-space:nowrap" class="ft019"><i>Salmonella</i></p>
<p style="position:absolute;top:107px;left:741px;white-space:nowrap" class="ft013">&#160;</p>
<p style="position:absolute;top:127px;left:108px;white-space:nowrap" class="ft032">bacteremia&#160;20 to 100 times and mortality as much as seven times&#160;compared to people who&#160;do not&#160;<br/>have HIV.</p>
<p style="position:absolute;top:145px;left:180px;white-space:nowrap" class="ft038">19,46</p>
<p style="position:absolute;top:184px;left:108px;white-space:nowrap" class="ft013">The treatment of choice for susceptible&#160;nontyphoidal&#160;</p>
<p style="position:absolute;top:184px;left:477px;white-space:nowrap" class="ft019"><i>Salmonella&#160;</i></p>
<p style="position:absolute;top:184px;left:559px;white-space:nowrap" class="ft013">spp.</p>
<p style="position:absolute;top:184px;left:587px;white-space:nowrap" class="ft019"><i>&#160;</i></p>
<p style="position:absolute;top:184px;left:591px;white-space:nowrap" class="ft013">infection is a fluoroquinolone&#160;</p>
<p style="position:absolute;top:204px;left:108px;white-space:nowrap" class="ft012"><b>(AIII).</b></p>
<p style="position:absolute;top:204px;left:156px;white-space:nowrap" class="ft013">&#160;Ciprofloxacin is the&#160;preferred agent&#160;</p>
<p style="position:absolute;top:204px;left:411px;white-space:nowrap" class="ft012"><b>(AIII).</b></p>
<p style="position:absolute;top:202px;left:460px;white-space:nowrap" class="ft038">47</p>
<p style="position:absolute;top:204px;left:471px;white-space:nowrap" class="ft012"><b>&#160;</b></p>
<p style="position:absolute;top:204px;left:475px;white-space:nowrap" class="ft013">Other fluoroquinolones—such as&#160;levofloxacin&#160;</p>
<p style="position:absolute;top:223px;left:108px;white-space:nowrap" class="ft013">and moxifloxacin are&#160;recommended as alternatives to ciprofloxacin&#160;</p>
<p style="position:absolute;top:223px;left:577px;white-space:nowrap" class="ft012"><b>(BIII).</b></p>
<p style="position:absolute;top:223px;left:625px;white-space:nowrap" class="ft013">&#160;Although they have not&#160;</p>
<p style="position:absolute;top:243px;left:108px;white-space:nowrap" class="ft032">been well&#160;evaluated in clinical&#160;trials, they&#160;likely would be&#160;effective in treating salmonellosis in&#160;<br/>people with&#160;HIV</p>
<p style="position:absolute;top:263px;left:224px;white-space:nowrap" class="ft012"><b>.</b></p>
<p style="position:absolute;top:263px;left:228px;white-space:nowrap" class="ft013">&#160;Depending on antibiotic&#160;susceptibility, alternatives to the&#160;fluoroquinolones include&#160;</p>
<p style="position:absolute;top:283px;left:108px;white-space:nowrap" class="ft013">TMP-SMX or expanded-spectrum cephalosporins,&#160;such as ceftriaxone&#160;</p>
<p style="position:absolute;top:283px;left:597px;white-space:nowrap" class="ft012"><b>(BIII).&#160;</b></p>
<p style="position:absolute;top:283px;left:649px;white-space:nowrap" class="ft013">Fluoroquinolone&#160;</p>
<p style="position:absolute;top:303px;left:108px;white-space:nowrap" class="ft013">resistance in nontyphoidal&#160;</p>
<p style="position:absolute;top:303px;left:293px;white-space:nowrap" class="ft019"><i>Salmonella</i></p>
<p style="position:absolute;top:303px;left:371px;white-space:nowrap" class="ft013">&#160;spp. appears&#160;to be&#160;increasing, with preliminary CDC data&#160;</p>
<p style="position:absolute;top:323px;left:108px;white-space:nowrap" class="ft013">showing&#160;genetic&#160;markers of fluoroquinolone&#160;resistance&#160;among 19% of 20,831 nontyphoidal&#160;</p>
<p style="position:absolute;top:342px;left:108px;white-space:nowrap" class="ft019"><i>Salmonella</i></p>
<p style="position:absolute;top:342px;left:186px;white-space:nowrap" class="ft013">&#160;spp. isolates tested in the United States in 2023.</p>
<p style="position:absolute;top:341px;left:520px;white-space:nowrap" class="ft038">48</p>
<p style="position:absolute;top:342px;left:535px;white-space:nowrap" class="ft013">In agreement with IDSA&#160;guidelines,&#160;</p>
<p style="position:absolute;top:362px;left:108px;white-space:nowrap" class="ft032">the&#160;Panel recommends ceftriaxone over ciprofloxacin if invasive disease is suspected or confirmed,&#160;<br/>at&#160;least until&#160;susceptibilities return&#160;</p>
<p style="position:absolute;top:382px;left:349px;white-space:nowrap" class="ft012"><b>(BIII).</b></p>
<p style="position:absolute;top:381px;left:396px;white-space:nowrap" class="ft038">47,48</p>
<p style="position:absolute;top:382px;left:422px;white-space:nowrap" class="ft013">&#160;</p>
<p style="position:absolute;top:419px;left:108px;white-space:nowrap" class="ft013">The&#160;optimal duration of therapy for&#160;HIV-related nontyphoidal&#160;</p>
<p style="position:absolute;top:419px;left:540px;white-space:nowrap" class="ft019"><i>Salmonella</i></p>
<p style="position:absolute;top:419px;left:617px;white-space:nowrap" class="ft013">&#160;infection has&#160;not been&#160;</p>
<p style="position:absolute;top:439px;left:108px;white-space:nowrap" class="ft018">defined. For&#160;patients with CD4 counts&#160;</p>
<p style="position:absolute;top:439px;left:376px;white-space:nowrap" class="ft069">≥</p>
<p style="position:absolute;top:439px;left:385px;white-space:nowrap" class="ft018">200 cells/mm</p>
<p style="position:absolute;top:438px;left:479px;white-space:nowrap" class="ft038">3</p>
<p style="position:absolute;top:439px;left:484px;white-space:nowrap" class="ft013">&#160;who&#160;have&#160;mild gastroenteritis without&#160;</p>
<p style="position:absolute;top:459px;left:108px;white-space:nowrap" class="ft013">bacteremia, 7 to 14 days&#160;of treatment is recommended&#160;</p>
<p style="position:absolute;top:459px;left:486px;white-space:nowrap" class="ft012"><b>(BIII).</b></p>
<p style="position:absolute;top:459px;left:534px;white-space:nowrap" class="ft013">&#160;For the&#160;same&#160;patients with bacteremia,&#160;</p>
<p style="position:absolute;top:479px;left:108px;white-space:nowrap" class="ft032">14 days is appropriate provided clearance of bacteremia&#160;is documented. Longer treatment is&#160;<br/>recommended if bacteremia&#160;persists or&#160;if the infection is complicated (i.e., if metastatic&#160;foci&#160;are&#160;<br/>present)&#160;</p>
<p style="position:absolute;top:518px;left:168px;white-space:nowrap" class="ft012"><b>(BIII).</b></p>
<p style="position:absolute;top:518px;left:215px;white-space:nowrap" class="ft013">&#160;&#160;</p>
<p style="position:absolute;top:555px;left:108px;white-space:nowrap" class="ft013">For any patients with advanced HIV disease (CD4 count &lt;200 cells/mm</p>
<p style="position:absolute;top:554px;left:605px;white-space:nowrap" class="ft038">3</p>
<p style="position:absolute;top:555px;left:611px;white-space:nowrap" class="ft013">) and&#160;</p>
<p style="position:absolute;top:555px;left:650px;white-space:nowrap" class="ft019"><i>Salmonella</i></p>
<p style="position:absolute;top:555px;left:728px;white-space:nowrap" class="ft013">&#160;infection, a&#160;</p>
<p style="position:absolute;top:575px;left:108px;white-space:nowrap" class="ft032">minimum of 2 weeks&#160;with&#160;extension up&#160;to 6 weeks&#160;of antibiotics in severe disease or bacteremia&#160;is&#160;<br/>often recommended&#160;</p>
<p style="position:absolute;top:595px;left:250px;white-space:nowrap" class="ft012"><b>(BIII).</b></p>
<p style="position:absolute;top:594px;left:297px;white-space:nowrap" class="ft038">49</p>
<p style="position:absolute;top:595px;left:308px;white-space:nowrap" class="ft013">&#160;</p>
<p style="position:absolute;top:632px;left:108px;white-space:nowrap" class="ft013">People&#160;with&#160;HIV&#160;and&#160;</p>
<p style="position:absolute;top:632px;left:258px;white-space:nowrap" class="ft019"><i>Salmonella&#160;</i></p>
<p style="position:absolute;top:632px;left:340px;white-space:nowrap" class="ft013">bacteremia, which typically occurs in those with advanced HIV&#160;</p>
<p style="position:absolute;top:652px;left:108px;white-space:nowrap" class="ft013">disease, should be&#160;monitored clinically&#160;for recurrence&#160;after treatment&#160;</p>
<p style="position:absolute;top:652px;left:587px;white-space:nowrap" class="ft012"><b>(BIII).</b></p>
<p style="position:absolute;top:652px;left:635px;white-space:nowrap" class="ft013">&#160;As&#160;people&#160;with HIV&#160;</p>
<p style="position:absolute;top:672px;left:108px;white-space:nowrap" class="ft013">age, it is also important to remember that&#160;rates of invasive&#160;</p>
<p style="position:absolute;top:672px;left:513px;white-space:nowrap" class="ft019"><i>Salmonella</i></p>
<p style="position:absolute;top:672px;left:590px;white-space:nowrap" class="ft013">&#160;infections increase&#160;with age in&#160;</p>
<p style="position:absolute;top:692px;left:108px;white-space:nowrap" class="ft013">each age&#160;group beyond infancy.</p>
<p style="position:absolute;top:690px;left:328px;white-space:nowrap" class="ft038">50,51</p>
<p style="position:absolute;top:692px;left:353px;white-space:nowrap" class="ft013">&#160;Recurrence may present&#160;as&#160;bacteremia or as an anatomically&#160;</p>
<p style="position:absolute;top:712px;left:108px;white-space:nowrap" class="ft032">localized infection, including intraabdominal, endothelial, urinary tract, soft&#160;tissue, bone&#160;and joint,&#160;<br/>lung, or meningeal&#160;foci. Secondary prophylaxis should be&#160;considered for patients with recurrent&#160;</p>
<p style="position:absolute;top:751px;left:108px;white-space:nowrap" class="ft019"><i>Salmonella</i></p>
<p style="position:absolute;top:751px;left:186px;white-space:nowrap" class="ft013">&#160;bacteremia&#160;</p>
<p style="position:absolute;top:751px;left:270px;white-space:nowrap" class="ft012"><b>(BIII),</b></p>
<p style="position:absolute;top:751px;left:317px;white-space:nowrap" class="ft013">&#160;and it also might be&#160;considered for patients with recurrent&#160;</p>
<p style="position:absolute;top:771px;left:108px;white-space:nowrap" class="ft013">gastroenteritis (with or&#160;without&#160;bacteremia), and in those with CD4 counts&#160;&lt;200 cells/mm</p>
<p style="position:absolute;top:770px;left:729px;white-space:nowrap" class="ft038">3&#160;</p>
<p style="position:absolute;top:771px;left:737px;white-space:nowrap" class="ft013">with&#160;</p>
<p style="position:absolute;top:791px;left:108px;white-space:nowrap" class="ft013">severe diarrhea&#160;</p>
<p style="position:absolute;top:791px;left:217px;white-space:nowrap" class="ft012"><b>(BIII).&#160;</b></p>
<p style="position:absolute;top:791px;left:269px;white-space:nowrap" class="ft013">The value of this secondary&#160;prophylaxis&#160;has not been&#160;established and must be&#160;</p>
<p style="position:absolute;top:811px;left:108px;white-space:nowrap" class="ft013">weighed against the&#160;risks&#160;of long-term&#160;antibiotic&#160;exposure. Recurrent&#160;</p>
<p style="position:absolute;top:811px;left:589px;white-space:nowrap" class="ft019"><i>Salmonella</i></p>
<p style="position:absolute;top:811px;left:667px;white-space:nowrap" class="ft013">&#160;bacteremia&#160;</p>
<p style="position:absolute;top:831px;left:108px;white-space:nowrap" class="ft013">constitutes an AIDS-defining illness,</p>
<p style="position:absolute;top:829px;left:363px;white-space:nowrap" class="ft038">31</p>
<p style="position:absolute;top:831px;left:374px;white-space:nowrap" class="ft013">&#160;and&#160;HIV&#160;suppression&#160;with ART appears to decrease the&#160;risk&#160;</p>
<p style="position:absolute;top:850px;left:108px;white-space:nowrap" class="ft013">of recurrent illnesses.&#160;</p>
<p style="position:absolute;top:887px;left:108px;white-space:nowrap" class="ft013">In patients whose&#160;</p>
<p style="position:absolute;top:887px;left:233px;white-space:nowrap" class="ft019"><i>Salmonella</i></p>
<p style="position:absolute;top:887px;left:310px;white-space:nowrap" class="ft013">&#160;infection&#160;is resolved and who&#160;have&#160;responded to ART&#160;with sustained&#160;</p>
<p style="position:absolute;top:907px;left:108px;white-space:nowrap" class="ft013">viral suppression and CD4 counts &gt;200 cells/mm</p>
<p style="position:absolute;top:906px;left:448px;white-space:nowrap" class="ft038">3</p>
<p style="position:absolute;top:907px;left:454px;white-space:nowrap" class="ft013">, secondary prophylaxis for&#160;salmonellosis likely&#160;</p>
<p style="position:absolute;top:927px;left:108px;white-space:nowrap" class="ft013">can be&#160;discontinued&#160;</p>
<p style="position:absolute;top:927px;left:249px;white-space:nowrap" class="ft012"><b>(CII).</b></p>
<p style="position:absolute;top:927px;left:291px;white-space:nowrap" class="ft013">&#160;Clinicians also should be aware&#160;that recurrence may indicate development&#160;</p>
<p style="position:absolute;top:947px;left:108px;white-space:nowrap" class="ft013">of antimicrobial resistance during therapy.&#160;</p>
<p style="position:absolute;top:984px;left:108px;white-space:nowrap" class="ft071"><i><b>Shigella&#160;</b></i></p>
<p style="position:absolute;top:984px;left:174px;white-space:nowrap" class="ft070"><b>Species</b></p>
<p style="position:absolute;top:1022px;left:108px;white-space:nowrap" class="ft013">Therapy for&#160;</p>
<p style="position:absolute;top:1022px;left:194px;white-space:nowrap" class="ft019"><i>Shigella&#160;</i></p>
<p style="position:absolute;top:1022px;left:255px;white-space:nowrap" class="ft013">infections should&#160;be considered because it&#160;may slightly shorten the duration of&#160;</p>
<p style="position:absolute;top:1042px;left:108px;white-space:nowrap" class="ft013">illness&#160;and help prevent&#160;transmission to others&#160;</p>
<p style="position:absolute;top:1042px;left:431px;white-space:nowrap" class="ft012"><b>(AIII);</b></p>
<p style="position:absolute;top:1042px;left:481px;white-space:nowrap" class="ft013">&#160;however,&#160;because antimicrobial&#160;resistance of&#160;</p>
<p style="position:absolute;top:1062px;left:108px;white-space:nowrap" class="ft019"><i>Shigella&#160;</i></p>
<p style="position:absolute;top:1062px;left:169px;white-space:nowrap" class="ft013">spp.&#160;is increasing&#160;and limited data demonstrate that&#160;antibiotic&#160;therapy limits transmission,&#160;</p>
</div>
<!-- Page 26 -->
<a name="26"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page26-div" style="position:relative;width:917px;height:1187px;">
<p style="position:absolute;top:1114px;left:108px;white-space:nowrap" class="ft024"><i>Guidelines for the Prevention and Treatment&#160;of&#160;Opportunistic&#160;Infections in Adults&#160;and Adolescents&#160;With HIV&#160;</i></p>
<p style="position:absolute;top:1114px;left:784px;white-space:nowrap" class="ft024"><i>B-11&#160;</i></p>
<p style="position:absolute;top:87px;left:108px;white-space:nowrap" class="ft013">antibiotic treatment may be&#160;withheld in people with HIV and CD4 &gt;500 cells/mm</p>
<p style="position:absolute;top:86px;left:673px;white-space:nowrap" class="ft038">3&#160;</p>
<p style="position:absolute;top:87px;left:682px;white-space:nowrap" class="ft013">with&#160;mild&#160;</p>
<p style="position:absolute;top:107px;left:108px;white-space:nowrap" class="ft013">symptoms or&#160;whose&#160;diarrhea is resolving before culture&#160;confirmation of&#160;</p>
<p style="position:absolute;top:107px;left:608px;white-space:nowrap" class="ft019"><i>Shigella</i></p>
<p style="position:absolute;top:107px;left:664px;white-space:nowrap" class="ft013">&#160;infection</p>
<p style="position:absolute;top:107px;left:730px;white-space:nowrap" class="ft012"><b>&#160;(CIII).</b></p>
<p style="position:absolute;top:107px;left:783px;white-space:nowrap" class="ft013">&#160;</p>
<p style="position:absolute;top:127px;left:108px;white-space:nowrap" class="ft032">When treatment is offered, antibiotic selection should be guided&#160;by the&#160;results&#160;of antibiotic&#160;<br/>susceptibility testing.</p>
<p style="position:absolute;top:145px;left:255px;white-space:nowrap" class="ft038">43,52-55</p>
<p style="position:absolute;top:184px;left:108px;white-space:nowrap" class="ft032">Preferred treatment for susceptible&#160;shigellosis is a fluoroquinolone, preferably ciprofloxacin, for 5 to&#160;<br/>10 days&#160;</p>
<p style="position:absolute;top:204px;left:166px;white-space:nowrap" class="ft012"><b>(AIII)</b></p>
<p style="position:absolute;top:204px;left:210px;white-space:nowrap" class="ft013">&#160;with levofloxacin serving as an alternative&#160;</p>
<p style="position:absolute;top:204px;left:510px;white-space:nowrap" class="ft012"><b>(BIII).</b></p>
<p style="position:absolute;top:204px;left:558px;white-space:nowrap" class="ft013">&#160;Importantly, preliminary CDC data&#160;</p>
<p style="position:absolute;top:223px;left:108px;white-space:nowrap" class="ft013">estimate&#160;60% of&#160;</p>
<p style="position:absolute;top:223px;left:224px;white-space:nowrap" class="ft019"><i>Shigella</i></p>
<p style="position:absolute;top:223px;left:281px;white-space:nowrap" class="ft013">&#160;spp. isolated among the&#160;general U.S.&#160;population in 2023 harbored genetic&#160;</p>
<p style="position:absolute;top:243px;left:108px;white-space:nowrap" class="ft032">markers of resistance to ciprofloxacin,&#160;and 55% of&#160;such isolates tested in 2022&#160;had a ciprofloxacin&#160;<br/>minimum inhibitory concentration (MIC) of&#160;</p>
<p style="position:absolute;top:263px;left:417px;white-space:nowrap" class="ft069">≥</p>
<p style="position:absolute;top:263px;left:426px;white-space:nowrap" class="ft013">0.12&#160;µg/mL.</p>
<p style="position:absolute;top:262px;left:513px;white-space:nowrap" class="ft038">48</p>
<p style="position:absolute;top:263px;left:524px;white-space:nowrap" class="ft013">&#160;Although current Clinical&#160;and&#160;</p>
<p style="position:absolute;top:283px;left:108px;white-space:nowrap" class="ft013">Laboratory Standards Institute criteria&#160;categorize&#160;</p>
<p style="position:absolute;top:283px;left:450px;white-space:nowrap" class="ft019"><i>Shigella</i></p>
<p style="position:absolute;top:283px;left:507px;white-space:nowrap" class="ft013">&#160;isolates with a ciprofloxacin MIC of 0.12&#160;</p>
<p style="position:absolute;top:303px;left:108px;white-space:nowrap" class="ft032">and 0.25&#160;µg/mL&#160;as susceptible and a MIC of&#160;0.5&#160;µg/mL as intermediate, these isolates typically&#160;<br/>harbor a fluoroquinolone&#160;resistance gene or mutation. Until the clinical significance of these findings&#160;<br/>can be&#160;determined, alternative&#160;antibiotics should be&#160;considered to treat patients whose isolates have&#160;</p>
<p style="position:absolute;top:362px;left:108px;white-space:nowrap" class="ft018">ciprofloxacin MICs&#160;</p>
<p style="position:absolute;top:362px;left:248px;white-space:nowrap" class="ft069">≥</p>
<p style="position:absolute;top:362px;left:257px;white-space:nowrap" class="ft018">0.12&#160;µg/m</p>
<p style="position:absolute;top:362px;left:329px;white-space:nowrap" class="ft013">L&#160;</p>
<p style="position:absolute;top:362px;left:343px;white-space:nowrap" class="ft012"><b>(BIII).</b></p>
<p style="position:absolute;top:361px;left:391px;white-space:nowrap" class="ft038">56&#160;</p>
<p style="position:absolute;top:362px;left:405px;white-space:nowrap" class="ft013">In&#160;general, automated antimicrobial susceptibility test&#160;</p>
<p style="position:absolute;top:382px;left:108px;white-space:nowrap" class="ft032">panels do not&#160;have doubling dilutions that&#160;span the&#160;MIC range to determine&#160;susceptibility to&#160;<br/>ciprofloxacin based on the&#160;CDC recommendation of&#160;</p>
<p style="position:absolute;top:402px;left:473px;white-space:nowrap" class="ft069">≤</p>
<p style="position:absolute;top:402px;left:483px;white-space:nowrap" class="ft013">0.06. As such, a clinically validated manual&#160;</p>
<p style="position:absolute;top:422px;left:108px;white-space:nowrap" class="ft032">antimicrobial susceptibility testing method such as reference&#160;broth microdilution or a&#160;gradient&#160;<br/>diffusion method would be required to&#160;confirm susceptibility at the lower MIC range. Ciprofloxacin-<br/>resistant&#160;</p>
<p style="position:absolute;top:461px;left:170px;white-space:nowrap" class="ft019"><i>S. sonnei&#160;</i></p>
<p style="position:absolute;top:461px;left:236px;white-space:nowrap" class="ft013">and</p>
<p style="position:absolute;top:461px;left:261px;white-space:nowrap" class="ft019"><i>&#160;S.&#160;flexneri&#160;</i></p>
<p style="position:absolute;top:461px;left:340px;white-space:nowrap" class="ft013">infections in the United States are associated with international&#160;</p>
<p style="position:absolute;top:481px;left:108px;white-space:nowrap" class="ft032">travel, homelessness, and&#160;men who have sex with&#160;men (MSM);&#160;ciprofloxacin-resistant shigellosis&#160;<br/>among MSM&#160;appears to be acquired predominantly within the&#160;United States, rather than during&#160;<br/>travel.</p>
<p style="position:absolute;top:520px;left:152px;white-space:nowrap" class="ft038">43</p>
<p style="position:absolute;top:521px;left:163px;white-space:nowrap" class="ft013">&#160;&#160;</p>
<p style="position:absolute;top:558px;left:108px;white-space:nowrap" class="ft032">Depending on antibiotic susceptibilities, in stable&#160;patients without&#160;concern for bacteremia,&#160;<br/>azithromycin (5 days)&#160;or&#160;TMP-SMX (5–7 days)&#160;may be alternatives&#160;</p>
<p style="position:absolute;top:578px;left:581px;white-space:nowrap" class="ft012"><b>(BIII).</b></p>
<p style="position:absolute;top:578px;left:629px;white-space:nowrap" class="ft013">&#160;Azithromycin has not&#160;</p>
<p style="position:absolute;top:598px;left:108px;white-space:nowrap" class="ft032">been evaluated in people&#160;with HIV and shigellosis,&#160;and the&#160;therapy suggested is extrapolated from&#160;<br/>limited data in immunocompetent&#160;hosts.</p>
<p style="position:absolute;top:616px;left:385px;white-space:nowrap" class="ft038">56</p>
<p style="position:absolute;top:617px;left:397px;white-space:nowrap" class="ft013">&#160;Azithromycin susceptibility testing is not widely available&#160;</p>
<p style="position:absolute;top:637px;left:108px;white-space:nowrap" class="ft032">in clinical laboratories but can be performed by many state public&#160;health laboratories. Preliminary&#160;<br/>CDC data estimate 34% of&#160;</p>
<p style="position:absolute;top:657px;left:297px;white-space:nowrap" class="ft019"><i>Shigella</i></p>
<p style="position:absolute;top:657px;left:354px;white-space:nowrap" class="ft013">&#160;spp. isolated among the general&#160;U.S. population in 2023&#160;</p>
<p style="position:absolute;top:677px;left:108px;white-space:nowrap" class="ft013">harbored genetic&#160;markers of resistance&#160;to azithromycin.</p>
<p style="position:absolute;top:676px;left:492px;white-space:nowrap" class="ft038">48</p>
<p style="position:absolute;top:677px;left:503px;white-space:nowrap" class="ft013">&#160;Azithromycin-resistant&#160;</p>
<p style="position:absolute;top:677px;left:670px;white-space:nowrap" class="ft019"><i>Shigella&#160;</i></p>
<p style="position:absolute;top:677px;left:731px;white-space:nowrap" class="ft013">spp.&#160;</p>
<p style="position:absolute;top:697px;left:108px;white-space:nowrap" class="ft013">infections in MSM with&#160;HIV have been&#160;reported.</p>
<p style="position:absolute;top:695px;left:448px;white-space:nowrap" class="ft038">57-59</p>
<p style="position:absolute;top:697px;left:474px;white-space:nowrap" class="ft013">&#160;&#160;</p>
<p style="position:absolute;top:734px;left:108px;white-space:nowrap" class="ft032">Multidrug resistance is common among shigellae, and clinicians should be&#160;aware that&#160;rates of&#160;<br/>infections caused by extensively drug&#160;resistant&#160;</p>
<p style="position:absolute;top:754px;left:434px;white-space:nowrap" class="ft019"><i>Shigella</i></p>
<p style="position:absolute;top:754px;left:490px;white-space:nowrap" class="ft013">&#160;strains&#160;(strains resistant&#160;to azithromycin,&#160;</p>
<p style="position:absolute;top:774px;left:108px;white-space:nowrap" class="ft032">ciprofloxacin, ceftriaxone, trimethoprim-sulfamethoxazole, and&#160;ampicillin) are increasing&#160;in the&#160;<br/>United States.</p>
<p style="position:absolute;top:792px;left:205px;white-space:nowrap" class="ft038">60</p>
<p style="position:absolute;top:793px;left:216px;white-space:nowrap" class="ft013">&#160;Therefore, while&#160;IV ceftriaxone is recommended therapy for&#160;susceptible&#160;</p>
<p style="position:absolute;top:793px;left:723px;white-space:nowrap" class="ft019"><i>Shigella</i></p>
<p style="position:absolute;top:793px;left:779px;white-space:nowrap" class="ft013">, in&#160;</p>
<p style="position:absolute;top:813px;left:108px;white-space:nowrap" class="ft032">severely ill people&#160;requiring empiric parenteral&#160;therapy, carbapenems can be&#160;initiated before&#160;<br/>antimicrobial susceptibilities are available&#160;</p>
<p style="position:absolute;top:833px;left:403px;white-space:nowrap" class="ft012"><b>(BIII).</b></p>
<p style="position:absolute;top:833px;left:450px;white-space:nowrap" class="ft013">&#160;</p>
<p style="position:absolute;top:870px;left:108px;white-space:nowrap" class="ft013">Treatment&#160;for people with&#160;</p>
<p style="position:absolute;top:870px;left:293px;white-space:nowrap" class="ft019"><i>Shigella</i></p>
<p style="position:absolute;top:870px;left:349px;white-space:nowrap" class="ft013">&#160;bacteremia&#160;is less&#160;well&#160;defined but extending treatment to at least&#160;</p>
<p style="position:absolute;top:890px;left:108px;white-space:nowrap" class="ft013">14 days is&#160;recommended&#160;</p>
<p style="position:absolute;top:890px;left:283px;white-space:nowrap" class="ft012"><b>(BIII).</b></p>
<p style="position:absolute;top:890px;left:331px;white-space:nowrap" class="ft013">&#160;Azithromycin&#160;</p>
<p style="position:absolute;top:890px;left:435px;white-space:nowrap" class="ft012"><b>is not recommended</b></p>
<p style="position:absolute;top:890px;left:584px;white-space:nowrap" class="ft013">&#160;for treatment&#160;of&#160;</p>
<p style="position:absolute;top:890px;left:700px;white-space:nowrap" class="ft019"><i>Shigella&#160;</i></p>
<p style="position:absolute;top:890px;left:761px;white-space:nowrap" class="ft013">spp.&#160;</p>
<p style="position:absolute;top:910px;left:108px;white-space:nowrap" class="ft013">bacteremia&#160;</p>
<p style="position:absolute;top:910px;left:188px;white-space:nowrap" class="ft012"><b>(AIII).</b></p>
<p style="position:absolute;top:910px;left:236px;white-space:nowrap" class="ft013">&#160;Chronic&#160;suppressive or maintenance&#160;therapy&#160;</p>
<p style="position:absolute;top:910px;left:551px;white-space:nowrap" class="ft012"><b>is&#160;not recommended</b></p>
<p style="position:absolute;top:910px;left:700px;white-space:nowrap" class="ft013">&#160;for&#160;first-time&#160;</p>
<p style="position:absolute;top:930px;left:108px;white-space:nowrap" class="ft019"><i>Shigella&#160;</i></p>
<p style="position:absolute;top:930px;left:169px;white-space:nowrap" class="ft013">infections&#160;</p>
<p style="position:absolute;top:930px;left:241px;white-space:nowrap" class="ft012"><b>(BIII).</b></p>
<p style="position:absolute;top:930px;left:289px;white-space:nowrap" class="ft013">&#160;Recurrent infections can&#160;occur, particularly in individuals with&#160;CD4&#160;</p>
<p style="position:absolute;top:950px;left:108px;white-space:nowrap" class="ft013">counts &lt;200&#160;cells/mm</p>
<p style="position:absolute;top:948px;left:260px;white-space:nowrap" class="ft038">3</p>
<p style="position:absolute;top:950px;left:266px;white-space:nowrap" class="ft013">, in which case,&#160;extending antimicrobial&#160;therapy for up to 6 weeks&#160;is&#160;</p>
<p style="position:absolute;top:969px;left:108px;white-space:nowrap" class="ft013">recommended&#160;</p>
<p style="position:absolute;top:969px;left:210px;white-space:nowrap" class="ft012"><b>(BIII).</b></p>
<p style="position:absolute;top:969px;left:257px;white-space:nowrap" class="ft013">&#160;Because of&#160;</p>
<p style="position:absolute;top:969px;left:342px;white-space:nowrap" class="ft019"><i>Shigella’s</i></p>
<p style="position:absolute;top:969px;left:411px;white-space:nowrap" class="ft013">&#160;extremely low infectious dose, patients with shigellosis&#160;</p>
<p style="position:absolute;top:989px;left:108px;white-space:nowrap" class="ft013">should be counseled about transmission prevention.&#160;As&#160;with&#160;</p>
<p style="position:absolute;top:989px;left:527px;white-space:nowrap" class="ft019"><i>Salmonella</i></p>
<p style="position:absolute;top:989px;left:604px;white-space:nowrap" class="ft013">&#160;infections, suppression of&#160;</p>
<p style="position:absolute;top:1009px;left:108px;white-space:nowrap" class="ft013">HIV&#160;replication with ART is expected to decrease the risk of recurrent&#160;shigellosis.&#160;</p>
</div>
<!-- Page 27 -->
<a name="27"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}	.ft072{font-size:17px;font-family:BTLIFY+Tinos;color:#333333;}
-->
</style>
<div id="page27-div" style="position:relative;width:917px;height:1187px;">
<p style="position:absolute;top:1114px;left:108px;white-space:nowrap" class="ft024"><i>Guidelines for the Prevention and Treatment&#160;of&#160;Opportunistic&#160;Infections in Adults&#160;and Adolescents&#160;With HIV&#160;</i></p>
<p style="position:absolute;top:1114px;left:784px;white-space:nowrap" class="ft024"><i>B-12&#160;</i></p>
<p style="position:absolute;top:87px;left:108px;white-space:nowrap" class="ft071"><i><b>Campylobacter</b></i></p>
<p style="position:absolute;top:87px;left:220px;white-space:nowrap" class="ft070"><b>&#160;Species</b></p>
<p style="position:absolute;top:87px;left:280px;white-space:nowrap" class="ft071"><i><b>&#160;</b></i></p>
<p style="position:absolute;top:125px;left:108px;white-space:nowrap" class="ft032">The&#160;optimal treatment of campylobacteriosis in people&#160;with HIV&#160;is poorly defined and multidrug&#160;<br/>resistance might&#160;occur.</p>
<p style="position:absolute;top:144px;left:268px;white-space:nowrap" class="ft038">61,62</p>
<p style="position:absolute;top:145px;left:293px;white-space:nowrap" class="ft013">&#160;Culture and&#160;testing for the antibiotic&#160;susceptibility of&#160;</p>
<p style="position:absolute;top:145px;left:667px;white-space:nowrap" class="ft019"><i>Campylobacter</i></p>
<p style="position:absolute;top:145px;left:773px;white-space:nowrap" class="ft013">&#160;</p>
<p style="position:absolute;top:165px;left:108px;white-space:nowrap" class="ft013">isolates is recommended&#160;</p>
<p style="position:absolute;top:165px;left:282px;white-space:nowrap" class="ft012"><b>(BIII).</b></p>
<p style="position:absolute;top:165px;left:329px;white-space:nowrap" class="ft013">&#160;In the&#160;United States in 2018,&#160;29% of&#160;</p>
<p style="position:absolute;top:165px;left:590px;white-space:nowrap" class="ft019"><i>C. jejuni</i></p>
<p style="position:absolute;top:165px;left:649px;white-space:nowrap" class="ft013">&#160;isolates were resistant&#160;</p>
<p style="position:absolute;top:185px;left:108px;white-space:nowrap" class="ft013">to ciprofloxacin, and 2%&#160;were resistant to azithromycin; among&#160;</p>
<p style="position:absolute;top:185px;left:551px;white-space:nowrap" class="ft019"><i>C. coli</i></p>
<p style="position:absolute;top:185px;left:597px;white-space:nowrap" class="ft013">&#160;isolates, 41% of isolates were&#160;</p>
<p style="position:absolute;top:204px;left:108px;white-space:nowrap" class="ft013">resistant to fluoroquinolones, and 13% were resistant to azithromycin.</p>
<p style="position:absolute;top:203px;left:592px;white-space:nowrap" class="ft038">48</p>
<p style="position:absolute;top:204px;left:603px;white-space:nowrap" class="ft072"><b>&#160;</b></p>
<p style="position:absolute;top:241px;left:108px;white-space:nowrap" class="ft013">For people&#160;with mild disease and CD4&#160;counts &gt;200&#160;cells/mm</p>
<p style="position:absolute;top:240px;left:530px;white-space:nowrap" class="ft038">3</p>
<p style="position:absolute;top:241px;left:536px;white-space:nowrap" class="ft013">, therapy should be withheld unless&#160;</p>
<p style="position:absolute;top:261px;left:108px;white-space:nowrap" class="ft013">symptoms persist for more than several days&#160;</p>
<p style="position:absolute;top:261px;left:420px;white-space:nowrap" class="ft012"><b>(CIII).</b></p>
<p style="position:absolute;top:261px;left:468px;white-space:nowrap" class="ft013">&#160;For mild-to-moderate campylobacteriosis,&#160;</p>
<p style="position:absolute;top:281px;left:108px;white-space:nowrap" class="ft032">initiating therapy with azithromycin for 5 days or a&#160;fluoroquinolone—such as ciprofloxacin—for 7 to&#160;<br/>10 days (if the organism is&#160;sensitive) is&#160;recommended&#160;</p>
<p style="position:absolute;top:301px;left:484px;white-space:nowrap" class="ft012"><b>(BIII).</b></p>
<p style="position:absolute;top:301px;left:531px;white-space:nowrap" class="ft013">&#160;Azithromycin has not been evaluated&#160;</p>
<p style="position:absolute;top:321px;left:108px;white-space:nowrap" class="ft032">in people&#160;with HIV and campylobacteriosis, and the therapy suggested is extrapolated from&#160;limited&#160;<br/>data in immunocompetent hosts.</p>
<p style="position:absolute;top:339px;left:332px;white-space:nowrap" class="ft038">39</p>
<p style="position:absolute;top:341px;left:344px;white-space:nowrap" class="ft013">&#160;Azithromycin susceptibility testing, however, is not widely&#160;</p>
<p style="position:absolute;top:361px;left:108px;white-space:nowrap" class="ft013">available&#160;in clinical&#160;laboratories but can be performed by many state public&#160;health laboratories.&#160;</p>
<p style="position:absolute;top:380px;left:108px;white-space:nowrap" class="ft019"><i>Campylobacter</i></p>
<p style="position:absolute;top:380px;left:214px;white-space:nowrap" class="ft013">&#160;bacteremia&#160;should be treated for at&#160;least 14 days&#160;using a fluoroquinolone if the&#160;isolate&#160;</p>
<p style="position:absolute;top:400px;left:108px;white-space:nowrap" class="ft013">is sensitive&#160;</p>
<p style="position:absolute;top:400px;left:188px;white-space:nowrap" class="ft012"><b>(BIII).</b></p>
<p style="position:absolute;top:399px;left:236px;white-space:nowrap" class="ft038">63</p>
<p style="position:absolute;top:400px;left:247px;white-space:nowrap" class="ft013">&#160;Adding a&#160;second&#160;active agent—such as&#160;an&#160;aminoglycoside—may be prudent&#160;in&#160;</p>
<p style="position:absolute;top:420px;left:108px;white-space:nowrap" class="ft013">patients with bacteremia&#160;to limit the emergence&#160;of&#160;antibiotic resistance&#160;</p>
<p style="position:absolute;top:420px;left:600px;white-space:nowrap" class="ft012"><b>(BIII).</b></p>
<p style="position:absolute;top:420px;left:647px;white-space:nowrap" class="ft013">&#160;Third generation&#160;</p>
<p style="position:absolute;top:440px;left:108px;white-space:nowrap" class="ft032">cephalosporins are not reliably active&#160;and use of alternative&#160;cell-wall&#160;active&#160;agents such as&#160;<br/>carbapenems&#160;may be necessary in&#160;severely ill people requiring empiric&#160;parenteral therapy until&#160;<br/>antimicrobial susceptibilities return. Antibiotic&#160;choice should be&#160;guided by antibiotic&#160;susceptibility&#160;<br/>tests. Azithromycin&#160;</p>
<p style="position:absolute;top:499px;left:247px;white-space:nowrap" class="ft012"><b>is not&#160;recommended</b></p>
<p style="position:absolute;top:499px;left:396px;white-space:nowrap" class="ft013">&#160;for treatment of&#160;</p>
<p style="position:absolute;top:499px;left:513px;white-space:nowrap" class="ft019"><i>Campylobacter</i></p>
<p style="position:absolute;top:499px;left:619px;white-space:nowrap" class="ft013">&#160;bacteremia&#160;</p>
<p style="position:absolute;top:499px;left:703px;white-space:nowrap" class="ft012"><b>(AIII).&#160;</b></p>
<p style="position:absolute;top:519px;left:108px;white-space:nowrap" class="ft013">Chronic&#160;suppressive or&#160;maintenance therapy&#160;</p>
<p style="position:absolute;top:519px;left:419px;white-space:nowrap" class="ft012"><b>is not recommended</b></p>
<p style="position:absolute;top:519px;left:567px;white-space:nowrap" class="ft013">&#160;for&#160;first-time&#160;</p>
<p style="position:absolute;top:519px;left:664px;white-space:nowrap" class="ft019"><i>Campylobacter&#160;</i></p>
<p style="position:absolute;top:539px;left:108px;white-space:nowrap" class="ft013">infections in people&#160;with&#160;HIV&#160;</p>
<p style="position:absolute;top:539px;left:318px;white-space:nowrap" class="ft012"><b>(BIII).</b></p>
<p style="position:absolute;top:539px;left:366px;white-space:nowrap" class="ft013">&#160;However, recurrent&#160;infections can occur, particularly in people&#160;</p>
<p style="position:absolute;top:559px;left:108px;white-space:nowrap" class="ft013">with CD4 counts &lt;200 cells/mm</p>
<p style="position:absolute;top:558px;left:332px;white-space:nowrap" class="ft038">3</p>
<p style="position:absolute;top:559px;left:338px;white-space:nowrap" class="ft013">. In recurrent disease, extending the&#160;length of antimicrobial&#160;therapy&#160;</p>
<p style="position:absolute;top:579px;left:108px;white-space:nowrap" class="ft013">for 2 to 6&#160;weeks is reasonable&#160;</p>
<p style="position:absolute;top:579px;left:317px;white-space:nowrap" class="ft012"><b>(BIII).</b></p>
<p style="position:absolute;top:579px;left:365px;white-space:nowrap" class="ft013">&#160;As&#160;with&#160;</p>
<p style="position:absolute;top:579px;left:427px;white-space:nowrap" class="ft019"><i>Salmonella</i></p>
<p style="position:absolute;top:579px;left:505px;white-space:nowrap" class="ft013">&#160;infections, suppression of&#160;HIV replication&#160;</p>
<p style="position:absolute;top:598px;left:108px;white-space:nowrap" class="ft013">with ART is&#160;expected to decrease the&#160;risk of recurrent&#160;</p>
<p style="position:absolute;top:598px;left:485px;white-space:nowrap" class="ft019"><i>Campylobacter&#160;</i></p>
<p style="position:absolute;top:598px;left:596px;white-space:nowrap" class="ft013">spp. infections.</p>
<p style="position:absolute;top:597px;left:701px;white-space:nowrap" class="ft038">64</p>
<p style="position:absolute;top:598px;left:712px;white-space:nowrap" class="ft013">&#160;</p>
<p style="position:absolute;top:636px;left:108px;white-space:nowrap" class="ft071"><i><b>Clostridioides difficile&#160;</b></i></p>
<p style="position:absolute;top:636px;left:276px;white-space:nowrap" class="ft070"><b>&#160;</b></p>
<p style="position:absolute;top:674px;left:108px;white-space:nowrap" class="ft032">No randomized controlled trials have been conducted for CDI therapy in people&#160;with HIV. Available&#160;<br/>data suggest&#160;that people&#160;with HIV respond to treatment of CDI&#160;similarly to people without HIV.</p>
<p style="position:absolute;top:692px;left:772px;white-space:nowrap" class="ft038">9</p>
<p style="position:absolute;top:693px;left:778px;white-space:nowrap" class="ft013">&#160;</p>
<p style="position:absolute;top:713px;left:108px;white-space:nowrap" class="ft032">Thus, treatment of CDI in&#160;people with&#160;HIV&#160;is the same as in people&#160;without&#160;HIV.&#160;Guidelines and&#160;<br/>subsequent updates for treatment of CDI have been&#160;published</p>
<p style="position:absolute;top:732px;left:533px;white-space:nowrap" class="ft038">29,65</p>
<p style="position:absolute;top:733px;left:559px;white-space:nowrap" class="ft013">&#160;and should&#160;be consulted&#160;for further&#160;</p>
<p style="position:absolute;top:753px;left:108px;white-space:nowrap" class="ft013">information.&#160;</p>
<p style="position:absolute;top:790px;left:108px;white-space:nowrap" class="ft019"><i>Treatment of&#160;an Initial&#160;Episode of Clostridioides difficile–Associated Infection&#160;</i></p>
<p style="position:absolute;top:827px;left:108px;white-space:nowrap" class="ft032">Four randomized clinical&#160;trials all conducted in the&#160;general population (two&#160;identical&#160;studies with&#160;<br/>~60% hospitalized patients;&#160;two studies restricted to hospitalized patients)</p>
<p style="position:absolute;top:846px;left:619px;white-space:nowrap" class="ft038">66-69</p>
<p style="position:absolute;top:847px;left:646px;white-space:nowrap" class="ft013">&#160;have&#160;revealed that,&#160;</p>
<p style="position:absolute;top:867px;left:108px;white-space:nowrap" class="ft032">when compared to oral&#160;vancomycin, fidaxomicin increased the likelihood of a&#160;sustained clinical&#160;<br/>response&#160;of&#160;CDI (at 28&#160;days) in the initial therapy&#160;of CDI (relative&#160;risk [RR]&#160;1.16; 95% confidence&#160;<br/>interval&#160;[CI], 1.09–1.24).</p>
<p style="position:absolute;top:905px;left:282px;white-space:nowrap" class="ft038">65</p>
<p style="position:absolute;top:906px;left:293px;white-space:nowrap" class="ft013">&#160;Fidaxomicin was equivalent to oral&#160;vancomycin in initial clinical cure,&#160;</p>
<p style="position:absolute;top:926px;left:108px;white-space:nowrap" class="ft013">serious adverse events and&#160;all-cause mortality. Given these data, the&#160;</p>
<p style="position:absolute;top:926px;left:582px;white-space:nowrap" class="ft034">2021 IDSA CDI Clinical&#160;</p>
<p style="position:absolute;top:946px;left:108px;white-space:nowrap" class="ft034">Practice Guideline&#160;update</p>
<p style="position:absolute;top:945px;left:286px;white-space:nowrap" class="ft038">65</p>
<p style="position:absolute;top:946px;left:298px;white-space:nowrap" class="ft013">&#160;for adults&#160;suggests treatment with fidaxomicin rather than oral&#160;</p>
<p style="position:absolute;top:966px;left:108px;white-space:nowrap" class="ft032">vancomycin, for initial&#160;CDI whether&#160;CDI is&#160;severe or nonsevere. Fidaxomicin remains very&#160;<br/>expensive but should be&#160;considered in&#160;people with&#160;HIV&#160;and CDI, if available&#160;</p>
<p style="position:absolute;top:986px;left:644px;white-space:nowrap" class="ft012"><b>(AI).</b></p>
<p style="position:absolute;top:986px;left:679px;white-space:nowrap" class="ft013">&#160;Oral vancomycin&#160;</p>
<p style="position:absolute;top:1006px;left:108px;white-space:nowrap" class="ft013">is also an acceptable&#160;option for initial&#160;CDI&#160;</p>
<p style="position:absolute;top:1006px;left:405px;white-space:nowrap" class="ft012"><b>(AI).</b></p>
<p style="position:absolute;top:1006px;left:440px;white-space:nowrap" class="ft013">&#160;Earlier multicenter, randomized, double-blind&#160;</p>
<p style="position:absolute;top:1025px;left:108px;white-space:nowrap" class="ft013">studies identified that&#160;oral&#160;vancomycin is superior to metronidazole&#160;for treatment&#160;of CDI.</p>
<p style="position:absolute;top:1024px;left:725px;white-space:nowrap" class="ft038">70,71</p>
<p style="position:absolute;top:1025px;left:750px;white-space:nowrap" class="ft013">&#160;Thus,&#160;</p>
<p style="position:absolute;top:1045px;left:108px;white-space:nowrap" class="ft013">metronidazole&#160;is to be&#160;considered as an&#160;alternative&#160;drug for CDI therapy only if fidaxomicin or&#160;</p>
</div>
<!-- Page 28 -->
<a name="28"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}	.ft073{font-size:20px;line-height:24px;font-family:QZPFRO+Tinos;color:#000000;}
-->
</style>
<div id="page28-div" style="position:relative;width:917px;height:1187px;">
<p style="position:absolute;top:1114px;left:108px;white-space:nowrap" class="ft024"><i>Guidelines for the Prevention and Treatment&#160;of&#160;Opportunistic&#160;Infections in Adults&#160;and Adolescents&#160;With HIV&#160;</i></p>
<p style="position:absolute;top:1114px;left:784px;white-space:nowrap" class="ft024"><i>B-13&#160;</i></p>
<p style="position:absolute;top:87px;left:108px;white-space:nowrap" class="ft032">vancomycin are unavailable and CDI&#160;is nonsevere&#160;(white&#160;blood&#160;cell count &lt;15,000 cells/mL and&#160;<br/>serum creatinine concentrations &lt;1.5&#160;mg/dL)&#160;</p>
<p style="position:absolute;top:107px;left:423px;white-space:nowrap" class="ft012"><b>(CI).</b></p>
<p style="position:absolute;top:106px;left:458px;white-space:nowrap" class="ft038">29</p>
<p style="position:absolute;top:107px;left:470px;white-space:nowrap" class="ft013">&#160;</p>
<p style="position:absolute;top:144px;left:108px;white-space:nowrap" class="ft019"><i>Treatment of&#160;Recurrent&#160;Clostridioides&#160;difficile–Associated Infection&#160;</i></p>
<p style="position:absolute;top:181px;left:108px;white-space:nowrap" class="ft032">Treatment&#160;of recurrent CDI is complex and, in part, defined by the specific&#160;circumstances&#160;of the&#160;<br/>patient with recurrent&#160;CDI&#160;and the number of prior&#160;CDI episodes. Brief guidance&#160;is provided here;&#160;<br/>the&#160;2017 and&#160;2021 IDSA&#160;CDI guidelines should&#160;be&#160;consulted for&#160;a full discussion of this topic.</p>
<p style="position:absolute;top:219px;left:763px;white-space:nowrap" class="ft038">29,65</p>
<p style="position:absolute;top:221px;left:788px;white-space:nowrap" class="ft013">&#160;</p>
<p style="position:absolute;top:241px;left:108px;white-space:nowrap" class="ft013">Risk factors&#160;for CDI recurrence&#160;are age&#160;</p>
<p style="position:absolute;top:241px;left:384px;white-space:nowrap" class="ft069">≥</p>
<p style="position:absolute;top:241px;left:394px;white-space:nowrap" class="ft013">65 years,&#160;history of CDI, compromised immunity, severe&#160;</p>
<p style="position:absolute;top:260px;left:108px;white-space:nowrap" class="ft032">CDI, and certain virulent strains (ribotypes 027/078/244). Similar to an initial episode of&#160;CDI and&#160;<br/>also based on the&#160;randomized clinical&#160;trials cited above,</p>
<p style="position:absolute;top:279px;left:494px;white-space:nowrap" class="ft038">66-69</p>
<p style="position:absolute;top:280px;left:520px;white-space:nowrap" class="ft013">&#160;the&#160;Panel recommends administering&#160;</p>
<p style="position:absolute;top:300px;left:108px;white-space:nowrap" class="ft013">fidaxomicin, instead of oral&#160;vancomycin, to adults with recurrent CDI&#160;</p>
<p style="position:absolute;top:300px;left:594px;white-space:nowrap" class="ft012"><b>(AI),</b></p>
<p style="position:absolute;top:300px;left:629px;white-space:nowrap" class="ft013">&#160;consistent with the&#160;</p>
<p style="position:absolute;top:320px;left:108px;white-space:nowrap" class="ft034">2021 IDSA&#160;CDI Clinical&#160;Practice Guideline&#160;update</p>
<p style="position:absolute;top:320px;left:463px;white-space:nowrap" class="ft013">.</p>
<p style="position:absolute;top:319px;left:467px;white-space:nowrap" class="ft038">65</p>
<p style="position:absolute;top:320px;left:478px;white-space:nowrap" class="ft013">&#160;Fidaxomicin therapy increased the&#160;likelihood&#160;</p>
<p style="position:absolute;top:340px;left:108px;white-space:nowrap" class="ft032">of a sustained clinical&#160;response for&#160;recurrent CDI at&#160;30 days (RR&#160;1.27; 95% CI, 1.05–1.54). For&#160;<br/>treatment of an initial CDI recurrence,&#160;fidaxomicin was equivalent to oral&#160;vancomycin in initial&#160;<br/>clinical&#160;cure,&#160;serious adverse events, and all-cause&#160;mortality. Vancomycin is&#160;also an acceptable&#160;<br/>option for recurrent&#160;CDI (see the&#160;</p>
<p style="position:absolute;top:399px;left:339px;white-space:nowrap" class="ft034">IDSA Guideline</p>
<p style="position:absolute;top:399px;left:452px;white-space:nowrap" class="ft013">&#160;for tapered and pulsed regimens)&#160;</p>
<p style="position:absolute;top:399px;left:687px;white-space:nowrap" class="ft012"><b>(AI).</b></p>
<p style="position:absolute;top:399px;left:722px;white-space:nowrap" class="ft013">&#160;</p>
<p style="position:absolute;top:436px;left:108px;white-space:nowrap" class="ft013">Bezlotoxumab is a humanized monoclonal&#160;antibody against&#160;</p>
<p style="position:absolute;top:436px;left:524px;white-space:nowrap" class="ft019"><i>C.&#160;difficile</i></p>
<p style="position:absolute;top:436px;left:596px;white-space:nowrap" class="ft013">&#160;toxin B approved for&#160;</p>
<p style="position:absolute;top:456px;left:108px;white-space:nowrap" class="ft032">prevention of recurrent CDI in high-risk adults&#160;when used in conjunction with standard-of-<br/>care (SOC) antibiotic&#160;therapy. The&#160;</p>
<p style="position:absolute;top:476px;left:351px;white-space:nowrap" class="ft034">2021 IDSA CDI&#160;Clinical&#160;Practice Guideline&#160;update</p>
<p style="position:absolute;top:476px;left:706px;white-space:nowrap" class="ft013">&#160;suggests use&#160;</p>
<p style="position:absolute;top:496px;left:108px;white-space:nowrap" class="ft032">of bezlotoxumab as a cointervention along with vancomycin as&#160;the&#160;SOC antibiotic&#160;in patients with a&#160;<br/>history of CDI in the&#160;last&#160;6 months or&#160;other risk factors for recurrence (</p>
<p style="position:absolute;top:516px;left:599px;white-space:nowrap" class="ft018">i.e., age&#160;</p>
<p style="position:absolute;top:516px;left:657px;white-space:nowrap" class="ft069">≥</p>
<p style="position:absolute;top:516px;left:666px;white-space:nowrap" class="ft018">65 years,&#160;</p>
<p style="position:absolute;top:536px;left:108px;white-space:nowrap" class="ft013">compromised immunity, severe CDI,&#160;or certain virulent strains&#160;(ribotypes 027/078/244).</p>
<p style="position:absolute;top:534px;left:717px;white-space:nowrap" class="ft038">65</p>
<p style="position:absolute;top:536px;left:729px;white-space:nowrap" class="ft013">&#160;However,&#160;</p>
<p style="position:absolute;top:555px;left:108px;white-space:nowrap" class="ft032">data on the benefit&#160;of bezlotoxumab therapy when&#160;fidaxomicin is used as the&#160;SOC antibiotic&#160;are&#160;<br/>limited. Limited case reports suggest that fecal microbiota therapy (FMT) (i.e., fecal transplant) may&#160;<br/>be successful&#160;and safe to treat&#160;recurrent CDI in people&#160;with HIV.</p>
<p style="position:absolute;top:594px;left:556px;white-space:nowrap" class="ft038">72-74</p>
<p style="position:absolute;top:595px;left:583px;white-space:nowrap" class="ft013">&#160;However, it is important&#160;to note&#160;</p>
<p style="position:absolute;top:615px;left:108px;white-space:nowrap" class="ft032">that complications of FMT, including transmission&#160;of enteric pathogens and antibiotic-resistant&#160;<br/>bacteria with deaths, have&#160;been reported.</p>
<p style="position:absolute;top:633px;left:390px;white-space:nowrap" class="ft038">75,76</p>
<p style="position:absolute;top:635px;left:415px;white-space:nowrap" class="ft013">&#160;FMT for treatment of recurrent&#160;CDI may be&#160;considered&#160;</p>
<p style="position:absolute;top:655px;left:108px;white-space:nowrap" class="ft013">after three total CDI episodes (initial&#160;and two recurrent&#160;CDI episodes)&#160;</p>
<p style="position:absolute;top:655px;left:595px;white-space:nowrap" class="ft012"><b>(CIII).</b></p>
<p style="position:absolute;top:653px;left:644px;white-space:nowrap" class="ft038">29,65</p>
<p style="position:absolute;top:655px;left:669px;white-space:nowrap" class="ft013">&#160;The effect&#160;of ART&#160;</p>
<p style="position:absolute;top:674px;left:108px;white-space:nowrap" class="ft032">on recurrence of CDI is unknown, but&#160;ART initiation should&#160;follow standard&#160;guidelines, similar to&#160;<br/>other enteric infections (see the Special&#160;Considerations Regarding ART Initiation section below).&#160;</p>
<p style="position:absolute;top:732px;left:108px;white-space:nowrap" class="ft029"><i><b>Special Considerations Regarding ART Initiation&#160;</b></i></p>
<p style="position:absolute;top:773px;left:108px;white-space:nowrap" class="ft032">ART initiation should&#160;follow standard&#160;guidelines. The presence&#160;of an enteric infection should not&#160;<br/>delay ART initiation&#160;</p>
<p style="position:absolute;top:793px;left:255px;white-space:nowrap" class="ft012"><b>(AIII).</b></p>
<p style="position:absolute;top:793px;left:303px;white-space:nowrap" class="ft013">&#160;The presence&#160;of a diarrheal illness is relevant only in terms of a patient’s&#160;</p>
<p style="position:absolute;top:812px;left:108px;white-space:nowrap" class="ft013">ability to ingest and absorb ART. If&#160;recurrent&#160;enteric infections are documented or&#160;</p>
<p style="position:absolute;top:812px;left:680px;white-space:nowrap" class="ft019"><i>Salmonella&#160;</i></p>
<p style="position:absolute;top:832px;left:108px;white-space:nowrap" class="ft013">bacteremia&#160;occurs, prompt initiation of ART should&#160;be considered regardless&#160;of CD4 count.&#160;</p>
<p style="position:absolute;top:870px;left:108px;white-space:nowrap" class="ft073"><i><b>Monitoring of&#160;Response&#160;to&#160;Therapy and&#160;Adverse Events (Including Immune&#160;<br/>Reconstitution&#160;Inflammatory Syndrome)&#160;</b></i></p>
<p style="position:absolute;top:935px;left:108px;white-space:nowrap" class="ft032">Patients should be&#160;monitored closely for response to treatment, defined clinically by improvement in&#160;<br/>systemic signs and symptoms, resolution of diarrhea, and sterilization of infected tissues or body&#160;<br/>fluids, such as blood.&#160;Follow-up&#160;stool testing may be required when public&#160;health considerations and&#160;<br/>state policies dictate the need to ensure&#160;microbiologic&#160;cure, such&#160;as in health care or food&#160;service&#160;<br/>workers. Follow-up&#160;stool&#160;culture&#160;and antibiotic susceptibility testing should be considered&#160;for&#160;<br/>patients with incomplete&#160;clinical response to appropriate&#160;antimicrobial&#160;therapy. In patients with&#160;<br/>persistent or&#160;recurrent diarrhea&#160;despite&#160;therapy, clinicians should&#160;consider other enteric&#160;infections&#160;<br/>(including STIs; see the&#160;Diagnosis&#160;section above) in the&#160;context of the patient’s immune&#160;status and&#160;</p>
</div>
<!-- Page 29 -->
<a name="29"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}	.ft074{font-size:18px;font-family:MTYWKL+Calibri;color:#000000;}
	.ft075{font-size:17px;font-family:TURBHP+Tinos;color:#211e1f;}
	.ft076{font-size:11px;font-family:TURBHP+Tinos;color:#211e1f;}
	.ft077{font-size:17px;line-height:19px;font-family:BTLIFY+Tinos;color:#000000;}
-->
</style>
<div id="page29-div" style="position:relative;width:917px;height:1187px;">
<p style="position:absolute;top:1114px;left:108px;white-space:nowrap" class="ft024"><i>Guidelines for the Prevention and Treatment&#160;of&#160;Opportunistic&#160;Infections in Adults&#160;and Adolescents&#160;With HIV&#160;</i></p>
<p style="position:absolute;top:1114px;left:784px;white-space:nowrap" class="ft024"><i>B-14&#160;</i></p>
<p style="position:absolute;top:87px;left:108px;white-space:nowrap" class="ft013">exposures, as&#160;well as the&#160;possibility of&#160;</p>
<p style="position:absolute;top:87px;left:377px;white-space:nowrap" class="ft019"><i>C. difficile</i></p>
<p style="position:absolute;top:87px;left:450px;white-space:nowrap" class="ft013">&#160;or&#160;the&#160;development of antimicrobial&#160;resistance&#160;</p>
<p style="position:absolute;top:107px;left:108px;white-space:nowrap" class="ft012"><b>(BIII).</b></p>
<p style="position:absolute;top:107px;left:155px;white-space:nowrap" class="ft013">&#160;</p>
<p style="position:absolute;top:144px;left:108px;white-space:nowrap" class="ft032">Observational studies suggest that plasma&#160;drug concentrations in people&#160;with HIV may be decreased&#160;<br/>as a result&#160;of&#160;severe diarrhea&#160;or malabsorption.</p>
<p style="position:absolute;top:163px;left:431px;white-space:nowrap" class="ft038">77,78</p>
<p style="position:absolute;top:166px;left:456px;white-space:nowrap" class="ft074">&#160;</p>
<p style="position:absolute;top:164px;left:460px;white-space:nowrap" class="ft013">Coadministration of fluoroquinolones&#160;with&#160;</p>
<p style="position:absolute;top:184px;left:108px;white-space:nowrap" class="ft032">magnesium-&#160;or aluminum-containing antacids or with calcium, zinc, or iron should be&#160;avoided&#160;<br/>because these agents interfere with fluoroquinolone&#160;absorption&#160;</p>
<p style="position:absolute;top:204px;left:545px;white-space:nowrap" class="ft012"><b>(AII).</b></p>
<p style="position:absolute;top:202px;left:587px;white-space:nowrap" class="ft038">79</p>
<p style="position:absolute;top:204px;left:598px;white-space:nowrap" class="ft013">&#160;Although larger prospective&#160;</p>
<p style="position:absolute;top:223px;left:108px;white-space:nowrap" class="ft032">studies are needed to determine the impact&#160;of severe diarrhea&#160;on&#160;antibiotic absorption, it&#160;is&#160;prudent&#160;to&#160;<br/>use IV antibiotics in clinically unstable patients&#160;</p>
<p style="position:absolute;top:243px;left:440px;white-space:nowrap" class="ft012"><b>(AIII).</b></p>
<p style="position:absolute;top:243px;left:488px;white-space:nowrap" class="ft013">&#160;</p>
<p style="position:absolute;top:280px;left:108px;white-space:nowrap" class="ft032">Immune reconstitution inflammatory syndrome&#160;has&#160;not been described in association with treatment&#160;<br/>for typical&#160;bacterial enteric pathogens.&#160;</p>
<p style="position:absolute;top:337px;left:108px;white-space:nowrap" class="ft026"><b>Preventing&#160;Recurrence&#160;&#160;</b></p>
<p style="position:absolute;top:379px;left:108px;white-space:nowrap" class="ft032">The&#160;pharmacologic approach to recurrent&#160;enteric infections is covered in the&#160;section on directed&#160;<br/>therapy for each bacterial&#160;species. As noted above, secondary prophylaxis should be&#160;considered for&#160;<br/>patients with recurrent&#160;</p>
<p style="position:absolute;top:418px;left:267px;white-space:nowrap" class="ft019"><i>Salmonella</i></p>
<p style="position:absolute;top:418px;left:345px;white-space:nowrap" class="ft013">&#160;bacteremia&#160;</p>
<p style="position:absolute;top:418px;left:429px;white-space:nowrap" class="ft012"><b>(BIII)&#160;</b></p>
<p style="position:absolute;top:418px;left:477px;white-space:nowrap" class="ft013">and, in&#160;some&#160;circumstances, for those with&#160;</p>
<p style="position:absolute;top:438px;left:108px;white-space:nowrap" class="ft013">recurrent shigellosis&#160;</p>
<p style="position:absolute;top:438px;left:252px;white-space:nowrap" class="ft012"><b>(BIII)</b></p>
<p style="position:absolute;top:438px;left:295px;white-space:nowrap" class="ft013">&#160;or campylobacteriosis&#160;</p>
<p style="position:absolute;top:438px;left:455px;white-space:nowrap" class="ft012"><b>(BIII).</b></p>
<p style="position:absolute;top:438px;left:502px;white-space:nowrap" class="ft013">&#160;</p>
<p style="position:absolute;top:475px;left:108px;white-space:nowrap" class="ft026"><b>Special&#160;Considerations During&#160;Pregnancy&#160;</b></p>
<p style="position:absolute;top:517px;left:108px;white-space:nowrap" class="ft032">During pregnancy, the diagnosis and&#160;management&#160;of bacterial enteric infection are the same&#160;as for&#160;<br/>other people with HIV, with several considerations.&#160;</p>
<p style="position:absolute;top:536px;left:468px;white-space:nowrap" class="ft012"><b>Based on their safety profile, expanded-</b></p>
<p style="position:absolute;top:556px;left:108px;white-space:nowrap" class="ft077"><b>spectrum cephalosporins or azithromycin should be the first-line therapy for bacterial enteric&#160;<br/>infections&#160;during pregnancy if antimicrobials are required,&#160;depending&#160;on the organism and the&#160;<br/>results of&#160;susceptibility testing (BIII).</b></p>
<p style="position:absolute;top:595px;left:382px;white-space:nowrap" class="ft038">80</p>
<p style="position:absolute;top:596px;left:393px;white-space:nowrap" class="ft013">&#160;Arthropathy has been&#160;noted in the offspring&#160;of&#160;animals&#160;</p>
<p style="position:absolute;top:616px;left:108px;white-space:nowrap" class="ft013">treated with quinolones during pregnancy.&#160;</p>
<p style="position:absolute;top:616px;left:404px;white-space:nowrap" class="ft075">However, studies evaluating quinolone use during&#160;</p>
<p style="position:absolute;top:635px;left:108px;white-space:nowrap" class="ft075">pregnancy did not find an&#160;increased risk of birth defects or musculoskeletal&#160;abnormalities.</p>
<p style="position:absolute;top:634px;left:730px;white-space:nowrap" class="ft076">81-83</p>
<p style="position:absolute;top:635px;left:757px;white-space:nowrap" class="ft075">&#160;</p>
<p style="position:absolute;top:635px;left:761px;white-space:nowrap" class="ft013">Thus,&#160;</p>
<p style="position:absolute;top:655px;left:108px;white-space:nowrap" class="ft032">quinolones can be used for bacterial&#160;enteric&#160;infections if indicated by susceptibility testing&#160;or failure&#160;<br/>of first-line&#160;therapy, as listed above with a&#160;shared&#160;medical decision-making&#160;decision model in&#160;<br/>discussion&#160;with the&#160;patient.&#160;</p>
<p style="position:absolute;top:695px;left:300px;white-space:nowrap" class="ft012"><b>(BIII).</b></p>
<p style="position:absolute;top:695px;left:347px;white-space:nowrap" class="ft013">&#160;TMP-SMX use in the&#160;first trimester should be avoided, if&#160;</p>
<p style="position:absolute;top:715px;left:108px;white-space:nowrap" class="ft032">possible, because of an association with an increased risk of birth defects, specifically neural tube,&#160;<br/>cardiovascular, and urinary tract&#160;defects&#160;</p>
<p style="position:absolute;top:735px;left:388px;white-space:nowrap" class="ft012"><b>(BIII).</b></p>
<p style="position:absolute;top:733px;left:436px;white-space:nowrap" class="ft038">84-86</p>
<p style="position:absolute;top:735px;left:462px;white-space:nowrap" class="ft013">&#160;However, a&#160;review of potential&#160;risks related to&#160;</p>
<p style="position:absolute;top:755px;left:108px;white-space:nowrap" class="ft032">TMP-SMX use cites the low quality of&#160;current&#160;data and supports&#160;the&#160;use of TMP-SMX during&#160;<br/>pregnancy as&#160;clinically indicated.</p>
<p style="position:absolute;top:773px;left:339px;white-space:nowrap" class="ft038">87</p>
<p style="position:absolute;top:774px;left:350px;white-space:nowrap" class="ft013">&#160;As&#160;soon as&#160;possible during the&#160;trimester of pregnancy, or when&#160;</p>
<p style="position:absolute;top:794px;left:108px;white-space:nowrap" class="ft032">anticipating&#160;or attempting conception, any administration of TMP-SMX should be&#160;supplemented&#160;<br/>with folic&#160;acid 4 mg/day&#160;</p>
<p style="position:absolute;top:814px;left:281px;white-space:nowrap" class="ft012"><b>(BIII).</b></p>
<p style="position:absolute;top:813px;left:328px;white-space:nowrap" class="ft038">84,85,88</p>
<p style="position:absolute;top:814px;left:368px;white-space:nowrap" class="ft013">&#160;Neonatal care&#160;providers&#160;should be&#160;informed if maternal&#160;sulfa&#160;</p>
<p style="position:absolute;top:834px;left:108px;white-space:nowrap" class="ft032">therapy was&#160;used near delivery because of the theoretical&#160;increased risk of hyperbilirubinemia&#160;and&#160;<br/>kernicterus in the newborn. Because oral&#160;rifaximin and fidaxomicin are not&#160;absorbed&#160;systemically,&#160;<br/>they can be used during pregnancy. However, this&#160;should be&#160;a shared decision&#160;made between&#160;<br/>providers and patients ensuring that&#160;patients are made aware of&#160;the limited data about&#160;fidaxomicin in&#160;<br/>pregnancy&#160;</p>
<p style="position:absolute;top:913px;left:184px;white-space:nowrap" class="ft012"><b>(BIII).</b></p>
<p style="position:absolute;top:913px;left:232px;white-space:nowrap" class="ft013">&#160;&#160;</p>
<p style="position:absolute;top:950px;left:108px;white-space:nowrap" class="ft032">Vancomycin&#160;and metronidazole are&#160;two antimicrobials that&#160;have been utilized in the perinatal period&#160;<br/>in the United States. Intravenous vancomycin has been utilized as intrapartum prophylaxis&#160;in the&#160;<br/>penicillin allergic&#160;patient colonized with group B&#160;streptococcus,</p>
<p style="position:absolute;top:989px;left:550px;white-space:nowrap" class="ft038">89</p>
<p style="position:absolute;top:990px;left:561px;white-space:nowrap" class="ft013">&#160;and minimal&#160;absorption&#160;is&#160;</p>
<p style="position:absolute;top:1010px;left:108px;white-space:nowrap" class="ft032">expected with oral therapy. Although&#160;vancomycin for enteric&#160;disease is recommended for use only in&#160;<br/>its oral formulation, which is not&#160;absorbed in meaningful concentrations from the gastrointestinal&#160;<br/>tract,</p>
<p style="position:absolute;top:1048px;left:143px;white-space:nowrap" class="ft038">90</p>
<p style="position:absolute;top:1049px;left:154px;white-space:nowrap" class="ft013">&#160;it&#160;should be&#160;noted&#160;that with intravenous use,&#160;vancomycin readily crosses the placenta.</p>
<p style="position:absolute;top:1048px;left:750px;white-space:nowrap" class="ft038">91</p>
<p style="position:absolute;top:1049px;left:761px;white-space:nowrap" class="ft013">&#160;A&#160;</p>
<p style="position:absolute;top:1069px;left:108px;white-space:nowrap" class="ft013">study of 10 infants evaluated after the second or third trimester for&#160;</p>
<p style="position:absolute;top:1069px;left:570px;white-space:nowrap" class="ft019"><i>in utero</i></p>
<p style="position:absolute;top:1069px;left:625px;white-space:nowrap" class="ft013">&#160;exposure of maternal&#160;</p>
</div>
<!-- Page 30 -->
<a name="30"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page30-div" style="position:relative;width:917px;height:1187px;">
<p style="position:absolute;top:1114px;left:108px;white-space:nowrap" class="ft024"><i>Guidelines for the Prevention and Treatment&#160;of&#160;Opportunistic&#160;Infections in Adults&#160;and Adolescents&#160;With HIV&#160;</i></p>
<p style="position:absolute;top:1114px;left:784px;white-space:nowrap" class="ft024"><i>B-15&#160;</i></p>
<p style="position:absolute;top:87px;left:108px;white-space:nowrap" class="ft032">intravenous&#160;vancomycin therapy for serious staphylococcal infections found&#160;no hearing loss&#160;or&#160;renal&#160;<br/>toxicity attributed to vancomycin.</p>
<p style="position:absolute;top:106px;left:342px;white-space:nowrap" class="ft038">91</p>
<p style="position:absolute;top:107px;left:353px;white-space:nowrap" class="ft013">&#160;A&#160;review of metronidazole use in pregnancy for treatment of&#160;</p>
<p style="position:absolute;top:127px;left:108px;white-space:nowrap" class="ft013">trichomoniasis or bacterial&#160;vaginosis found no increase in risk of birth defects.</p>
<p style="position:absolute;top:125px;left:649px;white-space:nowrap" class="ft038">92</p>
<p style="position:absolute;top:127px;left:661px;white-space:nowrap" class="ft013">&#160;Studies on the&#160;use of&#160;</p>
<p style="position:absolute;top:147px;left:108px;white-space:nowrap" class="ft013">metronidazole&#160;for CDI in&#160;pregnancy&#160;were not&#160;found.&#160;</p>
</div>
<!-- Page 31 -->
<a name="31"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page31-div" style="position:relative;width:917px;height:1187px;">
<p style="position:absolute;top:1114px;left:108px;white-space:nowrap" class="ft024"><i>Guidelines for the Prevention and Treatment&#160;of&#160;Opportunistic&#160;Infections in Adults&#160;and Adolescents&#160;With HIV&#160;</i></p>
<p style="position:absolute;top:1114px;left:784px;white-space:nowrap" class="ft024"><i>B-16&#160;</i></p>
<p style="position:absolute;top:87px;left:108px;white-space:nowrap" class="ft026"><b>References&#160;</b></p>
<p style="position:absolute;top:128px;left:108px;white-space:nowrap" class="ft013">1.</p>
<p style="position:absolute;top:128px;left:121px;white-space:nowrap" class="ft046">&#160;</p>
<p style="position:absolute;top:128px;left:162px;white-space:nowrap" class="ft032">Sanchez&#160;TH,&#160;Brooks&#160;JT,&#160;Sullivan PS,&#160;et&#160;al. Bacterial diarrhea&#160;in persons with&#160;HIV infection,&#160;<br/>United States, 1992–2002.&#160;</p>
<p style="position:absolute;top:148px;left:349px;white-space:nowrap" class="ft019"><i>Clin Infect Dis</i></p>
<p style="position:absolute;top:148px;left:451px;white-space:nowrap" class="ft013">. 2005;41(11):1621-1627. Available&#160;at:&#160;</p>
<p style="position:absolute;top:168px;left:162px;white-space:nowrap" class="ft034">http://www.ncbi.nlm.nih.gov/pubmed/16267735</p>
<p style="position:absolute;top:168px;left:497px;white-space:nowrap" class="ft013">.&#160;</p>
<p style="position:absolute;top:205px;left:108px;white-space:nowrap" class="ft013">2.</p>
<p style="position:absolute;top:205px;left:121px;white-space:nowrap" class="ft046">&#160;</p>
<p style="position:absolute;top:205px;left:162px;white-space:nowrap" class="ft032">Newman&#160;KL, Newman&#160;GS, Cybulski RJ, Fang&#160;FC.&#160;Gastroenteritis in men who have sex&#160;with&#160;<br/>men in Seattle, Washington, 2017–2018.&#160;</p>
<p style="position:absolute;top:225px;left:447px;white-space:nowrap" class="ft019"><i>Clin Infect&#160;Dis</i></p>
<p style="position:absolute;top:225px;left:549px;white-space:nowrap" class="ft013">. 2020;71(1):109-115. Available at:&#160;</p>
<p style="position:absolute;top:245px;left:162px;white-space:nowrap" class="ft034">https://www.ncbi.nlm.nih.gov/pubmed/31621824</p>
<p style="position:absolute;top:245px;left:503px;white-space:nowrap" class="ft013">.&#160;</p>
<p style="position:absolute;top:282px;left:108px;white-space:nowrap" class="ft013">3.</p>
<p style="position:absolute;top:282px;left:121px;white-space:nowrap" class="ft046">&#160;</p>
<p style="position:absolute;top:282px;left:162px;white-space:nowrap" class="ft032">Verma A,&#160;Hine AM,&#160;Joelson A, et al. The influence of hospitalization and HIV severity on&#160;<br/>gastrointestinal PCR panel&#160;evaluation of HIV-related acute&#160;diarrhea&#160;in New&#160;York City:&#160;a&#160;<br/>retrospective, cross-sectional study.&#160;</p>
<p style="position:absolute;top:322px;left:412px;white-space:nowrap" class="ft019"><i>Therap Adv Gastroenterol</i></p>
<p style="position:absolute;top:322px;left:594px;white-space:nowrap" class="ft013">.&#160;</p>
<p style="position:absolute;top:341px;left:162px;white-space:nowrap" class="ft013">2022;15:17562848221092593. Available at:&#160;</p>
<p style="position:absolute;top:361px;left:162px;white-space:nowrap" class="ft034">https://www.ncbi.nlm.nih.gov/pubmed/35509422</p>
<p style="position:absolute;top:361px;left:503px;white-space:nowrap" class="ft013">.&#160;</p>
<p style="position:absolute;top:398px;left:108px;white-space:nowrap" class="ft013">4.</p>
<p style="position:absolute;top:398px;left:121px;white-space:nowrap" class="ft046">&#160;</p>
<p style="position:absolute;top:398px;left:162px;white-space:nowrap" class="ft013">Chou YJ, Lin HW,&#160;Yang&#160;CJ, et al. Risk of recurrent nontyphoid&#160;</p>
<p style="position:absolute;top:398px;left:607px;white-space:nowrap" class="ft019"><i>Salmonella</i></p>
<p style="position:absolute;top:398px;left:685px;white-space:nowrap" class="ft013">&#160;bacteremia&#160;in&#160;</p>
<p style="position:absolute;top:418px;left:162px;white-space:nowrap" class="ft032">human immunodeficiency virus-infected patients with short-term&#160;secondary prophylaxis in&#160;<br/>the&#160;era of combination antiretroviral&#160;therapy.&#160;</p>
<p style="position:absolute;top:438px;left:476px;white-space:nowrap" class="ft019"><i>J&#160;Microbiol Immunol Infect</i></p>
<p style="position:absolute;top:438px;left:666px;white-space:nowrap" class="ft013">. 2015. Available at:&#160;</p>
<p style="position:absolute;top:458px;left:162px;white-space:nowrap" class="ft034">http://www.ncbi.nlm.nih.gov/pubmed/26316009</p>
<p style="position:absolute;top:458px;left:497px;white-space:nowrap" class="ft013">.&#160;</p>
<p style="position:absolute;top:495px;left:108px;white-space:nowrap" class="ft013">5.</p>
<p style="position:absolute;top:495px;left:121px;white-space:nowrap" class="ft046">&#160;</p>
<p style="position:absolute;top:495px;left:162px;white-space:nowrap" class="ft013">Hung CC, Hung MN,&#160;Hsueh PR, et al. Risk of recurrent&#160;nontyphoid&#160;</p>
<p style="position:absolute;top:495px;left:635px;white-space:nowrap" class="ft019"><i>Salmonella</i></p>
<p style="position:absolute;top:495px;left:713px;white-space:nowrap" class="ft013">&#160;bacteremia&#160;</p>
<p style="position:absolute;top:515px;left:162px;white-space:nowrap" class="ft032">in HIV-infected patients in the era&#160;of highly active antiretroviral&#160;therapy and&#160;an increasing&#160;<br/>trend of fluoroquinolone resistance.&#160;</p>
<p style="position:absolute;top:535px;left:412px;white-space:nowrap" class="ft019"><i>Clin Infect&#160;Dis</i></p>
<p style="position:absolute;top:535px;left:514px;white-space:nowrap" class="ft013">.&#160;2007;45(5):e60-67.&#160;Available at:&#160;</p>
<p style="position:absolute;top:554px;left:162px;white-space:nowrap" class="ft034">http://www.ncbi.nlm.nih.gov/pubmed/17682981</p>
<p style="position:absolute;top:554px;left:497px;white-space:nowrap" class="ft013">.&#160;</p>
<p style="position:absolute;top:592px;left:108px;white-space:nowrap" class="ft013">6.</p>
<p style="position:absolute;top:591px;left:121px;white-space:nowrap" class="ft046">&#160;</p>
<p style="position:absolute;top:592px;left:162px;white-space:nowrap" class="ft013">Taramasso L, Tatarelli&#160;P, Di Biagio A.&#160;Bloodstream infections in HIV-infected patients.&#160;</p>
<p style="position:absolute;top:611px;left:162px;white-space:nowrap" class="ft019"><i>Virulence</i></p>
<p style="position:absolute;top:611px;left:229px;white-space:nowrap" class="ft013">. 2016;7(3):320-328. Available&#160;at:&#160;</p>
<p style="position:absolute;top:631px;left:162px;white-space:nowrap" class="ft034">https://www.ncbi.nlm.nih.gov/pubmed/26950194</p>
<p style="position:absolute;top:631px;left:503px;white-space:nowrap" class="ft013">.&#160;</p>
<p style="position:absolute;top:668px;left:108px;white-space:nowrap" class="ft013">7.</p>
<p style="position:absolute;top:668px;left:121px;white-space:nowrap" class="ft046">&#160;</p>
<p style="position:absolute;top:668px;left:162px;white-space:nowrap" class="ft032">Huang&#160;DB,&#160;Mohanty&#160;A,&#160;DuPont HL,&#160;Okhuysen PC, Chiang T.&#160;A review&#160;of&#160;an emerging&#160;<br/>enteric pathogen:&#160;enteroaggregative&#160;</p>
<p style="position:absolute;top:688px;left:413px;white-space:nowrap" class="ft019"><i>Escherichia coli</i></p>
<p style="position:absolute;top:688px;left:526px;white-space:nowrap" class="ft013">.&#160;</p>
<p style="position:absolute;top:688px;left:534px;white-space:nowrap" class="ft019"><i>J Med Microbiol</i></p>
<p style="position:absolute;top:688px;left:650px;white-space:nowrap" class="ft013">. 2006;55(Pt&#160;10):1303-</p>
<p style="position:absolute;top:708px;left:162px;white-space:nowrap" class="ft013">1311. Available&#160;at:&#160;</p>
<p style="position:absolute;top:708px;left:298px;white-space:nowrap" class="ft034">http://www.ncbi.nlm.nih.gov/pubmed/17005776</p>
<p style="position:absolute;top:708px;left:632px;white-space:nowrap" class="ft013">.&#160;</p>
<p style="position:absolute;top:745px;left:108px;white-space:nowrap" class="ft013">8.</p>
<p style="position:absolute;top:745px;left:162px;white-space:nowrap" class="ft013">Nevin DT,&#160;Morgan CJ,&#160;Graham DY,&#160;Genta RM.&#160;</p>
<p style="position:absolute;top:745px;left:500px;white-space:nowrap" class="ft019"><i>Helicobacter pylori</i></p>
<p style="position:absolute;top:745px;left:640px;white-space:nowrap" class="ft013">gastritis in HIV-infected</p>
<p style="position:absolute;top:765px;left:162px;white-space:nowrap" class="ft013">patients: a&#160;review.&#160;</p>
<p style="position:absolute;top:765px;left:292px;white-space:nowrap" class="ft019"><i>Helicobacter</i></p>
<p style="position:absolute;top:765px;left:382px;white-space:nowrap" class="ft013">. 2014;19(5):323-329. Available at:&#160;</p>
<p style="position:absolute;top:785px;left:162px;white-space:nowrap" class="ft034">https://www.ncbi.nlm.nih.gov/pubmed/24773336</p>
<p style="position:absolute;top:785px;left:503px;white-space:nowrap" class="ft013">.&#160;</p>
<p style="position:absolute;top:822px;left:108px;white-space:nowrap" class="ft013">9.</p>
<p style="position:absolute;top:822px;left:121px;white-space:nowrap" class="ft046">&#160;</p>
<p style="position:absolute;top:822px;left:162px;white-space:nowrap" class="ft013">Revolinski SL, Munoz-Price LS.&#160;</p>
<p style="position:absolute;top:822px;left:393px;white-space:nowrap" class="ft019"><i>Clostridium difficile</i></p>
<p style="position:absolute;top:822px;left:532px;white-space:nowrap" class="ft013">&#160;in immunocompromised hosts: a&#160;</p>
<p style="position:absolute;top:842px;left:162px;white-space:nowrap" class="ft013">review of epidemiology, risk factors, treatment, and prevention.&#160;</p>
<p style="position:absolute;top:842px;left:606px;white-space:nowrap" class="ft019"><i>Clin Infect&#160;Dis</i></p>
<p style="position:absolute;top:842px;left:708px;white-space:nowrap" class="ft013">.&#160;</p>
<p style="position:absolute;top:862px;left:162px;white-space:nowrap" class="ft013">2019;68(12):2144-2153.&#160;Available at:&#160;</p>
<p style="position:absolute;top:862px;left:428px;white-space:nowrap" class="ft034">https://www.ncbi.nlm.nih.gov/pubmed/30281082</p>
<p style="position:absolute;top:862px;left:770px;white-space:nowrap" class="ft013">.&#160;</p>
<p style="position:absolute;top:899px;left:108px;white-space:nowrap" class="ft013">10.</p>
<p style="position:absolute;top:898px;left:130px;white-space:nowrap" class="ft046">&#160;</p>
<p style="position:absolute;top:899px;left:162px;white-space:nowrap" class="ft013">Haines CF,&#160;Moore RD,&#160;Bartlett JG, et al.&#160;</p>
<p style="position:absolute;top:899px;left:448px;white-space:nowrap" class="ft019"><i>Clostridium difficile</i></p>
<p style="position:absolute;top:899px;left:587px;white-space:nowrap" class="ft013">&#160;in a HIV-infected cohort:&#160;</p>
<p style="position:absolute;top:918px;left:162px;white-space:nowrap" class="ft013">incidence, risk factors, and clinical&#160;outcomes.&#160;</p>
<p style="position:absolute;top:918px;left:481px;white-space:nowrap" class="ft019"><i>AIDS</i></p>
<p style="position:absolute;top:918px;left:519px;white-space:nowrap" class="ft013">. 2013;27(17):2799-2807.&#160;Available at:&#160;</p>
<p style="position:absolute;top:938px;left:162px;white-space:nowrap" class="ft034">http://www.ncbi.nlm.nih.gov/pubmed/23842125</p>
<p style="position:absolute;top:938px;left:497px;white-space:nowrap" class="ft013">.&#160;</p>
<p style="position:absolute;top:975px;left:108px;white-space:nowrap" class="ft013">11.</p>
<p style="position:absolute;top:975px;left:130px;white-space:nowrap" class="ft046">&#160;</p>
<p style="position:absolute;top:975px;left:162px;white-space:nowrap" class="ft032">Angulo&#160;FJ,&#160;Swerdlow&#160;DL.&#160;Bacterial&#160;enteric infections in persons infected with human&#160;<br/>immunodeficiency virus.&#160;</p>
<p style="position:absolute;top:995px;left:339px;white-space:nowrap" class="ft019"><i>Clin Infect Dis</i></p>
<p style="position:absolute;top:995px;left:440px;white-space:nowrap" class="ft013">. 1995;21&#160;Suppl 1:S84-93. Available at:&#160;</p>
<p style="position:absolute;top:1015px;left:162px;white-space:nowrap" class="ft034">http://www.ncbi.nlm.nih.gov/pubmed/8547518</p>
<p style="position:absolute;top:1015px;left:488px;white-space:nowrap" class="ft013">.&#160;</p>
</div>
<!-- Page 32 -->
<a name="32"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page32-div" style="position:relative;width:917px;height:1187px;">
<p style="position:absolute;top:1114px;left:108px;white-space:nowrap" class="ft024"><i>Guidelines for the Prevention and Treatment&#160;of&#160;Opportunistic&#160;Infections in Adults&#160;and Adolescents&#160;With HIV&#160;</i></p>
<p style="position:absolute;top:1114px;left:784px;white-space:nowrap" class="ft024"><i>B-17&#160;</i></p>
<p style="position:absolute;top:87px;left:108px;white-space:nowrap" class="ft013">12.</p>
<p style="position:absolute;top:87px;left:130px;white-space:nowrap" class="ft046">&#160;</p>
<p style="position:absolute;top:87px;left:162px;white-space:nowrap" class="ft032">Aragon TJ,&#160;Vugia DJ, Shallow S, et&#160;al. Case-control study of&#160;shigellosis in San Francisco:&#160;<br/>the&#160;role&#160;of sexual&#160;transmission and&#160;HIV infection.&#160;</p>
<p style="position:absolute;top:107px;left:511px;white-space:nowrap" class="ft019"><i>Clin Infect&#160;Dis</i></p>
<p style="position:absolute;top:107px;left:612px;white-space:nowrap" class="ft013">. 2007;44(3):327-334.&#160;</p>
<p style="position:absolute;top:127px;left:162px;white-space:nowrap" class="ft013">Available at:&#160;</p>
<p style="position:absolute;top:127px;left:255px;white-space:nowrap" class="ft034">http://www.ncbi.nlm.nih.gov/pubmed/17205436</p>
<p style="position:absolute;top:127px;left:589px;white-space:nowrap" class="ft013">.&#160;</p>
<p style="position:absolute;top:164px;left:108px;white-space:nowrap" class="ft013">13.</p>
<p style="position:absolute;top:164px;left:130px;white-space:nowrap" class="ft046">&#160;</p>
<p style="position:absolute;top:164px;left:162px;white-space:nowrap" class="ft013">Quinn TC,&#160;Goodell SE, Fennell C, et al. Infections&#160;with&#160;</p>
<p style="position:absolute;top:164px;left:551px;white-space:nowrap" class="ft019"><i>Campylobacter jejuni</i></p>
<p style="position:absolute;top:164px;left:700px;white-space:nowrap" class="ft013">&#160;and&#160;</p>
<p style="position:absolute;top:184px;left:162px;white-space:nowrap" class="ft019"><i>Campylobacter</i></p>
<p style="position:absolute;top:184px;left:268px;white-space:nowrap" class="ft013">-like organisms in homosexual&#160;men.&#160;</p>
<p style="position:absolute;top:184px;left:523px;white-space:nowrap" class="ft019"><i>Ann Intern&#160;Med</i></p>
<p style="position:absolute;top:184px;left:632px;white-space:nowrap" class="ft013">. 1984;101(2):187-192.&#160;</p>
<p style="position:absolute;top:204px;left:162px;white-space:nowrap" class="ft013">Available at:&#160;</p>
<p style="position:absolute;top:204px;left:255px;white-space:nowrap" class="ft034">http://www.ncbi.nlm.nih.gov/pubmed/6547580</p>
<p style="position:absolute;top:204px;left:581px;white-space:nowrap" class="ft013">.</p>
<p style="position:absolute;top:241px;left:108px;white-space:nowrap" class="ft013">14.</p>
<p style="position:absolute;top:240px;left:130px;white-space:nowrap" class="ft046">&#160;</p>
<p style="position:absolute;top:241px;left:162px;white-space:nowrap" class="ft032">Mitchell HD,&#160;Thomson&#160;NR, Jenkins&#160;C,&#160;et&#160;al. Linkage&#160;of whole genome sequencing,&#160;<br/>epidemiological, and clinical&#160;data to understand the genetic&#160;diversity and clinical outcomes&#160;<br/>of&#160;</p>
<p style="position:absolute;top:280px;left:181px;white-space:nowrap" class="ft019"><i>Shigella flexneri</i></p>
<p style="position:absolute;top:280px;left:294px;white-space:nowrap" class="ft013">&#160;among men who&#160;have&#160;sex with&#160;men in England.&#160;</p>
<p style="position:absolute;top:280px;left:635px;white-space:nowrap" class="ft019"><i>Microbiol Spectr</i></p>
<p style="position:absolute;top:280px;left:752px;white-space:nowrap" class="ft013">.&#160;</p>
<p style="position:absolute;top:300px;left:162px;white-space:nowrap" class="ft013">2021;9(3):e0121321.&#160;Available at:&#160;</p>
<p style="position:absolute;top:300px;left:404px;white-space:nowrap" class="ft034">https://www.ncbi.nlm.nih.gov/pubmed/34908501</p>
<p style="position:absolute;top:300px;left:746px;white-space:nowrap" class="ft013">.&#160;</p>
<p style="position:absolute;top:337px;left:108px;white-space:nowrap" class="ft013">15.</p>
<p style="position:absolute;top:337px;left:130px;white-space:nowrap" class="ft046">&#160;</p>
<p style="position:absolute;top:337px;left:162px;white-space:nowrap" class="ft032">Mohan&#160;K, Hibbert&#160;M, Rooney G, et al. What is the overlap between HIV&#160;and&#160;shigellosis&#160;<br/>epidemics in England:&#160;further evidence&#160;of MSM transmission?&#160;</p>
<p style="position:absolute;top:357px;left:600px;white-space:nowrap" class="ft019"><i>Sex Transm&#160;Infect</i></p>
<p style="position:absolute;top:357px;left:724px;white-space:nowrap" class="ft013">.&#160;</p>
<p style="position:absolute;top:377px;left:162px;white-space:nowrap" class="ft013">2018;94(1):67-71. Available&#160;at:&#160;</p>
<p style="position:absolute;top:377px;left:385px;white-space:nowrap" class="ft034">https://www.ncbi.nlm.nih.gov/pubmed/28490580</p>
<p style="position:absolute;top:377px;left:726px;white-space:nowrap" class="ft013">.&#160;</p>
<p style="position:absolute;top:414px;left:108px;white-space:nowrap" class="ft013">16.</p>
<p style="position:absolute;top:414px;left:130px;white-space:nowrap" class="ft046">&#160;</p>
<p style="position:absolute;top:414px;left:162px;white-space:nowrap" class="ft032">Kuhn&#160;KG,&#160;Hvass&#160;AK,&#160;Christiansen AH, Ethelberg&#160;S, Cowan SA. Sexual&#160;contact&#160;as risk&#160;<br/>factor for&#160;</p>
<p style="position:absolute;top:434px;left:231px;white-space:nowrap" class="ft019"><i>Campylobacter</i></p>
<p style="position:absolute;top:434px;left:337px;white-space:nowrap" class="ft013">&#160;infection, Denmark.&#160;</p>
<p style="position:absolute;top:434px;left:484px;white-space:nowrap" class="ft019"><i>Emerg Infect&#160;Dis</i></p>
<p style="position:absolute;top:434px;left:602px;white-space:nowrap" class="ft013">.&#160;2021;27(4):1133-1140.&#160;</p>
<p style="position:absolute;top:454px;left:162px;white-space:nowrap" class="ft013">Available at:&#160;</p>
<p style="position:absolute;top:454px;left:255px;white-space:nowrap" class="ft034">https://www.ncbi.nlm.nih.gov/pubmed/33754996</p>
<p style="position:absolute;top:454px;left:596px;white-space:nowrap" class="ft013">.&#160;</p>
<p style="position:absolute;top:491px;left:108px;white-space:nowrap" class="ft013">17.</p>
<p style="position:absolute;top:491px;left:130px;white-space:nowrap" class="ft046">&#160;</p>
<p style="position:absolute;top:491px;left:162px;white-space:nowrap" class="ft013">Tee&#160;W, Mijch A.&#160;</p>
<p style="position:absolute;top:491px;left:284px;white-space:nowrap" class="ft019"><i>Campylobacter jejuni&#160;</i></p>
<p style="position:absolute;top:491px;left:438px;white-space:nowrap" class="ft013">bacteremia&#160;in human immunodeficiency virus (HIV)-</p>
<p style="position:absolute;top:511px;left:162px;white-space:nowrap" class="ft013">infected and non-HIV-infected patients: comparison of clinical features and&#160;review.&#160;</p>
<p style="position:absolute;top:511px;left:743px;white-space:nowrap" class="ft019"><i>Clin&#160;</i></p>
<p style="position:absolute;top:530px;left:162px;white-space:nowrap" class="ft019"><i>Infect&#160;Dis</i></p>
<p style="position:absolute;top:530px;left:229px;white-space:nowrap" class="ft013">. 1998;26(1):91-96. Available at:&#160;</p>
<p style="position:absolute;top:530px;left:461px;white-space:nowrap" class="ft034">http://www.ncbi.nlm.nih.gov/pubmed/9455515</p>
<p style="position:absolute;top:530px;left:787px;white-space:nowrap" class="ft013">.&#160;</p>
<p style="position:absolute;top:568px;left:108px;white-space:nowrap" class="ft013">18.</p>
<p style="position:absolute;top:567px;left:130px;white-space:nowrap" class="ft046">&#160;</p>
<p style="position:absolute;top:568px;left:162px;white-space:nowrap" class="ft013">Tobin-D’Angelo M, Oosmanally N, Wilson SN,&#160;Anderson EJ, Segler S,&#160;Poventud L.&#160;</p>
<p style="position:absolute;top:568px;left:752px;white-space:nowrap" class="ft019"><i>Shigella</i></p>
<p style="position:absolute;top:568px;left:808px;white-space:nowrap" class="ft013">&#160;</p>
<p style="position:absolute;top:587px;left:162px;white-space:nowrap" class="ft013">bacteremia, Georgia, USA, 2002–2012(1).&#160;</p>
<p style="position:absolute;top:587px;left:460px;white-space:nowrap" class="ft019"><i>Emerg&#160;Infect&#160;Dis</i></p>
<p style="position:absolute;top:587px;left:578px;white-space:nowrap" class="ft013">. 2020;26(1):122-124.&#160;Available&#160;</p>
<p style="position:absolute;top:607px;left:162px;white-space:nowrap" class="ft013">at:&#160;</p>
<p style="position:absolute;top:607px;left:184px;white-space:nowrap" class="ft034">https://www.ncbi.nlm.nih.gov/pubmed/31855540</p>
<p style="position:absolute;top:607px;left:525px;white-space:nowrap" class="ft013">.&#160;</p>
<p style="position:absolute;top:644px;left:108px;white-space:nowrap" class="ft013">19.</p>
<p style="position:absolute;top:644px;left:130px;white-space:nowrap" class="ft046">&#160;</p>
<p style="position:absolute;top:644px;left:162px;white-space:nowrap" class="ft032">Celum CL, Chaisson RE, Rutherford&#160;GW, Barnhart JL, Echenberg DF. Incidence of&#160;<br/>salmonellosis in patients with AIDS.</p>
<p style="position:absolute;top:664px;left:420px;white-space:nowrap" class="ft019"><i>J&#160;Infect Dis</i></p>
<p style="position:absolute;top:664px;left:499px;white-space:nowrap" class="ft013">. 1987;156(6):998-1002.&#160;Available&#160;at:</p>
<p style="position:absolute;top:684px;left:162px;white-space:nowrap" class="ft034">http://www.ncbi.nlm.nih.gov/pubmed/3680999</p>
<p style="position:absolute;top:684px;left:488px;white-space:nowrap" class="ft013">.&#160;</p>
<p style="position:absolute;top:721px;left:108px;white-space:nowrap" class="ft013">20.</p>
<p style="position:absolute;top:721px;left:130px;white-space:nowrap" class="ft046">&#160;</p>
<p style="position:absolute;top:721px;left:162px;white-space:nowrap" class="ft013">Kristjansson&#160;M, Viner&#160;B,&#160;Maslow&#160;JN.&#160;Polymicrobial and recurrent&#160;bacteremia&#160;with&#160;</p>
<p style="position:absolute;top:721px;left:740px;white-space:nowrap" class="ft019"><i>Shigella</i></p>
<p style="position:absolute;top:721px;left:797px;white-space:nowrap" class="ft013">&#160;</p>
<p style="position:absolute;top:741px;left:162px;white-space:nowrap" class="ft013">in a&#160;patient with AIDS.&#160;</p>
<p style="position:absolute;top:741px;left:327px;white-space:nowrap" class="ft019"><i>Scand J Infect&#160;Dis</i></p>
<p style="position:absolute;top:741px;left:453px;white-space:nowrap" class="ft013">. 1994;26(4):411-416. Available at:&#160;</p>
<p style="position:absolute;top:761px;left:162px;white-space:nowrap" class="ft034">http://www.ncbi.nlm.nih.gov/pubmed/7984973</p>
<p style="position:absolute;top:761px;left:488px;white-space:nowrap" class="ft013">.&#160;</p>
<p style="position:absolute;top:798px;left:108px;white-space:nowrap" class="ft013">21.</p>
<p style="position:absolute;top:798px;left:130px;white-space:nowrap" class="ft046">&#160;</p>
<p style="position:absolute;top:798px;left:162px;white-space:nowrap" class="ft013">Casado JL,&#160;Valdezate S,&#160;Calderon C,&#160;et&#160;al. Zidovudine therapy protects against&#160;</p>
<p style="position:absolute;top:798px;left:711px;white-space:nowrap" class="ft019"><i>Salmonella</i></p>
<p style="position:absolute;top:798px;left:789px;white-space:nowrap" class="ft013">&#160;</p>
<p style="position:absolute;top:818px;left:162px;white-space:nowrap" class="ft013">bacteremia&#160;recurrence&#160;in human immunodeficiency virus-infected patients.&#160;</p>
<p style="position:absolute;top:818px;left:684px;white-space:nowrap" class="ft019"><i>J Infect&#160;Dis</i></p>
<p style="position:absolute;top:818px;left:763px;white-space:nowrap" class="ft013">.&#160;</p>
<p style="position:absolute;top:837px;left:162px;white-space:nowrap" class="ft013">1999;179(6):1553-1556.&#160;Available at:&#160;</p>
<p style="position:absolute;top:837px;left:428px;white-space:nowrap" class="ft034">https://www.ncbi.nlm.nih.gov/pubmed/10228081</p>
<p style="position:absolute;top:837px;left:770px;white-space:nowrap" class="ft013">.&#160;</p>
<p style="position:absolute;top:875px;left:108px;white-space:nowrap" class="ft013">22.</p>
<p style="position:absolute;top:874px;left:130px;white-space:nowrap" class="ft046">&#160;</p>
<p style="position:absolute;top:875px;left:162px;white-space:nowrap" class="ft013">Williamson DA,&#160;Chen MY. Emerging&#160;and reemerging sexually&#160;transmitted infections.&#160;</p>
<p style="position:absolute;top:875px;left:762px;white-space:nowrap" class="ft019"><i>N&#160;</i></p>
<p style="position:absolute;top:894px;left:162px;white-space:nowrap" class="ft019"><i>Engl&#160;J Med</i></p>
<p style="position:absolute;top:894px;left:241px;white-space:nowrap" class="ft013">.&#160;2020;382(21):2023-2032.&#160;Available at:&#160;</p>
<p style="position:absolute;top:914px;left:162px;white-space:nowrap" class="ft034">https://www.ncbi.nlm.nih.gov/pubmed/32433838</p>
<p style="position:absolute;top:914px;left:503px;white-space:nowrap" class="ft013">.&#160;</p>
<p style="position:absolute;top:951px;left:108px;white-space:nowrap" class="ft013">23.</p>
<p style="position:absolute;top:951px;left:130px;white-space:nowrap" class="ft046">&#160;</p>
<p style="position:absolute;top:951px;left:162px;white-space:nowrap" class="ft032">Thornhill&#160;JP,&#160;Barkati&#160;S,&#160;Walmsley S,&#160;et&#160;al. Monkeypox virus&#160;infection in humans across&#160;16&#160;<br/>countries - April–June 2022.&#160;</p>
<p style="position:absolute;top:971px;left:364px;white-space:nowrap" class="ft019"><i>N Engl&#160;J&#160;Med</i></p>
<p style="position:absolute;top:971px;left:459px;white-space:nowrap" class="ft013">. 2022;387(8):679-691. Available at:&#160;</p>
<p style="position:absolute;top:991px;left:162px;white-space:nowrap" class="ft034">https://www.ncbi.nlm.nih.gov/pubmed/35866746</p>
<p style="position:absolute;top:991px;left:503px;white-space:nowrap" class="ft013">.&#160;</p>
<p style="position:absolute;top:1028px;left:108px;white-space:nowrap" class="ft013">24.</p>
<p style="position:absolute;top:1028px;left:130px;white-space:nowrap" class="ft046">&#160;</p>
<p style="position:absolute;top:1028px;left:162px;white-space:nowrap" class="ft032">Arnold CA,&#160;Limketkai BN, Illei PB,&#160;Montgomery&#160;E, Voltaggio L. Syphilitic&#160;and&#160;<br/>lymphogranuloma venereum&#160;(LGV) proctocolitis: clues to a&#160;frequently missed diagnosis.&#160;</p>
<p style="position:absolute;top:1048px;left:782px;white-space:nowrap" class="ft019"><i>Am&#160;</i></p>
</div>
<!-- Page 33 -->
<a name="33"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}	.ft078{font-size:17px;line-height:19px;font-family:TURBHP+Tinos;color:#005299;}
-->
</style>
<div id="page33-div" style="position:relative;width:917px;height:1187px;">
<p style="position:absolute;top:1114px;left:108px;white-space:nowrap" class="ft024"><i>Guidelines for the Prevention and Treatment&#160;of&#160;Opportunistic&#160;Infections in Adults&#160;and Adolescents&#160;With HIV&#160;</i></p>
<p style="position:absolute;top:1114px;left:784px;white-space:nowrap" class="ft024"><i>B-18&#160;</i></p>
<p style="position:absolute;top:87px;left:162px;white-space:nowrap" class="ft019"><i>J Surg Pathol</i></p>
<p style="position:absolute;top:87px;left:257px;white-space:nowrap" class="ft013">. 2013;37(1):38-46. Available&#160;at:&#160;</p>
<p style="position:absolute;top:107px;left:162px;white-space:nowrap" class="ft034">https://www.ncbi.nlm.nih.gov/pubmed/23095509</p>
<p style="position:absolute;top:107px;left:503px;white-space:nowrap" class="ft013">.&#160;</p>
<p style="position:absolute;top:144px;left:108px;white-space:nowrap" class="ft013">25.</p>
<p style="position:absolute;top:144px;left:130px;white-space:nowrap" class="ft046">&#160;</p>
<p style="position:absolute;top:144px;left:162px;white-space:nowrap" class="ft032">Huang&#160;JY,&#160;Henao OL,&#160;Griffin PM,&#160;et&#160;al. Infection with pathogens transmitted commonly&#160;<br/>through food&#160;and the effect&#160;of increasing use of culture-independent&#160;diagnostic tests on&#160;<br/>surveillance–Foodborne Diseases Active Surveillance&#160;Network,&#160;10 U.S.&#160;sites,&#160;2012–2015.&#160;</p>
<p style="position:absolute;top:204px;left:162px;white-space:nowrap" class="ft019"><i>MMWR Morb Mortal Wkly Rep</i></p>
<p style="position:absolute;top:204px;left:380px;white-space:nowrap" class="ft013">. 2016;65(14):368-371. Available at:&#160;</p>
<p style="position:absolute;top:223px;left:162px;white-space:nowrap" class="ft034">https://www.ncbi.nlm.nih.gov/pubmed/27077946</p>
<p style="position:absolute;top:223px;left:503px;white-space:nowrap" class="ft013">.&#160;</p>
<p style="position:absolute;top:260px;left:108px;white-space:nowrap" class="ft013">26.</p>
<p style="position:absolute;top:260px;left:130px;white-space:nowrap" class="ft046">&#160;</p>
<p style="position:absolute;top:260px;left:162px;white-space:nowrap" class="ft013">Pulvirenti&#160;JJ,&#160;Mehra T,&#160;Hafiz I, et&#160;al. Epidemiology and outcome&#160;of&#160;</p>
<p style="position:absolute;top:260px;left:633px;white-space:nowrap" class="ft019"><i>Clostridium difficile</i></p>
<p style="position:absolute;top:260px;left:772px;white-space:nowrap" class="ft013">&#160;</p>
<p style="position:absolute;top:280px;left:162px;white-space:nowrap" class="ft013">infection and diarrhea in HIV&#160;infected inpatients.&#160;</p>
<p style="position:absolute;top:280px;left:506px;white-space:nowrap" class="ft019"><i>Diagn Microbiol&#160;Infect&#160;Dis</i></p>
<p style="position:absolute;top:280px;left:694px;white-space:nowrap" class="ft013">.&#160;</p>
<p style="position:absolute;top:300px;left:162px;white-space:nowrap" class="ft013">2002;44(4):325-330.&#160;Available&#160;at:&#160;</p>
<p style="position:absolute;top:300px;left:402px;white-space:nowrap" class="ft034">http://www.ncbi.nlm.nih.gov/pubmed/12543536</p>
<p style="position:absolute;top:300px;left:737px;white-space:nowrap" class="ft013">.&#160;</p>
<p style="position:absolute;top:337px;left:108px;white-space:nowrap" class="ft013">27.</p>
<p style="position:absolute;top:337px;left:130px;white-space:nowrap" class="ft046">&#160;</p>
<p style="position:absolute;top:337px;left:162px;white-space:nowrap" class="ft013">Kociolek LK, Gerding&#160;DN, Carrico R, et&#160;al. Strategies to prevent&#160;</p>
<p style="position:absolute;top:337px;left:615px;white-space:nowrap" class="ft019"><i>Clostridioides difficile&#160;</i></p>
<p style="position:absolute;top:357px;left:162px;white-space:nowrap" class="ft013">infections in acute-care hospitals: 2022 update.&#160;</p>
<p style="position:absolute;top:357px;left:491px;white-space:nowrap" class="ft019"><i>Infect&#160;Control Hosp Epidemiol</i></p>
<p style="position:absolute;top:357px;left:704px;white-space:nowrap" class="ft013">.&#160;</p>
<p style="position:absolute;top:377px;left:162px;white-space:nowrap" class="ft013">2023;44(4):527-549.&#160;Available&#160;at:&#160;</p>
<p style="position:absolute;top:377px;left:402px;white-space:nowrap" class="ft034">https://www.ncbi.nlm.nih.gov/pubmed/37042243</p>
<p style="position:absolute;top:377px;left:744px;white-space:nowrap" class="ft013">.&#160;</p>
<p style="position:absolute;top:414px;left:108px;white-space:nowrap" class="ft013">28.</p>
<p style="position:absolute;top:414px;left:130px;white-space:nowrap" class="ft046">&#160;</p>
<p style="position:absolute;top:414px;left:162px;white-space:nowrap" class="ft013">Mizusawa&#160;M, Carroll KC.&#160;The&#160;future&#160;of&#160;</p>
<p style="position:absolute;top:414px;left:442px;white-space:nowrap" class="ft019"><i>Clostridioides difficile</i></p>
<p style="position:absolute;top:414px;left:596px;white-space:nowrap" class="ft013">&#160;diagnostics.&#160;</p>
<p style="position:absolute;top:414px;left:687px;white-space:nowrap" class="ft019"><i>Curr&#160;Opin Infect&#160;</i></p>
<p style="position:absolute;top:434px;left:162px;white-space:nowrap" class="ft019"><i>Dis</i></p>
<p style="position:absolute;top:434px;left:186px;white-space:nowrap" class="ft013">. 2021;34(5):483-490.&#160;Available at:&#160;</p>
<p style="position:absolute;top:434px;left:435px;white-space:nowrap" class="ft034">https://www.ncbi.nlm.nih.gov/pubmed/34524199</p>
<p style="position:absolute;top:434px;left:776px;white-space:nowrap" class="ft013">.&#160;</p>
<p style="position:absolute;top:471px;left:108px;white-space:nowrap" class="ft013">29.</p>
<p style="position:absolute;top:471px;left:130px;white-space:nowrap" class="ft046">&#160;</p>
<p style="position:absolute;top:471px;left:162px;white-space:nowrap" class="ft013">McDonald LC, Gerding&#160;DN,&#160;Johnson&#160;S, et al. Clinical&#160;practice&#160;guidelines for&#160;</p>
<p style="position:absolute;top:471px;left:699px;white-space:nowrap" class="ft019"><i>Clostridium&#160;</i></p>
<p style="position:absolute;top:491px;left:162px;white-space:nowrap" class="ft019"><i>difficile</i></p>
<p style="position:absolute;top:491px;left:214px;white-space:nowrap" class="ft013">&#160;infection in adults and children:&#160;2017 update by the Infectious Diseases Society of&#160;</p>
<p style="position:absolute;top:511px;left:162px;white-space:nowrap" class="ft013">America (IDSA) and Society for Healthcare&#160;Epidemiology of&#160;America (SHEA).&#160;</p>
<p style="position:absolute;top:511px;left:720px;white-space:nowrap" class="ft019"><i>Clin Infect&#160;</i></p>
<p style="position:absolute;top:530px;left:162px;white-space:nowrap" class="ft019"><i>Dis</i></p>
<p style="position:absolute;top:530px;left:186px;white-space:nowrap" class="ft013">. 2018;66(7):987-994.&#160;Available at:&#160;</p>
<p style="position:absolute;top:530px;left:435px;white-space:nowrap" class="ft034">https://www.ncbi.nlm.nih.gov/pubmed/29562266</p>
<p style="position:absolute;top:530px;left:776px;white-space:nowrap" class="ft013">.&#160;</p>
<p style="position:absolute;top:568px;left:108px;white-space:nowrap" class="ft013">30.</p>
<p style="position:absolute;top:567px;left:130px;white-space:nowrap" class="ft046">&#160;</p>
<p style="position:absolute;top:568px;left:162px;white-space:nowrap" class="ft032">Workowski&#160;KA,&#160;Bachmann LH, Chan&#160;PA, et&#160;al. Sexually transmitted infections treatment&#160;<br/>guidelines, 2021.&#160;</p>
<p style="position:absolute;top:587px;left:285px;white-space:nowrap" class="ft019"><i>MMWR&#160;Recomm&#160;Rep</i></p>
<p style="position:absolute;top:587px;left:433px;white-space:nowrap" class="ft013">. 2021;70(4):1-187.&#160;Available at:&#160;</p>
<p style="position:absolute;top:607px;left:162px;white-space:nowrap" class="ft034">https://www.ncbi.nlm.nih.gov/pubmed/34292926</p>
<p style="position:absolute;top:607px;left:503px;white-space:nowrap" class="ft013">.&#160;</p>
<p style="position:absolute;top:644px;left:108px;white-space:nowrap" class="ft013">31.</p>
<p style="position:absolute;top:644px;left:130px;white-space:nowrap" class="ft046">&#160;</p>
<p style="position:absolute;top:644px;left:162px;white-space:nowrap" class="ft032">Schneider E,&#160;Whitmore&#160;S, Glynn&#160;KM,&#160;et&#160;al. Revised surveillance case definitions for&#160;HIV&#160;<br/>infection among adults, adolescents, and children aged &lt;18 months and for&#160;HIV infection&#160;and&#160;<br/>AIDS among&#160;children aged 18 months&#160;to &lt;13 years--United States, 2008.&#160;</p>
<p style="position:absolute;top:684px;left:673px;white-space:nowrap" class="ft019"><i>MMWR Recomm&#160;</i></p>
<p style="position:absolute;top:704px;left:162px;white-space:nowrap" class="ft019"><i>Rep</i></p>
<p style="position:absolute;top:704px;left:189px;white-space:nowrap" class="ft013">. 2008;57(RR-10):1-12. Available at:&#160;</p>
<p style="position:absolute;top:704px;left:449px;white-space:nowrap" class="ft034">http://www.ncbi.nlm.nih.gov/pubmed/19052530</p>
<p style="position:absolute;top:704px;left:784px;white-space:nowrap" class="ft013">.&#160;</p>
<p style="position:absolute;top:741px;left:108px;white-space:nowrap" class="ft013">32.</p>
<p style="position:absolute;top:741px;left:130px;white-space:nowrap" class="ft046">&#160;</p>
<p style="position:absolute;top:741px;left:162px;white-space:nowrap" class="ft032">de Vries&#160;HJC, Nori&#160;AV,&#160;Kiellberg Larsen H,&#160;et&#160;al. 2021 European guideline&#160;on the&#160;<br/>management&#160;of proctitis,&#160;proctocolitis and enteritis caused by sexually transmissible&#160;<br/>pathogens.&#160;</p>
<p style="position:absolute;top:780px;left:241px;white-space:nowrap" class="ft019"><i>J&#160;Eur Acad Dermatol&#160;Venereol</i></p>
<p style="position:absolute;top:780px;left:455px;white-space:nowrap" class="ft013">. 2021;35(7):1434-1443. Available at:&#160;</p>
<p style="position:absolute;top:800px;left:162px;white-space:nowrap" class="ft034">https://www.ncbi.nlm.nih.gov/pubmed/34057249</p>
<p style="position:absolute;top:800px;left:503px;white-space:nowrap" class="ft013">.&#160;</p>
<p style="position:absolute;top:837px;left:108px;white-space:nowrap" class="ft013">33.</p>
<p style="position:absolute;top:837px;left:130px;white-space:nowrap" class="ft046">&#160;</p>
<p style="position:absolute;top:837px;left:162px;white-space:nowrap" class="ft013">Centers for&#160;Disease Control&#160;and Prevention. Healthcare&#160;Resources. 2024.&#160;Available&#160;at:&#160;</p>
<p style="position:absolute;top:857px;left:162px;white-space:nowrap" class="ft078">https://www.cdc.gov/c-<br/>diff/hcp/resources/?CDC_AAref_Val=https://www.cdc.gov/cdiff/clinicians/resources.html#c<br/>dc_listing_res2-resources</p>
<p style="position:absolute;top:897px;left:338px;white-space:nowrap" class="ft013">.&#160;</p>
<p style="position:absolute;top:934px;left:108px;white-space:nowrap" class="ft013">34.</p>
<p style="position:absolute;top:934px;left:130px;white-space:nowrap" class="ft046">&#160;</p>
<p style="position:absolute;top:934px;left:162px;white-space:nowrap" class="ft013">Advice for travelers.&#160;</p>
<p style="position:absolute;top:934px;left:308px;white-space:nowrap" class="ft019"><i>Med&#160;Lett&#160;Drugs&#160;Ther</i></p>
<p style="position:absolute;top:934px;left:455px;white-space:nowrap" class="ft013">. 2019;61(1582):153-160. Available&#160;at:&#160;</p>
<p style="position:absolute;top:954px;left:162px;white-space:nowrap" class="ft034">https://www.ncbi.nlm.nih.gov/pubmed/31599872</p>
<p style="position:absolute;top:954px;left:503px;white-space:nowrap" class="ft013">.&#160;</p>
<p style="position:absolute;top:991px;left:108px;white-space:nowrap" class="ft013">35.</p>
<p style="position:absolute;top:991px;left:130px;white-space:nowrap" class="ft046">&#160;</p>
<p style="position:absolute;top:991px;left:162px;white-space:nowrap" class="ft032">Riddle MS,&#160;Connor BA,&#160;Beeching NJ, et&#160;al. Guidelines for the&#160;prevention and treatment of&#160;<br/>travelers’ diarrhea:&#160;a graded expert panel&#160;report.&#160;</p>
<p style="position:absolute;top:1011px;left:499px;white-space:nowrap" class="ft019"><i>J&#160;Travel Med</i></p>
<p style="position:absolute;top:1011px;left:591px;white-space:nowrap" class="ft013">.&#160;2017;24(suppl_1):S57-S74.&#160;</p>
<p style="position:absolute;top:1031px;left:162px;white-space:nowrap" class="ft013">Available at:&#160;</p>
<p style="position:absolute;top:1031px;left:255px;white-space:nowrap" class="ft034">https://www.ncbi.nlm.nih.gov/pubmed/28521004</p>
<p style="position:absolute;top:1031px;left:596px;white-space:nowrap" class="ft013">.&#160;</p>
</div>
<!-- Page 34 -->
<a name="34"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page34-div" style="position:relative;width:917px;height:1187px;">
<p style="position:absolute;top:1114px;left:108px;white-space:nowrap" class="ft024"><i>Guidelines for the Prevention and Treatment&#160;of&#160;Opportunistic&#160;Infections in Adults&#160;and Adolescents&#160;With HIV&#160;</i></p>
<p style="position:absolute;top:1114px;left:784px;white-space:nowrap" class="ft024"><i>B-19&#160;</i></p>
<p style="position:absolute;top:87px;left:108px;white-space:nowrap" class="ft013">36.</p>
<p style="position:absolute;top:87px;left:130px;white-space:nowrap" class="ft046">&#160;</p>
<p style="position:absolute;top:87px;left:162px;white-space:nowrap" class="ft032">Diptyanusa&#160;A, Ngamprasertchai&#160;T, Piyaphanee W.&#160;A review&#160;of&#160;antibiotic prophylaxis for&#160;<br/>traveler’s diarrhea:&#160;past to present.&#160;</p>
<p style="position:absolute;top:107px;left:405px;white-space:nowrap" class="ft019"><i>Trop Dis&#160;Travel&#160;Med Vaccines</i></p>
<p style="position:absolute;top:107px;left:618px;white-space:nowrap" class="ft013">. 2018;4:14.&#160;Available at:&#160;</p>
<p style="position:absolute;top:127px;left:162px;white-space:nowrap" class="ft034">https://www.ncbi.nlm.nih.gov/pubmed/30455974</p>
<p style="position:absolute;top:127px;left:503px;white-space:nowrap" class="ft013">.&#160;</p>
<p style="position:absolute;top:164px;left:108px;white-space:nowrap" class="ft013">37.</p>
<p style="position:absolute;top:164px;left:130px;white-space:nowrap" class="ft046">&#160;</p>
<p style="position:absolute;top:164px;left:162px;white-space:nowrap" class="ft032">Food and&#160;Drug Administration. FDA drug safety communication:&#160;FDA&#160;updates warnings for&#160;<br/>oral&#160;and injectable fluoroquinolone antibiotics due to disabling side&#160;effects. 2018. Available&#160;<br/>at:&#160;</p>
<p style="position:absolute;top:204px;left:184px;white-space:nowrap" class="ft034">https://www.fda.gov/drugs/drug-safety-and-availability/fda-drug-safety-communication-</p>
<p style="position:absolute;top:223px;left:162px;white-space:nowrap" class="ft034">fda-updates-warnings-oral-and-injectable-fluoroquinolone-antibiotics</p>
<p style="position:absolute;top:223px;left:642px;white-space:nowrap" class="ft013">.&#160;</p>
<p style="position:absolute;top:260px;left:108px;white-space:nowrap" class="ft013">38.</p>
<p style="position:absolute;top:260px;left:130px;white-space:nowrap" class="ft046">&#160;</p>
<p style="position:absolute;top:260px;left:162px;white-space:nowrap" class="ft032">Nwachukwu&#160;CE, Okebe&#160;JU. Antimotility agents for&#160;chronic diarrhoea in people with&#160;<br/>HIV/AIDS.&#160;</p>
<p style="position:absolute;top:280px;left:246px;white-space:nowrap" class="ft019"><i>Cochrane&#160;Database Syst&#160;Rev</i></p>
<p style="position:absolute;top:280px;left:447px;white-space:nowrap" class="ft013">. 2008(4):CD005644.&#160;Available at:&#160;</p>
<p style="position:absolute;top:300px;left:162px;white-space:nowrap" class="ft034">http://www.ncbi.nlm.nih.gov/pubmed/18843696</p>
<p style="position:absolute;top:300px;left:497px;white-space:nowrap" class="ft013">.&#160;</p>
<p style="position:absolute;top:337px;left:108px;white-space:nowrap" class="ft013">39.</p>
<p style="position:absolute;top:337px;left:130px;white-space:nowrap" class="ft046">&#160;</p>
<p style="position:absolute;top:337px;left:162px;white-space:nowrap" class="ft032">Kuschner RA, Trofa&#160;AF,&#160;Thomas RJ,&#160;et&#160;al. Use of&#160;azithromycin for the treatment of&#160;<br/>Campylobacter enteritis in travelers to Thailand, an area where ciprofloxacin resistance is&#160;<br/>prevalent.&#160;</p>
<p style="position:absolute;top:377px;left:235px;white-space:nowrap" class="ft019"><i>Clin Infect&#160;Dis</i></p>
<p style="position:absolute;top:377px;left:336px;white-space:nowrap" class="ft013">.&#160;1995;21(3):536-541.&#160;Available&#160;at:&#160;</p>
<p style="position:absolute;top:397px;left:162px;white-space:nowrap" class="ft034">http://www.ncbi.nlm.nih.gov/pubmed/8527539</p>
<p style="position:absolute;top:397px;left:488px;white-space:nowrap" class="ft013">.&#160;</p>
<p style="position:absolute;top:434px;left:108px;white-space:nowrap" class="ft013">40.</p>
<p style="position:absolute;top:434px;left:130px;white-space:nowrap" class="ft046">&#160;</p>
<p style="position:absolute;top:434px;left:162px;white-space:nowrap" class="ft032">Tribble&#160;DR,&#160;Sanders&#160;JW,&#160;Pang LW, et&#160;al. Traveler’s diarrhea&#160;in Thailand:&#160;randomized,&#160;<br/>double-blind&#160;trial&#160;comparing single-dose and 3-day&#160;azithromycin-based regimens with a&#160;3-<br/>day levofloxacin regimen.&#160;</p>
<p style="position:absolute;top:473px;left:347px;white-space:nowrap" class="ft019"><i>Clin Infect Dis</i></p>
<p style="position:absolute;top:473px;left:448px;white-space:nowrap" class="ft013">. 2007;44(3):338-346.&#160;Available at:&#160;</p>
<p style="position:absolute;top:493px;left:162px;white-space:nowrap" class="ft034">http://www.ncbi.nlm.nih.gov/pubmed/17205438</p>
<p style="position:absolute;top:493px;left:497px;white-space:nowrap" class="ft013">.&#160;</p>
<p style="position:absolute;top:530px;left:108px;white-space:nowrap" class="ft013">41.</p>
<p style="position:absolute;top:530px;left:130px;white-space:nowrap" class="ft046">&#160;</p>
<p style="position:absolute;top:530px;left:162px;white-space:nowrap" class="ft032">Kantele A, Laaveri T, Mero S, et al. Antimicrobials increase travelers’ risk of&#160;colonization by&#160;<br/>extended-spectrum betalactamase-producing Enterobacteriaceae.&#160;</p>
<p style="position:absolute;top:550px;left:614px;white-space:nowrap" class="ft019"><i>Clin Infect&#160;Dis</i></p>
<p style="position:absolute;top:550px;left:715px;white-space:nowrap" class="ft013">.&#160;</p>
<p style="position:absolute;top:570px;left:162px;white-space:nowrap" class="ft013">2015;60(6):837-846.&#160;Available&#160;at:&#160;</p>
<p style="position:absolute;top:570px;left:402px;white-space:nowrap" class="ft034">http://www.ncbi.nlm.nih.gov/pubmed/25613287</p>
<p style="position:absolute;top:570px;left:737px;white-space:nowrap" class="ft013">.&#160;</p>
<p style="position:absolute;top:607px;left:108px;white-space:nowrap" class="ft013">42.</p>
<p style="position:absolute;top:607px;left:130px;white-space:nowrap" class="ft046">&#160;</p>
<p style="position:absolute;top:607px;left:162px;white-space:nowrap" class="ft032">Barlow RS,&#160;Debess&#160;EE,&#160;Winthrop KL, Lapidus JA, Vega&#160;R,&#160;Cieslak PR.&#160;Travel-associated&#160;<br/>antimicrobial drug-resistant&#160;nontyphoidal&#160;Salmonellae, 2004–2009.&#160;</p>
<p style="position:absolute;top:627px;left:633px;white-space:nowrap" class="ft019"><i>Emerg Infect Dis</i></p>
<p style="position:absolute;top:627px;left:750px;white-space:nowrap" class="ft013">.&#160;</p>
<p style="position:absolute;top:647px;left:162px;white-space:nowrap" class="ft013">2014;20(4):603-611.&#160;Available&#160;at:&#160;</p>
<p style="position:absolute;top:647px;left:402px;white-space:nowrap" class="ft034">http://www.ncbi.nlm.nih.gov/pubmed/24655581</p>
<p style="position:absolute;top:647px;left:737px;white-space:nowrap" class="ft013">.&#160;</p>
<p style="position:absolute;top:684px;left:108px;white-space:nowrap" class="ft013">43.</p>
<p style="position:absolute;top:684px;left:130px;white-space:nowrap" class="ft046">&#160;</p>
<p style="position:absolute;top:684px;left:162px;white-space:nowrap" class="ft013">Centers for&#160;Disease Control&#160;and Prevention. Importation and domestic&#160;transmission of&#160;</p>
<p style="position:absolute;top:704px;left:162px;white-space:nowrap" class="ft019"><i>Shigella sonnei&#160;</i></p>
<p style="position:absolute;top:704px;left:272px;white-space:nowrap" class="ft013">resistant to ciprofloxacin — United&#160;States, May&#160;2014–February 2015.&#160;</p>
<p style="position:absolute;top:724px;left:162px;white-space:nowrap" class="ft019"><i>MMWR Morb Mortal Wkly Rep</i></p>
<p style="position:absolute;top:724px;left:380px;white-space:nowrap" class="ft013">. 2015;64(12):318-320. Available at:&#160;</p>
<p style="position:absolute;top:743px;left:162px;white-space:nowrap" class="ft034">http://www.cdc.gov/mmwr/preview/mmwrhtml/mm6412a2.htm?s_cid=mm6412a2_w</p>
<p style="position:absolute;top:743px;left:757px;white-space:nowrap" class="ft013">.&#160;</p>
<p style="position:absolute;top:780px;left:108px;white-space:nowrap" class="ft013">44.</p>
<p style="position:absolute;top:780px;left:130px;white-space:nowrap" class="ft046">&#160;</p>
<p style="position:absolute;top:780px;left:162px;white-space:nowrap" class="ft032">Ruppe E, Andremont A,&#160;Armand-Lefevre L. Digestive&#160;tract&#160;colonization by multidrug-<br/>resistant&#160;Enterobacteriaceae in travellers: an update.&#160;</p>
<p style="position:absolute;top:800px;left:525px;white-space:nowrap" class="ft019"><i>Travel&#160;Med&#160;Infect Dis</i></p>
<p style="position:absolute;top:800px;left:677px;white-space:nowrap" class="ft013">. 2018;21:28-35.&#160;</p>
<p style="position:absolute;top:820px;left:162px;white-space:nowrap" class="ft013">Available at:&#160;</p>
<p style="position:absolute;top:820px;left:255px;white-space:nowrap" class="ft034">https://www.ncbi.nlm.nih.gov/pubmed/29155322</p>
<p style="position:absolute;top:820px;left:596px;white-space:nowrap" class="ft013">.&#160;</p>
<p style="position:absolute;top:857px;left:108px;white-space:nowrap" class="ft013">45.</p>
<p style="position:absolute;top:857px;left:130px;white-space:nowrap" class="ft046">&#160;</p>
<p style="position:absolute;top:857px;left:162px;white-space:nowrap" class="ft032">Tribble&#160;DR.&#160;Resistant pathogens as&#160;causes of traveller’s diarrhea&#160;globally and impact(s) on&#160;<br/>treatment failure&#160;and recommendations.&#160;</p>
<p style="position:absolute;top:877px;left:441px;white-space:nowrap" class="ft019"><i>J Travel&#160;Med</i></p>
<p style="position:absolute;top:877px;left:533px;white-space:nowrap" class="ft013">. 2017;24(suppl_1):S6-S12.&#160;Available&#160;</p>
<p style="position:absolute;top:897px;left:162px;white-space:nowrap" class="ft013">at:&#160;</p>
<p style="position:absolute;top:897px;left:183px;white-space:nowrap" class="ft034">https://www.ncbi.nlm.nih.gov/pubmed/28520997</p>
<p style="position:absolute;top:897px;left:525px;white-space:nowrap" class="ft013">.&#160;</p>
<p style="position:absolute;top:934px;left:108px;white-space:nowrap" class="ft013">46.</p>
<p style="position:absolute;top:934px;left:130px;white-space:nowrap" class="ft046">&#160;</p>
<p style="position:absolute;top:934px;left:162px;white-space:nowrap" class="ft032">Cummings PL, Sorvillo F, Kuo T.&#160;Salmonellosis-related mortality in the United States,&#160;<br/>1990–2006.&#160;</p>
<p style="position:absolute;top:954px;left:248px;white-space:nowrap" class="ft019"><i>Foodborne Pathog Dis</i></p>
<p style="position:absolute;top:954px;left:407px;white-space:nowrap" class="ft013">.&#160;2010;7(11):1393-1399.&#160;Available&#160;at:&#160;</p>
<p style="position:absolute;top:974px;left:162px;white-space:nowrap" class="ft034">http://www.ncbi.nlm.nih.gov/pubmed/20617938</p>
<p style="position:absolute;top:974px;left:497px;white-space:nowrap" class="ft013">.&#160;</p>
<p style="position:absolute;top:1011px;left:108px;white-space:nowrap" class="ft013">47.</p>
<p style="position:absolute;top:1011px;left:130px;white-space:nowrap" class="ft046">&#160;</p>
<p style="position:absolute;top:1011px;left:162px;white-space:nowrap" class="ft032">Shane AL,&#160;Mody RK, Crump JA, et al. 2017 Infectious Diseases Society of&#160;America clinical&#160;<br/>practice guidelines for the diagnosis and management of infectious diarrhea.&#160;</p>
<p style="position:absolute;top:1031px;left:693px;white-space:nowrap" class="ft019"><i>Clin Infect&#160;Dis</i></p>
<p style="position:absolute;top:1031px;left:794px;white-space:nowrap" class="ft013">.&#160;</p>
<p style="position:absolute;top:1050px;left:162px;white-space:nowrap" class="ft013">2017;65(12):e45-e80. Available&#160;at:&#160;</p>
<p style="position:absolute;top:1050px;left:409px;white-space:nowrap" class="ft034">https://www.ncbi.nlm.nih.gov/pubmed/29053792</p>
<p style="position:absolute;top:1050px;left:750px;white-space:nowrap" class="ft013">.&#160;</p>
</div>
<!-- Page 35 -->
<a name="35"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page35-div" style="position:relative;width:917px;height:1187px;">
<p style="position:absolute;top:1114px;left:108px;white-space:nowrap" class="ft024"><i>Guidelines for the Prevention and Treatment&#160;of&#160;Opportunistic&#160;Infections in Adults&#160;and Adolescents&#160;With HIV&#160;</i></p>
<p style="position:absolute;top:1114px;left:784px;white-space:nowrap" class="ft024"><i>B-20&#160;</i></p>
<p style="position:absolute;top:87px;left:108px;white-space:nowrap" class="ft013">48.</p>
<p style="position:absolute;top:87px;left:130px;white-space:nowrap" class="ft046">&#160;</p>
<p style="position:absolute;top:87px;left:162px;white-space:nowrap" class="ft032">Centers for&#160;Disease Control&#160;and Prevention. National&#160;Antimicrobial Resistance&#160;Monitoring&#160;<br/>System (NARMS)&#160;Now:&#160;human data. 2023. Available at:&#160;</p>
<p style="position:absolute;top:107px;left:562px;white-space:nowrap" class="ft034">https://wwwn.cdc.gov/narmsnow</p>
<p style="position:absolute;top:107px;left:791px;white-space:nowrap" class="ft013">.&#160;</p>
<p style="position:absolute;top:144px;left:108px;white-space:nowrap" class="ft013">49.</p>
<p style="position:absolute;top:144px;left:130px;white-space:nowrap" class="ft046">&#160;</p>
<p style="position:absolute;top:144px;left:162px;white-space:nowrap" class="ft013">Gordon&#160;MA,&#160;Banda&#160;HT,&#160;Gondwe M,&#160;et&#160;al. Non-typhoidal&#160;</p>
<p style="position:absolute;top:144px;left:565px;white-space:nowrap" class="ft019"><i>Salmonella&#160;</i></p>
<p style="position:absolute;top:144px;left:647px;white-space:nowrap" class="ft013">bacteraemia&#160;among&#160;</p>
<p style="position:absolute;top:164px;left:162px;white-space:nowrap" class="ft013">HIV-infected Malawian adults: high mortality and frequent recrudescence.&#160;</p>
<p style="position:absolute;top:164px;left:681px;white-space:nowrap" class="ft019"><i>AIDS</i></p>
<p style="position:absolute;top:164px;left:719px;white-space:nowrap" class="ft013">.&#160;</p>
<p style="position:absolute;top:184px;left:162px;white-space:nowrap" class="ft013">2002;16(12):1633-1641.&#160;Available at:&#160;</p>
<p style="position:absolute;top:184px;left:428px;white-space:nowrap" class="ft034">http://www.ncbi.nlm.nih.gov/pubmed/12172085</p>
<p style="position:absolute;top:184px;left:763px;white-space:nowrap" class="ft013">.&#160;</p>
<p style="position:absolute;top:221px;left:108px;white-space:nowrap" class="ft013">50.</p>
<p style="position:absolute;top:221px;left:130px;white-space:nowrap" class="ft046">&#160;</p>
<p style="position:absolute;top:221px;left:162px;white-space:nowrap" class="ft032">Hsu RB, Tsay YG, Chen&#160;RJ, Chu&#160;SH.&#160;Risk factors&#160;for primary bacteremia&#160;and endovascular&#160;<br/>infection in patients without acquired immunodeficiency syndrome&#160;who have&#160;nontyphoid&#160;<br/>salmonellosis.&#160;</p>
<p style="position:absolute;top:260px;left:264px;white-space:nowrap" class="ft019"><i>Clin Infect&#160;Dis</i></p>
<p style="position:absolute;top:260px;left:366px;white-space:nowrap" class="ft013">. 2003;36(7):829-834. Available at:&#160;</p>
<p style="position:absolute;top:280px;left:162px;white-space:nowrap" class="ft034">https://www.ncbi.nlm.nih.gov/pubmed/12652381</p>
<p style="position:absolute;top:280px;left:503px;white-space:nowrap" class="ft013">.&#160;</p>
<p style="position:absolute;top:317px;left:108px;white-space:nowrap" class="ft013">51.</p>
<p style="position:absolute;top:317px;left:130px;white-space:nowrap" class="ft046">&#160;</p>
<p style="position:absolute;top:317px;left:162px;white-space:nowrap" class="ft032">Nielsen H,&#160;Gradel&#160;KO,&#160;Schonheyder&#160;HC. High incidence&#160;of intravascular focus in&#160;<br/>nontyphoid&#160;</p>
<p style="position:absolute;top:337px;left:245px;white-space:nowrap" class="ft019"><i>Salmonella&#160;</i></p>
<p style="position:absolute;top:337px;left:327px;white-space:nowrap" class="ft013">bacteremia&#160;in the age group&#160;above 50 years: a&#160;population-based&#160;</p>
<p style="position:absolute;top:357px;left:162px;white-space:nowrap" class="ft013">study.&#160;</p>
<p style="position:absolute;top:357px;left:208px;white-space:nowrap" class="ft019"><i>APMIS</i></p>
<p style="position:absolute;top:357px;left:258px;white-space:nowrap" class="ft013">. 2006;114(9):641-645.&#160;Available at:&#160;</p>
<p style="position:absolute;top:377px;left:162px;white-space:nowrap" class="ft034">https://www.ncbi.nlm.nih.gov/pubmed/16948817</p>
<p style="position:absolute;top:377px;left:503px;white-space:nowrap" class="ft013">.&#160;</p>
<p style="position:absolute;top:414px;left:108px;white-space:nowrap" class="ft013">52.</p>
<p style="position:absolute;top:414px;left:130px;white-space:nowrap" class="ft046">&#160;</p>
<p style="position:absolute;top:414px;left:162px;white-space:nowrap" class="ft013">Eikmeier D, Talley P, Bowen A,&#160;et&#160;al. Decreased&#160;susceptibility to azithromycin in clinical&#160;</p>
<p style="position:absolute;top:434px;left:162px;white-space:nowrap" class="ft019"><i>Shigella&#160;</i></p>
<p style="position:absolute;top:434px;left:223px;white-space:nowrap" class="ft013">isolates associated with HIV&#160;and sexually&#160;transmitted bacterial diseases,&#160;Minnesota,&#160;</p>
<p style="position:absolute;top:454px;left:162px;white-space:nowrap" class="ft013">USA, 2012–2015.&#160;</p>
<p style="position:absolute;top:454px;left:291px;white-space:nowrap" class="ft019"><i>Emerg&#160;Infect Dis</i></p>
<p style="position:absolute;top:454px;left:409px;white-space:nowrap" class="ft013">. 2020;26(4):667-674.&#160;Available at:&#160;</p>
<p style="position:absolute;top:473px;left:162px;white-space:nowrap" class="ft034">https://www.ncbi.nlm.nih.gov/pubmed/32186495</p>
<p style="position:absolute;top:473px;left:503px;white-space:nowrap" class="ft013">.&#160;</p>
<p style="position:absolute;top:511px;left:108px;white-space:nowrap" class="ft013">53.</p>
<p style="position:absolute;top:510px;left:130px;white-space:nowrap" class="ft046">&#160;</p>
<p style="position:absolute;top:511px;left:162px;white-space:nowrap" class="ft013">Hoffmann&#160;C,&#160;Sahly H,&#160;Jessen A, et al.&#160;High rates of&#160;quinolone-resistant strains of&#160;</p>
<p style="position:absolute;top:511px;left:728px;white-space:nowrap" class="ft019"><i>Shigella&#160;</i></p>
<p style="position:absolute;top:530px;left:162px;white-space:nowrap" class="ft019"><i>sonnei</i></p>
<p style="position:absolute;top:530px;left:207px;white-space:nowrap" class="ft013">&#160;in HIV-infected&#160;MSM.&#160;</p>
<p style="position:absolute;top:530px;left:374px;white-space:nowrap" class="ft019"><i>Infection</i></p>
<p style="position:absolute;top:530px;left:435px;white-space:nowrap" class="ft013">. 2013;41(5):999-1003. Available at:&#160;</p>
<p style="position:absolute;top:550px;left:162px;white-space:nowrap" class="ft034">https://www.ncbi.nlm.nih.gov/pubmed/23852945</p>
<p style="position:absolute;top:550px;left:503px;white-space:nowrap" class="ft013">.&#160;</p>
<p style="position:absolute;top:587px;left:108px;white-space:nowrap" class="ft013">54.</p>
<p style="position:absolute;top:587px;left:130px;white-space:nowrap" class="ft046">&#160;</p>
<p style="position:absolute;top:587px;left:162px;white-space:nowrap" class="ft013">Murray&#160;K, Reddy V,&#160;Kornblum&#160;JS, et&#160;al. Increasing antibiotic resistance in&#160;</p>
<p style="position:absolute;top:587px;left:683px;white-space:nowrap" class="ft019"><i>Shigella</i></p>
<p style="position:absolute;top:587px;left:739px;white-space:nowrap" class="ft013">&#160;spp.&#160;</p>
<p style="position:absolute;top:607px;left:162px;white-space:nowrap" class="ft013">from infected New&#160;York&#160;City residents, New York,&#160;USA.&#160;</p>
<p style="position:absolute;top:607px;left:564px;white-space:nowrap" class="ft019"><i>Emerg Infect&#160;Dis</i></p>
<p style="position:absolute;top:607px;left:682px;white-space:nowrap" class="ft013">.&#160;2017;23(2):332-</p>
<p style="position:absolute;top:627px;left:162px;white-space:nowrap" class="ft013">335. Available&#160;at:&#160;</p>
<p style="position:absolute;top:627px;left:289px;white-space:nowrap" class="ft034">https://www.ncbi.nlm.nih.gov/pubmed/28098543</p>
<p style="position:absolute;top:627px;left:631px;white-space:nowrap" class="ft013">.&#160;</p>
<p style="position:absolute;top:664px;left:108px;white-space:nowrap" class="ft013">55.</p>
<p style="position:absolute;top:664px;left:162px;white-space:nowrap" class="ft032">Gharpure&#160;R,&#160;Friedman CR, Fialkowski V, et&#160;al. Azithromycin and ciprofloxacin treatment<br/>outcomes during an outbreak of multidrug-resistant&#160;</p>
<p style="position:absolute;top:684px;left:521px;white-space:nowrap" class="ft019"><i>Shigella sonnei</i></p>
<p style="position:absolute;top:684px;left:627px;white-space:nowrap" class="ft013">&#160;infections in a retirement&#160;</p>
<p style="position:absolute;top:704px;left:162px;white-space:nowrap" class="ft013">community-Vermont, 2018.&#160;</p>
<p style="position:absolute;top:704px;left:359px;white-space:nowrap" class="ft019"><i>Clin Infect&#160;Dis</i></p>
<p style="position:absolute;top:704px;left:461px;white-space:nowrap" class="ft013">. 2022;74(3):455-460. Available at:&#160;</p>
<p style="position:absolute;top:724px;left:162px;white-space:nowrap" class="ft034">https://www.ncbi.nlm.nih.gov/pubmed/33993224</p>
<p style="position:absolute;top:724px;left:503px;white-space:nowrap" class="ft013">.&#160;</p>
<p style="position:absolute;top:761px;left:108px;white-space:nowrap" class="ft013">56.</p>
<p style="position:absolute;top:760px;left:130px;white-space:nowrap" class="ft046">&#160;</p>
<p style="position:absolute;top:761px;left:162px;white-space:nowrap" class="ft032">Centers for&#160;Disease Control&#160;and Prevention. CDC recommendations for diagnosing and&#160;<br/>managing&#160;</p>
<p style="position:absolute;top:780px;left:234px;white-space:nowrap" class="ft019"><i>Shigella</i></p>
<p style="position:absolute;top:780px;left:291px;white-space:nowrap" class="ft013">&#160;strains with possible&#160;reduced susceptibility to ciprofloxacin. 2017.&#160;</p>
<p style="position:absolute;top:800px;left:162px;white-space:nowrap" class="ft013">Available at:&#160;</p>
<p style="position:absolute;top:800px;left:255px;white-space:nowrap" class="ft034">https://emergency.cdc.gov/han/han00401.asp</p>
<p style="position:absolute;top:800px;left:567px;white-space:nowrap" class="ft013">.&#160;</p>
<p style="position:absolute;top:837px;left:108px;white-space:nowrap" class="ft013">57.</p>
<p style="position:absolute;top:837px;left:130px;white-space:nowrap" class="ft046">&#160;</p>
<p style="position:absolute;top:837px;left:162px;white-space:nowrap" class="ft013">Heiman KE,&#160;Karlsson M,&#160;Grass J, et al. Notes from&#160;the&#160;field:&#160;</p>
<p style="position:absolute;top:837px;left:587px;white-space:nowrap" class="ft019"><i>Shigella&#160;</i></p>
<p style="position:absolute;top:837px;left:648px;white-space:nowrap" class="ft013">with decreased&#160;</p>
<p style="position:absolute;top:857px;left:162px;white-space:nowrap" class="ft032">susceptibility to azithromycin among men who have&#160;sex with men&#160;- United States, 2002–<br/>2013.&#160;</p>
<p style="position:absolute;top:877px;left:205px;white-space:nowrap" class="ft019"><i>MMWR Morb&#160;Mortal Wkly Rep</i></p>
<p style="position:absolute;top:877px;left:423px;white-space:nowrap" class="ft013">. 2014;63(6):132-133.&#160;Available&#160;at:&#160;</p>
<p style="position:absolute;top:897px;left:162px;white-space:nowrap" class="ft034">http://www.ncbi.nlm.nih.gov/pubmed/24522098</p>
<p style="position:absolute;top:897px;left:497px;white-space:nowrap" class="ft013">.&#160;</p>
<p style="position:absolute;top:934px;left:108px;white-space:nowrap" class="ft013">58.</p>
<p style="position:absolute;top:934px;left:130px;white-space:nowrap" class="ft046">&#160;</p>
<p style="position:absolute;top:934px;left:162px;white-space:nowrap" class="ft013">Hassing&#160;RJ,&#160;Melles DC,&#160;Goessens WH, Rijnders&#160;BJ. Case of&#160;</p>
<p style="position:absolute;top:934px;left:585px;white-space:nowrap" class="ft019"><i>Shigella flexneri&#160;</i></p>
<p style="position:absolute;top:934px;left:703px;white-space:nowrap" class="ft013">infection with&#160;</p>
<p style="position:absolute;top:954px;left:162px;white-space:nowrap" class="ft013">treatment failure&#160;due to azithromycin resistance in an HIV-positive patient.&#160;</p>
<p style="position:absolute;top:954px;left:684px;white-space:nowrap" class="ft019"><i>Infection</i></p>
<p style="position:absolute;top:954px;left:745px;white-space:nowrap" class="ft013">. 2014.&#160;</p>
<p style="position:absolute;top:974px;left:162px;white-space:nowrap" class="ft013">Available at:&#160;</p>
<p style="position:absolute;top:974px;left:255px;white-space:nowrap" class="ft034">http://www.ncbi.nlm.nih.gov/pubmed/24488332</p>
<p style="position:absolute;top:974px;left:589px;white-space:nowrap" class="ft013">.&#160;</p>
<p style="position:absolute;top:1011px;left:108px;white-space:nowrap" class="ft013">59.</p>
<p style="position:absolute;top:1011px;left:130px;white-space:nowrap" class="ft046">&#160;</p>
<p style="position:absolute;top:1011px;left:162px;white-space:nowrap" class="ft032">Baker KS, Dallman TJ, Ashton PM, et&#160;al. Intercontinental dissemination of azithromycin-<br/>resistant shigellosis through sexual transmission:&#160;a&#160;cross-sectional study.&#160;</p>
<p style="position:absolute;top:1031px;left:668px;white-space:nowrap" class="ft019"><i>Lancet&#160;Infect&#160;Dis</i></p>
<p style="position:absolute;top:1031px;left:787px;white-space:nowrap" class="ft013">.&#160;</p>
<p style="position:absolute;top:1050px;left:162px;white-space:nowrap" class="ft013">2015;15(8):913-921.&#160;Available&#160;at:&#160;</p>
<p style="position:absolute;top:1050px;left:402px;white-space:nowrap" class="ft034">http://www.ncbi.nlm.nih.gov/pubmed/25936611</p>
<p style="position:absolute;top:1050px;left:737px;white-space:nowrap" class="ft013">.&#160;</p>
</div>
<!-- Page 36 -->
<a name="36"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page36-div" style="position:relative;width:917px;height:1187px;">
<p style="position:absolute;top:1114px;left:108px;white-space:nowrap" class="ft024"><i>Guidelines for the Prevention and Treatment&#160;of&#160;Opportunistic&#160;Infections in Adults&#160;and Adolescents&#160;With HIV&#160;</i></p>
<p style="position:absolute;top:1114px;left:784px;white-space:nowrap" class="ft024"><i>B-21&#160;</i></p>
<p style="position:absolute;top:87px;left:108px;white-space:nowrap" class="ft013">60.</p>
<p style="position:absolute;top:87px;left:130px;white-space:nowrap" class="ft046">&#160;</p>
<p style="position:absolute;top:87px;left:162px;white-space:nowrap" class="ft032">Centers for&#160;Disease Control&#160;and Prevention. Increase in extensively drug-resistant&#160;shigellosis&#160;<br/>in the United States. 2023. Available at:&#160;</p>
<p style="position:absolute;top:107px;left:442px;white-space:nowrap" class="ft034">https://emergency.cdc.gov/han/2023/han00486.asp</p>
<p style="position:absolute;top:107px;left:793px;white-space:nowrap" class="ft013">.&#160;</p>
<p style="position:absolute;top:144px;left:108px;white-space:nowrap" class="ft013">61.</p>
<p style="position:absolute;top:144px;left:130px;white-space:nowrap" class="ft046">&#160;</p>
<p style="position:absolute;top:144px;left:162px;white-space:nowrap" class="ft032">Gaudreau C,&#160;Rodrigues-Coutlee&#160;S, Pilon PA, Coutlee F, Bekal S. Long-lasting outbreak of&#160;<br/>erythromycin- and ciprofloxacin-resistant&#160;</p>
<p style="position:absolute;top:164px;left:453px;white-space:nowrap" class="ft019"><i>Campylobacter jejuni&#160;</i></p>
<p style="position:absolute;top:164px;left:608px;white-space:nowrap" class="ft013">subspecies&#160;</p>
<p style="position:absolute;top:164px;left:686px;white-space:nowrap" class="ft019"><i>jejuni</i></p>
<p style="position:absolute;top:164px;left:725px;white-space:nowrap" class="ft013">&#160;from&#160;2003&#160;</p>
<p style="position:absolute;top:184px;left:162px;white-space:nowrap" class="ft013">to 2013 in men who have&#160;sex with men, Quebec, Canada.&#160;</p>
<p style="position:absolute;top:184px;left:563px;white-space:nowrap" class="ft019"><i>Clin Infect&#160;Dis</i></p>
<p style="position:absolute;top:184px;left:665px;white-space:nowrap" class="ft013">. 2015;61(10):1549-</p>
<p style="position:absolute;top:204px;left:162px;white-space:nowrap" class="ft013">1552. Available&#160;at:&#160;</p>
<p style="position:absolute;top:204px;left:298px;white-space:nowrap" class="ft034">https://www.ncbi.nlm.nih.gov/pubmed/26187024</p>
<p style="position:absolute;top:204px;left:639px;white-space:nowrap" class="ft013">.&#160;</p>
<p style="position:absolute;top:241px;left:108px;white-space:nowrap" class="ft013">62.</p>
<p style="position:absolute;top:240px;left:130px;white-space:nowrap" class="ft046">&#160;</p>
<p style="position:absolute;top:241px;left:162px;white-space:nowrap" class="ft013">Greninger&#160;AL, Addetia A, Starr K, et&#160;al. International spread of&#160;multidrug-resistant&#160;</p>
<p style="position:absolute;top:260px;left:162px;white-space:nowrap" class="ft019"><i>Campylobacter coli</i></p>
<p style="position:absolute;top:260px;left:298px;white-space:nowrap" class="ft013">&#160;in men who have sex with men&#160;in Washington state and&#160;Quebec, 2015–</p>
<p style="position:absolute;top:280px;left:162px;white-space:nowrap" class="ft013">2018.&#160;</p>
<p style="position:absolute;top:280px;left:205px;white-space:nowrap" class="ft019"><i>Clin Infect&#160;Dis</i></p>
<p style="position:absolute;top:280px;left:307px;white-space:nowrap" class="ft013">. 2020;71(8):1896-1904.&#160;Available at:&#160;</p>
<p style="position:absolute;top:300px;left:162px;white-space:nowrap" class="ft034">https://www.ncbi.nlm.nih.gov/pubmed/31665255</p>
<p style="position:absolute;top:300px;left:503px;white-space:nowrap" class="ft013">.&#160;</p>
<p style="position:absolute;top:337px;left:108px;white-space:nowrap" class="ft013">63.</p>
<p style="position:absolute;top:337px;left:130px;white-space:nowrap" class="ft046">&#160;</p>
<p style="position:absolute;top:337px;left:162px;white-space:nowrap" class="ft013">Fernandez-Cruz A,&#160;Munoz P, Mohedano R, et&#160;al.&#160;</p>
<p style="position:absolute;top:337px;left:506px;white-space:nowrap" class="ft019"><i>Campylobacter</i></p>
<p style="position:absolute;top:337px;left:612px;white-space:nowrap" class="ft013">&#160;bacteremia:&#160;clinical&#160;</p>
<p style="position:absolute;top:357px;left:162px;white-space:nowrap" class="ft013">characteristics, incidence, and outcome over 23 years.&#160;</p>
<p style="position:absolute;top:357px;left:538px;white-space:nowrap" class="ft019"><i>Medicine (Baltimore)</i></p>
<p style="position:absolute;top:357px;left:687px;white-space:nowrap" class="ft013">. 2010;89(5):319-</p>
<p style="position:absolute;top:377px;left:162px;white-space:nowrap" class="ft013">330. Available&#160;at:&#160;</p>
<p style="position:absolute;top:377px;left:289px;white-space:nowrap" class="ft034">https://www.ncbi.nlm.nih.gov/pubmed/20827109</p>
<p style="position:absolute;top:377px;left:631px;white-space:nowrap" class="ft013">.&#160;</p>
<p style="position:absolute;top:414px;left:108px;white-space:nowrap" class="ft013">64.</p>
<p style="position:absolute;top:414px;left:130px;white-space:nowrap" class="ft046">&#160;</p>
<p style="position:absolute;top:414px;left:162px;white-space:nowrap" class="ft013">Larsen IK,&#160;Gradel&#160;KO,&#160;Helms M, et&#160;al. Non-typhoidal&#160;</p>
<p style="position:absolute;top:414px;left:541px;white-space:nowrap" class="ft019"><i>Salmonella&#160;</i></p>
<p style="position:absolute;top:414px;left:623px;white-space:nowrap" class="ft013">and&#160;</p>
<p style="position:absolute;top:414px;left:652px;white-space:nowrap" class="ft019"><i>Campylobacter</i></p>
<p style="position:absolute;top:414px;left:758px;white-space:nowrap" class="ft013">&#160;</p>
<p style="position:absolute;top:434px;left:162px;white-space:nowrap" class="ft013">infections among HIV-positive patients in Denmark.&#160;</p>
<p style="position:absolute;top:434px;left:529px;white-space:nowrap" class="ft019"><i>Scand J Infect&#160;Dis</i></p>
<p style="position:absolute;top:434px;left:655px;white-space:nowrap" class="ft013">. 2011;43(1):3-7.&#160;</p>
<p style="position:absolute;top:454px;left:162px;white-space:nowrap" class="ft013">Available at:&#160;</p>
<p style="position:absolute;top:454px;left:255px;white-space:nowrap" class="ft034">https://www.ncbi.nlm.nih.gov/pubmed/20849366</p>
<p style="position:absolute;top:454px;left:596px;white-space:nowrap" class="ft013">.&#160;</p>
<p style="position:absolute;top:491px;left:108px;white-space:nowrap" class="ft013">65.</p>
<p style="position:absolute;top:491px;left:130px;white-space:nowrap" class="ft046">&#160;</p>
<p style="position:absolute;top:491px;left:162px;white-space:nowrap" class="ft032">Johnson S, Lavergne&#160;V,&#160;Skinner AM,&#160;et&#160;al. Clinical practice guideline&#160;by the&#160;Infectious&#160;<br/>Diseases&#160;Society of America (IDSA) and Society for Healthcare&#160;Epidemiology of America&#160;<br/>(SHEA): 2021 focused update guidelines on management&#160;of&#160;</p>
<p style="position:absolute;top:530px;left:582px;white-space:nowrap" class="ft019"><i>Clostridioides difficile</i></p>
<p style="position:absolute;top:530px;left:737px;white-space:nowrap" class="ft013">&#160;infection&#160;</p>
<p style="position:absolute;top:550px;left:162px;white-space:nowrap" class="ft013">in adults.&#160;</p>
<p style="position:absolute;top:550px;left:229px;white-space:nowrap" class="ft019"><i>Clin Infect&#160;Dis</i></p>
<p style="position:absolute;top:550px;left:331px;white-space:nowrap" class="ft013">.&#160;2021;73(5):e1029-e1044.&#160;Available at:&#160;</p>
<p style="position:absolute;top:570px;left:162px;white-space:nowrap" class="ft034">https://www.ncbi.nlm.nih.gov/pubmed/34164674</p>
<p style="position:absolute;top:570px;left:503px;white-space:nowrap" class="ft013">.&#160;</p>
<p style="position:absolute;top:607px;left:108px;white-space:nowrap" class="ft013">66.</p>
<p style="position:absolute;top:607px;left:130px;white-space:nowrap" class="ft046">&#160;</p>
<p style="position:absolute;top:607px;left:162px;white-space:nowrap" class="ft013">Louie TJ, Miller MA,&#160;Mullane KM, et&#160;al. Fidaxomicin versus&#160;vancomycin for&#160;</p>
<p style="position:absolute;top:607px;left:705px;white-space:nowrap" class="ft019"><i>Clostridium&#160;</i></p>
<p style="position:absolute;top:627px;left:162px;white-space:nowrap" class="ft019"><i>difficile&#160;</i></p>
<p style="position:absolute;top:627px;left:219px;white-space:nowrap" class="ft013">infection.&#160;</p>
<p style="position:absolute;top:627px;left:289px;white-space:nowrap" class="ft019"><i>N Engl J&#160;Med</i></p>
<p style="position:absolute;top:627px;left:384px;white-space:nowrap" class="ft013">. 2011;364(5):422-431. Available at:&#160;</p>
<p style="position:absolute;top:647px;left:162px;white-space:nowrap" class="ft034">https://www.ncbi.nlm.nih.gov/pubmed/21288078</p>
<p style="position:absolute;top:647px;left:503px;white-space:nowrap" class="ft013">.&#160;</p>
<p style="position:absolute;top:684px;left:108px;white-space:nowrap" class="ft013">67.</p>
<p style="position:absolute;top:684px;left:130px;white-space:nowrap" class="ft046">&#160;</p>
<p style="position:absolute;top:684px;left:162px;white-space:nowrap" class="ft032">Cornely OA,&#160;Crook&#160;DW,&#160;Esposito R, et al. Fidaxomicin versus vancomycin for infection&#160;<br/>with&#160;</p>
<p style="position:absolute;top:704px;left:197px;white-space:nowrap" class="ft019"><i>Clostridium difficile</i></p>
<p style="position:absolute;top:704px;left:336px;white-space:nowrap" class="ft013">&#160;in Europe, Canada, and the&#160;USA: a double-blind, non-inferiority,&#160;</p>
<p style="position:absolute;top:724px;left:162px;white-space:nowrap" class="ft013">randomised&#160;controlled trial.&#160;</p>
<p style="position:absolute;top:724px;left:357px;white-space:nowrap" class="ft019"><i>Lancet&#160;Infect&#160;Dis</i></p>
<p style="position:absolute;top:724px;left:476px;white-space:nowrap" class="ft013">. 2012;12(4):281-289. Available at:&#160;</p>
<p style="position:absolute;top:743px;left:162px;white-space:nowrap" class="ft034">https://www.ncbi.nlm.nih.gov/pubmed/22321770</p>
<p style="position:absolute;top:743px;left:503px;white-space:nowrap" class="ft013">.&#160;</p>
<p style="position:absolute;top:780px;left:108px;white-space:nowrap" class="ft013">68.</p>
<p style="position:absolute;top:780px;left:130px;white-space:nowrap" class="ft046">&#160;</p>
<p style="position:absolute;top:780px;left:162px;white-space:nowrap" class="ft013">Guery B,&#160;Menichetti&#160;F, Anttila VJ, et al. Extended-pulsed fidaxomicin versus vancomycin for&#160;</p>
<p style="position:absolute;top:800px;left:162px;white-space:nowrap" class="ft019"><i>Clostridium&#160;difficile</i></p>
<p style="position:absolute;top:800px;left:301px;white-space:nowrap" class="ft013">&#160;infection in patients 60 years and older (EXTEND): a randomised,&#160;</p>
<p style="position:absolute;top:820px;left:162px;white-space:nowrap" class="ft013">controlled, open-label, phase 3b/4 trial.&#160;</p>
<p style="position:absolute;top:820px;left:437px;white-space:nowrap" class="ft019"><i>Lancet Infect&#160;Dis</i></p>
<p style="position:absolute;top:820px;left:555px;white-space:nowrap" class="ft013">. 2018;18(3):296-307. Available at:&#160;</p>
<p style="position:absolute;top:840px;left:162px;white-space:nowrap" class="ft034">https://www.ncbi.nlm.nih.gov/pubmed/29273269</p>
<p style="position:absolute;top:840px;left:503px;white-space:nowrap" class="ft013">.&#160;</p>
<p style="position:absolute;top:877px;left:108px;white-space:nowrap" class="ft013">69.</p>
<p style="position:absolute;top:877px;left:130px;white-space:nowrap" class="ft046">&#160;</p>
<p style="position:absolute;top:877px;left:162px;white-space:nowrap" class="ft032">Mikamo H,&#160;Tateda K, Yanagihara K,&#160;et&#160;al. Efficacy and safety&#160;of fidaxomicin for the&#160;<br/>treatment of&#160;</p>
<p style="position:absolute;top:897px;left:250px;white-space:nowrap" class="ft019"><i>Clostridioides (Clostridium) difficile</i></p>
<p style="position:absolute;top:897px;left:503px;white-space:nowrap" class="ft013">&#160;infection in a randomized, double-blind,&#160;</p>
<p style="position:absolute;top:917px;left:162px;white-space:nowrap" class="ft013">comparative&#160;phase III&#160;study in Japan.&#160;</p>
<p style="position:absolute;top:917px;left:424px;white-space:nowrap" class="ft019"><i>J Infect Chemother</i></p>
<p style="position:absolute;top:917px;left:556px;white-space:nowrap" class="ft013">. 2018;24(9):744-752. Available at:&#160;</p>
<p style="position:absolute;top:937px;left:162px;white-space:nowrap" class="ft034">https://www.ncbi.nlm.nih.gov/pubmed/29934056</p>
<p style="position:absolute;top:937px;left:503px;white-space:nowrap" class="ft013">.&#160;</p>
<p style="position:absolute;top:974px;left:108px;white-space:nowrap" class="ft013">70.</p>
<p style="position:absolute;top:973px;left:130px;white-space:nowrap" class="ft046">&#160;</p>
<p style="position:absolute;top:974px;left:162px;white-space:nowrap" class="ft013">Johnson S, Louie&#160;TJ, Gerding DN, et al. Vancomycin, metronidazole, or tolevamer for&#160;</p>
<p style="position:absolute;top:994px;left:162px;white-space:nowrap" class="ft019"><i>Clostridium&#160;difficile</i></p>
<p style="position:absolute;top:994px;left:301px;white-space:nowrap" class="ft013">&#160;infection:&#160;results from two multinational, randomized, controlled trials.&#160;</p>
<p style="position:absolute;top:1013px;left:162px;white-space:nowrap" class="ft019"><i>Clin Infect&#160;Dis</i></p>
<p style="position:absolute;top:1013px;left:263px;white-space:nowrap" class="ft013">. 2014;59(3):345-354.&#160;Available at:&#160;</p>
<p style="position:absolute;top:1033px;left:162px;white-space:nowrap" class="ft034">http://www.ncbi.nlm.nih.gov/pubmed/24799326</p>
<p style="position:absolute;top:1033px;left:497px;white-space:nowrap" class="ft013">.&#160;</p>
</div>
<!-- Page 37 -->
<a name="37"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page37-div" style="position:relative;width:917px;height:1187px;">
<p style="position:absolute;top:1114px;left:108px;white-space:nowrap" class="ft024"><i>Guidelines for the Prevention and Treatment&#160;of&#160;Opportunistic&#160;Infections in Adults&#160;and Adolescents&#160;With HIV&#160;</i></p>
<p style="position:absolute;top:1114px;left:784px;white-space:nowrap" class="ft024"><i>B-22&#160;</i></p>
<p style="position:absolute;top:87px;left:108px;white-space:nowrap" class="ft013">71.</p>
<p style="position:absolute;top:87px;left:130px;white-space:nowrap" class="ft046">&#160;</p>
<p style="position:absolute;top:87px;left:162px;white-space:nowrap" class="ft032">Zar FA, Bakkanagari SR,&#160;Moorthi&#160;KM, Davis MB. A comparison of vancomycin and&#160;<br/>metronidazole&#160;for the&#160;treatment&#160;of&#160;</p>
<p style="position:absolute;top:107px;left:403px;white-space:nowrap" class="ft019"><i>Clostridium difficile</i></p>
<p style="position:absolute;top:107px;left:542px;white-space:nowrap" class="ft013">-associated diarrhea,&#160;stratified by&#160;</p>
<p style="position:absolute;top:127px;left:162px;white-space:nowrap" class="ft013">disease severity.&#160;</p>
<p style="position:absolute;top:127px;left:279px;white-space:nowrap" class="ft019"><i>Clin Infect&#160;Dis</i></p>
<p style="position:absolute;top:127px;left:381px;white-space:nowrap" class="ft013">. 2007;45(3):302-307. Available at:&#160;</p>
<p style="position:absolute;top:147px;left:162px;white-space:nowrap" class="ft034">http://www.ncbi.nlm.nih.gov/pubmed/17599306</p>
<p style="position:absolute;top:147px;left:497px;white-space:nowrap" class="ft013">.&#160;</p>
<p style="position:absolute;top:184px;left:108px;white-space:nowrap" class="ft013">72.</p>
<p style="position:absolute;top:183px;left:130px;white-space:nowrap" class="ft046">&#160;</p>
<p style="position:absolute;top:184px;left:162px;white-space:nowrap" class="ft013">Di Bella&#160;S,&#160;Gouliouris T, Petrosillo N. Fecal&#160;microbiota&#160;transplantation (FMT) for&#160;</p>
<p style="position:absolute;top:204px;left:162px;white-space:nowrap" class="ft019"><i>Clostridium&#160;difficile</i></p>
<p style="position:absolute;top:204px;left:301px;white-space:nowrap" class="ft013">&#160;infection:&#160;focus on immunocompromised patients.&#160;</p>
<p style="position:absolute;top:204px;left:657px;white-space:nowrap" class="ft019"><i>J Infect&#160;Chemother</i></p>
<p style="position:absolute;top:204px;left:789px;white-space:nowrap" class="ft013">.&#160;</p>
<p style="position:absolute;top:223px;left:162px;white-space:nowrap" class="ft013">2015;21(4):230-237.&#160;Available&#160;at:&#160;</p>
<p style="position:absolute;top:223px;left:402px;white-space:nowrap" class="ft034">http://www.ncbi.nlm.nih.gov/pubmed/25703532</p>
<p style="position:absolute;top:223px;left:737px;white-space:nowrap" class="ft013">.&#160;</p>
<p style="position:absolute;top:260px;left:108px;white-space:nowrap" class="ft013">73.</p>
<p style="position:absolute;top:260px;left:130px;white-space:nowrap" class="ft046">&#160;</p>
<p style="position:absolute;top:260px;left:162px;white-space:nowrap" class="ft032">Serrano-Villar S, Talavera-Rodriguez&#160;A, Gosalbes&#160;MJ, et al. Fecal&#160;microbiota transplantation&#160;<br/>in HIV: a pilot placebo-controlled study.&#160;</p>
<p style="position:absolute;top:280px;left:447px;white-space:nowrap" class="ft019"><i>Nat&#160;Commun</i></p>
<p style="position:absolute;top:280px;left:538px;white-space:nowrap" class="ft013">. 2021;12(1):1139.&#160;Available&#160;at:&#160;</p>
<p style="position:absolute;top:300px;left:162px;white-space:nowrap" class="ft034">https://www.ncbi.nlm.nih.gov/pubmed/33602945</p>
<p style="position:absolute;top:300px;left:503px;white-space:nowrap" class="ft013">.&#160;</p>
<p style="position:absolute;top:337px;left:108px;white-space:nowrap" class="ft013">74.</p>
<p style="position:absolute;top:337px;left:130px;white-space:nowrap" class="ft046">&#160;</p>
<p style="position:absolute;top:337px;left:162px;white-space:nowrap" class="ft013">Kelly CR, Ihunnah C, Fischer M, et&#160;al.&#160;Fecal&#160;microbiota&#160;transplant&#160;for treatment of&#160;</p>
<p style="position:absolute;top:357px;left:162px;white-space:nowrap" class="ft019"><i>Clostridium&#160;difficile</i></p>
<p style="position:absolute;top:357px;left:301px;white-space:nowrap" class="ft013">&#160;infection in immunocompromised patients.&#160;</p>
<p style="position:absolute;top:357px;left:606px;white-space:nowrap" class="ft019"><i>Am J Gastroenterol</i></p>
<p style="position:absolute;top:357px;left:742px;white-space:nowrap" class="ft013">.&#160;</p>
<p style="position:absolute;top:377px;left:162px;white-space:nowrap" class="ft013">2014;109(7):1065-1071.&#160;Available at:&#160;</p>
<p style="position:absolute;top:377px;left:428px;white-space:nowrap" class="ft034">https://www.ncbi.nlm.nih.gov/pubmed/24890442</p>
<p style="position:absolute;top:377px;left:770px;white-space:nowrap" class="ft013">.&#160;</p>
<p style="position:absolute;top:414px;left:108px;white-space:nowrap" class="ft013">75.</p>
<p style="position:absolute;top:414px;left:130px;white-space:nowrap" class="ft046">&#160;</p>
<p style="position:absolute;top:414px;left:162px;white-space:nowrap" class="ft032">Food and&#160;Drug Administration. Fecal&#160;microbiota&#160;for transplantation:&#160;safety alert&#160;- risk of&#160;<br/>serious adverse events likely due to transmission of&#160;pathogenic&#160;organisms. 2020. Available&#160;<br/>at:&#160;</p>
<p style="position:absolute;top:454px;left:184px;white-space:nowrap" class="ft034">https://www.fda.gov/safety/medical-product-safety-information/fecal-microbiota-</p>
<p style="position:absolute;top:473px;left:162px;white-space:nowrap" class="ft034">transplantation-safety-alert-risk-serious-adverse-events-likely-due-transmission</p>
<p style="position:absolute;top:473px;left:711px;white-space:nowrap" class="ft013">.&#160;</p>
<p style="position:absolute;top:511px;left:108px;white-space:nowrap" class="ft013">76.</p>
<p style="position:absolute;top:510px;left:130px;white-space:nowrap" class="ft046">&#160;</p>
<p style="position:absolute;top:511px;left:162px;white-space:nowrap" class="ft013">DeFilipp Z,&#160;Bloom&#160;PP, Torres Soto M, et&#160;al. Drug-resistant&#160;</p>
<p style="position:absolute;top:511px;left:576px;white-space:nowrap" class="ft019"><i>E. coli&#160;</i></p>
<p style="position:absolute;top:511px;left:625px;white-space:nowrap" class="ft013">bacteremia transmitted by&#160;</p>
<p style="position:absolute;top:530px;left:162px;white-space:nowrap" class="ft013">fecal microbiota transplant.&#160;</p>
<p style="position:absolute;top:530px;left:355px;white-space:nowrap" class="ft019"><i>N Engl J&#160;Med</i></p>
<p style="position:absolute;top:530px;left:451px;white-space:nowrap" class="ft013">. 2019;381(21):2043-2050. Available&#160;at:&#160;</p>
<p style="position:absolute;top:550px;left:162px;white-space:nowrap" class="ft034">https://www.ncbi.nlm.nih.gov/pubmed/31665575</p>
<p style="position:absolute;top:550px;left:503px;white-space:nowrap" class="ft013">.&#160;</p>
<p style="position:absolute;top:587px;left:108px;white-space:nowrap" class="ft013">77.</p>
<p style="position:absolute;top:587px;left:130px;white-space:nowrap" class="ft046">&#160;</p>
<p style="position:absolute;top:587px;left:162px;white-space:nowrap" class="ft032">Gurumurthy&#160;P, Ramachandran G,&#160;Hemanth Kumar&#160;AK, et&#160;al.&#160;Malabsorption&#160;of rifampin and&#160;<br/>isoniazid in HIV-infected patients with and without tuberculosis.&#160;</p>
<p style="position:absolute;top:607px;left:613px;white-space:nowrap" class="ft019"><i>Clin Infect&#160;Dis</i></p>
<p style="position:absolute;top:607px;left:715px;white-space:nowrap" class="ft013">.&#160;</p>
<p style="position:absolute;top:627px;left:162px;white-space:nowrap" class="ft013">2004;38(2):280-283.&#160;Available&#160;at:&#160;</p>
<p style="position:absolute;top:627px;left:402px;white-space:nowrap" class="ft034">https://www.ncbi.nlm.nih.gov/pubmed/14699462</p>
<p style="position:absolute;top:627px;left:744px;white-space:nowrap" class="ft013">.&#160;</p>
<p style="position:absolute;top:664px;left:108px;white-space:nowrap" class="ft013">78.</p>
<p style="position:absolute;top:664px;left:162px;white-space:nowrap" class="ft032">Sahai&#160;J, Gallicano K, Swick L, et&#160;al. Reduced plasma&#160;concentrations of antituberculosis<br/>drugs in patients with HIV infection.&#160;</p>
<p style="position:absolute;top:684px;left:420px;white-space:nowrap" class="ft019"><i>Ann Intern&#160;Med</i></p>
<p style="position:absolute;top:684px;left:529px;white-space:nowrap" class="ft013">. 1997;127(4):289-293. Available at:&#160;</p>
<p style="position:absolute;top:704px;left:162px;white-space:nowrap" class="ft034">https://www.ncbi.nlm.nih.gov/pubmed/9265429</p>
<p style="position:absolute;top:704px;left:495px;white-space:nowrap" class="ft013">.&#160;</p>
<p style="position:absolute;top:741px;left:108px;white-space:nowrap" class="ft013">79.</p>
<p style="position:absolute;top:741px;left:130px;white-space:nowrap" class="ft046">&#160;</p>
<p style="position:absolute;top:741px;left:162px;white-space:nowrap" class="ft032">Highlights of&#160;prescribing information.&#160;CIPRO® (ciprofloxacin&#160;hydrochloride) tablet, for oral&#160;<br/>use CIPRO® (ciprofloxacin), for oral suspension&#160;[package insert]. U.S. Food&#160;and Drug&#160;<br/>Administration. 2021.&#160;Available&#160;at:&#160;</p>
<p style="position:absolute;top:800px;left:162px;white-space:nowrap" class="ft034">https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/019537s092lbl.pdf</p>
<p style="position:absolute;top:800px;left:711px;white-space:nowrap" class="ft013">.&#160;</p>
<p style="position:absolute;top:837px;left:108px;white-space:nowrap" class="ft013">80.</p>
<p style="position:absolute;top:837px;left:130px;white-space:nowrap" class="ft046">&#160;</p>
<p style="position:absolute;top:837px;left:162px;white-space:nowrap" class="ft032">Bérard A,&#160;Sheehy O, Zhao J, Nordeng&#160;H. Use of macrolides during pregnancy and the risk of&#160;<br/>birth defects: a&#160;population-based study.&#160;</p>
<p style="position:absolute;top:857px;left:438px;white-space:nowrap" class="ft019"><i>Pharmacoepidemiology&#160;and Drug Safety</i></p>
<p style="position:absolute;top:857px;left:720px;white-space:nowrap" class="ft013">.&#160;</p>
<p style="position:absolute;top:877px;left:162px;white-space:nowrap" class="ft013">2015;24(12):1241-1248.&#160;Available at:&#160;</p>
<p style="position:absolute;top:877px;left:428px;white-space:nowrap" class="ft034">http://www.ncbi.nlm.nih.gov/pubmed/26513406</p>
<p style="position:absolute;top:877px;left:763px;white-space:nowrap" class="ft013">.&#160;</p>
<p style="position:absolute;top:914px;left:108px;white-space:nowrap" class="ft013">81.</p>
<p style="position:absolute;top:914px;left:130px;white-space:nowrap" class="ft046">&#160;</p>
<p style="position:absolute;top:914px;left:162px;white-space:nowrap" class="ft032">Padberg S,&#160;Wacker E, Meister R, et&#160;al. Observational cohort study of pregnancy outcome&#160;<br/>after first-trimester exposure to fluoroquinolones.&#160;</p>
<p style="position:absolute;top:934px;left:508px;white-space:nowrap" class="ft019"><i>Antimicrob&#160;Agents Chemother</i></p>
<p style="position:absolute;top:934px;left:717px;white-space:nowrap" class="ft013">.&#160;</p>
<p style="position:absolute;top:954px;left:162px;white-space:nowrap" class="ft013">2014;58(8):4392-4398.&#160;Available at:&#160;</p>
<p style="position:absolute;top:954px;left:420px;white-space:nowrap" class="ft034">http://www.ncbi.nlm.nih.gov/pubmed/24841264</p>
<p style="position:absolute;top:954px;left:754px;white-space:nowrap" class="ft013">.&#160;</p>
<p style="position:absolute;top:991px;left:108px;white-space:nowrap" class="ft013">82.</p>
<p style="position:absolute;top:991px;left:130px;white-space:nowrap" class="ft046">&#160;</p>
<p style="position:absolute;top:991px;left:162px;white-space:nowrap" class="ft032">Schaefer C,&#160;Amoura-Elefant&#160;E, Vial&#160;T, et&#160;al. Pregnancy outcome after prenatal quinolone&#160;<br/>exposure. Evaluation of a case registry&#160;of the&#160;European Network&#160;of Teratology Information&#160;<br/>Services (ENTIS).&#160;</p>
<p style="position:absolute;top:1031px;left:294px;white-space:nowrap" class="ft019"><i>Eur J&#160;Obstet Gynecol&#160;Reprod Biol</i></p>
<p style="position:absolute;top:1031px;left:531px;white-space:nowrap" class="ft013">. 1996;69(2):83-89.&#160;Available&#160;at:&#160;</p>
<p style="position:absolute;top:1050px;left:162px;white-space:nowrap" class="ft034">http://www.ncbi.nlm.nih.gov/pubmed/8902438</p>
<p style="position:absolute;top:1050px;left:488px;white-space:nowrap" class="ft013">.&#160;</p>
</div>
<!-- Page 38 -->
<a name="38"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page38-div" style="position:relative;width:917px;height:1187px;">
<p style="position:absolute;top:1114px;left:108px;white-space:nowrap" class="ft024"><i>Guidelines for the Prevention and Treatment&#160;of&#160;Opportunistic&#160;Infections in Adults&#160;and Adolescents&#160;With HIV&#160;</i></p>
<p style="position:absolute;top:1114px;left:784px;white-space:nowrap" class="ft024"><i>B-23&#160;</i></p>
<p style="position:absolute;top:87px;left:108px;white-space:nowrap" class="ft013">83.</p>
<p style="position:absolute;top:87px;left:130px;white-space:nowrap" class="ft046">&#160;</p>
<p style="position:absolute;top:87px;left:162px;white-space:nowrap" class="ft032">Loebstein R,&#160;Addis&#160;A,&#160;Ho&#160;E, et al. Pregnancy outcome&#160;following gestational exposure to&#160;<br/>fluoroquinolones: a multicenter prospective controlled study.&#160;</p>
<p style="position:absolute;top:107px;left:588px;white-space:nowrap" class="ft019"><i>Antimicrob Agents Chemother</i></p>
<p style="position:absolute;top:107px;left:797px;white-space:nowrap" class="ft013">.&#160;</p>
<p style="position:absolute;top:127px;left:162px;white-space:nowrap" class="ft013">1998;42(6):1336-1339.&#160;Available at:&#160;</p>
<p style="position:absolute;top:127px;left:420px;white-space:nowrap" class="ft034">http://www.ncbi.nlm.nih.gov/pubmed/9624471</p>
<p style="position:absolute;top:127px;left:746px;white-space:nowrap" class="ft013">.&#160;</p>
<p style="position:absolute;top:164px;left:108px;white-space:nowrap" class="ft013">84.</p>
<p style="position:absolute;top:164px;left:130px;white-space:nowrap" class="ft046">&#160;</p>
<p style="position:absolute;top:164px;left:162px;white-space:nowrap" class="ft032">Czeizel&#160;AE, Rockenbauer&#160;M, Sorensen&#160;HT, Olsen J.&#160;The&#160;teratogenic risk of trimethoprim-<br/>sulfonamides: a&#160;population based case-control study.&#160;</p>
<p style="position:absolute;top:184px;left:531px;white-space:nowrap" class="ft019"><i>Reprod Toxicol</i></p>
<p style="position:absolute;top:184px;left:638px;white-space:nowrap" class="ft013">. 2001;15(6):637-646.&#160;</p>
<p style="position:absolute;top:204px;left:162px;white-space:nowrap" class="ft013">Available at:&#160;</p>
<p style="position:absolute;top:204px;left:255px;white-space:nowrap" class="ft034">http://www.ncbi.nlm.nih.gov/pubmed/11738517</p>
<p style="position:absolute;top:204px;left:589px;white-space:nowrap" class="ft013">.&#160;</p>
<p style="position:absolute;top:241px;left:108px;white-space:nowrap" class="ft013">85.</p>
<p style="position:absolute;top:240px;left:130px;white-space:nowrap" class="ft046">&#160;</p>
<p style="position:absolute;top:241px;left:162px;white-space:nowrap" class="ft032">Hernandez-Diaz&#160;S, Werler MM,&#160;Walker AM, Mitchell AA. Folic acid antagonists during&#160;<br/>pregnancy and the&#160;risk of&#160;birth defects.&#160;</p>
<p style="position:absolute;top:260px;left:436px;white-space:nowrap" class="ft019"><i>N Engl J&#160;Med</i></p>
<p style="position:absolute;top:260px;left:531px;white-space:nowrap" class="ft013">. 2000;343(22):1608-1614. Available&#160;</p>
<p style="position:absolute;top:280px;left:162px;white-space:nowrap" class="ft013">at:&#160;</p>
<p style="position:absolute;top:280px;left:184px;white-space:nowrap" class="ft034">http://www.ncbi.nlm.nih.gov/pubmed/11096168</p>
<p style="position:absolute;top:280px;left:518px;white-space:nowrap" class="ft013">.&#160;</p>
<p style="position:absolute;top:317px;left:108px;white-space:nowrap" class="ft013">86.</p>
<p style="position:absolute;top:317px;left:130px;white-space:nowrap" class="ft046">&#160;</p>
<p style="position:absolute;top:317px;left:162px;white-space:nowrap" class="ft032">Hernandez-Diaz S, Werler MM,&#160;Walker AM, Mitchell AA.&#160;Neural tube defects in relation to&#160;<br/>use of folic acid antagonists during pregnancy.&#160;</p>
<p style="position:absolute;top:337px;left:489px;white-space:nowrap" class="ft019"><i>Am&#160;J Epidemiol</i></p>
<p style="position:absolute;top:337px;left:599px;white-space:nowrap" class="ft013">. 2001;153(10):961-968.&#160;</p>
<p style="position:absolute;top:357px;left:162px;white-space:nowrap" class="ft013">Available at:&#160;</p>
<p style="position:absolute;top:357px;left:255px;white-space:nowrap" class="ft034">http://www.ncbi.nlm.nih.gov/pubmed/11384952</p>
<p style="position:absolute;top:357px;left:589px;white-space:nowrap" class="ft013">.&#160;</p>
<p style="position:absolute;top:394px;left:108px;white-space:nowrap" class="ft013">87.</p>
<p style="position:absolute;top:394px;left:162px;white-space:nowrap" class="ft032">Ford&#160;N, Shubber Z, Jao&#160;J, Abrams EJ,&#160;Frigati L, Mofenson L.&#160;Safety of cotrimoxazole&#160;in&#160;<br/>pregnancy: a&#160;systematic review and meta-analysis.&#160;</p>
<p style="position:absolute;top:414px;left:516px;white-space:nowrap" class="ft019"><i>J Acquir Immune&#160;Defic Syndr</i></p>
<p style="position:absolute;top:414px;left:721px;white-space:nowrap" class="ft013">.&#160;</p>
<p style="position:absolute;top:434px;left:162px;white-space:nowrap" class="ft013">2014;66(5):512-521.&#160;Available&#160;at:&#160;</p>
<p style="position:absolute;top:434px;left:402px;white-space:nowrap" class="ft034">http://www.ncbi.nlm.nih.gov/pubmed/24853309</p>
<p style="position:absolute;top:434px;left:737px;white-space:nowrap" class="ft013">.&#160;</p>
<p style="position:absolute;top:471px;left:108px;white-space:nowrap" class="ft013">88.</p>
<p style="position:absolute;top:471px;left:130px;white-space:nowrap" class="ft046">&#160;</p>
<p style="position:absolute;top:471px;left:162px;white-space:nowrap" class="ft032">Bortolus R,&#160;Filippini F, Cipriani S, et&#160;al. Efficacy of 4.0 mg versus&#160;0.4 mg folic acid&#160;<br/>supplementation on the reproductive&#160;outcomes: a randomized controlled trial.&#160;</p>
<p style="position:absolute;top:491px;left:702px;white-space:nowrap" class="ft019"><i>Nutrients</i></p>
<p style="position:absolute;top:491px;left:766px;white-space:nowrap" class="ft013">.&#160;</p>
<p style="position:absolute;top:511px;left:162px;white-space:nowrap" class="ft013">2021;13(12).&#160;Available at:&#160;</p>
<p style="position:absolute;top:511px;left:349px;white-space:nowrap" class="ft034">https://www.ncbi.nlm.nih.gov/pubmed/34959975</p>
<p style="position:absolute;top:511px;left:690px;white-space:nowrap" class="ft013">.&#160;</p>
<p style="position:absolute;top:548px;left:108px;white-space:nowrap" class="ft013">89.</p>
<p style="position:absolute;top:547px;left:130px;white-space:nowrap" class="ft046">&#160;</p>
<p style="position:absolute;top:548px;left:162px;white-space:nowrap" class="ft032">Puopolo&#160;KM, Lynfield R,&#160;Cummings JJ, et al. Management&#160;of infants at&#160;risk&#160;for group B&#160;<br/>streptococcal disease.&#160;</p>
<p style="position:absolute;top:568px;left:316px;white-space:nowrap" class="ft019"><i>Pediatrics</i></p>
<p style="position:absolute;top:568px;left:386px;white-space:nowrap" class="ft013">. 2019;144(2).&#160;Available at:&#160;</p>
<p style="position:absolute;top:587px;left:162px;white-space:nowrap" class="ft078">https://publications.aap.org/pediatrics/article/144/2/e20191881/38546/Management-of-<br/>Infants-at-Risk-for-Group-B?autologincheck=redirected</p>
<p style="position:absolute;top:607px;left:550px;white-space:nowrap" class="ft013">.&#160;</p>
<p style="position:absolute;top:644px;left:108px;white-space:nowrap" class="ft013">90.</p>
<p style="position:absolute;top:644px;left:130px;white-space:nowrap" class="ft046">&#160;</p>
<p style="position:absolute;top:644px;left:162px;white-space:nowrap" class="ft032">Rao S,&#160;Kupfer Y, Pagala&#160;M, Chapnick&#160;E, Tessler S.&#160;Systemic absorption of oral&#160;vancomycin&#160;<br/>in patients with</p>
<p style="position:absolute;top:664px;left:272px;white-space:nowrap" class="ft019"><i>Clostridium difficile</i></p>
<p style="position:absolute;top:664px;left:412px;white-space:nowrap" class="ft013">&#160;infection.&#160;</p>
<p style="position:absolute;top:664px;left:486px;white-space:nowrap" class="ft019"><i>Scand J Infect&#160;Dis</i></p>
<p style="position:absolute;top:664px;left:612px;white-space:nowrap" class="ft013">. 2011;43(5):386-388.&#160;</p>
<p style="position:absolute;top:684px;left:162px;white-space:nowrap" class="ft013">Available at:&#160;</p>
<p style="position:absolute;top:684px;left:255px;white-space:nowrap" class="ft034">https://www.ncbi.nlm.nih.gov/pubmed/21198337</p>
<p style="position:absolute;top:684px;left:596px;white-space:nowrap" class="ft013">.&#160;</p>
<p style="position:absolute;top:721px;left:108px;white-space:nowrap" class="ft013">91.</p>
<p style="position:absolute;top:721px;left:130px;white-space:nowrap" class="ft046">&#160;</p>
<p style="position:absolute;top:721px;left:162px;white-space:nowrap" class="ft032">Bourget&#160;P,&#160;Fernandez H,&#160;Delouis C, Ribou F. Transplacental&#160;passage of&#160;vancomycin during&#160;<br/>the&#160;second trimester of pregnancy.&#160;</p>
<p style="position:absolute;top:741px;left:404px;white-space:nowrap" class="ft019"><i>Obstet&#160;Gynecol</i></p>
<p style="position:absolute;top:741px;left:511px;white-space:nowrap" class="ft013">. 1991;78(5&#160;Pt 2):908-911.&#160;Available at:&#160;</p>
<p style="position:absolute;top:761px;left:162px;white-space:nowrap" class="ft034">http://www.ncbi.nlm.nih.gov/pubmed/1923224</p>
<p style="position:absolute;top:761px;left:488px;white-space:nowrap" class="ft013">.&#160;</p>
<p style="position:absolute;top:798px;left:108px;white-space:nowrap" class="ft013">92.</p>
<p style="position:absolute;top:798px;left:130px;white-space:nowrap" class="ft046">&#160;</p>
<p style="position:absolute;top:798px;left:162px;white-space:nowrap" class="ft032">Sheehy O, Santos F,&#160;Ferreira E, Berard A. The use&#160;of metronidazole&#160;during pregnancy:&#160;a&#160;<br/>review of evidence.&#160;</p>
<p style="position:absolute;top:818px;left:302px;white-space:nowrap" class="ft019"><i>Curr&#160;Drug&#160;Saf</i></p>
<p style="position:absolute;top:818px;left:402px;white-space:nowrap" class="ft013">. 2015;10(2):170-179. Available&#160;at:&#160;</p>
<p style="position:absolute;top:837px;left:162px;white-space:nowrap" class="ft034">http://www.ncbi.nlm.nih.gov/pubmed/25986038</p>
<p style="position:absolute;top:837px;left:497px;white-space:nowrap" class="ft013">.&#160;</p>
</div>
<!-- Page 39 -->
<a name="39"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}	.ft079{font-size:26px;font-family:BGKYCV+LiberationSansNarrow;color:#005299;}
	.ft080{font-size:17px;font-family:TURBHP+Tinos;color:#0000ff;}
-->
</style>
<div id="page39-div" style="position:relative;width:917px;height:1187px;">
<p style="position:absolute;top:1128px;left:108px;white-space:nowrap" class="ft024"><i>Guidelines for the Prevention and Treatment&#160;of&#160;Opportunistic&#160;Infections in Adults&#160;and Adolescents&#160;With HIV&#160;</i></p>
<p style="position:absolute;top:1128px;left:790px;white-space:nowrap" class="ft024"><i>C-1&#160;</i></p>
<p style="position:absolute;top:112px;left:108px;white-space:nowrap" class="ft025"><b>Bartonellosis</b></p>
<p style="position:absolute;top:119px;left:281px;white-space:nowrap" class="ft034">&#160;</p>
<p style="position:absolute;top:159px;left:108px;white-space:nowrap" class="ft035"><b>Updated:</b></p>
<p style="position:absolute;top:159px;left:172px;white-space:nowrap" class="ft036">&#160;November&#160;13, 2023</p>
<p style="position:absolute;top:159px;left:306px;white-space:nowrap" class="ft035"><b>&#160;</b></p>
<p style="position:absolute;top:180px;left:108px;white-space:nowrap" class="ft035"><b>Reviewed:</b></p>
<p style="position:absolute;top:180px;left:181px;white-space:nowrap" class="ft036">&#160;January 8,&#160;2025&#160;</p>
<p style="position:absolute;top:218px;left:108px;white-space:nowrap" class="ft026"><b>Epidemiology</b></p>
<p style="position:absolute;top:212px;left:221px;white-space:nowrap" class="ft079"><b>&#160;</b></p>
<p style="position:absolute;top:260px;left:108px;white-space:nowrap" class="ft019"><i>Bartonella</i></p>
<p style="position:absolute;top:260px;left:182px;white-space:nowrap" class="ft013">&#160;species cause&#160;infections that&#160;include cat&#160;scratch disease, retinitis, trench fever,&#160;relapsing&#160;</p>
<p style="position:absolute;top:280px;left:108px;white-space:nowrap" class="ft032">bacteremia, culture-negative endocarditis, bacillary angiomatosis&#160;(BA), and bacillary peliosis&#160;<br/>hepatis.</p>
<p style="position:absolute;top:298px;left:161px;white-space:nowrap" class="ft038">1</p>
<p style="position:absolute;top:299px;left:167px;white-space:nowrap" class="ft013">&#160;The&#160;latter two manifestations occur almost&#160;exclusively in individuals who are&#160;</p>
<p style="position:absolute;top:319px;left:108px;white-space:nowrap" class="ft013">immunocompromised. Thirty-seven species and three subspecies of&#160;</p>
<p style="position:absolute;top:319px;left:579px;white-space:nowrap" class="ft019"><i>Bartonella</i></p>
<p style="position:absolute;top:319px;left:653px;white-space:nowrap" class="ft013">&#160;have been&#160;described&#160;</p>
<p style="position:absolute;top:339px;left:108px;white-space:nowrap" class="ft013">and are&#160;officially recognized (see</p>
<p style="position:absolute;top:339px;left:338px;white-space:nowrap" class="ft080">&#160;</p>
<p style="position:absolute;top:339px;left:342px;white-space:nowrap" class="ft034">Bartonella on the List of Prokaryotic Names with Standing in&#160;</p>
<p style="position:absolute;top:359px;left:108px;white-space:nowrap" class="ft034">Nomenclature</p>
<p style="position:absolute;top:359px;left:206px;white-space:nowrap" class="ft013">); fourteen&#160;of these&#160;</p>
<p style="position:absolute;top:359px;left:341px;white-space:nowrap" class="ft019"><i>Bartonella</i></p>
<p style="position:absolute;top:359px;left:414px;white-space:nowrap" class="ft013">&#160;species have been implicated in&#160;human infections.&#160;</p>
<p style="position:absolute;top:396px;left:108px;white-space:nowrap" class="ft013">BA most often occurs late in HIV&#160;infection</p>
<p style="position:absolute;top:395px;left:406px;white-space:nowrap" class="ft038">2</p>
<p style="position:absolute;top:396px;left:412px;white-space:nowrap" class="ft013">&#160;in patients with median CD4 T lymphocyte&#160;(CD4) cell&#160;</p>
<p style="position:absolute;top:416px;left:108px;white-space:nowrap" class="ft013">counts &lt;50 cells/mm</p>
<p style="position:absolute;top:414px;left:252px;white-space:nowrap" class="ft038">3</p>
<p style="position:absolute;top:416px;left:257px;white-space:nowrap" class="ft013">. In&#160;people with&#160;HIV,&#160;bartonellosis is often&#160;a chronic illness, lasting&#160;for months&#160;</p>
<p style="position:absolute;top:436px;left:108px;white-space:nowrap" class="ft032">to more than a year, with&#160;BA lesions&#160;and intermittent bacteremia. Development&#160;of BA lesions caused&#160;<br/>by&#160;</p>
<p style="position:absolute;top:455px;left:130px;white-space:nowrap" class="ft019"><i>B. henselae</i></p>
<p style="position:absolute;top:455px;left:209px;white-space:nowrap" class="ft013">&#160;is statistically linked to cat&#160;exposure&#160;in people&#160;with HIV.</p>
<p style="position:absolute;top:454px;left:606px;white-space:nowrap" class="ft038">2</p>
<p style="position:absolute;top:455px;left:612px;white-space:nowrap" class="ft013">&#160;In contrast, BA caused by&#160;</p>
<p style="position:absolute;top:475px;left:108px;white-space:nowrap" class="ft019"><i>B. quintana&#160;</i></p>
<p style="position:absolute;top:475px;left:193px;white-space:nowrap" class="ft013">is associated&#160;with body louse infestation and homelessness.</p>
<p style="position:absolute;top:474px;left:603px;white-space:nowrap" class="ft038">2</p>
<p style="position:absolute;top:475px;left:609px;white-space:nowrap" class="ft013">&#160;The&#160;body louse&#160;serves as&#160;</p>
<p style="position:absolute;top:495px;left:108px;white-space:nowrap" class="ft013">the&#160;vector of&#160;</p>
<p style="position:absolute;top:495px;left:199px;white-space:nowrap" class="ft019"><i>B.</i></p>
<p style="position:absolute;top:495px;left:214px;white-space:nowrap" class="ft013">&#160;</p>
<p style="position:absolute;top:495px;left:219px;white-space:nowrap" class="ft019"><i>quintana</i></p>
<p style="position:absolute;top:495px;left:280px;white-space:nowrap" class="ft013">&#160;to humans. To avoid exposure to&#160;</p>
<p style="position:absolute;top:495px;left:515px;white-space:nowrap" class="ft019"><i>B. quintana</i></p>
<p style="position:absolute;top:495px;left:595px;white-space:nowrap" class="ft013">, people with HIV should&#160;</p>
<p style="position:absolute;top:515px;left:108px;white-space:nowrap" class="ft032">avoid body lice exposure&#160;and have&#160;prompt&#160;eradication of lice if infestation occurs. The cat&#160;flea&#160;is the&#160;<br/>vector of&#160;</p>
<p style="position:absolute;top:535px;left:174px;white-space:nowrap" class="ft019"><i>B.</i></p>
<p style="position:absolute;top:535px;left:189px;white-space:nowrap" class="ft013">&#160;</p>
<p style="position:absolute;top:535px;left:193px;white-space:nowrap" class="ft019"><i>henselae</i></p>
<p style="position:absolute;top:535px;left:254px;white-space:nowrap" class="ft013">&#160;in cats. Cats are&#160;the&#160;most common vector (via&#160;a scratch) responsible for&#160;</p>
<p style="position:absolute;top:555px;left:108px;white-space:nowrap" class="ft013">transmitting&#160;</p>
<p style="position:absolute;top:555px;left:196px;white-space:nowrap" class="ft019"><i>B.</i></p>
<p style="position:absolute;top:555px;left:210px;white-space:nowrap" class="ft013">&#160;</p>
<p style="position:absolute;top:555px;left:215px;white-space:nowrap" class="ft019"><i>henselae&#160;</i></p>
<p style="position:absolute;top:555px;left:279px;white-space:nowrap" class="ft013">to humans, most likely when their claws become&#160;contaminated with feces&#160;</p>
<p style="position:absolute;top:574px;left:108px;white-space:nowrap" class="ft013">from&#160;</p>
<p style="position:absolute;top:574px;left:146px;white-space:nowrap" class="ft019"><i>B.</i></p>
<p style="position:absolute;top:574px;left:161px;white-space:nowrap" class="ft013">&#160;</p>
<p style="position:absolute;top:574px;left:165px;white-space:nowrap" class="ft019"><i>henselae</i></p>
<p style="position:absolute;top:574px;left:225px;white-space:nowrap" class="ft013">-infected fleas. In some&#160;areas of the United States, the prevalence of&#160;</p>
<p style="position:absolute;top:574px;left:699px;white-space:nowrap" class="ft019"><i>B.</i></p>
<p style="position:absolute;top:574px;left:714px;white-space:nowrap" class="ft013">&#160;</p>
<p style="position:absolute;top:574px;left:718px;white-space:nowrap" class="ft019"><i>henselae</i></p>
<p style="position:absolute;top:574px;left:778px;white-space:nowrap" class="ft013">&#160;</p>
<p style="position:absolute;top:594px;left:108px;white-space:nowrap" class="ft013">bacteremia in pet cats approaches 50%;</p>
<p style="position:absolute;top:593px;left:381px;white-space:nowrap" class="ft038">3</p>
<p style="position:absolute;top:594px;left:386px;white-space:nowrap" class="ft013">&#160;infection is more common among&#160;kittens and feral&#160;cat&#160;</p>
<p style="position:absolute;top:614px;left:108px;white-space:nowrap" class="ft032">populations.&#160;Controlling cat&#160;flea infestation and avoiding cat scratches are therefore critical&#160;strategies&#160;<br/>for preventing&#160;</p>
<p style="position:absolute;top:634px;left:210px;white-space:nowrap" class="ft019"><i>B. henselae</i></p>
<p style="position:absolute;top:634px;left:290px;white-space:nowrap" class="ft013">&#160;infections in people with HIV.&#160;</p>
<p style="position:absolute;top:671px;left:108px;white-space:nowrap" class="ft026"><b>Clinical Manifestations&#160;</b></p>
<p style="position:absolute;top:712px;left:108px;white-space:nowrap" class="ft032">BA lesions&#160;have&#160;been associated with nearly every&#160;organ system, but cutaneous lesions are the most&#160;<br/>readily identified. These lesions can be&#160;clinically indistinguishable&#160;from Kaposi sarcoma, pyogenic&#160;<br/>granuloma, and other skin&#160;conditions.&#160;BA also can&#160;cause subcutaneous nodules. Osteomyelitis is&#160;<br/>usually caused by&#160;</p>
<p style="position:absolute;top:772px;left:235px;white-space:nowrap" class="ft019"><i>B. quintana</i></p>
<p style="position:absolute;top:772px;left:315px;white-space:nowrap" class="ft013">, and only&#160;</p>
<p style="position:absolute;top:772px;left:388px;white-space:nowrap" class="ft019"><i>B. henselae</i></p>
<p style="position:absolute;top:772px;left:468px;white-space:nowrap" class="ft013">&#160;causes bacillary peliosis hepatis.</p>
<p style="position:absolute;top:771px;left:696px;white-space:nowrap" class="ft038">2</p>
<p style="position:absolute;top:772px;left:702px;white-space:nowrap" class="ft013">&#160;Although&#160;</p>
<p style="position:absolute;top:792px;left:108px;white-space:nowrap" class="ft032">isolated organs can appear to be&#160;the&#160;principal focus of disease,&#160;BA represents a hematogenously&#160;<br/>disseminated infection, and systemic&#160;symptoms of&#160;fever, night sweats, and&#160;weight loss&#160;often&#160;<br/>accompany BA.&#160;</p>
<p style="position:absolute;top:831px;left:223px;white-space:nowrap" class="ft019"><i>Bartonella</i></p>
<p style="position:absolute;top:831px;left:297px;white-space:nowrap" class="ft013">&#160;infection is a major cause of unexplained fever in patients with advanced&#160;</p>
<p style="position:absolute;top:851px;left:108px;white-space:nowrap" class="ft032">HIV&#160;and should be&#160;considered in the differential diagnosis of patients with CD4 counts&#160;<br/>&lt;100 cells/mm</p>
<p style="position:absolute;top:870px;left:211px;white-space:nowrap" class="ft038">3</p>
<p style="position:absolute;top:871px;left:217px;white-space:nowrap" class="ft013">&#160;and fever.</p>
<p style="position:absolute;top:870px;left:290px;white-space:nowrap" class="ft038">4</p>
<p style="position:absolute;top:871px;left:300px;white-space:nowrap" class="ft019"><i>Bartonella</i></p>
<p style="position:absolute;top:871px;left:378px;white-space:nowrap" class="ft013">is&#160;a frequent&#160;cause of culture-negative endocarditis in&#160;</p>
<p style="position:absolute;top:891px;left:108px;white-space:nowrap" class="ft013">immunocompetent&#160;and immunocompromised humans and is most commonly caused by&#160;</p>
<p style="position:absolute;top:891px;left:718px;white-space:nowrap" class="ft019"><i>B. quintana</i></p>
<p style="position:absolute;top:891px;left:798px;white-space:nowrap" class="ft013">,&#160;</p>
<p style="position:absolute;top:911px;left:108px;white-space:nowrap" class="ft013">less&#160;frequently by&#160;</p>
<p style="position:absolute;top:911px;left:235px;white-space:nowrap" class="ft019"><i>B. henselae</i></p>
<p style="position:absolute;top:911px;left:314px;white-space:nowrap" class="ft013">, and rarely by other&#160;</p>
<p style="position:absolute;top:911px;left:458px;white-space:nowrap" class="ft019"><i>Bartonella&#160;</i></p>
<p style="position:absolute;top:911px;left:536px;white-space:nowrap" class="ft013">species</p>
<p style="position:absolute;top:911px;left:586px;white-space:nowrap" class="ft019"><i>.</i></p>
<p style="position:absolute;top:909px;left:590px;white-space:nowrap" class="ft038">5</p>
<p style="position:absolute;top:911px;left:596px;white-space:nowrap" class="ft013">&#160;Immune complex disease&#160;</p>
<p style="position:absolute;top:931px;left:108px;white-space:nowrap" class="ft013">(such as&#160;glomerulonephritis) may complicate&#160;endocarditis or other systemic&#160;</p>
<p style="position:absolute;top:931px;left:635px;white-space:nowrap" class="ft019"><i>Bartonella</i></p>
<p style="position:absolute;top:931px;left:709px;white-space:nowrap" class="ft013">&#160;infections;&#160;</p>
<p style="position:absolute;top:950px;left:108px;white-space:nowrap" class="ft032">assessment&#160;for immune&#160;complex formation may be&#160;warranted in&#160;such cases&#160;so that nephrotoxic&#160;<br/>agents can be avoided.</p>
<p style="position:absolute;top:967px;left:264px;white-space:nowrap" class="ft029"><i><b>&#160;</b></i></p>
</div>
<!-- Page 40 -->
<a name="40"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}	.ft081{font-size:17px;font-family:KPYRPS+Tinos;color:#005299;}
-->
</style>
<div id="page40-div" style="position:relative;width:917px;height:1187px;">
<p style="position:absolute;top:1128px;left:108px;white-space:nowrap" class="ft024"><i>Guidelines for the Prevention and Treatment&#160;of&#160;Opportunistic&#160;Infections in Adults&#160;and Adolescents&#160;With HIV&#160;</i></p>
<p style="position:absolute;top:1128px;left:790px;white-space:nowrap" class="ft024"><i>C-2&#160;</i></p>
<p style="position:absolute;top:108px;left:108px;white-space:nowrap" class="ft026"><b>Diagnosis&#160;</b></p>
<p style="position:absolute;top:150px;left:108px;white-space:nowrap" class="ft013">Diagnosis&#160;of&#160;BA can be confirmed by&#160;histopathologic&#160;examination of biopsied tissue.</p>
<p style="position:absolute;top:149px;left:699px;white-space:nowrap" class="ft038">6</p>
<p style="position:absolute;top:150px;left:705px;white-space:nowrap" class="ft013">&#160;BA lesions&#160;</p>
<p style="position:absolute;top:170px;left:108px;white-space:nowrap" class="ft032">are characterized by vascular proliferation, and a&#160;modified silver stain (such as Warthin-Starry stain)&#160;<br/>usually demonstrates numerous bacilli. Tissue Gram&#160;staining and acid-fast staining are negative.&#160;</p>
<p style="position:absolute;top:227px;left:108px;white-space:nowrap" class="ft032">A well-characterized indirect&#160;fluorescent&#160;antibody (IFA)&#160;serologic&#160;test was developed at&#160;the&#160;Centers&#160;<br/>for Disease&#160;Control&#160;and&#160;Prevention (CDC)</p>
<p style="position:absolute;top:245px;left:403px;white-space:nowrap" class="ft038">7</p>
<p style="position:absolute;top:247px;left:408px;white-space:nowrap" class="ft013">&#160;and is&#160;available at&#160;the&#160;CDC&#160;</p>
<p style="position:absolute;top:247px;left:606px;white-space:nowrap" class="ft034">Infectious Diseases&#160;</p>
<p style="position:absolute;top:266px;left:108px;white-space:nowrap" class="ft034">Laboratories</p>
<p style="position:absolute;top:266px;left:195px;white-space:nowrap" class="ft013">.&#160;In addition,&#160;several&#160;private&#160;laboratories offer IFA&#160;serological&#160;testing, but&#160;the&#160;</p>
<p style="position:absolute;top:286px;left:108px;white-space:nowrap" class="ft032">performance&#160;characteristics of these tests have not&#160;been validated&#160;for people with HIV. In&#160;<br/>immunocompetent patients, anti-</p>
<p style="position:absolute;top:306px;left:335px;white-space:nowrap" class="ft019"><i>Bartonella</i></p>
<p style="position:absolute;top:306px;left:409px;white-space:nowrap" class="ft013">&#160;antibodies might not&#160;be detectable for 6 weeks after&#160;</p>
<p style="position:absolute;top:326px;left:108px;white-space:nowrap" class="ft013">acute infection; in contrast, by the time&#160;</p>
<p style="position:absolute;top:326px;left:382px;white-space:nowrap" class="ft019"><i>Bartonella</i></p>
<p style="position:absolute;top:326px;left:456px;white-space:nowrap" class="ft013">&#160;infection is suspected in patients with late-stage&#160;</p>
<p style="position:absolute;top:346px;left:108px;white-space:nowrap" class="ft013">HIV&#160;infection, they usually have been&#160;infected with&#160;</p>
<p style="position:absolute;top:346px;left:469px;white-space:nowrap" class="ft019"><i>Bartonella</i></p>
<p style="position:absolute;top:346px;left:543px;white-space:nowrap" class="ft013">&#160;for months or&#160;even &gt;1 year.&#160;</p>
<p style="position:absolute;top:366px;left:108px;white-space:nowrap" class="ft013">However, as&#160;many as 25% of&#160;</p>
<p style="position:absolute;top:366px;left:314px;white-space:nowrap" class="ft019"><i>Bartonella</i></p>
<p style="position:absolute;top:366px;left:388px;white-space:nowrap" class="ft013">&#160;culture-positive patients never develop antibodies in the&#160;</p>
<p style="position:absolute;top:385px;left:108px;white-space:nowrap" class="ft013">setting of advanced HIV&#160;infection.</p>
<p style="position:absolute;top:384px;left:347px;white-space:nowrap" class="ft038">4</p>
<p style="position:absolute;top:385px;left:353px;white-space:nowrap" class="ft013">&#160;In&#160;those patients who&#160;do develop anti-</p>
<p style="position:absolute;top:385px;left:620px;white-space:nowrap" class="ft019"><i>Bartonella</i></p>
<p style="position:absolute;top:385px;left:694px;white-space:nowrap" class="ft013">&#160;antibodies,&#160;</p>
<p style="position:absolute;top:405px;left:108px;white-space:nowrap" class="ft013">monitoring of antibody levels can be useful in following treatment response&#160;of&#160;</p>
<p style="position:absolute;top:405px;left:654px;white-space:nowrap" class="ft019"><i>Bartonella</i></p>
<p style="position:absolute;top:405px;left:727px;white-space:nowrap" class="ft013">&#160;infection&#160;</p>
<p style="position:absolute;top:425px;left:108px;white-space:nowrap" class="ft013">to antibiotics, reflecting resolution</p>
<p style="position:absolute;top:424px;left:346px;white-space:nowrap" class="ft038">8</p>
<p style="position:absolute;top:425px;left:351px;white-space:nowrap" class="ft013">&#160;or&#160;recrudescence. Because of interlaboratory variability,&#160;</p>
<p style="position:absolute;top:445px;left:108px;white-space:nowrap" class="ft032">longitudinal&#160;testing should be conducted at the same laboratory to enable direct&#160;comparison of titers&#160;<br/>over time.&#160;</p>
<p style="position:absolute;top:502px;left:108px;white-space:nowrap" class="ft013">Because of their fastidious nature,</p>
<p style="position:absolute;top:502px;left:343px;white-space:nowrap" class="ft019"><i>&#160;Bartonella&#160;</i></p>
<p style="position:absolute;top:502px;left:425px;white-space:nowrap" class="ft013">organisms can be isolated only&#160;with difficulty from&#160;</p>
<p style="position:absolute;top:522px;left:108px;white-space:nowrap" class="ft032">blood (drawn into ethylenediaminetetraacetic acid [EDTA] tubes, centrifuged, and then plated&#160;<br/>directly onto fresh chocolate agar).&#160;</p>
<p style="position:absolute;top:542px;left:353px;white-space:nowrap" class="ft019"><i>Bartonella&#160;</i></p>
<p style="position:absolute;top:542px;left:431px;white-space:nowrap" class="ft013">has&#160;been cultured directly from&#160;tissue in only a&#160;few&#160;</p>
<p style="position:absolute;top:561px;left:108px;white-space:nowrap" class="ft013">laboratories</p>
<p style="position:absolute;top:561px;left:189px;white-space:nowrap" class="ft019"><i>.</i></p>
<p style="position:absolute;top:560px;left:194px;white-space:nowrap" class="ft038">2</p>
<p style="position:absolute;top:561px;left:199px;white-space:nowrap" class="ft013">&#160;Removing samples from&#160;blood culture bottles after 8 days of incubation, followed by&#160;</p>
<p style="position:absolute;top:581px;left:108px;white-space:nowrap" class="ft013">staining with acridine&#160;orange, has facilitated identification and subsequent&#160;culture of&#160;</p>
<p style="position:absolute;top:581px;left:695px;white-space:nowrap" class="ft019"><i>Bartonella</i></p>
<p style="position:absolute;top:581px;left:768px;white-space:nowrap" class="ft013">&#160;</p>
<p style="position:absolute;top:601px;left:108px;white-space:nowrap" class="ft013">species.</p>
<p style="position:absolute;top:600px;left:162px;white-space:nowrap" class="ft038">9</p>
<p style="position:absolute;top:601px;left:172px;white-space:nowrap" class="ft013">Additionally, the CDC&#160;can&#160;perform&#160;polymerase chain reaction&#160;(PCR) amplification with</p>
<p style="position:absolute;top:621px;left:108px;white-space:nowrap" class="ft013">universal and/or specific&#160;primers&#160;to detect&#160;</p>
<p style="position:absolute;top:621px;left:402px;white-space:nowrap" class="ft019"><i>Bartonella</i></p>
<p style="position:absolute;top:621px;left:475px;white-space:nowrap" class="ft013">&#160;in EDTA&#160;blood samples (</p>
<p style="position:absolute;top:621px;left:657px;white-space:nowrap" class="ft034">see&#160;</p>
<p style="position:absolute;top:621px;left:684px;white-space:nowrap" class="ft081"><i>Bartonella&#160;</i></p>
<p style="position:absolute;top:641px;left:108px;white-space:nowrap" class="ft081"><i>quintana</i></p>
<p style="position:absolute;top:641px;left:169px;white-space:nowrap" class="ft034">&#160;Molecular Detection</p>
<p style="position:absolute;top:641px;left:316px;white-space:nowrap" class="ft013">); these molecular detection tests also are increasingly available&#160;</p>
<p style="position:absolute;top:661px;left:108px;white-space:nowrap" class="ft013">through private laboratories. Finally,&#160;molecular detection of&#160;</p>
<p style="position:absolute;top:661px;left:525px;white-space:nowrap" class="ft019"><i>Bartonella</i></p>
<p style="position:absolute;top:661px;left:598px;white-space:nowrap" class="ft013">&#160;in BA skin lesions or other&#160;</p>
<p style="position:absolute;top:680px;left:108px;white-space:nowrap" class="ft013">vascular lesions, lymph nodes, or resected cardiac&#160;valves from&#160;unfixed tissue biopsy samples (at the&#160;</p>
<p style="position:absolute;top:700px;left:108px;white-space:nowrap" class="ft034">University of&#160;Washington</p>
<p style="position:absolute;top:700px;left:287px;white-space:nowrap" class="ft013">) or from formalin-fixed tissue (at the&#160;</p>
<p style="position:absolute;top:700px;left:550px;white-space:nowrap" class="ft034">CDC Infectious Disease&#160;Pathology&#160;</p>
<p style="position:absolute;top:720px;left:108px;white-space:nowrap" class="ft034">Branch</p>
<p style="position:absolute;top:720px;left:158px;white-space:nowrap" class="ft013">) can&#160;be performed.</p>
<p style="position:absolute;top:719px;left:293px;white-space:nowrap" class="ft038">8,10</p>
<p style="position:absolute;top:720px;left:313px;white-space:nowrap" class="ft013">&#160;</p>
<p style="position:absolute;top:720px;left:317px;white-space:nowrap" class="ft019"><i>Bartonella&#160;</i></p>
<p style="position:absolute;top:720px;left:395px;white-space:nowrap" class="ft013">species may also be&#160;detected from&#160;blood or plasma using&#160;</p>
<p style="position:absolute;top:740px;left:108px;white-space:nowrap" class="ft013">metagenomic&#160;next&#160;generation sequencing.</p>
<p style="position:absolute;top:739px;left:398px;white-space:nowrap" class="ft038">11-13</p>
<p style="position:absolute;top:740px;left:425px;white-space:nowrap" class="ft013">&#160;Clinicians should&#160;be aware that&#160;results from&#160;the&#160;CDC&#160;</p>
<p style="position:absolute;top:760px;left:108px;white-space:nowrap" class="ft032">may take longer—several&#160;weeks to months—for&#160;serologic and molecular testing, respectively,&#160;<br/>compared with some private laboratories. A&#160;notable&#160;update was&#160;published in&#160;the&#160;</p>
<p style="position:absolute;top:780px;left:666px;white-space:nowrap" class="ft034">2023 Duke-ISCVID&#160;</p>
<p style="position:absolute;top:799px;left:108px;white-space:nowrap" class="ft034">Criteria&#160;for Infective Endocarditis</p>
<p style="position:absolute;top:799px;left:342px;white-space:nowrap" class="ft013">, indicating that&#160;an IFA immunoglobulin G&#160;(IgG)&#160;</p>
<p style="position:absolute;top:799px;left:686px;white-space:nowrap" class="ft018">titer of&#160;</p>
<p style="position:absolute;top:799px;left:736px;white-space:nowrap" class="ft069">≥</p>
<p style="position:absolute;top:799px;left:746px;white-space:nowrap" class="ft018">1:800 for&#160;</p>
<p style="position:absolute;top:819px;left:108px;white-space:nowrap" class="ft019"><i>B. quintana</i></p>
<p style="position:absolute;top:819px;left:189px;white-space:nowrap" class="ft013">&#160;or&#160;</p>
<p style="position:absolute;top:819px;left:211px;white-space:nowrap" class="ft019"><i>B. henselae</i></p>
<p style="position:absolute;top:819px;left:291px;white-space:nowrap" class="ft013">&#160;or identification of a&#160;</p>
<p style="position:absolute;top:819px;left:441px;white-space:nowrap" class="ft019"><i>Bartonella</i></p>
<p style="position:absolute;top:819px;left:514px;white-space:nowrap" class="ft013">&#160;</p>
<p style="position:absolute;top:819px;left:519px;white-space:nowrap" class="ft019"><i>sp.</i></p>
<p style="position:absolute;top:819px;left:538px;white-space:nowrap" class="ft013">&#160;by PCR or&#160;other nucleic acid–based&#160;</p>
<p style="position:absolute;top:839px;left:108px;white-space:nowrap" class="ft032">techniques (including metagenomic&#160;sequencing) from blood are&#160;now considered major criteria&#160;for the&#160;<br/>diagnosis of&#160;</p>
<p style="position:absolute;top:859px;left:196px;white-space:nowrap" class="ft019"><i>Bartonella</i></p>
<p style="position:absolute;top:859px;left:270px;white-space:nowrap" class="ft013">&#160;endocarditis.</p>
<p style="position:absolute;top:858px;left:363px;white-space:nowrap" class="ft038">14</p>
<p style="position:absolute;top:859px;left:374px;white-space:nowrap" class="ft013">&#160;</p>
<p style="position:absolute;top:896px;left:108px;white-space:nowrap" class="ft032">In summary,&#160;diagnosis of&#160;bartonellosis&#160;may require&#160;multiple&#160;testing modalities, including serologic&#160;<br/>testing (which is the&#160;most&#160;accessible test, and when&#160;positive, is helpful both for diagnosis&#160;and&#160;<br/>subsequent monitoring of treatment&#160;response),&#160;histopathology,&#160;and, especially,&#160;molecular testing for&#160;<br/>biopsied or resected tissue&#160;(e.g.,</p>
<p style="position:absolute;top:956px;left:329px;white-space:nowrap" class="ft019"><i>&#160;</i></p>
<p style="position:absolute;top:956px;left:333px;white-space:nowrap" class="ft013">BA lesion tissue or&#160;heart valve tissue).&#160;</p>
<p style="position:absolute;top:992px;left:108px;white-space:nowrap" class="ft026"><b>Preventing&#160;Exposure&#160;</b></p>
<p style="position:absolute;top:1034px;left:108px;white-space:nowrap" class="ft032">People&#160;with&#160;HIV,&#160;specifically those who are severely immunocompromised (CD4 counts&#160;<br/>&lt;100 cells/mm</p>
<p style="position:absolute;top:1052px;left:211px;white-space:nowrap" class="ft038">3</p>
<p style="position:absolute;top:1054px;left:217px;white-space:nowrap" class="ft013">), are at high risk of&#160;severe disease&#160;when infected by&#160;</p>
<p style="position:absolute;top:1054px;left:582px;white-space:nowrap" class="ft019"><i>B.</i></p>
<p style="position:absolute;top:1054px;left:597px;white-space:nowrap" class="ft013">&#160;</p>
<p style="position:absolute;top:1054px;left:602px;white-space:nowrap" class="ft019"><i>quintana</i></p>
<p style="position:absolute;top:1054px;left:663px;white-space:nowrap" class="ft013">&#160;or&#160;</p>
<p style="position:absolute;top:1054px;left:686px;white-space:nowrap" class="ft019"><i>B.</i></p>
<p style="position:absolute;top:1054px;left:701px;white-space:nowrap" class="ft013">&#160;</p>
<p style="position:absolute;top:1054px;left:705px;white-space:nowrap" class="ft019"><i>henselae</i></p>
<p style="position:absolute;top:1054px;left:765px;white-space:nowrap" class="ft013">. The&#160;</p>
</div>
<!-- Page 41 -->
<a name="41"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}	.ft082{font-size:17px;font-family:TMWRTT+LiberationSansNarrow;color:#000000;}
-->
</style>
<div id="page41-div" style="position:relative;width:917px;height:1187px;">
<p style="position:absolute;top:1128px;left:108px;white-space:nowrap" class="ft024"><i>Guidelines for the Prevention and Treatment&#160;of&#160;Opportunistic&#160;Infections in Adults&#160;and Adolescents&#160;With HIV&#160;</i></p>
<p style="position:absolute;top:1128px;left:790px;white-space:nowrap" class="ft024"><i>C-3&#160;</i></p>
<p style="position:absolute;top:109px;left:108px;white-space:nowrap" class="ft013">major risk factors for acquisition of&#160;</p>
<p style="position:absolute;top:109px;left:357px;white-space:nowrap" class="ft019"><i>B. henselae</i></p>
<p style="position:absolute;top:109px;left:436px;white-space:nowrap" class="ft013">&#160;are&#160;contact&#160;with cats infested with fleas and&#160;</p>
<p style="position:absolute;top:129px;left:108px;white-space:nowrap" class="ft032">receiving cat&#160;scratches. Immunocompromised individuals should consider the potential risks of&#160;cat&#160;<br/>ownership&#160;</p>
<p style="position:absolute;top:148px;left:184px;white-space:nowrap" class="ft012"><b>(AIII).</b></p>
<p style="position:absolute;top:148px;left:233px;white-space:nowrap" class="ft013">&#160;People with HIV&#160;who&#160;want cats should acquire animals that&#160;are&#160;older than 1 year&#160;</p>
<p style="position:absolute;top:168px;left:108px;white-space:nowrap" class="ft013">of age and in&#160;good health&#160;</p>
<p style="position:absolute;top:168px;left:287px;white-space:nowrap" class="ft012"><b>(BII).</b></p>
<p style="position:absolute;top:168px;left:328px;white-space:nowrap" class="ft013">&#160;Cats should be acquired from a&#160;known environment, have a&#160;</p>
<p style="position:absolute;top:188px;left:108px;white-space:nowrap" class="ft032">documented health history, and be free of fleas. Stray cats and cats with flea infestation should be&#160;<br/>avoided. Declawing is not&#160;advised, but&#160;individuals with HIV should avoid rough play with cats and&#160;<br/>situations in which scratches are likely&#160;</p>
<p style="position:absolute;top:228px;left:379px;white-space:nowrap" class="ft012"><b>(AII).</b></p>
<p style="position:absolute;top:228px;left:421px;white-space:nowrap" class="ft013">&#160;People&#160;with HIV should avoid&#160;contact&#160;with flea feces&#160;</p>
<p style="position:absolute;top:248px;left:108px;white-space:nowrap" class="ft013">(i.e., flea dirt), and any cat-associated wound&#160;should be washed&#160;promptly with soap and&#160;water&#160;</p>
<p style="position:absolute;top:248px;left:759px;white-space:nowrap" class="ft012"><b>(BIII).</b></p>
<p style="position:absolute;top:248px;left:807px;white-space:nowrap" class="ft013">&#160;</p>
<p style="position:absolute;top:267px;left:108px;white-space:nowrap" class="ft032">Care of cats&#160;should include a&#160;comprehensive, ongoing flea-control&#160;program&#160;under the supervision of&#160;<br/>a veterinarian&#160;</p>
<p style="position:absolute;top:287px;left:207px;white-space:nowrap" class="ft012"><b>(BIII).</b></p>
<p style="position:absolute;top:287px;left:254px;white-space:nowrap" class="ft013">&#160;No&#160;evidence indicates any benefits to cats or their owners from routine culture&#160;</p>
<p style="position:absolute;top:307px;left:108px;white-space:nowrap" class="ft013">or serologic testing of the&#160;pet&#160;for&#160;</p>
<p style="position:absolute;top:307px;left:338px;white-space:nowrap" class="ft019"><i>Bartonella</i></p>
<p style="position:absolute;top:307px;left:412px;white-space:nowrap" class="ft013">&#160;infection or from antibiotic treatment of healthy,&#160;</p>
<p style="position:absolute;top:327px;left:108px;white-space:nowrap" class="ft013">serologically positive&#160;cats&#160;</p>
<p style="position:absolute;top:327px;left:291px;white-space:nowrap" class="ft012"><b>(BII).</b></p>
<p style="position:absolute;top:327px;left:332px;white-space:nowrap" class="ft013">&#160;The&#160;major risk factor for&#160;</p>
<p style="position:absolute;top:327px;left:511px;white-space:nowrap" class="ft019"><i>B. quintana</i></p>
<p style="position:absolute;top:327px;left:591px;white-space:nowrap" class="ft013">&#160;infection is body lice&#160;</p>
<p style="position:absolute;top:347px;left:108px;white-space:nowrap" class="ft032">infestation. People with HIV who are experiencing homelessness or are in marginal&#160;housing should&#160;<br/>be informed&#160;that body louse infestation can be associated with serious illness&#160;and should be provided&#160;<br/>with appropriate&#160;measures to eradicate body lice, if present&#160;</p>
<p style="position:absolute;top:386px;left:520px;white-space:nowrap" class="ft012"><b>(AII).</b></p>
<p style="position:absolute;top:386px;left:561px;white-space:nowrap" class="ft013">&#160;Regardless&#160;of CD4 count, people&#160;</p>
<p style="position:absolute;top:406px;left:108px;white-space:nowrap" class="ft013">with both HIV and solid organ transplantation may be&#160;at&#160;risk of&#160;developing more severe&#160;</p>
<p style="position:absolute;top:406px;left:719px;white-space:nowrap" class="ft019"><i>Bartonella</i></p>
<p style="position:absolute;top:406px;left:793px;white-space:nowrap" class="ft013">&#160;</p>
<p style="position:absolute;top:426px;left:108px;white-space:nowrap" class="ft013">infections, similar to transplant&#160;recipients without&#160;HIV.</p>
<p style="position:absolute;top:425px;left:490px;white-space:nowrap" class="ft038">15</p>
<p style="position:absolute;top:426px;left:501px;white-space:nowrap" class="ft013">&#160;</p>
<p style="position:absolute;top:463px;left:108px;white-space:nowrap" class="ft026"><b>Preventing&#160;Disease&#160;</b></p>
<p style="position:absolute;top:505px;left:108px;white-space:nowrap" class="ft013">Primary chemoprophylaxis for&#160;</p>
<p style="position:absolute;top:505px;left:324px;white-space:nowrap" class="ft019"><i>Bartonella</i></p>
<p style="position:absolute;top:505px;left:398px;white-space:nowrap" class="ft013">-associated disease is&#160;not recommended&#160;</p>
<p style="position:absolute;top:505px;left:677px;white-space:nowrap" class="ft012"><b>(BIII).</b></p>
<p style="position:absolute;top:505px;left:724px;white-space:nowrap" class="ft013">&#160;However,&#160;</p>
<p style="position:absolute;top:524px;left:108px;white-space:nowrap" class="ft013">note&#160;that&#160;in a&#160;retrospective case-control study, use of a macrolide (such as&#160;for&#160;</p>
<p style="position:absolute;top:524px;left:645px;white-space:nowrap" class="ft019"><i>Mycobacterium avium</i></p>
<p style="position:absolute;top:524px;left:800px;white-space:nowrap" class="ft013">&#160;</p>
<p style="position:absolute;top:544px;left:108px;white-space:nowrap" class="ft013">complex prophylaxis) was protective&#160;against developing&#160;</p>
<p style="position:absolute;top:544px;left:502px;white-space:nowrap" class="ft019"><i>Bartonella</i></p>
<p style="position:absolute;top:544px;left:575px;white-space:nowrap" class="ft013">&#160;infection.</p>
<p style="position:absolute;top:543px;left:645px;white-space:nowrap" class="ft038">2</p>
<p style="position:absolute;top:544px;left:651px;white-space:nowrap" class="ft013">&#160;</p>
<p style="position:absolute;top:581px;left:108px;white-space:nowrap" class="ft026"><b>Treating Disease&#160;</b></p>
<p style="position:absolute;top:633px;left:283px;white-space:nowrap" class="ft02"><b>Recommendations for Treating&#160;</b></p>
<p style="position:absolute;top:633px;left:495px;white-space:nowrap" class="ft082"><i><b>Bartonella</b></i></p>
<p style="position:absolute;top:633px;left:565px;white-space:nowrap" class="ft02"><b>&#160;Infections</b></p>
<p style="position:absolute;top:634px;left:636px;white-space:nowrap" class="ft042"><b>&#160;</b></p>
<p style="position:absolute;top:667px;left:117px;white-space:nowrap" class="ft024"><i>Preferred&#160;Therapy&#160;&#160;</i></p>
<p style="position:absolute;top:693px;left:117px;white-space:nowrap" class="ft041">For&#160;Cat Scratch&#160;Disease, Bacillary&#160;Angiomatosis,&#160;Peliosis&#160;Hepatis,&#160;Bacteremia, and Osteomyelitis&#160;</p>
<p style="position:absolute;top:721px;left:133px;white-space:nowrap" class="ft062">o</p>
<p style="position:absolute;top:720px;left:142px;white-space:nowrap" class="ft057">&#160;</p>
<p style="position:absolute;top:719px;left:149px;white-space:nowrap" class="ft041">Doxycycline 100&#160;mg PO&#160;or IV&#160;every&#160;12&#160;hours&#160;</p>
<p style="position:absolute;top:719px;left:398px;white-space:nowrap" class="ft042"><b>(AII),</b></p>
<p style="position:absolute;top:719px;left:425px;white-space:nowrap" class="ft041">&#160;</p>
<p style="position:absolute;top:719px;left:429px;white-space:nowrap" class="ft024"><i>or</i></p>
<p style="position:absolute;top:719px;left:440px;white-space:nowrap" class="ft041">&#160;</p>
<p style="position:absolute;top:747px;left:133px;white-space:nowrap" class="ft062">o</p>
<p style="position:absolute;top:746px;left:142px;white-space:nowrap" class="ft057">&#160;</p>
<p style="position:absolute;top:745px;left:149px;white-space:nowrap" class="ft041">Erythromycin&#160;500 mg&#160;PO or IV every&#160;6 hours&#160;</p>
<p style="position:absolute;top:745px;left:398px;white-space:nowrap" class="ft042"><b>(AII)</b></p>
<p style="position:absolute;top:745px;left:421px;white-space:nowrap" class="ft041">&#160;</p>
<p style="position:absolute;top:772px;left:117px;white-space:nowrap" class="ft041">For&#160;Infections Involving the CNS&#160;</p>
<p style="position:absolute;top:799px;left:133px;white-space:nowrap" class="ft062">o</p>
<p style="position:absolute;top:798px;left:142px;white-space:nowrap" class="ft057">&#160;</p>
<p style="position:absolute;top:798px;left:149px;white-space:nowrap" class="ft041">Doxycycline 100&#160;mg PO&#160;or IV&#160;every&#160;12&#160;hours&#160;+/–&#160;rifampin&#160;300&#160;mg PO or&#160;IV&#160;every&#160;12&#160;hours&#160;</p>
<p style="position:absolute;top:798px;left:646px;white-space:nowrap" class="ft042"><b>(AIII)</b></p>
<p style="position:absolute;top:798px;left:673px;white-space:nowrap" class="ft041">&#160;</p>
<p style="position:absolute;top:824px;left:117px;white-space:nowrap" class="ft041">For&#160;Confirmed&#160;Bartonella&#160;Endocarditis&#160;</p>
<p style="position:absolute;top:852px;left:133px;white-space:nowrap" class="ft062">o</p>
<p style="position:absolute;top:851px;left:142px;white-space:nowrap" class="ft057">&#160;</p>
<p style="position:absolute;top:850px;left:149px;white-space:nowrap" class="ft041">(Doxycycline 100 mg IV&#160;every 12 hours&#160;+&#160;rifampin 300 mg&#160;IV&#160;or PO every&#160;12&#160;hours) for 6&#160;weeks,&#160;then&#160;continue&#160;with&#160;</p>
<p style="position:absolute;top:867px;left:150px;white-space:nowrap" class="ft041">doxycycline 100 mg IV&#160;or PO every&#160;12&#160;hours&#160;for</p>
<p style="position:absolute;top:867px;left:411px;white-space:nowrap" class="ft042"><b>&#160;</b></p>
<p style="position:absolute;top:867px;left:414px;white-space:nowrap" class="ft064">≥</p>
<p style="position:absolute;top:867px;left:422px;white-space:nowrap" class="ft065">3</p>
<p style="position:absolute;top:867px;left:429px;white-space:nowrap" class="ft041">&#160;months</p>
<p style="position:absolute;top:867px;left:473px;white-space:nowrap" class="ft042"><b>&#160;(BII),</b></p>
<p style="position:absolute;top:867px;left:504px;white-space:nowrap" class="ft041">&#160;</p>
<p style="position:absolute;top:867px;left:507px;white-space:nowrap" class="ft024"><i>or</i></p>
<p style="position:absolute;top:867px;left:518px;white-space:nowrap" class="ft042"><b>&#160;</b></p>
<p style="position:absolute;top:894px;left:117px;white-space:nowrap" class="ft041">For&#160;Other Severe Infections (Multifocal Disease or&#160;with Clinical&#160;Decompensation)&#160;</p>
<p style="position:absolute;top:921px;left:133px;white-space:nowrap" class="ft062">o</p>
<p style="position:absolute;top:920px;left:142px;white-space:nowrap" class="ft057">&#160;</p>
<p style="position:absolute;top:920px;left:150px;white-space:nowrap" class="ft041">Doxycycline 100&#160;mg PO&#160;or IV every&#160;12&#160;hours&#160;+&#160;rifampin 300 mg&#160;PO or IV every&#160;12 hours&#160;</p>
<p style="position:absolute;top:920px;left:636px;white-space:nowrap" class="ft042"><b>(BIII),&#160;</b></p>
<p style="position:absolute;top:920px;left:670px;white-space:nowrap" class="ft024"><i>or</i></p>
<p style="position:absolute;top:920px;left:681px;white-space:nowrap" class="ft041">&#160;</p>
<p style="position:absolute;top:948px;left:133px;white-space:nowrap" class="ft062">o</p>
<p style="position:absolute;top:947px;left:142px;white-space:nowrap" class="ft057">&#160;</p>
<p style="position:absolute;top:946px;left:150px;white-space:nowrap" class="ft041">Erythromycin&#160;500 mg&#160;PO or IV every&#160;6 hours&#160;+&#160;rifampin&#160;300 mg&#160;PO or IV every&#160;12&#160;hours&#160;</p>
<p style="position:absolute;top:946px;left:635px;white-space:nowrap" class="ft042"><b>(BIII)</b></p>
<p style="position:absolute;top:946px;left:662px;white-space:nowrap" class="ft041">&#160;</p>
<p style="position:absolute;top:978px;left:117px;white-space:nowrap" class="ft042"><b>Note:</b></p>
<p style="position:absolute;top:978px;left:149px;white-space:nowrap" class="ft041">&#160;IV therapy&#160;may be needed&#160;initially&#160;</p>
<p style="position:absolute;top:978px;left:340px;white-space:nowrap" class="ft042"><b>(AIII).&#160;</b></p>
<p style="position:absolute;top:1011px;left:117px;white-space:nowrap" class="ft024"><i>Alternative Therapy&#160;&#160;</i></p>
<p style="position:absolute;top:1037px;left:117px;white-space:nowrap" class="ft041">For&#160;Confirmed Bartonella Endocarditis&#160;</p>
</div>
<!-- Page 42 -->
<a name="42"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}	.ft083{font-size:15px;font-family:TMWRTT+LiberationSansNarrow;color:#000000;}
	.ft084{font-size:9px;font-family:QZSKMX+LiberationSansNarrow;color:#000000;}
-->
</style>
<div id="page42-div" style="position:relative;width:917px;height:1187px;">
<p style="position:absolute;top:1128px;left:108px;white-space:nowrap" class="ft024"><i>Guidelines for the Prevention and Treatment&#160;of&#160;Opportunistic&#160;Infections in Adults&#160;and Adolescents&#160;With HIV&#160;</i></p>
<p style="position:absolute;top:1128px;left:790px;white-space:nowrap" class="ft024"><i>C-4&#160;</i></p>
<p style="position:absolute;top:111px;left:133px;white-space:nowrap" class="ft062">o</p>
<p style="position:absolute;top:110px;left:142px;white-space:nowrap" class="ft057">&#160;</p>
<p style="position:absolute;top:110px;left:149px;white-space:nowrap" class="ft041">(Doxycycline 100 mg IV&#160;every 12 hours&#160;+ gentamicin&#160;1 mg/kg IV&#160;every&#160;8 hours) for 2 weeks, then&#160;continue&#160;with&#160;</p>
<p style="position:absolute;top:127px;left:149px;white-space:nowrap" class="ft041">doxycycline 100 mg IV&#160;or PO&#160;</p>
<p style="position:absolute;top:127px;left:312px;white-space:nowrap" class="ft065">every&#160;12&#160;hours&#160;for&#160;</p>
<p style="position:absolute;top:127px;left:414px;white-space:nowrap" class="ft064">≥</p>
<p style="position:absolute;top:127px;left:422px;white-space:nowrap" class="ft065">3</p>
<p style="position:absolute;top:127px;left:429px;white-space:nowrap" class="ft041">&#160;months&#160;</p>
<p style="position:absolute;top:127px;left:476px;white-space:nowrap" class="ft042"><b>(BII)</b></p>
<p style="position:absolute;top:127px;left:500px;white-space:nowrap" class="ft041">&#160;</p>
<p style="position:absolute;top:127px;left:503px;white-space:nowrap" class="ft042"><b>&#160;</b></p>
<p style="position:absolute;top:153px;left:117px;white-space:nowrap" class="ft041">For&#160;Bartonella&#160;Infections&#160;Other than Endocarditis&#160;or CNS Infections&#160;</p>
<p style="position:absolute;top:180px;left:117px;white-space:nowrap" class="ft030">•</p>
<p style="position:absolute;top:181px;left:124px;white-space:nowrap" class="ft057">&#160;</p>
<p style="position:absolute;top:181px;left:133px;white-space:nowrap" class="ft041">Azithromycin&#160;500 mg&#160;PO daily&#160;</p>
<p style="position:absolute;top:181px;left:301px;white-space:nowrap" class="ft042"><b>(BIII)</b></p>
<p style="position:absolute;top:181px;left:329px;white-space:nowrap" class="ft041">,&#160;</p>
<p style="position:absolute;top:181px;left:335px;white-space:nowrap" class="ft024"><i>or</i></p>
<p style="position:absolute;top:181px;left:346px;white-space:nowrap" class="ft041">&#160;</p>
<p style="position:absolute;top:207px;left:117px;white-space:nowrap" class="ft030">•</p>
<p style="position:absolute;top:208px;left:124px;white-space:nowrap" class="ft057">&#160;</p>
<p style="position:absolute;top:208px;left:133px;white-space:nowrap" class="ft041">Clarithromycin 500 mg&#160;PO twice&#160;daily&#160;</p>
<p style="position:absolute;top:208px;left:341px;white-space:nowrap" class="ft042"><b>(BIII)</b></p>
<p style="position:absolute;top:208px;left:368px;white-space:nowrap" class="ft024"><i>&#160;</i></p>
<p style="position:absolute;top:240px;left:117px;white-space:nowrap" class="ft024"><i>Duration of Therapy&#160;</i></p>
<p style="position:absolute;top:266px;left:117px;white-space:nowrap" class="ft030">•</p>
<p style="position:absolute;top:268px;left:124px;white-space:nowrap" class="ft057">&#160;</p>
<p style="position:absolute;top:267px;left:133px;white-space:nowrap" class="ft041">At&#160;least 3 months for all&#160;manifestations of&#160;</p>
<p style="position:absolute;top:267px;left:362px;white-space:nowrap" class="ft024"><i>Bartonella</i></p>
<p style="position:absolute;top:267px;left:417px;white-space:nowrap" class="ft041">&#160;infection in patients&#160;with&#160;HIV&#160;</p>
<p style="position:absolute;top:307px;left:349px;white-space:nowrap" class="ft02"><b>Long-Term Suppressive&#160;Therapy&#160;</b></p>
<p style="position:absolute;top:342px;left:117px;white-space:nowrap" class="ft024"><i>Indication for&#160;Long-Term Suppressive Therapy&#160;</i></p>
<p style="position:absolute;top:368px;left:117px;white-space:nowrap" class="ft041">If a&#160;relapse occurs&#160;after&#160;a&#160;</p>
<p style="position:absolute;top:368px;left:259px;white-space:nowrap" class="ft064">≥</p>
<p style="position:absolute;top:368px;left:267px;white-space:nowrap" class="ft041">3-month&#160;course of primary&#160;treatment:&#160;</p>
<p style="position:absolute;top:394px;left:117px;white-space:nowrap" class="ft030">•</p>
<p style="position:absolute;top:395px;left:124px;white-space:nowrap" class="ft057">&#160;</p>
<p style="position:absolute;top:395px;left:133px;white-space:nowrap" class="ft041">A macrolide or doxycycline&#160;as long as&#160;the&#160;CD4&#160;count remains &lt;200 cells/mm</p>
<p style="position:absolute;top:396px;left:551px;white-space:nowrap" class="ft058">3</p>
<p style="position:absolute;top:395px;left:556px;white-space:nowrap" class="ft041">&#160;</p>
<p style="position:absolute;top:395px;left:559px;white-space:nowrap" class="ft042"><b>(AIII)&#160;</b></p>
<p style="position:absolute;top:427px;left:117px;white-space:nowrap" class="ft024"><i>Indications&#160;for Discontinuing Long-Term Suppressive Therapy&#160;</i></p>
<p style="position:absolute;top:427px;left:457px;white-space:nowrap" class="ft083"><i><b>(CIII)</b></i></p>
<p style="position:absolute;top:427px;left:485px;white-space:nowrap" class="ft024"><i>&#160;</i></p>
<p style="position:absolute;top:454px;left:117px;white-space:nowrap" class="ft030">•</p>
<p style="position:absolute;top:455px;left:124px;white-space:nowrap" class="ft057">&#160;</p>
<p style="position:absolute;top:455px;left:133px;white-space:nowrap" class="ft041">Received at least 3–4 months&#160;of treatment,&#160;</p>
<p style="position:absolute;top:455px;left:371px;white-space:nowrap" class="ft024"><i>and</i></p>
<p style="position:absolute;top:455px;left:391px;white-space:nowrap" class="ft041">&#160;</p>
<p style="position:absolute;top:481px;left:117px;white-space:nowrap" class="ft030">•</p>
<p style="position:absolute;top:482px;left:124px;white-space:nowrap" class="ft057">&#160;</p>
<p style="position:absolute;top:482px;left:133px;white-space:nowrap" class="ft041">CD4 count&#160;&gt;200&#160;cells/mm</p>
<p style="position:absolute;top:483px;left:274px;white-space:nowrap" class="ft058">3</p>
<p style="position:absolute;top:483px;left:279px;white-space:nowrap" class="ft084"><i>&#160;</i></p>
<p style="position:absolute;top:482px;left:281px;white-space:nowrap" class="ft041">for at&#160;least 6 months&#160;</p>
<p style="position:absolute;top:508px;left:117px;white-space:nowrap" class="ft030">•</p>
<p style="position:absolute;top:509px;left:124px;white-space:nowrap" class="ft057">&#160;</p>
<p style="position:absolute;top:509px;left:133px;white-space:nowrap" class="ft041">Some specialists&#160;would discontinue&#160;therapy only&#160;if&#160;</p>
<p style="position:absolute;top:509px;left:410px;white-space:nowrap" class="ft024"><i>Bartonella</i></p>
<p style="position:absolute;top:509px;left:465px;white-space:nowrap" class="ft041">&#160;titers&#160;have also decreased by&#160;4-fold&#160;</p>
<p style="position:absolute;top:509px;left:666px;white-space:nowrap" class="ft042"><b>(CIII)</b></p>
<p style="position:absolute;top:509px;left:694px;white-space:nowrap" class="ft041">.&#160;</p>
<p style="position:absolute;top:549px;left:387px;white-space:nowrap" class="ft02"><b>Other&#160;Considerations&#160;</b></p>
<p style="position:absolute;top:583px;left:115px;white-space:nowrap" class="ft030">•</p>
<p style="position:absolute;top:585px;left:122px;white-space:nowrap" class="ft057">&#160;</p>
<p style="position:absolute;top:584px;left:131px;white-space:nowrap" class="ft041">Rifamycin&#160;class&#160;antibiotics&#160;are potent hepatic&#160;enzyme inducers&#160;and may lead to&#160;significant&#160;interaction&#160;with&#160;many drugs,&#160;</p>
<p style="position:absolute;top:601px;left:131px;white-space:nowrap" class="ft041">including ARV agents (see&#160;the Dosing&#160;Recommendations for Anti-TB Drugs table&#160;in the&#160;</p>
<p style="position:absolute;top:601px;left:610px;white-space:nowrap" class="ft043">Mycobacterium&#160;tuberculosis&#160;</p>
<p style="position:absolute;top:619px;left:131px;white-space:nowrap" class="ft043">Infection&#160;and Disease section</p>
<p style="position:absolute;top:619px;left:292px;white-space:nowrap" class="ft041">&#160;for&#160;dosing recommendations).</p>
<p style="position:absolute;top:619px;left:458px;white-space:nowrap" class="ft042"><b>&#160;</b></p>
<p style="position:absolute;top:645px;left:115px;white-space:nowrap" class="ft030">•</p>
<p style="position:absolute;top:646px;left:122px;white-space:nowrap" class="ft057">&#160;</p>
<p style="position:absolute;top:646px;left:131px;white-space:nowrap" class="ft041">In pregnancy, erythromycin or an&#160;alternative macrolide&#160;should be&#160;used as&#160;first-line therapy&#160;</p>
<p style="position:absolute;top:646px;left:625px;white-space:nowrap" class="ft042"><b>(AIII)</b></p>
<p style="position:absolute;top:646px;left:652px;white-space:nowrap" class="ft041">&#160;rather than tetracyclines&#160;</p>
<p style="position:absolute;top:663px;left:131px;white-space:nowrap" class="ft041">(such as doxycycline) due&#160;to toxicity profile; third-generation cephalosporins may&#160;have efficacy&#160;but are second&#160;line.</p>
<p style="position:absolute;top:663px;left:756px;white-space:nowrap" class="ft042"><b>&#160;</b></p>
<p style="position:absolute;top:663px;left:759px;white-space:nowrap" class="ft041">First-&#160;</p>
<p style="position:absolute;top:680px;left:131px;white-space:nowrap" class="ft041">and&#160;second-generation cephalosporins&#160;are not&#160;recommended because of&#160;their lack&#160;of&#160;efficacy&#160;against&#160;</p>
<p style="position:absolute;top:680px;left:688px;white-space:nowrap" class="ft024"><i>Bartonella</i></p>
<p style="position:absolute;top:680px;left:743px;white-space:nowrap" class="ft041">&#160;</p>
<p style="position:absolute;top:680px;left:747px;white-space:nowrap" class="ft042"><b>(AII).&#160;</b></p>
<p style="position:absolute;top:711px;left:108px;white-space:nowrap" class="ft042"><b>Key:</b></p>
<p style="position:absolute;top:711px;left:135px;white-space:nowrap" class="ft041">&#160;</p>
<p style="position:absolute;top:711px;left:138px;white-space:nowrap" class="ft065">+/</p>
<p style="position:absolute;top:711px;left:149px;white-space:nowrap" class="ft064">−</p>
<p style="position:absolute;top:711px;left:156px;white-space:nowrap" class="ft065">&#160;=&#160;with&#160;or without; ARV&#160;= antiretroviral; CD4 = CD4 T lymphocyte;&#160;CNS</p>
<p style="position:absolute;top:711px;left:542px;white-space:nowrap" class="ft041">&#160;</p>
<p style="position:absolute;top:711px;left:545px;white-space:nowrap" class="ft065">=</p>
<p style="position:absolute;top:711px;left:552px;white-space:nowrap" class="ft041">&#160;central nervous&#160;system;&#160;IV&#160;</p>
<p style="position:absolute;top:711px;left:704px;white-space:nowrap" class="ft065">=</p>
<p style="position:absolute;top:711px;left:711px;white-space:nowrap" class="ft041">&#160;intravenously;&#160;</p>
<p style="position:absolute;top:728px;left:108px;white-space:nowrap" class="ft065">PO = orally</p>
<p style="position:absolute;top:728px;left:169px;white-space:nowrap" class="ft041">&#160;</p>
<p style="position:absolute;top:763px;left:108px;white-space:nowrap" class="ft013">All patients with HIV and&#160;</p>
<p style="position:absolute;top:763px;left:291px;white-space:nowrap" class="ft019"><i>Bartonella</i></p>
<p style="position:absolute;top:763px;left:365px;white-space:nowrap" class="ft013">&#160;infection should receive antibiotic&#160;treatment&#160;</p>
<p style="position:absolute;top:763px;left:678px;white-space:nowrap" class="ft012"><b>(AII).</b></p>
<p style="position:absolute;top:763px;left:720px;white-space:nowrap" class="ft013">&#160;No&#160;</p>
<p style="position:absolute;top:783px;left:108px;white-space:nowrap" class="ft032">randomized, controlled clinical&#160;trials have&#160;evaluated antimicrobial treatment&#160;of bartonellosis in&#160;<br/>patients with HIV. Erythromycin and&#160;doxycycline&#160;have been used successfully to treat&#160;BA, peliosis&#160;<br/>hepatis, bacteremia, and osteomyelitis; either drug is considered&#160;first-line&#160;treatment for bartonellosis&#160;<br/>on the&#160;basis&#160;of reported experience in case series&#160;</p>
<p style="position:absolute;top:842px;left:448px;white-space:nowrap" class="ft012"><b>(AII).</b></p>
<p style="position:absolute;top:841px;left:490px;white-space:nowrap" class="ft038">1,2</p>
<p style="position:absolute;top:842px;left:504px;white-space:nowrap" class="ft013">&#160;Anecdotal and limited published case&#160;</p>
<p style="position:absolute;top:862px;left:108px;white-space:nowrap" class="ft013">reports</p>
<p style="position:absolute;top:861px;left:156px;white-space:nowrap" class="ft038">16</p>
<p style="position:absolute;top:862px;left:172px;white-space:nowrap" class="ft013">suggest that&#160;other macrolide&#160;antibiotics&#160;(such as azithromycin or clarithromycin) are&#160;</p>
<p style="position:absolute;top:882px;left:108px;white-space:nowrap" class="ft013">effective in treating&#160;</p>
<p style="position:absolute;top:882px;left:247px;white-space:nowrap" class="ft019"><i>Bartonella</i></p>
<p style="position:absolute;top:882px;left:321px;white-space:nowrap" class="ft013">&#160;infections in patients&#160;with HIV and may be better tolerated than&#160;</p>
<p style="position:absolute;top:902px;left:108px;white-space:nowrap" class="ft013">erythromycin;&#160;either of these can be&#160;an alternative therapy for&#160;</p>
<p style="position:absolute;top:902px;left:539px;white-space:nowrap" class="ft019"><i>Bartonella</i></p>
<p style="position:absolute;top:902px;left:612px;white-space:nowrap" class="ft013">&#160;infections (except&#160;for&#160;</p>
<p style="position:absolute;top:922px;left:108px;white-space:nowrap" class="ft013">endocarditis or central nervous system&#160;[CNS] infections)&#160;</p>
<p style="position:absolute;top:922px;left:505px;white-space:nowrap" class="ft012"><b>(BIII).</b></p>
<p style="position:absolute;top:922px;left:552px;white-space:nowrap" class="ft013">&#160;Therapy should be&#160;administered for&#160;</p>
<p style="position:absolute;top:941px;left:108px;white-space:nowrap" class="ft013">at&#160;least 3 months&#160;</p>
<p style="position:absolute;top:941px;left:229px;white-space:nowrap" class="ft012"><b>(AII).</b></p>
<p style="position:absolute;top:941px;left:270px;white-space:nowrap" class="ft013">&#160;Doxycycline, preferably in&#160;combination with a&#160;rifamycin class antibiotic, is&#160;</p>
<p style="position:absolute;top:961px;left:108px;white-space:nowrap" class="ft013">the&#160;treatment&#160;of choice for bartonellosis infection involving the&#160;CNS&#160;</p>
<p style="position:absolute;top:961px;left:587px;white-space:nowrap" class="ft012"><b>(AIII).</b></p>
<p style="position:absolute;top:961px;left:635px;white-space:nowrap" class="ft013">&#160;For severe&#160;</p>
<p style="position:absolute;top:961px;left:716px;white-space:nowrap" class="ft019"><i>Bartonella</i></p>
<p style="position:absolute;top:961px;left:790px;white-space:nowrap" class="ft013">&#160;</p>
<p style="position:absolute;top:981px;left:108px;white-space:nowrap" class="ft032">infections (i.e., patients with multifocal disease or evidence of clinical&#160;decompensation), combination&#160;<br/>therapy using erythromycin or doxycycline&#160;with a&#160;rifamycin class antibiotic is recommended&#160;</p>
<p style="position:absolute;top:1001px;left:753px;white-space:nowrap" class="ft012"><b>(BIII);</b></p>
<p style="position:absolute;top:1001px;left:802px;white-space:nowrap" class="ft013">&#160;</p>
<p style="position:absolute;top:1021px;left:108px;white-space:nowrap" class="ft013">intravenous therapy may&#160;be needed initially&#160;</p>
<p style="position:absolute;top:1021px;left:414px;white-space:nowrap" class="ft012"><b>(AIII).</b></p>
<p style="position:absolute;top:1021px;left:463px;white-space:nowrap" class="ft013">&#160;Treatment of&#160;</p>
<p style="position:absolute;top:1021px;left:561px;white-space:nowrap" class="ft019"><i>Bartonella</i></p>
<p style="position:absolute;top:1021px;left:635px;white-space:nowrap" class="ft013">&#160;endocarditis should&#160;</p>
<p style="position:absolute;top:1041px;left:108px;white-space:nowrap" class="ft013">include&#160;doxycycline&#160;with the addition of a rifamycin class antibiotic&#160;for a minimum&#160;of 6&#160;weeks&#160;</p>
<p style="position:absolute;top:1041px;left:769px;white-space:nowrap" class="ft012"><b>(BII).</b></p>
<p style="position:absolute;top:1041px;left:809px;white-space:nowrap" class="ft013">&#160;</p>
<p style="position:absolute;top:1060px;left:108px;white-space:nowrap" class="ft013">Doxycycline&#160;for 6&#160;weeks&#160;plus gentamicin for the first 2 weeks may also be considered but&#160;is less&#160;</p>
</div>
<!-- Page 43 -->
<a name="43"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page43-div" style="position:relative;width:917px;height:1187px;">
<p style="position:absolute;top:1128px;left:108px;white-space:nowrap" class="ft024"><i>Guidelines for the Prevention and Treatment&#160;of&#160;Opportunistic&#160;Infections in Adults&#160;and Adolescents&#160;With HIV&#160;</i></p>
<p style="position:absolute;top:1128px;left:790px;white-space:nowrap" class="ft024"><i>C-5&#160;</i></p>
<p style="position:absolute;top:109px;left:108px;white-space:nowrap" class="ft032">preferred due to the&#160;intrinsic&#160;nephrotoxicity of gentamicin and&#160;the&#160;frequency of vasculitis-induced&#160;<br/>renal&#160;dysfunction complicating&#160;</p>
<p style="position:absolute;top:129px;left:327px;white-space:nowrap" class="ft019"><i>Bartonella&#160;</i></p>
<p style="position:absolute;top:129px;left:405px;white-space:nowrap" class="ft013">endocarditis&#160;</p>
<p style="position:absolute;top:129px;left:493px;white-space:nowrap" class="ft012"><b>(BII).</b></p>
<p style="position:absolute;top:127px;left:534px;white-space:nowrap" class="ft038">17</p>
<p style="position:absolute;top:129px;left:546px;white-space:nowrap" class="ft013">&#160;</p>
<p style="position:absolute;top:166px;left:108px;white-space:nowrap" class="ft013">Penicillins and first-generation cephalosporins&#160;have no&#160;</p>
<p style="position:absolute;top:166px;left:491px;white-space:nowrap" class="ft019"><i>in vivo&#160;</i></p>
<p style="position:absolute;top:166px;left:542px;white-space:nowrap" class="ft013">activity and should not be&#160;used for&#160;</p>
<p style="position:absolute;top:185px;left:108px;white-space:nowrap" class="ft013">treatment of bartonellosis&#160;</p>
<p style="position:absolute;top:185px;left:288px;white-space:nowrap" class="ft012"><b>(AII).</b></p>
<p style="position:absolute;top:184px;left:330px;white-space:nowrap" class="ft038">18</p>
<p style="position:absolute;top:185px;left:342px;white-space:nowrap" class="ft013">&#160;</p>
<p style="position:absolute;top:185px;left:346px;white-space:nowrap" class="ft019"><i>Bartonella&#160;</i></p>
<p style="position:absolute;top:185px;left:424px;white-space:nowrap" class="ft013">species have been&#160;isolated from patients with HIV&#160;</p>
<p style="position:absolute;top:205px;left:108px;white-space:nowrap" class="ft013">during documented treatment or prophylaxis with&#160;trimethoprim-sulfamethoxazole (TMP-SMX);</p>
<p style="position:absolute;top:204px;left:772px;white-space:nowrap" class="ft038">2</p>
<p style="position:absolute;top:205px;left:778px;white-space:nowrap" class="ft013">&#160;</p>
<p style="position:absolute;top:225px;left:108px;white-space:nowrap" class="ft013">quinolones and TMP-SMX also have&#160;variable&#160;</p>
<p style="position:absolute;top:225px;left:429px;white-space:nowrap" class="ft019"><i>in vitro</i></p>
<p style="position:absolute;top:225px;left:479px;white-space:nowrap" class="ft013">&#160;activity and an inconsistent&#160;clinical&#160;response in&#160;</p>
<p style="position:absolute;top:245px;left:108px;white-space:nowrap" class="ft013">case reports&#160;and are&#160;not recommended&#160;</p>
<p style="position:absolute;top:245px;left:377px;white-space:nowrap" class="ft012"><b>(AIII).&#160;</b></p>
<p style="position:absolute;top:245px;left:430px;white-space:nowrap" class="ft013">&#160;</p>
<p style="position:absolute;top:282px;left:108px;white-space:nowrap" class="ft029"><i><b>Monitoring of&#160;Response&#160;to&#160;Therapy and&#160;Adverse Effects&#160;(Including&#160;IRIS)&#160;&#160;</b></i></p>
<p style="position:absolute;top:323px;left:108px;white-space:nowrap" class="ft032">The&#160;potential exists for immune&#160;reconstitution inflammatory syndrome&#160;(IRIS) in association with&#160;<br/>bartonellosis&#160;treatment&#160;and initiation of antiretroviral&#160;therapy (ART) in people with HIV. In ART-<br/>naive patients, ART&#160;generally can be initiated at&#160;the same&#160;time&#160;as&#160;</p>
<p style="position:absolute;top:363px;left:564px;white-space:nowrap" class="ft019"><i>Bartonella</i></p>
<p style="position:absolute;top:363px;left:638px;white-space:nowrap" class="ft013">-directed treatment;&#160;</p>
<p style="position:absolute;top:383px;left:108px;white-space:nowrap" class="ft013">however, patients with&#160;</p>
<p style="position:absolute;top:383px;left:269px;white-space:nowrap" class="ft019"><i>Bartonella</i></p>
<p style="position:absolute;top:383px;left:343px;white-space:nowrap" class="ft013">&#160;CNS or ophthalmic lesions probably should be&#160;treated with&#160;</p>
<p style="position:absolute;top:403px;left:108px;white-space:nowrap" class="ft013">doxycycline&#160;and a rifamycin class antibiotic for 2 to 4 weeks before instituting ART&#160;</p>
<p style="position:absolute;top:403px;left:693px;white-space:nowrap" class="ft012"><b>(CIII).</b></p>
<p style="position:absolute;top:403px;left:741px;white-space:nowrap" class="ft013">&#160;</p>
<p style="position:absolute;top:440px;left:108px;white-space:nowrap" class="ft013">Because of the propensity for relapse&#160;of&#160;</p>
<p style="position:absolute;top:440px;left:387px;white-space:nowrap" class="ft019"><i>Bartonella</i></p>
<p style="position:absolute;top:440px;left:461px;white-space:nowrap" class="ft013">&#160;infection, patients should have anti-</p>
<p style="position:absolute;top:440px;left:712px;white-space:nowrap" class="ft019"><i>Bartonella</i></p>
<p style="position:absolute;top:440px;left:785px;white-space:nowrap" class="ft013">&#160;</p>
<p style="position:absolute;top:460px;left:108px;white-space:nowrap" class="ft013">IFA&#160;IgG antibody titers checked at&#160;the&#160;time&#160;of diagnosis (</p>
<p style="position:absolute;top:460px;left:506px;white-space:nowrap" class="ft018">Note:&#160;It is&#160;</p>
<p style="position:absolute;top:460px;left:579px;white-space:nowrap" class="ft013">important&#160;to specify&#160;to the&#160;</p>
<p style="position:absolute;top:480px;left:108px;white-space:nowrap" class="ft032">receiving lab that the sample&#160;must be&#160;diluted to endpoint.) and,&#160;if positive, should be&#160;followed&#160;with&#160;<br/>sequential&#160;endpoint titers every 6 to 8&#160;weeks during treatment, preferably until at&#160;least a&#160;fourfold&#160;<br/>decrease is documented&#160;</p>
<p style="position:absolute;top:519px;left:276px;white-space:nowrap" class="ft012"><b>(CIII).</b></p>
<p style="position:absolute;top:518px;left:325px;white-space:nowrap" class="ft038">8</p>
<p style="position:absolute;top:519px;left:330px;white-space:nowrap" class="ft013">&#160;Patients treated with oral doxycycline&#160;should be cautioned about&#160;</p>
<p style="position:absolute;top:539px;left:108px;white-space:nowrap" class="ft032">pill-associated esophagitis&#160;and photosensitivity. Adverse effects&#160;associated with macrolides include&#160;<br/>nausea, vomiting, abdominal pain, and elevations of liver transaminase levels; potential&#160;QT interval&#160;<br/>prolongation&#160;also should&#160;be considered. Serious&#160;side effects can occur during treatment with&#160;<br/>rifamycin class antibiotics, including hypersensitivity reactions (thrombocytopenia, interstitial&#160;<br/>nephritis, and hemolytic&#160;anemia) and hepatitis. Administration of rifamycin class&#160;antibiotics strongly&#160;<br/>induces the&#160;cytochrome P450 enzyme&#160;system, which is an important consideration when other&#160;<br/>medications, including many antiretroviral drugs, are taken simultaneously.&#160;</p>
<p style="position:absolute;top:695px;left:108px;white-space:nowrap" class="ft029"><i><b>Managing&#160;Treatment Failure&#160;</b></i></p>
<p style="position:absolute;top:737px;left:108px;white-space:nowrap" class="ft013">Relapse of&#160;</p>
<p style="position:absolute;top:737px;left:186px;white-space:nowrap" class="ft019"><i>Bartonella</i></p>
<p style="position:absolute;top:737px;left:259px;white-space:nowrap" class="ft013">&#160;infections occurs frequently,&#160;especially in patients with BA.&#160;Among&#160;patients&#160;</p>
<p style="position:absolute;top:756px;left:108px;white-space:nowrap" class="ft032">who fail&#160;to respond to initial&#160;treatment, switching to a different&#160;preferred regimen (for example, from&#160;<br/>doxycycline&#160;to erythromycin) may be considered,&#160;</p>
<p style="position:absolute;top:776px;left:455px;white-space:nowrap" class="ft018">again with treatment duration of&#160;</p>
<p style="position:absolute;top:776px;left:681px;white-space:nowrap" class="ft069">≥</p>
<p style="position:absolute;top:776px;left:691px;white-space:nowrap" class="ft018">3 months</p>
<p style="position:absolute;top:776px;left:755px;white-space:nowrap" class="ft013">&#160;</p>
<p style="position:absolute;top:776px;left:759px;white-space:nowrap" class="ft012"><b>(AIII).</b></p>
<p style="position:absolute;top:776px;left:807px;white-space:nowrap" class="ft013">&#160;</p>
<p style="position:absolute;top:796px;left:108px;white-space:nowrap" class="ft013">For severe infections, the&#160;addition of a rifamycin class&#160;antibiotic is indicated&#160;</p>
<p style="position:absolute;top:796px;left:640px;white-space:nowrap" class="ft012"><b>(AIII).</b></p>
<p style="position:absolute;top:796px;left:688px;white-space:nowrap" class="ft013">&#160;For patients&#160;with&#160;</p>
<p style="position:absolute;top:816px;left:108px;white-space:nowrap" class="ft032">positive or increasing antibody titers, but with clinical improvement, treatment should continue&#160;until&#160;<br/>at&#160;least a fourfold decrease in the&#160;antibody titers is&#160;documented&#160;</p>
<p style="position:absolute;top:836px;left:548px;white-space:nowrap" class="ft012"><b>(CIII).</b></p>
<p style="position:absolute;top:834px;left:597px;white-space:nowrap" class="ft038">8</p>
<p style="position:absolute;top:836px;left:602px;white-space:nowrap" class="ft013">&#160;</p>
<p style="position:absolute;top:872px;left:108px;white-space:nowrap" class="ft026"><b>Preventing&#160;Recurrence&#160;</b></p>
<p style="position:absolute;top:914px;left:108px;white-space:nowrap" class="ft032">After a primary course of&#160;treatment (minimum&#160;of 3 months), treatment may be discontinued, with&#160;<br/>close monitoring for evidence&#160;of relapse (e.g., symptoms, increase in&#160;antibody titers).&#160;</p>
<p style="position:absolute;top:971px;left:108px;white-space:nowrap" class="ft032">If a relapse occurs, an additional course of treatment&#160;is recommended, followed by long-term&#160;<br/>suppression&#160;of infection with doxycycline&#160;or a macrolide&#160;</p>
<p style="position:absolute;top:991px;left:505px;white-space:nowrap" class="ft012"><b>(AIII).</b></p>
<p style="position:absolute;top:991px;left:554px;white-space:nowrap" class="ft013">&#160;</p>
<p style="position:absolute;top:1028px;left:108px;white-space:nowrap" class="ft032">Long-term&#160;suppression can be&#160;discontinued after the patient has received at&#160;least 3 to 4 months of&#160;<br/>therapy and&#160;when the&#160;CD4 count&#160;remains &gt;200 cells/mm</p>
<p style="position:absolute;top:1046px;left:502px;white-space:nowrap" class="ft038">3</p>
<p style="position:absolute;top:1048px;left:508px;white-space:nowrap" class="ft013">&#160;on effective ART&#160;</p>
<p style="position:absolute;top:1048px;left:637px;white-space:nowrap" class="ft018">for&#160;</p>
<p style="position:absolute;top:1048px;left:661px;white-space:nowrap" class="ft069">≥</p>
<p style="position:absolute;top:1048px;left:671px;white-space:nowrap" class="ft018">6</p>
<p style="position:absolute;top:1048px;left:679px;white-space:nowrap" class="ft013">&#160;months&#160;</p>
<p style="position:absolute;top:1048px;left:739px;white-space:nowrap" class="ft012"><b>(CIII).</b></p>
<p style="position:absolute;top:1046px;left:787px;white-space:nowrap" class="ft038">8</p>
<p style="position:absolute;top:1048px;left:793px;white-space:nowrap" class="ft013">&#160;</p>
</div>
<!-- Page 44 -->
<a name="44"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page44-div" style="position:relative;width:917px;height:1187px;">
<p style="position:absolute;top:1128px;left:108px;white-space:nowrap" class="ft024"><i>Guidelines for the Prevention and Treatment&#160;of&#160;Opportunistic&#160;Infections in Adults&#160;and Adolescents&#160;With HIV&#160;</i></p>
<p style="position:absolute;top:1128px;left:790px;white-space:nowrap" class="ft024"><i>C-6&#160;</i></p>
<p style="position:absolute;top:109px;left:108px;white-space:nowrap" class="ft013">Some specialists would&#160;discontinue&#160;therapy only if the&#160;</p>
<p style="position:absolute;top:109px;left:489px;white-space:nowrap" class="ft019"><i>Bartonella</i></p>
<p style="position:absolute;top:109px;left:563px;white-space:nowrap" class="ft013">&#160;titers also have decreased at&#160;least&#160;</p>
<p style="position:absolute;top:129px;left:108px;white-space:nowrap" class="ft013">fourfold&#160;</p>
<p style="position:absolute;top:129px;left:169px;white-space:nowrap" class="ft012"><b>(CIII).</b></p>
<p style="position:absolute;top:129px;left:217px;white-space:nowrap" class="ft013">&#160;</p>
<p style="position:absolute;top:165px;left:108px;white-space:nowrap" class="ft026"><b>Special&#160;Considerations During&#160;Pregnancy&#160;</b></p>
<p style="position:absolute;top:207px;left:108px;white-space:nowrap" class="ft013">Infection with&#160;</p>
<p style="position:absolute;top:207px;left:210px;white-space:nowrap" class="ft019"><i>B.</i></p>
<p style="position:absolute;top:207px;left:224px;white-space:nowrap" class="ft013">&#160;</p>
<p style="position:absolute;top:207px;left:229px;white-space:nowrap" class="ft019"><i>bacilliformis</i></p>
<p style="position:absolute;top:207px;left:317px;white-space:nowrap" class="ft013">&#160;in immunocompetent&#160;patients during pregnancy has been&#160;associated&#160;</p>
<p style="position:absolute;top:227px;left:108px;white-space:nowrap" class="ft013">with increased complications&#160;and risk&#160;of death, but&#160;no data are available on the effect&#160;of&#160;</p>
<p style="position:absolute;top:227px;left:719px;white-space:nowrap" class="ft019"><i>B. quintana</i></p>
<p style="position:absolute;top:227px;left:800px;white-space:nowrap" class="ft013">&#160;</p>
<p style="position:absolute;top:247px;left:108px;white-space:nowrap" class="ft013">or&#160;</p>
<p style="position:absolute;top:247px;left:127px;white-space:nowrap" class="ft019"><i>B. henselae</i></p>
<p style="position:absolute;top:247px;left:206px;white-space:nowrap" class="ft013">&#160;infection&#160;during pregnancy.&#160;</p>
<p style="position:absolute;top:284px;left:108px;white-space:nowrap" class="ft013">During pregnancy, the diagnosis and&#160;management&#160;of&#160;</p>
<p style="position:absolute;top:284px;left:477px;white-space:nowrap" class="ft019"><i>Bartonella</i></p>
<p style="position:absolute;top:284px;left:550px;white-space:nowrap" class="ft013">&#160;infections&#160;are the same&#160;as for other&#160;</p>
<p style="position:absolute;top:304px;left:108px;white-space:nowrap" class="ft032">people with&#160;HIV.&#160;Erythromycin treatment (or an alternative&#160;macrolide) should be used as first-line&#160;<br/>therapy&#160;</p>
<p style="position:absolute;top:323px;left:164px;white-space:nowrap" class="ft012"><b>(AIII)</b></p>
<p style="position:absolute;top:323px;left:208px;white-space:nowrap" class="ft013">&#160;rather than&#160;tetracyclines (such as&#160;doxycycline) during pregnancy because of&#160;the&#160;</p>
<p style="position:absolute;top:343px;left:108px;white-space:nowrap" class="ft032">increased risk of hepatotoxicity and the accumulation of tetracycline&#160;in fetal&#160;teeth and bones,&#160;<br/>resulting in dark, permanent staining of&#160;fetal&#160;teeth. Third-generation cephalosporins, such as&#160;<br/>ceftizoxime</p>
<p style="position:absolute;top:382px;left:189px;white-space:nowrap" class="ft038">19</p>
<p style="position:absolute;top:383px;left:201px;white-space:nowrap" class="ft013">&#160;or ceftriaxone, may have&#160;efficacy against&#160;</p>
<p style="position:absolute;top:383px;left:493px;white-space:nowrap" class="ft019"><i>Bartonella</i></p>
<p style="position:absolute;top:383px;left:567px;white-space:nowrap" class="ft013">&#160;during pregnancy, but&#160;it should be&#160;</p>
<p style="position:absolute;top:403px;left:108px;white-space:nowrap" class="ft032">considered second-line therapy after a&#160;macrolide. First- and second-generation cephalosporins are not&#160;<br/>recommended because of&#160;their lack of efficacy against&#160;</p>
<p style="position:absolute;top:423px;left:488px;white-space:nowrap" class="ft019"><i>Bartonella</i></p>
<p style="position:absolute;top:423px;left:562px;white-space:nowrap" class="ft013">&#160;</p>
<p style="position:absolute;top:423px;left:566px;white-space:nowrap" class="ft012"><b>(AII).</b></p>
<p style="position:absolute;top:423px;left:608px;white-space:nowrap" class="ft013">&#160;</p>
</div>
<!-- Page 45 -->
<a name="45"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}	.ft085{font-size:16px;font-family:AWFWWM+TimesNewRomanPSMT;color:#000000;}
	.ft086{font-size:16px;font-family:AWFWWM+TimesNewRomanPSMT;color:#005299;}
	.ft087{font-size:16px;line-height:18px;font-family:AWFWWM+TimesNewRomanPSMT;color:#000000;}
-->
</style>
<div id="page45-div" style="position:relative;width:917px;height:1187px;">
<p style="position:absolute;top:1128px;left:108px;white-space:nowrap" class="ft024"><i>Guidelines for the Prevention and Treatment&#160;of&#160;Opportunistic&#160;Infections in Adults&#160;and Adolescents&#160;With HIV&#160;</i></p>
<p style="position:absolute;top:1128px;left:790px;white-space:nowrap" class="ft024"><i>C-7&#160;</i></p>
<p style="position:absolute;top:108px;left:108px;white-space:nowrap" class="ft026"><b>References&#160;</b></p>
<p style="position:absolute;top:150px;left:108px;white-space:nowrap" class="ft047">1.&#160;</p>
<p style="position:absolute;top:150px;left:162px;white-space:nowrap" class="ft047">Rose SR, Koehler J. Bartonella, including&#160;cat-</p>
<p style="position:absolute;top:150px;left:467px;white-space:nowrap" class="ft085">scratch&#160;disease. In: Mandell,&#160;Douglas,&#160;and&#160;</p>
<p style="position:absolute;top:169px;left:162px;white-space:nowrap" class="ft047">Bennett's Principles and&#160;Practice of Infectious Disease. J. E. Bennett,&#160;R. Dolin&#160;and&#160;M. J.&#160;Blaser.&#160;</p>
<p style="position:absolute;top:188px;left:162px;white-space:nowrap" class="ft085">9th&#160;ed.&#160;Philadelphia, PA: Elsevier Press; 2020.</p>
<p style="position:absolute;top:188px;left:470px;white-space:nowrap" class="ft047">&#160;</p>
<p style="position:absolute;top:225px;left:108px;white-space:nowrap" class="ft047">2.&#160;</p>
<p style="position:absolute;top:225px;left:162px;white-space:nowrap" class="ft051">Koehler JE,&#160;Sanchez MA,&#160;Garrido&#160;CS,&#160;et&#160;al. Molecular epidemiology of bartonella infections in&#160;<br/>patients with&#160;bacillary&#160;angiomatosis-peliosis.&#160;</p>
<p style="position:absolute;top:244px;left:464px;white-space:nowrap" class="ft049"><i>N Engl J&#160;Med</i></p>
<p style="position:absolute;top:244px;left:555px;white-space:nowrap" class="ft085">.&#160;1997;337(26):1876</p>
<p style="position:absolute;top:244px;left:690px;white-space:nowrap" class="ft047">-1883. Available&#160;</p>
<p style="position:absolute;top:263px;left:162px;white-space:nowrap" class="ft085">at:&#160;</p>
<p style="position:absolute;top:263px;left:183px;white-space:nowrap" class="ft086">https://www.pubmed.ncbi.nlm.nih.gov/9407154</p>
<p style="position:absolute;top:263px;left:500px;white-space:nowrap" class="ft047">.&#160;</p>
<p style="position:absolute;top:300px;left:108px;white-space:nowrap" class="ft047">3.&#160;</p>
<p style="position:absolute;top:300px;left:162px;white-space:nowrap" class="ft051">Koehler JE,&#160;Glaser&#160;CA, Tappero&#160;JW.&#160;Rochalimaea henselae infection. A new zoonosis with&#160;the&#160;<br/>domestic cat&#160;as reservoir.&#160;</p>
<p style="position:absolute;top:319px;left:334px;white-space:nowrap" class="ft049"><i>JAMA</i></p>
<p style="position:absolute;top:319px;left:375px;white-space:nowrap" class="ft085">. 1994;271(7):531</p>
<p style="position:absolute;top:319px;left:494px;white-space:nowrap" class="ft047">-</p>
<p style="position:absolute;top:319px;left:500px;white-space:nowrap" class="ft085">535. Available at:&#160;</p>
<p style="position:absolute;top:338px;left:162px;white-space:nowrap" class="ft086">https://www.pubmed.ncbi.nlm.nih.gov/8301768</p>
<p style="position:absolute;top:338px;left:480px;white-space:nowrap" class="ft047">.&#160;</p>
<p style="position:absolute;top:375px;left:108px;white-space:nowrap" class="ft047">4.&#160;</p>
<p style="position:absolute;top:375px;left:162px;white-space:nowrap" class="ft051">Koehler JE,&#160;Sanchez MA,&#160;Tye S,&#160;et al.&#160;Prevalence of&#160;Bartonella infection&#160;among&#160;human&#160;<br/>immunodeficiency&#160;virus-infected&#160;patients with&#160;fever.&#160;</p>
<p style="position:absolute;top:394px;left:516px;white-space:nowrap" class="ft049"><i>Clin&#160;Infect Dis</i></p>
<p style="position:absolute;top:394px;left:613px;white-space:nowrap" class="ft085">. 2003;37(4):559</p>
<p style="position:absolute;top:394px;left:724px;white-space:nowrap" class="ft047">-566.&#160;</p>
<p style="position:absolute;top:413px;left:162px;white-space:nowrap" class="ft085">Available at:&#160;</p>
<p style="position:absolute;top:413px;left:251px;white-space:nowrap" class="ft086">https://www.pubmed.ncbi.nlm.nih.gov/12905141</p>
<p style="position:absolute;top:413px;left:577px;white-space:nowrap" class="ft047">.&#160;</p>
<p style="position:absolute;top:450px;left:108px;white-space:nowrap" class="ft047">5.&#160;</p>
<p style="position:absolute;top:450px;left:162px;white-space:nowrap" class="ft047">Fournier PE,&#160;Thuny F, Richet H,&#160;et al.&#160;Comprehensive diagnostic strategy&#160;for blood&#160;culture-</p>
<p style="position:absolute;top:469px;left:162px;white-space:nowrap" class="ft085">negative endocarditis: a prospective study&#160;of 819&#160;new&#160;cases.&#160;</p>
<p style="position:absolute;top:469px;left:564px;white-space:nowrap" class="ft049"><i>Clin&#160;Infect Dis</i></p>
<p style="position:absolute;top:469px;left:661px;white-space:nowrap" class="ft085">. 2010;51(2):131</p>
<p style="position:absolute;top:469px;left:772px;white-space:nowrap" class="ft047">-140.&#160;</p>
<p style="position:absolute;top:488px;left:162px;white-space:nowrap" class="ft085">Available at:&#160;</p>
<p style="position:absolute;top:488px;left:251px;white-space:nowrap" class="ft086">https://www.pubmed.ncbi.nlm.nih.gov/20540619</p>
<p style="position:absolute;top:488px;left:577px;white-space:nowrap" class="ft047">.&#160;</p>
<p style="position:absolute;top:525px;left:108px;white-space:nowrap" class="ft047">6.&#160;</p>
<p style="position:absolute;top:525px;left:162px;white-space:nowrap" class="ft051">LeBoit&#160;PE,&#160;Berger TG, Egbert BM, Beckstead&#160;JH, Yen&#160;TS,&#160;Stoler&#160;MH.&#160;Bacillary&#160;angiomatosis.&#160;<br/>The histopathology and&#160;differential diagnosis of a pseudoneoplastic infection&#160;in&#160;patients with&#160;<br/>human&#160;immunodeficiency&#160;virus disease.&#160;</p>
<p style="position:absolute;top:563px;left:432px;white-space:nowrap" class="ft049"><i>Am J Surg&#160;Pathol</i></p>
<p style="position:absolute;top:563px;left:549px;white-space:nowrap" class="ft085">.&#160;1989;13(11):909</p>
<p style="position:absolute;top:563px;left:668px;white-space:nowrap" class="ft047">-</p>
<p style="position:absolute;top:563px;left:673px;white-space:nowrap" class="ft085">920. Available at:&#160;</p>
<p style="position:absolute;top:582px;left:162px;white-space:nowrap" class="ft086">https://www.pubmed.ncbi.nlm.nih.gov/2802010</p>
<p style="position:absolute;top:582px;left:480px;white-space:nowrap" class="ft047">.&#160;</p>
<p style="position:absolute;top:619px;left:108px;white-space:nowrap" class="ft047">7.&#160;</p>
<p style="position:absolute;top:619px;left:162px;white-space:nowrap" class="ft051">Regnery&#160;RL,&#160;Olson&#160;JG, Perkins BA, Bibb&#160;W.&#160;Serological response to&#160;&#34;Rochalimaea henselae&#34;&#160;<br/>antigen&#160;in&#160;suspected cat-scratch disease.&#160;</p>
<p style="position:absolute;top:638px;left:431px;white-space:nowrap" class="ft049"><i>Lancet</i></p>
<p style="position:absolute;top:638px;left:476px;white-space:nowrap" class="ft085">.&#160;1992;339(8807):1443</p>
<p style="position:absolute;top:638px;left:628px;white-space:nowrap" class="ft047">-</p>
<p style="position:absolute;top:638px;left:634px;white-space:nowrap" class="ft085">1445. Available at:&#160;</p>
<p style="position:absolute;top:657px;left:162px;white-space:nowrap" class="ft086">https://www.pubmed.ncbi.nlm.nih.gov/1351130</p>
<p style="position:absolute;top:657px;left:480px;white-space:nowrap" class="ft047">.&#160;</p>
<p style="position:absolute;top:693px;left:108px;white-space:nowrap" class="ft047">8.&#160;</p>
<p style="position:absolute;top:693px;left:162px;white-space:nowrap" class="ft051">Lee SA, Plett&#160;SK,&#160;Luetkemeyer AF,&#160;et al. Bartonella quintana aortitis in&#160;a man with&#160;AIDS,&#160;<br/>diagnosed&#160;by&#160;needle biopsy&#160;and&#160;16S&#160;rRNA gene amplification.&#160;</p>
<p style="position:absolute;top:712px;left:582px;white-space:nowrap" class="ft049"><i>J Clin&#160;Microbiol</i></p>
<p style="position:absolute;top:712px;left:692px;white-space:nowrap" class="ft047">.&#160;</p>
<p style="position:absolute;top:731px;left:162px;white-space:nowrap" class="ft085">2015;53(8):2773</p>
<p style="position:absolute;top:731px;left:273px;white-space:nowrap" class="ft047">-</p>
<p style="position:absolute;top:731px;left:278px;white-space:nowrap" class="ft085">2776.&#160;Available at:&#160;</p>
<p style="position:absolute;top:731px;left:408px;white-space:nowrap" class="ft086">https://www.pubmed.ncbi.nlm.nih.gov/26063867</p>
<p style="position:absolute;top:731px;left:735px;white-space:nowrap" class="ft047">.&#160;</p>
<p style="position:absolute;top:768px;left:108px;white-space:nowrap" class="ft047">9.&#160;</p>
<p style="position:absolute;top:768px;left:162px;white-space:nowrap" class="ft051">Larson&#160;AM,&#160;Dougherty&#160;MJ, Nowowiejski DJ, et&#160;al. Detection&#160;of Bartonella (Rochalimaea)&#160;<br/>quintana by&#160;routine acridine&#160;orange staining&#160;of&#160;broth blood&#160;cultures.&#160;</p>
<p style="position:absolute;top:787px;left:616px;white-space:nowrap" class="ft049"><i>J Clin&#160;Microbiol</i></p>
<p style="position:absolute;top:787px;left:726px;white-space:nowrap" class="ft047">.&#160;</p>
<p style="position:absolute;top:806px;left:162px;white-space:nowrap" class="ft085">1994;32(6):1492</p>
<p style="position:absolute;top:806px;left:273px;white-space:nowrap" class="ft047">-</p>
<p style="position:absolute;top:806px;left:278px;white-space:nowrap" class="ft085">1496.&#160;Available at:&#160;</p>
<p style="position:absolute;top:806px;left:408px;white-space:nowrap" class="ft086">https://www.pubmed.ncbi.nlm.nih.gov/7521357</p>
<p style="position:absolute;top:806px;left:726px;white-space:nowrap" class="ft047">.&#160;</p>
<p style="position:absolute;top:843px;left:108px;white-space:nowrap" class="ft047">10.&#160;</p>
<p style="position:absolute;top:843px;left:162px;white-space:nowrap" class="ft087">Dumler JS,&#160;Carroll KS,&#160;Patel&#160;R. Bartonella. In: Manual of Clinical Microbiology. K.&#160;C. Carroll,&#160;<br/>M.&#160;A. Pfaller and&#160;M.&#160;Landry. 12th ed. Washington,&#160;DC: American&#160;Society&#160;for&#160;</p>
<p style="position:absolute;top:862px;left:683px;white-space:nowrap" class="ft047">Microbiology;&#160;</p>
<p style="position:absolute;top:881px;left:162px;white-space:nowrap" class="ft047">2019.&#160;</p>
<p style="position:absolute;top:918px;left:108px;white-space:nowrap" class="ft047">11.&#160;</p>
<p style="position:absolute;top:918px;left:162px;white-space:nowrap" class="ft051">Li&#160;M,&#160;Yan&#160;K, Jia P,&#160;Wei E,&#160;Wang&#160;H. Metagenomic next-generation&#160;sequencing&#160;may assist&#160;<br/>diagnosis of&#160;cat-scratch disease.</p>
<p style="position:absolute;top:937px;left:377px;white-space:nowrap" class="ft049"><i>Front Cell&#160;Infect Microbiol</i></p>
<p style="position:absolute;top:937px;left:558px;white-space:nowrap" class="ft085">.&#160;2022;12:7. Available at:&#160;</p>
<p style="position:absolute;top:956px;left:162px;white-space:nowrap" class="ft086">https://www.pubmed.ncbi.nlm.nih.gov/36189365</p>
<p style="position:absolute;top:956px;left:488px;white-space:nowrap" class="ft047">.&#160;</p>
<p style="position:absolute;top:993px;left:108px;white-space:nowrap" class="ft047">12.&#160;</p>
<p style="position:absolute;top:993px;left:162px;white-space:nowrap" class="ft051">Flurin&#160;L,&#160;Wolf MJ, Fisher CR,&#160;et al.&#160;Pathogen detection&#160;in&#160;infective endocarditis using&#160;targeted&#160;<br/>metagenomics on&#160;whole blood&#160;and p</p>
<p style="position:absolute;top:1012px;left:404px;white-space:nowrap" class="ft085">lasma: a&#160;</p>
<p style="position:absolute;top:1012px;left:463px;white-space:nowrap" class="ft047">prospective pilot study.&#160;</p>
<p style="position:absolute;top:1012px;left:621px;white-space:nowrap" class="ft049"><i>J Clin&#160;Microbiol</i></p>
<p style="position:absolute;top:1012px;left:731px;white-space:nowrap" class="ft047">.&#160;</p>
<p style="position:absolute;top:1031px;left:162px;white-space:nowrap" class="ft085">2022;60(9):e0062122. Available at:&#160;</p>
<p style="position:absolute;top:1031px;left:402px;white-space:nowrap" class="ft086">https://www.pubmed.ncbi.nlm.nih.gov/36040200</p>
<p style="position:absolute;top:1031px;left:728px;white-space:nowrap" class="ft047">.&#160;</p>
</div>
<!-- Page 46 -->
<a name="46"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page46-div" style="position:relative;width:917px;height:1187px;">
<p style="position:absolute;top:1128px;left:108px;white-space:nowrap" class="ft024"><i>Guidelines for the Prevention and Treatment&#160;of&#160;Opportunistic&#160;Infections in Adults&#160;and Adolescents&#160;With HIV&#160;</i></p>
<p style="position:absolute;top:1128px;left:790px;white-space:nowrap" class="ft024"><i>C-8&#160;</i></p>
<p style="position:absolute;top:109px;left:108px;white-space:nowrap" class="ft047">13.&#160;</p>
<p style="position:absolute;top:109px;left:162px;white-space:nowrap" class="ft047">Downey&#160;RD, Russo SM,&#160;Hauger SB,&#160;et al.&#160;Identification&#160;of an&#160;emergent&#160;pathogen,&#160;</p>
<p style="position:absolute;top:109px;left:711px;white-space:nowrap" class="ft049"><i>Bartonella&#160;</i></p>
<p style="position:absolute;top:128px;left:162px;white-space:nowrap" class="ft049"><i>vinsonii</i></p>
<p style="position:absolute;top:128px;left:214px;white-space:nowrap" class="ft047">,&#160;using&#160;next-generation&#160;sequencing&#160;in&#160;a&#160;patient with&#160;culture-negative endocarditis.&#160;</p>
<p style="position:absolute;top:128px;left:759px;white-space:nowrap" class="ft049"><i>J&#160;</i></p>
<p style="position:absolute;top:147px;left:162px;white-space:nowrap" class="ft049"><i>Pediatric Infect Dis Soc</i></p>
<p style="position:absolute;top:147px;left:320px;white-space:nowrap" class="ft085">. 2021;10(2):213</p>
<p style="position:absolute;top:147px;left:431px;white-space:nowrap" class="ft047">-</p>
<p style="position:absolute;top:147px;left:436px;white-space:nowrap" class="ft085">216. Available&#160;at:&#160;</p>
<p style="position:absolute;top:166px;left:162px;white-space:nowrap" class="ft086">https://www.pubmed.ncbi.nlm.nih.gov/32092135</p>
<p style="position:absolute;top:166px;left:488px;white-space:nowrap" class="ft047">.&#160;</p>
<p style="position:absolute;top:203px;left:108px;white-space:nowrap" class="ft047">14.&#160;</p>
<p style="position:absolute;top:203px;left:162px;white-space:nowrap" class="ft051">Fowler VG,&#160;Durack&#160;DT,&#160;Selton-Suty&#160;C,&#160;et al.&#160;The 2023&#160;Duke-ISCVID Criteria for infective&#160;<br/>e</p>
<p style="position:absolute;top:222px;left:169px;white-space:nowrap" class="ft085">ndocarditis:&#160;</p>
<p style="position:absolute;top:222px;left:251px;white-space:nowrap" class="ft047">updating the&#160;modified&#160;Duke Criteria.&#160;</p>
<p style="position:absolute;top:222px;left:499px;white-space:nowrap" class="ft049"><i>Clin&#160;Infect Dis</i></p>
<p style="position:absolute;top:222px;left:596px;white-space:nowrap" class="ft085">. 2023. Available at:&#160;</p>
<p style="position:absolute;top:241px;left:162px;white-space:nowrap" class="ft086">https://www.pubmed.ncbi.nlm.nih.gov/37138445</p>
<p style="position:absolute;top:241px;left:488px;white-space:nowrap" class="ft047">.&#160;</p>
<p style="position:absolute;top:278px;left:108px;white-space:nowrap" class="ft047">15.&#160;</p>
<p style="position:absolute;top:278px;left:162px;white-space:nowrap" class="ft047">Psarros G, Riddell Jt,&#160;Gandhi&#160;T,&#160;Kauffman&#160;CA, Cinti&#160;SK. Bartonella henselae infections in&#160;solid&#160;</p>
<p style="position:absolute;top:296px;left:162px;white-space:nowrap" class="ft085">organ transplant&#160;recipients: report of 5 cases&#160;and&#160;review&#160;of the literature.&#160;</p>
<p style="position:absolute;top:296px;left:645px;white-space:nowrap" class="ft049"><i>Medicine (Baltimore)</i></p>
<p style="position:absolute;top:296px;left:787px;white-space:nowrap" class="ft047">.&#160;</p>
<p style="position:absolute;top:315px;left:162px;white-space:nowrap" class="ft085">2012;91(2):111</p>
<p style="position:absolute;top:315px;left:265px;white-space:nowrap" class="ft047">-</p>
<p style="position:absolute;top:315px;left:270px;white-space:nowrap" class="ft085">121.&#160;Available at:&#160;</p>
<p style="position:absolute;top:315px;left:392px;white-space:nowrap" class="ft086">https://www.pubmed.ncbi.nlm.nih.gov/22391473</p>
<p style="position:absolute;top:315px;left:718px;white-space:nowrap" class="ft047">.&#160;</p>
<p style="position:absolute;top:352px;left:108px;white-space:nowrap" class="ft047">16.&#160;</p>
<p style="position:absolute;top:352px;left:162px;white-space:nowrap" class="ft051">Guerra LG, Neira CJ, Boman&#160;D, et al.&#160;Rapid&#160;response of&#160;AIDS-related&#160;bacillary&#160;angiomatosis to&#160;<br/>azithromycin.&#160;</p>
<p style="position:absolute;top:371px;left:257px;white-space:nowrap" class="ft049"><i>Clin&#160;Infect Dis</i></p>
<p style="position:absolute;top:371px;left:354px;white-space:nowrap" class="ft085">. 1993;17(2):264</p>
<p style="position:absolute;top:371px;left:465px;white-space:nowrap" class="ft047">-</p>
<p style="position:absolute;top:371px;left:471px;white-space:nowrap" class="ft085">266.&#160;Available at:&#160;</p>
<p style="position:absolute;top:390px;left:162px;white-space:nowrap" class="ft086">https://www.pubmed.ncbi.nlm.nih.gov/8399879</p>
<p style="position:absolute;top:390px;left:480px;white-space:nowrap" class="ft047">.&#160;</p>
<p style="position:absolute;top:427px;left:108px;white-space:nowrap" class="ft047">17.&#160;</p>
<p style="position:absolute;top:427px;left:162px;white-space:nowrap" class="ft047">Raybould&#160;JE,&#160;Raybould&#160;AL,&#160;Morales MK, et&#160;al.&#160;Bartonella endocarditis and&#160;Pauci-immune&#160;</p>
<p style="position:absolute;top:446px;left:162px;white-space:nowrap" class="ft085">glomerulonephritis: a case&#160;report and&#160;review of the literature.&#160;</p>
<p style="position:absolute;top:446px;left:570px;white-space:nowrap" class="ft049"><i>Infect Dis Clin&#160;Pract (Baltim Md)</i></p>
<p style="position:absolute;top:446px;left:793px;white-space:nowrap" class="ft047">.&#160;</p>
<p style="position:absolute;top:465px;left:162px;white-space:nowrap" class="ft085">2016;24(5):254</p>
<p style="position:absolute;top:465px;left:265px;white-space:nowrap" class="ft047">-</p>
<p style="position:absolute;top:465px;left:270px;white-space:nowrap" class="ft085">260.&#160;Available at:&#160;</p>
<p style="position:absolute;top:465px;left:392px;white-space:nowrap" class="ft086">https://www.pubmed.ncbi.nlm.nih.gov/27885316</p>
<p style="position:absolute;top:465px;left:718px;white-space:nowrap" class="ft047">.&#160;</p>
<p style="position:absolute;top:502px;left:108px;white-space:nowrap" class="ft047">18.&#160;</p>
<p style="position:absolute;top:502px;left:162px;white-space:nowrap" class="ft051">Koehler JE,&#160;LeBoit&#160;PE,&#160;Egbert BM,&#160;Berger&#160;TG. Cutaneous vascular lesions and&#160;disseminated&#160;cat-<br/>scratch&#160;disease in&#160;patients with&#160;the acquired&#160;immunodeficiency&#160;syndrome&#160;(AIDS)&#160;and&#160;AIDS-<br/>related&#160;complex.&#160;</p>
<p style="position:absolute;top:540px;left:276px;white-space:nowrap" class="ft049"><i>Ann&#160;Intern&#160;Med</i></p>
<p style="position:absolute;top:540px;left:380px;white-space:nowrap" class="ft085">.&#160;1988;109(6):449</p>
<p style="position:absolute;top:540px;left:500px;white-space:nowrap" class="ft047">-</p>
<p style="position:absolute;top:540px;left:505px;white-space:nowrap" class="ft085">455. Available at:&#160;</p>
<p style="position:absolute;top:559px;left:162px;white-space:nowrap" class="ft086">https://www.pubmed.ncbi.nlm.nih.gov/3415105</p>
<p style="position:absolute;top:559px;left:480px;white-space:nowrap" class="ft047">.&#160;</p>
<p style="position:absolute;top:596px;left:108px;white-space:nowrap" class="ft047">19.&#160;</p>
<p style="position:absolute;top:596px;left:162px;white-space:nowrap" class="ft051">Riley&#160;LE, Tuomala RE.&#160;Bacillary angiomatosis in&#160;a pregnant&#160;patient with&#160;acquired&#160;<br/>immunodeficiency&#160;syndrome.&#160;</p>
<p style="position:absolute;top:615px;left:363px;white-space:nowrap" class="ft049"><i>Obstet Gynecol</i></p>
<p style="position:absolute;top:615px;left:465px;white-space:nowrap" class="ft085">. 1992;79(5, Part 2):818</p>
<p style="position:absolute;top:615px;left:623px;white-space:nowrap" class="ft047">-</p>
<p style="position:absolute;top:615px;left:629px;white-space:nowrap" class="ft085">819. Available at:&#160;</p>
<p style="position:absolute;top:634px;left:162px;white-space:nowrap" class="ft086">https://www.pubmed.ncbi.nlm.nih.gov/1565376</p>
<p style="position:absolute;top:634px;left:480px;white-space:nowrap" class="ft047">.&#160;</p>
</div>
<!-- Page 47 -->
<a name="47"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}	.ft088{font-size:24px;font-family:LKZECW+DejaVuSans;color:#074d8d;}
	.ft089{font-size:26px;font-family:BTLIFY+Tinos;color:#005299;}
-->
</style>
<div id="page47-div" style="position:relative;width:917px;height:1187px;">
<p style="position:absolute;top:1117px;left:108px;white-space:nowrap" class="ft024"><i>Guidelines for the Prevention and Treatment&#160;of&#160;Opportunistic&#160;Infections in Adults&#160;and Adolescents&#160;With HIV&#160;</i></p>
<p style="position:absolute;top:1117px;left:790px;white-space:nowrap" class="ft024"><i>D-1&#160;</i></p>
<p style="position:absolute;top:112px;left:108px;white-space:nowrap" class="ft088"><b>Candidiasis&#160;</b></p>
<p style="position:absolute;top:112px;left:268px;white-space:nowrap" class="ft025"><b>(Mucocutaneous)&#160;</b></p>
<p style="position:absolute;top:159px;left:108px;white-space:nowrap" class="ft035"><b>Updated:</b></p>
<p style="position:absolute;top:159px;left:172px;white-space:nowrap" class="ft036">&#160;September&#160;16, 2024&#160;</p>
<p style="position:absolute;top:180px;left:108px;white-space:nowrap" class="ft035"><b>Reviewed:</b></p>
<p style="position:absolute;top:180px;left:181px;white-space:nowrap" class="ft036">&#160;January 8,&#160;2025&#160;</p>
<p style="position:absolute;top:218px;left:108px;white-space:nowrap" class="ft026"><b>Epidemiology</b></p>
<p style="position:absolute;top:213px;left:221px;white-space:nowrap" class="ft089"><b>&#160;</b></p>
<p style="position:absolute;top:260px;left:108px;white-space:nowrap" class="ft013">Oropharyngeal and esophageal candidiasis are common in people with HIV.</p>
<p style="position:absolute;top:258px;left:635px;white-space:nowrap" class="ft038">1</p>
<p style="position:absolute;top:260px;left:641px;white-space:nowrap" class="ft013">&#160;The&#160;vast majority of&#160;</p>
<p style="position:absolute;top:280px;left:108px;white-space:nowrap" class="ft013">such infections are caused&#160;by&#160;</p>
<p style="position:absolute;top:280px;left:314px;white-space:nowrap" class="ft019"><i>Candida&#160;albicans,&#160;</i></p>
<p style="position:absolute;top:280px;left:445px;white-space:nowrap" class="ft013">although infections caused&#160;by non–</p>
<p style="position:absolute;top:280px;left:689px;white-space:nowrap" class="ft019"><i>C.</i></p>
<p style="position:absolute;top:280px;left:705px;white-space:nowrap" class="ft013">&#160;</p>
<p style="position:absolute;top:280px;left:709px;white-space:nowrap" class="ft019"><i>albicans</i></p>
<p style="position:absolute;top:280px;left:768px;white-space:nowrap" class="ft013">&#160;</p>
<p style="position:absolute;top:299px;left:108px;white-space:nowrap" class="ft032">species have&#160;been&#160;increasingly reported worldwide,&#160;in part due&#160;to increased selection pressure from&#160;<br/>increased use of azoles.</p>
<p style="position:absolute;top:318px;left:271px;white-space:nowrap" class="ft038">2-9</p>
<p style="position:absolute;top:319px;left:286px;white-space:nowrap" class="ft013">&#160;The&#160;occurrence&#160;of oropharyngeal&#160;or&#160;esophageal candidiasis is&#160;recognized&#160;</p>
<p style="position:absolute;top:339px;left:108px;white-space:nowrap" class="ft032">as an indicator of immune suppression and is most&#160;often observed in people with CD4 T&#160;<br/>lymphocyte (CD4) cell&#160;counts &lt;200 cells/mm</p>
<p style="position:absolute;top:358px;left:424px;white-space:nowrap" class="ft038">3</p>
<p style="position:absolute;top:359px;left:429px;white-space:nowrap" class="ft013">, with esophageal&#160;disease typically occurring at&#160;lower&#160;</p>
<p style="position:absolute;top:379px;left:108px;white-space:nowrap" class="ft013">CD4 counts than oropharyngeal disease.</p>
<p style="position:absolute;top:377px;left:386px;white-space:nowrap" class="ft038">10,11</p>
<p style="position:absolute;top:379px;left:412px;white-space:nowrap" class="ft013">&#160;In contrast, vulvovaginal&#160;candidiasis—whether&#160;a single&#160;</p>
<p style="position:absolute;top:399px;left:108px;white-space:nowrap" class="ft013">episode or recurrent—is common in healthy adults and does not suggest HIV.&#160;</p>
<p style="position:absolute;top:435px;left:108px;white-space:nowrap" class="ft026"><b>Clinical Manifestations</b></p>
<p style="position:absolute;top:438px;left:295px;white-space:nowrap" class="ft036">&#160;</p>
<p style="position:absolute;top:477px;left:108px;white-space:nowrap" class="ft032">Oropharyngeal candidiasis (oral thrush) is characterized by painless, creamy&#160;white, plaque-like&#160;<br/>lesions that&#160;can occur on the buccal&#160;surface, hard or&#160;soft palate, gums, oropharynx, or tongue surface.&#160;<br/>In many cases, lesions can&#160;be scraped off with a&#160;tongue depressor or other instrument. Less&#160;<br/>commonly, erythematous&#160;patches without white plaques can be seen on the&#160;anterior or posterior&#160;<br/>upper palate or diffusely&#160;on the&#160;tongue. Angular cheilosis also&#160;can be caused by&#160;</p>
<p style="position:absolute;top:556px;left:663px;white-space:nowrap" class="ft019"><i>Candida</i></p>
<p style="position:absolute;top:556px;left:722px;white-space:nowrap" class="ft013">. Because a&#160;</p>
<p style="position:absolute;top:576px;left:108px;white-space:nowrap" class="ft032">proportion of&#160;people with&#160;HIV&#160;who&#160;have oropharyngeal&#160;candidiasis also manifest esophageal&#160;<br/>involvement, clinicians should ascertain whether there are symptoms suggestive&#160;of esophageal&#160;<br/>disease in people&#160;with oropharyngeal candidiasis.&#160;&#160;</p>
<p style="position:absolute;top:653px;left:108px;white-space:nowrap" class="ft032">Esophageal candidiasis generally presents with retrosternal&#160;burning pain or discomfort&#160;along with&#160;<br/>odynophagia; occasionally, esophageal candidiasis can be asymptomatic. Endoscopic examination&#160;<br/>reveals whitish plaques&#160;similar to those observed&#160;with oropharyngeal&#160;disease. On occasion, the&#160;<br/>plaques may&#160;progress to superficial&#160;ulcerations of the esophageal&#160;mucosa with&#160;central&#160;or peripheral&#160;<br/>whitish exudates.&#160;</p>
<p style="position:absolute;top:769px;left:108px;white-space:nowrap" class="ft032">In contrast to&#160;oropharyngeal&#160;candidiasis, vulvovaginal&#160;candidiasis is less common in people with&#160;<br/>HIV&#160;and when it occurs,&#160;it&#160;is uncommonly refractory to azole&#160;therapy unless&#160;caused by&#160;<br/>non-</p>
<p style="position:absolute;top:809px;left:140px;white-space:nowrap" class="ft019"><i>C.</i></p>
<p style="position:absolute;top:809px;left:156px;white-space:nowrap" class="ft013">&#160;</p>
<p style="position:absolute;top:809px;left:160px;white-space:nowrap" class="ft019"><i>albicans&#160;</i></p>
<p style="position:absolute;top:809px;left:222px;white-space:nowrap" class="ft013">species.&#160;In people with HIV,</p>
<p style="position:absolute;top:809px;left:420px;white-space:nowrap" class="ft019"><i>&#160;Candida</i></p>
<p style="position:absolute;top:809px;left:483px;white-space:nowrap" class="ft013">&#160;vulvovaginitis usually presents&#160;with white&#160;</p>
<p style="position:absolute;top:829px;left:108px;white-space:nowrap" class="ft032">adherent vaginal discharge associated&#160;with mucosal burning and&#160;itching of mild-to-moderate severity&#160;<br/>and sporadic&#160;recurrences.&#160;In those&#160;with advanced immunosuppression, episodes may be&#160;more severe&#160;<br/>and recur more frequently. &#160;</p>
<p style="position:absolute;top:905px;left:108px;white-space:nowrap" class="ft026"><b>Diagnosis</b></p>
<p style="position:absolute;top:908px;left:190px;white-space:nowrap" class="ft036">&#160;</p>
<p style="position:absolute;top:947px;left:108px;white-space:nowrap" class="ft032">Oropharyngeal candidiasis is usually diagnosed clinically based on the characteristic&#160;appearance of&#160;<br/>lesions. In contrast to oral hairy leukoplakia, the white plaques of&#160;oropharyngeal&#160;candidiasis can be&#160;<br/>scraped off the mucosa. If laboratory&#160;confirmation is required,&#160;scrapings can be examined&#160;<br/>microscopically for characteristic yeast or hyphal&#160;forms, using a potassium&#160;hydroxide&#160;preparation.&#160;<br/>Cultures of clinical&#160;exudative&#160;material&#160;yield the species of&#160;</p>
<p style="position:absolute;top:1026px;left:513px;white-space:nowrap" class="ft019"><i>Candida</i></p>
<p style="position:absolute;top:1026px;left:573px;white-space:nowrap" class="ft013">&#160;present.&#160;</p>
</div>
<!-- Page 48 -->
<a name="48"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}	.ft090{font-size:11px;font-family:MTYWKL+Calibri;color:#c00000;}
-->
</style>
<div id="page48-div" style="position:relative;width:917px;height:1187px;">
<p style="position:absolute;top:1117px;left:108px;white-space:nowrap" class="ft024"><i>Guidelines for the Prevention and Treatment&#160;of&#160;Opportunistic&#160;Infections in Adults&#160;and Adolescents&#160;With HIV&#160;</i></p>
<p style="position:absolute;top:1117px;left:790px;white-space:nowrap" class="ft024"><i>D-2&#160;</i></p>
<p style="position:absolute;top:109px;left:108px;white-space:nowrap" class="ft032">Esophageal candidiasis should be&#160;suspected in people&#160;with low&#160;CD4 count&#160;with substernal chest&#160;<br/>pain, dysphagia, and odynophagia, especially if there is oral thrush present (though the absence of&#160;<br/>oral&#160;thrush does not rule&#160;out esophageal&#160;involvement). The&#160;diagnosis of esophageal candidiasis is&#160;<br/>often made empirically based on symptoms plus response to therapy. The definitive&#160;diagnosis of&#160;<br/>esophageal candidiasis requires direct endoscopic visualization of lesions&#160;with histopathologic&#160;<br/>demonstration of characteristic&#160;</p>
<p style="position:absolute;top:208px;left:326px;white-space:nowrap" class="ft019"><i>Candida&#160;</i></p>
<p style="position:absolute;top:208px;left:390px;white-space:nowrap" class="ft013">yeast forms in tissue and confirmation by fungal&#160;culture&#160;and&#160;</p>
<p style="position:absolute;top:228px;left:108px;white-space:nowrap" class="ft013">speciation.&#160;</p>
<p style="position:absolute;top:265px;left:108px;white-space:nowrap" class="ft032">Vulvovaginal candidiasis usually is diagnosed based on clinical&#160;presentation coupled with&#160;the&#160;<br/>demonstration of characteristic blastosphere&#160;and hyphal&#160;yeast&#160;forms in vaginal&#160;secretions when&#160;<br/>examined microscopically after potassium hydroxide preparation. Culture confirmation is rarely&#160;<br/>required but&#160;may provide&#160;supportive&#160;information. Self-diagnosis&#160;of vulvovaginitis is unreliable;&#160;<br/>microscopic&#160;and culture confirmation is required to&#160;avoid unnecessary exposure to treatment and to&#160;<br/>assess for other potential pathogens including those that&#160;cause sexually transmitted infections (STIs).&#160;</p>
<p style="position:absolute;top:401px;left:108px;white-space:nowrap" class="ft026"><b>Preventing&#160;Exposure</b></p>
<p style="position:absolute;top:403px;left:280px;white-space:nowrap" class="ft036">&#160;</p>
<p style="position:absolute;top:442px;left:108px;white-space:nowrap" class="ft019"><i>Candida</i></p>
<p style="position:absolute;top:442px;left:167px;white-space:nowrap" class="ft013">&#160;organisms are common commensals on&#160;mucosal surfaces in healthy individuals. No&#160;</p>
<p style="position:absolute;top:462px;left:108px;white-space:nowrap" class="ft013">measures are&#160;available&#160;to reduce exposure to these fungi.&#160;</p>
<p style="position:absolute;top:499px;left:108px;white-space:nowrap" class="ft026"><b>Preventing&#160;Disease</b></p>
<p style="position:absolute;top:501px;left:267px;white-space:nowrap" class="ft036">&#160;</p>
<p style="position:absolute;top:541px;left:108px;white-space:nowrap" class="ft013">Routine primary prophylaxis&#160;</p>
<p style="position:absolute;top:541px;left:312px;white-space:nowrap" class="ft012"><b>is not&#160;recommended</b></p>
<p style="position:absolute;top:541px;left:460px;white-space:nowrap" class="ft013">&#160;because mucosal disease is associated&#160;with very&#160;</p>
<p style="position:absolute;top:561px;left:108px;white-space:nowrap" class="ft013">low attributable&#160;morbidity and mortality and, moreover, acute&#160;therapy is highly effective.</p>
<p style="position:absolute;top:559px;left:724px;white-space:nowrap" class="ft038">12,13</p>
<p style="position:absolute;top:561px;left:749px;white-space:nowrap" class="ft013">&#160;Primary&#160;</p>
<p style="position:absolute;top:580px;left:108px;white-space:nowrap" class="ft013">antifungal prophylaxis can lead to infections caused by drug-resistant&#160;</p>
<p style="position:absolute;top:580px;left:591px;white-space:nowrap" class="ft019"><i>Candida</i></p>
<p style="position:absolute;top:580px;left:650px;white-space:nowrap" class="ft013">&#160;strains and introduce&#160;</p>
<p style="position:absolute;top:600px;left:108px;white-space:nowrap" class="ft032">significant&#160;drug–drug interactions and&#160;QTc (QT corrected for heart&#160;rate) prolongation. In&#160;addition,&#160;<br/>long-term&#160;oral prophylaxis is expensive. Therefore,&#160;routine primary prophylaxis&#160;</p>
<p style="position:absolute;top:620px;left:665px;white-space:nowrap" class="ft012"><b>is not&#160;</b></p>
<p style="position:absolute;top:640px;left:108px;white-space:nowrap" class="ft012"><b>recommended</b></p>
<p style="position:absolute;top:640px;left:212px;white-space:nowrap" class="ft013">&#160;</p>
<p style="position:absolute;top:640px;left:217px;white-space:nowrap" class="ft012"><b>(AIII).</b></p>
<p style="position:absolute;top:640px;left:265px;white-space:nowrap" class="ft013">&#160;Administration of antiretroviral&#160;therapy (ART) and immune restoration is the&#160;</p>
<p style="position:absolute;top:660px;left:108px;white-space:nowrap" class="ft013">most effective&#160;means to prevent&#160;disease.&#160;</p>
<p style="position:absolute;top:696px;left:108px;white-space:nowrap" class="ft026"><b>Treating Disease&#160;</b></p>
<p style="position:absolute;top:748px;left:359px;white-space:nowrap" class="ft02"><b>Treating&#160;Mucosal&#160;Candidiasis&#160;</b></p>
<p style="position:absolute;top:782px;left:115px;white-space:nowrap" class="ft042"><b>Oropharyngeal&#160;Candidiasis: Initial Episodes (Duration&#160;of&#160;Therapy:&#160;7–14&#160;Days)&#160;</b></p>
<p style="position:absolute;top:808px;left:115px;white-space:nowrap" class="ft024"><i>Preferred&#160;Therapy</i></p>
<p style="position:absolute;top:808px;left:215px;white-space:nowrap" class="ft083"><i><b>&#160;</b></i></p>
<p style="position:absolute;top:834px;left:115px;white-space:nowrap" class="ft030">•</p>
<p style="position:absolute;top:836px;left:122px;white-space:nowrap" class="ft057">&#160;</p>
<p style="position:absolute;top:836px;left:131px;white-space:nowrap" class="ft041">Fluconazole&#160;200-mg loading&#160;dose, followed by&#160;100–200 mg&#160;PO&#160;once daily&#160;</p>
<p style="position:absolute;top:836px;left:539px;white-space:nowrap" class="ft042"><b>(AI)</b></p>
<p style="position:absolute;top:841px;left:560px;white-space:nowrap" class="ft090">&#160;</p>
<p style="position:absolute;top:836px;left:562px;white-space:nowrap" class="ft041">&#160;</p>
<p style="position:absolute;top:868px;left:115px;white-space:nowrap" class="ft024"><i>Alternative Therapy&#160;</i></p>
<p style="position:absolute;top:894px;left:115px;white-space:nowrap" class="ft030">•</p>
<p style="position:absolute;top:895px;left:131px;white-space:nowrap" class="ft041">One&#160;50-mg miconazole&#160;mucoadhesive buccal&#160;tablet once daily:&#160;Apply&#160;to mucosal&#160;surface over&#160;the&#160;canine fossa (do&#160;not</p>
<p style="position:absolute;top:912px;left:131px;white-space:nowrap" class="ft041">swallow, chew,&#160;or crush tablet).&#160;Refer to the&#160;</p>
<p style="position:absolute;top:912px;left:373px;white-space:nowrap" class="ft043">product label</p>
<p style="position:absolute;top:912px;left:444px;white-space:nowrap" class="ft041">&#160;for more detailed application instructions.&#160;</p>
<p style="position:absolute;top:912px;left:674px;white-space:nowrap" class="ft042"><b>(BI),</b></p>
<p style="position:absolute;top:912px;left:698px;white-space:nowrap" class="ft041">&#160;</p>
<p style="position:absolute;top:912px;left:701px;white-space:nowrap" class="ft024"><i>or</i></p>
<p style="position:absolute;top:912px;left:712px;white-space:nowrap" class="ft041">&#160;</p>
<p style="position:absolute;top:938px;left:115px;white-space:nowrap" class="ft030">•</p>
<p style="position:absolute;top:940px;left:122px;white-space:nowrap" class="ft057">&#160;</p>
<p style="position:absolute;top:939px;left:131px;white-space:nowrap" class="ft041">One 10-mg&#160;clotrimazole&#160;troche PO five times a day&#160;</p>
<p style="position:absolute;top:939px;left:413px;white-space:nowrap" class="ft042"><b>(BI),</b></p>
<p style="position:absolute;top:939px;left:437px;white-space:nowrap" class="ft041">&#160;</p>
<p style="position:absolute;top:939px;left:440px;white-space:nowrap" class="ft024"><i>or</i></p>
<p style="position:absolute;top:939px;left:451px;white-space:nowrap" class="ft041">&#160;</p>
<p style="position:absolute;top:966px;left:115px;white-space:nowrap" class="ft030">•</p>
<p style="position:absolute;top:967px;left:122px;white-space:nowrap" class="ft057">&#160;</p>
<p style="position:absolute;top:967px;left:131px;white-space:nowrap" class="ft041">Nystatin suspension 4–6 mL&#160;PO&#160;four times&#160;daily&#160;</p>
<p style="position:absolute;top:967px;left:391px;white-space:nowrap" class="ft042"><b>(BII),&#160;</b></p>
<p style="position:absolute;top:967px;left:422px;white-space:nowrap" class="ft024"><i>or</i></p>
<p style="position:absolute;top:967px;left:433px;white-space:nowrap" class="ft041">&#160;</p>
<p style="position:absolute;top:993px;left:115px;white-space:nowrap" class="ft030">•</p>
<p style="position:absolute;top:994px;left:122px;white-space:nowrap" class="ft057">&#160;</p>
<p style="position:absolute;top:994px;left:131px;white-space:nowrap" class="ft041">Itraconazole oral&#160;solution&#160;200&#160;mg&#160;PO daily&#160;</p>
<p style="position:absolute;top:994px;left:366px;white-space:nowrap" class="ft042"><b>(BI),</b></p>
<p style="position:absolute;top:994px;left:389px;white-space:nowrap" class="ft041">&#160;</p>
<p style="position:absolute;top:994px;left:393px;white-space:nowrap" class="ft024"><i>or</i></p>
<p style="position:absolute;top:994px;left:404px;white-space:nowrap" class="ft041">&#160;</p>
<p style="position:absolute;top:1020px;left:115px;white-space:nowrap" class="ft030">•</p>
<p style="position:absolute;top:1022px;left:122px;white-space:nowrap" class="ft057">&#160;</p>
<p style="position:absolute;top:1021px;left:131px;white-space:nowrap" class="ft041">Posaconazole oral&#160;suspension 400 mg (10 mL) PO twice daily&#160;for&#160;1 day, then 400&#160;mg daily&#160;</p>
<p style="position:absolute;top:1021px;left:628px;white-space:nowrap" class="ft042"><b>(BI),&#160;</b></p>
<p style="position:absolute;top:1021px;left:655px;white-space:nowrap" class="ft024"><i>or</i></p>
<p style="position:absolute;top:1021px;left:666px;white-space:nowrap" class="ft041">&#160;</p>
</div>
<!-- Page 49 -->
<a name="49"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page49-div" style="position:relative;width:917px;height:1187px;">
<p style="position:absolute;top:1117px;left:108px;white-space:nowrap" class="ft024"><i>Guidelines for the Prevention and Treatment&#160;of&#160;Opportunistic&#160;Infections in Adults&#160;and Adolescents&#160;With HIV&#160;</i></p>
<p style="position:absolute;top:1117px;left:790px;white-space:nowrap" class="ft024"><i>D-3&#160;</i></p>
<p style="position:absolute;top:110px;left:115px;white-space:nowrap" class="ft030">•</p>
<p style="position:absolute;top:111px;left:122px;white-space:nowrap" class="ft057">&#160;</p>
<p style="position:absolute;top:111px;left:131px;white-space:nowrap" class="ft041">Posaconazole tablet 300 mg PO&#160;twice daily for 1&#160;day, then&#160;300 mg daily&#160;</p>
<p style="position:absolute;top:111px;left:526px;white-space:nowrap" class="ft042"><b>(BI)</b></p>
<p style="position:absolute;top:111px;left:547px;white-space:nowrap" class="ft041">&#160;</p>
<p style="position:absolute;top:143px;left:115px;white-space:nowrap" class="ft042"><b>Esophageal Candidiasis&#160;(Duration of Therapy:&#160;14–21 Days)&#160;</b></p>
<p style="position:absolute;top:169px;left:115px;white-space:nowrap" class="ft042"><b>Note:</b></p>
<p style="position:absolute;top:169px;left:146px;white-space:nowrap" class="ft041">&#160;Systemic&#160;antifungals&#160;are required for effective treatment&#160;of&#160;esophageal candidiasis&#160;</p>
<p style="position:absolute;top:169px;left:603px;white-space:nowrap" class="ft042"><b>(AI);</b></p>
<p style="position:absolute;top:169px;left:627px;white-space:nowrap" class="ft041">&#160;topical&#160;therapy&#160;alone is&#160;not&#160;</p>
<p style="position:absolute;top:187px;left:115px;white-space:nowrap" class="ft041">recommended&#160;</p>
<p style="position:absolute;top:187px;left:197px;white-space:nowrap" class="ft042"><b>(AI).</b></p>
<p style="position:absolute;top:187px;left:221px;white-space:nowrap" class="ft041">&#160;</p>
<p style="position:absolute;top:213px;left:115px;white-space:nowrap" class="ft024"><i>Preferred&#160;Therapy&#160;</i></p>
<p style="position:absolute;top:239px;left:115px;white-space:nowrap" class="ft030">•</p>
<p style="position:absolute;top:241px;left:122px;white-space:nowrap" class="ft057">&#160;</p>
<p style="position:absolute;top:240px;left:131px;white-space:nowrap" class="ft041">Fluconazole&#160;200-mg loading&#160;dose, followed by&#160;100–200 mg (up to 400 mg)&#160;PO or&#160;IV&#160;daily&#160;</p>
<p style="position:absolute;top:240px;left:622px;white-space:nowrap" class="ft042"><b>(AI);</b></p>
<p style="position:absolute;top:240px;left:646px;white-space:nowrap" class="ft041">&#160;consider oral&#160;suspension&#160;</p>
<p style="position:absolute;top:257px;left:131px;white-space:nowrap" class="ft041">for people with severe&#160;symptoms&#160;and&#160;difficulty swallowing.&#160;</p>
<p style="position:absolute;top:290px;left:115px;white-space:nowrap" class="ft024"><i>Alternative Therapy</i></p>
<p style="position:absolute;top:290px;left:221px;white-space:nowrap" class="ft083"><i><b>&#160;</b></i></p>
<p style="position:absolute;top:316px;left:115px;white-space:nowrap" class="ft030">•</p>
<p style="position:absolute;top:317px;left:122px;white-space:nowrap" class="ft057">&#160;</p>
<p style="position:absolute;top:317px;left:131px;white-space:nowrap" class="ft041">Itraconazole oral&#160;solution 200 mg PO&#160;daily&#160;</p>
<p style="position:absolute;top:317px;left:365px;white-space:nowrap" class="ft042"><b>(AI),&#160;</b></p>
<p style="position:absolute;top:317px;left:393px;white-space:nowrap" class="ft024"><i>or</i></p>
<p style="position:absolute;top:317px;left:404px;white-space:nowrap" class="ft041">&#160;</p>
<p style="position:absolute;top:343px;left:115px;white-space:nowrap" class="ft030">•</p>
<p style="position:absolute;top:344px;left:122px;white-space:nowrap" class="ft057">&#160;</p>
<p style="position:absolute;top:344px;left:131px;white-space:nowrap" class="ft041">Isavuconazole 400 mg&#160;PO as a loading dose, followed by&#160;isavuconazole&#160;100 mg&#160;PO daily&#160;</p>
<p style="position:absolute;top:344px;left:623px;white-space:nowrap" class="ft042"><b>(BI),&#160;</b></p>
<p style="position:absolute;top:344px;left:650px;white-space:nowrap" class="ft024"><i>or</i></p>
<p style="position:absolute;top:344px;left:661px;white-space:nowrap" class="ft042"><b>&#160;</b></p>
<p style="position:absolute;top:370px;left:115px;white-space:nowrap" class="ft030">•</p>
<p style="position:absolute;top:372px;left:122px;white-space:nowrap" class="ft057">&#160;</p>
<p style="position:absolute;top:371px;left:131px;white-space:nowrap" class="ft041">Isavuconazole 400 mg&#160;PO once&#160;weekly&#160;</p>
<p style="position:absolute;top:371px;left:350px;white-space:nowrap" class="ft042"><b>(BI),&#160;</b></p>
<p style="position:absolute;top:371px;left:377px;white-space:nowrap" class="ft024"><i>or</i></p>
<p style="position:absolute;top:371px;left:388px;white-space:nowrap" class="ft042"><b>&#160;</b></p>
<p style="position:absolute;top:397px;left:115px;white-space:nowrap" class="ft030">•</p>
<p style="position:absolute;top:399px;left:122px;white-space:nowrap" class="ft057">&#160;</p>
<p style="position:absolute;top:398px;left:131px;white-space:nowrap" class="ft041">Voriconazole 200 mg PO&#160;or IV twice daily&#160;</p>
<p style="position:absolute;top:398px;left:361px;white-space:nowrap" class="ft042"><b>(BI),&#160;</b></p>
<p style="position:absolute;top:398px;left:388px;white-space:nowrap" class="ft024"><i>or</i></p>
<p style="position:absolute;top:398px;left:399px;white-space:nowrap" class="ft042"><b>&#160;</b></p>
<p style="position:absolute;top:425px;left:115px;white-space:nowrap" class="ft030">•</p>
<p style="position:absolute;top:426px;left:122px;white-space:nowrap" class="ft057">&#160;</p>
<p style="position:absolute;top:426px;left:131px;white-space:nowrap" class="ft041">Posaconazole oral&#160;suspension 400&#160;mg (10 mL) PO&#160;twice daily for&#160;1 day, then 400&#160;mg daily&#160;</p>
<p style="position:absolute;top:426px;left:628px;white-space:nowrap" class="ft042"><b>(BI),&#160;</b></p>
<p style="position:absolute;top:426px;left:655px;white-space:nowrap" class="ft024"><i>or</i></p>
<p style="position:absolute;top:426px;left:666px;white-space:nowrap" class="ft041">&#160;</p>
<p style="position:absolute;top:452px;left:115px;white-space:nowrap" class="ft030">•</p>
<p style="position:absolute;top:453px;left:122px;white-space:nowrap" class="ft057">&#160;</p>
<p style="position:absolute;top:453px;left:131px;white-space:nowrap" class="ft041">Posaconazole tablet 300 mg PO&#160;twice daily for 1&#160;day, then 300 mg daily&#160;</p>
<p style="position:absolute;top:453px;left:526px;white-space:nowrap" class="ft042"><b>(BI),&#160;</b></p>
<p style="position:absolute;top:453px;left:554px;white-space:nowrap" class="ft024"><i>or</i></p>
<p style="position:absolute;top:453px;left:564px;white-space:nowrap" class="ft041">&#160;</p>
<p style="position:absolute;top:479px;left:115px;white-space:nowrap" class="ft030">•</p>
<p style="position:absolute;top:481px;left:122px;white-space:nowrap" class="ft057">&#160;</p>
<p style="position:absolute;top:480px;left:131px;white-space:nowrap" class="ft041">Lipid formulation&#160;of amphotericin&#160;B&#160;3–4 mg/kg IV&#160;daily&#160;</p>
<p style="position:absolute;top:480px;left:428px;white-space:nowrap" class="ft042"><b>(BI)</b></p>
<p style="position:absolute;top:480px;left:449px;white-space:nowrap" class="ft041">&#160;</p>
<p style="position:absolute;top:506px;left:115px;white-space:nowrap" class="ft030">•</p>
<p style="position:absolute;top:508px;left:122px;white-space:nowrap" class="ft057">&#160;</p>
<p style="position:absolute;top:507px;left:131px;white-space:nowrap" class="ft041">Caspofungin 70-mg loading&#160;dose IV, followed by&#160;50&#160;mg IV&#160;daily&#160;</p>
<p style="position:absolute;top:507px;left:480px;white-space:nowrap" class="ft042"><b>(BI),</b></p>
<p style="position:absolute;top:507px;left:504px;white-space:nowrap" class="ft041">&#160;</p>
<p style="position:absolute;top:507px;left:507px;white-space:nowrap" class="ft024"><i>or</i></p>
<p style="position:absolute;top:507px;left:518px;white-space:nowrap" class="ft041">&#160;</p>
<p style="position:absolute;top:534px;left:115px;white-space:nowrap" class="ft030">•</p>
<p style="position:absolute;top:535px;left:122px;white-space:nowrap" class="ft057">&#160;</p>
<p style="position:absolute;top:535px;left:131px;white-space:nowrap" class="ft041">Micafungin 150 mg&#160;IV&#160;daily</p>
<p style="position:absolute;top:535px;left:279px;white-space:nowrap" class="ft042"><b>&#160;(BI),</b></p>
<p style="position:absolute;top:535px;left:306px;white-space:nowrap" class="ft041">&#160;</p>
<p style="position:absolute;top:535px;left:310px;white-space:nowrap" class="ft024"><i>or</i></p>
<p style="position:absolute;top:535px;left:320px;white-space:nowrap" class="ft041">&#160;</p>
<p style="position:absolute;top:561px;left:115px;white-space:nowrap" class="ft030">•</p>
<p style="position:absolute;top:562px;left:122px;white-space:nowrap" class="ft057">&#160;</p>
<p style="position:absolute;top:562px;left:131px;white-space:nowrap" class="ft041">Anidulafungin 100 mg&#160;IV for one&#160;dose, then anidulafungin 50 mg&#160;IV&#160;daily&#160;</p>
<p style="position:absolute;top:562px;left:529px;white-space:nowrap" class="ft042"><b>(BI)</b></p>
<p style="position:absolute;top:562px;left:550px;white-space:nowrap" class="ft041">&#160;</p>
<p style="position:absolute;top:594px;left:115px;white-space:nowrap" class="ft042"><b>Note:</b></p>
<p style="position:absolute;top:594px;left:146px;white-space:nowrap" class="ft041">&#160;A higher&#160;rate&#160;of esophageal&#160;candidiasis&#160;relapse has been&#160;reported&#160;with&#160;echinocandins than&#160;with&#160;fluconazole.</p>
<p style="position:absolute;top:594px;left:741px;white-space:nowrap" class="ft042"><b>&#160;</b></p>
<p style="position:absolute;top:626px;left:115px;white-space:nowrap" class="ft042"><b>Uncomplicated&#160;Vulvovaginal Candidiasis&#160;</b></p>
<p style="position:absolute;top:653px;left:115px;white-space:nowrap" class="ft030">•</p>
<p style="position:absolute;top:654px;left:122px;white-space:nowrap" class="ft057">&#160;</p>
<p style="position:absolute;top:654px;left:131px;white-space:nowrap" class="ft041">Fluconazole&#160;150&#160;mg PO&#160;for&#160;one&#160;dose&#160;</p>
<p style="position:absolute;top:654px;left:338px;white-space:nowrap" class="ft042"><b>(AII),</b></p>
<p style="position:absolute;top:654px;left:366px;white-space:nowrap" class="ft041">&#160;</p>
<p style="position:absolute;top:654px;left:369px;white-space:nowrap" class="ft024"><i>or</i></p>
<p style="position:absolute;top:654px;left:380px;white-space:nowrap" class="ft041">&#160;</p>
<p style="position:absolute;top:680px;left:115px;white-space:nowrap" class="ft030">•</p>
<p style="position:absolute;top:681px;left:122px;white-space:nowrap" class="ft057">&#160;</p>
<p style="position:absolute;top:681px;left:131px;white-space:nowrap" class="ft041">Topical&#160;azoles&#160;(i.e., clotrimazole,&#160;butoconazole,&#160;miconazole,&#160;tioconazole,&#160;or terconazole)&#160;for 3–7&#160;days&#160;</p>
<p style="position:absolute;top:681px;left:688px;white-space:nowrap" class="ft042"><b>(AII),&#160;</b></p>
<p style="position:absolute;top:681px;left:718px;white-space:nowrap" class="ft024"><i>or</i></p>
<p style="position:absolute;top:681px;left:729px;white-space:nowrap" class="ft041">&#160;</p>
<p style="position:absolute;top:707px;left:115px;white-space:nowrap" class="ft030">•</p>
<p style="position:absolute;top:708px;left:122px;white-space:nowrap" class="ft057">&#160;</p>
<p style="position:absolute;top:708px;left:131px;white-space:nowrap" class="ft041">Ibrexafungerp 300 mg PO&#160;twice&#160;daily&#160;for 1 day&#160;</p>
<p style="position:absolute;top:708px;left:388px;white-space:nowrap" class="ft042"><b>(BI),&#160;</b></p>
<p style="position:absolute;top:708px;left:415px;white-space:nowrap" class="ft024"><i>or</i></p>
<p style="position:absolute;top:708px;left:426px;white-space:nowrap" class="ft041">&#160;</p>
<p style="position:absolute;top:734px;left:115px;white-space:nowrap" class="ft030">•</p>
<p style="position:absolute;top:736px;left:122px;white-space:nowrap" class="ft057">&#160;</p>
<p style="position:absolute;top:735px;left:131px;white-space:nowrap" class="ft041">For&#160;azole-refractory&#160;</p>
<p style="position:absolute;top:735px;left:242px;white-space:nowrap" class="ft024"><i>Candida glabrata</i></p>
<p style="position:absolute;top:735px;left:336px;white-space:nowrap" class="ft041">&#160;vaginitis, boric acid 600 mg&#160;vaginal&#160;suppository&#160;once daily&#160;for&#160;14&#160;days&#160;</p>
<p style="position:absolute;top:735px;left:722px;white-space:nowrap" class="ft042"><b>(BII)&#160;</b></p>
<p style="position:absolute;top:767px;left:115px;white-space:nowrap" class="ft042"><b>Severe or Recurrent&#160;Vulvovaginal Candidiasis&#160;</b></p>
<p style="position:absolute;top:794px;left:115px;white-space:nowrap" class="ft030">•</p>
<p style="position:absolute;top:795px;left:122px;white-space:nowrap" class="ft057">&#160;</p>
<p style="position:absolute;top:795px;left:131px;white-space:nowrap" class="ft041">Oral fluconazole (100–200&#160;mg) PO&#160;daily&#160;</p>
<p style="position:absolute;top:795px;left:353px;white-space:nowrap" class="ft065">or topical&#160;antifungals&#160;for&#160;</p>
<p style="position:absolute;top:795px;left:487px;white-space:nowrap" class="ft064">≥</p>
<p style="position:absolute;top:795px;left:496px;white-space:nowrap" class="ft065">7 days&#160;</p>
<p style="position:absolute;top:795px;left:535px;white-space:nowrap" class="ft042"><b>(AII)&#160;</b></p>
<p style="position:absolute;top:821px;left:115px;white-space:nowrap" class="ft030">•</p>
<p style="position:absolute;top:822px;left:122px;white-space:nowrap" class="ft057">&#160;</p>
<p style="position:absolute;top:822px;left:131px;white-space:nowrap" class="ft024"><i>For&#160;recurrent&#160;only&#160;(the following regimens&#160;include&#160;treatment&#160;for the acute&#160;episode&#160;plus treatment to&#160;reduce incidence of&#160;</i></p>
<p style="position:absolute;top:839px;left:131px;white-space:nowrap" class="ft024"><i>recurrent episodes):&#160;</i></p>
<p style="position:absolute;top:839px;left:244px;white-space:nowrap" class="ft083"><i><b>&#160;</b></i></p>
<p style="position:absolute;top:867px;left:131px;white-space:nowrap" class="ft062">o</p>
<p style="position:absolute;top:866px;left:140px;white-space:nowrap" class="ft057">&#160;</p>
<p style="position:absolute;top:865px;left:148px;white-space:nowrap" class="ft041">Oteseconazole 600 mg PO&#160;at Day 1, 450&#160;mg at&#160;Day&#160;2,&#160;followed&#160;by once&#160;weekly&#160;150&#160;mg dosing starting&#160;at Day&#160;14&#160;for&#160;</p>
<p style="position:absolute;top:883px;left:148px;white-space:nowrap" class="ft041">11 weeks&#160;</p>
<p style="position:absolute;top:883px;left:203px;white-space:nowrap" class="ft042"><b>(AI)&#160;</b></p>
<p style="position:absolute;top:883px;left:227px;white-space:nowrap" class="ft041">(for those who are&#160;not&#160;of reproductive potential);&#160;</p>
<p style="position:absolute;top:883px;left:492px;white-space:nowrap" class="ft024"><i>or</i></p>
<p style="position:absolute;top:883px;left:503px;white-space:nowrap" class="ft041">&#160;&#160;</p>
<p style="position:absolute;top:910px;left:131px;white-space:nowrap" class="ft062">o</p>
<p style="position:absolute;top:909px;left:140px;white-space:nowrap" class="ft057">&#160;</p>
<p style="position:absolute;top:909px;left:148px;white-space:nowrap" class="ft044">Fluconazole&#160;150&#160;mg PO at Days&#160;1, 4, and 7,&#160;followed by oteseconazole&#160;150 mg&#160;PO daily at Days&#160;14 through&#160;20,&#160;<br/>followed by&#160;oteseconazole 150&#160;mg once weekly&#160;starting at&#160;Day&#160;28 for&#160;11&#160;weeks&#160;(Weeks&#160;4–14)&#160;</p>
<p style="position:absolute;top:926px;left:664px;white-space:nowrap" class="ft042"><b>(AI)</b></p>
<p style="position:absolute;top:926px;left:684px;white-space:nowrap" class="ft041">&#160;(for&#160;those&#160;who are&#160;</p>
<p style="position:absolute;top:943px;left:148px;white-space:nowrap" class="ft041">not&#160;of reproductive potential); or&#160;&#160;</p>
<p style="position:absolute;top:971px;left:131px;white-space:nowrap" class="ft062">o</p>
<p style="position:absolute;top:970px;left:140px;white-space:nowrap" class="ft057">&#160;</p>
<p style="position:absolute;top:969px;left:148px;white-space:nowrap" class="ft041">Fluconazole&#160;150&#160;mg PO every&#160;72 hours&#160;x&#160;3 doses, followed by&#160;ibrexafungerp 300&#160;mg PO&#160;twice daily 1 day per&#160;month for&#160;</p>
<p style="position:absolute;top:987px;left:148px;white-space:nowrap" class="ft041">6 months&#160;</p>
<p style="position:absolute;top:987px;left:202px;white-space:nowrap" class="ft042"><b>(BI)&#160;</b></p>
<p style="position:absolute;top:987px;left:225px;white-space:nowrap" class="ft041">(use an effective form of contraception&#160;during treatment and&#160;for 4&#160;days&#160;after the last dose)&#160;</p>
<p style="position:absolute;top:987px;left:718px;white-space:nowrap" class="ft042"><b>&#160;</b></p>
</div>
<!-- Page 50 -->
<a name="50"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page50-div" style="position:relative;width:917px;height:1187px;">
<p style="position:absolute;top:1117px;left:108px;white-space:nowrap" class="ft024"><i>Guidelines for the Prevention and Treatment&#160;of&#160;Opportunistic&#160;Infections in Adults&#160;and Adolescents&#160;With HIV&#160;</i></p>
<p style="position:absolute;top:1117px;left:790px;white-space:nowrap" class="ft024"><i>D-4&#160;</i></p>
<p style="position:absolute;top:114px;left:115px;white-space:nowrap" class="ft056"><b>Other&#160;Considerations&#160;</b></p>
<p style="position:absolute;top:143px;left:115px;white-space:nowrap" class="ft030">•</p>
<p style="position:absolute;top:144px;left:122px;white-space:nowrap" class="ft057">&#160;</p>
<p style="position:absolute;top:144px;left:131px;white-space:nowrap" class="ft041">Systemic&#160;azoles&#160;may have&#160;</p>
<p style="position:absolute;top:144px;left:280px;white-space:nowrap" class="ft042"><b>significant</b></p>
<p style="position:absolute;top:144px;left:342px;white-space:nowrap" class="ft041">&#160;drug–drug interactions&#160;with ARV drugs&#160;(refer to&#160;</p>
<p style="position:absolute;top:144px;left:606px;white-space:nowrap" class="ft043">Drug–Drug&#160;Interactions&#160;section of&#160;</p>
<p style="position:absolute;top:161px;left:131px;white-space:nowrap" class="ft043">the&#160;Adult and Adolescent Antiretroviral Guidelines</p>
<p style="position:absolute;top:161px;left:402px;white-space:nowrap" class="ft041">) and other drugs&#160;used for the treatment of&#160;opportunistic&#160;infections&#160;(refer&#160;</p>
<p style="position:absolute;top:178px;left:131px;white-space:nowrap" class="ft041">to&#160;</p>
<p style="position:absolute;top:178px;left:145px;white-space:nowrap" class="ft043">Table 4:&#160;Significant Pharmacokinetic Interactions Between&#160;Drugs Used&#160;to Treat&#160;or Prevent&#160;Opportunistic&#160;Infections</p>
<p style="position:absolute;top:178px;left:768px;white-space:nowrap" class="ft041">).&#160;</p>
<p style="position:absolute;top:195px;left:131px;white-space:nowrap" class="ft041">Consider&#160;TDM if&#160;prolonged use is&#160;indicated.&#160;</p>
<p style="position:absolute;top:222px;left:115px;white-space:nowrap" class="ft030">•</p>
<p style="position:absolute;top:223px;left:122px;white-space:nowrap" class="ft057">&#160;</p>
<p style="position:absolute;top:223px;left:131px;white-space:nowrap" class="ft041">Fluconazole, itraconazole, posaconazole,&#160;and&#160;voriconazole can increase the risk&#160;for QTc prolongation,&#160;especially&#160;when&#160;co-</p>
<p style="position:absolute;top:240px;left:131px;white-space:nowrap" class="ft041">administered with other QTc&#160;prolonging drugs&#160;that are cleared by&#160;CYP3A4. &#160;</p>
<p style="position:absolute;top:266px;left:115px;white-space:nowrap" class="ft030">•</p>
<p style="position:absolute;top:268px;left:122px;white-space:nowrap" class="ft057">&#160;</p>
<p style="position:absolute;top:267px;left:131px;white-space:nowrap" class="ft041">Chronic&#160;or prolonged use of&#160;azoles might promote development of&#160;resistance.&#160;&#160;</p>
<p style="position:absolute;top:303px;left:115px;white-space:nowrap" class="ft056"><b>Considerations During&#160;Pregnancy&#160;and&#160;Lactation&#160;</b></p>
<p style="position:absolute;top:331px;left:115px;white-space:nowrap" class="ft030">•</p>
<p style="position:absolute;top:333px;left:122px;white-space:nowrap" class="ft057">&#160;</p>
<p style="position:absolute;top:332px;left:131px;white-space:nowrap" class="ft041">Topical&#160;therapy&#160;is&#160;preferable for&#160;treatment of&#160;oral&#160;candidiasis&#160;and&#160;vulvovaginal&#160;candidiasis&#160;in pregnancy.&#160;Oral&#160;fluconazole&#160;</p>
<p style="position:absolute;top:350px;left:131px;white-space:nowrap" class="ft041">should be&#160;avoided when treating vulvovaginal&#160;candidiasis in the first trimester&#160;</p>
<p style="position:absolute;top:350px;left:555px;white-space:nowrap" class="ft042"><b>(AIII).</b></p>
<p style="position:absolute;top:350px;left:586px;white-space:nowrap" class="ft041">&#160;</p>
<p style="position:absolute;top:376px;left:115px;white-space:nowrap" class="ft030">•</p>
<p style="position:absolute;top:377px;left:122px;white-space:nowrap" class="ft057">&#160;</p>
<p style="position:absolute;top:377px;left:131px;white-space:nowrap" class="ft041">During pregnancy, substitution of amphotericin B&#160;for fluconazole&#160;in the first trimester is recommended for invasive or&#160;</p>
<p style="position:absolute;top:394px;left:131px;white-space:nowrap" class="ft041">refractory&#160;esophageal&#160;</p>
<p style="position:absolute;top:394px;left:253px;white-space:nowrap" class="ft024"><i>Candida</i></p>
<p style="position:absolute;top:394px;left:299px;white-space:nowrap" class="ft041">&#160;infections&#160;</p>
<p style="position:absolute;top:394px;left:358px;white-space:nowrap" class="ft042"><b>(AIII).</b></p>
<p style="position:absolute;top:394px;left:389px;white-space:nowrap" class="ft041">&#160;</p>
<p style="position:absolute;top:420px;left:115px;white-space:nowrap" class="ft030">•</p>
<p style="position:absolute;top:422px;left:122px;white-space:nowrap" class="ft057">&#160;</p>
<p style="position:absolute;top:421px;left:131px;white-space:nowrap" class="ft041">Human data&#160;are&#160;not&#160;available for&#160;micafungin, anidulafungin, caspofungin, thus their use in human pregnancy&#160;is&#160;not&#160;</p>
<p style="position:absolute;top:438px;left:131px;white-space:nowrap" class="ft041">recommended&#160;</p>
<p style="position:absolute;top:438px;left:213px;white-space:nowrap" class="ft042"><b>(AIII).&#160;</b></p>
<p style="position:absolute;top:438px;left:247px;white-space:nowrap" class="ft041">Human data on the use of voriconazole&#160;are&#160;also not available, so its use</p>
<p style="position:absolute;top:438px;left:640px;white-space:nowrap" class="ft042"><b>&#160;</b></p>
<p style="position:absolute;top:438px;left:643px;white-space:nowrap" class="ft041">is&#160;</p>
<p style="position:absolute;top:438px;left:655px;white-space:nowrap" class="ft042"><b>not&#160;recommended.</b></p>
<p style="position:absolute;top:438px;left:765px;white-space:nowrap" class="ft041">&#160;</p>
<p style="position:absolute;top:465px;left:115px;white-space:nowrap" class="ft030">•</p>
<p style="position:absolute;top:466px;left:122px;white-space:nowrap" class="ft057">&#160;</p>
<p style="position:absolute;top:466px;left:131px;white-space:nowrap" class="ft041">Oteseconazole is&#160;</p>
<p style="position:absolute;top:466px;left:229px;white-space:nowrap" class="ft042"><b>contraindicated</b></p>
<p style="position:absolute;top:466px;left:320px;white-space:nowrap" class="ft041">&#160;during&#160;pregnancy&#160;and&#160;when lactating as animal&#160;studies have&#160;shown fetal&#160;malformations&#160;</p>
<p style="position:absolute;top:483px;left:131px;white-space:nowrap" class="ft044">including ocular toxicity.&#160;Due to&#160;its&#160;long&#160;half-life,&#160;it&#160;is&#160;also contraindicated in females of reproductive potential&#160;despite the&#160;<br/>use of oral&#160;or other contraception. &#160;</p>
<p style="position:absolute;top:526px;left:115px;white-space:nowrap" class="ft030">•</p>
<p style="position:absolute;top:528px;left:122px;white-space:nowrap" class="ft057">&#160;</p>
<p style="position:absolute;top:527px;left:131px;white-space:nowrap" class="ft041">Ibrexafungerp is&#160;teratogenic&#160;in animal&#160;studies. Use during&#160;pregnancy&#160;and&#160;when&#160;lactating is&#160;</p>
<p style="position:absolute;top:527px;left:627px;white-space:nowrap" class="ft042"><b>contraindicated.</b></p>
<p style="position:absolute;top:527px;left:722px;white-space:nowrap" class="ft041">&#160;</p>
<p style="position:absolute;top:558px;left:108px;white-space:nowrap" class="ft042"><b>Key:</b></p>
<p style="position:absolute;top:558px;left:135px;white-space:nowrap" class="ft041">&#160;ARV = antiretroviral; CYP&#160;=&#160;cytochrome P450; IV&#160;= intravenous; PO = orally;&#160;QTc =&#160;QT&#160;corrected&#160;for&#160;heart rate;&#160;</p>
<p style="position:absolute;top:575px;left:108px;white-space:nowrap" class="ft041">TDM = therapeutic&#160;drug monitoring&#160;</p>
<p style="position:absolute;top:610px;left:108px;white-space:nowrap" class="ft029"><i><b>Oropharyngeal Candidiasis&#160;</b></i></p>
<p style="position:absolute;top:651px;left:108px;white-space:nowrap" class="ft013">Oral fluconazole is as effective&#160;as or superior to topical therapy for oropharyngeal&#160;candidiasis.</p>
<p style="position:absolute;top:650px;left:759px;white-space:nowrap" class="ft038">14</p>
<p style="position:absolute;top:651px;left:771px;white-space:nowrap" class="ft013">&#160;In&#160;</p>
<p style="position:absolute;top:671px;left:108px;white-space:nowrap" class="ft032">addition, oral&#160;therapy is more convenient than topical&#160;therapy and usually better tolerated. Oral&#160;<br/>therapy has the additional&#160;benefit&#160;over&#160;topical&#160;regimens of being&#160;efficacious in treating esophageal&#160;<br/>candidiasis.&#160;Oral fluconazole at&#160;100 to 200 mg once a&#160;day is considered the drug of choice to treat&#160;<br/>oropharyngeal&#160;candidiasis except during pregnancy&#160;</p>
<p style="position:absolute;top:731px;left:467px;white-space:nowrap" class="ft012"><b>(AI).</b></p>
<p style="position:absolute;top:729px;left:503px;white-space:nowrap" class="ft038">14</p>
<p style="position:absolute;top:731px;left:514px;white-space:nowrap" class="ft013">&#160;One to 2 weeks&#160;of therapy until resolution&#160;</p>
<p style="position:absolute;top:751px;left:108px;white-space:nowrap" class="ft013">of infection is recommended for oropharyngeal candidiasis.</p>
<p style="position:absolute;top:749px;left:519px;white-space:nowrap" class="ft038">14</p>
<p style="position:absolute;top:751px;left:531px;white-space:nowrap" class="ft013">&#160;</p>
<p style="position:absolute;top:788px;left:108px;white-space:nowrap" class="ft032">Using topical agents to treat&#160;oropharyngeal&#160;candidiasis includes several advantages: it reduces&#160;<br/>systemic drug exposure,&#160;diminishes the risk of drug–drug interactions and&#160;systemic adverse events,&#160;<br/>and may reduce&#160;the&#160;likelihood that antifungal&#160;resistance&#160;develops. As an alternative&#160;to oral&#160;<br/>fluconazole, once-daily miconazole in 50-mg mucoadhesive&#160;buccal&#160;tablets&#160;</p>
<p style="position:absolute;top:847px;left:626px;white-space:nowrap" class="ft012"><b>(BI)</b></p>
<p style="position:absolute;top:847px;left:656px;white-space:nowrap" class="ft013">&#160;or five-times-per-day&#160;</p>
<p style="position:absolute;top:867px;left:108px;white-space:nowrap" class="ft013">clotrimazole&#160;troches can be used to treat oropharyngeal&#160;candidiasis&#160;</p>
<p style="position:absolute;top:867px;left:574px;white-space:nowrap" class="ft012"><b>(BI);</b></p>
<p style="position:absolute;top:867px;left:610px;white-space:nowrap" class="ft013">&#160;these&#160;regimens were shown&#160;</p>
<p style="position:absolute;top:887px;left:108px;white-space:nowrap" class="ft032">to be&#160;equivalent&#160;in a&#160;multicenter, randomized study.&#160;Nystatin suspension four&#160;times daily remains an&#160;<br/>additional&#160;alternative&#160;</p>
<p style="position:absolute;top:907px;left:258px;white-space:nowrap" class="ft012"><b>(BII).</b></p>
<p style="position:absolute;top:905px;left:299px;white-space:nowrap" class="ft038">15</p>
<p style="position:absolute;top:907px;left:315px;white-space:nowrap" class="ft013">Unfavorable&#160;taste and multiple daily dosing,&#160;such as in the cases of&#160;</p>
<p style="position:absolute;top:927px;left:108px;white-space:nowrap" class="ft032">clotrimazole&#160;and nystatin,&#160;may lead to decreased tolerability of and adherence&#160;to these topical&#160;<br/>therapies. If&#160;esophageal involvement is suspected, topical&#160;therapy alone is not recommended&#160;</p>
<p style="position:absolute;top:946px;left:750px;white-space:nowrap" class="ft012"><b>(AI).</b></p>
<p style="position:absolute;top:946px;left:785px;white-space:nowrap" class="ft013">&#160;</p>
<p style="position:absolute;top:983px;left:108px;white-space:nowrap" class="ft032">Itraconazole&#160;is formulated as an oral solution or capsules, which&#160;differ in dosing and efficacy. Oral&#160;<br/>itraconazole for 7 to 14 days is as effective&#160;as oral&#160;fluconazole for oropharyngeal&#160;candidiasis but less&#160;<br/>well&#160;tolerated.</p>
<p style="position:absolute;top:1022px;left:207px;white-space:nowrap" class="ft038">16</p>
<p style="position:absolute;top:1023px;left:218px;white-space:nowrap" class="ft013">&#160;Posaconazole oral&#160;suspension</p>
<p style="position:absolute;top:1022px;left:427px;white-space:nowrap" class="ft038">17</p>
<p style="position:absolute;top:1023px;left:438px;white-space:nowrap" class="ft013">&#160;is&#160;also as effective&#160;as fluconazole and generally&#160;</p>
<p style="position:absolute;top:1043px;left:108px;white-space:nowrap" class="ft013">better tolerated than itraconazole solution, but it is more expensive. Although both posaconazole and&#160;</p>
</div>
<!-- Page 51 -->
<a name="51"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page51-div" style="position:relative;width:917px;height:1187px;">
<p style="position:absolute;top:1117px;left:108px;white-space:nowrap" class="ft024"><i>Guidelines for the Prevention and Treatment&#160;of&#160;Opportunistic&#160;Infections in Adults&#160;and Adolescents&#160;With HIV&#160;</i></p>
<p style="position:absolute;top:1117px;left:790px;white-space:nowrap" class="ft024"><i>D-5&#160;</i></p>
<p style="position:absolute;top:109px;left:108px;white-space:nowrap" class="ft013">itraconazole have&#160;more&#160;drug–drug interactions than fluconazole,</p>
<p style="position:absolute;top:109px;left:553px;white-space:nowrap" class="ft012"><b>&#160;</b></p>
<p style="position:absolute;top:109px;left:557px;white-space:nowrap" class="ft013">there are&#160;a few situations, such as&#160;</p>
<p style="position:absolute;top:109px;left:792px;white-space:nowrap" class="ft019"><i>in&#160;</i></p>
<p style="position:absolute;top:129px;left:108px;white-space:nowrap" class="ft019"><i>vitro</i></p>
<p style="position:absolute;top:129px;left:141px;white-space:nowrap" class="ft013">&#160;resistance or poor clinical&#160;response, that would&#160;suggest these drugs be&#160;used in preference to&#160;</p>
<p style="position:absolute;top:148px;left:108px;white-space:nowrap" class="ft013">fluconazole solely to treat&#160;mucosal candidiasis&#160;</p>
<p style="position:absolute;top:148px;left:433px;white-space:nowrap" class="ft012"><b>(BI).&#160;</b></p>
<p style="position:absolute;top:148px;left:472px;white-space:nowrap" class="ft013">In a multicenter, randomized study,&#160;</p>
<p style="position:absolute;top:168px;left:108px;white-space:nowrap" class="ft032">posaconazole was found&#160;to be more effective than fluconazole&#160;in sustaining&#160;clinical success after&#160;<br/>antifungal therapy was&#160;discontinued.</p>
<p style="position:absolute;top:187px;left:362px;white-space:nowrap" class="ft038">17</p>
<p style="position:absolute;top:188px;left:373px;white-space:nowrap" class="ft013">&#160;A oral delayed-release tablet&#160;formulation of posaconazole,&#160;</p>
<p style="position:absolute;top:208px;left:108px;white-space:nowrap" class="ft013">which exhibits less&#160;variable&#160;absorption&#160;than the&#160;oral&#160;suspension,&#160;has been&#160;available.</p>
<p style="position:absolute;top:207px;left:686px;white-space:nowrap" class="ft038">18</p>
<p style="position:absolute;top:208px;left:697px;white-space:nowrap" class="ft013">&#160;Whether it&#160;</p>
<p style="position:absolute;top:228px;left:108px;white-space:nowrap" class="ft032">offers any advantage&#160;for the treatment of oropharyngeal&#160;candidiasis has not been formally tested;&#160;<br/>however, it&#160;has been shown that switching from&#160;the&#160;oral&#160;suspension to the tablet&#160;formulation of&#160;<br/>posaconazole results in greater serum&#160;concentrations.</p>
<p style="position:absolute;top:266px;left:476px;white-space:nowrap" class="ft038">19</p>
<p style="position:absolute;top:267px;left:487px;white-space:nowrap" class="ft013">&#160;Itraconazole capsules&#160;are less effective than&#160;</p>
<p style="position:absolute;top:287px;left:108px;white-space:nowrap" class="ft032">fluconazole because of their more&#160;variable absorption, and they&#160;are associated with more&#160;drug–drug&#160;<br/>interactions than fluconazole.&#160;</p>
<p style="position:absolute;top:344px;left:108px;white-space:nowrap" class="ft029"><i><b>Esophageal&#160;Candidiasis&#160;</b></i></p>
<p style="position:absolute;top:386px;left:108px;white-space:nowrap" class="ft013">Systemic antifungals are required for effective&#160;treatment of esophageal candidiasis&#160;</p>
<p style="position:absolute;top:386px;left:682px;white-space:nowrap" class="ft012"><b>(AI).</b></p>
<p style="position:absolute;top:386px;left:717px;white-space:nowrap" class="ft013">&#160;A 14-day&#160;to&#160;</p>
<p style="position:absolute;top:405px;left:108px;white-space:nowrap" class="ft032">21-day course of either fluconazole (oral&#160;or intravenous [IV])&#160;or&#160;oral&#160;itraconazole solution is highly&#160;<br/>effective and therefore&#160;recommended&#160;</p>
<p style="position:absolute;top:425px;left:370px;white-space:nowrap" class="ft012"><b>(AI).</b></p>
<p style="position:absolute;top:425px;left:405px;white-space:nowrap" class="ft013">&#160;As&#160;with&#160;oropharyngeal&#160;candidiasis, however, itraconazole&#160;</p>
<p style="position:absolute;top:445px;left:108px;white-space:nowrap" class="ft032">capsules for&#160;esophageal candidiasis may be less effective than fluconazole because of variable&#160;<br/>absorption &#160;Therefore, oral or IV fluconazole remains the preferred therapy for esophageal&#160;<br/>candidiasis&#160;</p>
<p style="position:absolute;top:485px;left:189px;white-space:nowrap" class="ft012"><b>(AI).</b></p>
<p style="position:absolute;top:485px;left:224px;white-space:nowrap" class="ft013">&#160;People&#160;with severe symptoms initially may have difficulty swallowing&#160;oral&#160;drugs;&#160;</p>
<p style="position:absolute;top:505px;left:108px;white-space:nowrap" class="ft032">oral&#160;fluconazole suspension is available and should&#160;be considered in such patients. A&#160;2-week course&#160;<br/>of isavuconazole, given orally at an initial loading dose of 400 mg followed by 100 mg once&#160;daily&#160;</p>
<p style="position:absolute;top:544px;left:108px;white-space:nowrap" class="ft012"><b>(BI)</b></p>
<p style="position:absolute;top:544px;left:138px;white-space:nowrap" class="ft013">&#160;or&#160;400&#160;mg once weekly, is as effective&#160;as fluconazole for uncomplicated esophageal candidiasis&#160;</p>
<p style="position:absolute;top:564px;left:108px;white-space:nowrap" class="ft013">and is recommended as an alternative&#160;regimen&#160;</p>
<p style="position:absolute;top:564px;left:432px;white-space:nowrap" class="ft012"><b>(BI);</b></p>
<p style="position:absolute;top:564px;left:467px;white-space:nowrap" class="ft013">&#160;however,&#160;a&#160;higher rate of gastrointestinal&#160;</p>
<p style="position:absolute;top:584px;left:108px;white-space:nowrap" class="ft032">adverse effects was&#160;seen&#160;with the 100-mg, once-daily isavuconazole regimen than with fluconazole&#160;<br/>and the other isavuconazole&#160;regimens.</p>
<p style="position:absolute;top:602px;left:372px;white-space:nowrap" class="ft038">20</p>
<p style="position:absolute;top:604px;left:383px;white-space:nowrap" class="ft013">&#160;Posaconazole, voriconazole, amphotericin B (lipid&#160;</p>
<p style="position:absolute;top:624px;left:108px;white-space:nowrap" class="ft032">formulations), and the echinocandins&#160;caspofungin,&#160;micafungin, and anidulafungin all&#160;effectively&#160;treat&#160;<br/>esophageal candidiasis and also can be&#160;administered as alternatives</p>
<p style="position:absolute;top:643px;left:571px;white-space:nowrap" class="ft012"><b>&#160;(BI);</b></p>
<p style="position:absolute;top:643px;left:611px;white-space:nowrap" class="ft013">&#160;however, esophageal&#160;</p>
<p style="position:absolute;top:663px;left:108px;white-space:nowrap" class="ft013">candidiasis appears to have a higher relapse rate after treatment with the echinocandins.</p>
<p style="position:absolute;top:662px;left:713px;white-space:nowrap" class="ft038">21,22</p>
<p style="position:absolute;top:663px;left:738px;white-space:nowrap" class="ft013">&#160;Cost and&#160;</p>
<p style="position:absolute;top:683px;left:108px;white-space:nowrap" class="ft013">insurance&#160;coverage also&#160;might be&#160;issues for the&#160;newer therapies. &#160;</p>
<p style="position:absolute;top:720px;left:108px;white-space:nowrap" class="ft032">Although infection with other pathogens that&#160;can cause esophagitis (e.g., cytomegalovirus, herpes&#160;<br/>simplex virus) can result&#160;in symptoms&#160;that mimic&#160;those of esophageal&#160;candidiasis, a diagnostic&#160;and&#160;<br/>therapeutic&#160;trial of antifungal&#160;therapy is usually&#160;warranted before&#160;endoscopy.&#160;In those&#160;who&#160;do not&#160;<br/>respond to antifungal&#160;therapy within 7&#160;days, endoscopy is recommended to identify other potential&#160;<br/>causes of esophagitis or drug-resistant&#160;</p>
<p style="position:absolute;top:800px;left:376px;white-space:nowrap" class="ft019"><i>Candida</i></p>
<p style="position:absolute;top:800px;left:435px;white-space:nowrap" class="ft013">&#160;</p>
<p style="position:absolute;top:800px;left:439px;white-space:nowrap" class="ft012"><b>(AII).</b></p>
<p style="position:absolute;top:800px;left:481px;white-space:nowrap" class="ft013">&#160;</p>
<p style="position:absolute;top:837px;left:108px;white-space:nowrap" class="ft029"><i><b>Vulvovaginal&#160;Candidiasis&#160;</b></i></p>
<p style="position:absolute;top:878px;left:108px;white-space:nowrap" class="ft032">In most people&#160;with HIV,&#160;vulvovaginal candidiasis is uncomplicated and responds readily to short-<br/>course oral&#160;or topical&#160;treatment with any of several therapies, including the following:&#160;</p>
<p style="position:absolute;top:934px;left:108px;white-space:nowrap" class="ft040">•</p>
<p style="position:absolute;top:936px;left:116px;white-space:nowrap" class="ft046">&#160;</p>
<p style="position:absolute;top:936px;left:135px;white-space:nowrap" class="ft013">Oral fluconazole&#160;</p>
<p style="position:absolute;top:936px;left:255px;white-space:nowrap" class="ft012"><b>(AII)</b></p>
<p style="position:absolute;top:936px;left:292px;white-space:nowrap" class="ft013">&#160;</p>
<p style="position:absolute;top:964px;left:108px;white-space:nowrap" class="ft040">•</p>
<p style="position:absolute;top:966px;left:116px;white-space:nowrap" class="ft046">&#160;</p>
<p style="position:absolute;top:966px;left:135px;white-space:nowrap" class="ft013">Topical&#160;azoles (i.e., clotrimazole, butoconazole, miconazole, tioconazole, or&#160;terconazole)&#160;</p>
<p style="position:absolute;top:966px;left:754px;white-space:nowrap" class="ft012"><b>(AII)</b></p>
<p style="position:absolute;top:966px;left:791px;white-space:nowrap" class="ft013">&#160;</p>
<p style="position:absolute;top:994px;left:108px;white-space:nowrap" class="ft040">•</p>
<p style="position:absolute;top:996px;left:116px;white-space:nowrap" class="ft046">&#160;</p>
<p style="position:absolute;top:996px;left:135px;white-space:nowrap" class="ft013">Oral ibrexafungerp&#160;</p>
<p style="position:absolute;top:996px;left:271px;white-space:nowrap" class="ft012"><b>(BI)</b></p>
<p style="position:absolute;top:996px;left:301px;white-space:nowrap" class="ft013">&#160;</p>
<p style="position:absolute;top:1033px;left:108px;white-space:nowrap" class="ft013">Severe or recurrent&#160;episodes of vaginitis should&#160;be treated with oral fluconazole&#160;or topical&#160;antifungal&#160;</p>
<p style="position:absolute;top:1053px;left:108px;white-space:nowrap" class="ft018">therapy for&#160;</p>
<p style="position:absolute;top:1053px;left:188px;white-space:nowrap" class="ft069">≥</p>
<p style="position:absolute;top:1053px;left:198px;white-space:nowrap" class="ft018">7 days&#160;</p>
<p style="position:absolute;top:1053px;left:247px;white-space:nowrap" class="ft012"><b>(AII).</b></p>
<p style="position:absolute;top:1053px;left:288px;white-space:nowrap" class="ft013">&#160;&#160;</p>
</div>
<!-- Page 52 -->
<a name="52"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}	.ft091{font-size:17px;font-family:TURBHP+Tinos;color:#202020;}
-->
</style>
<div id="page52-div" style="position:relative;width:917px;height:1187px;">
<p style="position:absolute;top:1117px;left:108px;white-space:nowrap" class="ft024"><i>Guidelines for the Prevention and Treatment&#160;of&#160;Opportunistic&#160;Infections in Adults&#160;and Adolescents&#160;With HIV&#160;</i></p>
<p style="position:absolute;top:1117px;left:790px;white-space:nowrap" class="ft024"><i>D-6&#160;</i></p>
<p style="position:absolute;top:109px;left:108px;white-space:nowrap" class="ft032">There are&#160;now additional options for recurrent vulvovaginal&#160;candidiasis that&#160;include treatment&#160;for the&#160;<br/>acute episode plus treatment to reduce incidence&#160;of recurrent episodes.</p>
<p style="position:absolute;top:129px;left:595px;white-space:nowrap" class="ft012"><b>&#160;</b></p>
<p style="position:absolute;top:129px;left:600px;white-space:nowrap" class="ft013">One option</p>
<p style="position:absolute;top:129px;left:677px;white-space:nowrap" class="ft012"><b>&#160;</b></p>
<p style="position:absolute;top:129px;left:681px;white-space:nowrap" class="ft013">for people who&#160;</p>
<p style="position:absolute;top:148px;left:108px;white-space:nowrap" class="ft032">are not&#160;of reproductive&#160;potential is oteseconazole, a new tetrazole antifungal&#160;that was U.S.&#160;Food and&#160;<br/>Drug&#160;Administration (FDA)–approved&#160;in 2022. It&#160;exhibited efficacy when administered as 600 mg&#160;<br/>on Day 1 and 450 mg on&#160;Day 2, followed by once-weekly 150&#160;mg dosing&#160;starting at Day 14 for&#160;<br/>11 weeks&#160;or&#160;when it&#160;was&#160;administered after three fluconazole&#160;150-mg doses administered at Days 1,&#160;<br/>4, and 7, followed by&#160;oteseconazole 150 mg daily dosing at&#160;Days 14 through&#160;20, followed&#160;by&#160;<br/>oteseconazole&#160;150 mg once weekly starting at Day 28 for 11&#160;weeks (Weeks&#160;4 through 14)&#160;</p>
<p style="position:absolute;top:248px;left:732px;white-space:nowrap" class="ft012"><b>(AI).</b></p>
<p style="position:absolute;top:246px;left:768px;white-space:nowrap" class="ft038">23,24</p>
<p style="position:absolute;top:248px;left:793px;white-space:nowrap" class="ft012"><b>&#160;&#160;</b></p>
<p style="position:absolute;top:285px;left:108px;white-space:nowrap" class="ft013">Ibrexafungerp is an oral b-glucan synthase inhibitor that belongs in the&#160;class&#160;of&#160;</p>
<p style="position:absolute;top:285px;left:658px;white-space:nowrap" class="ft091">triterpenoids. It was&#160;</p>
<p style="position:absolute;top:304px;left:108px;white-space:nowrap" class="ft091">effective in Phase 2 and&#160;Phase 3 clinical&#160;trials of</p>
<p style="position:absolute;top:304px;left:443px;white-space:nowrap" class="ft013">&#160;uncomplicated vulvovaginal candidiasis&#160;and was&#160;</p>
<p style="position:absolute;top:324px;left:108px;white-space:nowrap" class="ft013">approved by&#160;the&#160;FDA in 2021.</p>
<p style="position:absolute;top:323px;left:319px;white-space:nowrap" class="ft038">25,26</p>
<p style="position:absolute;top:324px;left:344px;white-space:nowrap" class="ft013">&#160;In December 2022, ibrexafungerp was approved by the&#160;FDA for&#160;</p>
<p style="position:absolute;top:344px;left:108px;white-space:nowrap" class="ft032">women with&#160;recurrent vulvovaginal candidiasis. Specifically, administration of fluconazole 150 mg&#160;<br/>every 72 hours for three&#160;doses, followed by ibrexafungerp 300 mg twice daily 1 day per month for&#160;<br/>6 months&#160;was associated&#160;with absence&#160;of recurrent&#160;infection through week&#160;24 in 65.4% of women&#160;<br/>compared to 53.1% of&#160;women who received placebo. These findings have been reported only in a&#160;<br/>press release,</p>
<p style="position:absolute;top:422px;left:200px;white-space:nowrap" class="ft038">27</p>
<p style="position:absolute;top:424px;left:211px;white-space:nowrap" class="ft013">&#160;with results available at&#160;</p>
<p style="position:absolute;top:424px;left:383px;white-space:nowrap" class="ft034">ClinicalTrials.gov</p>
<p style="position:absolute;top:424px;left:508px;white-space:nowrap" class="ft013">&#160;and on the&#160;FDA label,</p>
<p style="position:absolute;top:422px;left:665px;white-space:nowrap" class="ft038">28</p>
<p style="position:absolute;top:424px;left:677px;white-space:nowrap" class="ft013">&#160;and are&#160;thereby&#160;</p>
<p style="position:absolute;top:443px;left:108px;white-space:nowrap" class="ft032">less&#160;compelling than peer-reviewed publication. Therefore, ibrexafungerp can be administered for&#160;<br/>recurrent vulvovaginal&#160;candidiasis&#160;</p>
<p style="position:absolute;top:463px;left:350px;white-space:nowrap" class="ft012"><b>(BI).</b></p>
<p style="position:absolute;top:463px;left:384px;white-space:nowrap" class="ft013">&#160;Given the&#160;potential&#160;teratogenic&#160;effects of ibrexafungerp,&#160;</p>
<p style="position:absolute;top:483px;left:108px;white-space:nowrap" class="ft032">treatment of women with&#160;recurrent vulvovaginal&#160;candidiasis who may become&#160;pregnant&#160;requires&#160;<br/>institution and documentation of effective&#160;contraception during&#160;treatment and for 4 days&#160;after the last&#160;<br/>dose.</p>
<p style="position:absolute;top:521px;left:144px;white-space:nowrap" class="ft038">29</p>
<p style="position:absolute;top:523px;left:155px;white-space:nowrap" class="ft013">&#160;For additional advice on managing&#160;</p>
<p style="position:absolute;top:523px;left:404px;white-space:nowrap" class="ft034">Vulvovaginal Candidiasis</p>
<p style="position:absolute;top:523px;left:583px;white-space:nowrap" class="ft013">, see the&#160;section in the&#160;</p>
<p style="position:absolute;top:523px;left:740px;white-space:nowrap" class="ft034">STI&#160;</p>
<p style="position:absolute;top:543px;left:108px;white-space:nowrap" class="ft034">Treatment Guidelines</p>
<p style="position:absolute;top:543px;left:258px;white-space:nowrap" class="ft013">&#160;from the Centers for&#160;Disease&#160;Control&#160;and&#160;Prevention.&#160;</p>
<p style="position:absolute;top:580px;left:108px;white-space:nowrap" class="ft029"><i><b>Special Considerations with&#160;Regard to&#160;Starting&#160;ART</b></i></p>
<p style="position:absolute;top:621px;left:108px;white-space:nowrap" class="ft032">There are&#160;no&#160;special&#160;considerations regarding initiation of ART in people with mucocutaneous&#160;<br/>candidiasis.&#160;Specifically, there&#160;is currently no evidence&#160;that treatment&#160;with ART needs to&#160;be delayed&#160;<br/>until treatment for candidiasis has been completed. For information about drug–drug interactions&#160;<br/>between azoles and ARV&#160;agents, see the&#160;</p>
<p style="position:absolute;top:680px;left:392px;white-space:nowrap" class="ft034">Drug–Drug Interactions section in the Guidelines for the&#160;</p>
<p style="position:absolute;top:700px;left:108px;white-space:nowrap" class="ft034">Use of&#160;Antiretroviral Agents in Adults&#160;and Adolescents with HIV</p>
<p style="position:absolute;top:700px;left:562px;white-space:nowrap" class="ft013">. For information about&#160;drug–drug&#160;</p>
<p style="position:absolute;top:720px;left:108px;white-space:nowrap" class="ft013">interactions between azoles and other&#160;drugs used for the treatment of opportunistic infections, see&#160;</p>
<p style="position:absolute;top:740px;left:108px;white-space:nowrap" class="ft078">Table&#160;4: Significant&#160;Pharmacokinetic Interactions Between Drugs Used to Treat or Prevent&#160;<br/>Opportunistic&#160;Infections</p>
<p style="position:absolute;top:760px;left:276px;white-space:nowrap" class="ft013">.&#160;</p>
<p style="position:absolute;top:797px;left:108px;white-space:nowrap" class="ft029"><i><b>Monitoring of&#160;Response&#160;to&#160;Therapy and&#160;Adverse Events (Including IRIS)&#160;</b></i></p>
<p style="position:absolute;top:838px;left:108px;white-space:nowrap" class="ft032">For most people&#160;with mucocutaneous candidiasis, response to antifungal therapy is rapid;&#160;signs and&#160;<br/>symptoms improve&#160;within 48 to 72 hours.&#160;Short courses&#160;of topical&#160;therapy rarely result in adverse&#160;<br/>effects, although people&#160;may experience cutaneous hypersensitivity reactions characterized by rash&#160;<br/>and pruritus.&#160;Oral azole therapy can be&#160;associated with nausea, vomiting, diarrhea, abdominal&#160;pain,&#160;<br/>or transaminase elevations. Liver function and the QTc interval&#160;should be monitored if azole therapy&#160;<br/>is anticipated&#160;for &gt;21 days, especially in people with other hepatic&#160;comorbidities or on concomitant&#160;<br/>hepatotoxic drugs&#160;</p>
<p style="position:absolute;top:957px;left:235px;white-space:nowrap" class="ft012"><b>(AII).</b></p>
<p style="position:absolute;top:957px;left:277px;white-space:nowrap" class="ft013">&#160;The echinocandins appear to be&#160;associated with very few adverse reactions:&#160;</p>
<p style="position:absolute;top:977px;left:108px;white-space:nowrap" class="ft032">histamine-related infusion&#160;toxicity, transaminase elevations, and&#160;rash have been attributed to these&#160;<br/>drugs.&#160;No dose adjustments are&#160;required in renal&#160;failure.</p>
<p style="position:absolute;top:996px;left:496px;white-space:nowrap" class="ft038">30</p>
<p style="position:absolute;top:997px;left:507px;white-space:nowrap" class="ft013">&#160;</p>
</div>
<!-- Page 53 -->
<a name="53"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page53-div" style="position:relative;width:917px;height:1187px;">
<p style="position:absolute;top:1117px;left:108px;white-space:nowrap" class="ft024"><i>Guidelines for the Prevention and Treatment&#160;of&#160;Opportunistic&#160;Infections in Adults&#160;and Adolescents&#160;With HIV&#160;</i></p>
<p style="position:absolute;top:1117px;left:790px;white-space:nowrap" class="ft024"><i>D-7&#160;</i></p>
<p style="position:absolute;top:109px;left:108px;white-space:nowrap" class="ft032">Immune reconstitution inflammatory syndrome&#160;(IRIS) with&#160;ART has&#160;rarely&#160;been reported for&#160;<br/>mucocutaneous candidiasis in people with HIV. Indeed, ART is&#160;associated with a markedly reduced&#160;<br/>incidence of candidiasis.</p>
<p style="position:absolute;top:147px;left:278px;white-space:nowrap" class="ft038">31,32</p>
<p style="position:absolute;top:148px;left:303px;white-space:nowrap" class="ft013">&#160;</p>
<p style="position:absolute;top:186px;left:108px;white-space:nowrap" class="ft029"><i><b>Managing&#160;Treatment Failure&#160;</b></i></p>
<p style="position:absolute;top:227px;left:108px;white-space:nowrap" class="ft032">Antifungal treatment&#160;failure is typically defined as&#160;the&#160;persistence of signs&#160;or symptoms&#160;of&#160;<br/>oropharyngeal or esophageal&#160;candidiasis within 7 days of appropriate&#160;antifungal therapy. Refractory&#160;<br/>disease occurs in approximately 4% to 5% of people with HIV&#160;who have oral&#160;or esophageal&#160;<br/>candidiasis, typically those with CD4 counts &lt;50 cells/mm</p>
<p style="position:absolute;top:285px;left:514px;white-space:nowrap" class="ft038">3</p>
<p style="position:absolute;top:286px;left:520px;white-space:nowrap" class="ft013">&#160;who&#160;have&#160;received multiple&#160;courses of&#160;</p>
<p style="position:absolute;top:306px;left:108px;white-space:nowrap" class="ft013">azole antifungals.</p>
<p style="position:absolute;top:305px;left:230px;white-space:nowrap" class="ft038">4</p>
<p style="position:absolute;top:306px;left:235px;white-space:nowrap" class="ft013">&#160;Confirmatory culture with drug&#160;susceptibilities and, in the&#160;case of esophageal&#160;</p>
<p style="position:absolute;top:326px;left:108px;white-space:nowrap" class="ft032">candidiasis,&#160;endoscopy, are necessary&#160;to&#160;assess for&#160;treatment failure&#160;due to azole resistance&#160;or other&#160;<br/>causes of esophagitis, especially if these procedures were not initially performed.&#160;</p>
<p style="position:absolute;top:383px;left:108px;white-space:nowrap" class="ft032">Posaconazole immediate-release oral&#160;suspension&#160;(400 mg twice&#160;daily for 28&#160;days) is effective in 75%&#160;<br/>of people with azole-refractory oropharyngeal&#160;or esophageal candidiasis&#160;and is therefore&#160;<br/>recommended&#160;</p>
<p style="position:absolute;top:423px;left:210px;white-space:nowrap" class="ft012"><b>(AI).</b></p>
<p style="position:absolute;top:421px;left:245px;white-space:nowrap" class="ft038">33</p>
<p style="position:absolute;top:423px;left:256px;white-space:nowrap" class="ft013">&#160;Again, although the delayed-release tablet&#160;formulation of posaconazole is now&#160;</p>
<p style="position:absolute;top:442px;left:108px;white-space:nowrap" class="ft032">available, it&#160;is not known&#160;whether it offers an advantage over the suspension for treating this&#160;<br/>particular disease.&#160;Alternatively, oral&#160;itraconazole solution is effective, at&#160;least transiently, in&#160;<br/>approximately two-thirds&#160;of people&#160;with fluconazole-refractory&#160;mucosal candidiasis&#160;and&#160;can be&#160;used&#160;<br/>as alternative&#160;therapy</p>
<p style="position:absolute;top:502px;left:255px;white-space:nowrap" class="ft012"><b>&#160;(BII).</b></p>
<p style="position:absolute;top:501px;left:301px;white-space:nowrap" class="ft038">16</p>
<p style="position:absolute;top:502px;left:312px;white-space:nowrap" class="ft013">&#160;If necessary, azole-refractory esophageal candidiasis also can be&#160;</p>
<p style="position:absolute;top:522px;left:108px;white-space:nowrap" class="ft013">treated with anidulafungin&#160;</p>
<p style="position:absolute;top:522px;left:294px;white-space:nowrap" class="ft012"><b>(BII),</b></p>
<p style="position:absolute;top:522px;left:335px;white-space:nowrap" class="ft013">&#160;caspofungin&#160;</p>
<p style="position:absolute;top:522px;left:428px;white-space:nowrap" class="ft012"><b>(BII),</b></p>
<p style="position:absolute;top:522px;left:469px;white-space:nowrap" class="ft013">&#160;micafungin&#160;</p>
<p style="position:absolute;top:522px;left:556px;white-space:nowrap" class="ft012"><b>(BII),</b></p>
<p style="position:absolute;top:522px;left:596px;white-space:nowrap" class="ft013">&#160;or voriconazole&#160;</p>
<p style="position:absolute;top:522px;left:713px;white-space:nowrap" class="ft012"><b>(BII).</b></p>
<p style="position:absolute;top:520px;left:754px;white-space:nowrap" class="ft038">21,22,34,35</p>
<p style="position:absolute;top:522px;left:807px;white-space:nowrap" class="ft013">&#160;</p>
<p style="position:absolute;top:559px;left:108px;white-space:nowrap" class="ft013">IV amphotericin B&#160;</p>
<p style="position:absolute;top:559px;left:242px;white-space:nowrap" class="ft012"><b>(BII),</b></p>
<p style="position:absolute;top:559px;left:282px;white-space:nowrap" class="ft013">&#160;amphotericin B deoxycholate&#160;</p>
<p style="position:absolute;top:559px;left:494px;white-space:nowrap" class="ft012"><b>(BII),</b></p>
<p style="position:absolute;top:559px;left:535px;white-space:nowrap" class="ft013">&#160;and the&#160;lipid preparations of&#160;</p>
<p style="position:absolute;top:579px;left:108px;white-space:nowrap" class="ft013">amphotericin B&#160;</p>
<p style="position:absolute;top:579px;left:219px;white-space:nowrap" class="ft012"><b>(BII)</b></p>
<p style="position:absolute;top:579px;left:255px;white-space:nowrap" class="ft013">&#160;are&#160;usually effective for treating azole-refractory disease and are therefore&#160;</p>
<p style="position:absolute;top:599px;left:108px;white-space:nowrap" class="ft032">recommended. Amphotericin B oral suspension (1&#160;mL&#160;of the&#160;100-mg/mL&#160;suspension four&#160;times&#160;<br/>daily) can be administered to people&#160;with refractory oropharyngeal&#160;candidiasis who cannot take&#160;other&#160;<br/>oral&#160;options&#160;</p>
<p style="position:absolute;top:638px;left:194px;white-space:nowrap" class="ft012"><b>(BII),</b></p>
<p style="position:absolute;top:638px;left:235px;white-space:nowrap" class="ft013">&#160;but this&#160;product&#160;is not commercially available in the&#160;United States and&#160;requires&#160;</p>
<p style="position:absolute;top:658px;left:108px;white-space:nowrap" class="ft013">compounding by pharmacies.</p>
<p style="position:absolute;top:657px;left:312px;white-space:nowrap" class="ft038">36</p>
<p style="position:absolute;top:658px;left:323px;white-space:nowrap" class="ft013">&#160;</p>
<p style="position:absolute;top:695px;left:108px;white-space:nowrap" class="ft032">Patients with refractory vaginal&#160;candidiasis may benefit from&#160;intravaginal&#160;boric&#160;acid suppositories,&#160;<br/>which are&#160;commercially available at 600 mg.</p>
<p style="position:absolute;top:714px;left:419px;white-space:nowrap" class="ft038">37,38</p>
<p style="position:absolute;top:715px;left:444px;white-space:nowrap" class="ft013">&#160;</p>
<p style="position:absolute;top:752px;left:108px;white-space:nowrap" class="ft026"><b>Preventing&#160;Recurrence&#160;</b></p>
<p style="position:absolute;top:803px;left:382px;white-space:nowrap" class="ft02"><b>Preventing&#160;Recurrence&#160;</b></p>
<p style="position:absolute;top:837px;left:115px;white-space:nowrap" class="ft030">•</p>
<p style="position:absolute;top:839px;left:122px;white-space:nowrap" class="ft057">&#160;</p>
<p style="position:absolute;top:838px;left:131px;white-space:nowrap" class="ft041">Chronic&#160;suppressive therapy&#160;for&#160;recurrent&#160;oropharyngeal&#160;or vulvovaginal&#160;candidiasis&#160;is usually&#160;not&#160;recommended unless&#160;</p>
<p style="position:absolute;top:856px;left:131px;white-space:nowrap" class="ft041">people have frequent or severe&#160;recurrences&#160;</p>
<p style="position:absolute;top:856px;left:373px;white-space:nowrap" class="ft042"><b>(CIII).</b></p>
<p style="position:absolute;top:856px;left:404px;white-space:nowrap" class="ft041">&#160;</p>
<p style="position:absolute;top:882px;left:115px;white-space:nowrap" class="ft030">•</p>
<p style="position:absolute;top:883px;left:131px;white-space:nowrap" class="ft041">If used,&#160;it&#160;is&#160;reasonable to&#160;discontinue&#160;therapy&#160;if CD4 count increased to &gt;200 cells/mm</p>
<p style="position:absolute;top:884px;left:606px;white-space:nowrap" class="ft058">3</p>
<p style="position:absolute;top:883px;left:610px;white-space:nowrap" class="ft041">&#160;following&#160;initiation&#160;of&#160;ART&#160;</p>
<p style="position:absolute;top:883px;left:755px;white-space:nowrap" class="ft042"><b>(AIII).</b></p>
<p style="position:absolute;top:883px;left:786px;white-space:nowrap" class="ft041">&#160;</p>
<p style="position:absolute;top:915px;left:115px;white-space:nowrap" class="ft042"><b>If the Decision Is to&#160;Use Suppressive Therapy&#160;Because of Frequent&#160;or Severe Recurrences&#160;</b></p>
<p style="position:absolute;top:941px;left:115px;white-space:nowrap" class="ft024"><i>Oropharyngeal&#160;Candidiasis&#160;</i></p>
<p style="position:absolute;top:967px;left:115px;white-space:nowrap" class="ft030">•</p>
<p style="position:absolute;top:969px;left:122px;white-space:nowrap" class="ft057">&#160;</p>
<p style="position:absolute;top:968px;left:131px;white-space:nowrap" class="ft041">Fluconazole&#160;100&#160;mg&#160;PO once daily or three times&#160;weekly&#160;</p>
<p style="position:absolute;top:968px;left:445px;white-space:nowrap" class="ft042"><b>(BI)&#160;</b></p>
<p style="position:absolute;top:1001px;left:115px;white-space:nowrap" class="ft024"><i>Esophageal&#160;Candidiasis&#160;</i></p>
<p style="position:absolute;top:1027px;left:115px;white-space:nowrap" class="ft030">•</p>
<p style="position:absolute;top:1028px;left:122px;white-space:nowrap" class="ft057">&#160;</p>
<p style="position:absolute;top:1028px;left:131px;white-space:nowrap" class="ft041">Fluconazole&#160;100–200 mg PO daily&#160;</p>
<p style="position:absolute;top:1028px;left:323px;white-space:nowrap" class="ft042"><b>(BI)</b></p>
<p style="position:absolute;top:1028px;left:343px;white-space:nowrap" class="ft041">,&#160;</p>
<p style="position:absolute;top:1028px;left:350px;white-space:nowrap" class="ft024"><i>or</i></p>
<p style="position:absolute;top:1028px;left:361px;white-space:nowrap" class="ft041">&#160;</p>
</div>
<!-- Page 54 -->
<a name="54"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page54-div" style="position:relative;width:917px;height:1187px;">
<p style="position:absolute;top:1117px;left:108px;white-space:nowrap" class="ft024"><i>Guidelines for the Prevention and Treatment&#160;of&#160;Opportunistic&#160;Infections in Adults&#160;and Adolescents&#160;With HIV&#160;</i></p>
<p style="position:absolute;top:1117px;left:790px;white-space:nowrap" class="ft024"><i>D-8&#160;</i></p>
<p style="position:absolute;top:110px;left:115px;white-space:nowrap" class="ft030">•</p>
<p style="position:absolute;top:111px;left:122px;white-space:nowrap" class="ft057">&#160;</p>
<p style="position:absolute;top:111px;left:131px;white-space:nowrap" class="ft041">Posaconazole oral&#160;suspension 400 mg&#160;PO twice&#160;daily&#160;</p>
<p style="position:absolute;top:111px;left:427px;white-space:nowrap" class="ft042"><b>(BII),&#160;</b></p>
<p style="position:absolute;top:111px;left:458px;white-space:nowrap" class="ft024"><i>or</i></p>
<p style="position:absolute;top:111px;left:469px;white-space:nowrap" class="ft042"><b>&#160;</b></p>
<p style="position:absolute;top:137px;left:115px;white-space:nowrap" class="ft030">•</p>
<p style="position:absolute;top:139px;left:122px;white-space:nowrap" class="ft057">&#160;</p>
<p style="position:absolute;top:138px;left:131px;white-space:nowrap" class="ft041">Posaconazole tablet 300 mg PO daily (</p>
<p style="position:absolute;top:138px;left:344px;white-space:nowrap" class="ft042"><b>BII)&#160;</b></p>
<p style="position:absolute;top:170px;left:115px;white-space:nowrap" class="ft024"><i>Vulvovaginal&#160;Candidiasis</i></p>
<p style="position:absolute;top:170px;left:252px;white-space:nowrap" class="ft083"><i><b>&#160;</b></i></p>
<p style="position:absolute;top:196px;left:115px;white-space:nowrap" class="ft030">•</p>
<p style="position:absolute;top:198px;left:122px;white-space:nowrap" class="ft057">&#160;</p>
<p style="position:absolute;top:198px;left:131px;white-space:nowrap" class="ft041">Fluconazole&#160;150&#160;mg&#160;PO once&#160;weekly&#160;</p>
<p style="position:absolute;top:198px;left:337px;white-space:nowrap" class="ft042"><b>(BII)&#160;</b></p>
<p style="position:absolute;top:198px;left:365px;white-space:nowrap" class="ft024"><i>or</i></p>
<p style="position:absolute;top:198px;left:376px;white-space:nowrap" class="ft041">&#160;</p>
<p style="position:absolute;top:224px;left:115px;white-space:nowrap" class="ft030">•</p>
<p style="position:absolute;top:225px;left:122px;white-space:nowrap" class="ft057">&#160;</p>
<p style="position:absolute;top:225px;left:131px;white-space:nowrap" class="ft041">Oteseconazole 600 mg&#160;at Day 1, 450 mg&#160;at Day&#160;2 for treatment&#160;of the&#160;acute episode, followed&#160;by once-weekly&#160;150-mg&#160;</p>
<p style="position:absolute;top:242px;left:131px;white-space:nowrap" class="ft041">doses&#160;starting at&#160;Day&#160;14&#160;for 11&#160;weeks&#160;</p>
<p style="position:absolute;top:242px;left:340px;white-space:nowrap" class="ft042"><b>(AI)&#160;</b></p>
<p style="position:absolute;top:242px;left:364px;white-space:nowrap" class="ft041">(for&#160;those who are not&#160;of reproductive potential);</p>
<p style="position:absolute;top:242px;left:626px;white-space:nowrap" class="ft042"><b>&#160;</b></p>
<p style="position:absolute;top:242px;left:629px;white-space:nowrap" class="ft024"><i>or</i></p>
<p style="position:absolute;top:242px;left:640px;white-space:nowrap" class="ft041">&#160;&#160;</p>
<p style="position:absolute;top:268px;left:115px;white-space:nowrap" class="ft030">•</p>
<p style="position:absolute;top:270px;left:122px;white-space:nowrap" class="ft057">&#160;</p>
<p style="position:absolute;top:269px;left:131px;white-space:nowrap" class="ft041">Fluconazole&#160;150&#160;mg&#160;at Days&#160;1, 4, and 7 for treatment of&#160;the&#160;acute episode, followed by&#160;oteseconazole 150 mg&#160;daily&#160;at&#160;</p>
<p style="position:absolute;top:286px;left:131px;white-space:nowrap" class="ft041">Days&#160;14–20,&#160;followed by&#160;oteseconazole 150&#160;mg once weekly&#160;starting at Day&#160;28 for 11 weeks&#160;(Weeks&#160;4–14)&#160;(</p>
<p style="position:absolute;top:286px;left:724px;white-space:nowrap" class="ft042"><b>AI</b></p>
<p style="position:absolute;top:286px;left:736px;white-space:nowrap" class="ft041">)&#160;(for those&#160;</p>
<p style="position:absolute;top:304px;left:131px;white-space:nowrap" class="ft041">who are not of&#160;reproductive potential);&#160;</p>
<p style="position:absolute;top:304px;left:341px;white-space:nowrap" class="ft024"><i>or</i></p>
<p style="position:absolute;top:304px;left:352px;white-space:nowrap" class="ft041">&#160;&#160;</p>
<p style="position:absolute;top:330px;left:115px;white-space:nowrap" class="ft030">•</p>
<p style="position:absolute;top:331px;left:122px;white-space:nowrap" class="ft057">&#160;</p>
<p style="position:absolute;top:331px;left:131px;white-space:nowrap" class="ft041">Ibrexafungerp 300&#160;mg twice daily&#160;1 day&#160;per&#160;month for&#160;6 months&#160;</p>
<p style="position:absolute;top:331px;left:479px;white-space:nowrap" class="ft042"><b>(BI)&#160;</b></p>
<p style="position:absolute;top:331px;left:503px;white-space:nowrap" class="ft041">(use an&#160;effective form of&#160;contraception during&#160;</p>
<p style="position:absolute;top:348px;left:131px;white-space:nowrap" class="ft041">treatment and for&#160;4 days&#160;after the last dose.)&#160;</p>
<p style="position:absolute;top:384px;left:115px;white-space:nowrap" class="ft056"><b>Considerations During&#160;Pregnancy&#160;and&#160;Lactation&#160;</b></p>
<p style="position:absolute;top:412px;left:115px;white-space:nowrap" class="ft030">•</p>
<p style="position:absolute;top:414px;left:122px;white-space:nowrap" class="ft057">&#160;</p>
<p style="position:absolute;top:413px;left:131px;white-space:nowrap" class="ft041">Chemoprophylaxis, either&#160;chronic&#160;maintenance therapy or&#160;secondary&#160;prophylaxis, against oropharyngeal, esophageal,&#160;or&#160;</p>
<p style="position:absolute;top:430px;left:131px;white-space:nowrap" class="ft041">vaginal&#160;candidiasis&#160;using systemically absorbed&#160;azoles&#160;should not be&#160;initiated during&#160;pregnancy&#160;</p>
<p style="position:absolute;top:430px;left:655px;white-space:nowrap" class="ft042"><b>(AIII).</b></p>
<p style="position:absolute;top:430px;left:686px;white-space:nowrap" class="ft041">&#160;Furthermore,&#160;</p>
<p style="position:absolute;top:448px;left:131px;white-space:nowrap" class="ft041">prophylaxis&#160;with&#160;systemic&#160;azoles&#160;should be&#160;discontinued during&#160;pregnancy&#160;</p>
<p style="position:absolute;top:448px;left:540px;white-space:nowrap" class="ft042"><b>(AIII).</b></p>
<p style="position:absolute;top:448px;left:571px;white-space:nowrap" class="ft041">&#160;</p>
<p style="position:absolute;top:474px;left:115px;white-space:nowrap" class="ft030">•</p>
<p style="position:absolute;top:475px;left:122px;white-space:nowrap" class="ft057">&#160;</p>
<p style="position:absolute;top:475px;left:131px;white-space:nowrap" class="ft041">Oteseconazole is&#160;</p>
<p style="position:absolute;top:475px;left:229px;white-space:nowrap" class="ft042"><b>contraindicated</b></p>
<p style="position:absolute;top:475px;left:320px;white-space:nowrap" class="ft041">&#160;during&#160;pregnancy&#160;and&#160;when&#160;lactating as animal&#160;studies have&#160;shown fetal&#160;malformations&#160;</p>
<p style="position:absolute;top:492px;left:131px;white-space:nowrap" class="ft044">including ocular toxicity.&#160;Due to&#160;its&#160;long&#160;half-life, it&#160;is&#160;also contraindicated&#160;in females of reproductive potential&#160;despite the&#160;<br/>use of oral&#160;or other contraception.&#160;</p>
<p style="position:absolute;top:536px;left:115px;white-space:nowrap" class="ft030">•</p>
<p style="position:absolute;top:537px;left:122px;white-space:nowrap" class="ft057">&#160;</p>
<p style="position:absolute;top:537px;left:131px;white-space:nowrap" class="ft041">Ibrexafungerp is&#160;teratogenic&#160;in animal&#160;studies. Use during&#160;pregnancy&#160;or&#160;when lactation is&#160;</p>
<p style="position:absolute;top:537px;left:618px;white-space:nowrap" class="ft042"><b>contraindicated</b></p>
<p style="position:absolute;top:537px;left:709px;white-space:nowrap" class="ft041">.&#160;</p>
<p style="position:absolute;top:567px;left:108px;white-space:nowrap" class="ft042"><b>Key:</b></p>
<p style="position:absolute;top:567px;left:135px;white-space:nowrap" class="ft041">&#160;ART = antiretroviral&#160;therapy; CD4&#160;= CD4&#160;T&#160;lymphocyte;&#160;PO&#160;= orally&#160;</p>
<p style="position:absolute;top:602px;left:108px;white-space:nowrap" class="ft029"><i><b>When to&#160;Start&#160;Suppressive Therapy</b></i></p>
<p style="position:absolute;top:643px;left:108px;white-space:nowrap" class="ft013">A randomized clinical&#160;trial</p>
<p style="position:absolute;top:642px;left:293px;white-space:nowrap" class="ft038">39</p>
<p style="position:absolute;top:643px;left:305px;white-space:nowrap" class="ft013">&#160;of people&#160;with HIV who had CD4 counts &lt;150 cells/mm</p>
<p style="position:absolute;top:642px;left:700px;white-space:nowrap" class="ft038">3</p>
<p style="position:absolute;top:643px;left:706px;white-space:nowrap" class="ft013">&#160;documented&#160;</p>
<p style="position:absolute;top:663px;left:108px;white-space:nowrap" class="ft032">significantly fewer episodes of oropharyngeal&#160;candidiasis and other invasive&#160;fungal&#160;infections with&#160;<br/>continuous fluconazole therapy (three times a week)&#160;than with episodic&#160;fluconazole treatment&#160;for&#160;<br/>recurrences.&#160;This clinical&#160;trial&#160;also demonstrated no difference&#160;in the risk of&#160;developing clinically&#160;<br/>significant&#160;fluconazole resistance between the two&#160;fluconazole-treated groups among patients who&#160;<br/>were receiving ART.&#160;</p>
<p style="position:absolute;top:780px;left:108px;white-space:nowrap" class="ft032">However, secondary prophylaxis (chronic&#160;suppressive therapy) for recurrent&#160;oropharyngeal&#160;or&#160;<br/>vulvovaginal candidiasis&#160;</p>
<p style="position:absolute;top:800px;left:283px;white-space:nowrap" class="ft012"><b>is not&#160;recommended</b></p>
<p style="position:absolute;top:800px;left:432px;white-space:nowrap" class="ft013">&#160;by&#160;most HIV specialists unless&#160;people&#160;have frequent&#160;</p>
<p style="position:absolute;top:819px;left:108px;white-space:nowrap" class="ft013">or severe recurrences&#160;</p>
<p style="position:absolute;top:819px;left:259px;white-space:nowrap" class="ft012"><b>(CIII)&#160;</b></p>
<p style="position:absolute;top:819px;left:307px;white-space:nowrap" class="ft013">because therapy for acute disease is&#160;effective, mortality associated with&#160;</p>
<p style="position:absolute;top:839px;left:108px;white-space:nowrap" class="ft032">mucocutaneous disease is&#160;low, potential&#160;exists for drug interactions and for the development&#160;of&#160;<br/>antifungal-resistant&#160;</p>
<p style="position:absolute;top:859px;left:245px;white-space:nowrap" class="ft019"><i>Candida</i></p>
<p style="position:absolute;top:859px;left:305px;white-space:nowrap" class="ft013">, and prophylaxis is costly.&#160;</p>
<p style="position:absolute;top:896px;left:108px;white-space:nowrap" class="ft032">If recurrences are frequent or severe, oral&#160;fluconazole can be used as suppressive&#160;therapy for&#160;<br/>oropharyngeal&#160;</p>
<p style="position:absolute;top:916px;left:212px;white-space:nowrap" class="ft012"><b>(BI),</b></p>
<p style="position:absolute;top:916px;left:246px;white-space:nowrap" class="ft013">&#160;esophageal&#160;</p>
<p style="position:absolute;top:916px;left:331px;white-space:nowrap" class="ft012"><b>(BI),</b></p>
<p style="position:absolute;top:916px;left:365px;white-space:nowrap" class="ft013">&#160;or vulvovaginal&#160;</p>
<p style="position:absolute;top:916px;left:482px;white-space:nowrap" class="ft012"><b>(AII)</b></p>
<p style="position:absolute;top:916px;left:520px;white-space:nowrap" class="ft013">&#160;candidiasis.</p>
<p style="position:absolute;top:915px;left:605px;white-space:nowrap" class="ft038">40-42</p>
<p style="position:absolute;top:916px;left:632px;white-space:nowrap" class="ft013">&#160;Oral posaconazole twice&#160;</p>
<p style="position:absolute;top:936px;left:108px;white-space:nowrap" class="ft013">daily is also effective for esophageal&#160;candidiasis&#160;</p>
<p style="position:absolute;top:936px;left:445px;white-space:nowrap" class="ft012"><b>(BII).</b></p>
<p style="position:absolute;top:934px;left:486px;white-space:nowrap" class="ft038">43</p>
<p style="position:absolute;top:936px;left:498px;white-space:nowrap" class="ft013">&#160;The&#160;potential for development&#160;of secondary&#160;</p>
<p style="position:absolute;top:956px;left:108px;white-space:nowrap" class="ft032">azole resistance&#160;should be considered&#160;when contemplating chronic&#160;maintenance therapy using azoles&#160;<br/>in people with HIV who are severely immunocompromised.</p>
<p style="position:absolute;top:974px;left:523px;white-space:nowrap" class="ft038">44</p>
<p style="position:absolute;top:976px;left:534px;white-space:nowrap" class="ft013">&#160;Several important&#160;factors should be&#160;</p>
<p style="position:absolute;top:995px;left:108px;white-space:nowrap" class="ft032">considered when making the&#160;decision to use secondary prophylaxis. These factors include the effect&#160;<br/>of recurrences on the person’s&#160;well-being and quality of life, the need for prophylaxis against other&#160;<br/>fungal&#160;infections, cost, adverse events,&#160;and, most importantly, drug–drug interactions.</p>
<p style="position:absolute;top:1034px;left:701px;white-space:nowrap" class="ft038">45</p>
<p style="position:absolute;top:1035px;left:712px;white-space:nowrap" class="ft013">&#160;</p>
</div>
<!-- Page 55 -->
<a name="55"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page55-div" style="position:relative;width:917px;height:1187px;">
<p style="position:absolute;top:1117px;left:108px;white-space:nowrap" class="ft024"><i>Guidelines for the Prevention and Treatment&#160;of&#160;Opportunistic&#160;Infections in Adults&#160;and Adolescents&#160;With HIV&#160;</i></p>
<p style="position:absolute;top:1117px;left:790px;white-space:nowrap" class="ft024"><i>D-9&#160;</i></p>
<p style="position:absolute;top:109px;left:108px;white-space:nowrap" class="ft032">Rates of relapse are high&#160;in people&#160;with azole-refractory oropharyngeal&#160;or esophageal candidiasis&#160;<br/>who have initially responded to echinocandins, voriconazole, or posaconazole&#160;therapy. In&#160;such&#160;<br/>people, secondary prophylaxis should&#160;be instituted until immune reconstitution is achieved with the&#160;<br/>use of&#160;ART&#160;</p>
<p style="position:absolute;top:168px;left:193px;white-space:nowrap" class="ft012"><b>(AIII).&#160;</b></p>
<p style="position:absolute;top:205px;left:108px;white-space:nowrap" class="ft032">For information regarding oteseconazole&#160;and ibrexafungerp, see&#160;the&#160;Vulvovaginal Candidiasis&#160;<br/>Treatment Section above. &#160;</p>
<p style="position:absolute;top:262px;left:108px;white-space:nowrap" class="ft029"><i><b>When to&#160;Stop Suppressive Therapy&#160;</b></i></p>
<p style="position:absolute;top:304px;left:108px;white-space:nowrap" class="ft032">In situations&#160;where secondary prophylaxis has been&#160;instituted, no data exist to guide&#160;<br/>recommendations regarding its discontinuation. Based on experience&#160;with other opportunistic&#160;<br/>infections, it&#160;would be reasonable&#160;to discontinue secondary prophylaxis when&#160;the&#160;CD4 count has&#160;<br/>increased to&#160;&gt;200 cells/mm</p>
<p style="position:absolute;top:362px;left:298px;white-space:nowrap" class="ft038">3</p>
<p style="position:absolute;top:363px;left:304px;white-space:nowrap" class="ft013">&#160;following&#160;initiation of ART&#160;</p>
<p style="position:absolute;top:363px;left:504px;white-space:nowrap" class="ft012"><b>(AIII).</b></p>
<p style="position:absolute;top:363px;left:552px;white-space:nowrap" class="ft013">&#160;</p>
<p style="position:absolute;top:400px;left:108px;white-space:nowrap" class="ft026"><b>Special&#160;Considerations During&#160;Pregnancy</b></p>
<p style="position:absolute;top:402px;left:451px;white-space:nowrap" class="ft036">&#160;</p>
<p style="position:absolute;top:442px;left:108px;white-space:nowrap" class="ft013">Pregnancy increases the risk of vaginal&#160;colonization with&#160;</p>
<p style="position:absolute;top:442px;left:506px;white-space:nowrap" class="ft019"><i>Candida&#160;</i></p>
<p style="position:absolute;top:442px;left:570px;white-space:nowrap" class="ft013">species.&#160;During pregnancy,&#160;</p>
<p style="position:absolute;top:461px;left:108px;white-space:nowrap" class="ft032">diagnosis and management&#160;of oropharyngeal, esophageal, and vulvovaginal candidiasis are the&#160;same&#160;<br/>as for other people with HIV,&#160;with several considerations.&#160;</p>
<p style="position:absolute;top:518px;left:108px;white-space:nowrap" class="ft032">Topical therapy is preferable&#160;for treatment of oral candidiasis and vulvovaginal&#160;candidiasis in&#160;<br/>pregnancy.&#160;Oral fluconazole should be avoided when treating vulvovaginal&#160;candidiasis in the&#160;first&#160;<br/>trimester&#160;</p>
<p style="position:absolute;top:558px;left:174px;white-space:nowrap" class="ft012"><b>(AIII).</b></p>
<p style="position:absolute;top:558px;left:222px;white-space:nowrap" class="ft013">&#160;Data derived from women with vulvovaginal&#160;candidiasis suggest that&#160;fluconazole&#160;</p>
<p style="position:absolute;top:578px;left:108px;white-space:nowrap" class="ft032">should not be used at&#160;any&#160;dose (including a&#160;single&#160;150-mg dose) in the first trimester due to the&#160;risk&#160;<br/>of spontaneous abortion,&#160;while&#160;higher&#160;exposures (&gt;150 mg dosing) during the&#160;first trimester are&#160;<br/>associated with cardiac septal&#160;closure defects.</p>
<p style="position:absolute;top:616px;left:424px;white-space:nowrap" class="ft038">46-50</p>
<p style="position:absolute;top:617px;left:450px;white-space:nowrap" class="ft013">&#160;A recent&#160;analysis of registry data&#160;from&#160;Sweden and&#160;</p>
<p style="position:absolute;top:637px;left:108px;white-space:nowrap" class="ft032">Denmark did&#160;not find any&#160;increase in stillbirth or neonatal death associated with exposure&#160;to&#160;<br/>fluconazole at&#160;any dose during pregnancy.</p>
<p style="position:absolute;top:656px;left:400px;white-space:nowrap" class="ft038">51</p>
<p style="position:absolute;top:657px;left:412px;white-space:nowrap" class="ft013">&#160;Five cases of a&#160;syndrome consisting of craniosynostosis,&#160;</p>
<p style="position:absolute;top:677px;left:108px;white-space:nowrap" class="ft032">characteristic facies, digital&#160;synostosis,&#160;and limb contractures (fluconazole embryopathy)&#160;have&#160;been&#160;<br/>reported in women chronically prescribed fluconazole&#160;at&#160;doses&#160;of 400 mg daily or higher&#160;in&#160;<br/>pregnancy.</p>
<p style="position:absolute;top:715px;left:184px;white-space:nowrap" class="ft038">48</p>
<p style="position:absolute;top:717px;left:195px;white-space:nowrap" class="ft013">&#160;A report from a&#160;national cohort register in Denmark found an increased hazard&#160;</p>
<p style="position:absolute;top:737px;left:108px;white-space:nowrap" class="ft032">ratio (HR) of&#160;1.48 for&#160;spontaneous pregnancy loss&#160;with any exposure to oral&#160;fluconazole from&#160;7 to&#160;<br/>22 weeks&#160;of&#160;pregnancy compared to unexposed, matched controls.</p>
<p style="position:absolute;top:755px;left:567px;white-space:nowrap" class="ft038">49</p>
<p style="position:absolute;top:756px;left:578px;white-space:nowrap" class="ft013">&#160;An increased HR&#160;of&#160;1.47 was&#160;</p>
<p style="position:absolute;top:776px;left:108px;white-space:nowrap" class="ft032">also noted with low-dose&#160;(150–300-mg&#160;cumulative dose) exposure. No increase in stillbirth was&#160;seen&#160;<br/>with fluconazole exposure broadly, but an increase in risk of stillbirth (HR, 4.10) was noted with&#160;<br/>fluconazole doses &gt;300&#160;mg. &#160;</p>
<p style="position:absolute;top:853px;left:108px;white-space:nowrap" class="ft032">Based on these data, substitution of amphotericin B for fluconazole&#160;in the first trimester is&#160;<br/>recommended for invasive or refractory esophageal&#160;</p>
<p style="position:absolute;top:873px;left:468px;white-space:nowrap" class="ft019"><i>Candida</i></p>
<p style="position:absolute;top:873px;left:527px;white-space:nowrap" class="ft013">&#160;infections&#160;</p>
<p style="position:absolute;top:873px;left:604px;white-space:nowrap" class="ft012"><b>(AIII).</b></p>
<p style="position:absolute;top:873px;left:652px;white-space:nowrap" class="ft013">&#160;Neonates born to&#160;</p>
<p style="position:absolute;top:893px;left:108px;white-space:nowrap" class="ft032">those receiving chronic&#160;amphotericin B at&#160;delivery should be evaluated for renal dysfunction and&#160;<br/>hypokalemia.&#160;</p>
<p style="position:absolute;top:950px;left:108px;white-space:nowrap" class="ft032">Other azoles&#160;are similarly not&#160;recommended in pregnancy. Itraconazole at&#160;high doses&#160;has been shown&#160;<br/>to be&#160;teratogenic in animals,</p>
<p style="position:absolute;top:968px;left:303px;white-space:nowrap" class="ft038">52</p>
<p style="position:absolute;top:969px;left:314px;white-space:nowrap" class="ft013">&#160;but the metabolic mechanism accounting for&#160;these defects&#160;is not&#160;</p>
<p style="position:absolute;top:989px;left:108px;white-space:nowrap" class="ft032">present&#160;in humans, so the&#160;data supporting this finding are of uncertain significance to human&#160;<br/>pregnancy. Case series in&#160;humans do not suggest an&#160;increased risk of birth defects with&#160;<br/>itraconazole,</p>
<p style="position:absolute;top:1027px;left:197px;white-space:nowrap" class="ft038">53</p>
<p style="position:absolute;top:1029px;left:208px;white-space:nowrap" class="ft013">&#160;but experience&#160;is limited. Human data&#160;are not&#160;available for posaconazole;&#160;however,&#160;</p>
<p style="position:absolute;top:1049px;left:108px;white-space:nowrap" class="ft013">the&#160;drug was&#160;associated with skeletal abnormalities in rats and was embryotoxic&#160;in rabbits when&#160;</p>
</div>
<!-- Page 56 -->
<a name="56"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page56-div" style="position:relative;width:917px;height:1187px;">
<p style="position:absolute;top:1117px;left:108px;white-space:nowrap" class="ft024"><i>Guidelines for the Prevention and Treatment&#160;of&#160;Opportunistic&#160;Infections in Adults&#160;and Adolescents&#160;With HIV&#160;</i></p>
<p style="position:absolute;top:1117px;left:783px;white-space:nowrap" class="ft024"><i>D-10&#160;</i></p>
<p style="position:absolute;top:109px;left:108px;white-space:nowrap" class="ft013">given at&#160;doses that&#160;produced plasma&#160;levels equivalent&#160;to those seen in humans.</p>
<p style="position:absolute;top:107px;left:652px;white-space:nowrap" class="ft038">54</p>
<p style="position:absolute;top:109px;left:663px;white-space:nowrap" class="ft013">&#160;Evidence&#160;is&#160;</p>
<p style="position:absolute;top:129px;left:108px;white-space:nowrap" class="ft032">inconclusive or inadequate&#160;for determining fetal&#160;risk associated&#160;with voriconazole use during&#160;<br/>pregnancy.&#160;An association with cleft palate and renal&#160;defects has been seen&#160;in rats, as well&#160;as&#160;<br/>embryotoxicity seen in rabbits.</p>
<p style="position:absolute;top:167px;left:322px;white-space:nowrap" class="ft038">55</p>
<p style="position:absolute;top:168px;left:337px;white-space:nowrap" class="ft013">Human data on the use of voriconazole are not&#160;available, so its use&#160;</p>
<p style="position:absolute;top:188px;left:108px;white-space:nowrap" class="ft012"><b>is not recommended.</b></p>
<p style="position:absolute;top:188px;left:261px;white-space:nowrap" class="ft013">&#160;In&#160;animals, multiple&#160;anomalies have been&#160;seen with exposure to micafungin,&#160;</p>
<p style="position:absolute;top:208px;left:108px;white-space:nowrap" class="ft013">and ossification defects have been seen&#160;with the use&#160;of anidulafungin and caspofungin.</p>
<p style="position:absolute;top:207px;left:707px;white-space:nowrap" class="ft038">56</p>
<p style="position:absolute;top:208px;left:719px;white-space:nowrap" class="ft013">&#160;Human data&#160;</p>
<p style="position:absolute;top:228px;left:108px;white-space:nowrap" class="ft013">are not&#160;available&#160;for these drugs, thus&#160;their use in human pregnancy&#160;</p>
<p style="position:absolute;top:228px;left:578px;white-space:nowrap" class="ft012"><b>is not recommended</b></p>
<p style="position:absolute;top:228px;left:727px;white-space:nowrap" class="ft013">&#160;</p>
<p style="position:absolute;top:228px;left:731px;white-space:nowrap" class="ft012"><b>(AIII).&#160;</b></p>
<p style="position:absolute;top:265px;left:108px;white-space:nowrap" class="ft032">The recently FDA-approved drugs&#160;for&#160;the&#160;treatment&#160;of vulvovaginal&#160;candidiasis, ibrexafungerp and&#160;<br/>oteseconazole, are</p>
<p style="position:absolute;top:285px;left:234px;white-space:nowrap" class="ft012"><b>&#160;contraindicated</b></p>
<p style="position:absolute;top:285px;left:355px;white-space:nowrap" class="ft013">&#160;in&#160;pregnancy as&#160;animal studies have shown fetal malformations&#160;</p>
<p style="position:absolute;top:304px;left:108px;white-space:nowrap" class="ft013">including ocular toxicity from&#160;oteseconazole.</p>
<p style="position:absolute;top:303px;left:421px;white-space:nowrap" class="ft038">29,57</p>
<p style="position:absolute;top:304px;left:446px;white-space:nowrap" class="ft013">&#160;&#160;</p>
<p style="position:absolute;top:342px;left:108px;white-space:nowrap" class="ft032">Chemoprophylaxis, either chronic maintenance&#160;therapy or secondary prophylaxis, against&#160;<br/>oropharyngeal, esophageal, or vaginal candidiasis&#160;using systemically absorbed azoles&#160;</p>
<p style="position:absolute;top:361px;left:702px;white-space:nowrap" class="ft012"><b>should not be&#160;</b></p>
<p style="position:absolute;top:381px;left:108px;white-space:nowrap" class="ft012"><b>initiated</b></p>
<p style="position:absolute;top:381px;left:169px;white-space:nowrap" class="ft013">&#160;during pregnancy&#160;</p>
<p style="position:absolute;top:381px;left:299px;white-space:nowrap" class="ft012"><b>(AIII).</b></p>
<p style="position:absolute;top:381px;left:347px;white-space:nowrap" class="ft013">&#160;Furthermore, prophylaxis with systemic&#160;azoles&#160;</p>
<p style="position:absolute;top:381px;left:679px;white-space:nowrap" class="ft012"><b>should&#160;be&#160;</b></p>
<p style="position:absolute;top:401px;left:108px;white-space:nowrap" class="ft012"><b>discontinued</b></p>
<p style="position:absolute;top:401px;left:202px;white-space:nowrap" class="ft013">&#160;during pregnancy&#160;</p>
<p style="position:absolute;top:401px;left:332px;white-space:nowrap" class="ft012"><b>(AIII).&#160;</b></p>
<p style="position:absolute;top:401px;left:596px;white-space:nowrap" class="ft012"><b>&#160;</b></p>
</div>
<!-- Page 57 -->
<a name="57"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page57-div" style="position:relative;width:917px;height:1187px;">
<p style="position:absolute;top:1117px;left:108px;white-space:nowrap" class="ft024"><i>Guidelines for the Prevention and Treatment&#160;of&#160;Opportunistic&#160;Infections in Adults&#160;and Adolescents&#160;With HIV&#160;</i></p>
<p style="position:absolute;top:1117px;left:783px;white-space:nowrap" class="ft024"><i>D-11&#160;</i></p>
<p style="position:absolute;top:108px;left:108px;white-space:nowrap" class="ft026"><b>References&#160;</b></p>
<p style="position:absolute;top:150px;left:108px;white-space:nowrap" class="ft013">1.</p>
<p style="position:absolute;top:150px;left:121px;white-space:nowrap" class="ft046">&#160;</p>
<p style="position:absolute;top:150px;left:162px;white-space:nowrap" class="ft032">Boesecke&#160;C,&#160;Schellberg S,&#160;Schneider J,&#160;Schuettfort&#160;G, Stocker&#160;H. Prevalence,&#160;characteristics&#160;<br/>and challenges of late HIV diagnosis in Germany:&#160;an expert narrative&#160;review. Infection.&#160;<br/>2023;51(5):1223-1239.&#160;Available at:&#160;</p>
<p style="position:absolute;top:190px;left:420px;white-space:nowrap" class="ft034">https://www.ncbi.nlm.nih.gov/pubmed/37470977</p>
<p style="position:absolute;top:190px;left:761px;white-space:nowrap" class="ft013">.&#160;</p>
<p style="position:absolute;top:227px;left:108px;white-space:nowrap" class="ft013">2.</p>
<p style="position:absolute;top:227px;left:121px;white-space:nowrap" class="ft046">&#160;</p>
<p style="position:absolute;top:227px;left:162px;white-space:nowrap" class="ft032">Martins MD,&#160;Lozano-Chiu M, Rex&#160;JH. Point prevalence of oropharyngeal carriage of&#160;<br/>fluconazole-resistant&#160;</p>
<p style="position:absolute;top:247px;left:310px;white-space:nowrap" class="ft019"><i>Candida</i></p>
<p style="position:absolute;top:247px;left:369px;white-space:nowrap" class="ft013">&#160;in human immunodeficiency virus-infected patients.&#160;</p>
<p style="position:absolute;top:247px;left:738px;white-space:nowrap" class="ft019"><i>Clin&#160;</i></p>
<p style="position:absolute;top:266px;left:162px;white-space:nowrap" class="ft019"><i>Infect&#160;Dis</i></p>
<p style="position:absolute;top:266px;left:229px;white-space:nowrap" class="ft013">. 1997;25(4):843-846.&#160;Available&#160;at:&#160;</p>
<p style="position:absolute;top:266px;left:479px;white-space:nowrap" class="ft034">http://www.ncbi.nlm.nih.gov/pubmed/9356799</p>
<p style="position:absolute;top:266px;left:804px;white-space:nowrap" class="ft013">.&#160;</p>
<p style="position:absolute;top:304px;left:108px;white-space:nowrap" class="ft013">3.</p>
<p style="position:absolute;top:303px;left:121px;white-space:nowrap" class="ft046">&#160;</p>
<p style="position:absolute;top:304px;left:162px;white-space:nowrap" class="ft032">Maenza&#160;JR,&#160;Merz WG,&#160;Romagnoli MJ, Keruly JC,&#160;Moore RD,&#160;Gallant&#160;JE. Infection due&#160;to&#160;<br/>fluconazole-resistant&#160;</p>
<p style="position:absolute;top:323px;left:310px;white-space:nowrap" class="ft019"><i>Candida</i></p>
<p style="position:absolute;top:323px;left:369px;white-space:nowrap" class="ft013">&#160;in patients with AIDS: prevalence and microbiology.&#160;</p>
<p style="position:absolute;top:323px;left:743px;white-space:nowrap" class="ft019"><i>Clin&#160;</i></p>
<p style="position:absolute;top:343px;left:162px;white-space:nowrap" class="ft019"><i>Infect&#160;Dis</i></p>
<p style="position:absolute;top:343px;left:229px;white-space:nowrap" class="ft013">. 1997;24(1):28-34. Available at:&#160;</p>
<p style="position:absolute;top:343px;left:461px;white-space:nowrap" class="ft034">http://www.ncbi.nlm.nih.gov/pubmed/8994752</p>
<p style="position:absolute;top:343px;left:787px;white-space:nowrap" class="ft013">.&#160;</p>
<p style="position:absolute;top:380px;left:108px;white-space:nowrap" class="ft013">4.</p>
<p style="position:absolute;top:380px;left:121px;white-space:nowrap" class="ft046">&#160;</p>
<p style="position:absolute;top:380px;left:162px;white-space:nowrap" class="ft032">Fichtenbaum CJ, Koletar S, Yiannoutsos C, et al. Refractory mucosal&#160;candidiasis in advanced&#160;<br/>human immunodeficiency virus infection.&#160;</p>
<p style="position:absolute;top:400px;left:456px;white-space:nowrap" class="ft019"><i>Clin Infect&#160;Dis</i></p>
<p style="position:absolute;top:400px;left:557px;white-space:nowrap" class="ft013">. 2000;30(5):749-756. Available at:&#160;</p>
<p style="position:absolute;top:420px;left:162px;white-space:nowrap" class="ft034">http://www.ncbi.nlm.nih.gov/pubmed/10816143</p>
<p style="position:absolute;top:420px;left:497px;white-space:nowrap" class="ft013">.&#160;</p>
<p style="position:absolute;top:457px;left:108px;white-space:nowrap" class="ft013">5.</p>
<p style="position:absolute;top:457px;left:162px;white-space:nowrap" class="ft013">Rex JH,&#160;Rinaldi MG, Pfaller MA. Resistance of&#160;</p>
<p style="position:absolute;top:457px;left:497px;white-space:nowrap" class="ft019"><i>Candida</i></p>
<p style="position:absolute;top:457px;left:556px;white-space:nowrap" class="ft013">&#160;species to fluconazole.&#160;</p>
<p style="position:absolute;top:457px;left:721px;white-space:nowrap" class="ft019"><i>Antimicrob</i></p>
<p style="position:absolute;top:477px;left:162px;white-space:nowrap" class="ft019"><i>Agents Chemother</i></p>
<p style="position:absolute;top:477px;left:290px;white-space:nowrap" class="ft013">. 1995;39(1):1-8.&#160;Available&#160;at:&#160;</p>
<p style="position:absolute;top:497px;left:162px;white-space:nowrap" class="ft034">http://www.ncbi.nlm.nih.gov/pubmed/7695288</p>
<p style="position:absolute;top:497px;left:488px;white-space:nowrap" class="ft013">.&#160;</p>
<p style="position:absolute;top:534px;left:108px;white-space:nowrap" class="ft013">6.</p>
<p style="position:absolute;top:534px;left:121px;white-space:nowrap" class="ft046">&#160;</p>
<p style="position:absolute;top:534px;left:162px;white-space:nowrap" class="ft032">Patel PK, Erlandsen JE,&#160;Kirkpatrick WR, et al. The changing epidemiology of oropharyngeal&#160;<br/>candidiasis in patients with HIV/AIDS in the&#160;era of antiretroviral&#160;therapy.&#160;</p>
<p style="position:absolute;top:554px;left:675px;white-space:nowrap" class="ft019"><i>AIDS Res&#160;Treat</i></p>
<p style="position:absolute;top:554px;left:783px;white-space:nowrap" class="ft013">.&#160;</p>
<p style="position:absolute;top:574px;left:162px;white-space:nowrap" class="ft013">2012;2012:262471.&#160;Available at:&#160;</p>
<p style="position:absolute;top:574px;left:394px;white-space:nowrap" class="ft034">http://www.ncbi.nlm.nih.gov/pubmed/22970352</p>
<p style="position:absolute;top:574px;left:728px;white-space:nowrap" class="ft013">.&#160;</p>
<p style="position:absolute;top:611px;left:108px;white-space:nowrap" class="ft013">7.</p>
<p style="position:absolute;top:610px;left:121px;white-space:nowrap" class="ft046">&#160;</p>
<p style="position:absolute;top:611px;left:162px;white-space:nowrap" class="ft032">Thanyasrisung P,&#160;Kesakomol&#160;P, Pipattanagovit P,&#160;Youngnak-Piboonratanakit P, Pitiphat W,&#160;<br/>Matangkasombut&#160;O. Oral&#160;</p>
<p style="position:absolute;top:630px;left:342px;white-space:nowrap" class="ft019"><i>Candida</i></p>
<p style="position:absolute;top:630px;left:402px;white-space:nowrap" class="ft013">&#160;carriage and immune status in Thai human&#160;</p>
<p style="position:absolute;top:650px;left:162px;white-space:nowrap" class="ft013">immunodeficiency virus-infected individuals.&#160;</p>
<p style="position:absolute;top:650px;left:481px;white-space:nowrap" class="ft019"><i>J Med Microbiol</i></p>
<p style="position:absolute;top:650px;left:597px;white-space:nowrap" class="ft013">.&#160;2014;63(Pt&#160;5):753-759.&#160;</p>
<p style="position:absolute;top:670px;left:162px;white-space:nowrap" class="ft013">Available at:&#160;</p>
<p style="position:absolute;top:670px;left:255px;white-space:nowrap" class="ft034">http://www.ncbi.nlm.nih.gov/pubmed/24591706</p>
<p style="position:absolute;top:670px;left:589px;white-space:nowrap" class="ft013">.&#160;</p>
<p style="position:absolute;top:707px;left:108px;white-space:nowrap" class="ft013">8.</p>
<p style="position:absolute;top:707px;left:121px;white-space:nowrap" class="ft046">&#160;</p>
<p style="position:absolute;top:707px;left:162px;white-space:nowrap" class="ft013">Mushi&#160;MF,&#160;Mtemisika&#160;CI, Bader O,&#160;et al. High oral carriage of non-</p>
<p style="position:absolute;top:707px;left:632px;white-space:nowrap" class="ft019"><i>albicans</i></p>
<p style="position:absolute;top:707px;left:691px;white-space:nowrap" class="ft013">&#160;</p>
<p style="position:absolute;top:707px;left:695px;white-space:nowrap" class="ft019"><i>Candida</i></p>
<p style="position:absolute;top:707px;left:754px;white-space:nowrap" class="ft013">&#160;spp.&#160;</p>
<p style="position:absolute;top:727px;left:162px;white-space:nowrap" class="ft013">among HIV-infected individuals.&#160;</p>
<p style="position:absolute;top:727px;left:395px;white-space:nowrap" class="ft019"><i>Int J&#160;Infect Dis</i></p>
<p style="position:absolute;top:727px;left:498px;white-space:nowrap" class="ft013">. 2016;49:185-188. Available&#160;at:&#160;</p>
<p style="position:absolute;top:747px;left:162px;white-space:nowrap" class="ft034">http://www.ncbi.nlm.nih.gov/pubmed/27401585</p>
<p style="position:absolute;top:747px;left:497px;white-space:nowrap" class="ft013">.&#160;</p>
<p style="position:absolute;top:784px;left:108px;white-space:nowrap" class="ft013">9.</p>
<p style="position:absolute;top:784px;left:121px;white-space:nowrap" class="ft046">&#160;</p>
<p style="position:absolute;top:784px;left:162px;white-space:nowrap" class="ft013">Clark-Ordóñez I, Callejas-Negrete&#160;OA, Aréchiga-Carvajal&#160;ET, Mouriño-Perez RR.&#160;</p>
<p style="position:absolute;top:784px;left:739px;white-space:nowrap" class="ft019"><i>Candida</i></p>
<p style="position:absolute;top:784px;left:798px;white-space:nowrap" class="ft013">&#160;</p>
<p style="position:absolute;top:804px;left:162px;white-space:nowrap" class="ft032">species diversity and antifungal susceptibility patterns in oral&#160;samples of HIV/AIDS&#160;patients&#160;<br/>in Baja&#160;California, Mexico.&#160;</p>
<p style="position:absolute;top:824px;left:355px;white-space:nowrap" class="ft019"><i>Med Mycol</i></p>
<p style="position:absolute;top:824px;left:433px;white-space:nowrap" class="ft013">. 2016. Available&#160;at:&#160;</p>
<p style="position:absolute;top:843px;left:162px;white-space:nowrap" class="ft034">http://www.ncbi.nlm.nih.gov/pubmed/27630251</p>
<p style="position:absolute;top:843px;left:497px;white-space:nowrap" class="ft013">.&#160;</p>
<p style="position:absolute;top:881px;left:108px;white-space:nowrap" class="ft013">10.</p>
<p style="position:absolute;top:880px;left:130px;white-space:nowrap" class="ft046">&#160;</p>
<p style="position:absolute;top:881px;left:162px;white-space:nowrap" class="ft032">Klein RS,&#160;Harris CA,&#160;Small CB, Moll&#160;B, Lesser&#160;M,&#160;Friedland GH. Oral&#160;candidiasis in high-<br/>risk patients&#160;as the initial&#160;manifestation of the acquired immunodeficiency syndrome.&#160;</p>
<p style="position:absolute;top:900px;left:754px;white-space:nowrap" class="ft019"><i>N Engl&#160;</i></p>
<p style="position:absolute;top:920px;left:162px;white-space:nowrap" class="ft019"><i>J Med</i></p>
<p style="position:absolute;top:920px;left:205px;white-space:nowrap" class="ft013">. 1984;311(6):354-358. Available at:&#160;</p>
<p style="position:absolute;top:920px;left:462px;white-space:nowrap" class="ft034">http://www.ncbi.nlm.nih.gov/pubmed/6738653</p>
<p style="position:absolute;top:920px;left:788px;white-space:nowrap" class="ft013">.&#160;</p>
<p style="position:absolute;top:957px;left:108px;white-space:nowrap" class="ft013">11.</p>
<p style="position:absolute;top:957px;left:130px;white-space:nowrap" class="ft046">&#160;</p>
<p style="position:absolute;top:957px;left:162px;white-space:nowrap" class="ft032">Bonacini M,&#160;Young T, Laine&#160;L. The causes of esophageal symptoms in human&#160;<br/>immunodeficiency virus infection. A prospective&#160;study of 110 patients.&#160;</p>
<p style="position:absolute;top:977px;left:657px;white-space:nowrap" class="ft019"><i>Arch Intern Med</i></p>
<p style="position:absolute;top:977px;left:772px;white-space:nowrap" class="ft013">.&#160;</p>
<p style="position:absolute;top:997px;left:162px;white-space:nowrap" class="ft013">1991;151(8):1567-1572.&#160;Available at:&#160;</p>
<p style="position:absolute;top:997px;left:428px;white-space:nowrap" class="ft034">http://www.ncbi.nlm.nih.gov/pubmed/1651690</p>
<p style="position:absolute;top:997px;left:754px;white-space:nowrap" class="ft013">.&#160;</p>
</div>
<!-- Page 58 -->
<a name="58"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page58-div" style="position:relative;width:917px;height:1187px;">
<p style="position:absolute;top:1117px;left:108px;white-space:nowrap" class="ft024"><i>Guidelines for the Prevention and Treatment&#160;of&#160;Opportunistic&#160;Infections in Adults&#160;and Adolescents&#160;With HIV&#160;</i></p>
<p style="position:absolute;top:1117px;left:783px;white-space:nowrap" class="ft024"><i>D-12&#160;</i></p>
<p style="position:absolute;top:109px;left:108px;white-space:nowrap" class="ft013">12.</p>
<p style="position:absolute;top:108px;left:130px;white-space:nowrap" class="ft046">&#160;</p>
<p style="position:absolute;top:109px;left:162px;white-space:nowrap" class="ft032">Brion LP,&#160;Uko SE,&#160;Goldman DL. Risk of resistance associated&#160;with fluconazole&#160;prophylaxis:&#160;<br/>systematic review.&#160;</p>
<p style="position:absolute;top:129px;left:295px;white-space:nowrap" class="ft019"><i>J Infect</i></p>
<p style="position:absolute;top:129px;left:346px;white-space:nowrap" class="ft013">. 2007;54(6):521-529.&#160;Available&#160;at:&#160;</p>
<p style="position:absolute;top:148px;left:162px;white-space:nowrap" class="ft034">https://www.ncbi.nlm.nih.gov/pubmed/17239952</p>
<p style="position:absolute;top:148px;left:503px;white-space:nowrap" class="ft013">.&#160;</p>
<p style="position:absolute;top:185px;left:108px;white-space:nowrap" class="ft013">13.</p>
<p style="position:absolute;top:185px;left:130px;white-space:nowrap" class="ft046">&#160;</p>
<p style="position:absolute;top:185px;left:162px;white-space:nowrap" class="ft032">Salem M, Reichlin T, Fasel&#160;D, Leuppi-Taegtmeyer A. Torsade&#160;de pointes and systemic azole&#160;<br/>antifungal agents: analysis of global&#160;spontaneous&#160;safety reports.&#160;</p>
<p style="position:absolute;top:205px;left:607px;white-space:nowrap" class="ft019"><i>Glob Cardiol Sci Pract</i></p>
<p style="position:absolute;top:205px;left:767px;white-space:nowrap" class="ft013">.&#160;</p>
<p style="position:absolute;top:225px;left:162px;white-space:nowrap" class="ft013">2017;2017(2):11. Available&#160;at:&#160;</p>
<p style="position:absolute;top:225px;left:379px;white-space:nowrap" class="ft034">https://www.ncbi.nlm.nih.gov/pubmed/29644223</p>
<p style="position:absolute;top:225px;left:721px;white-space:nowrap" class="ft013">.&#160;</p>
<p style="position:absolute;top:262px;left:108px;white-space:nowrap" class="ft013">14.</p>
<p style="position:absolute;top:262px;left:130px;white-space:nowrap" class="ft046">&#160;</p>
<p style="position:absolute;top:262px;left:162px;white-space:nowrap" class="ft032">Pappas&#160;PG,&#160;Kauffman CA, Andes&#160;DR, et&#160;al. Clinical&#160;practice&#160;guideline for the management&#160;<br/>of candidiasis: 2016 update&#160;by the&#160;Infectious Diseases Society of&#160;America.&#160;</p>
<p style="position:absolute;top:282px;left:683px;white-space:nowrap" class="ft019"><i>Clin Infect&#160;Dis</i></p>
<p style="position:absolute;top:282px;left:784px;white-space:nowrap" class="ft013">.&#160;</p>
<p style="position:absolute;top:302px;left:162px;white-space:nowrap" class="ft013">2016;62(4):e1-50. Available&#160;at:&#160;</p>
<p style="position:absolute;top:302px;left:384px;white-space:nowrap" class="ft034">http://www.ncbi.nlm.nih.gov/pubmed/26679628</p>
<p style="position:absolute;top:302px;left:719px;white-space:nowrap" class="ft013">.&#160;</p>
<p style="position:absolute;top:339px;left:108px;white-space:nowrap" class="ft013">15.</p>
<p style="position:absolute;top:339px;left:130px;white-space:nowrap" class="ft046">&#160;</p>
<p style="position:absolute;top:339px;left:162px;white-space:nowrap" class="ft032">Vazquez JA,&#160;Patton LL, Epstein JB, et al. Randomized, comparative, double-blind, double-<br/>dummy, multicenter trial&#160;of miconazole&#160;buccal tablet&#160;and clotrimazole troches for the&#160;<br/>treatment of oropharyngeal&#160;candidiasis: study of miconazole Lauriad(R) efficacy and safety&#160;<br/>(SMiLES).&#160;</p>
<p style="position:absolute;top:399px;left:242px;white-space:nowrap" class="ft019"><i>HIV Clin Trials</i></p>
<p style="position:absolute;top:399px;left:351px;white-space:nowrap" class="ft013">. 2010;11(4):186-196.&#160;Available at:&#160;</p>
<p style="position:absolute;top:418px;left:162px;white-space:nowrap" class="ft034">http://www.ncbi.nlm.nih.gov/pubmed/20974574</p>
<p style="position:absolute;top:418px;left:497px;white-space:nowrap" class="ft013">.&#160;</p>
<p style="position:absolute;top:455px;left:108px;white-space:nowrap" class="ft013">16.</p>
<p style="position:absolute;top:455px;left:130px;white-space:nowrap" class="ft046">&#160;</p>
<p style="position:absolute;top:455px;left:162px;white-space:nowrap" class="ft032">Vazquez&#160;JA.&#160;Optimal&#160;management&#160;of oropharyngeal&#160;and esophageal candidiasis in patients&#160;<br/>living with HIV infection.&#160;</p>
<p style="position:absolute;top:475px;left:346px;white-space:nowrap" class="ft019"><i>HIV AIDS (Auckl)</i></p>
<p style="position:absolute;top:475px;left:472px;white-space:nowrap" class="ft013">. 2010;2(1):89-101.&#160;Available at:&#160;</p>
<p style="position:absolute;top:495px;left:162px;white-space:nowrap" class="ft034">http://www.ncbi.nlm.nih.gov/pubmed/22096388</p>
<p style="position:absolute;top:495px;left:497px;white-space:nowrap" class="ft013">.&#160;</p>
<p style="position:absolute;top:532px;left:108px;white-space:nowrap" class="ft013">17.</p>
<p style="position:absolute;top:532px;left:130px;white-space:nowrap" class="ft046">&#160;</p>
<p style="position:absolute;top:532px;left:162px;white-space:nowrap" class="ft032">Vazquez JA,&#160;Skiest DJ, Nieto L, et&#160;al.&#160;A multicenter randomized&#160;trial&#160;evaluating&#160;<br/>posaconazole versus&#160;fluconazole for the treatment of oropharyngeal&#160;candidiasis in subjects&#160;<br/>with HIV/AIDS.&#160;</p>
<p style="position:absolute;top:572px;left:281px;white-space:nowrap" class="ft019"><i>Clin Infect&#160;Dis</i></p>
<p style="position:absolute;top:572px;left:383px;white-space:nowrap" class="ft013">. 2006;42(8):1179-1186. Available&#160;at:&#160;</p>
<p style="position:absolute;top:592px;left:162px;white-space:nowrap" class="ft034">http://www.ncbi.nlm.nih.gov/pubmed/16575739</p>
<p style="position:absolute;top:592px;left:497px;white-space:nowrap" class="ft013">.&#160;</p>
<p style="position:absolute;top:629px;left:108px;white-space:nowrap" class="ft013">18.</p>
<p style="position:absolute;top:628px;left:130px;white-space:nowrap" class="ft046">&#160;</p>
<p style="position:absolute;top:629px;left:162px;white-space:nowrap" class="ft032">Krishna&#160;G,&#160;Ma L, Martinho M,&#160;Preston RA,&#160;O’Mara E. A new&#160;solid oral tablet&#160;formulation of&#160;<br/>posaconazole:&#160;a randomized clinical&#160;trial to investigate&#160;rising single- and multiple-dose&#160;<br/>pharmacokinetics and safety in healthy volunteers.&#160;</p>
<p style="position:absolute;top:668px;left:516px;white-space:nowrap" class="ft019"><i>J Antimicrob Chemother</i></p>
<p style="position:absolute;top:668px;left:686px;white-space:nowrap" class="ft013">.&#160;</p>
<p style="position:absolute;top:688px;left:162px;white-space:nowrap" class="ft013">2012;67(11):2725-2730.&#160;Available at:&#160;</p>
<p style="position:absolute;top:688px;left:428px;white-space:nowrap" class="ft034">http://www.ncbi.nlm.nih.gov/pubmed/22833639</p>
<p style="position:absolute;top:688px;left:763px;white-space:nowrap" class="ft013">.&#160;</p>
<p style="position:absolute;top:725px;left:108px;white-space:nowrap" class="ft013">19.</p>
<p style="position:absolute;top:725px;left:130px;white-space:nowrap" class="ft046">&#160;</p>
<p style="position:absolute;top:725px;left:162px;white-space:nowrap" class="ft032">Jung&#160;DS, Tverdek FP,&#160;Kontoyiannis DP. Switching from&#160;posaconazole suspension to tablets&#160;<br/>increases serum drug levels in leukemia&#160;patients without&#160;clinically relevant&#160;hepatotoxicity.&#160;</p>
<p style="position:absolute;top:765px;left:162px;white-space:nowrap" class="ft019"><i>Antimicrob&#160;Agents Chemother</i></p>
<p style="position:absolute;top:765px;left:372px;white-space:nowrap" class="ft013">. 2014;58(11):6993-6995. Available&#160;at:&#160;</p>
<p style="position:absolute;top:785px;left:162px;white-space:nowrap" class="ft034">https://www.ncbi.nlm.nih.gov/pubmed/25199774</p>
<p style="position:absolute;top:785px;left:503px;white-space:nowrap" class="ft013">.&#160;</p>
<p style="position:absolute;top:822px;left:108px;white-space:nowrap" class="ft013">20.</p>
<p style="position:absolute;top:822px;left:130px;white-space:nowrap" class="ft046">&#160;</p>
<p style="position:absolute;top:822px;left:162px;white-space:nowrap" class="ft032">Viljoen J, Azie&#160;N, Schmitt-Hoffmann&#160;AH,&#160;Ghannoum M.&#160;A phase 2, randomized, double-<br/>blind, multicenter trial&#160;to evaluate the safety and efficacy of three dosing regimens of&#160;<br/>isavuconazole compared&#160;with fluconazole in patients with uncomplicated esophageal&#160;<br/>candidiasis.&#160;</p>
<p style="position:absolute;top:881px;left:247px;white-space:nowrap" class="ft019"><i>Antimicrob&#160;Agents Chemother</i></p>
<p style="position:absolute;top:881px;left:457px;white-space:nowrap" class="ft013">. 2015;59(3):1671-1679. Available&#160;at:&#160;</p>
<p style="position:absolute;top:901px;left:162px;white-space:nowrap" class="ft034">http://www.ncbi.nlm.nih.gov/pubmed/25561337</p>
<p style="position:absolute;top:901px;left:497px;white-space:nowrap" class="ft013">.&#160;</p>
<p style="position:absolute;top:938px;left:108px;white-space:nowrap" class="ft013">21.</p>
<p style="position:absolute;top:938px;left:130px;white-space:nowrap" class="ft046">&#160;</p>
<p style="position:absolute;top:938px;left:162px;white-space:nowrap" class="ft032">de Wet&#160;N, Llanos-Cuentas A,&#160;Suleiman J, et al. A randomized, double-blind, parallel-group,&#160;<br/>dose-response study of micafungin compared with&#160;fluconazole&#160;for the treatment&#160;of&#160;<br/>esophageal candidiasis in&#160;HIV-positive&#160;patients.&#160;</p>
<p style="position:absolute;top:978px;left:499px;white-space:nowrap" class="ft019"><i>Clin Infect&#160;Dis</i></p>
<p style="position:absolute;top:978px;left:600px;white-space:nowrap" class="ft013">.&#160;2004;39(6):842-849.&#160;</p>
<p style="position:absolute;top:998px;left:162px;white-space:nowrap" class="ft013">Available at:&#160;</p>
<p style="position:absolute;top:998px;left:255px;white-space:nowrap" class="ft034">http://www.ncbi.nlm.nih.gov/pubmed/15472817</p>
<p style="position:absolute;top:998px;left:589px;white-space:nowrap" class="ft013">.&#160;</p>
</div>
<!-- Page 59 -->
<a name="59"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page59-div" style="position:relative;width:917px;height:1187px;">
<p style="position:absolute;top:1117px;left:108px;white-space:nowrap" class="ft024"><i>Guidelines for the Prevention and Treatment&#160;of&#160;Opportunistic&#160;Infections in Adults&#160;and Adolescents&#160;With HIV&#160;</i></p>
<p style="position:absolute;top:1117px;left:783px;white-space:nowrap" class="ft024"><i>D-13&#160;</i></p>
<p style="position:absolute;top:109px;left:108px;white-space:nowrap" class="ft013">22.</p>
<p style="position:absolute;top:108px;left:130px;white-space:nowrap" class="ft046">&#160;</p>
<p style="position:absolute;top:109px;left:162px;white-space:nowrap" class="ft032">Krause&#160;DS,&#160;Simjee AE, van Rensburg C, et&#160;al. A&#160;randomized, double-blind&#160;trial&#160;of&#160;<br/>anidulafungin versus fluconazole for the treatment&#160;of esophageal candidiasis.&#160;</p>
<p style="position:absolute;top:129px;left:699px;white-space:nowrap" class="ft019"><i>Clin Infect&#160;Dis</i></p>
<p style="position:absolute;top:129px;left:800px;white-space:nowrap" class="ft013">.&#160;</p>
<p style="position:absolute;top:148px;left:162px;white-space:nowrap" class="ft013">2004;39(6):770-775.&#160;Available&#160;at:&#160;</p>
<p style="position:absolute;top:148px;left:402px;white-space:nowrap" class="ft034">http://www.ncbi.nlm.nih.gov/pubmed/15472806</p>
<p style="position:absolute;top:148px;left:737px;white-space:nowrap" class="ft013">.&#160;</p>
<p style="position:absolute;top:185px;left:108px;white-space:nowrap" class="ft013">23.</p>
<p style="position:absolute;top:185px;left:130px;white-space:nowrap" class="ft046">&#160;</p>
<p style="position:absolute;top:185px;left:162px;white-space:nowrap" class="ft032">Martens&#160;MG, Maximos B, Degenhardt&#160;T, et al. Phase 3 study evaluating the safety and&#160;<br/>efficacy of oteseconazole&#160;in the treatment of recurrent&#160;vulvovaginal candidiasis and acute&#160;<br/>vulvovaginal candidiasis infections.&#160;</p>
<p style="position:absolute;top:225px;left:414px;white-space:nowrap" class="ft019"><i>Am J Obstet&#160;Gynecol</i></p>
<p style="position:absolute;top:225px;left:560px;white-space:nowrap" class="ft013">. 2022;227(6):880&#160;e881-880 e811.&#160;</p>
<p style="position:absolute;top:245px;left:162px;white-space:nowrap" class="ft013">Available at:&#160;</p>
<p style="position:absolute;top:245px;left:255px;white-space:nowrap" class="ft034">https://www.ncbi.nlm.nih.gov/pubmed/35863457</p>
<p style="position:absolute;top:245px;left:596px;white-space:nowrap" class="ft013">.&#160;</p>
<p style="position:absolute;top:282px;left:108px;white-space:nowrap" class="ft013">24.</p>
<p style="position:absolute;top:282px;left:130px;white-space:nowrap" class="ft046">&#160;</p>
<p style="position:absolute;top:282px;left:162px;white-space:nowrap" class="ft032">Sobel JD, Donders&#160;G, Degenhardt&#160;T, et al. Efficacy and safety of oteseconazole&#160;in recurrent&#160;<br/>vulvovaginal candidiasis.&#160;</p>
<p style="position:absolute;top:302px;left:341px;white-space:nowrap" class="ft019"><i>NEJM Evid</i></p>
<p style="position:absolute;top:302px;left:421px;white-space:nowrap" class="ft013">. 2022;1(8):1-13. Available at:&#160;</p>
<p style="position:absolute;top:322px;left:162px;white-space:nowrap" class="ft034">https://evidence.nejm.org/doi/full/10.1056/EVIDoa2100055</p>
<p style="position:absolute;top:322px;left:577px;white-space:nowrap" class="ft013">.&#160;</p>
<p style="position:absolute;top:359px;left:108px;white-space:nowrap" class="ft013">25.</p>
<p style="position:absolute;top:359px;left:130px;white-space:nowrap" class="ft046">&#160;</p>
<p style="position:absolute;top:359px;left:162px;white-space:nowrap" class="ft032">Schwebke&#160;JR, Sobel R,&#160;Gersten JK,&#160;et&#160;al. Ibrexafungerp versus placebo for&#160;vulvovaginal&#160;<br/>candidiasis treatment: a&#160;phase 3, randomized, controlled superiority trial&#160;(VANISH 303).&#160;</p>
<p style="position:absolute;top:399px;left:162px;white-space:nowrap" class="ft019"><i>Clin Infect&#160;Dis</i></p>
<p style="position:absolute;top:399px;left:263px;white-space:nowrap" class="ft013">. 2022;74(11):1979-1985. Available at:&#160;</p>
<p style="position:absolute;top:418px;left:162px;white-space:nowrap" class="ft034">https://www.ncbi.nlm.nih.gov/pubmed/34467969</p>
<p style="position:absolute;top:418px;left:503px;white-space:nowrap" class="ft013">.&#160;</p>
<p style="position:absolute;top:455px;left:108px;white-space:nowrap" class="ft013">26.</p>
<p style="position:absolute;top:455px;left:130px;white-space:nowrap" class="ft046">&#160;</p>
<p style="position:absolute;top:455px;left:162px;white-space:nowrap" class="ft032">Nyirjesy P, Schwebke JR,&#160;Angulo&#160;DA,&#160;Harriott IA,&#160;Azie NE, Sobel&#160;JD.&#160;Phase 2 randomized&#160;<br/>study of oral&#160;ibrexafungerp versus fluconazole in vulvovaginal candidiasis.&#160;</p>
<p style="position:absolute;top:475px;left:685px;white-space:nowrap" class="ft019"><i>Clin Infect Dis</i></p>
<p style="position:absolute;top:475px;left:786px;white-space:nowrap" class="ft013">.&#160;</p>
<p style="position:absolute;top:495px;left:162px;white-space:nowrap" class="ft013">2022;74(12):2129-2135.&#160;Available at:&#160;</p>
<p style="position:absolute;top:495px;left:428px;white-space:nowrap" class="ft034">https://www.ncbi.nlm.nih.gov/pubmed/34555149</p>
<p style="position:absolute;top:495px;left:770px;white-space:nowrap" class="ft013">.&#160;</p>
<p style="position:absolute;top:532px;left:108px;white-space:nowrap" class="ft013">27.</p>
<p style="position:absolute;top:532px;left:130px;white-space:nowrap" class="ft046">&#160;</p>
<p style="position:absolute;top:532px;left:162px;white-space:nowrap" class="ft032">SCYNEXIS&#160;presents positive data&#160;from its pivotal&#160;phase 3 CANDLE&#160;study&#160;of oral&#160;<br/>ibrexafungerp for prevention of recurrent vaginal yeast infections during the&#160;2022 IDSOG&#160;<br/>annual&#160;meeting [press release]. Jersey&#160;City, NJ.&#160;SCYNEXIS,&#160;Inc. 2022.&#160;Available at:&#160;</p>
<p style="position:absolute;top:592px;left:162px;white-space:nowrap" class="ft078">https://d1io3yog0oux5.cloudfront.net/_b74ab29ee08f7c716ae5e6710e5dba4b/scynexis/news/<br/>2022-08-04_SCYNEXIS_Presents_Positive_Data_from_Its_Pivotal_298.pdf</p>
<p style="position:absolute;top:612px;left:694px;white-space:nowrap" class="ft013">.&#160;</p>
<p style="position:absolute;top:649px;left:108px;white-space:nowrap" class="ft013">28.</p>
<p style="position:absolute;top:648px;left:130px;white-space:nowrap" class="ft046">&#160;</p>
<p style="position:absolute;top:649px;left:162px;white-space:nowrap" class="ft032">BREXAFEMME®&#160;(ibrexafungerp tablets), for oral&#160;use [package insert]. U.S. Food&#160;and&#160;Drug&#160;<br/>Administration. 2021.&#160;Available&#160;at:&#160;</p>
<p style="position:absolute;top:688px;left:162px;white-space:nowrap" class="ft034">https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/214900s002lbl.pdf</p>
<p style="position:absolute;top:688px;left:711px;white-space:nowrap" class="ft013">.&#160;</p>
<p style="position:absolute;top:725px;left:108px;white-space:nowrap" class="ft013">29.</p>
<p style="position:absolute;top:725px;left:130px;white-space:nowrap" class="ft046">&#160;</p>
<p style="position:absolute;top:725px;left:162px;white-space:nowrap" class="ft032">Sucher AJ, Thai&#160;A, Tran&#160;C, Mantena&#160;N, Noronha&#160;A, Chahine&#160;EB. Ibrexafungerp:&#160;a new&#160;<br/>triterpenoid antifungal.&#160;</p>
<p style="position:absolute;top:745px;left:325px;white-space:nowrap" class="ft019"><i>Am J Health Syst Pharm</i></p>
<p style="position:absolute;top:745px;left:495px;white-space:nowrap" class="ft013">. 2022;79(24):2208-2221.&#160;Available at:&#160;</p>
<p style="position:absolute;top:765px;left:162px;white-space:nowrap" class="ft034">https://www.ncbi.nlm.nih.gov/pubmed/36083109</p>
<p style="position:absolute;top:765px;left:503px;white-space:nowrap" class="ft013">.&#160;</p>
<p style="position:absolute;top:802px;left:108px;white-space:nowrap" class="ft013">30.</p>
<p style="position:absolute;top:802px;left:130px;white-space:nowrap" class="ft046">&#160;</p>
<p style="position:absolute;top:802px;left:162px;white-space:nowrap" class="ft013">Chang YL,&#160;Yu SJ, Heitman J, Wellington M, Chen YL. New&#160;facets of antifungal therapy.&#160;</p>
<p style="position:absolute;top:822px;left:162px;white-space:nowrap" class="ft019"><i>Virulence</i></p>
<p style="position:absolute;top:822px;left:229px;white-space:nowrap" class="ft013">. 2017;8(2):222-236. Available&#160;at:&#160;</p>
<p style="position:absolute;top:842px;left:162px;white-space:nowrap" class="ft034">https://www.ncbi.nlm.nih.gov/pubmed/27820668</p>
<p style="position:absolute;top:842px;left:503px;white-space:nowrap" class="ft013">.&#160;</p>
<p style="position:absolute;top:879px;left:108px;white-space:nowrap" class="ft013">31.</p>
<p style="position:absolute;top:879px;left:130px;white-space:nowrap" class="ft046">&#160;</p>
<p style="position:absolute;top:879px;left:162px;white-space:nowrap" class="ft032">Thambuchetty N,&#160;Mehta&#160;K, Arumugam K, Shekarappa UG, Idiculla&#160;J, Shet&#160;A. The&#160;<br/>epidemiology of IRIS in&#160;southern India: an observational&#160;cohort&#160;study.&#160;</p>
<p style="position:absolute;top:899px;left:655px;white-space:nowrap" class="ft019"><i>J Int&#160;Assoc Provid&#160;</i></p>
<p style="position:absolute;top:919px;left:162px;white-space:nowrap" class="ft019"><i>AIDS Care</i></p>
<p style="position:absolute;top:919px;left:238px;white-space:nowrap" class="ft013">.&#160;2017;16(5):475-480.&#160;Available&#160;at:&#160;</p>
<p style="position:absolute;top:938px;left:162px;white-space:nowrap" class="ft034">https://www.ncbi.nlm.nih.gov/pubmed/28399724</p>
<p style="position:absolute;top:938px;left:503px;white-space:nowrap" class="ft013">.&#160;</p>
<p style="position:absolute;top:976px;left:108px;white-space:nowrap" class="ft013">32.</p>
<p style="position:absolute;top:975px;left:130px;white-space:nowrap" class="ft046">&#160;</p>
<p style="position:absolute;top:976px;left:162px;white-space:nowrap" class="ft032">Ramirez-Amador V,&#160;Patton LL, Naglik&#160;JR, Nittayananta W. Innovations for prevention and&#160;<br/>care&#160;of oral&#160;candidiasis in&#160;HIV-infected individuals: are they available?-A workshop report.&#160;</p>
<p style="position:absolute;top:1015px;left:162px;white-space:nowrap" class="ft019"><i>Oral&#160;Dis</i></p>
<p style="position:absolute;top:1015px;left:223px;white-space:nowrap" class="ft013">. 2020;26 Suppl&#160;1:91-102.&#160;Available&#160;at:&#160;</p>
<p style="position:absolute;top:1035px;left:162px;white-space:nowrap" class="ft034">https://www.ncbi.nlm.nih.gov/pubmed/32862535</p>
<p style="position:absolute;top:1035px;left:503px;white-space:nowrap" class="ft013">.&#160;</p>
</div>
<!-- Page 60 -->
<a name="60"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page60-div" style="position:relative;width:917px;height:1187px;">
<p style="position:absolute;top:1117px;left:108px;white-space:nowrap" class="ft024"><i>Guidelines for the Prevention and Treatment&#160;of&#160;Opportunistic&#160;Infections in Adults&#160;and Adolescents&#160;With HIV&#160;</i></p>
<p style="position:absolute;top:1117px;left:783px;white-space:nowrap" class="ft024"><i>D-14&#160;</i></p>
<p style="position:absolute;top:109px;left:108px;white-space:nowrap" class="ft013">33.</p>
<p style="position:absolute;top:108px;left:130px;white-space:nowrap" class="ft046">&#160;</p>
<p style="position:absolute;top:109px;left:162px;white-space:nowrap" class="ft032">Skiest DJ, Vazquez JA,&#160;Anstead&#160;GM, et al. Posaconazole for the treatment of azole-<br/>refractory oropharyngeal&#160;and esophageal&#160;candidiasis in subjects&#160;with HIV infection.&#160;</p>
<p style="position:absolute;top:129px;left:746px;white-space:nowrap" class="ft019"><i>Clin&#160;</i></p>
<p style="position:absolute;top:148px;left:162px;white-space:nowrap" class="ft019"><i>Infect&#160;Dis</i></p>
<p style="position:absolute;top:148px;left:229px;white-space:nowrap" class="ft013">. 2007;44(4):607-614.&#160;Available&#160;at:&#160;</p>
<p style="position:absolute;top:168px;left:162px;white-space:nowrap" class="ft034">http://www.ncbi.nlm.nih.gov/pubmed/17243069</p>
<p style="position:absolute;top:168px;left:497px;white-space:nowrap" class="ft013">.&#160;</p>
<p style="position:absolute;top:205px;left:108px;white-space:nowrap" class="ft013">34.</p>
<p style="position:absolute;top:205px;left:130px;white-space:nowrap" class="ft046">&#160;</p>
<p style="position:absolute;top:205px;left:162px;white-space:nowrap" class="ft032">Villanueva A, Gotuzzo&#160;E, Arathoon&#160;EG, et&#160;al. A randomized double-blind study of&#160;<br/>caspofungin&#160;versus&#160;fluconazole&#160;for the treatment of esophageal&#160;candidiasis.&#160;</p>
<p style="position:absolute;top:225px;left:687px;white-space:nowrap" class="ft019"><i>Am J Med</i></p>
<p style="position:absolute;top:225px;left:757px;white-space:nowrap" class="ft013">.&#160;</p>
<p style="position:absolute;top:245px;left:162px;white-space:nowrap" class="ft013">2002;113(4):294-299.&#160;Available&#160;at:&#160;</p>
<p style="position:absolute;top:245px;left:411px;white-space:nowrap" class="ft034">https://www.ncbi.nlm.nih.gov/pubmed/12361815</p>
<p style="position:absolute;top:245px;left:752px;white-space:nowrap" class="ft013">.&#160;</p>
<p style="position:absolute;top:282px;left:108px;white-space:nowrap" class="ft013">35.</p>
<p style="position:absolute;top:282px;left:130px;white-space:nowrap" class="ft046">&#160;</p>
<p style="position:absolute;top:282px;left:162px;white-space:nowrap" class="ft032">Ally R, Schurmann D,&#160;Kreisel W, et&#160;al. A randomized, double-blind, double-dummy,&#160;<br/>multicenter trial&#160;of voriconazole and fluconazole&#160;in the treatment&#160;of esophageal&#160;candidiasis in&#160;<br/>immunocompromised patients.&#160;</p>
<p style="position:absolute;top:322px;left:380px;white-space:nowrap" class="ft019"><i>Clin Infect&#160;Dis</i></p>
<p style="position:absolute;top:322px;left:481px;white-space:nowrap" class="ft013">. 2001;33(9):1447-1454.&#160;Available at:&#160;</p>
<p style="position:absolute;top:342px;left:162px;white-space:nowrap" class="ft034">https://www.ncbi.nlm.nih.gov/pubmed/11577374</p>
<p style="position:absolute;top:342px;left:503px;white-space:nowrap" class="ft013">.&#160;</p>
<p style="position:absolute;top:379px;left:108px;white-space:nowrap" class="ft013">36.</p>
<p style="position:absolute;top:378px;left:130px;white-space:nowrap" class="ft046">&#160;</p>
<p style="position:absolute;top:379px;left:162px;white-space:nowrap" class="ft032">Dentinger PJ, Swenson CF, Anaizi&#160;NH. Stability of amphotericin B in an extemporaneously&#160;<br/>compounded&#160;oral&#160;suspension.&#160;</p>
<p style="position:absolute;top:399px;left:371px;white-space:nowrap" class="ft019"><i>Am J Health Syst Pharm</i></p>
<p style="position:absolute;top:399px;left:540px;white-space:nowrap" class="ft013">. 2001;58(11):1021-1024. Available&#160;</p>
<p style="position:absolute;top:418px;left:162px;white-space:nowrap" class="ft013">at:&#160;</p>
<p style="position:absolute;top:418px;left:184px;white-space:nowrap" class="ft034">https://www.ncbi.nlm.nih.gov/pubmed/11402476</p>
<p style="position:absolute;top:418px;left:525px;white-space:nowrap" class="ft013">.&#160;</p>
<p style="position:absolute;top:455px;left:108px;white-space:nowrap" class="ft013">37.</p>
<p style="position:absolute;top:455px;left:130px;white-space:nowrap" class="ft046">&#160;</p>
<p style="position:absolute;top:455px;left:162px;white-space:nowrap" class="ft032">Powell A,&#160;Ghanem KG,&#160;Rogers L, et&#160;al. Clinicians’ use of intravaginal&#160;boric&#160;acid&#160;<br/>maintenance therapy for recurrent vulvovaginal&#160;candidiasis and&#160;bacterial vaginosis.&#160;</p>
<p style="position:absolute;top:475px;left:742px;white-space:nowrap" class="ft019"><i>Sex&#160;</i></p>
<p style="position:absolute;top:495px;left:162px;white-space:nowrap" class="ft019"><i>Transm&#160;Dis</i></p>
<p style="position:absolute;top:495px;left:243px;white-space:nowrap" class="ft013">.&#160;2019;46(12):810-812.&#160;Available&#160;at:&#160;</p>
<p style="position:absolute;top:515px;left:162px;white-space:nowrap" class="ft034">https://www.ncbi.nlm.nih.gov/pubmed/31663976</p>
<p style="position:absolute;top:515px;left:503px;white-space:nowrap" class="ft013">.&#160;</p>
<p style="position:absolute;top:552px;left:108px;white-space:nowrap" class="ft013">38.</p>
<p style="position:absolute;top:552px;left:130px;white-space:nowrap" class="ft046">&#160;</p>
<p style="position:absolute;top:552px;left:162px;white-space:nowrap" class="ft032">Nyirjesy P,&#160;Brookhart C,&#160;Lazenby G,&#160;Schwebke&#160;J,&#160;Sobel JD. Vulvovaginal&#160;candidiasis: a&#160;<br/>review of the&#160;evidence&#160;for&#160;the&#160;2021 Centers for&#160;Disease Control&#160;and Prevention of sexually&#160;<br/>transmitted Infections treatment&#160;guidelines.&#160;</p>
<p style="position:absolute;top:592px;left:466px;white-space:nowrap" class="ft019"><i>Clin Infect&#160;Dis</i></p>
<p style="position:absolute;top:592px;left:567px;white-space:nowrap" class="ft013">. 2022;74(Suppl_2):S162-S168.&#160;</p>
<p style="position:absolute;top:612px;left:162px;white-space:nowrap" class="ft013">Available at:&#160;</p>
<p style="position:absolute;top:612px;left:255px;white-space:nowrap" class="ft034">https://www.ncbi.nlm.nih.gov/pubmed/35416967</p>
<p style="position:absolute;top:612px;left:596px;white-space:nowrap" class="ft013">.&#160;</p>
<p style="position:absolute;top:649px;left:108px;white-space:nowrap" class="ft013">39.</p>
<p style="position:absolute;top:648px;left:130px;white-space:nowrap" class="ft046">&#160;</p>
<p style="position:absolute;top:649px;left:162px;white-space:nowrap" class="ft032">Goldman M,&#160;Cloud GA,&#160;Wade&#160;KD,&#160;et&#160;al. A randomized study&#160;of the&#160;use of&#160;fluconazole in&#160;<br/>continuous versus episodic therapy in patients with advanced HIV infection and a history&#160;of&#160;<br/>oropharyngeal candidiasis: AIDS&#160;Clinical&#160;Trials Group Study&#160;323/Mycoses Study Group&#160;<br/>Study 40.&#160;</p>
<p style="position:absolute;top:708px;left:233px;white-space:nowrap" class="ft019"><i>Clin Infect Dis</i></p>
<p style="position:absolute;top:708px;left:334px;white-space:nowrap" class="ft013">.&#160;2005;41(10):1473-1480.&#160;Available at:&#160;</p>
<p style="position:absolute;top:728px;left:162px;white-space:nowrap" class="ft034">http://www.ncbi.nlm.nih.gov/pubmed/16231260</p>
<p style="position:absolute;top:728px;left:497px;white-space:nowrap" class="ft013">.&#160;</p>
<p style="position:absolute;top:765px;left:108px;white-space:nowrap" class="ft013">40.</p>
<p style="position:absolute;top:765px;left:130px;white-space:nowrap" class="ft046">&#160;</p>
<p style="position:absolute;top:765px;left:162px;white-space:nowrap" class="ft032">Powderly&#160;WG, Finkelstein D, Feinberg J, et al. A randomized trial comparing fluconazole&#160;<br/>with clotrimazole troches for the prevention of fungal&#160;infections in patients with advanced&#160;<br/>human immunodeficiency virus infection. NIAID AIDS Clinical&#160;Trials Group.&#160;</p>
<p style="position:absolute;top:805px;left:709px;white-space:nowrap" class="ft019"><i>N Engl&#160;J Med</i></p>
<p style="position:absolute;top:805px;left:804px;white-space:nowrap" class="ft013">.&#160;</p>
<p style="position:absolute;top:825px;left:162px;white-space:nowrap" class="ft013">1995;332(11):700-705.&#160;Available&#160;at:&#160;</p>
<p style="position:absolute;top:825px;left:420px;white-space:nowrap" class="ft034">http://www.ncbi.nlm.nih.gov/pubmed/7854376</p>
<p style="position:absolute;top:825px;left:746px;white-space:nowrap" class="ft013">.&#160;</p>
<p style="position:absolute;top:862px;left:108px;white-space:nowrap" class="ft013">41.</p>
<p style="position:absolute;top:861px;left:130px;white-space:nowrap" class="ft046">&#160;</p>
<p style="position:absolute;top:862px;left:162px;white-space:nowrap" class="ft032">Schuman P,&#160;Capps L, Peng G, et al.&#160;Weekly fluconazole&#160;for the prevention of mucosal&#160;<br/>candidiasis in women&#160;with HIV infection. A randomized, double-blind, placebo-controlled&#160;<br/>trial. Terry Beirn Community Programs for Clinical Research on&#160;AIDS.&#160;</p>
<p style="position:absolute;top:901px;left:662px;white-space:nowrap" class="ft019"><i>Ann&#160;Intern Med</i></p>
<p style="position:absolute;top:901px;left:771px;white-space:nowrap" class="ft013">.&#160;</p>
<p style="position:absolute;top:921px;left:162px;white-space:nowrap" class="ft013">1997;126(9):689-696.&#160;Available&#160;at:&#160;</p>
<p style="position:absolute;top:921px;left:411px;white-space:nowrap" class="ft034">http://www.ncbi.nlm.nih.gov/pubmed/9139554</p>
<p style="position:absolute;top:921px;left:737px;white-space:nowrap" class="ft013">.&#160;</p>
<p style="position:absolute;top:958px;left:108px;white-space:nowrap" class="ft013">42.</p>
<p style="position:absolute;top:958px;left:130px;white-space:nowrap" class="ft046">&#160;</p>
<p style="position:absolute;top:958px;left:162px;white-space:nowrap" class="ft032">Havlir DV,&#160;Dube&#160;MP,&#160;McCutchan JA, et al. Prophylaxis with&#160;weekly versus daily&#160;<br/>fluconazole for fungal&#160;infections in patients with AIDS.&#160;</p>
<p style="position:absolute;top:978px;left:551px;white-space:nowrap" class="ft019"><i>Clin Infect&#160;Dis</i></p>
<p style="position:absolute;top:978px;left:653px;white-space:nowrap" class="ft013">. 1998;27(6):1369-</p>
<p style="position:absolute;top:998px;left:162px;white-space:nowrap" class="ft013">1375. Available&#160;at:&#160;</p>
<p style="position:absolute;top:998px;left:298px;white-space:nowrap" class="ft034">http://www.ncbi.nlm.nih.gov/pubmed/9868644</p>
<p style="position:absolute;top:998px;left:624px;white-space:nowrap" class="ft013">.&#160;</p>
<p style="position:absolute;top:1035px;left:108px;white-space:nowrap" class="ft013">43.</p>
<p style="position:absolute;top:1035px;left:130px;white-space:nowrap" class="ft046">&#160;</p>
<p style="position:absolute;top:1035px;left:162px;white-space:nowrap" class="ft032">Vazquez&#160;JA,&#160;Skiest DJ, Tissot-Dupont&#160;H, Lennox&#160;JL, Boparai N, Isaacs R.&#160;Safety and&#160;<br/>efficacy of posaconazole&#160;in the long-term&#160;treatment of azole-refractory oropharyngeal and&#160;</p>
</div>
<!-- Page 61 -->
<a name="61"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page61-div" style="position:relative;width:917px;height:1187px;">
<p style="position:absolute;top:1117px;left:108px;white-space:nowrap" class="ft024"><i>Guidelines for the Prevention and Treatment&#160;of&#160;Opportunistic&#160;Infections in Adults&#160;and Adolescents&#160;With HIV&#160;</i></p>
<p style="position:absolute;top:1117px;left:783px;white-space:nowrap" class="ft024"><i>D-15&#160;</i></p>
<p style="position:absolute;top:109px;left:162px;white-space:nowrap" class="ft013">esophageal candidiasis in&#160;patients with HIV&#160;infection.&#160;</p>
<p style="position:absolute;top:109px;left:539px;white-space:nowrap" class="ft019"><i>HIV Clin&#160;Trials</i></p>
<p style="position:absolute;top:109px;left:647px;white-space:nowrap" class="ft013">. 2007;8(2):86-97.&#160;</p>
<p style="position:absolute;top:129px;left:162px;white-space:nowrap" class="ft013">Available at:&#160;</p>
<p style="position:absolute;top:129px;left:255px;white-space:nowrap" class="ft034">http://www.ncbi.nlm.nih.gov/pubmed/17507324</p>
<p style="position:absolute;top:129px;left:589px;white-space:nowrap" class="ft013">.&#160;</p>
<p style="position:absolute;top:166px;left:108px;white-space:nowrap" class="ft013">44.</p>
<p style="position:absolute;top:165px;left:130px;white-space:nowrap" class="ft046">&#160;</p>
<p style="position:absolute;top:166px;left:162px;white-space:nowrap" class="ft032">Johnson EM,&#160;Warnock DW, Luker J,&#160;Porter SR,&#160;Scully C. Emergence of azole&#160;drug&#160;<br/>resistance in&#160;</p>
<p style="position:absolute;top:185px;left:252px;white-space:nowrap" class="ft019"><i>Candida</i></p>
<p style="position:absolute;top:185px;left:311px;white-space:nowrap" class="ft013">&#160;species from HIV-infected patients receiving prolonged fluconazole&#160;</p>
<p style="position:absolute;top:205px;left:162px;white-space:nowrap" class="ft013">therapy for oral&#160;candidosis.&#160;</p>
<p style="position:absolute;top:205px;left:355px;white-space:nowrap" class="ft019"><i>J Antimicrob Chemother</i></p>
<p style="position:absolute;top:205px;left:525px;white-space:nowrap" class="ft013">. 1995;35(1):103-114.&#160;Available&#160;at:&#160;</p>
<p style="position:absolute;top:225px;left:162px;white-space:nowrap" class="ft034">https://www.ncbi.nlm.nih.gov/pubmed/7768758</p>
<p style="position:absolute;top:225px;left:495px;white-space:nowrap" class="ft013">.&#160;</p>
<p style="position:absolute;top:262px;left:108px;white-space:nowrap" class="ft013">45.</p>
<p style="position:absolute;top:262px;left:130px;white-space:nowrap" class="ft046">&#160;</p>
<p style="position:absolute;top:262px;left:162px;white-space:nowrap" class="ft013">Marty F,&#160;Mylonakis E. Antifungal&#160;use&#160;in HIV&#160;infection.&#160;</p>
<p style="position:absolute;top:262px;left:553px;white-space:nowrap" class="ft019"><i>Expert Opin Pharmacother</i></p>
<p style="position:absolute;top:262px;left:741px;white-space:nowrap" class="ft013">.&#160;</p>
<p style="position:absolute;top:282px;left:162px;white-space:nowrap" class="ft013">2002;3(2):91-102. Available&#160;at:&#160;</p>
<p style="position:absolute;top:282px;left:385px;white-space:nowrap" class="ft034">https://www.ncbi.nlm.nih.gov/pubmed/11829723</p>
<p style="position:absolute;top:282px;left:726px;white-space:nowrap" class="ft013">.&#160;</p>
<p style="position:absolute;top:319px;left:108px;white-space:nowrap" class="ft013">46.</p>
<p style="position:absolute;top:319px;left:130px;white-space:nowrap" class="ft046">&#160;</p>
<p style="position:absolute;top:319px;left:162px;white-space:nowrap" class="ft032">Alsaad AM,&#160;Kaplan YC,&#160;Koren&#160;G. Exposure to fluconazole&#160;and risk of congenital&#160;<br/>malformations in the&#160;offspring:&#160;a systematic review and meta-analysis.&#160;</p>
<p style="position:absolute;top:339px;left:655px;white-space:nowrap" class="ft019"><i>Reprod Toxicol</i></p>
<p style="position:absolute;top:339px;left:762px;white-space:nowrap" class="ft013">.&#160;</p>
<p style="position:absolute;top:359px;left:162px;white-space:nowrap" class="ft013">2015;52:78-82. Available at:&#160;</p>
<p style="position:absolute;top:359px;left:365px;white-space:nowrap" class="ft034">http://www.ncbi.nlm.nih.gov/pubmed/25724389</p>
<p style="position:absolute;top:359px;left:700px;white-space:nowrap" class="ft013">.&#160;</p>
<p style="position:absolute;top:396px;left:108px;white-space:nowrap" class="ft013">47.</p>
<p style="position:absolute;top:396px;left:130px;white-space:nowrap" class="ft046">&#160;</p>
<p style="position:absolute;top:396px;left:162px;white-space:nowrap" class="ft032">Molgaard-Nielsen D, Pasternak B, Hviid A. Use of&#160;oral&#160;fluconazole during pregnancy and&#160;<br/>the&#160;risk of birth defects.&#160;</p>
<p style="position:absolute;top:416px;left:330px;white-space:nowrap" class="ft019"><i>N Engl&#160;J Med</i></p>
<p style="position:absolute;top:416px;left:426px;white-space:nowrap" class="ft013">. 2013;369(9):830-839.&#160;Available at:&#160;</p>
<p style="position:absolute;top:436px;left:162px;white-space:nowrap" class="ft034">http://www.ncbi.nlm.nih.gov/pubmed/23984730</p>
<p style="position:absolute;top:436px;left:497px;white-space:nowrap" class="ft013">.&#160;</p>
<p style="position:absolute;top:473px;left:108px;white-space:nowrap" class="ft013">48.</p>
<p style="position:absolute;top:472px;left:130px;white-space:nowrap" class="ft046">&#160;</p>
<p style="position:absolute;top:473px;left:162px;white-space:nowrap" class="ft032">Lopez-Rangel&#160;E, Van Allen MI.&#160;Prenatal exposure&#160;to fluconazole:&#160;an identifiable dysmorphic&#160;<br/>phenotype.&#160;</p>
<p style="position:absolute;top:492px;left:243px;white-space:nowrap" class="ft019"><i>Birth Defects&#160;Res A Clin Mol&#160;Teratol</i></p>
<p style="position:absolute;top:492px;left:499px;white-space:nowrap" class="ft013">.&#160;2005;73(11):919-923.&#160;Available&#160;at:&#160;</p>
<p style="position:absolute;top:512px;left:162px;white-space:nowrap" class="ft034">http://www.ncbi.nlm.nih.gov/pubmed/16265639</p>
<p style="position:absolute;top:512px;left:497px;white-space:nowrap" class="ft013">.&#160;</p>
<p style="position:absolute;top:549px;left:108px;white-space:nowrap" class="ft013">49.</p>
<p style="position:absolute;top:549px;left:130px;white-space:nowrap" class="ft046">&#160;</p>
<p style="position:absolute;top:549px;left:162px;white-space:nowrap" class="ft032">Molgaard-Nielsen D, Svanstrom H,&#160;Melbye M, Hviid A, Pasternak B. Association between&#160;<br/>use of oral&#160;fluconazole&#160;during pregnancy and risk of spontaneous abortion and stillbirth.&#160;</p>
<p style="position:absolute;top:589px;left:162px;white-space:nowrap" class="ft019"><i>JAMA</i></p>
<p style="position:absolute;top:589px;left:205px;white-space:nowrap" class="ft013">. 2016;315(1):58-67. Available at:&#160;</p>
<p style="position:absolute;top:589px;left:445px;white-space:nowrap" class="ft034">https://www.ncbi.nlm.nih.gov/pubmed/26746458</p>
<p style="position:absolute;top:589px;left:787px;white-space:nowrap" class="ft013">.&#160;</p>
<p style="position:absolute;top:626px;left:108px;white-space:nowrap" class="ft013">50.</p>
<p style="position:absolute;top:626px;left:130px;white-space:nowrap" class="ft046">&#160;</p>
<p style="position:absolute;top:626px;left:162px;white-space:nowrap" class="ft032">Berard A,&#160;Sheehy O, Zhao JP, et&#160;al. Associations between low-&#160;and high-dose oral&#160;<br/>fluconazole and pregnancy outcomes: 3 nested case-control studies.&#160;</p>
<p style="position:absolute;top:646px;left:633px;white-space:nowrap" class="ft019"><i>CMAJ</i></p>
<p style="position:absolute;top:646px;left:678px;white-space:nowrap" class="ft013">.&#160;</p>
<p style="position:absolute;top:666px;left:162px;white-space:nowrap" class="ft013">2019;191(7):E179-E187.&#160;Available at:&#160;</p>
<p style="position:absolute;top:666px;left:432px;white-space:nowrap" class="ft034">https://www.ncbi.nlm.nih.gov/pubmed/30782643</p>
<p style="position:absolute;top:666px;left:773px;white-space:nowrap" class="ft013">.&#160;</p>
<p style="position:absolute;top:703px;left:108px;white-space:nowrap" class="ft013">51.</p>
<p style="position:absolute;top:703px;left:130px;white-space:nowrap" class="ft046">&#160;</p>
<p style="position:absolute;top:703px;left:162px;white-space:nowrap" class="ft032">Pasternak B,&#160;Wintzell&#160;V, Furu&#160;K, Engeland A, Neovius M,&#160;Stephansson&#160;O.&#160;Oral fluconazole&#160;<br/>in pregnancy&#160;and risk of&#160;stillbirth and&#160;neonatal death.&#160;</p>
<p style="position:absolute;top:723px;left:534px;white-space:nowrap" class="ft019"><i>JAMA</i></p>
<p style="position:absolute;top:723px;left:577px;white-space:nowrap" class="ft013">. 2018;319(22):2333-2335.&#160;</p>
<p style="position:absolute;top:743px;left:162px;white-space:nowrap" class="ft013">Available at:&#160;</p>
<p style="position:absolute;top:743px;left:255px;white-space:nowrap" class="ft034">https://www.ncbi.nlm.nih.gov/pubmed/29896619</p>
<p style="position:absolute;top:743px;left:596px;white-space:nowrap" class="ft013">.&#160;</p>
<p style="position:absolute;top:780px;left:108px;white-space:nowrap" class="ft013">52.</p>
<p style="position:absolute;top:779px;left:130px;white-space:nowrap" class="ft046">&#160;</p>
<p style="position:absolute;top:780px;left:162px;white-space:nowrap" class="ft032">SPORANOX® (itraconazole) oral&#160;solution [package insert]. U.S. Food&#160;and&#160;Drug&#160;<br/>Administration. 2003.&#160;Available&#160;at:&#160;</p>
<p style="position:absolute;top:819px;left:162px;white-space:nowrap" class="ft034">https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/020657s038lbl.pdf</p>
<p style="position:absolute;top:819px;left:711px;white-space:nowrap" class="ft013">.&#160;</p>
<p style="position:absolute;top:856px;left:108px;white-space:nowrap" class="ft013">53.</p>
<p style="position:absolute;top:856px;left:130px;white-space:nowrap" class="ft046">&#160;</p>
<p style="position:absolute;top:856px;left:162px;white-space:nowrap" class="ft032">De Santis&#160;M,&#160;Di Gianantonio E, Cesari&#160;E, Ambrosini G, Straface G, Clementi M. First-<br/>trimester itraconazole&#160;exposure and pregnancy outcome: a&#160;prospective cohort study of&#160;<br/>women contacting teratology information services in Italy.&#160;</p>
<p style="position:absolute;top:896px;left:571px;white-space:nowrap" class="ft019"><i>Drug&#160;Saf</i></p>
<p style="position:absolute;top:896px;left:633px;white-space:nowrap" class="ft013">. 2009;32(3):239-244.&#160;</p>
<p style="position:absolute;top:916px;left:162px;white-space:nowrap" class="ft013">Available at:&#160;</p>
<p style="position:absolute;top:916px;left:255px;white-space:nowrap" class="ft034">http://www.ncbi.nlm.nih.gov/pubmed/19338381</p>
<p style="position:absolute;top:916px;left:589px;white-space:nowrap" class="ft013">.&#160;</p>
<p style="position:absolute;top:953px;left:108px;white-space:nowrap" class="ft013">54.</p>
<p style="position:absolute;top:953px;left:130px;white-space:nowrap" class="ft046">&#160;</p>
<p style="position:absolute;top:953px;left:162px;white-space:nowrap" class="ft032">NOXAFIL&#160;Highlights of&#160;prescribing information [package insert]. U.S.&#160;Food and Drug&#160;<br/>Administration. 2015.&#160;Available&#160;at:&#160;</p>
<p style="position:absolute;top:993px;left:162px;white-space:nowrap" class="ft078">https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/022003s018s020,0205053s002s<br/>004,0205596s001s003lbl.pdf</p>
<p style="position:absolute;top:1013px;left:363px;white-space:nowrap" class="ft013">.&#160;</p>
</div>
<!-- Page 62 -->
<a name="62"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page62-div" style="position:relative;width:917px;height:1187px;">
<p style="position:absolute;top:1117px;left:108px;white-space:nowrap" class="ft024"><i>Guidelines for the Prevention and Treatment&#160;of&#160;Opportunistic&#160;Infections in Adults&#160;and Adolescents&#160;With HIV&#160;</i></p>
<p style="position:absolute;top:1117px;left:783px;white-space:nowrap" class="ft024"><i>D-16&#160;</i></p>
<p style="position:absolute;top:109px;left:108px;white-space:nowrap" class="ft013">55.</p>
<p style="position:absolute;top:108px;left:130px;white-space:nowrap" class="ft046">&#160;</p>
<p style="position:absolute;top:109px;left:162px;white-space:nowrap" class="ft013">VFEND®&#160;[package insert]. U.S. Food&#160;and Drug&#160;Administration. 2010. Available&#160;at:&#160;</p>
<p style="position:absolute;top:129px;left:162px;white-space:nowrap" class="ft034">https://www.accessdata.fda.gov/drugsatfda_docs/label/2010/021266s032lbl.pdf</p>
<p style="position:absolute;top:129px;left:711px;white-space:nowrap" class="ft013">.&#160;</p>
<p style="position:absolute;top:166px;left:108px;white-space:nowrap" class="ft013">56.</p>
<p style="position:absolute;top:165px;left:130px;white-space:nowrap" class="ft046">&#160;</p>
<p style="position:absolute;top:166px;left:162px;white-space:nowrap" class="ft032">Pilmis B, Jullien V, Sobel&#160;J, Lecuit M,&#160;Lortholary O, Charlier C.&#160;Antifungal drugs during&#160;<br/>pregnancy: an updated review.&#160;</p>
<p style="position:absolute;top:185px;left:378px;white-space:nowrap" class="ft019"><i>J Antimicrob Chemother</i></p>
<p style="position:absolute;top:185px;left:548px;white-space:nowrap" class="ft013">. 2015;70(1):14-22.&#160;Available at:&#160;</p>
<p style="position:absolute;top:205px;left:162px;white-space:nowrap" class="ft034">https://www.ncbi.nlm.nih.gov/pubmed/25204341</p>
<p style="position:absolute;top:205px;left:503px;white-space:nowrap" class="ft013">.&#160;</p>
<p style="position:absolute;top:242px;left:108px;white-space:nowrap" class="ft013">57.</p>
<p style="position:absolute;top:242px;left:130px;white-space:nowrap" class="ft046">&#160;</p>
<p style="position:absolute;top:242px;left:162px;white-space:nowrap" class="ft013">Oteseconazole.&#160;</p>
<p style="position:absolute;top:242px;left:271px;white-space:nowrap" class="ft019"><i>Am J Health Syst Pharm</i></p>
<p style="position:absolute;top:242px;left:441px;white-space:nowrap" class="ft013">. 2022;79(23):2083-2085. Available at:&#160;</p>
<p style="position:absolute;top:262px;left:162px;white-space:nowrap" class="ft034">https://www.ncbi.nlm.nih.gov/pubmed/36173878</p>
<p style="position:absolute;top:262px;left:503px;white-space:nowrap" class="ft013">.&#160;</p>
</div>
<!-- Page 63 -->
<a name="63"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page63-div" style="position:relative;width:917px;height:1187px;">
<p style="position:absolute;top:1117px;left:108px;white-space:nowrap" class="ft024"><i>Guidelines for the Prevention and Treatment&#160;of&#160;Opportunistic&#160;Infections in Adults&#160;and Adolescents&#160;With HIV&#160;</i></p>
<p style="position:absolute;top:1117px;left:791px;white-space:nowrap" class="ft024"><i>E-1&#160;</i></p>
<p style="position:absolute;top:112px;left:108px;white-space:nowrap" class="ft025"><b>Chagas&#160;Disease&#160;</b></p>
<p style="position:absolute;top:159px;left:108px;white-space:nowrap" class="ft035"><b>Updated:&#160;</b></p>
<p style="position:absolute;top:159px;left:176px;white-space:nowrap" class="ft036">June 14,&#160;2023&#160;</p>
<p style="position:absolute;top:180px;left:108px;white-space:nowrap" class="ft035"><b>Reviewed:</b></p>
<p style="position:absolute;top:180px;left:181px;white-space:nowrap" class="ft036">&#160;January 8,&#160;2025&#160;</p>
<p style="position:absolute;top:218px;left:108px;white-space:nowrap" class="ft026"><b>Epidemiology&#160;</b></p>
<p style="position:absolute;top:260px;left:108px;white-space:nowrap" class="ft013">Chagas disease (American trypanosomiasis) is caused by the&#160;protozoan parasite&#160;</p>
<p style="position:absolute;top:260px;left:662px;white-space:nowrap" class="ft019"><i>Trypanosoma cruzi</i></p>
<p style="position:absolute;top:260px;left:796px;white-space:nowrap" class="ft013">.&#160;</p>
<p style="position:absolute;top:280px;left:108px;white-space:nowrap" class="ft032">It is transmitted to humans&#160;by infected triatomine&#160;bugs (“kissing&#160;bugs”), and&#160;less commonly by&#160;<br/>transfusion,&#160;organ transplant, from mother to infant, and, in rare&#160;instances, by&#160;ingestion of&#160;<br/>contaminated food or&#160;drink.</p>
<p style="position:absolute;top:318px;left:301px;white-space:nowrap" class="ft038">1-4</p>
<p style="position:absolute;top:319px;left:316px;white-space:nowrap" class="ft013">&#160;</p>
<p style="position:absolute;top:356px;left:108px;white-space:nowrap" class="ft032">Vector-borne&#160;transmission&#160;occurs only&#160;in the Americas, where an estimated 6 million people&#160;have&#160;<br/>Chagas disease.</p>
<p style="position:absolute;top:375px;left:217px;white-space:nowrap" class="ft038">5,6</p>
<p style="position:absolute;top:376px;left:236px;white-space:nowrap" class="ft013">Historically, transmission occurred largely in rural&#160;areas in&#160;Latin America, where</p>
<p style="position:absolute;top:396px;left:108px;white-space:nowrap" class="ft013">houses&#160;built of mud brick&#160;are vulnerable&#160;to colonization by the triatomine&#160;vectors.</p>
<p style="position:absolute;top:395px;left:675px;white-space:nowrap" class="ft038">4</p>
<p style="position:absolute;top:396px;left:680px;white-space:nowrap" class="ft013">&#160;In&#160;such areas,&#160;</p>
<p style="position:absolute;top:416px;left:108px;white-space:nowrap" class="ft032">Chagas disease usually is&#160;acquired in childhood. In&#160;the&#160;last several&#160;decades, successful vector control&#160;<br/>programs have substantially decreased transmission&#160;rates in much of Latin America.</p>
<p style="position:absolute;top:434px;left:690px;white-space:nowrap" class="ft038">4,7,8</p>
<p style="position:absolute;top:436px;left:713px;white-space:nowrap" class="ft013">&#160;</p>
<p style="position:absolute;top:473px;left:108px;white-space:nowrap" class="ft013">Infected triatomine vectors and&#160;</p>
<p style="position:absolute;top:473px;left:327px;white-space:nowrap" class="ft019"><i>T. cruzi</i></p>
<p style="position:absolute;top:473px;left:380px;white-space:nowrap" class="ft013">–infected domestic&#160;and wild animals are&#160;found across&#160;the&#160;</p>
<p style="position:absolute;top:493px;left:108px;white-space:nowrap" class="ft032">southern half&#160;of the&#160;United States, and&#160;rare cases of&#160;autochthonous vector-borne transmission have&#160;<br/>been documented.</p>
<p style="position:absolute;top:511px;left:233px;white-space:nowrap" class="ft038">9-11&#160;</p>
<p style="position:absolute;top:512px;left:257px;white-space:nowrap" class="ft013">However, the risk&#160;of vector-borne infection within the United States appears to&#160;</p>
<p style="position:absolute;top:532px;left:108px;white-space:nowrap" class="ft013">be very low.</p>
<p style="position:absolute;top:531px;left:194px;white-space:nowrap" class="ft038">12</p>
<p style="position:absolute;top:532px;left:205px;white-space:nowrap" class="ft013">&#160;</p>
<p style="position:absolute;top:532px;left:209px;white-space:nowrap" class="ft019"><i>T. cruzi</i></p>
<p style="position:absolute;top:532px;left:262px;white-space:nowrap" class="ft013">&#160;can&#160;also be transmitted in blood; screening of blood donations for&#160;anti-</p>
<p style="position:absolute;top:532px;left:755px;white-space:nowrap" class="ft019"><i>T. cruzi</i></p>
<p style="position:absolute;top:532px;left:808px;white-space:nowrap" class="ft013">&#160;</p>
<p style="position:absolute;top:552px;left:108px;white-space:nowrap" class="ft032">antibodies was introduced in 2007 after the U.S.&#160;Food and&#160;Drug Administration approved a&#160;<br/>serological test for that purpose.</p>
<p style="position:absolute;top:571px;left:330px;white-space:nowrap" class="ft038">13,14</p>
<p style="position:absolute;top:572px;left:355px;white-space:nowrap" class="ft013">&#160;</p>
<p style="position:absolute;top:609px;left:108px;white-space:nowrap" class="ft013">In people chronically infected with&#160;</p>
<p style="position:absolute;top:609px;left:353px;white-space:nowrap" class="ft019"><i>T.&#160;cruzi</i></p>
<p style="position:absolute;top:609px;left:406px;white-space:nowrap" class="ft013">&#160;as a result&#160;of prior infection, profound&#160;</p>
<p style="position:absolute;top:629px;left:108px;white-space:nowrap" class="ft032">immunosuppression (e.g.,&#160;due to advanced HIV) may lead to reactivation of the disease,&#160;<br/>characterized by parasitemia, which is associated&#160;with increased intracellular parasite replication and&#160;<br/>lack of immunological&#160;control of the infection.</p>
<p style="position:absolute;top:667px;left:431px;white-space:nowrap" class="ft038">15-17</p>
<p style="position:absolute;top:669px;left:458px;white-space:nowrap" class="ft013">&#160;</p>
<p style="position:absolute;top:705px;left:108px;white-space:nowrap" class="ft026"><b>Clinical Manifestations&#160;</b></p>
<p style="position:absolute;top:747px;left:108px;white-space:nowrap" class="ft012"><b>Acute Phase.</b></p>
<p style="position:absolute;top:747px;left:203px;white-space:nowrap" class="ft013">&#160;The acute phase of&#160;</p>
<p style="position:absolute;top:747px;left:341px;white-space:nowrap" class="ft019"><i>T.&#160;cruzi</i></p>
<p style="position:absolute;top:747px;left:394px;white-space:nowrap" class="ft013">&#160;infection, which typically goes unrecognized, lasts up to&#160;</p>
<p style="position:absolute;top:767px;left:108px;white-space:nowrap" class="ft032">90 days and&#160;is characterized by circulating trypomastigotes detectable on microscopy of fresh blood&#160;<br/>or buffy coat&#160;smears.</p>
<p style="position:absolute;top:785px;left:254px;white-space:nowrap" class="ft038">2,4</p>
<p style="position:absolute;top:787px;left:268px;white-space:nowrap" class="ft013">&#160;If&#160;the&#160;portal of infection was the conjunctiva, patients may develop the&#160;</p>
<p style="position:absolute;top:806px;left:108px;white-space:nowrap" class="ft032">characteristic Romaña’s sign—unilateral&#160;painless&#160;swelling of the upper and lower eyelids—which&#160;<br/>usually lasts&#160;several&#160;weeks. The other&#160;symptoms of&#160;acute infection are usually limited to a&#160;non-<br/>specific febrile illness. In&#160;a small&#160;proportion of patients, however, acute, life-threatening myocarditis&#160;<br/>or meningoencephalitis may occur.</p>
<p style="position:absolute;top:865px;left:350px;white-space:nowrap" class="ft038">2,4</p>
<p style="position:absolute;top:866px;left:364px;white-space:nowrap" class="ft013">&#160;At the&#160;end of the&#160;acute phase, typically 60 to 90 days after&#160;</p>
<p style="position:absolute;top:886px;left:108px;white-space:nowrap" class="ft032">infection, parasitemia&#160;falls&#160;below levels&#160;detectable by microscopy, and in the&#160;absence&#160;of effective&#160;<br/>antitrypanosomal treatment,&#160;</p>
<p style="position:absolute;top:906px;left:306px;white-space:nowrap" class="ft019"><i>T. cruzi</i></p>
<p style="position:absolute;top:906px;left:358px;white-space:nowrap" class="ft013">&#160;infection passes into the chronic phase.</p>
<p style="position:absolute;top:904px;left:633px;white-space:nowrap" class="ft038">2,4</p>
<p style="position:absolute;top:906px;left:647px;white-space:nowrap" class="ft013">&#160;</p>
<p style="position:absolute;top:943px;left:108px;white-space:nowrap" class="ft012"><b>Chronic Phase.&#160;</b></p>
<p style="position:absolute;top:943px;left:224px;white-space:nowrap" class="ft013">Most patients with chronic&#160;</p>
<p style="position:absolute;top:943px;left:413px;white-space:nowrap" class="ft019"><i>T. cruzi</i></p>
<p style="position:absolute;top:943px;left:466px;white-space:nowrap" class="ft013">&#160;infection have no signs&#160;or symptoms&#160;and are&#160;</p>
<p style="position:absolute;top:963px;left:108px;white-space:nowrap" class="ft032">said to have&#160;the indeterminate&#160;form of&#160;the&#160;disease.&#160;Over the&#160;course of their lives, 20% to&#160;30% of&#160;<br/>these patients will&#160;progress&#160;to clinically evident Chagas disease—most commonly,&#160;<br/>cardiomyopathy.</p>
<p style="position:absolute;top:1001px;left:224px;white-space:nowrap" class="ft038">2,4</p>
<p style="position:absolute;top:1002px;left:239px;white-space:nowrap" class="ft013">&#160;The&#160;earliest manifestations are&#160;usually conduction system&#160;abnormalities, such as&#160;</p>
<p style="position:absolute;top:1022px;left:108px;white-space:nowrap" class="ft032">right&#160;bundle&#160;branch block, alone or in&#160;combination with frequent premature&#160;ventricular contractions,&#160;<br/>which may develop years&#160;to decades after infection.</p>
<p style="position:absolute;top:1041px;left:466px;white-space:nowrap" class="ft038">4,18</p>
<p style="position:absolute;top:1042px;left:490px;white-space:nowrap" class="ft013">Over time, the disease&#160;may progress to&#160;</p>
</div>
<!-- Page 64 -->
<a name="64"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page64-div" style="position:relative;width:917px;height:1187px;">
<p style="position:absolute;top:1117px;left:108px;white-space:nowrap" class="ft024"><i>Guidelines for the Prevention and Treatment&#160;of&#160;Opportunistic&#160;Infections in Adults&#160;and Adolescents&#160;With HIV&#160;</i></p>
<p style="position:absolute;top:1117px;left:791px;white-space:nowrap" class="ft024"><i>E-2&#160;</i></p>
<p style="position:absolute;top:109px;left:108px;white-space:nowrap" class="ft032">higher-grade&#160;heart block and complex ventricular arrhythmias. In patients with more advanced&#160;<br/>cardiomyopathy, poor prognostic&#160;factors include&#160;congestive heart failure, ventricular aneurysm, and&#160;<br/>complete heart block;&#160;these are associated with short-term mortality, including sudden&#160;<br/>death.</p>
<p style="position:absolute;top:167px;left:150px;white-space:nowrap" class="ft038">19</p>
<p style="position:absolute;top:168px;left:161px;white-space:nowrap" class="ft013">&#160;Chagas digestive&#160;disease is much less common than cardiomyopathy.</p>
<p style="position:absolute;top:167px;left:645px;white-space:nowrap" class="ft038">20&#160;</p>
<p style="position:absolute;top:168px;left:659px;white-space:nowrap" class="ft013">Dysphagia is the&#160;</p>
<p style="position:absolute;top:188px;left:108px;white-space:nowrap" class="ft032">characteristic symptom of&#160;megaesophagus, and prolonged constipation is the most common&#160;<br/>complaint&#160;associated with megacolon.&#160;</p>
<p style="position:absolute;top:245px;left:108px;white-space:nowrap" class="ft019"><i>T. cruzi</i></p>
<p style="position:absolute;top:245px;left:161px;white-space:nowrap" class="ft013">&#160;reactivation during the chronic phase of Chagas disease&#160;is characterized by a&#160;return to high&#160;</p>
<p style="position:absolute;top:265px;left:108px;white-space:nowrap" class="ft032">levels of parasite replication and parasitemia, which are usually&#160;detectable&#160;by microscopy.&#160;<br/>Reactivation&#160;can occur in&#160;individuals on immunosuppressive medications or&#160;cancer chemotherapy&#160;<br/>and in people with HIV.</p>
<p style="position:absolute;top:303px;left:275px;white-space:nowrap" class="ft038">16,21-25</p>
<p style="position:absolute;top:304px;left:316px;white-space:nowrap" class="ft013">&#160;Even in the absence of symptoms, people with HIV&#160;and&#160;chronic&#160;</p>
<p style="position:absolute;top:324px;left:108px;white-space:nowrap" class="ft013">Chagas disease have significantly higher levels of&#160;</p>
<p style="position:absolute;top:324px;left:456px;white-space:nowrap" class="ft019"><i>T. cruzi</i></p>
<p style="position:absolute;top:324px;left:509px;white-space:nowrap" class="ft013">&#160;parasitemia than their immunocompetent&#160;</p>
<p style="position:absolute;top:344px;left:108px;white-space:nowrap" class="ft013">counterparts.</p>
<p style="position:absolute;top:343px;left:198px;white-space:nowrap" class="ft038">24</p>
<p style="position:absolute;top:344px;left:209px;white-space:nowrap" class="ft013">&#160;Most cases&#160;of clinically&#160;apparent reactivation occur with CD4&#160;T lymphocyte&#160;cell&#160;</p>
<p style="position:absolute;top:364px;left:108px;white-space:nowrap" class="ft013">counts &lt;200&#160;cells/mm</p>
<p style="position:absolute;top:363px;left:260px;white-space:nowrap" class="ft038">3</p>
<p style="position:absolute;top:364px;left:266px;white-space:nowrap" class="ft013">, a history of prior opportunistic&#160;infections, or both.</p>
<p style="position:absolute;top:363px;left:621px;white-space:nowrap" class="ft038">16</p>
<p style="position:absolute;top:364px;left:633px;white-space:nowrap" class="ft013">&#160;&#160;</p>
<p style="position:absolute;top:401px;left:108px;white-space:nowrap" class="ft032">The clinical features of reactivated Chagas disease&#160;in people&#160;with HIV differ&#160;from those observed in&#160;<br/>individuals who are immunosuppressed for other reasons. The&#160;most common manifestations consist&#160;<br/>of&#160;</p>
<p style="position:absolute;top:441px;left:127px;white-space:nowrap" class="ft019"><i>T. cruzi</i></p>
<p style="position:absolute;top:441px;left:179px;white-space:nowrap" class="ft013">&#160;meningoencephalitis, with or without brain abscesses&#160;(chagomas).</p>
<p style="position:absolute;top:439px;left:641px;white-space:nowrap" class="ft038">15,16,26,27</p>
<p style="position:absolute;top:441px;left:694px;white-space:nowrap" class="ft013">&#160;The&#160;</p>
<p style="position:absolute;top:461px;left:108px;white-space:nowrap" class="ft032">presentation in people&#160;with HIV may be confused&#160;with central nervous&#160;system&#160;(CNS) toxoplasmosis&#160;<br/>and should be considered&#160;in the differential&#160;diagnosis of CNS symptoms or mass lesions&#160;on imaging.&#160;<br/>The&#160;second&#160;most frequently reported manifestation of reactivation in people with HIV is&#160;acute&#160;<br/>myocarditis, sometimes superimposed&#160;on pre-existing chronic Chagas heart disease.</p>
<p style="position:absolute;top:519px;left:689px;white-space:nowrap" class="ft038">16,17</p>
<p style="position:absolute;top:520px;left:718px;white-space:nowrap" class="ft013">Patients may</p>
<p style="position:absolute;top:540px;left:108px;white-space:nowrap" class="ft032">present&#160;with&#160;new arrhythmias, pericardial effusion,&#160;acute cardiac decompensation, or rapid&#160;<br/>progression&#160;of existing chronic&#160;cardiomyopathy.</p>
<p style="position:absolute;top:558px;left:443px;white-space:nowrap" class="ft038">16,28</p>
<p style="position:absolute;top:560px;left:468px;white-space:nowrap" class="ft013">&#160;Less frequent&#160;manifestations of reactivation&#160;</p>
<p style="position:absolute;top:580px;left:108px;white-space:nowrap" class="ft032">include&#160;skin&#160;lesions, erythema nodosum, and parasitic&#160;invasion of the&#160;peritoneum, stomach, or&#160;<br/>intestine.</p>
<p style="position:absolute;top:598px;left:171px;white-space:nowrap" class="ft038">16,28</p>
<p style="position:absolute;top:599px;left:196px;white-space:nowrap" class="ft013">&#160;&#160;</p>
<p style="position:absolute;top:636px;left:108px;white-space:nowrap" class="ft026"><b>Diagnosis&#160;</b></p>
<p style="position:absolute;top:678px;left:108px;white-space:nowrap" class="ft032">Screening with serological testing is recommended for all&#160;individuals who&#160;have lived in Mexico or&#160;<br/>Central&#160;or South America for greater than 6 months.</p>
<p style="position:absolute;top:696px;left:469px;white-space:nowrap" class="ft038">29</p>
<p style="position:absolute;top:698px;left:480px;white-space:nowrap" class="ft013">&#160;</p>
<p style="position:absolute;top:735px;left:108px;white-space:nowrap" class="ft013">Most persons infected with&#160;</p>
<p style="position:absolute;top:735px;left:300px;white-space:nowrap" class="ft019"><i>T. cruzi</i></p>
<p style="position:absolute;top:735px;left:352px;white-space:nowrap" class="ft013">&#160;are&#160;in the chronic&#160;phase and are typically unaware of&#160;their&#160;</p>
<p style="position:absolute;top:755px;left:108px;white-space:nowrap" class="ft032">infection. Screening for infection to identify persons with the&#160;indeterminate&#160;or early clinical forms of&#160;<br/>chronic Chagas disease is important to identify those who might benefit from&#160;antiparasitic treatment&#160;<br/>and counseling regarding&#160;potential&#160;transmission of&#160;</p>
<p style="position:absolute;top:794px;left:461px;white-space:nowrap" class="ft019"><i>T. cruzi</i></p>
<p style="position:absolute;top:794px;left:514px;white-space:nowrap" class="ft013">&#160;to others (e.g.,&#160;blood donation, organ&#160;</p>
<p style="position:absolute;top:814px;left:108px;white-space:nowrap" class="ft032">donation). This is particularly important&#160;for people&#160;with HIV because of the&#160;risk of reactivation&#160;<br/>disease.&#160;</p>
<p style="position:absolute;top:871px;left:108px;white-space:nowrap" class="ft032">Diagnosis&#160;of&#160;chronic infection relies on serological&#160;methods to detect&#160;immunoglobulin G&#160;antibodies&#160;<br/>to&#160;</p>
<p style="position:absolute;top:891px;left:126px;white-space:nowrap" class="ft019"><i>T. cruzi</i></p>
<p style="position:absolute;top:891px;left:178px;white-space:nowrap" class="ft013">, most commonly enzyme-linked immunosorbent assay (ELISA)&#160;and immunofluorescent&#160;</p>
<p style="position:absolute;top:911px;left:108px;white-space:nowrap" class="ft032">antibody assay (IFA). No&#160;available&#160;assay has sufficient sensitivity and specificity to be used alone;&#160;a&#160;<br/>single&#160;positive result does not constitute&#160;a confirmed diagnosis.&#160;Two serological&#160;tests based on&#160;<br/>different&#160;antigens (i.e.,&#160;whole&#160;parasite lysate&#160;and recombinant antigens) and/or techniques&#160;<br/>(e.g., ELISA&#160;and IFA) should be&#160;used&#160;for individuals with suspected Chagas.&#160;In some cases, the&#160;<br/>infection status remains difficult&#160;to resolve even after a third test, because there is no true&#160;gold&#160;<br/>standard assay for chronic&#160;</p>
<p style="position:absolute;top:1010px;left:293px;white-space:nowrap" class="ft019"><i>T. cruzi</i></p>
<p style="position:absolute;top:1010px;left:346px;white-space:nowrap" class="ft013">&#160;infection.</p>
<p style="position:absolute;top:1009px;left:416px;white-space:nowrap" class="ft038">29,30&#160;&#160;</p>
</div>
<!-- Page 65 -->
<a name="65"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page65-div" style="position:relative;width:917px;height:1187px;">
<p style="position:absolute;top:1117px;left:108px;white-space:nowrap" class="ft024"><i>Guidelines for the Prevention and Treatment&#160;of&#160;Opportunistic&#160;Infections in Adults&#160;and Adolescents&#160;With HIV&#160;</i></p>
<p style="position:absolute;top:1117px;left:791px;white-space:nowrap" class="ft024"><i>E-3&#160;</i></p>
<p style="position:absolute;top:109px;left:108px;white-space:nowrap" class="ft032">Data suggest that the sensitivity of serological&#160;assays varies by&#160;geographical&#160;location, possibly&#160;<br/>because of&#160;</p>
<p style="position:absolute;top:129px;left:186px;white-space:nowrap" class="ft019"><i>T.&#160;cruzi</i></p>
<p style="position:absolute;top:129px;left:238px;white-space:nowrap" class="ft013">&#160;strain&#160;differences and resulting&#160;antibody responses.</p>
<p style="position:absolute;top:127px;left:596px;white-space:nowrap" class="ft038">31,32</p>
<p style="position:absolute;top:129px;left:622px;white-space:nowrap" class="ft013">&#160;Options for&#160;</p>
<p style="position:absolute;top:148px;left:108px;white-space:nowrap" class="ft019"><i>T. cruzi</i></p>
<p style="position:absolute;top:148px;left:161px;white-space:nowrap" class="ft013">&#160;serological&#160;testing in the&#160;United States include&#160;diagnostic&#160;ELISA&#160;kits based on parasite&#160;</p>
<p style="position:absolute;top:168px;left:108px;white-space:nowrap" class="ft013">lysate or recombinant&#160;antigens.</p>
<p style="position:absolute;top:167px;left:324px;white-space:nowrap" class="ft038">29,33</p>
<p style="position:absolute;top:168px;left:349px;white-space:nowrap" class="ft013">&#160;In&#160;general, polymerase chain reaction (PCR) is not a&#160;useful&#160;</p>
<p style="position:absolute;top:188px;left:108px;white-space:nowrap" class="ft013">diagnostic&#160;test for chronic&#160;</p>
<p style="position:absolute;top:188px;left:292px;white-space:nowrap" class="ft019"><i>T. cruzi</i></p>
<p style="position:absolute;top:188px;left:345px;white-space:nowrap" class="ft013">&#160;infection, as its sensitivity is highly variable.</p>
<p style="position:absolute;top:187px;left:658px;white-space:nowrap" class="ft038">30,34,35</p>
<p style="position:absolute;top:188px;left:697px;white-space:nowrap" class="ft013">&#160;&#160;</p>
<p style="position:absolute;top:225px;left:108px;white-space:nowrap" class="ft013">In people with HIV and epidemiologic risk factors for Chagas disease, coinfection with&#160;</p>
<p style="position:absolute;top:225px;left:715px;white-space:nowrap" class="ft019"><i>T.&#160;cruzi</i></p>
<p style="position:absolute;top:225px;left:768px;white-space:nowrap" class="ft013">&#160;and&#160;</p>
<p style="position:absolute;top:245px;left:108px;white-space:nowrap" class="ft032">reactivation disease should be&#160;considered in the&#160;differential diagnosis of&#160;CNS&#160;mass&#160;lesions,&#160;<br/>meningoencephalitis, arrhythmias or heart failure.</p>
<p style="position:absolute;top:263px;left:453px;white-space:nowrap" class="ft038">16,25,26</p>
<p style="position:absolute;top:265px;left:492px;white-space:nowrap" class="ft013">&#160;The&#160;imaging pattern of brain chagoma&#160;is&#160;</p>
<p style="position:absolute;top:285px;left:108px;white-space:nowrap" class="ft013">similar to that&#160;of cerebral&#160;toxoplasmosis, although chagomas tend to be larger&#160;than&#160;</p>
<p style="position:absolute;top:285px;left:682px;white-space:nowrap" class="ft019"><i>Toxoplasma</i></p>
<p style="position:absolute;top:285px;left:767px;white-space:nowrap" class="ft013">&#160;</p>
<p style="position:absolute;top:304px;left:108px;white-space:nowrap" class="ft013">lesions.</p>
<p style="position:absolute;top:303px;left:160px;white-space:nowrap" class="ft038">17,26,27</p>
<p style="position:absolute;top:304px;left:200px;white-space:nowrap" class="ft013">&#160;Computed tomography and magnetic&#160;resonance&#160;imaging show subcortical&#160;hypodense&#160;</p>
<p style="position:absolute;top:324px;left:108px;white-space:nowrap" class="ft032">lesions that&#160;enhance with&#160;contrast or gadolinium. These lesions&#160;most often involve&#160;brain&#160;white&#160;<br/>matter. Histopathology shows&#160;inflammation and the&#160;presence&#160;of&#160;</p>
<p style="position:absolute;top:344px;left:554px;white-space:nowrap" class="ft019"><i>T. cruzi</i></p>
<p style="position:absolute;top:344px;left:606px;white-space:nowrap" class="ft013">&#160;amastigotes in glial cells&#160;</p>
<p style="position:absolute;top:364px;left:108px;white-space:nowrap" class="ft032">and, less often, in neurons. Cerebrospinal&#160;fluid (CSF) typically shows&#160;a mild&#160;pleocytosis&#160;<br/>(lymphocyte&#160;predominance), increased&#160;protein, and&#160;</p>
<p style="position:absolute;top:384px;left:467px;white-space:nowrap" class="ft019"><i>T. cruzi</i></p>
<p style="position:absolute;top:384px;left:520px;white-space:nowrap" class="ft013">&#160;trypomastigotes.</p>
<p style="position:absolute;top:382px;left:639px;white-space:nowrap" class="ft038">16,17,26,27</p>
<p style="position:absolute;top:384px;left:693px;white-space:nowrap" class="ft013">&#160;In a&#160;case series&#160;</p>
<p style="position:absolute;top:404px;left:108px;white-space:nowrap" class="ft013">that included 15 people coinfected with HIV and&#160;</p>
<p style="position:absolute;top:404px;left:449px;white-space:nowrap" class="ft019"><i>T.&#160;cruzi</i></p>
<p style="position:absolute;top:404px;left:501px;white-space:nowrap" class="ft013">&#160;with clinical&#160;meningoencephalitis,&#160;</p>
<p style="position:absolute;top:424px;left:108px;white-space:nowrap" class="ft013">trypomastigotes were visualized in CSF in 85%.</p>
<p style="position:absolute;top:422px;left:441px;white-space:nowrap" class="ft038">36</p>
<p style="position:absolute;top:424px;left:452px;white-space:nowrap" class="ft013">&#160;</p>
<p style="position:absolute;top:461px;left:108px;white-space:nowrap" class="ft032">A definitive diagnosis of&#160;reactivation is&#160;established&#160;by identification of the&#160;parasite or its products in&#160;<br/>tissue, such as on brain biopsy, in CSF, or in blood.</p>
<p style="position:absolute;top:479px;left:464px;white-space:nowrap" class="ft038">16</p>
<p style="position:absolute;top:480px;left:475px;white-space:nowrap" class="ft013">&#160;In&#160;chronically infected patients who&#160;are&#160;</p>
<p style="position:absolute;top:500px;left:108px;white-space:nowrap" class="ft032">immunocompetent&#160;or who have&#160;HIV&#160;coinfection in the absence of reactivation, trypomastigotes&#160;<br/>typically are undetectable in the circulating blood.</p>
<p style="position:absolute;top:519px;left:454px;white-space:nowrap" class="ft038">24&#160;</p>
<p style="position:absolute;top:520px;left:468px;white-space:nowrap" class="ft013">If observed in a&#160;coinfected patient, circulating&#160;</p>
<p style="position:absolute;top:540px;left:108px;white-space:nowrap" class="ft013">parasites suggest reactivation and the&#160;need for treatment.&#160;</p>
<p style="position:absolute;top:577px;left:108px;white-space:nowrap" class="ft013">Testing to identify&#160;</p>
<p style="position:absolute;top:577px;left:240px;white-space:nowrap" class="ft019"><i>T. cruzi</i></p>
<p style="position:absolute;top:577px;left:297px;white-space:nowrap" class="ft013">should be&#160;considered in all at-risk individuals with suspected&#160;reactivation&#160;</p>
<p style="position:absolute;top:597px;left:108px;white-space:nowrap" class="ft032">of chronic Chagas disease. Initial assessment can be done by evaluation of a&#160;peripheral&#160;blood smear.&#160;<br/>Blood concentration techniques, such&#160;as capillary centrifugation, can improve sensitivity.</p>
<p style="position:absolute;top:615px;left:725px;white-space:nowrap" class="ft038">34</p>
<p style="position:absolute;top:617px;left:736px;white-space:nowrap" class="ft013">&#160;In&#160;</p>
<p style="position:absolute;top:637px;left:108px;white-space:nowrap" class="ft013">centrifuged blood,&#160;</p>
<p style="position:absolute;top:637px;left:239px;white-space:nowrap" class="ft019"><i>T. cruzi</i></p>
<p style="position:absolute;top:637px;left:291px;white-space:nowrap" class="ft013">&#160;trypomastigotes are found just above&#160;the&#160;buffy coat. Parasites also may be&#160;</p>
<p style="position:absolute;top:656px;left:108px;white-space:nowrap" class="ft032">observed in lymph nodes,&#160;bone marrow, skin lesions, or pericardial fluid. Hemoculture is somewhat&#160;<br/>more&#160;sensitive than direct methods but takes 2 to 8&#160;weeks to demonstrate&#160;parasites. Quantitative PCR&#160;<br/>assays&#160;performed on serial blood specimens that&#160;show rising&#160;parasite numbers over time provide the&#160;<br/>earliest and most sensitive indicator of reactivation.</p>
<p style="position:absolute;top:714px;left:464px;white-space:nowrap" class="ft038">37,38</p>
<p style="position:absolute;top:716px;left:492px;white-space:nowrap" class="ft013">As such,&#160;clinicians should consider obtaining&#160;</p>
<p style="position:absolute;top:736px;left:108px;white-space:nowrap" class="ft032">PCR testing in all individuals in whom&#160;there is high&#160;clinical&#160;suspicion and blood and/or tissue tests&#160;<br/>are negative.&#160;</p>
<p style="position:absolute;top:793px;left:108px;white-space:nowrap" class="ft032">In people with HIV who have&#160;suspected CNS Chagas disease, centrifugation and microscopic&#160;<br/>examination of CSF&#160;should be conducted. Few published data exist on PCR of CSF,&#160;but it would be&#160;<br/>expected to have high sensitivity for the&#160;diagnosis of reactivation in the&#160;CNS.</p>
<p style="position:absolute;top:831px;left:643px;white-space:nowrap" class="ft038">39&#160;</p>
<p style="position:absolute;top:869px;left:108px;white-space:nowrap" class="ft013">In the&#160;United&#160;States, Chagas disease molecular detection (PCR testing for&#160;</p>
<p style="position:absolute;top:869px;left:620px;white-space:nowrap" class="ft019"><i>T.&#160;cruzi</i></p>
<p style="position:absolute;top:869px;left:673px;white-space:nowrap" class="ft013">&#160;DNA) is available&#160;</p>
<p style="position:absolute;top:889px;left:108px;white-space:nowrap" class="ft032">at&#160;the&#160;Centers for&#160;Disease&#160;Control&#160;and&#160;Prevention (CDC); consultations and testing requests should&#160;<br/>be addressed&#160;to Parasitic&#160;Diseases&#160;Hotline for Healthcare Providers (404-718-4745,&#160;</p>
<p style="position:absolute;top:929px;left:108px;white-space:nowrap" class="ft034">parasites@cdc.gov</p>
<p style="position:absolute;top:929px;left:238px;white-space:nowrap" class="ft013">, hours: 8 a.m.–4 p.m. ET/Monday–Friday)&#160;or through the CDC Emergency&#160;</p>
<p style="position:absolute;top:949px;left:108px;white-space:nowrap" class="ft032">Operations Center (770-488-7100)&#160;for&#160;emergencies after business hours, on&#160;weekends, and&#160;federal&#160;<br/>holidays.&#160;</p>
</div>
<!-- Page 66 -->
<a name="66"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}	.ft092{font-size:17px;font-family:TURBHP+Tinos;color:#232323;}
	.ft093{font-size:17px;line-height:19px;font-family:TURBHP+Tinos;color:#232323;}
-->
</style>
<div id="page66-div" style="position:relative;width:917px;height:1187px;">
<p style="position:absolute;top:1117px;left:108px;white-space:nowrap" class="ft024"><i>Guidelines for the Prevention and Treatment&#160;of&#160;Opportunistic&#160;Infections in Adults&#160;and Adolescents&#160;With HIV&#160;</i></p>
<p style="position:absolute;top:1117px;left:791px;white-space:nowrap" class="ft024"><i>E-4&#160;</i></p>
<p style="position:absolute;top:108px;left:108px;white-space:nowrap" class="ft026"><b>Preventing&#160;Exposure&#160;</b></p>
<p style="position:absolute;top:150px;left:108px;white-space:nowrap" class="ft013">Travelers to&#160;endemic&#160;countries may be at&#160;risk of infection with&#160;</p>
<p style="position:absolute;top:150px;left:546px;white-space:nowrap" class="ft019"><i>T. cruzi</i></p>
<p style="position:absolute;top:150px;left:598px;white-space:nowrap" class="ft013">&#160;if they visit rural areas and&#160;</p>
<p style="position:absolute;top:170px;left:108px;white-space:nowrap" class="ft032">stay in rustic&#160;lodging. The triatomine&#160;vector typically infests cracks in walls&#160;and roofing&#160;of poor-<br/>quality buildings that are constructed&#160;of adobe brick, mud, or thatch.</p>
<p style="position:absolute;top:188px;left:581px;white-space:nowrap" class="ft038">40</p>
<p style="position:absolute;top:190px;left:592px;white-space:nowrap" class="ft013">&#160;Because the insects&#160;feed at&#160;</p>
<p style="position:absolute;top:210px;left:108px;white-space:nowrap" class="ft032">night, individuals who&#160;live in or visit&#160;Chagas disease–endemic&#160;areas should&#160;avoid sleeping in such&#160;<br/>dwellings or&#160;outdoors.&#160;Control&#160;programs in endemic&#160;areas rely on spraying infested dwellings with&#160;<br/>residual-action insecticide. If sleeping&#160;outdoors&#160;or&#160;in suspect&#160;dwellings cannot be&#160;avoided, sleeping&#160;<br/>under insecticide-treated bed nets provides significant protection.</p>
<p style="position:absolute;top:268px;left:559px;white-space:nowrap" class="ft038">41</p>
<p style="position:absolute;top:269px;left:570px;white-space:nowrap" class="ft013">&#160;</p>
<p style="position:absolute;top:306px;left:108px;white-space:nowrap" class="ft032">In the&#160;United&#160;States, all&#160;blood donors are screened for Chagas disease when they first donate blood.&#160;<br/>Universal&#160;screening of blood donors has been implemented in 21 Chagas disease–endemic&#160;<br/>Latin American countries.</p>
<p style="position:absolute;top:344px;left:289px;white-space:nowrap" class="ft038">42</p>
<p style="position:absolute;top:346px;left:300px;white-space:nowrap" class="ft013">&#160;Although&#160;transfusion-acquired cases have been&#160;uncommon in the&#160;</p>
<p style="position:absolute;top:366px;left:108px;white-space:nowrap" class="ft032">United States, transfusion&#160;with infected blood products remains&#160;a risk for acquiring Chagas disease.&#160;<br/>No drugs or&#160;vaccines for&#160;preventing&#160;</p>
<p style="position:absolute;top:385px;left:361px;white-space:nowrap" class="ft019"><i>T.&#160;cruzi</i></p>
<p style="position:absolute;top:385px;left:414px;white-space:nowrap" class="ft013">&#160;infection are available.&#160;</p>
<p style="position:absolute;top:422px;left:108px;white-space:nowrap" class="ft026"><b>Preventing&#160;Disease&#160;</b></p>
<p style="position:absolute;top:464px;left:108px;white-space:nowrap" class="ft032">All people&#160;with HIV&#160;with epidemiologic risk factors for Chagas&#160;disease should be&#160;tested for antibody&#160;<br/>to&#160;</p>
<p style="position:absolute;top:484px;left:126px;white-space:nowrap" class="ft019"><i>T. cruzi</i></p>
<p style="position:absolute;top:484px;left:178px;white-space:nowrap" class="ft013">&#160;to detect&#160;latent&#160;infection.</p>
<p style="position:absolute;top:482px;left:354px;white-space:nowrap" class="ft038">29,43&#160;</p>
<p style="position:absolute;top:521px;left:108px;white-space:nowrap" class="ft032">For people&#160;living with HIV, a single course of treatment&#160;with benznidazole or nifurtimox&#160;should be&#160;<br/>offered to individuals with&#160;</p>
<p style="position:absolute;top:541px;left:296px;white-space:nowrap" class="ft019"><i>T. cruzi</i></p>
<p style="position:absolute;top:541px;left:348px;white-space:nowrap" class="ft013">&#160;infection who have not&#160;been&#160;previously treated and who do not&#160;</p>
<p style="position:absolute;top:561px;left:108px;white-space:nowrap" class="ft032">have advanced Chagas cardiomyopathy, with a&#160;discussion of potential risks&#160;and benefits and shared&#160;<br/>decision making&#160;</p>
<p style="position:absolute;top:580px;left:226px;white-space:nowrap" class="ft012"><b>(BIII).</b></p>
<p style="position:absolute;top:580px;left:273px;white-space:nowrap" class="ft013">&#160;However, the&#160;efficacy of currently available&#160;drugs in the&#160;chronic phase is&#160;</p>
<p style="position:absolute;top:600px;left:108px;white-space:nowrap" class="ft032">suboptimal, there is no useful&#160;test of cure, and treated individuals are&#160;still considered at risk for&#160;<br/>reactivation.</p>
<p style="position:absolute;top:619px;left:194px;white-space:nowrap" class="ft038">32,44</p>
<p style="position:absolute;top:620px;left:219px;white-space:nowrap" class="ft013">&#160;There are&#160;no direct&#160;studies&#160;evaluating interactions between antiretroviral&#160;</p>
<p style="position:absolute;top:640px;left:108px;white-space:nowrap" class="ft013">medications and either benznidazole or nifurtimox.&#160;</p>
<p style="position:absolute;top:640px;left:465px;white-space:nowrap" class="ft092">However, as&#160;benznidazole may be partially&#160;</p>
<p style="position:absolute;top:660px;left:108px;white-space:nowrap" class="ft093">metabolized by the&#160;cytochrome&#160;P450&#160;(CYP) system, medications that&#160;inhibit&#160;this system&#160;may&#160;<br/>increase benznidazole toxicity and those that&#160;induce CYP enzymes may reduce benznidazole&#160;<br/>efficacy</p>
<p style="position:absolute;top:699px;left:164px;white-space:nowrap" class="ft013">.</p>
<p style="position:absolute;top:698px;left:168px;white-space:nowrap" class="ft038">43,45</p>
<p style="position:absolute;top:699px;left:193px;white-space:nowrap" class="ft013">&#160;</p>
<p style="position:absolute;top:736px;left:108px;white-space:nowrap" class="ft032">Although direct data&#160;are lacking, optimization of antiretroviral therapy (ART) may help prevent&#160;<br/>Chagas reactivation in coinfected patients</p>
<p style="position:absolute;top:756px;left:396px;white-space:nowrap" class="ft012"><b>.</b></p>
<p style="position:absolute;top:756px;left:400px;white-space:nowrap" class="ft013">&#160;Most symptomatic reactivation cases have occurred in&#160;</p>
<p style="position:absolute;top:776px;left:108px;white-space:nowrap" class="ft013">people with&#160;HIV&#160;who&#160;were not&#160;virologically suppressed on&#160;ART.</p>
<p style="position:absolute;top:775px;left:559px;white-space:nowrap" class="ft038">16,43</p>
<p style="position:absolute;top:776px;left:584px;white-space:nowrap" class="ft013">&#160;</p>
<p style="position:absolute;top:813px;left:108px;white-space:nowrap" class="ft026"><b>Treating Disease&#160;</b></p>
<p style="position:absolute;top:855px;left:108px;white-space:nowrap" class="ft032">Therapy for&#160;Chagas disease with benznidazole or nifurtimox is effective&#160;in reducing parasitemia and&#160;<br/>preventing clinical manifestations or slowing progression in patients with acute and reactivated&#160;<br/>disease.</p>
<p style="position:absolute;top:893px;left:162px;white-space:nowrap" class="ft038">44,46</p>
<p style="position:absolute;top:894px;left:188px;white-space:nowrap" class="ft013">&#160;These drugs&#160;have&#160;limited&#160;efficacy, however, in achieving parasitological&#160;cure. As&#160;both&#160;</p>
<p style="position:absolute;top:914px;left:108px;white-space:nowrap" class="ft032">drugs are&#160;U.S. Food&#160;and&#160;Drug&#160;Administration (FDA)–approved&#160;only for children, use for&#160;the&#160;<br/>treatment of adults in the United States is off-label.&#160;Individuals&#160;with advanced Chagas&#160;<br/>cardiomyopathy will not&#160;benefit&#160;from treatment. Consultation with a specialist should be&#160;sought.&#160;<br/>Consultations with experts at the CDC&#160;can be&#160;addressed to the&#160;Parasitic&#160;Diseases Hotline for&#160;<br/>Healthcare&#160;Providers (404-718-4745,&#160;</p>
<p style="position:absolute;top:993px;left:369px;white-space:nowrap" class="ft034">parasites@cdc.gov</p>
<p style="position:absolute;top:993px;left:500px;white-space:nowrap" class="ft013">).&#160;</p>
<p style="position:absolute;top:1030px;left:108px;white-space:nowrap" class="ft013">Benznidazole (commercially available at&#160;</p>
<p style="position:absolute;top:1030px;left:394px;white-space:nowrap" class="ft034">http://www.benznidazoletablets.com/en</p>
<p style="position:absolute;top:1030px;left:668px;white-space:nowrap" class="ft013">) is approved by the&#160;</p>
<p style="position:absolute;top:1050px;left:108px;white-space:nowrap" class="ft013">FDA for use&#160;in children 2 to 12 years of age. The use of benznidazole&#160;to treat a patient outside of the&#160;</p>
</div>
<!-- Page 67 -->
<a name="67"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page67-div" style="position:relative;width:917px;height:1187px;">
<p style="position:absolute;top:1117px;left:108px;white-space:nowrap" class="ft024"><i>Guidelines for the Prevention and Treatment&#160;of&#160;Opportunistic&#160;Infections in Adults&#160;and Adolescents&#160;With HIV&#160;</i></p>
<p style="position:absolute;top:1117px;left:791px;white-space:nowrap" class="ft024"><i>E-5&#160;</i></p>
<p style="position:absolute;top:109px;left:108px;white-space:nowrap" class="ft032">FDA-approved age&#160;range&#160;is based on clinical&#160;diagnosis and decision by a treating physician under&#160;<br/>practice of medicine. The regimen of 5&#160;to 8 mg/kg/day in two divided doses taken with or&#160;without&#160;<br/>food for&#160;60 days is the recommended treatment&#160;</p>
<p style="position:absolute;top:148px;left:438px;white-space:nowrap" class="ft012"><b>(BIII);</b></p>
<p style="position:absolute;top:148px;left:487px;white-space:nowrap" class="ft013">&#160;a daily maximum&#160;dose of 300 mg is&#160;</p>
<p style="position:absolute;top:168px;left:108px;white-space:nowrap" class="ft013">recommended by most experts.</p>
<p style="position:absolute;top:167px;left:324px;white-space:nowrap" class="ft038">47,48</p>
<p style="position:absolute;top:168px;left:349px;white-space:nowrap" class="ft013">&#160;</p>
<p style="position:absolute;top:205px;left:108px;white-space:nowrap" class="ft013">Nifurtimox (Lampit</p>
<p style="position:absolute;top:204px;left:245px;white-space:nowrap" class="ft038">®</p>
<p style="position:absolute;top:205px;left:254px;white-space:nowrap" class="ft013">) is also FDA approved for children less&#160;than 18 years&#160;of&#160;age and is available&#160;</p>
<p style="position:absolute;top:225px;left:108px;white-space:nowrap" class="ft013">from retail&#160;sources.</p>
<p style="position:absolute;top:224px;left:242px;white-space:nowrap" class="ft038">49,50</p>
<p style="position:absolute;top:225px;left:267px;white-space:nowrap" class="ft013">&#160;Use of nifurtimox to treat&#160;a patient outside of the FDA-approved&#160;age&#160;range is&#160;</p>
<p style="position:absolute;top:245px;left:108px;white-space:nowrap" class="ft032">based on clinical&#160;diagnosis and decision by the&#160;treating physician under practice of medicine. The&#160;<br/>recommended regimen is&#160;8 to 10 mg/kg/day in three divided doses with food&#160;for 60 days&#160;</p>
<p style="position:absolute;top:265px;left:725px;white-space:nowrap" class="ft012"><b>(BIII).</b></p>
<p style="position:absolute;top:263px;left:772px;white-space:nowrap" class="ft038">51</p>
<p style="position:absolute;top:265px;left:784px;white-space:nowrap" class="ft013">&#160;</p>
<p style="position:absolute;top:302px;left:108px;white-space:nowrap" class="ft032">Treatment&#160;of patients outside&#160;of the&#160;FDA-approved&#160;age ranges for either drug&#160;is based on clinical&#160;<br/>diagnosis and decision by&#160;the&#160;treating physician under practice of medicine. The duration of therapy&#160;<br/>with either of these agents has not been studied in&#160;people with&#160;HIV.&#160;Mortality is high for&#160;<br/>symptomatic&#160;reactivated&#160;</p>
<p style="position:absolute;top:361px;left:281px;white-space:nowrap" class="ft019"><i>T. cruzi</i></p>
<p style="position:absolute;top:361px;left:334px;white-space:nowrap" class="ft013">&#160;infection, even in patients who&#160;receive chemotherapy.</p>
<p style="position:absolute;top:360px;left:711px;white-space:nowrap" class="ft038">16,26</p>
<p style="position:absolute;top:361px;left:736px;white-space:nowrap" class="ft013">&#160;Limited&#160;</p>
<p style="position:absolute;top:381px;left:108px;white-space:nowrap" class="ft013">data suggest&#160;that early recognition and&#160;treatment of reactivation may improve&#160;prognosis.</p>
<p style="position:absolute;top:380px;left:719px;white-space:nowrap" class="ft038">16</p>
<p style="position:absolute;top:381px;left:730px;white-space:nowrap" class="ft013">&#160;</p>
<p style="position:absolute;top:419px;left:108px;white-space:nowrap" class="ft029"><i><b>Special Considerations with&#160;Regard to&#160;Starting&#160;Antiretroviral Therapy&#160;</b></i></p>
<p style="position:absolute;top:460px;left:108px;white-space:nowrap" class="ft032">As&#160;with other parasitic infections that localize in the CNS, the&#160;decision to initiate ART must be&#160;<br/>carefully considered in people&#160;with HIV&#160;and&#160;reactivated</p>
<p style="position:absolute;top:480px;left:499px;white-space:nowrap" class="ft019"><i>T. cruzi</i></p>
<p style="position:absolute;top:480px;left:552px;white-space:nowrap" class="ft013">&#160;infection involving the&#160;brain. Only&#160;</p>
<p style="position:absolute;top:499px;left:108px;white-space:nowrap" class="ft032">anecdotal information exists on the consequences of starting ART after a diagnosis of CNS Chagas&#160;<br/>disease, but there are no cases of Chagas-related immune&#160;reconstitution inflammatory syndrome&#160;<br/>(IRIS) that&#160;have been well described.&#160;Therefore, there&#160;is no known contraindication to starting or&#160;<br/>optimizing ART in patients with CNS&#160;Chagas disease. ART&#160;should be&#160;initiated in all patients with&#160;<br/>concomitant&#160;</p>
<p style="position:absolute;top:579px;left:197px;white-space:nowrap" class="ft019"><i>T. cruzi</i></p>
<p style="position:absolute;top:579px;left:250px;white-space:nowrap" class="ft013">&#160;</p>
<p style="position:absolute;top:579px;left:254px;white-space:nowrap" class="ft012"><b>(AIII).</b></p>
<p style="position:absolute;top:579px;left:303px;white-space:nowrap" class="ft013">&#160;In general, as IRIS is not recognized as a common manifestation in the&#160;</p>
<p style="position:absolute;top:599px;left:108px;white-space:nowrap" class="ft013">setting of coinfection, treatment of&#160;</p>
<p style="position:absolute;top:599px;left:351px;white-space:nowrap" class="ft019"><i>T. cruzi</i></p>
<p style="position:absolute;top:599px;left:404px;white-space:nowrap" class="ft013">&#160;does not&#160;warrant&#160;delay in ART.&#160;</p>
<p style="position:absolute;top:636px;left:108px;white-space:nowrap" class="ft029"><i><b>Monitoring for Adverse Events&#160;&#160;</b></i></p>
<p style="position:absolute;top:677px;left:108px;white-space:nowrap" class="ft032">Patients undergoing treatment should&#160;be monitored closely because both benznidazole and&#160;<br/>nifurtimox are associated&#160;with significant&#160;toxicities.</p>
<p style="position:absolute;top:695px;left:466px;white-space:nowrap" class="ft038">46</p>
<p style="position:absolute;top:697px;left:478px;white-space:nowrap" class="ft013">&#160;</p>
<p style="position:absolute;top:734px;left:108px;white-space:nowrap" class="ft032">Benznidazole-associated&#160;adverse drug&#160;reactions include&#160;abdominal symptoms&#160;(abdominal&#160;pain,&#160;<br/>nausea, vomiting, diarrhea), reversible&#160;peripheral&#160;neuropathy, rash, and granulocytopenia.&#160;<br/>Comprehensive metabolic panel (CMP) and complete&#160;blood count (CBC) should be&#160;monitored&#160;<br/>before initiation and during therapy. Co-administration of benznidazole with disulfiram, alcohol, and&#160;<br/>products that&#160;contain propylene glycol&#160;should be avoided.&#160;</p>
<p style="position:absolute;top:850px;left:108px;white-space:nowrap" class="ft032">Nifurtimox-associated adverse drug&#160;reactions include anorexia,&#160;nausea, vomiting, abdominal pain&#160;<br/>and weight&#160;loss, rash, restlessness, tremors, and dose-dependent&#160;peripheral&#160;neuropathy. Alcohol&#160;<br/>consumption&#160;with nifurtimox should&#160;be avoided.&#160;CMP&#160;and CBC should&#160;be monitored before&#160;<br/>initiation and&#160;during treatment with nifurtimox.&#160;</p>
<p style="position:absolute;top:947px;left:108px;white-space:nowrap" class="ft032">The frequency of monitoring CMP and&#160;CBC during&#160;treatment, though not standardized, is&#160;generally&#160;<br/>every 2 weeks. The adverse effects of both drugs&#160;wane when the&#160;drugs are discontinued. For more&#160;<br/>information, refer to the&#160;</p>
<p style="position:absolute;top:987px;left:278px;white-space:nowrap" class="ft034">Adverse&#160;Drug Reactions table</p>
<p style="position:absolute;top:987px;left:486px;white-space:nowrap" class="ft013">.&#160;</p>
<p style="position:absolute;top:1024px;left:108px;white-space:nowrap" class="ft013">As&#160;stated above,&#160;there are no reports&#160;at&#160;this time regarding&#160;</p>
<p style="position:absolute;top:1024px;left:515px;white-space:nowrap" class="ft019"><i>T. cruzi</i></p>
<p style="position:absolute;top:1024px;left:568px;white-space:nowrap" class="ft013">&#160;infection and IRIS.&#160;</p>
</div>
<!-- Page 68 -->
<a name="68"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page68-div" style="position:relative;width:917px;height:1187px;">
<p style="position:absolute;top:1117px;left:108px;white-space:nowrap" class="ft024"><i>Guidelines for the Prevention and Treatment&#160;of&#160;Opportunistic&#160;Infections in Adults&#160;and Adolescents&#160;With HIV&#160;</i></p>
<p style="position:absolute;top:1117px;left:791px;white-space:nowrap" class="ft024"><i>E-6&#160;</i></p>
<p style="position:absolute;top:109px;left:108px;white-space:nowrap" class="ft029"><i><b>Managing&#160;Treatment Failure&#160;&#160;</b></i></p>
<p style="position:absolute;top:150px;left:108px;white-space:nowrap" class="ft032">People&#160;with&#160;HIV&#160;are at risk for clinical&#160;manifestations because&#160;of intermittent reactivation of chronic&#160;<br/>infection.</p>
<p style="position:absolute;top:169px;left:174px;white-space:nowrap" class="ft038">43</p>
<p style="position:absolute;top:170px;left:185px;white-space:nowrap" class="ft013">&#160;Benznidazole and nifurtimox are only&#160;partially effective in the chronic&#160;phase&#160;</p>
<p style="position:absolute;top:190px;left:108px;white-space:nowrap" class="ft013">of&#160;</p>
<p style="position:absolute;top:190px;left:127px;white-space:nowrap" class="ft019"><i>T. cruzi</i></p>
<p style="position:absolute;top:190px;left:179px;white-space:nowrap" class="ft013">&#160;infection and may be suppressive rather than curative.</p>
<p style="position:absolute;top:188px;left:556px;white-space:nowrap" class="ft038">44</p>
<p style="position:absolute;top:190px;left:568px;white-space:nowrap" class="ft013">&#160;Because&#160;the drugs are&#160;toxic and&#160;</p>
<p style="position:absolute;top:210px;left:108px;white-space:nowrap" class="ft013">experience&#160;with their use in people&#160;with HIV is limited, expert&#160;advice should&#160;be sought.</p>
<p style="position:absolute;top:208px;left:714px;white-space:nowrap" class="ft038">46</p>
<p style="position:absolute;top:210px;left:730px;white-space:nowrap" class="ft013">Whether</p>
<p style="position:absolute;top:229px;left:108px;white-space:nowrap" class="ft032">secondary prophylaxis or&#160;chronic maintenance therapy should&#160;be used in people&#160;with HIV&#160;with latent&#160;<br/>Chagas disease is unclear,&#160;particularly when potent&#160;ART is used.&#160;</p>
<p style="position:absolute;top:286px;left:108px;white-space:nowrap" class="ft013">There are&#160;no&#160;current&#160;recommendations for monitoring for reactivation after treatment.&#160;</p>
<p style="position:absolute;top:286px;left:704px;white-space:nowrap" class="ft019"><i>T. cruzi</i></p>
<p style="position:absolute;top:286px;left:757px;white-space:nowrap" class="ft013">&#160;</p>
<p style="position:absolute;top:306px;left:108px;white-space:nowrap" class="ft032">antibodies may persist after treatment. Reactivation&#160;after treatment is diagnosed based on&#160;compatible&#160;<br/>clinical&#160;symptoms and identification of the&#160;parasite&#160;in blood or&#160;CNS&#160;fluid/tissue by microscopy or&#160;<br/>PCR. Although no efficacy data&#160;are available, retreatment with benznidazole or&#160;nifurtimox is&#160;<br/>recommended for people&#160;with HIV and&#160;</p>
<p style="position:absolute;top:366px;left:384px;white-space:nowrap" class="ft019"><i>T. cruzi</i></p>
<p style="position:absolute;top:366px;left:436px;white-space:nowrap" class="ft013">&#160;reactivation who fail&#160;to respond or&#160;who reactivate&#160;</p>
<p style="position:absolute;top:386px;left:108px;white-space:nowrap" class="ft013">again after initial antitrypanosomal therapy&#160;</p>
<p style="position:absolute;top:386px;left:410px;white-space:nowrap" class="ft012"><b>(AIII).</b></p>
<p style="position:absolute;top:386px;left:458px;white-space:nowrap" class="ft013">&#160;</p>
<p style="position:absolute;top:422px;left:108px;white-space:nowrap" class="ft026"><b>Special&#160;Considerations During&#160;Pregnancy&#160;</b></p>
<p style="position:absolute;top:464px;left:108px;white-space:nowrap" class="ft032">Anyone&#160;who&#160;has lived in&#160;endemic areas should&#160;be screened for&#160;Chagas disease, particularly if&#160;<br/>pregnant, to identify maternal&#160;infection and possible&#160;risk of infection in their offspring.. See the&#160;</p>
<p style="position:absolute;top:484px;left:772px;white-space:nowrap" class="ft034">CDC&#160;</p>
<p style="position:absolute;top:504px;left:108px;white-space:nowrap" class="ft034">resource for&#160;congenital Chagas disease</p>
<p style="position:absolute;top:504px;left:376px;white-space:nowrap" class="ft013">&#160;for more&#160;information.&#160;</p>
<p style="position:absolute;top:541px;left:108px;white-space:nowrap" class="ft013">Between 1%&#160;to 10% of infants of mothers with&#160;</p>
<p style="position:absolute;top:541px;left:437px;white-space:nowrap" class="ft019"><i>T.&#160;cruzi</i></p>
<p style="position:absolute;top:541px;left:490px;white-space:nowrap" class="ft013">&#160;are born&#160;with acute&#160;</p>
<p style="position:absolute;top:541px;left:631px;white-space:nowrap" class="ft019"><i>T.&#160;cruzi</i></p>
<p style="position:absolute;top:541px;left:683px;white-space:nowrap" class="ft013">&#160;infection.</p>
<p style="position:absolute;top:539px;left:754px;white-space:nowrap" class="ft038">52</p>
<p style="position:absolute;top:541px;left:765px;white-space:nowrap" class="ft013">&#160;Most&#160;</p>
<p style="position:absolute;top:561px;left:108px;white-space:nowrap" class="ft013">congenital</p>
<p style="position:absolute;top:561px;left:184px;white-space:nowrap" class="ft019"><i>T. cruzi</i></p>
<p style="position:absolute;top:561px;left:237px;white-space:nowrap" class="ft013">&#160;infections are&#160;asymptomatic&#160;or cause non-specific&#160;signs; laboratory screening is</p>
<p style="position:absolute;top:580px;left:108px;white-space:nowrap" class="ft013">required for&#160;detection of these cases.</p>
<p style="position:absolute;top:579px;left:361px;white-space:nowrap" class="ft038">53</p>
<p style="position:absolute;top:580px;left:372px;white-space:nowrap" class="ft013">&#160;In a small&#160;proportion of patients, congenital infection causes&#160;</p>
<p style="position:absolute;top:600px;left:108px;white-space:nowrap" class="ft032">severe morbidity, including low birthweight, hepatosplenomegaly, anemia, meningoencephalitis,&#160;<br/>and/or respiratory insufficiency, with high risk of&#160;mortality.</p>
<p style="position:absolute;top:619px;left:520px;white-space:nowrap" class="ft038">52,54</p>
<p style="position:absolute;top:620px;left:546px;white-space:nowrap" class="ft013">&#160;Limited data suggest that the rate of&#160;</p>
<p style="position:absolute;top:640px;left:108px;white-space:nowrap" class="ft013">congenital transmission is higher for&#160;women with&#160;HIV&#160;than&#160;in immunocompetent&#160;women.</p>
<p style="position:absolute;top:639px;left:730px;white-space:nowrap" class="ft038">16,55&#160;</p>
<p style="position:absolute;top:640px;left:758px;white-space:nowrap" class="ft013">Infants&#160;</p>
<p style="position:absolute;top:660px;left:108px;white-space:nowrap" class="ft013">with HIV and concomitant&#160;</p>
<p style="position:absolute;top:660px;left:297px;white-space:nowrap" class="ft019"><i>T. cruzi</i></p>
<p style="position:absolute;top:660px;left:349px;white-space:nowrap" class="ft013">&#160;also may be&#160;more likely to have symptoms, especially neurologic&#160;</p>
<p style="position:absolute;top:680px;left:108px;white-space:nowrap" class="ft013">symptoms.</p>
<p style="position:absolute;top:678px;left:183px;white-space:nowrap" class="ft038">56,57</p>
<p style="position:absolute;top:680px;left:209px;white-space:nowrap" class="ft013">&#160;</p>
<p style="position:absolute;top:717px;left:108px;white-space:nowrap" class="ft032">Minimal&#160;data&#160;are available&#160;on the&#160;potential&#160;reproductive&#160;toxicity&#160;of benznidazole and nifurtimox,&#160;<br/>although both drugs&#160;have&#160;been associated with increased detection of chromosomal&#160;aberrations in&#160;<br/>children being treated for&#160;Chagas disease.</p>
<p style="position:absolute;top:755px;left:396px;white-space:nowrap" class="ft038">58,59</p>
<p style="position:absolute;top:756px;left:422px;white-space:nowrap" class="ft013">&#160;Benznidazole crosses the placenta&#160;in rats.</p>
<p style="position:absolute;top:755px;left:712px;white-space:nowrap" class="ft038">60</p>
<p style="position:absolute;top:756px;left:724px;white-space:nowrap" class="ft013">&#160;Due to the&#160;</p>
<p style="position:absolute;top:776px;left:108px;white-space:nowrap" class="ft032">toxicity and limited experience with use of these drugs in pregnancy, treatment of&#160;<br/>acute&#160;</p>
<p style="position:absolute;top:796px;left:149px;white-space:nowrap" class="ft019"><i>T. cruzi</i></p>
<p style="position:absolute;top:796px;left:201px;white-space:nowrap" class="ft013">&#160;infection during pregnancy should only be&#160;undertaken in consultation with a&#160;specialist&#160;</p>
<p style="position:absolute;top:816px;left:108px;white-space:nowrap" class="ft032">in this area, and treatment of chronic&#160;disease should&#160;be considered only after completion of the&#160;<br/>pregnancy and breastfeeding. In cases of symptomatic reactivation of&#160;</p>
<p style="position:absolute;top:836px;left:590px;white-space:nowrap" class="ft019"><i>T. cruzi</i></p>
<p style="position:absolute;top:836px;left:643px;white-space:nowrap" class="ft013">&#160;infection during&#160;</p>
<p style="position:absolute;top:856px;left:108px;white-space:nowrap" class="ft013">pregnancy,&#160;ART should&#160;be initiated&#160;</p>
<p style="position:absolute;top:856px;left:359px;white-space:nowrap" class="ft012"><b>(AIII)</b></p>
<p style="position:absolute;top:856px;left:403px;white-space:nowrap" class="ft013">&#160;as&#160;initial&#160;treatment.&#160;Only two cases of treatment&#160;of&#160;</p>
<p style="position:absolute;top:875px;left:108px;white-space:nowrap" class="ft013">Chagas disease in pregnancy with benznidazole have&#160;been reported in people with HIV.</p>
<p style="position:absolute;top:874px;left:715px;white-space:nowrap" class="ft038">61,62</p>
<p style="position:absolute;top:875px;left:740px;white-space:nowrap" class="ft013">&#160;One&#160;</p>
<p style="position:absolute;top:895px;left:108px;white-space:nowrap" class="ft013">infant was born with a low birthweight.</p>
<p style="position:absolute;top:894px;left:381px;white-space:nowrap" class="ft038">62</p>
<p style="position:absolute;top:895px;left:392px;white-space:nowrap" class="ft013">&#160;All infants born to&#160;women with&#160;</p>
<p style="position:absolute;top:895px;left:617px;white-space:nowrap" class="ft019"><i>T.&#160;cruzi</i></p>
<p style="position:absolute;top:895px;left:670px;white-space:nowrap" class="ft013">&#160;should&#160;undergo&#160;</p>
<p style="position:absolute;top:915px;left:108px;white-space:nowrap" class="ft013">appropriate testing for congenitally acquired&#160;</p>
<p style="position:absolute;top:915px;left:419px;white-space:nowrap" class="ft019"><i>T. cruzi</i></p>
<p style="position:absolute;top:915px;left:471px;white-space:nowrap" class="ft013">&#160;infection and be treated promptly if infection is&#160;</p>
<p style="position:absolute;top:935px;left:108px;white-space:nowrap" class="ft013">confirmed.</p>
<p style="position:absolute;top:934px;left:183px;white-space:nowrap" class="ft038">63,64</p>
<p style="position:absolute;top:935px;left:209px;white-space:nowrap" class="ft013">&#160;Refer&#160;to the&#160;</p>
<p style="position:absolute;top:935px;left:299px;white-space:nowrap" class="ft034">Opportunistic Infection Drugs During Pregnancy&#160;table</p>
<p style="position:absolute;top:935px;left:675px;white-space:nowrap" class="ft013">&#160;for additional&#160;</p>
<p style="position:absolute;top:955px;left:108px;white-space:nowrap" class="ft013">information.&#160;</p>
</div>
<!-- Page 69 -->
<a name="69"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}	.ft094{font-size:18px;line-height:20px;font-family:BTLIFY+Tinos;color:#000000;}
-->
</style>
<div id="page69-div" style="position:relative;width:917px;height:1187px;">
<p style="position:absolute;top:1117px;left:108px;white-space:nowrap" class="ft024"><i>Guidelines for the Prevention and Treatment&#160;of&#160;Opportunistic&#160;Infections in Adults&#160;and Adolescents&#160;With HIV&#160;</i></p>
<p style="position:absolute;top:1117px;left:791px;white-space:nowrap" class="ft024"><i>E-7&#160;</i></p>
<p style="position:absolute;top:109px;left:108px;white-space:nowrap" class="ft094"><b>Recommendations for&#160;Preventing&#160;and Treating Chagas Disease&#160;(American&#160;<br/>Trypanosomiasis)&#160;</b></p>
<p style="position:absolute;top:176px;left:306px;white-space:nowrap" class="ft02"><b>Preventing Manifestations of Chagas Disease&#160;</b></p>
<p style="position:absolute;top:206px;left:116px;white-space:nowrap" class="ft030">•</p>
<p style="position:absolute;top:207px;left:123px;white-space:nowrap" class="ft057">&#160;</p>
<p style="position:absolute;top:207px;left:133px;white-space:nowrap" class="ft041">All&#160;people with HIV&#160;who have epidemiologic risk&#160;factors&#160;for&#160;Chagas&#160;disease should&#160;be&#160;tested for&#160;antibody&#160;to&#160;</p>
<p style="position:absolute;top:207px;left:721px;white-space:nowrap" class="ft024"><i>T. cruzi</i></p>
<p style="position:absolute;top:207px;left:761px;white-space:nowrap" class="ft041">&#160;using&#160;</p>
<p style="position:absolute;top:224px;left:133px;white-space:nowrap" class="ft041">at least two serological&#160;tests&#160;based&#160;on different&#160;antigens (e.g., whole parasite lysate and recombinant&#160;antigens) and/or&#160;</p>
<p style="position:absolute;top:241px;left:133px;white-space:nowrap" class="ft041">techniques&#160;(e.g.,&#160;ELISA and&#160;IFA).&#160;</p>
<p style="position:absolute;top:241px;left:319px;white-space:nowrap" class="ft024"><i>&#160;</i></p>
<p style="position:absolute;top:274px;left:116px;white-space:nowrap" class="ft024"><i>Indication&#160;</i></p>
<p style="position:absolute;top:300px;left:116px;white-space:nowrap" class="ft030">•</p>
<p style="position:absolute;top:301px;left:123px;white-space:nowrap" class="ft057">&#160;</p>
<p style="position:absolute;top:301px;left:133px;white-space:nowrap" class="ft041">Individuals&#160;with&#160;epidemiological&#160;risk factors&#160;for&#160;Chagas disease who have tested positive for antibody to&#160;</p>
<p style="position:absolute;top:301px;left:699px;white-space:nowrap" class="ft024"><i>T.&#160;cruzi</i></p>
<p style="position:absolute;top:301px;left:740px;white-space:nowrap" class="ft041">, have not&#160;</p>
<p style="position:absolute;top:318px;left:133px;white-space:nowrap" class="ft041">been previously&#160;treated, and do not have advanced&#160;Chagas&#160;cardiomyopathy&#160;</p>
<p style="position:absolute;top:344px;left:116px;white-space:nowrap" class="ft024"><i>Therapy&#160;</i></p>
<p style="position:absolute;top:370px;left:116px;white-space:nowrap" class="ft030">•</p>
<p style="position:absolute;top:372px;left:123px;white-space:nowrap" class="ft057">&#160;</p>
<p style="position:absolute;top:371px;left:133px;white-space:nowrap" class="ft041">A single course&#160;of benznidazole&#160;or nifurtimox&#160;is&#160;recommended&#160;by&#160;some experts&#160;(doses&#160;and duration same as&#160;for&#160;treatment&#160;</p>
<p style="position:absolute;top:389px;left:133px;white-space:nowrap" class="ft041">of acute&#160;or&#160;reactivated infection).&#160;&#160;</p>
<p style="position:absolute;top:416px;left:133px;white-space:nowrap" class="ft062">o</p>
<p style="position:absolute;top:415px;left:142px;white-space:nowrap" class="ft057">&#160;</p>
<p style="position:absolute;top:415px;left:149px;white-space:nowrap" class="ft041">Benznidazole 5–8 mg/kg/day PO&#160;in 2 divided&#160;doses&#160;for 60 days</p>
<p style="position:absolute;top:415px;left:494px;white-space:nowrap" class="ft042"><b>&#160;(BIII)</b></p>
<p style="position:absolute;top:415px;left:528px;white-space:nowrap" class="ft041">(commercially&#160;available&#160;at&#160;</p>
<p style="position:absolute;top:432px;left:149px;white-space:nowrap" class="ft043">http://www.benznidazoletablets.com/en</p>
<p style="position:absolute;top:432px;left:362px;white-space:nowrap" class="ft041">).&#160;Most experts&#160;recommend a&#160;daily maximum of 300 mg.&#160;</p>
<p style="position:absolute;top:460px;left:133px;white-space:nowrap" class="ft062">o</p>
<p style="position:absolute;top:459px;left:142px;white-space:nowrap" class="ft057">&#160;</p>
<p style="position:absolute;top:458px;left:149px;white-space:nowrap" class="ft041">Nifurtimox&#160;(Lampit®)&#160;8–10&#160;mg/kg/day PO in 3&#160;divided&#160;doses&#160;for&#160;60&#160;days&#160;</p>
<p style="position:absolute;top:458px;left:543px;white-space:nowrap" class="ft042"><b>(BIII)</b></p>
<p style="position:absolute;top:458px;left:571px;white-space:nowrap" class="ft041">&#160;(commercially&#160;available&#160;through&#160;retail&#160;</p>
<p style="position:absolute;top:476px;left:149px;white-space:nowrap" class="ft041">sources)&#160;</p>
<p style="position:absolute;top:502px;left:116px;white-space:nowrap" class="ft042"><b>Note:</b></p>
<p style="position:absolute;top:502px;left:148px;white-space:nowrap" class="ft041">&#160;Efficacy of&#160;both therapies&#160;is&#160;suboptimal, and treated patients&#160;are&#160;still&#160;at risk&#160;of reactivation.&#160;</p>
<p style="position:absolute;top:538px;left:301px;white-space:nowrap" class="ft02"><b>Treating&#160;Acute&#160;or&#160;Reactivated&#160;</b></p>
<p style="position:absolute;top:538px;left:505px;white-space:nowrap" class="ft082"><i><b>T. cruzi</b></i></p>
<p style="position:absolute;top:538px;left:554px;white-space:nowrap" class="ft02"><b>&#160;Infection&#160;</b></p>
<p style="position:absolute;top:567px;left:116px;white-space:nowrap" class="ft024"><i>Indication&#160;</i></p>
<p style="position:absolute;top:594px;left:116px;white-space:nowrap" class="ft030">•</p>
<p style="position:absolute;top:595px;left:123px;white-space:nowrap" class="ft057">&#160;</p>
<p style="position:absolute;top:595px;left:133px;white-space:nowrap" class="ft041">Individuals&#160;with&#160;acute or&#160;reactivated&#160;</p>
<p style="position:absolute;top:595px;left:331px;white-space:nowrap" class="ft024"><i>T. cruzi</i></p>
<p style="position:absolute;top:595px;left:371px;white-space:nowrap" class="ft041">&#160;infection&#160;as manifested by&#160;presence&#160;of parasitemia should be&#160;treated&#160;</p>
<p style="position:absolute;top:595px;left:753px;white-space:nowrap" class="ft042"><b>(AII).</b></p>
<p style="position:absolute;top:595px;left:781px;white-space:nowrap" class="ft041">&#160;</p>
<p style="position:absolute;top:627px;left:116px;white-space:nowrap" class="ft024"><i>Therapy&#160;</i></p>
<p style="position:absolute;top:653px;left:116px;white-space:nowrap" class="ft030">•</p>
<p style="position:absolute;top:654px;left:123px;white-space:nowrap" class="ft057">&#160;</p>
<p style="position:absolute;top:654px;left:133px;white-space:nowrap" class="ft041">Benznidazole 5–8 mg/kg/day PO&#160;in 2 divided&#160;doses&#160;for 60 days&#160;</p>
<p style="position:absolute;top:654px;left:481px;white-space:nowrap" class="ft042"><b>(BIII)</b></p>
<p style="position:absolute;top:654px;left:509px;white-space:nowrap" class="ft041">&#160;(commercially available&#160;</p>
<p style="position:absolute;top:671px;left:133px;white-space:nowrap" class="ft041">at&#160;</p>
<p style="position:absolute;top:671px;left:146px;white-space:nowrap" class="ft043">http://www.benznidazoletablets.com/en</p>
<p style="position:absolute;top:671px;left:360px;white-space:nowrap" class="ft041">). Most&#160;experts&#160;recommend&#160;a daily&#160;maximum&#160;of 300&#160;mg.&#160;</p>
<p style="position:absolute;top:697px;left:116px;white-space:nowrap" class="ft030">•</p>
<p style="position:absolute;top:699px;left:123px;white-space:nowrap" class="ft057">&#160;</p>
<p style="position:absolute;top:698px;left:133px;white-space:nowrap" class="ft041">Nifurtimox&#160;(Lampit</p>
<p style="position:absolute;top:700px;left:232px;white-space:nowrap" class="ft058">®</p>
<p style="position:absolute;top:698px;left:238px;white-space:nowrap" class="ft041">) 8–10&#160;mg/kg/day&#160;PO in&#160;3 divided&#160;doses for&#160;60&#160;days&#160;</p>
<p style="position:absolute;top:698px;left:524px;white-space:nowrap" class="ft042"><b>(BIII)</b></p>
<p style="position:absolute;top:698px;left:551px;white-space:nowrap" class="ft041">&#160;(commercially&#160;available&#160;through retail&#160;</p>
<p style="position:absolute;top:716px;left:133px;white-space:nowrap" class="ft041">sources)&#160;</p>
<p style="position:absolute;top:742px;left:116px;white-space:nowrap" class="ft030">•</p>
<p style="position:absolute;top:743px;left:123px;white-space:nowrap" class="ft057">&#160;</p>
<p style="position:absolute;top:743px;left:133px;white-space:nowrap" class="ft041">Initiation or optimization&#160;of ART&#160;is recommended&#160;for all&#160;people&#160;with HIV&#160;with&#160;concomitant&#160;</p>
<p style="position:absolute;top:743px;left:619px;white-space:nowrap" class="ft024"><i>T. cruzi</i></p>
<p style="position:absolute;top:743px;left:660px;white-space:nowrap" class="ft041">&#160;</p>
<p style="position:absolute;top:743px;left:663px;white-space:nowrap" class="ft042"><b>(AIII).</b></p>
<p style="position:absolute;top:743px;left:694px;white-space:nowrap" class="ft041">&#160;</p>
<p style="position:absolute;top:775px;left:116px;white-space:nowrap" class="ft042"><b>Note:&#160;</b></p>
<p style="position:absolute;top:775px;left:151px;white-space:nowrap" class="ft041">Treatment&#160;is&#160;not recommended for patients&#160;with advanced&#160;chagasic&#160;cardiomyopathy.&#160;</p>
<p style="position:absolute;top:805px;left:108px;white-space:nowrap" class="ft042"><b>Key:</b></p>
<p style="position:absolute;top:805px;left:135px;white-space:nowrap" class="ft041">&#160;ART = antiretroviral&#160;therapy; CDC = Centers&#160;for&#160;Disease&#160;Control&#160;and&#160;Prevention;&#160;ELISA = enzyme-linked immunosorbent&#160;</p>
<p style="position:absolute;top:823px;left:108px;white-space:nowrap" class="ft041">assays; IFA = immunofluorescence assays; PO&#160;=&#160;orally</p>
</div>
<!-- Page 70 -->
<a name="70"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page70-div" style="position:relative;width:917px;height:1187px;">
<p style="position:absolute;top:1117px;left:108px;white-space:nowrap" class="ft024"><i>Guidelines for the Prevention and Treatment&#160;of&#160;Opportunistic&#160;Infections in Adults&#160;and Adolescents&#160;With HIV&#160;</i></p>
<p style="position:absolute;top:1117px;left:791px;white-space:nowrap" class="ft024"><i>E-8&#160;</i></p>
<p style="position:absolute;top:108px;left:108px;white-space:nowrap" class="ft026"><b>References&#160;</b></p>
<p style="position:absolute;top:150px;left:108px;white-space:nowrap" class="ft013">1.</p>
<p style="position:absolute;top:150px;left:121px;white-space:nowrap" class="ft046">&#160;</p>
<p style="position:absolute;top:150px;left:162px;white-space:nowrap" class="ft032">Messenger LA, Bern C. Congenital Chagas disease:&#160;current&#160;diagnostics, limitations and&#160;<br/>future&#160;perspectives.&#160;</p>
<p style="position:absolute;top:170px;left:301px;white-space:nowrap" class="ft019"><i>Curr&#160;Opin Infect&#160;Dis</i></p>
<p style="position:absolute;top:170px;left:445px;white-space:nowrap" class="ft013">. 2018;31(5):415-421.&#160;Available at:&#160;</p>
<p style="position:absolute;top:190px;left:162px;white-space:nowrap" class="ft034">https://www.pubmed.ncbi.nlm.nih.gov/30095485</p>
<p style="position:absolute;top:190px;left:503px;white-space:nowrap" class="ft013">.&#160;</p>
<p style="position:absolute;top:227px;left:108px;white-space:nowrap" class="ft013">2.</p>
<p style="position:absolute;top:227px;left:121px;white-space:nowrap" class="ft046">&#160;</p>
<p style="position:absolute;top:227px;left:162px;white-space:nowrap" class="ft013">Maguire J.&#160;</p>
<p style="position:absolute;top:227px;left:240px;white-space:nowrap" class="ft019"><i>Trypanosoma</i></p>
<p style="position:absolute;top:227px;left:335px;white-space:nowrap" class="ft013">.&#160;Vol. 2nd ed.&#160;Philadelphia, PA: Lippincott, Williams, &amp; Wilkins;&#160;</p>
<p style="position:absolute;top:247px;left:162px;white-space:nowrap" class="ft013">2004.&#160;</p>
<p style="position:absolute;top:284px;left:108px;white-space:nowrap" class="ft013">3.</p>
<p style="position:absolute;top:284px;left:121px;white-space:nowrap" class="ft046">&#160;</p>
<p style="position:absolute;top:284px;left:162px;white-space:nowrap" class="ft032">Benchimol&#160;Barbosa PR. The oral transmission of Chagas' disease:&#160;an acute&#160;form of infection&#160;<br/>responsible&#160;for regional&#160;outbreaks.&#160;</p>
<p style="position:absolute;top:304px;left:406px;white-space:nowrap" class="ft019"><i>Int&#160;J Cardiol</i></p>
<p style="position:absolute;top:304px;left:495px;white-space:nowrap" class="ft013">. 2006;112(1):132-133.&#160;Available at:&#160;</p>
<p style="position:absolute;top:323px;left:162px;white-space:nowrap" class="ft034">https://www.pubmed.ncbi.nlm.nih.gov/16600406</p>
<p style="position:absolute;top:323px;left:503px;white-space:nowrap" class="ft013">.&#160;</p>
<p style="position:absolute;top:361px;left:108px;white-space:nowrap" class="ft013">4.</p>
<p style="position:absolute;top:360px;left:121px;white-space:nowrap" class="ft046">&#160;</p>
<p style="position:absolute;top:361px;left:162px;white-space:nowrap" class="ft013">Rassi A,&#160;Jr.,&#160;Rassi A,&#160;Marin-Neto JA.&#160;Chagas disease.&#160;</p>
<p style="position:absolute;top:361px;left:540px;white-space:nowrap" class="ft019"><i>Lancet</i></p>
<p style="position:absolute;top:361px;left:587px;white-space:nowrap" class="ft013">. 2010;375(9723):1388-1402.&#160;</p>
<p style="position:absolute;top:380px;left:162px;white-space:nowrap" class="ft013">Available at:&#160;</p>
<p style="position:absolute;top:380px;left:255px;white-space:nowrap" class="ft034">https://www.pubmed.ncbi.nlm.nih.gov/20399979</p>
<p style="position:absolute;top:380px;left:596px;white-space:nowrap" class="ft013">.&#160;</p>
<p style="position:absolute;top:417px;left:108px;white-space:nowrap" class="ft013">5.</p>
<p style="position:absolute;top:417px;left:121px;white-space:nowrap" class="ft046">&#160;</p>
<p style="position:absolute;top:417px;left:162px;white-space:nowrap" class="ft032">World Health Organization. Chagas&#160;disease in Latin America:&#160;an epidemiological&#160;update&#160;<br/>based on 2010 estimates.&#160;</p>
<p style="position:absolute;top:437px;left:339px;white-space:nowrap" class="ft019"><i>Wkly&#160;Epidemiol&#160;Rec</i></p>
<p style="position:absolute;top:437px;left:478px;white-space:nowrap" class="ft013">. 2015;90(6):33-43.&#160;Available at:&#160;</p>
<p style="position:absolute;top:457px;left:162px;white-space:nowrap" class="ft034">https://www.pubmed.ncbi.nlm.nih.gov/25671846</p>
<p style="position:absolute;top:457px;left:503px;white-space:nowrap" class="ft013">.</p>
<p style="position:absolute;top:494px;left:108px;white-space:nowrap" class="ft013">6.</p>
<p style="position:absolute;top:494px;left:121px;white-space:nowrap" class="ft046">&#160;</p>
<p style="position:absolute;top:494px;left:162px;white-space:nowrap" class="ft013">Pan American Health Organization. Chagas disease.&#160;2022.&#160;Available at:&#160;</p>
<p style="position:absolute;top:514px;left:162px;white-space:nowrap" class="ft034">https://www.paho.org/en/topics/chagas-disease</p>
<p style="position:absolute;top:514px;left:487px;white-space:nowrap" class="ft013">.&#160;</p>
<p style="position:absolute;top:551px;left:108px;white-space:nowrap" class="ft013">7.</p>
<p style="position:absolute;top:551px;left:121px;white-space:nowrap" class="ft046">&#160;</p>
<p style="position:absolute;top:551px;left:162px;white-space:nowrap" class="ft032">Gascon&#160;J, Bern C, Pinazo&#160;MJ. Chagas&#160;disease in Spain, the&#160;United States and&#160;other non-<br/>endemic&#160;countries.&#160;</p>
<p style="position:absolute;top:571px;left:296px;white-space:nowrap" class="ft019"><i>Acta Trop</i></p>
<p style="position:absolute;top:571px;left:366px;white-space:nowrap" class="ft013">.&#160;2010;115(1-2):22-27. Available at:&#160;</p>
<p style="position:absolute;top:591px;left:162px;white-space:nowrap" class="ft034">https://www.pubmed.ncbi.nlm.nih.gov/19646412</p>
<p style="position:absolute;top:591px;left:503px;white-space:nowrap" class="ft013">.&#160;</p>
<p style="position:absolute;top:628px;left:108px;white-space:nowrap" class="ft013">8.</p>
<p style="position:absolute;top:628px;left:121px;white-space:nowrap" class="ft046">&#160;</p>
<p style="position:absolute;top:628px;left:162px;white-space:nowrap" class="ft032">Moncayo&#160;A.&#160;Chagas disease: current epidemiological&#160;trends after the interruption of vectorial&#160;<br/>and transfusional&#160;transmission in the&#160;Southern Cone countries.&#160;</p>
<p style="position:absolute;top:648px;left:598px;white-space:nowrap" class="ft019"><i>Mem Inst Oswaldo Cruz</i></p>
<p style="position:absolute;top:648px;left:766px;white-space:nowrap" class="ft013">.&#160;</p>
<p style="position:absolute;top:668px;left:162px;white-space:nowrap" class="ft013">2003;98(5):577-591.&#160;Available&#160;at:&#160;</p>
<p style="position:absolute;top:668px;left:402px;white-space:nowrap" class="ft034">https://www.pubmed.ncbi.nlm.nih.gov/12973523</p>
<p style="position:absolute;top:668px;left:743px;white-space:nowrap" class="ft013">.&#160;</p>
<p style="position:absolute;top:705px;left:108px;white-space:nowrap" class="ft013">9.</p>
<p style="position:absolute;top:705px;left:162px;white-space:nowrap" class="ft032">Lynn MK, Bossak BH,&#160;Sandifer PA,&#160;Watson A,&#160;Nolan MS. Contemporary autochthonous<br/>human Chagas disease in&#160;the&#160;USA.&#160;</p>
<p style="position:absolute;top:724px;left:409px;white-space:nowrap" class="ft019"><i>Acta Trop</i></p>
<p style="position:absolute;top:724px;left:478px;white-space:nowrap" class="ft013">. 2020;205:105361.&#160;Available at:&#160;</p>
<p style="position:absolute;top:744px;left:162px;white-space:nowrap" class="ft034">https://www.pubmed.ncbi.nlm.nih.gov/32006523</p>
<p style="position:absolute;top:744px;left:503px;white-space:nowrap" class="ft013">.&#160;</p>
<p style="position:absolute;top:781px;left:108px;white-space:nowrap" class="ft013">10.</p>
<p style="position:absolute;top:781px;left:130px;white-space:nowrap" class="ft046">&#160;</p>
<p style="position:absolute;top:781px;left:162px;white-space:nowrap" class="ft032">Bern C, Messenger LA,&#160;Whitman JD,&#160;Maguire&#160;JH.&#160;Chagas disease in the&#160;United States: a&#160;<br/>public health approach.&#160;</p>
<p style="position:absolute;top:801px;left:328px;white-space:nowrap" class="ft019"><i>Clin Microbiol Rev</i></p>
<p style="position:absolute;top:801px;left:461px;white-space:nowrap" class="ft013">. 2019;33(1). Available at:&#160;</p>
<p style="position:absolute;top:821px;left:162px;white-space:nowrap" class="ft034">https://www.pubmed.ncbi.nlm.nih.gov/31776135</p>
<p style="position:absolute;top:821px;left:503px;white-space:nowrap" class="ft013">.&#160;</p>
<p style="position:absolute;top:858px;left:108px;white-space:nowrap" class="ft013">11.</p>
<p style="position:absolute;top:858px;left:130px;white-space:nowrap" class="ft046">&#160;</p>
<p style="position:absolute;top:858px;left:162px;white-space:nowrap" class="ft032">Kjos SA,&#160;Snowden&#160;KF,&#160;Craig TM, Lewis B, Ronald N, Olson&#160;JK.&#160;Distribution and&#160;<br/>characterization of canine&#160;Chagas disease in Texas.&#160;</p>
<p style="position:absolute;top:878px;left:521px;white-space:nowrap" class="ft019"><i>Vet Parasitol</i></p>
<p style="position:absolute;top:878px;left:612px;white-space:nowrap" class="ft013">. 2008;152(3-4):249-256.&#160;</p>
<p style="position:absolute;top:898px;left:162px;white-space:nowrap" class="ft013">Available at:&#160;</p>
<p style="position:absolute;top:898px;left:255px;white-space:nowrap" class="ft034">https://www.pubmed.ncbi.nlm.nih.gov/18255233</p>
<p style="position:absolute;top:898px;left:596px;white-space:nowrap" class="ft013">.&#160;</p>
<p style="position:absolute;top:935px;left:108px;white-space:nowrap" class="ft013">12.</p>
<p style="position:absolute;top:935px;left:130px;white-space:nowrap" class="ft046">&#160;</p>
<p style="position:absolute;top:935px;left:162px;white-space:nowrap" class="ft032">Klotz&#160;SA,&#160;Dorn PL,&#160;Klotz&#160;JH, et&#160;al. Feeding behavior of triatomines from the&#160;southwestern&#160;<br/>United States: an update&#160;on potential&#160;risk for transmission of Chagas disease.&#160;</p>
<p style="position:absolute;top:955px;left:699px;white-space:nowrap" class="ft019"><i>Acta Trop</i></p>
<p style="position:absolute;top:955px;left:768px;white-space:nowrap" class="ft013">.&#160;</p>
<p style="position:absolute;top:975px;left:162px;white-space:nowrap" class="ft013">2009;111(2):114-118.&#160;Available&#160;at:&#160;</p>
<p style="position:absolute;top:975px;left:411px;white-space:nowrap" class="ft034">https://www.pubmed.ncbi.nlm.nih.gov/19524078</p>
<p style="position:absolute;top:975px;left:752px;white-space:nowrap" class="ft013">.&#160;</p>
<p style="position:absolute;top:1012px;left:108px;white-space:nowrap" class="ft013">13.</p>
<p style="position:absolute;top:1011px;left:130px;white-space:nowrap" class="ft046">&#160;</p>
<p style="position:absolute;top:1012px;left:162px;white-space:nowrap" class="ft032">Bern C, Montgomery SP,&#160;Katz L, Caglioti S, Stramer SL. Chagas disease and&#160;the&#160;U.S. blood&#160;<br/>supply.&#160;</p>
<p style="position:absolute;top:1031px;left:217px;white-space:nowrap" class="ft019"><i>Curr&#160;Opin Infect&#160;Dis</i></p>
<p style="position:absolute;top:1031px;left:361px;white-space:nowrap" class="ft013">. 2008;21(5):476-482.&#160;Available at:&#160;</p>
<p style="position:absolute;top:1051px;left:162px;white-space:nowrap" class="ft034">https://www.pubmed.ncbi.nlm.nih.gov/18725796</p>
<p style="position:absolute;top:1051px;left:503px;white-space:nowrap" class="ft013">.&#160;</p>
</div>
<!-- Page 71 -->
<a name="71"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page71-div" style="position:relative;width:917px;height:1187px;">
<p style="position:absolute;top:1117px;left:108px;white-space:nowrap" class="ft024"><i>Guidelines for the Prevention and Treatment&#160;of&#160;Opportunistic&#160;Infections in Adults&#160;and Adolescents&#160;With HIV&#160;</i></p>
<p style="position:absolute;top:1117px;left:791px;white-space:nowrap" class="ft024"><i>E-9&#160;</i></p>
<p style="position:absolute;top:109px;left:108px;white-space:nowrap" class="ft013">14.</p>
<p style="position:absolute;top:108px;left:130px;white-space:nowrap" class="ft046">&#160;</p>
<p style="position:absolute;top:109px;left:162px;white-space:nowrap" class="ft013">Centers for&#160;Disease Control&#160;Prevention. Blood donor screening&#160;for chagas disease</p>
<p style="position:absolute;top:109px;left:729px;white-space:nowrap" class="ft047">—</p>
<p style="position:absolute;top:109px;left:745px;white-space:nowrap" class="ft013">United&#160;</p>
<p style="position:absolute;top:129px;left:162px;white-space:nowrap" class="ft013">States, 2006-2007.&#160;</p>
<p style="position:absolute;top:129px;left:295px;white-space:nowrap" class="ft019"><i>MMWR</i></p>
<p style="position:absolute;top:129px;left:349px;white-space:nowrap" class="ft013">. 2007;56(7):141-143.&#160;Available&#160;at:&#160;</p>
<p style="position:absolute;top:148px;left:162px;white-space:nowrap" class="ft034">https://www.pubmed.ncbi.nlm.nih.gov/17318113</p>
<p style="position:absolute;top:148px;left:503px;white-space:nowrap" class="ft013">.&#160;</p>
<p style="position:absolute;top:185px;left:108px;white-space:nowrap" class="ft013">15.</p>
<p style="position:absolute;top:185px;left:130px;white-space:nowrap" class="ft046">&#160;</p>
<p style="position:absolute;top:185px;left:162px;white-space:nowrap" class="ft032">Rocha A, de&#160;Meneses&#160;AC, da Silva AM, et al. Pathology of patients with Chagas' disease&#160;and&#160;<br/>acquired immunodeficiency syndrome.&#160;</p>
<p style="position:absolute;top:205px;left:436px;white-space:nowrap" class="ft019"><i>Am J Trop&#160;Med Hyg</i></p>
<p style="position:absolute;top:205px;left:577px;white-space:nowrap" class="ft013">.&#160;1994;50(3):261-268.&#160;Available&#160;</p>
<p style="position:absolute;top:225px;left:162px;white-space:nowrap" class="ft013">at:&#160;</p>
<p style="position:absolute;top:225px;left:184px;white-space:nowrap" class="ft034">https://www.pubmed.ncbi.nlm.nih.gov/8147485</p>
<p style="position:absolute;top:225px;left:516px;white-space:nowrap" class="ft013">.&#160;</p>
<p style="position:absolute;top:262px;left:108px;white-space:nowrap" class="ft013">16.</p>
<p style="position:absolute;top:262px;left:130px;white-space:nowrap" class="ft046">&#160;</p>
<p style="position:absolute;top:262px;left:162px;white-space:nowrap" class="ft032">Sartori&#160;AM,&#160;Ibrahim KY,&#160;Nunes&#160;Westphalen EV, et al. Manifestations of Chagas disease&#160;<br/>(American trypanosomiasis) in patients with HIV/AIDS.&#160;</p>
<p style="position:absolute;top:282px;left:557px;white-space:nowrap" class="ft019"><i>Ann&#160;Trop Med Parasitol</i></p>
<p style="position:absolute;top:282px;left:726px;white-space:nowrap" class="ft013">.&#160;</p>
<p style="position:absolute;top:302px;left:162px;white-space:nowrap" class="ft013">2007;101(1):31-50.&#160;Available at:&#160;</p>
<p style="position:absolute;top:302px;left:394px;white-space:nowrap" class="ft034">https://www.pubmed.ncbi.nlm.nih.gov/17244408</p>
<p style="position:absolute;top:302px;left:735px;white-space:nowrap" class="ft013">.&#160;</p>
<p style="position:absolute;top:339px;left:108px;white-space:nowrap" class="ft013">17.</p>
<p style="position:absolute;top:339px;left:130px;white-space:nowrap" class="ft046">&#160;</p>
<p style="position:absolute;top:339px;left:162px;white-space:nowrap" class="ft013">Vaidian AK,&#160;Weiss&#160;LM,&#160;Tanowitz HB. Chagas' disease and&#160;AIDS.&#160;</p>
<p style="position:absolute;top:339px;left:628px;white-space:nowrap" class="ft019"><i>Kinetoplastid Biol&#160;Dis</i></p>
<p style="position:absolute;top:339px;left:782px;white-space:nowrap" class="ft013">.&#160;</p>
<p style="position:absolute;top:359px;left:162px;white-space:nowrap" class="ft013">2004;3(1):2.&#160;Available&#160;at:&#160;</p>
<p style="position:absolute;top:359px;left:345px;white-space:nowrap" class="ft034">https://www.pubmed.ncbi.nlm.nih.gov/15142278</p>
<p style="position:absolute;top:359px;left:686px;white-space:nowrap" class="ft013">.&#160;</p>
<p style="position:absolute;top:396px;left:108px;white-space:nowrap" class="ft013">18.</p>
<p style="position:absolute;top:396px;left:130px;white-space:nowrap" class="ft046">&#160;</p>
<p style="position:absolute;top:396px;left:162px;white-space:nowrap" class="ft032">Nunes&#160;MCP,&#160;Beaton A,&#160;Acquatella&#160;H, et al. Chagas cardiomyopathy: an update of current&#160;<br/>clinical knowledge and&#160;management:&#160;a scientific statement from&#160;the&#160;American Heart&#160;<br/>Association.&#160;</p>
<p style="position:absolute;top:436px;left:252px;white-space:nowrap" class="ft019"><i>Circulation</i></p>
<p style="position:absolute;top:436px;left:332px;white-space:nowrap" class="ft013">. 2018;138(12):e169-e209.&#160;Available at:&#160;</p>
<p style="position:absolute;top:455px;left:162px;white-space:nowrap" class="ft034">https://www.pubmed.ncbi.nlm.nih.gov/30354432</p>
<p style="position:absolute;top:455px;left:503px;white-space:nowrap" class="ft013">.&#160;</p>
<p style="position:absolute;top:492px;left:108px;white-space:nowrap" class="ft013">19.</p>
<p style="position:absolute;top:492px;left:130px;white-space:nowrap" class="ft046">&#160;</p>
<p style="position:absolute;top:492px;left:162px;white-space:nowrap" class="ft013">Rassi A,&#160;Jr.,&#160;Rassi SG, Rassi A.&#160;Sudden death in Chagas' disease.&#160;</p>
<p style="position:absolute;top:492px;left:617px;white-space:nowrap" class="ft019"><i>Arq Bras&#160;Cardiol</i></p>
<p style="position:absolute;top:492px;left:738px;white-space:nowrap" class="ft013">.&#160;</p>
<p style="position:absolute;top:512px;left:162px;white-space:nowrap" class="ft013">2001;76(1):75-96. Available&#160;at:&#160;</p>
<p style="position:absolute;top:512px;left:385px;white-space:nowrap" class="ft034">https://www.pubmed.ncbi.nlm.nih.gov/11175486</p>
<p style="position:absolute;top:512px;left:726px;white-space:nowrap" class="ft013">.&#160;</p>
<p style="position:absolute;top:549px;left:108px;white-space:nowrap" class="ft013">20.</p>
<p style="position:absolute;top:549px;left:130px;white-space:nowrap" class="ft046">&#160;</p>
<p style="position:absolute;top:549px;left:162px;white-space:nowrap" class="ft032">de Oliveira RB, Troncon&#160;LE, Dantas&#160;RO,&#160;Menghelli UG. Gastrointestinal&#160;manifestations of&#160;<br/>Chagas'&#160;disease.&#160;</p>
<p style="position:absolute;top:569px;left:279px;white-space:nowrap" class="ft019"><i>Am J&#160;Gastroenterol</i></p>
<p style="position:absolute;top:569px;left:414px;white-space:nowrap" class="ft013">.&#160;1998;93(6):884-889.&#160;Available&#160;at:&#160;</p>
<p style="position:absolute;top:589px;left:162px;white-space:nowrap" class="ft034">https://www.pubmed.ncbi.nlm.nih.gov/9647012</p>
<p style="position:absolute;top:589px;left:494px;white-space:nowrap" class="ft013">.&#160;</p>
<p style="position:absolute;top:626px;left:108px;white-space:nowrap" class="ft013">21.</p>
<p style="position:absolute;top:626px;left:130px;white-space:nowrap" class="ft046">&#160;</p>
<p style="position:absolute;top:626px;left:162px;white-space:nowrap" class="ft032">Radisic MV,&#160;Repetto SA.&#160;American trypanosomiasis (Chagas disease) in solid organ&#160;<br/>transplantation.&#160;</p>
<p style="position:absolute;top:646px;left:273px;white-space:nowrap" class="ft019"><i>Transpl Infect&#160;Dis</i></p>
<p style="position:absolute;top:646px;left:398px;white-space:nowrap" class="ft013">. 2020;22(6):e13429. Available&#160;at:&#160;</p>
<p style="position:absolute;top:666px;left:162px;white-space:nowrap" class="ft034">https://www.pubmed.ncbi.nlm.nih.gov/32738158</p>
<p style="position:absolute;top:666px;left:503px;white-space:nowrap" class="ft013">.&#160;</p>
<p style="position:absolute;top:703px;left:108px;white-space:nowrap" class="ft013">22.</p>
<p style="position:absolute;top:703px;left:130px;white-space:nowrap" class="ft046">&#160;</p>
<p style="position:absolute;top:703px;left:162px;white-space:nowrap" class="ft032">Czech MM,&#160;Nayak AK,&#160;Subramanian&#160;K, et al. Reactivation of Chagas disease in a patient&#160;<br/>with an autoimmune rheumatic disease: case report&#160;and review&#160;of the&#160;literature.&#160;</p>
<p style="position:absolute;top:723px;left:715px;white-space:nowrap" class="ft019"><i>Open Forum&#160;</i></p>
<p style="position:absolute;top:743px;left:162px;white-space:nowrap" class="ft019"><i>Infect&#160;Dis</i></p>
<p style="position:absolute;top:743px;left:229px;white-space:nowrap" class="ft013">. 2021;8(2):ofaa642. Available&#160;at:&#160;</p>
<p style="position:absolute;top:762px;left:162px;white-space:nowrap" class="ft034">https://www.pubmed.ncbi.nlm.nih.gov/33575423</p>
<p style="position:absolute;top:762px;left:503px;white-space:nowrap" class="ft013">.&#160;</p>
<p style="position:absolute;top:800px;left:108px;white-space:nowrap" class="ft013">23.</p>
<p style="position:absolute;top:799px;left:130px;white-space:nowrap" class="ft046">&#160;</p>
<p style="position:absolute;top:800px;left:162px;white-space:nowrap" class="ft032">Riarte&#160;A, Luna C, Sabatiello R, et&#160;al. Chagas'&#160;disease in patients with kidney transplants: 7&#160;<br/>years of experience&#160;1989-1996.&#160;</p>
<p style="position:absolute;top:819px;left:384px;white-space:nowrap" class="ft019"><i>Clin Infect&#160;Dis</i></p>
<p style="position:absolute;top:819px;left:485px;white-space:nowrap" class="ft013">. 1999;29(3):561-567. Available&#160;at:&#160;</p>
<p style="position:absolute;top:839px;left:162px;white-space:nowrap" class="ft034">https://www.pubmed.ncbi.nlm.nih.gov/10530448</p>
<p style="position:absolute;top:839px;left:503px;white-space:nowrap" class="ft013">.&#160;</p>
<p style="position:absolute;top:876px;left:108px;white-space:nowrap" class="ft013">24.</p>
<p style="position:absolute;top:876px;left:130px;white-space:nowrap" class="ft046">&#160;</p>
<p style="position:absolute;top:876px;left:162px;white-space:nowrap" class="ft013">de Freitas VL, da Silva SC, Sartori&#160;AM, et al. Real-time&#160;PCR in HIV/</p>
<p style="position:absolute;top:876px;left:643px;white-space:nowrap" class="ft019"><i>Trypanosoma cruzi</i></p>
<p style="position:absolute;top:876px;left:777px;white-space:nowrap" class="ft013">&#160;</p>
<p style="position:absolute;top:896px;left:162px;white-space:nowrap" class="ft032">coinfection with and without Chagas&#160;disease reactivation: association with HIV&#160;viral load&#160;<br/>and CD4 level.&#160;</p>
<p style="position:absolute;top:916px;left:270px;white-space:nowrap" class="ft019"><i>PLoS Negl Trop&#160;Dis</i></p>
<p style="position:absolute;top:916px;left:411px;white-space:nowrap" class="ft013">. 2011;5(8):e1277. Available at:&#160;</p>
<p style="position:absolute;top:936px;left:162px;white-space:nowrap" class="ft034">https://www.pubmed.ncbi.nlm.nih.gov/21912712</p>
<p style="position:absolute;top:936px;left:503px;white-space:nowrap" class="ft013">.&#160;</p>
<p style="position:absolute;top:973px;left:108px;white-space:nowrap" class="ft013">25.</p>
<p style="position:absolute;top:973px;left:130px;white-space:nowrap" class="ft046">&#160;</p>
<p style="position:absolute;top:973px;left:162px;white-space:nowrap" class="ft032">Sartori&#160;AM,&#160;Lopes MH,&#160;Benvenuti LA, et al. Reactivation of Chagas'&#160;disease in a&#160;human&#160;<br/>immunodeficiency virus-infected patient leading to severe heart&#160;disease with&#160;a late&#160;positive&#160;<br/>direct&#160;microscopic&#160;examination of the blood.&#160;</p>
<p style="position:absolute;top:1013px;left:476px;white-space:nowrap" class="ft019"><i>Am J&#160;Trop&#160;Med Hyg</i></p>
<p style="position:absolute;top:1013px;left:616px;white-space:nowrap" class="ft013">. 1998;59(5):784-786.&#160;</p>
<p style="position:absolute;top:1032px;left:162px;white-space:nowrap" class="ft013">Available at:&#160;</p>
<p style="position:absolute;top:1032px;left:255px;white-space:nowrap" class="ft034">https://www.pubmed.ncbi.nlm.nih.gov/9840598</p>
<p style="position:absolute;top:1032px;left:587px;white-space:nowrap" class="ft013">.&#160;</p>
</div>
<!-- Page 72 -->
<a name="72"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page72-div" style="position:relative;width:917px;height:1187px;">
<p style="position:absolute;top:1117px;left:108px;white-space:nowrap" class="ft024"><i>Guidelines for the Prevention and Treatment&#160;of&#160;Opportunistic&#160;Infections in Adults&#160;and Adolescents&#160;With HIV&#160;</i></p>
<p style="position:absolute;top:1117px;left:784px;white-space:nowrap" class="ft024"><i>E-10&#160;</i></p>
<p style="position:absolute;top:109px;left:108px;white-space:nowrap" class="ft013">26.</p>
<p style="position:absolute;top:108px;left:130px;white-space:nowrap" class="ft046">&#160;</p>
<p style="position:absolute;top:109px;left:162px;white-space:nowrap" class="ft013">Almeida&#160;EA,&#160;Ramos Junior AN, Correia&#160;D, Shikanai-Yasuda&#160;MA. Co-infection&#160;</p>
<p style="position:absolute;top:129px;left:162px;white-space:nowrap" class="ft019"><i>Trypanosoma cruzi</i></p>
<p style="position:absolute;top:129px;left:296px;white-space:nowrap" class="ft013">/HIV:&#160;systematic&#160;review (1980–2010).&#160;</p>
<p style="position:absolute;top:129px;left:566px;white-space:nowrap" class="ft019"><i>Rev Soc Bras&#160;Med&#160;Trop</i></p>
<p style="position:absolute;top:129px;left:731px;white-space:nowrap" class="ft013">.&#160;</p>
<p style="position:absolute;top:148px;left:162px;white-space:nowrap" class="ft013">2011;44(6):762-770.&#160;Available&#160;at:&#160;</p>
<p style="position:absolute;top:148px;left:402px;white-space:nowrap" class="ft034">https://www.pubmed.ncbi.nlm.nih.gov/22231251</p>
<p style="position:absolute;top:148px;left:743px;white-space:nowrap" class="ft013">.&#160;</p>
<p style="position:absolute;top:185px;left:108px;white-space:nowrap" class="ft013">27.</p>
<p style="position:absolute;top:185px;left:130px;white-space:nowrap" class="ft046">&#160;</p>
<p style="position:absolute;top:185px;left:162px;white-space:nowrap" class="ft032">Diazgranados CA,&#160;Saavedra-Trujillo CH,&#160;Mantilla M, Valderrama&#160;SL, Alquichire C, Franco-<br/>Paredes C.&#160;Chagasic encephalitis in HIV patients: common presentation of an evolving&#160;<br/>epidemiological&#160;and clinical&#160;association.&#160;</p>
<p style="position:absolute;top:225px;left:447px;white-space:nowrap" class="ft019"><i>Lancet&#160;Infect&#160;Dis</i></p>
<p style="position:absolute;top:225px;left:565px;white-space:nowrap" class="ft013">. 2009;9(5):324-330. Available at:&#160;</p>
<p style="position:absolute;top:245px;left:162px;white-space:nowrap" class="ft034">https://www.pubmed.ncbi.nlm.nih.gov/19393962</p>
<p style="position:absolute;top:245px;left:503px;white-space:nowrap" class="ft013">.&#160;</p>
<p style="position:absolute;top:282px;left:108px;white-space:nowrap" class="ft013">28.</p>
<p style="position:absolute;top:282px;left:130px;white-space:nowrap" class="ft046">&#160;</p>
<p style="position:absolute;top:282px;left:162px;white-space:nowrap" class="ft032">Ferreira MS,&#160;Nishioka&#160;Sde A, Silvestre MT, Borges AS, Nunes-Araujo FR,&#160;Rocha&#160;A.&#160;<br/>Reactivation&#160;of Chagas'&#160;disease in patients with AIDS: report&#160;of three new cases and review&#160;<br/>of the&#160;literature.&#160;</p>
<p style="position:absolute;top:322px;left:277px;white-space:nowrap" class="ft019"><i>Clin Infect&#160;Dis</i></p>
<p style="position:absolute;top:322px;left:378px;white-space:nowrap" class="ft013">. 1997;25(6):1397-1400. Available&#160;at:&#160;</p>
<p style="position:absolute;top:342px;left:162px;white-space:nowrap" class="ft034">https://www.pubmed.ncbi.nlm.nih.gov/9431385</p>
<p style="position:absolute;top:342px;left:494px;white-space:nowrap" class="ft013">.&#160;</p>
<p style="position:absolute;top:379px;left:108px;white-space:nowrap" class="ft013">29.</p>
<p style="position:absolute;top:378px;left:130px;white-space:nowrap" class="ft046">&#160;</p>
<p style="position:absolute;top:379px;left:162px;white-space:nowrap" class="ft032">Forsyth&#160;CJ,&#160;Manne-Goehler&#160;J, Bern C,&#160;et&#160;al. Recommendations for screening&#160;and diagnosis&#160;<br/>of Chagas disease in the&#160;United States.&#160;</p>
<p style="position:absolute;top:399px;left:434px;white-space:nowrap" class="ft019"><i>J Infect Dis</i></p>
<p style="position:absolute;top:399px;left:513px;white-space:nowrap" class="ft013">. 2021.&#160;Available&#160;at:&#160;</p>
<p style="position:absolute;top:418px;left:162px;white-space:nowrap" class="ft034">https://www.pubmed.ncbi.nlm.nih.gov/34623435</p>
<p style="position:absolute;top:418px;left:503px;white-space:nowrap" class="ft013">.&#160;</p>
<p style="position:absolute;top:455px;left:108px;white-space:nowrap" class="ft013">30.</p>
<p style="position:absolute;top:455px;left:130px;white-space:nowrap" class="ft046">&#160;</p>
<p style="position:absolute;top:455px;left:162px;white-space:nowrap" class="ft032">Whitman JD,&#160;Bulman CA,&#160;Gunderson&#160;EL, et&#160;al. Chagas disease&#160;serological&#160;test performance&#160;<br/>in U.S. blood&#160;donor specimens.&#160;</p>
<p style="position:absolute;top:475px;left:383px;white-space:nowrap" class="ft019"><i>J Clin&#160;Microbiol</i></p>
<p style="position:absolute;top:475px;left:498px;white-space:nowrap" class="ft013">. 2019;57(12).&#160;Available at:&#160;</p>
<p style="position:absolute;top:495px;left:162px;white-space:nowrap" class="ft034">https://www.pubmed.ncbi.nlm.nih.gov/31511333</p>
<p style="position:absolute;top:495px;left:503px;white-space:nowrap" class="ft013">.&#160;</p>
<p style="position:absolute;top:532px;left:108px;white-space:nowrap" class="ft013">31.</p>
<p style="position:absolute;top:532px;left:130px;white-space:nowrap" class="ft046">&#160;</p>
<p style="position:absolute;top:532px;left:162px;white-space:nowrap" class="ft032">Sosa-Estani&#160;S, Gamboa-Leon MR,&#160;Del&#160;Cid-Lemus J, et&#160;al. Use&#160;of a rapid test on umbilical&#160;<br/>cord blood to&#160;screen for&#160;</p>
<p style="position:absolute;top:552px;left:331px;white-space:nowrap" class="ft019"><i>Trypanosoma&#160;cruzi</i></p>
<p style="position:absolute;top:552px;left:465px;white-space:nowrap" class="ft013">&#160;infection in pregnant&#160;women in&#160;Argentina,&#160;</p>
<p style="position:absolute;top:572px;left:162px;white-space:nowrap" class="ft013">Bolivia, Honduras, and&#160;Mexico.&#160;</p>
<p style="position:absolute;top:572px;left:388px;white-space:nowrap" class="ft019"><i>Am J&#160;Trop&#160;Med Hyg</i></p>
<p style="position:absolute;top:572px;left:528px;white-space:nowrap" class="ft013">. 2008;79(5):755-759.&#160;Available at:&#160;</p>
<p style="position:absolute;top:592px;left:162px;white-space:nowrap" class="ft034">https://www.pubmed.ncbi.nlm.nih.gov/18981518</p>
<p style="position:absolute;top:592px;left:503px;white-space:nowrap" class="ft013">.&#160;</p>
<p style="position:absolute;top:629px;left:108px;white-space:nowrap" class="ft013">32.</p>
<p style="position:absolute;top:628px;left:130px;white-space:nowrap" class="ft046">&#160;</p>
<p style="position:absolute;top:629px;left:162px;white-space:nowrap" class="ft032">Tarleton RL, Reithinger R, Urbina&#160;JA, Kitron U, Gurtler RE. The challenges of Chagas&#160;<br/>disease—grim outlook or&#160;glimmer of hope.&#160;</p>
<p style="position:absolute;top:649px;left:465px;white-space:nowrap" class="ft019"><i>PLoS&#160;Med</i></p>
<p style="position:absolute;top:649px;left:537px;white-space:nowrap" class="ft013">. 2007;4(12):e332.&#160;Available&#160;at:&#160;</p>
<p style="position:absolute;top:668px;left:162px;white-space:nowrap" class="ft034">https://www.pubmed.ncbi.nlm.nih.gov/18162039</p>
<p style="position:absolute;top:668px;left:503px;white-space:nowrap" class="ft013">.&#160;</p>
<p style="position:absolute;top:706px;left:108px;white-space:nowrap" class="ft013">33.</p>
<p style="position:absolute;top:705px;left:130px;white-space:nowrap" class="ft046">&#160;</p>
<p style="position:absolute;top:706px;left:162px;white-space:nowrap" class="ft032">Verani JR,&#160;Seitz&#160;A, Gilman RH, et al.&#160;Geographic&#160;variation in the&#160;sensitivity of recombinant&#160;<br/>antigen-based rapid tests&#160;for chronic Trypanosoma&#160;cruzi&#160;infection.&#160;</p>
<p style="position:absolute;top:725px;left:625px;white-space:nowrap" class="ft019"><i>Am J Trop&#160;Med Hyg</i></p>
<p style="position:absolute;top:725px;left:766px;white-space:nowrap" class="ft013">.&#160;</p>
<p style="position:absolute;top:745px;left:162px;white-space:nowrap" class="ft013">2009;80(3):410-415.&#160;Available&#160;at:&#160;</p>
<p style="position:absolute;top:745px;left:402px;white-space:nowrap" class="ft034">https://www.pubmed.ncbi.nlm.nih.gov/19270291</p>
<p style="position:absolute;top:745px;left:743px;white-space:nowrap" class="ft013">.&#160;</p>
<p style="position:absolute;top:782px;left:108px;white-space:nowrap" class="ft013">34.</p>
<p style="position:absolute;top:782px;left:130px;white-space:nowrap" class="ft046">&#160;</p>
<p style="position:absolute;top:782px;left:162px;white-space:nowrap" class="ft013">Gorlin J, Rossmann S, Robertson G, et al. Evaluation of a new&#160;</p>
<p style="position:absolute;top:782px;left:598px;white-space:nowrap" class="ft019"><i>Trypanosoma&#160;cruzi</i></p>
<p style="position:absolute;top:782px;left:731px;white-space:nowrap" class="ft013">&#160;antibody&#160;</p>
<p style="position:absolute;top:802px;left:162px;white-space:nowrap" class="ft013">assay for&#160;blood donor&#160;screening.&#160;</p>
<p style="position:absolute;top:802px;left:391px;white-space:nowrap" class="ft019"><i>Transfusion</i></p>
<p style="position:absolute;top:802px;left:473px;white-space:nowrap" class="ft013">. 2008;48(3):531-540. Available at:&#160;</p>
<p style="position:absolute;top:822px;left:162px;white-space:nowrap" class="ft034">https://www.pubmed.ncbi.nlm.nih.gov/18067497</p>
<p style="position:absolute;top:822px;left:503px;white-space:nowrap" class="ft013">.&#160;</p>
<p style="position:absolute;top:859px;left:108px;white-space:nowrap" class="ft013">35.</p>
<p style="position:absolute;top:859px;left:130px;white-space:nowrap" class="ft046">&#160;</p>
<p style="position:absolute;top:859px;left:162px;white-space:nowrap" class="ft032">Junqueira&#160;AC, Chiari E, Wincker P.&#160;Comparison&#160;of the&#160;polymerase chain reaction with two&#160;<br/>classical&#160;parasitological&#160;methods for the diagnosis&#160;of Chagas disease in an endemic&#160;region of&#160;<br/>north-eastern&#160;Brazil.&#160;</p>
<p style="position:absolute;top:899px;left:308px;white-space:nowrap" class="ft019"><i>Trans R Soc Trop&#160;Med Hyg</i></p>
<p style="position:absolute;top:899px;left:498px;white-space:nowrap" class="ft013">.&#160;1996;90(2):129-132.&#160;Available&#160;at:&#160;</p>
<p style="position:absolute;top:919px;left:162px;white-space:nowrap" class="ft034">https://www.pubmed.ncbi.nlm.nih.gov/8761570</p>
<p style="position:absolute;top:919px;left:494px;white-space:nowrap" class="ft013">.&#160;</p>
<p style="position:absolute;top:956px;left:108px;white-space:nowrap" class="ft013">36.</p>
<p style="position:absolute;top:955px;left:130px;white-space:nowrap" class="ft046">&#160;</p>
<p style="position:absolute;top:956px;left:162px;white-space:nowrap" class="ft032">Cordova E,&#160;Boschi A,&#160;Ambrosioni&#160;J,&#160;Cudos C,&#160;Corti&#160;M. Reactivation of Chagas disease&#160;with&#160;<br/>central&#160;nervous system&#160;involvement&#160;in HIV-infected patients in Argentina, 1992-2007.&#160;</p>
<p style="position:absolute;top:976px;left:765px;white-space:nowrap" class="ft019"><i>Int J&#160;</i></p>
<p style="position:absolute;top:995px;left:162px;white-space:nowrap" class="ft019"><i>Infect&#160;Dis</i></p>
<p style="position:absolute;top:995px;left:229px;white-space:nowrap" class="ft013">. 2008;12(6):587-592.&#160;Available&#160;at:&#160;</p>
<p style="position:absolute;top:1015px;left:162px;white-space:nowrap" class="ft034">https://www.pubmed.ncbi.nlm.nih.gov/18337139</p>
<p style="position:absolute;top:1015px;left:503px;white-space:nowrap" class="ft013">.&#160;</p>
</div>
<!-- Page 73 -->
<a name="73"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page73-div" style="position:relative;width:917px;height:1187px;">
<p style="position:absolute;top:1117px;left:108px;white-space:nowrap" class="ft024"><i>Guidelines for the Prevention and Treatment&#160;of&#160;Opportunistic&#160;Infections in Adults&#160;and Adolescents&#160;With HIV&#160;</i></p>
<p style="position:absolute;top:1117px;left:784px;white-space:nowrap" class="ft024"><i>E-11&#160;</i></p>
<p style="position:absolute;top:109px;left:108px;white-space:nowrap" class="ft013">37.</p>
<p style="position:absolute;top:108px;left:130px;white-space:nowrap" class="ft046">&#160;</p>
<p style="position:absolute;top:109px;left:162px;white-space:nowrap" class="ft032">Ramirez&#160;JD,&#160;Guhl F,&#160;Umezawa ES, et&#160;al. Evaluation of adult chronic&#160;Chagas' heart disease&#160;<br/>diagnosis by&#160;molecular and serological&#160;methods.&#160;</p>
<p style="position:absolute;top:129px;left:502px;white-space:nowrap" class="ft019"><i>J&#160;Clin Microbiol</i></p>
<p style="position:absolute;top:129px;left:617px;white-space:nowrap" class="ft013">. 2009;47(12):3945-3951.&#160;</p>
<p style="position:absolute;top:148px;left:162px;white-space:nowrap" class="ft013">Available at:&#160;</p>
<p style="position:absolute;top:148px;left:255px;white-space:nowrap" class="ft034">https://www.pubmed.ncbi.nlm.nih.gov/19846646</p>
<p style="position:absolute;top:148px;left:596px;white-space:nowrap" class="ft013">.&#160;</p>
<p style="position:absolute;top:185px;left:108px;white-space:nowrap" class="ft013">38.</p>
<p style="position:absolute;top:185px;left:130px;white-space:nowrap" class="ft046">&#160;</p>
<p style="position:absolute;top:185px;left:162px;white-space:nowrap" class="ft032">Duffy T,&#160;Bisio M, Altcheh J, et al. Accurate real-time PCR strategy for monitoring&#160;<br/>bloodstream&#160;parasitic loads in chagas&#160;disease patients.&#160;</p>
<p style="position:absolute;top:205px;left:540px;white-space:nowrap" class="ft019"><i>PLoS Negl Trop&#160;Dis</i></p>
<p style="position:absolute;top:205px;left:680px;white-space:nowrap" class="ft013">.&#160;2009;3(4):e419.&#160;</p>
<p style="position:absolute;top:225px;left:162px;white-space:nowrap" class="ft013">Available at:&#160;</p>
<p style="position:absolute;top:225px;left:255px;white-space:nowrap" class="ft034">https://www.pubmed.ncbi.nlm.nih.gov/19381287</p>
<p style="position:absolute;top:225px;left:596px;white-space:nowrap" class="ft013">.&#160;</p>
<p style="position:absolute;top:262px;left:108px;white-space:nowrap" class="ft013">39.</p>
<p style="position:absolute;top:262px;left:130px;white-space:nowrap" class="ft046">&#160;</p>
<p style="position:absolute;top:262px;left:162px;white-space:nowrap" class="ft013">Schijman AG, Vigliano&#160;C, Burgos J,&#160;et&#160;al. Early diagnosis of recurrence&#160;of&#160;</p>
<p style="position:absolute;top:262px;left:682px;white-space:nowrap" class="ft019"><i>Trypanosoma&#160;</i></p>
<p style="position:absolute;top:282px;left:162px;white-space:nowrap" class="ft019"><i>cruzi</i></p>
<p style="position:absolute;top:282px;left:197px;white-space:nowrap" class="ft013">&#160;infection by polymerase chain reaction after heart transplantation of a chronic Chagas'&#160;</p>
<p style="position:absolute;top:302px;left:162px;white-space:nowrap" class="ft013">heart&#160;disease&#160;patient.&#160;</p>
<p style="position:absolute;top:302px;left:310px;white-space:nowrap" class="ft019"><i>J Heart Lung&#160;Transplant</i></p>
<p style="position:absolute;top:302px;left:482px;white-space:nowrap" class="ft013">. 2000;19(11):1114-1117.&#160;Available&#160;at:&#160;</p>
<p style="position:absolute;top:322px;left:162px;white-space:nowrap" class="ft034">https://www.pubmed.ncbi.nlm.nih.gov/11077230</p>
<p style="position:absolute;top:322px;left:503px;white-space:nowrap" class="ft013">.&#160;</p>
<p style="position:absolute;top:359px;left:108px;white-space:nowrap" class="ft013">40.</p>
<p style="position:absolute;top:359px;left:130px;white-space:nowrap" class="ft046">&#160;</p>
<p style="position:absolute;top:359px;left:162px;white-space:nowrap" class="ft032">Qvarnstrom&#160;Y, Schijman&#160;AG,&#160;Veron&#160;V, Aznar C,&#160;Steurer F, da&#160;Silva&#160;AJ.&#160;Sensitive&#160;and&#160;<br/>specific detection of&#160;</p>
<p style="position:absolute;top:379px;left:306px;white-space:nowrap" class="ft019"><i>Trypanosoma cruzi</i></p>
<p style="position:absolute;top:379px;left:440px;white-space:nowrap" class="ft013">&#160;DNA in clinical specimens using a&#160;multi-target real-</p>
<p style="position:absolute;top:399px;left:162px;white-space:nowrap" class="ft013">time&#160;PCR approach.&#160;</p>
<p style="position:absolute;top:399px;left:306px;white-space:nowrap" class="ft019"><i>PLoS Negl&#160;Trop&#160;Dis</i></p>
<p style="position:absolute;top:399px;left:446px;white-space:nowrap" class="ft013">. 2012;6(7):e1689. Available&#160;at:&#160;</p>
<p style="position:absolute;top:418px;left:162px;white-space:nowrap" class="ft034">https://www.pubmed.ncbi.nlm.nih.gov/22802973</p>
<p style="position:absolute;top:418px;left:503px;white-space:nowrap" class="ft013">.&#160;</p>
<p style="position:absolute;top:455px;left:108px;white-space:nowrap" class="ft013">41.</p>
<p style="position:absolute;top:455px;left:130px;white-space:nowrap" class="ft046">&#160;</p>
<p style="position:absolute;top:455px;left:162px;white-space:nowrap" class="ft032">Mott KE,&#160;Muniz&#160;TM, Lehman JS,&#160;Jr.,&#160;et&#160;al. House&#160;construction,&#160;triatomine&#160;distribution, and&#160;<br/>household distribution of&#160;seroreactivity to&#160;</p>
<p style="position:absolute;top:475px;left:455px;white-space:nowrap" class="ft019"><i>Trypanosoma cruzi</i></p>
<p style="position:absolute;top:475px;left:589px;white-space:nowrap" class="ft013">&#160;in a rural community in&#160;</p>
<p style="position:absolute;top:495px;left:162px;white-space:nowrap" class="ft013">northeast Brazil.&#160;</p>
<p style="position:absolute;top:495px;left:280px;white-space:nowrap" class="ft019"><i>Am J Trop Med&#160;Hyg</i></p>
<p style="position:absolute;top:495px;left:421px;white-space:nowrap" class="ft013">.&#160;1978;27(6):1116-1122.&#160;Available at:&#160;</p>
<p style="position:absolute;top:515px;left:162px;white-space:nowrap" class="ft034">https://www.pubmed.ncbi.nlm.nih.gov/103445</p>
<p style="position:absolute;top:515px;left:485px;white-space:nowrap" class="ft013">.&#160;</p>
<p style="position:absolute;top:552px;left:108px;white-space:nowrap" class="ft013">42.</p>
<p style="position:absolute;top:552px;left:130px;white-space:nowrap" class="ft046">&#160;</p>
<p style="position:absolute;top:552px;left:162px;white-space:nowrap" class="ft032">Kroeger&#160;A,&#160;Villegas E, Ordonez-Gonzalez J, Pabon E, Scorza&#160;JV.&#160;Prevention of the&#160;<br/>transmission&#160;of Chagas' disease with pyrethroid-impregnated materials.&#160;</p>
<p style="position:absolute;top:572px;left:659px;white-space:nowrap" class="ft019"><i>Am J Trop&#160;Med&#160;Hyg</i></p>
<p style="position:absolute;top:572px;left:800px;white-space:nowrap" class="ft013">.&#160;</p>
<p style="position:absolute;top:592px;left:162px;white-space:nowrap" class="ft013">2003;68(3):307-311.&#160;Available&#160;at:&#160;</p>
<p style="position:absolute;top:592px;left:402px;white-space:nowrap" class="ft034">https://www.pubmed.ncbi.nlm.nih.gov/12685636</p>
<p style="position:absolute;top:592px;left:743px;white-space:nowrap" class="ft013">.&#160;</p>
<p style="position:absolute;top:629px;left:108px;white-space:nowrap" class="ft013">43.</p>
<p style="position:absolute;top:628px;left:130px;white-space:nowrap" class="ft046">&#160;</p>
<p style="position:absolute;top:629px;left:162px;white-space:nowrap" class="ft032">Perez-Molina JA, Rodriguez-Guardado A, Soriano&#160;A, et al. Guidelines on the treatment of&#160;<br/>chronic coinfection by&#160;</p>
<p style="position:absolute;top:649px;left:321px;white-space:nowrap" class="ft019"><i>Trypanosoma cruzi</i></p>
<p style="position:absolute;top:649px;left:455px;white-space:nowrap" class="ft013">&#160;and HIV&#160;outside&#160;endemic areas.&#160;</p>
<p style="position:absolute;top:649px;left:684px;white-space:nowrap" class="ft019"><i>HIV Clin Trials</i></p>
<p style="position:absolute;top:649px;left:792px;white-space:nowrap" class="ft013">.&#160;</p>
<p style="position:absolute;top:668px;left:162px;white-space:nowrap" class="ft013">2011;12(6):287-298.&#160;Available&#160;at:&#160;</p>
<p style="position:absolute;top:668px;left:402px;white-space:nowrap" class="ft034">https://www.pubmed.ncbi.nlm.nih.gov/22189148</p>
<p style="position:absolute;top:668px;left:743px;white-space:nowrap" class="ft013">.&#160;</p>
<p style="position:absolute;top:706px;left:108px;white-space:nowrap" class="ft013">44.</p>
<p style="position:absolute;top:705px;left:130px;white-space:nowrap" class="ft046">&#160;</p>
<p style="position:absolute;top:706px;left:162px;white-space:nowrap" class="ft013">Rodriques Coura J, de Castro SL.&#160;A critical&#160;review on Chagas disease chemotherapy.&#160;</p>
<p style="position:absolute;top:706px;left:755px;white-space:nowrap" class="ft019"><i>Mem&#160;</i></p>
<p style="position:absolute;top:725px;left:162px;white-space:nowrap" class="ft019"><i>Inst Oswaldo&#160;Cruz</i></p>
<p style="position:absolute;top:725px;left:291px;white-space:nowrap" class="ft013">.&#160;2002;97(1):3-24.&#160;Available at:&#160;</p>
<p style="position:absolute;top:745px;left:162px;white-space:nowrap" class="ft034">https://www.pubmed.ncbi.nlm.nih.gov/11992141</p>
<p style="position:absolute;top:745px;left:503px;white-space:nowrap" class="ft013">.&#160;</p>
<p style="position:absolute;top:782px;left:108px;white-space:nowrap" class="ft013">45.</p>
<p style="position:absolute;top:782px;left:130px;white-space:nowrap" class="ft046">&#160;</p>
<p style="position:absolute;top:782px;left:162px;white-space:nowrap" class="ft032">Perez Montilla&#160;CA, Moroni S, Moscatelli&#160;G, et al. Major benznidazole metabolites in patients&#160;<br/>treated for Chagas disease:&#160;mass spectrometry-based identification, structural&#160;analysis and&#160;<br/>detoxification pathways.&#160;</p>
<p style="position:absolute;top:822px;left:336px;white-space:nowrap" class="ft019"><i>Toxicol Lett</i></p>
<p style="position:absolute;top:822px;left:419px;white-space:nowrap" class="ft013">. 2023;377:71-82. Available at:&#160;</p>
<p style="position:absolute;top:842px;left:162px;white-space:nowrap" class="ft034">https://www.pubmed.ncbi.nlm.nih.gov/36775077</p>
<p style="position:absolute;top:842px;left:503px;white-space:nowrap" class="ft013">.&#160;</p>
<p style="position:absolute;top:879px;left:108px;white-space:nowrap" class="ft013">46.</p>
<p style="position:absolute;top:879px;left:130px;white-space:nowrap" class="ft046">&#160;</p>
<p style="position:absolute;top:879px;left:162px;white-space:nowrap" class="ft032">Bern C, Montgomery SP,&#160;Herwaldt BL, et&#160;al. Evaluation and treatment of chagas disease&#160;in&#160;<br/>the&#160;United States: a systematic review.&#160;</p>
<p style="position:absolute;top:899px;left:433px;white-space:nowrap" class="ft019"><i>JAMA</i></p>
<p style="position:absolute;top:899px;left:476px;white-space:nowrap" class="ft013">. 2007;298(18):2171-2181.&#160;Available at:&#160;</p>
<p style="position:absolute;top:919px;left:162px;white-space:nowrap" class="ft034">https://www.pubmed.ncbi.nlm.nih.gov/18000201</p>
<p style="position:absolute;top:919px;left:503px;white-space:nowrap" class="ft013">.&#160;</p>
<p style="position:absolute;top:956px;left:108px;white-space:nowrap" class="ft013">47.</p>
<p style="position:absolute;top:955px;left:130px;white-space:nowrap" class="ft046">&#160;</p>
<p style="position:absolute;top:956px;left:162px;white-space:nowrap" class="ft032">U.S.&#160;Food and Drug&#160;Administration. Benznidazole tablets [package&#160;insert]. Exeltis USA, Inc.&#160;<br/>2021. Available&#160;at:&#160;</p>
<p style="position:absolute;top:995px;left:162px;white-space:nowrap" class="ft034">https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/209570s002lbl.pdf</p>
<p style="position:absolute;top:995px;left:711px;white-space:nowrap" class="ft013">.&#160;</p>
<p style="position:absolute;top:1032px;left:108px;white-space:nowrap" class="ft013">48.</p>
<p style="position:absolute;top:1032px;left:130px;white-space:nowrap" class="ft046">&#160;</p>
<p style="position:absolute;top:1032px;left:162px;white-space:nowrap" class="ft032">Altcheh J,&#160;Moscatelli&#160;G, Mastrantonio&#160;G, et al. Population pharmacokinetic&#160;study of&#160;<br/>benznidazole in pediatric&#160;Chagas disease suggests efficacy despite&#160;lower plasma&#160;</p>
</div>
<!-- Page 74 -->
<a name="74"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page74-div" style="position:relative;width:917px;height:1187px;">
<p style="position:absolute;top:1117px;left:108px;white-space:nowrap" class="ft024"><i>Guidelines for the Prevention and Treatment&#160;of&#160;Opportunistic&#160;Infections in Adults&#160;and Adolescents&#160;With HIV&#160;</i></p>
<p style="position:absolute;top:1117px;left:784px;white-space:nowrap" class="ft024"><i>E-12&#160;</i></p>
<p style="position:absolute;top:109px;left:162px;white-space:nowrap" class="ft013">concentrations than in adults.&#160;</p>
<p style="position:absolute;top:109px;left:368px;white-space:nowrap" class="ft019"><i>PLoS Negl Trop&#160;Dis</i></p>
<p style="position:absolute;top:109px;left:509px;white-space:nowrap" class="ft013">.&#160;2014;8(5):e2907. Available&#160;at:&#160;</p>
<p style="position:absolute;top:129px;left:162px;white-space:nowrap" class="ft034">https://www.pubmed.ncbi.nlm.nih.gov/24853169</p>
<p style="position:absolute;top:129px;left:503px;white-space:nowrap" class="ft013">.&#160;</p>
<p style="position:absolute;top:166px;left:108px;white-space:nowrap" class="ft013">49.</p>
<p style="position:absolute;top:165px;left:130px;white-space:nowrap" class="ft046">&#160;</p>
<p style="position:absolute;top:166px;left:162px;white-space:nowrap" class="ft032">Abbott A,&#160;Montgomery SP, Chancey&#160;RJ. Characteristics and adverse events&#160;of patients for&#160;<br/>whom nifurtimox was&#160;released through&#160;CDC-sponsored investigational new drug program&#160;<br/>for treatment of Chagas&#160;disease—United States, 2001–2021.&#160;</p>
<p style="position:absolute;top:205px;left:584px;white-space:nowrap" class="ft019"><i>MMWR Morb&#160;Mortal Wkly&#160;Rep</i></p>
<p style="position:absolute;top:205px;left:802px;white-space:nowrap" class="ft013">.&#160;</p>
<p style="position:absolute;top:225px;left:162px;white-space:nowrap" class="ft013">2022;71(10):371-374.&#160;Available&#160;at:&#160;</p>
<p style="position:absolute;top:225px;left:411px;white-space:nowrap" class="ft034">https://www.pubmed.ncbi.nlm.nih.gov/35271563</p>
<p style="position:absolute;top:225px;left:752px;white-space:nowrap" class="ft013">.&#160;</p>
<p style="position:absolute;top:262px;left:108px;white-space:nowrap" class="ft013">50.</p>
<p style="position:absolute;top:262px;left:130px;white-space:nowrap" class="ft046">&#160;</p>
<p style="position:absolute;top:262px;left:162px;white-space:nowrap" class="ft032">Falk N, Berenstein AJ,&#160;Moscatelli&#160;G, et al. Effectiveness of&#160;nifurtimox in the&#160;treatment of&#160;<br/>Chagas disease: a long-term retrospective cohort&#160;study in children and adults.&#160;</p>
<p style="position:absolute;top:282px;left:701px;white-space:nowrap" class="ft019"><i>Antimicrob&#160;</i></p>
<p style="position:absolute;top:302px;left:162px;white-space:nowrap" class="ft019"><i>Agents Chemother</i></p>
<p style="position:absolute;top:302px;left:290px;white-space:nowrap" class="ft013">. 2022;66(5):e0202121. Available&#160;at:&#160;</p>
<p style="position:absolute;top:322px;left:162px;white-space:nowrap" class="ft034">https://www.pubmed.ncbi.nlm.nih.gov/35416710</p>
<p style="position:absolute;top:322px;left:503px;white-space:nowrap" class="ft013">.&#160;</p>
<p style="position:absolute;top:359px;left:108px;white-space:nowrap" class="ft013">51.</p>
<p style="position:absolute;top:359px;left:130px;white-space:nowrap" class="ft046">&#160;</p>
<p style="position:absolute;top:359px;left:162px;white-space:nowrap" class="ft032">U.S.&#160;Food and Drug&#160;Administration. LAMPIT (nifurtimox) tablets, for oral&#160;use [package&#160;<br/>insert]. Bayer HealthCare&#160;Pharmaceuticals Inc. 2023. Available at:&#160;</p>
<p style="position:absolute;top:399px;left:162px;white-space:nowrap" class="ft034">https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/213464s004lbl.pdf</p>
<p style="position:absolute;top:399px;left:711px;white-space:nowrap" class="ft013">.&#160;</p>
<p style="position:absolute;top:436px;left:108px;white-space:nowrap" class="ft013">52.</p>
<p style="position:absolute;top:435px;left:130px;white-space:nowrap" class="ft046">&#160;</p>
<p style="position:absolute;top:436px;left:162px;white-space:nowrap" class="ft013">Torrico F,&#160;Alonso-Vega C, Suarez E, et&#160;al. Maternal&#160;</p>
<p style="position:absolute;top:436px;left:527px;white-space:nowrap" class="ft019"><i>Trypanosoma cruzi</i></p>
<p style="position:absolute;top:436px;left:661px;white-space:nowrap" class="ft013">&#160;infection, pregnancy&#160;</p>
<p style="position:absolute;top:455px;left:162px;white-space:nowrap" class="ft032">outcome, morbidity, and mortality of congenitally infected and non-infected&#160;newborns in&#160;<br/>Bolivia.&#160;</p>
<p style="position:absolute;top:475px;left:221px;white-space:nowrap" class="ft019"><i>Am J Trop&#160;Med&#160;Hyg</i></p>
<p style="position:absolute;top:475px;left:362px;white-space:nowrap" class="ft013">. 2004;70(2):201-209. Available at:&#160;</p>
<p style="position:absolute;top:495px;left:162px;white-space:nowrap" class="ft034">https://www.pubmed.ncbi.nlm.nih.gov/14993634</p>
<p style="position:absolute;top:495px;left:503px;white-space:nowrap" class="ft013">.&#160;</p>
<p style="position:absolute;top:532px;left:108px;white-space:nowrap" class="ft013">53.</p>
<p style="position:absolute;top:532px;left:130px;white-space:nowrap" class="ft046">&#160;</p>
<p style="position:absolute;top:532px;left:162px;white-space:nowrap" class="ft032">Klein MD, Proano A,&#160;Noazin S, Sciaudone M,&#160;Gilman RH, Bowman NM.&#160;Risk factors&#160;for&#160;<br/>vertical&#160;transmission of Chagas disease:&#160;a systematic&#160;review and meta-analysis.&#160;</p>
<p style="position:absolute;top:552px;left:715px;white-space:nowrap" class="ft019"><i>Int J Infect&#160;</i></p>
<p style="position:absolute;top:572px;left:162px;white-space:nowrap" class="ft019"><i>Dis</i></p>
<p style="position:absolute;top:572px;left:186px;white-space:nowrap" class="ft013">. 2021;105:357-373.&#160;Available at:&#160;</p>
<p style="position:absolute;top:572px;left:423px;white-space:nowrap" class="ft034">https://www.pubmed.ncbi.nlm.nih.gov/33618005</p>
<p style="position:absolute;top:572px;left:764px;white-space:nowrap" class="ft013">.&#160;</p>
<p style="position:absolute;top:609px;left:108px;white-space:nowrap" class="ft013">54.</p>
<p style="position:absolute;top:609px;left:130px;white-space:nowrap" class="ft046">&#160;</p>
<p style="position:absolute;top:609px;left:162px;white-space:nowrap" class="ft013">Chancey RJ,&#160;Edwards&#160;MS, Montgomery SP. Congenital&#160;Chagas disease.&#160;</p>
<p style="position:absolute;top:609px;left:667px;white-space:nowrap" class="ft019"><i>Pediatr Rev</i></p>
<p style="position:absolute;top:609px;left:749px;white-space:nowrap" class="ft013">.&#160;</p>
<p style="position:absolute;top:629px;left:162px;white-space:nowrap" class="ft013">2023;44(4):213-221.&#160;Available&#160;at:&#160;</p>
<p style="position:absolute;top:629px;left:402px;white-space:nowrap" class="ft034">https://www.pubmed.ncbi.nlm.nih.gov/37002357</p>
<p style="position:absolute;top:629px;left:743px;white-space:nowrap" class="ft013">.&#160;</p>
<p style="position:absolute;top:666px;left:108px;white-space:nowrap" class="ft013">55.</p>
<p style="position:absolute;top:666px;left:130px;white-space:nowrap" class="ft046">&#160;</p>
<p style="position:absolute;top:666px;left:162px;white-space:nowrap" class="ft032">Scapellato PG, Bottaro EG, Rodriguez-Brieschke&#160;MT. Mother-child transmission of&#160;Chagas&#160;<br/>disease: could coinfection with human&#160;immunodeficiency virus increase the&#160;risk?&#160;</p>
<p style="position:absolute;top:686px;left:728px;white-space:nowrap" class="ft019"><i>Rev Soc&#160;</i></p>
<p style="position:absolute;top:706px;left:162px;white-space:nowrap" class="ft019"><i>Bras Med&#160;Trop</i></p>
<p style="position:absolute;top:706px;left:267px;white-space:nowrap" class="ft013">. 2009;42(2):107-109.&#160;Available at:&#160;</p>
<p style="position:absolute;top:725px;left:162px;white-space:nowrap" class="ft034">https://www.pubmed.ncbi.nlm.nih.gov/19448923</p>
<p style="position:absolute;top:725px;left:503px;white-space:nowrap" class="ft013">.&#160;</p>
<p style="position:absolute;top:762px;left:108px;white-space:nowrap" class="ft013">56.</p>
<p style="position:absolute;top:762px;left:130px;white-space:nowrap" class="ft046">&#160;</p>
<p style="position:absolute;top:762px;left:162px;white-space:nowrap" class="ft013">Freilij&#160;H, Altcheh J. Congenital Chagas' disease: diagnostic and&#160;clinical&#160;aspects.&#160;</p>
<p style="position:absolute;top:762px;left:718px;white-space:nowrap" class="ft019"><i>Clin Infect&#160;</i></p>
<p style="position:absolute;top:782px;left:162px;white-space:nowrap" class="ft019"><i>Dis</i></p>
<p style="position:absolute;top:782px;left:186px;white-space:nowrap" class="ft013">. 1995;21(3):551-555.&#160;Available at:&#160;</p>
<p style="position:absolute;top:782px;left:435px;white-space:nowrap" class="ft034">https://www.pubmed.ncbi.nlm.nih.gov/8527542</p>
<p style="position:absolute;top:782px;left:767px;white-space:nowrap" class="ft013">.&#160;</p>
<p style="position:absolute;top:819px;left:108px;white-space:nowrap" class="ft013">57.</p>
<p style="position:absolute;top:819px;left:130px;white-space:nowrap" class="ft046">&#160;</p>
<p style="position:absolute;top:819px;left:162px;white-space:nowrap" class="ft032">Freilij&#160;H, Altcheh J, Muchinik G. Perinatal human immunodeficiency virus infection and&#160;<br/>congenital Chagas'&#160;disease.&#160;</p>
<p style="position:absolute;top:839px;left:355px;white-space:nowrap" class="ft019"><i>Pediatr Infect&#160;Dis J</i></p>
<p style="position:absolute;top:839px;left:490px;white-space:nowrap" class="ft013">. 1995;14(2):161-162. Available&#160;at:&#160;</p>
<p style="position:absolute;top:859px;left:162px;white-space:nowrap" class="ft034">https://www.pubmed.ncbi.nlm.nih.gov/7746707</p>
<p style="position:absolute;top:859px;left:494px;white-space:nowrap" class="ft013">.&#160;</p>
<p style="position:absolute;top:896px;left:108px;white-space:nowrap" class="ft013">58.</p>
<p style="position:absolute;top:896px;left:130px;white-space:nowrap" class="ft046">&#160;</p>
<p style="position:absolute;top:896px;left:162px;white-space:nowrap" class="ft032">Gorla NB, Ledesma OS,&#160;Barbieri&#160;GP,&#160;Larripa IB.&#160;Assessment&#160;of cytogenetic&#160;damage in&#160;<br/>chagasic children treated with benznidazole.&#160;</p>
<p style="position:absolute;top:916px;left:472px;white-space:nowrap" class="ft019"><i>Mutat Res</i></p>
<p style="position:absolute;top:916px;left:542px;white-space:nowrap" class="ft013">. 1988;206(2):217-220. Available at:&#160;</p>
<p style="position:absolute;top:936px;left:162px;white-space:nowrap" class="ft034">https://www.pubmed.ncbi.nlm.nih.gov/3140001</p>
<p style="position:absolute;top:936px;left:494px;white-space:nowrap" class="ft013">.&#160;</p>
<p style="position:absolute;top:973px;left:108px;white-space:nowrap" class="ft013">59.</p>
<p style="position:absolute;top:973px;left:130px;white-space:nowrap" class="ft046">&#160;</p>
<p style="position:absolute;top:973px;left:162px;white-space:nowrap" class="ft032">Gorla NB, Ledesma OS,&#160;Barbieri&#160;GP,&#160;Larripa IB. Thirteenfold increase of chromosomal&#160;<br/>aberrations non-randomly&#160;distributed in chagasic&#160;children treated with nifurtimox.&#160;</p>
<p style="position:absolute;top:993px;left:733px;white-space:nowrap" class="ft019"><i>Mutat&#160;Res</i></p>
<p style="position:absolute;top:993px;left:804px;white-space:nowrap" class="ft013">.&#160;</p>
<p style="position:absolute;top:1013px;left:162px;white-space:nowrap" class="ft013">1989;224(2):263-267.&#160;Available&#160;at:&#160;</p>
<p style="position:absolute;top:1013px;left:411px;white-space:nowrap" class="ft034">https://www.pubmed.ncbi.nlm.nih.gov/2507913</p>
<p style="position:absolute;top:1013px;left:743px;white-space:nowrap" class="ft013">.&#160;</p>
</div>
<!-- Page 75 -->
<a name="75"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page75-div" style="position:relative;width:917px;height:1187px;">
<p style="position:absolute;top:1117px;left:108px;white-space:nowrap" class="ft024"><i>Guidelines for the Prevention and Treatment&#160;of&#160;Opportunistic&#160;Infections in Adults&#160;and Adolescents&#160;With HIV&#160;</i></p>
<p style="position:absolute;top:1117px;left:784px;white-space:nowrap" class="ft024"><i>E-13&#160;</i></p>
<p style="position:absolute;top:109px;left:108px;white-space:nowrap" class="ft013">60.</p>
<p style="position:absolute;top:108px;left:130px;white-space:nowrap" class="ft046">&#160;</p>
<p style="position:absolute;top:109px;left:162px;white-space:nowrap" class="ft032">de Toranzo&#160;EG, Masana&#160;M, Castro&#160;JA. Administration of benznidazole, a chemotherapeutic&#160;<br/>agent&#160;against Chagas disease, to pregnant&#160;rats. Covalent binding of reactive&#160;metabolites to&#160;<br/>fetal&#160;and maternal&#160;proteins.&#160;</p>
<p style="position:absolute;top:148px;left:355px;white-space:nowrap" class="ft019"><i>Arch Int&#160;Pharmacodyn&#160;Ther</i></p>
<p style="position:absolute;top:148px;left:550px;white-space:nowrap" class="ft013">. 1984;272(1):17-23.&#160;Available at:&#160;</p>
<p style="position:absolute;top:168px;left:162px;white-space:nowrap" class="ft034">https://www.pubmed.ncbi.nlm.nih.gov/6440493</p>
<p style="position:absolute;top:168px;left:494px;white-space:nowrap" class="ft013">.&#160;</p>
<p style="position:absolute;top:205px;left:108px;white-space:nowrap" class="ft013">61.</p>
<p style="position:absolute;top:205px;left:130px;white-space:nowrap" class="ft046">&#160;</p>
<p style="position:absolute;top:205px;left:162px;white-space:nowrap" class="ft032">Correa VR,&#160;Barbosa FG,&#160;Melo Junior&#160;CA,&#160;D'Albuquerque e&#160;Castro LF, Andrade Junior&#160;HF,&#160;<br/>Nascimento&#160;N. Uneventful benznidazole treatment of acute&#160;Chagas disease during&#160;<br/>pregnancy: a&#160;case report.&#160;</p>
<p style="position:absolute;top:245px;left:339px;white-space:nowrap" class="ft019"><i>Rev&#160;Soc Bras&#160;Med Trop</i></p>
<p style="position:absolute;top:245px;left:503px;white-space:nowrap" class="ft013">. 2014;47(3):397-400.&#160;Available at:&#160;</p>
<p style="position:absolute;top:265px;left:162px;white-space:nowrap" class="ft034">https://www.pubmed.ncbi.nlm.nih.gov/25075496</p>
<p style="position:absolute;top:265px;left:503px;white-space:nowrap" class="ft013">.&#160;</p>
<p style="position:absolute;top:302px;left:108px;white-space:nowrap" class="ft013">62.</p>
<p style="position:absolute;top:302px;left:130px;white-space:nowrap" class="ft046">&#160;</p>
<p style="position:absolute;top:302px;left:162px;white-space:nowrap" class="ft032">Bisio M,&#160;Altcheh J, Lattner J, et al. Benznidazole treatment of chagasic encephalitis in&#160;<br/>pregnant&#160;woman with AIDS.&#160;</p>
<p style="position:absolute;top:322px;left:366px;white-space:nowrap" class="ft019"><i>Emerg Infect&#160;Dis</i></p>
<p style="position:absolute;top:322px;left:483px;white-space:nowrap" class="ft013">. 2013;19(9):1490-1492.&#160;Available&#160;at:&#160;</p>
<p style="position:absolute;top:342px;left:162px;white-space:nowrap" class="ft034">https://www.pubmed.ncbi.nlm.nih.gov/23965334</p>
<p style="position:absolute;top:342px;left:503px;white-space:nowrap" class="ft013">.&#160;</p>
<p style="position:absolute;top:379px;left:108px;white-space:nowrap" class="ft013">63.</p>
<p style="position:absolute;top:378px;left:130px;white-space:nowrap" class="ft046">&#160;</p>
<p style="position:absolute;top:379px;left:162px;white-space:nowrap" class="ft032">Oliveira&#160;I, Torrico F,&#160;Munoz J,&#160;Gascon J. Congenital transmission of Chagas&#160;disease:&#160;a&#160;<br/>clinical&#160;approach.&#160;</p>
<p style="position:absolute;top:399px;left:289px;white-space:nowrap" class="ft019"><i>Expert&#160;Rev&#160;Anti Infect&#160;Ther</i></p>
<p style="position:absolute;top:399px;left:478px;white-space:nowrap" class="ft013">. 2010;8(8):945-956. Available at:&#160;</p>
<p style="position:absolute;top:418px;left:162px;white-space:nowrap" class="ft034">https://www.pubmed.ncbi.nlm.nih.gov/20695749</p>
<p style="position:absolute;top:418px;left:503px;white-space:nowrap" class="ft013">.&#160;</p>
<p style="position:absolute;top:455px;left:108px;white-space:nowrap" class="ft013">64.</p>
<p style="position:absolute;top:455px;left:130px;white-space:nowrap" class="ft046">&#160;</p>
<p style="position:absolute;top:455px;left:162px;white-space:nowrap" class="ft032">Edwards&#160;MS, Stimpert&#160;KK, Bialek SR, Montgomery SP. Evaluation and management of&#160;<br/>congenital Chagas disease in the&#160;United States.&#160;</p>
<p style="position:absolute;top:475px;left:491px;white-space:nowrap" class="ft019"><i>J&#160;Pediatric Infect&#160;Dis Soc</i></p>
<p style="position:absolute;top:475px;left:668px;white-space:nowrap" class="ft013">.&#160;2019;8(5):461-</p>
<p style="position:absolute;top:495px;left:162px;white-space:nowrap" class="ft013">469. Available&#160;at:&#160;</p>
<p style="position:absolute;top:495px;left:289px;white-space:nowrap" class="ft034">https://www.pubmed.ncbi.nlm.nih.gov/31016324</p>
<p style="position:absolute;top:495px;left:630px;white-space:nowrap" class="ft013">.&#160;</p>
</div>
<!-- Page 76 -->
<a name="76"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}	.ft095{font-size:17px;font-family:BTLIFY+Tinos;color:#ff0000;}
-->
</style>
<div id="page76-div" style="position:relative;width:917px;height:1187px;">
<p style="position:absolute;top:1128px;left:108px;white-space:nowrap" class="ft024"><i>Guidelines for the Prevention and Treatment&#160;of&#160;Opportunistic&#160;Infections in Adults&#160;and Adolescents&#160;With HIV&#160;</i></p>
<p style="position:absolute;top:1128px;left:791px;white-space:nowrap" class="ft024"><i>F-1</i></p>
<p style="position:absolute;top:112px;left:108px;white-space:nowrap" class="ft025"><b>Coccidioidomycosis&#160;</b></p>
<p style="position:absolute;top:159px;left:108px;white-space:nowrap" class="ft035"><b>Updated:</b></p>
<p style="position:absolute;top:159px;left:172px;white-space:nowrap" class="ft036">&#160;October&#160;29,&#160;2024&#160;</p>
<p style="position:absolute;top:180px;left:108px;white-space:nowrap" class="ft035"><b>Reviewed:</b></p>
<p style="position:absolute;top:180px;left:181px;white-space:nowrap" class="ft036">&#160;</p>
<p style="position:absolute;top:180px;left:185px;white-space:nowrap" class="ft037">January 8, 2025</p>
<p style="position:absolute;top:180px;left:291px;white-space:nowrap" class="ft036">&#160;</p>
<p style="position:absolute;top:218px;left:108px;white-space:nowrap" class="ft026"><b>Epidemiology&#160;</b></p>
<p style="position:absolute;top:260px;left:108px;white-space:nowrap" class="ft013">Coccidioidomycosis is caused by either of two&#160;soil-dwelling dimorphic fungi:&#160;</p>
<p style="position:absolute;top:260px;left:650px;white-space:nowrap" class="ft019"><i>Coccidioides&#160;immitis</i></p>
<p style="position:absolute;top:260px;left:795px;white-space:nowrap" class="ft013">&#160;</p>
<p style="position:absolute;top:280px;left:108px;white-space:nowrap" class="ft013">and&#160;</p>
<p style="position:absolute;top:280px;left:137px;white-space:nowrap" class="ft019"><i>Coccidioides posadasii</i></p>
<p style="position:absolute;top:280px;left:298px;white-space:nowrap" class="ft013">. Most cases of coccidioidomycosis in people with HIV&#160;have&#160;been&#160;</p>
<p style="position:absolute;top:299px;left:108px;white-space:nowrap" class="ft013">reported in the&#160;areas in which the&#160;disease is highly&#160;endemic.</p>
<p style="position:absolute;top:298px;left:523px;white-space:nowrap" class="ft038">1</p>
<p style="position:absolute;top:299px;left:529px;white-space:nowrap" class="ft013">&#160;Cases also may&#160;be identified outside of&#160;</p>
<p style="position:absolute;top:319px;left:108px;white-space:nowrap" class="ft032">these areas when a person&#160;gives a history of having traveled through an endemic&#160;region. In&#160;the&#160;<br/>United States, the endemic areas include&#160;the&#160;lower&#160;San Joaquin&#160;Valley and other arid regions in&#160;<br/>California;&#160;much of Arizona;&#160;the&#160;southern regions&#160;of Utah,&#160;Nevada, and New Mexico;&#160;and western&#160;<br/>Texas and Northern Mexico.</p>
<p style="position:absolute;top:377px;left:306px;white-space:nowrap" class="ft038">2</p>
<p style="position:absolute;top:379px;left:312px;white-space:nowrap" class="ft013">&#160;Several&#160;cases of coccidioidomycosis in individuals who acquired the&#160;</p>
<p style="position:absolute;top:399px;left:108px;white-space:nowrap" class="ft013">infection in eastern Washington state&#160;have been reported and phylogenetically linked to local&#160;</p>
<p style="position:absolute;top:418px;left:108px;white-space:nowrap" class="ft019"><i>Coccidioides immitis&#160;</i></p>
<p style="position:absolute;top:418px;left:257px;white-space:nowrap" class="ft013">isolates in nature.</p>
<p style="position:absolute;top:417px;left:379px;white-space:nowrap" class="ft038">2</p>
<p style="position:absolute;top:418px;left:384px;white-space:nowrap" class="ft013">&#160;These observations and&#160;others suggest that&#160;the&#160;coccidioidal&#160;</p>
<p style="position:absolute;top:438px;left:108px;white-space:nowrap" class="ft013">endemic range may be&#160;expanding outside&#160;the&#160;traditional&#160;endemic range.&#160;</p>
<p style="position:absolute;top:475px;left:108px;white-space:nowrap" class="ft032">The&#160;risk of developing symptomatic coccidioidomycosis after infection is increased in people with&#160;<br/>HIV who&#160;have CD4 T lymphocyte&#160;(CD4) cell counts&#160;&lt;250 cells/mm</p>
<p style="position:absolute;top:494px;left:581px;white-space:nowrap" class="ft038">3</p>
<p style="position:absolute;top:495px;left:587px;white-space:nowrap" class="ft013">&#160;and&#160;who are not&#160;virologically&#160;</p>
<p style="position:absolute;top:515px;left:108px;white-space:nowrap" class="ft013">suppressed.</p>
<p style="position:absolute;top:514px;left:188px;white-space:nowrap" class="ft038">3,4</p>
<p style="position:absolute;top:515px;left:202px;white-space:nowrap" class="ft013">&#160;The&#160;incidence&#160;and severity of HIV-associated coccidioidomycosis have declined since&#160;</p>
<p style="position:absolute;top:535px;left:108px;white-space:nowrap" class="ft013">the&#160;introduction of effective&#160;antiretroviral&#160;therapy (ART).</p>
<p style="position:absolute;top:533px;left:506px;white-space:nowrap" class="ft038">3,5</p>
<p style="position:absolute;top:535px;left:520px;white-space:nowrap" class="ft013">&#160;</p>
<p style="position:absolute;top:571px;left:108px;white-space:nowrap" class="ft026"><b>Clinical Manifestations&#160;</b></p>
<p style="position:absolute;top:613px;left:108px;white-space:nowrap" class="ft032">Four common clinical&#160;syndromes of coccidioidomycosis have been described:&#160;focal pneumonia;&#160;<br/>diffuse pneumonia;&#160;extrathoracic&#160;involvement, including meningitis, osteoarticular infection, and&#160;<br/>other extrathoracic sites; and positive&#160;coccidioidal serology tests without evidence of localized&#160;<br/>infection.</p>
<p style="position:absolute;top:671px;left:174px;white-space:nowrap" class="ft038">6</p>
<p style="position:absolute;top:673px;left:179px;white-space:nowrap" class="ft013">&#160;In&#160;people with&#160;HIV,&#160;lack of&#160;viral suppression and CD4 count&#160;&lt;250&#160;cells/mm</p>
<p style="position:absolute;top:671px;left:712px;white-space:nowrap" class="ft038">3</p>
<p style="position:absolute;top:673px;left:718px;white-space:nowrap" class="ft013">&#160;are&#160;</p>
<p style="position:absolute;top:693px;left:108px;white-space:nowrap" class="ft013">associated with increased severity of the presentation of coccidioidomycosis.</p>
<p style="position:absolute;top:691px;left:639px;white-space:nowrap" class="ft038">7</p>
<p style="position:absolute;top:693px;left:645px;white-space:nowrap" class="ft012"><b>&#160;</b></p>
<p style="position:absolute;top:693px;left:652px;white-space:nowrap" class="ft095"><b>&#160;</b></p>
<p style="position:absolute;top:730px;left:108px;white-space:nowrap" class="ft018">Focal&#160;pneumonia&#160;is most&#160;common in people with CD4 counts&#160;</p>
<p style="position:absolute;top:730px;left:539px;white-space:nowrap" class="ft069">≥</p>
<p style="position:absolute;top:730px;left:548px;white-space:nowrap" class="ft018">250 cells/mm</p>
<p style="position:absolute;top:728px;left:642px;white-space:nowrap" class="ft038">3</p>
<p style="position:absolute;top:730px;left:648px;white-space:nowrap" class="ft013">. Focal&#160;pneumonia&#160;can&#160;</p>
<p style="position:absolute;top:750px;left:108px;white-space:nowrap" class="ft032">be difficult&#160;to distinguish&#160;from bacterial&#160;or viral community-acquired pneumonia; patients&#160;present&#160;<br/>with symptoms that&#160;include&#160;cough, fever, and pleuritic&#160;chest pain.</p>
<p style="position:absolute;top:768px;left:563px;white-space:nowrap" class="ft038">7,8</p>
<p style="position:absolute;top:769px;left:577px;white-space:nowrap" class="ft013">&#160;However, symptoms such as&#160;</p>
<p style="position:absolute;top:789px;left:108px;white-space:nowrap" class="ft032">hilar or mediastinal&#160;adenopathy, upper&#160;lobe&#160;infiltrates, nodules,&#160;peripheral&#160;blood eosinophilia, or&#160;<br/>rash—all&#160;of&#160;which are&#160;uncommon in bacterial pneumonia—may point&#160;towards coccidioidomycosis,&#160;<br/>particularly in patients who reside&#160;in, previously resided in, or have traveled to a&#160;known endemic&#160;<br/>area.&#160;</p>
<p style="position:absolute;top:886px;left:108px;white-space:nowrap" class="ft032">Diffuse pneumonia and extrathoracic&#160;disease usually occur in more apparently immunocompromised&#160;<br/>patients. Diffuse pulmonary disease presents with fever and dyspnea with a&#160;diffuse reticulonodular&#160;<br/>pattern on chest imaging, and in some&#160;instances may be&#160;difficult to distinguish clinically from&#160;</p>
<p style="position:absolute;top:945px;left:108px;white-space:nowrap" class="ft019"><i>Pneumocystis</i></p>
<p style="position:absolute;top:945px;left:203px;white-space:nowrap" class="ft013">&#160;pneumonia.</p>
<p style="position:absolute;top:944px;left:288px;white-space:nowrap" class="ft038">9</p>
<p style="position:absolute;top:945px;left:294px;white-space:nowrap" class="ft013">&#160;Hypoxemia&#160;may be severe. Furthermore, serological tests&#160;may be&#160;</p>
<p style="position:absolute;top:965px;left:108px;white-space:nowrap" class="ft013">negative&#160;at&#160;early presentation of infection.&#160;</p>
<p style="position:absolute;top:1002px;left:108px;white-space:nowrap" class="ft032">Patients with meningitis present with a&#160;persistent headache and progressive lethargy. The&#160;<br/>cerebrospinal fluid (CSF)&#160;profile in meningitis demonstrates low glucose levels, elevated protein&#160;<br/>levels, and a lymphocytic&#160;pleocytosis.&#160;Eosinophils&#160;may also be&#160;present&#160;on CSF&#160;analysis.&#160;</p>
</div>
<!-- Page 77 -->
<a name="77"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page77-div" style="position:relative;width:917px;height:1187px;">
<p style="position:absolute;top:1128px;left:108px;white-space:nowrap" class="ft024"><i>Guidelines for the Prevention and Treatment&#160;of&#160;Opportunistic&#160;Infections in Adults&#160;and Adolescents&#160;With HIV&#160;</i></p>
<p style="position:absolute;top:1128px;left:791px;white-space:nowrap" class="ft024"><i>F-2&#160;</i></p>
<p style="position:absolute;top:109px;left:108px;white-space:nowrap" class="ft032">Elevated coccidioidal&#160;antibody titers even without&#160;symptoms can indicate risk of subsequent&#160;<br/>symptomatic&#160;diseases&#160;in people with HIV and advanced immunosuppression&#160;when CD4 count&#160;<br/>decreases to&#160;10 cells/mm</p>
<p style="position:absolute;top:147px;left:281px;white-space:nowrap" class="ft038">3</p>
<p style="position:absolute;top:148px;left:287px;white-space:nowrap" class="ft013">&#160;or less.</p>
<p style="position:absolute;top:147px;left:340px;white-space:nowrap" class="ft038">10</p>
<p style="position:absolute;top:185px;left:108px;white-space:nowrap" class="ft026"><b>Diagnosis&#160;</b></p>
<p style="position:absolute;top:227px;left:108px;white-space:nowrap" class="ft032">The&#160;diagnosis of coccidioidomycosis is based on serology, histology, culture,&#160;and clinical&#160;<br/>presentation. Culture of the organism&#160;from clinical&#160;specimens or by demonstration of typical&#160;<br/>spherules on&#160;histopathological&#160;examination of infected tissue—such as sputum, bronchoalveolar&#160;<br/>lavage fluid, joint&#160;aspirate, or tissue biopsy—proves the diagnosis. Positive blood cultures&#160;are rare&#160;<br/>and usually found only in&#160;those with diffuse pulmonary disease.&#160;CSF cultures&#160;are positive&#160;in fewer&#160;<br/>than one-third of patients&#160;with coccidioidal meningitis.&#160;</p>
<p style="position:absolute;top:363px;left:108px;white-space:nowrap" class="ft013">Unlike&#160;other&#160;endemic&#160;fungi,&#160;</p>
<p style="position:absolute;top:363px;left:307px;white-space:nowrap" class="ft019"><i>Coccidioides</i></p>
<p style="position:absolute;top:363px;left:397px;white-space:nowrap" class="ft013">&#160;species grow relatively rapidly at 37°C on routine bacterial&#160;</p>
<p style="position:absolute;top:383px;left:108px;white-space:nowrap" class="ft032">media, especially blood agar. Growth&#160;of a nonpigmented mold may be observed in as few&#160;as 3 to&#160;<br/>7 days.&#160;</p>
<p style="position:absolute;top:403px;left:161px;white-space:nowrap" class="ft019"><i>Coccidioides</i></p>
<p style="position:absolute;top:403px;left:251px;white-space:nowrap" class="ft013">&#160;growth on an agar plate is a significant laboratory biosafety hazard because of&#160;</p>
<p style="position:absolute;top:423px;left:108px;white-space:nowrap" class="ft032">the&#160;risk of inhalation of dislodged arthroconidia. When a&#160;specimen is sent for&#160;culture, laboratory&#160;<br/>personnel&#160;should be alerted to the possibility of suspected coccidioidomycosis; in the&#160;laboratory, the&#160;<br/>culture&#160;plate&#160;lid should be&#160;kept&#160;secured&#160;with tape.</p>
<p style="position:absolute;top:461px;left:450px;white-space:nowrap" class="ft038">11</p>
<p style="position:absolute;top:462px;left:462px;white-space:nowrap" class="ft013">&#160;Identification of the&#160;fungus should be&#160;performed&#160;</p>
<p style="position:absolute;top:482px;left:108px;white-space:nowrap" class="ft013">only in a biosafety level&#160;3 or 2+ containment&#160;laboratory. &#160; &#160;&#160;</p>
<p style="position:absolute;top:482px;left:518px;white-space:nowrap" class="ft012"><b>&#160;</b></p>
<p style="position:absolute;top:519px;left:108px;white-space:nowrap" class="ft032">Most commonly, the diagnosis of coccidioidomycosis is based on a positive&#160;coccidioidal serological&#160;<br/>test and a&#160;compatible&#160;clinical&#160;syndrome. However,&#160;it&#160;may take several weeks&#160;for antibodies to&#160;<br/>develop in normal hosts and probably longer in immunocompromised hosts.&#160;Negative serology&#160;<br/>cannot&#160;be used to rule&#160;out disease, and&#160;therefore, tissue biopsy&#160;may be necessary. Repeat&#160;testing&#160;<br/>every 1 to 2&#160;weeks&#160;should be considered if the&#160;patient&#160;is ill and the&#160;diagnosis&#160;has not been&#160;<br/>established.&#160;</p>
<p style="position:absolute;top:655px;left:108px;white-space:nowrap" class="ft032">On the other&#160;hand, patients with past coccidioidal infection and without&#160;disease activity usually&#160;<br/>revert&#160;to negative&#160;serological&#160;tests over 1 to 2 years. Thus, screening with an&#160;enzyme&#160;<br/>immunoassay (EIA)&#160;for immunoglobulin M (IgM)&#160;and immunoglobulin G (IgG) antibody&#160;is&#160;<br/>recommended to detect the possibility of active&#160;disease. The EIA&#160;has a rapid turnaround time&#160;and is&#160;<br/>available&#160;in&#160;many clinical&#160;laboratories. These tests&#160;are very sensitive&#160;but occasionally have been&#160;<br/>associated with false positive results, particularly for IgM.</p>
<p style="position:absolute;top:753px;left:510px;white-space:nowrap" class="ft038">12</p>
<p style="position:absolute;top:755px;left:521px;white-space:nowrap" class="ft013">&#160;If either EIA test is positive, antibody&#160;</p>
<p style="position:absolute;top:774px;left:108px;white-space:nowrap" class="ft032">assays&#160;by immunodiffusion (ID) and&#160;by complement&#160;fixation (CF) should be obtained to confirm the&#160;<br/>result&#160;and be&#160;used for&#160;further follow-up&#160;</p>
<p style="position:absolute;top:794px;left:384px;white-space:nowrap" class="ft012"><b>(AI).</b></p>
<p style="position:absolute;top:794px;left:419px;white-space:nowrap" class="ft013">&#160;In cases of EIA positivity with negative&#160;ID,&#160;the&#160;clinical&#160;</p>
<p style="position:absolute;top:814px;left:108px;white-space:nowrap" class="ft032">context&#160;needs to be&#160;carefully considered, as well&#160;as&#160;the&#160;value&#160;of further diagnostic&#160;workup. CF has&#160;<br/>been particularly useful in&#160;cerebrospinal&#160;fluid. A&#160;lateral flow assay has become available, but it is far&#160;<br/>less&#160;sensitive than EIA.</p>
<p style="position:absolute;top:852px;left:270px;white-space:nowrap" class="ft038">13</p>
<p style="position:absolute;top:854px;left:281px;white-space:nowrap" class="ft013">&#160;</p>
<p style="position:absolute;top:891px;left:108px;white-space:nowrap" class="ft032">A coccidioidomycosis-specific&#160;antigen assay is commercially available. It&#160;has been shown to detect&#160;<br/>antigen in urine,</p>
<p style="position:absolute;top:909px;left:221px;white-space:nowrap" class="ft038">14</p>
<p style="position:absolute;top:911px;left:232px;white-space:nowrap" class="ft013">&#160;serum,</p>
<p style="position:absolute;top:909px;left:283px;white-space:nowrap" class="ft038">15</p>
<p style="position:absolute;top:911px;left:294px;white-space:nowrap" class="ft013">&#160;and other body fluids,&#160;such as CSF,</p>
<p style="position:absolute;top:909px;left:544px;white-space:nowrap" class="ft038">16,17</p>
<p style="position:absolute;top:911px;left:569px;white-space:nowrap" class="ft013">&#160;in&#160;samples from individuals with&#160;</p>
<p style="position:absolute;top:931px;left:108px;white-space:nowrap" class="ft013">active&#160;coccidioidomycosis.</p>
<p style="position:absolute;top:929px;left:295px;white-space:nowrap" class="ft038">18</p>
<p style="position:absolute;top:931px;left:306px;white-space:nowrap" class="ft013">&#160;The&#160;assay&#160;is most useful in diagnosing disseminated&#160;</p>
<p style="position:absolute;top:950px;left:108px;white-space:nowrap" class="ft032">coccidioidomycosis.&#160;Detection of coccidioidal antigen in CSF&#160;has been reported to have a very high&#160;<br/>sensitivity and specificity for diagnosing coccidioidal meningitis, but assessing therapeutic responses&#160;<br/>with this method is more&#160;difficult.</p>
<p style="position:absolute;top:989px;left:344px;white-space:nowrap" class="ft038">19</p>
<p style="position:absolute;top:990px;left:355px;white-space:nowrap" class="ft013">&#160;</p>
<p style="position:absolute;top:1027px;left:108px;white-space:nowrap" class="ft032">In addition, real-time polymerase chain reaction (RT-PCR) testing, if available, can be&#160;used on&#160;<br/>unfixed clinical specimens and on formalin-fixed tissue to aid in the&#160;diagnosis of&#160;</p>
</div>
<!-- Page 78 -->
<a name="78"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page78-div" style="position:relative;width:917px;height:1187px;">
<p style="position:absolute;top:1128px;left:108px;white-space:nowrap" class="ft024"><i>Guidelines for the Prevention and Treatment&#160;of&#160;Opportunistic&#160;Infections in Adults&#160;and Adolescents&#160;With HIV&#160;</i></p>
<p style="position:absolute;top:1128px;left:791px;white-space:nowrap" class="ft024"><i>F-3&#160;</i></p>
<p style="position:absolute;top:109px;left:108px;white-space:nowrap" class="ft013">coccidioidomycosis.&#160;A&#160;</p>
<p style="position:absolute;top:109px;left:270px;white-space:nowrap" class="ft019"><i>Coccidioides</i></p>
<p style="position:absolute;top:109px;left:360px;white-space:nowrap" class="ft013">&#160;RT-PCR assay is commercially available, but it has neither been&#160;</p>
<p style="position:absolute;top:129px;left:108px;white-space:nowrap" class="ft013">U.S.&#160;Food and Drug&#160;Administration–approved nor tested in people with HIV.</p>
<p style="position:absolute;top:127px;left:643px;white-space:nowrap" class="ft038">20</p>
<p style="position:absolute;top:129px;left:654px;white-space:nowrap" class="ft013">&#160;&#160;</p>
<p style="position:absolute;top:165px;left:108px;white-space:nowrap" class="ft026"><b>Preventing&#160;Exposure&#160;</b></p>
<p style="position:absolute;top:207px;left:108px;white-space:nowrap" class="ft013">People with&#160;HIV&#160;living in or visiting&#160;areas in which&#160;</p>
<p style="position:absolute;top:207px;left:470px;white-space:nowrap" class="ft019"><i>Coccidioides</i></p>
<p style="position:absolute;top:207px;left:560px;white-space:nowrap" class="ft013">&#160;spp. are endemic&#160;cannot avoid&#160;</p>
<p style="position:absolute;top:227px;left:108px;white-space:nowrap" class="ft032">exposure to the fungus. They should,&#160;however, avoid extensive exposure to&#160;disturbed native&#160;soil,&#160;<br/>such as at building excavation sites, without wearing proper&#160;N95&#160;masks.&#160;Furthermore, in endemic&#160;<br/>areas, they should stay inside during dust storms&#160;</p>
<p style="position:absolute;top:266px;left:447px;white-space:nowrap" class="ft012"><b>(BIII),&#160;</b></p>
<p style="position:absolute;top:266px;left:498px;white-space:nowrap" class="ft013">although the&#160;exact risk remains&#160;</p>
<p style="position:absolute;top:286px;left:108px;white-space:nowrap" class="ft013">controversial.</p>
<p style="position:absolute;top:285px;left:202px;white-space:nowrap" class="ft038">21-23</p>
<p style="position:absolute;top:286px;left:229px;white-space:nowrap" class="ft013">&#160;However, no evidence&#160;indicates that&#160;gardening in cultivated soil&#160;in a&#160;coccidioidal&#160;</p>
<p style="position:absolute;top:306px;left:108px;white-space:nowrap" class="ft013">endemic&#160;region increases&#160;the&#160;risk of acquiring coccidioidomycosis.&#160;</p>
<p style="position:absolute;top:343px;left:108px;white-space:nowrap" class="ft026"><b>Preventing&#160;Disease&#160;</b></p>
<p style="position:absolute;top:394px;left:352px;white-space:nowrap" class="ft02"><b>Preventing&#160;Coccidioidomycosis&#160;</b></p>
<p style="position:absolute;top:423px;left:116px;white-space:nowrap" class="ft041">Yearly or&#160;twice-yearly serological&#160;testing for&#160;coccidioidomycosis&#160;should be&#160;considered for&#160;serologically negative individuals&#160;</p>
<p style="position:absolute;top:440px;left:116px;white-space:nowrap" class="ft041">with&#160;HIV who&#160;live&#160;in&#160;endemic&#160;areas</p>
<p style="position:absolute;top:440px;left:311px;white-space:nowrap" class="ft042"><b>(BIII).</b></p>
<p style="position:absolute;top:473px;left:116px;white-space:nowrap" class="ft041">Primary&#160;antifungal&#160;prophylaxis or&#160;pre-emptive therapy&#160;</p>
<p style="position:absolute;top:473px;left:412px;white-space:nowrap" class="ft042"><b>is</b></p>
<p style="position:absolute;top:473px;left:422px;white-space:nowrap" class="ft041">&#160;</p>
<p style="position:absolute;top:473px;left:425px;white-space:nowrap" class="ft042"><b>not recommended&#160;</b></p>
<p style="position:absolute;top:473px;left:535px;white-space:nowrap" class="ft041">for&#160;individuals&#160;with&#160;HIV&#160;and&#160;low CD4 counts&#160;</p>
<p style="position:absolute;top:490px;left:116px;white-space:nowrap" class="ft041">who live in endemic areas&#160;and&#160;who have negative serologic&#160;tests&#160;for&#160;</p>
<p style="position:absolute;top:490px;left:491px;white-space:nowrap" class="ft024"><i>Coccidioides&#160;</i></p>
<p style="position:absolute;top:490px;left:564px;white-space:nowrap" class="ft042"><b>(AIII).&#160;</b></p>
<p style="position:absolute;top:490px;left:598px;white-space:nowrap" class="ft041">&#160;</p>
<p style="position:absolute;top:522px;left:116px;white-space:nowrap" class="ft042"><b>Indications for Primary&#160;Prophylaxis/Pre-Emptive Therapy&#160;(AIII):&#160;</b></p>
<p style="position:absolute;top:549px;left:116px;white-space:nowrap" class="ft030">•</p>
<p style="position:absolute;top:550px;left:123px;white-space:nowrap" class="ft057">&#160;</p>
<p style="position:absolute;top:550px;left:133px;white-space:nowrap" class="ft041">Previously&#160;tested negative and with a&#160;new positive IgM or IgG test for&#160;</p>
<p style="position:absolute;top:550px;left:513px;white-space:nowrap" class="ft024"><i>Coccidioides</i></p>
<p style="position:absolute;top:550px;left:582px;white-space:nowrap" class="ft041">,&#160;</p>
<p style="position:absolute;top:550px;left:589px;white-space:nowrap" class="ft024"><i>and</i></p>
<p style="position:absolute;top:550px;left:610px;white-space:nowrap" class="ft041">&#160;</p>
<p style="position:absolute;top:576px;left:116px;white-space:nowrap" class="ft030">•</p>
<p style="position:absolute;top:577px;left:123px;white-space:nowrap" class="ft057">&#160;</p>
<p style="position:absolute;top:577px;left:133px;white-space:nowrap" class="ft041">No signs,&#160;symptoms, or laboratory&#160;abnormalities compatible with active&#160;coccidioidomycosis,&#160;</p>
<p style="position:absolute;top:577px;left:635px;white-space:nowrap" class="ft024"><i>and</i></p>
<p style="position:absolute;top:577px;left:656px;white-space:nowrap" class="ft041">&#160;</p>
<p style="position:absolute;top:603px;left:117px;white-space:nowrap" class="ft030">•</p>
<p style="position:absolute;top:605px;left:123px;white-space:nowrap" class="ft057">&#160;</p>
<p style="position:absolute;top:604px;left:133px;white-space:nowrap" class="ft041">CD4 count&#160;&lt;250&#160;cells/mm</p>
<p style="position:absolute;top:605px;left:274px;white-space:nowrap" class="ft058">3</p>
<p style="position:absolute;top:604px;left:278px;white-space:nowrap" class="ft041">&#160;</p>
<p style="position:absolute;top:636px;left:116px;white-space:nowrap" class="ft042"><b>Preferred Therapy&#160;</b></p>
<p style="position:absolute;top:663px;left:116px;white-space:nowrap" class="ft030">•</p>
<p style="position:absolute;top:664px;left:123px;white-space:nowrap" class="ft057">&#160;</p>
<p style="position:absolute;top:664px;left:133px;white-space:nowrap" class="ft041">Fluconazole&#160;400&#160;mg&#160;PO once daily&#160;</p>
<p style="position:absolute;top:664px;left:327px;white-space:nowrap" class="ft042"><b>(AIII)</b></p>
<p style="position:absolute;top:664px;left:354px;white-space:nowrap" class="ft041">&#160;</p>
<p style="position:absolute;top:696px;left:116px;white-space:nowrap" class="ft042"><b>Discontinuation of Primary&#160;Prophylaxis/Pre-Emptive&#160;Therapy&#160;</b></p>
<p style="position:absolute;top:722px;left:116px;white-space:nowrap" class="ft030">•</p>
<p style="position:absolute;top:723px;left:123px;white-space:nowrap" class="ft057">&#160;</p>
<p style="position:absolute;top:723px;left:133px;white-space:nowrap" class="ft041">CD4 count&#160;</p>
<p style="position:absolute;top:723px;left:194px;white-space:nowrap" class="ft064">≥</p>
<p style="position:absolute;top:723px;left:202px;white-space:nowrap" class="ft065">250&#160;cells/mm</p>
<p style="position:absolute;top:724px;left:275px;white-space:nowrap" class="ft058">3</p>
<p style="position:absolute;top:723px;left:279px;white-space:nowrap" class="ft041">&#160;with&#160;virologic&#160;suppression on ART&#160;</p>
<p style="position:absolute;top:723px;left:471px;white-space:nowrap" class="ft042"><b>(BIII)</b></p>
<p style="position:absolute;top:723px;left:499px;white-space:nowrap" class="ft041">&#160;</p>
<p style="position:absolute;top:750px;left:108px;white-space:nowrap" class="ft042"><b>Key:</b></p>
<p style="position:absolute;top:750px;left:135px;white-space:nowrap" class="ft041">&#160;ART = antiretroviral&#160;therapy; CD4&#160;= CD4&#160;T&#160;lymphocyte;&#160;IgG&#160;= immunoglobulin&#160;G; IgM = immunoglobulin&#160;M; PO&#160;= orally&#160;</p>
<p style="position:absolute;top:785px;left:108px;white-space:nowrap" class="ft032">Primary antifungal prophylaxis (i.e., prophylaxis for&#160;individuals with negative results on&#160;serological&#160;<br/>tests for&#160;</p>
<p style="position:absolute;top:805px;left:167px;white-space:nowrap" class="ft019"><i>Coccidioides</i></p>
<p style="position:absolute;top:805px;left:257px;white-space:nowrap" class="ft013">) does not appear&#160;to benefit people&#160;with HIV who have&#160;low CD4 counts and&#160;</p>
<p style="position:absolute;top:825px;left:108px;white-space:nowrap" class="ft013">live in regions in which&#160;</p>
<p style="position:absolute;top:825px;left:275px;white-space:nowrap" class="ft019"><i>Coccidioides</i></p>
<p style="position:absolute;top:825px;left:365px;white-space:nowrap" class="ft013">&#160;spp. are endemic,</p>
<p style="position:absolute;top:823px;left:490px;white-space:nowrap" class="ft038">5</p>
<p style="position:absolute;top:825px;left:496px;white-space:nowrap" class="ft013">&#160;and it&#160;</p>
<p style="position:absolute;top:825px;left:543px;white-space:nowrap" class="ft012"><b>is not recommended</b></p>
<p style="position:absolute;top:825px;left:692px;white-space:nowrap" class="ft013">&#160;</p>
<p style="position:absolute;top:825px;left:696px;white-space:nowrap" class="ft012"><b>(AIII).</b></p>
<p style="position:absolute;top:825px;left:744px;white-space:nowrap" class="ft013">&#160;Yearly&#160;</p>
<p style="position:absolute;top:845px;left:108px;white-space:nowrap" class="ft032">or twice-yearly serological&#160;testing for coccidioidomycosis should be considered for serologically&#160;<br/>negative&#160;individuals with&#160;HIV&#160;who live in endemic areas&#160;</p>
<p style="position:absolute;top:865px;left:506px;white-space:nowrap" class="ft012"><b>(BIII).</b></p>
<p style="position:absolute;top:865px;left:553px;white-space:nowrap" class="ft013">&#160;Testing is advised also for&#160;</p>
<p style="position:absolute;top:884px;left:108px;white-space:nowrap" class="ft032">individuals who have previously traveled to or lived in endemic&#160;areas. Both&#160;IgM and&#160;IgG antibody&#160;<br/>testing using&#160;either an EIA or ID&#160;technique are recommended&#160;</p>
<p style="position:absolute;top:904px;left:537px;white-space:nowrap" class="ft012"><b>(BIII).</b></p>
<p style="position:absolute;top:904px;left:584px;white-space:nowrap" class="ft013">&#160;In people&#160;who have&#160;CD4&#160;</p>
<p style="position:absolute;top:924px;left:108px;white-space:nowrap" class="ft013">counts &lt;250&#160;cells/mm</p>
<p style="position:absolute;top:923px;left:260px;white-space:nowrap" class="ft038">3</p>
<p style="position:absolute;top:924px;left:266px;white-space:nowrap" class="ft013">&#160;and who previously tested negative&#160;for&#160;</p>
<p style="position:absolute;top:924px;left:542px;white-space:nowrap" class="ft019"><i>Coccidioides</i></p>
<p style="position:absolute;top:924px;left:632px;white-space:nowrap" class="ft013">, a new positive&#160;</p>
<p style="position:absolute;top:944px;left:108px;white-space:nowrap" class="ft013">serological&#160;test suggests&#160;possible active disease</p>
<p style="position:absolute;top:942px;left:435px;white-space:nowrap" class="ft038">10</p>
<p style="position:absolute;top:944px;left:446px;white-space:nowrap" class="ft013">&#160;and should prompt&#160;further clinical&#160;evaluation. If no&#160;</p>
<p style="position:absolute;top:964px;left:108px;white-space:nowrap" class="ft032">signs,&#160;symptoms, or laboratory abnormalities compatible with active coccidioidomycosis&#160;are&#160;<br/>identified, pre-emptive antifungal therapy with fluconazole 400&#160;mg daily is recommended without&#160;<br/>definitive&#160;trials for those&#160;with a&#160;new positive serological&#160;test and CD4 counts &lt;250 cells/mm</p>
<p style="position:absolute;top:1002px;left:748px;white-space:nowrap" class="ft038">3</p>
<p style="position:absolute;top:1003px;left:754px;white-space:nowrap" class="ft013">&#160;</p>
<p style="position:absolute;top:1003px;left:758px;white-space:nowrap" class="ft012"><b>(AIII).</b></p>
<p style="position:absolute;top:1003px;left:807px;white-space:nowrap" class="ft013">&#160;</p>
<p style="position:absolute;top:1023px;left:108px;white-space:nowrap" class="ft018">This regimen should be continued until&#160;the&#160;CD4 count is&#160;</p>
<p style="position:absolute;top:1023px;left:503px;white-space:nowrap" class="ft069">≥</p>
<p style="position:absolute;top:1023px;left:513px;white-space:nowrap" class="ft018">250 cells/mm</p>
<p style="position:absolute;top:1022px;left:607px;white-space:nowrap" class="ft038">3</p>
<p style="position:absolute;top:1023px;left:612px;white-space:nowrap" class="ft013">&#160;and virologic suppression is&#160;</p>
<p style="position:absolute;top:1043px;left:108px;white-space:nowrap" class="ft013">documented&#160;</p>
<p style="position:absolute;top:1043px;left:197px;white-space:nowrap" class="ft012"><b>(BIII).</b></p>
<p style="position:absolute;top:1043px;left:244px;white-space:nowrap" class="ft013">&#160;</p>
<p style="position:absolute;top:1043px;left:248px;white-space:nowrap" class="ft018">For those with CD4 counts&#160;already&#160;</p>
<p style="position:absolute;top:1043px;left:493px;white-space:nowrap" class="ft069">≥</p>
<p style="position:absolute;top:1043px;left:503px;white-space:nowrap" class="ft018">250 cells/mm</p>
<p style="position:absolute;top:1042px;left:597px;white-space:nowrap" class="ft038">3</p>
<p style="position:absolute;top:1043px;left:602px;white-space:nowrap" class="ft013">&#160;and with viral suppression&#160;on&#160;</p>
</div>
<!-- Page 79 -->
<a name="79"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page79-div" style="position:relative;width:917px;height:1187px;">
<p style="position:absolute;top:1128px;left:108px;white-space:nowrap" class="ft024"><i>Guidelines for the Prevention and Treatment&#160;of&#160;Opportunistic&#160;Infections in Adults&#160;and Adolescents&#160;With HIV&#160;</i></p>
<p style="position:absolute;top:1128px;left:791px;white-space:nowrap" class="ft024"><i>F-4</i></p>
<p style="position:absolute;top:109px;left:108px;white-space:nowrap" class="ft013">antiretrovirals (ARVs), close clinical&#160;follow-up&#160;without&#160;antifungal&#160;therapy is recommended&#160;</p>
<p style="position:absolute;top:109px;left:744px;white-space:nowrap" class="ft012"><b>(BIII).&#160;</b></p>
<p style="position:absolute;top:129px;left:108px;white-space:nowrap" class="ft032">For asymptomatic patients who&#160;have&#160;not lived in or traveled to endemic regions, routine testing does&#160;<br/>not appear useful&#160;and&#160;</p>
<p style="position:absolute;top:148px;left:260px;white-space:nowrap" class="ft012"><b>should not&#160;be performed (AIII).</b></p>
<p style="position:absolute;top:148px;left:494px;white-space:nowrap" class="ft013">&#160;</p>
<p style="position:absolute;top:185px;left:108px;white-space:nowrap" class="ft026"><b>Treating Disease&#160;</b></p>
<p style="position:absolute;top:237px;left:360px;white-space:nowrap" class="ft02"><b>Treating&#160;Coccidioidomycosis&#160;</b></p>
<p style="position:absolute;top:271px;left:115px;white-space:nowrap" class="ft042"><b>Mild-to-Moderate Pulmonary&#160;Infections&#160;</b></p>
<p style="position:absolute;top:297px;left:115px;white-space:nowrap" class="ft024"><i>Indications for&#160;Treatment&#160;</i></p>
<p style="position:absolute;top:323px;left:115px;white-space:nowrap" class="ft030">•</p>
<p style="position:absolute;top:324px;left:131px;white-space:nowrap" class="ft041">Clinically mild&#160;infection, such as focal pneumonia</p>
<p style="position:absolute;top:356px;left:115px;white-space:nowrap" class="ft024"><i>Preferred&#160;Therapy&#160;</i></p>
<p style="position:absolute;top:383px;left:115px;white-space:nowrap" class="ft030">•</p>
<p style="position:absolute;top:384px;left:131px;white-space:nowrap" class="ft041">Fluconazole&#160;400&#160;mg&#160;PO once daily&#160;</p>
<p style="position:absolute;top:384px;left:325px;white-space:nowrap" class="ft042"><b>(AII),</b></p>
<p style="position:absolute;top:384px;left:352px;white-space:nowrap" class="ft041">&#160;</p>
<p style="position:absolute;top:384px;left:356px;white-space:nowrap" class="ft024"><i>or</i></p>
<p style="position:absolute;top:410px;left:115px;white-space:nowrap" class="ft030">•</p>
<p style="position:absolute;top:411px;left:131px;white-space:nowrap" class="ft041">Itraconazole 200 mg PO&#160;three times daily&#160;for 3 days&#160;then twice daily&#160;</p>
<p style="position:absolute;top:411px;left:505px;white-space:nowrap" class="ft042"><b>(AII)</b></p>
<p style="position:absolute;top:437px;left:115px;white-space:nowrap" class="ft024"><i>Alternative Therapy (For&#160;Patients&#160;Who Failed to Respond&#160;to Fluconazole or&#160;Itraconazole)</i></p>
<p style="position:absolute;top:463px;left:115px;white-space:nowrap" class="ft030">•</p>
<p style="position:absolute;top:464px;left:131px;white-space:nowrap" class="ft041">Voriconazole loading dose of 400 mg PO twice daily&#160;on Day&#160;1,&#160;followed by&#160;200&#160;mg&#160;PO&#160;twice daily&#160;</p>
<p style="position:absolute;top:464px;left:665px;white-space:nowrap" class="ft042"><b>(BIII),</b></p>
<p style="position:absolute;top:464px;left:696px;white-space:nowrap" class="ft024"><i>&#160;or</i></p>
<p style="position:absolute;top:491px;left:115px;white-space:nowrap" class="ft030">•</p>
<p style="position:absolute;top:492px;left:131px;white-space:nowrap" class="ft041">Posaconazole delayed-release tablet 300 mg PO twice daily on&#160;Day&#160;1, followed&#160;by 300&#160;mg once&#160;daily&#160;</p>
<p style="position:absolute;top:492px;left:686px;white-space:nowrap" class="ft042"><b>(BIII),</b></p>
<p style="position:absolute;top:492px;left:717px;white-space:nowrap" class="ft041">&#160;</p>
<p style="position:absolute;top:492px;left:720px;white-space:nowrap" class="ft024"><i>or</i></p>
<p style="position:absolute;top:518px;left:115px;white-space:nowrap" class="ft030">•</p>
<p style="position:absolute;top:519px;left:131px;white-space:nowrap" class="ft041">Isavuconazole sulfate&#160;372&#160;mg (isavuconazole 200 mg)&#160;PO every&#160;8 hours&#160;for six doses, followed by&#160;isavuconazole sulfate</p>
<p style="position:absolute;top:536px;left:131px;white-space:nowrap" class="ft041">372&#160;mg (isavuconazole 200 mg)&#160;PO once daily&#160;</p>
<p style="position:absolute;top:536px;left:389px;white-space:nowrap" class="ft042"><b>(BIII)</b></p>
<p style="position:absolute;top:568px;left:115px;white-space:nowrap" class="ft042"><b>Severe Pulmonary or Extrapulmonary Infection (Except&#160;Meningitis)&#160;</b></p>
<p style="position:absolute;top:595px;left:115px;white-space:nowrap" class="ft024"><i>Preferred&#160;Therapy&#160;</i></p>
<p style="position:absolute;top:621px;left:115px;white-space:nowrap" class="ft030">•</p>
<p style="position:absolute;top:622px;left:131px;white-space:nowrap" class="ft041">Amphotericin B&#160;deoxycholate 0.7–1.0 mg/kg IV&#160;daily&#160;</p>
<p style="position:absolute;top:622px;left:419px;white-space:nowrap" class="ft042"><b>(AII),&#160;</b></p>
<p style="position:absolute;top:622px;left:450px;white-space:nowrap" class="ft024"><i>or</i></p>
<p style="position:absolute;top:648px;left:115px;white-space:nowrap" class="ft030">•</p>
<p style="position:absolute;top:649px;left:131px;white-space:nowrap" class="ft041">Lipid formulation&#160;amphotericin B&#160;3–5&#160;mg/kg IV&#160;daily&#160;</p>
<p style="position:absolute;top:649px;left:415px;white-space:nowrap" class="ft042"><b>(AIII),</b></p>
<p style="position:absolute;top:649px;left:446px;white-space:nowrap" class="ft024"><i>&#160;</i></p>
<p style="position:absolute;top:649px;left:449px;white-space:nowrap" class="ft041">particularly for&#160;those with underlying renal&#160;dysfunction</p>
<p style="position:absolute;top:681px;left:115px;white-space:nowrap" class="ft041">Use until&#160;clinical&#160;improvement,&#160;then switch to triazole (fluconazole&#160;400&#160;mg PO&#160;daily&#160;or itraconazole&#160;200&#160;mg PO&#160;twice daily)</p>
<p style="position:absolute;top:681px;left:781px;white-space:nowrap" class="ft042"><b>&#160;</b></p>
<p style="position:absolute;top:698px;left:115px;white-space:nowrap" class="ft042"><b>(BIII).</b></p>
<p style="position:absolute;top:698px;left:146px;white-space:nowrap" class="ft041">&#160;</p>
<p style="position:absolute;top:731px;left:115px;white-space:nowrap" class="ft024"><i>Alternative Therapy&#160;</i></p>
<p style="position:absolute;top:757px;left:115px;white-space:nowrap" class="ft030">•</p>
<p style="position:absolute;top:758px;left:131px;white-space:nowrap" class="ft041">Some specialists&#160;recommend&#160;combining amphotericin&#160;B deoxycholate or lipid formulation amphotericin&#160;B (see&#160;above</p>
<p style="position:absolute;top:775px;left:131px;white-space:nowrap" class="ft041">dosing) with a&#160;triazole&#160;(fluconazole&#160;or itraconazole 400 mg&#160;daily)&#160;as initial&#160;therapy and&#160;continue the&#160;triazole&#160;once</p>
<p style="position:absolute;top:792px;left:131px;white-space:nowrap" class="ft041">amphotericin&#160;B&#160;is stopped&#160;</p>
<p style="position:absolute;top:792px;left:276px;white-space:nowrap" class="ft042"><b>(CIII).</b></p>
<p style="position:absolute;top:824px;left:115px;white-space:nowrap" class="ft042"><b>Meningeal Infections (Consultation With a Specialist Is Advised [AIII])&#160;</b></p>
<p style="position:absolute;top:851px;left:115px;white-space:nowrap" class="ft024"><i>Preferred&#160;Therapy&#160;</i></p>
<p style="position:absolute;top:877px;left:115px;white-space:nowrap" class="ft030">•</p>
<p style="position:absolute;top:878px;left:131px;white-space:nowrap" class="ft041">Fluconazole&#160;800–1,200&#160;mg PO&#160;once daily&#160;</p>
<p style="position:absolute;top:878px;left:363px;white-space:nowrap" class="ft042"><b>(AII)</b></p>
<p style="position:absolute;top:910px;left:115px;white-space:nowrap" class="ft024"><i>Alternative Therapy&#160;</i></p>
<p style="position:absolute;top:936px;left:115px;white-space:nowrap" class="ft030">•</p>
<p style="position:absolute;top:937px;left:131px;white-space:nowrap" class="ft041">Itraconazole 200 mg PO two to three times daily&#160;</p>
<p style="position:absolute;top:937px;left:396px;white-space:nowrap" class="ft042"><b>(BII),</b></p>
<p style="position:absolute;top:937px;left:424px;white-space:nowrap" class="ft041">&#160;</p>
<p style="position:absolute;top:937px;left:427px;white-space:nowrap" class="ft024"><i>or</i></p>
<p style="position:absolute;top:964px;left:115px;white-space:nowrap" class="ft030">•</p>
<p style="position:absolute;top:965px;left:131px;white-space:nowrap" class="ft041">Voriconazole 200–400&#160;mg PO&#160;twice daily&#160;</p>
<p style="position:absolute;top:965px;left:359px;white-space:nowrap" class="ft042"><b>(BIII),</b></p>
<p style="position:absolute;top:965px;left:389px;white-space:nowrap" class="ft041">&#160;</p>
<p style="position:absolute;top:965px;left:393px;white-space:nowrap" class="ft024"><i>or</i></p>
<p style="position:absolute;top:991px;left:115px;white-space:nowrap" class="ft030">•</p>
<p style="position:absolute;top:992px;left:131px;white-space:nowrap" class="ft041">Posaconazole delayed-release tablet 300 mg&#160;PO&#160;twice on&#160;Day&#160;1, followed by 300 mg PO once&#160;daily&#160;</p>
<p style="position:absolute;top:992px;left:679px;white-space:nowrap" class="ft042"><b>(CIII),</b></p>
<p style="position:absolute;top:992px;left:710px;white-space:nowrap" class="ft041">&#160;</p>
<p style="position:absolute;top:992px;left:713px;white-space:nowrap" class="ft024"><i>or</i></p>
<p style="position:absolute;top:1018px;left:115px;white-space:nowrap" class="ft030">•</p>
<p style="position:absolute;top:1019px;left:131px;white-space:nowrap" class="ft041">Isavuconazole sulfate&#160;372&#160;mg (isavuconazole 200 mg)&#160;PO every&#160;8 hours&#160;for six&#160;doses, followed by&#160;isavuconazole sulfate</p>
<p style="position:absolute;top:1036px;left:131px;white-space:nowrap" class="ft041">372&#160;mg (isavuconazole 200 mg)&#160;PO once daily&#160;</p>
<p style="position:absolute;top:1036px;left:390px;white-space:nowrap" class="ft042"><b>(CIII),&#160;</b></p>
<p style="position:absolute;top:1036px;left:424px;white-space:nowrap" class="ft024"><i>or</i></p>
</div>
<!-- Page 80 -->
<a name="80"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}	.ft096{font-size:17px;font-family:BTLIFY+Tinos;color:#6f2f9f;}
-->
</style>
<div id="page80-div" style="position:relative;width:917px;height:1187px;">
<p style="position:absolute;top:1128px;left:108px;white-space:nowrap" class="ft024"><i>Guidelines for the Prevention and Treatment&#160;of&#160;Opportunistic&#160;Infections in Adults&#160;and Adolescents&#160;With HIV&#160;</i></p>
<p style="position:absolute;top:1128px;left:791px;white-space:nowrap" class="ft024"><i>F-5</i></p>
<p style="position:absolute;top:110px;left:115px;white-space:nowrap" class="ft030">•</p>
<p style="position:absolute;top:111px;left:131px;white-space:nowrap" class="ft041">Intrathecal amphotericin&#160;B deoxycholate&#160;</p>
<p style="position:absolute;top:111px;left:353px;white-space:nowrap" class="ft042"><b>(AIII)</b></p>
<p style="position:absolute;top:111px;left:380px;white-space:nowrap" class="ft041">&#160;when triazole&#160;antifungals&#160;are not&#160;effective. Use in consultation with&#160;a</p>
<p style="position:absolute;top:128px;left:131px;white-space:nowrap" class="ft041">specialist and ensure administration&#160;by a clinician experienced in this&#160;drug delivery&#160;technique.</p>
<p style="position:absolute;top:154px;left:115px;white-space:nowrap" class="ft042"><b>Treatment&#160;in Pregnancy&#160;</b></p>
<p style="position:absolute;top:180px;left:115px;white-space:nowrap" class="ft024"><i>Preferred&#160;Therapy During the First Trimester&#160;</i></p>
<p style="position:absolute;top:207px;left:115px;white-space:nowrap" class="ft030">•</p>
<p style="position:absolute;top:208px;left:131px;white-space:nowrap" class="ft041">Lipid formulation&#160;amphotericin B&#160;3–5&#160;mg/kg IV&#160;daily&#160;</p>
<p style="position:absolute;top:208px;left:415px;white-space:nowrap" class="ft042"><b>(AIII),&#160;</b></p>
<p style="position:absolute;top:208px;left:449px;white-space:nowrap" class="ft024"><i>or</i></p>
<p style="position:absolute;top:234px;left:115px;white-space:nowrap" class="ft030">•</p>
<p style="position:absolute;top:235px;left:131px;white-space:nowrap" class="ft041">Amphotericin B&#160;deoxycholate 0.7–1.0 mg/kg IV&#160;daily&#160;</p>
<p style="position:absolute;top:235px;left:419px;white-space:nowrap" class="ft042"><b>(AIII)</b></p>
<p style="position:absolute;top:261px;left:115px;white-space:nowrap" class="ft030">•</p>
<p style="position:absolute;top:262px;left:131px;white-space:nowrap" class="ft042"><b>Note:&#160;</b></p>
<p style="position:absolute;top:262px;left:166px;white-space:nowrap" class="ft041">In general, azole antifungal&#160;agents should&#160;be avoided&#160;in the first trimester of pregnancy&#160;because of&#160;potential</p>
<p style="position:absolute;top:279px;left:131px;white-space:nowrap" class="ft041">teratogenic effect unless&#160;benefit is&#160;thought&#160;to outweigh risk&#160;</p>
<p style="position:absolute;top:279px;left:454px;white-space:nowrap" class="ft042"><b>(Blll).</b></p>
<p style="position:absolute;top:306px;left:115px;white-space:nowrap" class="ft030">•</p>
<p style="position:absolute;top:307px;left:131px;white-space:nowrap" class="ft041">After the first trimester or&#160;when&#160;disease is&#160;diagnosed after the first trimester, treatment with fluconazole or itraconazole</p>
<p style="position:absolute;top:324px;left:131px;white-space:nowrap" class="ft041">could be&#160;considered&#160;</p>
<p style="position:absolute;top:324px;left:245px;white-space:nowrap" class="ft042"><b>(AIII).</b></p>
<p style="position:absolute;top:364px;left:382px;white-space:nowrap" class="ft02"><b>Discontinuing Therapy&#160;</b></p>
<p style="position:absolute;top:398px;left:115px;white-space:nowrap" class="ft042"><b>Focal Coccidioidal Pneumonia&#160;(AII)</b></p>
<p style="position:absolute;top:398px;left:320px;white-space:nowrap" class="ft041">&#160;</p>
<p style="position:absolute;top:424px;left:115px;white-space:nowrap" class="ft030">•</p>
<p style="position:absolute;top:425px;left:131px;white-space:nowrap" class="ft041">Discontinuation&#160;can be considered&#160;after&#160;the&#160;following:</p>
<p style="position:absolute;top:453px;left:131px;white-space:nowrap" class="ft062">o</p>
<p style="position:absolute;top:451px;left:147px;white-space:nowrap" class="ft041">Clinical&#160;response&#160;to 3–6&#160;months&#160;of&#160;antifungal&#160;therapy,&#160;</p>
<p style="position:absolute;top:451px;left:444px;white-space:nowrap" class="ft024"><i>and</i></p>
<p style="position:absolute;top:479px;left:131px;white-space:nowrap" class="ft062">o</p>
<p style="position:absolute;top:478px;left:147px;white-space:nowrap" class="ft065">CD4 count&#160;</p>
<p style="position:absolute;top:478px;left:209px;white-space:nowrap" class="ft064">≥</p>
<p style="position:absolute;top:478px;left:217px;white-space:nowrap" class="ft065">250&#160;cells/mm</p>
<p style="position:absolute;top:479px;left:290px;white-space:nowrap" class="ft058">3</p>
<p style="position:absolute;top:478px;left:294px;white-space:nowrap" class="ft041">,&#160;</p>
<p style="position:absolute;top:478px;left:301px;white-space:nowrap" class="ft024"><i>and</i></p>
<p style="position:absolute;top:505px;left:131px;white-space:nowrap" class="ft062">o</p>
<p style="position:absolute;top:504px;left:147px;white-space:nowrap" class="ft041">Virologic&#160;suppression on ART,&#160;</p>
<p style="position:absolute;top:504px;left:316px;white-space:nowrap" class="ft024"><i>and</i></p>
<p style="position:absolute;top:530px;left:115px;white-space:nowrap" class="ft030">•</p>
<p style="position:absolute;top:531px;left:131px;white-space:nowrap" class="ft041">Continued monitoring&#160;for recurrence can be performed&#160;using&#160;serial&#160;chest radiograph and coccidioidal&#160;serology.</p>
<p style="position:absolute;top:563px;left:115px;white-space:nowrap" class="ft042"><b>Diffuse Pulmonary&#160;Disease&#160;or&#160;Non-Meningeal&#160;Disseminated&#160;Coccidioidomycosis</b></p>
<p style="position:absolute;top:563px;left:587px;white-space:nowrap" class="ft041">&#160;</p>
<p style="position:absolute;top:589px;left:115px;white-space:nowrap" class="ft030">•</p>
<p style="position:absolute;top:590px;left:131px;white-space:nowrap" class="ft065">Relapse can&#160;occur in&#160;25% to 33% of people&#160;without HIV&#160;and in people&#160;with HIV&#160;who have CD4&#160;count&#160;</p>
<p style="position:absolute;top:590px;left:683px;white-space:nowrap" class="ft064">≥</p>
<p style="position:absolute;top:590px;left:691px;white-space:nowrap" class="ft065">250&#160;cells/mm</p>
<p style="position:absolute;top:592px;left:764px;white-space:nowrap" class="ft058">3</p>
<p style="position:absolute;top:590px;left:769px;white-space:nowrap" class="ft041">.</p>
<p style="position:absolute;top:617px;left:115px;white-space:nowrap" class="ft030">•</p>
<p style="position:absolute;top:618px;left:131px;white-space:nowrap" class="ft041">Discontinuation&#160;may be considered after&#160;</p>
<p style="position:absolute;top:618px;left:354px;white-space:nowrap" class="ft064">≥</p>
<p style="position:absolute;top:618px;left:362px;white-space:nowrap" class="ft041">12 months&#160;of therapy&#160;based on&#160;clinical&#160;and serological&#160;response, and&#160;the</p>
<p style="position:absolute;top:635px;left:131px;white-space:nowrap" class="ft041">decision&#160;should&#160;be made&#160;in&#160;consultation with experts&#160;</p>
<p style="position:absolute;top:635px;left:422px;white-space:nowrap" class="ft042"><b>(BIII).</b></p>
<p style="position:absolute;top:661px;left:115px;white-space:nowrap" class="ft030">•</p>
<p style="position:absolute;top:662px;left:131px;white-space:nowrap" class="ft041">For&#160;diffuse pulmonary&#160;disease,&#160;continued&#160;monitoring&#160;for recurrence can be&#160;performed&#160;using serial&#160;chest&#160;radiograph and</p>
<p style="position:absolute;top:679px;left:131px;white-space:nowrap" class="ft041">coccidioidal&#160;serology.</p>
<p style="position:absolute;top:712px;left:115px;white-space:nowrap" class="ft042"><b>Coccidioidal&#160;Meningitis&#160;</b></p>
<p style="position:absolute;top:738px;left:115px;white-space:nowrap" class="ft030">•</p>
<p style="position:absolute;top:739px;left:131px;white-space:nowrap" class="ft041">Relapse has been reported&#160;in 80% of patients&#160;after stopping triazoles; suppressive therapy&#160;at treatment doses&#160;should be</p>
<p style="position:absolute;top:756px;left:131px;white-space:nowrap" class="ft041">lifelong. Discontinuation&#160;of therapy&#160;</p>
<p style="position:absolute;top:756px;left:323px;white-space:nowrap" class="ft042"><b>is not&#160;recommended</b></p>
<p style="position:absolute;top:756px;left:443px;white-space:nowrap" class="ft041">&#160;</p>
<p style="position:absolute;top:756px;left:446px;white-space:nowrap" class="ft042"><b>(AII).</b></p>
<p style="position:absolute;top:796px;left:387px;white-space:nowrap" class="ft02"><b>Other&#160;Considerations&#160;</b></p>
<p style="position:absolute;top:830px;left:115px;white-space:nowrap" class="ft030">•</p>
<p style="position:absolute;top:831px;left:131px;white-space:nowrap" class="ft041">Certain&#160;patients&#160;with meningitis&#160;may develop hydrocephalus and&#160;require CSF&#160;shunting in addition to&#160;antifungal&#160;therapy.</p>
<p style="position:absolute;top:848px;left:131px;white-space:nowrap" class="ft041">Use&#160;of&#160;corticosteroids&#160;</p>
<p style="position:absolute;top:848px;left:253px;white-space:nowrap" class="ft042"><b>is not&#160;recommended</b></p>
<p style="position:absolute;top:848px;left:373px;white-space:nowrap" class="ft041">.</p>
<p style="position:absolute;top:874px;left:115px;white-space:nowrap" class="ft030">•</p>
<p style="position:absolute;top:876px;left:131px;white-space:nowrap" class="ft041">All&#160;the&#160;triazole antifungals have the&#160;potential&#160;to interact&#160;with&#160;certain ARV agents and other&#160;anti-infective agents. These</p>
<p style="position:absolute;top:893px;left:131px;white-space:nowrap" class="ft041">interactions are&#160;complex&#160;and&#160;can be&#160;bidirectional. The&#160;</p>
<p style="position:absolute;top:893px;left:429px;white-space:nowrap" class="ft043">Drug–Drug Interactions&#160;tables</p>
<p style="position:absolute;top:893px;left:593px;white-space:nowrap" class="ft041">&#160;in the&#160;Adult&#160;and&#160;Adolescent</p>
<p style="position:absolute;top:910px;left:131px;white-space:nowrap" class="ft041">Antiretroviral&#160;Guidelines list these interactions and&#160;recommend dosage&#160;adjustments&#160;where feasible.</p>
<p style="position:absolute;top:940px;left:108px;white-space:nowrap" class="ft042"><b>Key:</b></p>
<p style="position:absolute;top:940px;left:135px;white-space:nowrap" class="ft041">&#160;ARV = antiretroviral; CD4 =&#160;CD4 T&#160;lymphocyte;&#160;CSF&#160;= cerebrospinal&#160;fluid; DDI = drug–drug interaction; IV&#160;= intravenous;&#160;</p>
<p style="position:absolute;top:958px;left:108px;white-space:nowrap" class="ft041">PO = orally&#160;</p>
<p style="position:absolute;top:993px;left:108px;white-space:nowrap" class="ft012"><b>Treatment of mild-to-moderate&#160;pulmonary coccidioidal&#160;infection:</b></p>
<p style="position:absolute;top:993px;left:590px;white-space:nowrap" class="ft013">&#160;Therapy with an&#160;oral&#160;triazole</p>
<p style="position:absolute;top:1012px;left:108px;white-space:nowrap" class="ft032">antifungal agent&#160;is appropriate&#160;for patients who&#160;have clinically&#160;mild infection, such as&#160;focal&#160;<br/>pneumonia&#160;</p>
<p style="position:absolute;top:1032px;left:189px;white-space:nowrap" class="ft012"><b>(AII).</b></p>
<p style="position:absolute;top:1032px;left:231px;white-space:nowrap" class="ft013">&#160;Fluconazole should&#160;be given as 400 mg daily&#160;</p>
<p style="position:absolute;top:1032px;left:551px;white-space:nowrap" class="ft012"><b>(AII);</b></p>
<p style="position:absolute;top:1032px;left:594px;white-space:nowrap" class="ft013">&#160;itraconazole should be given&#160;</p>
<p style="position:absolute;top:1052px;left:108px;white-space:nowrap" class="ft013">in divided doses of 200 mg three times daily for 3 days,</p>
<p style="position:absolute;top:1052px;left:492px;white-space:nowrap" class="ft096"><b>&#160;</b></p>
<p style="position:absolute;top:1052px;left:497px;white-space:nowrap" class="ft013">followed by 200 mg&#160;twice daily&#160;</p>
<p style="position:absolute;top:1052px;left:721px;white-space:nowrap" class="ft012"><b>(AII).</b></p>
<p style="position:absolute;top:1051px;left:762px;white-space:nowrap" class="ft038">24,25</p>
<p style="position:absolute;top:1052px;left:788px;white-space:nowrap" class="ft012"><b>&#160;</b></p>
</div>
<!-- Page 81 -->
<a name="81"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}	.ft097{font-size:17px;font-family:TURBHP+Tinos;color:#6657e6;}
	.ft098{font-size:17px;font-family:TURBHP+Tinos;color:#6f2f9f;}
	.ft099{font-size:17px;line-height:21px;font-family:TURBHP+Tinos;color:#000000;}
-->
</style>
<div id="page81-div" style="position:relative;width:917px;height:1187px;">
<p style="position:absolute;top:1128px;left:108px;white-space:nowrap" class="ft024"><i>Guidelines for the Prevention and Treatment&#160;of&#160;Opportunistic&#160;Infections in Adults&#160;and Adolescents&#160;With HIV&#160;</i></p>
<p style="position:absolute;top:1128px;left:791px;white-space:nowrap" class="ft024"><i>F-6&#160;</i></p>
<p style="position:absolute;top:109px;left:108px;white-space:nowrap" class="ft013">Itraconazole&#160;is preferred for those&#160;who&#160;have bone&#160;or joint disease&#160;</p>
<p style="position:absolute;top:109px;left:563px;white-space:nowrap" class="ft012"><b>(AI).</b></p>
<p style="position:absolute;top:107px;left:598px;white-space:nowrap" class="ft038">26</p>
<p style="position:absolute;top:109px;left:610px;white-space:nowrap" class="ft013">&#160;Serum itraconazole&#160;</p>
<p style="position:absolute;top:129px;left:108px;white-space:nowrap" class="ft099">concentrations should be&#160;measured after the drug reaches steady state at&#160;2 weeks to ensure adequate&#160;<br/>absorption. Target&#160;random&#160;serum concentrations (the sum of the parent&#160;itraconazole and hydroxyl&#160;<br/>itraconazole metabolite levels), measured by high-performance&#160;liquid chromatography, should be&#160;<br/>between 1.0&#160;to 2.0&#160;</p>
<p style="position:absolute;top:187px;left:239px;white-space:nowrap" class="ft040">µ</p>
<p style="position:absolute;top:189px;left:249px;white-space:nowrap" class="ft013">g/mL.</p>
<p style="position:absolute;top:188px;left:291px;white-space:nowrap" class="ft038">27</p>
<p style="position:absolute;top:189px;left:302px;white-space:nowrap" class="ft013">&#160;</p>
<p style="position:absolute;top:226px;left:108px;white-space:nowrap" class="ft013">Data to support clinical&#160;efficacy for treatment with posaconazole,</p>
<p style="position:absolute;top:225px;left:560px;white-space:nowrap" class="ft038">28,29</p>
<p style="position:absolute;top:226px;left:585px;white-space:nowrap" class="ft013">&#160;voriconazole,</p>
<p style="position:absolute;top:225px;left:683px;white-space:nowrap" class="ft038">30</p>
<p style="position:absolute;top:226px;left:694px;white-space:nowrap" class="ft013">&#160;or&#160;</p>
<p style="position:absolute;top:246px;left:108px;white-space:nowrap" class="ft013">isavuconazole</p>
<p style="position:absolute;top:245px;left:206px;white-space:nowrap" class="ft038">31</p>
<p style="position:absolute;top:246px;left:217px;white-space:nowrap" class="ft013">&#160;are limited, but&#160;these agents are recommended for patients who do not respond to&#160;</p>
<p style="position:absolute;top:266px;left:108px;white-space:nowrap" class="ft013">fluconazole or itraconazole&#160;</p>
<p style="position:absolute;top:266px;left:300px;white-space:nowrap" class="ft012"><b>(BIII).</b></p>
<p style="position:absolute;top:266px;left:347px;white-space:nowrap" class="ft013">&#160;Voriconazole&#160;is given as a loading dose of 400 mg twice&#160;on Day&#160;</p>
<p style="position:absolute;top:286px;left:108px;white-space:nowrap" class="ft099">1, followed thereafter by&#160;200 mg twice daily. Trough serum&#160;voriconazole concentrations should be&#160;<br/>measured to&#160;ensure efficacy and avoid&#160;toxicity;&#160;a concentration of 1 to 5&#160;</p>
<p style="position:absolute;top:305px;left:611px;white-space:nowrap" class="ft040">µ</p>
<p style="position:absolute;top:307px;left:621px;white-space:nowrap" class="ft013">g/mL&#160;is desired. Several&#160;</p>
<p style="position:absolute;top:327px;left:108px;white-space:nowrap" class="ft032">dosage formulations of posaconazole&#160;have&#160;been studied for coccidioidomycosis.&#160;A dose&#160;of 400 mg&#160;<br/>twice daily of the older liquid formulation of posaconazole has&#160;been used,</p>
<p style="position:absolute;top:345px;left:619px;white-space:nowrap" class="ft038">29</p>
<p style="position:absolute;top:347px;left:630px;white-space:nowrap" class="ft097">&#160;</p>
<p style="position:absolute;top:347px;left:634px;white-space:nowrap" class="ft013">but the current delayed-</p>
<p style="position:absolute;top:367px;left:108px;white-space:nowrap" class="ft013">release tablet&#160;formulation of posaconazole&#160;at&#160;a dosage of</p>
<p style="position:absolute;top:367px;left:500px;white-space:nowrap" class="ft012"><b>&#160;</b></p>
<p style="position:absolute;top:367px;left:504px;white-space:nowrap" class="ft013">300 mg&#160;twice on the first day and&#160;then 300&#160;</p>
<p style="position:absolute;top:386px;left:108px;white-space:nowrap" class="ft032">mg once daily is better tolerated by people&#160;and provides more reliable&#160;serum concentrations and is&#160;<br/>therefore recommended&#160;</p>
<p style="position:absolute;top:406px;left:276px;white-space:nowrap" class="ft012"><b>(BIII).</b></p>
<p style="position:absolute;top:406px;left:324px;white-space:nowrap" class="ft013">&#160;A&#160;syndrome&#160;of mineralocorticoid excess manifesting as hypertension&#160;</p>
<p style="position:absolute;top:426px;left:108px;white-space:nowrap" class="ft013">with hypokalemia&#160;was reported in some patients taking posaconazole.</p>
<p style="position:absolute;top:425px;left:590px;white-space:nowrap" class="ft038">32</p>
<p style="position:absolute;top:426px;left:602px;white-space:nowrap" class="ft012"><b>&#160;</b></p>
<p style="position:absolute;top:426px;left:606px;white-space:nowrap" class="ft013">Monitoring of blood pressure&#160;</p>
<p style="position:absolute;top:446px;left:108px;white-space:nowrap" class="ft013">and serum&#160;potassium&#160;levels is appropriate in patients taking posaconazole.&#160;</p>
<p style="position:absolute;top:483px;left:108px;white-space:nowrap" class="ft032">Data supporting isavuconazole treatment&#160;in people&#160;with HIV are limited;&#160;however, in a cohort of&#160;<br/>82 patients that included three people&#160;with HIV and CD4&#160;</p>
<p style="position:absolute;top:503px;left:506px;white-space:nowrap" class="ft069">≥</p>
<p style="position:absolute;top:503px;left:516px;white-space:nowrap" class="ft013">200&#160;cells/mm</p>
<p style="position:absolute;top:501px;left:609px;white-space:nowrap" class="ft038">3</p>
<p style="position:absolute;top:503px;left:615px;white-space:nowrap" class="ft013">, improvement occurred in&#160;</p>
<p style="position:absolute;top:523px;left:108px;white-space:nowrap" class="ft013">70% of patients.</p>
<p style="position:absolute;top:521px;left:221px;white-space:nowrap" class="ft038">31</p>
<p style="position:absolute;top:523px;left:232px;white-space:nowrap" class="ft013">&#160;Isavuconazole is given as isavuconazole sulfate&#160;372 mg (equivalent to&#160;</p>
<p style="position:absolute;top:543px;left:108px;white-space:nowrap" class="ft099">isavuconazole 200 mg) every 8 hours for six doses then isavuconazole sulfate 372 mg (equivalent&#160;to&#160;<br/>isavuconazole 200 mg) once daily. Target serum&#160;isavuconazole levels are not&#160;always measured, but&#160;<br/>concentrations of 1 to&#160;4.6&#160;</p>
<p style="position:absolute;top:582px;left:288px;white-space:nowrap" class="ft040">µ</p>
<p style="position:absolute;top:583px;left:298px;white-space:nowrap" class="ft013">g/mL&#160;are preferred, with adverse events increasingly common in&#160;</p>
<p style="position:absolute;top:605px;left:108px;white-space:nowrap" class="ft013">concentrations exceeding&#160;4.6&#160;</p>
<p style="position:absolute;top:603px;left:313px;white-space:nowrap" class="ft040">µ</p>
<p style="position:absolute;top:605px;left:323px;white-space:nowrap" class="ft013">g/mL.</p>
<p style="position:absolute;top:603px;left:365px;white-space:nowrap" class="ft038">33</p>
<p style="position:absolute;top:605px;left:376px;white-space:nowrap" class="ft013">&#160;</p>
<p style="position:absolute;top:642px;left:108px;white-space:nowrap" class="ft032">All triazole&#160;antifungals have the potential for complex and possibly bidirectional interactions with&#160;<br/>certain ARV&#160;agents and other anti-infective&#160;agents. The&#160;</p>
<p style="position:absolute;top:662px;left:497px;white-space:nowrap" class="ft034">Drug–Drug Interactions tables</p>
<p style="position:absolute;top:662px;left:707px;white-space:nowrap" class="ft013">&#160;in&#160;the&#160;Adult&#160;</p>
<p style="position:absolute;top:681px;left:108px;white-space:nowrap" class="ft013">and Adolescent&#160;Antiretroviral&#160;Guidelines and&#160;</p>
<p style="position:absolute;top:681px;left:427px;white-space:nowrap" class="ft034">Table 4. Significant Pharmacokinetic Interactions&#160;</p>
<p style="position:absolute;top:701px;left:108px;white-space:nowrap" class="ft034">Between Drugs Used to Treat&#160;or Prevent Opportunistic&#160;Infections</p>
<p style="position:absolute;top:701px;left:561px;white-space:nowrap" class="ft019"><i>&#160;</i></p>
<p style="position:absolute;top:701px;left:566px;white-space:nowrap" class="ft013">list such interactions and&#160;</p>
<p style="position:absolute;top:721px;left:108px;white-space:nowrap" class="ft013">recommendations for therapeutic&#160;drug monitoring and dosage adjustments, where feasible.&#160;</p>
<p style="position:absolute;top:758px;left:108px;white-space:nowrap" class="ft012"><b>Treatment of severe&#160;pulmonary coccidioidal&#160;infection or extrapulmonary infection:&#160;</b></p>
<p style="position:absolute;top:778px;left:108px;white-space:nowrap" class="ft032">Amphotericin B is the preferred initial&#160;therapy for patients who have diffuse pulmonary involvement<br/>or who are severely ill with extrathoracic disseminated disease&#160;</p>
<p style="position:absolute;top:798px;left:544px;white-space:nowrap" class="ft012"><b>(AII).</b></p>
<p style="position:absolute;top:796px;left:586px;white-space:nowrap" class="ft038">25</p>
<p style="position:absolute;top:798px;left:597px;white-space:nowrap" class="ft098">&#160;</p>
<p style="position:absolute;top:798px;left:602px;white-space:nowrap" class="ft013">Most&#160;experience&#160;has been&#160;</p>
<p style="position:absolute;top:818px;left:108px;white-space:nowrap" class="ft032">with the deoxycholate formulation using a dose of&#160;amphotericin B of 0.7 to 1.0 mg/kg&#160;<br/>intravenously (IV)&#160;daily. There are only retrospective&#160;reports from studies that&#160;used lipid&#160;<br/>formulations&#160;of amphotericin B for the treatment&#160;of coccidioidomycosis.</p>
<p style="position:absolute;top:856px;left:610px;white-space:nowrap" class="ft038">34</p>
<p style="position:absolute;top:857px;left:621px;white-space:nowrap" class="ft013">&#160;Lipid formulations are&#160;</p>
<p style="position:absolute;top:877px;left:108px;white-space:nowrap" class="ft032">likely to be as effective&#160;as&#160;the&#160;deoxycholate formulation and should be&#160;favored initial&#160;therapy,&#160;<br/>particularly in patients with underlying renal&#160;dysfunction&#160;</p>
<p style="position:absolute;top:897px;left:506px;white-space:nowrap" class="ft012"><b>(AIII).</b></p>
<p style="position:absolute;top:897px;left:554px;white-space:nowrap" class="ft013">&#160;For lipid formulations, a daily dose&#160;</p>
<p style="position:absolute;top:917px;left:108px;white-space:nowrap" class="ft032">of amphotericin B of 3 to&#160;5 mg/kg IV is appropriate. Therapy with amphotericin B should&#160;continue&#160;<br/>until clinical&#160;improvement&#160;is observed&#160;and then changed to an oral&#160;triazole antifungal&#160;</p>
<p style="position:absolute;top:937px;left:702px;white-space:nowrap" class="ft012"><b>(BIII).</b></p>
<p style="position:absolute;top:937px;left:749px;white-space:nowrap" class="ft013">&#160;&#160;</p>
<p style="position:absolute;top:974px;left:108px;white-space:nowrap" class="ft032">Some specialists recommend combining amphotericin B with a triazole&#160;antifungal (400 mg&#160;of&#160;<br/>fluconazole or itraconazole&#160;daily) at initiation of therapy, and then continuing the&#160;triazole once&#160;<br/>amphotericin B is stopped&#160;</p>
<p style="position:absolute;top:1013px;left:293px;white-space:nowrap" class="ft012"><b>(CIII).</b></p>
<p style="position:absolute;top:1012px;left:341px;white-space:nowrap" class="ft038">25</p>
<p style="position:absolute;top:1013px;left:353px;white-space:nowrap" class="ft013">&#160;No&#160;experience has been reported with single-dose liposomal&#160;</p>
<p style="position:absolute;top:1033px;left:108px;white-space:nowrap" class="ft013">amphotericin at 10 mg/kg&#160;combined with azoles as&#160;used in cryptococcosis.</p>
<p style="position:absolute;top:1032px;left:624px;white-space:nowrap" class="ft038">35</p>
<p style="position:absolute;top:1033px;left:635px;white-space:nowrap" class="ft012"><b>&#160;</b></p>
</div>
<!-- Page 82 -->
<a name="82"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}	.ft0100{font-size:20px;font-family:BTLIFY+Tinos;color:#000000;}
-->
</style>
<div id="page82-div" style="position:relative;width:917px;height:1187px;">
<p style="position:absolute;top:1128px;left:108px;white-space:nowrap" class="ft024"><i>Guidelines for the Prevention and Treatment&#160;of&#160;Opportunistic&#160;Infections in Adults&#160;and Adolescents&#160;With HIV&#160;</i></p>
<p style="position:absolute;top:1128px;left:791px;white-space:nowrap" class="ft024"><i>F-7&#160;</i></p>
<p style="position:absolute;top:109px;left:108px;white-space:nowrap" class="ft012"><b>Treatment of patients with coccidioidal&#160;meningitis:&#160;</b></p>
<p style="position:absolute;top:109px;left:487px;white-space:nowrap" class="ft013">Treatment of coccidioidal&#160;meningitis</p>
<p style="position:absolute;top:109px;left:742px;white-space:nowrap" class="ft012"><b>&#160;</b></p>
<p style="position:absolute;top:109px;left:747px;white-space:nowrap" class="ft013">requires&#160;</p>
<p style="position:absolute;top:129px;left:108px;white-space:nowrap" class="ft013">consultation with a specialist in the&#160;treatment&#160;of coccidioidal meningitis&#160;</p>
<p style="position:absolute;top:129px;left:609px;white-space:nowrap" class="ft012"><b>(AIII).</b></p>
<p style="position:absolute;top:127px;left:658px;white-space:nowrap" class="ft038">36</p>
<p style="position:absolute;top:129px;left:669px;white-space:nowrap" class="ft013">&#160;Intravenous&#160;</p>
<p style="position:absolute;top:148px;left:108px;white-space:nowrap" class="ft032">amphotericin B alone&#160;is ineffective as treatment for coccidioidal&#160;meningitis. Treatment with a&#160;<br/>triazole&#160;antifungal&#160;is recommended instead with the early addition of the polyene. Fluconazole&#160;<br/>(800 to 1,200 mg daily) is the&#160;preferred regimen&#160;</p>
<p style="position:absolute;top:188px;left:445px;white-space:nowrap" class="ft012"><b>(AII),</b></p>
<p style="position:absolute;top:187px;left:487px;white-space:nowrap" class="ft038">24,37</p>
<p style="position:absolute;top:188px;left:512px;white-space:nowrap" class="ft013">&#160;but itraconazole 400 to 600 mg&#160;daily also&#160;</p>
<p style="position:absolute;top:208px;left:108px;white-space:nowrap" class="ft013">has been successfully used&#160;</p>
<p style="position:absolute;top:208px;left:297px;white-space:nowrap" class="ft012"><b>(BII).</b></p>
<p style="position:absolute;top:207px;left:338px;white-space:nowrap" class="ft038">38</p>
<p style="position:absolute;top:208px;left:349px;white-space:nowrap" class="ft013">&#160;Therapy with voriconazole&#160;</p>
<p style="position:absolute;top:208px;left:543px;white-space:nowrap" class="ft012"><b>(BIII),</b></p>
<p style="position:absolute;top:207px;left:591px;white-space:nowrap" class="ft038">39-41</p>
<p style="position:absolute;top:208px;left:617px;white-space:nowrap" class="ft013">&#160;posaconazole&#160;</p>
<p style="position:absolute;top:208px;left:719px;white-space:nowrap" class="ft012"><b>(CIII),</b></p>
<p style="position:absolute;top:207px;left:767px;white-space:nowrap" class="ft038">29,42</p>
<p style="position:absolute;top:208px;left:792px;white-space:nowrap" class="ft013">&#160;</p>
<p style="position:absolute;top:228px;left:108px;white-space:nowrap" class="ft013">and isavuconazole&#160;</p>
<p style="position:absolute;top:228px;left:239px;white-space:nowrap" class="ft012"><b>(CIII)</b></p>
<p style="position:absolute;top:226px;left:283px;white-space:nowrap" class="ft038">43</p>
<p style="position:absolute;top:228px;left:295px;white-space:nowrap" class="ft012"><b>&#160;</b></p>
<p style="position:absolute;top:228px;left:299px;white-space:nowrap" class="ft013">has been limited and described in individual case reports but has been&#160;</p>
<p style="position:absolute;top:248px;left:108px;white-space:nowrap" class="ft032">successful&#160;and is generally used&#160;with expert&#160;opinions. Despite&#160;appropriate antifungal&#160;therapy, some&#160;<br/>patients may develop hydrocephalus and require CSF shunting.&#160;In some instances, triazole&#160;<br/>antifungals are ineffective and intrathecal amphotericin B deoxycholate is recommended&#160;</p>
<p style="position:absolute;top:287px;left:723px;white-space:nowrap" class="ft012"><b>(AIII).</b></p>
<p style="position:absolute;top:286px;left:772px;white-space:nowrap" class="ft038">44</p>
<p style="position:absolute;top:287px;left:784px;white-space:nowrap" class="ft013">&#160;</p>
<p style="position:absolute;top:307px;left:108px;white-space:nowrap" class="ft032">When required, intrathecal&#160;therapy should be&#160;administered by someone very&#160;experienced in this drug&#160;<br/>delivery technique.&#160;</p>
<p style="position:absolute;top:364px;left:108px;white-space:nowrap" class="ft029"><i><b>Monitoring of&#160;Response&#160;to&#160;Therapy and&#160;Adverse Events (Including IRIS)&#160;</b></i></p>
<p style="position:absolute;top:405px;left:108px;white-space:nowrap" class="ft032">Monitoring the CF antibody titer is useful&#160;to assess&#160;response to therapy, which should be&#160;measured&#160;<br/>every 12 weeks. More&#160;than a twofold rise suggests recurrence&#160;or&#160;worsening of&#160;clinical&#160;disease and&#160;<br/>should prompt reassessment&#160;of management. Immune reconstitution inflammatory syndrome&#160;(IRIS)&#160;<br/>has been reported infrequently in people with HIV&#160;and</p>
<p style="position:absolute;top:465px;left:485px;white-space:nowrap" class="ft095"><b>&#160;</b></p>
<p style="position:absolute;top:465px;left:490px;white-space:nowrap" class="ft013">coccidioidomycosis.</p>
<p style="position:absolute;top:464px;left:631px;white-space:nowrap" class="ft038">45-47</p>
<p style="position:absolute;top:465px;left:657px;white-space:nowrap" class="ft013">&#160;In&#160;general, delaying&#160;</p>
<p style="position:absolute;top:485px;left:108px;white-space:nowrap" class="ft013">initiation of&#160;ART while treating coccidioidomycosis&#160;</p>
<p style="position:absolute;top:485px;left:473px;white-space:nowrap" class="ft012"><b>may not be&#160;necessary&#160;(BIII).</b></p>
<p style="position:absolute;top:485px;left:681px;white-space:nowrap" class="ft039">&#160;</p>
<p style="position:absolute;top:485px;left:686px;white-space:nowrap" class="ft013">However, in&#160;</p>
<p style="position:absolute;top:505px;left:108px;white-space:nowrap" class="ft013">highly immunosuppressed patients (i.e., CD4 counts &lt;100 cells/mm</p>
<p style="position:absolute;top:503px;left:577px;white-space:nowrap" class="ft038">3</p>
<p style="position:absolute;top:505px;left:582px;white-space:nowrap" class="ft013">) with disseminated disease,&#160;</p>
<p style="position:absolute;top:524px;left:108px;white-space:nowrap" class="ft013">clinical&#160;decline may occur with initiation of ART.</p>
<p style="position:absolute;top:523px;left:453px;white-space:nowrap" class="ft038">48</p>
<p style="position:absolute;top:524px;left:464px;white-space:nowrap" class="ft013">&#160;It might&#160;be prudent&#160;to delay ART for&#160;4 to&#160;</p>
<p style="position:absolute;top:544px;left:108px;white-space:nowrap" class="ft032">6 weeks after&#160;initiating antifungal therapy in severely immunosuppressed&#160;patients who&#160;have&#160;<br/>disseminated or central nervous&#160;system&#160;(CNS) disease&#160;</p>
<p style="position:absolute;top:564px;left:487px;white-space:nowrap" class="ft012"><b>(CIII).</b></p>
<p style="position:absolute;top:564px;left:535px;white-space:nowrap" class="ft013">&#160;On the&#160;other hand, ART delay may not&#160;</p>
<p style="position:absolute;top:584px;left:108px;white-space:nowrap" class="ft032">always prevent IRIS, as&#160;reported in at least one&#160;patient with disseminated disease and who received&#160;<br/>treatment with fluconazole&#160;for 28 days&#160;but still had worsening symptoms within a&#160;week after starting&#160;<br/>ART.</p>
<p style="position:absolute;top:622px;left:147px;white-space:nowrap" class="ft038">49</p>
<p style="position:absolute;top:624px;left:162px;white-space:nowrap" class="ft013">Thus, close monitoring for clinical&#160;worsening, particularly if meningitis is present,&#160;is</p>
<p style="position:absolute;top:643px;left:108px;white-space:nowrap" class="ft032">essential&#160;when treating highly immunosuppressed&#160;people who&#160;have HIV and disseminated&#160;<br/>coccidioidomycosis.</p>
<p style="position:absolute;top:663px;left:249px;white-space:nowrap" class="ft095"><b>&#160;</b></p>
<p style="position:absolute;top:701px;left:108px;white-space:nowrap" class="ft029"><i><b>Managing&#160;Treatment Failure</b></i></p>
<p style="position:absolute;top:701px;left:363px;white-space:nowrap" class="ft0100"><b>&#160;</b></p>
<p style="position:absolute;top:743px;left:108px;white-space:nowrap" class="ft013">Therapeutic random&#160;itraconazole&#160;concentrations of&#160;1.0&#160;</p>
<p style="position:absolute;top:741px;left:489px;white-space:nowrap" class="ft040">µ</p>
<p style="position:absolute;top:743px;left:499px;white-space:nowrap" class="ft013">g/mL&#160;to&#160;2.0&#160;</p>
<p style="position:absolute;top:741px;left:585px;white-space:nowrap" class="ft040">µ</p>
<p style="position:absolute;top:743px;left:595px;white-space:nowrap" class="ft013">g/mL&#160;should be&#160;the&#160;goal&#160;in&#160;</p>
<p style="position:absolute;top:763px;left:108px;white-space:nowrap" class="ft032">patients with severe coccidioidomycosis who do not respond to treatment with itraconazole. In the&#160;<br/>case of confirmed treatment failure with adequate serum&#160;concentrations of the azole, treatment&#160;<br/>should be changed to IV&#160;amphotericin B, either deoxycholate&#160;or a lipid formulation for patients who&#160;<br/>are severely ill&#160;</p>
<p style="position:absolute;top:822px;left:214px;white-space:nowrap" class="ft012"><b>(AIII).</b></p>
<p style="position:absolute;top:822px;left:262px;white-space:nowrap" class="ft013">&#160;For&#160;those who are not&#160;severely ill, posaconazole&#160;</p>
<p style="position:absolute;top:822px;left:603px;white-space:nowrap" class="ft012"><b>(BIII),</b></p>
<p style="position:absolute;top:822px;left:650px;white-space:nowrap" class="ft013">&#160;voriconazole</p>
<p style="position:absolute;top:822px;left:748px;white-space:nowrap" class="ft012"><b>(BIII),&#160;</b></p>
<p style="position:absolute;top:842px;left:108px;white-space:nowrap" class="ft013">or isavuconazole</p>
<p style="position:absolute;top:842px;left:224px;white-space:nowrap" class="ft012"><b>&#160;(BIII)</b></p>
<p style="position:absolute;top:842px;left:272px;white-space:nowrap" class="ft013">&#160;are appropriate alternatives. Drug interactions may limit the use of&#160;</p>
<p style="position:absolute;top:862px;left:108px;white-space:nowrap" class="ft032">voriconazole in patients who are taking non-nucleoside reverse&#160;transcriptase&#160;inhibitors or&#160;ritonavir-&#160;<br/>or cobicistat-boosted regimens (see the&#160;</p>
<p style="position:absolute;top:882px;left:381px;white-space:nowrap" class="ft034">Drug–Drug&#160;Interactions tables</p>
<p style="position:absolute;top:882px;left:591px;white-space:nowrap" class="ft013">&#160;in the Adult&#160;and Adolescent&#160;</p>
<p style="position:absolute;top:902px;left:108px;white-space:nowrap" class="ft032">Antiretroviral&#160;Guidelines). Posaconazole&#160;and voriconazole&#160;have&#160;known&#160;drug–drug interactions with&#160;<br/>ARVs.</p>
<p style="position:absolute;top:920px;left:156px;white-space:nowrap" class="ft038">50</p>
<p style="position:absolute;top:922px;left:167px;white-space:nowrap" class="ft013">&#160;In certain situations, surgical&#160;intervention may be&#160;indicated and is a bedside&#160;decision.</p>
<p style="position:absolute;top:920px;left:760px;white-space:nowrap" class="ft038">24</p>
<p style="position:absolute;top:922px;left:772px;white-space:nowrap" class="ft012"><b>&#160;</b></p>
<p style="position:absolute;top:959px;left:108px;white-space:nowrap" class="ft029"><i><b>Therapy&#160;After Immune Reconstitution&#160;</b></i></p>
<p style="position:absolute;top:1000px;left:108px;white-space:nowrap" class="ft013">People&#160;with&#160;HIV&#160;and peripheral&#160;blood&#160;CD4 counts&#160;</p>
<p style="position:absolute;top:1000px;left:462px;white-space:nowrap" class="ft069">≥</p>
<p style="position:absolute;top:1000px;left:472px;white-space:nowrap" class="ft018">250 cells/mm</p>
<p style="position:absolute;top:999px;left:565px;white-space:nowrap" class="ft038">3</p>
<p style="position:absolute;top:1000px;left:571px;white-space:nowrap" class="ft013">&#160;appear capable of maintaining&#160;</p>
<p style="position:absolute;top:1020px;left:108px;white-space:nowrap" class="ft013">their coccidioidal-specific cellular immune response.</p>
<p style="position:absolute;top:1018px;left:473px;white-space:nowrap" class="ft038">51</p>
<p style="position:absolute;top:1020px;left:485px;white-space:nowrap" class="ft013">&#160;Moreover, a prospective study has&#160;</p>
<p style="position:absolute;top:1040px;left:108px;white-space:nowrap" class="ft032">demonstrated that&#160;coccidioidomycosis&#160;is less&#160;severe in those with lower HIV&#160;RNA and higher CD4&#160;<br/>counts.</p>
<p style="position:absolute;top:1058px;left:157px;white-space:nowrap" class="ft038">3</p>
<p style="position:absolute;top:1060px;left:163px;white-space:nowrap" class="ft013">&#160;Given these facts, in people&#160;with HIV who have&#160;undetectable HIV&#160;RNA&#160;on potent ART and&#160;</p>
</div>
<!-- Page 83 -->
<a name="83"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}	.ft0101{font-size:17px;font-family:OUOJFR+TimesNewRoman;color:#000000;}
-->
</style>
<div id="page83-div" style="position:relative;width:917px;height:1187px;">
<p style="position:absolute;top:1128px;left:108px;white-space:nowrap" class="ft024"><i>Guidelines for the Prevention and Treatment&#160;of&#160;Opportunistic&#160;Infections in Adults&#160;and Adolescents&#160;With HIV&#160;</i></p>
<p style="position:absolute;top:1128px;left:791px;white-space:nowrap" class="ft024"><i>F-8</i></p>
<p style="position:absolute;top:109px;left:108px;white-space:nowrap" class="ft018">who have CD4 count&#160;</p>
<p style="position:absolute;top:109px;left:259px;white-space:nowrap" class="ft069">≥</p>
<p style="position:absolute;top:109px;left:268px;white-space:nowrap" class="ft018">250 cells/mm</p>
<p style="position:absolute;top:107px;left:361px;white-space:nowrap" class="ft038">3</p>
<p style="position:absolute;top:109px;left:367px;white-space:nowrap" class="ft013">, coccidioidomycosis should be&#160;managed no differently than it&#160;</p>
<p style="position:absolute;top:129px;left:108px;white-space:nowrap" class="ft013">is in patients in the&#160;general&#160;population&#160;</p>
<p style="position:absolute;top:129px;left:376px;white-space:nowrap" class="ft012"><b>(AII).&#160;</b></p>
<p style="position:absolute;top:166px;left:108px;white-space:nowrap" class="ft032">For patients&#160;with focal&#160;pulmonary disease who meet the above criteria, treatment with a triazole&#160;<br/>antifungal agent&#160;should continue for a&#160;minimum of 3 to 6 months&#160;</p>
<p style="position:absolute;top:185px;left:563px;white-space:nowrap" class="ft012"><b>(AII).</b></p>
<p style="position:absolute;top:185px;left:604px;white-space:nowrap" class="ft013">&#160;For&#160;patients with diffuse&#160;</p>
<p style="position:absolute;top:205px;left:108px;white-space:nowrap" class="ft032">pulmonary disease or those with extrathoracic dissemination, antifungal&#160;therapy should&#160;continue&#160;for&#160;<br/>at&#160;least 12 months and usually much longer. Therapy should&#160;be discontinued based on clinical&#160;and&#160;<br/>immunological&#160;response and in consultation with an expert&#160;</p>
<p style="position:absolute;top:245px;left:520px;white-space:nowrap" class="ft012"><b>(BIII).</b></p>
<p style="position:absolute;top:245px;left:567px;white-space:nowrap" class="ft013">&#160;For people&#160;with&#160;detectable&#160;HIV&#160;</p>
<p style="position:absolute;top:265px;left:108px;white-space:nowrap" class="ft013">viremia or CD4 count&#160;&lt;250 cells/mm</p>
<p style="position:absolute;top:263px;left:366px;white-space:nowrap" class="ft038">3</p>
<p style="position:absolute;top:265px;left:372px;white-space:nowrap" class="ft013">, antifungal therapy at&#160;full&#160;dose should&#160;continue&#160;</p>
<p style="position:absolute;top:265px;left:706px;white-space:nowrap" class="ft012"><b>(BIII).</b></p>
<p style="position:absolute;top:265px;left:753px;white-space:nowrap" class="ft017"><i><b>&#160;</b></i></p>
<p style="position:absolute;top:302px;left:108px;white-space:nowrap" class="ft029"><i><b>Preventing&#160;Relapse&#160;</b></i></p>
<p style="position:absolute;top:343px;left:108px;white-space:nowrap" class="ft032">Relapse of coccidioidomycosis occurs in 25% to 33% of individuals without HIV&#160;who have diffuse&#160;<br/>pulmonary coccidioidomycosis or&#160;non-meningeal&#160;disseminated&#160;coccidioidomycosis</p>
<p style="position:absolute;top:362px;left:686px;white-space:nowrap" class="ft038">52,53</p>
<p style="position:absolute;top:363px;left:711px;white-space:nowrap" class="ft013">&#160;and may&#160;</p>
<p style="position:absolute;top:383px;left:108px;white-space:nowrap" class="ft018">occur in people&#160;with HIV&#160;who have&#160;CD4 counts&#160;</p>
<p style="position:absolute;top:383px;left:445px;white-space:nowrap" class="ft069">≥</p>
<p style="position:absolute;top:383px;left:455px;white-space:nowrap" class="ft018">250 cells/mm</p>
<p style="position:absolute;top:382px;left:549px;white-space:nowrap" class="ft038">3</p>
<p style="position:absolute;top:383px;left:554px;white-space:nowrap" class="ft013">&#160;and are virologically suppressed on&#160;</p>
<p style="position:absolute;top:403px;left:108px;white-space:nowrap" class="ft013">ARVs.</p>
<p style="position:absolute;top:401px;left:156px;white-space:nowrap" class="ft038">1,54</p>
<p style="position:absolute;top:403px;left:175px;white-space:nowrap" class="ft013">&#160;Patients&#160;with&#160;diffuse or&#160;focal coccidioidal&#160;pneumonia&#160;should have serial&#160;chest radiographs&#160;</p>
<p style="position:absolute;top:423px;left:108px;white-space:nowrap" class="ft032">and coccidioidal&#160;serology&#160;tests every 3&#160;to 6 months&#160;during coccidioidomycosis therapy and for 2 to&#160;<br/>3 years&#160;after&#160;therapy discontinuation&#160;</p>
<p style="position:absolute;top:442px;left:364px;white-space:nowrap" class="ft012"><b>(BIII).</b></p>
<p style="position:absolute;top:442px;left:411px;white-space:nowrap" class="ft013">&#160;Relapses have been reported in&#160;</p>
<p style="position:absolute;top:442px;left:634px;white-space:nowrap" class="ft069">≥</p>
<p style="position:absolute;top:442px;left:644px;white-space:nowrap" class="ft013">80% of patients with&#160;</p>
<p style="position:absolute;top:462px;left:108px;white-space:nowrap" class="ft013">meningitis in whom triazoles have been discontinued.</p>
<p style="position:absolute;top:461px;left:479px;white-space:nowrap" class="ft038">55</p>
<p style="position:absolute;top:462px;left:490px;white-space:nowrap" class="ft013">&#160;Therefore, therapy for coccidioidal&#160;</p>
<p style="position:absolute;top:482px;left:108px;white-space:nowrap" class="ft032">meningitis with treatment&#160;doses&#160;of the&#160;azole&#160;should&#160;be continued for life even&#160;in those with immune&#160;<br/>reconstitution&#160;</p>
<p style="position:absolute;top:502px;left:207px;white-space:nowrap" class="ft012"><b>(AII).</b></p>
<p style="position:absolute;top:502px;left:249px;white-space:nowrap" class="ft013">&#160;</p>
<p style="position:absolute;top:538px;left:108px;white-space:nowrap" class="ft026"><b>Special Considerations During&#160;Pregnancy&#160;</b></p>
<p style="position:absolute;top:580px;left:108px;white-space:nowrap" class="ft0101">During pregnancy, c</p>
<p style="position:absolute;top:580px;left:249px;white-space:nowrap" class="ft013">occidioidomycosis should&#160;be&#160;considered in the differential&#160;diagnosis of&#160;a&#160;</p>
<p style="position:absolute;top:600px;left:108px;white-space:nowrap" class="ft013">consistent clinical&#160;presentation&#160;</p>
<p style="position:absolute;top:600px;left:325px;white-space:nowrap" class="ft0101">and the presence of epidemiological risk such as&#160;</p>
<p style="position:absolute;top:600px;left:664px;white-space:nowrap" class="ft013">living in an&#160;</p>
<p style="position:absolute;top:620px;left:108px;white-space:nowrap" class="ft013">endemic region or&#160;</p>
<p style="position:absolute;top:620px;left:238px;white-space:nowrap" class="ft0101">having</p>
<p style="position:absolute;top:620px;left:285px;white-space:nowrap" class="ft013">&#160;an appropriate&#160;travel history.&#160;Reactivation&#160;during pregnancy in individuals&#160;</p>
<p style="position:absolute;top:640px;left:108px;white-space:nowrap" class="ft032">with prior&#160;coccidioidomycosis but without&#160;active&#160;disease is uncommon, though&#160;the&#160;risk&#160;may be&#160;<br/>somewhat higher&#160;with a history&#160;of disseminated coccidioidomycosis.</p>
<p style="position:absolute;top:658px;left:585px;white-space:nowrap" class="ft038">56</p>
<p style="position:absolute;top:660px;left:596px;white-space:nowrap" class="ft039">&#160;</p>
<p style="position:absolute;top:660px;left:600px;white-space:nowrap" class="ft013">When coccidioidomycosis&#160;is&#160;</p>
<p style="position:absolute;top:680px;left:108px;white-space:nowrap" class="ft032">acquired later in&#160;pregnancy (e.g.,&#160;during the&#160;second or third trimester) the infection is more likely to&#160;<br/>be more&#160;severe and potentially disseminated,&#160;with the greatest severity&#160;occurring during&#160;the&#160;<br/>immediate postpartum&#160;period.</p>
<p style="position:absolute;top:718px;left:316px;white-space:nowrap" class="ft038">56</p>
<p style="position:absolute;top:719px;left:327px;white-space:nowrap" class="ft013">&#160;There is no&#160;evidence that maternal&#160;coccidioidomycosis increases&#160;</p>
<p style="position:absolute;top:739px;left:108px;white-space:nowrap" class="ft032">risk for&#160;pregnancy&#160;loss&#160;or&#160;premature delivery. Perinatal&#160;infection is uncommon&#160;and most&#160;likely&#160;<br/>acquired during delivery.</p>
<p style="position:absolute;top:758px;left:282px;white-space:nowrap" class="ft038">56</p>
<p style="position:absolute;top:759px;left:293px;white-space:nowrap" class="ft012"><b>&#160;</b></p>
<p style="position:absolute;top:796px;left:108px;white-space:nowrap" class="ft032">Intravenous&#160;amphotericin B, formulated with deoxycholate&#160;or as&#160;a lipid preparation, is the preferred&#160;<br/>treatment for non-meningeal&#160;coccidioidomycosis during&#160;the&#160;first trimester&#160;of pregnancy&#160;</p>
<p style="position:absolute;top:816px;left:719px;white-space:nowrap" class="ft012"><b>(AIII).</b></p>
<p style="position:absolute;top:816px;left:767px;white-space:nowrap" class="ft013">&#160;</p>
<p style="position:absolute;top:836px;left:108px;white-space:nowrap" class="ft032">Extensive clinical&#160;use of amphotericin B has not been&#160;associated&#160;with&#160;teratogenicity.&#160;There&#160;remain&#160;<br/>significant gaps in determining&#160;optimal&#160;dosing regimens in&#160;pregnancy;&#160;a recent&#160;review of dosing&#160;<br/>strategies in&#160;pregnancy recommended use&#160;of ideal&#160;body weight&#160;rather than total body weight&#160;to&#160;<br/>minimize risk&#160;of adverse&#160;effects to&#160;the&#160;fetus while&#160;maintaining efficacy.</p>
<p style="position:absolute;top:894px;left:604px;white-space:nowrap" class="ft038">57</p>
<p style="position:absolute;top:895px;left:616px;white-space:nowrap" class="ft013">&#160;Neonates born&#160;to women&#160;</p>
<p style="position:absolute;top:915px;left:108px;white-space:nowrap" class="ft032">on chronic amphotericin B&#160;at delivery may&#160;be at&#160;increased risk&#160;for renal toxicity and electrolyte&#160;<br/>abnormalities and&#160;should&#160;be appropriately evaluated as newborns.</p>
<p style="position:absolute;top:933px;left:564px;white-space:nowrap" class="ft038">58</p>
<p style="position:absolute;top:935px;left:575px;white-space:nowrap" class="ft013">&#160;</p>
<p style="position:absolute;top:972px;left:108px;white-space:nowrap" class="ft032">For coccidioidal meningitis in the first&#160;trimester, for&#160;which the only&#160;alternative treatment to&#160;triazole&#160;<br/>antifungals is&#160;intrathecal amphotericin&#160;B, the decision regarding choice of&#160;treatment should be based&#160;<br/>on considerations of benefit versus&#160;potential risk&#160;and made in consultation with the p</p>
<p style="position:absolute;top:1012px;left:694px;white-space:nowrap" class="ft0101">atient</p>
<p style="position:absolute;top:1012px;left:733px;white-space:nowrap" class="ft013">,&#160;the&#160;</p>
<p style="position:absolute;top:1031px;left:108px;white-space:nowrap" class="ft013">infectious diseases consultant,&#160;and the&#160;obstetrician.</p>
<p style="position:absolute;top:1030px;left:461px;white-space:nowrap" class="ft038">56</p>
<p style="position:absolute;top:1031px;left:472px;white-space:nowrap" class="ft013">&#160;</p>
</div>
<!-- Page 84 -->
<a name="84"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}	.ft0102{font-size:17px;font-family:TURBHP+Tinos;color:#1f1f1f;}
	.ft0103{font-size:17px;font-family:OUOJFR+TimesNewRoman;color:#1f1f1f;}
	.ft0104{font-size:11px;font-family:TURBHP+Tinos;color:#1f1f1f;}
	.ft0105{font-size:17px;font-family:ICIUHX+TimesNewRomanPSMT;color:#1f1f1f;}
	.ft0106{font-size:17px;font-family:KPYRPS+Tinos;color:#1f1f1f;}
	.ft0107{font-size:17px;font-family:AWFWWM+TimesNewRomanPSMT;color:#1f1f1f;}
	.ft0108{font-size:11px;font-family:TURBHP+Tinos;color:#202020;}
	.ft0109{font-size:17px;font-family:ICIUHX+TimesNewRomanPSMT;color:#202020;}
	.ft0110{font-size:17px;line-height:19px;font-family:TURBHP+Tinos;color:#1f1f1f;}
-->
</style>
<div id="page84-div" style="position:relative;width:917px;height:1187px;">
<p style="position:absolute;top:1128px;left:108px;white-space:nowrap" class="ft024"><i>Guidelines for the Prevention and Treatment&#160;of&#160;Opportunistic&#160;Infections in Adults&#160;and Adolescents&#160;With HIV&#160;</i></p>
<p style="position:absolute;top:1128px;left:791px;white-space:nowrap" class="ft024"><i>F-9</i></p>
<p style="position:absolute;top:109px;left:108px;white-space:nowrap" class="ft013">In general, azole antifungals&#160;</p>
<p style="position:absolute;top:109px;left:307px;white-space:nowrap" class="ft012"><b>should be avoided</b></p>
<p style="position:absolute;top:109px;left:440px;white-space:nowrap" class="ft013">&#160;during the first&#160;trimester of pregnancy unless&#160;the&#160;</p>
<p style="position:absolute;top:129px;left:108px;white-space:nowrap" class="ft013">benefit&#160;is felt to outweigh&#160;the risk</p>
<p style="position:absolute;top:129px;left:341px;white-space:nowrap" class="ft012"><b>&#160;(BIII).</b></p>
<p style="position:absolute;top:129px;left:392px;white-space:nowrap" class="ft013">&#160;Fluconazole&#160;has teratogenic potential in the&#160;first trimester.&#160;</p>
<p style="position:absolute;top:148px;left:108px;white-space:nowrap" class="ft032">After the first trimester or when disease is diagnosed after the first trimester, treatment with&#160;<br/>fluconazole&#160;or itraconazole could be&#160;considered&#160;</p>
<p style="position:absolute;top:168px;left:442px;white-space:nowrap" class="ft012"><b>(AIII).</b></p>
<p style="position:absolute;top:167px;left:491px;white-space:nowrap" class="ft038">24</p>
<p style="position:absolute;top:168px;left:502px;white-space:nowrap" class="ft012"><b>&#160;</b></p>
<p style="position:absolute;top:168px;left:506px;white-space:nowrap" class="ft013">Congenital&#160;malformations, including&#160;</p>
<p style="position:absolute;top:188px;left:108px;white-space:nowrap" class="ft032">craniofacial&#160;and limb abnormalities similar to those observed in&#160;animals&#160;exposed to fluconazole,&#160;<br/>have&#160;been reported in infants born to&#160;mothers who&#160;received fluconazole&#160;through or beyond the&#160;first&#160;<br/>trimester of pregnancy.</p>
<p style="position:absolute;top:226px;left:269px;white-space:nowrap" class="ft038">56,59</p>
<p style="position:absolute;top:228px;left:294px;white-space:nowrap" class="ft013">&#160;Furthermore animal&#160;data suggest that moderate&#160;alcohol&#160;consumption&#160;</p>
<p style="position:absolute;top:248px;left:108px;white-space:nowrap" class="ft032">during pregnancy may increase the potency of fluconazole&#160;resulting in increased risk of craniofacial&#160;<br/>defects.</p>
<p style="position:absolute;top:266px;left:161px;white-space:nowrap" class="ft038">60</p>
<p style="position:absolute;top:267px;left:173px;white-space:nowrap" class="ft095"><b>&#160;</b></p>
<p style="position:absolute;top:304px;left:108px;white-space:nowrap" class="ft032">Most studies&#160;on the&#160;effects of fluconazole&#160;in pregnancy have involved low doses and&#160;short-term&#160;<br/>exposure.&#160;A&#160;meta-analysis of literature&#160;</p>
<p style="position:absolute;top:324px;left:380px;white-space:nowrap" class="ft0102">describing birth defects in infants&#160;exposed to fluconazole&#160;</p>
<p style="position:absolute;top:344px;left:108px;white-space:nowrap" class="ft0110">during the first trimester evaluated nine cohort, case-control or randomized controlled studies,&#160;<br/>including 53,407&#160;</p>
<p style="position:absolute;top:364px;left:229px;white-space:nowrap" class="ft0103">pregnancies</p>
<p style="position:absolute;top:364px;left:312px;white-space:nowrap" class="ft0102">&#160;</p>
<p style="position:absolute;top:364px;left:316px;white-space:nowrap" class="ft0103">with fluconazole exposure&#160;</p>
<p style="position:absolute;top:364px;left:503px;white-space:nowrap" class="ft0102">and 3,319,353&#160;</p>
<p style="position:absolute;top:364px;left:605px;white-space:nowrap" class="ft0103">without</p>
<p style="position:absolute;top:364px;left:658px;white-space:nowrap" class="ft0102">&#160;</p>
<p style="position:absolute;top:364px;left:662px;white-space:nowrap" class="ft0103">fluconazole&#160;</p>
<p style="position:absolute;top:384px;left:108px;white-space:nowrap" class="ft0103">exposure</p>
<p style="position:absolute;top:384px;left:170px;white-space:nowrap" class="ft0102">.</p>
<p style="position:absolute;top:382px;left:175px;white-space:nowrap" class="ft0104">61</p>
<p style="position:absolute;top:384px;left:186px;white-space:nowrap" class="ft0102">&#160;Maternal fluconazole use was correlated with an increased prevalence of heart defects in&#160;</p>
<p style="position:absolute;top:404px;left:108px;white-space:nowrap" class="ft0102">infants for both a low dose (</p>
<p style="position:absolute;top:404px;left:303px;white-space:nowrap" class="ft0105">≤</p>
<p style="position:absolute;top:404px;left:312px;white-space:nowrap" class="ft0102">150 mg) (odds ratio [OR]&#160;1.95;&#160;95%&#160;confidence&#160;interval&#160;[CI],&#160;1.18–</p>
<p style="position:absolute;top:424px;left:108px;white-space:nowrap" class="ft0102">3.21;&#160;</p>
<p style="position:absolute;top:424px;left:147px;white-space:nowrap" class="ft0106"><i>P</i></p>
<p style="position:absolute;top:424px;left:158px;white-space:nowrap" class="ft0107">&#160;=&#160;0.01)&#160;</p>
<p style="position:absolute;top:424px;left:208px;white-space:nowrap" class="ft0102">and any dose (OR 1.79; 95% CI, 1.18–2.71;&#160;</p>
<p style="position:absolute;top:424px;left:516px;white-space:nowrap" class="ft0106"><i>P</i></p>
<p style="position:absolute;top:424px;left:526px;white-space:nowrap" class="ft0107">&#160;=&#160;0.01). No association was found&#160;</p>
<p style="position:absolute;top:443px;left:108px;white-space:nowrap" class="ft0107">between&#160;</p>
<p style="position:absolute;top:443px;left:170px;white-space:nowrap" class="ft0102">fluconazole exposure and orofacial, CNS, genitourinary, musculoskeletal, or gastrointestinal&#160;</p>
<p style="position:absolute;top:463px;left:108px;white-space:nowrap" class="ft0102">defects at&#160;either&#160;low- or high-dose exposure to fluconazole.&#160;</p>
<p style="position:absolute;top:463px;left:522px;white-space:nowrap" class="ft013">One registry-based cohort study of 7,352&#160;</p>
<p style="position:absolute;top:483px;left:108px;white-space:nowrap" class="ft013">women&#160;reported&#160;a&#160;threefold increase in incidence of Tetralogy of Fallot,</p>
<p style="position:absolute;top:482px;left:606px;white-space:nowrap" class="ft038">62</p>
<p style="position:absolute;top:483px;left:617px;white-space:nowrap" class="ft013">&#160;and a large population-</p>
<p style="position:absolute;top:503px;left:108px;white-space:nowrap" class="ft032">based&#160;case-control study specifically noted an increase in transposition of the great arteries (OR 7.56;&#160;<br/>95% CI, 1.22–35.45).</p>
<p style="position:absolute;top:521px;left:258px;white-space:nowrap" class="ft038">63</p>
<p style="position:absolute;top:523px;left:269px;white-space:nowrap" class="ft013">&#160;The latter study also suggested an increase in cleft lip with cleft palate (OR&#160;</p>
<p style="position:absolute;top:543px;left:108px;white-space:nowrap" class="ft032">5.53; 95% CI, 1.68–18.24). In three nested case-control studies using data from the Quebec&#160;<br/>Prescription Drug Insurance&#160;database, there was&#160;an increased prevalence&#160;of cardiac septal closure&#160;<br/>anomalies for maternal fluconazole&#160;doses greater than&#160;150 mg during&#160;pregnancy (OR&#160;1.81; 95% CI,&#160;<br/>1.04–3.14).</p>
<p style="position:absolute;top:601px;left:187px;white-space:nowrap" class="ft038">64</p>
<p style="position:absolute;top:602px;left:199px;white-space:nowrap" class="ft013">&#160;A recent population-based cohort study (included in the meta-analysis) of 1,969,954&#160;</p>
<p style="position:absolute;top:622px;left:108px;white-space:nowrap" class="ft032">pregnancies, including 37,650 pregnancies exposed to fluconazole, found an increased risk of&#160;<br/>musculoskeletal malformations following exposure to fluconazole during the first trimester of&#160;<br/>pregnancy&#160;</p>
<p style="position:absolute;top:662px;left:184px;white-space:nowrap" class="ft0102">(risk of 52.1 per 10,000 pregnancies exposed to fluconazole versus 37.3 per 10,000&#160;</p>
<p style="position:absolute;top:681px;left:108px;white-space:nowrap" class="ft0102">pregnancies exposed to topical azoles)</p>
<p style="position:absolute;top:681px;left:374px;white-space:nowrap" class="ft013">.</p>
<p style="position:absolute;top:680px;left:378px;white-space:nowrap" class="ft038">65</p>
<p style="position:absolute;top:681px;left:389px;white-space:nowrap" class="ft013">&#160;</p>
<p style="position:absolute;top:718px;left:108px;white-space:nowrap" class="ft032">A systematic review and&#160;meta-analysis of 6 cohort&#160;or case-control&#160;studies that analyzed more than&#160;<br/>16,000 exposures and&#160;reported fetal&#160;outcomes after&#160;exposure&#160;to fluconazole used&#160;in the first trimester&#160;<br/>of pregnancy&#160;found a marginal&#160;association with&#160;increased risk&#160;of congenital&#160;malformations (OR&#160;<br/>1.09;&#160;95% CI, 0.99–1.2,&#160;</p>
<p style="position:absolute;top:778px;left:278px;white-space:nowrap" class="ft019"><i>P&#160;</i></p>
<p style="position:absolute;top:778px;left:293px;white-space:nowrap" class="ft013">=&#160;0.088), including&#160;heart defects, as well&#160;as&#160;spontaneous&#160;abortion;&#160;</p>
<p style="position:absolute;top:798px;left:108px;white-space:nowrap" class="ft013">exposure to more&#160;than 150 mg&#160;was&#160;associated with an&#160;overall&#160;increase in congenital&#160;malformations.</p>
<p style="position:absolute;top:796px;left:797px;white-space:nowrap" class="ft038">61</p>
<p style="position:absolute;top:798px;left:809px;white-space:nowrap" class="ft013">&#160;</p>
<p style="position:absolute;top:835px;left:108px;white-space:nowrap" class="ft032">A nationwide&#160;cohort&#160;study in&#160;Denmark found&#160;that exposure to&#160;oral fluconazole&#160;during pregnancy&#160;<br/>was&#160;associated with an increased risk of&#160;spontaneous abortion&#160;compared with&#160;unexposed pregnancies&#160;</p>
<p style="position:absolute;top:875px;left:108px;white-space:nowrap" class="ft091">(n = 16,561;&#160;hazard ratio [HR] 1.48; 95%&#160;CI, 1.23–1.77)</p>
<p style="position:absolute;top:873px;left:500px;white-space:nowrap" class="ft0108">&#160;</p>
<p style="position:absolute;top:875px;left:502px;white-space:nowrap" class="ft013">or those&#160;with topical azole&#160;exposure only&#160;</p>
<p style="position:absolute;top:875px;left:791px;white-space:nowrap" class="ft091">(n&#160;</p>
<p style="position:absolute;top:894px;left:108px;white-space:nowrap" class="ft091">= 5,646;&#160;HR 1.62; 95%&#160;CI, 1.26–2.07)</p>
<p style="position:absolute;top:894px;left:374px;white-space:nowrap" class="ft013">.</p>
<p style="position:absolute;top:893px;left:379px;white-space:nowrap" class="ft038">66</p>
<p style="position:absolute;top:894px;left:390px;white-space:nowrap" class="ft013">&#160;Similarly,&#160;the&#160;nested&#160;case-control&#160;studies in&#160;Canada&#160;</p>
<p style="position:absolute;top:914px;left:108px;white-space:nowrap" class="ft013">(n =&#160;</p>
<p style="position:absolute;top:914px;left:141px;white-space:nowrap" class="ft091">320,868 pregnancies)</p>
<p style="position:absolute;top:914px;left:290px;white-space:nowrap" class="ft013">&#160;found that exposure to oral fluconazole during pregnancy was associated&#160;</p>
<p style="position:absolute;top:934px;left:108px;white-space:nowrap" class="ft032">with an increased risk of spontaneous abortion compared with unexposed pregnancies and that risk&#160;<br/>was greater with higher dose of fluconazole exposure&#160;</p>
<p style="position:absolute;top:954px;left:481px;white-space:nowrap" class="ft091">(adjusted OR for&#160;</p>
<p style="position:absolute;top:954px;left:602px;white-space:nowrap" class="ft0109">≤</p>
<p style="position:absolute;top:954px;left:611px;white-space:nowrap" class="ft091">150&#160;mg&#160;fluconazole&#160;2.23;&#160;</p>
<p style="position:absolute;top:974px;left:108px;white-space:nowrap" class="ft091">95% CI, 1.96–2.54; adjusted OR for&#160;&gt;150&#160;mg&#160;fluconazole&#160;3.20; 95% CI, 2.73–3.75)</p>
<p style="position:absolute;top:974px;left:690px;white-space:nowrap" class="ft013">.</p>
<p style="position:absolute;top:972px;left:694px;white-space:nowrap" class="ft038">64</p>
<p style="position:absolute;top:974px;left:705px;white-space:nowrap" class="ft013">&#160;However, a&#160;</p>
<p style="position:absolute;top:994px;left:108px;white-space:nowrap" class="ft032">cohort study using Swedish and Norwegian registry data (n = 1,485,316 pregnancies) found no&#160;<br/>association between fluconazole use during pregnancy and risk of stillbirth or neonatal death.</p>
<p style="position:absolute;top:1012px;left:753px;white-space:nowrap" class="ft038">67</p>
<p style="position:absolute;top:1013px;left:765px;white-space:nowrap" class="ft013">&#160;The&#160;</p>
<p style="position:absolute;top:1033px;left:108px;white-space:nowrap" class="ft013">meta-analysis noted above also found&#160;</p>
<p style="position:absolute;top:1033px;left:372px;white-space:nowrap" class="ft0102">no association between fluconazole exposure and risk of&#160;</p>
</div>
<!-- Page 85 -->
<a name="85"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page85-div" style="position:relative;width:917px;height:1187px;">
<p style="position:absolute;top:1128px;left:108px;white-space:nowrap" class="ft024"><i>Guidelines for the Prevention and Treatment&#160;of&#160;Opportunistic&#160;Infections in Adults&#160;and Adolescents&#160;With HIV&#160;</i></p>
<p style="position:absolute;top:1128px;left:784px;white-space:nowrap" class="ft024"><i>F-10&#160;</i></p>
<p style="position:absolute;top:109px;left:108px;white-space:nowrap" class="ft0102">abortion or stillbirth.</p>
<p style="position:absolute;top:109px;left:251px;white-space:nowrap" class="ft013">&#160;On the basis of&#160;reported birth&#160;defects, the&#160;use of fluconazole in the first&#160;</p>
<p style="position:absolute;top:129px;left:108px;white-space:nowrap" class="ft013">trimester should be&#160;considered only if the&#160;benefits clearly outweigh the&#160;risks. &#160;</p>
<p style="position:absolute;top:166px;left:108px;white-space:nowrap" class="ft032">Although case reports of birth defects in infants exposed to itraconazole have&#160;occurred, a recent&#160;<br/>systematic review and meta-analysis of four cohort studies involving 971,450&#160;pregnant&#160;women with&#160;<br/>1,311 exposures found&#160;no&#160;significant&#160;difference&#160;in the overall&#160;risk of birth defects between those with&#160;<br/>maternal&#160;exposure to itraconazole and&#160;non-exposure.</p>
<p style="position:absolute;top:224px;left:473px;white-space:nowrap" class="ft038">68</p>
<p style="position:absolute;top:225px;left:484px;white-space:nowrap" class="ft013">&#160;Although limb and congenital&#160;heart defects&#160;</p>
<p style="position:absolute;top:245px;left:108px;white-space:nowrap" class="ft032">were the&#160;most common defects seen, they were within the rates of these defects published by&#160;<br/>EUROCAT (the&#160;European&#160;network of&#160;population-based registries for epidemiological&#160;surveillance of&#160;<br/>congenital anomalies). However, the&#160;rate of eye&#160;defects was higher than that&#160;published by&#160;<br/>EUROCAT.&#160;No difference was found&#160;in rates of in&#160;spontaneous&#160;abortion or stillbirth based on&#160;<br/>itraconazole exposure. In&#160;sum, itraconazole&#160;should&#160;be used in pregnancy depending on a&#160;cost-benefit&#160;<br/>analysis.&#160;&#160;</p>
<p style="position:absolute;top:381px;left:108px;white-space:nowrap" class="ft032">Voriconazole (at doses lower than recommended human doses),&#160;posaconazole, and isavuconazole&#160;are&#160;<br/>teratogenic and embryotoxic&#160;in animal studies; no adequately controlled studies have assessed their&#160;<br/>teratogenicity and embryotoxicity in humans. Voriconazole, posaconazole, and isavuconazole&#160;</p>
<p style="position:absolute;top:421px;left:760px;white-space:nowrap" class="ft012"><b>are&#160;</b></p>
<p style="position:absolute;top:441px;left:108px;white-space:nowrap" class="ft012"><b>not recommended</b></p>
<p style="position:absolute;top:441px;left:241px;white-space:nowrap" class="ft013">&#160;for use during pregnancy, especially in the first trimester&#160;</p>
<p style="position:absolute;top:441px;left:640px;white-space:nowrap" class="ft012"><b>(AIII).</b></p>
<p style="position:absolute;top:441px;left:689px;white-space:nowrap" class="ft095"><b>&#160;</b></p>
</div>
<!-- Page 86 -->
<a name="86"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}	.ft0111{font-size:18px;font-family:TURBHP+Tinos;color:#000000;}
	.ft0112{font-size:18px;font-family:KPYRPS+Tinos;color:#000000;}
	.ft0113{font-size:18px;font-family:TURBHP+Tinos;color:#005299;}
	.ft0114{font-size:18px;line-height:20px;font-family:TURBHP+Tinos;color:#000000;}
-->
</style>
<div id="page86-div" style="position:relative;width:917px;height:1187px;">
<p style="position:absolute;top:1128px;left:108px;white-space:nowrap" class="ft024"><i>Guidelines for the Prevention and Treatment&#160;of&#160;Opportunistic&#160;Infections in Adults&#160;and Adolescents&#160;With HIV&#160;</i></p>
<p style="position:absolute;top:1128px;left:784px;white-space:nowrap" class="ft024"><i>F-11&#160;</i></p>
<p style="position:absolute;top:108px;left:108px;white-space:nowrap" class="ft026"><b>References&#160;</b></p>
<p style="position:absolute;top:150px;left:108px;white-space:nowrap" class="ft0111">1.</p>
<p style="position:absolute;top:150px;left:162px;white-space:nowrap" class="ft0111">1.&#160;</p>
<p style="position:absolute;top:150px;left:216px;white-space:nowrap" class="ft0111">Jones&#160;JL, Fleming PL, Ciesielski CA, Hu DJ, Kaplan JE, Ward JW.&#160;</p>
<p style="position:absolute;top:171px;left:162px;white-space:nowrap" class="ft0111">Coccidioidomycosis&#160;among persons&#160;with AIDS in the United&#160;States.&#160;</p>
<p style="position:absolute;top:171px;left:660px;white-space:nowrap" class="ft0112"><i>J Infect Dis</i></p>
<p style="position:absolute;top:171px;left:743px;white-space:nowrap" class="ft0111">.&#160;</p>
<p style="position:absolute;top:192px;left:162px;white-space:nowrap" class="ft0111">1995;171(4):961-966. Available&#160;at:&#160;</p>
<p style="position:absolute;top:192px;left:422px;white-space:nowrap" class="ft0113">http://www.ncbi.nlm.nih.gov/pubmed/7706825</p>
<p style="position:absolute;top:192px;left:762px;white-space:nowrap" class="ft0111">.&#160;</p>
<p style="position:absolute;top:212px;left:108px;white-space:nowrap" class="ft0111">2.</p>
<p style="position:absolute;top:212px;left:162px;white-space:nowrap" class="ft0111">2.&#160;</p>
<p style="position:absolute;top:212px;left:216px;white-space:nowrap" class="ft0111">Litvintseva&#160;AP, Marsden-Haug N, Hurst S, et&#160;al. Valley&#160;fever: finding new places&#160;</p>
<p style="position:absolute;top:233px;left:162px;white-space:nowrap" class="ft0114">for&#160;an old disease:&#160;Coccidioides&#160;immitis&#160;found in&#160;Washington&#160;State soil associated with&#160;<br/>recent&#160;human infection.&#160;</p>
<p style="position:absolute;top:254px;left:337px;white-space:nowrap" class="ft0112"><i>Clin Infect&#160;Dis</i></p>
<p style="position:absolute;top:254px;left:443px;white-space:nowrap" class="ft0111">. 2015;60(1):e1-3. Available at:&#160;</p>
<p style="position:absolute;top:274px;left:162px;white-space:nowrap" class="ft0113">http://www.ncbi.nlm.nih.gov/pubmed/25165087</p>
<p style="position:absolute;top:274px;left:511px;white-space:nowrap" class="ft0111">.&#160;</p>
<p style="position:absolute;top:295px;left:108px;white-space:nowrap" class="ft0111">3.</p>
<p style="position:absolute;top:295px;left:162px;white-space:nowrap" class="ft0111">3.&#160;</p>
<p style="position:absolute;top:295px;left:216px;white-space:nowrap" class="ft0111">Masannat&#160;FY, Ampel NM. Coccidioidomycosis&#160;in patients&#160;with HIV-1 infection&#160;</p>
<p style="position:absolute;top:316px;left:162px;white-space:nowrap" class="ft0111">in the era of&#160;potent antiretroviral&#160;therapy.&#160;</p>
<p style="position:absolute;top:316px;left:464px;white-space:nowrap" class="ft0112"><i>Clin Infect Dis</i></p>
<p style="position:absolute;top:316px;left:570px;white-space:nowrap" class="ft0111">. 2010;50(1):1-7.&#160;Available at:&#160;</p>
<p style="position:absolute;top:336px;left:162px;white-space:nowrap" class="ft0113">http://www.ncbi.nlm.nih.gov/pubmed/19995218</p>
<p style="position:absolute;top:336px;left:511px;white-space:nowrap" class="ft0111">.&#160;</p>
<p style="position:absolute;top:357px;left:108px;white-space:nowrap" class="ft0111">4.</p>
<p style="position:absolute;top:357px;left:162px;white-space:nowrap" class="ft0111">4.&#160;</p>
<p style="position:absolute;top:357px;left:216px;white-space:nowrap" class="ft0111">Ampel&#160;NM, Dols&#160;CL, Galgiani&#160;JN. Coccidioidomycosis during human&#160;</p>
<p style="position:absolute;top:378px;left:162px;white-space:nowrap" class="ft0114">immunodeficiency virus&#160;infection: results&#160;of a&#160;prospective&#160;study in a coccidioidal&#160;<br/>endemic area.&#160;</p>
<p style="position:absolute;top:399px;left:266px;white-space:nowrap" class="ft0112"><i>Am&#160;J Med</i></p>
<p style="position:absolute;top:399px;left:339px;white-space:nowrap" class="ft0111">. 1993;94(3):235-240. Available&#160;at:&#160;</p>
<p style="position:absolute;top:419px;left:162px;white-space:nowrap" class="ft0113">http://www.ncbi.nlm.nih.gov/pubmed/8095771</p>
<p style="position:absolute;top:419px;left:502px;white-space:nowrap" class="ft0111">.&#160;</p>
<p style="position:absolute;top:440px;left:108px;white-space:nowrap" class="ft0111">5.</p>
<p style="position:absolute;top:440px;left:162px;white-space:nowrap" class="ft0111">5.&#160;</p>
<p style="position:absolute;top:440px;left:216px;white-space:nowrap" class="ft0111">Woods CW, McRill&#160;C, Plikaytis BD, et&#160;al. Coccidioidomycosis in human&#160;</p>
<p style="position:absolute;top:461px;left:162px;white-space:nowrap" class="ft0114">immunodeficiency virus-infected persons in Arizona, 1994-1997:&#160;incidence, risk&#160;factors,&#160;<br/>and prevention.&#160;</p>
<p style="position:absolute;top:481px;left:278px;white-space:nowrap" class="ft0112"><i>J Infect&#160;Dis</i></p>
<p style="position:absolute;top:481px;left:361px;white-space:nowrap" class="ft0111">. 2000;181(4):1428-1434. Available&#160;at:&#160;</p>
<p style="position:absolute;top:502px;left:162px;white-space:nowrap" class="ft0113">http://www.ncbi.nlm.nih.gov/pubmed/10753734</p>
<p style="position:absolute;top:502px;left:511px;white-space:nowrap" class="ft0111">.&#160;</p>
<p style="position:absolute;top:523px;left:108px;white-space:nowrap" class="ft0111">6.</p>
<p style="position:absolute;top:523px;left:162px;white-space:nowrap" class="ft0111">6.&#160;</p>
<p style="position:absolute;top:523px;left:216px;white-space:nowrap" class="ft0111">Fish DG, Ampel&#160;NM, Galgiani JN, et al. Coccidioidomycosis&#160;during human&#160;</p>
<p style="position:absolute;top:543px;left:162px;white-space:nowrap" class="ft0111">immunodeficiency virus&#160;infection. A&#160;review&#160;of 77&#160;patients.&#160;</p>
<p style="position:absolute;top:543px;left:593px;white-space:nowrap" class="ft0112"><i>Medicine (Baltimore)</i></p>
<p style="position:absolute;top:543px;left:748px;white-space:nowrap" class="ft0111">.&#160;</p>
<p style="position:absolute;top:564px;left:162px;white-space:nowrap" class="ft0111">1990;69(6):384-391. Available&#160;at:&#160;</p>
<p style="position:absolute;top:564px;left:413px;white-space:nowrap" class="ft0113">https://pubmed.ncbi.nlm.nih.gov/2146461/</p>
<p style="position:absolute;top:564px;left:721px;white-space:nowrap" class="ft0111">.&#160;</p>
<p style="position:absolute;top:585px;left:108px;white-space:nowrap" class="ft0111">7.</p>
<p style="position:absolute;top:585px;left:162px;white-space:nowrap" class="ft0111">7.&#160;</p>
<p style="position:absolute;top:585px;left:216px;white-space:nowrap" class="ft0111">Valdivia&#160;L,&#160;Nix D, Wright M, et&#160;al.&#160;Coccidioidomycosis&#160;as a common cause of&#160;</p>
<p style="position:absolute;top:606px;left:162px;white-space:nowrap" class="ft0111">community-acquired pneumonia.&#160;</p>
<p style="position:absolute;top:606px;left:405px;white-space:nowrap" class="ft0112"><i>Emerg Infect&#160;Dis</i></p>
<p style="position:absolute;top:606px;left:528px;white-space:nowrap" class="ft0111">. 2006;12(6):958-962. Available&#160;at:&#160;</p>
<p style="position:absolute;top:626px;left:162px;white-space:nowrap" class="ft0113">http://www.ncbi.nlm.nih.gov/pubmed/16707052</p>
<p style="position:absolute;top:626px;left:511px;white-space:nowrap" class="ft0111">.&#160;</p>
<p style="position:absolute;top:647px;left:108px;white-space:nowrap" class="ft0111">8.</p>
<p style="position:absolute;top:647px;left:162px;white-space:nowrap" class="ft0111">8.&#160;</p>
<p style="position:absolute;top:647px;left:216px;white-space:nowrap" class="ft0111">Kim MM, Blair JE, Carey EJ, Wu Q, Smilack JD. Coccidioidal&#160;pneumonia,&#160;</p>
<p style="position:absolute;top:668px;left:162px;white-space:nowrap" class="ft0111">Phoenix, Arizona, USA,&#160;2000-2004.&#160;</p>
<p style="position:absolute;top:668px;left:429px;white-space:nowrap" class="ft0112"><i>Emerg Infect&#160;Dis</i></p>
<p style="position:absolute;top:668px;left:552px;white-space:nowrap" class="ft0111">. 2009;15(3):397-401. Available at:&#160;</p>
<p style="position:absolute;top:688px;left:162px;white-space:nowrap" class="ft0113">http://www.ncbi.nlm.nih.gov/pubmed/19239751</p>
<p style="position:absolute;top:688px;left:511px;white-space:nowrap" class="ft0111">.&#160;</p>
<p style="position:absolute;top:709px;left:108px;white-space:nowrap" class="ft0111">9.</p>
<p style="position:absolute;top:709px;left:162px;white-space:nowrap" class="ft0111">9.&#160;</p>
<p style="position:absolute;top:709px;left:216px;white-space:nowrap" class="ft0111">Mahaffey KW, Hippenmeyer&#160;CL,&#160;Mandel R,&#160;Ampel&#160;NM. Unrecognized&#160;</p>
<p style="position:absolute;top:730px;left:162px;white-space:nowrap" class="ft0114">coccidioidomycosis&#160;complicating Pneumocystis&#160;carinii&#160;pneumonia&#160;in patients&#160;infected&#160;<br/>with the human immunodeficiency&#160;virus and&#160;treated with&#160;corticosteroids. A report of two&#160;<br/>cases.&#160;</p>
<p style="position:absolute;top:771px;left:209px;white-space:nowrap" class="ft0112"><i>Arch&#160;Intern&#160;Med</i></p>
<p style="position:absolute;top:771px;left:329px;white-space:nowrap" class="ft0111">.&#160;1993;153(12):1496-1498. Available at:&#160;</p>
<p style="position:absolute;top:792px;left:162px;white-space:nowrap" class="ft0113">http://www.ncbi.nlm.nih.gov/pubmed/8512440</p>
<p style="position:absolute;top:792px;left:502px;white-space:nowrap" class="ft0111">.&#160;</p>
<p style="position:absolute;top:813px;left:108px;white-space:nowrap" class="ft0111">10.</p>
<p style="position:absolute;top:813px;left:162px;white-space:nowrap" class="ft0111">10.&#160;</p>
<p style="position:absolute;top:813px;left:216px;white-space:nowrap" class="ft0111">Arguinchona HL, Ampel&#160;NM, Dols CL, Galgiani&#160;JN, Mohler&#160;MJ, Fish DG.&#160;</p>
<p style="position:absolute;top:833px;left:162px;white-space:nowrap" class="ft0114">Persistent&#160;coccidioidal&#160;seropositivity&#160;without clinical&#160;evidence of active&#160;<br/>coccidioidomycosis&#160;in patients&#160;infected with human immunodeficiency&#160;virus.&#160;</p>
<p style="position:absolute;top:854px;left:725px;white-space:nowrap" class="ft0112"><i>Clin Infect&#160;</i></p>
<p style="position:absolute;top:875px;left:162px;white-space:nowrap" class="ft0112"><i>Dis</i></p>
<p style="position:absolute;top:875px;left:187px;white-space:nowrap" class="ft0111">. 1995;20(5):1281-1285. Available&#160;at:&#160;</p>
<p style="position:absolute;top:875px;left:465px;white-space:nowrap" class="ft0113">http://www.ncbi.nlm.nih.gov/pubmed/7620011</p>
<p style="position:absolute;top:875px;left:805px;white-space:nowrap" class="ft0111">.&#160;</p>
<p style="position:absolute;top:895px;left:108px;white-space:nowrap" class="ft0111">11.</p>
<p style="position:absolute;top:895px;left:162px;white-space:nowrap" class="ft0111">11.&#160;</p>
<p style="position:absolute;top:895px;left:216px;white-space:nowrap" class="ft0111">Stevens DA, Clemons KV, Levine&#160;HB, et&#160;al. Expert opinion:&#160;what to do&#160;when&#160;</p>
<p style="position:absolute;top:916px;left:162px;white-space:nowrap" class="ft0111">there&#160;is Coccidioides exposure in a&#160;laboratory.&#160;</p>
<p style="position:absolute;top:916px;left:501px;white-space:nowrap" class="ft0112"><i>Clin Infect Dis</i></p>
<p style="position:absolute;top:916px;left:606px;white-space:nowrap" class="ft0111">. 2009;49(6):919-923.&#160;</p>
<p style="position:absolute;top:937px;left:162px;white-space:nowrap" class="ft0111">Available at:&#160;</p>
<p style="position:absolute;top:937px;left:259px;white-space:nowrap" class="ft0113">http://www.ncbi.nlm.nih.gov/pubmed/19663562</p>
<p style="position:absolute;top:937px;left:608px;white-space:nowrap" class="ft0111">.&#160;</p>
<p style="position:absolute;top:957px;left:108px;white-space:nowrap" class="ft0111">12.</p>
<p style="position:absolute;top:957px;left:162px;white-space:nowrap" class="ft0111">12.&#160;</p>
<p style="position:absolute;top:957px;left:216px;white-space:nowrap" class="ft0111">Blair JE, Ampel NM, Hoover SE. Coccidioidomycosis in&#160;selected&#160;</p>
<p style="position:absolute;top:978px;left:162px;white-space:nowrap" class="ft0111">immunosuppressed hosts.&#160;</p>
<p style="position:absolute;top:978px;left:351px;white-space:nowrap" class="ft0112"><i>Med Mycol</i></p>
<p style="position:absolute;top:978px;left:433px;white-space:nowrap" class="ft0111">. 2019;57(Supplement_1):S56-s63. Available at:&#160;</p>
<p style="position:absolute;top:999px;left:162px;white-space:nowrap" class="ft0113">https://pubmed.ncbi.nlm.nih.gov/29669037/</p>
<p style="position:absolute;top:999px;left:479px;white-space:nowrap" class="ft0111">.&#160;</p>
<p style="position:absolute;top:1020px;left:108px;white-space:nowrap" class="ft0111">13.</p>
<p style="position:absolute;top:1020px;left:162px;white-space:nowrap" class="ft0111">13.&#160;</p>
<p style="position:absolute;top:1020px;left:216px;white-space:nowrap" class="ft0111">Donovan FM, Ramadan FA, Khan&#160;SA, et&#160;al. Comparison of a&#160;Novel Rapid&#160;</p>
<p style="position:absolute;top:1040px;left:162px;white-space:nowrap" class="ft0111">Lateral Flow Assay to Enzyme&#160;Immunoassay&#160;Results&#160;for&#160;Early Diagnosis of&#160;</p>
</div>
<!-- Page 87 -->
<a name="87"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page87-div" style="position:relative;width:917px;height:1187px;">
<p style="position:absolute;top:1128px;left:108px;white-space:nowrap" class="ft024"><i>Guidelines for the Prevention and Treatment&#160;of&#160;Opportunistic&#160;Infections in Adults&#160;and Adolescents&#160;With HIV&#160;</i></p>
<p style="position:absolute;top:1128px;left:784px;white-space:nowrap" class="ft024"><i>F-12&#160;</i></p>
<p style="position:absolute;top:109px;left:162px;white-space:nowrap" class="ft0111">Coccidioidomycosis.&#160;</p>
<p style="position:absolute;top:109px;left:318px;white-space:nowrap" class="ft0112"><i>Clin Infect Dis</i></p>
<p style="position:absolute;top:109px;left:424px;white-space:nowrap" class="ft0111">.&#160;2021;73(9):e2746-e2753. Available&#160;at:&#160;</p>
<p style="position:absolute;top:129px;left:162px;white-space:nowrap" class="ft0113">https://pubmed.ncbi.nlm.nih.gov/32818956/</p>
<p style="position:absolute;top:129px;left:479px;white-space:nowrap" class="ft0111">.&#160;</p>
<p style="position:absolute;top:150px;left:108px;white-space:nowrap" class="ft0111">14.</p>
<p style="position:absolute;top:150px;left:162px;white-space:nowrap" class="ft0111">14.&#160;</p>
<p style="position:absolute;top:150px;left:216px;white-space:nowrap" class="ft0111">Durkin M,&#160;Connolly P, Kuberski T,&#160;et&#160;al. Diagnosis of&#160;coccidioidomycosis with&#160;</p>
<p style="position:absolute;top:171px;left:162px;white-space:nowrap" class="ft0111">use of&#160;the&#160;Coccidioides&#160;antigen&#160;enzyme&#160;immunoassay.&#160;</p>
<p style="position:absolute;top:171px;left:561px;white-space:nowrap" class="ft0112"><i>Clin&#160;Infect&#160;Dis</i></p>
<p style="position:absolute;top:171px;left:666px;white-space:nowrap" class="ft0111">. 2008;47(8):e69-</p>
<p style="position:absolute;top:192px;left:162px;white-space:nowrap" class="ft0111">73. Available at:&#160;</p>
<p style="position:absolute;top:192px;left:286px;white-space:nowrap" class="ft0113">http://www.ncbi.nlm.nih.gov/pubmed/18781884</p>
<p style="position:absolute;top:192px;left:635px;white-space:nowrap" class="ft0111">.&#160;</p>
<p style="position:absolute;top:212px;left:108px;white-space:nowrap" class="ft0111">15.</p>
<p style="position:absolute;top:212px;left:162px;white-space:nowrap" class="ft0111">15.&#160;</p>
<p style="position:absolute;top:212px;left:216px;white-space:nowrap" class="ft0111">Durkin M, Estok L, Hospenthal&#160;D, et&#160;al. Detection of Coccidioides&#160;antigenemia&#160;</p>
<p style="position:absolute;top:233px;left:162px;white-space:nowrap" class="ft0111">following dissociation of&#160;immune complexes.&#160;</p>
<p style="position:absolute;top:233px;left:496px;white-space:nowrap" class="ft0112"><i>Clin Vaccine&#160;Immunol</i></p>
<p style="position:absolute;top:233px;left:657px;white-space:nowrap" class="ft0111">. 2009;16(10):1453-</p>
<p style="position:absolute;top:254px;left:162px;white-space:nowrap" class="ft0111">1456. Available&#160;at:&#160;</p>
<p style="position:absolute;top:254px;left:304px;white-space:nowrap" class="ft0113">http://www.ncbi.nlm.nih.gov/pubmed/19675225</p>
<p style="position:absolute;top:254px;left:653px;white-space:nowrap" class="ft0111">.&#160;</p>
<p style="position:absolute;top:274px;left:108px;white-space:nowrap" class="ft0111">16.</p>
<p style="position:absolute;top:274px;left:162px;white-space:nowrap" class="ft0111">16.&#160;</p>
<p style="position:absolute;top:274px;left:216px;white-space:nowrap" class="ft0111">Grill FJ, Grys TE, Grill&#160;MF, Roeder A, Blair JE,&#160;Lake DF. Development&#160;of a&#160;</p>
<p style="position:absolute;top:295px;left:162px;white-space:nowrap" class="ft0111">Quantitative&#160;Antigen Assay to Detect Coccidioidal&#160;Chitinase-1 (CTS1) in Human Serum.&#160;</p>
<p style="position:absolute;top:316px;left:162px;white-space:nowrap" class="ft0112"><i>Open Forum&#160;Infect&#160;Dis</i></p>
<p style="position:absolute;top:316px;left:329px;white-space:nowrap" class="ft0111">. 2021;8(7):ofab344. Available&#160;at:&#160;</p>
<p style="position:absolute;top:336px;left:162px;white-space:nowrap" class="ft0113">https://www.ncbi.nlm.nih.gov/pubmed/34337097</p>
<p style="position:absolute;top:336px;left:518px;white-space:nowrap" class="ft0111">.&#160;</p>
<p style="position:absolute;top:357px;left:108px;white-space:nowrap" class="ft0111">17.</p>
<p style="position:absolute;top:357px;left:162px;white-space:nowrap" class="ft0111">17.&#160;</p>
<p style="position:absolute;top:357px;left:216px;white-space:nowrap" class="ft0111">McHardy IH, Barker&#160;B, Thompson GR, 3rd. Review&#160;of Clinical&#160;and Laboratory&#160;</p>
<p style="position:absolute;top:378px;left:162px;white-space:nowrap" class="ft0111">Diagnostics&#160;for&#160;Coccidioidomycosis.&#160;</p>
<p style="position:absolute;top:378px;left:433px;white-space:nowrap" class="ft0112"><i>J Clin Microbiol</i></p>
<p style="position:absolute;top:378px;left:553px;white-space:nowrap" class="ft0111">. 2023;61(5):e0158122. Available&#160;</p>
<p style="position:absolute;top:399px;left:162px;white-space:nowrap" class="ft0111">at:&#160;</p>
<p style="position:absolute;top:399px;left:185px;white-space:nowrap" class="ft0113">https://www.ncbi.nlm.nih.gov/pubmed/36883820</p>
<p style="position:absolute;top:399px;left:541px;white-space:nowrap" class="ft0111">.&#160;</p>
<p style="position:absolute;top:419px;left:108px;white-space:nowrap" class="ft0111">18.</p>
<p style="position:absolute;top:419px;left:162px;white-space:nowrap" class="ft0111">18.&#160;</p>
<p style="position:absolute;top:419px;left:216px;white-space:nowrap" class="ft0111">Bamberger&#160;DM, Pepito&#160;BS, Proia LA, et al. Cerebrospinal fluid Coccidioides&#160;</p>
<p style="position:absolute;top:440px;left:162px;white-space:nowrap" class="ft0114">antigen&#160;testing in the diagnosis and&#160;management of central nervous system&#160;<br/>coccidioidomycosis.&#160;</p>
<p style="position:absolute;top:461px;left:314px;white-space:nowrap" class="ft0112"><i>Mycoses</i></p>
<p style="position:absolute;top:461px;left:376px;white-space:nowrap" class="ft0111">. 2015;58(10):598-602. Available&#160;at:&#160;</p>
<p style="position:absolute;top:481px;left:162px;white-space:nowrap" class="ft0113">https://www.ncbi.nlm.nih.gov/pubmed/26393436</p>
<p style="position:absolute;top:481px;left:518px;white-space:nowrap" class="ft0111">.&#160;</p>
<p style="position:absolute;top:502px;left:108px;white-space:nowrap" class="ft0111">19.</p>
<p style="position:absolute;top:502px;left:162px;white-space:nowrap" class="ft0111">19.&#160;</p>
<p style="position:absolute;top:502px;left:216px;white-space:nowrap" class="ft0111">Kassis C, Zaidi&#160;S, Kuberski T, et&#160;al.&#160;Role of&#160;Coccidioides Antigen Testing in the&#160;</p>
<p style="position:absolute;top:523px;left:162px;white-space:nowrap" class="ft0111">Cerebrospinal&#160;Fluid&#160;for&#160;the Diagnosis of&#160;Coccidioidal Meningitis.&#160;</p>
<p style="position:absolute;top:523px;left:641px;white-space:nowrap" class="ft0112"><i>Clin Infect&#160;Dis</i></p>
<p style="position:absolute;top:523px;left:747px;white-space:nowrap" class="ft0111">.&#160;</p>
<p style="position:absolute;top:543px;left:162px;white-space:nowrap" class="ft0111">2015;61(10):1521-1526.&#160;Available at:&#160;</p>
<p style="position:absolute;top:543px;left:440px;white-space:nowrap" class="ft0113">http://www.ncbi.nlm.nih.gov/pubmed/26209683</p>
<p style="position:absolute;top:543px;left:789px;white-space:nowrap" class="ft0111">.&#160;</p>
<p style="position:absolute;top:564px;left:108px;white-space:nowrap" class="ft0111">20.</p>
<p style="position:absolute;top:564px;left:162px;white-space:nowrap" class="ft0111">20.&#160;</p>
<p style="position:absolute;top:564px;left:216px;white-space:nowrap" class="ft0111">Dizon D, Mitchell M, Dizon B, Libke R, Peterson MW. The&#160;utility of real-time&#160;</p>
<p style="position:absolute;top:585px;left:162px;white-space:nowrap" class="ft0114">polymerase&#160;chain reaction in detecting Coccidioides immitis&#160;among clinical specimens in&#160;<br/>the&#160;Central&#160;California San Joaquin&#160;Valley.</p>
<p style="position:absolute;top:606px;left:472px;white-space:nowrap" class="ft0112"><i>Med&#160;Mycol</i></p>
<p style="position:absolute;top:606px;left:554px;white-space:nowrap" class="ft0111">. 2019;57(6):688-693. Available&#160;at:&#160;</p>
<p style="position:absolute;top:626px;left:162px;white-space:nowrap" class="ft0113">https://www.ncbi.nlm.nih.gov/pubmed/30462288</p>
<p style="position:absolute;top:626px;left:518px;white-space:nowrap" class="ft0111">.&#160;</p>
<p style="position:absolute;top:647px;left:108px;white-space:nowrap" class="ft0111">21.</p>
<p style="position:absolute;top:647px;left:162px;white-space:nowrap" class="ft0111">21.&#160;</p>
<p style="position:absolute;top:647px;left:216px;white-space:nowrap" class="ft0111">Comrie AC. No consistent link between dust storms and Valley Fever&#160;</p>
<p style="position:absolute;top:668px;left:162px;white-space:nowrap" class="ft0111">(Coccidioidomycosis).&#160;</p>
<p style="position:absolute;top:668px;left:330px;white-space:nowrap" class="ft0112"><i>Geohealth</i></p>
<p style="position:absolute;top:668px;left:405px;white-space:nowrap" class="ft0111">.&#160;2021;5(12):e2021GH000504. Available at:&#160;</p>
<p style="position:absolute;top:688px;left:162px;white-space:nowrap" class="ft0113">https://www.ncbi.nlm.nih.gov/pubmed/34877441</p>
<p style="position:absolute;top:688px;left:518px;white-space:nowrap" class="ft0111">.&#160;</p>
<p style="position:absolute;top:709px;left:108px;white-space:nowrap" class="ft0111">22.</p>
<p style="position:absolute;top:709px;left:162px;white-space:nowrap" class="ft0111">22.&#160;</p>
<p style="position:absolute;top:709px;left:216px;white-space:nowrap" class="ft0111">Freedman&#160;M, Jackson&#160;BR, McCotter&#160;O, Benedict K. Coccidioidomycosis&#160;</p>
<p style="position:absolute;top:730px;left:162px;white-space:nowrap" class="ft0111">outbreaks, United States&#160;and worldwide, 1940-2015.&#160;</p>
<p style="position:absolute;top:730px;left:545px;white-space:nowrap" class="ft0112"><i>Emerg Infect&#160;Dis</i></p>
<p style="position:absolute;top:730px;left:668px;white-space:nowrap" class="ft0111">. 2018;24(3):417-</p>
<p style="position:absolute;top:750px;left:162px;white-space:nowrap" class="ft0111">423. Available at:&#160;</p>
<p style="position:absolute;top:750px;left:295px;white-space:nowrap" class="ft0113">https://www.ncbi.nlm.nih.gov/pubmed/29460741</p>
<p style="position:absolute;top:750px;left:651px;white-space:nowrap" class="ft0111">.&#160;</p>
<p style="position:absolute;top:771px;left:108px;white-space:nowrap" class="ft0111">23.</p>
<p style="position:absolute;top:771px;left:162px;white-space:nowrap" class="ft0111">23.&#160;</p>
<p style="position:absolute;top:771px;left:216px;white-space:nowrap" class="ft0111">Tong DQ, Gorris&#160;ME, Gill&#160;TE, Ardon-Dryer K, Wang J, Ren L. Dust storms,&#160;</p>
<p style="position:absolute;top:792px;left:162px;white-space:nowrap" class="ft0111">Valley Fever, and public&#160;awareness.&#160;</p>
<p style="position:absolute;top:792px;left:427px;white-space:nowrap" class="ft0112"><i>Geohealth</i></p>
<p style="position:absolute;top:792px;left:502px;white-space:nowrap" class="ft0111">.&#160;2022;6(8):e2022GH000642. Available&#160;</p>
<p style="position:absolute;top:813px;left:162px;white-space:nowrap" class="ft0111">at:&#160;</p>
<p style="position:absolute;top:813px;left:185px;white-space:nowrap" class="ft0113">https://www.ncbi.nlm.nih.gov/pubmed/35949254</p>
<p style="position:absolute;top:813px;left:541px;white-space:nowrap" class="ft0111">.&#160;</p>
<p style="position:absolute;top:833px;left:108px;white-space:nowrap" class="ft0111">24.</p>
<p style="position:absolute;top:833px;left:162px;white-space:nowrap" class="ft0111">24.&#160;</p>
<p style="position:absolute;top:833px;left:216px;white-space:nowrap" class="ft0111">Galgiani&#160;JN, Ampel&#160;NM, Blair&#160;JE, et&#160;al. 2016 Infectious&#160;Diseases&#160;Society&#160;of&#160;</p>
<p style="position:absolute;top:854px;left:162px;white-space:nowrap" class="ft0111">America (IDSA) clinical&#160;practice&#160;guideline&#160;for&#160;the treatment&#160;of coccidioidomycosis.&#160;</p>
<p style="position:absolute;top:854px;left:773px;white-space:nowrap" class="ft0112"><i>Clin&#160;</i></p>
<p style="position:absolute;top:875px;left:162px;white-space:nowrap" class="ft0112"><i>Infect&#160;Dis</i></p>
<p style="position:absolute;top:875px;left:232px;white-space:nowrap" class="ft0111">. 2016;63(6):e112–e146. Available at:&#160;</p>
<p style="position:absolute;top:875px;left:511px;white-space:nowrap" class="ft0113">https://www.idsociety.org/practice-</p>
<p style="position:absolute;top:895px;left:162px;white-space:nowrap" class="ft0113">guideline/coccidioidomycosis</p>
<p style="position:absolute;top:895px;left:377px;white-space:nowrap" class="ft0111">.&#160;</p>
<p style="position:absolute;top:916px;left:108px;white-space:nowrap" class="ft0111">25.</p>
<p style="position:absolute;top:916px;left:162px;white-space:nowrap" class="ft0111">25.&#160;</p>
<p style="position:absolute;top:916px;left:216px;white-space:nowrap" class="ft0111">Galgiani&#160;JN, Ampel&#160;NM, Blair&#160;JE, et&#160;al. Coccidioidomycosis.&#160;</p>
<p style="position:absolute;top:916px;left:666px;white-space:nowrap" class="ft0112"><i>Clin Infect&#160;Dis</i></p>
<p style="position:absolute;top:916px;left:771px;white-space:nowrap" class="ft0111">.&#160;</p>
<p style="position:absolute;top:937px;left:162px;white-space:nowrap" class="ft0111">2005;41(9):1217-1223. Available at:&#160;</p>
<p style="position:absolute;top:937px;left:431px;white-space:nowrap" class="ft0113">http://www.ncbi.nlm.nih.gov/pubmed/16206093</p>
<p style="position:absolute;top:937px;left:780px;white-space:nowrap" class="ft0111">.&#160;</p>
<p style="position:absolute;top:957px;left:108px;white-space:nowrap" class="ft0111">26.</p>
<p style="position:absolute;top:957px;left:162px;white-space:nowrap" class="ft0111">26.&#160;</p>
<p style="position:absolute;top:957px;left:216px;white-space:nowrap" class="ft0111">Galgiani&#160;JN, Catanzaro&#160;A, Cloud GA, et al. Comparison of&#160;oral fluconazole&#160;and&#160;</p>
<p style="position:absolute;top:978px;left:162px;white-space:nowrap" class="ft0114">itraconazole for progressive, nonmeningeal&#160;coccidioidomycosis. A randomized, double-<br/>blind trial.&#160;Mycoses Study Group.&#160;</p>
<p style="position:absolute;top:999px;left:411px;white-space:nowrap" class="ft0112"><i>Ann Intern&#160;Med</i></p>
<p style="position:absolute;top:999px;left:525px;white-space:nowrap" class="ft0111">. 2000;133(9):676-686. Available at:&#160;</p>
<p style="position:absolute;top:1020px;left:162px;white-space:nowrap" class="ft0113">http://www.ncbi.nlm.nih.gov/pubmed/11074900</p>
<p style="position:absolute;top:1020px;left:511px;white-space:nowrap" class="ft0111">.&#160;</p>
</div>
<!-- Page 88 -->
<a name="88"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page88-div" style="position:relative;width:917px;height:1187px;">
<p style="position:absolute;top:1128px;left:108px;white-space:nowrap" class="ft024"><i>Guidelines for the Prevention and Treatment&#160;of&#160;Opportunistic&#160;Infections in Adults&#160;and Adolescents&#160;With HIV&#160;</i></p>
<p style="position:absolute;top:1128px;left:784px;white-space:nowrap" class="ft024"><i>F-13&#160;</i></p>
<p style="position:absolute;top:109px;left:108px;white-space:nowrap" class="ft0111">27.</p>
<p style="position:absolute;top:109px;left:162px;white-space:nowrap" class="ft0111">27.&#160;</p>
<p style="position:absolute;top:109px;left:216px;white-space:nowrap" class="ft0111">Wiederhold&#160;NP, Schwartz IS, Patterson TF, Thompson GR, 3rd. Variability of&#160;</p>
<p style="position:absolute;top:129px;left:162px;white-space:nowrap" class="ft0111">hydroxy-itraconazole&#160;in&#160;relation&#160;to itraconazole&#160;bloodstream&#160;concentrations.&#160;</p>
<p style="position:absolute;top:129px;left:716px;white-space:nowrap" class="ft0112"><i>Antimicrob&#160;</i></p>
<p style="position:absolute;top:150px;left:162px;white-space:nowrap" class="ft0112"><i>Agents&#160;Chemother</i></p>
<p style="position:absolute;top:150px;left:295px;white-space:nowrap" class="ft0111">. 2021;65(4). Available&#160;at:</p>
<p style="position:absolute;top:171px;left:162px;white-space:nowrap" class="ft0113">https://www.ncbi.nlm.nih.gov/pubmed/33468480</p>
<p style="position:absolute;top:171px;left:518px;white-space:nowrap" class="ft0111">.&#160;</p>
<p style="position:absolute;top:192px;left:108px;white-space:nowrap" class="ft0111">28.</p>
<p style="position:absolute;top:192px;left:162px;white-space:nowrap" class="ft0111">28.&#160;</p>
<p style="position:absolute;top:192px;left:216px;white-space:nowrap" class="ft0111">Anstead GM, Corcoran&#160;G, Lewis J, Berg D, Graybill JR. Refractory&#160;</p>
<p style="position:absolute;top:212px;left:162px;white-space:nowrap" class="ft0111">coccidioidomycosis&#160;treated with posaconazole.&#160;</p>
<p style="position:absolute;top:212px;left:505px;white-space:nowrap" class="ft0112"><i>Clin Infect&#160;Dis</i></p>
<p style="position:absolute;top:212px;left:611px;white-space:nowrap" class="ft0111">. 2005;40(12):1770-1776.&#160;</p>
<p style="position:absolute;top:233px;left:162px;white-space:nowrap" class="ft0111">Available at:&#160;</p>
<p style="position:absolute;top:233px;left:259px;white-space:nowrap" class="ft0113">http://www.ncbi.nlm.nih.gov/pubmed/15909265</p>
<p style="position:absolute;top:233px;left:608px;white-space:nowrap" class="ft0111">.&#160;</p>
<p style="position:absolute;top:254px;left:108px;white-space:nowrap" class="ft0111">29.</p>
<p style="position:absolute;top:254px;left:162px;white-space:nowrap" class="ft0111">29.&#160;</p>
<p style="position:absolute;top:254px;left:216px;white-space:nowrap" class="ft0111">Stevens DA, Rendon A,&#160;Gaona-Flores V, et&#160;al. Posaconazole&#160;therapy for chronic&#160;</p>
<p style="position:absolute;top:274px;left:162px;white-space:nowrap" class="ft0111">refractory coccidioidomycosis.&#160;</p>
<p style="position:absolute;top:274px;left:389px;white-space:nowrap" class="ft0112"><i>Chest</i></p>
<p style="position:absolute;top:274px;left:430px;white-space:nowrap" class="ft0111">. 2007;132(3):952-958.&#160;Available at:&#160;</p>
<p style="position:absolute;top:295px;left:162px;white-space:nowrap" class="ft0113">http://www.ncbi.nlm.nih.gov/pubmed/17573510</p>
<p style="position:absolute;top:295px;left:511px;white-space:nowrap" class="ft0111">.&#160;</p>
<p style="position:absolute;top:316px;left:108px;white-space:nowrap" class="ft0111">30.</p>
<p style="position:absolute;top:316px;left:162px;white-space:nowrap" class="ft0111">30.&#160;</p>
<p style="position:absolute;top:316px;left:216px;white-space:nowrap" class="ft0111">Kim MM, Vikram HR, Kusne S, Seville MT, Blair JE. Treatment of refractory&#160;</p>
<p style="position:absolute;top:336px;left:162px;white-space:nowrap" class="ft0111">coccidioidomycosis with voriconazole&#160;or posaconazole.&#160;</p>
<p style="position:absolute;top:336px;left:569px;white-space:nowrap" class="ft0112"><i>Clin Infect Dis</i></p>
<p style="position:absolute;top:336px;left:674px;white-space:nowrap" class="ft0111">.&#160;</p>
<p style="position:absolute;top:357px;left:162px;white-space:nowrap" class="ft0111">2011;53(11):1060-1066.&#160;Available at:&#160;</p>
<p style="position:absolute;top:357px;left:440px;white-space:nowrap" class="ft0113">https://www.ncbi.nlm.nih.gov/pubmed/22045955</p>
<p style="position:absolute;top:357px;left:796px;white-space:nowrap" class="ft0111">.&#160;</p>
<p style="position:absolute;top:378px;left:108px;white-space:nowrap" class="ft0111">31.</p>
<p style="position:absolute;top:378px;left:162px;white-space:nowrap" class="ft0111">31.&#160;</p>
<p style="position:absolute;top:378px;left:216px;white-space:nowrap" class="ft0111">Heidari A, Sharma&#160;R, Shakir Q, et&#160;al.&#160;Isavuconazole&#160;in&#160;the&#160;treatment of&#160;chronic&#160;</p>
<p style="position:absolute;top:399px;left:162px;white-space:nowrap" class="ft0111">forms&#160;of coccidioidomycosis.&#160;</p>
<p style="position:absolute;top:399px;left:380px;white-space:nowrap" class="ft0112"><i>Clin&#160;Infect&#160;Dis</i></p>
<p style="position:absolute;top:399px;left:486px;white-space:nowrap" class="ft0111">. 2023;76(12):2196-2199. Available&#160;at:&#160;</p>
<p style="position:absolute;top:419px;left:162px;white-space:nowrap" class="ft0113">https://www.ncbi.nlm.nih.gov/pubmed/36905151</p>
<p style="position:absolute;top:419px;left:518px;white-space:nowrap" class="ft0111">.&#160;</p>
<p style="position:absolute;top:440px;left:108px;white-space:nowrap" class="ft0111">32.</p>
<p style="position:absolute;top:440px;left:162px;white-space:nowrap" class="ft0111">32.&#160;</p>
<p style="position:absolute;top:440px;left:216px;white-space:nowrap" class="ft0111">Thompson GR, 3rd, Beck KR, Patt&#160;M, Kratschmar&#160;DV, Odermatt&#160;A.&#160;</p>
<p style="position:absolute;top:461px;left:162px;white-space:nowrap" class="ft0114">Posaconazole-Induced Hypertension&#160;Due to Inhibition of 11beta-Hydroxylase&#160;and&#160;<br/>11beta-Hydroxysteroid&#160;Dehydrogenase&#160;2.&#160;</p>
<p style="position:absolute;top:481px;left:468px;white-space:nowrap" class="ft0112"><i>J Endocr Soc</i></p>
<p style="position:absolute;top:481px;left:564px;white-space:nowrap" class="ft0111">. 2019;3(7):1361-1366. Available&#160;</p>
<p style="position:absolute;top:502px;left:162px;white-space:nowrap" class="ft0111">at:&#160;</p>
<p style="position:absolute;top:502px;left:185px;white-space:nowrap" class="ft0113">https://www.ncbi.nlm.nih.gov/pubmed/31286100</p>
<p style="position:absolute;top:502px;left:541px;white-space:nowrap" class="ft0111">.&#160;</p>
<p style="position:absolute;top:523px;left:108px;white-space:nowrap" class="ft0111">33.</p>
<p style="position:absolute;top:523px;left:162px;white-space:nowrap" class="ft0111">33.&#160;</p>
<p style="position:absolute;top:523px;left:216px;white-space:nowrap" class="ft0111">Kosmidis&#160;C,&#160;Otu A, Moore CB, Richardson MD,&#160;Rautemaa-Richardson R.&#160;</p>
<p style="position:absolute;top:543px;left:162px;white-space:nowrap" class="ft0114">Isavuconazole therapeutic drug monitoring during&#160;long-term&#160;treatment&#160;for&#160;chronic&#160;<br/>pulmonary aspergillosis.&#160;</p>
<p style="position:absolute;top:564px;left:343px;white-space:nowrap" class="ft0112"><i>Antimicrob&#160;Agents Chemother</i></p>
<p style="position:absolute;top:564px;left:562px;white-space:nowrap" class="ft0111">. 2020;65(1). Available&#160;at:&#160;</p>
<p style="position:absolute;top:585px;left:162px;white-space:nowrap" class="ft0113">https://www.ncbi.nlm.nih.gov/pubmed/33077653</p>
<p style="position:absolute;top:585px;left:518px;white-space:nowrap" class="ft0111">.&#160;</p>
<p style="position:absolute;top:606px;left:108px;white-space:nowrap" class="ft0111">34.</p>
<p style="position:absolute;top:606px;left:162px;white-space:nowrap" class="ft0111">34.&#160;</p>
<p style="position:absolute;top:606px;left:216px;white-space:nowrap" class="ft0111">Sidhu R, Lash DB, Heidari A, Natarajan P, Johnson RH. Evaluation of&#160;</p>
<p style="position:absolute;top:626px;left:162px;white-space:nowrap" class="ft0111">amphotericin B lipid formulations&#160;for treatment of severe coccidioidomycosis.&#160;</p>
<p style="position:absolute;top:647px;left:162px;white-space:nowrap" class="ft0112"><i>Antimicrob&#160;Agents Chemother</i></p>
<p style="position:absolute;top:647px;left:381px;white-space:nowrap" class="ft0111">. 2018;62(7). Available&#160;at:</p>
<p style="position:absolute;top:668px;left:162px;white-space:nowrap" class="ft0113">https://www.ncbi.nlm.nih.gov/pubmed/29686150</p>
<p style="position:absolute;top:668px;left:518px;white-space:nowrap" class="ft0111">.&#160;</p>
<p style="position:absolute;top:688px;left:108px;white-space:nowrap" class="ft0111">35.</p>
<p style="position:absolute;top:688px;left:162px;white-space:nowrap" class="ft0111">35.&#160;</p>
<p style="position:absolute;top:688px;left:216px;white-space:nowrap" class="ft0111">Jarvis&#160;JN, Lawrence DS, Meya DB, et al. Single-dose liposomal amphotericin B&#160;</p>
<p style="position:absolute;top:709px;left:162px;white-space:nowrap" class="ft0111">treatment for cryptococcal&#160;meningitis.&#160;</p>
<p style="position:absolute;top:709px;left:441px;white-space:nowrap" class="ft0112"><i>N&#160;Engl J&#160;Med</i></p>
<p style="position:absolute;top:709px;left:541px;white-space:nowrap" class="ft0111">. 2022;386(12):1109-1120. Available</p>
<p style="position:absolute;top:730px;left:162px;white-space:nowrap" class="ft0111">at:&#160;</p>
<p style="position:absolute;top:730px;left:185px;white-space:nowrap" class="ft0113">https://www.ncbi.nlm.nih.gov/pubmed/35320642</p>
<p style="position:absolute;top:730px;left:541px;white-space:nowrap" class="ft0111">.&#160;</p>
<p style="position:absolute;top:750px;left:108px;white-space:nowrap" class="ft0111">36.</p>
<p style="position:absolute;top:750px;left:162px;white-space:nowrap" class="ft0111">36.&#160;</p>
<p style="position:absolute;top:750px;left:216px;white-space:nowrap" class="ft0111">Thompson GR, Ampel NM, Blair JE, et&#160;al. Controversies&#160;in&#160;the&#160;management&#160;of&#160;</p>
<p style="position:absolute;top:771px;left:162px;white-space:nowrap" class="ft0111">central&#160;nervous system coccidioidomycosis.&#160;</p>
<p style="position:absolute;top:771px;left:483px;white-space:nowrap" class="ft0112"><i>Clin&#160;Infect Dis</i></p>
<p style="position:absolute;top:771px;left:589px;white-space:nowrap" class="ft0111">. 2022;75(4):555-559.&#160;</p>
<p style="position:absolute;top:792px;left:162px;white-space:nowrap" class="ft0111">Available at:&#160;</p>
<p style="position:absolute;top:792px;left:259px;white-space:nowrap" class="ft0113">https://www.ncbi.nlm.nih.gov/pubmed/35717645</p>
<p style="position:absolute;top:792px;left:615px;white-space:nowrap" class="ft0111">.&#160;</p>
<p style="position:absolute;top:813px;left:108px;white-space:nowrap" class="ft0111">37.</p>
<p style="position:absolute;top:813px;left:162px;white-space:nowrap" class="ft0111">37.&#160;</p>
<p style="position:absolute;top:813px;left:216px;white-space:nowrap" class="ft0111">Galgiani&#160;JN, Catanzaro&#160;A, Cloud GA, et al. Fluconazole&#160;therapy for&#160;coccidioidal&#160;</p>
<p style="position:absolute;top:833px;left:162px;white-space:nowrap" class="ft0111">meningitis.&#160;The NIAID-Mycoses Study Group.&#160;</p>
<p style="position:absolute;top:833px;left:506px;white-space:nowrap" class="ft0112"><i>Ann Intern&#160;Med</i></p>
<p style="position:absolute;top:833px;left:620px;white-space:nowrap" class="ft0111">. 1993;119(1):28-35.&#160;</p>
<p style="position:absolute;top:854px;left:162px;white-space:nowrap" class="ft0111">Available at:&#160;</p>
<p style="position:absolute;top:854px;left:259px;white-space:nowrap" class="ft0113">http://www.ncbi.nlm.nih.gov/pubmed/8498760</p>
<p style="position:absolute;top:854px;left:599px;white-space:nowrap" class="ft0111">.&#160;</p>
<p style="position:absolute;top:875px;left:108px;white-space:nowrap" class="ft0111">38.</p>
<p style="position:absolute;top:875px;left:162px;white-space:nowrap" class="ft0111">38.&#160;</p>
<p style="position:absolute;top:875px;left:216px;white-space:nowrap" class="ft0111">Tucker&#160;RM, Denning DW, Dupont B, Stevens DA. Itraconazole&#160;therapy for&#160;</p>
<p style="position:absolute;top:895px;left:162px;white-space:nowrap" class="ft0111">chronic&#160;coccidioidal&#160;meningitis.&#160;</p>
<p style="position:absolute;top:895px;left:398px;white-space:nowrap" class="ft0112"><i>Ann&#160;Intern&#160;Med</i></p>
<p style="position:absolute;top:895px;left:512px;white-space:nowrap" class="ft0111">.&#160;1990;112(2):108-112. Available&#160;at:&#160;</p>
<p style="position:absolute;top:916px;left:162px;white-space:nowrap" class="ft0113">http://www.ncbi.nlm.nih.gov/pubmed/2153012</p>
<p style="position:absolute;top:916px;left:502px;white-space:nowrap" class="ft0111">.&#160;</p>
<p style="position:absolute;top:937px;left:108px;white-space:nowrap" class="ft0111">39.</p>
<p style="position:absolute;top:937px;left:162px;white-space:nowrap" class="ft0111">39.&#160;</p>
<p style="position:absolute;top:937px;left:216px;white-space:nowrap" class="ft0111">Cortez KJ,&#160;Walsh TJ, Bennett&#160;JE. Successful treatment of&#160;coccidioidal&#160;meningitis&#160;</p>
<p style="position:absolute;top:957px;left:162px;white-space:nowrap" class="ft0111">with voriconazole.&#160;</p>
<p style="position:absolute;top:957px;left:300px;white-space:nowrap" class="ft0112"><i>Clin Infect&#160;Dis</i></p>
<p style="position:absolute;top:957px;left:406px;white-space:nowrap" class="ft0111">. 2003;36(12):1619-1622. Available&#160;at:&#160;</p>
<p style="position:absolute;top:978px;left:162px;white-space:nowrap" class="ft0113">http://www.ncbi.nlm.nih.gov/pubmed/12802765</p>
<p style="position:absolute;top:978px;left:511px;white-space:nowrap" class="ft0111">.&#160;</p>
<p style="position:absolute;top:999px;left:108px;white-space:nowrap" class="ft0111">40.</p>
<p style="position:absolute;top:999px;left:162px;white-space:nowrap" class="ft0111">40.&#160;</p>
<p style="position:absolute;top:999px;left:216px;white-space:nowrap" class="ft0111">Proia LA, Tenorio AR. Successful&#160;use of&#160;voriconazole&#160;for&#160;treatment of&#160;</p>
<p style="position:absolute;top:1020px;left:162px;white-space:nowrap" class="ft0111">Coccidioides meningitis.&#160;</p>
<p style="position:absolute;top:1020px;left:345px;white-space:nowrap" class="ft0112"><i>Antimicrob&#160;Agents Chemother</i></p>
<p style="position:absolute;top:1020px;left:564px;white-space:nowrap" class="ft0111">. 2004;48(6):2341. Available&#160;at:&#160;</p>
<p style="position:absolute;top:1040px;left:162px;white-space:nowrap" class="ft0113">http://www.ncbi.nlm.nih.gov/pubmed/15155250</p>
<p style="position:absolute;top:1040px;left:511px;white-space:nowrap" class="ft0111">.&#160;</p>
</div>
<!-- Page 89 -->
<a name="89"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page89-div" style="position:relative;width:917px;height:1187px;">
<p style="position:absolute;top:1128px;left:108px;white-space:nowrap" class="ft024"><i>Guidelines for the Prevention and Treatment&#160;of&#160;Opportunistic&#160;Infections in Adults&#160;and Adolescents&#160;With HIV&#160;</i></p>
<p style="position:absolute;top:1128px;left:784px;white-space:nowrap" class="ft024"><i>F-14&#160;</i></p>
<p style="position:absolute;top:109px;left:108px;white-space:nowrap" class="ft0111">41.</p>
<p style="position:absolute;top:109px;left:162px;white-space:nowrap" class="ft0111">41.&#160;</p>
<p style="position:absolute;top:109px;left:216px;white-space:nowrap" class="ft0111">Freifeld A, Proia L, Andes D, et al.&#160;Voriconazole use for&#160;endemic&#160;fungal&#160;</p>
<p style="position:absolute;top:129px;left:162px;white-space:nowrap" class="ft0111">infections.&#160;</p>
<p style="position:absolute;top:129px;left:242px;white-space:nowrap" class="ft0112"><i>Antimicrob Agents Chemother</i></p>
<p style="position:absolute;top:129px;left:461px;white-space:nowrap" class="ft0111">. 2009;53(4):1648-1651. Available&#160;at:&#160;</p>
<p style="position:absolute;top:150px;left:162px;white-space:nowrap" class="ft0113">http://www.ncbi.nlm.nih.gov/pubmed/19139290</p>
<p style="position:absolute;top:150px;left:511px;white-space:nowrap" class="ft0111">.&#160;</p>
<p style="position:absolute;top:171px;left:108px;white-space:nowrap" class="ft0111">42.</p>
<p style="position:absolute;top:171px;left:162px;white-space:nowrap" class="ft0111">42.&#160;</p>
<p style="position:absolute;top:171px;left:216px;white-space:nowrap" class="ft0111">Schein R, Homans J, Larsen RA, Neely M. Posaconazole&#160;for chronic&#160;refractory&#160;</p>
<p style="position:absolute;top:192px;left:162px;white-space:nowrap" class="ft0111">coccidioidal&#160;meningitis.&#160;</p>
<p style="position:absolute;top:192px;left:339px;white-space:nowrap" class="ft0112"><i>Clin Infect&#160;Dis</i></p>
<p style="position:absolute;top:192px;left:445px;white-space:nowrap" class="ft0111">. 2011;53(12):1252-1254. Available&#160;at:&#160;</p>
<p style="position:absolute;top:212px;left:162px;white-space:nowrap" class="ft0113">http://www.ncbi.nlm.nih.gov/pubmed/21987729</p>
<p style="position:absolute;top:212px;left:511px;white-space:nowrap" class="ft0111">.&#160;</p>
<p style="position:absolute;top:233px;left:108px;white-space:nowrap" class="ft0111">43.</p>
<p style="position:absolute;top:233px;left:162px;white-space:nowrap" class="ft0111">43.&#160;</p>
<p style="position:absolute;top:233px;left:216px;white-space:nowrap" class="ft0111">Heidari A,&#160;Quinlan M,&#160;Benjamin DJ, et&#160;al. Isavuconazole&#160;in&#160;the&#160;Treatment of&#160;</p>
<p style="position:absolute;top:254px;left:162px;white-space:nowrap" class="ft0111">Coccidioidal Meningitis.&#160;</p>
<p style="position:absolute;top:254px;left:345px;white-space:nowrap" class="ft0112"><i>Antimicrob&#160;Agents Chemother</i></p>
<p style="position:absolute;top:254px;left:564px;white-space:nowrap" class="ft0111">. 2019;63(3). Available&#160;at:&#160;</p>
<p style="position:absolute;top:274px;left:162px;white-space:nowrap" class="ft0113">https://www.ncbi.nlm.nih.gov/pubmed/30559134</p>
<p style="position:absolute;top:274px;left:518px;white-space:nowrap" class="ft0111">.&#160;</p>
<p style="position:absolute;top:295px;left:108px;white-space:nowrap" class="ft0111">44.</p>
<p style="position:absolute;top:295px;left:162px;white-space:nowrap" class="ft0111">44.&#160;</p>
<p style="position:absolute;top:295px;left:216px;white-space:nowrap" class="ft0111">Johnson RH, Einstein HE. Coccidioidal meningitis.&#160;</p>
<p style="position:absolute;top:295px;left:591px;white-space:nowrap" class="ft0112"><i>Clin Infect&#160;Dis</i></p>
<p style="position:absolute;top:295px;left:697px;white-space:nowrap" class="ft0111">.&#160;</p>
<p style="position:absolute;top:316px;left:162px;white-space:nowrap" class="ft0111">2006;42(1):103-107. Available&#160;at:&#160;</p>
<p style="position:absolute;top:316px;left:413px;white-space:nowrap" class="ft0113">https://www.ncbi.nlm.nih.gov/pubmed/16323099</p>
<p style="position:absolute;top:316px;left:769px;white-space:nowrap" class="ft0111">.&#160;</p>
<p style="position:absolute;top:336px;left:108px;white-space:nowrap" class="ft0111">45.</p>
<p style="position:absolute;top:336px;left:162px;white-space:nowrap" class="ft0111">45.&#160;</p>
<p style="position:absolute;top:336px;left:216px;white-space:nowrap" class="ft0111">Mortimer RB, Libke R, Eghbalieh B, Bilello JF.&#160;Immune reconstitution&#160;</p>
<p style="position:absolute;top:357px;left:162px;white-space:nowrap" class="ft0114">inflammatory syndrome&#160;presenting as superior vena cava&#160;syndrome secondary to&#160;<br/>Coccidioides lymphadenopathy in an&#160;HIV-infected patient.&#160;</p>
<p style="position:absolute;top:378px;left:592px;white-space:nowrap" class="ft0112"><i>J&#160;Int&#160;Assoc Physicians&#160;AIDS&#160;</i></p>
<p style="position:absolute;top:399px;left:162px;white-space:nowrap" class="ft0112"><i>Care (Chic)</i></p>
<p style="position:absolute;top:399px;left:248px;white-space:nowrap" class="ft0111">.&#160;2008;7(6):283-285. Available&#160;at:</p>
<p style="position:absolute;top:419px;left:162px;white-space:nowrap" class="ft0113">http://www.ncbi.nlm.nih.gov/pubmed/18948432</p>
<p style="position:absolute;top:419px;left:511px;white-space:nowrap" class="ft0111">.&#160;</p>
<p style="position:absolute;top:440px;left:108px;white-space:nowrap" class="ft0111">46.</p>
<p style="position:absolute;top:440px;left:162px;white-space:nowrap" class="ft0111">46.&#160;</p>
<p style="position:absolute;top:440px;left:216px;white-space:nowrap" class="ft0111">D'Avino A,&#160;Di Giambenedetto S, Fabbiani&#160;M, Farina&#160;S. Coccidioidomycosis of&#160;</p>
<p style="position:absolute;top:461px;left:162px;white-space:nowrap" class="ft0114">cervical&#160;lymph nodes in&#160;an HIV-infected patient&#160;with immunologic&#160;reconstitution on&#160;<br/>potent HAART: a&#160;rare&#160;observation in a nonendemic area.&#160;</p>
<p style="position:absolute;top:481px;left:579px;white-space:nowrap" class="ft0112"><i>Diagn Microbiol Infect Dis</i></p>
<p style="position:absolute;top:481px;left:775px;white-space:nowrap" class="ft0111">.&#160;</p>
<p style="position:absolute;top:502px;left:162px;white-space:nowrap" class="ft0111">2012;72(2):185-187. Available&#160;at:&#160;</p>
<p style="position:absolute;top:502px;left:413px;white-space:nowrap" class="ft0113">http://www.ncbi.nlm.nih.gov/pubmed/22104185</p>
<p style="position:absolute;top:502px;left:762px;white-space:nowrap" class="ft0111">.&#160;</p>
<p style="position:absolute;top:523px;left:108px;white-space:nowrap" class="ft0111">47.</p>
<p style="position:absolute;top:523px;left:162px;white-space:nowrap" class="ft0111">47.&#160;</p>
<p style="position:absolute;top:523px;left:216px;white-space:nowrap" class="ft0111">Trible&#160;R, Edgerton N, Hayek S, Winkel&#160;D, Anderson AM. Antiretroviral&#160;therapy-</p>
<p style="position:absolute;top:543px;left:162px;white-space:nowrap" class="ft0111">associated coccidioidal&#160;meningitis.&#160;</p>
<p style="position:absolute;top:543px;left:418px;white-space:nowrap" class="ft0112"><i>Emerg Infect Dis</i></p>
<p style="position:absolute;top:543px;left:541px;white-space:nowrap" class="ft0111">. 2013;19(1):163-165. Available at:</p>
<p style="position:absolute;top:564px;left:162px;white-space:nowrap" class="ft0113">http://www.ncbi.nlm.nih.gov/pubmed/23260018</p>
<p style="position:absolute;top:564px;left:511px;white-space:nowrap" class="ft0111">.&#160;</p>
<p style="position:absolute;top:585px;left:108px;white-space:nowrap" class="ft0111">48.</p>
<p style="position:absolute;top:585px;left:162px;white-space:nowrap" class="ft0111">48.&#160;</p>
<p style="position:absolute;top:585px;left:216px;white-space:nowrap" class="ft0111">Mu A, Shein TT, Jayachandran P, Paul&#160;S. Immune Reconstitution Inflammatory&#160;</p>
<p style="position:absolute;top:606px;left:162px;white-space:nowrap" class="ft0114">Syndrome in patients&#160;with AIDS and disseminated coccidioidomycosis:&#160;a&#160;case series and&#160;<br/>review of&#160;the literature.&#160;</p>
<p style="position:absolute;top:626px;left:335px;white-space:nowrap" class="ft0112"><i>J Int Assoc&#160;Provid AIDS Care</i></p>
<p style="position:absolute;top:626px;left:552px;white-space:nowrap" class="ft0111">. 2017;16(6):540-545. Available at:&#160;</p>
<p style="position:absolute;top:647px;left:162px;white-space:nowrap" class="ft0113">https://www.ncbi.nlm.nih.gov/pubmed/28911256</p>
<p style="position:absolute;top:647px;left:518px;white-space:nowrap" class="ft0111">.&#160;</p>
<p style="position:absolute;top:668px;left:108px;white-space:nowrap" class="ft0111">49.</p>
<p style="position:absolute;top:668px;left:162px;white-space:nowrap" class="ft0111">49.&#160;</p>
<p style="position:absolute;top:668px;left:216px;white-space:nowrap" class="ft0111">Lin AY, Chun V, Dhamija A, Bordin-Wosk T,&#160;Kadakia&#160;A. Immune reconstitution&#160;</p>
<p style="position:absolute;top:688px;left:162px;white-space:nowrap" class="ft0114">inflammatory syndrome&#160;in an HIV-infected patient with disseminated&#160;<br/>coccidioidomycosis.&#160;</p>
<p style="position:absolute;top:709px;left:314px;white-space:nowrap" class="ft0112"><i>Int J STD&#160;AIDS</i></p>
<p style="position:absolute;top:709px;left:426px;white-space:nowrap" class="ft0111">. 2019;30(9):923-926.&#160;Available at:&#160;</p>
<p style="position:absolute;top:730px;left:162px;white-space:nowrap" class="ft0113">https://www.ncbi.nlm.nih.gov/pubmed/31159717</p>
<p style="position:absolute;top:730px;left:518px;white-space:nowrap" class="ft0111">.&#160;</p>
<p style="position:absolute;top:750px;left:108px;white-space:nowrap" class="ft0111">50.</p>
<p style="position:absolute;top:750px;left:162px;white-space:nowrap" class="ft0111">50.&#160;</p>
<p style="position:absolute;top:750px;left:216px;white-space:nowrap" class="ft0111">Vadlapatla&#160;RK, Patel M, Paturi DK, Pal&#160;D, Mitra&#160;AK. Clinically relevant&#160;drug-</p>
<p style="position:absolute;top:771px;left:162px;white-space:nowrap" class="ft0111">drug interactions&#160;between antiretrovirals&#160;and&#160;antifungals.&#160;</p>
<p style="position:absolute;top:771px;left:577px;white-space:nowrap" class="ft0112"><i>Expert&#160;Opin Drug Metab&#160;</i></p>
<p style="position:absolute;top:792px;left:162px;white-space:nowrap" class="ft0112"><i>Toxicol</i></p>
<p style="position:absolute;top:792px;left:216px;white-space:nowrap" class="ft0111">. 2014;10(4):561-580. Available at:&#160;</p>
<p style="position:absolute;top:813px;left:162px;white-space:nowrap" class="ft0113">https://www.ncbi.nlm.nih.gov/pubmed/24521092</p>
<p style="position:absolute;top:813px;left:518px;white-space:nowrap" class="ft0111">.&#160;</p>
<p style="position:absolute;top:833px;left:108px;white-space:nowrap" class="ft0111">51.</p>
<p style="position:absolute;top:833px;left:162px;white-space:nowrap" class="ft0111">51.&#160;</p>
<p style="position:absolute;top:833px;left:216px;white-space:nowrap" class="ft0111">Ampel&#160;NM. Delayed-type hypersensitivity, in vitro T-cell responsiveness&#160;and risk&#160;</p>
<p style="position:absolute;top:854px;left:162px;white-space:nowrap" class="ft0114">of active coccidioidomycosis among&#160;HIV-infected patients&#160;living in the coccidioidal&#160;<br/>endemic area.&#160;</p>
<p style="position:absolute;top:875px;left:266px;white-space:nowrap" class="ft0112"><i>Med Mycol</i></p>
<p style="position:absolute;top:875px;left:348px;white-space:nowrap" class="ft0111">. 1999;37(4):245-250.&#160;Available at:&#160;</p>
<p style="position:absolute;top:895px;left:162px;white-space:nowrap" class="ft0113">https://pubmed.ncbi.nlm.nih.gov/10421859/</p>
<p style="position:absolute;top:895px;left:479px;white-space:nowrap" class="ft0111">.&#160;</p>
<p style="position:absolute;top:916px;left:108px;white-space:nowrap" class="ft0111">52.</p>
<p style="position:absolute;top:916px;left:162px;white-space:nowrap" class="ft0111">52.&#160;</p>
<p style="position:absolute;top:916px;left:216px;white-space:nowrap" class="ft0111">Graybill JR, Stevens DA, Galgiani&#160;JN, Dismukes WE, Cloud GA. Itraconazole&#160;</p>
<p style="position:absolute;top:937px;left:162px;white-space:nowrap" class="ft0111">treatment of&#160;coccidioidomycosis. NAIAD&#160;Mycoses Study Group.&#160;</p>
<p style="position:absolute;top:937px;left:638px;white-space:nowrap" class="ft0112"><i>Am&#160;J Med</i></p>
<p style="position:absolute;top:937px;left:711px;white-space:nowrap" class="ft0111">.&#160;</p>
<p style="position:absolute;top:957px;left:162px;white-space:nowrap" class="ft0111">1990;89(3):282-290. Available&#160;at:&#160;</p>
<p style="position:absolute;top:957px;left:413px;white-space:nowrap" class="ft0113">https://pubmed.ncbi.nlm.nih.gov/2168126/</p>
<p style="position:absolute;top:957px;left:721px;white-space:nowrap" class="ft0111">.&#160;</p>
<p style="position:absolute;top:978px;left:108px;white-space:nowrap" class="ft0111">53.</p>
<p style="position:absolute;top:978px;left:162px;white-space:nowrap" class="ft0111">53.&#160;</p>
<p style="position:absolute;top:978px;left:216px;white-space:nowrap" class="ft0111">Catanzaro A, Galgiani&#160;JN, Levine BE, et al. Fluconazole&#160;in the treatment&#160;of&#160;</p>
<p style="position:absolute;top:999px;left:162px;white-space:nowrap" class="ft0114">chronic&#160;pulmonary and&#160;nonmeningeal&#160;disseminated coccidioidomycosis.&#160;NIAID&#160;Mycoses&#160;<br/>Study Group.&#160;</p>
<p style="position:absolute;top:1020px;left:263px;white-space:nowrap" class="ft0112"><i>Am J Med</i></p>
<p style="position:absolute;top:1020px;left:336px;white-space:nowrap" class="ft0111">. 1995;98(3):249-256. Available&#160;at:&#160;</p>
<p style="position:absolute;top:1040px;left:162px;white-space:nowrap" class="ft0113">https://pubmed.ncbi.nlm.nih.gov/7872341/</p>
<p style="position:absolute;top:1040px;left:470px;white-space:nowrap" class="ft0111">.&#160;</p>
</div>
<!-- Page 90 -->
<a name="90"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page90-div" style="position:relative;width:917px;height:1187px;">
<p style="position:absolute;top:1128px;left:108px;white-space:nowrap" class="ft024"><i>Guidelines for the Prevention and Treatment&#160;of&#160;Opportunistic&#160;Infections in Adults&#160;and Adolescents&#160;With HIV&#160;</i></p>
<p style="position:absolute;top:1128px;left:784px;white-space:nowrap" class="ft024"><i>F-15&#160;</i></p>
<p style="position:absolute;top:109px;left:108px;white-space:nowrap" class="ft0111">54.</p>
<p style="position:absolute;top:109px;left:162px;white-space:nowrap" class="ft0111">54.&#160;</p>
<p style="position:absolute;top:109px;left:216px;white-space:nowrap" class="ft0111">Mathew G, Smedema&#160;M, Wheat&#160;LJ,&#160;Goldman M.&#160;Relapse of&#160;coccidioidomycosis&#160;</p>
<p style="position:absolute;top:129px;left:162px;white-space:nowrap" class="ft0114">despite immune reconstitution&#160;after&#160;fluconazole&#160;secondary prophylaxis&#160;in&#160;a patient with&#160;<br/>AIDS.&#160;</p>
<p style="position:absolute;top:150px;left:213px;white-space:nowrap" class="ft0112"><i>Mycoses</i></p>
<p style="position:absolute;top:150px;left:275px;white-space:nowrap" class="ft0111">. 2003;46(1-2):42-44.&#160;Available at:&#160;</p>
<p style="position:absolute;top:171px;left:162px;white-space:nowrap" class="ft0113">http://www.ncbi.nlm.nih.gov/pubmed/12588482</p>
<p style="position:absolute;top:171px;left:511px;white-space:nowrap" class="ft0111">.&#160;</p>
<p style="position:absolute;top:192px;left:108px;white-space:nowrap" class="ft0111">55.</p>
<p style="position:absolute;top:192px;left:162px;white-space:nowrap" class="ft0111">55.&#160;</p>
<p style="position:absolute;top:192px;left:216px;white-space:nowrap" class="ft0111">Dewsnup DH, Galgiani&#160;JN, Graybill&#160;JR, et al.&#160;Is&#160;it&#160;ever safe&#160;to stop azole&#160;therapy&#160;</p>
<p style="position:absolute;top:212px;left:162px;white-space:nowrap" class="ft0111">for&#160;Coccidioides immitis&#160;meningitis?&#160;</p>
<p style="position:absolute;top:212px;left:434px;white-space:nowrap" class="ft0112"><i>Ann Intern&#160;Med</i></p>
<p style="position:absolute;top:212px;left:548px;white-space:nowrap" class="ft0111">. 1996;124(3):305-310. Available&#160;</p>
<p style="position:absolute;top:233px;left:162px;white-space:nowrap" class="ft0111">at:&#160;</p>
<p style="position:absolute;top:233px;left:185px;white-space:nowrap" class="ft0113">https://pubmed.ncbi.nlm.nih.gov/8554225/</p>
<p style="position:absolute;top:233px;left:493px;white-space:nowrap" class="ft0111">.&#160;</p>
<p style="position:absolute;top:254px;left:108px;white-space:nowrap" class="ft0111">56.</p>
<p style="position:absolute;top:254px;left:162px;white-space:nowrap" class="ft0111">56.&#160;</p>
<p style="position:absolute;top:254px;left:216px;white-space:nowrap" class="ft0111">Bercovitch&#160;RS, Catanzaro A, Schwartz BS, Pappagianis D, Watts DH, Ampel&#160;</p>
<p style="position:absolute;top:274px;left:162px;white-space:nowrap" class="ft0114">NM. Coccidioidomycosis during pregnancy:&#160;a&#160;review and recommendations for&#160;<br/>management.&#160;</p>
<p style="position:absolute;top:295px;left:263px;white-space:nowrap" class="ft0112"><i>Clin Infect&#160;Dis</i></p>
<p style="position:absolute;top:295px;left:369px;white-space:nowrap" class="ft0111">. 2011;53(4):363-368. Available&#160;at:&#160;</p>
<p style="position:absolute;top:316px;left:162px;white-space:nowrap" class="ft0113">https://pubmed.ncbi.nlm.nih.gov/21810749/</p>
<p style="position:absolute;top:316px;left:479px;white-space:nowrap" class="ft0111">.&#160;</p>
<p style="position:absolute;top:336px;left:108px;white-space:nowrap" class="ft0111">57.</p>
<p style="position:absolute;top:336px;left:162px;white-space:nowrap" class="ft0111">57.&#160;</p>
<p style="position:absolute;top:336px;left:216px;white-space:nowrap" class="ft0111">O'Grady N,&#160;McManus D, Briggs&#160;N, Azar&#160;MM, Topal&#160;J, Davis MW. Dosing&#160;</p>
<p style="position:absolute;top:357px;left:162px;white-space:nowrap" class="ft0111">implications&#160;for&#160;liposomal&#160;amphotericin B in pregnancy.&#160;</p>
<p style="position:absolute;top:357px;left:575px;white-space:nowrap" class="ft0112"><i>Pharmacotherapy</i></p>
<p style="position:absolute;top:357px;left:704px;white-space:nowrap" class="ft0111">.&#160;</p>
<p style="position:absolute;top:378px;left:162px;white-space:nowrap" class="ft0111">2023;43(5):452-462. Available&#160;at:&#160;</p>
<p style="position:absolute;top:378px;left:413px;white-space:nowrap" class="ft0113">https://www.ncbi.nlm.nih.gov/pubmed/36862037</p>
<p style="position:absolute;top:378px;left:769px;white-space:nowrap" class="ft0111">.&#160;</p>
<p style="position:absolute;top:399px;left:108px;white-space:nowrap" class="ft0111">58.</p>
<p style="position:absolute;top:399px;left:162px;white-space:nowrap" class="ft0111">58.&#160;</p>
<p style="position:absolute;top:399px;left:216px;white-space:nowrap" class="ft0111">AmBisome®(amphotericin B)&#160;liposome&#160;for&#160;injection&#160;[Type]. Northbrook, IL:&#160;</p>
<p style="position:absolute;top:419px;left:162px;white-space:nowrap" class="ft0111">Astellas Pharma US, Inc.&#160;;&#160;2018.&#160;</p>
<p style="position:absolute;top:440px;left:108px;white-space:nowrap" class="ft0111">59.</p>
<p style="position:absolute;top:440px;left:162px;white-space:nowrap" class="ft0111">59.&#160;</p>
<p style="position:absolute;top:440px;left:216px;white-space:nowrap" class="ft0111">Pursley TJ,&#160;Blomquist&#160;IK, Abraham&#160;J, Andersen&#160;HF, Bartley&#160;JA. Fluconazole-</p>
<p style="position:absolute;top:461px;left:162px;white-space:nowrap" class="ft0111">induced congenital anomalies in&#160;three infants.&#160;</p>
<p style="position:absolute;top:461px;left:497px;white-space:nowrap" class="ft0112"><i>Clin Infect Dis</i></p>
<p style="position:absolute;top:461px;left:603px;white-space:nowrap" class="ft0111">. 1996;22(2):336-340.&#160;</p>
<p style="position:absolute;top:481px;left:162px;white-space:nowrap" class="ft0111">Available at:&#160;</p>
<p style="position:absolute;top:481px;left:259px;white-space:nowrap" class="ft0113">https://pubmed.ncbi.nlm.nih.gov/8838193/</p>
<p style="position:absolute;top:481px;left:567px;white-space:nowrap" class="ft0111">.&#160;</p>
<p style="position:absolute;top:502px;left:108px;white-space:nowrap" class="ft0111">60.</p>
<p style="position:absolute;top:502px;left:162px;white-space:nowrap" class="ft0111">60.&#160;</p>
<p style="position:absolute;top:502px;left:216px;white-space:nowrap" class="ft0111">Metruccio F, Battistoni&#160;M, Di Renzo F, Moretto&#160;A, Menegola E. Moderate&#160;</p>
<p style="position:absolute;top:523px;left:162px;white-space:nowrap" class="ft0114">alcohol&#160;consumption during pregnancy increases&#160;potency of&#160;two different&#160;drugs&#160;(the&#160;<br/>antifungal&#160;fluconazole&#160;and the&#160;antiepileptic&#160;valproate) in&#160;inducing craniofacial defects:&#160;<br/>prediction by the&#160;in vitro rat whole&#160;embryo culture.&#160;</p>
<p style="position:absolute;top:564px;left:536px;white-space:nowrap" class="ft0112"><i>Arch Toxicol</i></p>
<p style="position:absolute;top:564px;left:629px;white-space:nowrap" class="ft0111">. 2023;97(2):619-629.&#160;</p>
<p style="position:absolute;top:585px;left:162px;white-space:nowrap" class="ft0111">Available at:&#160;</p>
<p style="position:absolute;top:585px;left:259px;white-space:nowrap" class="ft0113">https://www.ncbi.nlm.nih.gov/pubmed/36385218</p>
<p style="position:absolute;top:585px;left:615px;white-space:nowrap" class="ft0111">.&#160;</p>
<p style="position:absolute;top:606px;left:108px;white-space:nowrap" class="ft0111">61.</p>
<p style="position:absolute;top:606px;left:162px;white-space:nowrap" class="ft0111">61.&#160;</p>
<p style="position:absolute;top:606px;left:216px;white-space:nowrap" class="ft0111">Budani MC, Fensore S,&#160;Di Marzio&#160;M, Tiboni&#160;GM. Maternal use of&#160;fluconazole&#160;</p>
<p style="position:absolute;top:626px;left:162px;white-space:nowrap" class="ft0111">and congenital&#160;malformations&#160;in the&#160;progeny: A&#160;meta-analysis of the&#160;literature.&#160;</p>
<p style="position:absolute;top:626px;left:735px;white-space:nowrap" class="ft0112"><i>Reprod&#160;</i></p>
<p style="position:absolute;top:647px;left:162px;white-space:nowrap" class="ft0112"><i>Toxicol</i></p>
<p style="position:absolute;top:647px;left:216px;white-space:nowrap" class="ft0111">. 2021;100:42-51. Available at:&#160;</p>
<p style="position:absolute;top:647px;left:446px;white-space:nowrap" class="ft0113">https://www.ncbi.nlm.nih.gov/pubmed/33383164</p>
<p style="position:absolute;top:647px;left:802px;white-space:nowrap" class="ft0111">.&#160;</p>
<p style="position:absolute;top:668px;left:108px;white-space:nowrap" class="ft0111">62.</p>
<p style="position:absolute;top:668px;left:162px;white-space:nowrap" class="ft0111">62.&#160;</p>
<p style="position:absolute;top:668px;left:216px;white-space:nowrap" class="ft0111">Molgaard-Nielsen D, Pasternak B, Hviid A. Use of&#160;oral&#160;fluconazole during&#160;</p>
<p style="position:absolute;top:688px;left:162px;white-space:nowrap" class="ft0111">pregnancy and the risk of birth defects.&#160;</p>
<p style="position:absolute;top:688px;left:448px;white-space:nowrap" class="ft0112"><i>N Engl J&#160;Med</i></p>
<p style="position:absolute;top:688px;left:547px;white-space:nowrap" class="ft0111">. 2013;369(9):830-839. Available&#160;</p>
<p style="position:absolute;top:709px;left:162px;white-space:nowrap" class="ft0111">at:&#160;</p>
<p style="position:absolute;top:709px;left:185px;white-space:nowrap" class="ft0113">http://www.ncbi.nlm.nih.gov/pubmed/23984730</p>
<p style="position:absolute;top:709px;left:534px;white-space:nowrap" class="ft0111">.&#160;</p>
<p style="position:absolute;top:730px;left:108px;white-space:nowrap" class="ft0111">63.</p>
<p style="position:absolute;top:730px;left:162px;white-space:nowrap" class="ft0111">63.&#160;</p>
<p style="position:absolute;top:730px;left:216px;white-space:nowrap" class="ft0111">Howley MM, Carter TC, Browne&#160;ML, Romitti&#160;PA, Cunniff&#160;CM, Druschel CM.&#160;</p>
<p style="position:absolute;top:750px;left:162px;white-space:nowrap" class="ft0111">Fluconazole&#160;use and birth defects in&#160;the&#160;National Birth Defects Prevention Study.&#160;</p>
<p style="position:absolute;top:750px;left:753px;white-space:nowrap" class="ft0112"><i>Am J&#160;</i></p>
<p style="position:absolute;top:771px;left:162px;white-space:nowrap" class="ft0112"><i>Obstet&#160;Gynecol</i></p>
<p style="position:absolute;top:771px;left:273px;white-space:nowrap" class="ft0111">. 2016;214(5):657.e651-659. Available&#160;at:&#160;</p>
<p style="position:absolute;top:792px;left:162px;white-space:nowrap" class="ft0113">https://pubmed.ncbi.nlm.nih.gov/26640069/</p>
<p style="position:absolute;top:792px;left:479px;white-space:nowrap" class="ft0111">.&#160;</p>
<p style="position:absolute;top:813px;left:108px;white-space:nowrap" class="ft0111">64.</p>
<p style="position:absolute;top:813px;left:162px;white-space:nowrap" class="ft0111">64.&#160;</p>
<p style="position:absolute;top:813px;left:216px;white-space:nowrap" class="ft0111">Berard A, Sheehy O, Zhao JP, et&#160;al.&#160;Associations&#160;between low- and high-dose&#160;</p>
<p style="position:absolute;top:833px;left:162px;white-space:nowrap" class="ft0111">oral fluconazole and pregnancy outcomes:&#160;3 nested case-control&#160;studies.&#160;</p>
<p style="position:absolute;top:833px;left:686px;white-space:nowrap" class="ft0112"><i>CMAJ</i></p>
<p style="position:absolute;top:833px;left:732px;white-space:nowrap" class="ft0111">.&#160;</p>
<p style="position:absolute;top:854px;left:162px;white-space:nowrap" class="ft0111">2019;191(7):E179-E187.&#160;Available at:&#160;</p>
<p style="position:absolute;top:854px;left:444px;white-space:nowrap" class="ft0113">https://www.ncbi.nlm.nih.gov/pubmed/30782643</p>
<p style="position:absolute;top:854px;left:800px;white-space:nowrap" class="ft0111">.&#160;</p>
<p style="position:absolute;top:875px;left:108px;white-space:nowrap" class="ft0111">65.</p>
<p style="position:absolute;top:875px;left:162px;white-space:nowrap" class="ft0111">65.&#160;</p>
<p style="position:absolute;top:875px;left:216px;white-space:nowrap" class="ft0111">Zhu Y, Bateman BT, Gray KJ, et al.&#160;Oral&#160;fluconazole use&#160;in the first&#160;trimester&#160;and&#160;</p>
<p style="position:absolute;top:895px;left:162px;white-space:nowrap" class="ft0111">risk of&#160;congenital malformations: population based cohort study.&#160;</p>
<p style="position:absolute;top:895px;left:632px;white-space:nowrap" class="ft0112"><i>BMJ</i></p>
<p style="position:absolute;top:895px;left:666px;white-space:nowrap" class="ft0111">. 2020;369:m1494.&#160;</p>
<p style="position:absolute;top:916px;left:162px;white-space:nowrap" class="ft0111">Available at:&#160;</p>
<p style="position:absolute;top:916px;left:259px;white-space:nowrap" class="ft0113">https://www.ncbi.nlm.nih.gov/pubmed/32434758</p>
<p style="position:absolute;top:916px;left:615px;white-space:nowrap" class="ft0111">.&#160;</p>
<p style="position:absolute;top:937px;left:108px;white-space:nowrap" class="ft0111">66.</p>
<p style="position:absolute;top:937px;left:162px;white-space:nowrap" class="ft0111">66.&#160;</p>
<p style="position:absolute;top:937px;left:216px;white-space:nowrap" class="ft0111">Mølgaard-Nielsen D, Svanström&#160;H, Melbye M,&#160;Hviid A, Pasternak B. Association&#160;</p>
<p style="position:absolute;top:957px;left:162px;white-space:nowrap" class="ft0114">Between Use of&#160;Oral&#160;Fluconazole During Pregnancy and Risk of&#160;Spontaneous Abortion&#160;<br/>and Stillbirth.&#160;</p>
<p style="position:absolute;top:978px;left:265px;white-space:nowrap" class="ft0112"><i>Jama</i></p>
<p style="position:absolute;top:978px;left:304px;white-space:nowrap" class="ft0111">. 2016;315(1):58-67. Available&#160;at:&#160;</p>
<p style="position:absolute;top:999px;left:162px;white-space:nowrap" class="ft0113">https://pubmed.ncbi.nlm.nih.gov/26746458/</p>
<p style="position:absolute;top:999px;left:479px;white-space:nowrap" class="ft0111">.&#160;</p>
</div>
<!-- Page 91 -->
<a name="91"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page91-div" style="position:relative;width:917px;height:1187px;">
<p style="position:absolute;top:1128px;left:108px;white-space:nowrap" class="ft024"><i>Guidelines for the Prevention and Treatment&#160;of&#160;Opportunistic&#160;Infections in Adults&#160;and Adolescents&#160;With HIV&#160;</i></p>
<p style="position:absolute;top:1128px;left:784px;white-space:nowrap" class="ft024"><i>F-16&#160;</i></p>
<p style="position:absolute;top:109px;left:108px;white-space:nowrap" class="ft0111">67.</p>
<p style="position:absolute;top:109px;left:162px;white-space:nowrap" class="ft0111">67.&#160;</p>
<p style="position:absolute;top:109px;left:216px;white-space:nowrap" class="ft0111">Pasternak B,&#160;Wintzell&#160;V,&#160;Furu K, Engeland A, Neovius M, Stephansson&#160;O. Oral&#160;</p>
<p style="position:absolute;top:129px;left:162px;white-space:nowrap" class="ft0111">Fluconazole&#160;in Pregnancy and Risk of Stillbirth and Neonatal&#160;Death.&#160;</p>
<p style="position:absolute;top:129px;left:661px;white-space:nowrap" class="ft0112"><i>Jama</i></p>
<p style="position:absolute;top:129px;left:700px;white-space:nowrap" class="ft0111">.&#160;</p>
<p style="position:absolute;top:150px;left:162px;white-space:nowrap" class="ft0111">2018;319(22):2333-2335. Available at:&#160;</p>
<p style="position:absolute;top:150px;left:449px;white-space:nowrap" class="ft0113">https://pubmed.ncbi.nlm.nih.gov/29896619/</p>
<p style="position:absolute;top:150px;left:766px;white-space:nowrap" class="ft0111">.&#160;</p>
<p style="position:absolute;top:171px;left:108px;white-space:nowrap" class="ft0111">68.</p>
<p style="position:absolute;top:171px;left:162px;white-space:nowrap" class="ft0111">68.&#160;</p>
<p style="position:absolute;top:171px;left:216px;white-space:nowrap" class="ft0111">Liu D, Zhang C, Wu L, Zhang L, Zhang L. Fetal&#160;outcomes after&#160;maternal&#160;</p>
<p style="position:absolute;top:192px;left:162px;white-space:nowrap" class="ft0114">exposure to&#160;oral&#160;antifungal&#160;agents&#160;during pregnancy:&#160;A&#160;systematic review&#160;and meta-<br/>analysis.&#160;</p>
<p style="position:absolute;top:212px;left:229px;white-space:nowrap" class="ft0112"><i>Int&#160;J Gynaecol&#160;Obstet</i></p>
<p style="position:absolute;top:212px;left:386px;white-space:nowrap" class="ft0111">. 2020;148(1):6-13. Available at:&#160;</p>
<p style="position:absolute;top:233px;left:162px;white-space:nowrap" class="ft0113">https://www.ncbi.nlm.nih.gov/pubmed/31691277</p>
<p style="position:absolute;top:233px;left:518px;white-space:nowrap" class="ft0111">.&#160;</p>
<p style="position:absolute;top:271px;left:108px;white-space:nowrap" class="ft0111">69.</p>
</div>
<!-- Page 92 -->
<a name="92"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}	.ft0115{font-size:17px;font-family:TURBHP+Tinos;color:#005297;}
	.ft0116{font-size:15px;font-family:XZWEHL+Arial,Bold;color:#000000;}
	.ft0117{font-size:15px;font-family:XZWEHL+Arial,Bold;color:#005299;}
-->
</style>
<div id="page92-div" style="position:relative;width:917px;height:1187px;">
<p style="position:absolute;top:1114px;left:108px;white-space:nowrap" class="ft024"><i>Guidelines for the Prevention and Treatment&#160;of&#160;Opportunistic&#160;Infections in Adults&#160;and Adolescents&#160;With HIV&#160;</i></p>
<p style="position:absolute;top:1114px;left:789px;white-space:nowrap" class="ft024"><i>G-1</i></p>
<p style="position:absolute;top:112px;left:108px;white-space:nowrap" class="ft025"><b>Community-Acquired&#160;Pneumonia&#160;</b></p>
<p style="position:absolute;top:159px;left:108px;white-space:nowrap" class="ft035"><b>Updated:</b></p>
<p style="position:absolute;top:159px;left:172px;white-space:nowrap" class="ft036">&#160;September&#160;7,&#160;2022&#160;</p>
<p style="position:absolute;top:180px;left:108px;white-space:nowrap" class="ft035"><b>Reviewed:</b></p>
<p style="position:absolute;top:180px;left:181px;white-space:nowrap" class="ft036">&#160;January 8,&#160;2025&#160;</p>
<p style="position:absolute;top:218px;left:108px;white-space:nowrap" class="ft026"><b>Epidemiology&#160;</b></p>
<p style="position:absolute;top:260px;left:108px;white-space:nowrap" class="ft032">Bacterial&#160;respiratory diseases, including sinusitis,&#160;bronchitis, otitis, and pneumonia, are among the&#160;<br/>most common infectious&#160;complications in people with HIV, occurring with increased frequency at all&#160;<br/>CD4 T lymphocyte cell (CD4) counts.</p>
<p style="position:absolute;top:298px;left:372px;white-space:nowrap" class="ft038">1</p>
<p style="position:absolute;top:299px;left:378px;white-space:nowrap" class="ft013">&#160;This chapter will&#160;focus on the&#160;diagnosis, prevention, and&#160;</p>
<p style="position:absolute;top:319px;left:108px;white-space:nowrap" class="ft032">management&#160;of bacterial community-acquired pneumonia (CAP) in people with HIV. While viral&#160;<br/>pneumonias&#160;are a&#160;frequent cause of CAP, particularly influenza&#160;and severe&#160;acute respiratory&#160;<br/>syndrome coronavirus-2&#160;(SARS-CoV-2), the&#160;management&#160;of coronavirus-19&#160;(COVID-19) disease is&#160;<br/>outside&#160;the&#160;scope of these&#160;guidelines (refer to&#160;</p>
<p style="position:absolute;top:379px;left:425px;white-space:nowrap" class="ft0115">NIH&#160;COVID-19&#160;Treatment Guidelines</p>
<p style="position:absolute;top:379px;left:692px;white-space:nowrap" class="ft013">&#160;for&#160;updated&#160;</p>
<p style="position:absolute;top:399px;left:108px;white-space:nowrap" class="ft032">treatment recommendations).&#160;These&#160;guidelines&#160;also do not consider hospital acquired pneumonia&#160;and&#160;<br/>ventilator-associated pneumonia; limited data suggest that&#160;these do not differ&#160;in terms of&#160;<br/>microbiology, clinical&#160;course, treatment, or prevention in people&#160;with HIV as compared to in people&#160;<br/>without&#160;HIV&#160;with similar HIV-unrelated comorbidities.&#160;</p>
<p style="position:absolute;top:495px;left:108px;white-space:nowrap" class="ft032">Bacterial&#160;pneumonia&#160;is a common cause of HIV-associated morbidity. Recurrent&#160;pneumonia,&#160;<br/>considered two or more episodes&#160;within a 1-year period, is an AIDS-defining&#160;condition. The&#160;<br/>incidence of bacterial&#160;pneumonia&#160;in individuals with HIV has&#160;decreased progressively with the&#160;<br/>advent&#160;of combination antiretroviral therapy (ART).</p>
<p style="position:absolute;top:553px;left:468px;white-space:nowrap" class="ft038">2-7</p>
<p style="position:absolute;top:555px;left:483px;white-space:nowrap" class="ft013">&#160;In one&#160;study, the&#160;incidence of bacterial&#160;</p>
<p style="position:absolute;top:574px;left:108px;white-space:nowrap" class="ft032">pneumonia&#160;declined from 22.7 episodes per 100&#160;person-years before the introduction of ART to 9.1&#160;<br/>episodes per&#160;100 person-years by 1997&#160;after ART was introduced. Since&#160;then, the&#160;incidence of&#160;<br/>bacterial&#160;pneumonia&#160;among people with HIV in&#160;developed countries has continued to drop. In the&#160;<br/>Strategic Timing of AntiRetroviral&#160;Treatment (START) study,&#160;the&#160;incidence rate&#160;of serious bacterial&#160;<br/>infections overall&#160;was 0.87 per 100 person-years, and approximately 40% of these infections were&#160;<br/>due to bacterial&#160;pneumonia.</p>
<p style="position:absolute;top:672px;left:300px;white-space:nowrap" class="ft038">4</p>
<p style="position:absolute;top:674px;left:305px;white-space:nowrap" class="ft013">&#160;Recurrent&#160;bacterial pneumonia as an AIDS-defining illness is also less&#160;</p>
<p style="position:absolute;top:694px;left:108px;white-space:nowrap" class="ft032">frequently encountered in individuals on ART;&#160;however, its exact&#160;incidence is hard to evaluate&#160;<br/>because surveillance&#160;data&#160;for it&#160;are not&#160;collected systematically as for other&#160;opportunistic infections&#160;<br/>(OIs).</p>
<p style="position:absolute;top:732px;left:149px;white-space:nowrap" class="ft038">8</p>
<p style="position:absolute;top:733px;left:154px;white-space:nowrap" class="ft013">&#160;</p>
<p style="position:absolute;top:771px;left:108px;white-space:nowrap" class="ft029"><i><b>Risk Factors&#160;</b></i></p>
<p style="position:absolute;top:812px;left:108px;white-space:nowrap" class="ft032">Yet despite&#160;ART, bacterial&#160;pneumonia&#160;remains more common&#160;in people&#160;with HIV than in those who&#160;<br/>do not have&#160;HIV.</p>
<p style="position:absolute;top:830px;left:228px;white-space:nowrap" class="ft038">9-11</p>
<p style="position:absolute;top:832px;left:248px;white-space:nowrap" class="ft013">&#160;Bacterial&#160;pneumonia&#160;may be the first manifestation of underlying HIV infection&#160;</p>
<p style="position:absolute;top:851px;left:108px;white-space:nowrap" class="ft032">and can occur at&#160;any stage&#160;of HIV disease and at any CD4 count. Bacterial pneumonia in individuals&#160;<br/>with HIV results from multiple risk factors, particularly immune&#160;defects. A CD4 count&#160;decrease,&#160;<br/>especially when below 100 cells/mm</p>
<p style="position:absolute;top:890px;left:363px;white-space:nowrap" class="ft038">3</p>
<p style="position:absolute;top:891px;left:369px;white-space:nowrap" class="ft013">, continues to be a major risk factor for pneumonia&#160;due to&#160;</p>
<p style="position:absolute;top:911px;left:108px;white-space:nowrap" class="ft032">routine bacterial pathogens. Other immune defects include quantitative&#160;and qualitative B-cell&#160;<br/>abnormalities&#160;that result in impaired pathogen-specific antibody production, abnormalities in&#160;<br/>neutrophil&#160;function or numbers, and abnormalities in alveolar macrophage function.</p>
<p style="position:absolute;top:949px;left:687px;white-space:nowrap" class="ft038">12,13</p>
<p style="position:absolute;top:950px;left:712px;white-space:nowrap" class="ft013">&#160;Lack of ART&#160;</p>
<p style="position:absolute;top:970px;left:108px;white-space:nowrap" class="ft032">or intermittent use of&#160;ART increases the risk for&#160;pneumonia, likely due&#160;to uncontrolled HIV&#160;<br/>viremia.</p>
<p style="position:absolute;top:989px;left:165px;white-space:nowrap" class="ft038">14</p>
<p style="position:absolute;top:990px;left:176px;white-space:nowrap" class="ft013">&#160;</p>
<p style="position:absolute;top:1027px;left:108px;white-space:nowrap" class="ft032">Additional&#160;risk factors that contribute&#160;to the continued risk for&#160;bacterial pneumonia&#160;in individuals&#160;<br/>with HIV include&#160;chronic viral&#160;hepatitis, tobacco, alcohol, injection drug use&#160;and prescribed opioid&#160;</p>
<p style="position:absolute;top:67px;left:117px;white-space:nowrap" class="ft0116"><b>Update coming soon. See</b></p>
<p style="position:absolute;top:67px;left:300px;white-space:nowrap" class="ft0117"><b>&#160;Immunization&#160;</b></p>
<p style="position:absolute;top:67px;left:405px;white-space:nowrap" class="ft0116"><b>chapter for the most current vaccine recommendations.</b></p>
</div>
<!-- Page 93 -->
<a name="93"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}	.ft0118{font-size:20px;font-family:TMWRTT+LiberationSansNarrow;color:#005299;}
-->
</style>
<div id="page93-div" style="position:relative;width:917px;height:1187px;">
<p style="position:absolute;top:1114px;left:108px;white-space:nowrap" class="ft024"><i>Guidelines for the Prevention and Treatment&#160;of&#160;Opportunistic&#160;Infections in Adults&#160;and Adolescents&#160;With HIV&#160;</i></p>
<p style="position:absolute;top:1114px;left:789px;white-space:nowrap" class="ft024"><i>G-2&#160;</i></p>
<p style="position:absolute;top:109px;left:108px;white-space:nowrap" class="ft013">use, particularly higher doses and opioids with immunosuppressive properties.</p>
<p style="position:absolute;top:107px;left:649px;white-space:nowrap" class="ft038">3,10,15,16,17</p>
<p style="position:absolute;top:109px;left:711px;white-space:nowrap" class="ft013">&#160;Chronic&#160;</p>
<p style="position:absolute;top:129px;left:108px;white-space:nowrap" class="ft032">obstructive&#160;pulmonary disease (COPD), malignancy, renal&#160;insufficiency, and congestive heart&#160;failure&#160;<br/>(CHF) are emerging as risk factors for&#160;pneumonia,&#160;particularly in the population of older&#160;adults with&#160;<br/>HIV.</p>
<p style="position:absolute;top:167px;left:143px;white-space:nowrap" class="ft038">18</p>
<p style="position:absolute;top:168px;left:154px;white-space:nowrap" class="ft013">&#160;Risk&#160;for CAP can&#160;also increase&#160;with obesity</p>
<p style="position:absolute;top:167px;left:463px;white-space:nowrap" class="ft038">4</p>
<p style="position:absolute;top:168px;left:468px;white-space:nowrap" class="ft013">, an emerging health problem in people living&#160;</p>
<p style="position:absolute;top:188px;left:108px;white-space:nowrap" class="ft013">with HIV.&#160;</p>
<p style="position:absolute;top:225px;left:108px;white-space:nowrap" class="ft026"><b>Microbiology</b></p>
<p style="position:absolute;top:225px;left:215px;white-space:nowrap" class="ft0118"><i><b>&#160;</b></i></p>
<p style="position:absolute;top:266px;left:108px;white-space:nowrap" class="ft013">In individuals with HIV,&#160;</p>
<p style="position:absolute;top:266px;left:282px;white-space:nowrap" class="ft019"><i>Streptococcus pneumoniae</i></p>
<p style="position:absolute;top:266px;left:467px;white-space:nowrap" class="ft013">&#160;(</p>
<p style="position:absolute;top:266px;left:477px;white-space:nowrap" class="ft019"><i>S. pneumoniae)&#160;</i></p>
<p style="position:absolute;top:266px;left:589px;white-space:nowrap" class="ft013">and&#160;</p>
<p style="position:absolute;top:266px;left:618px;white-space:nowrap" class="ft019"><i>Haemophilus&#160;</i></p>
<p style="position:absolute;top:266px;left:714px;white-space:nowrap" class="ft013">species are&#160;</p>
<p style="position:absolute;top:286px;left:108px;white-space:nowrap" class="ft032">the&#160;most frequently identified&#160;causes&#160;of&#160;community-acquired&#160;bacterial&#160;pneumonia,&#160;the&#160;same as in&#160;<br/>individuals without&#160;HIV.</p>
<p style="position:absolute;top:305px;left:281px;white-space:nowrap" class="ft038">19-25</p>
<p style="position:absolute;top:306px;left:306px;white-space:nowrap" class="ft013">&#160;</p>
<p style="position:absolute;top:306px;left:310px;white-space:nowrap" class="ft019"><i>Staphylococcus aureus</i></p>
<p style="position:absolute;top:306px;left:468px;white-space:nowrap" class="ft013">&#160;(</p>
<p style="position:absolute;top:306px;left:478px;white-space:nowrap" class="ft019"><i>S. aureus)&#160;</i></p>
<p style="position:absolute;top:306px;left:552px;white-space:nowrap" class="ft013">and&#160;</p>
<p style="position:absolute;top:306px;left:581px;white-space:nowrap" class="ft019"><i>S. pneumoniae</i></p>
<p style="position:absolute;top:306px;left:683px;white-space:nowrap" class="ft013">&#160;are&#160;among the&#160;</p>
<p style="position:absolute;top:326px;left:108px;white-space:nowrap" class="ft013">most common etiologies of pneumonia in association with influenza&#160;infection.</p>
<p style="position:absolute;top:325px;left:649px;white-space:nowrap" class="ft038">26,27</p>
<p style="position:absolute;top:326px;left:675px;white-space:nowrap" class="ft013">&#160;Atypical&#160;bacterial&#160;</p>
<p style="position:absolute;top:346px;left:108px;white-space:nowrap" class="ft013">pathogens such as&#160;</p>
<p style="position:absolute;top:346px;left:237px;white-space:nowrap" class="ft019"><i>Legionella pneumophila</i></p>
<p style="position:absolute;top:346px;left:405px;white-space:nowrap" class="ft013">,&#160;</p>
<p style="position:absolute;top:346px;left:413px;white-space:nowrap" class="ft019"><i>Mycoplasma pneumoniae</i></p>
<p style="position:absolute;top:346px;left:590px;white-space:nowrap" class="ft013">, and&#160;</p>
<p style="position:absolute;top:346px;left:628px;white-space:nowrap" class="ft019"><i>Chlamydophila&#160;</i></p>
<p style="position:absolute;top:346px;left:739px;white-space:nowrap" class="ft013">species&#160;</p>
<p style="position:absolute;top:366px;left:108px;white-space:nowrap" class="ft013">have been reported as infrequent causes of CAP&#160;in individuals with HIV.</p>
<p style="position:absolute;top:364px;left:612px;white-space:nowrap" class="ft038">22,28</p>
<p style="position:absolute;top:366px;left:637px;white-space:nowrap" class="ft013">&#160;However, when more&#160;</p>
<p style="position:absolute;top:385px;left:108px;white-space:nowrap" class="ft032">extensive&#160;testing such as&#160;serology to detect&#160;IgM antibodies (IgM) antibodies&#160;and/or positive&#160;<br/>polymerase chain reaction (PCR) of respiratory secretions was performed, additional infections due&#160;<br/>to&#160;</p>
<p style="position:absolute;top:425px;left:126px;white-space:nowrap" class="ft019"><i>Mycoplasma</i></p>
<p style="position:absolute;top:425px;left:214px;white-space:nowrap" class="ft013">&#160;and&#160;</p>
<p style="position:absolute;top:425px;left:247px;white-space:nowrap" class="ft019"><i>Chlamydia</i></p>
<p style="position:absolute;top:425px;left:323px;white-space:nowrap" class="ft013">&#160;were&#160;detected.</p>
<p style="position:absolute;top:424px;left:427px;white-space:nowrap" class="ft038">29</p>
<p style="position:absolute;top:425px;left:438px;white-space:nowrap" class="ft013">&#160;</p>
<p style="position:absolute;top:462px;left:108px;white-space:nowrap" class="ft013">Additional&#160;microbial&#160;etiologies of CAP that&#160;should&#160;be considered in people&#160;with HIV include&#160;</p>
<p style="position:absolute;top:482px;left:108px;white-space:nowrap" class="ft019"><i>Mycobacterium tuberculosis, Pneumocystis</i></p>
<p style="position:absolute;top:482px;left:408px;white-space:nowrap" class="ft013">, other opportunistic&#160;infections, and respiratory&#160;viruses.&#160;</p>
<p style="position:absolute;top:502px;left:108px;white-space:nowrap" class="ft032">The&#160;incidence of these different&#160;organisms will vary depending&#160;on geographic region and&#160;patient risk&#160;<br/>factors including degree&#160;of immunocompromise&#160;when considering opportunistic infections. For&#160;<br/>example, in a recent prospective&#160;study from South&#160;Africa of 284 patients with HIV and suspected&#160;<br/>pneumonia, sputum&#160;real-time&#160;multiplex&#160;PCR testing&#160;found that tuberculosis&#160;was more common than&#160;<br/>bacterial causes of CAP in this setting; viruses&#160;were detected in 203 patients,&#160;with the most common&#160;<br/>being human&#160;metapneumovirus, although the&#160;pathogenic significance&#160;of the viral&#160;pathogens was&#160;<br/>uncertain.</p>
<p style="position:absolute;top:620px;left:176px;white-space:nowrap" class="ft038">30</p>
<p style="position:absolute;top:621px;left:188px;white-space:nowrap" class="ft013">&#160;As&#160;noted,&#160;respiratory viruses, influenza and SARS-CoV-2 are also common causes of&#160;</p>
<p style="position:absolute;top:641px;left:108px;white-space:nowrap" class="ft032">CAP&#160;in people&#160;with HIV.&#160;While&#160;influenza&#160;and COVID-19 generally present similarly in people&#160;with&#160;<br/>and without&#160;HIV,&#160;some studies suggest mortality may be increased among people&#160;with HIV for these&#160;<br/>viral infections, particularly in low-and-middle&#160;income&#160;country settings.</p>
<p style="position:absolute;top:679px;left:606px;white-space:nowrap" class="ft038">31-36</p>
<p style="position:absolute;top:680px;left:632px;white-space:nowrap" class="ft013">&#160;</p>
<p style="position:absolute;top:718px;left:108px;white-space:nowrap" class="ft029"><i><b>Risk Factors for&#160;</b></i></p>
<p style="position:absolute;top:718px;left:254px;white-space:nowrap" class="ft0100"><b>Pseudomonas&#160;aeruginosa</b></p>
<p style="position:absolute;top:718px;left:480px;white-space:nowrap" class="ft029"><i><b>&#160;and Methicillin-Resistant&#160;</b></i></p>
<p style="position:absolute;top:742px;left:108px;white-space:nowrap" class="ft0100"><b>Staphylococcus aureus</b></p>
<p style="position:absolute;top:742px;left:311px;white-space:nowrap" class="ft029"><i><b>&#160;</b></i></p>
<p style="position:absolute;top:783px;left:108px;white-space:nowrap" class="ft013">The&#160;frequency of&#160;</p>
<p style="position:absolute;top:783px;left:231px;white-space:nowrap" class="ft019"><i>Pseudomonas aeruginosa</i></p>
<p style="position:absolute;top:783px;left:409px;white-space:nowrap" class="ft013">&#160;(</p>
<p style="position:absolute;top:783px;left:419px;white-space:nowrap" class="ft019"><i>P. aeruginosa)&#160;</i></p>
<p style="position:absolute;top:783px;left:526px;white-space:nowrap" class="ft013">and&#160;</p>
<p style="position:absolute;top:783px;left:555px;white-space:nowrap" class="ft019"><i>S. aureus</i></p>
<p style="position:absolute;top:783px;left:619px;white-space:nowrap" class="ft013">&#160;as&#160;community-acquired&#160;</p>
<p style="position:absolute;top:803px;left:108px;white-space:nowrap" class="ft032">pathogens is&#160;higher in individuals with HIV than in&#160;those without HIV based&#160;on studies in&#160;the&#160;early&#160;<br/>combination ART era.</p>
<p style="position:absolute;top:821px;left:263px;white-space:nowrap" class="ft038">23,37</p>
<p style="position:absolute;top:823px;left:288px;white-space:nowrap" class="ft013">&#160;Many of these patients often had poorly controlled HIV&#160;or the&#160;presence&#160;of&#160;</p>
<p style="position:absolute;top:843px;left:108px;white-space:nowrap" class="ft013">other concomitant risk factors that&#160;contributed to risk for&#160;</p>
<p style="position:absolute;top:843px;left:504px;white-space:nowrap" class="ft019"><i>P. aeruginosa</i></p>
<p style="position:absolute;top:843px;left:601px;white-space:nowrap" class="ft013">&#160;or&#160;</p>
<p style="position:absolute;top:843px;left:624px;white-space:nowrap" class="ft019"><i>S.&#160;aureus</i></p>
<p style="position:absolute;top:843px;left:688px;white-space:nowrap" class="ft013">.&#160;Patients with&#160;</p>
<p style="position:absolute;top:862px;left:108px;white-space:nowrap" class="ft018">advanced HIV disease (CD4 count&#160;</p>
<p style="position:absolute;top:862px;left:352px;white-space:nowrap" class="ft069">≤</p>
<p style="position:absolute;top:862px;left:361px;white-space:nowrap" class="ft018">50 cells/mm</p>
<p style="position:absolute;top:861px;left:446px;white-space:nowrap" class="ft038">3</p>
<p style="position:absolute;top:862px;left:452px;white-space:nowrap" class="ft013">) or underlying neutropenia, as well&#160;as&#160;pre-existing&#160;</p>
<p style="position:absolute;top:882px;left:108px;white-space:nowrap" class="ft013">lung disease&#160;such as bronchiectasis or severe COPD have an increased risk&#160;of infection with&#160;</p>
<p style="position:absolute;top:882px;left:748px;white-space:nowrap" class="ft019"><i>P.&#160;</i></p>
<p style="position:absolute;top:902px;left:108px;white-space:nowrap" class="ft019"><i>aeruginosa</i></p>
<p style="position:absolute;top:902px;left:186px;white-space:nowrap" class="ft013">.&#160;Other risk factors for infection include&#160;the&#160;use of corticosteroids,&#160;severe malnutrition,&#160;</p>
<p style="position:absolute;top:922px;left:108px;white-space:nowrap" class="ft032">hospitalization within the&#160;past 90 days, residence in&#160;a health care&#160;facility or nursing home,&#160;and&#160;<br/>chronic hemodialysis.</p>
<p style="position:absolute;top:940px;left:259px;white-space:nowrap" class="ft038">38</p>
<p style="position:absolute;top:942px;left:271px;white-space:nowrap" class="ft013">&#160;</p>
<p style="position:absolute;top:979px;left:108px;white-space:nowrap" class="ft019"><i>S. aureus</i></p>
<p style="position:absolute;top:979px;left:172px;white-space:nowrap" class="ft013">&#160;should be&#160;considered in patients with recent&#160;viral infection (particularly influenza), a&#160;</p>
<p style="position:absolute;top:999px;left:108px;white-space:nowrap" class="ft013">history of injection drug use, or severe,&#160;bilateral, necrotizing pneumonia. Risk&#160;factors for&#160;</p>
<p style="position:absolute;top:999px;left:726px;white-space:nowrap" class="ft019"><i>S. aureus</i></p>
<p style="position:absolute;top:999px;left:790px;white-space:nowrap" class="ft013">&#160;</p>
<p style="position:absolute;top:1019px;left:108px;white-space:nowrap" class="ft032">pneumonia&#160;in patients with HIV include receipt&#160;of antibiotics prior to hospital admission,&#160;comorbid&#160;<br/>illnesses, and&#160;recent&#160;healthcare contact.</p>
<p style="position:absolute;top:1037px;left:380px;white-space:nowrap" class="ft038">39</p>
<p style="position:absolute;top:1038px;left:391px;white-space:nowrap" class="ft013">&#160;Community outbreaks&#160;of methicillin-resistant&#160;</p>
<p style="position:absolute;top:1038px;left:714px;white-space:nowrap" class="ft019"><i>S.&#160;aureus&#160;</i></p>
<p style="position:absolute;top:1058px;left:108px;white-space:nowrap" class="ft013">(MRSA) infection have also been seen&#160;among men&#160;who have&#160;sex with men.</p>
<p style="position:absolute;top:1057px;left:632px;white-space:nowrap" class="ft038">40</p>
<p style="position:absolute;top:1058px;left:643px;white-space:nowrap" class="ft013">&#160;Studies of&#160;patients&#160;</p>
</div>
<!-- Page 94 -->
<a name="94"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page94-div" style="position:relative;width:917px;height:1187px;">
<p style="position:absolute;top:1114px;left:108px;white-space:nowrap" class="ft024"><i>Guidelines for the Prevention and Treatment&#160;of&#160;Opportunistic&#160;Infections in Adults&#160;and Adolescents&#160;With HIV&#160;</i></p>
<p style="position:absolute;top:1114px;left:789px;white-space:nowrap" class="ft024"><i>G-3&#160;</i></p>
<p style="position:absolute;top:109px;left:108px;white-space:nowrap" class="ft032">without&#160;HIV&#160;have identified hemodialysis, known&#160;prior colonization or infection with MRSA, as&#160;<br/>well&#160;as recurrent&#160;skin infections to be&#160;risk factors for MRSA pneumonia.</p>
<p style="position:absolute;top:127px;left:611px;white-space:nowrap" class="ft038">38</p>
<p style="position:absolute;top:129px;left:622px;white-space:nowrap" class="ft013">&#160;Notably, nasal carriage&#160;</p>
<p style="position:absolute;top:148px;left:108px;white-space:nowrap" class="ft032">and colonization of skin sites with MRSA&#160;is more common in individuals with HIV than in those&#160;<br/>without&#160;HIV,&#160;and is more&#160;likely in patients recently incarcerated and/or hospitalized.</p>
<p style="position:absolute;top:167px;left:693px;white-space:nowrap" class="ft038">41,42</p>
<p style="position:absolute;top:168px;left:718px;white-space:nowrap" class="ft013">&#160;</p>
<p style="position:absolute;top:205px;left:108px;white-space:nowrap" class="ft026"><b>Clinical Manifestations&#160;</b></p>
<p style="position:absolute;top:247px;left:108px;white-space:nowrap" class="ft029"><i><b>Clinical and Radiographic Presentation&#160;</b></i></p>
<p style="position:absolute;top:288px;left:108px;white-space:nowrap" class="ft032">The&#160;clinical&#160;and radiographic&#160;presentation of bacterial&#160;pneumonia in individuals with HIV,&#160;<br/>particularly in those with&#160;higher CD4&#160;count&#160;and HIV viral&#160;suppression, is&#160;similar to that&#160;in&#160;<br/>individuals without&#160;HIV.</p>
<p style="position:absolute;top:326px;left:281px;white-space:nowrap" class="ft038">43</p>
<p style="position:absolute;top:328px;left:292px;white-space:nowrap" class="ft013">&#160;Patients&#160;with pneumonia&#160;caused by&#160;bacteria such as&#160;</p>
<p style="position:absolute;top:328px;left:657px;white-space:nowrap" class="ft019"><i>S. pneumoniae</i></p>
<p style="position:absolute;top:328px;left:759px;white-space:nowrap" class="ft013">&#160;or&#160;</p>
<p style="position:absolute;top:348px;left:108px;white-space:nowrap" class="ft019"><i>Haemophilus&#160;</i></p>
<p style="position:absolute;top:348px;left:204px;white-space:nowrap" class="ft013">species characteristically&#160;have acute&#160;onset (3&#160;to 5 days) of&#160;symptoms, including fevers,&#160;</p>
<p style="position:absolute;top:367px;left:108px;white-space:nowrap" class="ft013">chills, rigors,&#160;chest pain or pleurisy, cough productive of purulent&#160;sputum,&#160;and&#160;dyspnea.</p>
<p style="position:absolute;top:366px;left:705px;white-space:nowrap" class="ft038">44</p>
<p style="position:absolute;top:367px;left:716px;white-space:nowrap" class="ft013">&#160;The&#160;presence&#160;</p>
<p style="position:absolute;top:387px;left:108px;white-space:nowrap" class="ft032">of&#160;fever,&#160;tachycardia,&#160;and/or&#160;hypotension&#160;can&#160;be&#160;indicators&#160;of&#160;sepsis.&#160;Tachypnea&#160;and&#160;decreased&#160;arterial&#160;<br/>oxygen&#160;saturation&#160;indicate&#160;moderate-to-severe&#160;pneumonia,&#160;and&#160;in&#160;such&#160;cases,&#160;clinicians&#160;should&#160;strongly&#160;<br/>consider&#160;hospitalizing&#160;the&#160;patient.&#160;</p>
<p style="position:absolute;top:464px;left:108px;white-space:nowrap" class="ft032">Patients with bacterial&#160;pneumonia&#160;typically have signs of focal&#160;consolidation, such as&#160;egophony,&#160;<br/>and/or pleural effusion on&#160;lung examination. In contrast, lung examination often is normal&#160;in those&#160;<br/>with&#160;</p>
<p style="position:absolute;top:504px;left:143px;white-space:nowrap" class="ft019"><i>Pneumocystis</i></p>
<p style="position:absolute;top:504px;left:238px;white-space:nowrap" class="ft013">&#160;pneumonia (PCP),&#160;and if abnormal, reveals inspiratory crackles. In patients with&#160;</p>
<p style="position:absolute;top:524px;left:108px;white-space:nowrap" class="ft032">bacterial&#160;pneumonia, the&#160;white&#160;blood&#160;cell (WBC) count&#160;usually&#160;is elevated. The elevation may be&#160;<br/>relative&#160;to baseline WBC&#160;count&#160;in those with advanced HIV. Neutrophilia or a left&#160;shift in WBC&#160;<br/>differential may be present.&#160;</p>
<p style="position:absolute;top:600px;left:108px;white-space:nowrap" class="ft032">Individuals&#160;with bacterial&#160;pneumonia&#160;characteristically exhibit unilateral, focal, segmental, or lobar&#160;<br/>consolidation on chest radiograph. The frequency&#160;of these typical&#160;radiographic findings,&#160;however,&#160;<br/>may depend&#160;on the&#160;underlying bacterial&#160;pathogen. Those with pneumonia&#160;due to&#160;</p>
<p style="position:absolute;top:640px;left:667px;white-space:nowrap" class="ft019"><i>S. pneumoniae&#160;</i></p>
<p style="position:absolute;top:640px;left:773px;white-space:nowrap" class="ft013">or&#160;</p>
<p style="position:absolute;top:660px;left:108px;white-space:nowrap" class="ft019"><i>Haemophilus</i></p>
<p style="position:absolute;top:660px;left:200px;white-space:nowrap" class="ft013">&#160;typically present with consolidation, whereas cavitation may be a feature more&#160;</p>
<p style="position:absolute;top:680px;left:108px;white-space:nowrap" class="ft013">suggestive&#160;of&#160;</p>
<p style="position:absolute;top:680px;left:204px;white-space:nowrap" class="ft019"><i>P. aeruginosa&#160;</i></p>
<p style="position:absolute;top:680px;left:305px;white-space:nowrap" class="ft013">or&#160;</p>
<p style="position:absolute;top:680px;left:324px;white-space:nowrap" class="ft019"><i>S.&#160;aureus</i></p>
<p style="position:absolute;top:680px;left:388px;white-space:nowrap" class="ft013">.&#160;</p>
<p style="position:absolute;top:717px;left:108px;white-space:nowrap" class="ft029"><i><b>Risk Factors for Bacteremia&#160;</b></i></p>
<p style="position:absolute;top:758px;left:108px;white-space:nowrap" class="ft032">In individuals with HIV the incidence&#160;of bacteremia&#160;accompanying pneumonia&#160;is greater than in&#160;<br/>individuals without&#160;HIV,&#160;especially when infection is due to&#160;</p>
<p style="position:absolute;top:778px;left:528px;white-space:nowrap" class="ft019"><i>S.&#160;pneumoniae</i></p>
<p style="position:absolute;top:778px;left:630px;white-space:nowrap" class="ft013">.</p>
<p style="position:absolute;top:777px;left:635px;white-space:nowrap" class="ft038">45</p>
<p style="position:absolute;top:778px;left:646px;white-space:nowrap" class="ft013">&#160;In&#160;data from the CDC,&#160;</p>
<p style="position:absolute;top:798px;left:108px;white-space:nowrap" class="ft032">the&#160;incidence of invasive&#160;pneumococcal&#160;disease, inclusive of bacteremia, was significantly higher in&#160;<br/>individuals with HIV: rates were 173&#160;cases per 100,000 in those with HIV infection, compared to 3.8&#160;<br/>per 100,000&#160;in younger adults aged 18–</p>
<p style="position:absolute;top:837px;left:381px;white-space:nowrap" class="ft018">34 years and&#160;36.4 per 100,000 among those aged&#160;</p>
<p style="position:absolute;top:837px;left:723px;white-space:nowrap" class="ft069">≥</p>
<p style="position:absolute;top:837px;left:732px;white-space:nowrap" class="ft018">65 years in&#160;</p>
<p style="position:absolute;top:857px;left:108px;white-space:nowrap" class="ft013">the&#160;general population.</p>
<p style="position:absolute;top:856px;left:267px;white-space:nowrap" class="ft038">46</p>
<p style="position:absolute;top:857px;left:278px;white-space:nowrap" class="ft013">&#160;Similarly, in a study from&#160;Kenya, the&#160;rate of pneumococcal bacteremia&#160;was&#160;</p>
<p style="position:absolute;top:877px;left:108px;white-space:nowrap" class="ft032">significantly higher in individuals with HIV infection (rate&#160;ratio of HIV-infected versus&#160;HIV-<br/>negative&#160;adults, 19.7, 95% CI 12.4-31.1).</p>
<p style="position:absolute;top:896px;left:393px;white-space:nowrap" class="ft038">47</p>
<p style="position:absolute;top:897px;left:404px;white-space:nowrap" class="ft013">&#160;With the introduction of ART and pneumococcal&#160;</p>
<p style="position:absolute;top:917px;left:108px;white-space:nowrap" class="ft032">conjugate vaccines for both the general&#160;pediatric&#160;population and individuals living with HIV, this&#160;<br/>disparity in incidence rates of bacteremia between people with&#160;and without&#160;HIV&#160;has narrowed but&#160;<br/>has not been&#160;eliminated.</p>
<p style="position:absolute;top:955px;left:276px;white-space:nowrap" class="ft038">48-52</p>
<p style="position:absolute;top:956px;left:302px;white-space:nowrap" class="ft013">&#160;In&#160;one recent&#160;study of invasive&#160;pneumococcal&#160;disease (IPD),&#160;which&#160;</p>
<p style="position:absolute;top:976px;left:108px;white-space:nowrap" class="ft032">includes bacteremia,&#160;IPD&#160;was&#160;more&#160;common in people&#160;with HIV&#160;who had&#160;CD4 counts &lt; 500&#160;<br/>cells/mm</p>
<p style="position:absolute;top:995px;left:171px;white-space:nowrap" class="ft038">3</p>
<p style="position:absolute;top:996px;left:177px;white-space:nowrap" class="ft013">, but even those&#160;with counts&#160;&gt; 500 cells/mm</p>
<p style="position:absolute;top:995px;left:481px;white-space:nowrap" class="ft038">3</p>
<p style="position:absolute;top:996px;left:487px;white-space:nowrap" class="ft013">, had a higher incidence&#160;than in the&#160;general&#160;</p>
<p style="position:absolute;top:1016px;left:108px;white-space:nowrap" class="ft013">population.</p>
<p style="position:absolute;top:1015px;left:186px;white-space:nowrap" class="ft038">53</p>
<p style="position:absolute;top:1016px;left:197px;white-space:nowrap" class="ft013">&#160;Risk factors&#160;associated with bacteremia include lack of ART,&#160;low CD4 count&#160;</p>
<p style="position:absolute;top:1036px;left:108px;white-space:nowrap" class="ft013">(particularly &lt;100 cells/mm</p>
<p style="position:absolute;top:1034px;left:301px;white-space:nowrap" class="ft038">3</p>
<p style="position:absolute;top:1036px;left:306px;white-space:nowrap" class="ft013">), as&#160;well&#160;as alcohol abuse, current&#160;smoking, and&#160;comorbidities,&#160;</p>
<p style="position:absolute;top:1056px;left:108px;white-space:nowrap" class="ft013">particularly liver disease.</p>
<p style="position:absolute;top:1054px;left:282px;white-space:nowrap" class="ft038">49</p>
</div>
<!-- Page 95 -->
<a name="95"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page95-div" style="position:relative;width:917px;height:1187px;">
<p style="position:absolute;top:1114px;left:108px;white-space:nowrap" class="ft024"><i>Guidelines for the Prevention and Treatment&#160;of&#160;Opportunistic&#160;Infections in Adults&#160;and Adolescents&#160;With HIV&#160;</i></p>
<p style="position:absolute;top:1114px;left:789px;white-space:nowrap" class="ft024"><i>G-4&#160;</i></p>
<p style="position:absolute;top:109px;left:108px;white-space:nowrap" class="ft029"><i><b>Severity of Illness&#160;&#160;</b></i></p>
<p style="position:absolute;top:150px;left:108px;white-space:nowrap" class="ft032">Disease severity and arterial&#160;oxygenation should&#160;be assessed in&#160;all&#160;patients with pneumonia.&#160;<br/>Noninvasive&#160;measurement of arterial&#160;oxygen saturation by pulse&#160;oximetry is an appropriate screening&#160;<br/>test. Arterial&#160;blood gas analysis is indicated for patients with evidence&#160;of hypoxemia suggested by&#160;<br/>noninvasive&#160;assessment&#160;and for patients who have tachypnea and/or respiratory distress. Assessment&#160;<br/>of additional&#160;clinical&#160;features and the use of severity&#160;scoring systems for pneumonia such as the&#160;<br/>Pneumonia Severity Index&#160;(PSI)&#160;and CURB-65&#160;and&#160;their application to patients with HIV are&#160;<br/>discussed in&#160;the&#160;Treating Disease section.&#160;</p>
<p style="position:absolute;top:306px;left:108px;white-space:nowrap" class="ft029"><i><b>Outcomes&#160;</b></i></p>
<p style="position:absolute;top:348px;left:108px;white-space:nowrap" class="ft032">Although some&#160;studies suggest that bacterial&#160;pneumonia is associated with increased mortality in&#160;<br/>individuals with HIV,</p>
<p style="position:absolute;top:366px;left:259px;white-space:nowrap" class="ft038">23,54,55</p>
<p style="position:absolute;top:367px;left:298px;white-space:nowrap" class="ft013">&#160;others do&#160;not.</p>
<p style="position:absolute;top:366px;left:397px;white-space:nowrap" class="ft038">43,56-58</p>
<p style="position:absolute;top:367px;left:437px;white-space:nowrap" class="ft013">&#160;Independent predictors of increased mortality in a&#160;</p>
<p style="position:absolute;top:387px;left:108px;white-space:nowrap" class="ft032">prospective,&#160;multicenter study of individuals with&#160;HIV&#160;with community-acquired bacterial&#160;<br/>pneumonia&#160;were CD4 count &lt;100 cells/mm</p>
<p style="position:absolute;top:406px;left:409px;white-space:nowrap" class="ft038">3</p>
<p style="position:absolute;top:407px;left:415px;white-space:nowrap" class="ft013">, radiographic progression of&#160;disease, and presence of&#160;</p>
<p style="position:absolute;top:427px;left:108px;white-space:nowrap" class="ft013">shock.</p>
<p style="position:absolute;top:426px;left:153px;white-space:nowrap" class="ft038">59</p>
<p style="position:absolute;top:427px;left:164px;white-space:nowrap" class="ft013">&#160;In that&#160;study, multilobar infiltrates, cavitary infiltrates, and pleural&#160;effusion on&#160;baseline&#160;</p>
<p style="position:absolute;top:447px;left:108px;white-space:nowrap" class="ft032">imaging were all independent&#160;predictors of radiographic progression of&#160;disease. However, in patients&#160;<br/>on ART&#160;with controlled HIV viremia, and high CD4&#160;counts (&gt;350 cells/mm</p>
<p style="position:absolute;top:465px;left:633px;white-space:nowrap" class="ft038">3</p>
<p style="position:absolute;top:467px;left:639px;white-space:nowrap" class="ft013">), the&#160;clinical&#160;courses&#160;</p>
<p style="position:absolute;top:486px;left:108px;white-space:nowrap" class="ft013">and outcomes of pneumonia&#160;appear to be&#160;similar to those in patients without&#160;HIV.</p>
<p style="position:absolute;top:485px;left:674px;white-space:nowrap" class="ft038">43</p>
<p style="position:absolute;top:486px;left:686px;white-space:nowrap" class="ft013">&#160;</p>
<p style="position:absolute;top:524px;left:108px;white-space:nowrap" class="ft032">As&#160;in patients without&#160;HIV, pneumonia may have&#160;an impact&#160;on longer term outcomes of patients&#160;<br/>with HIV. This includes&#160;greater long-term mortality, as hospitalization for pneumonia has been&#160;<br/>associated with increased mortality up to one year later.</p>
<p style="position:absolute;top:562px;left:493px;white-space:nowrap" class="ft038">60</p>
<p style="position:absolute;top:563px;left:508px;white-space:nowrap" class="ft013">One factor that&#160;may add to this&#160;long-term&#160;</p>
<p style="position:absolute;top:583px;left:108px;white-space:nowrap" class="ft032">mortality is cardiovascular disease associated with CAP,&#160;which&#160;occurs at&#160;a similar rate in those with&#160;<br/>HIV&#160;infection , as those&#160;without, even though in one retrospective&#160;cohort&#160;study of 4,384&#160;patients,&#160;<br/>people with&#160;HIV&#160;were younger, had less&#160;severe CAP and fewer traditional cardiovascular risk factors&#160;<br/>than those without&#160;HIV infection.</p>
<p style="position:absolute;top:641px;left:340px;white-space:nowrap" class="ft038">61</p>
<p style="position:absolute;top:643px;left:352px;white-space:nowrap" class="ft013">&#160;Pneumonia&#160;has&#160;also been associated with impaired lung function&#160;</p>
<p style="position:absolute;top:662px;left:108px;white-space:nowrap" class="ft013">and risk of&#160;subsequent&#160;lung cancer in&#160;individuals with HIV.</p>
<p style="position:absolute;top:661px;left:520px;white-space:nowrap" class="ft038">62-64</p>
<p style="position:absolute;top:662px;left:546px;white-space:nowrap" class="ft012"><b>&#160;</b></p>
<p style="position:absolute;top:699px;left:108px;white-space:nowrap" class="ft026"><b>Diagnosis&#160;</b></p>
<p style="position:absolute;top:741px;left:108px;white-space:nowrap" class="ft029"><i><b>General&#160;Approach&#160;</b></i></p>
<p style="position:absolute;top:782px;left:108px;white-space:nowrap" class="ft032">Patients with clinical symptoms and signs suggestive of CAP should have&#160;posteroanterior and lateral&#160;<br/>chest&#160;radiographs; evidence of pneumonia&#160;can also be found on&#160;chest computed tomography (CT)&#160;<br/>scan, but&#160;routine use of chest CT&#160;scan&#160;for this purpose is not recommended.&#160;Lung ultrasound can also&#160;<br/>be used to aid in the diagnosis pneumonia. If previous radiographs are available, they should be&#160;<br/>reviewed to&#160;assess for new findings.&#160;The&#160;clinical&#160;diagnosis of&#160;bacterial&#160;pneumonia&#160;requires a&#160;<br/>demonstrable infiltrate&#160;by chest radiograph or other imaging technique in conjunction with&#160;<br/>compatible clinical symptoms and signs.&#160;</p>
<p style="position:absolute;top:938px;left:108px;white-space:nowrap" class="ft032">The&#160;differential&#160;diagnosis&#160;of pneumonia in individuals with HIV&#160;is broad and&#160;a confirmed&#160;<br/>microbiologic&#160;diagnosis should be&#160;pursued. Microbial identification can allow clinicians to target&#160;the&#160;<br/>specific pathogen(s) and&#160;discontinue&#160;broad spectrum antibiotic&#160;therapy and/or empiric&#160;therapy that&#160;<br/>targets non-bacterial pathogens.&#160;Microbiologic&#160;testing should include evaluation of the upper&#160;<br/>respiratory tract&#160;for SARS-CoV-2, influenza in the appropriate season, and may include testing other&#160;<br/>respiratory viruses.</p>
<p style="position:absolute;top:1036px;left:240px;white-space:nowrap" class="ft038">65</p>
<p style="position:absolute;top:1038px;left:252px;white-space:nowrap" class="ft013">&#160;Given the increased incidence of&#160;</p>
<p style="position:absolute;top:1038px;left:486px;white-space:nowrap" class="ft019"><i>Mycobacterium tuberculosis&#160;</i></p>
<p style="position:absolute;top:1038px;left:687px;white-space:nowrap" class="ft013">(</p>
<p style="position:absolute;top:1038px;left:693px;white-space:nowrap" class="ft019"><i>M.&#160;tuberculosis</i></p>
<p style="position:absolute;top:1038px;left:800px;white-space:nowrap" class="ft013">)</p>
<p style="position:absolute;top:1038px;left:806px;white-space:nowrap" class="ft019"><i>&#160;</i></p>
<p style="position:absolute;top:1057px;left:108px;white-space:nowrap" class="ft013">in individuals with HIV,&#160;a tuberculosis (TB) diagnosis should always be considered in patients with&#160;</p>
</div>
<!-- Page 96 -->
<a name="96"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}	.ft0119{font-size:17px;font-family:KPYRPS+Tinos;color:#005297;}
	.ft0120{font-size:18px;font-family:RHXCLC+Cambria;color:#000000;}
-->
</style>
<div id="page96-div" style="position:relative;width:917px;height:1187px;">
<p style="position:absolute;top:1114px;left:108px;white-space:nowrap" class="ft024"><i>Guidelines for the Prevention and Treatment&#160;of&#160;Opportunistic&#160;Infections in Adults&#160;and Adolescents&#160;With HIV&#160;</i></p>
<p style="position:absolute;top:1114px;left:789px;white-space:nowrap" class="ft024"><i>G-5&#160;</i></p>
<p style="position:absolute;top:109px;left:108px;white-space:nowrap" class="ft032">HIV&#160;who&#160;have pneumonia, particularly in high incidence areas.&#160;Those with clinical&#160;and radiographic&#160;<br/>findings suggestive of TB should be&#160;managed as&#160;potentially having TB (i.e., airborne precautions for&#160;<br/>hospitalized patients), and two to three sputum&#160;specimens should be obtained for acid fast bacilli&#160;<br/>evaluation (including TB&#160;PCR; see&#160;</p>
<p style="position:absolute;top:168px;left:354px;white-space:nowrap" class="ft0119"><i>Mycobacterium&#160;tuberculosis</i></p>
<p style="position:absolute;top:168px;left:551px;white-space:nowrap" class="ft0115">&#160;Infection and&#160;Disease&#160;section</p>
<p style="position:absolute;top:168px;left:758px;white-space:nowrap" class="ft013">).&#160;</p>
<p style="position:absolute;top:188px;left:108px;white-space:nowrap" class="ft032">Bronchoscopy with bronchoalveolar lavage&#160;should&#160;be considered, especially if the&#160;differential&#160;<br/>diagnosis includes opportunistic pathogens such&#160;as&#160;</p>
<p style="position:absolute;top:208px;left:463px;white-space:nowrap" class="ft019"><i>Pneumocystis jirovecii</i></p>
<p style="position:absolute;top:208px;left:620px;white-space:nowrap" class="ft013">.&#160;</p>
<p style="position:absolute;top:245px;left:108px;white-space:nowrap" class="ft032">Procalcitonin (PCT) testing has been proposed as&#160;a tool to distinguish between&#160;bacterial&#160;and viral&#160;<br/>respiratory infections. One&#160;study from Africa specifically evaluated the usefulness of&#160;PCT testing to&#160;<br/>distinguish CAP&#160;due to&#160;bacteria (non-TB),&#160;</p>
<p style="position:absolute;top:285px;left:405px;white-space:nowrap" class="ft019"><i>M. tuberculosis</i></p>
<p style="position:absolute;top:285px;left:513px;white-space:nowrap" class="ft013">, and&#160;PCP&#160;in people&#160;with HIV. In general,&#160;</p>
<p style="position:absolute;top:304px;left:108px;white-space:nowrap" class="ft032">PCT levels associated with bacterial&#160;pneumonia&#160;are higher than those associated with viral or fungal&#160;<br/>pneumonias,&#160;but levels can also be elevated in non-bacterial&#160;pulmonary infections.</p>
<p style="position:absolute;top:323px;left:678px;white-space:nowrap" class="ft038">66</p>
<p style="position:absolute;top:324px;left:689px;white-space:nowrap" class="ft013">&#160;Specific&#160;PCT&#160;</p>
<p style="position:absolute;top:344px;left:108px;white-space:nowrap" class="ft032">thresholds have not&#160;been established or&#160;validated in HIV-associated bacterial pneumonia.&#160;Thus,&#160;<br/>given the&#160;lack of data, the use of&#160;PCT to guide decisions regarding etiology of&#160;pneumonia,&#160;initiation&#160;<br/>of anti-bacterial treatment, or duration&#160;of treatment in patients with HIV is&#160;not recommended.&#160;</p>
<p style="position:absolute;top:421px;left:108px;white-space:nowrap" class="ft029"><i><b>Recommended Diagnostic&#160;Evaluation in CAP&#160;</b></i></p>
<p style="position:absolute;top:462px;left:108px;white-space:nowrap" class="ft032">American Thoracic Society (ATS) and&#160;the&#160;Infectious Diseases Society of America&#160;(IDSA)&#160;guidelines&#160;<br/>for microbiologic testing for diagnosis&#160;of CAP in individuals without HIV generally also apply to&#160;<br/>people with&#160;HIV.</p>
<p style="position:absolute;top:501px;left:228px;white-space:nowrap" class="ft038">67</p>
<p style="position:absolute;top:502px;left:239px;white-space:nowrap" class="ft013">&#160;</p>
<p style="position:absolute;top:538px;left:108px;white-space:nowrap" class="ft040">•</p>
<p style="position:absolute;top:540px;left:116px;white-space:nowrap" class="ft046">&#160;</p>
<p style="position:absolute;top:540px;left:135px;white-space:nowrap" class="ft013">In patients with HIV&#160;with CAP&#160;who are well&#160;enough to be&#160;treated as outpatients, routine</p>
<p style="position:absolute;top:539px;left:744px;white-space:nowrap" class="ft0120">&#160;</p>
<p style="position:absolute;top:560px;left:135px;white-space:nowrap" class="ft032">diagnostic&#160;tests to identify a bacterial&#160;etiologic&#160;diagnosis are optional, especially if the&#160;<br/>microbiologic&#160;studies cannot be&#160;performed promptly</p>
<p style="position:absolute;top:580px;left:498px;white-space:nowrap" class="ft012"><b>.</b></p>
<p style="position:absolute;top:580px;left:503px;white-space:nowrap" class="ft013">&#160;</p>
<p style="position:absolute;top:608px;left:108px;white-space:nowrap" class="ft040">•</p>
<p style="position:absolute;top:610px;left:116px;white-space:nowrap" class="ft046">&#160;</p>
<p style="position:absolute;top:610px;left:135px;white-space:nowrap" class="ft032">In patients with HIV&#160;hospitalized for CAP, a&#160;Gram&#160;stain of expectorated sputum and two&#160;blood&#160;<br/>cultures are recommended, particularly in those with severe pneumonia, in those who are&#160;not on&#160;<br/>ART; or in those who are&#160;known to&#160;have a&#160;CD4 count &lt;350 cells/mm</p>
<p style="position:absolute;top:648px;left:616px;white-space:nowrap" class="ft038">3</p>
<p style="position:absolute;top:650px;left:621px;white-space:nowrap" class="ft013">&#160;(and especially if &lt;100&#160;</p>
<p style="position:absolute;top:670px;left:135px;white-space:nowrap" class="ft013">cells/mm</p>
<p style="position:absolute;top:668px;left:198px;white-space:nowrap" class="ft038">3</p>
<p style="position:absolute;top:670px;left:204px;white-space:nowrap" class="ft013">) prior to hospitalization. Specimens should ideally be obtained before&#160;initiation of&#160;</p>
<p style="position:absolute;top:689px;left:135px;white-space:nowrap" class="ft013">antibiotics, or within 12 hours to 18&#160;hours of&#160;such initiation.&#160;</p>
<p style="position:absolute;top:717px;left:108px;white-space:nowrap" class="ft040">•</p>
<p style="position:absolute;top:719px;left:116px;white-space:nowrap" class="ft046">&#160;</p>
<p style="position:absolute;top:719px;left:135px;white-space:nowrap" class="ft013">Urinary antigen tests for&#160;</p>
<p style="position:absolute;top:719px;left:307px;white-space:nowrap" class="ft019"><i>L. pneumophila</i></p>
<p style="position:absolute;top:719px;left:415px;white-space:nowrap" class="ft013">&#160;and&#160;</p>
<p style="position:absolute;top:719px;left:449px;white-space:nowrap" class="ft019"><i>S. pneumoniae</i></p>
<p style="position:absolute;top:719px;left:551px;white-space:nowrap" class="ft013">&#160;are recommended in hospitalized&#160;</p>
<p style="position:absolute;top:739px;left:135px;white-space:nowrap" class="ft032">patients, particularly those with severe&#160;CAP.&#160;In addition, lower respiratory tract&#160;secretions should&#160;<br/>be cultured for&#160;</p>
<p style="position:absolute;top:759px;left:241px;white-space:nowrap" class="ft019"><i>Legionella</i></p>
<p style="position:absolute;top:759px;left:314px;white-space:nowrap" class="ft013">&#160;on selective media or undergo&#160;</p>
<p style="position:absolute;top:759px;left:531px;white-space:nowrap" class="ft019"><i>Legionella</i></p>
<p style="position:absolute;top:759px;left:605px;white-space:nowrap" class="ft013">&#160;nucleic acid amplification&#160;</p>
<p style="position:absolute;top:779px;left:135px;white-space:nowrap" class="ft032">testing in adults with severe CAP. Legionella testing should also be done&#160;in&#160;people&#160;with&#160;HIV&#160;<br/>with non-severe CAP&#160;when indicated by epidemiological&#160;factors, such as association with a&#160;</p>
<p style="position:absolute;top:819px;left:135px;white-space:nowrap" class="ft019"><i>Legionella</i></p>
<p style="position:absolute;top:819px;left:209px;white-space:nowrap" class="ft013">&#160;outbreak or recent&#160;travel.&#160;</p>
<p style="position:absolute;top:847px;left:108px;white-space:nowrap" class="ft040">•</p>
<p style="position:absolute;top:849px;left:116px;white-space:nowrap" class="ft046">&#160;</p>
<p style="position:absolute;top:849px;left:135px;white-space:nowrap" class="ft032">Microbiologic diagnostic testing is indicated whenever epidemiologic, clinical, or radiologic&#160;<br/>clues prompt&#160;suspicion of&#160;specific&#160;pathogens that&#160;could alter standard empirical&#160;management&#160;<br/>decisions.&#160;</p>
<p style="position:absolute;top:917px;left:108px;white-space:nowrap" class="ft040">•</p>
<p style="position:absolute;top:918px;left:116px;white-space:nowrap" class="ft046">&#160;</p>
<p style="position:absolute;top:919px;left:135px;white-space:nowrap" class="ft032">If available, rapid MRSA&#160;nasal testing should be performed, particularly in patients with risk&#160;<br/>factors for&#160;MRSA or in a&#160;high prevalence&#160;setting, as results can&#160;direct&#160;empiric antibiotic&#160;<br/>therapy.</p>
<p style="position:absolute;top:957px;left:191px;white-space:nowrap" class="ft038">68</p>
<p style="position:absolute;top:958px;left:202px;white-space:nowrap" class="ft013">&#160;</p>
<p style="position:absolute;top:995px;left:108px;white-space:nowrap" class="ft032">Gram stain and culture&#160;of&#160;sputum&#160;is recommended in all hospitalized patients&#160;meeting the criteria&#160;<br/>stated above, and is optional&#160;in people&#160;with HIV with CAP not meeting these criteria. In general,&#160;<br/>Gram stain and culture&#160;of&#160;expectorated sputum&#160;should be&#160;performed only if a good-quality specimen&#160;<br/>can be&#160;obtained prior to—or not more than 12hours&#160;to 18 hours after—initiation of antibiotics, and&#160;</p>
</div>
<!-- Page 97 -->
<a name="97"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page97-div" style="position:relative;width:917px;height:1187px;">
<p style="position:absolute;top:1114px;left:108px;white-space:nowrap" class="ft024"><i>Guidelines for the Prevention and Treatment&#160;of&#160;Opportunistic&#160;Infections in Adults&#160;and Adolescents&#160;With HIV&#160;</i></p>
<p style="position:absolute;top:1114px;left:789px;white-space:nowrap" class="ft024"><i>G-6&#160;</i></p>
<p style="position:absolute;top:109px;left:108px;white-space:nowrap" class="ft032">quality performance measures for collection, transport, and processing of&#160;samples can be&#160;met.&#160;<br/>Sputum cultures in people with HIV have been shown to identify a bacterial etiology in up to 30-40%&#160;<br/>of good quality specimens</p>
<p style="position:absolute;top:147px;left:290px;white-space:nowrap" class="ft038">55,69</p>
<p style="position:absolute;top:148px;left:315px;white-space:nowrap" class="ft013">&#160;although&#160;yield is less&#160;in other studies.</p>
<p style="position:absolute;top:147px;left:578px;white-space:nowrap" class="ft038">14,29</p>
<p style="position:absolute;top:148px;left:604px;white-space:nowrap" class="ft013">&#160;Correlation of sputum&#160;</p>
<p style="position:absolute;top:168px;left:108px;white-space:nowrap" class="ft032">culture&#160;with Gram&#160;stain can help in interpretation of sputum&#160;culture data. For&#160;intubated patients, an&#160;<br/>endotracheal&#160;aspirate&#160;sample should be&#160;obtained promptly after intubation, or&#160;bronchoscopy may be&#160;<br/>indicated.&#160;</p>
<p style="position:absolute;top:245px;left:108px;white-space:nowrap" class="ft032">Blood cultures are more likely to be positive&#160;in people&#160;with HIV than in those without&#160;HIV. Patients&#160;<br/>with HIV, particularly those with lower CD4 counts, are&#160;at&#160;increased risk of&#160;invasive infection with&#160;</p>
<p style="position:absolute;top:285px;left:108px;white-space:nowrap" class="ft019"><i>S. pneumoniae</i></p>
<p style="position:absolute;top:285px;left:210px;white-space:nowrap" class="ft013">. Given concerns for&#160;drug-resistant&#160;</p>
<p style="position:absolute;top:285px;left:454px;white-space:nowrap" class="ft019"><i>S. pneumoniae</i></p>
<p style="position:absolute;top:283px;left:555px;white-space:nowrap" class="ft038">70,71</p>
<p style="position:absolute;top:285px;left:581px;white-space:nowrap" class="ft013">, as&#160;well&#160;as&#160;</p>
<p style="position:absolute;top:285px;left:661px;white-space:nowrap" class="ft019"><i>S. aureus</i></p>
<p style="position:absolute;top:285px;left:725px;white-space:nowrap" class="ft013">&#160;and/or&#160;</p>
<p style="position:absolute;top:304px;left:108px;white-space:nowrap" class="ft032">other drug-resistant&#160;pathogens, blood cultures are recommended for patients&#160;with HIV who meet the&#160;<br/>criteria&#160;as noted above, and are optional for those&#160;who do not meet&#160;the&#160;criteria&#160;listed.&#160;</p>
<p style="position:absolute;top:361px;left:108px;white-space:nowrap" class="ft032">Diagnostic thoracentesis&#160;should be performed in all&#160;patients with pleural&#160;effusion if concern exists&#160;<br/>for accompanying empyema, and pleural&#160;fluid should be&#160;sent for&#160;microbiologic studies. Therapeutic&#160;<br/>thoracentesis should be performed to relieve respiratory distress secondary to&#160;a moderate-to-large-<br/>sized pleural&#160;effusion.&#160;Given the&#160;increased risk of invasive&#160;pneumococcal disease in patients with&#160;<br/>HIV,&#160;clinicians should be&#160;vigilant for evidence of extra-pulmonary complications of infection.</p>
<p style="position:absolute;top:441px;left:758px;white-space:nowrap" class="ft012"><b>&#160;</b></p>
<p style="position:absolute;top:477px;left:108px;white-space:nowrap" class="ft026"><b>Preventing&#160;Exposure&#160;</b></p>
<p style="position:absolute;top:519px;left:108px;white-space:nowrap" class="ft013">No effective&#160;means exist to reduce&#160;exposure to&#160;</p>
<p style="position:absolute;top:519px;left:435px;white-space:nowrap" class="ft019"><i>S. pneumoniae</i></p>
<p style="position:absolute;top:519px;left:537px;white-space:nowrap" class="ft013">&#160;and&#160;</p>
<p style="position:absolute;top:519px;left:570px;white-space:nowrap" class="ft019"><i>Haemophilus influenzae</i></p>
<p style="position:absolute;top:519px;left:738px;white-space:nowrap" class="ft013">, which&#160;</p>
<p style="position:absolute;top:539px;left:108px;white-space:nowrap" class="ft032">are common in the community. General&#160;precautions to maintain health, such&#160;as adhering to hand&#160;<br/>hygiene and&#160;cough etiquette&#160;and refraining from close contact&#160;with individuals who&#160;have respiratory&#160;<br/>infections, should be&#160;emphasized for patients with HIV&#160;as for&#160;other patient populations.&#160;</p>
<p style="position:absolute;top:615px;left:108px;white-space:nowrap" class="ft026"><b>Preventing&#160;Disease&#160;</b></p>
<p style="position:absolute;top:657px;left:108px;white-space:nowrap" class="ft029"><i><b>Pneumococcal Vaccine&#160;</b></i></p>
<p style="position:absolute;top:698px;left:108px;white-space:nowrap" class="ft013">Vaccination against&#160;</p>
<p style="position:absolute;top:698px;left:249px;white-space:nowrap" class="ft019"><i>S. pneumoniae</i></p>
<p style="position:absolute;top:698px;left:350px;white-space:nowrap" class="ft013">&#160;is&#160;an important measure in preventing bacterial&#160;pneumonia. Some&#160;</p>
<p style="position:absolute;top:718px;left:108px;white-space:nowrap" class="ft032">observational studies have reported benefits of pneumococcal polysaccharide vaccine (PPSV) use in&#160;<br/>people with&#160;HIV&#160;against&#160;IPD&#160;(e.g., bacteremia, meningitis)</p>
<p style="position:absolute;top:737px;left:516px;white-space:nowrap" class="ft038">49,72</p>
<p style="position:absolute;top:738px;left:541px;white-space:nowrap" class="ft013">,&#160;and all-cause pneumonia;</p>
<p style="position:absolute;top:737px;left:726px;white-space:nowrap" class="ft038">73-75</p>
<p style="position:absolute;top:738px;left:752px;white-space:nowrap" class="ft013">&#160;</p>
<p style="position:absolute;top:758px;left:108px;white-space:nowrap" class="ft013">however, results have been variable.</p>
<p style="position:absolute;top:757px;left:359px;white-space:nowrap" class="ft038">72,76-78</p>
<p style="position:absolute;top:758px;left:399px;white-space:nowrap" class="ft013">&#160;One randomized placebo-controlled trial&#160;of PPSV in&#160;</p>
<p style="position:absolute;top:778px;left:108px;white-space:nowrap" class="ft032">Africa paradoxically found that&#160;vaccination was associated with an increased&#160;risk of pneumonia, and&#160;<br/>there was no&#160;evidence&#160;of reduced risk of IPD among&#160;vaccinated participants.</p>
<p style="position:absolute;top:796px;left:638px;white-space:nowrap" class="ft038">79</p>
<p style="position:absolute;top:798px;left:649px;white-space:nowrap" class="ft013">&#160;Follow-up&#160;of&#160;this&#160;</p>
<p style="position:absolute;top:818px;left:108px;white-space:nowrap" class="ft032">cohort&#160;not only confirmed the increase in pneumonia in vaccinated participants, but also showed a&#160;<br/>decrease in all-cause mortality, although participants in this study were not treated with ART.</p>
<p style="position:absolute;top:836px;left:754px;white-space:nowrap" class="ft038">80</p>
<p style="position:absolute;top:837px;left:766px;white-space:nowrap" class="ft013">&#160;A&#160;</p>
<p style="position:absolute;top:857px;left:108px;white-space:nowrap" class="ft013">recent study</p>
<p style="position:absolute;top:856px;left:192px;white-space:nowrap" class="ft038">81</p>
<p style="position:absolute;top:857px;left:203px;white-space:nowrap" class="ft013">&#160;evaluating the impact of the 13-valent pneumococcal&#160;conjugate vaccine (PCV13)&#160;</p>
<p style="position:absolute;top:877px;left:108px;white-space:nowrap" class="ft032">vaccination on the&#160;rates&#160;of IPD in adults with HIV between 2008 and 2018 found that&#160;IPD&#160;rates&#160;<br/>remained high despite reductions with&#160;the&#160;introduction of PCV13. PCV20/non-PCV15 serotypes&#160;<br/>comprised 16.5% of cases of IPD,&#160;suggesting that the use of higher valent&#160;conjugate pneumococcal&#160;<br/>vaccines may reduce&#160;IPD.&#160;</p>
<p style="position:absolute;top:974px;left:108px;white-space:nowrap" class="ft032">In 2021, two&#160;PCVs, 15-valent (PCV15) and 20-valent (PCV20),&#160;were licensed by the&#160;FDA for use in&#160;<br/>U.S. adults.</p>
<p style="position:absolute;top:992px;left:189px;white-space:nowrap" class="ft038">82</p>
<p style="position:absolute;top:994px;left:200px;white-space:nowrap" class="ft013">&#160;PCV15 and&#160;PCV20 were&#160;licensed based on safety&#160;and immunogenicity data&#160;compared&#160;</p>
<p style="position:absolute;top:1013px;left:108px;white-space:nowrap" class="ft032">with the 13-valent&#160;PCV&#160;or&#160;23-valent pneumococcal polysaccharide vaccine (PPSV23).&#160;Effectiveness&#160;<br/>data of these&#160;vaccine against pneumococcal disease in adults with HIV infection are currently not&#160;<br/>available. One phase 3 clinical&#160;trial&#160;of PCV15 followed by&#160;PPSV23 8&#160;weeks&#160;later in people&#160;with HIV&#160;</p>
</div>
<!-- Page 98 -->
<a name="98"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}	.ft0121{font-size:20px;font-family:NWXNMS+Calibri;color:#000000;}
-->
</style>
<div id="page98-div" style="position:relative;width:917px;height:1187px;">
<p style="position:absolute;top:1114px;left:108px;white-space:nowrap" class="ft024"><i>Guidelines for the Prevention and Treatment&#160;of&#160;Opportunistic&#160;Infections in Adults&#160;and Adolescents&#160;With HIV&#160;</i></p>
<p style="position:absolute;top:1114px;left:789px;white-space:nowrap" class="ft024"><i>G-7&#160;</i></p>
<p style="position:absolute;top:109px;left:108px;white-space:nowrap" class="ft013">demonstrated safety and&#160;immunogenicity of this approach.</p>
<p style="position:absolute;top:107px;left:513px;white-space:nowrap" class="ft038">83</p>
<p style="position:absolute;top:109px;left:524px;white-space:nowrap" class="ft013">&#160;No clinical&#160;data exist for the use of&#160;</p>
<p style="position:absolute;top:129px;left:108px;white-space:nowrap" class="ft032">PCV20 in people&#160;with HIV. To date, one&#160;randomized, double-blind, placebo-controlled trial has&#160;<br/>assessed the&#160;efficacy of PCV against pneumococcal disease in adults with HIV. This&#160;was&#160;a trial on 7-<br/>valent&#160;PCV&#160;(PCV7) among adults with&#160;HIV in Malawi, which demonstrated 74% efficacy&#160;against&#160;<br/>vaccine-type IPD,&#160;with clear evidence of efficacy in those with CD4 counts&#160;&lt;200 cells/mm</p>
<p style="position:absolute;top:187px;left:737px;white-space:nowrap" class="ft038">3</p>
<p style="position:absolute;top:188px;left:742px;white-space:nowrap" class="ft013">.</p>
<p style="position:absolute;top:187px;left:747px;white-space:nowrap" class="ft038">84</p>
<p style="position:absolute;top:188px;left:758px;white-space:nowrap" class="ft013">&#160;</p>
<p style="position:absolute;top:208px;left:108px;white-space:nowrap" class="ft032">However, study participants were&#160;those&#160;who had&#160;recovered from&#160;IPD, and received two doses of&#160;<br/>PCV7&#160;four&#160;weeks apart. Therefore, findings may not be&#160;directly applicable to adults with&#160;HIV&#160;<br/>infection.</p>
<p style="position:absolute;top:246px;left:174px;white-space:nowrap" class="ft038">&#160;</p>
<p style="position:absolute;top:285px;left:108px;white-space:nowrap" class="ft013">Patients&#160;with&#160;CD4&#160;counts&#160;</p>
<p style="position:absolute;top:285px;left:284px;white-space:nowrap" class="ft069">≥</p>
<p style="position:absolute;top:285px;left:293px;white-space:nowrap" class="ft013">200&#160;cells/mm</p>
<p style="position:absolute;top:283px;left:385px;white-space:nowrap" class="ft038">3</p>
<p style="position:absolute;top:285px;left:391px;white-space:nowrap" class="ft013">&#160;should&#160;receive&#160;a&#160;dose&#160;of&#160;PPSV23&#160;at&#160;least&#160;8&#160;weeks&#160;later&#160;</p>
<p style="position:absolute;top:304px;left:108px;white-space:nowrap" class="ft012"><b>(AI).</b></p>
<p style="position:absolute;top:303px;left:142px;white-space:nowrap" class="ft038">72-75,85-89</p>
<p style="position:absolute;top:304px;left:198px;white-space:nowrap" class="ft013">&#160;While&#160;individuals with HIV with CD4&#160;counts &lt;200&#160;cells/mm</p>
<p style="position:absolute;top:303px;left:624px;white-space:nowrap" class="ft038">3</p>
<p style="position:absolute;top:304px;left:629px;white-space:nowrap" class="ft013">&#160;can also be offered&#160;</p>
<p style="position:absolute;top:324px;left:108px;white-space:nowrap" class="ft013">PPSV23 at&#160;least 8 weeks&#160;after receiving PCV15&#160;</p>
<p style="position:absolute;top:324px;left:443px;white-space:nowrap" class="ft012"><b>(CIII)&#160;</b></p>
<p style="position:absolute;top:324px;left:491px;white-space:nowrap" class="ft013">(such as&#160;if there are concerns&#160;with retention&#160;</p>
<p style="position:absolute;top:344px;left:108px;white-space:nowrap" class="ft032">in care), PPSV23 should&#160;preferably be&#160;deferred until&#160;after an individual’s CD4 count increases to&#160;<br/>&gt;200 cells/mm</p>
<p style="position:absolute;top:363px;left:211px;white-space:nowrap" class="ft038">3</p>
<p style="position:absolute;top:364px;left:217px;white-space:nowrap" class="ft013">&#160;while&#160;on&#160;ART</p>
<p style="position:absolute;top:364px;left:320px;white-space:nowrap" class="ft012"><b>&#160;(BIII).</b></p>
<p style="position:absolute;top:364px;left:372px;white-space:nowrap" class="ft013">&#160;Clinical&#160;evidence supporting use of&#160;PPSV23 in&#160;persons with&#160;</p>
<p style="position:absolute;top:384px;left:108px;white-space:nowrap" class="ft013">CD4 counts&#160;&lt;200 cells/mm</p>
<p style="position:absolute;top:382px;left:297px;white-space:nowrap" class="ft038">3</p>
<p style="position:absolute;top:384px;left:303px;white-space:nowrap" class="ft013">&#160;appears&#160;strongest in patients who also have&#160;HIV&#160;RNA&#160;&lt;100,000&#160;</p>
<p style="position:absolute;top:404px;left:108px;white-space:nowrap" class="ft013">copies/mL;</p>
<p style="position:absolute;top:402px;left:186px;white-space:nowrap" class="ft038">75,89</p>
<p style="position:absolute;top:404px;left:211px;white-space:nowrap" class="ft013">&#160;evidence&#160;also suggests&#160;benefit for those who start&#160;ART before&#160;receiving PPSV&#160;</p>
<p style="position:absolute;top:424px;left:108px;white-space:nowrap" class="ft013">vaccination.</p>
<p style="position:absolute;top:422px;left:192px;white-space:nowrap" class="ft038">72,90</p>
<p style="position:absolute;top:424px;left:217px;white-space:nowrap" class="ft013">&#160;</p>
<p style="position:absolute;top:461px;left:108px;white-space:nowrap" class="ft032">People&#160;with&#160;HIV&#160;who&#160;have received PCV13 but have not&#160;completed their recommended&#160;<br/>pneumococcal vaccine series with PPSV23,&#160;one dose of PCV20 may be used if PPSV23&#160;is not&#160;<br/>available. If PCV20 is used, their pneumococcal&#160;vaccinations are complete&#160;</p>
<p style="position:absolute;top:500px;left:629px;white-space:nowrap" class="ft012"><b>(CIII).</b></p>
<p style="position:absolute;top:500px;left:677px;white-space:nowrap" class="ft013">&#160;</p>
<p style="position:absolute;top:538px;left:108px;white-space:nowrap" class="ft029"><i><b>Influenza&#160;Vaccine</b></i></p>
<p style="position:absolute;top:541px;left:267px;white-space:nowrap" class="ft0121"><i><b>&#160;</b></i></p>
<p style="position:absolute;top:579px;left:108px;white-space:nowrap" class="ft032">Influenza vaccination is pertinent&#160;to prevention of&#160;CAP&#160;from influenza&#160;or influenza-associated&#160;<br/>bacterial&#160;pneumonia, which can occur&#160;as a complication of influenza. Influenza&#160;and pneumococcal&#160;<br/>vaccines can be administered during the same visit. Use of&#160;high-dose inactivated influenza vaccine&#160;is&#160;<br/>associated with decreased incidence&#160;of influenza&#160;and greater antibody response in adults without HIV&#160;<br/>age&#160;</p>
<p style="position:absolute;top:658px;left:136px;white-space:nowrap" class="ft069">≥</p>
<p style="position:absolute;top:658px;left:146px;white-space:nowrap" class="ft013">65 years compared&#160;with standard-dose inactivated vaccine.</p>
<p style="position:absolute;top:657px;left:552px;white-space:nowrap" class="ft038">91,92</p>
<p style="position:absolute;top:658px;left:578px;white-space:nowrap" class="ft013">&#160;One trial found greater&#160;</p>
<p style="position:absolute;top:678px;left:108px;white-space:nowrap" class="ft013">immunogenicity in people&#160;</p>
<p style="position:absolute;top:678px;left:293px;white-space:nowrap" class="ft018">with HIV age&#160;</p>
<p style="position:absolute;top:678px;left:391px;white-space:nowrap" class="ft069">≥</p>
<p style="position:absolute;top:678px;left:401px;white-space:nowrap" class="ft018">18 years&#160;who&#160;were given high</p>
<p style="position:absolute;top:678px;left:608px;white-space:nowrap" class="ft013">-dose influenza vaccine&#160;</p>
<p style="position:absolute;top:698px;left:108px;white-space:nowrap" class="ft013">compared with standard-dose inactivated vaccine.</p>
<p style="position:absolute;top:696px;left:452px;white-space:nowrap" class="ft038">93</p>
<p style="position:absolute;top:698px;left:464px;white-space:nowrap" class="ft013">&#160;See the&#160;“Influenza&#160;Vaccine” section in the&#160;</p>
<p style="position:absolute;top:718px;left:108px;white-space:nowrap" class="ft0115">Immunization section</p>
<p style="position:absolute;top:718px;left:258px;white-space:nowrap" class="ft013">&#160;of the Adult&#160;and&#160;Adolescent&#160;Opportunistic&#160;Infections&#160;Guidelines for a detailed&#160;</p>
<p style="position:absolute;top:737px;left:108px;white-space:nowrap" class="ft013">evidence</p>
<p style="position:absolute;top:737px;left:169px;white-space:nowrap" class="ft019"><i>&#160;</i></p>
<p style="position:absolute;top:737px;left:174px;white-space:nowrap" class="ft013">summary.</p>
<p style="position:absolute;top:737px;left:242px;white-space:nowrap" class="ft019"><i>&#160;</i></p>
<p style="position:absolute;top:775px;left:108px;white-space:nowrap" class="ft013">All people&#160;with HIV&#160;infection during influenza season&#160;</p>
<p style="position:absolute;top:775px;left:488px;white-space:nowrap" class="ft012"><b>(AI)</b></p>
<p style="position:absolute;top:775px;left:519px;white-space:nowrap" class="ft013">&#160;should be immunized against influenza&#160;</p>
<p style="position:absolute;top:794px;left:108px;white-space:nowrap" class="ft013">with inactivated, standard&#160;dose or recombinant&#160;influenza&#160;vaccine&#160;per recommendation of the season&#160;</p>
<p style="position:absolute;top:814px;left:108px;white-space:nowrap" class="ft012"><b>(AI).</b></p>
<p style="position:absolute;top:814px;left:143px;white-space:nowrap" class="ft013">&#160;High-dose inactivated influenza vaccine may be given to individuals age &gt;65 years&#160;</p>
<p style="position:absolute;top:814px;left:725px;white-space:nowrap" class="ft012"><b>(AIII).</b></p>
<p style="position:absolute;top:814px;left:773px;white-space:nowrap" class="ft013">&#160;The&#160;</p>
<p style="position:absolute;top:834px;left:108px;white-space:nowrap" class="ft013">inactivated influenza&#160;or recombinant&#160;vaccine can be administered&#160;at&#160;any time during pregnancy&#160;</p>
<p style="position:absolute;top:834px;left:771px;white-space:nowrap" class="ft012"><b>(AI).</b></p>
<p style="position:absolute;top:834px;left:806px;white-space:nowrap" class="ft013">&#160;</p>
<p style="position:absolute;top:871px;left:108px;white-space:nowrap" class="ft029"><i><b>Additional&#160;Vaccines&#160;</b></i></p>
<p style="position:absolute;top:913px;left:108px;white-space:nowrap" class="ft013">The incidence of&#160;</p>
<p style="position:absolute;top:913px;left:228px;white-space:nowrap" class="ft019"><i>H. influenzae</i></p>
<p style="position:absolute;top:913px;left:320px;white-space:nowrap" class="ft013">&#160;type b infection in adults with HIV is low. Therefore,&#160;</p>
<p style="position:absolute;top:913px;left:697px;white-space:nowrap" class="ft019"><i>H. influenzae</i></p>
<p style="position:absolute;top:913px;left:789px;white-space:nowrap" class="ft013">&#160;</p>
<p style="position:absolute;top:932px;left:108px;white-space:nowrap" class="ft013">type&#160;vaccine&#160;is not usually&#160;recommended for adult&#160;use&#160;</p>
<p style="position:absolute;top:932px;left:488px;white-space:nowrap" class="ft012"><b>(BIII)</b></p>
<p style="position:absolute;top:931px;left:531px;white-space:nowrap" class="ft038">90</p>
<p style="position:absolute;top:932px;left:542px;white-space:nowrap" class="ft013">&#160;unless&#160;a patient&#160;also has&#160;anatomic&#160;or&#160;</p>
<p style="position:absolute;top:952px;left:108px;white-space:nowrap" class="ft013">functional asplenia.&#160;</p>
<p style="position:absolute;top:989px;left:108px;white-space:nowrap" class="ft013">Recommendations for COVID-19&#160;vaccination are provided in&#160;the&#160;</p>
<p style="position:absolute;top:989px;left:565px;white-space:nowrap" class="ft0115">Immunization section</p>
<p style="position:absolute;top:989px;left:715px;white-space:nowrap" class="ft013">&#160;of the&#160;Adult&#160;</p>
<p style="position:absolute;top:1009px;left:108px;white-space:nowrap" class="ft013">and Adolescent&#160;Opportunistic Infections Guidelines.</p>
<p style="position:absolute;top:1009px;left:470px;white-space:nowrap" class="ft019"><i>&#160;</i></p>
</div>
<!-- Page 99 -->
<a name="99"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page99-div" style="position:relative;width:917px;height:1187px;">
<p style="position:absolute;top:1114px;left:108px;white-space:nowrap" class="ft024"><i>Guidelines for the Prevention and Treatment&#160;of&#160;Opportunistic&#160;Infections in Adults&#160;and Adolescents&#160;With HIV&#160;</i></p>
<p style="position:absolute;top:1114px;left:789px;white-space:nowrap" class="ft024"><i>G-8&#160;</i></p>
<p style="position:absolute;top:109px;left:108px;white-space:nowrap" class="ft029"><i><b>Prophylaxis and Risk&#160;Reduction&#160;</b></i></p>
<p style="position:absolute;top:150px;left:108px;white-space:nowrap" class="ft032">Several&#160;factors are associated with a decreased risk&#160;of bacterial&#160;pneumonia&#160;in HIV,&#160;including use of&#160;<br/>ART and trimethoprim-sulfamethoxazole (TMP-SMX)&#160;for PCP prophylaxis.</p>
<p style="position:absolute;top:169px;left:638px;white-space:nowrap" class="ft038">55</p>
<p style="position:absolute;top:170px;left:650px;white-space:nowrap" class="ft013">&#160;In many&#160;studies, daily&#160;</p>
<p style="position:absolute;top:190px;left:108px;white-space:nowrap" class="ft032">administration of TMP-SMX for PCP&#160;prophylaxis reduced the frequency of bacterial respiratory&#160;<br/>infections.</p>
<p style="position:absolute;top:208px;left:180px;white-space:nowrap" class="ft038">9,94,95</p>
<p style="position:absolute;top:210px;left:214px;white-space:nowrap" class="ft013">&#160;This point&#160;should be considered when selecting an agent&#160;for PCP prophylaxis;</p>
<p style="position:absolute;top:229px;left:108px;white-space:nowrap" class="ft032">however, indiscriminate use of TMP-SMX (when&#160;not indicated for PCP&#160;prophylaxis or other specific&#160;<br/>reasons) may&#160;promote development of TMP-SMX-resistant organisms. Thus,&#160;in the United States,</p>
<p style="position:absolute;top:249px;left:786px;white-space:nowrap" class="ft012"><b>&#160;</b></p>
<p style="position:absolute;top:269px;left:108px;white-space:nowrap" class="ft013">TMP-SMX should not be&#160;prescribed solely to prevent&#160;bacterial&#160;respiratory infection&#160;</p>
<p style="position:absolute;top:269px;left:691px;white-space:nowrap" class="ft012"><b>(AIII).</b></p>
<p style="position:absolute;top:269px;left:740px;white-space:nowrap" class="ft013">&#160;</p>
<p style="position:absolute;top:289px;left:108px;white-space:nowrap" class="ft032">Similarly, clarithromycin or azithromycin should&#160;not be&#160;prescribed solely for preventing bacterial&#160;<br/>respiratory infection&#160;</p>
<p style="position:absolute;top:309px;left:252px;white-space:nowrap" class="ft012"><b>(AIII).&#160;</b></p>
<p style="position:absolute;top:346px;left:108px;white-space:nowrap" class="ft013">A decreased&#160;absolute neutrophil&#160;count&#160;(e.g., &lt;500 cells/mm</p>
<p style="position:absolute;top:344px;left:519px;white-space:nowrap" class="ft038">3</p>
<p style="position:absolute;top:346px;left:525px;white-space:nowrap" class="ft013">) is associated with an increased risk of&#160;</p>
<p style="position:absolute;top:366px;left:108px;white-space:nowrap" class="ft032">bacterial&#160;infections, including pneumonia, although this risk has&#160;been demonstrated primarily in&#160;<br/>persons&#160;with&#160;malignant&#160;neoplasms. To&#160;reduce the risk of&#160;such bacterial&#160;infections, clinicians should&#160;<br/>take steps to&#160;reverse neutropenia, such&#160;as by stopping myelosuppressive drugs&#160;</p>
<p style="position:absolute;top:405px;left:652px;white-space:nowrap" class="ft012"><b>(CIII).</b></p>
<p style="position:absolute;top:405px;left:700px;white-space:nowrap" class="ft013">&#160;Studies of&#160;</p>
<p style="position:absolute;top:425px;left:108px;white-space:nowrap" class="ft032">granulocyte-colony stimulating factor (G-CSF) in people&#160;with HIV have failed to document&#160;<br/>benefit.</p>
<p style="position:absolute;top:444px;left:160px;white-space:nowrap" class="ft038">96,97</p>
<p style="position:absolute;top:445px;left:185px;white-space:nowrap" class="ft012"><b>&#160;</b></p>
<p style="position:absolute;top:482px;left:108px;white-space:nowrap" class="ft032">Modifiable&#160;factors associated with an increased risk of bacterial&#160;pneumonia&#160;include&#160;smoking&#160;<br/>cigarettes, using injection drugs, and consuming alcohol.</p>
<p style="position:absolute;top:501px;left:500px;white-space:nowrap" class="ft038">9,74,98-100</p>
<p style="position:absolute;top:502px;left:555px;white-space:nowrap" class="ft013">&#160;Clinicians should encourage&#160;</p>
<p style="position:absolute;top:522px;left:108px;white-space:nowrap" class="ft032">cessation of these behaviors, refer patients to appropriate&#160;services, and/or prescribe medications to&#160;<br/>support quitting. Data demonstrate&#160;that smoking cessation can&#160;decrease the&#160;risk of bacterial&#160;<br/>pneumonia.</p>
<p style="position:absolute;top:560px;left:189px;white-space:nowrap" class="ft038">15</p>
<p style="position:absolute;top:562px;left:200px;white-space:nowrap" class="ft013">&#160;</p>
<p style="position:absolute;top:598px;left:108px;white-space:nowrap" class="ft026"><b>Treating Disease&#160;</b></p>
<p style="position:absolute;top:640px;left:108px;white-space:nowrap" class="ft029"><i><b>General&#160;Approach to Treatment&#160;</b></i></p>
<p style="position:absolute;top:681px;left:108px;white-space:nowrap" class="ft032">The&#160;basic principles of antibiotic&#160;treatment of CAP&#160;are&#160;the&#160;same for patients&#160;with HIV as&#160;for those&#160;<br/>who do&#160;not have&#160;HIV.</p>
<p style="position:absolute;top:700px;left:262px;white-space:nowrap" class="ft038">67</p>
<p style="position:absolute;top:701px;left:273px;white-space:nowrap" class="ft013">&#160;As discussed in the&#160;Diagnosis section, if&#160;specimens are to be collected for&#160;</p>
<p style="position:absolute;top:721px;left:108px;white-space:nowrap" class="ft032">diagnosis, they should preferably be&#160;collected before antibiotic therapy is initiated or within 12 hours&#160;<br/>to 18 hours of antibiotic initiation. However, antibiotic&#160;therapy should be&#160;administered promptly,&#160;<br/>without&#160;waiting for the results of diagnostic&#160;testing. Empiric therapy varies based on geographic&#160;<br/>region and common pathogens in these regions, and should take&#160;into account local&#160;resistance&#160;<br/>patterns, results of MRSA rapid swab&#160;testing if done, and individual patient&#160;risk factors, including&#160;<br/>severity of immunocompromise (recent CD4 cell count, HIV viral&#160;load) and&#160;use of&#160;ART.&#160;</p>
<p style="position:absolute;top:857px;left:108px;white-space:nowrap" class="ft032">In patients with HIV, providers must also consider the risk of opportunistic lung infections, such as&#160;<br/>PCP, that&#160;would alter empiric treatment. In settings&#160;where the&#160;prevalence&#160;of TB is high, initiation of&#160;<br/>empiric therapy for both&#160;bacterial&#160;pneumonia&#160;and TB may be appropriate&#160;for&#160;patients in whom both&#160;<br/>diagnoses are strong considerations and after diagnostic&#160;studies&#160;are&#160;undertaken. Because&#160;respiratory&#160;<br/>fluoroquinolones are also&#160;active against&#160;</p>
<p style="position:absolute;top:937px;left:386px;white-space:nowrap" class="ft019"><i>M. tuberculosis,&#160;</i></p>
<p style="position:absolute;top:937px;left:502px;white-space:nowrap" class="ft013">they should be&#160;used&#160;with caution in patients&#160;</p>
<p style="position:absolute;top:956px;left:108px;white-space:nowrap" class="ft013">with suspected TB who are not&#160;being treated with concurrent&#160;standard four-drug TB therapy.</p>
<p style="position:absolute;top:956px;left:748px;white-space:nowrap" class="ft019"><i>&#160;</i></p>
<p style="position:absolute;top:956px;left:753px;white-space:nowrap" class="ft013">Thus,&#160;</p>
<p style="position:absolute;top:976px;left:108px;white-space:nowrap" class="ft032">patients with TB who are&#160;treated with fluoroquinolones in the absence of standard four-drug TB&#160;<br/>therapy may have&#160;an initial, but&#160;misleading response, that could delay diagnosis of TB and initiation&#160;<br/>of appropriate multidrug TB therapy, increasing the&#160;risk of drug-resistant&#160;TB&#160;and TB transmission.&#160;</p>
</div>
<!-- Page 100 -->
<a name="100"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page100-div" style="position:relative;width:917px;height:1187px;">
<p style="position:absolute;top:1114px;left:108px;white-space:nowrap" class="ft024"><i>Guidelines for the Prevention and Treatment&#160;of&#160;Opportunistic&#160;Infections in Adults&#160;and Adolescents&#160;With HIV&#160;</i></p>
<p style="position:absolute;top:1114px;left:789px;white-space:nowrap" class="ft024"><i>G-9&#160;</i></p>
<p style="position:absolute;top:109px;left:108px;white-space:nowrap" class="ft029"><i><b>Assessing Severity&#160;of&#160;Disease and&#160;Treatment Location&#160;</b></i></p>
<p style="position:absolute;top:150px;left:108px;white-space:nowrap" class="ft032">Whether patients should be treated on an outpatient basis or admitted to the hospital&#160;depends on&#160;<br/>several&#160;factors. In addition to considerations regarding ability to&#160;take oral&#160;medications, adherence,&#160;<br/>and other confounding factors (housing, comorbid&#160;diseases, etc.), severity of&#160;illness&#160;is a key factor&#160;<br/>that helps to guide decisions regarding&#160;treatment location for CAP—outpatient versus&#160;inpatient,&#160;<br/>including intensive&#160;care&#160;unit&#160;(ICU).&#160;Notably, no prospective&#160;randomized clinical&#160;trials have assessed&#160;<br/>the&#160;performance of the&#160;</p>
<p style="position:absolute;top:249px;left:269px;white-space:nowrap" class="ft0115">Pneumonia&#160;Severity Index (PSI) for CAP</p>
<p style="position:absolute;top:249px;left:555px;white-space:nowrap" class="ft013">&#160;or other&#160;severity scores&#160;(e.g., the&#160;</p>
<p style="position:absolute;top:269px;left:108px;white-space:nowrap" class="ft013">ATS/IDSA severity criteria</p>
<p style="position:absolute;top:268px;left:298px;white-space:nowrap" class="ft038">67</p>
<p style="position:absolute;top:269px;left:309px;white-space:nowrap" class="ft013">&#160;or&#160;</p>
<p style="position:absolute;top:269px;left:332px;white-space:nowrap" class="ft0115">CURB-65 Score&#160;for Pneumonia Severity</p>
<p style="position:absolute;top:269px;left:614px;white-space:nowrap" class="ft013">, to guide decisions&#160;</p>
<p style="position:absolute;top:289px;left:108px;white-space:nowrap" class="ft032">regarding inpatient or outpatient treatment&#160;location for people&#160;with HIV. However, the&#160;PSI, CURB-<br/>65, the&#160;ATS/IDSA severity criteria, and other scoring systems&#160;appear to be&#160;valid for predicting&#160;<br/>mortality in&#160;patients with HIV&#160;with CAP, especially when used&#160;in combination with CD4&#160;<br/>count.</p>
<p style="position:absolute;top:347px;left:151px;white-space:nowrap" class="ft038">59,101,102</p>
<p style="position:absolute;top:348px;left:201px;white-space:nowrap" class="ft013">&#160;</p>
<p style="position:absolute;top:386px;left:108px;white-space:nowrap" class="ft032">Whether the performance&#160;of severity indices is improved by including HIV-related variables is&#160;<br/>uncertain. One study suggested that&#160;the&#160;site&#160;of care decision be&#160;dictated by considering the&#160;PSI&#160;score&#160;<br/>and CD4 count together.</p>
<p style="position:absolute;top:424px;left:278px;white-space:nowrap" class="ft038">101</p>
<p style="position:absolute;top:425px;left:294px;white-space:nowrap" class="ft013">&#160;Mortality was increased&#160;in patients with higher PSI risk class; however,&#160;</p>
<p style="position:absolute;top:445px;left:108px;white-space:nowrap" class="ft013">even in those&#160;without&#160;an increased mortality risk by PSI, a&#160;CD4&#160;count&#160;&lt;200&#160;cells/mm</p>
<p style="position:absolute;top:444px;left:698px;white-space:nowrap" class="ft038">3</p>
<p style="position:absolute;top:445px;left:704px;white-space:nowrap" class="ft013">&#160;was associated&#160;</p>
<p style="position:absolute;top:465px;left:108px;white-space:nowrap" class="ft013">with an increased risk of&#160;death.</p>
<p style="position:absolute;top:464px;left:324px;white-space:nowrap" class="ft038">101</p>
<p style="position:absolute;top:465px;left:340px;white-space:nowrap" class="ft013">&#160;This led to the suggestion to&#160;hospitalize&#160;CAP&#160;patients&#160;with CD4&#160;</p>
<p style="position:absolute;top:485px;left:108px;white-space:nowrap" class="ft013">counts &lt;200&#160;cells/mm</p>
<p style="position:absolute;top:483px;left:260px;white-space:nowrap" class="ft038">3</p>
<p style="position:absolute;top:485px;left:266px;white-space:nowrap" class="ft013">&#160;and to use the&#160;PSI to help guide&#160;decision-making in those with higher CD4&#160;</p>
<p style="position:absolute;top:505px;left:108px;white-space:nowrap" class="ft013">counts.</p>
<p style="position:absolute;top:503px;left:157px;white-space:nowrap" class="ft038">103</p>
<p style="position:absolute;top:505px;left:174px;white-space:nowrap" class="ft013">&#160;</p>
<p style="position:absolute;top:542px;left:108px;white-space:nowrap" class="ft013">However, other studies have found the PSI&#160;was predictive&#160;of outcomes independent&#160;of CD4 count.</p>
<p style="position:absolute;top:540px;left:788px;white-space:nowrap" class="ft038">104</p>
<p style="position:absolute;top:542px;left:805px;white-space:nowrap" class="ft013">&#160;</p>
<p style="position:absolute;top:562px;left:108px;white-space:nowrap" class="ft032">Furthermore,&#160;CD4 count or HIV RNA level are not&#160;clearly associated with short-term&#160;outcomes of&#160;<br/>CAP.</p>
<p style="position:absolute;top:580px;left:146px;white-space:nowrap" class="ft038">105</p>
<p style="position:absolute;top:581px;left:163px;white-space:nowrap" class="ft013">&#160;Other HIV-specific&#160;scoring systems such&#160;as the&#160;</p>
<p style="position:absolute;top:581px;left:499px;white-space:nowrap" class="ft0115">Veterans Aging Cohort Study (VACS)&#160;</p>
<p style="position:absolute;top:601px;left:108px;white-space:nowrap" class="ft0115">Index</p>
<p style="position:absolute;top:601px;left:147px;white-space:nowrap" class="ft013">, although originally designed to&#160;predict&#160;overall mortality,&#160;may also be&#160;useful in predicting ICU&#160;</p>
<p style="position:absolute;top:621px;left:108px;white-space:nowrap" class="ft032">admission and mortality. In a study of&#160;older patients with and&#160;without HIV&#160;with CAP, a higher&#160;<br/>VACS Index&#160;was associated with greater 30-day mortality, readmission, and&#160;length of stay.</p>
<p style="position:absolute;top:639px;left:739px;white-space:nowrap" class="ft038">106</p>
<p style="position:absolute;top:641px;left:756px;white-space:nowrap" class="ft013">&#160;</p>
<p style="position:absolute;top:661px;left:108px;white-space:nowrap" class="ft013">Another possible tool is the SWAT-Bp&#160;tool&#160;developed in Malawi.</p>
<p style="position:absolute;top:659px;left:562px;white-space:nowrap" class="ft038">107</p>
<p style="position:absolute;top:661px;left:579px;white-space:nowrap" class="ft013">&#160;This tool&#160;measures male&#160;[S]ex,&#160;</p>
<p style="position:absolute;top:680px;left:108px;white-space:nowrap" class="ft032">muscle [W]asting, non-[A]mbulatory, [T]emperature (&gt;38°C or&#160;&lt;35°C), and&#160;[B]lood [p]ressure&#160;<br/>(systolic&lt;100 and/or diastolic&lt;60)). In a&#160;retrospective study of&#160;216 patients&#160;(84%&#160;with HIV),&#160;<br/>demonstrated moderate discriminatory power,&#160;while the CURB-65 was less&#160;accurate.&#160;</p>
<p style="position:absolute;top:757px;left:108px;white-space:nowrap" class="ft032">Thus in general, validated clinical prediction scores&#160;for prognosis&#160;can be&#160;used&#160;in patients with HIV in&#160;<br/>conjunction with clinical&#160;judgement to guide&#160;treatment location for CAP. Low risk patients for whom&#160;<br/>there are&#160;no&#160;other concerns regarding&#160;adherence or&#160;complicating factors can&#160;be treated as outpatients.&#160;<br/>Patients with severe CAP,&#160;including those presenting with shock&#160;or respiratory failure, usually&#160;<br/>require a higher level&#160;of care, typically ICU admission. Additionally, severe&#160;CAP&#160;criteria&#160;can include&#160;<br/>PSI risk class of III&#160;or IV&#160;or CURB-65 scores&#160;</p>
<p style="position:absolute;top:856px;left:427px;white-space:nowrap" class="ft069">≥</p>
<p style="position:absolute;top:856px;left:436px;white-space:nowrap" class="ft013">3.&#160;Patients with&#160;</p>
<p style="position:absolute;top:856px;left:547px;white-space:nowrap" class="ft069">≥</p>
<p style="position:absolute;top:856px;left:557px;white-space:nowrap" class="ft013">3 of the ATS/IDSA minor severity&#160;</p>
<p style="position:absolute;top:876px;left:108px;white-space:nowrap" class="ft013">criteria&#160;for CAP</p>
<p style="position:absolute;top:875px;left:219px;white-space:nowrap" class="ft038">67</p>
<p style="position:absolute;top:876px;left:230px;white-space:nowrap" class="ft013">&#160;often&#160;require ICU or&#160;higher level&#160;of care, as&#160;well.&#160;</p>
<p style="position:absolute;top:914px;left:108px;white-space:nowrap" class="ft029"><i><b>Empiric&#160;Antibiotic&#160;Therapy by&#160;Treatment&#160;Setting and&#160;Severity&#160;of&#160;Diseases&#160;</b></i></p>
<p style="position:absolute;top:955px;left:108px;white-space:nowrap" class="ft032">There is a general&#160;paucity of clinical&#160;trials evaluating different antibiotic&#160;regimens for treating CAP&#160;<br/>in populations with HIV and a lack of&#160;evidence&#160;that treatment response to antibiotics is different&#160;in&#160;<br/>individuals with HIV than in those without&#160;HIV. Therefore, treatment&#160;recommendations for CAP in&#160;<br/>individuals with HIV are&#160;generally consistent&#160;with&#160;the&#160;ATS/IDSA guidelines&#160;for people without&#160;<br/>HIV.</p>
<p style="position:absolute;top:1033px;left:143px;white-space:nowrap" class="ft038">67</p>
<p style="position:absolute;top:1034px;left:154px;white-space:nowrap" class="ft017"><i><b>&#160;</b></i></p>
</div>
<!-- Page 101 -->
<a name="101"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page101-div" style="position:relative;width:917px;height:1187px;">
<p style="position:absolute;top:1114px;left:108px;white-space:nowrap" class="ft024"><i>Guidelines for the Prevention and Treatment&#160;of&#160;Opportunistic&#160;Infections in Adults&#160;and Adolescents&#160;With HIV&#160;</i></p>
<p style="position:absolute;top:1114px;left:782px;white-space:nowrap" class="ft024"><i>G-10&#160;</i></p>
<p style="position:absolute;top:109px;left:108px;white-space:nowrap" class="ft029"><i><b>Outpatient CAP&#160;Treatment&#160;</b></i></p>
<p style="position:absolute;top:150px;left:108px;white-space:nowrap" class="ft032">Individuals&#160;with HIV who are being treated as outpatients should receive an oral&#160;beta-lactam plus a&#160;<br/>macrolide&#160;</p>
<p style="position:absolute;top:170px;left:181px;white-space:nowrap" class="ft012"><b>(AI),</b></p>
<p style="position:absolute;top:170px;left:216px;white-space:nowrap" class="ft013">&#160;or a respiratory fluoroquinolone</p>
<p style="position:absolute;top:170px;left:441px;white-space:nowrap" class="ft012"><b>&#160;(AI).</b></p>
<p style="position:absolute;top:170px;left:480px;white-space:nowrap" class="ft013">&#160;Preferred&#160;beta-lactams are high-dose&#160;</p>
<p style="position:absolute;top:190px;left:108px;white-space:nowrap" class="ft032">amoxicillin or amoxicillin-clavulanate; alternatives are cefpodoxime or cefuroxime. Preferred&#160;<br/>macrolides are azithromycin or clarithromycin. Preferred respiratory fluoroquinolones are&#160;<br/>moxifloxacin or levofloxacin. A respiratory fluoroquinolone (moxifloxacin or levofloxacin) should&#160;<br/>be used as an&#160;alternative&#160;to a beta lactam in patients who are allergic to penicillin. If a patient&#160;has&#160;<br/>contraindications to a&#160;macrolide&#160;or a fluoroquinolone, then doxycycline&#160;should be given&#160;as an&#160;<br/>alternative&#160;</p>
<p style="position:absolute;top:289px;left:185px;white-space:nowrap" class="ft012"><b>(BIII)&#160;</b></p>
<p style="position:absolute;top:289px;left:232px;white-space:nowrap" class="ft013">in addition to a&#160;beta-lactam.&#160;</p>
<p style="position:absolute;top:326px;left:108px;white-space:nowrap" class="ft032">Empirical&#160;monotherapy&#160;with a&#160;macrolide for outpatient CAP is&#160;not routinely recommended in&#160;<br/>patients with HIV&#160;for two&#160;reasons&#160;</p>
<p style="position:absolute;top:346px;left:346px;white-space:nowrap" class="ft012"><b>(BIII).</b></p>
<p style="position:absolute;top:346px;left:394px;white-space:nowrap" class="ft013">&#160;First, increasing rates&#160;of pneumococcal resistance&#160;have&#160;</p>
<p style="position:absolute;top:366px;left:108px;white-space:nowrap" class="ft013">been reported with erythromycin-resistant rates up to 30%,</p>
<p style="position:absolute;top:364px;left:514px;white-space:nowrap" class="ft038">108</p>
<p style="position:absolute;top:366px;left:531px;white-space:nowrap" class="ft013">&#160;prompting concerns for possible&#160;</p>
<p style="position:absolute;top:386px;left:108px;white-space:nowrap" class="ft032">treatment failure. In this regard, local drug resistance patterns, if available, can help inform treatment&#160;<br/>decisions</p>
<p style="position:absolute;top:405px;left:172px;white-space:nowrap" class="ft012"><b>.&#160;</b></p>
<p style="position:absolute;top:405px;left:181px;white-space:nowrap" class="ft013">Additionally, patients who are already receiving a macrolide for MAC prophylaxis may&#160;</p>
<p style="position:absolute;top:425px;left:108px;white-space:nowrap" class="ft032">have resistance&#160;due to chronic&#160;exposure, and should&#160;also not receive&#160;macrolide&#160;monotherapy for&#160;<br/>empiric treatment of bacterial&#160;pneumonia. However, macrolides can be used&#160;as part of a combination&#160;<br/>CAP&#160;regimen.&#160;</p>
<p style="position:absolute;top:502px;left:108px;white-space:nowrap" class="ft029"><i><b>Non-Severe&#160;CAP&#160;Inpatient Treatment&#160;</b></i></p>
<p style="position:absolute;top:543px;left:108px;white-space:nowrap" class="ft032">Individuals&#160;with HIV who are being treated as inpatients should&#160;receive an intravenous (IV) beta-<br/>lactam&#160;plus a macrolide</p>
<p style="position:absolute;top:563px;left:272px;white-space:nowrap" class="ft012"><b>&#160;(AI)&#160;</b></p>
<p style="position:absolute;top:563px;left:311px;white-space:nowrap" class="ft013">or a respiratory fluoroquinolone</p>
<p style="position:absolute;top:563px;left:532px;white-space:nowrap" class="ft012"><b>&#160;(AI).</b></p>
<p style="position:absolute;top:563px;left:571px;white-space:nowrap" class="ft013">&#160;Monotherapy with a&#160;macrolide&#160;is&#160;</p>
<p style="position:absolute;top:583px;left:108px;white-space:nowrap" class="ft032">not recommended in the&#160;inpatient&#160;setting. The&#160;role&#160;for dual&#160;therapy with a macrolide&#160;is somewhat&#160;<br/>controversial&#160;based on prior observational&#160;studies and two prospective clinical trials in patients&#160;<br/>without&#160;HIV&#160;with CAP that&#160;evaluated outcomes in&#160;those treated with beta-lactam&#160;monotherapy and&#160;<br/>those treated with dual-therapy including a&#160;macrolide.</p>
<p style="position:absolute;top:641px;left:481px;white-space:nowrap" class="ft038">109,110</p>
<p style="position:absolute;top:643px;left:518px;white-space:nowrap" class="ft013">&#160;In one study, beta-lactam&#160;monotherapy&#160;</p>
<p style="position:absolute;top:662px;left:108px;white-space:nowrap" class="ft032">was not found to be&#160;non-inferior to beta-lactam/macrolide&#160;combination therapy. Notably,&#160;in the&#160;<br/>monotherapy&#160;arm, patients who&#160;had more severe&#160;CAP, as indicated by a PSI&#160;</p>
<p style="position:absolute;top:682px;left:639px;white-space:nowrap" class="ft069">≥</p>
<p style="position:absolute;top:682px;left:648px;white-space:nowrap" class="ft013">IV, or&#160;who&#160;had&#160;</p>
<p style="position:absolute;top:702px;left:108px;white-space:nowrap" class="ft032">atypical&#160;pathogens&#160;were less&#160;likely to reach clinical stability. There were&#160;also more&#160;30-day&#160;<br/>readmissions&#160;among the&#160;patients on monotherapy.</p>
<p style="position:absolute;top:721px;left:454px;white-space:nowrap" class="ft038">109</p>
<p style="position:absolute;top:722px;left:471px;white-space:nowrap" class="ft013">&#160;While&#160;there was a trend&#160;towards improved&#160;</p>
<p style="position:absolute;top:742px;left:108px;white-space:nowrap" class="ft032">outcomes in&#160;those on dual&#160;therapy, the difference between arms&#160;was not&#160;statistically significant. In a&#160;<br/>pragmatic, cluster-randomized, cross-over trial of non-ICU&#160;hospitalized patients with CAP, beta-<br/>lactam&#160;monotherapy was&#160;found to be&#160;non-inferior to beta-lactam/macrolide&#160;combination therapy or&#160;<br/>fluoroquinolone monotherapy.</p>
<p style="position:absolute;top:800px;left:319px;white-space:nowrap" class="ft038">110</p>
<p style="position:absolute;top:801px;left:336px;white-space:nowrap" class="ft013">&#160;However in this study, the diagnosis of CAP did not require&#160;</p>
<p style="position:absolute;top:821px;left:108px;white-space:nowrap" class="ft013">radiographic&#160;confirmation, illness&#160;was&#160;mild, and there were cross-overs between groups.&#160;</p>
<p style="position:absolute;top:858px;left:108px;white-space:nowrap" class="ft032">Only one&#160;study thus far&#160;has compared&#160;a cephalosporin (ceftriaxone) to dual therapy with a&#160;<br/>cephalosporin (ceftriaxone) plus macrolide in 225 people with&#160;HIV&#160;with CAP, finding&#160;no difference<br/>between in-hospital or 14-day mortality between the groups; most patients had lower severity of&#160;<br/>disease, with&#160;only 7% of the cohort&#160;having a&#160;CURB-65 score &gt;2 and 17%&#160;with a PSI risk&#160;class&#160;<br/>&gt;III.</p>
<p style="position:absolute;top:936px;left:139px;white-space:nowrap" class="ft038">111</p>
<p style="position:absolute;top:938px;left:156px;white-space:nowrap" class="ft013">&#160;Given the&#160;heterogeneity and limitations of recent&#160;studies and scarce&#160;data in patients with&#160;</p>
<p style="position:absolute;top:957px;left:108px;white-space:nowrap" class="ft032">HIV,&#160;the&#160;recommendation for patients&#160;with HIV who are hospitalized with non-severe CAP&#160;remains&#160;<br/>that same as in people without HIV: to administer either beta-lactam/macrolide combination therapy,&#160;<br/>or a single drug regimen of a respiratory fluoroquinolone&#160;</p>
<p style="position:absolute;top:997px;left:506px;white-space:nowrap" class="ft012"><b>(AI).</b></p>
<p style="position:absolute;top:997px;left:541px;white-space:nowrap" class="ft013">&#160;</p>
<p style="position:absolute;top:1034px;left:108px;white-space:nowrap" class="ft032">Preferred beta-lactams are ceftriaxone, cefotaxime, or ampicillin-sulbactam. Preferred macrolides are&#160;<br/>azithromycin and clarithromycin. Preferred respiratory fluoroquinolones are&#160;moxifloxacin or&#160;</p>
</div>
<!-- Page 102 -->
<a name="102"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page102-div" style="position:relative;width:917px;height:1187px;">
<p style="position:absolute;top:1114px;left:108px;white-space:nowrap" class="ft024"><i>Guidelines for the Prevention and Treatment&#160;of&#160;Opportunistic&#160;Infections in Adults&#160;and Adolescents&#160;With HIV&#160;</i></p>
<p style="position:absolute;top:1114px;left:782px;white-space:nowrap" class="ft024"><i>G-11&#160;</i></p>
<p style="position:absolute;top:109px;left:108px;white-space:nowrap" class="ft032">levofloxacin. If a patient has contraindications to a&#160;macrolide&#160;or a fluoroquinolone, then doxycycline&#160;<br/>should be given as an alternative&#160;</p>
<p style="position:absolute;top:129px;left:338px;white-space:nowrap" class="ft012"><b>(BIII)&#160;</b></p>
<p style="position:absolute;top:129px;left:385px;white-space:nowrap" class="ft013">in addition&#160;to a&#160;beta-lactam. Clinical and Laboratory&#160;</p>
<p style="position:absolute;top:148px;left:108px;white-space:nowrap" class="ft032">Standards Institute and U. S. Food and&#160;Drug&#160;Administration (FDA) changes in the&#160;penicillin&#160;<br/>breakpoints for treatment of non-meningitis pneumococcal&#160;disease imply IV&#160;penicillin is an&#160;<br/>acceptable option for treatment of pneumococcal disease in patients with HIV&#160;</p>
<p style="position:absolute;top:188px;left:649px;white-space:nowrap" class="ft012"><b>(BIII).</b></p>
<p style="position:absolute;top:187px;left:697px;white-space:nowrap" class="ft038">112</p>
<p style="position:absolute;top:188px;left:714px;white-space:nowrap" class="ft013">&#160;In patients&#160;</p>
<p style="position:absolute;top:208px;left:108px;white-space:nowrap" class="ft032">who are allergic&#160;to penicillin, a&#160;respiratory fluoroquinolone (moxifloxacin or levofloxacin [750&#160;<br/>mg/day]) alone should be&#160;used</p>
<p style="position:absolute;top:228px;left:320px;white-space:nowrap" class="ft012"><b>&#160;(AI).</b></p>
<p style="position:absolute;top:228px;left:359px;white-space:nowrap" class="ft013">&#160;As noted, fluoroquinolone&#160;monotherapy&#160;should be used with&#160;</p>
<p style="position:absolute;top:248px;left:108px;white-space:nowrap" class="ft032">caution in patients in whom TB is suspected but&#160;who are not&#160;being treated with concurrent&#160;standard&#160;<br/>four-drug TB therapy.&#160;</p>
<p style="position:absolute;top:305px;left:108px;white-space:nowrap" class="ft029"><i><b>Severe CAP Treatment&#160;</b></i></p>
<p style="position:absolute;top:346px;left:108px;white-space:nowrap" class="ft032">Patients with severe CAP&#160;should not receive empiric monotherapy, even with a fluoroquinolone,&#160;<br/>because of the range&#160;of potential&#160;pathogens and the&#160;desirability of prompt and&#160;microbiologically&#160;<br/>active&#160;therapy (AI).&#160;In one study, the use of dual&#160;therapy (usually with a&#160;beta-lactam&#160;plus a&#160;<br/>macrolide) was associated&#160;with reduced mortality in patients with bacteremic&#160;pneumococcal&#160;<br/>pneumonia, including those admitted to the&#160;ICU.</p>
<p style="position:absolute;top:424px;left:445px;white-space:nowrap" class="ft038">113</p>
<p style="position:absolute;top:425px;left:462px;white-space:nowrap" class="ft012"><b>&#160;</b></p>
<p style="position:absolute;top:425px;left:466px;white-space:nowrap" class="ft013">Patients with severe pneumonia should be&#160;treated&#160;</p>
<p style="position:absolute;top:445px;left:108px;white-space:nowrap" class="ft013">with an IV&#160;beta-lactam&#160;plus either azithromycin&#160;</p>
<p style="position:absolute;top:445px;left:442px;white-space:nowrap" class="ft012"><b>(AI)&#160;</b></p>
<p style="position:absolute;top:445px;left:477px;white-space:nowrap" class="ft013">or a respiratory fluoroquinolone (moxifloxacin&#160;</p>
<p style="position:absolute;top:465px;left:108px;white-space:nowrap" class="ft013">or levofloxacin [750 mg/day])</p>
<p style="position:absolute;top:465px;left:316px;white-space:nowrap" class="ft012"><b>&#160;(AI).</b></p>
<p style="position:absolute;top:465px;left:356px;white-space:nowrap" class="ft013">&#160;Both have a strong recommendation. Weak observational&#160;data,&#160;</p>
<p style="position:absolute;top:485px;left:108px;white-space:nowrap" class="ft032">in the absence of prospective&#160;randomized controlled data, suggest that&#160;beta-lactam&#160;plus macrolide&#160;<br/>may be associated with decreased mortality.</p>
<p style="position:absolute;top:503px;left:413px;white-space:nowrap" class="ft038">77,114,115</p>
<p style="position:absolute;top:505px;left:463px;white-space:nowrap" class="ft013">&#160;Preferred beta-lactams are ceftriaxone,&#160;</p>
<p style="position:absolute;top:524px;left:108px;white-space:nowrap" class="ft032">cefotaxime, or ampicillin-sulbactam. In patients who are&#160;allergic to penicillin,&#160;aztreonam&#160;plus a&#160;<br/>respiratory fluoroquinolone (moxifloxacin or levofloxacin [750&#160;mg/day]) should be&#160;used</p>
<p style="position:absolute;top:544px;left:719px;white-space:nowrap" class="ft012"><b>&#160;(BIII).&#160;</b></p>
<p style="position:absolute;top:581px;left:108px;white-space:nowrap" class="ft032">The&#160;majority of CAP pathogens can be&#160;treated adequately with recommended empiric regimens. The&#160;<br/>increased incidence of&#160;</p>
<p style="position:absolute;top:601px;left:266px;white-space:nowrap" class="ft019"><i>P.&#160;aeruginosa</i></p>
<p style="position:absolute;top:601px;left:363px;white-space:nowrap" class="ft013">&#160;and&#160;</p>
<p style="position:absolute;top:601px;left:397px;white-space:nowrap" class="ft019"><i>S. aureus</i></p>
<p style="position:absolute;top:601px;left:461px;white-space:nowrap" class="ft013">&#160;(including community-acquired MRSA) as&#160;</p>
<p style="position:absolute;top:621px;left:108px;white-space:nowrap" class="ft032">causes of CAP are exceptions. Both of&#160;these pathogens occur in&#160;specific&#160;epidemiologic&#160;patterns with&#160;<br/>distinct&#160;clinical presentations for&#160;which empiric antibiotic coverage&#160;may be warranted.&#160;Diagnostic&#160;<br/>tests (sputum&#160;Gram stain&#160;and culture)&#160;are likely to be of high yield for these&#160;pathogens, allowing&#160;<br/>early discontinuation of empiric treatment if results are negative.&#160;In the&#160;most recent&#160;ATS/IDSA CAP&#160;<br/>guidelines, empiric&#160;therapy for&#160;</p>
<p style="position:absolute;top:700px;left:325px;white-space:nowrap" class="ft019"><i>P. aeruginosa</i></p>
<p style="position:absolute;top:700px;left:422px;white-space:nowrap" class="ft013">&#160;or&#160;MRSA is recommended in those with&#160;severe CAP,&#160;</p>
<p style="position:absolute;top:720px;left:108px;white-space:nowrap" class="ft032">who have had these organisms previously isolated from sputum&#160;cultures, with de-escalation if these&#160;<br/>organisms are not&#160;isolated from current&#160;cultures.</p>
<p style="position:absolute;top:739px;left:443px;white-space:nowrap" class="ft038">67</p>
<p style="position:absolute;top:740px;left:454px;white-space:nowrap" class="ft013">&#160;</p>
<p style="position:absolute;top:777px;left:108px;white-space:nowrap" class="ft032">The&#160;addition of corticosteroids for treating CAP&#160;has&#160;not been studied in people&#160;with HIV.&#160;Data from&#160;<br/>studies in people&#160;without&#160;HIV&#160;with CAP&#160;suggest that&#160;corticosteroids may decrease a composite&#160;<br/>outcome&#160;of&#160;mortality, time to clinical stability, and length of hospital stay.</p>
<p style="position:absolute;top:815px;left:621px;white-space:nowrap" class="ft038">116</p>
<p style="position:absolute;top:817px;left:637px;white-space:nowrap" class="ft013">&#160;Importantly, effects of&#160;</p>
<p style="position:absolute;top:837px;left:108px;white-space:nowrap" class="ft032">corticosteroids appear variable&#160;according to etiology and severity of pneumonia, however, as&#160;<br/>corticosteroids may increase mortality in influenza&#160;pneumonia,</p>
<p style="position:absolute;top:855px;left:543px;white-space:nowrap" class="ft038">117</p>
<p style="position:absolute;top:856px;left:560px;white-space:nowrap" class="ft013">&#160;but decrease mortality in patients&#160;</p>
<p style="position:absolute;top:876px;left:108px;white-space:nowrap" class="ft013">with COVID-19 who require&#160;higher levels of respiratory support.</p>
<p style="position:absolute;top:875px;left:559px;white-space:nowrap" class="ft038">118</p>
<p style="position:absolute;top:876px;left:576px;white-space:nowrap" class="ft013">&#160;The&#160;optimal regimen including&#160;</p>
<p style="position:absolute;top:896px;left:108px;white-space:nowrap" class="ft032">dose, duration, and formulation of corticosteroid, and the&#160;patient&#160;population with bacterial non-viral&#160;<br/>related CAP&#160;most likely to benefit from the additional use of corticosteroids&#160;remain uncertain.&#160;<br/>Selecting HIV-uninfected&#160;patients with severe CAP and increased inflammation as defined by C-<br/>reactive protein levels &gt;150 mg/mL&#160;is one strategy&#160;for treatment of CAP&#160;that has been shown to be&#160;<br/>beneficial.</p>
<p style="position:absolute;top:974px;left:180px;white-space:nowrap" class="ft038">119</p>
<p style="position:absolute;top:975px;left:197px;white-space:nowrap" class="ft013">&#160;</p>
<p style="position:absolute;top:1013px;left:108px;white-space:nowrap" class="ft013">ATS/IDSA guidelines recommend not&#160;using corticosteroids routinely in non-severe&#160;</p>
<p style="position:absolute;top:1013px;left:689px;white-space:nowrap" class="ft012"><b>(AI)</b></p>
<p style="position:absolute;top:1013px;left:719px;white-space:nowrap" class="ft013">&#160;or&#160;severe&#160;</p>
<p style="position:absolute;top:1032px;left:108px;white-space:nowrap" class="ft013">CAP&#160;</p>
<p style="position:absolute;top:1032px;left:146px;white-space:nowrap" class="ft012"><b>(BII)</b></p>
<p style="position:absolute;top:1032px;left:182px;white-space:nowrap" class="ft013">&#160;but endorse use in CAP&#160;with refractory shock</p>
<p style="position:absolute;top:1031px;left:501px;white-space:nowrap" class="ft038">67</p>
<p style="position:absolute;top:1032px;left:513px;white-space:nowrap" class="ft013">&#160;Similarly, the use&#160;of corticosteroids in&#160;</p>
<p style="position:absolute;top:1052px;left:108px;white-space:nowrap" class="ft013">HIV-infected patients with severe CAP is not routinely recommended&#160;</p>
<p style="position:absolute;top:1052px;left:594px;white-space:nowrap" class="ft012"><b>(BII)</b></p>
<p style="position:absolute;top:1052px;left:630px;white-space:nowrap" class="ft013">&#160;given the&#160;lack of data&#160;</p>
</div>
<!-- Page 103 -->
<a name="103"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page103-div" style="position:relative;width:917px;height:1187px;">
<p style="position:absolute;top:1114px;left:108px;white-space:nowrap" class="ft024"><i>Guidelines for the Prevention and Treatment&#160;of&#160;Opportunistic&#160;Infections in Adults&#160;and Adolescents&#160;With HIV&#160;</i></p>
<p style="position:absolute;top:1114px;left:782px;white-space:nowrap" class="ft024"><i>G-12&#160;</i></p>
<p style="position:absolute;top:109px;left:108px;white-space:nowrap" class="ft032">specifically in HIV-infected population. If providers administer&#160;corticosteroids to HIV-infected&#160;<br/>patients with severe CAP,&#160;they must&#160;ensure that no&#160;other contraindications to steroids exist;&#160;in&#160;<br/>patients who&#160;have no contraindications and have&#160;persistent&#160;shock despite fluid resuscitation,&#160;<br/>Surviving Sepsis Guidelines</p>
<p style="position:absolute;top:167px;left:304px;white-space:nowrap" class="ft038">120</p>
<p style="position:absolute;top:168px;left:320px;white-space:nowrap" class="ft013">&#160;provide&#160;a weak recommendation for administering hydrocortisone&#160;</p>
<p style="position:absolute;top:188px;left:108px;white-space:nowrap" class="ft013">200 mg IV daily for 5 to&#160;7 days or tapering once&#160;vasopressors&#160;are no longer&#160;needed</p>
<p style="position:absolute;top:188px;left:682px;white-space:nowrap" class="ft012"><b>.</b></p>
<p style="position:absolute;top:188px;left:687px;white-space:nowrap" class="ft013">&#160;</p>
<p style="position:absolute;top:225px;left:108px;white-space:nowrap" class="ft029"><i><b>Empiric&#160;</b></i></p>
<p style="position:absolute;top:225px;left:183px;white-space:nowrap" class="ft0100"><b>Pseudomonas&#160;aeruginosa</b></p>
<p style="position:absolute;top:225px;left:409px;white-space:nowrap" class="ft029"><i><b>&#160;Treatment&#160;</b></i></p>
<p style="position:absolute;top:267px;left:108px;white-space:nowrap" class="ft013">If risk factors for&#160;</p>
<p style="position:absolute;top:267px;left:230px;white-space:nowrap" class="ft019"><i>Pseudomonas</i></p>
<p style="position:absolute;top:267px;left:325px;white-space:nowrap" class="ft013">&#160;infection are present, an antipneumococcal, antipseudomonal&#160;beta-</p>
<p style="position:absolute;top:286px;left:108px;white-space:nowrap" class="ft013">lactam&#160;plus either ciprofloxacin or levofloxacin (750-mg dose)&#160;should be&#160;used</p>
<p style="position:absolute;top:286px;left:648px;white-space:nowrap" class="ft012"><b>&#160;(AI).</b></p>
<p style="position:absolute;top:286px;left:687px;white-space:nowrap" class="ft013">&#160;Preferred beta-</p>
<p style="position:absolute;top:306px;left:108px;white-space:nowrap" class="ft032">lactams are piperacillin-tazobactam, cefepime, imipenem, or meropenem. Alternative&#160;therapeutic&#160;<br/>agents that&#160;are&#160;recommended are&#160;an antipneumococcal, antipseudomonal beta-lactam&#160;plus an&#160;<br/>aminoglycoside&#160;and azithromycin</p>
<p style="position:absolute;top:346px;left:342px;white-space:nowrap" class="ft012"><b>&#160;(BII)&#160;</b></p>
<p style="position:absolute;top:346px;left:387px;white-space:nowrap" class="ft013">or an antipneumococcal, antipseudomonal beta-lactam&#160;plus&#160;</p>
<p style="position:absolute;top:366px;left:108px;white-space:nowrap" class="ft013">an aminoglycoside and an antipneumococcal fluoroquinolone</p>
<p style="position:absolute;top:366px;left:533px;white-space:nowrap" class="ft012"><b>&#160;(BII).</b></p>
<p style="position:absolute;top:366px;left:578px;white-space:nowrap" class="ft013">&#160;In patients who are allergic to&#160;</p>
<p style="position:absolute;top:386px;left:108px;white-space:nowrap" class="ft013">penicillin, aztreonam&#160;is recommended to be&#160;used in&#160;place of the beta-lactam&#160;</p>
<p style="position:absolute;top:386px;left:637px;white-space:nowrap" class="ft012"><b>(BII).</b></p>
<p style="position:absolute;top:386px;left:678px;white-space:nowrap" class="ft013">&#160;</p>
<p style="position:absolute;top:423px;left:108px;white-space:nowrap" class="ft029"><i><b>Empiric&#160;</b></i></p>
<p style="position:absolute;top:423px;left:183px;white-space:nowrap" class="ft0100"><b>Staphylococcus aureus</b></p>
<p style="position:absolute;top:423px;left:387px;white-space:nowrap" class="ft029"><i><b>&#160;Treatment&#160;</b></i></p>
<p style="position:absolute;top:464px;left:108px;white-space:nowrap" class="ft032">A nasal swab&#160;for MRSA&#160;can help inform decision-making whether initial empiric coverage&#160;should&#160;<br/>include&#160;MRSA. In&#160;studies&#160;of patients without HIV,&#160;negative&#160;test results have&#160;a high negative&#160;<br/>predictive&#160;value for pneumonia due to MRSA. If the nasal&#160;swab&#160;is negative&#160;for MRSA&#160;and the&#160;<br/>pneumonia&#160;is not severe&#160;and no other&#160;risk factors or features suggestive of&#160;MRSA pneumonia are&#160;<br/>present, empiric coverage&#160;for MRSA&#160;may be&#160;withheld&#160;</p>
<p style="position:absolute;top:543px;left:486px;white-space:nowrap" class="ft012"><b>(BII).</b></p>
<p style="position:absolute;top:542px;left:528px;white-space:nowrap" class="ft038">68</p>
<p style="position:absolute;top:543px;left:539px;white-space:nowrap" class="ft013">&#160;</p>
<p style="position:absolute;top:580px;left:108px;white-space:nowrap" class="ft013">However, in&#160;patients who&#160;have risk factors for&#160;</p>
<p style="position:absolute;top:580px;left:432px;white-space:nowrap" class="ft019"><i>S.&#160;aureus</i></p>
<p style="position:absolute;top:580px;left:496px;white-space:nowrap" class="ft013">&#160;infection, vancomycin or linezolid should be&#160;</p>
<p style="position:absolute;top:600px;left:108px;white-space:nowrap" class="ft013">added to the&#160;antibiotic regimen&#160;</p>
<p style="position:absolute;top:600px;left:327px;white-space:nowrap" class="ft012"><b>(AII).</b></p>
<p style="position:absolute;top:600px;left:368px;white-space:nowrap" class="ft013">&#160;Empiric coverage for MRSA&#160;should&#160;also be added if a&#160;rapid&#160;</p>
<p style="position:absolute;top:620px;left:108px;white-space:nowrap" class="ft032">nasal&#160;swab is&#160;positive for&#160;MRSA, although the&#160;positive&#160;predictive&#160;value for pneumonia&#160;is&#160;only&#160;<br/>moderate, and therapy should be&#160;de-escalated if cultures are negative&#160;</p>
<p style="position:absolute;top:640px;left:588px;white-space:nowrap" class="ft012"><b>(BIII).</b></p>
<p style="position:absolute;top:640px;left:635px;white-space:nowrap" class="ft013">&#160;Although not&#160;routinely&#160;</p>
<p style="position:absolute;top:660px;left:108px;white-space:nowrap" class="ft032">recommended, the addition of clindamycin to vancomycin (but&#160;not to linezolid) or the use&#160;of&#160;<br/>linezolid alone, is recommended by&#160;many experts if severe&#160;necrotizing pneumonia is&#160;present to&#160;<br/>minimize bacterial&#160;toxin&#160;production&#160;</p>
<p style="position:absolute;top:699px;left:360px;white-space:nowrap" class="ft012"><b>(CII).</b></p>
<p style="position:absolute;top:699px;left:401px;white-space:nowrap" class="ft013">&#160;</p>
<p style="position:absolute;top:737px;left:108px;white-space:nowrap" class="ft013">Telavancin is an alternative&#160;agent&#160;that can be used&#160;for&#160;</p>
<p style="position:absolute;top:737px;left:483px;white-space:nowrap" class="ft019"><i>S. aureus&#160;</i></p>
<p style="position:absolute;top:737px;left:552px;white-space:nowrap" class="ft013">pneumonia&#160;</p>
<p style="position:absolute;top:737px;left:633px;white-space:nowrap" class="ft012"><b>(BIII);</b></p>
<p style="position:absolute;top:737px;left:681px;white-space:nowrap" class="ft013">&#160;it&#160;is currently&#160;</p>
<p style="position:absolute;top:756px;left:108px;white-space:nowrap" class="ft032">FDA-approved for treatment of hospital-acquired and ventilator-associated (rather than community-<br/>acquired) pneumonia&#160;based on studies&#160;in people&#160;without&#160;HIV infection.</p>
<p style="position:absolute;top:775px;left:601px;white-space:nowrap" class="ft038">121</p>
<p style="position:absolute;top:776px;left:618px;white-space:nowrap" class="ft013">&#160;While ceftaroline has&#160;</p>
<p style="position:absolute;top:796px;left:108px;white-space:nowrap" class="ft032">activity against MRSA, and data suggest it can be effective&#160;for MRSA pneumonia, it has been FDA&#160;<br/>approved for&#160;treatment of bacterial CAP based on two studies&#160;that did not include any MRSA&#160;<br/>isolates.</p>
<p style="position:absolute;top:834px;left:164px;white-space:nowrap" class="ft038">122</p>
<p style="position:absolute;top:836px;left:181px;white-space:nowrap" class="ft013">&#160;Neither telavancin or ceftaroline&#160;have been specifically studied in&#160;patients with HIV&#160;with&#160;</p>
<p style="position:absolute;top:856px;left:108px;white-space:nowrap" class="ft013">bacterial&#160;pneumonia. Daptomycin should not&#160;be used to treat&#160;pneumonia&#160;as it&#160;is not active&#160;in the lung&#160;</p>
<p style="position:absolute;top:875px;left:108px;white-space:nowrap" class="ft012"><b>(AI).</b></p>
<p style="position:absolute;top:875px;left:143px;white-space:nowrap" class="ft013">&#160;</p>
<p style="position:absolute;top:913px;left:108px;white-space:nowrap" class="ft029"><i><b>Pathogen-Directed Therapy&#160;</b></i></p>
<p style="position:absolute;top:954px;left:108px;white-space:nowrap" class="ft032">When the etiology of the&#160;pneumonia&#160;has been identified based on reliable&#160;microbiological&#160;methods,&#160;<br/>antimicrobial therapy should be&#160;modified and directed at&#160;the&#160;identified pathogen&#160;</p>
<p style="position:absolute;top:974px;left:666px;white-space:nowrap" class="ft012"><b>(BIII).</b></p>
<p style="position:absolute;top:974px;left:714px;white-space:nowrap" class="ft017"><i><b>&#160;</b></i></p>
</div>
<!-- Page 104 -->
<a name="104"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page104-div" style="position:relative;width:917px;height:1187px;">
<p style="position:absolute;top:1114px;left:108px;white-space:nowrap" class="ft024"><i>Guidelines for the Prevention and Treatment&#160;of&#160;Opportunistic&#160;Infections in Adults&#160;and Adolescents&#160;With HIV&#160;</i></p>
<p style="position:absolute;top:1114px;left:782px;white-space:nowrap" class="ft024"><i>G-13&#160;</i></p>
<p style="position:absolute;top:109px;left:108px;white-space:nowrap" class="ft029"><i><b>Switch From Intravenous to&#160;Oral Therapy&#160;</b></i></p>
<p style="position:absolute;top:150px;left:108px;white-space:nowrap" class="ft032">A switch to oral&#160;therapy&#160;should be considered in patients with CAP on IV&#160;antibiotic therapy who&#160;<br/>have improved clinically,&#160;can swallow&#160;and tolerate&#160;oral medications, and have intact&#160;gastrointestinal&#160;<br/>function.</p>
<p style="position:absolute;top:188px;left:170px;white-space:nowrap" class="ft038">67</p>
<p style="position:absolute;top:190px;left:181px;white-space:nowrap" class="ft013">&#160;A&#160;longer duration of IV and overall antibiotic&#160;therapy is often necessary in patients who&#160;</p>
<p style="position:absolute;top:210px;left:108px;white-space:nowrap" class="ft013">have severe&#160;CAP&#160;or who&#160;have&#160;bacteremia, particularly if due to&#160;</p>
<p style="position:absolute;top:210px;left:550px;white-space:nowrap" class="ft019"><i>S. pneumoniae</i></p>
<p style="position:absolute;top:210px;left:652px;white-space:nowrap" class="ft013">&#160;or&#160;</p>
<p style="position:absolute;top:210px;left:675px;white-space:nowrap" class="ft019"><i>S. aureus</i></p>
<p style="position:absolute;top:210px;left:739px;white-space:nowrap" class="ft013">&#160;and&#160;</p>
<p style="position:absolute;top:229px;left:108px;white-space:nowrap" class="ft013">complicated infection is present.&#160;</p>
<p style="position:absolute;top:267px;left:108px;white-space:nowrap" class="ft029"><i><b>Special Considerations Regarding When to&#160;Start&#160;Antiretroviral Therapy&#160;</b></i></p>
<p style="position:absolute;top:308px;left:108px;white-space:nowrap" class="ft032">In patients with bacterial&#160;pneumonia&#160;who are not&#160;already on ART, ART should be&#160;initiated promptly&#160;<br/>(i.e., within 2 weeks&#160;of initiating therapy for the pneumonia) unless comorbidities make ART unwise&#160;</p>
<p style="position:absolute;top:348px;left:108px;white-space:nowrap" class="ft012"><b>(AI)</b></p>
<p style="position:absolute;top:348px;left:139px;white-space:nowrap" class="ft013">.&#160;</p>
<p style="position:absolute;top:385px;left:108px;white-space:nowrap" class="ft029"><i><b>Monitoring of&#160;Response&#160;to&#160;Therapy and&#160;Adverse Events (Including IRIS)&#160;&#160;</b></i></p>
<p style="position:absolute;top:426px;left:108px;white-space:nowrap" class="ft032">The&#160;clinical&#160;response to appropriate&#160;antimicrobial therapy for CAP&#160;is&#160;similar in patients with and&#160;<br/>without&#160;HIV.</p>
<p style="position:absolute;top:445px;left:200px;white-space:nowrap" class="ft038">43,58</p>
<p style="position:absolute;top:446px;left:225px;white-space:nowrap" class="ft013">&#160;A&#160;clinical&#160;response (i.e., reduction in fever and&#160;improvement&#160;in respiratory&#160;</p>
<p style="position:absolute;top:466px;left:108px;white-space:nowrap" class="ft032">symptoms, physical&#160;findings, and laboratory studies) typically is observed within 48 to 72 hours after&#160;<br/>initiation of&#160;appropriate antimicrobial&#160;therapy. A review of patients with CAP found that&#160;advanced&#160;<br/>HIV&#160;infection and CD4 count &lt;100 cells/mm</p>
<p style="position:absolute;top:504px;left:420px;white-space:nowrap" class="ft038">3</p>
<p style="position:absolute;top:505px;left:426px;white-space:nowrap" class="ft013">&#160;were&#160;predictors for longer time&#160;to clinical&#160;stability&#160;</p>
<p style="position:absolute;top:525px;left:108px;white-space:nowrap" class="ft032">(i.e., &gt;7 days) and that&#160;patients who received ART tended to become&#160;clinically stable sooner and had&#160;<br/>better outcomes.</p>
<p style="position:absolute;top:544px;left:222px;white-space:nowrap" class="ft038">103,106</p>
<p style="position:absolute;top:545px;left:259px;white-space:nowrap" class="ft013">&#160;The presence&#160;of bacteremia&#160;is a significant&#160;factor that&#160;impacts outcomes.&#160;</p>
<p style="position:absolute;top:565px;left:108px;white-space:nowrap" class="ft032">Among those with pneumococcal pneumonia, longer time to clinical&#160;stability is more&#160;often seen in&#160;<br/>the&#160;setting of bacteremia. As&#160;in patients without&#160;HIV, radiographic&#160;improvement&#160;usually lags behind&#160;<br/>clinical&#160;improvement.&#160;</p>
<p style="position:absolute;top:642px;left:108px;white-space:nowrap" class="ft032">Immune reconstitution inflammatory syndrome&#160;(IRIS) has&#160;been&#160;rarely described in association with&#160;<br/>bacterial&#160;CAP&#160;and initiation of treatment with ART&#160;in patients with HIV. This could be secondary to&#160;<br/>a number of&#160;reasons: 1)&#160;patients with recurrent&#160;pneumonia have&#160;not been included in the&#160;study&#160;<br/>population; 2) IRIS among participants with bacterial pneumonia has not been specified or 3) this&#160;<br/>complication&#160;has truly not&#160;been observed.</p>
<p style="position:absolute;top:720px;left:396px;white-space:nowrap" class="ft038">2,123</p>
<p style="position:absolute;top:721px;left:422px;white-space:nowrap" class="ft013">&#160;Only&#160;case reports&#160;describe&#160;IRIS with pneumonia due to&#160;</p>
<p style="position:absolute;top:741px;left:108px;white-space:nowrap" class="ft019"><i>Rhodococcus&#160;equii</i></p>
<p style="position:absolute;top:741px;left:239px;white-space:nowrap" class="ft013">. More&#160;commonly IRIS occurs&#160;with pneumonia&#160;due to&#160;</p>
<p style="position:absolute;top:741px;left:616px;white-space:nowrap" class="ft019"><i>Pneumocystis&#160;</i></p>
<p style="position:absolute;top:741px;left:715px;white-space:nowrap" class="ft013">and&#160;</p>
<p style="position:absolute;top:761px;left:108px;white-space:nowrap" class="ft013">mycobacterial&#160;infections.&#160;</p>
<p style="position:absolute;top:798px;left:108px;white-space:nowrap" class="ft029"><i><b>Managing&#160;Treatment Failure&#160;</b></i></p>
<p style="position:absolute;top:839px;left:108px;white-space:nowrap" class="ft032">Patients who&#160;do not respond to appropriate antimicrobial&#160;therapy should undergo further&#160;evaluation&#160;<br/>to search for&#160;complications secondary to pneumonia&#160;(empyema, abscess&#160;formation, metastatic&#160;<br/>infection), other infectious process, the presence of&#160;a drug-resistant&#160;pathogen, and/or noninfectious&#160;<br/>causes of pulmonary dysfunction (pulmonary embolus, COPD).&#160;</p>
<p style="position:absolute;top:935px;left:108px;white-space:nowrap" class="ft026"><b>Preventing&#160;Recurrence&#160;</b></p>
<p style="position:absolute;top:977px;left:108px;white-space:nowrap" class="ft013">Patients with HIV should&#160;receive&#160;pneumococcal&#160;</p>
<p style="position:absolute;top:977px;left:445px;white-space:nowrap" class="ft012"><b>(AI)&#160;</b></p>
<p style="position:absolute;top:977px;left:480px;white-space:nowrap" class="ft013">and influenza vaccines&#160;</p>
<p style="position:absolute;top:977px;left:641px;white-space:nowrap" class="ft012"><b>(AI)&#160;</b></p>
<p style="position:absolute;top:977px;left:676px;white-space:nowrap" class="ft013">as recommended</p>
<p style="position:absolute;top:977px;left:792px;white-space:nowrap" class="ft012"><b>.</b></p>
<p style="position:absolute;top:977px;left:797px;white-space:nowrap" class="ft013">&#160;</p>
<p style="position:absolute;top:997px;left:108px;white-space:nowrap" class="ft032">Antibiotic chemoprophylaxis generally is not recommended specifically to prevent&#160;recurrences of&#160;<br/>bacterial&#160;respiratory infections because of the&#160;potential for development of drug-resistant&#160;<br/>microorganisms and drug&#160;toxicity&#160;</p>
<p style="position:absolute;top:1037px;left:345px;white-space:nowrap" class="ft012"><b>(AI).</b></p>
<p style="position:absolute;top:1037px;left:380px;white-space:nowrap" class="ft013">&#160;Smoking cessation reduces the&#160;risk of&#160;bacterial&#160;pneumonia&#160;</p>
<p style="position:absolute;top:1057px;left:108px;white-space:nowrap" class="ft013">(by approximately 27%),</p>
<p style="position:absolute;top:1055px;left:281px;white-space:nowrap" class="ft038">124</p>
<p style="position:absolute;top:1057px;left:298px;white-space:nowrap" class="ft013">&#160;and patients who&#160;smoke tobacco should be&#160;encouraged to quit&#160;and&#160;</p>
</div>
<!-- Page 105 -->
<a name="105"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}	.ft0122{font-size:20px;font-family:BGKYCV+LiberationSansNarrow;color:#000000;}
-->
</style>
<div id="page105-div" style="position:relative;width:917px;height:1187px;">
<p style="position:absolute;top:1114px;left:108px;white-space:nowrap" class="ft024"><i>Guidelines for the Prevention and Treatment&#160;of&#160;Opportunistic&#160;Infections in Adults&#160;and Adolescents&#160;With HIV&#160;</i></p>
<p style="position:absolute;top:1114px;left:782px;white-space:nowrap" class="ft024"><i>G-14&#160;</i></p>
<p style="position:absolute;top:109px;left:108px;white-space:nowrap" class="ft013">provided with the&#160;appropriate&#160;tools and referrals whenever possible&#160;</p>
<p style="position:absolute;top:109px;left:577px;white-space:nowrap" class="ft012"><b>(AI).</b></p>
<p style="position:absolute;top:109px;left:613px;white-space:nowrap" class="ft013">&#160;Likewise, patients with&#160;</p>
<p style="position:absolute;top:129px;left:108px;white-space:nowrap" class="ft032">substance use disorders&#160;(alcohol, injection or non-injection drugs) should be&#160;referred for&#160;appropriate&#160;<br/>counseling and services&#160;</p>
<p style="position:absolute;top:148px;left:276px;white-space:nowrap" class="ft012"><b>(AI).</b></p>
<p style="position:absolute;top:148px;left:311px;white-space:nowrap" class="ft013">&#160;However, likely the&#160;most important&#160;intervention for prevention of&#160;</p>
<p style="position:absolute;top:168px;left:108px;white-space:nowrap" class="ft032">bacterial&#160;pneumonia&#160;(first&#160;episode or recurrence) is&#160;initiation and adherence to ART,&#160;which is&#160;<br/>beneficial&#160;even among those with high CD4 count at time of ART initiation.</p>
<p style="position:absolute;top:187px;left:634px;white-space:nowrap" class="ft038">4</p>
<p style="position:absolute;top:188px;left:640px;white-space:nowrap" class="ft013">&#160;Thus&#160;prompt initiation&#160;</p>
<p style="position:absolute;top:208px;left:108px;white-space:nowrap" class="ft013">or re-initiation of ART is recommended for all patients with HIV&#160;with bacterial&#160;pneumonia&#160;</p>
<p style="position:absolute;top:208px;left:741px;white-space:nowrap" class="ft012"><b>(AI).</b></p>
<p style="position:absolute;top:208px;left:776px;white-space:nowrap" class="ft013">&#160;</p>
<p style="position:absolute;top:244px;left:108px;white-space:nowrap" class="ft026"><b>Special&#160;Considerations During&#160;Pregnancy</b></p>
<p style="position:absolute;top:244px;left:451px;white-space:nowrap" class="ft0122"><b>&#160;</b></p>
<p style="position:absolute;top:286px;left:108px;white-space:nowrap" class="ft032">The&#160;diagnosis of bacterial&#160;respiratory tract&#160;infections in pregnant&#160;women is the same as in&#160;those who&#160;<br/>are not&#160;pregnant, with appropriate&#160;shielding of the abdomen during radiographic&#160;procedures.&#160;<br/>Bacterial&#160;respiratory tract&#160;infections should be&#160;managed in pregnant&#160;women&#160;as in women&#160;who are not&#160;<br/>pregnant, with certain exceptions. Among macrolides, clarithromycin is not recommended because of&#160;<br/>an increased&#160;risk of birth&#160;defects seen&#160;in some&#160;animal studies. Two studies,&#160;each involving at&#160;least&#160;<br/>100 women&#160;with first-trimester exposure to clarithromycin, did&#160;not document a&#160;clear increase in or&#160;<br/>specific pattern of birth defects, although an increased risk of&#160;spontaneous abortion was noted in one&#160;<br/>study.</p>
<p style="position:absolute;top:424px;left:150px;white-space:nowrap" class="ft038">125,126</p>
<p style="position:absolute;top:425px;left:186px;white-space:nowrap" class="ft013">&#160;Azithromycin did not produce&#160;birth defects in animal studies, but experience&#160;with human&#160;</p>
<p style="position:absolute;top:445px;left:108px;white-space:nowrap" class="ft032">use in the first trimester is limited. Azithromycin is recommended when a macrolide&#160;is indicated in&#160;<br/>pregnancy</p>
<p style="position:absolute;top:465px;left:180px;white-space:nowrap" class="ft012"><b>&#160;(BIII).&#160;</b></p>
<p style="position:absolute;top:465px;left:236px;white-space:nowrap" class="ft013">Arthropathy has been noted in immature&#160;animals with&#160;</p>
<p style="position:absolute;top:465px;left:612px;white-space:nowrap" class="ft019"><i>in utero</i></p>
<p style="position:absolute;top:465px;left:666px;white-space:nowrap" class="ft013">&#160;exposure to&#160;</p>
<p style="position:absolute;top:485px;left:108px;white-space:nowrap" class="ft032">quinolones.&#160;Studies evaluating quinolone&#160;use in pregnant women did not find an increased risk of&#160;<br/>birth defects or musculoskeletal abnormalities.</p>
<p style="position:absolute;top:503px;left:430px;white-space:nowrap" class="ft038">127,128</p>
<p style="position:absolute;top:505px;left:467px;white-space:nowrap" class="ft013">&#160;When indicated, quinolones can be used in&#160;</p>
<p style="position:absolute;top:524px;left:108px;white-space:nowrap" class="ft013">pregnancy for serious&#160;respiratory infections only&#160;when a safer alternative&#160;is not available&#160;</p>
<p style="position:absolute;top:524px;left:725px;white-space:nowrap" class="ft012"><b>(CIII).</b></p>
<p style="position:absolute;top:523px;left:774px;white-space:nowrap" class="ft038">129</p>
<p style="position:absolute;top:524px;left:791px;white-space:nowrap" class="ft013">&#160;&#160;</p>
<p style="position:absolute;top:561px;left:108px;white-space:nowrap" class="ft032">Doxycycline&#160;is not recommended for use during pregnancy because of increased hepatotoxicity and&#160;<br/>staining of fetal teeth and bones. Beta-lactam&#160;antibiotics have not been associated with teratogenicity&#160;<br/>or increased&#160;toxicity in pregnancy. Clindamycin use in pregnancy has not been associated&#160;with an&#160;<br/>increased risk of birth defects or adverse outcomes.</p>
<p style="position:absolute;top:620px;left:462px;white-space:nowrap" class="ft038">130</p>
<p style="position:absolute;top:621px;left:479px;white-space:nowrap" class="ft013">&#160;Aminoglycosides can be used as needed. A&#160;</p>
<p style="position:absolute;top:641px;left:108px;white-space:nowrap" class="ft032">theoretical&#160;risk of fetal renal&#160;or eighth nerve damage exists with&#160;aminoglycoside&#160;exposure&#160;during&#160;<br/>pregnancy, but this finding has not been documented in humans,&#160;except&#160;with streptomycin (10% risk)&#160;<br/>and kanamycin (2% risk).&#160;Animal reproductive&#160;toxicity studies in rats and rabbits were negative&#160;for&#160;<br/>vancomycin, but data&#160;on first trimester exposure in&#160;humans are&#160;limited.</p>
<p style="position:absolute;top:699px;left:600px;white-space:nowrap" class="ft038">131</p>
<p style="position:absolute;top:700px;left:617px;white-space:nowrap" class="ft013">&#160;A&#160;study of neonates after&#160;</p>
<p style="position:absolute;top:720px;left:108px;white-space:nowrap" class="ft013">in utero exposure did not&#160;find evidence of renal&#160;or ototoxicity.</p>
<p style="position:absolute;top:719px;left:538px;white-space:nowrap" class="ft038">132</p>
<p style="position:absolute;top:720px;left:555px;white-space:nowrap" class="ft013">&#160;Reproductive toxicity studies of&#160;</p>
<p style="position:absolute;top:740px;left:108px;white-space:nowrap" class="ft032">televancin in animals have shown increased rates of limb malformations in rats, rabbits, and mini&#160;<br/>pigs at&#160;doses&#160;similar to human exposure;&#160;no human&#160;data are&#160;available.</p>
<p style="position:absolute;top:758px;left:591px;white-space:nowrap" class="ft038">131</p>
<p style="position:absolute;top:760px;left:608px;white-space:nowrap" class="ft013">&#160;Use&#160;of telavancin should be&#160;</p>
<p style="position:absolute;top:780px;left:108px;white-space:nowrap" class="ft032">avoided in the&#160;first trimester if alternate&#160;agents with&#160;more&#160;experience in use in&#160;pregnancy are&#160;<br/>available. Cases of exposure to telavancin in pregnancy should&#160;be reported to the&#160;Televancin&#160;<br/>Pregnancy Registry at&#160;1-855-633-8479. Experience&#160;with linezolid in human pregnancy has&#160;been&#160;<br/>limited, but it was not teratogenic in mice, rats, and rabbits.&#160;</p>
<p style="position:absolute;top:876px;left:108px;white-space:nowrap" class="ft032">Pneumonia during pregnancy is associated with increased rates&#160;of preterm&#160;labor and delivery.&#160;<br/>Pregnant&#160;women with pneumonia&#160;after 20 weeks’&#160;gestation should be&#160;monitored for evidence of&#160;<br/>contractions</p>
<p style="position:absolute;top:916px;left:192px;white-space:nowrap" class="ft012"><b>&#160;(BII).</b></p>
<p style="position:absolute;top:916px;left:237px;white-space:nowrap" class="ft013">&#160;Pneumococcal vaccine can be administered during pregnancy</p>
<p style="position:absolute;top:916px;left:667px;white-space:nowrap" class="ft012"><b>&#160;(AIII).&#160;</b></p>
<p style="position:absolute;top:916px;left:724px;white-space:nowrap" class="ft013">A study&#160;</p>
<p style="position:absolute;top:936px;left:108px;white-space:nowrap" class="ft032">comparing administration of PCV10,&#160;PPSV23, or control&#160;(1:1:1) among 347&#160;women during weeks&#160;<br/>13–34 of&#160;pregnancy found that PCV10 and PPSV23 were equally safe&#160;and immunogenic in pregnant&#160;<br/>women with&#160;HIV&#160;and conferred similar levels of seroprotection to their infants.</p>
<p style="position:absolute;top:974px;left:656px;white-space:nowrap" class="ft038">133</p>
<p style="position:absolute;top:975px;left:673px;white-space:nowrap" class="ft013">&#160;No adverse&#160;</p>
<p style="position:absolute;top:995px;left:108px;white-space:nowrap" class="ft032">consequences have been reported among newborns&#160;whose mothers were&#160;vaccinated during&#160;<br/>pregnancy.&#160;Women who&#160;did not&#160;receive&#160;vaccines&#160;during pregnancy were&#160;vaccinated post-partum;&#160;<br/>these data demonstrated higher antibody responses&#160;compared to&#160;women vaccinated ante-partum,&#160;<br/>suggesting that&#160;postpartum booster doses may be&#160;beneficial&#160;and require further study.</p>
<p style="position:absolute;top:1053px;left:698px;white-space:nowrap" class="ft038">134</p>
<p style="position:absolute;top:1055px;left:715px;white-space:nowrap" class="ft013">&#160;&#160;</p>
</div>
<!-- Page 106 -->
<a name="106"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page106-div" style="position:relative;width:917px;height:1187px;">
<p style="position:absolute;top:1114px;left:108px;white-space:nowrap" class="ft024"><i>Guidelines for the Prevention and Treatment&#160;of&#160;Opportunistic&#160;Infections in Adults&#160;and Adolescents&#160;With HIV&#160;</i></p>
<p style="position:absolute;top:1114px;left:782px;white-space:nowrap" class="ft024"><i>G-15&#160;</i></p>
<p style="position:absolute;top:109px;left:108px;white-space:nowrap" class="ft013">Inactivated influenza&#160;vaccine&#160;is recommended for all&#160;pregnant&#160;women during&#160;influenza&#160;season</p>
<p style="position:absolute;top:109px;left:761px;white-space:nowrap" class="ft012"><b>&#160;(AI).&#160;</b></p>
<p style="position:absolute;top:129px;left:108px;white-space:nowrap" class="ft013">Live attenuated influenza&#160;vaccine&#160;should not&#160;be used in people</p>
<p style="position:absolute;top:129px;left:541px;white-space:nowrap" class="ft012"><b>&#160;</b></p>
<p style="position:absolute;top:129px;left:545px;white-space:nowrap" class="ft013">with HIV&#160;</p>
<p style="position:absolute;top:129px;left:615px;white-space:nowrap" class="ft012"><b>(AIII).</b></p>
<p style="position:absolute;top:129px;left:664px;white-space:nowrap" class="ft013">&#160;Because&#160;</p>
<p style="position:absolute;top:148px;left:108px;white-space:nowrap" class="ft032">administration of vaccines&#160;can be&#160;associated with a transient rise&#160;in plasma&#160;HIV RNA levels,&#160;<br/>vaccination of pregnant&#160;women is recommended after ART has&#160;been initiated to minimize increases&#160;<br/>in plasma HIV RNA levels that&#160;might increase the&#160;risk of perinatal&#160;transmission of HIV.</p>
</div>
<!-- Page 107 -->
<a name="107"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}	.ft0123{font-size:15px;font-family:HMWZHS+Wingdings;color:#000000;}
-->
</style>
<div id="page107-div" style="position:relative;width:917px;height:1187px;">
<p style="position:absolute;top:1114px;left:108px;white-space:nowrap" class="ft024"><i>Guidelines for the Prevention and Treatment&#160;of&#160;Opportunistic&#160;Infections in Adults&#160;and Adolescents&#160;With HIV&#160;</i></p>
<p style="position:absolute;top:1114px;left:782px;white-space:nowrap" class="ft024"><i>G-16&#160;</i></p>
<p style="position:absolute;top:109px;left:108px;white-space:nowrap" class="ft012"><b>Recommendations for Preventing and&#160;Treating&#160;Community-Acquired Pneumonia&#160;</b></p>
<p style="position:absolute;top:155px;left:109px;white-space:nowrap" class="ft02"><b>Preventing&#160;</b></p>
<p style="position:absolute;top:155px;left:186px;white-space:nowrap" class="ft082"><i><b>Streptococcus&#160;pneumoniae</b></i></p>
<p style="position:absolute;top:155px;left:372px;white-space:nowrap" class="ft02"><b>&#160;Infections&#160;</b></p>
<p style="position:absolute;top:184px;left:109px;white-space:nowrap" class="ft042"><b>Indications for Pneumococcal&#160;Vaccination&#160;</b></p>
<p style="position:absolute;top:210px;left:109px;white-space:nowrap" class="ft030">•</p>
<p style="position:absolute;top:211px;left:116px;white-space:nowrap" class="ft057">&#160;</p>
<p style="position:absolute;top:211px;left:126px;white-space:nowrap" class="ft041">All&#160;people with&#160;HIV regardless&#160;of&#160;CD4 count&#160;</p>
<p style="position:absolute;top:211px;left:368px;white-space:nowrap" class="ft042"><b>(AI)</b></p>
<p style="position:absolute;top:211px;left:389px;white-space:nowrap" class="ft041">&#160;</p>
<p style="position:absolute;top:240px;left:109px;white-space:nowrap" class="ft042"><b>Vaccination Recommendations&#160;</b></p>
<p style="position:absolute;top:266px;left:109px;white-space:nowrap" class="ft030">•</p>
<p style="position:absolute;top:268px;left:116px;white-space:nowrap" class="ft057">&#160;</p>
<p style="position:absolute;top:267px;left:126px;white-space:nowrap" class="ft041">For&#160;all&#160;people with HIV&#160;without&#160;history&#160;of pneumococcal&#160;vaccination&#160;or unknown&#160;vaccine history:&#160;</p>
<p style="position:absolute;top:295px;left:126px;white-space:nowrap" class="ft062">o</p>
<p style="position:absolute;top:294px;left:135px;white-space:nowrap" class="ft057">&#160;</p>
<p style="position:absolute;top:294px;left:142px;white-space:nowrap" class="ft041">Administer either&#160;15-valent&#160;pneumococcal&#160;conjugate&#160;vaccine (PCV15) or 20-valent pneumococcal&#160;conjugate vaccine&#160;</p>
<p style="position:absolute;top:311px;left:142px;white-space:nowrap" class="ft041">(PCV20)&#160;</p>
<p style="position:absolute;top:311px;left:192px;white-space:nowrap" class="ft042"><b>(AII).</b></p>
<p style="position:absolute;top:311px;left:220px;white-space:nowrap" class="ft041">&#160;If&#160;PCV20 is&#160;used, their&#160;pneumococcal&#160;vaccination is&#160;complete.&#160;</p>
<p style="position:absolute;top:339px;left:126px;white-space:nowrap" class="ft062">o</p>
<p style="position:absolute;top:337px;left:135px;white-space:nowrap" class="ft057">&#160;</p>
<p style="position:absolute;top:337px;left:142px;white-space:nowrap" class="ft041">If PCV15&#160;is used, a&#160;dose of PPSV23 should be administered at least 8 weeks&#160;later&#160;</p>
<p style="position:absolute;top:337px;left:594px;white-space:nowrap" class="ft042"><b>(AII).</b></p>
<p style="position:absolute;top:337px;left:621px;white-space:nowrap" class="ft041">* No additional&#160;pneumococcal&#160;</p>
<p style="position:absolute;top:354px;left:142px;white-space:nowrap" class="ft041">vaccine doses&#160;are recommended. &#160;</p>
<p style="position:absolute;top:380px;left:109px;white-space:nowrap" class="ft030">•</p>
<p style="position:absolute;top:382px;left:116px;white-space:nowrap" class="ft057">&#160;</p>
<p style="position:absolute;top:381px;left:126px;white-space:nowrap" class="ft041">For&#160;people with&#160;HIV who&#160;previously&#160;started&#160;or&#160;completed a&#160;pneumococcal&#160;vaccination series, there is&#160;no&#160;need to&#160;restart the&#160;</p>
<p style="position:absolute;top:399px;left:126px;white-space:nowrap" class="ft041">series.**&#160;</p>
<p style="position:absolute;top:426px;left:126px;white-space:nowrap" class="ft062">o</p>
<p style="position:absolute;top:425px;left:135px;white-space:nowrap" class="ft057">&#160;</p>
<p style="position:absolute;top:425px;left:142px;white-space:nowrap" class="ft041">People with HIV&#160;who received PCV13&#160;and were&#160;65 or older when&#160;they&#160;received a&#160;dose of PPSV23 do&#160;not require further&#160;</p>
<p style="position:absolute;top:442px;left:142px;white-space:nowrap" class="ft041">doses&#160;of&#160;PPSV23; for those who&#160;received&#160;PPSV23 younger than&#160;age&#160;65, additional&#160;doses&#160;of&#160;PPSV23 are recommended&#160;</p>
<p style="position:absolute;top:459px;left:142px;white-space:nowrap" class="ft041">as indicated below&#160;</p>
<p style="position:absolute;top:459px;left:246px;white-space:nowrap" class="ft042"><b>(BIII).</b></p>
<p style="position:absolute;top:459px;left:277px;white-space:nowrap" class="ft041">&#160;</p>
<p style="position:absolute;top:486px;left:142px;white-space:nowrap" class="ft0123"></p>
<p style="position:absolute;top:486px;left:149px;white-space:nowrap" class="ft057">&#160;</p>
<p style="position:absolute;top:485px;left:158px;white-space:nowrap" class="ft044">People with HIV&#160;who have received PCV13&#160;and&#160;PPSV23 at&#160;age&#160;&lt;65&#160;should&#160;receive a&#160;second dose&#160;of PPSV23 at&#160;<br/>least 5 years&#160;after the first dose.&#160;If they are age&#160;65 or older at the&#160;time of their&#160;second dose, they do not require&#160;</p>
<p style="position:absolute;top:520px;left:158px;white-space:nowrap" class="ft041">additional&#160;doses&#160;of PPSV23.&#160;&#160;</p>
<p style="position:absolute;top:547px;left:142px;white-space:nowrap" class="ft0123"></p>
<p style="position:absolute;top:547px;left:149px;white-space:nowrap" class="ft057">&#160;</p>
<p style="position:absolute;top:546px;left:158px;white-space:nowrap" class="ft041">If they were&#160;&lt;65&#160;at the time of the&#160;second dose, they should&#160;receive a third and final&#160;dose at or after&#160;age&#160;65, at&#160;least 5&#160;</p>
<p style="position:absolute;top:563px;left:158px;white-space:nowrap" class="ft041">years&#160;after the&#160;second PPSV23 dose.&#160;</p>
<p style="position:absolute;top:591px;left:126px;white-space:nowrap" class="ft062">o</p>
<p style="position:absolute;top:590px;left:135px;white-space:nowrap" class="ft057">&#160;</p>
<p style="position:absolute;top:590px;left:142px;white-space:nowrap" class="ft041">People with HIV&#160;who have only&#160;received PPSV</p>
<p style="position:absolute;top:590px;left:397px;white-space:nowrap" class="ft065">23 may&#160;receive a&#160;PCV&#160;(either PCV20 or PCV15)&#160;</p>
<p style="position:absolute;top:590px;left:665px;white-space:nowrap" class="ft064">≥</p>
<p style="position:absolute;top:590px;left:673px;white-space:nowrap" class="ft065">1 year after their&#160;last&#160;</p>
<p style="position:absolute;top:607px;left:142px;white-space:nowrap" class="ft044">PPSV23 dose. When PCV15&#160;is&#160;used in those with history&#160;of PPSV23 receipt, it need not be followed by another&#160;dose of&#160;<br/>PPSV23 at any&#160;age&#160;</p>
<p style="position:absolute;top:624px;left:253px;white-space:nowrap" class="ft042"><b>(BIII).</b></p>
<p style="position:absolute;top:624px;left:283px;white-space:nowrap" class="ft041">&#160;</p>
<p style="position:absolute;top:653px;left:110px;white-space:nowrap" class="ft024"><i>Footnotes</i></p>
<p style="position:absolute;top:653px;left:164px;white-space:nowrap" class="ft041">&#160;</p>
<p style="position:absolute;top:680px;left:110px;white-space:nowrap" class="ft041">* Patients with&#160;CD4 counts&#160;&gt;200&#160;cells/mm</p>
<p style="position:absolute;top:680px;left:338px;white-space:nowrap" class="ft058">3</p>
<p style="position:absolute;top:679px;left:343px;white-space:nowrap" class="ft041">&#160;should receive a&#160;dose&#160;of PPSV23 at&#160;least 8 weeks&#160;later&#160;</p>
<p style="position:absolute;top:679px;left:651px;white-space:nowrap" class="ft042"><b>(AI).</b></p>
<p style="position:absolute;top:679px;left:675px;white-space:nowrap" class="ft041">&#160;While individuals with&#160;</p>
<p style="position:absolute;top:697px;left:109px;white-space:nowrap" class="ft041">HIV with CD4&#160;counts&#160;&lt;200&#160;cells/mm</p>
<p style="position:absolute;top:698px;left:306px;white-space:nowrap" class="ft058">3</p>
<p style="position:absolute;top:697px;left:310px;white-space:nowrap" class="ft041">&#160;can&#160;also be&#160;offered PPSV23 at&#160;least 8 weeks&#160;after receiving&#160;PCV15&#160;</p>
<p style="position:absolute;top:697px;left:686px;white-space:nowrap" class="ft042"><b>(CIII)&#160;</b></p>
<p style="position:absolute;top:697px;left:717px;white-space:nowrap" class="ft041">(such as if&#160;</p>
<p style="position:absolute;top:714px;left:109px;white-space:nowrap" class="ft041">there are&#160;concerns with retention&#160;in care), PPSV23 should preferably&#160;be&#160;deferred&#160;until&#160;after an individual’s CD4&#160;count&#160;</p>
<p style="position:absolute;top:731px;left:109px;white-space:nowrap" class="ft041">increases&#160;to &gt;200 cells/mm</p>
<p style="position:absolute;top:732px;left:259px;white-space:nowrap" class="ft058">3</p>
<p style="position:absolute;top:731px;left:263px;white-space:nowrap" class="ft041">&#160;while&#160;on ART</p>
<p style="position:absolute;top:731px;left:340px;white-space:nowrap" class="ft042"><b>&#160;(BIII).</b></p>
<p style="position:absolute;top:731px;left:374px;white-space:nowrap" class="ft041">&#160;Clinical&#160;evidence supporting use&#160;of PPSV23 in persons&#160;with&#160;CD4&#160;counts&#160;</p>
<p style="position:absolute;top:749px;left:109px;white-space:nowrap" class="ft041">&lt;200&#160;cells/mm</p>
<p style="position:absolute;top:749px;left:189px;white-space:nowrap" class="ft058">3</p>
<p style="position:absolute;top:749px;left:197px;white-space:nowrap" class="ft041">appears&#160;strongest in patients&#160;who also have HIV&#160;RNA &lt;100,000 copies/mL; evidence also&#160;suggests benefit&#160;for&#160;</p>
<p style="position:absolute;top:766px;left:109px;white-space:nowrap" class="ft041">those who&#160;start&#160;ART before&#160;receiving PPSV vaccination.&#160;&#160;</p>
<p style="position:absolute;top:792px;left:109px;white-space:nowrap" class="ft041">** People with HIV&#160;who have received PCV13&#160;but&#160;have not completed their&#160;recommended&#160;pneumococcal&#160;vaccine&#160;series&#160;with&#160;</p>
<p style="position:absolute;top:809px;left:109px;white-space:nowrap" class="ft044">PPSV23,&#160;one&#160;dose of&#160;PCV20&#160;may&#160;be&#160;used if PPSV23 is&#160;not available. If PCV20&#160;is&#160;used, their pneumococcal&#160;vaccinations are&#160;<br/>complete&#160;</p>
<p style="position:absolute;top:826px;left:163px;white-space:nowrap" class="ft042"><b>(CIII).</b></p>
<p style="position:absolute;top:826px;left:193px;white-space:nowrap" class="ft041">&#160;</p>
<p style="position:absolute;top:856px;left:109px;white-space:nowrap" class="ft042"><b>Preventing&#160;Influenza and Bacterial Pneumonia as&#160;a Complication of&#160;Influenza&#160;</b></p>
<p style="position:absolute;top:882px;left:109px;white-space:nowrap" class="ft024"><i>Indication&#160;for Influenza Vaccination&#160;</i></p>
<p style="position:absolute;top:908px;left:109px;white-space:nowrap" class="ft030">•</p>
<p style="position:absolute;top:910px;left:116px;white-space:nowrap" class="ft057">&#160;</p>
<p style="position:absolute;top:909px;left:126px;white-space:nowrap" class="ft041">All people&#160;with HIV&#160;infection during&#160;influenza season&#160;</p>
<p style="position:absolute;top:909px;left:415px;white-space:nowrap" class="ft042"><b>(AI)</b></p>
<p style="position:absolute;top:909px;left:435px;white-space:nowrap" class="ft041">&#160;</p>
<p style="position:absolute;top:938px;left:109px;white-space:nowrap" class="ft024"><i>Vaccination&#160;</i></p>
<p style="position:absolute;top:964px;left:109px;white-space:nowrap" class="ft030">•</p>
<p style="position:absolute;top:966px;left:116px;white-space:nowrap" class="ft057">&#160;</p>
<p style="position:absolute;top:966px;left:126px;white-space:nowrap" class="ft065">Adults age&#160;</p>
<p style="position:absolute;top:966px;left:187px;white-space:nowrap" class="ft064">≥</p>
<p style="position:absolute;top:966px;left:195px;white-space:nowrap" class="ft065">65&#160;years&#160;are&#160;recommended&#160;to&#160;receive high</p>
<p style="position:absolute;top:966px;left:429px;white-space:nowrap" class="ft041">-dose IIV&#160;(Fluzone® High-Dose) or adjuvanted&#160;IIV&#160;(FLUAD®)&#160;over&#160;</p>
<p style="position:absolute;top:983px;left:126px;white-space:nowrap" class="ft041">standard-dose unadjuvanted&#160;vaccine&#160;</p>
<p style="position:absolute;top:983px;left:330px;white-space:nowrap" class="ft042"><b>(AII).</b></p>
<p style="position:absolute;top:983px;left:357px;white-space:nowrap" class="ft041">&#160;</p>
<p style="position:absolute;top:1009px;left:109px;white-space:nowrap" class="ft030">•</p>
<p style="position:absolute;top:1011px;left:116px;white-space:nowrap" class="ft057">&#160;</p>
<p style="position:absolute;top:1010px;left:126px;white-space:nowrap" class="ft065">People age&#160;</p>
<p style="position:absolute;top:1010px;left:191px;white-space:nowrap" class="ft064">≥</p>
<p style="position:absolute;top:1010px;left:199px;white-space:nowrap" class="ft065">18 years&#160;also may&#160;use RIV&#160;(Flublok® Quadrivalent).&#160;</p>
<p style="position:absolute;top:1010px;left:487px;white-space:nowrap" class="ft041">&#160;</p>
</div>
<!-- Page 108 -->
<a name="108"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page108-div" style="position:relative;width:917px;height:1187px;">
<p style="position:absolute;top:55px;left:108px;white-space:nowrap" class="ft012"><b>Recommendations for Preventing and&#160;Treating&#160;Community-Acquired Pneumonia&#160;</b></p>
<p style="position:absolute;top:1114px;left:108px;white-space:nowrap" class="ft024"><i>Guidelines for the Prevention and Treatment&#160;of&#160;Opportunistic&#160;Infections in Adults&#160;and Adolescents&#160;With HIV&#160;</i></p>
<p style="position:absolute;top:1114px;left:782px;white-space:nowrap" class="ft024"><i>G-17&#160;</i></p>
<p style="position:absolute;top:109px;left:109px;white-space:nowrap" class="ft030">•</p>
<p style="position:absolute;top:110px;left:116px;white-space:nowrap" class="ft057">&#160;</p>
<p style="position:absolute;top:110px;left:126px;white-space:nowrap" class="ft041">For&#160;people with&#160;egg allergy, use&#160;IIV&#160;or RIV appropriate&#160;for age&#160;(if&#160;the&#160;allergic reaction is&#160;more severe than&#160;hives, give the&#160;</p>
<p style="position:absolute;top:127px;left:126px;white-space:nowrap" class="ft041">vaccine in a medical&#160;setting appropriate to&#160;manage severe allergic reaction).&#160;</p>
<p style="position:absolute;top:153px;left:109px;white-space:nowrap" class="ft030">•</p>
<p style="position:absolute;top:155px;left:116px;white-space:nowrap" class="ft057">&#160;</p>
<p style="position:absolute;top:154px;left:126px;white-space:nowrap" class="ft041">The inactivated&#160;influenza or recombinant vaccine can be&#160;administered at&#160;any time&#160;during pregnancy&#160;</p>
<p style="position:absolute;top:154px;left:672px;white-space:nowrap" class="ft042"><b>(AI).</b></p>
<p style="position:absolute;top:154px;left:696px;white-space:nowrap" class="ft041">&#160;</p>
<p style="position:absolute;top:180px;left:109px;white-space:nowrap" class="ft030">•</p>
<p style="position:absolute;top:182px;left:116px;white-space:nowrap" class="ft057">&#160;</p>
<p style="position:absolute;top:182px;left:126px;white-space:nowrap" class="ft041">Influenza vaccines are quadrivalent, with formulations that&#160;change from season&#160;to&#160;season.&#160;</p>
<p style="position:absolute;top:208px;left:109px;white-space:nowrap" class="ft042"><b>Note:</b></p>
<p style="position:absolute;top:208px;left:141px;white-space:nowrap" class="ft041">&#160;Live attenuated influenza vaccine is&#160;contraindicated in people with HIV&#160;</p>
<p style="position:absolute;top:208px;left:531px;white-space:nowrap" class="ft042"><b>(AIII).</b></p>
<p style="position:absolute;top:208px;left:562px;white-space:nowrap" class="ft041">&#160;</p>
<p style="position:absolute;top:244px;left:109px;white-space:nowrap" class="ft02"><b>Treating&#160;Community-Acquired Bacterial&#160;Pneumonia&#160;</b></p>
<p style="position:absolute;top:273px;left:109px;white-space:nowrap" class="ft042"><b>Note:</b></p>
<p style="position:absolute;top:273px;left:141px;white-space:nowrap" class="ft041">&#160;Empiric&#160;antimicrobial&#160;therapy should be&#160;initiated&#160;promptly&#160;for patients presenting&#160;with&#160;clinical&#160;and&#160;radiographic&#160;evidence&#160;</p>
<p style="position:absolute;top:290px;left:109px;white-space:nowrap" class="ft041">consistent&#160;with&#160;bacterial&#160;pneumonia. The recommendations listed&#160;below are suggested empiric&#160;therapy.&#160;The regimen&#160;should&#160;</p>
<p style="position:absolute;top:307px;left:109px;white-space:nowrap" class="ft044">be&#160;modified as&#160;needed&#160;once microbiologic&#160;and drug susceptibility results are available. Providers&#160;must also&#160;consider the risk&#160;<br/>of opportunistic&#160;lung&#160;infections such as&#160;PCP&#160;or TB, which may&#160;alter the empiric&#160;therapy as&#160;needed.&#160;</p>
<p style="position:absolute;top:353px;left:109px;white-space:nowrap" class="ft042"><b>Empiric&#160;Outpatient&#160;Therapy&#160;(Oral)&#160;</b></p>
<p style="position:absolute;top:380px;left:109px;white-space:nowrap" class="ft024"><i>Preferred&#160;Therapy&#160;</i></p>
<p style="position:absolute;top:406px;left:109px;white-space:nowrap" class="ft030">•</p>
<p style="position:absolute;top:407px;left:116px;white-space:nowrap" class="ft057">&#160;</p>
<p style="position:absolute;top:407px;left:126px;white-space:nowrap" class="ft041">An&#160;oral beta-lactam + a&#160;macrolide (azithromycin or clarithromycin)&#160;</p>
<p style="position:absolute;top:407px;left:487px;white-space:nowrap" class="ft042"><b>(AI)</b></p>
<p style="position:absolute;top:407px;left:508px;white-space:nowrap" class="ft024"><i>&#160;&#160;</i></p>
<p style="position:absolute;top:432px;left:126px;white-space:nowrap" class="ft062">o</p>
<p style="position:absolute;top:431px;left:135px;white-space:nowrap" class="ft057">&#160;</p>
<p style="position:absolute;top:430px;left:142px;white-space:nowrap" class="ft024"><i>Preferred&#160;beta-lactams</i></p>
<p style="position:absolute;top:430px;left:267px;white-space:nowrap" class="ft041">: high-dose amoxicillin or amoxicillin/clavulanate</p>
<p style="position:absolute;top:430px;left:528px;white-space:nowrap" class="ft042"><b>&#160;</b></p>
<p style="position:absolute;top:455px;left:126px;white-space:nowrap" class="ft062">o</p>
<p style="position:absolute;top:454px;left:135px;white-space:nowrap" class="ft057">&#160;</p>
<p style="position:absolute;top:453px;left:142px;white-space:nowrap" class="ft024"><i>Alternative beta-lactams:</i></p>
<p style="position:absolute;top:453px;left:277px;white-space:nowrap" class="ft041">&#160;cefpodoxime&#160;or&#160;cefuroxime</p>
<p style="position:absolute;top:453px;left:428px;white-space:nowrap" class="ft042"><b>&#160;</b></p>
<p style="position:absolute;top:480px;left:109px;white-space:nowrap" class="ft024"><i>or</i></p>
<p style="position:absolute;top:480px;left:120px;white-space:nowrap" class="ft083"><i><b>&#160;</b></i></p>
<p style="position:absolute;top:506px;left:109px;white-space:nowrap" class="ft030">•</p>
<p style="position:absolute;top:507px;left:116px;white-space:nowrap" class="ft057">&#160;</p>
<p style="position:absolute;top:507px;left:126px;white-space:nowrap" class="ft041">A respiratory&#160;fluoroquinolone&#160;(levofloxacin or moxifloxacin)</p>
<p style="position:absolute;top:508px;left:444px;white-space:nowrap" class="ft058">a</p>
<p style="position:absolute;top:507px;left:449px;white-space:nowrap" class="ft041">&#160;</p>
<p style="position:absolute;top:507px;left:452px;white-space:nowrap" class="ft042"><b>(AI)</b></p>
<p style="position:absolute;top:507px;left:473px;white-space:nowrap" class="ft041">,&#160;especially for patients&#160;with&#160;penicillin allergies.</p>
<p style="position:absolute;top:507px;left:726px;white-space:nowrap" class="ft042"><b>&#160;</b></p>
<p style="position:absolute;top:536px;left:109px;white-space:nowrap" class="ft024"><i>Alternative Therapy&#160;</i></p>
<p style="position:absolute;top:562px;left:109px;white-space:nowrap" class="ft030">•</p>
<p style="position:absolute;top:564px;left:116px;white-space:nowrap" class="ft057">&#160;</p>
<p style="position:absolute;top:563px;left:126px;white-space:nowrap" class="ft041">A beta-lactam</p>
<p style="position:absolute;top:563px;left:201px;white-space:nowrap" class="ft042"><b>&#160;</b></p>
<p style="position:absolute;top:563px;left:205px;white-space:nowrap" class="ft041">+&#160;doxycycline&#160;</p>
<p style="position:absolute;top:563px;left:282px;white-space:nowrap" class="ft042"><b>(BIII)&#160;</b></p>
<p style="position:absolute;top:592px;left:109px;white-space:nowrap" class="ft042"><b>Empiric&#160;Therapy for Hospitalized Patients with Non-Severe CAP&#160;</b></p>
<p style="position:absolute;top:619px;left:109px;white-space:nowrap" class="ft024"><i>Preferred&#160;Therapy&#160;</i></p>
<p style="position:absolute;top:645px;left:109px;white-space:nowrap" class="ft030">•</p>
<p style="position:absolute;top:646px;left:116px;white-space:nowrap" class="ft057">&#160;</p>
<p style="position:absolute;top:646px;left:126px;white-space:nowrap" class="ft041">An&#160;IV&#160;beta-lactam + a macrolide (azithromycin&#160;or&#160;clarithromycin)&#160;</p>
<p style="position:absolute;top:646px;left:478px;white-space:nowrap" class="ft042"><b>(AI)</b></p>
<p style="position:absolute;top:646px;left:499px;white-space:nowrap" class="ft041">&#160;</p>
<p style="position:absolute;top:671px;left:126px;white-space:nowrap" class="ft062">o</p>
<p style="position:absolute;top:670px;left:135px;white-space:nowrap" class="ft057">&#160;</p>
<p style="position:absolute;top:669px;left:142px;white-space:nowrap" class="ft024"><i>Preferred&#160;beta-lactams:</i></p>
<p style="position:absolute;top:669px;left:270px;white-space:nowrap" class="ft041">&#160;ceftriaxone, cefotaxime,&#160;or ampicillin-sulbactam&#160;</p>
<p style="position:absolute;top:694px;left:109px;white-space:nowrap" class="ft024"><i>or</i></p>
<p style="position:absolute;top:694px;left:120px;white-space:nowrap" class="ft083"><i><b>&#160;</b></i></p>
<p style="position:absolute;top:720px;left:109px;white-space:nowrap" class="ft030">•</p>
<p style="position:absolute;top:721px;left:116px;white-space:nowrap" class="ft057">&#160;</p>
<p style="position:absolute;top:721px;left:126px;white-space:nowrap" class="ft041">A respiratory&#160;fluoroquinolone&#160;(levofloxacin or moxifloxacin</p>
<p style="position:absolute;top:722px;left:440px;white-space:nowrap" class="ft058">)a</p>
<p style="position:absolute;top:721px;left:447px;white-space:nowrap" class="ft041">&#160;</p>
<p style="position:absolute;top:721px;left:451px;white-space:nowrap" class="ft042"><b>(AI),&#160;</b></p>
<p style="position:absolute;top:721px;left:478px;white-space:nowrap" class="ft041">especially for patients with penicillin allergies.</p>
<p style="position:absolute;top:721px;left:725px;white-space:nowrap" class="ft024"><i>&#160;</i></p>
<p style="position:absolute;top:750px;left:109px;white-space:nowrap" class="ft024"><i>Alternative Therapy&#160;</i></p>
<p style="position:absolute;top:776px;left:109px;white-space:nowrap" class="ft030">•</p>
<p style="position:absolute;top:778px;left:116px;white-space:nowrap" class="ft057">&#160;</p>
<p style="position:absolute;top:777px;left:126px;white-space:nowrap" class="ft041">An&#160;IV&#160;beta-lactam + doxycycline&#160;</p>
<p style="position:absolute;top:777px;left:304px;white-space:nowrap" class="ft042"><b>(BIII)&#160;</b></p>
<p style="position:absolute;top:801px;left:109px;white-space:nowrap" class="ft030">•</p>
<p style="position:absolute;top:802px;left:116px;white-space:nowrap" class="ft057">&#160;</p>
<p style="position:absolute;top:802px;left:126px;white-space:nowrap" class="ft041">IV&#160;penicillin&#160;may&#160;be&#160;used for&#160;confirmed&#160;pneumococcal&#160;pneumonia&#160;</p>
<p style="position:absolute;top:802px;left:487px;white-space:nowrap" class="ft042"><b>(BIII)&#160;</b></p>
<p style="position:absolute;top:831px;left:109px;white-space:nowrap" class="ft042"><b>Empiric&#160;Therapy for Patients&#160;with&#160;Severe&#160;CAP&#160;</b></p>
<p style="position:absolute;top:857px;left:109px;white-space:nowrap" class="ft024"><i>Preferred&#160;Therapy&#160;</i></p>
<p style="position:absolute;top:883px;left:109px;white-space:nowrap" class="ft030">•</p>
<p style="position:absolute;top:885px;left:116px;white-space:nowrap" class="ft057">&#160;</p>
<p style="position:absolute;top:884px;left:126px;white-space:nowrap" class="ft041">An&#160;IV&#160;beta-lactam + azithromycin&#160;</p>
<p style="position:absolute;top:884px;left:310px;white-space:nowrap" class="ft042"><b>(AI),</b></p>
<p style="position:absolute;top:884px;left:334px;white-space:nowrap" class="ft041">&#160;</p>
<p style="position:absolute;top:884px;left:337px;white-space:nowrap" class="ft024"><i>or</i></p>
<p style="position:absolute;top:884px;left:348px;white-space:nowrap" class="ft042"><b>&#160;</b></p>
<p style="position:absolute;top:908px;left:109px;white-space:nowrap" class="ft030">•</p>
<p style="position:absolute;top:909px;left:116px;white-space:nowrap" class="ft057">&#160;</p>
<p style="position:absolute;top:909px;left:126px;white-space:nowrap" class="ft041">An&#160;IV&#160;beta-lactam + a respiratory&#160;fluoroquinolone&#160;(levofloxacin&#160;or moxifloxacin)</p>
<p style="position:absolute;top:910px;left:555px;white-space:nowrap" class="ft058">a</p>
<p style="position:absolute;top:909px;left:559px;white-space:nowrap" class="ft041">&#160;</p>
<p style="position:absolute;top:909px;left:563px;white-space:nowrap" class="ft042"><b>(AI)&#160;</b></p>
<p style="position:absolute;top:936px;left:126px;white-space:nowrap" class="ft062">o</p>
<p style="position:absolute;top:935px;left:135px;white-space:nowrap" class="ft057">&#160;</p>
<p style="position:absolute;top:935px;left:142px;white-space:nowrap" class="ft024"><i>Preferred&#160;beta-lactams</i></p>
<p style="position:absolute;top:935px;left:267px;white-space:nowrap" class="ft041">:&#160;ceftriaxone, cefotaxime,&#160;or ampicillin-sulbactam</p>
<p style="position:absolute;top:935px;left:532px;white-space:nowrap" class="ft042"><b>&#160;</b></p>
<p style="position:absolute;top:964px;left:109px;white-space:nowrap" class="ft024"><i>Alternative Therapy&#160;</i></p>
<p style="position:absolute;top:990px;left:109px;white-space:nowrap" class="ft024"><i>For&#160;Penicillin-Allergic&#160;Patients&#160;</i></p>
<p style="position:absolute;top:1016px;left:109px;white-space:nowrap" class="ft030">•</p>
<p style="position:absolute;top:1018px;left:116px;white-space:nowrap" class="ft057">&#160;</p>
<p style="position:absolute;top:1018px;left:126px;white-space:nowrap" class="ft041">Aztreonam&#160;(IV)&#160;+ a respiratory fluoroquinolone&#160;(moxifloxacin or levofloxacin)</p>
<p style="position:absolute;top:1019px;left:540px;white-space:nowrap" class="ft058">a</p>
<p style="position:absolute;top:1018px;left:544px;white-space:nowrap" class="ft041">&#160;</p>
<p style="position:absolute;top:1018px;left:547px;white-space:nowrap" class="ft042"><b>(BIII)&#160;</b></p>
<p style="position:absolute;top:1050px;left:109px;white-space:nowrap" class="ft042"><b>Empiric&#160;Therapy for Patients at Risk&#160;of&#160;Pseudomonas Pneumonia&#160;</b></p>
</div>
<!-- Page 109 -->
<a name="109"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page109-div" style="position:relative;width:917px;height:1187px;">
<p style="position:absolute;top:55px;left:108px;white-space:nowrap" class="ft012"><b>Recommendations for Preventing and&#160;Treating&#160;Community-Acquired Pneumonia&#160;</b></p>
<p style="position:absolute;top:1114px;left:108px;white-space:nowrap" class="ft024"><i>Guidelines for the Prevention and Treatment&#160;of&#160;Opportunistic&#160;Infections in Adults&#160;and Adolescents&#160;With HIV&#160;</i></p>
<p style="position:absolute;top:1114px;left:782px;white-space:nowrap" class="ft024"><i>G-18&#160;</i></p>
<p style="position:absolute;top:109px;left:109px;white-space:nowrap" class="ft024"><i>Preferred&#160;Therapy&#160;</i></p>
<p style="position:absolute;top:135px;left:109px;white-space:nowrap" class="ft030">•</p>
<p style="position:absolute;top:137px;left:116px;white-space:nowrap" class="ft057">&#160;</p>
<p style="position:absolute;top:136px;left:126px;white-space:nowrap" class="ft041">An&#160;IV&#160;antipneumococcal, antipseudomonal&#160;beta-lactam + (ciprofloxacin IV or levofloxacin IV&#160;750&#160;mg/day)&#160;</p>
<p style="position:absolute;top:136px;left:700px;white-space:nowrap" class="ft042"><b>(AI)&#160;</b></p>
<p style="position:absolute;top:161px;left:126px;white-space:nowrap" class="ft062">o</p>
<p style="position:absolute;top:160px;left:135px;white-space:nowrap" class="ft057">&#160;</p>
<p style="position:absolute;top:159px;left:142px;white-space:nowrap" class="ft024"><i>Preferred&#160;beta-lactams</i></p>
<p style="position:absolute;top:159px;left:267px;white-space:nowrap" class="ft041">: piperacillin-tazobactam,&#160;cefepime,&#160;imipenem, or meropenem</p>
<p style="position:absolute;top:159px;left:603px;white-space:nowrap" class="ft042"><b>&#160;</b></p>
<p style="position:absolute;top:188px;left:109px;white-space:nowrap" class="ft024"><i>Alternative Therapy</i></p>
<p style="position:absolute;top:215px;left:109px;white-space:nowrap" class="ft030">•</p>
<p style="position:absolute;top:216px;left:116px;white-space:nowrap" class="ft057">&#160;</p>
<p style="position:absolute;top:216px;left:126px;white-space:nowrap" class="ft041">An&#160;IV&#160;antipneumococcal, antipseudomonal&#160;beta-lactam + an IV&#160;aminoglycoside&#160;+&#160;IV&#160;azithromycin&#160;</p>
<p style="position:absolute;top:216px;left:659px;white-space:nowrap" class="ft042"><b>(BII),&#160;</b></p>
<p style="position:absolute;top:216px;left:690px;white-space:nowrap" class="ft024"><i>or</i></p>
<p style="position:absolute;top:216px;left:700px;white-space:nowrap" class="ft041">&#160;&#160;</p>
<p style="position:absolute;top:239px;left:109px;white-space:nowrap" class="ft030">•</p>
<p style="position:absolute;top:240px;left:116px;white-space:nowrap" class="ft057">&#160;</p>
<p style="position:absolute;top:240px;left:126px;white-space:nowrap" class="ft044">An&#160;IV&#160;antipneumococcal, antipseudomonal&#160;beta-lactam + an IV aminoglycoside&#160;+&#160;an&#160;antipneumococcal&#160;fluoroquinolone&#160;<br/>(moxifloxacin or&#160;levofloxacin)&#160;</p>
<p style="position:absolute;top:257px;left:287px;white-space:nowrap" class="ft042"><b>(BII)&#160;</b></p>
<p style="position:absolute;top:286px;left:109px;white-space:nowrap" class="ft024"><i>For&#160;Penicillin-Allergic&#160;Patients&#160;</i></p>
<p style="position:absolute;top:312px;left:109px;white-space:nowrap" class="ft030">•</p>
<p style="position:absolute;top:314px;left:116px;white-space:nowrap" class="ft057">&#160;</p>
<p style="position:absolute;top:314px;left:126px;white-space:nowrap" class="ft041">Replace the&#160;beta-lactam with aztreonam&#160;</p>
<p style="position:absolute;top:314px;left:349px;white-space:nowrap" class="ft042"><b>(BII).&#160;</b></p>
<p style="position:absolute;top:343px;left:109px;white-space:nowrap" class="ft042"><b>Empiric&#160;Therapy for Patients at Risk&#160;of Methicillin-Resistant&#160;</b></p>
<p style="position:absolute;top:343px;left:462px;white-space:nowrap" class="ft083"><i><b>Staphylococcus aureus</b></i></p>
<p style="position:absolute;top:343px;left:600px;white-space:nowrap" class="ft042"><b>&#160;(MRSA)&#160;Pneumonia&#160;</b></p>
<p style="position:absolute;top:369px;left:109px;white-space:nowrap" class="ft024"><i>Preferred&#160;Therapy&#160;</i></p>
<p style="position:absolute;top:395px;left:109px;white-space:nowrap" class="ft030">•</p>
<p style="position:absolute;top:397px;left:116px;white-space:nowrap" class="ft057">&#160;</p>
<p style="position:absolute;top:396px;left:126px;white-space:nowrap" class="ft041">A nasal swab for&#160;MRSA&#160;can&#160;help inform decision&#160;of initial&#160;coverage for&#160;MRSA&#160;(see&#160;text for discussion)&#160;</p>
<p style="position:absolute;top:419px;left:109px;white-space:nowrap" class="ft030">•</p>
<p style="position:absolute;top:421px;left:116px;white-space:nowrap" class="ft057">&#160;</p>
<p style="position:absolute;top:421px;left:126px;white-space:nowrap" class="ft041">Vancomycin&#160;IV&#160;or linezolid&#160;(IV or&#160;PO)&#160;should be&#160;added&#160;to the baseline regimen&#160;</p>
<p style="position:absolute;top:421px;left:557px;white-space:nowrap" class="ft042"><b>(AII).&#160;</b></p>
<p style="position:absolute;top:444px;left:109px;white-space:nowrap" class="ft030">•</p>
<p style="position:absolute;top:445px;left:116px;white-space:nowrap" class="ft057">&#160;</p>
<p style="position:absolute;top:445px;left:126px;white-space:nowrap" class="ft041">Although&#160;not routinely&#160;recommended, the addition&#160;of clindamycin&#160;to vancomycin (but not&#160;to linezolid)&#160;may be&#160;considered for&#160;</p>
<p style="position:absolute;top:462px;left:126px;white-space:nowrap" class="ft041">severe necrotizing pneumonia&#160;to minimize bacterial&#160;toxin&#160;production&#160;</p>
<p style="position:absolute;top:462px;left:499px;white-space:nowrap" class="ft042"><b>(CII).&#160;</b></p>
<p style="position:absolute;top:493px;left:109px;white-space:nowrap" class="ft042"><b>Duration&#160;of&#160;Therapy&#160;</b></p>
<p style="position:absolute;top:520px;left:109px;white-space:nowrap" class="ft030">•</p>
<p style="position:absolute;top:521px;left:116px;white-space:nowrap" class="ft057">&#160;</p>
<p style="position:absolute;top:521px;left:126px;white-space:nowrap" class="ft041">For&#160;most patients: 5–7&#160;days. The&#160;patient&#160;should be&#160;afebrile for&#160;48–72 hours, and&#160;should be&#160;clinically&#160;stable&#160;before&#160;</p>
<p style="position:absolute;top:538px;left:126px;white-space:nowrap" class="ft041">discontinuation&#160;of therapy.&#160;</p>
<p style="position:absolute;top:561px;left:109px;white-space:nowrap" class="ft030">•</p>
<p style="position:absolute;top:562px;left:116px;white-space:nowrap" class="ft057">&#160;</p>
<p style="position:absolute;top:562px;left:126px;white-space:nowrap" class="ft041">Longer duration&#160;of antibiotics&#160;is&#160;often&#160;required&#160;if&#160;severe&#160;CAP&#160;or bacteremia is&#160;present, and particularly&#160;if&#160;due to&#160;</p>
<p style="position:absolute;top:579px;left:126px;white-space:nowrap" class="ft024"><i>S.&#160;pneumoniae</i></p>
<p style="position:absolute;top:579px;left:208px;white-space:nowrap" class="ft041">&#160;or&#160;complicated&#160;</p>
<p style="position:absolute;top:579px;left:295px;white-space:nowrap" class="ft024"><i>S. aureus</i></p>
<p style="position:absolute;top:579px;left:348px;white-space:nowrap" class="ft041">&#160;infection.&#160;</p>
<p style="position:absolute;top:608px;left:109px;white-space:nowrap" class="ft042"><b>Switch from IV&#160;to&#160;PO&#160;Therapy&#160;</b></p>
<p style="position:absolute;top:635px;left:109px;white-space:nowrap" class="ft030">•</p>
<p style="position:absolute;top:636px;left:116px;white-space:nowrap" class="ft057">&#160;</p>
<p style="position:absolute;top:636px;left:126px;white-space:nowrap" class="ft044">A switch&#160;should be considered for&#160;patients who&#160;have improved clinically, can swallow and&#160;tolerate oral&#160;medications, and&#160;<br/>have intact gastrointestinal&#160;function&#160;</p>
<p style="position:absolute;top:653px;left:321px;white-space:nowrap" class="ft042"><b>(BIII).</b></p>
<p style="position:absolute;top:653px;left:352px;white-space:nowrap" class="ft041">&#160;</p>
<p style="position:absolute;top:682px;left:109px;white-space:nowrap" class="ft042"><b>Other Considerations&#160;</b></p>
<p style="position:absolute;top:708px;left:109px;white-space:nowrap" class="ft030">•</p>
<p style="position:absolute;top:710px;left:116px;white-space:nowrap" class="ft057">&#160;</p>
<p style="position:absolute;top:709px;left:126px;white-space:nowrap" class="ft041">Empiric&#160;therapy&#160;with&#160;a macrolide&#160;alone is&#160;not&#160;routinely&#160;recommended&#160;because of increasing pneumococcal&#160;resistance (up&#160;</p>
<p style="position:absolute;top:727px;left:126px;white-space:nowrap" class="ft041">to 30%)&#160;</p>
<p style="position:absolute;top:727px;left:171px;white-space:nowrap" class="ft042"><b>(BIII)</b></p>
<p style="position:absolute;top:727px;left:199px;white-space:nowrap" class="ft041">, and&#160;patients receiving a&#160;macrolide for MAC prophylaxis&#160;may have resistance due to&#160;chronic&#160;exposure&#160;</p>
<p style="position:absolute;top:727px;left:761px;white-space:nowrap" class="ft042"><b>(BIII).</b></p>
<p style="position:absolute;top:727px;left:791px;white-space:nowrap" class="ft041">&#160;</p>
<p style="position:absolute;top:750px;left:109px;white-space:nowrap" class="ft030">•</p>
<p style="position:absolute;top:751px;left:116px;white-space:nowrap" class="ft057">&#160;</p>
<p style="position:absolute;top:751px;left:126px;white-space:nowrap" class="ft041">Fluoroquinolones&#160;should be&#160;used with caution&#160;in&#160;patients&#160;in whom TB is&#160;suspected&#160;but&#160;who are not being&#160;treated&#160;with&#160;</p>
<p style="position:absolute;top:768px;left:126px;white-space:nowrap" class="ft041">concurrent&#160;standard four-drug&#160;TB&#160;therapy&#160;</p>
<p style="position:absolute;top:768px;left:355px;white-space:nowrap" class="ft042"><b>(BIII).</b></p>
<p style="position:absolute;top:768px;left:386px;white-space:nowrap" class="ft041">&#160;</p>
<p style="position:absolute;top:791px;left:109px;white-space:nowrap" class="ft030">•</p>
<p style="position:absolute;top:793px;left:116px;white-space:nowrap" class="ft057">&#160;</p>
<p style="position:absolute;top:792px;left:126px;white-space:nowrap" class="ft041">Once the&#160;pathogen has been&#160;identified by&#160;reliable microbiologic&#160;methods, antibiotic&#160;therapy&#160;should be&#160;modified to&#160;target the&#160;</p>
<p style="position:absolute;top:809px;left:126px;white-space:nowrap" class="ft041">pathogen&#160;</p>
<p style="position:absolute;top:809px;left:180px;white-space:nowrap" class="ft042"><b>(BIII).&#160;</b></p>
<p style="position:absolute;top:833px;left:109px;white-space:nowrap" class="ft030">•</p>
<p style="position:absolute;top:834px;left:116px;white-space:nowrap" class="ft057">&#160;</p>
<p style="position:absolute;top:834px;left:126px;white-space:nowrap" class="ft041">If drug-resistant&#160;pathogens have&#160;not been identified by reliable microbiologic&#160;methods, antibiotic&#160;therapy&#160;can&#160;be de-</p>
<p style="position:absolute;top:851px;left:126px;white-space:nowrap" class="ft041">escalated&#160;to&#160;cover routine&#160;causes&#160;of CAP&#160;</p>
<p style="position:absolute;top:851px;left:355px;white-space:nowrap" class="ft042"><b>(BIII).&#160;</b></p>
<p style="position:absolute;top:874px;left:109px;white-space:nowrap" class="ft030">•</p>
<p style="position:absolute;top:876px;left:116px;white-space:nowrap" class="ft057">&#160;</p>
<p style="position:absolute;top:875px;left:126px;white-space:nowrap" class="ft044">Antibiotics&#160;chemoprophylaxis&#160;is&#160;generally&#160;not recommended&#160;because of&#160;the&#160;potential&#160;for development&#160;of drug&#160;resistance&#160;<br/>microorganisms&#160;and&#160;drug toxicities (</p>
<p style="position:absolute;top:893px;left:322px;white-space:nowrap" class="ft042"><b>AI).&#160;</b></p>
<p style="position:absolute;top:922px;left:108px;white-space:nowrap" class="ft058">a</p>
<p style="position:absolute;top:921px;left:112px;white-space:nowrap" class="ft041">&#160;Respiratory</p>
<p style="position:absolute;top:921px;left:179px;white-space:nowrap" class="ft042"><b>&#160;</b></p>
<p style="position:absolute;top:921px;left:182px;white-space:nowrap" class="ft041">fluoroquinolones&#160;such as&#160;levofloxacin&#160;or moxifloxacin are also active against&#160;</p>
<p style="position:absolute;top:921px;left:600px;white-space:nowrap" class="ft024"><i>Mycobacterium tuberculosis</i></p>
<p style="position:absolute;top:921px;left:753px;white-space:nowrap" class="ft041">. In&#160;</p>
<p style="position:absolute;top:938px;left:108px;white-space:nowrap" class="ft041">patients&#160;with&#160;undiagnosed TB, fluoroquinolones may&#160;alter response to&#160;therapy, delay&#160;TB diagnosis,&#160;and&#160;increase the risk&#160;of drug&#160;</p>
<p style="position:absolute;top:955px;left:108px;white-space:nowrap" class="ft041">resistance.&#160;These drugs&#160;should&#160;be&#160;used with&#160;caution&#160;in&#160;patients in&#160;whom TB is&#160;suspected but&#160;who&#160;are not receiving&#160;a standard&#160;</p>
<p style="position:absolute;top:973px;left:108px;white-space:nowrap" class="ft041">4-drug TB&#160;regimen.&#160;</p>
<p style="position:absolute;top:999px;left:108px;white-space:nowrap" class="ft042"><b>Key:&#160;</b></p>
<p style="position:absolute;top:999px;left:138px;white-space:nowrap" class="ft041">ART = antiretroviral&#160;therapy; CD4&#160;= CD4&#160;T&#160;lymphocyte cell;&#160;IM = intramuscularly; IV =&#160;intravenously;&#160;</p>
<p style="position:absolute;top:1016px;left:108px;white-space:nowrap" class="ft041">MAC =&#160;</p>
<p style="position:absolute;top:1016px;left:149px;white-space:nowrap" class="ft024"><i>Mycobacterium avium</i></p>
<p style="position:absolute;top:1016px;left:269px;white-space:nowrap" class="ft041">&#160;complex; MRSA =&#160;methicillin-resistant&#160;</p>
<p style="position:absolute;top:1016px;left:482px;white-space:nowrap" class="ft024"><i>Staphylococcus&#160;aureus;</i></p>
<p style="position:absolute;top:1016px;left:613px;white-space:nowrap" class="ft041">&#160;PCV13 = 13-Valent&#160;</p>
<p style="position:absolute;top:1033px;left:108px;white-space:nowrap" class="ft041">Pneumococcal&#160;Conjugate Vaccine; PO&#160;= orally;&#160;PPSV23 –&#160;23-Valent&#160;Pneumococcal&#160;Polysaccharide&#160;Vaccine; TB&#160;= tuberculosis</p>
<p style="position:absolute;top:1060px;left:108px;white-space:nowrap" class="ft024"><i>&#160;</i></p>
</div>
<!-- Page 110 -->
<a name="110"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page110-div" style="position:relative;width:917px;height:1187px;">
<p style="position:absolute;top:1114px;left:108px;white-space:nowrap" class="ft024"><i>Guidelines for the Prevention and Treatment&#160;of&#160;Opportunistic&#160;Infections in Adults&#160;and Adolescents&#160;With HIV&#160;</i></p>
<p style="position:absolute;top:1114px;left:782px;white-space:nowrap" class="ft024"><i>G-19&#160;</i></p>
<p style="position:absolute;top:108px;left:108px;white-space:nowrap" class="ft026"><b>References&#160;</b></p>
<p style="position:absolute;top:150px;left:108px;white-space:nowrap" class="ft013">1.&#160;</p>
<p style="position:absolute;top:150px;left:162px;white-space:nowrap" class="ft032">Wallace JM,&#160;Hansen&#160;NI,&#160;Lavange L, et al. Respiratory disease trends in the Pulmonary&#160;<br/>Complications of&#160;HIV Infection Study cohort. Pulmonary Complications of HIV&#160;Infection&#160;<br/>Study Group.&#160;</p>
<p style="position:absolute;top:190px;left:259px;white-space:nowrap" class="ft019"><i>Am J Respir Crit Care&#160;Med</i></p>
<p style="position:absolute;top:190px;left:449px;white-space:nowrap" class="ft013">. 1997;155(1):72-80.&#160;Available at:&#160;</p>
<p style="position:absolute;top:210px;left:162px;white-space:nowrap" class="ft0115">https://www.ncbi.nlm.nih.gov/pubmed/9001292</p>
<p style="position:absolute;top:210px;left:495px;white-space:nowrap" class="ft013">.</p>
<p style="position:absolute;top:247px;left:108px;white-space:nowrap" class="ft013">2.&#160;</p>
<p style="position:absolute;top:247px;left:162px;white-space:nowrap" class="ft032">Zolopa A,&#160;Andersen J, Powderly W, et&#160;al. Early antiretroviral therapy reduces AIDS&#160;<br/>progression/death in individuals with&#160;acute opportunistic infections: a&#160;multicenter&#160;<br/>randomized strategy trial.&#160;</p>
<p style="position:absolute;top:286px;left:343px;white-space:nowrap" class="ft019"><i>PLoS One</i></p>
<p style="position:absolute;top:286px;left:413px;white-space:nowrap" class="ft013">. 2009;4(5):e5575. Available at:&#160;</p>
<p style="position:absolute;top:306px;left:162px;white-space:nowrap" class="ft0115">https://www.ncbi.nlm.nih.gov/pubmed/19440326</p>
<p style="position:absolute;top:306px;left:503px;white-space:nowrap" class="ft013">.&#160;</p>
<p style="position:absolute;top:343px;left:108px;white-space:nowrap" class="ft013">3.&#160;</p>
<p style="position:absolute;top:343px;left:162px;white-space:nowrap" class="ft032">Mussini C,&#160;Galli&#160;L, Lepri&#160;AC, et al. Incidence, timing, and determinants of bacterial&#160;<br/>pneumonia&#160;among HIV-infected patients: data from the ICONA Foundation cohort.&#160;</p>
<p style="position:absolute;top:363px;left:744px;white-space:nowrap" class="ft019"><i>J Acquir&#160;</i></p>
<p style="position:absolute;top:383px;left:162px;white-space:nowrap" class="ft019"><i>Immune&#160;Defic Syndr</i></p>
<p style="position:absolute;top:383px;left:304px;white-space:nowrap" class="ft013">. 2013;63(3):339-345. Available&#160;at:&#160;</p>
<p style="position:absolute;top:403px;left:162px;white-space:nowrap" class="ft0115">https://www.ncbi.nlm.nih.gov/pubmed/23591636</p>
<p style="position:absolute;top:403px;left:503px;white-space:nowrap" class="ft013">.&#160;</p>
<p style="position:absolute;top:440px;left:108px;white-space:nowrap" class="ft013">4.&#160;</p>
<p style="position:absolute;top:440px;left:162px;white-space:nowrap" class="ft032">O’Connor J,&#160;Vjecha&#160;MJ,&#160;Phillips AN,&#160;et&#160;al. Effect&#160;of immediate initiation of antiretroviral&#160;<br/>therapy on risk of&#160;severe&#160;bacterial&#160;infections in HIV-positive people with CD4 cell counts of&#160;<br/>more&#160;than 500 cells per muL:&#160;secondary outcome results from a&#160;randomised controlled trial.&#160;</p>
<p style="position:absolute;top:499px;left:162px;white-space:nowrap" class="ft019"><i>Lancet&#160;HIV</i></p>
<p style="position:absolute;top:499px;left:242px;white-space:nowrap" class="ft013">.&#160;2017;4(3):e105-e112.&#160;Available&#160;at:&#160;</p>
<p style="position:absolute;top:519px;left:162px;white-space:nowrap" class="ft0115">https://www.ncbi.nlm.nih.gov/pubmed/28063815</p>
<p style="position:absolute;top:519px;left:503px;white-space:nowrap" class="ft013">.&#160;</p>
<p style="position:absolute;top:556px;left:108px;white-space:nowrap" class="ft013">5.&#160;</p>
<p style="position:absolute;top:556px;left:162px;white-space:nowrap" class="ft032">Jones&#160;JL, Hanson&#160;DL, Dworkin&#160;MS,&#160;et&#160;al. Surveillance for AIDS-defining&#160;opportunistic&#160;<br/>illnesses, 1992–1997.&#160;</p>
<p style="position:absolute;top:576px;left:315px;white-space:nowrap" class="ft019"><i>MMWR CDC Surveill Summ</i></p>
<p style="position:absolute;top:576px;left:513px;white-space:nowrap" class="ft013">. 1999;48(2):1-22. Available&#160;at:&#160;</p>
<p style="position:absolute;top:596px;left:162px;white-space:nowrap" class="ft0115">https://www.ncbi.nlm.nih.gov/pubmed/12412613</p>
<p style="position:absolute;top:596px;left:503px;white-space:nowrap" class="ft013">.&#160;</p>
<p style="position:absolute;top:633px;left:108px;white-space:nowrap" class="ft013">6.&#160;</p>
<p style="position:absolute;top:633px;left:162px;white-space:nowrap" class="ft032">Sullivan JH,&#160;Moore RD,&#160;Keruly JC, Chaisson RE.&#160;Effect&#160;of antiretroviral&#160;therapy on the&#160;<br/>incidence of bacterial&#160;pneumonia&#160;in patients with advanced HIV infection.&#160;</p>
<p style="position:absolute;top:653px;left:680px;white-space:nowrap" class="ft019"><i>Am J Respir&#160;Crit&#160;</i></p>
<p style="position:absolute;top:673px;left:162px;white-space:nowrap" class="ft019"><i>Care Med</i></p>
<p style="position:absolute;top:673px;left:232px;white-space:nowrap" class="ft013">.&#160;2000;162(1):64-67. Available&#160;at:&#160;</p>
<p style="position:absolute;top:693px;left:162px;white-space:nowrap" class="ft0115">https://www.ncbi.nlm.nih.gov/pubmed/10903221</p>
<p style="position:absolute;top:693px;left:503px;white-space:nowrap" class="ft013">.&#160;</p>
<p style="position:absolute;top:730px;left:108px;white-space:nowrap" class="ft013">7.&#160;</p>
<p style="position:absolute;top:730px;left:162px;white-space:nowrap" class="ft032">Serraino D,&#160;Puro&#160;V, Boumis E, et&#160;al. Epidemiological&#160;aspects of major opportunistic&#160;<br/>infections of&#160;the&#160;respiratory tract&#160;in persons&#160;with AIDS: Europe,&#160;1993–2000.&#160;</p>
<p style="position:absolute;top:749px;left:696px;white-space:nowrap" class="ft019"><i>AIDS</i></p>
<p style="position:absolute;top:749px;left:733px;white-space:nowrap" class="ft013">.&#160;</p>
<p style="position:absolute;top:769px;left:162px;white-space:nowrap" class="ft013">2003;17(14):2109-2116.&#160;Available at:&#160;</p>
<p style="position:absolute;top:769px;left:428px;white-space:nowrap" class="ft0115">https://www.ncbi.nlm.nih.gov/pubmed/14502014</p>
<p style="position:absolute;top:769px;left:770px;white-space:nowrap" class="ft013">.&#160;</p>
<p style="position:absolute;top:806px;left:108px;white-space:nowrap" class="ft013">8.&#160;</p>
<p style="position:absolute;top:806px;left:162px;white-space:nowrap" class="ft032">Buchacz K,&#160;Lau B, Jing&#160;Y, et al. Incidence&#160;of AIDS-defining&#160;opportunistic&#160;infections in a&#160;<br/>multicohort&#160;analysis of&#160;HIV-infected&#160;persons&#160;in the United States and Canada, 2000–2010.&#160;</p>
<p style="position:absolute;top:846px;left:162px;white-space:nowrap" class="ft019"><i>J Infect&#160;Dis</i></p>
<p style="position:absolute;top:846px;left:241px;white-space:nowrap" class="ft013">.&#160;2016;214(6):862-872.&#160;Available&#160;at:&#160;</p>
<p style="position:absolute;top:866px;left:162px;white-space:nowrap" class="ft0115">https://www.ncbi.nlm.nih.gov/pubmed/27559122</p>
<p style="position:absolute;top:866px;left:503px;white-space:nowrap" class="ft013">.&#160;</p>
<p style="position:absolute;top:903px;left:108px;white-space:nowrap" class="ft013">9.&#160;</p>
<p style="position:absolute;top:903px;left:162px;white-space:nowrap" class="ft032">Hirschtick RE, Glassroth&#160;J, Jordan MC, et&#160;al. Bacterial&#160;pneumonia&#160;in persons infected with&#160;<br/>the&#160;human immunodeficiency virus.&#160;Pulmonary Complications of HIV Infection Study&#160;<br/>Group.&#160;</p>
<p style="position:absolute;top:943px;left:215px;white-space:nowrap" class="ft019"><i>N Engl J&#160;Med</i></p>
<p style="position:absolute;top:943px;left:310px;white-space:nowrap" class="ft013">. 1995;333(13):845-851.&#160;Available&#160;at:&#160;</p>
<p style="position:absolute;top:962px;left:162px;white-space:nowrap" class="ft0115">https://www.ncbi.nlm.nih.gov/pubmed/7651475</p>
<p style="position:absolute;top:962px;left:495px;white-space:nowrap" class="ft013">.&#160;</p>
<p style="position:absolute;top:1000px;left:108px;white-space:nowrap" class="ft013">10.&#160;</p>
<p style="position:absolute;top:1000px;left:162px;white-space:nowrap" class="ft032">Sogaard&#160;OS,&#160;Lohse N,&#160;Gerstoft J, et&#160;al.&#160;Hospitalization for pneumonia among individuals&#160;<br/>with and without HIV infection, 1995-2007: a&#160;Danish population-based, nationwide cohort&#160;<br/>study.&#160;</p>
<p style="position:absolute;top:1039px;left:208px;white-space:nowrap" class="ft019"><i>Clin Infect&#160;Dis</i></p>
<p style="position:absolute;top:1039px;left:309px;white-space:nowrap" class="ft013">. 2008;47(10):1345-1353.&#160;Available at:&#160;</p>
<p style="position:absolute;top:1059px;left:162px;white-space:nowrap" class="ft0115">https://www.ncbi.nlm.nih.gov/pubmed/18834317</p>
<p style="position:absolute;top:1059px;left:503px;white-space:nowrap" class="ft013">.&#160;</p>
</div>
<!-- Page 111 -->
<a name="111"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page111-div" style="position:relative;width:917px;height:1187px;">
<p style="position:absolute;top:1114px;left:108px;white-space:nowrap" class="ft024"><i>Guidelines for the Prevention and Treatment&#160;of&#160;Opportunistic&#160;Infections in Adults&#160;and Adolescents&#160;With HIV&#160;</i></p>
<p style="position:absolute;top:1114px;left:782px;white-space:nowrap" class="ft024"><i>G-20&#160;</i></p>
<p style="position:absolute;top:109px;left:108px;white-space:nowrap" class="ft013">11.&#160;</p>
<p style="position:absolute;top:109px;left:162px;white-space:nowrap" class="ft032">Aston&#160;SJ,&#160;Ho&#160;A, Jary H, et&#160;al. Aetiology and risk factors for mortality in an adult&#160;community-<br/>acquired pneumonia cohort in Malawi.&#160;</p>
<p style="position:absolute;top:129px;left:434px;white-space:nowrap" class="ft019"><i>Am J Respir&#160;Crit Care Med</i></p>
<p style="position:absolute;top:129px;left:624px;white-space:nowrap" class="ft013">. 2019.&#160;Available&#160;at:&#160;</p>
<p style="position:absolute;top:148px;left:162px;white-space:nowrap" class="ft0115">https://www.ncbi.nlm.nih.gov/pubmed/30625278</p>
<p style="position:absolute;top:148px;left:503px;white-space:nowrap" class="ft013">.&#160;</p>
<p style="position:absolute;top:185px;left:108px;white-space:nowrap" class="ft013">12.&#160;</p>
<p style="position:absolute;top:185px;left:162px;white-space:nowrap" class="ft032">Jambo KC,&#160;Banda&#160;DH,&#160;Kankwatira&#160;AM, et&#160;al. Small&#160;alveolar&#160;macrophages are infected&#160;<br/>preferentially by HIV and exhibit&#160;impaired phagocytic function.&#160;</p>
<p style="position:absolute;top:205px;left:608px;white-space:nowrap" class="ft019"><i>Mucosal Immunol</i></p>
<p style="position:absolute;top:205px;left:733px;white-space:nowrap" class="ft013">.&#160;</p>
<p style="position:absolute;top:225px;left:162px;white-space:nowrap" class="ft013">2014;7(5):1116-1126.&#160;Available&#160;at:&#160;</p>
<p style="position:absolute;top:225px;left:411px;white-space:nowrap" class="ft0115">https://www.ncbi.nlm.nih.gov/pubmed/24472847</p>
<p style="position:absolute;top:225px;left:752px;white-space:nowrap" class="ft013">.&#160;</p>
<p style="position:absolute;top:262px;left:108px;white-space:nowrap" class="ft013">13.&#160;</p>
<p style="position:absolute;top:262px;left:162px;white-space:nowrap" class="ft032">Charles TP,&#160;Shellito JE. Human immunodeficiency virus infection and host&#160;defense in the&#160;<br/>lungs.&#160;</p>
<p style="position:absolute;top:282px;left:208px;white-space:nowrap" class="ft019"><i>Semin Respir Crit&#160;Care Med</i></p>
<p style="position:absolute;top:282px;left:405px;white-space:nowrap" class="ft013">.&#160;2016;37(2):147-156.&#160;Available at:&#160;</p>
<p style="position:absolute;top:302px;left:162px;white-space:nowrap" class="ft0115">https://www.ncbi.nlm.nih.gov/pubmed/26974294</p>
<p style="position:absolute;top:302px;left:503px;white-space:nowrap" class="ft013">.&#160;</p>
<p style="position:absolute;top:339px;left:108px;white-space:nowrap" class="ft013">14.&#160;</p>
<p style="position:absolute;top:339px;left:162px;white-space:nowrap" class="ft032">Gordin&#160;FM,&#160;Roediger MP, Girard&#160;PM, et al. Pneumonia in HIV-infected persons: increased&#160;<br/>risk with cigarette smoking and treatment&#160;interruption.&#160;</p>
<p style="position:absolute;top:359px;left:543px;white-space:nowrap" class="ft019"><i>Am J&#160;Respir Crit&#160;Care Med</i></p>
<p style="position:absolute;top:359px;left:733px;white-space:nowrap" class="ft013">.&#160;</p>
<p style="position:absolute;top:379px;left:162px;white-space:nowrap" class="ft013">2008;178(6):630-636.&#160;Available&#160;at:&#160;</p>
<p style="position:absolute;top:379px;left:411px;white-space:nowrap" class="ft0115">https://www.ncbi.nlm.nih.gov/pubmed/18617640</p>
<p style="position:absolute;top:379px;left:752px;white-space:nowrap" class="ft013">.&#160;</p>
<p style="position:absolute;top:416px;left:108px;white-space:nowrap" class="ft013">15.&#160;</p>
<p style="position:absolute;top:416px;left:162px;white-space:nowrap" class="ft032">Benard A,&#160;Mercie&#160;P, Alioum A, et&#160;al.&#160;Bacterial&#160;pneumonia among HIV-infected patients:&#160;<br/>decreased risk after tobacco smoking cessation. ANRS CO3 Aquitaine Cohort, 2000-2007.&#160;</p>
<p style="position:absolute;top:455px;left:162px;white-space:nowrap" class="ft019"><i>PLoS One</i></p>
<p style="position:absolute;top:455px;left:232px;white-space:nowrap" class="ft013">. 2010;5(1):e8896. Available at:&#160;</p>
<p style="position:absolute;top:455px;left:457px;white-space:nowrap" class="ft0115">https://www.ncbi.nlm.nih.gov/pubmed/20126646</p>
<p style="position:absolute;top:455px;left:799px;white-space:nowrap" class="ft013">.&#160;</p>
<p style="position:absolute;top:492px;left:108px;white-space:nowrap" class="ft013">16.&#160;</p>
<p style="position:absolute;top:492px;left:162px;white-space:nowrap" class="ft032">Lamas CC,&#160;Coelho LE, Grinsztejn BJ, Veloso VG. Community-acquired lower respiratory&#160;<br/>tract&#160;infections in HIV-infected patients on antiretroviral&#160;therapy: predictors&#160;in a&#160;<br/>contemporary cohort&#160;study.&#160;</p>
<p style="position:absolute;top:532px;left:356px;white-space:nowrap" class="ft019"><i>Infection</i></p>
<p style="position:absolute;top:532px;left:418px;white-space:nowrap" class="ft013">. 2017;45(6):801-809.&#160;Available&#160;at:&#160;</p>
<p style="position:absolute;top:552px;left:162px;white-space:nowrap" class="ft0115">https://www.ncbi.nlm.nih.gov/pubmed/28660356</p>
<p style="position:absolute;top:552px;left:503px;white-space:nowrap" class="ft013">.&#160;</p>
<p style="position:absolute;top:589px;left:108px;white-space:nowrap" class="ft013">17.&#160;</p>
<p style="position:absolute;top:589px;left:162px;white-space:nowrap" class="ft032">Edelman EJ, Gordon&#160;KS,&#160;Crothers&#160;K,&#160;et al. Association of prescribed opioids with increased&#160;<br/>risk of community-acquired pneumonia&#160;among patients with and&#160;without&#160;HIV.&#160;</p>
<p style="position:absolute;top:609px;left:709px;white-space:nowrap" class="ft019"><i>JAMA&#160;Intern&#160;</i></p>
<p style="position:absolute;top:629px;left:162px;white-space:nowrap" class="ft019"><i>Med</i></p>
<p style="position:absolute;top:629px;left:193px;white-space:nowrap" class="ft013">. 2019;179(3):297-304. Available at:&#160;</p>
<p style="position:absolute;top:629px;left:450px;white-space:nowrap" class="ft0115">https://www.ncbi.nlm.nih.gov/pubmed/30615036</p>
<p style="position:absolute;top:629px;left:792px;white-space:nowrap" class="ft013">.&#160;</p>
<p style="position:absolute;top:666px;left:108px;white-space:nowrap" class="ft013">18.&#160;</p>
<p style="position:absolute;top:666px;left:162px;white-space:nowrap" class="ft032">Attia EF, McGinnis&#160;KA,&#160;Feemster LC, et&#160;al. Association of COPD&#160;with risk&#160;for pulmonary&#160;<br/>infections requiring hospitalization in&#160;HIV-infected veterans.&#160;</p>
<p style="position:absolute;top:686px;left:588px;white-space:nowrap" class="ft019"><i>J&#160;Acquir Immune Defic Syndr</i></p>
<p style="position:absolute;top:686px;left:792px;white-space:nowrap" class="ft013">.&#160;</p>
<p style="position:absolute;top:706px;left:162px;white-space:nowrap" class="ft013">2015;70(3):280-288.&#160;Available&#160;at:&#160;</p>
<p style="position:absolute;top:706px;left:402px;white-space:nowrap" class="ft0115">http://www.ncbi.nlm.nih.gov/pubmed/26181820</p>
<p style="position:absolute;top:706px;left:737px;white-space:nowrap" class="ft013">.&#160;</p>
<p style="position:absolute;top:743px;left:108px;white-space:nowrap" class="ft013">19.&#160;</p>
<p style="position:absolute;top:743px;left:162px;white-space:nowrap" class="ft032">Polsky B,&#160;Gold JW, Whimbey E, et al. Bacterial&#160;pneumonia in patients with the acquired&#160;<br/>immunodeficiency syndrome.&#160;</p>
<p style="position:absolute;top:762px;left:372px;white-space:nowrap" class="ft019"><i>Ann Intern Med</i></p>
<p style="position:absolute;top:762px;left:481px;white-space:nowrap" class="ft013">. 1986;104(1):38-41. Available at:&#160;</p>
<p style="position:absolute;top:782px;left:162px;white-space:nowrap" class="ft0115">https://www.ncbi.nlm.nih.gov/pubmed/3484420</p>
<p style="position:absolute;top:782px;left:495px;white-space:nowrap" class="ft013">.&#160;</p>
<p style="position:absolute;top:819px;left:108px;white-space:nowrap" class="ft013">20.&#160;</p>
<p style="position:absolute;top:819px;left:162px;white-space:nowrap" class="ft032">Burack JH,&#160;Hahn JA,&#160;Saint-Maurice&#160;D, Jacobson&#160;MA.&#160;Microbiology of community-acquired&#160;<br/>bacterial&#160;pneumonia&#160;in persons&#160;with and at&#160;risk for&#160;human immunodeficiency virus type 1&#160;<br/>infection. Implications for rational empiric&#160;antibiotic therapy.&#160;</p>
<p style="position:absolute;top:859px;left:590px;white-space:nowrap" class="ft019"><i>Arch Intern Med</i></p>
<p style="position:absolute;top:859px;left:705px;white-space:nowrap" class="ft013">.&#160;</p>
<p style="position:absolute;top:879px;left:162px;white-space:nowrap" class="ft013">1994;154(22):2589-2596.&#160;Available at:&#160;</p>
<p style="position:absolute;top:879px;left:437px;white-space:nowrap" class="ft0115">https://www.ncbi.nlm.nih.gov/pubmed/7979856</p>
<p style="position:absolute;top:879px;left:769px;white-space:nowrap" class="ft013">.&#160;</p>
<p style="position:absolute;top:916px;left:108px;white-space:nowrap" class="ft013">21.&#160;</p>
<p style="position:absolute;top:916px;left:162px;white-space:nowrap" class="ft032">Miller RF, Foley NM,&#160;Kessel&#160;D,&#160;Jeffrey AA. Community acquired lobar pneumonia in&#160;<br/>patients with HIV&#160;infection and AIDS.&#160;</p>
<p style="position:absolute;top:936px;left:433px;white-space:nowrap" class="ft019"><i>Thorax</i></p>
<p style="position:absolute;top:936px;left:483px;white-space:nowrap" class="ft013">.&#160;1994;49(4):367-368. Available&#160;at:&#160;</p>
<p style="position:absolute;top:956px;left:162px;white-space:nowrap" class="ft0115">https://www.ncbi.nlm.nih.gov/pubmed/8202910</p>
<p style="position:absolute;top:956px;left:495px;white-space:nowrap" class="ft013">.&#160;</p>
<p style="position:absolute;top:993px;left:108px;white-space:nowrap" class="ft013">22.&#160;</p>
<p style="position:absolute;top:993px;left:162px;white-space:nowrap" class="ft032">Mundy LM,&#160;Auwaerter&#160;PG, Oldach&#160;D,&#160;et&#160;al. Community-acquired pneumonia: impact&#160;of&#160;<br/>immune&#160;status.&#160;</p>
<p style="position:absolute;top:1013px;left:271px;white-space:nowrap" class="ft019"><i>Am J Respir Crit Care&#160;Med</i></p>
<p style="position:absolute;top:1013px;left:461px;white-space:nowrap" class="ft013">. 1995;152(4 Pt 1):1309-1315.&#160;Available&#160;at:&#160;</p>
<p style="position:absolute;top:1032px;left:162px;white-space:nowrap" class="ft0115">https://www.ncbi.nlm.nih.gov/pubmed/7551387</p>
<p style="position:absolute;top:1032px;left:495px;white-space:nowrap" class="ft013">.&#160;</p>
</div>
<!-- Page 112 -->
<a name="112"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page112-div" style="position:relative;width:917px;height:1187px;">
<p style="position:absolute;top:1114px;left:108px;white-space:nowrap" class="ft024"><i>Guidelines for the Prevention and Treatment&#160;of&#160;Opportunistic&#160;Infections in Adults&#160;and Adolescents&#160;With HIV&#160;</i></p>
<p style="position:absolute;top:1114px;left:782px;white-space:nowrap" class="ft024"><i>G-21&#160;</i></p>
<p style="position:absolute;top:109px;left:108px;white-space:nowrap" class="ft013">23.&#160;</p>
<p style="position:absolute;top:109px;left:162px;white-space:nowrap" class="ft032">Afessa B, Green B. Bacterial&#160;pneumonia&#160;in hospitalized patients with HIV infection:&#160;the&#160;<br/>Pulmonary Complications, ICU&#160;Support, and Prognostic&#160;Factors&#160;of Hospitalized Patients&#160;<br/>with HIV (PIP) Study.&#160;</p>
<p style="position:absolute;top:148px;left:321px;white-space:nowrap" class="ft019"><i>Chest</i></p>
<p style="position:absolute;top:148px;left:361px;white-space:nowrap" class="ft013">. 2000;117(4):1017-1022. Available at:&#160;</p>
<p style="position:absolute;top:168px;left:162px;white-space:nowrap" class="ft0115">https://www.ncbi.nlm.nih.gov/pubmed/10767233</p>
<p style="position:absolute;top:168px;left:503px;white-space:nowrap" class="ft013">.&#160;</p>
<p style="position:absolute;top:205px;left:108px;white-space:nowrap" class="ft013">24.&#160;</p>
<p style="position:absolute;top:205px;left:162px;white-space:nowrap" class="ft032">Park DR, Sherbin VL,&#160;Goodman MS,&#160;et&#160;al. The&#160;etiology of community-acquired pneumonia&#160;<br/>at&#160;an urban public hospital: influence of human immunodeficiency virus infection and initial&#160;<br/>severity of illness.&#160;</p>
<p style="position:absolute;top:245px;left:292px;white-space:nowrap" class="ft019"><i>J Infect&#160;Dis</i></p>
<p style="position:absolute;top:245px;left:372px;white-space:nowrap" class="ft013">. 2001;184(3):268-277. Available at:&#160;</p>
<p style="position:absolute;top:265px;left:162px;white-space:nowrap" class="ft0115">https://www.ncbi.nlm.nih.gov/pubmed/11443551</p>
<p style="position:absolute;top:265px;left:503px;white-space:nowrap" class="ft013">.&#160;</p>
<p style="position:absolute;top:302px;left:108px;white-space:nowrap" class="ft013">25.&#160;</p>
<p style="position:absolute;top:302px;left:162px;white-space:nowrap" class="ft032">Rimland D,&#160;Navin TR, Lennox JL, et&#160;al. Prospective study of etiologic agents of community-<br/>acquired pneumonia in patients with HIV infection.&#160;</p>
<p style="position:absolute;top:322px;left:522px;white-space:nowrap" class="ft019"><i>AIDS</i></p>
<p style="position:absolute;top:322px;left:559px;white-space:nowrap" class="ft013">. 2002;16(1):85-95.&#160;Available at:&#160;</p>
<p style="position:absolute;top:342px;left:162px;white-space:nowrap" class="ft0115">https://www.ncbi.nlm.nih.gov/pubmed/11741166</p>
<p style="position:absolute;top:342px;left:503px;white-space:nowrap" class="ft013">.&#160;</p>
<p style="position:absolute;top:379px;left:108px;white-space:nowrap" class="ft013">26.&#160;</p>
<p style="position:absolute;top:379px;left:162px;white-space:nowrap" class="ft032">Lobo LJ, Reed KD,&#160;Wunderink RG. Expanded clinical&#160;presentation of community-acquired&#160;<br/>methicillin-resistant</p>
<p style="position:absolute;top:399px;left:300px;white-space:nowrap" class="ft019"><i>&#160;Staphylococcus aureus&#160;</i></p>
<p style="position:absolute;top:399px;left:467px;white-space:nowrap" class="ft013">pneumonia.&#160;</p>
<p style="position:absolute;top:399px;left:552px;white-space:nowrap" class="ft019"><i>Chest</i></p>
<p style="position:absolute;top:399px;left:591px;white-space:nowrap" class="ft013">.&#160;2010;138(1):130-136.&#160;</p>
<p style="position:absolute;top:418px;left:162px;white-space:nowrap" class="ft013">Available at:&#160;</p>
<p style="position:absolute;top:418px;left:255px;white-space:nowrap" class="ft0115">https://www.ncbi.nlm.nih.gov/pubmed/20173050</p>
<p style="position:absolute;top:418px;left:596px;white-space:nowrap" class="ft013">.&#160;</p>
<p style="position:absolute;top:455px;left:108px;white-space:nowrap" class="ft013">27.&#160;</p>
<p style="position:absolute;top:455px;left:162px;white-space:nowrap" class="ft032">Klein EY,&#160;Monteforte B,&#160;Gupta A, et al. The frequency of influenza&#160;and bacterial&#160;<br/>coinfection:&#160;a systematic&#160;review and&#160;meta-analysis.&#160;</p>
<p style="position:absolute;top:475px;left:521px;white-space:nowrap" class="ft019"><i>Influenza&#160;Other Respir&#160;Viruses</i></p>
<p style="position:absolute;top:475px;left:735px;white-space:nowrap" class="ft013">.&#160;</p>
<p style="position:absolute;top:495px;left:162px;white-space:nowrap" class="ft013">2016;10(5):394-403.&#160;Available&#160;at:&#160;</p>
<p style="position:absolute;top:495px;left:402px;white-space:nowrap" class="ft0115">https://www.ncbi.nlm.nih.gov/pubmed/27232677</p>
<p style="position:absolute;top:495px;left:744px;white-space:nowrap" class="ft013">.&#160;</p>
<p style="position:absolute;top:532px;left:108px;white-space:nowrap" class="ft013">28.&#160;</p>
<p style="position:absolute;top:532px;left:162px;white-space:nowrap" class="ft032">Tarp B, Jensen JS,&#160;Ostergaard L, Andersen PL.&#160;Search for agents causing atypical&#160;pneumonia&#160;<br/>in HIV-positive patients by inhibitor-controlled PCR assays.&#160;</p>
<p style="position:absolute;top:552px;left:583px;white-space:nowrap" class="ft019"><i>Eur Respir J</i></p>
<p style="position:absolute;top:552px;left:670px;white-space:nowrap" class="ft013">. 1999;13(1):175-</p>
<p style="position:absolute;top:572px;left:162px;white-space:nowrap" class="ft013">179. Available&#160;at:&#160;</p>
<p style="position:absolute;top:572px;left:289px;white-space:nowrap" class="ft0115">https://www.ncbi.nlm.nih.gov/pubmed/10836344</p>
<p style="position:absolute;top:572px;left:631px;white-space:nowrap" class="ft013">.&#160;</p>
<p style="position:absolute;top:609px;left:108px;white-space:nowrap" class="ft013">29.&#160;</p>
<p style="position:absolute;top:609px;left:162px;white-space:nowrap" class="ft032">Figueiredo-Mello C, Naucler P, Negra MD, Levin&#160;AS.&#160;Prospective&#160;etiological investigation&#160;<br/>of community-acquired pulmonary infections in hospitalized people living with HIV.&#160;</p>
<p style="position:absolute;top:649px;left:162px;white-space:nowrap" class="ft019"><i>Medicine (Baltimore)</i></p>
<p style="position:absolute;top:649px;left:311px;white-space:nowrap" class="ft013">. 2017;96(4):e5778. Available at:&#160;</p>
<p style="position:absolute;top:668px;left:162px;white-space:nowrap" class="ft0115">https://www.ncbi.nlm.nih.gov/pubmed/28121925</p>
<p style="position:absolute;top:668px;left:503px;white-space:nowrap" class="ft013">.&#160;</p>
<p style="position:absolute;top:706px;left:108px;white-space:nowrap" class="ft013">30.&#160;</p>
<p style="position:absolute;top:706px;left:162px;white-space:nowrap" class="ft032">Maartens&#160;G,&#160;Griesel&#160;R,&#160;Dube F,&#160;Nicol M, Mendelson M. Etiology of pulmonary infections&#160;in&#160;<br/>human immunodeficiency virus-infected inpatients using sputum&#160;multiplex&#160;real-time&#160;<br/>polymerase chain reaction.&#160;</p>
<p style="position:absolute;top:745px;left:351px;white-space:nowrap" class="ft019"><i>Clin Infect&#160;Dis</i></p>
<p style="position:absolute;top:745px;left:453px;white-space:nowrap" class="ft013">. 2020;70(6):1147-1152. Available at:&#160;</p>
<p style="position:absolute;top:765px;left:162px;white-space:nowrap" class="ft0115">https://www.ncbi.nlm.nih.gov/pubmed/31286137</p>
<p style="position:absolute;top:765px;left:503px;white-space:nowrap" class="ft013">.&#160;</p>
<p style="position:absolute;top:802px;left:108px;white-space:nowrap" class="ft013">31.&#160;</p>
<p style="position:absolute;top:802px;left:162px;white-space:nowrap" class="ft032">Coleman BL, Fadel&#160;SA, Fitzpatrick T, Thomas SM.&#160;Risk factors&#160;for serious outcomes&#160;<br/>associated with influenza&#160;illness&#160;in high- versus low- and middle-income&#160;countries:&#160;<br/>systematic literature review and meta-analysis.&#160;</p>
<p style="position:absolute;top:842px;left:489px;white-space:nowrap" class="ft019"><i>Influenza&#160;Other&#160;Respir Viruses</i></p>
<p style="position:absolute;top:842px;left:703px;white-space:nowrap" class="ft013">.&#160;</p>
<p style="position:absolute;top:862px;left:162px;white-space:nowrap" class="ft013">2018;12(1):22-29. Available&#160;at:&#160;</p>
<p style="position:absolute;top:862px;left:385px;white-space:nowrap" class="ft0115">https://www.ncbi.nlm.nih.gov/pubmed/29197154</p>
<p style="position:absolute;top:862px;left:726px;white-space:nowrap" class="ft013">.&#160;</p>
<p style="position:absolute;top:899px;left:108px;white-space:nowrap" class="ft013">32.&#160;</p>
<p style="position:absolute;top:899px;left:162px;white-space:nowrap" class="ft032">Kenmoe S,&#160;Bigna&#160;JJ,&#160;Fatawou&#160;Modiyingi&#160;A, et al. Case fatality rate and viral&#160;aetiologies of&#160;<br/>acute respiratory tract infections in HIV positive&#160;and negative&#160;people in Africa:&#160;the&#160;<br/>VARIAFRICA-HIV&#160;systematic&#160;review and meta-analysis.&#160;</p>
<p style="position:absolute;top:938px;left:569px;white-space:nowrap" class="ft019"><i>J Clin Virol</i></p>
<p style="position:absolute;top:938px;left:650px;white-space:nowrap" class="ft013">. 2019;117:96-102.&#160;</p>
<p style="position:absolute;top:958px;left:162px;white-space:nowrap" class="ft013">Available at:&#160;</p>
<p style="position:absolute;top:958px;left:255px;white-space:nowrap" class="ft0115">https://www.ncbi.nlm.nih.gov/pubmed/31272038</p>
<p style="position:absolute;top:958px;left:596px;white-space:nowrap" class="ft013">.&#160;</p>
<p style="position:absolute;top:995px;left:108px;white-space:nowrap" class="ft013">33.&#160;</p>
<p style="position:absolute;top:995px;left:162px;white-space:nowrap" class="ft032">Collins JP, Campbell AP,&#160;Openo&#160;K, et&#160;al. Outcomes&#160;of immunocompromised&#160;adults&#160;<br/>hospitalized&#160;with&#160;laboratory-confirmed&#160;influenza&#160;in the United States, 2011–2015.&#160;</p>
<p style="position:absolute;top:1015px;left:735px;white-space:nowrap" class="ft019"><i>Clin Infect</i></p>
<p style="position:absolute;top:1035px;left:162px;white-space:nowrap" class="ft019"><i>Dis</i></p>
<p style="position:absolute;top:1035px;left:186px;white-space:nowrap" class="ft013">. 2020;70(10):2121-2130. Available at:&#160;</p>
<p style="position:absolute;top:1035px;left:461px;white-space:nowrap" class="ft0115">https://www.ncbi.nlm.nih.gov/pubmed/31298691</p>
<p style="position:absolute;top:1035px;left:802px;white-space:nowrap" class="ft013">.&#160;</p>
</div>
<!-- Page 113 -->
<a name="113"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page113-div" style="position:relative;width:917px;height:1187px;">
<p style="position:absolute;top:1114px;left:108px;white-space:nowrap" class="ft024"><i>Guidelines for the Prevention and Treatment&#160;of&#160;Opportunistic&#160;Infections in Adults&#160;and Adolescents&#160;With HIV&#160;</i></p>
<p style="position:absolute;top:1114px;left:782px;white-space:nowrap" class="ft024"><i>G-22&#160;</i></p>
<p style="position:absolute;top:109px;left:108px;white-space:nowrap" class="ft013">34.&#160;</p>
<p style="position:absolute;top:109px;left:162px;white-space:nowrap" class="ft032">Mellor MM,&#160;Bast AC,&#160;Jones NR, et al.&#160;Risk of adverse coronavirus disease 2019 outcomes&#160;<br/>for people living with HIV.&#160;</p>
<p style="position:absolute;top:129px;left:356px;white-space:nowrap" class="ft019"><i>AIDS</i></p>
<p style="position:absolute;top:129px;left:393px;white-space:nowrap" class="ft013">. 2021;35(4):F1-F10.&#160;Available at:&#160;</p>
<p style="position:absolute;top:148px;left:162px;white-space:nowrap" class="ft0115">https://www.ncbi.nlm.nih.gov/pubmed/33587448</p>
<p style="position:absolute;top:148px;left:503px;white-space:nowrap" class="ft013">.&#160;</p>
<p style="position:absolute;top:185px;left:108px;white-space:nowrap" class="ft013">35.&#160;</p>
<p style="position:absolute;top:185px;left:162px;white-space:nowrap" class="ft032">Danwang C,&#160;Noubiap JJ,&#160;Robert&#160;A,&#160;Yombi&#160;JC. Outcomes of patients with HIV and&#160;<br/>COVID-19 co-infection: a&#160;systematic review and&#160;meta-analysis.&#160;</p>
<p style="position:absolute;top:205px;left:609px;white-space:nowrap" class="ft019"><i>AIDS&#160;Res&#160;Ther</i></p>
<p style="position:absolute;top:205px;left:712px;white-space:nowrap" class="ft013">.&#160;</p>
<p style="position:absolute;top:225px;left:162px;white-space:nowrap" class="ft013">2022;19(1):3. Available at:&#160;</p>
<p style="position:absolute;top:225px;left:354px;white-space:nowrap" class="ft0115">https://www.ncbi.nlm.nih.gov/pubmed/35031068</p>
<p style="position:absolute;top:225px;left:695px;white-space:nowrap" class="ft013">.&#160;</p>
<p style="position:absolute;top:262px;left:108px;white-space:nowrap" class="ft013">36.&#160;</p>
<p style="position:absolute;top:262px;left:162px;white-space:nowrap" class="ft013">Dong&#160;Y, Li&#160;Z, Ding S, et&#160;al. HIV infection and risk of COVID-19 mortality: a&#160;meta-analysis.&#160;</p>
<p style="position:absolute;top:282px;left:162px;white-space:nowrap" class="ft019"><i>Medicine (Baltimore)</i></p>
<p style="position:absolute;top:282px;left:311px;white-space:nowrap" class="ft013">. 2021;100(26):e26573.&#160;Available at:&#160;</p>
<p style="position:absolute;top:302px;left:162px;white-space:nowrap" class="ft0115">https://www.ncbi.nlm.nih.gov/pubmed/34190201</p>
<p style="position:absolute;top:302px;left:503px;white-space:nowrap" class="ft013">.&#160;</p>
<p style="position:absolute;top:339px;left:108px;white-space:nowrap" class="ft013">37.&#160;</p>
<p style="position:absolute;top:339px;left:162px;white-space:nowrap" class="ft013">Levine SJ,&#160;White&#160;DA,&#160;Fels AO.&#160;The&#160;incidence&#160;and significance of&#160;</p>
<p style="position:absolute;top:339px;left:622px;white-space:nowrap" class="ft019"><i>Staphylococcus aureus</i></p>
<p style="position:absolute;top:339px;left:781px;white-space:nowrap" class="ft013">&#160;in&#160;</p>
<p style="position:absolute;top:359px;left:162px;white-space:nowrap" class="ft013">respiratory cultures from&#160;patients infected with the&#160;human immunodeficiency virus.&#160;</p>
<p style="position:absolute;top:359px;left:744px;white-space:nowrap" class="ft019"><i>Am&#160;Rev&#160;</i></p>
<p style="position:absolute;top:379px;left:162px;white-space:nowrap" class="ft019"><i>Respir Dis</i></p>
<p style="position:absolute;top:379px;left:235px;white-space:nowrap" class="ft013">. 1990;141(1):89-93. Available at:&#160;</p>
<p style="position:absolute;top:399px;left:162px;white-space:nowrap" class="ft0115">https://www.ncbi.nlm.nih.gov/pubmed/2297190</p>
<p style="position:absolute;top:399px;left:495px;white-space:nowrap" class="ft013">.&#160;</p>
<p style="position:absolute;top:436px;left:108px;white-space:nowrap" class="ft013">38.&#160;</p>
<p style="position:absolute;top:436px;left:162px;white-space:nowrap" class="ft032">Shorr&#160;AF, Zilberberg MD, Micek ST,&#160;Kollef MH.&#160;Prediction of&#160;infection due&#160;to antibiotic-<br/>resistant bacteria by select&#160;risk factors for health care-associated&#160;pneumonia.&#160;</p>
<p style="position:absolute;top:455px;left:695px;white-space:nowrap" class="ft019"><i>Arch Intern&#160;</i></p>
<p style="position:absolute;top:475px;left:162px;white-space:nowrap" class="ft019"><i>Med</i></p>
<p style="position:absolute;top:475px;left:193px;white-space:nowrap" class="ft013">. 2008;168(20):2205-2210. Available&#160;at:&#160;</p>
<p style="position:absolute;top:495px;left:162px;white-space:nowrap" class="ft0115">http://archinte.jamanetwork.com/data/Journals/INTEMED/5723/ioi80120_2205_2210.pdf</p>
<p style="position:absolute;top:495px;left:784px;white-space:nowrap" class="ft013">.&#160;</p>
<p style="position:absolute;top:532px;left:108px;white-space:nowrap" class="ft013">39.&#160;</p>
<p style="position:absolute;top:532px;left:162px;white-space:nowrap" class="ft032">Everett&#160;CK,&#160;Subramanian&#160;A, Jarisberg&#160;LG, Fei M,&#160;Huang L. Characteristics of drug-<br/>susceptible and drug-resistant&#160;</p>
<p style="position:absolute;top:552px;left:371px;white-space:nowrap" class="ft019"><i>Staphylococcus aureus</i></p>
<p style="position:absolute;top:552px;left:530px;white-space:nowrap" class="ft013">&#160;pneumonia&#160;in patients with HIV.&#160;</p>
<p style="position:absolute;top:572px;left:162px;white-space:nowrap" class="ft019"><i>Epidemiology (Sunnyvale)</i></p>
<p style="position:absolute;top:572px;left:344px;white-space:nowrap" class="ft013">. 2013;3(1).&#160;Available at:&#160;</p>
<p style="position:absolute;top:592px;left:162px;white-space:nowrap" class="ft0115">https://www.ncbi.nlm.nih.gov/pubmed/25346868</p>
<p style="position:absolute;top:592px;left:503px;white-space:nowrap" class="ft013">.&#160;</p>
<p style="position:absolute;top:629px;left:108px;white-space:nowrap" class="ft013">40.&#160;</p>
<p style="position:absolute;top:629px;left:162px;white-space:nowrap" class="ft032">Diep BA,&#160;Chambers HF,&#160;Graber CJ, et al. Emergence&#160;of multidrug-resistant,&#160;community-<br/>associated,&#160;methicillin-resistant&#160;</p>
<p style="position:absolute;top:649px;left:383px;white-space:nowrap" class="ft019"><i>Staphylococcus aureus</i></p>
<p style="position:absolute;top:649px;left:542px;white-space:nowrap" class="ft013">&#160;clone&#160;USA300 in&#160;men who have sex&#160;</p>
<p style="position:absolute;top:668px;left:162px;white-space:nowrap" class="ft013">with men.&#160;</p>
<p style="position:absolute;top:668px;left:235px;white-space:nowrap" class="ft019"><i>Ann Intern Med</i></p>
<p style="position:absolute;top:668px;left:344px;white-space:nowrap" class="ft013">. 2008;148(4):249-257.&#160;Available&#160;at:&#160;</p>
<p style="position:absolute;top:688px;left:162px;white-space:nowrap" class="ft0115">https://www.ncbi.nlm.nih.gov/pubmed/18283202</p>
<p style="position:absolute;top:688px;left:503px;white-space:nowrap" class="ft013">.&#160;</p>
<p style="position:absolute;top:725px;left:108px;white-space:nowrap" class="ft013">41.&#160;</p>
<p style="position:absolute;top:725px;left:162px;white-space:nowrap" class="ft013">Popovich&#160;KJ, Hota&#160;B,&#160;Aroutcheva&#160;A,&#160;et&#160;al. Community-associated methicillin-resistant&#160;</p>
<p style="position:absolute;top:745px;left:162px;white-space:nowrap" class="ft019"><i>Staphylococcus aureus</i></p>
<p style="position:absolute;top:745px;left:321px;white-space:nowrap" class="ft013">&#160;colonization burden in HIV-infected patients.&#160;</p>
<p style="position:absolute;top:745px;left:643px;white-space:nowrap" class="ft019"><i>Clin Infect Dis</i></p>
<p style="position:absolute;top:745px;left:744px;white-space:nowrap" class="ft013">.&#160;</p>
<p style="position:absolute;top:765px;left:162px;white-space:nowrap" class="ft013">2013;56(8):1067-1074.&#160;Available at:&#160;</p>
<p style="position:absolute;top:765px;left:420px;white-space:nowrap" class="ft0115">https://www.ncbi.nlm.nih.gov/pubmed/23325428</p>
<p style="position:absolute;top:765px;left:761px;white-space:nowrap" class="ft013">.&#160;</p>
<p style="position:absolute;top:802px;left:108px;white-space:nowrap" class="ft013">42.&#160;</p>
<p style="position:absolute;top:802px;left:162px;white-space:nowrap" class="ft032">Zervou FN,&#160;Zacharioudakis IM, Ziakas PD, Rich&#160;JD,&#160;Mylonakis E. Prevalence of&#160;and risk&#160;<br/>factors for&#160;methicillin-resistant&#160;</p>
<p style="position:absolute;top:822px;left:380px;white-space:nowrap" class="ft019"><i>Staphylococcus aureus</i></p>
<p style="position:absolute;top:822px;left:538px;white-space:nowrap" class="ft013">&#160;colonization in HIV infection:&#160;a meta-</p>
<p style="position:absolute;top:842px;left:162px;white-space:nowrap" class="ft013">analysis.&#160;</p>
<p style="position:absolute;top:842px;left:226px;white-space:nowrap" class="ft019"><i>Clin Infect&#160;Dis</i></p>
<p style="position:absolute;top:842px;left:328px;white-space:nowrap" class="ft013">.&#160;2014;59(9):1302-1311.&#160;Available&#160;at:&#160;</p>
<p style="position:absolute;top:862px;left:162px;white-space:nowrap" class="ft0115">https://www.ncbi.nlm.nih.gov/pubmed/25031291</p>
<p style="position:absolute;top:862px;left:503px;white-space:nowrap" class="ft013">.&#160;</p>
<p style="position:absolute;top:899px;left:108px;white-space:nowrap" class="ft013">43.&#160;</p>
<p style="position:absolute;top:899px;left:162px;white-space:nowrap" class="ft032">Cilloniz C, Torres&#160;A, Manzardo C, et al. Community-acquired pneumococcal pneumonia in&#160;<br/>virologically suppressed&#160;HIV-infected adult patients: a&#160;matched case-control&#160;study.&#160;</p>
<p style="position:absolute;top:919px;left:741px;white-space:nowrap" class="ft019"><i>Chest</i></p>
<p style="position:absolute;top:919px;left:780px;white-space:nowrap" class="ft013">.&#160;</p>
<p style="position:absolute;top:938px;left:162px;white-space:nowrap" class="ft013">2017;152(2):295-303.&#160;Available&#160;at:&#160;</p>
<p style="position:absolute;top:938px;left:411px;white-space:nowrap" class="ft0115">https://www.ncbi.nlm.nih.gov/pubmed/28302496</p>
<p style="position:absolute;top:938px;left:752px;white-space:nowrap" class="ft013">.&#160;</p>
<p style="position:absolute;top:976px;left:108px;white-space:nowrap" class="ft013">44.&#160;</p>
<p style="position:absolute;top:976px;left:162px;white-space:nowrap" class="ft013">Selwyn&#160;PA,&#160;Pumerantz AS, Durante A, et&#160;al. Clinical predictors of&#160;</p>
<p style="position:absolute;top:976px;left:627px;white-space:nowrap" class="ft019"><i>Pneumocystis carinii</i></p>
<p style="position:absolute;top:976px;left:772px;white-space:nowrap" class="ft013">&#160;</p>
<p style="position:absolute;top:995px;left:162px;white-space:nowrap" class="ft013">pneumonia,&#160;bacterial&#160;pneumonia&#160;and tuberculosis in HIV-infected patients.&#160;</p>
<p style="position:absolute;top:995px;left:685px;white-space:nowrap" class="ft019"><i>AIDS</i></p>
<p style="position:absolute;top:995px;left:722px;white-space:nowrap" class="ft013">.&#160;</p>
<p style="position:absolute;top:1015px;left:162px;white-space:nowrap" class="ft013">1998;12(8):885-893.&#160;Available&#160;at:&#160;</p>
<p style="position:absolute;top:1015px;left:402px;white-space:nowrap" class="ft0115">https://www.ncbi.nlm.nih.gov/pubmed/9631142</p>
<p style="position:absolute;top:1015px;left:735px;white-space:nowrap" class="ft013">.&#160;</p>
</div>
<!-- Page 114 -->
<a name="114"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page114-div" style="position:relative;width:917px;height:1187px;">
<p style="position:absolute;top:1114px;left:108px;white-space:nowrap" class="ft024"><i>Guidelines for the Prevention and Treatment&#160;of&#160;Opportunistic&#160;Infections in Adults&#160;and Adolescents&#160;With HIV&#160;</i></p>
<p style="position:absolute;top:1114px;left:782px;white-space:nowrap" class="ft024"><i>G-23&#160;</i></p>
<p style="position:absolute;top:109px;left:108px;white-space:nowrap" class="ft013">45.&#160;</p>
<p style="position:absolute;top:109px;left:162px;white-space:nowrap" class="ft032">Bordon&#160;JM,&#160;Fernandez-Botran R, Wiemken TL, et&#160;al. Bacteremic pneumococcal&#160;pneumonia:&#160;<br/>clinical&#160;outcomes and preliminary results of inflammatory response.&#160;</p>
<p style="position:absolute;top:129px;left:636px;white-space:nowrap" class="ft019"><i>Infection</i></p>
<p style="position:absolute;top:129px;left:698px;white-space:nowrap" class="ft013">.&#160;</p>
<p style="position:absolute;top:148px;left:162px;white-space:nowrap" class="ft013">2015;43(6):729-738.&#160;Available&#160;at:&#160;</p>
<p style="position:absolute;top:148px;left:402px;white-space:nowrap" class="ft0115">https://www.ncbi.nlm.nih.gov/pubmed/26424683</p>
<p style="position:absolute;top:148px;left:744px;white-space:nowrap" class="ft013">.&#160;</p>
<p style="position:absolute;top:185px;left:108px;white-space:nowrap" class="ft013">46.&#160;</p>
<p style="position:absolute;top:185px;left:162px;white-space:nowrap" class="ft032">Centers for&#160;Disease Control&#160;and Prevention. Use of&#160;13-valent&#160;pneumococcal conjugate&#160;<br/>vaccine and 23-valent&#160;pneumococcal&#160;polysaccharide vaccine for adults with&#160;<br/>immunocompromising conditions: recommendations of the&#160;Advisory Committee on&#160;<br/>Immunization Practices (ACIP).&#160;</p>
<p style="position:absolute;top:245px;left:389px;white-space:nowrap" class="ft019"><i>MMWR Morb&#160;Mortal Wkly&#160;Rep</i></p>
<p style="position:absolute;top:245px;left:607px;white-space:nowrap" class="ft013">. 2012;61(40):816-819.&#160;</p>
<p style="position:absolute;top:265px;left:162px;white-space:nowrap" class="ft013">Available at:&#160;</p>
<p style="position:absolute;top:265px;left:255px;white-space:nowrap" class="ft0115">https://www.ncbi.nlm.nih.gov/pubmed/23051612</p>
<p style="position:absolute;top:265px;left:596px;white-space:nowrap" class="ft013">.&#160;</p>
<p style="position:absolute;top:302px;left:108px;white-space:nowrap" class="ft013">47.&#160;</p>
<p style="position:absolute;top:302px;left:162px;white-space:nowrap" class="ft032">Feikin DR,&#160;Jagero G,&#160;Aura B, et&#160;al. High rate of pneumococcal&#160;bacteremia in a prospective&#160;<br/>cohort&#160;of older children and adults in&#160;an area of high HIV prevalence in rural western Kenya.&#160;</p>
<p style="position:absolute;top:342px;left:162px;white-space:nowrap" class="ft019"><i>BMC Infect&#160;Dis</i></p>
<p style="position:absolute;top:342px;left:270px;white-space:nowrap" class="ft013">. 2010;10:186. Available&#160;at:&#160;</p>
<p style="position:absolute;top:361px;left:162px;white-space:nowrap" class="ft0115">https://www.ncbi.nlm.nih.gov/pubmed/20573224</p>
<p style="position:absolute;top:361px;left:503px;white-space:nowrap" class="ft013">.&#160;</p>
<p style="position:absolute;top:399px;left:108px;white-space:nowrap" class="ft013">48.&#160;</p>
<p style="position:absolute;top:399px;left:162px;white-space:nowrap" class="ft013">Heffernan&#160;RT, Barrett NL, Gallagher&#160;KM, et&#160;al.&#160;Declining incidence of invasive&#160;</p>
<p style="position:absolute;top:418px;left:162px;white-space:nowrap" class="ft019"><i>Streptococcus pneumoniae</i></p>
<p style="position:absolute;top:418px;left:347px;white-space:nowrap" class="ft013">&#160;infections among persons with AIDS&#160;in an era of highly active&#160;</p>
<p style="position:absolute;top:438px;left:162px;white-space:nowrap" class="ft013">antiretroviral&#160;therapy, 1995-2000.&#160;</p>
<p style="position:absolute;top:438px;left:400px;white-space:nowrap" class="ft019"><i>J Infect Dis</i></p>
<p style="position:absolute;top:438px;left:479px;white-space:nowrap" class="ft013">. 2005;191(12):2038-2045.&#160;Available&#160;at:&#160;</p>
<p style="position:absolute;top:458px;left:162px;white-space:nowrap" class="ft0115">https://www.ncbi.nlm.nih.gov/pubmed/15897989</p>
<p style="position:absolute;top:458px;left:503px;white-space:nowrap" class="ft013">.&#160;</p>
<p style="position:absolute;top:495px;left:108px;white-space:nowrap" class="ft013">49.&#160;</p>
<p style="position:absolute;top:495px;left:162px;white-space:nowrap" class="ft032">Grau I,&#160;Pallares R, Tubau&#160;F, et al. Epidemiologic changes in bacteremic&#160;pneumococcal&#160;<br/>disease in patients with human immunodeficiency virus in the&#160;era of highly&#160;active&#160;<br/>antiretroviral&#160;therapy.&#160;</p>
<p style="position:absolute;top:535px;left:317px;white-space:nowrap" class="ft019"><i>Arch Intern Med</i></p>
<p style="position:absolute;top:535px;left:431px;white-space:nowrap" class="ft013">. 2005;165(13):1533-1540. Available at:&#160;</p>
<p style="position:absolute;top:555px;left:162px;white-space:nowrap" class="ft0115">https://www.ncbi.nlm.nih.gov/pubmed/16009870</p>
<p style="position:absolute;top:555px;left:503px;white-space:nowrap" class="ft013">.&#160;</p>
<p style="position:absolute;top:592px;left:108px;white-space:nowrap" class="ft013">50.&#160;</p>
<p style="position:absolute;top:592px;left:162px;white-space:nowrap" class="ft032">Flannery B,&#160;Heffernan&#160;RT, Harrison&#160;LH, et&#160;al. Changes in invasive pneumococcal disease&#160;<br/>among HIV-infected adults living in the era of childhood pneumococcal&#160;immunization.&#160;</p>
<p style="position:absolute;top:612px;left:768px;white-space:nowrap" class="ft019"><i>Ann&#160;</i></p>
<p style="position:absolute;top:631px;left:162px;white-space:nowrap" class="ft019"><i>Intern Med</i></p>
<p style="position:absolute;top:631px;left:239px;white-space:nowrap" class="ft013">.&#160;2006;144(1):1-9. Available at:&#160;</p>
<p style="position:absolute;top:631px;left:462px;white-space:nowrap" class="ft0115">https://www.ncbi.nlm.nih.gov/pubmed/16389249</p>
<p style="position:absolute;top:631px;left:803px;white-space:nowrap" class="ft013">.&#160;</p>
<p style="position:absolute;top:668px;left:108px;white-space:nowrap" class="ft013">51.&#160;</p>
<p style="position:absolute;top:668px;left:162px;white-space:nowrap" class="ft032">Cohen AL,&#160;Harrison LH,&#160;Farley MM,&#160;et&#160;al. Prevention of invasive pneumococcal disease&#160;<br/>among HIV-infected adults in the era&#160;of childhood&#160;pneumococcal&#160;immunization.&#160;</p>
<p style="position:absolute;top:688px;left:723px;white-space:nowrap" class="ft019"><i>AIDS</i></p>
<p style="position:absolute;top:688px;left:761px;white-space:nowrap" class="ft013">.&#160;</p>
<p style="position:absolute;top:708px;left:162px;white-space:nowrap" class="ft013">2010;24(14):2253-2262.&#160;Available at:&#160;</p>
<p style="position:absolute;top:708px;left:428px;white-space:nowrap" class="ft0115">https://www.ncbi.nlm.nih.gov/pubmed/20671543</p>
<p style="position:absolute;top:708px;left:770px;white-space:nowrap" class="ft013">.&#160;</p>
<p style="position:absolute;top:745px;left:108px;white-space:nowrap" class="ft013">52.&#160;</p>
<p style="position:absolute;top:745px;left:162px;white-space:nowrap" class="ft032">Burgos&#160;J, Penaranda&#160;M,&#160;Payeras&#160;A, et al. Invasive&#160;pneumococcal&#160;disease in HIV-infected&#160;<br/>adults: clinical&#160;changes after the&#160;introduction of the pneumococcal&#160;conjugate vaccine in&#160;<br/>children.&#160;</p>
<p style="position:absolute;top:785px;left:227px;white-space:nowrap" class="ft019"><i>J Acquir Immune Defic Syndr</i></p>
<p style="position:absolute;top:785px;left:432px;white-space:nowrap" class="ft013">. 2012;59(1):31-38. Available&#160;at:&#160;</p>
<p style="position:absolute;top:805px;left:162px;white-space:nowrap" class="ft0115">https://www.ncbi.nlm.nih.gov/pubmed/22156821</p>
<p style="position:absolute;top:805px;left:503px;white-space:nowrap" class="ft013">.&#160;</p>
<p style="position:absolute;top:842px;left:108px;white-space:nowrap" class="ft013">53.&#160;</p>
<p style="position:absolute;top:842px;left:162px;white-space:nowrap" class="ft032">Garcia&#160;Garrido HM, Mak&#160;AMR, Wit F, et&#160;al. Incidence&#160;and risk factors for invasive&#160;<br/>pneumococcal disease and community-acquired pneumonia&#160;in human immunodeficiency&#160;<br/>virus-infected individuals in a&#160;high-income setting.&#160;</p>
<p style="position:absolute;top:881px;left:519px;white-space:nowrap" class="ft019"><i>Clin Infect&#160;Dis</i></p>
<p style="position:absolute;top:881px;left:620px;white-space:nowrap" class="ft013">. 2020;71(1):41-50.&#160;</p>
<p style="position:absolute;top:901px;left:162px;white-space:nowrap" class="ft013">Available at:&#160;</p>
<p style="position:absolute;top:901px;left:255px;white-space:nowrap" class="ft0115">https://www.ncbi.nlm.nih.gov/pubmed/31634398</p>
<p style="position:absolute;top:901px;left:596px;white-space:nowrap" class="ft013">.&#160;</p>
<p style="position:absolute;top:938px;left:108px;white-space:nowrap" class="ft013">54.&#160;</p>
<p style="position:absolute;top:938px;left:162px;white-space:nowrap" class="ft013">Osmond&#160;DH,&#160;Chin DP, Glassroth&#160;J, et al. Impact of bacterial pneumonia&#160;and&#160;</p>
<p style="position:absolute;top:938px;left:695px;white-space:nowrap" class="ft019"><i>Pneumocystis&#160;</i></p>
<p style="position:absolute;top:958px;left:162px;white-space:nowrap" class="ft019"><i>carinii</i></p>
<p style="position:absolute;top:958px;left:208px;white-space:nowrap" class="ft013">&#160;pneumonia on human immunodeficiency virus disease&#160;progression. Pulmonary&#160;</p>
<p style="position:absolute;top:978px;left:162px;white-space:nowrap" class="ft013">Complications of&#160;HIV Study Group.&#160;</p>
<p style="position:absolute;top:978px;left:418px;white-space:nowrap" class="ft019"><i>Clin Infect&#160;Dis</i></p>
<p style="position:absolute;top:978px;left:519px;white-space:nowrap" class="ft013">. 1999;29(3):536-543.&#160;Available&#160;at:&#160;</p>
<p style="position:absolute;top:998px;left:162px;white-space:nowrap" class="ft0115">https://www.ncbi.nlm.nih.gov/pubmed/10530443</p>
<p style="position:absolute;top:998px;left:503px;white-space:nowrap" class="ft013">.&#160;</p>
</div>
<!-- Page 115 -->
<a name="115"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page115-div" style="position:relative;width:917px;height:1187px;">
<p style="position:absolute;top:1114px;left:108px;white-space:nowrap" class="ft024"><i>Guidelines for the Prevention and Treatment&#160;of&#160;Opportunistic&#160;Infections in Adults&#160;and Adolescents&#160;With HIV&#160;</i></p>
<p style="position:absolute;top:1114px;left:782px;white-space:nowrap" class="ft024"><i>G-24&#160;</i></p>
<p style="position:absolute;top:109px;left:108px;white-space:nowrap" class="ft013">55.&#160;</p>
<p style="position:absolute;top:109px;left:162px;white-space:nowrap" class="ft032">Kohli R, Lo&#160;Y, Homel&#160;P,&#160;et&#160;al. Bacterial&#160;pneumonia, HIV therapy, and disease progression&#160;<br/>among HIV-infected women in the&#160;HIV epidemiologic&#160;research&#160;(HER)&#160;study.&#160;</p>
<p style="position:absolute;top:129px;left:703px;white-space:nowrap" class="ft019"><i>Clin Infect&#160;Dis</i></p>
<p style="position:absolute;top:129px;left:805px;white-space:nowrap" class="ft013">.&#160;</p>
<p style="position:absolute;top:148px;left:162px;white-space:nowrap" class="ft013">2006;43(1):90-98. Available&#160;at:&#160;</p>
<p style="position:absolute;top:148px;left:385px;white-space:nowrap" class="ft0115">https://www.ncbi.nlm.nih.gov/pubmed/16758423</p>
<p style="position:absolute;top:148px;left:726px;white-space:nowrap" class="ft013">.&#160;</p>
<p style="position:absolute;top:185px;left:108px;white-space:nowrap" class="ft013">56.&#160;</p>
<p style="position:absolute;top:185px;left:162px;white-space:nowrap" class="ft032">Malinis M,&#160;Myers&#160;J, Bordon J, et al.&#160;Clinical&#160;outcomes of&#160;HIV-infected patients hospitalized&#160;<br/>with bacterial&#160;community-acquired pneumonia.&#160;</p>
<p style="position:absolute;top:205px;left:494px;white-space:nowrap" class="ft019"><i>Int J&#160;Infect Dis</i></p>
<p style="position:absolute;top:205px;left:597px;white-space:nowrap" class="ft013">.&#160;2010;14(1):e22-27.&#160;</p>
<p style="position:absolute;top:225px;left:162px;white-space:nowrap" class="ft013">Available at:&#160;</p>
<p style="position:absolute;top:225px;left:255px;white-space:nowrap" class="ft0115">https://www.ncbi.nlm.nih.gov/pubmed/19586789</p>
<p style="position:absolute;top:225px;left:596px;white-space:nowrap" class="ft013">.&#160;</p>
<p style="position:absolute;top:262px;left:108px;white-space:nowrap" class="ft013">57.&#160;</p>
<p style="position:absolute;top:262px;left:162px;white-space:nowrap" class="ft013">Sanders&#160;KM,&#160;Marras TK,&#160;Chan CK.&#160;Pneumonia&#160;severity index in the&#160;immunocompromised.&#160;</p>
<p style="position:absolute;top:282px;left:162px;white-space:nowrap" class="ft019"><i>Can Respir J</i></p>
<p style="position:absolute;top:282px;left:252px;white-space:nowrap" class="ft013">. 2006;13(2):89-93.&#160;Available at:&#160;</p>
<p style="position:absolute;top:302px;left:162px;white-space:nowrap" class="ft0115">https://www.ncbi.nlm.nih.gov/pubmed/16550266</p>
<p style="position:absolute;top:302px;left:503px;white-space:nowrap" class="ft013">.&#160;</p>
<p style="position:absolute;top:339px;left:108px;white-space:nowrap" class="ft013">58.&#160;</p>
<p style="position:absolute;top:339px;left:162px;white-space:nowrap" class="ft032">Christensen&#160;D, Feldman&#160;C, Rossi&#160;P, et al. HIV infection does not influence clinical&#160;outcomes&#160;<br/>in hospitalized patients with bacterial&#160;community-acquired pneumonia:&#160;results from the&#160;<br/>CAPO international cohort study.&#160;</p>
<p style="position:absolute;top:379px;left:398px;white-space:nowrap" class="ft019"><i>Clin&#160;Infect&#160;Dis</i></p>
<p style="position:absolute;top:379px;left:499px;white-space:nowrap" class="ft013">. 2005;41(4):554-556.&#160;Available at:&#160;</p>
<p style="position:absolute;top:399px;left:162px;white-space:nowrap" class="ft0115">https://www.ncbi.nlm.nih.gov/pubmed/16028168</p>
<p style="position:absolute;top:399px;left:503px;white-space:nowrap" class="ft013">.&#160;</p>
<p style="position:absolute;top:436px;left:108px;white-space:nowrap" class="ft013">59.&#160;</p>
<p style="position:absolute;top:436px;left:162px;white-space:nowrap" class="ft032">Cordero E,&#160;Pachon J, Rivero A, et al.&#160;Community-acquired bacterial&#160;pneumonia in human&#160;<br/>immunodeficiency virus-infected patients: validation of severity&#160;criteria. The Grupo&#160;Andaluz&#160;<br/>para el&#160;Estudio de las Enfermedades Infecciosas.&#160;</p>
<p style="position:absolute;top:475px;left:503px;white-space:nowrap" class="ft019"><i>Am J Respir&#160;Crit Care Med</i></p>
<p style="position:absolute;top:475px;left:693px;white-space:nowrap" class="ft013">.&#160;</p>
<p style="position:absolute;top:495px;left:162px;white-space:nowrap" class="ft013">2000;162(6):2063-2068.&#160;Available at:&#160;</p>
<p style="position:absolute;top:495px;left:428px;white-space:nowrap" class="ft0115">https://www.ncbi.nlm.nih.gov/pubmed/11112115</p>
<p style="position:absolute;top:495px;left:770px;white-space:nowrap" class="ft013">.&#160;</p>
<p style="position:absolute;top:532px;left:108px;white-space:nowrap" class="ft013">60.&#160;</p>
<p style="position:absolute;top:532px;left:162px;white-space:nowrap" class="ft032">Sogaard&#160;OS,&#160;Lohse N,&#160;Gerstoft J, et&#160;al.&#160;Mortality after hospitalization for pneumonia among&#160;<br/>individuals with HIV, 1995–2008: a&#160;Danish cohort study.&#160;</p>
<p style="position:absolute;top:552px;left:563px;white-space:nowrap" class="ft019"><i>PLoS One</i></p>
<p style="position:absolute;top:552px;left:634px;white-space:nowrap" class="ft013">. 2009;4(9):e7022.&#160;</p>
<p style="position:absolute;top:572px;left:162px;white-space:nowrap" class="ft013">Available at:&#160;</p>
<p style="position:absolute;top:572px;left:255px;white-space:nowrap" class="ft0115">https://www.ncbi.nlm.nih.gov/pubmed/19750011</p>
<p style="position:absolute;top:572px;left:596px;white-space:nowrap" class="ft013">.&#160;</p>
<p style="position:absolute;top:609px;left:108px;white-space:nowrap" class="ft013">61.&#160;</p>
<p style="position:absolute;top:609px;left:162px;white-space:nowrap" class="ft032">Zifodya JS,&#160;Duncan&#160;MS,&#160;So-Armah KA, et al. Community-acquired pneumonia&#160;and risk&#160;of&#160;<br/>cardiovascular events in&#160;people living with HIV.&#160;</p>
<p style="position:absolute;top:629px;left:502px;white-space:nowrap" class="ft019"><i>J&#160;Am Heart Assoc</i></p>
<p style="position:absolute;top:629px;left:626px;white-space:nowrap" class="ft013">. 2020;9(23):e017645.&#160;</p>
<p style="position:absolute;top:649px;left:162px;white-space:nowrap" class="ft013">Available at:&#160;</p>
<p style="position:absolute;top:649px;left:255px;white-space:nowrap" class="ft0115">https://www.ncbi.nlm.nih.gov/pubmed/33222591</p>
<p style="position:absolute;top:649px;left:596px;white-space:nowrap" class="ft013">.&#160;</p>
<p style="position:absolute;top:686px;left:108px;white-space:nowrap" class="ft013">62.&#160;</p>
<p style="position:absolute;top:686px;left:162px;white-space:nowrap" class="ft032">Marcus&#160;JL,&#160;Leyden WA,&#160;Chao CR, et&#160;al. Immunodeficiency, AIDS-related pneumonia, and&#160;<br/>risk of lung cancer among&#160;HIV-infected individuals.&#160;</p>
<p style="position:absolute;top:706px;left:528px;white-space:nowrap" class="ft019"><i>AIDS</i></p>
<p style="position:absolute;top:706px;left:565px;white-space:nowrap" class="ft013">. 2017;31(7):989-993. Available&#160;</p>
<p style="position:absolute;top:725px;left:162px;white-space:nowrap" class="ft013">at:&#160;</p>
<p style="position:absolute;top:725px;left:184px;white-space:nowrap" class="ft0115">https://www.ncbi.nlm.nih.gov/pubmed/28252529</p>
<p style="position:absolute;top:725px;left:525px;white-space:nowrap" class="ft013">.&#160;</p>
<p style="position:absolute;top:762px;left:108px;white-space:nowrap" class="ft013">63.&#160;</p>
<p style="position:absolute;top:762px;left:162px;white-space:nowrap" class="ft032">Sigel&#160;K, Wisnivesky J,&#160;Crothers K, et&#160;al. Immunological&#160;and infectious risk factors for lung&#160;<br/>cancer in US&#160;veterans with HIV: a longitudinal cohort study.&#160;</p>
<p style="position:absolute;top:782px;left:586px;white-space:nowrap" class="ft019"><i>Lancet&#160;HIV</i></p>
<p style="position:absolute;top:782px;left:665px;white-space:nowrap" class="ft013">. 2017;4(2):e67-e73.&#160;</p>
<p style="position:absolute;top:802px;left:162px;white-space:nowrap" class="ft013">Available at:&#160;</p>
<p style="position:absolute;top:802px;left:255px;white-space:nowrap" class="ft0115">https://www.ncbi.nlm.nih.gov/pubmed/27916584</p>
<p style="position:absolute;top:802px;left:596px;white-space:nowrap" class="ft013">.&#160;</p>
<p style="position:absolute;top:839px;left:108px;white-space:nowrap" class="ft013">64.&#160;</p>
<p style="position:absolute;top:839px;left:162px;white-space:nowrap" class="ft032">Morris&#160;AM,&#160;Huang L, Bacchetti&#160;P, et al. Permanent&#160;declines in pulmonary function following&#160;<br/>pneumonia&#160;in human immunodeficiency virus-infected persons. The Pulmonary&#160;<br/>Complications of&#160;HIV Infection Study Group.&#160;</p>
<p style="position:absolute;top:879px;left:484px;white-space:nowrap" class="ft019"><i>Am&#160;J Respir Crit Care Med</i></p>
<p style="position:absolute;top:879px;left:674px;white-space:nowrap" class="ft013">.&#160;</p>
<p style="position:absolute;top:899px;left:162px;white-space:nowrap" class="ft013">2000;162(2&#160;Pt 1):612-616. Available at:&#160;</p>
<p style="position:absolute;top:899px;left:443px;white-space:nowrap" class="ft0115">https://www.ncbi.nlm.nih.gov/pubmed/10934095</p>
<p style="position:absolute;top:899px;left:784px;white-space:nowrap" class="ft013">.&#160;</p>
<p style="position:absolute;top:936px;left:108px;white-space:nowrap" class="ft013">65.&#160;</p>
<p style="position:absolute;top:936px;left:162px;white-space:nowrap" class="ft032">Evans SE,&#160;Jennerich AL,&#160;Azar MM, et&#160;al. Nucleic acid-based testing for noninfluenza viral&#160;<br/>pathogens in&#160;adults with suspected community-acquired pneumonia. An official American&#160;<br/>Thoracic&#160;Society clinical&#160;practice&#160;guideline.&#160;</p>
<p style="position:absolute;top:976px;left:470px;white-space:nowrap" class="ft019"><i>Am J Respir Crit Care Med</i></p>
<p style="position:absolute;top:976px;left:660px;white-space:nowrap" class="ft013">. 2021;203(9):1070-</p>
<p style="position:absolute;top:995px;left:162px;white-space:nowrap" class="ft013">1087. Available&#160;at:&#160;</p>
<p style="position:absolute;top:995px;left:298px;white-space:nowrap" class="ft0115">https://www.ncbi.nlm.nih.gov/pubmed/33929301</p>
<p style="position:absolute;top:995px;left:639px;white-space:nowrap" class="ft013">.&#160;</p>
</div>
<!-- Page 116 -->
<a name="116"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page116-div" style="position:relative;width:917px;height:1187px;">
<p style="position:absolute;top:1114px;left:108px;white-space:nowrap" class="ft024"><i>Guidelines for the Prevention and Treatment&#160;of&#160;Opportunistic&#160;Infections in Adults&#160;and Adolescents&#160;With HIV&#160;</i></p>
<p style="position:absolute;top:1114px;left:782px;white-space:nowrap" class="ft024"><i>G-25&#160;</i></p>
<p style="position:absolute;top:109px;left:108px;white-space:nowrap" class="ft013">66.&#160;</p>
<p style="position:absolute;top:109px;left:162px;white-space:nowrap" class="ft032">Nyamande&#160;K, Lalloo UG.&#160;Serum procalcitonin distinguishes CAP due to bacteria,&#160;<br/>Mycobacterium tuberculosis and PJP.&#160;</p>
<p style="position:absolute;top:129px;left:427px;white-space:nowrap" class="ft019"><i>Int J&#160;Tuberc&#160;Lung&#160;Dis</i></p>
<p style="position:absolute;top:129px;left:579px;white-space:nowrap" class="ft013">. 2006;10(5):510-515. Available&#160;</p>
<p style="position:absolute;top:148px;left:162px;white-space:nowrap" class="ft013">at:&#160;</p>
<p style="position:absolute;top:148px;left:184px;white-space:nowrap" class="ft0115">https://www.ncbi.nlm.nih.gov/pubmed/16704032</p>
<p style="position:absolute;top:148px;left:525px;white-space:nowrap" class="ft013">.&#160;</p>
<p style="position:absolute;top:185px;left:108px;white-space:nowrap" class="ft013">67.&#160;</p>
<p style="position:absolute;top:185px;left:162px;white-space:nowrap" class="ft032">Metlay JP,&#160;Waterer GW, Long AC, et al. Diagnosis and treatment of adults&#160;with community-<br/>acquired pneumonia. An&#160;official&#160;clinical practice&#160;guideline of the American&#160;Thoracic&#160;Society&#160;<br/>and Infectious Diseases Society of America.&#160;</p>
<p style="position:absolute;top:225px;left:472px;white-space:nowrap" class="ft019"><i>Am J Respir Crit&#160;Care Med</i></p>
<p style="position:absolute;top:225px;left:662px;white-space:nowrap" class="ft013">. 2019;200(7):e45-</p>
<p style="position:absolute;top:245px;left:162px;white-space:nowrap" class="ft013">e67. Available&#160;at:&#160;</p>
<p style="position:absolute;top:245px;left:288px;white-space:nowrap" class="ft0115">https://www.ncbi.nlm.nih.gov/pubmed/31573350</p>
<p style="position:absolute;top:245px;left:630px;white-space:nowrap" class="ft013">.&#160;</p>
<p style="position:absolute;top:282px;left:108px;white-space:nowrap" class="ft013">68.&#160;</p>
<p style="position:absolute;top:282px;left:162px;white-space:nowrap" class="ft032">Parente DM,&#160;Cunha CB,&#160;Mylonakis E, Timbrook&#160;TT. The&#160;clinical&#160;utility of&#160;methicillin-<br/>resistant&#160;</p>
<p style="position:absolute;top:302px;left:224px;white-space:nowrap" class="ft019"><i>Staphylococcus&#160;aureus</i></p>
<p style="position:absolute;top:302px;left:382px;white-space:nowrap" class="ft013">&#160;(MRSA) nasal screening to rule out&#160;MRSA pneumonia:&#160;a&#160;</p>
<p style="position:absolute;top:322px;left:162px;white-space:nowrap" class="ft013">diagnostic&#160;meta-analysis with antimicrobial&#160;stewardship implications.&#160;</p>
<p style="position:absolute;top:322px;left:648px;white-space:nowrap" class="ft019"><i>Clin Infect&#160;Dis</i></p>
<p style="position:absolute;top:322px;left:749px;white-space:nowrap" class="ft013">.&#160;</p>
<p style="position:absolute;top:342px;left:162px;white-space:nowrap" class="ft013">2018;67(1):1-7. Available at:&#160;</p>
<p style="position:absolute;top:342px;left:368px;white-space:nowrap" class="ft0115">https://www.ncbi.nlm.nih.gov/pubmed/29340593</p>
<p style="position:absolute;top:342px;left:709px;white-space:nowrap" class="ft013">.&#160;</p>
<p style="position:absolute;top:379px;left:108px;white-space:nowrap" class="ft013">69.&#160;</p>
<p style="position:absolute;top:379px;left:162px;white-space:nowrap" class="ft032">Cordero E,&#160;Pachon J, Rivero A, et al.&#160;Usefulness&#160;of sputum culture for diagnosis of bacterial&#160;<br/>pneumonia&#160;in HIV-infected patients.&#160;</p>
<p style="position:absolute;top:399px;left:419px;white-space:nowrap" class="ft019"><i>Eur J Clin Microbiol Infect&#160;Dis</i></p>
<p style="position:absolute;top:399px;left:636px;white-space:nowrap" class="ft013">. 2002;21(5):362-367.&#160;</p>
<p style="position:absolute;top:418px;left:162px;white-space:nowrap" class="ft013">Available at:&#160;</p>
<p style="position:absolute;top:418px;left:255px;white-space:nowrap" class="ft0115">https://www.ncbi.nlm.nih.gov/pubmed/12072920</p>
<p style="position:absolute;top:418px;left:596px;white-space:nowrap" class="ft013">.&#160;</p>
<p style="position:absolute;top:455px;left:108px;white-space:nowrap" class="ft013">70.&#160;</p>
<p style="position:absolute;top:455px;left:162px;white-space:nowrap" class="ft032">Jordano&#160;Q, Falco V, Almirante B, et&#160;al. Invasive&#160;pneumococcal&#160;disease in patients infected&#160;<br/>with HIV: still a&#160;threat&#160;in the era of highly active&#160;antiretroviral therapy.&#160;</p>
<p style="position:absolute;top:475px;left:658px;white-space:nowrap" class="ft019"><i>Clin Infect&#160;Dis</i></p>
<p style="position:absolute;top:475px;left:759px;white-space:nowrap" class="ft013">.&#160;</p>
<p style="position:absolute;top:495px;left:162px;white-space:nowrap" class="ft013">2004;38(11):1623-1628.&#160;Available at:&#160;</p>
<p style="position:absolute;top:495px;left:428px;white-space:nowrap" class="ft0115">https://www.ncbi.nlm.nih.gov/pubmed/15156452</p>
<p style="position:absolute;top:495px;left:770px;white-space:nowrap" class="ft013">.&#160;</p>
<p style="position:absolute;top:532px;left:108px;white-space:nowrap" class="ft013">71.&#160;</p>
<p style="position:absolute;top:532px;left:162px;white-space:nowrap" class="ft032">Hamel&#160;MJ,&#160;Greene C, Chiller T, et al. Does cotrimoxazole prophylaxis for&#160;the&#160;prevention of&#160;<br/>HIV-associated opportunistic infections select for resistant pathogens in&#160;Kenyan adults?&#160;</p>
<p style="position:absolute;top:552px;left:774px;white-space:nowrap" class="ft019"><i>Am J&#160;</i></p>
<p style="position:absolute;top:572px;left:162px;white-space:nowrap" class="ft019"><i>Trop&#160;Med Hyg</i></p>
<p style="position:absolute;top:572px;left:264px;white-space:nowrap" class="ft013">. 2008;79(3):320-330.&#160;Available at:&#160;</p>
<p style="position:absolute;top:592px;left:162px;white-space:nowrap" class="ft0115">https://www.ncbi.nlm.nih.gov/pubmed/18784222</p>
<p style="position:absolute;top:592px;left:503px;white-space:nowrap" class="ft013">.&#160;</p>
<p style="position:absolute;top:629px;left:108px;white-space:nowrap" class="ft013">72.&#160;</p>
<p style="position:absolute;top:629px;left:162px;white-space:nowrap" class="ft032">Hung CC, Chen MY, Hsieh SM,&#160;Hsiao CF, Sheng&#160;WH, Chang&#160;SC. Clinical&#160;experience of the&#160;<br/>23-valent&#160;capsular polysaccharide pneumococcal&#160;vaccination in HIV-1-infected patients&#160;<br/>receiving highly active&#160;antiretroviral therapy:&#160;a prospective&#160;observational study.&#160;</p>
<p style="position:absolute;top:668px;left:718px;white-space:nowrap" class="ft019"><i>Vaccine</i></p>
<p style="position:absolute;top:668px;left:774px;white-space:nowrap" class="ft013">.&#160;</p>
<p style="position:absolute;top:688px;left:162px;white-space:nowrap" class="ft013">2004;22(15-16):2006-2012. Available at:&#160;</p>
<p style="position:absolute;top:688px;left:451px;white-space:nowrap" class="ft0115">https://www.ncbi.nlm.nih.gov/pubmed/15121313</p>
<p style="position:absolute;top:688px;left:793px;white-space:nowrap" class="ft013">.&#160;</p>
<p style="position:absolute;top:725px;left:108px;white-space:nowrap" class="ft013">73.&#160;</p>
<p style="position:absolute;top:725px;left:162px;white-space:nowrap" class="ft032">Guerrero&#160;M,&#160;Kruger&#160;S, Saitoh A, et al. Pneumonia in HIV-infected patients: a case-control&#160;<br/>survey of&#160;factors involved&#160;in risk and prevention.&#160;</p>
<p style="position:absolute;top:745px;left:506px;white-space:nowrap" class="ft019"><i>AIDS</i></p>
<p style="position:absolute;top:745px;left:544px;white-space:nowrap" class="ft013">. 1999;13(14):1971-1975. Available&#160;</p>
<p style="position:absolute;top:765px;left:162px;white-space:nowrap" class="ft013">at:&#160;</p>
<p style="position:absolute;top:765px;left:184px;white-space:nowrap" class="ft0115">https://www.ncbi.nlm.nih.gov/pubmed/10513657</p>
<p style="position:absolute;top:765px;left:525px;white-space:nowrap" class="ft013">.&#160;</p>
<p style="position:absolute;top:802px;left:108px;white-space:nowrap" class="ft013">74.&#160;</p>
<p style="position:absolute;top:802px;left:162px;white-space:nowrap" class="ft032">Rodriguez-Barradas MC,&#160;Goulet&#160;J, Brown S, et&#160;al. Impact&#160;of pneumococcal vaccination on&#160;<br/>the&#160;incidence of pneumonia by HIV infection status among patients enrolled in the Veterans&#160;<br/>Aging Cohort 5-Site&#160;Study.&#160;</p>
<p style="position:absolute;top:842px;left:356px;white-space:nowrap" class="ft019"><i>Clin Infect&#160;Dis</i></p>
<p style="position:absolute;top:842px;left:457px;white-space:nowrap" class="ft013">. 2008;46(7):1093-1100. Available at:&#160;</p>
<p style="position:absolute;top:862px;left:162px;white-space:nowrap" class="ft0115">https://www.ncbi.nlm.nih.gov/pubmed/18444830</p>
<p style="position:absolute;top:862px;left:503px;white-space:nowrap" class="ft013">.&#160;</p>
<p style="position:absolute;top:899px;left:108px;white-space:nowrap" class="ft013">75.&#160;</p>
<p style="position:absolute;top:899px;left:162px;white-space:nowrap" class="ft032">Teshale EH,&#160;Hanson&#160;D,&#160;Flannery B, et&#160;al. Effectiveness of&#160;23-valent polysaccharide&#160;<br/>pneumococcal&#160;vaccine&#160;on pneumonia&#160;in HIV-infected adults in the United States, 1998–<br/>2003.&#160;</p>
<p style="position:absolute;top:938px;left:205px;white-space:nowrap" class="ft019"><i>Vaccine</i></p>
<p style="position:absolute;top:938px;left:261px;white-space:nowrap" class="ft013">. 2008;26(46):5830-5834. Available at:&#160;</p>
<p style="position:absolute;top:958px;left:162px;white-space:nowrap" class="ft0115">https://www.ncbi.nlm.nih.gov/pubmed/18786586</p>
<p style="position:absolute;top:958px;left:503px;white-space:nowrap" class="ft013">.&#160;</p>
<p style="position:absolute;top:995px;left:108px;white-space:nowrap" class="ft013">76.&#160;</p>
<p style="position:absolute;top:995px;left:162px;white-space:nowrap" class="ft032">Barry PM, Zetola&#160;N, Keruly JC,&#160;Moore RD,&#160;Gebo&#160;KA, Lucas GM. Invasive&#160;pneumococcal&#160;<br/>disease in a cohort of&#160;HIV-infected adults: incidence and risk factors, 1990–2003.&#160;</p>
<p style="position:absolute;top:1015px;left:731px;white-space:nowrap" class="ft019"><i>AIDS</i></p>
<p style="position:absolute;top:1015px;left:768px;white-space:nowrap" class="ft013">.&#160;</p>
<p style="position:absolute;top:1035px;left:162px;white-space:nowrap" class="ft013">2006;20(3):437-444.&#160;Available&#160;at:&#160;</p>
<p style="position:absolute;top:1035px;left:402px;white-space:nowrap" class="ft0115">https://www.ncbi.nlm.nih.gov/pubmed/16439878</p>
<p style="position:absolute;top:1035px;left:744px;white-space:nowrap" class="ft013">.&#160;</p>
</div>
<!-- Page 117 -->
<a name="117"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page117-div" style="position:relative;width:917px;height:1187px;">
<p style="position:absolute;top:1114px;left:108px;white-space:nowrap" class="ft024"><i>Guidelines for the Prevention and Treatment&#160;of&#160;Opportunistic&#160;Infections in Adults&#160;and Adolescents&#160;With HIV&#160;</i></p>
<p style="position:absolute;top:1114px;left:782px;white-space:nowrap" class="ft024"><i>G-26&#160;</i></p>
<p style="position:absolute;top:109px;left:108px;white-space:nowrap" class="ft013">77.&#160;</p>
<p style="position:absolute;top:109px;left:162px;white-space:nowrap" class="ft032">Veras&#160;MA, Enanoria&#160;WT,&#160;Castilho EA,&#160;Reingold AL. Effectiveness of the polysaccharide&#160;<br/>pneumococcal&#160;vaccine&#160;among HIV-infected persons in Brazil: a&#160;case control&#160;study.&#160;</p>
<p style="position:absolute;top:129px;left:741px;white-space:nowrap" class="ft019"><i>BMC&#160;</i></p>
<p style="position:absolute;top:148px;left:162px;white-space:nowrap" class="ft019"><i>Infect&#160;Dis</i></p>
<p style="position:absolute;top:148px;left:229px;white-space:nowrap" class="ft013">. 2007;7:119. Available at:&#160;</p>
<p style="position:absolute;top:148px;left:418px;white-space:nowrap" class="ft0115">https://www.ncbi.nlm.nih.gov/pubmed/17956620</p>
<p style="position:absolute;top:148px;left:760px;white-space:nowrap" class="ft013">.&#160;</p>
<p style="position:absolute;top:185px;left:108px;white-space:nowrap" class="ft013">78.&#160;</p>
<p style="position:absolute;top:185px;left:162px;white-space:nowrap" class="ft032">Marcus&#160;JL,&#160;Baxter R, Leyden WA, et&#160;al. Invasive&#160;pneumococcal disease among HIV-infected&#160;<br/>and HIV-uninfected adults in a&#160;large&#160;integrated healthcare&#160;system.&#160;</p>
<p style="position:absolute;top:205px;left:623px;white-space:nowrap" class="ft019"><i>AIDS Patient&#160;Care STDS</i></p>
<p style="position:absolute;top:205px;left:797px;white-space:nowrap" class="ft013">.&#160;</p>
<p style="position:absolute;top:225px;left:162px;white-space:nowrap" class="ft013">2016;30(10):463-470.&#160;Available&#160;at:&#160;</p>
<p style="position:absolute;top:225px;left:411px;white-space:nowrap" class="ft0115">https://www.ncbi.nlm.nih.gov/pubmed/27749111</p>
<p style="position:absolute;top:225px;left:752px;white-space:nowrap" class="ft013">.&#160;</p>
<p style="position:absolute;top:262px;left:108px;white-space:nowrap" class="ft013">79.&#160;</p>
<p style="position:absolute;top:262px;left:162px;white-space:nowrap" class="ft032">French N, Nakiyingi&#160;J, Carpenter LM,&#160;et&#160;al. 23-valent pneumococcal&#160;polysaccharide&#160;vaccine&#160;<br/>in HIV-1-infected Ugandan adults: double-blind, randomised and placebo controlled trial.&#160;</p>
<p style="position:absolute;top:302px;left:162px;white-space:nowrap" class="ft019"><i>Lancet</i></p>
<p style="position:absolute;top:302px;left:209px;white-space:nowrap" class="ft013">. 2000;355(9221):2106-2111.&#160;Available&#160;at:&#160;</p>
<p style="position:absolute;top:322px;left:162px;white-space:nowrap" class="ft0115">https://www.ncbi.nlm.nih.gov/pubmed/10902624</p>
<p style="position:absolute;top:322px;left:503px;white-space:nowrap" class="ft013">.&#160;</p>
<p style="position:absolute;top:359px;left:108px;white-space:nowrap" class="ft013">80.&#160;</p>
<p style="position:absolute;top:359px;left:162px;white-space:nowrap" class="ft032">Watera C, Nakiyingi&#160;J, Miiro G, et al. 23-valent pneumococcal&#160;polysaccharide vaccine&#160;in&#160;<br/>HIV-infected Ugandan adults: 6-year follow-up of&#160;a clinical trial cohort.&#160;</p>
<p style="position:absolute;top:379px;left:666px;white-space:nowrap" class="ft019"><i>AIDS</i></p>
<p style="position:absolute;top:379px;left:703px;white-space:nowrap" class="ft013">.&#160;</p>
<p style="position:absolute;top:399px;left:162px;white-space:nowrap" class="ft013">2004;18(8):1210-1213.&#160;Available at:&#160;</p>
<p style="position:absolute;top:399px;left:420px;white-space:nowrap" class="ft0115">https://www.ncbi.nlm.nih.gov/pubmed/15166540</p>
<p style="position:absolute;top:399px;left:761px;white-space:nowrap" class="ft013">.&#160;</p>
<p style="position:absolute;top:436px;left:108px;white-space:nowrap" class="ft013">81.&#160;</p>
<p style="position:absolute;top:436px;left:162px;white-space:nowrap" class="ft032">Kobayashi M, Matanock A,&#160;Xing W, et&#160;al. Impact&#160;of 13-valent pneumococcal&#160;conjugate&#160;<br/>vaccine on invasive&#160;pneumococcal&#160;disease among&#160;adults with&#160;HIV—United States, 2008–<br/>2018.&#160;</p>
<p style="position:absolute;top:475px;left:205px;white-space:nowrap" class="ft019"><i>J Acquir Immune&#160;Defic&#160;Syndr</i></p>
<p style="position:absolute;top:475px;left:410px;white-space:nowrap" class="ft013">. 2022;90(1):6-14. Available at:&#160;</p>
<p style="position:absolute;top:495px;left:162px;white-space:nowrap" class="ft0115">https://www.ncbi.nlm.nih.gov/pubmed/35384920</p>
<p style="position:absolute;top:495px;left:503px;white-space:nowrap" class="ft013">.&#160;</p>
<p style="position:absolute;top:532px;left:108px;white-space:nowrap" class="ft013">82.&#160;</p>
<p style="position:absolute;top:532px;left:162px;white-space:nowrap" class="ft032">Kobayashi M, Farrar JL,&#160;Gierke R, et&#160;al. Use of&#160;15-valent&#160;pneumococcal conjugate vaccine&#160;<br/>and 20-valent pneumococcal&#160;conjugate vaccine&#160;among U.S. adults: updated&#160;<br/>recommendations of the&#160;Advisory Committee on Immunization Practices—United States,&#160;<br/>2022.&#160;</p>
<p style="position:absolute;top:592px;left:205px;white-space:nowrap" class="ft019"><i>MMWR Morb&#160;Mortal Wkly Rep</i></p>
<p style="position:absolute;top:592px;left:423px;white-space:nowrap" class="ft013">. 2022;71(4):109-117.&#160;Available&#160;at:&#160;</p>
<p style="position:absolute;top:612px;left:162px;white-space:nowrap" class="ft0115">https://www.ncbi.nlm.nih.gov/pubmed/35085226</p>
<p style="position:absolute;top:612px;left:503px;white-space:nowrap" class="ft013">.&#160;</p>
<p style="position:absolute;top:649px;left:108px;white-space:nowrap" class="ft013">83.&#160;</p>
<p style="position:absolute;top:649px;left:162px;white-space:nowrap" class="ft032">Mohapi L, Pinedo Y,&#160;Osiyemi O, et&#160;al. Safety and immunogenicity of V114,&#160;a 15-valent&#160;<br/>pneumococcal&#160;conjugate&#160;vaccine, in adults living with HIV.&#160;</p>
<p style="position:absolute;top:668px;left:580px;white-space:nowrap" class="ft019"><i>AIDS</i></p>
<p style="position:absolute;top:668px;left:618px;white-space:nowrap" class="ft013">. 2022;36(3):373-382.&#160;</p>
<p style="position:absolute;top:688px;left:162px;white-space:nowrap" class="ft013">Available at:&#160;</p>
<p style="position:absolute;top:688px;left:255px;white-space:nowrap" class="ft0115">https://www.ncbi.nlm.nih.gov/pubmed/34750291</p>
<p style="position:absolute;top:688px;left:596px;white-space:nowrap" class="ft013">.&#160;</p>
<p style="position:absolute;top:725px;left:108px;white-space:nowrap" class="ft013">84.&#160;</p>
<p style="position:absolute;top:725px;left:162px;white-space:nowrap" class="ft032">French N, Gordon SB, Mwalukomo T,&#160;et&#160;al. A trial of a&#160;7-valent&#160;pneumococcal&#160;conjugate&#160;<br/>vaccine in HIV-infected adults.&#160;</p>
<p style="position:absolute;top:745px;left:383px;white-space:nowrap" class="ft019"><i>N Engl&#160;J Med</i></p>
<p style="position:absolute;top:745px;left:478px;white-space:nowrap" class="ft013">. 2010;362(9):812-822. Available&#160;at:&#160;</p>
<p style="position:absolute;top:765px;left:162px;white-space:nowrap" class="ft0115">https://www.ncbi.nlm.nih.gov/pubmed/20200385</p>
<p style="position:absolute;top:765px;left:503px;white-space:nowrap" class="ft013">.&#160;</p>
<p style="position:absolute;top:802px;left:108px;white-space:nowrap" class="ft013">85.&#160;</p>
<p style="position:absolute;top:802px;left:162px;white-space:nowrap" class="ft032">Advisory Committee on Immunization Practices. Recommended adult immunization&#160;<br/>schedule:&#160;United States, October 2007–September&#160;2008.&#160;</p>
<p style="position:absolute;top:822px;left:557px;white-space:nowrap" class="ft019"><i>Ann Intern Med</i></p>
<p style="position:absolute;top:822px;left:666px;white-space:nowrap" class="ft013">. 2007;147(10):725-</p>
<p style="position:absolute;top:842px;left:162px;white-space:nowrap" class="ft013">729. Available&#160;at:&#160;</p>
<p style="position:absolute;top:842px;left:289px;white-space:nowrap" class="ft0115">https://www.ncbi.nlm.nih.gov/pubmed/17947396</p>
<p style="position:absolute;top:842px;left:631px;white-space:nowrap" class="ft013">.&#160;</p>
<p style="position:absolute;top:879px;left:108px;white-space:nowrap" class="ft013">86.&#160;</p>
<p style="position:absolute;top:879px;left:162px;white-space:nowrap" class="ft032">Gebo&#160;KA,&#160;Moore RD,&#160;Keruly JC, Chaisson RE.&#160;Risk factors for&#160;pneumococcal&#160;disease in&#160;<br/>human immunodeficiency virus-infected patients.&#160;</p>
<p style="position:absolute;top:899px;left:509px;white-space:nowrap" class="ft019"><i>J Infect&#160;Dis</i></p>
<p style="position:absolute;top:899px;left:588px;white-space:nowrap" class="ft013">. 1996;173(4):857-862.&#160;</p>
<p style="position:absolute;top:919px;left:162px;white-space:nowrap" class="ft013">Available at:&#160;</p>
<p style="position:absolute;top:919px;left:255px;white-space:nowrap" class="ft0115">https://www.ncbi.nlm.nih.gov/pubmed/8603963</p>
<p style="position:absolute;top:919px;left:588px;white-space:nowrap" class="ft013">.&#160;</p>
<p style="position:absolute;top:956px;left:108px;white-space:nowrap" class="ft013">87.&#160;</p>
<p style="position:absolute;top:956px;left:162px;white-space:nowrap" class="ft032">Breiman RF,&#160;Keller DW,&#160;Phelan MA,&#160;et&#160;al. Evaluation of effectiveness of&#160;the&#160;23-valent&#160;<br/>pneumococcal&#160;capsular polysaccharide vaccine for HIV-infected patients.&#160;</p>
<p style="position:absolute;top:976px;left:675px;white-space:nowrap" class="ft019"><i>Arch Intern&#160;Med</i></p>
<p style="position:absolute;top:976px;left:790px;white-space:nowrap" class="ft013">.&#160;</p>
<p style="position:absolute;top:995px;left:162px;white-space:nowrap" class="ft013">2000;160(17):2633-2638.&#160;Available at:&#160;</p>
<p style="position:absolute;top:995px;left:437px;white-space:nowrap" class="ft0115">https://www.ncbi.nlm.nih.gov/pubmed/10999977</p>
<p style="position:absolute;top:995px;left:778px;white-space:nowrap" class="ft013">.&#160;</p>
</div>
<!-- Page 118 -->
<a name="118"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page118-div" style="position:relative;width:917px;height:1187px;">
<p style="position:absolute;top:1114px;left:108px;white-space:nowrap" class="ft024"><i>Guidelines for the Prevention and Treatment&#160;of&#160;Opportunistic&#160;Infections in Adults&#160;and Adolescents&#160;With HIV&#160;</i></p>
<p style="position:absolute;top:1114px;left:782px;white-space:nowrap" class="ft024"><i>G-27&#160;</i></p>
<p style="position:absolute;top:109px;left:108px;white-space:nowrap" class="ft013">88.&#160;</p>
<p style="position:absolute;top:109px;left:162px;white-space:nowrap" class="ft013">Dworkin MS, Hanson DL, Navin TR.&#160;Survival&#160;of patients with AIDS, after&#160;diagnosis of&#160;</p>
<p style="position:absolute;top:129px;left:162px;white-space:nowrap" class="ft019"><i>Pneumocystis carinii</i></p>
<p style="position:absolute;top:129px;left:307px;white-space:nowrap" class="ft013">&#160;pneumonia, in the&#160;United States.&#160;</p>
<p style="position:absolute;top:129px;left:541px;white-space:nowrap" class="ft019"><i>J Infect&#160;Dis</i></p>
<p style="position:absolute;top:129px;left:620px;white-space:nowrap" class="ft013">. 2001;183(9):1409-1412.&#160;</p>
<p style="position:absolute;top:148px;left:162px;white-space:nowrap" class="ft013">Available at:&#160;</p>
<p style="position:absolute;top:148px;left:255px;white-space:nowrap" class="ft0115">http://www.ncbi.nlm.nih.gov/pubmed/11294675</p>
<p style="position:absolute;top:148px;left:589px;white-space:nowrap" class="ft013">.&#160;</p>
<p style="position:absolute;top:185px;left:108px;white-space:nowrap" class="ft013">89.&#160;</p>
<p style="position:absolute;top:185px;left:162px;white-space:nowrap" class="ft032">Penaranda&#160;M, Falco V,&#160;Payeras A, et al. Effectiveness of&#160;polysaccharide&#160;pneumococcal&#160;<br/>vaccine in HIV-infected&#160;patients: a&#160;case-control study.&#160;</p>
<p style="position:absolute;top:205px;left:542px;white-space:nowrap" class="ft019"><i>Clin Infect Dis</i></p>
<p style="position:absolute;top:205px;left:643px;white-space:nowrap" class="ft013">. 2007;45(7):e82-87.&#160;</p>
<p style="position:absolute;top:225px;left:162px;white-space:nowrap" class="ft013">Available at:&#160;</p>
<p style="position:absolute;top:225px;left:255px;white-space:nowrap" class="ft0115">https://www.ncbi.nlm.nih.gov/pubmed/17806042</p>
<p style="position:absolute;top:225px;left:596px;white-space:nowrap" class="ft013">.&#160;</p>
<p style="position:absolute;top:262px;left:108px;white-space:nowrap" class="ft013">90.&#160;</p>
<p style="position:absolute;top:262px;left:162px;white-space:nowrap" class="ft032">Rubin LG, Levin MJ, Ljungman P, et&#160;al. 2013 IDSA clinical&#160;practice guideline&#160;for&#160;<br/>vaccination of the&#160;immunocompromised host.&#160;</p>
<p style="position:absolute;top:282px;left:483px;white-space:nowrap" class="ft019"><i>Clin Infect&#160;Dis</i></p>
<p style="position:absolute;top:282px;left:584px;white-space:nowrap" class="ft013">.&#160;2014;58(3):309-318.&#160;Available&#160;</p>
<p style="position:absolute;top:302px;left:162px;white-space:nowrap" class="ft013">at:&#160;</p>
<p style="position:absolute;top:302px;left:184px;white-space:nowrap" class="ft0115">https://www.ncbi.nlm.nih.gov/pubmed/24421306</p>
<p style="position:absolute;top:302px;left:525px;white-space:nowrap" class="ft013">.&#160;</p>
<p style="position:absolute;top:339px;left:108px;white-space:nowrap" class="ft013">91.&#160;</p>
<p style="position:absolute;top:339px;left:162px;white-space:nowrap" class="ft032">DiazGranados CA,&#160;Dunning AJ, Kimmel M, et&#160;al. Efficacy of high-dose versus&#160;standard-<br/>dose influenza vaccine in older adults.&#160;</p>
<p style="position:absolute;top:359px;left:430px;white-space:nowrap" class="ft019"><i>N Engl&#160;J Med</i></p>
<p style="position:absolute;top:359px;left:526px;white-space:nowrap" class="ft013">. 2014;371(7):635-645.&#160;Available&#160;at:&#160;</p>
<p style="position:absolute;top:379px;left:162px;white-space:nowrap" class="ft0115">https://www.ncbi.nlm.nih.gov/pubmed/25119609</p>
<p style="position:absolute;top:379px;left:503px;white-space:nowrap" class="ft013">.&#160;</p>
<p style="position:absolute;top:416px;left:108px;white-space:nowrap" class="ft013">92.&#160;</p>
<p style="position:absolute;top:416px;left:162px;white-space:nowrap" class="ft032">Grohskopf LA. National&#160;Center for Immunization and Respiratory Diseases&#160;(U.S.) United&#160;<br/>States. Advisory Committee on Immunization Practices. Influenza Division. Influenza<br/>vaccines for&#160;older adults: GRADE summary. Presented at: ACIP meeting Influenza;&#160;2022.&#160;<br/>Atlanta, GA.&#160;Available at:&#160;</p>
<p style="position:absolute;top:475px;left:348px;white-space:nowrap" class="ft0115">https://stacks.cdc.gov/view/cdc/114834</p>
<p style="position:absolute;top:475px;left:620px;white-space:nowrap" class="ft013">.&#160;</p>
<p style="position:absolute;top:512px;left:108px;white-space:nowrap" class="ft013">93.&#160;</p>
<p style="position:absolute;top:512px;left:162px;white-space:nowrap" class="ft032">McKittrick N, Frank I, Jacobson JM,&#160;et&#160;al. Improved immunogenicity with high-dose&#160;<br/>seasonal influenza vaccine in HIV-infected persons: a single-center, parallel, randomized&#160;<br/>trial.&#160;</p>
<p style="position:absolute;top:552px;left:198px;white-space:nowrap" class="ft019"><i>Ann Intern Med</i></p>
<p style="position:absolute;top:552px;left:308px;white-space:nowrap" class="ft013">. 2013;158(1):19-26. Available at:&#160;</p>
<p style="position:absolute;top:572px;left:162px;white-space:nowrap" class="ft0115">https://www.ncbi.nlm.nih.gov/pubmed/23277897</p>
<p style="position:absolute;top:572px;left:503px;white-space:nowrap" class="ft013">.&#160;</p>
<p style="position:absolute;top:609px;left:108px;white-space:nowrap" class="ft013">94.&#160;</p>
<p style="position:absolute;top:609px;left:162px;white-space:nowrap" class="ft032">Anglaret&#160;X,&#160;Chene G,&#160;Attia A, et al. Early chemoprophylaxis with trimethoprim-<br/>sulphamethoxazole&#160;for HIV-1-infected&#160;adults in Abidjan, Cote d’Ivoire:&#160;a randomised trial.&#160;<br/>Cotrimo-CI&#160;Study Group.&#160;</p>
<p style="position:absolute;top:649px;left:344px;white-space:nowrap" class="ft019"><i>Lancet</i></p>
<p style="position:absolute;top:649px;left:391px;white-space:nowrap" class="ft013">. 1999;353(9163):1463-1468.&#160;Available at:&#160;</p>
<p style="position:absolute;top:668px;left:162px;white-space:nowrap" class="ft0115">http://www.ncbi.nlm.nih.gov/pubmed/10232311</p>
<p style="position:absolute;top:668px;left:497px;white-space:nowrap" class="ft013">.&#160;</p>
<p style="position:absolute;top:706px;left:108px;white-space:nowrap" class="ft013">95.&#160;</p>
<p style="position:absolute;top:706px;left:162px;white-space:nowrap" class="ft032">Hardy WD,&#160;Feinberg J,&#160;Finkelstein DM, et al. A controlled trial of trimethoprim-<br/>sulfamethoxazole&#160;or aerosolized pentamidine&#160;for secondary prophylaxis of&#160;</p>
<p style="position:absolute;top:725px;left:682px;white-space:nowrap" class="ft019"><i>Pneumocystis&#160;</i></p>
<p style="position:absolute;top:745px;left:162px;white-space:nowrap" class="ft019"><i>carinii</i></p>
<p style="position:absolute;top:745px;left:208px;white-space:nowrap" class="ft013">&#160;pneumonia in patients with the&#160;acquired immunodeficiency syndrome. AIDS Clinical&#160;</p>
<p style="position:absolute;top:765px;left:162px;white-space:nowrap" class="ft013">Trials Group&#160;Protocol&#160;021.&#160;</p>
<p style="position:absolute;top:765px;left:352px;white-space:nowrap" class="ft019"><i>N Engl&#160;J&#160;Med</i></p>
<p style="position:absolute;top:765px;left:447px;white-space:nowrap" class="ft013">. 1992;327(26):1842-1848. Available&#160;at:&#160;</p>
<p style="position:absolute;top:785px;left:162px;white-space:nowrap" class="ft0115">http://www.ncbi.nlm.nih.gov/pubmed/1448121</p>
<p style="position:absolute;top:785px;left:488px;white-space:nowrap" class="ft013">.&#160;</p>
<p style="position:absolute;top:822px;left:108px;white-space:nowrap" class="ft013">96.&#160;</p>
<p style="position:absolute;top:822px;left:162px;white-space:nowrap" class="ft032">Angel JB,&#160;High K, Rhame F, et&#160;al. Phase III study of granulocyte-macrophage&#160;colony-<br/>stimulating factor in advanced HIV disease:&#160;effect&#160;on infections,&#160;CD4 cell&#160;counts and HIV&#160;<br/>suppression.&#160;Leukine/HIV&#160;Study Group.&#160;</p>
<p style="position:absolute;top:862px;left:446px;white-space:nowrap" class="ft019"><i>AIDS</i></p>
<p style="position:absolute;top:862px;left:483px;white-space:nowrap" class="ft013">.&#160;2000;14(4):387-395. Available&#160;at:&#160;</p>
<p style="position:absolute;top:881px;left:162px;white-space:nowrap" class="ft0115">https://www.ncbi.nlm.nih.gov/pubmed/10770541</p>
<p style="position:absolute;top:881px;left:503px;white-space:nowrap" class="ft013">.&#160;</p>
<p style="position:absolute;top:919px;left:108px;white-space:nowrap" class="ft013">97.&#160;</p>
<p style="position:absolute;top:919px;left:162px;white-space:nowrap" class="ft032">Keiser P,&#160;Rademacher S,&#160;Smith JW, Skiest D, Vadde V.&#160;Granulocyte colony-stimulating&#160;<br/>factor use is&#160;associated with decreased bacteremia&#160;and increased&#160;survival&#160;in neutropenic&#160;<br/>HIV-infected patients.&#160;</p>
<p style="position:absolute;top:958px;left:320px;white-space:nowrap" class="ft019"><i>Am&#160;J Med</i></p>
<p style="position:absolute;top:958px;left:390px;white-space:nowrap" class="ft013">. 1998;104(1):48-55. Available at:&#160;</p>
<p style="position:absolute;top:978px;left:162px;white-space:nowrap" class="ft0115">https://www.ncbi.nlm.nih.gov/pubmed/9528719</p>
<p style="position:absolute;top:978px;left:495px;white-space:nowrap" class="ft013">.&#160;</p>
<p style="position:absolute;top:1015px;left:108px;white-space:nowrap" class="ft013">98.&#160;</p>
<p style="position:absolute;top:1015px;left:162px;white-space:nowrap" class="ft032">Crothers&#160;K,&#160;Griffith TA,&#160;McGinnis&#160;KA, et al. The impact&#160;of cigarette smoking on mortality,&#160;<br/>quality of life, and comorbid illness among HIV-positive veterans.&#160;</p>
<p style="position:absolute;top:1035px;left:625px;white-space:nowrap" class="ft019"><i>J Gen&#160;Intern Med</i></p>
<p style="position:absolute;top:1035px;left:747px;white-space:nowrap" class="ft013">.&#160;</p>
<p style="position:absolute;top:1055px;left:162px;white-space:nowrap" class="ft013">2005;20(12):1142-1145.&#160;Available at:&#160;</p>
<p style="position:absolute;top:1055px;left:428px;white-space:nowrap" class="ft0115">https://www.ncbi.nlm.nih.gov/pubmed/16423106</p>
<p style="position:absolute;top:1055px;left:770px;white-space:nowrap" class="ft013">.&#160;</p>
</div>
<!-- Page 119 -->
<a name="119"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page119-div" style="position:relative;width:917px;height:1187px;">
<p style="position:absolute;top:1114px;left:108px;white-space:nowrap" class="ft024"><i>Guidelines for the Prevention and Treatment&#160;of&#160;Opportunistic&#160;Infections in Adults&#160;and Adolescents&#160;With HIV&#160;</i></p>
<p style="position:absolute;top:1114px;left:782px;white-space:nowrap" class="ft024"><i>G-28&#160;</i></p>
<p style="position:absolute;top:109px;left:108px;white-space:nowrap" class="ft013">99.&#160;</p>
<p style="position:absolute;top:109px;left:162px;white-space:nowrap" class="ft032">Navin TR, Rimland D, Lennox JL, et&#160;al. Risk factors for community-acquired pneumonia&#160;<br/>among persons infected with human immunodeficiency virus.&#160;</p>
<p style="position:absolute;top:129px;left:593px;white-space:nowrap" class="ft019"><i>J Infect&#160;Dis</i></p>
<p style="position:absolute;top:129px;left:672px;white-space:nowrap" class="ft013">. 2000;181(1):158-</p>
<p style="position:absolute;top:148px;left:162px;white-space:nowrap" class="ft013">164. Available&#160;at:&#160;</p>
<p style="position:absolute;top:148px;left:289px;white-space:nowrap" class="ft0115">https://www.ncbi.nlm.nih.gov/pubmed/10608762</p>
<p style="position:absolute;top:148px;left:631px;white-space:nowrap" class="ft013">.&#160;</p>
<p style="position:absolute;top:185px;left:108px;white-space:nowrap" class="ft013">100.&#160;</p>
<p style="position:absolute;top:185px;left:162px;white-space:nowrap" class="ft032">Justice AC,&#160;Lasky E, McGinnis&#160;KA, et al. Medical disease and alcohol use among veterans&#160;<br/>with human immunodeficiency infection: a comparison of disease measurement&#160;strategies.&#160;</p>
<p style="position:absolute;top:225px;left:162px;white-space:nowrap" class="ft019"><i>Med Care</i></p>
<p style="position:absolute;top:225px;left:232px;white-space:nowrap" class="ft013">.&#160;2006;44(8 Suppl 2):S52-60. Available at:&#160;</p>
<p style="position:absolute;top:245px;left:162px;white-space:nowrap" class="ft0115">https://www.ncbi.nlm.nih.gov/pubmed/16849969</p>
<p style="position:absolute;top:245px;left:503px;white-space:nowrap" class="ft013">.&#160;</p>
<p style="position:absolute;top:282px;left:108px;white-space:nowrap" class="ft013">101.&#160;</p>
<p style="position:absolute;top:282px;left:162px;white-space:nowrap" class="ft032">Curran A, Falco V, Crespo M, et al. Bacterial&#160;pneumonia&#160;in HIV-infected patients: use of the&#160;<br/>pneumonia&#160;severity index and impact&#160;of current management&#160;on incidence, aetiology and&#160;<br/>outcome.&#160;</p>
<p style="position:absolute;top:322px;left:230px;white-space:nowrap" class="ft019"><i>HIV Med</i></p>
<p style="position:absolute;top:322px;left:294px;white-space:nowrap" class="ft013">. 2008;9(8):609-615. Available at:&#160;</p>
<p style="position:absolute;top:342px;left:162px;white-space:nowrap" class="ft0115">https://www.ncbi.nlm.nih.gov/pubmed/18557951</p>
<p style="position:absolute;top:342px;left:503px;white-space:nowrap" class="ft013">.&#160;</p>
<p style="position:absolute;top:379px;left:108px;white-space:nowrap" class="ft013">102.&#160;</p>
<p style="position:absolute;top:379px;left:162px;white-space:nowrap" class="ft032">Almeida&#160;A,&#160;Almeida&#160;AR,&#160;Castelo Branco S,&#160;Vesza&#160;Z, Pereira R. CURB-65 and other markers&#160;<br/>of illness&#160;severity in community-acquired pneumonia&#160;among HIV-positive patients.&#160;</p>
<p style="position:absolute;top:399px;left:743px;white-space:nowrap" class="ft019"><i>Int J STD&#160;</i></p>
<p style="position:absolute;top:418px;left:162px;white-space:nowrap" class="ft019"><i>AIDS</i></p>
<p style="position:absolute;top:418px;left:199px;white-space:nowrap" class="ft013">. 2016;27(11):998-1004. Available&#160;at:&#160;</p>
<p style="position:absolute;top:438px;left:162px;white-space:nowrap" class="ft0115">https://www.ncbi.nlm.nih.gov/pubmed/26394997</p>
<p style="position:absolute;top:438px;left:503px;white-space:nowrap" class="ft013">.&#160;</p>
<p style="position:absolute;top:475px;left:108px;white-space:nowrap" class="ft013">103.&#160;</p>
<p style="position:absolute;top:475px;left:162px;white-space:nowrap" class="ft032">Madeddu&#160;G,&#160;Laura Fiori&#160;M, Stella Mura M. Bacterial&#160;community-acquired pneumonia&#160;in&#160;<br/>HIV-infected patients.&#160;</p>
<p style="position:absolute;top:495px;left:320px;white-space:nowrap" class="ft019"><i>Curr&#160;Opin Pulm Med</i></p>
<p style="position:absolute;top:495px;left:468px;white-space:nowrap" class="ft013">. 2010;16(3):201-207. Available at:&#160;</p>
<p style="position:absolute;top:515px;left:162px;white-space:nowrap" class="ft0115">https://www.ncbi.nlm.nih.gov/pubmed/20154625</p>
<p style="position:absolute;top:515px;left:503px;white-space:nowrap" class="ft013">.&#160;</p>
<p style="position:absolute;top:552px;left:108px;white-space:nowrap" class="ft013">104.&#160;</p>
<p style="position:absolute;top:552px;left:162px;white-space:nowrap" class="ft032">Chew&#160;KW,&#160;Yen IH, Li JZ, Winston&#160;LG. Predictors of pneumonia&#160;severity in HIV-infected&#160;<br/>adults admitted to an Urban public&#160;hospital.&#160;</p>
<p style="position:absolute;top:572px;left:468px;white-space:nowrap" class="ft019"><i>AIDS Patient Care STDS</i></p>
<p style="position:absolute;top:572px;left:642px;white-space:nowrap" class="ft013">.&#160;2011;25(5):273-277.&#160;</p>
<p style="position:absolute;top:592px;left:162px;white-space:nowrap" class="ft013">Available at:&#160;</p>
<p style="position:absolute;top:592px;left:255px;white-space:nowrap" class="ft0115">https://www.ncbi.nlm.nih.gov/pubmed/21488749</p>
<p style="position:absolute;top:592px;left:596px;white-space:nowrap" class="ft013">.&#160;</p>
<p style="position:absolute;top:629px;left:108px;white-space:nowrap" class="ft013">105.&#160;</p>
<p style="position:absolute;top:629px;left:162px;white-space:nowrap" class="ft032">Bordon&#160;J, Kapoor R,&#160;Martinez C, et&#160;al. CD4+ cell counts and&#160;HIV-RNA&#160;levels do not predict&#160;<br/>outcomes of&#160;community-acquired pneumonia in hospitalized HIV-infected patients.&#160;</p>
<p style="position:absolute;top:649px;left:743px;white-space:nowrap" class="ft019"><i>Int J&#160;</i></p>
<p style="position:absolute;top:668px;left:162px;white-space:nowrap" class="ft019"><i>Infect&#160;Dis</i></p>
<p style="position:absolute;top:668px;left:229px;white-space:nowrap" class="ft013">. 2011;15(12):e822-827.&#160;Available&#160;at:&#160;</p>
<p style="position:absolute;top:688px;left:162px;white-space:nowrap" class="ft0115">https://www.ncbi.nlm.nih.gov/pubmed/21885316</p>
<p style="position:absolute;top:688px;left:503px;white-space:nowrap" class="ft013">.&#160;</p>
<p style="position:absolute;top:725px;left:108px;white-space:nowrap" class="ft013">106.&#160;</p>
<p style="position:absolute;top:725px;left:162px;white-space:nowrap" class="ft032">Barakat LA,&#160;Juthani-Mehta M, Allore&#160;H, et al. Comparing clinical&#160;outcomes in HIV-infected&#160;<br/>and uninfected older men hospitalized with community-acquired pneumonia.&#160;</p>
<p style="position:absolute;top:745px;left:698px;white-space:nowrap" class="ft019"><i>HIV Med</i></p>
<p style="position:absolute;top:745px;left:761px;white-space:nowrap" class="ft013">.&#160;</p>
<p style="position:absolute;top:765px;left:162px;white-space:nowrap" class="ft013">2015;16(7):421-430.&#160;Available&#160;at:&#160;</p>
<p style="position:absolute;top:765px;left:402px;white-space:nowrap" class="ft0115">https://www.ncbi.nlm.nih.gov/pubmed/25959543</p>
<p style="position:absolute;top:765px;left:744px;white-space:nowrap" class="ft013">.&#160;</p>
<p style="position:absolute;top:802px;left:108px;white-space:nowrap" class="ft013">107.&#160;</p>
<p style="position:absolute;top:802px;left:162px;white-space:nowrap" class="ft032">Buss&#160;IM, Birkhamshaw E, Innes&#160;MA,&#160;Magadoro&#160;I,&#160;Waitt&#160;PI, Rylance J. Validating a&#160;novel&#160;<br/>index (SWAT-Bp) to predict mortality risk of community-acquired pneumonia&#160;in Malawi.&#160;</p>
<p style="position:absolute;top:842px;left:162px;white-space:nowrap" class="ft019"><i>Malawi&#160;Med&#160;J</i></p>
<p style="position:absolute;top:842px;left:262px;white-space:nowrap" class="ft013">. 2018;30(4):230-235.&#160;Available at:&#160;</p>
<p style="position:absolute;top:862px;left:162px;white-space:nowrap" class="ft0115">https://www.ncbi.nlm.nih.gov/pubmed/31798800</p>
<p style="position:absolute;top:862px;left:503px;white-space:nowrap" class="ft013">.&#160;</p>
<p style="position:absolute;top:899px;left:108px;white-space:nowrap" class="ft013">108.&#160;</p>
<p style="position:absolute;top:899px;left:162px;white-space:nowrap" class="ft013">Centers for&#160;Disease Control&#160;and Prevention.&#160;</p>
<p style="position:absolute;top:899px;left:471px;white-space:nowrap" class="ft019"><i>Streptococcus pneumoniae</i></p>
<p style="position:absolute;top:899px;left:656px;white-space:nowrap" class="ft013">, 2019. &#160;2019.&#160;</p>
<p style="position:absolute;top:919px;left:162px;white-space:nowrap" class="ft013">Available at:&#160;</p>
<p style="position:absolute;top:919px;left:255px;white-space:nowrap" class="ft0115">https://www.cdc.gov/abcs/downloads/SPN_Surveillance_Report_2019.pdf</p>
<p style="position:absolute;top:919px;left:771px;white-space:nowrap" class="ft013">.&#160;</p>
<p style="position:absolute;top:956px;left:108px;white-space:nowrap" class="ft013">109.&#160;</p>
<p style="position:absolute;top:956px;left:162px;white-space:nowrap" class="ft032">Garin N,&#160;Genne D, Carballo S, et al. beta-Lactam&#160;monotherapy&#160;vs beta-lactam-macrolide&#160;<br/>combination treatment in&#160;moderately severe community-acquired pneumonia: a&#160;randomized&#160;<br/>noninferiority trial.&#160;</p>
<p style="position:absolute;top:995px;left:298px;white-space:nowrap" class="ft019"><i>JAMA Intern Med</i></p>
<p style="position:absolute;top:995px;left:423px;white-space:nowrap" class="ft013">. 2014;174(12):1894-1901. Available at:&#160;</p>
<p style="position:absolute;top:1015px;left:162px;white-space:nowrap" class="ft0115">https://www.ncbi.nlm.nih.gov/pubmed/25286173</p>
<p style="position:absolute;top:1015px;left:503px;white-space:nowrap" class="ft013">.&#160;</p>
</div>
<!-- Page 120 -->
<a name="120"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page120-div" style="position:relative;width:917px;height:1187px;">
<p style="position:absolute;top:1114px;left:108px;white-space:nowrap" class="ft024"><i>Guidelines for the Prevention and Treatment&#160;of&#160;Opportunistic&#160;Infections in Adults&#160;and Adolescents&#160;With HIV&#160;</i></p>
<p style="position:absolute;top:1114px;left:782px;white-space:nowrap" class="ft024"><i>G-29&#160;</i></p>
<p style="position:absolute;top:109px;left:108px;white-space:nowrap" class="ft013">110.&#160;</p>
<p style="position:absolute;top:109px;left:162px;white-space:nowrap" class="ft032">Postma DF,&#160;van Werkhoven CH, van&#160;Elden LJ, et al. Antibiotic&#160;treatment&#160;strategies for&#160;<br/>community-acquired pneumonia in adults.&#160;</p>
<p style="position:absolute;top:129px;left:458px;white-space:nowrap" class="ft019"><i>N Engl&#160;J Med</i></p>
<p style="position:absolute;top:129px;left:554px;white-space:nowrap" class="ft013">. 2015;372(14):1312-1323.&#160;</p>
<p style="position:absolute;top:148px;left:162px;white-space:nowrap" class="ft013">Available at:&#160;</p>
<p style="position:absolute;top:148px;left:255px;white-space:nowrap" class="ft0115">https://www.ncbi.nlm.nih.gov/pubmed/25830421</p>
<p style="position:absolute;top:148px;left:596px;white-space:nowrap" class="ft013">.&#160;</p>
<p style="position:absolute;top:185px;left:108px;white-space:nowrap" class="ft013">111.&#160;</p>
<p style="position:absolute;top:185px;left:162px;white-space:nowrap" class="ft032">Figueiredo-Mello C, Naucler P, Negra MD, Levin&#160;AS. Ceftriaxone versus ceftriaxone plus a&#160;<br/>macrolide&#160;for community-acquired pneumonia in hospitalized patients with HIV/AIDS:&#160;a&#160;<br/>randomized controlled trial.&#160;</p>
<p style="position:absolute;top:225px;left:358px;white-space:nowrap" class="ft019"><i>Clin Microbiol&#160;Infect</i></p>
<p style="position:absolute;top:225px;left:505px;white-space:nowrap" class="ft013">. 2018;24(2):146-151.&#160;Available at:&#160;</p>
<p style="position:absolute;top:245px;left:162px;white-space:nowrap" class="ft0115">https://www.ncbi.nlm.nih.gov/pubmed/28648859</p>
<p style="position:absolute;top:245px;left:503px;white-space:nowrap" class="ft013">.&#160;</p>
<p style="position:absolute;top:282px;left:108px;white-space:nowrap" class="ft013">112.&#160;</p>
<p style="position:absolute;top:282px;left:162px;white-space:nowrap" class="ft032">Weinstein MP, Klugman&#160;KP,&#160;Jones&#160;RN. Rationale for revised penicillin susceptibility&#160;<br/>breakpoints&#160;versus&#160;</p>
<p style="position:absolute;top:302px;left:295px;white-space:nowrap" class="ft019"><i>Streptococcus pneumoniae</i></p>
<p style="position:absolute;top:302px;left:480px;white-space:nowrap" class="ft013">:&#160;coping with antimicrobial&#160;susceptibility in an&#160;</p>
<p style="position:absolute;top:322px;left:162px;white-space:nowrap" class="ft013">era of resistance.&#160;</p>
<p style="position:absolute;top:322px;left:283px;white-space:nowrap" class="ft019"><i>Clin Infect Dis</i></p>
<p style="position:absolute;top:322px;left:384px;white-space:nowrap" class="ft013">. 2009;48(11):1596-1600.&#160;Available at:&#160;</p>
<p style="position:absolute;top:342px;left:162px;white-space:nowrap" class="ft0115">https://www.ncbi.nlm.nih.gov/pubmed/19400744</p>
<p style="position:absolute;top:342px;left:503px;white-space:nowrap" class="ft013">.&#160;</p>
<p style="position:absolute;top:379px;left:108px;white-space:nowrap" class="ft013">113.&#160;</p>
<p style="position:absolute;top:379px;left:162px;white-space:nowrap" class="ft032">Baddour LM, Yu&#160;VL, Klugman KP, et&#160;al. Combination antibiotic therapy lowers mortality&#160;<br/>among severely ill&#160;patients with pneumococcal&#160;bacteremia.&#160;</p>
<p style="position:absolute;top:399px;left:574px;white-space:nowrap" class="ft019"><i>Am J Respir Crit Care Med</i></p>
<p style="position:absolute;top:399px;left:765px;white-space:nowrap" class="ft013">.&#160;</p>
<p style="position:absolute;top:418px;left:162px;white-space:nowrap" class="ft013">2004;170(4):440-444.&#160;Available&#160;at:&#160;</p>
<p style="position:absolute;top:418px;left:411px;white-space:nowrap" class="ft0115">https://www.ncbi.nlm.nih.gov/pubmed/15184200</p>
<p style="position:absolute;top:418px;left:752px;white-space:nowrap" class="ft013">.&#160;</p>
<p style="position:absolute;top:455px;left:108px;white-space:nowrap" class="ft013">114.&#160;</p>
<p style="position:absolute;top:455px;left:162px;white-space:nowrap" class="ft032">Sligl&#160;WI, Asadi&#160;L, Eurich DT, Tjosvold L, Marrie&#160;TJ, Majumdar SR.&#160;Macrolides and&#160;<br/>mortality in&#160;critically ill&#160;patients with community-acquired pneumonia: a&#160;systematic review&#160;<br/>and meta-analysis.&#160;</p>
<p style="position:absolute;top:495px;left:295px;white-space:nowrap" class="ft019"><i>Crit&#160;Care Med</i></p>
<p style="position:absolute;top:495px;left:396px;white-space:nowrap" class="ft013">. 2014;42(2):420-432. Available&#160;at:&#160;</p>
<p style="position:absolute;top:515px;left:162px;white-space:nowrap" class="ft0115">https://www.ncbi.nlm.nih.gov/pubmed/24158175</p>
<p style="position:absolute;top:515px;left:503px;white-space:nowrap" class="ft013">.&#160;</p>
<p style="position:absolute;top:552px;left:108px;white-space:nowrap" class="ft013">115.&#160;</p>
<p style="position:absolute;top:552px;left:162px;white-space:nowrap" class="ft032">Vardakas&#160;KZ, Trigkidis KK,&#160;Falagas&#160;ME. Fluoroquinolones or&#160;macrolides in combination&#160;<br/>with beta-lactams in adult patients hospitalized with community acquired pneumonia: a&#160;<br/>systematic review and meta-analysis.&#160;</p>
<p style="position:absolute;top:592px;left:423px;white-space:nowrap" class="ft019"><i>Clin Microbiol Infect</i></p>
<p style="position:absolute;top:592px;left:569px;white-space:nowrap" class="ft013">. 2017;23(4):234-241. Available&#160;</p>
<p style="position:absolute;top:612px;left:162px;white-space:nowrap" class="ft013">at:&#160;</p>
<p style="position:absolute;top:612px;left:184px;white-space:nowrap" class="ft0115">https://www.ncbi.nlm.nih.gov/pubmed/27965070</p>
<p style="position:absolute;top:612px;left:525px;white-space:nowrap" class="ft013">.&#160;</p>
<p style="position:absolute;top:649px;left:108px;white-space:nowrap" class="ft013">116.&#160;</p>
<p style="position:absolute;top:649px;left:162px;white-space:nowrap" class="ft032">Siemieniuk RA,&#160;Meade&#160;MO,&#160;Alonso-Coello P, et&#160;al. Corticosteroid therapy&#160;for patients&#160;<br/>hospitalized with community-acquired pneumonia: a systematic&#160;review and&#160;meta-analysis.&#160;</p>
<p style="position:absolute;top:688px;left:162px;white-space:nowrap" class="ft019"><i>Ann Intern&#160;Med</i></p>
<p style="position:absolute;top:688px;left:271px;white-space:nowrap" class="ft013">. 2015;163(7):519-528. Available at:&#160;</p>
<p style="position:absolute;top:708px;left:162px;white-space:nowrap" class="ft0115">https://www.ncbi.nlm.nih.gov/pubmed/26258555</p>
<p style="position:absolute;top:708px;left:503px;white-space:nowrap" class="ft013">.&#160;</p>
<p style="position:absolute;top:745px;left:108px;white-space:nowrap" class="ft013">117.&#160;</p>
<p style="position:absolute;top:745px;left:162px;white-space:nowrap" class="ft032">Ni YN, Chen&#160;G, Sun J, Liang BM, Liang ZA. The&#160;effect&#160;of corticosteroids on&#160;mortality of&#160;<br/>patients with influenza pneumonia:&#160;a systematic&#160;review and meta-analysis.&#160;</p>
<p style="position:absolute;top:765px;left:682px;white-space:nowrap" class="ft019"><i>Crit Care</i></p>
<p style="position:absolute;top:765px;left:748px;white-space:nowrap" class="ft013">.&#160;</p>
<p style="position:absolute;top:785px;left:162px;white-space:nowrap" class="ft013">2019;23(1):99. Available at:&#160;</p>
<p style="position:absolute;top:785px;left:362px;white-space:nowrap" class="ft0115">https://www.ncbi.nlm.nih.gov/pubmed/30917856</p>
<p style="position:absolute;top:785px;left:703px;white-space:nowrap" class="ft013">.&#160;</p>
<p style="position:absolute;top:822px;left:108px;white-space:nowrap" class="ft013">118.&#160;</p>
<p style="position:absolute;top:822px;left:162px;white-space:nowrap" class="ft032">RECOVERY Collaborative&#160;Group,&#160;Horby P, Lim&#160;WS, et&#160;al. Dexamethasone in hospitalized&#160;<br/>patients with Covid-19.&#160;</p>
<p style="position:absolute;top:842px;left:329px;white-space:nowrap" class="ft019"><i>N&#160;Engl&#160;J Med</i></p>
<p style="position:absolute;top:842px;left:424px;white-space:nowrap" class="ft013">.&#160;2021;384(8):693-704.&#160;Available&#160;at:&#160;</p>
<p style="position:absolute;top:862px;left:162px;white-space:nowrap" class="ft0115">https://www.ncbi.nlm.nih.gov/pubmed/32678530</p>
<p style="position:absolute;top:862px;left:503px;white-space:nowrap" class="ft013">.&#160;</p>
<p style="position:absolute;top:899px;left:108px;white-space:nowrap" class="ft013">119.&#160;</p>
<p style="position:absolute;top:899px;left:162px;white-space:nowrap" class="ft032">Torres A, Sibila O, Ferrer M, et al. Effect of corticosteroids on&#160;treatment failure&#160;among&#160;<br/>hospitalized patients with severe community-acquired pneumonia&#160;and high inflammatory&#160;<br/>response: a randomized clinical&#160;trial.&#160;</p>
<p style="position:absolute;top:938px;left:420px;white-space:nowrap" class="ft019"><i>JAMA</i></p>
<p style="position:absolute;top:938px;left:463px;white-space:nowrap" class="ft013">. 2015;313(7):677-686. Available at:&#160;</p>
<p style="position:absolute;top:958px;left:162px;white-space:nowrap" class="ft0115">https://www.ncbi.nlm.nih.gov/pubmed/25688779</p>
<p style="position:absolute;top:958px;left:503px;white-space:nowrap" class="ft013">.&#160;</p>
<p style="position:absolute;top:995px;left:108px;white-space:nowrap" class="ft013">120.&#160;</p>
<p style="position:absolute;top:995px;left:162px;white-space:nowrap" class="ft032">Evans L, Rhodes A,&#160;Alhazzani W, et&#160;al. Surviving&#160;sepsis&#160;campaign:&#160;international&#160;guidelines&#160;<br/>for management&#160;of sepsis&#160;and septic&#160;shock 2021.&#160;</p>
<p style="position:absolute;top:1015px;left:504px;white-space:nowrap" class="ft019"><i>Crit&#160;Care Med</i></p>
<p style="position:absolute;top:1015px;left:606px;white-space:nowrap" class="ft013">.&#160;2021;49(11):e1063-e1143.&#160;</p>
<p style="position:absolute;top:1035px;left:162px;white-space:nowrap" class="ft013">Available at:&#160;</p>
<p style="position:absolute;top:1035px;left:255px;white-space:nowrap" class="ft0115">https://www.ncbi.nlm.nih.gov/pubmed/34605781</p>
<p style="position:absolute;top:1035px;left:596px;white-space:nowrap" class="ft013">.&#160;</p>
</div>
<!-- Page 121 -->
<a name="121"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page121-div" style="position:relative;width:917px;height:1187px;">
<p style="position:absolute;top:1114px;left:108px;white-space:nowrap" class="ft024"><i>Guidelines for the Prevention and Treatment&#160;of&#160;Opportunistic&#160;Infections in Adults&#160;and Adolescents&#160;With HIV&#160;</i></p>
<p style="position:absolute;top:1114px;left:782px;white-space:nowrap" class="ft024"><i>G-30&#160;</i></p>
<p style="position:absolute;top:109px;left:108px;white-space:nowrap" class="ft013">121.&#160;</p>
<p style="position:absolute;top:109px;left:162px;white-space:nowrap" class="ft032">Rubinstein E, Lalani&#160;T, Corey GR, et&#160;al. Telavancin versus&#160;vancomycin for hospital-acquired&#160;<br/>pneumonia&#160;due to gram-positive pathogens.&#160;</p>
<p style="position:absolute;top:129px;left:468px;white-space:nowrap" class="ft019"><i>Clin Infect&#160;Dis</i></p>
<p style="position:absolute;top:129px;left:570px;white-space:nowrap" class="ft013">. 2011;52(1):31-40. Available at:&#160;</p>
<p style="position:absolute;top:148px;left:162px;white-space:nowrap" class="ft0115">https://www.ncbi.nlm.nih.gov/pubmed/21148517</p>
<p style="position:absolute;top:148px;left:503px;white-space:nowrap" class="ft013">.&#160;</p>
<p style="position:absolute;top:185px;left:108px;white-space:nowrap" class="ft013">122.&#160;</p>
<p style="position:absolute;top:185px;left:162px;white-space:nowrap" class="ft032">File&#160;TM, Jr.,&#160;Low DE, Eckburg PB, et&#160;al. Integrated analysis of&#160;FOCUS&#160;1&#160;and FOCUS&#160;2:&#160;<br/>randomized, doubled-blinded, multicenter phase 3&#160;trials of the efficacy and safety of&#160;<br/>ceftaroline&#160;fosamil versus ceftriaxone&#160;in patients with community-acquired pneumonia.&#160;</p>
<p style="position:absolute;top:225px;left:770px;white-space:nowrap" class="ft019"><i>Clin&#160;</i></p>
<p style="position:absolute;top:245px;left:162px;white-space:nowrap" class="ft019"><i>Infect&#160;Dis</i></p>
<p style="position:absolute;top:245px;left:229px;white-space:nowrap" class="ft013">. 2010;51(12):1395-1405.&#160;Available&#160;at:&#160;</p>
<p style="position:absolute;top:265px;left:162px;white-space:nowrap" class="ft0115">https://www.ncbi.nlm.nih.gov/pubmed/21067350</p>
<p style="position:absolute;top:265px;left:503px;white-space:nowrap" class="ft013">.&#160;</p>
<p style="position:absolute;top:302px;left:108px;white-space:nowrap" class="ft013">123.&#160;</p>
<p style="position:absolute;top:302px;left:162px;white-space:nowrap" class="ft032">Novak RM,&#160;Richardson&#160;JT, Buchacz&#160;K, et al. Immune&#160;reconstitution inflammatory&#160;<br/>syndrome:&#160;incidence&#160;and implications for mortality.&#160;</p>
<p style="position:absolute;top:322px;left:524px;white-space:nowrap" class="ft019"><i>AIDS</i></p>
<p style="position:absolute;top:322px;left:562px;white-space:nowrap" class="ft013">. 2012;26(6):721-730. Available at:&#160;</p>
<p style="position:absolute;top:342px;left:162px;white-space:nowrap" class="ft0115">https://www.ncbi.nlm.nih.gov/pubmed/22233655</p>
<p style="position:absolute;top:342px;left:503px;white-space:nowrap" class="ft013">.&#160;</p>
<p style="position:absolute;top:379px;left:108px;white-space:nowrap" class="ft013">124.&#160;</p>
<p style="position:absolute;top:379px;left:162px;white-space:nowrap" class="ft032">De P,&#160;Farley&#160;A, Lindson&#160;N, Aveyard&#160;P. Systematic&#160;review and&#160;meta-analysis: influence of&#160;<br/>smoking cessation on incidence of pneumonia&#160;in HIV.&#160;</p>
<p style="position:absolute;top:399px;left:542px;white-space:nowrap" class="ft019"><i>BMC&#160;Med</i></p>
<p style="position:absolute;top:399px;left:613px;white-space:nowrap" class="ft013">. 2013;11:15. Available&#160;at:&#160;</p>
<p style="position:absolute;top:418px;left:162px;white-space:nowrap" class="ft0115">https://www.ncbi.nlm.nih.gov/pubmed/23339513</p>
<p style="position:absolute;top:418px;left:503px;white-space:nowrap" class="ft013">.&#160;</p>
<p style="position:absolute;top:455px;left:108px;white-space:nowrap" class="ft013">125.&#160;</p>
<p style="position:absolute;top:455px;left:162px;white-space:nowrap" class="ft032">Einarson A,&#160;Phillips E, Mawji&#160;F, et al. A prospective&#160;controlled multicentre study of&#160;<br/>clarithromycin in pregnancy.&#160;</p>
<p style="position:absolute;top:475px;left:366px;white-space:nowrap" class="ft019"><i>Am J Perinatol</i></p>
<p style="position:absolute;top:475px;left:470px;white-space:nowrap" class="ft013">. 1998;15(9):523-525. Available at:&#160;</p>
<p style="position:absolute;top:495px;left:162px;white-space:nowrap" class="ft0115">http://www.ncbi.nlm.nih.gov/pubmed/9890248</p>
<p style="position:absolute;top:495px;left:488px;white-space:nowrap" class="ft013">.&#160;</p>
<p style="position:absolute;top:532px;left:108px;white-space:nowrap" class="ft013">126.&#160;</p>
<p style="position:absolute;top:532px;left:162px;white-space:nowrap" class="ft032">Drinkard CR, Shatin D, Clouse J.&#160;Postmarketing surveillance&#160;of medications and pregnancy&#160;<br/>outcomes: clarithromycin and birth malformations.&#160;</p>
<p style="position:absolute;top:552px;left:518px;white-space:nowrap" class="ft019"><i>Pharmacoepidemiol Drug Saf</i></p>
<p style="position:absolute;top:552px;left:725px;white-space:nowrap" class="ft013">.&#160;</p>
<p style="position:absolute;top:572px;left:162px;white-space:nowrap" class="ft013">2000;9(7):549-556.&#160;Available at:&#160;</p>
<p style="position:absolute;top:572px;left:394px;white-space:nowrap" class="ft0115">http://www.ncbi.nlm.nih.gov/pubmed/11338912</p>
<p style="position:absolute;top:572px;left:728px;white-space:nowrap" class="ft013">.&#160;</p>
<p style="position:absolute;top:609px;left:108px;white-space:nowrap" class="ft013">127.&#160;</p>
<p style="position:absolute;top:609px;left:162px;white-space:nowrap" class="ft032">Schaefer C,&#160;Amoura-Elefant&#160;E, Vial&#160;T, et al. Pregnancy outcome after prenatal quinolone&#160;<br/>exposure. Evaluation of a case registry&#160;of the&#160;European Network&#160;of Teratology Information&#160;<br/>Services (ENTIS).&#160;</p>
<p style="position:absolute;top:649px;left:294px;white-space:nowrap" class="ft019"><i>Eur J&#160;Obstet Gynecol&#160;Reprod Biol</i></p>
<p style="position:absolute;top:649px;left:531px;white-space:nowrap" class="ft013">. 1996;69(2):83-89.&#160;Available&#160;at:&#160;</p>
<p style="position:absolute;top:668px;left:162px;white-space:nowrap" class="ft0115">http://www.ncbi.nlm.nih.gov/pubmed/8902438</p>
<p style="position:absolute;top:668px;left:488px;white-space:nowrap" class="ft013">.&#160;</p>
<p style="position:absolute;top:706px;left:108px;white-space:nowrap" class="ft013">128.&#160;</p>
<p style="position:absolute;top:706px;left:162px;white-space:nowrap" class="ft032">Loebstein R,&#160;Addis&#160;A,&#160;Ho&#160;E, et&#160;al. Pregnancy outcome following gestational exposure to&#160;<br/>fluoroquinolones: a multicenter prospective controlled study.&#160;</p>
<p style="position:absolute;top:725px;left:588px;white-space:nowrap" class="ft019"><i>Antimicrob Agents Chemother</i></p>
<p style="position:absolute;top:725px;left:797px;white-space:nowrap" class="ft013">.&#160;</p>
<p style="position:absolute;top:745px;left:162px;white-space:nowrap" class="ft013">1998;42(6):1336-1339.&#160;Available at:&#160;</p>
<p style="position:absolute;top:745px;left:420px;white-space:nowrap" class="ft0115">http://www.ncbi.nlm.nih.gov/pubmed/9624471</p>
<p style="position:absolute;top:745px;left:746px;white-space:nowrap" class="ft013">.&#160;</p>
<p style="position:absolute;top:782px;left:108px;white-space:nowrap" class="ft013">129.&#160;</p>
<p style="position:absolute;top:782px;left:162px;white-space:nowrap" class="ft032">Nahum GG,&#160;Uhl K,&#160;Kennedy DL.&#160;Antibiotic use in pregnancy and lactation:&#160;what is and is&#160;<br/>not known&#160;about&#160;teratogenic and toxic&#160;risks.&#160;</p>
<p style="position:absolute;top:802px;left:472px;white-space:nowrap" class="ft019"><i>Obstet&#160;Gynecol</i></p>
<p style="position:absolute;top:802px;left:579px;white-space:nowrap" class="ft013">. 2006;107(5):1120-1138.&#160;</p>
<p style="position:absolute;top:822px;left:162px;white-space:nowrap" class="ft013">Available at:&#160;</p>
<p style="position:absolute;top:822px;left:255px;white-space:nowrap" class="ft0115">http://www.ncbi.nlm.nih.gov/pubmed/16648419</p>
<p style="position:absolute;top:822px;left:589px;white-space:nowrap" class="ft013">.&#160;</p>
<p style="position:absolute;top:859px;left:108px;white-space:nowrap" class="ft013">130.&#160;</p>
<p style="position:absolute;top:859px;left:162px;white-space:nowrap" class="ft032">McCormack&#160;WM, Rosner&#160;B, Lee YH,&#160;Munoz&#160;A, Charles D,&#160;Kass&#160;EH. Effect&#160;on birth weight&#160;<br/>of erythromycin treatment&#160;of pregnant&#160;women.&#160;</p>
<p style="position:absolute;top:879px;left:490px;white-space:nowrap" class="ft019"><i>Obstet&#160;Gynecol</i></p>
<p style="position:absolute;top:879px;left:597px;white-space:nowrap" class="ft013">. 1987;69(2):202-207.&#160;</p>
<p style="position:absolute;top:899px;left:162px;white-space:nowrap" class="ft013">Available at:&#160;</p>
<p style="position:absolute;top:899px;left:255px;white-space:nowrap" class="ft0115">https://www.ncbi.nlm.nih.gov/pubmed/3543767</p>
<p style="position:absolute;top:899px;left:588px;white-space:nowrap" class="ft013">.&#160;</p>
<p style="position:absolute;top:936px;left:108px;white-space:nowrap" class="ft013">131.&#160;</p>
<p style="position:absolute;top:936px;left:162px;white-space:nowrap" class="ft032">Bookstaver&#160;PB, Bland CM, Griffin B,&#160;Stover KR,&#160;Eiland LS, McLaughlin&#160;M. A&#160;review&#160;of&#160;<br/>antibiotic use in pregnancy.&#160;</p>
<p style="position:absolute;top:956px;left:357px;white-space:nowrap" class="ft019"><i>Pharmacotherapy</i></p>
<p style="position:absolute;top:956px;left:481px;white-space:nowrap" class="ft013">. 2015;35(11):1052-1062.&#160;Available at:&#160;</p>
<p style="position:absolute;top:976px;left:162px;white-space:nowrap" class="ft0115">https://www.ncbi.nlm.nih.gov/pubmed/26598097</p>
<p style="position:absolute;top:976px;left:503px;white-space:nowrap" class="ft013">.&#160;</p>
<p style="position:absolute;top:1013px;left:108px;white-space:nowrap" class="ft013">132.&#160;</p>
<p style="position:absolute;top:1013px;left:162px;white-space:nowrap" class="ft032">Reyes MP,&#160;Ostrea EM,&#160;Jr., Cabinian&#160;AE, Schmitt&#160;C, Rintelmann W. Vancomycin during&#160;<br/>pregnancy: does it&#160;cause&#160;hearing loss&#160;or nephrotoxicity in the infant?&#160;</p>
<p style="position:absolute;top:1032px;left:641px;white-space:nowrap" class="ft019"><i>Am J Obstet&#160;Gynecol</i></p>
<p style="position:absolute;top:1032px;left:787px;white-space:nowrap" class="ft013">.&#160;</p>
<p style="position:absolute;top:1052px;left:162px;white-space:nowrap" class="ft013">1989;161(4):977-981.&#160;Available&#160;at:&#160;</p>
<p style="position:absolute;top:1052px;left:411px;white-space:nowrap" class="ft0115">https://www.ncbi.nlm.nih.gov/pubmed/2801848</p>
<p style="position:absolute;top:1052px;left:744px;white-space:nowrap" class="ft013">.&#160;</p>
</div>
<!-- Page 122 -->
<a name="122"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page122-div" style="position:relative;width:917px;height:1187px;">
<p style="position:absolute;top:1114px;left:108px;white-space:nowrap" class="ft024"><i>Guidelines for the Prevention and Treatment&#160;of&#160;Opportunistic&#160;Infections in Adults&#160;and Adolescents&#160;With HIV&#160;</i></p>
<p style="position:absolute;top:1114px;left:782px;white-space:nowrap" class="ft024"><i>G-31&#160;</i></p>
<p style="position:absolute;top:109px;left:108px;white-space:nowrap" class="ft013">133.&#160;</p>
<p style="position:absolute;top:109px;left:162px;white-space:nowrap" class="ft032">Weinberg A,&#160;Muresan&#160;P,&#160;Laimon L, et al. Safety, immunogenicity, and transplacental&#160;<br/>antibody transport of conjugated and polysaccharide pneumococcal&#160;vaccines administered to&#160;<br/>pregnant&#160;women with HIV: a multicentre randomised controlled trial.&#160;</p>
<p style="position:absolute;top:148px;left:646px;white-space:nowrap" class="ft019"><i>Lancet&#160;HIV</i></p>
<p style="position:absolute;top:148px;left:726px;white-space:nowrap" class="ft013">.&#160;</p>
<p style="position:absolute;top:168px;left:162px;white-space:nowrap" class="ft013">2021;8(7):e408-e419.&#160;Available&#160;at:&#160;</p>
<p style="position:absolute;top:168px;left:409px;white-space:nowrap" class="ft0115">https://www.ncbi.nlm.nih.gov/pubmed/33915104</p>
<p style="position:absolute;top:168px;left:750px;white-space:nowrap" class="ft013">.&#160;</p>
<p style="position:absolute;top:205px;left:108px;white-space:nowrap" class="ft013">134.&#160;</p>
<p style="position:absolute;top:205px;left:162px;white-space:nowrap" class="ft032">Duarte G,&#160;Muresan P,&#160;Ward S, et al. Immunogenicity of conjugated and polysaccharide&#160;<br/>pneumococcal vaccines administered during pregnancy or postpartum to women with HIV.&#160;</p>
<p style="position:absolute;top:245px;left:162px;white-space:nowrap" class="ft019"><i>J</i></p>
<p style="position:absolute;top:246px;left:170px;white-space:nowrap" class="ft049"><i>&#160;</i></p>
<p style="position:absolute;top:245px;left:174px;white-space:nowrap" class="ft019"><i>Infect&#160;Dis</i></p>
<p style="position:absolute;top:245px;left:241px;white-space:nowrap" class="ft013">.&#160;2022;225(6):1021-1031.&#160;Available&#160;at:&#160;</p>
<p style="position:absolute;top:265px;left:162px;white-space:nowrap" class="ft0115">https://www.ncbi.nlm.nih.gov/pubmed/34791324</p>
<p style="position:absolute;top:265px;left:503px;white-space:nowrap" class="ft013">.&#160;</p>
</div>
<!-- Page 123 -->
<a name="123"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page123-div" style="position:relative;width:917px;height:1187px;">
<p style="position:absolute;top:1117px;left:108px;white-space:nowrap" class="ft024"><i>Guidelines for the Prevention and Treatment&#160;of&#160;Opportunistic&#160;Infections in Adults&#160;and Adolescents&#160;With HIV&#160;</i></p>
<p style="position:absolute;top:1117px;left:790px;white-space:nowrap" class="ft024"><i>H-1</i></p>
<p style="position:absolute;top:112px;left:108px;white-space:nowrap" class="ft025"><b>Cryptococcosis&#160;</b></p>
<p style="position:absolute;top:159px;left:108px;white-space:nowrap" class="ft035"><b>Updated:</b></p>
<p style="position:absolute;top:159px;left:172px;white-space:nowrap" class="ft036">&#160;October&#160;29, 2024&#160;</p>
<p style="position:absolute;top:180px;left:108px;white-space:nowrap" class="ft035"><b>Reviewed:</b></p>
<p style="position:absolute;top:180px;left:181px;white-space:nowrap" class="ft036">&#160;January 8,&#160;2025</p>
<p style="position:absolute;top:180px;left:291px;white-space:nowrap" class="ft035"><b>&#160;</b></p>
<p style="position:absolute;top:218px;left:108px;white-space:nowrap" class="ft026"><b>Epidemiology&#160;</b></p>
<p style="position:absolute;top:260px;left:108px;white-space:nowrap" class="ft013">Most&#160;HIV-associated cryptococcal&#160;infections are caused by&#160;</p>
<p style="position:absolute;top:260px;left:522px;white-space:nowrap" class="ft019"><i>Cryptococcus neoformans</i></p>
<p style="position:absolute;top:260px;left:702px;white-space:nowrap" class="ft013">, but&#160;</p>
<p style="position:absolute;top:280px;left:108px;white-space:nowrap" class="ft013">occasionally&#160;</p>
<p style="position:absolute;top:280px;left:198px;white-space:nowrap" class="ft019"><i>Cryptococcus gattii</i></p>
<p style="position:absolute;top:280px;left:334px;white-space:nowrap" class="ft013">&#160;is the&#160;cause.&#160;</p>
<p style="position:absolute;top:280px;left:426px;white-space:nowrap" class="ft019"><i>C. neoformans</i></p>
<p style="position:absolute;top:280px;left:528px;white-space:nowrap" class="ft013">&#160;is found worldwide, whereas&#160;</p>
<p style="position:absolute;top:280px;left:736px;white-space:nowrap" class="ft019"><i>C. gattii</i></p>
<p style="position:absolute;top:280px;left:792px;white-space:nowrap" class="ft013">&#160;</p>
<p style="position:absolute;top:299px;left:108px;white-space:nowrap" class="ft032">most often is&#160;found in&#160;Australia&#160;and similar subtropical&#160;regions and in the U.S. Pacific Northwest.&#160;<br/>Before the era of effective antiretroviral therapy (ART), approximately 5% to 8% of people with&#160;<br/>advanced HIV in some high-resourced&#160;countries had disseminated cryptococcosis.</p>
<p style="position:absolute;top:338px;left:677px;white-space:nowrap" class="ft038">1</p>
<p style="position:absolute;top:339px;left:682px;white-space:nowrap" class="ft013">&#160;In a surveillance&#160;</p>
<p style="position:absolute;top:359px;left:108px;white-space:nowrap" class="ft032">study in the late 1990s, people&#160;with HIV who developed cryptococcosis were&#160;severely&#160;<br/>immunosuppressed and&#160;had barriers to&#160;accessing routine HIV&#160;medical&#160;care.</p>
<p style="position:absolute;top:377px;left:629px;white-space:nowrap" class="ft038">2</p>
<p style="position:absolute;top:379px;left:635px;white-space:nowrap" class="ft013">&#160;Estimates indicate that&#160;</p>
<p style="position:absolute;top:399px;left:108px;white-space:nowrap" class="ft032">every year, approximately 280,000 cases of cryptococcal infection in people&#160;with AIDS&#160;occur&#160;<br/>worldwide, and the disease accounts for 15% of&#160;AIDS-related deaths.</p>
<p style="position:absolute;top:417px;left:589px;white-space:nowrap" class="ft038">3</p>
<p style="position:absolute;top:418px;left:594px;white-space:nowrap" class="ft013">&#160;Overall, 90% of cryptococcal&#160;</p>
<p style="position:absolute;top:438px;left:108px;white-space:nowrap" class="ft032">cases in people&#160;with HIV&#160;are&#160;observed&#160;in those who&#160;have CD4 T&#160;lymphocyte (CD4) cell counts&#160;<br/>&lt;100 cells/mm</p>
<p style="position:absolute;top:457px;left:211px;white-space:nowrap" class="ft038">3</p>
<p style="position:absolute;top:458px;left:217px;white-space:nowrap" class="ft013">. The&#160;incidence of the&#160;disease has declined substantially among people treated&#160;</p>
<p style="position:absolute;top:478px;left:108px;white-space:nowrap" class="ft013">effectively with ART.</p>
<p style="position:absolute;top:477px;left:260px;white-space:nowrap" class="ft038">4</p>
<p style="position:absolute;top:514px;left:108px;white-space:nowrap" class="ft026"><b>Clinical Manifestations&#160;</b></p>
<p style="position:absolute;top:556px;left:108px;white-space:nowrap" class="ft032">In people with HIV, cryptococcosis commonly presents as subacute meningitis or&#160;<br/>meningoencephalitis with fever, malaise, and headache slowly developing over many weeks, with a&#160;<br/>median duration of 2 weeks.</p>
<p style="position:absolute;top:595px;left:304px;white-space:nowrap" class="ft038">1</p>
<p style="position:absolute;top:596px;left:310px;white-space:nowrap" class="ft013">&#160;Classic&#160;meningeal&#160;symptoms and&#160;signs—such&#160;as neck stiffness and&#160;</p>
<p style="position:absolute;top:616px;left:108px;white-space:nowrap" class="ft032">photophobia—occur in only one-quarter to one-third of people.&#160;Some individuals experience&#160;<br/>encephalopathic&#160;symptoms—such&#160;as lethargy, altered mentation, personality changes, and&#160;memory&#160;<br/>loss—that&#160;are usually a result of increased intracranial pressure (ICP).</p>
<p style="position:absolute;top:654px;left:592px;white-space:nowrap" class="ft038">5</p>
<p style="position:absolute;top:656px;left:597px;white-space:nowrap" class="ft013">&#160;Among people presenting&#160;</p>
<p style="position:absolute;top:675px;left:108px;white-space:nowrap" class="ft032">with cryptococcal meningitis shortly&#160;after initiating ART, the&#160;symptom onset&#160;can be&#160;more&#160;acute,&#160;<br/>likely related&#160;to an unmasking immune reconstitution inflammatory syndrome (IRIS).</p>
<p style="position:absolute;top:694px;left:700px;white-space:nowrap" class="ft038">6</p>
<p style="position:absolute;top:695px;left:706px;white-space:nowrap" class="ft013">&#160;</p>
<p style="position:absolute;top:732px;left:108px;white-space:nowrap" class="ft032">Despite&#160;manifesting principally as a central nervous&#160;system (CNS) disease, cryptococcosis&#160;may&#160;<br/>involve any&#160;bodily organ.&#160;In fact, despite widespread disseminated disease, people&#160;with HIV may&#160;<br/>manifest few&#160;symptoms.&#160;Skin lesions&#160;may show different&#160;manifestations, including umbilicated skin&#160;<br/>lesions that&#160;mimic those seen with molluscum contagiosum. Isolated pulmonary infection is also&#160;<br/>possible;&#160;symptoms and&#160;signs include&#160;cough and dyspnea in association with an abnormal&#160;chest&#160;<br/>radiograph,&#160;which typically demonstrates lobar consolidation, although nodular infiltrates have been&#160;<br/>reported. Pulmonary cryptococcosis may present&#160;as&#160;acute respiratory distress&#160;syndrome and even&#160;<br/>mimic&#160;</p>
<p style="position:absolute;top:871px;left:156px;white-space:nowrap" class="ft019"><i>Pneumocystis</i></p>
<p style="position:absolute;top:871px;left:251px;white-space:nowrap" class="ft013">&#160;pneumonia.&#160;</p>
<p style="position:absolute;top:908px;left:108px;white-space:nowrap" class="ft026"><b>Diagnosis&#160;</b></p>
<p style="position:absolute;top:950px;left:108px;white-space:nowrap" class="ft032">In people with HIV, cryptococcosis is&#160;usually disseminated at&#160;the time of diagnosis and&#160;most&#160;<br/>commonly presents as&#160;subacute&#160;meningoencephalitis. Analysis&#160;of cerebrospinal fluid (CSF) in initial&#160;<br/>cases generally demonstrates mildly elevated protein levels, low-to-normal glucose concentrations,&#160;<br/>and a variable&#160;presence&#160;of&#160;pleocytosis&#160;consisting mostly of lymphocytes. Some&#160;people with advanced&#160;<br/>HIV&#160;may&#160;have very few&#160;CSF inflammatory cells. A Gram stain or an India&#160;ink preparation, if&#160;<br/>available, may reveal&#160;numerous yeast forms. In patients with HIV and cryptococcal&#160;meningitis, the&#160;</p>
</div>
<!-- Page 124 -->
<a name="124"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page124-div" style="position:relative;width:917px;height:1187px;">
<p style="position:absolute;top:1117px;left:108px;white-space:nowrap" class="ft024"><i>Guidelines for the Prevention and Treatment&#160;of&#160;Opportunistic&#160;Infections in Adults&#160;and Adolescents&#160;With HIV&#160;</i></p>
<p style="position:absolute;top:1117px;left:790px;white-space:nowrap" class="ft024"><i>H-2&#160;</i></p>
<p style="position:absolute;top:109px;left:108px;white-space:nowrap" class="ft013">opening pressure for the&#160;CSF may be&#160;elevated</p>
<p style="position:absolute;top:109px;left:426px;white-space:nowrap" class="ft018">, with pressures&#160;</p>
<p style="position:absolute;top:109px;left:538px;white-space:nowrap" class="ft069">≥</p>
<p style="position:absolute;top:109px;left:548px;white-space:nowrap" class="ft018">25 cm&#160;</p>
<p style="position:absolute;top:109px;left:595px;white-space:nowrap" class="ft013">CSF in 60% to 80% of&#160;</p>
<p style="position:absolute;top:129px;left:108px;white-space:nowrap" class="ft013">patients.</p>
<p style="position:absolute;top:127px;left:166px;white-space:nowrap" class="ft038">7,8</p>
<p style="position:absolute;top:166px;left:108px;white-space:nowrap" class="ft032">Cryptococcal&#160;disease can&#160;be diagnosed&#160;by culture,&#160;CSF microscopy, cryptococcal antigen (CrAg)&#160;<br/>detection, or CSF polymerase chain reaction (PCR). In HIV-related cryptococcal meningitis, most&#160;<br/>blood cultures and CSF cultures will&#160;be positive (47% to 70% and 90% to 94%, respectively).</p>
<p style="position:absolute;top:204px;left:756px;white-space:nowrap" class="ft038">5</p>
<p style="position:absolute;top:205px;left:762px;white-space:nowrap" class="ft013">&#160;</p>
<p style="position:absolute;top:225px;left:108px;white-space:nowrap" class="ft013">Visible&#160;</p>
<p style="position:absolute;top:225px;left:162px;white-space:nowrap" class="ft019"><i>Cryptococcus</i></p>
<p style="position:absolute;top:225px;left:257px;white-space:nowrap" class="ft013">&#160;colonies on a fungal Sabouraud dextrose agar plate, or&#160;even a&#160;standard aerobic&#160;</p>
<p style="position:absolute;top:245px;left:108px;white-space:nowrap" class="ft013">bacterial culture, generally can be&#160;detected within 7 days.&#160;</p>
<p style="position:absolute;top:245px;left:509px;white-space:nowrap" class="ft019"><i>Cryptococcus</i></p>
<p style="position:absolute;top:245px;left:603px;white-space:nowrap" class="ft013">&#160;may&#160;be identified&#160;</p>
<p style="position:absolute;top:265px;left:108px;white-space:nowrap" class="ft032">occasionally on a&#160;routine&#160;Gram stain preparation of&#160;CSF as poorly staining Gram-positive&#160;yeasts.&#160;<br/>India&#160;ink staining of CSF&#160;demonstrates&#160;encapsulated yeasts in 60% to 80%&#160;of cases, but&#160;many&#160;<br/>laboratories in the&#160;United&#160;States no longer perform&#160;this test. India ink is relatively insensitive early in&#160;<br/>disease when&#160;&lt;1,000&#160;</p>
<p style="position:absolute;top:324px;left:257px;white-space:nowrap" class="ft019"><i>Cryptococcus&#160;</i></p>
<p style="position:absolute;top:324px;left:356px;white-space:nowrap" class="ft013">colony-forming&#160;units (CFU)/mL&#160;are present.</p>
<p style="position:absolute;top:323px;left:664px;white-space:nowrap" class="ft038">9</p>
<p style="position:absolute;top:324px;left:670px;white-space:nowrap" class="ft013">&#160;In tissue&#160;or fluids,&#160;</p>
<p style="position:absolute;top:344px;left:108px;white-space:nowrap" class="ft032">yeasts will stain with Grocott methenamine silver&#160;stain, and the capsule will stain&#160;with mucicarmine&#160;<br/>or alcian blue&#160;stains. Positive cultures are required to prove yeast&#160;viability because strains can be&#160;<br/>stain positive&#160;with nonviable&#160;yeasts.&#160;</p>
<p style="position:absolute;top:421px;left:108px;white-space:nowrap" class="ft019"><i>Cryptococcus</i></p>
<p style="position:absolute;top:421px;left:203px;white-space:nowrap" class="ft013">&#160;can infect&#160;any part of the body, but&#160;brain and lungs are frequently target&#160;organs.&#160;</p>
<p style="position:absolute;top:441px;left:108px;white-space:nowrap" class="ft032">Cultures and/or histopathology are essential for precise diagnosis. However, in many patients with&#160;<br/>advanced HIV, the presentation is more&#160;commonly a meningeal syndrome&#160;rather than a pulmonary&#160;<br/>syndrome.&#160;</p>
<p style="position:absolute;top:518px;left:108px;white-space:nowrap" class="ft032">CSF CrAg is&#160;usually positive&#160;in people&#160;with cryptococcal meningoencephalitis; however,&#160;early&#160;<br/>meningitis can present&#160;with negative CSF studies and a positive CrAg in blood only.</p>
<p style="position:absolute;top:536px;left:692px;white-space:nowrap" class="ft038">10</p>
<p style="position:absolute;top:537px;left:703px;white-space:nowrap" class="ft013">&#160;Thus, serum&#160;</p>
<p style="position:absolute;top:557px;left:108px;white-space:nowrap" class="ft032">CrAg testing&#160;always should be&#160;performed in an immunocompromised individual with an&#160;unknown&#160;<br/>CNS&#160;disorder.</p>
<p style="position:absolute;top:576px;left:207px;white-space:nowrap" class="ft038">10</p>
<p style="position:absolute;top:577px;left:218px;white-space:nowrap" class="ft013">&#160;Serum CrAg is positive in both meningeal&#160;and non-meningeal&#160;cryptococcal&#160;</p>
<p style="position:absolute;top:597px;left:108px;white-space:nowrap" class="ft013">infections and may be present weeks to months before symptom&#160;onset.</p>
<p style="position:absolute;top:595px;left:596px;white-space:nowrap" class="ft038">11</p>
<p style="position:absolute;top:597px;left:612px;white-space:nowrap" class="ft013">All&#160;positive CrAg tests in&#160;</p>
<p style="position:absolute;top:617px;left:108px;white-space:nowrap" class="ft013">patients with HIV&#160;require&#160;consideration for therapy.&#160;</p>
<p style="position:absolute;top:654px;left:108px;white-space:nowrap" class="ft032">Three methods exist for antigen detection:&#160;latex agglutination, enzyme immunoassay (EIA), and&#160;<br/>lateral flow assay (LFA).&#160;The IMMY CrAg LFA&#160;(IMMY,&#160;Norman, Oklahoma) is the only&#160;LFA test&#160;<br/>for CrAg approved by the&#160;U.S.&#160;Food and Drug&#160;Administration (FDA).&#160;It is a useful initial screening&#160;<br/>tool&#160;for diagnosing cryptococcosis in&#160;people&#160;with&#160;HIV&#160;when applied to serum or plasma,</p>
<p style="position:absolute;top:712px;left:721px;white-space:nowrap" class="ft038">9,12</p>
<p style="position:absolute;top:713px;left:741px;white-space:nowrap" class="ft013">&#160;and it&#160;</p>
<p style="position:absolute;top:733px;left:108px;white-space:nowrap" class="ft032">also can be used with&#160;whole&#160;blood or CSF. CrAg testing of serum&#160;or plasma may be&#160;particularly&#160;<br/>useful when&#160;a lumbar puncture is delayed or refused. In a person&#160;with HIV, when serum CrAg LFA&#160;<br/>titers are &gt;1:160, disseminated disease&#160;becomes increasingly more likely, and when CrAg&#160;LFA titers&#160;<br/>are &gt;1:640, or when there&#160;is high clinical&#160;suspicion,&#160;disseminated and/or CNS&#160;involvement&#160;should be&#160;<br/>assumed, regardless&#160;of CSF antigen titer results.</p>
<p style="position:absolute;top:811px;left:441px;white-space:nowrap" class="ft038">13,14</p>
<p style="position:absolute;top:812px;left:466px;white-space:nowrap" class="ft013">&#160;Antigen titers by the LFA&#160;are approximately&#160;</p>
<p style="position:absolute;top:832px;left:108px;white-space:nowrap" class="ft032">fourfold higher than those&#160;with latex agglutination or EIA testing; thus, a titer of 1:640 by&#160;LFA is&#160;<br/>approximately equal&#160;to a&#160;titer of 1:160&#160;by EIA or latex agglutination. A prozone effect&#160;needs to be&#160;<br/>checked when CrAg&#160;with&#160;latex agglutination and LFA testing is&#160;negative&#160;despite observing yeasts in&#160;<br/>tissues or&#160;fluids.&#160;</p>
<p style="position:absolute;top:929px;left:108px;white-space:nowrap" class="ft032">In 2016, the&#160;BioFire&#160;FilmArray&#160;Meningitis/Encephalitis&#160;Panel&#160;PCR assay&#160;(BioFire Diagnostics, Salt&#160;<br/>Lake City, Utah) was&#160;approved by the&#160;FDA. This multiplex PCR tests for 14 targets, including&#160;</p>
<p style="position:absolute;top:969px;left:108px;white-space:nowrap" class="ft019"><i>C. neoformans&#160;</i></p>
<p style="position:absolute;top:969px;left:214px;white-space:nowrap" class="ft013">and&#160;</p>
<p style="position:absolute;top:969px;left:243px;white-space:nowrap" class="ft019"><i>C.&#160;gattii,&#160;</i></p>
<p style="position:absolute;top:969px;left:308px;white-space:nowrap" class="ft013">and</p>
<p style="position:absolute;top:969px;left:333px;white-space:nowrap" class="ft019"><i>&#160;</i></p>
<p style="position:absolute;top:969px;left:337px;white-space:nowrap" class="ft013">performs well in infections with a moderate-to-high fungal&#160;</p>
<p style="position:absolute;top:988px;left:108px;white-space:nowrap" class="ft013">burden.</p>
<p style="position:absolute;top:987px;left:160px;white-space:nowrap" class="ft038">15-17</p>
<p style="position:absolute;top:988px;left:187px;white-space:nowrap" class="ft013">&#160;False negative results have been noted&#160;to occur when there is a low burden of&#160;yeasts; in&#160;</p>
<p style="position:absolute;top:1008px;left:108px;white-space:nowrap" class="ft013">one study,&#160;when there were &lt;100 CFU/mL, the sensitivity of the PCR test fell to 50%.</p>
<p style="position:absolute;top:1007px;left:703px;white-space:nowrap" class="ft038">15</p>
<p style="position:absolute;top:1008px;left:714px;white-space:nowrap" class="ft013">&#160;In one well-</p>
<p style="position:absolute;top:1028px;left:108px;white-space:nowrap" class="ft032">described case, a woman&#160;who had two&#160;negative&#160;results with this&#160;PCR assay later had a positive result&#160;<br/>on a CrAg test&#160;done by IMMY LFA.</p>
<p style="position:absolute;top:1046px;left:362px;white-space:nowrap" class="ft038">18</p>
<p style="position:absolute;top:1048px;left:373px;white-space:nowrap" class="ft013">&#160;Thus, a&#160;negative&#160;CSF&#160;PCR does not completely exclude&#160;</p>
</div>
<!-- Page 125 -->
<a name="125"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page125-div" style="position:relative;width:917px;height:1187px;">
<p style="position:absolute;top:1117px;left:108px;white-space:nowrap" class="ft024"><i>Guidelines for the Prevention and Treatment&#160;of&#160;Opportunistic&#160;Infections in Adults&#160;and Adolescents&#160;With HIV&#160;</i></p>
<p style="position:absolute;top:1117px;left:790px;white-space:nowrap" class="ft024"><i>H-3&#160;</i></p>
<p style="position:absolute;top:109px;left:108px;white-space:nowrap" class="ft032">cryptococcal&#160;meningitis, and CrAg&#160;testing of CSF&#160;and blood should always&#160;be performed&#160;<br/>simultaneously. The PCR&#160;assay appears to have diagnostic utility when a&#160;second episode&#160;of&#160;<br/>cryptococcal&#160;meningitis is suspected;&#160;the&#160;test has been noted to differentiate&#160;a relapse (PCR positive)&#160;<br/>from IRIS&#160;(PCR negative).</p>
<p style="position:absolute;top:167px;left:294px;white-space:nowrap" class="ft038">15</p>
<p style="position:absolute;top:168px;left:305px;white-space:nowrap" class="ft013">&#160;</p>
<p style="position:absolute;top:205px;left:108px;white-space:nowrap" class="ft026"><b>Preventing&#160;Exposure&#160;</b></p>
<p style="position:absolute;top:247px;left:108px;white-space:nowrap" class="ft019"><i>Cryptococcus</i></p>
<p style="position:absolute;top:247px;left:203px;white-space:nowrap" class="ft013">&#160;is ubiquitous in the environment, and people with HIV cannot completely&#160;avoid&#160;</p>
<p style="position:absolute;top:266px;left:108px;white-space:nowrap" class="ft013">exposure to&#160;</p>
<p style="position:absolute;top:266px;left:192px;white-space:nowrap" class="ft019"><i>C</i></p>
<p style="position:absolute;top:266px;left:204px;white-space:nowrap" class="ft013">.&#160;</p>
<p style="position:absolute;top:266px;left:212px;white-space:nowrap" class="ft019"><i>neoformans&#160;</i></p>
<p style="position:absolute;top:266px;left:298px;white-space:nowrap" class="ft013">or</p>
<p style="position:absolute;top:266px;left:313px;white-space:nowrap" class="ft019"><i>&#160;C.&#160;gattii.&#160;</i></p>
<p style="position:absolute;top:266px;left:382px;white-space:nowrap" class="ft013">Limited epidemiological evidence suggests that exposure to&#160;</p>
<p style="position:absolute;top:286px;left:108px;white-space:nowrap" class="ft032">dried bird droppings, including those from chickens and pet birds, may increase the risk&#160;of infection&#160;<br/>and should be avoided. It is likely that&#160;many patients are infected with mixed strains of&#160;</p>
<p style="position:absolute;top:306px;left:712px;white-space:nowrap" class="ft019"><i>Cryptococcus</i></p>
<p style="position:absolute;top:306px;left:806px;white-space:nowrap" class="ft013">&#160;</p>
<p style="position:absolute;top:326px;left:108px;white-space:nowrap" class="ft013">over a lifetime, and clinical implications remain uncertain.</p>
<p style="position:absolute;top:325px;left:512px;white-space:nowrap" class="ft038">19,20</p>
<p style="position:absolute;top:326px;left:537px;white-space:nowrap" class="ft013">&#160;</p>
<p style="position:absolute;top:362px;left:108px;white-space:nowrap" class="ft026"><b>Preventing&#160;Disease&#160;</b></p>
<p style="position:absolute;top:404px;left:108px;white-space:nowrap" class="ft032">The&#160;incidence of cryptococcal disease is low among&#160;people with&#160;HIV&#160;in the&#160;United States. However,&#160;<br/>one report&#160;indicates that among study&#160;participants with HIV in&#160;the&#160;United States with peripheral&#160;</p>
<p style="position:absolute;top:444px;left:108px;white-space:nowrap" class="ft018">blood CD4&#160;counts&#160;</p>
<p style="position:absolute;top:444px;left:238px;white-space:nowrap" class="ft069">≤</p>
<p style="position:absolute;top:444px;left:247px;white-space:nowrap" class="ft018">100 cells/</p>
<p style="position:absolute;top:444px;left:314px;white-space:nowrap" class="ft013">mm</p>
<p style="position:absolute;top:443px;left:341px;white-space:nowrap" class="ft038">3</p>
<p style="position:absolute;top:444px;left:346px;white-space:nowrap" class="ft013">, the&#160;prevalence&#160;of cryptococcal&#160;antigenemia—a harbinger of&#160;</p>
<p style="position:absolute;top:464px;left:108px;white-space:nowrap" class="ft013">disease—was 2.9%,&#160;</p>
<p style="position:absolute;top:464px;left:251px;white-space:nowrap" class="ft018">and for those&#160;with CD4 counts&#160;</p>
<p style="position:absolute;top:464px;left:466px;white-space:nowrap" class="ft069">≤</p>
<p style="position:absolute;top:464px;left:476px;white-space:nowrap" class="ft018">50 cells/</p>
<p style="position:absolute;top:464px;left:533px;white-space:nowrap" class="ft013">mm</p>
<p style="position:absolute;top:463px;left:561px;white-space:nowrap" class="ft038">3</p>
<p style="position:absolute;top:464px;left:566px;white-space:nowrap" class="ft013">, the&#160;prevalence&#160;was 4.3%.</p>
<p style="position:absolute;top:463px;left:751px;white-space:nowrap" class="ft038">21</p>
<p style="position:absolute;top:464px;left:762px;white-space:nowrap" class="ft013">&#160;</p>
<p style="position:absolute;top:484px;left:108px;white-space:nowrap" class="ft013">Routine surveillance&#160;testing for serum&#160;CrAg in people with newly diagnosed&#160;HIV&#160;who&#160;have no overt&#160;</p>
<p style="position:absolute;top:504px;left:108px;white-space:nowrap" class="ft018">clinical&#160;signs of meningitis is recommended for patients whose CD4 counts&#160;are&#160;</p>
<p style="position:absolute;top:504px;left:658px;white-space:nowrap" class="ft069">≤</p>
<p style="position:absolute;top:504px;left:668px;white-space:nowrap" class="ft013">200 cells/mm</p>
<p style="position:absolute;top:502px;left:762px;white-space:nowrap" class="ft038">3</p>
<p style="position:absolute;top:504px;left:767px;white-space:nowrap" class="ft013">&#160;and&#160;</p>
<p style="position:absolute;top:523px;left:108px;white-space:nowrap" class="ft018">particularly in those with&#160;CD4 counts&#160;</p>
<p style="position:absolute;top:523px;left:371px;white-space:nowrap" class="ft069">≤</p>
<p style="position:absolute;top:523px;left:381px;white-space:nowrap" class="ft018">50 cells/</p>
<p style="position:absolute;top:523px;left:439px;white-space:nowrap" class="ft013">mm</p>
<p style="position:absolute;top:522px;left:466px;white-space:nowrap" class="ft038">3</p>
<p style="position:absolute;top:523px;left:471px;white-space:nowrap" class="ft013">&#160;</p>
<p style="position:absolute;top:523px;left:476px;white-space:nowrap" class="ft012"><b>(AII).</b></p>
<p style="position:absolute;top:522px;left:517px;white-space:nowrap" class="ft038">22</p>
<p style="position:absolute;top:523px;left:529px;white-space:nowrap" class="ft013">&#160;All positive&#160;tests generally should&#160;</p>
<p style="position:absolute;top:543px;left:108px;white-space:nowrap" class="ft013">prompt&#160;CSF&#160;evaluation for CNS&#160;infection, particularly when the serum&#160;LFA titer is&#160;</p>
<p style="position:absolute;top:543px;left:687px;white-space:nowrap" class="ft069">≥</p>
<p style="position:absolute;top:543px;left:697px;white-space:nowrap" class="ft013">1:160&#160;</p>
<p style="position:absolute;top:543px;left:740px;white-space:nowrap" class="ft012"><b>(AII).</b></p>
<p style="position:absolute;top:542px;left:782px;white-space:nowrap" class="ft038">23</p>
<p style="position:absolute;top:543px;left:794px;white-space:nowrap" class="ft013">&#160;</p>
<p style="position:absolute;top:563px;left:108px;white-space:nowrap" class="ft013">See section on Treatment of Asymptomatic Antigenemia.&#160;</p>
<p style="position:absolute;top:600px;left:108px;white-space:nowrap" class="ft032">Prospective&#160;controlled trials indicate that prophylactic&#160;fluconazole or itraconazole can reduce&#160;the&#160;<br/>frequency of&#160;primary cryptococcal disease in people with HIV who have CD4&#160;counts&#160;<br/>&lt;100 cells/mm.</p>
<p style="position:absolute;top:639px;left:215px;white-space:nowrap" class="ft038">24,25</p>
<p style="position:absolute;top:640px;left:241px;white-space:nowrap" class="ft013">&#160;However, in the&#160;United States, primary prophylaxis in the absence of&#160;a positive&#160;</p>
<p style="position:absolute;top:660px;left:108px;white-space:nowrap" class="ft032">serum CrAg&#160;test is not recommended because of the&#160;relative&#160;infrequency of cryptococcal disease,&#160;<br/>lack of clear survival benefit associated with prophylaxis,</p>
<p style="position:absolute;top:678px;left:506px;white-space:nowrap" class="ft038">26</p>
<p style="position:absolute;top:680px;left:517px;white-space:nowrap" class="ft013">&#160;possibility of drug–drug interactions,&#160;</p>
<p style="position:absolute;top:699px;left:108px;white-space:nowrap" class="ft013">potential development&#160;of antifungal drug resistance, and cost&#160;</p>
<p style="position:absolute;top:699px;left:533px;white-space:nowrap" class="ft012"><b>(BII).</b></p>
<p style="position:absolute;top:699px;left:573px;white-space:nowrap" class="ft013">&#160;</p>
<p style="position:absolute;top:736px;left:108px;white-space:nowrap" class="ft026"><b>Treating Disease&#160;</b></p>
<p style="position:absolute;top:787px;left:299px;white-space:nowrap" class="ft02"><b>Recommendations for Treating Cryptococcosis&#160;</b></p>
<p style="position:absolute;top:823px;left:116px;white-space:nowrap" class="ft056"><b>Treating&#160;CNS&#160;and/or Disseminated Disease&#160;</b></p>
<p style="position:absolute;top:847px;left:116px;white-space:nowrap" class="ft041">Treatment&#160;consists&#160;of three phases: induction, consolidation,&#160;and&#160;maintenance therapy.&#160;</p>
<p style="position:absolute;top:876px;left:116px;white-space:nowrap" class="ft042"><b>Induction&#160;Therapy (Duration:&#160;2 Weeks,&#160;Followed&#160;by Consolidation&#160;Therapy)&#160;</b></p>
<p style="position:absolute;top:902px;left:116px;white-space:nowrap" class="ft030">•</p>
<p style="position:absolute;top:904px;left:123px;white-space:nowrap" class="ft057">&#160;</p>
<p style="position:absolute;top:903px;left:133px;white-space:nowrap" class="ft041">Irrespective of&#160;which regimen&#160;is&#160;used, patients&#160;must be followed carefully&#160;in the hospital&#160;for at least&#160;7 days&#160;and ideally&#160;</p>
<p style="position:absolute;top:921px;left:133px;white-space:nowrap" class="ft041">14 days</p>
<p style="position:absolute;top:921px;left:176px;white-space:nowrap" class="ft042"><b>&#160;(AII).</b></p>
<p style="position:absolute;top:921px;left:207px;white-space:nowrap" class="ft041">&#160;LP should be&#160;performed at Day&#160;7&#160;and&#160;Day 14 to ensure an appropriate&#160;clinical&#160;response and&#160;culture&#160;sterility.&#160;</p>
<p style="position:absolute;top:938px;left:133px;white-space:nowrap" class="ft041">If increased ICP&#160;is documented,&#160;daily&#160;LP should be&#160;performed until&#160;the&#160;pressure is&#160;decreased into&#160;the&#160;normal range</p>
<p style="position:absolute;top:938px;left:761px;white-space:nowrap" class="ft042"><b>&#160;</b></p>
<p style="position:absolute;top:938px;left:764px;white-space:nowrap" class="ft041">and&#160;</p>
<p style="position:absolute;top:955px;left:133px;white-space:nowrap" class="ft041">symptoms&#160;have&#160;abated</p>
<p style="position:absolute;top:955px;left:260px;white-space:nowrap" class="ft042"><b>&#160;(AII).</b></p>
<p style="position:absolute;top:955px;left:291px;white-space:nowrap" class="ft041">&#160;</p>
<p style="position:absolute;top:984px;left:117px;white-space:nowrap" class="ft024"><i>Preferred&#160;Regimens&#160;&#160;</i></p>
<p style="position:absolute;top:1011px;left:117px;white-space:nowrap" class="ft030">•</p>
<p style="position:absolute;top:1012px;left:123px;white-space:nowrap" class="ft057">&#160;</p>
<p style="position:absolute;top:1012px;left:133px;white-space:nowrap" class="ft044">In the United&#160;States&#160;and&#160;other&#160;settings where daily&#160;monitoring&#160;of electrolytes&#160;and&#160;kidney function&#160;and administration of&#160;<br/>electrolytes&#160;and&#160;IV&#160;fluid is&#160;possible:&#160;</p>
<p style="position:absolute;top:1055px;left:133px;white-space:nowrap" class="ft062">o</p>
<p style="position:absolute;top:1054px;left:142px;white-space:nowrap" class="ft057">&#160;</p>
<p style="position:absolute;top:1054px;left:149px;white-space:nowrap" class="ft041">Liposomal&#160;amphotericin&#160;B 3–4 mg/kg IV&#160;once daily plus flucytosine 25&#160;mg/kg PO&#160;four times a day&#160;for 2 weeks&#160;</p>
<p style="position:absolute;top:1054px;left:748px;white-space:nowrap" class="ft042"><b>(AII)</b></p>
<p style="position:absolute;top:1054px;left:772px;white-space:nowrap" class="ft041">&#160;</p>
</div>
<!-- Page 126 -->
<a name="126"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page126-div" style="position:relative;width:917px;height:1187px;">
<p style="position:absolute;top:1117px;left:108px;white-space:nowrap" class="ft024"><i>Guidelines for the Prevention and Treatment&#160;of&#160;Opportunistic&#160;Infections in Adults&#160;and Adolescents&#160;With HIV&#160;</i></p>
<p style="position:absolute;top:1117px;left:790px;white-space:nowrap" class="ft024"><i>H-4&#160;</i></p>
<p style="position:absolute;top:109px;left:116px;white-space:nowrap" class="ft030">•</p>
<p style="position:absolute;top:110px;left:123px;white-space:nowrap" class="ft057">&#160;</p>
<p style="position:absolute;top:110px;left:133px;white-space:nowrap" class="ft041">In resource-limited health care systems, as&#160;recommended&#160;by the&#160;World Health Organization:&#160;</p>
<p style="position:absolute;top:138px;left:133px;white-space:nowrap" class="ft062">o</p>
<p style="position:absolute;top:136px;left:142px;white-space:nowrap" class="ft057">&#160;</p>
<p style="position:absolute;top:136px;left:149px;white-space:nowrap" class="ft041">Liposomal&#160;amphotericin B&#160;10 mg/kg IV as&#160;a&#160;single dose on&#160;Day&#160;1, followed by&#160;flucytosine 25&#160;mg/kg PO&#160;four&#160;times&#160;a day&#160;</p>
<p style="position:absolute;top:153px;left:149px;white-space:nowrap" class="ft041">plus fluconazole&#160;1,200&#160;mg PO daily&#160;for 2&#160;weeks&#160;</p>
<p style="position:absolute;top:153px;left:411px;white-space:nowrap" class="ft042"><b>(AI)</b></p>
<p style="position:absolute;top:153px;left:432px;white-space:nowrap" class="ft041">&#160;</p>
<p style="position:absolute;top:185px;left:117px;white-space:nowrap" class="ft024"><i>Alternative Regimens&#160;&#160;</i></p>
<p style="position:absolute;top:212px;left:117px;white-space:nowrap" class="ft030">•</p>
<p style="position:absolute;top:213px;left:123px;white-space:nowrap" class="ft057">&#160;</p>
<p style="position:absolute;top:213px;left:133px;white-space:nowrap" class="ft041">Amphotericin B&#160;lipid complex 5 mg/kg IV&#160;daily&#160;plus flucytosine&#160;25&#160;mg/kg PO four times a day for 2&#160;weeks&#160;</p>
<p style="position:absolute;top:213px;left:705px;white-space:nowrap" class="ft042"><b>(BII),&#160;</b></p>
<p style="position:absolute;top:213px;left:735px;white-space:nowrap" class="ft024"><i>or</i></p>
<p style="position:absolute;top:213px;left:746px;white-space:nowrap" class="ft041">&#160;</p>
<p style="position:absolute;top:239px;left:117px;white-space:nowrap" class="ft030">•</p>
<p style="position:absolute;top:240px;left:123px;white-space:nowrap" class="ft057">&#160;</p>
<p style="position:absolute;top:240px;left:133px;white-space:nowrap" class="ft041">Amphotericin B&#160;deoxycholate 1&#160;mg/kg IV&#160;daily plus flucytosine&#160;25&#160;mg/kg PO four&#160;times a day for 1&#160;week, followed by&#160;</p>
<p style="position:absolute;top:257px;left:133px;white-space:nowrap" class="ft041">fluconazole&#160;1,200 mg&#160;PO daily for&#160;an&#160;additional&#160;week&#160;</p>
<p style="position:absolute;top:257px;left:426px;white-space:nowrap" class="ft042"><b>(BI)</b></p>
<p style="position:absolute;top:257px;left:446px;white-space:nowrap" class="ft041">&#160;</p>
<p style="position:absolute;top:289px;left:117px;white-space:nowrap" class="ft042"><b>Note:</b></p>
<p style="position:absolute;top:289px;left:148px;white-space:nowrap" class="ft041">&#160;The flucytosine&#160;dose&#160;should be adjusted&#160;in&#160;renal&#160;impairment and&#160;ideally use TDM&#160;(see&#160;</p>
<p style="position:absolute;top:289px;left:625px;white-space:nowrap" class="ft043">Table 6</p>
<p style="position:absolute;top:289px;left:666px;white-space:nowrap" class="ft041">).&#160;</p>
<p style="position:absolute;top:322px;left:116px;white-space:nowrap" class="ft024"><i>Additional&#160;Studied Regimens&#160;(Duration of Therapy: 2 Weeks)&#160;</i></p>
<p style="position:absolute;top:348px;left:116px;white-space:nowrap" class="ft030">•</p>
<p style="position:absolute;top:349px;left:123px;white-space:nowrap" class="ft057">&#160;</p>
<p style="position:absolute;top:349px;left:133px;white-space:nowrap" class="ft041">Amphotericin B&#160;deoxycholate 0.7–1.0 mg/kg IV&#160;once daily&#160;plus flucytosine 25 mg/kg PO four times&#160;a day&#160;</p>
<p style="position:absolute;top:349px;left:704px;white-space:nowrap" class="ft042"><b>(BI)</b></p>
<p style="position:absolute;top:349px;left:724px;white-space:nowrap" class="ft041">&#160;</p>
<p style="position:absolute;top:375px;left:116px;white-space:nowrap" class="ft030">•</p>
<p style="position:absolute;top:377px;left:123px;white-space:nowrap" class="ft057">&#160;</p>
<p style="position:absolute;top:376px;left:133px;white-space:nowrap" class="ft041">Liposomal&#160;amphotericin B&#160;3–4 mg/kg IV once daily&#160;plus fluconazole 800–1,200 mg PO once daily&#160;</p>
<p style="position:absolute;top:376px;left:666px;white-space:nowrap" class="ft042"><b>(BIII)</b></p>
<p style="position:absolute;top:376px;left:693px;white-space:nowrap" class="ft041">&#160;</p>
<p style="position:absolute;top:402px;left:116px;white-space:nowrap" class="ft030">•</p>
<p style="position:absolute;top:404px;left:123px;white-space:nowrap" class="ft057">&#160;</p>
<p style="position:absolute;top:403px;left:133px;white-space:nowrap" class="ft041">Amphotericin B&#160;deoxycholate 0.7–1.0 mg/kg IV&#160;once daily&#160;plus fluconazole 800–1,200 mg&#160;PO once daily&#160;</p>
<p style="position:absolute;top:403px;left:704px;white-space:nowrap" class="ft042"><b>(BI)</b></p>
<p style="position:absolute;top:403px;left:725px;white-space:nowrap" class="ft041">&#160;</p>
<p style="position:absolute;top:430px;left:116px;white-space:nowrap" class="ft030">•</p>
<p style="position:absolute;top:431px;left:123px;white-space:nowrap" class="ft057">&#160;</p>
<p style="position:absolute;top:431px;left:133px;white-space:nowrap" class="ft041">Fluconazole&#160;1,200 mg PO&#160;or IV&#160;once daily plus flucytosine 25 mg/kg PO four&#160;times a day&#160;</p>
<p style="position:absolute;top:431px;left:620px;white-space:nowrap" class="ft042"><b>(BII)</b></p>
<p style="position:absolute;top:431px;left:644px;white-space:nowrap" class="ft041">&#160;</p>
<p style="position:absolute;top:463px;left:116px;white-space:nowrap" class="ft041">If the patient&#160;has not improved&#160;clinically&#160;or remains clinically&#160;unstable, continue&#160;or&#160;start&#160;(liposomal&#160;amphotericin B or&#160;</p>
<p style="position:absolute;top:480px;left:116px;white-space:nowrap" class="ft041">amphotericin B&#160;deoxycholate) plus flucytosine induction therapy&#160;until the CSF culture is&#160;confirmed&#160;to&#160;be negative&#160;</p>
<p style="position:absolute;top:480px;left:732px;white-space:nowrap" class="ft042"><b>(BIII).&#160;</b></p>
<p style="position:absolute;top:512px;left:116px;white-space:nowrap" class="ft024"><i>Additional&#160;Considerations&#160;&#160;</i></p>
<p style="position:absolute;top:538px;left:116px;white-space:nowrap" class="ft030">•</p>
<p style="position:absolute;top:540px;left:123px;white-space:nowrap" class="ft057">&#160;</p>
<p style="position:absolute;top:540px;left:133px;white-space:nowrap" class="ft041">CSF opening pressure should&#160;always&#160;be&#160;measured&#160;when an LP is&#160;performed. Repeated&#160;therapeutic&#160;LPs&#160;are essential&#160;to&#160;</p>
<p style="position:absolute;top:557px;left:133px;white-space:nowrap" class="ft041">manage&#160;symptomatic increased&#160;ICP and have a&#160;survival&#160;benefit&#160;</p>
<p style="position:absolute;top:557px;left:483px;white-space:nowrap" class="ft042"><b>(AII).</b></p>
<p style="position:absolute;top:557px;left:511px;white-space:nowrap" class="ft041">&#160;</p>
<p style="position:absolute;top:583px;left:116px;white-space:nowrap" class="ft030">•</p>
<p style="position:absolute;top:584px;left:123px;white-space:nowrap" class="ft057">&#160;</p>
<p style="position:absolute;top:584px;left:133px;white-space:nowrap" class="ft041">Corticosteroids&#160;should not be used routinely&#160;during induction&#160;therapy unless&#160;used for management&#160;of IRIS&#160;</p>
<p style="position:absolute;top:584px;left:713px;white-space:nowrap" class="ft042"><b>(AI).</b></p>
<p style="position:absolute;top:584px;left:737px;white-space:nowrap" class="ft041">&#160;</p>
<p style="position:absolute;top:610px;left:116px;white-space:nowrap" class="ft030">•</p>
<p style="position:absolute;top:612px;left:123px;white-space:nowrap" class="ft057">&#160;</p>
<p style="position:absolute;top:611px;left:133px;white-space:nowrap" class="ft041">Corticosteroids,&#160;acetazolamide,&#160;and&#160;mannitol&#160;are ineffective in&#160;reducing ICP&#160;and&#160;</p>
<p style="position:absolute;top:611px;left:573px;white-space:nowrap" class="ft042"><b>are not recommended</b></p>
<p style="position:absolute;top:611px;left:701px;white-space:nowrap" class="ft041">&#160;</p>
<p style="position:absolute;top:611px;left:705px;white-space:nowrap" class="ft042"><b>(AIII).</b></p>
<p style="position:absolute;top:611px;left:735px;white-space:nowrap" class="ft041">&#160;</p>
<p style="position:absolute;top:643px;left:116px;white-space:nowrap" class="ft061"><b>Consolidation&#160;Therapy&#160;(Duration&#160;of&#160;Therapy:&#160;</b></p>
<p style="position:absolute;top:643px;left:381px;white-space:nowrap" class="ft060"><b>≥</b></p>
<p style="position:absolute;top:643px;left:389px;white-space:nowrap" class="ft061"><b>8 Weeks, Followed by Maintenance Therapy)</b></p>
<p style="position:absolute;top:643px;left:650px;white-space:nowrap" class="ft042"><b>&#160;</b></p>
<p style="position:absolute;top:670px;left:116px;white-space:nowrap" class="ft041">Perform LP&#160;after&#160;1 week&#160;and/or 2&#160;weeks&#160;of&#160;induction therapy to document the culture is&#160;negative&#160;</p>
<p style="position:absolute;top:670px;left:644px;white-space:nowrap" class="ft042"><b>(AII).</b></p>
<p style="position:absolute;top:670px;left:672px;white-space:nowrap" class="ft041">&#160;After 2 weeks&#160;of&#160;</p>
<p style="position:absolute;top:687px;left:117px;white-space:nowrap" class="ft044">induction therapy, people who&#160;are clinically&#160;stable may&#160;be switched to consolidation therapy while&#160;awaiting&#160;culture results.&#160;<br/>Duration</p>
<p style="position:absolute;top:704px;left:163px;white-space:nowrap" class="ft042"><b>&#160;</b></p>
<p style="position:absolute;top:704px;left:166px;white-space:nowrap" class="ft041">of</p>
<p style="position:absolute;top:704px;left:177px;white-space:nowrap" class="ft042"><b>&#160;</b></p>
<p style="position:absolute;top:704px;left:180px;white-space:nowrap" class="ft041">consolidation therapy should be&#160;for at&#160;least 8 weeks&#160;after receiving CSF&#160;culture at 2&#160;weeks&#160;is&#160;negative&#160;</p>
<p style="position:absolute;top:704px;left:739px;white-space:nowrap" class="ft042"><b>(AII).</b></p>
<p style="position:absolute;top:704px;left:766px;white-space:nowrap" class="ft041">&#160;</p>
<p style="position:absolute;top:736px;left:117px;white-space:nowrap" class="ft024"><i>Preferred&#160;Regimen&#160;</i></p>
<p style="position:absolute;top:763px;left:117px;white-space:nowrap" class="ft030">•</p>
<p style="position:absolute;top:764px;left:123px;white-space:nowrap" class="ft057">&#160;</p>
<p style="position:absolute;top:764px;left:133px;white-space:nowrap" class="ft041">Fluconazole&#160;800&#160;mg&#160;PO daily&#160;</p>
<p style="position:absolute;top:764px;left:297px;white-space:nowrap" class="ft042"><b>(AI)</b></p>
<p style="position:absolute;top:764px;left:317px;white-space:nowrap" class="ft041">&#160;</p>
<p style="position:absolute;top:790px;left:117px;white-space:nowrap" class="ft030">•</p>
<p style="position:absolute;top:791px;left:123px;white-space:nowrap" class="ft057">&#160;</p>
<p style="position:absolute;top:791px;left:133px;white-space:nowrap" class="ft041">For&#160;clinically stable patients, continue&#160;fluconazole&#160;800&#160;mg&#160;until&#160;CSF cultures&#160;are&#160;known to be&#160;sterile and ART&#160;has&#160;been&#160;</p>
<p style="position:absolute;top:808px;left:133px;white-space:nowrap" class="ft041">initiated; dose then can be&#160;reduced&#160;to 400 mg PO daily&#160;</p>
<p style="position:absolute;top:808px;left:436px;white-space:nowrap" class="ft042"><b>(AII).</b></p>
<p style="position:absolute;top:808px;left:463px;white-space:nowrap" class="ft041">&#160;</p>
<p style="position:absolute;top:834px;left:117px;white-space:nowrap" class="ft030">•</p>
<p style="position:absolute;top:836px;left:123px;white-space:nowrap" class="ft057">&#160;</p>
<p style="position:absolute;top:835px;left:133px;white-space:nowrap" class="ft041">If CSF remains&#160;positive in a clinically&#160;stable patient after 2 weeks&#160;of induction&#160;therapy, use one of&#160;the following two options&#160;</p>
<p style="position:absolute;top:853px;left:133px;white-space:nowrap" class="ft041">for an&#160;additional&#160;2 weeks&#160;before&#160;reducing the dose to&#160;fluconazole&#160;800&#160;mg PO daily:&#160;</p>
<p style="position:absolute;top:880px;left:133px;white-space:nowrap" class="ft062">o</p>
<p style="position:absolute;top:879px;left:142px;white-space:nowrap" class="ft057">&#160;</p>
<p style="position:absolute;top:879px;left:149px;white-space:nowrap" class="ft041">Fluconazole&#160;1,200 mg PO&#160;daily&#160;plus flucytosine 25&#160;mg/kg PO&#160;four times a day&#160;for&#160;an&#160;additional&#160;2&#160;weeks&#160;</p>
<p style="position:absolute;top:879px;left:716px;white-space:nowrap" class="ft042"><b>(BIII),</b></p>
<p style="position:absolute;top:879px;left:747px;white-space:nowrap" class="ft041">&#160;or</p>
<p style="position:absolute;top:879px;left:761px;white-space:nowrap" class="ft042"><b>&#160;&#160;</b></p>
<p style="position:absolute;top:913px;left:133px;white-space:nowrap" class="ft062">o</p>
<p style="position:absolute;top:911px;left:142px;white-space:nowrap" class="ft057">&#160;</p>
<p style="position:absolute;top:911px;left:149px;white-space:nowrap" class="ft041">Fluconazole&#160;1,200 mg PO&#160;daily&#160;for an additional&#160;2 weeks&#160;</p>
<p style="position:absolute;top:911px;left:463px;white-space:nowrap" class="ft042"><b>(BIII)</b></p>
<p style="position:absolute;top:911px;left:490px;white-space:nowrap" class="ft041">&#160;</p>
<p style="position:absolute;top:943px;left:117px;white-space:nowrap" class="ft024"><i>Alternative Regimen&#160;</i></p>
<p style="position:absolute;top:969px;left:117px;white-space:nowrap" class="ft030">•</p>
<p style="position:absolute;top:971px;left:124px;white-space:nowrap" class="ft057">&#160;</p>
<p style="position:absolute;top:970px;left:133px;white-space:nowrap" class="ft041">Itraconazole 200 mg PO twice a&#160;day, if fluconazole is&#160;not&#160;available or not&#160;tolerated&#160;</p>
<p style="position:absolute;top:970px;left:583px;white-space:nowrap" class="ft042"><b>(CI)&#160;</b></p>
</div>
<!-- Page 127 -->
<a name="127"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}	.ft0124{font-size:16px;font-family:PZCZYN+ArialNarrow;color:#000000;}
	.ft0125{font-size:16px;font-family:LLJGTQ+ArialNarrow;color:#000000;}
	.ft0126{font-size:16px;line-height:19px;font-family:BGKYCV+LiberationSansNarrow;color:#000000;}
-->
</style>
<div id="page127-div" style="position:relative;width:917px;height:1187px;">
<p style="position:absolute;top:1117px;left:108px;white-space:nowrap" class="ft024"><i>Guidelines for the Prevention and Treatment&#160;of&#160;Opportunistic&#160;Infections in Adults&#160;and Adolescents&#160;With HIV&#160;</i></p>
<p style="position:absolute;top:1117px;left:790px;white-space:nowrap" class="ft024"><i>H-5&#160;</i></p>
<p style="position:absolute;top:109px;left:116px;white-space:nowrap" class="ft042"><b>Maintenance&#160;Therapy&#160;</b></p>
<p style="position:absolute;top:135px;left:116px;white-space:nowrap" class="ft024"><i>Preferred&#160;Regimen&#160;</i></p>
<p style="position:absolute;top:161px;left:116px;white-space:nowrap" class="ft030">•</p>
<p style="position:absolute;top:163px;left:123px;white-space:nowrap" class="ft057">&#160;</p>
<p style="position:absolute;top:162px;left:133px;white-space:nowrap" class="ft065">Fluconazole&#160;200&#160;mg&#160;PO&#160;once daily&#160;for&#160;</p>
<p style="position:absolute;top:162px;left:345px;white-space:nowrap" class="ft064">≥</p>
<p style="position:absolute;top:162px;left:353px;white-space:nowrap" class="ft065">1&#160;year from initiation of antifungal&#160;therapy&#160;</p>
<p style="position:absolute;top:162px;left:582px;white-space:nowrap" class="ft042"><b>(AI)</b></p>
<p style="position:absolute;top:162px;left:602px;white-space:nowrap" class="ft041">&#160;</p>
<p style="position:absolute;top:194px;left:116px;white-space:nowrap" class="ft024"><i>Alternative Regimen&#160;</i></p>
<p style="position:absolute;top:221px;left:116px;white-space:nowrap" class="ft030">•</p>
<p style="position:absolute;top:222px;left:123px;white-space:nowrap" class="ft057">&#160;</p>
<p style="position:absolute;top:222px;left:133px;white-space:nowrap" class="ft041">Itraconazole 200 mg&#160;PO twice a&#160;day</p>
<p style="position:absolute;top:222px;left:330px;white-space:nowrap" class="ft042"><b>,&#160;</b></p>
<p style="position:absolute;top:222px;left:337px;white-space:nowrap" class="ft041">if fluconazole is&#160;not available or&#160;not tolerated&#160;</p>
<p style="position:absolute;top:222px;left:583px;white-space:nowrap" class="ft042"><b>(CI)</b></p>
<p style="position:absolute;top:222px;left:604px;white-space:nowrap" class="ft041">&#160;</p>
<p style="position:absolute;top:248px;left:116px;white-space:nowrap" class="ft030">•</p>
<p style="position:absolute;top:249px;left:123px;white-space:nowrap" class="ft057">&#160;</p>
<p style="position:absolute;top:249px;left:133px;white-space:nowrap" class="ft041">If susceptibility&#160;studies have been performed and&#160;the&#160;fluconazole&#160;MIC is&#160;</p>
<p style="position:absolute;top:249px;left:527px;white-space:nowrap" class="ft064">≥</p>
<p style="position:absolute;top:249px;left:535px;white-space:nowrap" class="ft041">16 µ&#160;g/mL,&#160;the&#160;fluconazole dose may be&#160;</p>
<p style="position:absolute;top:266px;left:133px;white-space:nowrap" class="ft041">increased to&#160;400&#160;mg daily&#160;</p>
<p style="position:absolute;top:266px;left:276px;white-space:nowrap" class="ft042"><b>(BIII).</b></p>
<p style="position:absolute;top:266px;left:307px;white-space:nowrap" class="ft041">&#160;</p>
<p style="position:absolute;top:298px;left:116px;white-space:nowrap" class="ft024"><i>Criteria&#160;for Stopping&#160;Maintenance Therapy&#160;</i></p>
<p style="position:absolute;top:298px;left:352px;white-space:nowrap" class="ft083"><i><b>(BII)</b></i></p>
<p style="position:absolute;top:298px;left:375px;white-space:nowrap" class="ft024"><i>&#160;</i></p>
<p style="position:absolute;top:325px;left:116px;white-space:nowrap" class="ft030">•</p>
<p style="position:absolute;top:326px;left:123px;white-space:nowrap" class="ft057">&#160;</p>
<p style="position:absolute;top:326px;left:133px;white-space:nowrap" class="ft041">At&#160;least 1 year from initiation of antifungal&#160;therapy,&#160;</p>
<p style="position:absolute;top:326px;left:409px;white-space:nowrap" class="ft024"><i>and</i></p>
<p style="position:absolute;top:326px;left:430px;white-space:nowrap" class="ft041">&#160;</p>
<p style="position:absolute;top:352px;left:116px;white-space:nowrap" class="ft030">•</p>
<p style="position:absolute;top:353px;left:123px;white-space:nowrap" class="ft057">&#160;</p>
<p style="position:absolute;top:353px;left:133px;white-space:nowrap" class="ft041">Patient&#160;remains&#160;asymptomatic&#160;from cryptococcal&#160;infection,&#160;</p>
<p style="position:absolute;top:353px;left:453px;white-space:nowrap" class="ft024"><i>and</i></p>
<p style="position:absolute;top:353px;left:474px;white-space:nowrap" class="ft041">&#160;</p>
<p style="position:absolute;top:379px;left:116px;white-space:nowrap" class="ft030">•</p>
<p style="position:absolute;top:381px;left:123px;white-space:nowrap" class="ft057">&#160;</p>
<p style="position:absolute;top:380px;left:133px;white-space:nowrap" class="ft065">CD4 count&#160;</p>
<p style="position:absolute;top:380px;left:194px;white-space:nowrap" class="ft064">≥</p>
<p style="position:absolute;top:380px;left:202px;white-space:nowrap" class="ft065">100&#160;cells/</p>
<p style="position:absolute;top:380px;left:254px;white-space:nowrap" class="ft041">mm</p>
<p style="position:absolute;top:381px;left:275px;white-space:nowrap" class="ft058">3</p>
<p style="position:absolute;top:380px;left:279px;white-space:nowrap" class="ft041">&#160;and&#160;suppressed HIV&#160;RNA in response to&#160;effective ART&#160;</p>
<p style="position:absolute;top:412px;left:116px;white-space:nowrap" class="ft024"><i>Restarting&#160;Maintenance Therapy&#160;</i></p>
<p style="position:absolute;top:439px;left:116px;white-space:nowrap" class="ft030">•</p>
<p style="position:absolute;top:440px;left:123px;white-space:nowrap" class="ft057">&#160;</p>
<p style="position:absolute;top:440px;left:133px;white-space:nowrap" class="ft041">If CD4 count declines to &lt;100 cells/mm</p>
<p style="position:absolute;top:441px;left:346px;white-space:nowrap" class="ft058">3</p>
<p style="position:absolute;top:440px;left:351px;white-space:nowrap" class="ft041">&#160;</p>
<p style="position:absolute;top:440px;left:354px;white-space:nowrap" class="ft042"><b>(AIII)</b></p>
<p style="position:absolute;top:440px;left:381px;white-space:nowrap" class="ft041">&#160;</p>
<p style="position:absolute;top:471px;left:116px;white-space:nowrap" class="ft0126"><b>Treating&#160;Non-CNS Extrapulmonary&#160;Disease,&#160;Diffuse&#160;Pulmonary Disease,&#160;or Non-CNS Symptoms&#160;With&#160;<br/>Normal CSF&#160;and&#160;Serum&#160;CrAg&#160;Titer&#160;</b></p>
<p style="position:absolute;top:490px;left:341px;white-space:nowrap" class="ft0124"><b>≥</b></p>
<p style="position:absolute;top:490px;left:350px;white-space:nowrap" class="ft0125"><b>1:640&#160;</b></p>
<p style="position:absolute;top:490px;left:388px;white-space:nowrap" class="ft056"><b>by LFA&#160;</b></p>
<p style="position:absolute;top:490px;left:438px;white-space:nowrap" class="ft0125"><b>(or&#160;</b></p>
<p style="position:absolute;top:490px;left:460px;white-space:nowrap" class="ft0124"><b>≥</b></p>
<p style="position:absolute;top:490px;left:469px;white-space:nowrap" class="ft0125"><b>1:160 by&#160;EIA or&#160;</b></p>
<p style="position:absolute;top:490px;left:570px;white-space:nowrap" class="ft056"><b>Latex Agglutination)&#160;</b></p>
<p style="position:absolute;top:514px;left:116px;white-space:nowrap" class="ft041">Administer the&#160;same treatment as&#160;for&#160;patients&#160;with cryptococcal&#160;meningitis&#160;to people with the following&#160;conditions:&#160;</p>
<p style="position:absolute;top:540px;left:116px;white-space:nowrap" class="ft030">•</p>
<p style="position:absolute;top:542px;left:123px;white-space:nowrap" class="ft057">&#160;</p>
<p style="position:absolute;top:542px;left:133px;white-space:nowrap" class="ft041">Non-CNS extrapulmonary&#160;disease&#160;</p>
<p style="position:absolute;top:542px;left:323px;white-space:nowrap" class="ft042"><b>(BIII)</b></p>
<p style="position:absolute;top:542px;left:350px;white-space:nowrap" class="ft041">&#160;</p>
<p style="position:absolute;top:568px;left:116px;white-space:nowrap" class="ft030">•</p>
<p style="position:absolute;top:569px;left:123px;white-space:nowrap" class="ft057">&#160;</p>
<p style="position:absolute;top:569px;left:133px;white-space:nowrap" class="ft041">Diffuse pulmonary&#160;disease&#160;</p>
<p style="position:absolute;top:569px;left:281px;white-space:nowrap" class="ft042"><b>(BIII)</b></p>
<p style="position:absolute;top:569px;left:308px;white-space:nowrap" class="ft041">&#160;</p>
<p style="position:absolute;top:595px;left:116px;white-space:nowrap" class="ft030">•</p>
<p style="position:absolute;top:596px;left:123px;white-space:nowrap" class="ft057">&#160;</p>
<p style="position:absolute;top:596px;left:133px;white-space:nowrap" class="ft041">Non-CNS symptoms, normal&#160;CSF</p>
<p style="position:absolute;top:596px;left:317px;white-space:nowrap" class="ft065">, and serum CrAg&#160;titer&#160;</p>
<p style="position:absolute;top:596px;left:441px;white-space:nowrap" class="ft064">≥</p>
<p style="position:absolute;top:596px;left:449px;white-space:nowrap" class="ft065">1:640</p>
<p style="position:absolute;top:596px;left:480px;white-space:nowrap" class="ft041">&#160;by LFA&#160;</p>
<p style="position:absolute;top:596px;left:525px;white-space:nowrap" class="ft065">(or&#160;</p>
<p style="position:absolute;top:596px;left:544px;white-space:nowrap" class="ft064">≥</p>
<p style="position:absolute;top:596px;left:552px;white-space:nowrap" class="ft065">1:160 by&#160;EIA&#160;or latex&#160;agglutination)&#160;</p>
<p style="position:absolute;top:596px;left:747px;white-space:nowrap" class="ft042"><b>(BII)</b></p>
<p style="position:absolute;top:596px;left:771px;white-space:nowrap" class="ft041">&#160;</p>
<p style="position:absolute;top:628px;left:116px;white-space:nowrap" class="ft042"><b>Note:</b></p>
<p style="position:absolute;top:628px;left:148px;white-space:nowrap" class="ft041">&#160;All&#160;people with non-CNS extrapulmonary&#160;symptoms&#160;and&#160;cryptococcal&#160;antigenemia should have their&#160;CSF sampled&#160;to&#160;</p>
<p style="position:absolute;top:645px;left:116px;white-space:nowrap" class="ft041">rule out CNS disease.&#160;</p>
<p style="position:absolute;top:677px;left:116px;white-space:nowrap" class="ft056"><b>Treating&#160;Non-CNS Focal Pulmonary&#160;Infiltrates&#160;(With&#160;Mild&#160;Symptoms)&#160;and&#160;Negative&#160;Serum CrAg&#160;</b></p>
<p style="position:absolute;top:701px;left:116px;white-space:nowrap" class="ft030">•</p>
<p style="position:absolute;top:703px;left:123px;white-space:nowrap" class="ft057">&#160;</p>
<p style="position:absolute;top:702px;left:133px;white-space:nowrap" class="ft041">Fluconazole&#160;400&#160;mg daily for 6 to&#160;12&#160;months (duration&#160;guided&#160;by symptom resolution)&#160;</p>
<p style="position:absolute;top:702px;left:601px;white-space:nowrap" class="ft042"><b>(BIII)</b></p>
<p style="position:absolute;top:702px;left:628px;white-space:nowrap" class="ft041">&#160;</p>
<p style="position:absolute;top:733px;left:116px;white-space:nowrap" class="ft056"><b>Treating&#160;Isolated Asymptomatic Cryptococcal Antigenemia&#160;(Serum&#160;CrAg Titer of LFA &lt;</b></p>
<p style="position:absolute;top:733px;left:674px;white-space:nowrap" class="ft0125"><b>1:640&#160;</b></p>
<p style="position:absolute;top:733px;left:712px;white-space:nowrap" class="ft056"><b>[or&#160;</b></p>
<p style="position:absolute;top:733px;left:734px;white-space:nowrap" class="ft0125"><b>&lt;1:160&#160;by&#160;</b></p>
<p style="position:absolute;top:752px;left:116px;white-space:nowrap" class="ft056"><b>EIA or Latex&#160;Agglutination])</b></p>
<p style="position:absolute;top:753px;left:295px;white-space:nowrap" class="ft041">&#160;</p>
<p style="position:absolute;top:777px;left:116px;white-space:nowrap" class="ft030">•</p>
<p style="position:absolute;top:778px;left:123px;white-space:nowrap" class="ft057">&#160;</p>
<p style="position:absolute;top:778px;left:133px;white-space:nowrap" class="ft041">Fluconazole&#160;800–1,200&#160;mg PO&#160;daily for 2 weeks,&#160;followed by fluconazole&#160;400–800 mg&#160;PO daily for&#160;10&#160;weeks, then&#160;</p>
<p style="position:absolute;top:795px;left:133px;white-space:nowrap" class="ft041">fluconazole&#160;200&#160;mg PO&#160;daily for&#160;a total&#160;of 6&#160;months plus&#160;effective&#160;ART&#160;</p>
<p style="position:absolute;top:795px;left:518px;white-space:nowrap" class="ft042"><b>(BIII)</b></p>
<p style="position:absolute;top:795px;left:545px;white-space:nowrap" class="ft041">&#160;</p>
<p style="position:absolute;top:827px;left:116px;white-space:nowrap" class="ft042"><b>Note:</b></p>
<p style="position:absolute;top:827px;left:148px;white-space:nowrap" class="ft041">&#160;Those with lower risk&#160;and&#160;serum&#160;CrAg&#160;titer&#160;&lt;1:80 by LFA&#160;(&lt;1:20&#160;by&#160;</p>
<p style="position:absolute;top:827px;left:518px;white-space:nowrap" class="ft065">EIA&#160;</p>
<p style="position:absolute;top:827px;left:541px;white-space:nowrap" class="ft041">or latex agglutination) can be&#160;safely treated&#160;</p>
<p style="position:absolute;top:844px;left:117px;white-space:nowrap" class="ft041">without&#160;lumbar&#160;puncture&#160;</p>
<p style="position:absolute;top:844px;left:251px;white-space:nowrap" class="ft042"><b>(AI).</b></p>
<p style="position:absolute;top:844px;left:275px;white-space:nowrap" class="ft041">&#160;All&#160;others&#160;should&#160;undergo CSF&#160;sampling to&#160;rule&#160;out&#160;CNS disease.&#160;</p>
<p style="position:absolute;top:876px;left:116px;white-space:nowrap" class="ft056"><b>Treatment in&#160;Pregnancy&#160;</b></p>
<p style="position:absolute;top:900px;left:116px;white-space:nowrap" class="ft042"><b>Preferred Therapy During&#160;First&#160;Trimester&#160;</b></p>
<p style="position:absolute;top:926px;left:116px;white-space:nowrap" class="ft030">•</p>
<p style="position:absolute;top:928px;left:123px;white-space:nowrap" class="ft057">&#160;</p>
<p style="position:absolute;top:927px;left:133px;white-space:nowrap" class="ft041">Amphotericin B&#160;deoxycholate 0.7–1.0 mg/kg IV&#160;daily&#160;</p>
<p style="position:absolute;top:927px;left:420px;white-space:nowrap" class="ft042"><b>(AIII),</b></p>
<p style="position:absolute;top:927px;left:451px;white-space:nowrap" class="ft041">&#160;</p>
<p style="position:absolute;top:927px;left:455px;white-space:nowrap" class="ft024"><i>or</i></p>
<p style="position:absolute;top:927px;left:465px;white-space:nowrap" class="ft041">&#160;</p>
<p style="position:absolute;top:954px;left:116px;white-space:nowrap" class="ft030">•</p>
<p style="position:absolute;top:955px;left:123px;white-space:nowrap" class="ft057">&#160;</p>
<p style="position:absolute;top:955px;left:133px;white-space:nowrap" class="ft041">Lipid formulation&#160;amphotericin B 3–4 mg/kg IV&#160;daily&#160;</p>
<p style="position:absolute;top:955px;left:416px;white-space:nowrap" class="ft042"><b>(AIII)</b></p>
<p style="position:absolute;top:955px;left:444px;white-space:nowrap" class="ft041">&#160;&#160;</p>
<p style="position:absolute;top:981px;left:116px;white-space:nowrap" class="ft030">•</p>
<p style="position:absolute;top:982px;left:123px;white-space:nowrap" class="ft057">&#160;</p>
<p style="position:absolute;top:982px;left:133px;white-space:nowrap" class="ft041">Addition of flucytosine&#160;should be&#160;considered only&#160;when the&#160;benefits outweigh the risks, with&#160;delay&#160;until&#160;after the first&#160;</p>
<p style="position:absolute;top:999px;left:133px;white-space:nowrap" class="ft041">trimester&#160;when&#160;feasible&#160;</p>
<p style="position:absolute;top:999px;left:263px;white-space:nowrap" class="ft042"><b>(AIII).&#160;</b></p>
</div>
<!-- Page 128 -->
<a name="128"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}	.ft0127{font-size:17px;line-height:19px;font-family:TURBHP+Tinos;color:#202020;}
-->
</style>
<div id="page128-div" style="position:relative;width:917px;height:1187px;">
<p style="position:absolute;top:1117px;left:108px;white-space:nowrap" class="ft024"><i>Guidelines for the Prevention and Treatment&#160;of&#160;Opportunistic&#160;Infections in Adults&#160;and Adolescents&#160;With HIV&#160;</i></p>
<p style="position:absolute;top:1117px;left:790px;white-space:nowrap" class="ft024"><i>H-6&#160;</i></p>
<p style="position:absolute;top:109px;left:116px;white-space:nowrap" class="ft042"><b>Notes:&#160;</b></p>
<p style="position:absolute;top:109px;left:158px;white-space:nowrap" class="ft041">Optimal&#160;dosing of liposomal&#160;amphotericin B&#160;in pregnancy is unknown. Use of ideal&#160;body&#160;weight&#160;rather than total&#160;body&#160;</p>
<p style="position:absolute;top:126px;left:116px;white-space:nowrap" class="ft041">weight may&#160;minimize risk&#160;of&#160;adverse effects to the fetus while maintaining efficacy&#160;</p>
<p style="position:absolute;top:126px;left:564px;white-space:nowrap" class="ft042"><b>(BII).&#160;</b></p>
<p style="position:absolute;top:126px;left:595px;white-space:nowrap" class="ft041">In general, azole antifungal&#160;agents&#160;</p>
<p style="position:absolute;top:143px;left:116px;white-space:nowrap" class="ft041">should be&#160;avoided in the first trimester of pregnancy&#160;because of&#160;potential&#160;teratogenic&#160;effect, unless&#160;benefit is&#160;felt to outweigh&#160;</p>
<p style="position:absolute;top:161px;left:116px;white-space:nowrap" class="ft041">risk&#160;</p>
<p style="position:absolute;top:161px;left:139px;white-space:nowrap" class="ft042"><b>(BIII).</b></p>
<p style="position:absolute;top:161px;left:170px;white-space:nowrap" class="ft041">&#160;</p>
<p style="position:absolute;top:188px;left:108px;white-space:nowrap" class="ft042"><b>Key:</b></p>
<p style="position:absolute;top:188px;left:135px;white-space:nowrap" class="ft041">&#160;ART = antiretroviral&#160;therapy; CD4&#160;= CD4&#160;T&#160;lymphocyte;&#160;CNS&#160;= central&#160;nervous system;&#160;CrAg&#160;= cryptococcal&#160;antigen;&#160;</p>
<p style="position:absolute;top:205px;left:108px;white-space:nowrap" class="ft041">CSF =&#160;cerebrospinal&#160;fluid;&#160;</p>
<p style="position:absolute;top:205px;left:253px;white-space:nowrap" class="ft065">EIA&#160;=&#160;</p>
<p style="position:absolute;top:205px;left:287px;white-space:nowrap" class="ft041">enzyme immunoassay; ICP = intracranial&#160;pressure; IRIS&#160;= immune reconstitution inflammatory&#160;</p>
<p style="position:absolute;top:222px;left:108px;white-space:nowrap" class="ft041">syndrome; IV&#160;= intravenous; LFA&#160;= lateral&#160;flow assay; LP = lumbar puncture; MIC&#160;= minimum inhibitory&#160;concentration;&#160;</p>
<p style="position:absolute;top:239px;left:108px;white-space:nowrap" class="ft041">PO = orally;&#160;TDM =&#160;therapeutic&#160;drug monitoring&#160;</p>
<p style="position:absolute;top:275px;left:108px;white-space:nowrap" class="ft029"><i><b>Treatment&#160;of&#160;Central Nervous System&#160;and/or&#160;Disseminated Disease&#160;</b></i></p>
<p style="position:absolute;top:316px;left:108px;white-space:nowrap" class="ft077"><b>Treatment of CNS and disseminated&#160;disease consists&#160;of three&#160;phases: induction, consolidation,&#160;<br/>and maintenance.&#160;</b></p>
<p style="position:absolute;top:373px;left:108px;white-space:nowrap" class="ft070"><b>Induction Therapy&#160;</b></p>
<p style="position:absolute;top:411px;left:108px;white-space:nowrap" class="ft032">For induction treatment&#160;of cryptococcal&#160;meningitis and other forms of extrapulmonary&#160;<br/>cryptococcosis, an amphotericin B formulation given intravenously (IV), in&#160;combination with oral&#160;<br/>flucytosine, is recommended for 2&#160;weeks in a resource-available health&#160;care system&#160;</p>
<p style="position:absolute;top:450px;left:688px;white-space:nowrap" class="ft012"><b>(AII),&#160;</b></p>
<p style="position:absolute;top:450px;left:733px;white-space:nowrap" class="ft013">and in&#160;</p>
<p style="position:absolute;top:470px;left:108px;white-space:nowrap" class="ft032">resource-limited health care&#160;systems, a&#160;single&#160;dose&#160;of liposomal&#160;amphotericin B (10 mg/kg) is&#160;<br/>recommended, followed by 2 weeks of&#160;flucytosine&#160;and fluconazole&#160;</p>
<p style="position:absolute;top:490px;left:575px;white-space:nowrap" class="ft012"><b>(AI).</b></p>
<p style="position:absolute;top:490px;left:610px;white-space:nowrap" class="ft013">&#160;Historically, amphotericin&#160;</p>
<p style="position:absolute;top:510px;left:108px;white-space:nowrap" class="ft013">B deoxycholate at&#160;a dose of 0.7 to 1.0&#160;mg/kg daily had been the&#160;preferred formulation of the drug.</p>
<p style="position:absolute;top:509px;left:785px;white-space:nowrap" class="ft038">27</p>
<p style="position:absolute;top:510px;left:796px;white-space:nowrap" class="ft013">&#160;</p>
<p style="position:absolute;top:530px;left:108px;white-space:nowrap" class="ft032">In resource-available&#160;health care systems, however, lipid formulations of amphotericin B have&#160;<br/>become the standard polyene formulations because&#160;they are effective&#160;for cryptococcosis&#160;and have&#160;<br/>lower toxicity. A study that&#160;compared amphotericin B deoxycholate (0.7 mg/kg daily) and liposomal&#160;<br/>amphotericin B (AmBisome) at&#160;two doses (3 mg/kg daily and 6&#160;mg/kg daily) showed similar&#160;<br/>outcomes for&#160;all three regimens; however, lower nephrotoxicity was observed among those receiving&#160;<br/>the&#160;3 mg/kg daily liposomal&#160;amphotericin B regimen.</p>
<p style="position:absolute;top:628px;left:478px;white-space:nowrap" class="ft038">28</p>
<p style="position:absolute;top:629px;left:489px;white-space:nowrap" class="ft013">&#160;The&#160;noncomparative&#160;CLEAR study&#160;</p>
<p style="position:absolute;top:649px;left:108px;white-space:nowrap" class="ft032">demonstrated a&#160;58% response rate&#160;in&#160;people with&#160;HIV&#160;and cryptococcosis&#160;who&#160;were treated with&#160;<br/>amphotericin B lipid complex (Abelcet) at&#160;a mean dose of 4.4&#160;mg/kg daily.</p>
<p style="position:absolute;top:667px;left:626px;white-space:nowrap" class="ft038">29</p>
<p style="position:absolute;top:706px;left:108px;white-space:nowrap" class="ft032">Several&#160;large clinical&#160;trials&#160;that used shorter courses of amphotericin B have been reported from&#160;<br/>Africa.</p>
<p style="position:absolute;top:724px;left:156px;white-space:nowrap" class="ft038">30,31</p>
<p style="position:absolute;top:726px;left:182px;white-space:nowrap" class="ft013">&#160;A&#160;multicenter&#160;clinical&#160;trial that evaluated two different induction regimens in 721 African&#160;</p>
<p style="position:absolute;top:745px;left:108px;white-space:nowrap" class="ft032">adults with&#160;HIV&#160;found that an initial&#160;regimen of 1&#160;week of amphotericin B deoxycholate at&#160;<br/>1 mg/kg/day&#160;and flucytosine 25 mg/kg&#160;four times daily, followed&#160;by 1 week&#160;of oral&#160;fluconazole&#160;<br/>1,200 mg/day was&#160;non-inferior (95% confidence interval&#160;[CI], -12.5 to 5.35 at&#160;10 weeks)&#160;to the&#160;<br/>standard regimen of 2 weeks of amphotericin B deoxycholate 1 mg/kg/day and flucytosine 25 mg/kg&#160;<br/>four times daily when outcomes at&#160;10&#160;weeks&#160;were studied.</p>
<p style="position:absolute;top:823px;left:511px;white-space:nowrap" class="ft038">30</p>
<p style="position:absolute;top:825px;left:523px;white-space:nowrap" class="ft013">&#160;At&#160;1 year, follow-up of 236&#160;participants&#160;</p>
<p style="position:absolute;top:845px;left:108px;white-space:nowrap" class="ft032">from this treatment trial&#160;continued to show noninferiority of the 1-week amphotericin B deoxycholate&#160;<br/>regimen compared with the 2-week regimen.</p>
<p style="position:absolute;top:863px;left:417px;white-space:nowrap" class="ft038">32</p>
<p style="position:absolute;top:864px;left:429px;white-space:nowrap" class="ft013">&#160;</p>
<p style="position:absolute;top:901px;left:108px;white-space:nowrap" class="ft013">A phase&#160;3</p>
<p style="position:absolute;top:901px;left:177px;white-space:nowrap" class="ft012"><b>&#160;</b></p>
<p style="position:absolute;top:901px;left:181px;white-space:nowrap" class="ft013">open-label, randomized, controlled noninferiority trial&#160;of single-dose liposomal&#160;</p>
<p style="position:absolute;top:921px;left:108px;white-space:nowrap" class="ft013">amphotericin B was conducted at&#160;five&#160;sites in Africa in 814 patients.</p>
<p style="position:absolute;top:920px;left:580px;white-space:nowrap" class="ft038">33&#160;</p>
<p style="position:absolute;top:921px;left:594px;white-space:nowrap" class="ft013">Results of this&#160;study showed&#160;</p>
<p style="position:absolute;top:941px;left:108px;white-space:nowrap" class="ft032">that outcomes of people receiving a&#160;single&#160;dose of&#160;liposomal&#160;amphotericin B, 10 mg/kg,&#160;combined&#160;<br/>with 14 days&#160;of oral&#160;flucytosine, 25 mg/kg four times daily, and&#160;oral&#160;fluconazole, 1,200 mg/day, were&#160;<br/>not inferior to a control&#160;group that received therapy with amphotericin B deoxycholate, 1 mg/kg/day,&#160;<br/>and flucytosine, 25 mg/kg&#160;four times daily for 7 days, followed&#160;by oral&#160;fluconazole, 1,200 mg/day&#160;<br/>for another 7&#160;days.</p>
<p style="position:absolute;top:1019px;left:237px;white-space:nowrap" class="ft038">33</p>
<p style="position:absolute;top:1021px;left:249px;white-space:nowrap" class="ft013">&#160;</p>
<p style="position:absolute;top:1021px;left:253px;white-space:nowrap" class="ft091">At 10 weeks,&#160;deaths were reported in 101&#160;participants (24.8%; 95%&#160;CI,&#160;</p>
<p style="position:absolute;top:1040px;left:108px;white-space:nowrap" class="ft0127">20.7–29.3) in the liposomal amphotericin B group&#160;and 117 participants (28.7%; 95% CI,&#160;24.4–33.4)&#160;<br/>in the control group (difference,&#160;</p>
<p style="position:absolute;top:1060px;left:333px;white-space:nowrap" class="ft0109">−</p>
<p style="position:absolute;top:1060px;left:343px;white-space:nowrap" class="ft091">3.9 percentage points); the upper boundary&#160;of the&#160;one-sided&#160;</p>
</div>
<!-- Page 129 -->
<a name="129"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}	.ft0128{font-size:17px;font-family:KPYRPS+Tinos;color:#202020;}
	.ft0129{font-size:17px;font-family:TURBHP+Tinos;color:#1f1f1e;}
	.ft0130{font-size:17px;line-height:19px;font-family:TURBHP+Tinos;color:#1f1f1e;}
-->
</style>
<div id="page129-div" style="position:relative;width:917px;height:1187px;">
<p style="position:absolute;top:1117px;left:108px;white-space:nowrap" class="ft024"><i>Guidelines for the Prevention and Treatment&#160;of&#160;Opportunistic&#160;Infections in Adults&#160;and Adolescents&#160;With HIV&#160;</i></p>
<p style="position:absolute;top:1117px;left:790px;white-space:nowrap" class="ft024"><i>H-7&#160;</i></p>
<p style="position:absolute;top:109px;left:108px;white-space:nowrap" class="ft091">95% CI&#160;was&#160;1.2 percentage points (within the&#160;noninferiority margin;&#160;</p>
<p style="position:absolute;top:109px;left:585px;white-space:nowrap" class="ft0128"><i>P</i></p>
<p style="position:absolute;top:109px;left:596px;white-space:nowrap" class="ft091">&#160;&lt;0.001 for&#160;</p>
<p style="position:absolute;top:129px;left:108px;white-space:nowrap" class="ft091">noninferiority).&#160;</p>
<p style="position:absolute;top:129px;left:218px;white-space:nowrap" class="ft013">Grade&#160;3 or 4 toxicity was reduced&#160;in the single-dose liposomal&#160;amphotericin B group&#160;</p>
<p style="position:absolute;top:148px;left:108px;white-space:nowrap" class="ft013">compared with the amphotericin B deoxycholate group (50%&#160;vs.&#160;62.3%,&#160;</p>
<p style="position:absolute;top:148px;left:611px;white-space:nowrap" class="ft019"><i>P&#160;</i></p>
<p style="position:absolute;top:148px;left:626px;white-space:nowrap" class="ft013">&lt;0.001).</p>
<p style="position:absolute;top:147px;left:685px;white-space:nowrap" class="ft038">33</p>
<p style="position:absolute;top:148px;left:696px;white-space:nowrap" class="ft013">&#160;It is important&#160;</p>
<p style="position:absolute;top:168px;left:108px;white-space:nowrap" class="ft032">to note that patients in both groups were monitored closely in a hospital&#160;for a&#160;minimum of 7 days.&#160;<br/>Lumbar punctures were&#160;performed on&#160;Day 7 and&#160;Day 14 and daily if ICP was &gt;25 cm&#160;of&#160;CSF&#160;or if&#160;<br/>the&#160;patient demonstrated symptoms and signs consistent&#160;with elevated ICP.&#160;</p>
<p style="position:absolute;top:245px;left:108px;white-space:nowrap" class="ft013">Currently, several&#160;different treatment&#160;regimens for&#160;</p>
<p style="position:absolute;top:245px;left:461px;white-space:nowrap" class="ft012"><b>induction&#160;therapy</b></p>
<p style="position:absolute;top:245px;left:592px;white-space:nowrap" class="ft013">&#160;of cryptococcal meningitis are&#160;</p>
<p style="position:absolute;top:265px;left:108px;white-space:nowrap" class="ft013">recommended:&#160;</p>
<p style="position:absolute;top:301px;left:108px;white-space:nowrap" class="ft040">•</p>
<p style="position:absolute;top:303px;left:116px;white-space:nowrap" class="ft046">&#160;</p>
<p style="position:absolute;top:303px;left:135px;white-space:nowrap" class="ft032">Irrespective&#160;of which regimen is used,&#160;patients must be&#160;followed&#160;carefully in the hospital for at&#160;<br/>least 7 days&#160;and ideally 14 days</p>
<p style="position:absolute;top:323px;left:353px;white-space:nowrap" class="ft012"><b>&#160;(AII).</b></p>
<p style="position:absolute;top:323px;left:399px;white-space:nowrap" class="ft013">&#160;Lumbar puncture should&#160;be performed on Day&#160;7 and Day&#160;</p>
<p style="position:absolute;top:343px;left:135px;white-space:nowrap" class="ft032">14 of treatment to ensure&#160;an appropriate clinical&#160;response and culture sterility. If increased&#160;ICP&#160;is&#160;<br/>documented, daily lumbar punctures should be&#160;performed until the pressure and symptoms&#160;are&#160;<br/>decreased to&#160;the&#160;normal range</p>
<p style="position:absolute;top:383px;left:342px;white-space:nowrap" class="ft012"><b>&#160;(AII).</b></p>
<p style="position:absolute;top:383px;left:388px;white-space:nowrap" class="ft013">&#160;</p>
<p style="position:absolute;top:420px;left:108px;white-space:nowrap" class="ft0112"><i>Preferred Regimens&#160;</i></p>
<p style="position:absolute;top:458px;left:108px;white-space:nowrap" class="ft077"><b>In&#160;the&#160;United States and&#160;other settings where daily monitoring of electrolytes and kidney&#160;<br/>function&#160;and administration of electrolytes and&#160;intravenous&#160;fluids&#160;is&#160;possible:&#160;</b></p>
<p style="position:absolute;top:514px;left:108px;white-space:nowrap" class="ft040">•</p>
<p style="position:absolute;top:515px;left:116px;white-space:nowrap" class="ft046">&#160;</p>
<p style="position:absolute;top:516px;left:135px;white-space:nowrap" class="ft032">Liposomal&#160;amphotericin B (IV 3–4 mg/kg daily) plus flucytosine (25 mg/kg&#160;orally [PO]&#160;four&#160;<br/>times daily) for 2 weeks&#160;is&#160;the&#160;regimen preferred and recommended by the Panel&#160;on Guidelines&#160;<br/>for the&#160;Prevention and Treatment&#160;of Opportunistic Infections Adults and Adolescent With HIV&#160;<br/>(the Panel)&#160;</p>
<p style="position:absolute;top:575px;left:214px;white-space:nowrap" class="ft012"><b>(AII).</b></p>
<p style="position:absolute;top:574px;left:256px;white-space:nowrap" class="ft038">28,34</p>
<p style="position:absolute;top:575px;left:282px;white-space:nowrap" class="ft013">&#160;</p>
<p style="position:absolute;top:612px;left:108px;white-space:nowrap" class="ft012"><b>In&#160;resource-limited health care&#160;settings:&#160;&#160;</b></p>
<p style="position:absolute;top:649px;left:108px;white-space:nowrap" class="ft040">•</p>
<p style="position:absolute;top:650px;left:116px;white-space:nowrap" class="ft046">&#160;</p>
<p style="position:absolute;top:651px;left:135px;white-space:nowrap" class="ft032">A single dose of liposomal&#160;amphotericin B (IV 10&#160;mg/kg on Day 1) combined with oral&#160;<br/>flucytosine&#160;(25 mg/kg four times daily) and fluconazole (1,200&#160;mg/day) for&#160;2 weeks</p>
<p style="position:absolute;top:670px;left:716px;white-space:nowrap" class="ft012"><b>&#160;</b></p>
<p style="position:absolute;top:670px;left:720px;white-space:nowrap" class="ft013">is the&#160;</p>
<p style="position:absolute;top:690px;left:135px;white-space:nowrap" class="ft013">preferred regimen recommended by the World Health Organization&#160;</p>
<p style="position:absolute;top:690px;left:605px;white-space:nowrap" class="ft012"><b>(AI).</b></p>
<p style="position:absolute;top:689px;left:640px;white-space:nowrap" class="ft038">33</p>
<p style="position:absolute;top:690px;left:652px;white-space:nowrap" class="ft013">&#160;</p>
<p style="position:absolute;top:727px;left:108px;white-space:nowrap" class="ft0112"><i>Alternative&#160;Regimens &#160;</i></p>
<p style="position:absolute;top:765px;left:108px;white-space:nowrap" class="ft040">•</p>
<p style="position:absolute;top:766px;left:116px;white-space:nowrap" class="ft046">&#160;</p>
<p style="position:absolute;top:767px;left:135px;white-space:nowrap" class="ft032">If amphotericin B lipid complex is the&#160;only available&#160;lipid amphotericin B formulation available,&#160;<br/>a dosage of 5&#160;mg/kg IV daily combined with flucytosine 25 mg/kg PO&#160;four times daily should be&#160;<br/>administered for 2&#160;weeks&#160;</p>
<p style="position:absolute;top:806px;left:313px;white-space:nowrap" class="ft012"><b>(BII).</b></p>
<p style="position:absolute;top:806px;left:354px;white-space:nowrap" class="ft013">&#160;However, there is&#160;much less experience with amphotericin B&#160;</p>
<p style="position:absolute;top:826px;left:135px;white-space:nowrap" class="ft013">lipid complex than with the&#160;liposomal&#160;amphotericin B formulation.&#160;</p>
<p style="position:absolute;top:854px;left:108px;white-space:nowrap" class="ft040">•</p>
<p style="position:absolute;top:856px;left:116px;white-space:nowrap" class="ft046">&#160;</p>
<p style="position:absolute;top:856px;left:135px;white-space:nowrap" class="ft032">If amphotericin B deoxycholate&#160;is the&#160;only available&#160;formulation of amphotericin B, this can be&#160;<br/>used at&#160;a dosage&#160;of 1 mg/kg IV&#160;daily combined with flucytosine&#160;25 mg/kg PO four times&#160;daily&#160;<br/>for 1 week, followed by fluconazole&#160;1,200 mg/day&#160;PO&#160;for an additional week</p>
<p style="position:absolute;top:896px;left:669px;white-space:nowrap" class="ft012"><b>&#160;(BI).</b></p>
<p style="position:absolute;top:894px;left:708px;white-space:nowrap" class="ft038">30</p>
<p style="position:absolute;top:896px;left:719px;white-space:nowrap" class="ft013">&#160;&#160;</p>
<p style="position:absolute;top:933px;left:108px;white-space:nowrap" class="ft032">When using&#160;flucytosine, therapeutic drug monitoring should be&#160;performed, if&#160;available, particularly&#160;<br/>in patients who have&#160;renal impairment. Serum&#160;peak&#160;concentrations of flucytosine should be obtained&#160;<br/>2 hours&#160;post&#160;dose after three to five&#160;doses have been administered. Peak serum concentrations should&#160;<br/>be between 25 mg/L&#160;and 100 mg/L.</p>
<p style="position:absolute;top:991px;left:355px;white-space:nowrap" class="ft038">17</p>
<p style="position:absolute;top:992px;left:366px;white-space:nowrap" class="ft013">&#160;Renal&#160;function should&#160;be monitored closely and the&#160;flucytosine&#160;</p>
<p style="position:absolute;top:1012px;left:108px;white-space:nowrap" class="ft013">dose adjusted accordingly for those&#160;with renal&#160;impairment (see&#160;</p>
<p style="position:absolute;top:1012px;left:546px;white-space:nowrap" class="ft034">Table 6</p>
<p style="position:absolute;top:1012px;left:598px;white-space:nowrap" class="ft013">).&#160;</p>
<p style="position:absolute;top:1012px;left:613px;white-space:nowrap" class="ft0129">For&#160;those without access to&#160;</p>
<p style="position:absolute;top:1032px;left:108px;white-space:nowrap" class="ft0130">timely flucytosine&#160;concentrations, which is a common occurrence, frequent blood counts and renal&#160;<br/>functions are&#160;needed to detect&#160;bone marrow toxicity,&#160;especially when renal&#160;impairment&#160;is present.&#160;</p>
</div>
<!-- Page 130 -->
<a name="130"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page130-div" style="position:relative;width:917px;height:1187px;">
<p style="position:absolute;top:1117px;left:108px;white-space:nowrap" class="ft024"><i>Guidelines for the Prevention and Treatment&#160;of&#160;Opportunistic&#160;Infections in Adults&#160;and Adolescents&#160;With HIV&#160;</i></p>
<p style="position:absolute;top:1117px;left:790px;white-space:nowrap" class="ft024"><i>H-8&#160;</i></p>
<p style="position:absolute;top:109px;left:108px;white-space:nowrap" class="ft032">The&#160;addition of flucytosine to the&#160;amphotericin B regimen during acute treatment is associated with&#160;<br/>more&#160;rapid sterilization of CSF and&#160;survival benefit.</p>
<p style="position:absolute;top:127px;left:468px;white-space:nowrap" class="ft038">34-36</p>
<p style="position:absolute;top:129px;left:495px;white-space:nowrap" class="ft013">&#160;For instance, a randomized clinical trial&#160;of&#160;</p>
<p style="position:absolute;top:148px;left:108px;white-space:nowrap" class="ft032">299 patients&#160;showed&#160;that the combination of amphotericin B deoxycholate at a&#160;dose of 1&#160;mg/kg daily&#160;<br/>plus flucytosine&#160;was associated with improved survival compared to the&#160;same&#160;dose of amphotericin&#160;<br/>B without&#160;adjunctive flucytosine.</p>
<p style="position:absolute;top:187px;left:338px;white-space:nowrap" class="ft038">37</p>
<p style="position:absolute;top:188px;left:349px;white-space:nowrap" class="ft013">&#160;Adjunctive fluconazole&#160;800&#160;to 1,200 mg&#160;per day plus&#160;</p>
<p style="position:absolute;top:208px;left:108px;white-space:nowrap" class="ft032">amphotericin B has been&#160;used in the absence of flucytosine, but&#160;flucytosine&#160;has a survival advantage&#160;<br/>over fluconazole and is preferred&#160;</p>
<p style="position:absolute;top:228px;left:340px;white-space:nowrap" class="ft012"><b>(BI).</b></p>
<p style="position:absolute;top:226px;left:374px;white-space:nowrap" class="ft038">30</p>
<p style="position:absolute;top:228px;left:386px;white-space:nowrap" class="ft013">&#160;Amphotericin B deoxycholate with flucytosine&#160;</p>
<p style="position:absolute;top:228px;left:718px;white-space:nowrap" class="ft012"><b>(BI)&#160;</b></p>
<p style="position:absolute;top:228px;left:752px;white-space:nowrap" class="ft013">or&#160;with</p>
<p style="position:absolute;top:228px;left:801px;white-space:nowrap" class="ft012"><b>&#160;</b></p>
<p style="position:absolute;top:248px;left:108px;white-space:nowrap" class="ft013">fluconazole at&#160;a dose of 800 to 1,200&#160;mg per day&#160;</p>
<p style="position:absolute;top:248px;left:449px;white-space:nowrap" class="ft012"><b>(BI)</b></p>
<p style="position:absolute;top:248px;left:479px;white-space:nowrap" class="ft013">&#160;or liposomal amphotericin B with fluconazole&#160;</p>
<p style="position:absolute;top:267px;left:108px;white-space:nowrap" class="ft013">at&#160;a dose of 800 to 1,200&#160;mg per day&#160;</p>
<p style="position:absolute;top:267px;left:364px;white-space:nowrap" class="ft012"><b>(BIII)&#160;</b></p>
<p style="position:absolute;top:267px;left:412px;white-space:nowrap" class="ft013">may be&#160;reasonable&#160;alternatives in some circumstances.&#160;</p>
<p style="position:absolute;top:304px;left:108px;white-space:nowrap" class="ft013">Fluconazole, administered at 1,200 mg daily&#160;</p>
<p style="position:absolute;top:304px;left:419px;white-space:nowrap" class="ft012"><b>(CIII)</b></p>
<p style="position:absolute;top:304px;left:463px;white-space:nowrap" class="ft013">&#160;or with flucytosine&#160;</p>
<p style="position:absolute;top:304px;left:602px;white-space:nowrap" class="ft012"><b>(BII),</b></p>
<p style="position:absolute;top:304px;left:643px;white-space:nowrap" class="ft013">&#160;is a potential all-oral&#160;</p>
<p style="position:absolute;top:324px;left:108px;white-space:nowrap" class="ft013">alternative&#160;to&#160;amphotericin B regimens.</p>
<p style="position:absolute;top:323px;left:382px;white-space:nowrap" class="ft038">30,38</p>
<p style="position:absolute;top:324px;left:407px;white-space:nowrap" class="ft013">&#160;Based on studies assessing early fungicidal&#160;activity,&#160;</p>
<p style="position:absolute;top:344px;left:108px;white-space:nowrap" class="ft013">fluconazole alone (1,200&#160;mg/day) is inferior to amphotericin B for induction&#160;therapy.</p>
<p style="position:absolute;top:343px;left:696px;white-space:nowrap" class="ft038">39,40</p>
<p style="position:absolute;top:344px;left:721px;white-space:nowrap" class="ft013">&#160;Therefore,&#160;</p>
<p style="position:absolute;top:364px;left:108px;white-space:nowrap" class="ft032">fluconazole is preferably&#160;used with flucytosine. Fluconazole&#160;alone is recommended only&#160;for patients&#160;<br/>who cannot tolerate other agents or who do not respond to standard treatment, or when&#160;other&#160;<br/>antifungals are not available. &#160;</p>
<p style="position:absolute;top:441px;left:108px;white-space:nowrap" class="ft070"><b>Consolidation Therapy&#160;</b></p>
<p style="position:absolute;top:479px;left:108px;white-space:nowrap" class="ft032">A lumbar puncture and repeat&#160;CSF culture&#160;should be performed&#160;after 1 week&#160;and/or 2 weeks of&#160;<br/>induction therapy in all&#160;patients&#160;</p>
<p style="position:absolute;top:499px;left:331px;white-space:nowrap" class="ft012"><b>(AII).</b></p>
<p style="position:absolute;top:499px;left:372px;white-space:nowrap" class="ft013">&#160;After 2&#160;weeks of induction therapy, clinically stable&#160;patients&#160;</p>
<p style="position:absolute;top:518px;left:108px;white-space:nowrap" class="ft032">may be switched to consolidation therapy while awaiting CSF culture&#160;results.&#160;Successful induction&#160;<br/>therapy is defined as substantial&#160;clinical improvement&#160;and a negative&#160;CSF culture from&#160;the&#160;end-of-<br/>induction lumbar puncture. India ink&#160;and CSF&#160;CrAg may remain positive at&#160;Week 2 of therapy and&#160;<br/>are not&#160;indicative&#160;of failure. Monitoring serum or&#160;CSF&#160;CrAg titers is of&#160;no value&#160;in determining&#160;<br/>initial&#160;response to therapy&#160;and&#160;</p>
<p style="position:absolute;top:598px;left:320px;white-space:nowrap" class="ft012"><b>is&#160;not&#160;recommended</b></p>
<p style="position:absolute;top:598px;left:469px;white-space:nowrap" class="ft019"><i>&#160;</i></p>
<p style="position:absolute;top:598px;left:473px;white-space:nowrap" class="ft012"><b>(AII).</b></p>
<p style="position:absolute;top:596px;left:515px;white-space:nowrap" class="ft038">41,42</p>
<p style="position:absolute;top:598px;left:540px;white-space:nowrap" class="ft013">&#160;If new symptoms or clinical findings&#160;</p>
<p style="position:absolute;top:618px;left:108px;white-space:nowrap" class="ft032">occur later, a repeat lumbar puncture,&#160;with measurement&#160;of lumbar opening&#160;pressure and&#160;CSF&#160;<br/>culture, should be&#160;performed.&#160;</p>
<p style="position:absolute;top:674px;left:108px;white-space:nowrap" class="ft032">Consolidation therapy should be&#160;initiated with fluconazole 800&#160;mg daily for&#160;at&#160;least 8 weeks after&#160;<br/>receiving a&#160;clinically successful 2&#160;weeks of induction therapy&#160;</p>
<p style="position:absolute;top:694px;left:536px;white-space:nowrap" class="ft012"><b>(AII).</b></p>
<p style="position:absolute;top:694px;left:578px;white-space:nowrap" class="ft013">&#160;The&#160;recommendation to use&#160;</p>
<p style="position:absolute;top:714px;left:108px;white-space:nowrap" class="ft032">800 mg rather than 400 mg fluconazole for consolidation therapy is based on&#160;several&#160;findings. Early&#160;<br/>clinical&#160;trials that used 400 mg fluconazole for consolidation noted breakthrough infection during&#160;<br/>consolidation.</p>
<p style="position:absolute;top:752px;left:205px;white-space:nowrap" class="ft038">27</p>
<p style="position:absolute;top:754px;left:217px;white-space:nowrap" class="ft013">&#160;Fluconazole&#160;400 mg per day provides concentrations in the&#160;CSF that are only&#160;</p>
<p style="position:absolute;top:774px;left:108px;white-space:nowrap" class="ft032">fungistatic, and other studies showed that&#160;the&#160;early antifungal activity of fluconazole&#160;in CSF of&#160;<br/>people with&#160;cryptococcal&#160;meningitis increases linearly with increasing doses of the drug.</p>
<p style="position:absolute;top:792px;left:720px;white-space:nowrap" class="ft038">37,39</p>
<p style="position:absolute;top:794px;left:745px;white-space:nowrap" class="ft013">&#160;A&#160;phase&#160;</p>
<p style="position:absolute;top:813px;left:108px;white-space:nowrap" class="ft032">2 trial&#160;of treatment&#160;with either 400 mg&#160;or 800 mg fluconazole found that relapses&#160;were more frequent&#160;<br/>in people&#160;receiving 400 mg fluconazole.</p>
<p style="position:absolute;top:832px;left:386px;white-space:nowrap" class="ft038">43</p>
<p style="position:absolute;top:833px;left:397px;white-space:nowrap" class="ft013">&#160;In&#160;clinically stable&#160;people, the dose of fluconazole&#160;for&#160;</p>
<p style="position:absolute;top:853px;left:108px;white-space:nowrap" class="ft032">consolidation therapy should be&#160;800&#160;mg per day until CSF cultures are known to be sterile and ART&#160;<br/>is initiated, at which point&#160;the dose can&#160;be decreased to 400 mg&#160;per day&#160;</p>
<p style="position:absolute;top:873px;left:604px;white-space:nowrap" class="ft012"><b>(AII).</b></p>
<p style="position:absolute;top:871px;left:646px;white-space:nowrap" class="ft038">44</p>
<p style="position:absolute;top:873px;left:657px;white-space:nowrap" class="ft013">&#160;</p>
<p style="position:absolute;top:910px;left:108px;white-space:nowrap" class="ft032">For people&#160;who have completed first-line recommended or other&#160;regimen(s) as&#160;2-week&#160;induction&#160;<br/>therapy but&#160;have not&#160;improved clinically or remain clinically unstable, continuation or starting of&#160;<br/>amphotericin B plus flucytosine&#160;is recommended until the CSF fungal cultures are confirmed to be&#160;<br/>negative&#160;</p>
<p style="position:absolute;top:969px;left:171px;white-space:nowrap" class="ft012"><b>(BIII).</b></p>
<p style="position:absolute;top:969px;left:218px;white-space:nowrap" class="ft013">&#160;For outpatients who are not&#160;ill enough to be hospitalized but&#160;still have&#160;positive CSF&#160;</p>
<p style="position:absolute;top:989px;left:108px;white-space:nowrap" class="ft032">cultures after completing 2 weeks&#160;of induction therapy, flucytosine can continue&#160;to be&#160;administered&#160;<br/>for an additional&#160;2 weeks&#160;with fluconazole at&#160;a dose of 1,200 mg daily or fluconazole monotherapy&#160;<br/>can be&#160;administered at&#160;1,200 mg daily&#160;</p>
<p style="position:absolute;top:1029px;left:375px;white-space:nowrap" class="ft012"><b>(BIII).&#160;</b></p>
<p style="position:absolute;top:1029px;left:427px;white-space:nowrap" class="ft013">A lumbar puncture should be&#160;performed after 4 weeks&#160;</p>
<p style="position:absolute;top:1049px;left:108px;white-space:nowrap" class="ft013">of induction&#160;therapy</p>
<p style="position:absolute;top:1049px;left:248px;white-space:nowrap" class="ft012"><b>&#160;</b></p>
<p style="position:absolute;top:1049px;left:252px;white-space:nowrap" class="ft013">to confirm that&#160;the&#160;cultures have become&#160;negative;&#160;if still positive, another 2-</p>
</div>
<!-- Page 131 -->
<a name="131"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page131-div" style="position:relative;width:917px;height:1187px;">
<p style="position:absolute;top:1117px;left:108px;white-space:nowrap" class="ft024"><i>Guidelines for the Prevention and Treatment&#160;of&#160;Opportunistic&#160;Infections in Adults&#160;and Adolescents&#160;With HIV&#160;</i></p>
<p style="position:absolute;top:1117px;left:790px;white-space:nowrap" class="ft024"><i>H-9&#160;</i></p>
<p style="position:absolute;top:109px;left:108px;white-space:nowrap" class="ft032">week liposomal amphotericin B plus flucytosine&#160;induction course may be&#160;considered. For&#160;all&#160;people&#160;<br/>with CSF cultures positive at Week 2, the duration of consolidation therapy should be for&#160;8 weeks&#160;<br/>from the time the CSF cultures are confirmed as negative.</p>
<p style="position:absolute;top:147px;left:507px;white-space:nowrap" class="ft038">27,35,45</p>
<p style="position:absolute;top:148px;left:547px;white-space:nowrap" class="ft012"><b>&#160;</b></p>
<p style="position:absolute;top:185px;left:108px;white-space:nowrap" class="ft032">Itraconazole&#160;200 mg twice per day can&#160;be used as an alternative therapy for consolidation if&#160;<br/>fluconazole is not available&#160;or is not tolerated by an&#160;individual patient&#160;</p>
<p style="position:absolute;top:205px;left:594px;white-space:nowrap" class="ft012"><b>(CI),</b></p>
<p style="position:absolute;top:205px;left:629px;white-space:nowrap" class="ft013">&#160;but it is clearly&#160;inferior&#160;</p>
<p style="position:absolute;top:225px;left:108px;white-space:nowrap" class="ft013">to fluconazole.</p>
<p style="position:absolute;top:224px;left:211px;white-space:nowrap" class="ft038">45</p>
<p style="position:absolute;top:225px;left:222px;white-space:nowrap" class="ft013">&#160;Limited data&#160;are available&#160;for use&#160;of the newer&#160;triazoles—voriconazole,&#160;</p>
<p style="position:absolute;top:245px;left:108px;white-space:nowrap" class="ft032">posaconazole, and isavuconazole—for&#160;either consolidation or maintenance&#160;therapy for patients with&#160;<br/>cryptococcosis. Most of the reported data&#160;have been on the&#160;use of&#160;these extended-spectrum&#160;triazole&#160;<br/>antifungals for treatment of refractory&#160;cases, with&#160;success&#160;rates&#160;of approximately 50%.</p>
<p style="position:absolute;top:283px;left:705px;white-space:nowrap" class="ft038">46-48</p>
<p style="position:absolute;top:285px;left:732px;white-space:nowrap" class="ft013">&#160;Currently,&#160;</p>
<p style="position:absolute;top:304px;left:108px;white-space:nowrap" class="ft032">the&#160;role&#160;of posaconazole,&#160;voriconazole, and isavuconazole in the&#160;initial&#160;management&#160;of&#160;<br/>cryptococcosis has not been established, and these&#160;agents&#160;</p>
<p style="position:absolute;top:324px;left:508px;white-space:nowrap" class="ft012"><b>are</b></p>
<p style="position:absolute;top:324px;left:532px;white-space:nowrap" class="ft013">&#160;</p>
<p style="position:absolute;top:324px;left:536px;white-space:nowrap" class="ft012"><b>not initially recommended</b></p>
<p style="position:absolute;top:324px;left:729px;white-space:nowrap" class="ft013">&#160;for&#160;</p>
<p style="position:absolute;top:344px;left:108px;white-space:nowrap" class="ft013">consolidation or maintenance therapy&#160;</p>
<p style="position:absolute;top:344px;left:371px;white-space:nowrap" class="ft012"><b>(AIII).</b></p>
<p style="position:absolute;top:344px;left:420px;white-space:nowrap" class="ft013">&#160;Echinocandins have no clinical activity against&#160;</p>
<p style="position:absolute;top:364px;left:108px;white-space:nowrap" class="ft019"><i>Cryptococcus</i></p>
<p style="position:absolute;top:364px;left:203px;white-space:nowrap" class="ft013">&#160;spp. and&#160;</p>
<p style="position:absolute;top:364px;left:269px;white-space:nowrap" class="ft012"><b>are not recommended</b></p>
<p style="position:absolute;top:364px;left:430px;white-space:nowrap" class="ft013">&#160;for the clinical management&#160;of cryptococcosis&#160;</p>
<p style="position:absolute;top:364px;left:757px;white-space:nowrap" class="ft012"><b>(AII).</b></p>
<p style="position:absolute;top:364px;left:798px;white-space:nowrap" class="ft013">&#160;</p>
<p style="position:absolute;top:401px;left:108px;white-space:nowrap" class="ft070"><b>Maintenance Therapy&#160;</b></p>
<p style="position:absolute;top:439px;left:108px;white-space:nowrap" class="ft032">Fluconazole 200 mg per day is used for maintenance treatment&#160;and continued&#160;until at least&#160;1 year&#160;<br/>from initiation of antifungal&#160;therapy and assuming there is some&#160;immune&#160;reconstitution on ART and&#160;<br/>the&#160;patient is asymptomatic&#160;at&#160;the&#160;end of 1 year&#160;</p>
<p style="position:absolute;top:479px;left:438px;white-space:nowrap" class="ft012"><b>(AI)&#160;</b></p>
<p style="position:absolute;top:479px;left:473px;white-space:nowrap" class="ft013">(see the Preventing Recurrence section below).</p>
<p style="position:absolute;top:477px;left:798px;white-space:nowrap" class="ft038">49</p>
<p style="position:absolute;top:479px;left:810px;white-space:nowrap" class="ft013">&#160;</p>
<p style="position:absolute;top:516px;left:108px;white-space:nowrap" class="ft073"><i><b>Treatment&#160;of&#160;Non–Central Nervous&#160;System Cryptococcosis&#160;and Asymptomatic&#160;<br/>Antigenemia&#160;</b></i></p>
<p style="position:absolute;top:581px;left:108px;white-space:nowrap" class="ft032">Non-CNS&#160;extrapulmonary cryptococcosis and diffuse pulmonary disease should be&#160;treated the same&#160;<br/>as CNS disease&#160;</p>
<p style="position:absolute;top:601px;left:219px;white-space:nowrap" class="ft012"><b>(BIII).</b></p>
<p style="position:absolute;top:601px;left:266px;white-space:nowrap" class="ft013">&#160;For those with&#160;mild symptoms and only&#160;focal pulmonary infiltrates with&#160;</p>
<p style="position:absolute;top:621px;left:108px;white-space:nowrap" class="ft032">negative&#160;serum CrAg, treatment&#160;with fluconazole 400 mg per day&#160;for 6 to 12&#160;months combined with&#160;<br/>effective ART is recommended&#160;</p>
<p style="position:absolute;top:641px;left:329px;white-space:nowrap" class="ft012"><b>(BIII).</b></p>
<p style="position:absolute;top:641px;left:376px;white-space:nowrap" class="ft013">&#160;Duration of&#160;therapy should be&#160;guided by symptom&#160;</p>
<p style="position:absolute;top:661px;left:108px;white-space:nowrap" class="ft013">resolution.</p>
<p style="position:absolute;top:659px;left:181px;white-space:nowrap" class="ft038">22</p>
<p style="position:absolute;top:661px;left:193px;white-space:nowrap" class="ft013">&#160;</p>
<p style="position:absolute;top:698px;left:108px;white-space:nowrap" class="ft032">All people&#160;with non-CNS&#160;extrapulmonary symptoms and cryptococcal&#160;antigenemia&#160;should&#160;have their&#160;<br/>CSF sampled to rule out&#160;CNS&#160;disease.</p>
<p style="position:absolute;top:716px;left:372px;white-space:nowrap" class="ft038">13,23,50</p>
<p style="position:absolute;top:718px;left:411px;white-space:nowrap" class="ft013">&#160;If the&#160;CSF&#160;is normal&#160;but the&#160;</p>
<p style="position:absolute;top:718px;left:612px;white-space:nowrap" class="ft018">serum&#160;CrAg titer is&#160;</p>
<p style="position:absolute;top:718px;left:749px;white-space:nowrap" class="ft069">≥</p>
<p style="position:absolute;top:718px;left:759px;white-space:nowrap" class="ft018">1:640&#160;</p>
<p style="position:absolute;top:737px;left:108px;white-space:nowrap" class="ft013">by LFA&#160;</p>
<p style="position:absolute;top:737px;left:166px;white-space:nowrap" class="ft018">(or&#160;</p>
<p style="position:absolute;top:737px;left:191px;white-space:nowrap" class="ft069">≥</p>
<p style="position:absolute;top:737px;left:200px;white-space:nowrap" class="ft018">1:160 by&#160;</p>
<p style="position:absolute;top:737px;left:266px;white-space:nowrap" class="ft013">EIA or latex agglutination), even in the&#160;absence&#160;of meningitis, the risk for&#160;</p>
<p style="position:absolute;top:757px;left:108px;white-space:nowrap" class="ft032">mortality and/or progression to meningitis increases with fluconazole&#160;monotherapy alone, and these&#160;<br/>patients should be&#160;treated the same as&#160;patients with cryptococcal meningitis&#160;</p>
<p style="position:absolute;top:777px;left:634px;white-space:nowrap" class="ft012"><b>(BII).</b></p>
<p style="position:absolute;top:776px;left:675px;white-space:nowrap" class="ft038">23</p>
<p style="position:absolute;top:777px;left:686px;white-space:nowrap" class="ft013">&#160;</p>
<p style="position:absolute;top:814px;left:108px;white-space:nowrap" class="ft032">Whether to sample&#160;the&#160;CSF&#160;to rule out CNS disease in people&#160;with isolated, fully asymptomatic&#160;<br/>cryptococcal&#160;antigenemia&#160;is dependent&#160;on underlying risk, such as advanced immunosuppression and&#160;<br/>absence&#160;of antiretroviral therapy, and the serum CrAg LFA titer. Those at&#160;lower risk and&#160;with serum&#160;<br/>CrAg titer &lt;1:80 by LFA (or &lt;1:20 by&#160;EIA or latex&#160;agglutination) can be safely treated without&#160;<br/>lumbar puncture, as empiric&#160;treatment for meningitis does not improve outcomes&#160;</p>
<p style="position:absolute;top:894px;left:671px;white-space:nowrap" class="ft012"><b>(AI).</b></p>
<p style="position:absolute;top:892px;left:706px;white-space:nowrap" class="ft038">51</p>
<p style="position:absolute;top:894px;left:718px;white-space:nowrap" class="ft013">&#160;All others&#160;</p>
<p style="position:absolute;top:913px;left:108px;white-space:nowrap" class="ft032">should undergo CSF&#160;sampling to rule out&#160;CNS&#160;disease. Those&#160;with normal CSF, fully asymptomatic&#160;<br/>cryptococcal antigenemia, and serum&#160;CrAg titers &lt;1:640 by LFA (or &lt;1:160&#160;by EIA or latex&#160;<br/>agglutination) should be treated with fluconazole&#160;800 to 1,200 mg per day for&#160;2 weeks,&#160;followed by&#160;<br/>400 to 800 mg per day for&#160;10 weeks, followed by 200 mg daily, for a total of 6 months combined&#160;<br/>with effective ART&#160;</p>
<p style="position:absolute;top:993px;left:246px;white-space:nowrap" class="ft012"><b>(BIII).</b></p>
<p style="position:absolute;top:991px;left:294px;white-space:nowrap" class="ft038">22</p>
<p style="position:absolute;top:993px;left:305px;white-space:nowrap" class="ft013">&#160;</p>
</div>
<!-- Page 132 -->
<a name="132"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page132-div" style="position:relative;width:917px;height:1187px;">
<p style="position:absolute;top:1117px;left:108px;white-space:nowrap" class="ft024"><i>Guidelines for the Prevention and Treatment&#160;of&#160;Opportunistic&#160;Infections in Adults&#160;and Adolescents&#160;With HIV&#160;</i></p>
<p style="position:absolute;top:1117px;left:783px;white-space:nowrap" class="ft024"><i>H-10&#160;</i></p>
<p style="position:absolute;top:109px;left:108px;white-space:nowrap" class="ft029"><i><b>Special Considerations Regarding ART Initiation&#160;</b></i></p>
<p style="position:absolute;top:150px;left:108px;white-space:nowrap" class="ft032">Unlike&#160;with&#160;other opportunistic infections (OIs),&#160;ART initiation&#160;generally is deferred for&#160;4 to 6 weeks&#160;<br/>after antifungal agents are started for treatment of CNS cryptococcosis&#160;</p>
<p style="position:absolute;top:170px;left:599px;white-space:nowrap" class="ft012"><b>(AI).</b></p>
<p style="position:absolute;top:170px;left:634px;white-space:nowrap" class="ft013">&#160;A randomized clinical&#160;</p>
<p style="position:absolute;top:190px;left:108px;white-space:nowrap" class="ft032">trial&#160;conducted at&#160;three&#160;sites in Africa&#160;compared patients with cryptococcal&#160;meningitis who started&#160;<br/>ART within&#160;1 to 2 weeks&#160;(median 9 days) after the&#160;diagnosis of&#160;meningitis with patients for whom&#160;<br/>ART was delayed for 4 to&#160;6 weeks&#160;(median 36 days) after diagnosis.</p>
<p style="position:absolute;top:228px;left:581px;white-space:nowrap" class="ft038">52</p>
<p style="position:absolute;top:229px;left:592px;white-space:nowrap" class="ft013">&#160;This clinical&#160;trial used&#160;</p>
<p style="position:absolute;top:249px;left:108px;white-space:nowrap" class="ft032">amphotericin B deoxycholate 0.7 to 1.0&#160;mg/kg once&#160;daily plus fluconazole 800&#160;mg once daily during&#160;<br/>the&#160;induction phase of antifungal treatment. A significantly greater increase in 6-month mortality&#160;<br/>occurred in the early ART group than&#160;in the delayed ART group (45% vs. 30%,&#160;</p>
<p style="position:absolute;top:289px;left:662px;white-space:nowrap" class="ft019"><i>P&#160;</i></p>
<p style="position:absolute;top:289px;left:677px;white-space:nowrap" class="ft013">= 0.03). This&#160;</p>
<p style="position:absolute;top:309px;left:108px;white-space:nowrap" class="ft013">increase was&#160;most&#160;pronounced during the first 8 to 30 days of the&#160;study (</p>
<p style="position:absolute;top:309px;left:610px;white-space:nowrap" class="ft019"><i>P&#160;</i></p>
<p style="position:absolute;top:309px;left:625px;white-space:nowrap" class="ft013">=&#160;0.007). The&#160;difference&#160;</p>
<p style="position:absolute;top:329px;left:108px;white-space:nowrap" class="ft032">in mortality&#160;between the&#160;early ART group and the&#160;delayed ART group&#160;was&#160;even greater among&#160;<br/>individuals with CSF&#160;white cell&#160;count &lt;5 cells/µL (</p>
<p style="position:absolute;top:348px;left:463px;white-space:nowrap" class="ft019"><i>P&#160;</i></p>
<p style="position:absolute;top:348px;left:478px;white-space:nowrap" class="ft013">= 0.008).&#160;The&#160;excess&#160;deaths in the early ART&#160;</p>
<p style="position:absolute;top:368px;left:108px;white-space:nowrap" class="ft032">group may have been attributable to paradoxical IRIS, although the&#160;timing and incidence&#160;of IRIS&#160;<br/>reportedly did not&#160;differ between the&#160;two groups.</p>
<p style="position:absolute;top:387px;left:447px;white-space:nowrap" class="ft038">53</p>
<p style="position:absolute;top:388px;left:458px;white-space:nowrap" class="ft013">&#160;In a trial conducted in China, 102 participants&#160;</p>
<p style="position:absolute;top:408px;left:108px;white-space:nowrap" class="ft032">with cryptococcal meningitis were randomized to start ART within either 2 to 5 weeks&#160;or &gt;5 weeks&#160;<br/>after starting antifungal&#160;therapy;&#160;the&#160;majority received amphotericin with flucytosine induction&#160;<br/>therapy. The&#160;primary analysis did not&#160;demonstrate a&#160;statistically&#160;significant difference in mortality;&#160;<br/>however, a&#160;smaller secondary analysis&#160;of 78 patients demonstrated excess risk of death in&#160;the&#160;early&#160;<br/>ART group compared with the&#160;deferred group&#160;within the&#160;window of 5 to&#160;10&#160;weeks after initiation of&#160;<br/>antifungal treatment.</p>
<p style="position:absolute;top:506px;left:252px;white-space:nowrap" class="ft038">54</p>
<p style="position:absolute;top:507px;left:263px;white-space:nowrap" class="ft013">&#160;It&#160;is not clear that&#160;the&#160;secondary analysis&#160;had adequate statistical power for&#160;the&#160;</p>
<p style="position:absolute;top:527px;left:108px;white-space:nowrap" class="ft032">comparison,&#160;making the overall&#160;interpretation of this study complicated. In a recently published&#160;<br/>retrospective observational&#160;cohort&#160;study of participants enrolled from high-resourced health care&#160;<br/>systems in Europe and&#160;North America, investigators used marginal&#160;structural&#160;modeling with category&#160;<br/>censoring, inverse proportional&#160;weighting, and adjustment&#160;for bias to simulate&#160;a randomized trial&#160;of&#160;<br/>earlier versus later initiation of ART.</p>
<p style="position:absolute;top:605px;left:364px;white-space:nowrap" class="ft038">53</p>
<p style="position:absolute;top:606px;left:375px;white-space:nowrap" class="ft013">&#160;A total of 630 people with HIV were&#160;identified with&#160;</p>
<p style="position:absolute;top:626px;left:108px;white-space:nowrap" class="ft032">cryptococcal&#160;meningitis from more than 30 cohorts between 1994 and 2012.&#160;Participants were&#160;<br/>eligible for the analyses if at&#160;meningitis diagnosis they were older than 16 years and had a&#160;CD4&#160;<br/>count, a viral&#160;load measurement&#160;and follow-up laboratory test results, study&#160;visits, and outcomes&#160;<br/>data. Among&#160;these, 432 (69%)&#160;were considered ineligible&#160;due to insufficient outcome data (256;&#160;<br/>41%) or missing baseline CD4 or&#160;HIV&#160;viral load (176;&#160;28%).&#160;Among the 190 eligible patients, 145&#160;<br/>started ART&#160;during treatment for cryptococcal meningitis.</p>
<p style="position:absolute;top:724px;left:510px;white-space:nowrap" class="ft038">55</p>
<p style="position:absolute;top:725px;left:521px;white-space:nowrap" class="ft013">&#160;The primary analysis for the&#160;simulated&#160;</p>
<p style="position:absolute;top:745px;left:108px;white-space:nowrap" class="ft032">trial&#160;compared initiation of ART&#160;within 14 days&#160;of&#160;cryptococcal&#160;meningitis diagnosis versus starting&#160;<br/>ART within&#160;14 to 56 days of diagnosis. There&#160;were 13 deaths in the&#160;early ART group and 20 deaths&#160;<br/>in the delayed ART group, with an adjusted hazard&#160;ratio (aHR) of 1.40 (0.66–2.95) for early versus&#160;<br/>later initiation of ART.&#160;The&#160;authors concluded that there was little evidence that earlier ART was&#160;<br/>associated with higher mortality. The&#160;incidence of IRIS&#160;was not&#160;reported.</p>
<p style="position:absolute;top:823px;left:615px;white-space:nowrap" class="ft038">55,56</p>
<p style="position:absolute;top:825px;left:640px;white-space:nowrap" class="ft013">&#160;&#160;</p>
<p style="position:absolute;top:862px;left:108px;white-space:nowrap" class="ft032">The&#160;issue of&#160;when to start&#160;ART in the&#160;setting of cryptococcal meningitis remains controversial. The&#160;<br/>randomized trials, most of&#160;which are&#160;more than a&#160;decade&#160;old, were largely done in low- and middle-&#160;<br/>income&#160;countries where&#160;access&#160;to currently recommended antifungal treatment, monitoring, and&#160;<br/>support may&#160;have been less optimal, and they demonstrated overall&#160;mortality rates substantially&#160;<br/>higher than had been reported in higher resourced&#160;settings. While the observational&#160;cohort&#160;study in&#160;<br/>higher resourced settings is limited by its observational, retrospective&#160;nature and cannot fully address&#160;<br/>unrecognized biases, it is&#160;unlikely that a&#160;suitably powered prospective randomized trial&#160;can be&#160;done&#160;<br/>in high-resourced settings&#160;now, given the precipitous decline&#160;in incidence of cryptococcal meningitis&#160;<br/>in people&#160;with HIV treated with more&#160;effective antifungal&#160;therapy and more effective and better&#160;<br/>tolerated ART regimens than were available in some of the earlier trials. Therefore, most&#160;experts aim&#160;<br/>to start ART&#160;within 4 weeks of antifungal&#160;therapy; however, individual patient factors may allow for&#160;</p>
</div>
<!-- Page 133 -->
<a name="133"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page133-div" style="position:relative;width:917px;height:1187px;">
<p style="position:absolute;top:1117px;left:108px;white-space:nowrap" class="ft024"><i>Guidelines for the Prevention and Treatment&#160;of&#160;Opportunistic&#160;Infections in Adults&#160;and Adolescents&#160;With HIV&#160;</i></p>
<p style="position:absolute;top:1117px;left:783px;white-space:nowrap" class="ft024"><i>H-11&#160;</i></p>
<p style="position:absolute;top:109px;left:108px;white-space:nowrap" class="ft032">earlier or later initiation of ART. In&#160;general, ensuring that&#160;the&#160;patient’s CSF cultures are sterile before&#160;<br/>starting ART&#160;will&#160;reduce the risk of IRIS.</p>
<p style="position:absolute;top:127px;left:395px;white-space:nowrap" class="ft038">57</p>
<p style="position:absolute;top:129px;left:407px;white-space:nowrap" class="ft019"><i>&#160;</i></p>
<p style="position:absolute;top:129px;left:411px;white-space:nowrap" class="ft013">If&#160;ART&#160;must be&#160;started sooner, the patient should be&#160;</p>
<p style="position:absolute;top:148px;left:108px;white-space:nowrap" class="ft032">monitored closely for paradoxical&#160;IRIS with a low&#160;threshold to intervene (see&#160;“Monitoring&#160;of&#160;<br/>Response to&#160;Therapy and&#160;Adverse Events,” below).</p>
<p style="position:absolute;top:167px;left:464px;white-space:nowrap" class="ft038">55</p>
<p style="position:absolute;top:168px;left:476px;white-space:nowrap" class="ft013">&#160;For non-CNS&#160;cryptococcosis, for&#160;which the&#160;</p>
<p style="position:absolute;top:188px;left:108px;white-space:nowrap" class="ft032">risk of symptomatic IRIS&#160;appears to be&#160;lower, the optimal time to begin ART&#160;after antifungal therapy&#160;<br/>is less&#160;clear.&#160;However, in&#160;patients with non-CNS&#160;cryptococcosis, it&#160;is prudent&#160;to delay initiation of&#160;<br/>ART for&#160;2 weeks after starting antifungal therapy&#160;</p>
<p style="position:absolute;top:228px;left:454px;white-space:nowrap" class="ft012"><b>(BIII).</b></p>
<p style="position:absolute;top:228px;left:501px;white-space:nowrap" class="ft013">&#160;</p>
<p style="position:absolute;top:265px;left:108px;white-space:nowrap" class="ft032">All of the triazole&#160;antifungals have the potential for complex and possibly&#160;bidirectional interactions&#160;<br/>with certain antiretroviral&#160;agents. These interactions and recommendations for dosage adjustments,&#160;<br/>where feasible, are listed in the&#160;</p>
<p style="position:absolute;top:304px;left:327px;white-space:nowrap" class="ft034">Drug–Drug Interaction tables</p>
<p style="position:absolute;top:304px;left:530px;white-space:nowrap" class="ft013">&#160;in the&#160;</p>
<p style="position:absolute;top:304px;left:577px;white-space:nowrap" class="ft034">Guidelines for the&#160;Use&#160;of&#160;</p>
<p style="position:absolute;top:324px;left:108px;white-space:nowrap" class="ft034">Antiretroviral&#160;Agents in&#160;Adults and&#160;Adolescents With HIV</p>
<p style="position:absolute;top:324px;left:516px;white-space:nowrap" class="ft013">.&#160;&#160;</p>
<p style="position:absolute;top:362px;left:108px;white-space:nowrap" class="ft029"><i><b>Monitoring and Management&#160;of&#160;Response to Therapy&#160;and Adverse Events&#160;</b></i></p>
<p style="position:absolute;top:403px;left:108px;white-space:nowrap" class="ft013">Elevation of ICP can cause clinical&#160;deterioration despite&#160;a microbiologic&#160;response; complications are&#160;</p>
<p style="position:absolute;top:423px;left:108px;white-space:nowrap" class="ft018">more&#160;likely to occur if the&#160;CSF&#160;lumbar&#160;opening pressure is&#160;</p>
<p style="position:absolute;top:423px;left:517px;white-space:nowrap" class="ft069">≥</p>
<p style="position:absolute;top:423px;left:527px;white-space:nowrap" class="ft018">25</p>
<p style="position:absolute;top:423px;left:544px;white-space:nowrap" class="ft013">&#160;cm&#160;CSF in the lateral&#160;decubitus&#160;</p>
<p style="position:absolute;top:442px;left:108px;white-space:nowrap" class="ft013">position.</p>
<p style="position:absolute;top:441px;left:168px;white-space:nowrap" class="ft038">7,27</p>
<p style="position:absolute;top:442px;left:188px;white-space:nowrap" class="ft013">&#160;In a large clinical&#160;trial&#160;in people with AIDS&#160;and cryptococcal meningitis, increased ICP&#160;</p>
<p style="position:absolute;top:462px;left:108px;white-space:nowrap" class="ft032">was associated with 92%&#160;of deaths during the first 2 weeks&#160;of antifungal&#160;therapy and 71% of deaths&#160;<br/>during Weeks 3 to 10.</p>
<p style="position:absolute;top:481px;left:261px;white-space:nowrap" class="ft038">7</p>
<p style="position:absolute;top:482px;left:266px;white-space:nowrap" class="ft013">&#160;In&#160;another clinical&#160;trial, people with HIV who received at&#160;least one&#160;</p>
<p style="position:absolute;top:502px;left:108px;white-space:nowrap" class="ft032">therapeutic&#160;lumbar puncture within 7&#160;days after diagnosis (median time&#160;of 3 days) had a 69% relative&#160;<br/>reduction in the&#160;risk of death through 11 days, regardless&#160;of initial opening pressure.</p>
<p style="position:absolute;top:520px;left:690px;white-space:nowrap" class="ft038">58</p>
<p style="position:absolute;top:522px;left:701px;white-space:nowrap" class="ft013">&#160;Although it is&#160;</p>
<p style="position:absolute;top:542px;left:108px;white-space:nowrap" class="ft032">uncertain which patients with high lumbar opening pressures&#160;will&#160;experience&#160;clinical&#160;deterioration,&#160;<br/>those with symptoms and&#160;signs of increased ICP require&#160;immediate clinical intervention to reduce&#160;<br/>ICP.&#160;</p>
<p style="position:absolute;top:618px;left:108px;white-space:nowrap" class="ft032">Control&#160;of elevated ICP is&#160;critical&#160;to reducing acute&#160;mortality. Lumbar opening pressure should be&#160;<br/>measured in&#160;all people&#160;with cryptococcal meningitis at the time of diagnosis.&#160;However, in&#160;routine&#160;<br/>practice, CSF opening pressure frequently is not measured. Among people in whom CSF&#160;opening&#160;<br/>pressure&#160;was&#160;not measured initially, a&#160;repeat&#160;lumbar puncture&#160;should be&#160;performed with&#160;<br/>measurement of opening pressure.&#160;For&#160;people with&#160;ongoing headaches, a repeat&#160;lumbar puncture&#160;<br/>should be performed with&#160;urgency, and among those without&#160;headaches, a repeat&#160;lumber puncture&#160;<br/>should be considered strongly within 48 hours&#160;of the initial procedure.</p>
<p style="position:absolute;top:736px;left:593px;white-space:nowrap" class="ft038">58</p>
<p style="position:absolute;top:737px;left:605px;white-space:nowrap" class="ft013">&#160;Measures&#160;to decrease ICP&#160;</p>
<p style="position:absolute;top:757px;left:108px;white-space:nowrap" class="ft032">should be used for all&#160;people&#160;with cryptococcal meningitis who have&#160;confusion, blurred vision,&#160;<br/>papilledema, lower extremity clonus, or other neurologic signs indicative&#160;of increased ICP. Drainage&#160;<br/>of CSF&#160;via&#160;lumbar puncture is recommended for initial management&#160;</p>
<p style="position:absolute;top:797px;left:584px;white-space:nowrap" class="ft012"><b>(AII).</b></p>
<p style="position:absolute;top:797px;left:625px;white-space:nowrap" class="ft013">&#160;One approach is to&#160;</p>
<p style="position:absolute;top:817px;left:108px;white-space:nowrap" class="ft032">remove a volume&#160;of CSF&#160;that reduces the&#160;opening pressure by at&#160;least 50% or&#160;normalizes the&#160;<br/>pressure to &lt;20 cm&#160;CSF.</p>
<p style="position:absolute;top:835px;left:279px;white-space:nowrap" class="ft038">58,59</p>
<p style="position:absolute;top:837px;left:305px;white-space:nowrap" class="ft013">&#160;In the&#160;absence&#160;of a manometer, removal&#160;of 20 to&#160;25 mL&#160;of CSF is&#160;</p>
<p style="position:absolute;top:856px;left:108px;white-space:nowrap" class="ft013">recommended&#160;</p>
<p style="position:absolute;top:856px;left:210px;white-space:nowrap" class="ft012"><b>(AIII).</b></p>
<p style="position:absolute;top:856px;left:258px;white-space:nowrap" class="ft013">&#160;Among patients&#160;with ongoing&#160;symptoms, therapeutic lumbar punctures should&#160;</p>
<p style="position:absolute;top:876px;left:108px;white-space:nowrap" class="ft032">be repeated at&#160;least daily until&#160;symptoms and signs&#160;consistently&#160;improve and&#160;opening pressure&#160;<br/>normalizes to &lt;20 cm CSF&#160;</p>
<p style="position:absolute;top:896px;left:297px;white-space:nowrap" class="ft012"><b>(AII).</b></p>
<p style="position:absolute;top:896px;left:339px;white-space:nowrap" class="ft013">&#160;Because a survival&#160;benefit&#160;is associated with therapeutic lumbar&#160;</p>
<p style="position:absolute;top:916px;left:108px;white-space:nowrap" class="ft032">puncture regardless of baseline CSF opening pressure, strong consideration&#160;should be given to&#160;<br/>repeating a&#160;therapeutic lumbar puncture within 72&#160;hours of the&#160;initial&#160;procedure&#160;in those&#160;who are&#160;<br/>relatively asymptomatic&#160;or who had a&#160;baseline CSF opening pressure of&#160;&lt;25 cm&#160;CSF,&#160;because ICP&#160;<br/>can be&#160;a dynamic&#160;process&#160;that changes over time&#160;</p>
<p style="position:absolute;top:975px;left:448px;white-space:nowrap" class="ft012"><b>(BII).</b></p>
<p style="position:absolute;top:974px;left:489px;white-space:nowrap" class="ft038">58</p>
<p style="position:absolute;top:975px;left:501px;white-space:nowrap" class="ft013">&#160;If the&#160;initial&#160;opening pressure was not&#160;</p>
<p style="position:absolute;top:995px;left:108px;white-space:nowrap" class="ft013">measured, a&#160;second lumbar puncture is recommended&#160;</p>
<p style="position:absolute;top:995px;left:482px;white-space:nowrap" class="ft012"><b>(AII).</b></p>
<p style="position:absolute;top:995px;left:524px;white-space:nowrap" class="ft013">&#160;&#160;</p>
<p style="position:absolute;top:1032px;left:108px;white-space:nowrap" class="ft032">CSF shunting through a&#160;lumbar drain&#160;or ventriculostomy should be considered for people&#160;who cannot&#160;<br/>tolerate repeated lumbar punctures or&#160;for those in&#160;whom signs&#160;and symptoms of increased ICP persist&#160;</p>
</div>
<!-- Page 134 -->
<a name="134"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page134-div" style="position:relative;width:917px;height:1187px;">
<p style="position:absolute;top:1117px;left:108px;white-space:nowrap" class="ft024"><i>Guidelines for the Prevention and Treatment&#160;of&#160;Opportunistic&#160;Infections in Adults&#160;and Adolescents&#160;With HIV&#160;</i></p>
<p style="position:absolute;top:1117px;left:783px;white-space:nowrap" class="ft024"><i>H-12&#160;</i></p>
<p style="position:absolute;top:109px;left:108px;white-space:nowrap" class="ft013">after multiple lumbar punctures&#160;</p>
<p style="position:absolute;top:109px;left:330px;white-space:nowrap" class="ft012"><b>(BIII).</b></p>
<p style="position:absolute;top:109px;left:377px;white-space:nowrap" class="ft013">&#160;Corticosteroids and mannitol have been shown to&#160;be&#160;</p>
<p style="position:absolute;top:129px;left:108px;white-space:nowrap" class="ft013">ineffective&#160;in managing ICP and&#160;</p>
<p style="position:absolute;top:129px;left:336px;white-space:nowrap" class="ft012"><b>are&#160;not recommended</b></p>
<p style="position:absolute;top:129px;left:497px;white-space:nowrap" class="ft013">&#160;</p>
<p style="position:absolute;top:129px;left:501px;white-space:nowrap" class="ft012"><b>(AIII).</b></p>
<p style="position:absolute;top:129px;left:550px;white-space:nowrap" class="ft013">&#160;Acetazolamide&#160;</p>
<p style="position:absolute;top:129px;left:662px;white-space:nowrap" class="ft012"><b>should&#160;not be&#160;used</b></p>
<p style="position:absolute;top:129px;left:798px;white-space:nowrap" class="ft013">&#160;</p>
<p style="position:absolute;top:148px;left:108px;white-space:nowrap" class="ft032">as therapy for increased ICP management because it may exacerbate hyperchloremic&#160;acidosis from&#160;<br/>amphotericin B and does&#160;not result in a meaningful decrease in ICP&#160;</p>
<p style="position:absolute;top:168px;left:578px;white-space:nowrap" class="ft012"><b>(AI).</b></p>
<p style="position:absolute;top:167px;left:613px;white-space:nowrap" class="ft038">60</p>
<p style="position:absolute;top:168px;left:625px;white-space:nowrap" class="ft013">&#160;A&#160;randomized study that&#160;</p>
<p style="position:absolute;top:188px;left:108px;white-space:nowrap" class="ft032">compared a&#160;6-week course of a tapering dose of dexamethasone with placebo among 451&#160;Asian and&#160;<br/>African patients with cryptococcal&#160;meningitis found that&#160;dexamethasone did not improve&#160;survival&#160;<br/>through 10&#160;weeks, was noted to not&#160;be as effective&#160;at&#160;killing of&#160;</p>
<p style="position:absolute;top:228px;left:546px;white-space:nowrap" class="ft019"><i>Cryptococcus,</i></p>
<p style="position:absolute;top:228px;left:645px;white-space:nowrap" class="ft013">&#160;and was associated&#160;</p>
<p style="position:absolute;top:248px;left:108px;white-space:nowrap" class="ft013">with more adverse events.</p>
<p style="position:absolute;top:246px;left:288px;white-space:nowrap" class="ft038">61</p>
<p style="position:absolute;top:248px;left:299px;white-space:nowrap" class="ft013">&#160;These data&#160;support the&#160;recommendation that&#160;</p>
<p style="position:absolute;top:248px;left:614px;white-space:nowrap" class="ft012"><b>corticosteroids</b></p>
<p style="position:absolute;top:248px;left:722px;white-space:nowrap" class="ft013">&#160;</p>
<p style="position:absolute;top:248px;left:726px;white-space:nowrap" class="ft012"><b>should&#160;not&#160;</b></p>
<p style="position:absolute;top:267px;left:108px;white-space:nowrap" class="ft012"><b>be used</b></p>
<p style="position:absolute;top:267px;left:163px;white-space:nowrap" class="ft013">&#160;during induction&#160;therapy for ICP control&#160;for HIV-associated cryptococcal meningitis unless&#160;</p>
<p style="position:absolute;top:287px;left:108px;white-space:nowrap" class="ft013">they are being used for treatment of IRIS&#160;</p>
<p style="position:absolute;top:287px;left:395px;white-space:nowrap" class="ft012"><b>(AI).&#160;</b></p>
<p style="position:absolute;top:324px;left:108px;white-space:nowrap" class="ft032">People&#160;treated with amphotericin B formulations should be&#160;monitored for nephrotoxicity and&#160;<br/>electrolyte disturbances.&#160;Pre-infusion administration of 500 to 1,000 mL&#160;of normal saline&#160;reduces the&#160;<br/>risk of nephrotoxicity during amphotericin B treatment. For people with severe infusion-related&#160;<br/>adverse reactions, acetaminophen (650&#160;mg) and diphenhydramine&#160;(25–50 mg)&#160;or hydrocortisone&#160;<br/>(50–100 mg)&#160;typically are&#160;administered 30 minutes&#160;before the infusion to reduce the severity of&#160;<br/>amphotericin B infusion reactions&#160;</p>
<p style="position:absolute;top:424px;left:346px;white-space:nowrap" class="ft012"><b>(CIII);</b></p>
<p style="position:absolute;top:424px;left:396px;white-space:nowrap" class="ft013">&#160;meperidine (25–50 mg titrated during infusion)&#160;is effective&#160;</p>
<p style="position:absolute;top:443px;left:108px;white-space:nowrap" class="ft032">for treating amphotericin B–associated&#160;rigors and&#160;should be given before each dose daily&#160;and after&#160;<br/>the&#160;first incidence of rigors to prevent future&#160;rigors&#160;</p>
<p style="position:absolute;top:463px;left:463px;white-space:nowrap" class="ft012"><b>(BII).</b></p>
<p style="position:absolute;top:463px;left:504px;white-space:nowrap" class="ft013">&#160;Routine use of potassium&#160;chloride (40 mEq&#160;</p>
<p style="position:absolute;top:483px;left:108px;white-space:nowrap" class="ft032">per day) and&#160;magnesium&#160;(8 mEq per day) supplementation should be&#160;considered because&#160;the&#160;risk of&#160;<br/>hypokalemia&#160;and hypomagnesemia&#160;becomes near universal after 1 week of therapy, regardless&#160;of the&#160;<br/>amphotericin B formulation used&#160;</p>
<p style="position:absolute;top:523px;left:341px;white-space:nowrap" class="ft012"><b>(AII).</b></p>
<p style="position:absolute;top:521px;left:382px;white-space:nowrap" class="ft038">62</p>
<p style="position:absolute;top:523px;left:394px;white-space:nowrap" class="ft013">&#160;</p>
<p style="position:absolute;top:560px;left:108px;white-space:nowrap" class="ft032">Flucytosine is associated&#160;with concentration-dependent&#160;bone marrow toxicity. Patients treated with&#160;<br/>flucytosine&#160;also should&#160;be monitored for hepatotoxicity and gastrointestinal toxicities. In people&#160;<br/>receiving flucytosine, dosage should be adjusted based on changes in creatinine clearance&#160;and can be&#160;<br/>guided by flucytosine concentrations. Peak serum flucytosine&#160;concentrations should be&#160;obtained&#160;<br/>2 hours after an oral&#160;dose;&#160;the therapeutic range is between 25 and 100 mg/L.&#160;If therapeutic drug&#160;<br/>monitoring is not possible or kidney dysfunction is&#160;not present,&#160;frequent&#160;complete blood counts&#160;with&#160;<br/>differential (i.e., at&#160;least biweekly) can&#160;be used to detect cytopenias&#160;</p>
<p style="position:absolute;top:679px;left:576px;white-space:nowrap" class="ft012"><b>(BII).</b></p>
<p style="position:absolute;top:677px;left:617px;white-space:nowrap" class="ft038">30</p>
<p style="position:absolute;top:679px;left:628px;white-space:nowrap" class="ft013">&#160;&#160;</p>
<p style="position:absolute;top:716px;left:108px;white-space:nowrap" class="ft032">Common side effects of higher dose fluconazole&#160;therapy can include dry skin&#160;(17% of&#160;patients) and&#160;<br/>alopecia (16% of patients).</p>
<p style="position:absolute;top:734px;left:294px;white-space:nowrap" class="ft038">63</p>
<p style="position:absolute;top:736px;left:305px;white-space:nowrap" class="ft013">&#160;Increased&#160;liver transaminases or alkaline&#160;phosphatase are&#160;relatively rare&#160;</p>
<p style="position:absolute;top:756px;left:108px;white-space:nowrap" class="ft032">in fluconazole&#160;dosages of&#160;400 to 800 mg, with only&#160;1 to 2% of patients having values &gt;5 times the&#160;<br/>upper limit&#160;of normal.</p>
<p style="position:absolute;top:774px;left:260px;white-space:nowrap" class="ft038">52</p>
<p style="position:absolute;top:775px;left:272px;white-space:nowrap" class="ft013">&#160;For people who have difficulty tolerating higher fluconazole&#160;doses, the&#160;</p>
<p style="position:absolute;top:795px;left:108px;white-space:nowrap" class="ft013">consolidation therapy fluconazole&#160;dose can be reduced to 400 mg per day after ART initiation.&#160;</p>
<p style="position:absolute;top:815px;left:108px;white-space:nowrap" class="ft012"><b>(BII).</b></p>
<p style="position:absolute;top:814px;left:149px;white-space:nowrap" class="ft038">44</p>
<p style="position:absolute;top:815px;left:160px;white-space:nowrap" class="ft013">&#160;</p>
<p style="position:absolute;top:852px;left:108px;white-space:nowrap" class="ft070"><b>Immune Reconstitution&#160;Inflammatory Syndrome&#160;</b></p>
<p style="position:absolute;top:890px;left:108px;white-space:nowrap" class="ft032">An estimated 10 to 30% of people with&#160;HIV who&#160;have cryptococcal&#160;meningitis&#160;experience&#160;IRIS after&#160;<br/>initiation or reinitiation of&#160;effective ART and both&#160;unmasking (before start of antifungal therapy) or&#160;<br/>paradoxical&#160;(after start of&#160;antifungal&#160;therapy) IRIS&#160;may occur.</p>
<p style="position:absolute;top:928px;left:537px;white-space:nowrap" class="ft038">64,65</p>
<p style="position:absolute;top:930px;left:562px;white-space:nowrap" class="ft013">&#160;People&#160;with HIV who have&#160;</p>
<p style="position:absolute;top:950px;left:108px;white-space:nowrap" class="ft032">cryptococcal&#160;IRIS are more likely to be ART naive&#160;and those&#160;whose CSF has less inflammation on&#160;<br/>presentation seem&#160;to be&#160;at&#160;higher risk of cryptococcal IRIS.</p>
<p style="position:absolute;top:968px;left:518px;white-space:nowrap" class="ft038">66</p>
<p style="position:absolute;top:969px;left:529px;white-space:nowrap" class="ft013">&#160;The risk of IRIS can be minimized by&#160;</p>
<p style="position:absolute;top:989px;left:108px;white-space:nowrap" class="ft032">achieving CSF culture&#160;sterility before starting ART, using fluconazole&#160;800&#160;mg per day as&#160;<br/>consolidation therapy, and deferring&#160;ART initiation for 4 to 6&#160;weeks from the start&#160;of antifungal&#160;<br/>therapy&#160;</p>
<p style="position:absolute;top:1029px;left:164px;white-space:nowrap" class="ft012"><b>(AII).</b></p>
<p style="position:absolute;top:1028px;left:206px;white-space:nowrap" class="ft038">52,67</p>
<p style="position:absolute;top:1029px;left:231px;white-space:nowrap" class="ft013">&#160;Distinguishing paradoxical&#160;IRIS&#160;from treatment&#160;failure&#160;with culture-positive&#160;</p>
<p style="position:absolute;top:1049px;left:108px;white-space:nowrap" class="ft013">relapse is difficult. In general, cryptococcal IRIS presents with&#160;worsening clinical&#160;disease despite&#160;</p>
</div>
<!-- Page 135 -->
<a name="135"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page135-div" style="position:relative;width:917px;height:1187px;">
<p style="position:absolute;top:1117px;left:108px;white-space:nowrap" class="ft024"><i>Guidelines for the Prevention and Treatment&#160;of&#160;Opportunistic&#160;Infections in Adults&#160;and Adolescents&#160;With HIV&#160;</i></p>
<p style="position:absolute;top:1117px;left:783px;white-space:nowrap" class="ft024"><i>H-13&#160;</i></p>
<p style="position:absolute;top:109px;left:108px;white-space:nowrap" class="ft013">microbiological&#160;evidence&#160;of effective&#160;antifungal therapy with sterile CSF cultures,</p>
<p style="position:absolute;top:107px;left:676px;white-space:nowrap" class="ft038">66,68</p>
<p style="position:absolute;top:109px;left:701px;white-space:nowrap" class="ft013">&#160;whereas&#160;</p>
<p style="position:absolute;top:129px;left:108px;white-space:nowrap" class="ft032">treatment failure&#160;is associated with continued positive cultures. The primary microbiological&#160;criterion&#160;<br/>for treatment failure is a CSF culture&#160;that yields&#160;</p>
<p style="position:absolute;top:148px;left:441px;white-space:nowrap" class="ft019"><i>Cryptococcus</i></p>
<p style="position:absolute;top:148px;left:536px;white-space:nowrap" class="ft013">,&#160;not the visual appearance&#160;of yeasts&#160;</p>
<p style="position:absolute;top:168px;left:108px;white-space:nowrap" class="ft032">during treatment;&#160;the culture&#160;may take days to weeks to become positive. A&#160;negative PCR test&#160;<br/>(e.g., BioFire&#160;FilmArray&#160;Meningitis/Encephalitis Panel) has a high predictive&#160;value for sterile CSF&#160;<br/>cultures and&#160;can be diagnostically useful&#160;for distinguishing paradoxical IRIS&#160;with a&#160;negative&#160;CSF&#160;<br/>PCR from culture-positive relapse with&#160;a positive&#160;CSF PCR.</p>
<p style="position:absolute;top:226px;left:526px;white-space:nowrap" class="ft038">15</p>
<p style="position:absolute;top:228px;left:538px;white-space:nowrap" class="ft013">&#160;</p>
<p style="position:absolute;top:265px;left:108px;white-space:nowrap" class="ft013">The&#160;appropriate management strategy for IRIS&#160;</p>
<p style="position:absolute;top:265px;left:434px;white-space:nowrap" class="ft012"><b>is to&#160;continue&#160;both ART and&#160;antifungal therapy</b></p>
<p style="position:absolute;top:265px;left:785px;white-space:nowrap" class="ft013">&#160;</p>
<p style="position:absolute;top:285px;left:108px;white-space:nowrap" class="ft013">and reduce&#160;elevated ICP if&#160;present&#160;</p>
<p style="position:absolute;top:285px;left:349px;white-space:nowrap" class="ft012"><b>(AII).</b></p>
<p style="position:absolute;top:285px;left:391px;white-space:nowrap" class="ft013">&#160;While&#160;diagnostic&#160;tests are pending, escalating antifungal&#160;</p>
<p style="position:absolute;top:304px;left:108px;white-space:nowrap" class="ft032">therapy (i.e.,&#160;restarting amphotericin B therapy or increasing the&#160;fluconazole dose to 1,200 mg per&#160;<br/>day) is recommended&#160;</p>
<p style="position:absolute;top:324px;left:261px;white-space:nowrap" class="ft012"><b>(BIII).</b></p>
<p style="position:absolute;top:324px;left:308px;white-space:nowrap" class="ft013">&#160;In people with severe&#160;symptoms of IRIS,&#160;some&#160;experts recommend a&#160;</p>
<p style="position:absolute;top:344px;left:108px;white-space:nowrap" class="ft032">brief course&#160;of tapering doses of corticosteroids.&#160;Dosages have varied but&#160;commonly start&#160;at&#160;<br/>1.0 mg/kg per day of prednisone; precise data-driven management&#160;strategies have not&#160;been&#160;<br/>developed. Serum&#160;C–reactive protein (CRP) is generally elevated at&#160;the time&#160;IRIS develops;</p>
<p style="position:absolute;top:382px;left:744px;white-space:nowrap" class="ft038">69</p>
<p style="position:absolute;top:384px;left:755px;white-space:nowrap" class="ft013">&#160;CRP</p>
<p style="position:absolute;top:404px;left:108px;white-space:nowrap" class="ft032">will&#160;decrease with corticosteroid therapy if IRIS is&#160;present&#160;and can be&#160;used to&#160;empirically&#160;monitor&#160;<br/>IRIS resolution. Once clinical improvement is evident, it&#160;is recommended that&#160;fluconazole at&#160;<br/>consolidation therapy doses should be&#160;continued or&#160;restarted upon hospital discharge&#160;</p>
<p style="position:absolute;top:443px;left:697px;white-space:nowrap" class="ft012"><b>(BIII).</b></p>
<p style="position:absolute;top:443px;left:745px;white-space:nowrap" class="ft013">&#160;</p>
<p style="position:absolute;top:480px;left:108px;white-space:nowrap" class="ft032">The&#160;risk of IRIS appears&#160;to be&#160;much lower and the&#160;syndrome&#160;seems to be less severe&#160;with other&#160;<br/>forms of cryptococcosis—such as&#160;lymphadenitis, cutaneous abscesses, and&#160;bony lesions—than with&#160;<br/>cryptococcal&#160;meningitis.</p>
<p style="position:absolute;top:519px;left:278px;white-space:nowrap" class="ft038">70</p>
<p style="position:absolute;top:520px;left:293px;white-space:nowrap" class="ft013">Management&#160;of IRIS&#160;with other forms of cryptococcosis&#160;is similar to that&#160;</p>
<p style="position:absolute;top:540px;left:108px;white-space:nowrap" class="ft032">for IRIS associated with cryptococcal meningitis, including continuing ART,&#160;initiating or continuing&#160;<br/>antifungal therapy&#160;</p>
<p style="position:absolute;top:560px;left:238px;white-space:nowrap" class="ft012"><b>(AIII),</b></p>
<p style="position:absolute;top:560px;left:287px;white-space:nowrap" class="ft013">&#160;and only considering the&#160;use of corticosteroids if clinical&#160;symptoms are&#160;</p>
<p style="position:absolute;top:580px;left:108px;white-space:nowrap" class="ft013">severe&#160;</p>
<p style="position:absolute;top:580px;left:156px;white-space:nowrap" class="ft012"><b>(CIII).</b></p>
<p style="position:absolute;top:580px;left:205px;white-space:nowrap" class="ft013">&#160;</p>
<p style="position:absolute;top:617px;left:108px;white-space:nowrap" class="ft029"><i><b>Managing&#160;Treatment Failure&#160;</b></i></p>
<p style="position:absolute;top:658px;left:108px;white-space:nowrap" class="ft032">Treatment&#160;failure is defined as (1) a lack of clinical&#160;improvement&#160;and continued positive cultures&#160;<br/>after 2 weeks&#160;of appropriate therapy that&#160;has included management&#160;of increased ICP,&#160;or (2) relapse&#160;<br/>after an initial clinical&#160;response, defined as recurrence&#160;of symptoms with a&#160;positive CSF culture after&#160;</p>
<p style="position:absolute;top:718px;left:108px;white-space:nowrap" class="ft069">≥</p>
<p style="position:absolute;top:718px;left:117px;white-space:nowrap" class="ft018">4 weeks of&#160;treatment. Primary fluconazole resistance&#160;in&#160;</p>
<p style="position:absolute;top:718px;left:505px;white-space:nowrap" class="ft019"><i>Cryptococcus&#160;</i></p>
<p style="position:absolute;top:718px;left:604px;white-space:nowrap" class="ft013">isolates</p>
<p style="position:absolute;top:718px;left:655px;white-space:nowrap" class="ft019"><i>&#160;</i></p>
<p style="position:absolute;top:718px;left:660px;white-space:nowrap" class="ft013">has&#160;been&#160;reported in&#160;</p>
<p style="position:absolute;top:737px;left:108px;white-space:nowrap" class="ft013">the&#160;United States but is uncommon.</p>
<p style="position:absolute;top:736px;left:354px;white-space:nowrap" class="ft038">71</p>
<p style="position:absolute;top:737px;left:366px;white-space:nowrap" class="ft013">&#160;Therefore, susceptibility testing is not recommended routinely&#160;</p>
<p style="position:absolute;top:757px;left:108px;white-space:nowrap" class="ft013">for initial&#160;management of cryptococcosis. However,&#160;if treatment&#160;failure&#160;or relapse occurs,&#160;</p>
<p style="position:absolute;top:777px;left:108px;white-space:nowrap" class="ft019"><i>Cryptococcus</i></p>
<p style="position:absolute;top:777px;left:203px;white-space:nowrap" class="ft013">&#160;isolates should undergo&#160;antifungal susceptibility testing. Robust clinical&#160;data are&#160;</p>
<p style="position:absolute;top:797px;left:108px;white-space:nowrap" class="ft013">lacking, but strains of&#160;</p>
<p style="position:absolute;top:797px;left:262px;white-space:nowrap" class="ft019"><i>Cryptococcus</i></p>
<p style="position:absolute;top:797px;left:356px;white-space:nowrap" class="ft013">&#160;with fluconazole minimum&#160;inhibitory concentrations (MIC)&#160;</p>
<p style="position:absolute;top:817px;left:108px;white-space:nowrap" class="ft069">≥</p>
<p style="position:absolute;top:817px;left:118px;white-space:nowrap" class="ft018">16</p>
<p style="position:absolute;top:817px;left:135px;white-space:nowrap" class="ft013">&#160;µg/mL are considered not fully susceptible.</p>
<p style="position:absolute;top:815px;left:439px;white-space:nowrap" class="ft038">72,73</p>
<p style="position:absolute;top:817px;left:464px;white-space:nowrap" class="ft013">&#160;</p>
<p style="position:absolute;top:854px;left:108px;white-space:nowrap" class="ft032">Optimal&#160;therapy for patients with treatment failure has not been&#160;established. If treatment&#160;failure&#160;<br/>occurs after induction with alternative&#160;regimens, preferred regimens&#160;should&#160;be started. Furthermore,&#160;<br/>those initially treated with an amphotericin B formulation should remain on this agent&#160;until clinical&#160;<br/>response&#160;occurs. In this&#160;setting, liposomal amphotericin B (3–6&#160;mg/kg daily) or amphotericin B lipid&#160;<br/>complex (5&#160;mg/kg daily) is better tolerated and has&#160;greater efficacy than the&#160;deoxycholate&#160;<br/>formulation</p>
<p style="position:absolute;top:952px;left:189px;white-space:nowrap" class="ft038">28,74,75</p>
<p style="position:absolute;top:953px;left:229px;white-space:nowrap" class="ft013">&#160;and&#160;should be&#160;considered when initial treatment with other regimens fails&#160;</p>
<p style="position:absolute;top:953px;left:744px;white-space:nowrap" class="ft012"><b>(AII).</b></p>
<p style="position:absolute;top:953px;left:785px;white-space:nowrap" class="ft013">&#160;</p>
<p style="position:absolute;top:990px;left:108px;white-space:nowrap" class="ft032">In the&#160;setting of treatment failure or relapse, verifying CSF culture sterility at&#160;the&#160;completion of re-<br/>induction therapy is critical&#160;</p>
<p style="position:absolute;top:1010px;left:301px;white-space:nowrap" class="ft012"><b>(AIII).</b></p>
<p style="position:absolute;top:1010px;left:350px;white-space:nowrap" class="ft013">&#160;After CSF sterility is achieved, outpatient&#160;consolidation therapy&#160;</p>
<p style="position:absolute;top:1030px;left:108px;white-space:nowrap" class="ft013">should consist of fluconazole at&#160;a higher dose of&#160;1,200 mg per&#160;day and optimization of ART. For&#160;</p>
<p style="position:absolute;top:1050px;left:108px;white-space:nowrap" class="ft019"><i>Cryptococcus&#160;</i></p>
<p style="position:absolute;top:1050px;left:207px;white-space:nowrap" class="ft013">with decreased</p>
<p style="position:absolute;top:1050px;left:310px;white-space:nowrap" class="ft019"><i>&#160;</i></p>
<p style="position:absolute;top:1050px;left:314px;white-space:nowrap" class="ft013">azole-susceptibility (i.e.,&#160;</p>
<p style="position:absolute;top:1050px;left:488px;white-space:nowrap" class="ft069">≥</p>
<p style="position:absolute;top:1050px;left:497px;white-space:nowrap" class="ft013">16 µg/mL MIC for fluconazole), adjunctive&#160;</p>
</div>
<!-- Page 136 -->
<a name="136"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page136-div" style="position:relative;width:917px;height:1187px;">
<p style="position:absolute;top:1117px;left:108px;white-space:nowrap" class="ft024"><i>Guidelines for the Prevention and Treatment&#160;of&#160;Opportunistic&#160;Infections in Adults&#160;and Adolescents&#160;With HIV&#160;</i></p>
<p style="position:absolute;top:1117px;left:783px;white-space:nowrap" class="ft024"><i>H-14&#160;</i></p>
<p style="position:absolute;top:109px;left:108px;white-space:nowrap" class="ft013">weekly amphotericin B administration during consolidation therapy may be&#160;considered&#160;</p>
<p style="position:absolute;top:109px;left:713px;white-space:nowrap" class="ft012"><b>(BIII).</b></p>
<p style="position:absolute;top:107px;left:761px;white-space:nowrap" class="ft038">73</p>
<p style="position:absolute;top:109px;left:772px;white-space:nowrap" class="ft013">&#160;</p>
<p style="position:absolute;top:129px;left:108px;white-space:nowrap" class="ft032">Higher doses&#160;of fluconazole&#160;(i.e., 1,200&#160;mg per day)&#160;in combination with flucytosine 25 mg/kg&#160;<br/>four times per day also may be considered&#160;</p>
<p style="position:absolute;top:148px;left:404px;white-space:nowrap" class="ft012"><b>(BI).</b></p>
<p style="position:absolute;top:148px;left:438px;white-space:nowrap" class="ft013">&#160;The newer triazoles—posaconazole, voriconazole,&#160;</p>
<p style="position:absolute;top:168px;left:108px;white-space:nowrap" class="ft013">and isavuconazole—have&#160;activity against&#160;</p>
<p style="position:absolute;top:168px;left:398px;white-space:nowrap" class="ft019"><i>Cryptococcus&#160;</i></p>
<p style="position:absolute;top:168px;left:497px;white-space:nowrap" class="ft013">spp</p>
<p style="position:absolute;top:168px;left:521px;white-space:nowrap" class="ft019"><i>. in&#160;vitro</i></p>
<p style="position:absolute;top:168px;left:580px;white-space:nowrap" class="ft013">&#160;and may have a role&#160;in salvage&#160;</p>
<p style="position:absolute;top:188px;left:108px;white-space:nowrap" class="ft013">therapy,</p>
<p style="position:absolute;top:187px;left:164px;white-space:nowrap" class="ft038">46-48</p>
<p style="position:absolute;top:188px;left:190px;white-space:nowrap" class="ft013">&#160;but they offer no specific&#160;advantages over fluconazole&#160;unless&#160;</p>
<p style="position:absolute;top:188px;left:620px;white-space:nowrap" class="ft019"><i>in&#160;vitro</i></p>
<p style="position:absolute;top:188px;left:670px;white-space:nowrap" class="ft013">&#160;susceptibility&#160;</p>
<p style="position:absolute;top:208px;left:108px;white-space:nowrap" class="ft032">testing indicates only high-level&#160;fluconazole resistance. Most clinical&#160;failures are not&#160;due to&#160;<br/>antifungal drug resistance&#160;but rather result from&#160;inadequate&#160;induction therapy, nonadherence,&#160;<br/>drug-drug interactions that&#160;decrease the&#160;serum concentrations of&#160;fluconazole (e.g., with rifampin), or&#160;<br/>the&#160;development of paradoxical&#160;IRIS.&#160;Failures also&#160;may occur&#160;with high fungal&#160;burden&#160;disease and/or&#160;<br/>severe immunosuppression of host.&#160;&#160;</p>
<p style="position:absolute;top:324px;left:108px;white-space:nowrap" class="ft026"><b>Preventing&#160;Recurrence&#160;</b></p>
<p style="position:absolute;top:366px;left:108px;white-space:nowrap" class="ft029"><i><b>When to&#160;Start&#160;Maintenance&#160;Therapy&#160;</b></i></p>
<p style="position:absolute;top:407px;left:108px;white-space:nowrap" class="ft032">People who&#160;have completed 10 weeks&#160;of induction&#160;and consolidation therapy for cryptococcal&#160;<br/>meningitis or disseminated cryptococcosis should be treated with chronic maintenance or suppressive&#160;<br/>therapy with&#160;fluconazole 200 mg per day for at&#160;least 1 year&#160;</p>
<p style="position:absolute;top:447px;left:520px;white-space:nowrap" class="ft012"><b>(AI).</b></p>
<p style="position:absolute;top:447px;left:555px;white-space:nowrap" class="ft013">&#160;Itraconazole is inferior to&#160;</p>
<p style="position:absolute;top:467px;left:108px;white-space:nowrap" class="ft013">fluconazole for preventing relapse of&#160;cryptococcal&#160;disease and&#160;should generally not&#160;be considered&#160;</p>
<p style="position:absolute;top:486px;left:108px;white-space:nowrap" class="ft012"><b>(CI).</b></p>
<p style="position:absolute;top:485px;left:143px;white-space:nowrap" class="ft038">45</p>
<p style="position:absolute;top:486px;left:154px;white-space:nowrap" class="ft012"><b>&#160;</b></p>
<p style="position:absolute;top:485px;left:159px;white-space:nowrap" class="ft038">73</p>
<p style="position:absolute;top:486px;left:170px;white-space:nowrap" class="ft013">&#160;For&#160;people in whom susceptibility studies have been performed and the&#160;fluconazole MIC is&#160;</p>
<p style="position:absolute;top:506px;left:108px;white-space:nowrap" class="ft069">≥</p>
<p style="position:absolute;top:506px;left:117px;white-space:nowrap" class="ft013">16 µg/mL, the fluconazole dose may&#160;be increased&#160;to 400 mg per day&#160;</p>
<p style="position:absolute;top:506px;left:594px;white-space:nowrap" class="ft012"><b>(BIII).</b></p>
<p style="position:absolute;top:506px;left:642px;white-space:nowrap" class="ft013">&#160;Failure to administer&#160;</p>
<p style="position:absolute;top:526px;left:108px;white-space:nowrap" class="ft032">this secondary prophylaxis for an entire year is the&#160;most common reason for&#160;subsequent relapse of&#160;<br/>cryptococcal disease.</p>
<p style="position:absolute;top:545px;left:255px;white-space:nowrap" class="ft038">76</p>
<p style="position:absolute;top:546px;left:266px;white-space:nowrap" class="ft013">&#160;</p>
<p style="position:absolute;top:583px;left:108px;white-space:nowrap" class="ft029"><i><b>When to&#160;Stop Maintenance Therapy&#160;</b></i></p>
<p style="position:absolute;top:624px;left:108px;white-space:nowrap" class="ft032">Data&#160;evaluating relapse after successful antifungal&#160;therapy for cryptococcosis&#160;and discontinuation of&#160;<br/>maintenance therapy while on ART are limited. In a&#160;European study, recurrences of cryptococcosis&#160;<br/>were not found among 39&#160;participants&#160;on potent ART whose antifungal&#160;therapy was&#160;discontinued. In&#160;<br/>this cohort,&#160;when maintenance therapy was&#160;stopped, the median CD4 count was 297 cells/mm</p>
<p style="position:absolute;top:683px;left:757px;white-space:nowrap" class="ft038">3</p>
<p style="position:absolute;top:684px;left:763px;white-space:nowrap" class="ft013">, the&#160;</p>
<p style="position:absolute;top:704px;left:108px;white-space:nowrap" class="ft032">median HIV&#160;RNA&#160;concentration was &lt;500 copies/mL, and the median time&#160;on potent ART was&#160;<br/>25 months.</p>
<p style="position:absolute;top:722px;left:185px;white-space:nowrap" class="ft038">77</p>
<p style="position:absolute;top:724px;left:196px;white-space:nowrap" class="ft013">&#160;A prospective&#160;randomized study of&#160;60 people in Thailand documented no recurrences&#160;</p>
<p style="position:absolute;top:743px;left:108px;white-space:nowrap" class="ft032">of cryptococcosis during&#160;48 weeks&#160;of&#160;follow-up among 22 patients whose antifungal&#160;therapy was&#160;<br/>discontinued&#160;after reaching a CD4 count &gt;100 cells/mm</p>
<p style="position:absolute;top:762px;left:495px;white-space:nowrap" class="ft038">3</p>
<p style="position:absolute;top:763px;left:500px;white-space:nowrap" class="ft013">&#160;with a&#160;sustained undetectable HIV&#160;RNA&#160;</p>
<p style="position:absolute;top:783px;left:108px;white-space:nowrap" class="ft013">level&#160;for 3 months on potent ART.</p>
<p style="position:absolute;top:782px;left:346px;white-space:nowrap" class="ft038">78</p>
<p style="position:absolute;top:783px;left:357px;white-space:nowrap" class="ft013">&#160;Given these&#160;data and inference from&#160;data on discontinuation of&#160;</p>
<p style="position:absolute;top:803px;left:108px;white-space:nowrap" class="ft032">secondary prophylaxis for&#160;other HIV-associated OIs, it&#160;is reasonable to discontinue&#160;maintenance&#160;<br/>therapy after at&#160;least 1 year from initiation of antifungal&#160;therapy in people&#160;whose CD4 counts are&#160;</p>
<p style="position:absolute;top:843px;left:108px;white-space:nowrap" class="ft069">≥</p>
<p style="position:absolute;top:843px;left:117px;white-space:nowrap" class="ft013">100 cells/mm</p>
<p style="position:absolute;top:841px;left:211px;white-space:nowrap" class="ft038">3</p>
<p style="position:absolute;top:843px;left:217px;white-space:nowrap" class="ft013">&#160;with undetectable viral loads on&#160;ART&#160;</p>
<p style="position:absolute;top:843px;left:484px;white-space:nowrap" class="ft012"><b>(BII).</b></p>
<p style="position:absolute;top:841px;left:525px;white-space:nowrap" class="ft038">79</p>
<p style="position:absolute;top:843px;left:536px;white-space:nowrap" class="ft013">&#160;Maintenance&#160;therapy should&#160;be&#160;</p>
<p style="position:absolute;top:862px;left:108px;white-space:nowrap" class="ft013">reinitiated if&#160;the&#160;CD4 count decreases&#160;to &lt;100 cells/mm</p>
<p style="position:absolute;top:861px;left:493px;white-space:nowrap" class="ft038">3</p>
<p style="position:absolute;top:862px;left:499px;white-space:nowrap" class="ft013">&#160;</p>
<p style="position:absolute;top:862px;left:503px;white-space:nowrap" class="ft012"><b>(AIII).</b></p>
<p style="position:absolute;top:862px;left:552px;white-space:nowrap" class="ft013">&#160;</p>
<p style="position:absolute;top:899px;left:108px;white-space:nowrap" class="ft026"><b>Special&#160;Considerations During&#160;Pregnancy&#160;</b></p>
<p style="position:absolute;top:942px;left:108px;white-space:nowrap" class="ft013">During pregnancy, the diagnosis of&#160;cryptococcal infections is&#160;</p>
<p style="position:absolute;top:941px;left:536px;white-space:nowrap" class="ft0111">the same&#160;as&#160;</p>
<p style="position:absolute;top:942px;left:623px;white-space:nowrap" class="ft013">for other people&#160;with HIV.&#160;</p>
<p style="position:absolute;top:962px;left:108px;white-space:nowrap" class="ft032">Treatment&#160;should be initiated promptly after a diagnosis is confirmed, with attention to management&#160;<br/>of increased&#160;ICP.&#160;During&#160;the&#160;postpartum period, anti-inflammatory responses&#160;in pregnancy&#160;<br/>(enhancement of&#160;Th2 and&#160;suppression&#160;of Th1 cytokines) are reversed and may lead to overt clinical&#160;<br/>manifestations of a previously asymptomatic&#160;cryptococcal&#160;infection resembling IRIS.</p>
<p style="position:absolute;top:1020px;left:698px;white-space:nowrap" class="ft038">80-82</p>
<p style="position:absolute;top:1021px;left:724px;white-space:nowrap" class="ft013">&#160;Close&#160;</p>
<p style="position:absolute;top:1041px;left:108px;white-space:nowrap" class="ft032">collaboration between obstetric and infectious disease experts is&#160;recommended. For most patients&#160;<br/>with cryptococcal infection, experts recommend deferring ART initiation for 4 to 6&#160;weeks after&#160;</p>
</div>
<!-- Page 137 -->
<a name="137"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page137-div" style="position:relative;width:917px;height:1187px;">
<p style="position:absolute;top:1117px;left:108px;white-space:nowrap" class="ft024"><i>Guidelines for the Prevention and Treatment&#160;of&#160;Opportunistic&#160;Infections in Adults&#160;and Adolescents&#160;With HIV&#160;</i></p>
<p style="position:absolute;top:1117px;left:783px;white-space:nowrap" class="ft024"><i>H-15&#160;</i></p>
<p style="position:absolute;top:109px;left:108px;white-space:nowrap" class="ft032">antifungal agents are started to reduce&#160;the&#160;risk of IRIS; in pregnancy, however, starting ART as&#160;<br/>expeditiously as possible&#160;is associated&#160;with lower risk of perinatal&#160;transmission of HIV. For CNS&#160;<br/>cryptococcal&#160;infection during pregnancy, decisions&#160;about&#160;the&#160;timing of ART initiation should be&#160;<br/>made in consultation with the&#160;patient, the infectious diseases consultant, and the&#160;obstetrician. If ART&#160;<br/>is started sooner than generally recommended, close monitoring for IRIS should be&#160;implemented&#160;<br/>with a&#160;low threshold for treatment for IRIS.&#160;During&#160;pregnancy, the risk of IRIS&#160;associated with non-<br/>CNS&#160;cryptococcosis appears to be&#160;lower, and a&#160;delay in ART initiation of no longer than 2&#160;weeks&#160;<br/>after starting antifungal&#160;therapy is recommended.&#160;</p>
<p style="position:absolute;top:285px;left:108px;white-space:nowrap" class="ft013">Extensive&#160;clinical experience with amphotericin B deoxycholate has not&#160;</p>
<p style="position:absolute;top:285px;left:611px;white-space:nowrap" class="ft0111">been&#160;associated&#160;with</p>
<p style="position:absolute;top:285px;left:760px;white-space:nowrap" class="ft013">&#160;</p>
<p style="position:absolute;top:305px;left:108px;white-space:nowrap" class="ft032">teratogenicity, and this remains a preferred therapy&#160;for cryptococcosis in the&#160;first trimester of&#160;<br/>pregnancy&#160;</p>
<p style="position:absolute;top:325px;left:184px;white-space:nowrap" class="ft012"><b>(AIII).</b></p>
<p style="position:absolute;top:325px;left:233px;white-space:nowrap" class="ft013">&#160;Although there is less experience in pregnancy with lipid formulations of&#160;</p>
<p style="position:absolute;top:345px;left:108px;white-space:nowrap" class="ft032">amphotericin B, these products have been associated with less&#160;nephrotoxicity and electrolyte&#160;<br/>abnormalities&#160;than amphotericin B deoxycholate and are an alternative&#160;as a preferred therapy for the&#160;<br/>initial&#160;regimen for the&#160;treatment of cryptococcal&#160;meningoencephalitis, disseminated disease, or&#160;<br/>severe pulmonary cryptococcosis during pregnancy&#160;</p>
<p style="position:absolute;top:405px;left:467px;white-space:nowrap" class="ft012"><b>(AIII).</b></p>
<p style="position:absolute;top:405px;left:516px;white-space:nowrap" class="ft013">&#160;Optimal&#160;dosing of liposomal&#160;</p>
<p style="position:absolute;top:424px;left:108px;white-space:nowrap" class="ft032">amphotericin B in pregnancy is unknown.&#160;A recent&#160;review of dosing strategies in pregnancy&#160;<br/>recommended use of ideal body weight rather than total&#160;body weight to minimize&#160;risk of&#160;adverse&#160;<br/>effects to the fetus while&#160;maintaining efficacy&#160;</p>
<p style="position:absolute;top:464px;left:428px;white-space:nowrap" class="ft012"><b>(BII).</b></p>
<p style="position:absolute;top:463px;left:469px;white-space:nowrap" class="ft038">83</p>
<p style="position:absolute;top:464px;left:481px;white-space:nowrap" class="ft013">&#160;Neonates&#160;born to women on chronic&#160;</p>
<p style="position:absolute;top:484px;left:108px;white-space:nowrap" class="ft032">amphotericin B at delivery may be&#160;at increased risk&#160;for renal&#160;toxicity and electrolyte&#160;abnormalities&#160;<br/>and should be appropriately evaluated as newborns.</p>
<p style="position:absolute;top:502px;left:465px;white-space:nowrap" class="ft038">84</p>
<p style="position:absolute;top:504px;left:476px;white-space:nowrap" class="ft013">&#160;</p>
<p style="position:absolute;top:541px;left:108px;white-space:nowrap" class="ft032">During pregnancy, flucytosine use&#160;should be&#160;considered only when the benefits outweigh the risks&#160;to&#160;<br/>the&#160;mother and fetus and&#160;should be delayed until after the first&#160;trimester when&#160;feasible&#160;</p>
<p style="position:absolute;top:561px;left:706px;white-space:nowrap" class="ft012"><b>(AIII).&#160;</b></p>
<p style="position:absolute;top:561px;left:758px;white-space:nowrap" class="ft013">In&#160;</p>
<p style="position:absolute;top:580px;left:108px;white-space:nowrap" class="ft032">animal studies, flucytosine is teratogenic and may be associated&#160;with cleft&#160;palate and other bone&#160;<br/>abnormalities. Flucytosine use in pregnancy is limited to case reports and&#160;small series, although&#160;<br/>normal outcomes have been described.</p>
<p style="position:absolute;top:619px;left:376px;white-space:nowrap" class="ft038">85-87</p>
<p style="position:absolute;top:620px;left:402px;white-space:nowrap" class="ft013">&#160;&#160;</p>
<p style="position:absolute;top:657px;left:108px;white-space:nowrap" class="ft013">In general, azole antifungals&#160;</p>
<p style="position:absolute;top:657px;left:307px;white-space:nowrap" class="ft012"><b>should be avoided</b></p>
<p style="position:absolute;top:657px;left:440px;white-space:nowrap" class="ft013">&#160;during the first&#160;trimester of pregnancy unless&#160;the&#160;</p>
<p style="position:absolute;top:677px;left:108px;white-space:nowrap" class="ft013">benefit outweighs the&#160;risk&#160;</p>
<p style="position:absolute;top:677px;left:291px;white-space:nowrap" class="ft012"><b>(BIII).&#160;</b></p>
<p style="position:absolute;top:677px;left:343px;white-space:nowrap" class="ft013">Fluconazole has teratogenic&#160;potential&#160;in the first&#160;trimester.&#160;</p>
<p style="position:absolute;top:697px;left:108px;white-space:nowrap" class="ft032">Congenital malformations similar to those observed in animals exposed to the drug—including&#160;<br/>craniofacial&#160;and limb abnormalities—have been reported in infants born to&#160;mothers who&#160;received&#160;</p>
<p style="position:absolute;top:737px;left:108px;white-space:nowrap" class="ft018">fluconazole at&#160;doses of&#160;</p>
<p style="position:absolute;top:737px;left:271px;white-space:nowrap" class="ft069">≥</p>
<p style="position:absolute;top:737px;left:280px;white-space:nowrap" class="ft018">400 mg</p>
<p style="position:absolute;top:737px;left:332px;white-space:nowrap" class="ft013">&#160;per day throughout or beyond the first trimester of pregnancy.</p>
<p style="position:absolute;top:735px;left:764px;white-space:nowrap" class="ft038">88</p>
<p style="position:absolute;top:737px;left:776px;white-space:nowrap" class="ft013">&#160;</p>
<p style="position:absolute;top:756px;left:108px;white-space:nowrap" class="ft032">Furthermore,&#160;animal data&#160;suggest that&#160;moderate alcohol&#160;consumption during&#160;pregnancy may increase&#160;<br/>the&#160;potency of fluconazole, resulting in increased risk of craniofacial&#160;defects.</p>
<p style="position:absolute;top:775px;left:640px;white-space:nowrap" class="ft038">89</p>
<p style="position:absolute;top:776px;left:651px;white-space:nowrap" class="ft013">&#160;&#160;</p>
<p style="position:absolute;top:813px;left:108px;white-space:nowrap" class="ft032">Most of the&#160;studies regarding effects of&#160;fluconazole in pregnancy&#160;have involved low doses&#160;and short-<br/>term exposure. A recent&#160;meta-analysis describing&#160;</p>
<p style="position:absolute;top:833px;left:453px;white-space:nowrap" class="ft0102">birth defects in infants exposed to fluconazole&#160;</p>
<p style="position:absolute;top:853px;left:108px;white-space:nowrap" class="ft0110">during the first trimester evaluated nine cohort, case-control or randomized controlled studies,&#160;<br/>including 53,407 pregnancies with fluconazole&#160;exposure and 3,319,353&#160;without&#160;fluconazole&#160;<br/>exposure.</p>
<p style="position:absolute;top:891px;left:175px;white-space:nowrap" class="ft0104">90</p>
<p style="position:absolute;top:893px;left:186px;white-space:nowrap" class="ft0102">&#160;Maternal exposure to fluconazole&#160;was&#160;correlated with an increased prevalence of heart&#160;</p>
<p style="position:absolute;top:913px;left:108px;white-space:nowrap" class="ft0102">defects in infants for both&#160;low dose&#160;(</p>
<p style="position:absolute;top:913px;left:361px;white-space:nowrap" class="ft0105">≤</p>
<p style="position:absolute;top:913px;left:371px;white-space:nowrap" class="ft0102">150 mg) (odds&#160;ratio [OR] 1.95; 95% CI,&#160;1.18–3.21;&#160;</p>
<p style="position:absolute;top:913px;left:731px;white-space:nowrap" class="ft0106"><i>P</i></p>
<p style="position:absolute;top:913px;left:741px;white-space:nowrap" class="ft0105"> </p>
<p style="position:absolute;top:913px;left:744px;white-space:nowrap" class="ft0107">=</p>
<p style="position:absolute;top:913px;left:754px;white-space:nowrap" class="ft0105"> </p>
<p style="position:absolute;top:913px;left:758px;white-space:nowrap" class="ft0107">0.01)&#160;</p>
<p style="position:absolute;top:932px;left:108px;white-space:nowrap" class="ft0102">or any dose (OR 1.79; 95% CI, 1.18–2.71;&#160;</p>
<p style="position:absolute;top:932px;left:405px;white-space:nowrap" class="ft0106"><i>P</i></p>
<p style="position:absolute;top:932px;left:415px;white-space:nowrap" class="ft0105"> </p>
<p style="position:absolute;top:932px;left:419px;white-space:nowrap" class="ft0107">=</p>
<p style="position:absolute;top:932px;left:429px;white-space:nowrap" class="ft0105"> </p>
<p style="position:absolute;top:932px;left:432px;white-space:nowrap" class="ft0107">0.01). No association was found between&#160;</p>
<p style="position:absolute;top:932px;left:720px;white-space:nowrap" class="ft0102">either low-&#160;</p>
<p style="position:absolute;top:952px;left:108px;white-space:nowrap" class="ft0110">or high-dose&#160;fluconazole exposure and&#160;orofacial, CNS, genitourinary, musculoskeletal, or&#160;<br/>gastrointestinal defects.</p>
<p style="position:absolute;top:971px;left:271px;white-space:nowrap" class="ft038">91</p>
<p style="position:absolute;top:972px;left:282px;white-space:nowrap" class="ft013">&#160;One registry-based cohort study</p>
<p style="position:absolute;top:971px;left:507px;white-space:nowrap" class="ft038">92</p>
<p style="position:absolute;top:972px;left:519px;white-space:nowrap" class="ft013">&#160;of 7,352 women&#160;reported a&#160;threefold&#160;</p>
<p style="position:absolute;top:992px;left:108px;white-space:nowrap" class="ft013">increase in incidence of Tetralogy of Fallot, and a large&#160;population-based case-control study</p>
<p style="position:absolute;top:991px;left:744px;white-space:nowrap" class="ft038">93</p>
<p style="position:absolute;top:992px;left:755px;white-space:nowrap" class="ft013">&#160;</p>
<p style="position:absolute;top:1012px;left:108px;white-space:nowrap" class="ft032">specifically noted an increase in transposition of the great&#160;arteries (OR&#160;7.56,&#160;95% CI, 1.22–35.45).&#160;<br/>The&#160;latter study also suggested an increase in cleft lip with cleft palate (OR 5.53; 95% CI,&#160;<br/>1.68–18.24).&#160;In three nested case-control studies using data from&#160;the&#160;Quebec&#160;Prescription&#160;Drug&#160;</p>
</div>
<!-- Page 138 -->
<a name="138"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page138-div" style="position:relative;width:917px;height:1187px;">
<p style="position:absolute;top:1117px;left:108px;white-space:nowrap" class="ft024"><i>Guidelines for the Prevention and Treatment&#160;of&#160;Opportunistic&#160;Infections in Adults&#160;and Adolescents&#160;With HIV&#160;</i></p>
<p style="position:absolute;top:1117px;left:783px;white-space:nowrap" class="ft024"><i>H-16&#160;</i></p>
<p style="position:absolute;top:109px;left:108px;white-space:nowrap" class="ft032">Insurance database, there was an increased prevalence of cardiac septal&#160;closure anomalies for&#160;<br/>maternal&#160;fluconazole doses greater than 150 mg during pregnancy (OR 1.81;&#160;95% CI,&#160;1.04–3.14).</p>
<p style="position:absolute;top:127px;left:782px;white-space:nowrap" class="ft038">94</p>
<p style="position:absolute;top:129px;left:794px;white-space:nowrap" class="ft013">&#160;</p>
<p style="position:absolute;top:148px;left:108px;white-space:nowrap" class="ft032">A recent&#160;population-based cohort&#160;study (included in the meta-analysis) of 1,969,954 pregnancies,&#160;<br/>including 37,650 pregnancies exposed&#160;to fluconazole, found an increased risk&#160;of musculoskeletal&#160;<br/>malformations following&#160;exposure to fluconazole during the&#160;first trimester of pregnancy&#160;</p>
<p style="position:absolute;top:188px;left:721px;white-space:nowrap" class="ft0102">(risk of 52.1&#160;</p>
<p style="position:absolute;top:208px;left:108px;white-space:nowrap" class="ft0110">per 10,000&#160;pregnancies exposed to fluconazole versus 37.3 per&#160;10,000 pregnancies exposed to topical&#160;<br/>azoles)</p>
<p style="position:absolute;top:228px;left:157px;white-space:nowrap" class="ft013">.</p>
<p style="position:absolute;top:226px;left:161px;white-space:nowrap" class="ft038">95</p>
<p style="position:absolute;top:228px;left:172px;white-space:nowrap" class="ft013">&#160;</p>
<p style="position:absolute;top:265px;left:108px;white-space:nowrap" class="ft013">A nationwide cohort&#160;study in Denmark</p>
<p style="position:absolute;top:263px;left:378px;white-space:nowrap" class="ft038">96</p>
<p style="position:absolute;top:265px;left:389px;white-space:nowrap" class="ft013">&#160;found that exposure to&#160;oral&#160;fluconazole during pregnancy&#160;</p>
<p style="position:absolute;top:285px;left:108px;white-space:nowrap" class="ft013">was associated with an increased risk&#160;of spontaneous abortion compared with unexposed&#160;pregnancies&#160;</p>
<p style="position:absolute;top:304px;left:108px;white-space:nowrap" class="ft091">(n = 16,561,&#160;HR, 1.48; 95% CI, 1.23–1.77)</p>
<p style="position:absolute;top:303px;left:405px;white-space:nowrap" class="ft0108">&#160;</p>
<p style="position:absolute;top:304px;left:408px;white-space:nowrap" class="ft013">or those&#160;with topical&#160;azole exposure only&#160;</p>
<p style="position:absolute;top:304px;left:696px;white-space:nowrap" class="ft091">(n =&#160;5,646,&#160;HR&#160;</p>
<p style="position:absolute;top:324px;left:108px;white-space:nowrap" class="ft091">1.62; 95% CI, 1.26–2.07).&#160;</p>
<p style="position:absolute;top:324px;left:292px;white-space:nowrap" class="ft013">Similarly, the&#160;nested case-control studies in Canada (n =&#160;</p>
<p style="position:absolute;top:324px;left:686px;white-space:nowrap" class="ft091">320,&#160;868&#160;</p>
<p style="position:absolute;top:344px;left:108px;white-space:nowrap" class="ft091">pregnancies)</p>
<p style="position:absolute;top:344px;left:196px;white-space:nowrap" class="ft013">&#160;found that exposure to oral&#160;fluconazole during pregnancy was associated with an&#160;</p>
<p style="position:absolute;top:364px;left:108px;white-space:nowrap" class="ft032">increased risk of spontaneous abortion compared&#160;with unexposed pregnancies, and that&#160;risk was&#160;<br/>greater with&#160;higher dose&#160;of fluconazole exposure&#160;</p>
<p style="position:absolute;top:384px;left:450px;white-space:nowrap" class="ft091">(adjusted odds&#160;ratio [aOR]&#160;with&#160;</p>
<p style="position:absolute;top:384px;left:672px;white-space:nowrap" class="ft0105">≤</p>
<p style="position:absolute;top:384px;left:682px;white-space:nowrap" class="ft091">150 mg 2.23, 95%&#160;</p>
<p style="position:absolute;top:404px;left:108px;white-space:nowrap" class="ft091">CI, 1.96–2.54; aOR with&#160;&gt;150 mg 3.20; 95% CI, 2.73–3.75)</p>
<p style="position:absolute;top:404px;left:525px;white-space:nowrap" class="ft013">.</p>
<p style="position:absolute;top:402px;left:529px;white-space:nowrap" class="ft038">94</p>
<p style="position:absolute;top:404px;left:541px;white-space:nowrap" class="ft013">&#160;However, a cohort study using&#160;</p>
<p style="position:absolute;top:424px;left:108px;white-space:nowrap" class="ft032">Swedish&#160;and&#160;Norwegian registry data (n = 1,485,316 pregnancies) found no association between&#160;<br/>fluconazole use during pregnancy and&#160;risk of stillbirth or neonatal&#160;death.</p>
<p style="position:absolute;top:442px;left:609px;white-space:nowrap" class="ft038">97</p>
<p style="position:absolute;top:443px;left:621px;white-space:nowrap" class="ft013">&#160;The meta-analysis noted&#160;</p>
<p style="position:absolute;top:463px;left:108px;white-space:nowrap" class="ft013">above also found&#160;</p>
<p style="position:absolute;top:463px;left:230px;white-space:nowrap" class="ft0102">no association between fluconazole&#160;exposure and risk of abortion or stillbirth.</p>
<p style="position:absolute;top:462px;left:767px;white-space:nowrap" class="ft0104">90</p>
<p style="position:absolute;top:463px;left:778px;white-space:nowrap" class="ft0102">&#160;</p>
<p style="position:absolute;top:483px;left:108px;white-space:nowrap" class="ft032">Most of the&#160;studies regarding effects of&#160;fluconazole during pregnancy have involved low doses of the&#160;<br/>drug and&#160;short-term exposure.&#160;</p>
<p style="position:absolute;top:540px;left:108px;white-space:nowrap" class="ft032">On the basis&#160;of reported birth defects, the use of fluconazole in the first trimester should be&#160;<br/>considered only if the benefits clearly outweigh the&#160;risks&#160;</p>
<p style="position:absolute;top:560px;left:503px;white-space:nowrap" class="ft012"><b>(CIII).</b></p>
<p style="position:absolute;top:560px;left:551px;white-space:nowrap" class="ft013">&#160;Amphotericin B should&#160;be&#160;</p>
<p style="position:absolute;top:580px;left:108px;white-space:nowrap" class="ft013">continued throughout&#160;the first&#160;trimester if possible&#160;</p>
<p style="position:absolute;top:580px;left:459px;white-space:nowrap" class="ft012"><b>(AIII).</b></p>
<p style="position:absolute;top:580px;left:507px;white-space:nowrap" class="ft013">&#160;After&#160;the&#160;first&#160;trimester, switching to oral&#160;</p>
<p style="position:absolute;top:600px;left:108px;white-space:nowrap" class="ft013">fluconazole may be considered if appropriate clinically&#160;</p>
<p style="position:absolute;top:599px;left:493px;white-space:nowrap" class="ft0111">for&#160;consolidation or&#160;maintenance therapy</p>
<p style="position:absolute;top:600px;left:789px;white-space:nowrap" class="ft013">&#160;</p>
<p style="position:absolute;top:620px;left:108px;white-space:nowrap" class="ft012"><b>(CIII).</b></p>
<p style="position:absolute;top:620px;left:156px;white-space:nowrap" class="ft013">&#160;</p>
<p style="position:absolute;top:657px;left:108px;white-space:nowrap" class="ft032">Although there have&#160;been&#160;case reports&#160;of birth defects in infants&#160;exposed to itraconazole, a recent&#160;<br/>systematic review and meta-analysis of four cohort studies involving 971,450&#160;pregnant&#160;women with&#160;<br/>1,311 exposures, found no&#160;significant&#160;difference&#160;in the overall&#160;risk of birth defects between&#160;those&#160;<br/>with maternal&#160;exposure to&#160;itraconazole and those not exposed.</p>
<p style="position:absolute;top:715px;left:538px;white-space:nowrap" class="ft038">98</p>
<p style="position:absolute;top:717px;left:553px;white-space:nowrap" class="ft013">While&#160;limb and congenital&#160;heart&#160;</p>
<p style="position:absolute;top:737px;left:108px;white-space:nowrap" class="ft032">defects were&#160;the&#160;most common defects seen, they&#160;were within the rates of the defects published by&#160;<br/>EUROCAT (the&#160;European&#160;network of&#160;population-based registries for epidemiological&#160;surveillance of&#160;<br/>congenital anomalies). However, the&#160;rate of eye&#160;defects was higher than that&#160;published by&#160;<br/>EUROCAT.&#160;There was no difference in the rates of&#160;spontaneous&#160;abortion or stillbirth from&#160;<br/>itraconazole exposure.&#160;</p>
<p style="position:absolute;top:853px;left:108px;white-space:nowrap" class="ft032">Voriconazole (at doses lower than recommended human doses),&#160;posaconazole, and isavuconazole&#160;are&#160;<br/>teratogenic and embryotoxic&#160;in animals; no adequately controlled studies have assessed their&#160;<br/>teratogenicity and embryotoxicity in humans. Voriconazole, posaconazole, and isavuconazole&#160;</p>
<p style="position:absolute;top:893px;left:760px;white-space:nowrap" class="ft012"><b>are&#160;</b></p>
<p style="position:absolute;top:913px;left:108px;white-space:nowrap" class="ft012"><b>not recommended</b></p>
<p style="position:absolute;top:913px;left:241px;white-space:nowrap" class="ft013">&#160;for use during pregnancy, especially in the first trimester&#160;</p>
<p style="position:absolute;top:913px;left:640px;white-space:nowrap" class="ft012"><b>(CIII).</b></p>
<p style="position:absolute;top:913px;left:689px;white-space:nowrap" class="ft013">&#160;</p>
<p style="position:absolute;top:913px;left:905px;white-space:nowrap" class="ft013">&#160;</p>
</div>
<!-- Page 139 -->
<a name="139"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page139-div" style="position:relative;width:917px;height:1187px;">
<p style="position:absolute;top:1117px;left:108px;white-space:nowrap" class="ft024"><i>Guidelines for the Prevention and Treatment&#160;of&#160;Opportunistic&#160;Infections in Adults&#160;and Adolescents&#160;With HIV&#160;</i></p>
<p style="position:absolute;top:1117px;left:783px;white-space:nowrap" class="ft024"><i>H-17&#160;</i></p>
<p style="position:absolute;top:108px;left:108px;white-space:nowrap" class="ft026"><b>References&#160;</b></p>
<p style="position:absolute;top:150px;left:108px;white-space:nowrap" class="ft013">1.</p>
<p style="position:absolute;top:150px;left:121px;white-space:nowrap" class="ft046">&#160;</p>
<p style="position:absolute;top:150px;left:162px;white-space:nowrap" class="ft032">Aberg&#160;J, WG. P. Cryptococcosis. In:&#160;AIDS&#160;Therapy. M.&#160;H. Dolin R, Saag&#160;MS, ed. New&#160;<br/>York,&#160;NY: Churchill&#160;Livingstone; 2002:498-510.&#160;&#160;</p>
<p style="position:absolute;top:207px;left:108px;white-space:nowrap" class="ft013">2.</p>
<p style="position:absolute;top:207px;left:121px;white-space:nowrap" class="ft046">&#160;</p>
<p style="position:absolute;top:207px;left:162px;white-space:nowrap" class="ft032">Mirza SA, Phelan M, Rimland D, et&#160;al. The&#160;changing epidemiology of cryptococcosis:&#160;an&#160;<br/>update from&#160;population-based active surveillance&#160;in 2 large metropolitan areas, 1992–2000.&#160;</p>
<p style="position:absolute;top:247px;left:162px;white-space:nowrap" class="ft019"><i>Clin Infect&#160;Dis</i></p>
<p style="position:absolute;top:247px;left:263px;white-space:nowrap" class="ft013">. 2003;36(6):789-794.&#160;Available at:&#160;</p>
<p style="position:absolute;top:266px;left:162px;white-space:nowrap" class="ft034">https://pubmed.ncbi.nlm.nih.gov/12627365</p>
<p style="position:absolute;top:266px;left:461px;white-space:nowrap" class="ft013">.&#160;</p>
<p style="position:absolute;top:304px;left:108px;white-space:nowrap" class="ft013">3.</p>
<p style="position:absolute;top:303px;left:121px;white-space:nowrap" class="ft046">&#160;</p>
<p style="position:absolute;top:304px;left:162px;white-space:nowrap" class="ft032">Rajasingham&#160;R, Govender NP,&#160;Jordan&#160;A, et al. The global&#160;burden of HIV-associated&#160;<br/>cryptococcal&#160;infection in adults in 2020: a&#160;modelling analysis.&#160;</p>
<p style="position:absolute;top:323px;left:595px;white-space:nowrap" class="ft019"><i>Lancet&#160;Infect&#160;Dis</i></p>
<p style="position:absolute;top:323px;left:713px;white-space:nowrap" class="ft013">.&#160;</p>
<p style="position:absolute;top:343px;left:162px;white-space:nowrap" class="ft013">2022;22(12):1748-1755.&#160;Available at:&#160;</p>
<p style="position:absolute;top:343px;left:428px;white-space:nowrap" class="ft034">https://www.ncbi.nlm.nih.gov/pubmed/36049486</p>
<p style="position:absolute;top:343px;left:770px;white-space:nowrap" class="ft013">.&#160;</p>
<p style="position:absolute;top:380px;left:108px;white-space:nowrap" class="ft013">4.</p>
<p style="position:absolute;top:380px;left:121px;white-space:nowrap" class="ft046">&#160;</p>
<p style="position:absolute;top:380px;left:162px;white-space:nowrap" class="ft032">Pyrgos V,&#160;Seitz AE, Steiner CA,&#160;Prevots DR, Williamson PR.&#160;Epidemiology of cryptococcal&#160;<br/>meningitis in the US: 1997–2009.&#160;</p>
<p style="position:absolute;top:400px;left:400px;white-space:nowrap" class="ft019"><i>PLoS One</i></p>
<p style="position:absolute;top:400px;left:470px;white-space:nowrap" class="ft013">. 2013;8(2):e56269.&#160;Available at:&#160;</p>
<p style="position:absolute;top:420px;left:162px;white-space:nowrap" class="ft034">https://www.pubmed.ncbi.nlm.nih.gov/23457543</p>
<p style="position:absolute;top:420px;left:503px;white-space:nowrap" class="ft013">.&#160;</p>
<p style="position:absolute;top:457px;left:108px;white-space:nowrap" class="ft013">5.</p>
<p style="position:absolute;top:457px;left:162px;white-space:nowrap" class="ft013">Maziarz EK,&#160;Perfect&#160;JR.&#160;Cryptococcosis.&#160;</p>
<p style="position:absolute;top:457px;left:449px;white-space:nowrap" class="ft019"><i>Infect Dis Clin North&#160;Am</i></p>
<p style="position:absolute;top:457px;left:622px;white-space:nowrap" class="ft013">. 2016;30(1):179-206.&#160;</p>
<p style="position:absolute;top:477px;left:162px;white-space:nowrap" class="ft013">Available at:&#160;</p>
<p style="position:absolute;top:477px;left:255px;white-space:nowrap" class="ft034">https://www.ncbi.nlm.nih.gov/pubmed/26897067</p>
<p style="position:absolute;top:477px;left:596px;white-space:nowrap" class="ft013">.&#160;</p>
<p style="position:absolute;top:514px;left:108px;white-space:nowrap" class="ft013">6.</p>
<p style="position:absolute;top:514px;left:121px;white-space:nowrap" class="ft046">&#160;</p>
<p style="position:absolute;top:514px;left:162px;white-space:nowrap" class="ft032">Rhein J, Hullsiek KH, Evans EE, et&#160;al. Detrimental&#160;outcomes of&#160;unmasking cryptococcal&#160;<br/>meningitis with recent ART initiation.&#160;</p>
<p style="position:absolute;top:534px;left:430px;white-space:nowrap" class="ft019"><i>Open Forum Infect&#160;Dis</i></p>
<p style="position:absolute;top:534px;left:590px;white-space:nowrap" class="ft013">.&#160;2018;5(8):ofy122. Available&#160;</p>
<p style="position:absolute;top:554px;left:162px;white-space:nowrap" class="ft013">at:&#160;</p>
<p style="position:absolute;top:554px;left:184px;white-space:nowrap" class="ft034">https://www.pubmed.ncbi.nlm.nih.gov/30094292</p>
<p style="position:absolute;top:554px;left:524px;white-space:nowrap" class="ft013">.&#160;</p>
<p style="position:absolute;top:591px;left:108px;white-space:nowrap" class="ft013">7.</p>
<p style="position:absolute;top:591px;left:121px;white-space:nowrap" class="ft046">&#160;</p>
<p style="position:absolute;top:591px;left:162px;white-space:nowrap" class="ft032">Graybill JR,&#160;Sobel J,&#160;Saag M, et al. Diagnosis and&#160;management&#160;of increased&#160;intracranial&#160;<br/>pressure in&#160;patients with AIDS and cryptococcal meningitis. The&#160;NIAID&#160;Mycoses&#160;Study&#160;<br/>Group and AIDS&#160;Cooperative Treatment Groups.&#160;</p>
<p style="position:absolute;top:630px;left:507px;white-space:nowrap" class="ft019"><i>Clin Infect&#160;Dis</i></p>
<p style="position:absolute;top:630px;left:609px;white-space:nowrap" class="ft013">. 2000;30(1):47-54.&#160;</p>
<p style="position:absolute;top:650px;left:162px;white-space:nowrap" class="ft013">Available at:&#160;</p>
<p style="position:absolute;top:650px;left:255px;white-space:nowrap" class="ft034">https://www.pubmed.ncbi.nlm.nih.gov/10619732</p>
<p style="position:absolute;top:650px;left:596px;white-space:nowrap" class="ft013">.&#160;</p>
<p style="position:absolute;top:687px;left:108px;white-space:nowrap" class="ft013">8.</p>
<p style="position:absolute;top:687px;left:121px;white-space:nowrap" class="ft046">&#160;</p>
<p style="position:absolute;top:687px;left:162px;white-space:nowrap" class="ft032">Bicanic T, Brouwer&#160;AE,&#160;Meintjes G,&#160;et&#160;al. Relationship of cerebrospinal&#160;fluid pressure,&#160;<br/>fungal&#160;burden and outcome&#160;in patients&#160;with cryptococcal&#160;meningitis undergoing serial&#160;lumbar&#160;<br/>punctures.&#160;</p>
<p style="position:absolute;top:727px;left:238px;white-space:nowrap" class="ft019"><i>AIDS</i></p>
<p style="position:absolute;top:727px;left:275px;white-space:nowrap" class="ft013">. 2009;23(6):701-706.&#160;Available at:&#160;</p>
<p style="position:absolute;top:747px;left:162px;white-space:nowrap" class="ft034">https://pubmed.ncbi.nlm.nih.gov/19279443</p>
<p style="position:absolute;top:747px;left:461px;white-space:nowrap" class="ft013">.&#160;</p>
<p style="position:absolute;top:784px;left:108px;white-space:nowrap" class="ft013">9.</p>
<p style="position:absolute;top:784px;left:121px;white-space:nowrap" class="ft046">&#160;</p>
<p style="position:absolute;top:784px;left:162px;white-space:nowrap" class="ft032">Boulware&#160;DR, Rolfes&#160;MA, Rajasingham&#160;R, et&#160;al. Multisite&#160;validation of cryptococcal&#160;antigen&#160;<br/>lateral&#160;flow assay and&#160;quantification by laser thermal&#160;contrast.&#160;</p>
<p style="position:absolute;top:804px;left:595px;white-space:nowrap" class="ft019"><i>Emerg Infect Dis</i></p>
<p style="position:absolute;top:804px;left:712px;white-space:nowrap" class="ft013">.&#160;</p>
<p style="position:absolute;top:824px;left:162px;white-space:nowrap" class="ft013">2014;20(1):45-53. Available&#160;at:&#160;</p>
<p style="position:absolute;top:824px;left:385px;white-space:nowrap" class="ft034">https://www.pubmed.ncbi.nlm.nih.gov/24378231</p>
<p style="position:absolute;top:824px;left:726px;white-space:nowrap" class="ft013">.&#160;</p>
<p style="position:absolute;top:861px;left:108px;white-space:nowrap" class="ft013">10.</p>
<p style="position:absolute;top:861px;left:130px;white-space:nowrap" class="ft046">&#160;</p>
<p style="position:absolute;top:861px;left:162px;white-space:nowrap" class="ft032">Ssebambulidde K, Bangdiwala AS,&#160;Kwizera&#160;R, et&#160;al. Symptomatic&#160;cryptococcal&#160;antigenemia&#160;<br/>presenting as&#160;early cryptococcal meningitis with negative cerebral&#160;spinal fluid analysis.&#160;</p>
<p style="position:absolute;top:881px;left:769px;white-space:nowrap" class="ft019"><i>Clin&#160;</i></p>
<p style="position:absolute;top:900px;left:162px;white-space:nowrap" class="ft019"><i>Infect&#160;Dis</i></p>
<p style="position:absolute;top:900px;left:229px;white-space:nowrap" class="ft013">. 2019;68(12):2094-2098.&#160;Available&#160;at:&#160;</p>
<p style="position:absolute;top:920px;left:162px;white-space:nowrap" class="ft034">https://www.pubmed.ncbi.nlm.nih.gov/30256903</p>
<p style="position:absolute;top:920px;left:503px;white-space:nowrap" class="ft013">.&#160;</p>
<p style="position:absolute;top:957px;left:108px;white-space:nowrap" class="ft013">11.</p>
<p style="position:absolute;top:957px;left:130px;white-space:nowrap" class="ft046">&#160;</p>
<p style="position:absolute;top:957px;left:162px;white-space:nowrap" class="ft032">French N, Gray K, Watera&#160;C, et&#160;al. Cryptococcal&#160;infection in a&#160;cohort&#160;of&#160;HIV-1-infected&#160;<br/>Ugandan adults.&#160;</p>
<p style="position:absolute;top:977px;left:278px;white-space:nowrap" class="ft019"><i>AIDS</i></p>
<p style="position:absolute;top:977px;left:316px;white-space:nowrap" class="ft013">. 2002;16(7):1031-1038.&#160;Available&#160;at:&#160;</p>
<p style="position:absolute;top:997px;left:162px;white-space:nowrap" class="ft034">https://www.pubmed.ncbi.nlm.nih.gov/11953469</p>
<p style="position:absolute;top:997px;left:503px;white-space:nowrap" class="ft013">.&#160;</p>
<p style="position:absolute;top:1034px;left:108px;white-space:nowrap" class="ft013">12.</p>
<p style="position:absolute;top:1034px;left:130px;white-space:nowrap" class="ft046">&#160;</p>
<p style="position:absolute;top:1034px;left:162px;white-space:nowrap" class="ft032">Powderly&#160;WG, Cloud&#160;GA, Dismukes&#160;WE, Saag&#160;MS.&#160;Measurement&#160;of cryptococcal&#160;antigen in&#160;<br/>serum and cerebrospinal fluid: value&#160;in the management&#160;of AIDS-associated cryptococcal&#160;</p>
</div>
<!-- Page 140 -->
<a name="140"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page140-div" style="position:relative;width:917px;height:1187px;">
<p style="position:absolute;top:1117px;left:108px;white-space:nowrap" class="ft024"><i>Guidelines for the Prevention and Treatment&#160;of&#160;Opportunistic&#160;Infections in Adults&#160;and Adolescents&#160;With HIV&#160;</i></p>
<p style="position:absolute;top:1117px;left:783px;white-space:nowrap" class="ft024"><i>H-18&#160;</i></p>
<p style="position:absolute;top:109px;left:162px;white-space:nowrap" class="ft013">meningitis.&#160;</p>
<p style="position:absolute;top:109px;left:243px;white-space:nowrap" class="ft019"><i>Clin Infect Dis</i></p>
<p style="position:absolute;top:109px;left:345px;white-space:nowrap" class="ft013">. 1994;18(5):789-792.&#160;Available at:&#160;</p>
<p style="position:absolute;top:129px;left:162px;white-space:nowrap" class="ft034">https://www.pubmed.ncbi.nlm.nih.gov/8075272</p>
<p style="position:absolute;top:129px;left:494px;white-space:nowrap" class="ft013">.&#160;</p>
<p style="position:absolute;top:166px;left:108px;white-space:nowrap" class="ft013">13.</p>
<p style="position:absolute;top:165px;left:130px;white-space:nowrap" class="ft046">&#160;</p>
<p style="position:absolute;top:166px;left:162px;white-space:nowrap" class="ft032">Beyene&#160;T, Zewde AG, Balcha A, et al. Inadequacy&#160;of high-dose&#160;fluconazole monotherapy&#160;<br/>among cerebrospinal&#160;fluid cryptococcal&#160;antigen (CrAg)-positive human immunodeficiency&#160;<br/>virus-infected persons in&#160;an Ethiopian CrAg&#160;screening program.&#160;</p>
<p style="position:absolute;top:205px;left:609px;white-space:nowrap" class="ft019"><i>Clin Infect Dis</i></p>
<p style="position:absolute;top:205px;left:710px;white-space:nowrap" class="ft013">.&#160;</p>
<p style="position:absolute;top:225px;left:162px;white-space:nowrap" class="ft013">2017;65(12):2126-2129.&#160;Available at:&#160;</p>
<p style="position:absolute;top:225px;left:428px;white-space:nowrap" class="ft034">https://www.pubmed.ncbi.nlm.nih.gov/29020172</p>
<p style="position:absolute;top:225px;left:769px;white-space:nowrap" class="ft013">.&#160;</p>
<p style="position:absolute;top:262px;left:108px;white-space:nowrap" class="ft013">14.</p>
<p style="position:absolute;top:262px;left:130px;white-space:nowrap" class="ft046">&#160;</p>
<p style="position:absolute;top:262px;left:162px;white-space:nowrap" class="ft032">Wake&#160;RM, Britz E, Sriruttan C, et&#160;al. High cryptococcal antigen titers in blood&#160;are predictive&#160;<br/>of subclinical&#160;cryptococcal&#160;meningitis among human immunodeficiency virus-infected&#160;<br/>patients.&#160;</p>
<p style="position:absolute;top:302px;left:224px;white-space:nowrap" class="ft019"><i>Clin Infect&#160;Dis</i></p>
<p style="position:absolute;top:302px;left:326px;white-space:nowrap" class="ft013">. 2018;66(5):686-692.&#160;Available&#160;at:&#160;</p>
<p style="position:absolute;top:322px;left:162px;white-space:nowrap" class="ft034">https://www.pubmed.ncbi.nlm.nih.gov/29028998</p>
<p style="position:absolute;top:322px;left:503px;white-space:nowrap" class="ft013">.&#160;</p>
<p style="position:absolute;top:359px;left:108px;white-space:nowrap" class="ft013">15.</p>
<p style="position:absolute;top:359px;left:130px;white-space:nowrap" class="ft046">&#160;</p>
<p style="position:absolute;top:359px;left:162px;white-space:nowrap" class="ft032">Rhein J, Bahr NC,&#160;Hemmert&#160;AC, et al. Diagnostic performance&#160;of a multiplex PCR assay for&#160;<br/>meningitis in an HIV-infected population in Uganda.&#160;</p>
<p style="position:absolute;top:379px;left:532px;white-space:nowrap" class="ft019"><i>Diagn Microbiol&#160;Infect Dis</i></p>
<p style="position:absolute;top:379px;left:720px;white-space:nowrap" class="ft013">.&#160;</p>
<p style="position:absolute;top:399px;left:162px;white-space:nowrap" class="ft013">2016;84(3):268-273.&#160;Available&#160;at:&#160;</p>
<p style="position:absolute;top:399px;left:402px;white-space:nowrap" class="ft034">https://www.pubmed.ncbi.nlm.nih.gov/26711635</p>
<p style="position:absolute;top:399px;left:743px;white-space:nowrap" class="ft013">.&#160;</p>
<p style="position:absolute;top:436px;left:108px;white-space:nowrap" class="ft013">16.</p>
<p style="position:absolute;top:435px;left:130px;white-space:nowrap" class="ft046">&#160;</p>
<p style="position:absolute;top:436px;left:162px;white-space:nowrap" class="ft032">Hanson&#160;KE,&#160;Slechta ES, Killpack JA,&#160;et&#160;al. Preclinical assessment of a&#160;fully&#160;automated&#160;<br/>multiplex PCR panel&#160;for detection of central nervous system&#160;pathogens.&#160;</p>
<p style="position:absolute;top:455px;left:662px;white-space:nowrap" class="ft019"><i>J Clin Microbiol</i></p>
<p style="position:absolute;top:455px;left:777px;white-space:nowrap" class="ft013">.&#160;</p>
<p style="position:absolute;top:475px;left:162px;white-space:nowrap" class="ft013">2016;54(3):785-787.&#160;Available&#160;at:&#160;</p>
<p style="position:absolute;top:475px;left:402px;white-space:nowrap" class="ft034">https://www.pubmed.ncbi.nlm.nih.gov/26719436</p>
<p style="position:absolute;top:475px;left:743px;white-space:nowrap" class="ft013">.&#160;</p>
<p style="position:absolute;top:512px;left:108px;white-space:nowrap" class="ft013">17.</p>
<p style="position:absolute;top:512px;left:130px;white-space:nowrap" class="ft046">&#160;</p>
<p style="position:absolute;top:512px;left:162px;white-space:nowrap" class="ft032">Leber AL, Everhart&#160;K, Balada-Llasat&#160;JM, et&#160;al. Multicenter evaluation of BioFire FilmArray&#160;<br/>Meningitis/Encephalitis Panel for detection of bacteria, viruses,&#160;and yeast in&#160;cerebrospinal&#160;<br/>fluid specimens.&#160;</p>
<p style="position:absolute;top:552px;left:279px;white-space:nowrap" class="ft019"><i>J Clin Microbiol</i></p>
<p style="position:absolute;top:552px;left:394px;white-space:nowrap" class="ft013">. 2016;54(9):2251-2261.&#160;Available at:&#160;</p>
<p style="position:absolute;top:573px;left:162px;white-space:nowrap" class="ft050">h</p>
<p style="position:absolute;top:572px;left:170px;white-space:nowrap" class="ft034">ttps://www.pubmed.ncbi.nlm.nih.gov/27335149</p>
<p style="position:absolute;top:572px;left:502px;white-space:nowrap" class="ft013">.&#160;</p>
<p style="position:absolute;top:609px;left:108px;white-space:nowrap" class="ft013">18.</p>
<p style="position:absolute;top:609px;left:130px;white-space:nowrap" class="ft046">&#160;</p>
<p style="position:absolute;top:609px;left:162px;white-space:nowrap" class="ft032">O'Halloran JA, Franklin A, Lainhart&#160;W, Burnham&#160;CA, Powderly W, Dubberke E. Pitfalls&#160;<br/>associated with the&#160;use of&#160;molecular diagnostic&#160;panels in the&#160;diagnosis of cryptococcal&#160;<br/>meningitis.&#160;</p>
<p style="position:absolute;top:649px;left:243px;white-space:nowrap" class="ft019"><i>Open Forum&#160;Infect&#160;Dis</i></p>
<p style="position:absolute;top:649px;left:404px;white-space:nowrap" class="ft013">. 2017;4(4):ofx242. Available&#160;at:&#160;</p>
<p style="position:absolute;top:668px;left:162px;white-space:nowrap" class="ft034">https://pubmed.ncbi.nlm.nih.gov/29255738</p>
<p style="position:absolute;top:668px;left:461px;white-space:nowrap" class="ft013">.&#160;</p>
<p style="position:absolute;top:706px;left:108px;white-space:nowrap" class="ft013">19.</p>
<p style="position:absolute;top:705px;left:130px;white-space:nowrap" class="ft046">&#160;</p>
<p style="position:absolute;top:706px;left:162px;white-space:nowrap" class="ft032">Kassi&#160;FK,&#160;Drakulovski P,&#160;Bellet V, et&#160;al. Cryptococcus genetic&#160;diversity and&#160;mixed&#160;<br/>infections in Ivorian HIV&#160;patients: a follow up study.&#160;</p>
<p style="position:absolute;top:725px;left:533px;white-space:nowrap" class="ft019"><i>PLoS Negl&#160;Trop&#160;Dis</i></p>
<p style="position:absolute;top:725px;left:673px;white-space:nowrap" class="ft013">.&#160;</p>
<p style="position:absolute;top:745px;left:162px;white-space:nowrap" class="ft013">2019;13(11):e0007812.&#160;Available&#160;at:&#160;</p>
<p style="position:absolute;top:745px;left:422px;white-space:nowrap" class="ft034">https://www.pubmed.ncbi.nlm.nih.gov/31738768</p>
<p style="position:absolute;top:745px;left:762px;white-space:nowrap" class="ft013">.&#160;</p>
<p style="position:absolute;top:782px;left:108px;white-space:nowrap" class="ft013">20.</p>
<p style="position:absolute;top:782px;left:130px;white-space:nowrap" class="ft046">&#160;</p>
<p style="position:absolute;top:782px;left:162px;white-space:nowrap" class="ft032">Desnos-Ollivier M, Patel&#160;S, Spaulding&#160;AR, et al. Mixed infections and in vivo evolution in&#160;<br/>the&#160;human fungal&#160;pathogen Cryptococcus neoformans.&#160;</p>
<p style="position:absolute;top:802px;left:544px;white-space:nowrap" class="ft019"><i>mBio</i></p>
<p style="position:absolute;top:802px;left:580px;white-space:nowrap" class="ft013">. 2010;1(1).&#160;Available&#160;at:&#160;</p>
<p style="position:absolute;top:822px;left:162px;white-space:nowrap" class="ft034">https://www.pubmed.ncbi.nlm.nih.gov/20689742</p>
<p style="position:absolute;top:822px;left:503px;white-space:nowrap" class="ft013">.&#160;</p>
<p style="position:absolute;top:859px;left:108px;white-space:nowrap" class="ft013">21.</p>
<p style="position:absolute;top:859px;left:130px;white-space:nowrap" class="ft046">&#160;</p>
<p style="position:absolute;top:859px;left:162px;white-space:nowrap" class="ft032">McKenney&#160;J,&#160;Bauman S,&#160;Neary B, et&#160;al. Prevalence, correlates, and outcomes&#160;of cryptococcal&#160;<br/>antigen positivity among patients with AIDS,&#160;United States, 1986–2012.&#160;</p>
<p style="position:absolute;top:879px;left:667px;white-space:nowrap" class="ft019"><i>Clin&#160;Infect Dis</i></p>
<p style="position:absolute;top:879px;left:768px;white-space:nowrap" class="ft013">.&#160;</p>
<p style="position:absolute;top:899px;left:162px;white-space:nowrap" class="ft013">2015;60(6):959-965.&#160;Available&#160;at:&#160;</p>
<p style="position:absolute;top:899px;left:402px;white-space:nowrap" class="ft034">https://www.pubmed.ncbi.nlm.nih.gov/25422390</p>
<p style="position:absolute;top:899px;left:743px;white-space:nowrap" class="ft013">.&#160;</p>
<p style="position:absolute;top:936px;left:108px;white-space:nowrap" class="ft013">22.</p>
<p style="position:absolute;top:936px;left:130px;white-space:nowrap" class="ft046">&#160;</p>
<p style="position:absolute;top:936px;left:162px;white-space:nowrap" class="ft032">Chang CC,&#160;Harrison TS,&#160;Bicanic&#160;TA, et al. Global guideline&#160;for the&#160;diagnosis and&#160;<br/>management&#160;of cryptococcosis: an initiative&#160;of the&#160;ECMM and ISHAM in cooperation with&#160;<br/>the&#160;ASM.&#160;</p>
<p style="position:absolute;top:976px;left:233px;white-space:nowrap" class="ft019"><i>Lancet&#160;Infect&#160;Dis</i></p>
<p style="position:absolute;top:976px;left:352px;white-space:nowrap" class="ft013">. 2024;24(8):e495-e512.&#160;Available at:&#160;</p>
<p style="position:absolute;top:995px;left:162px;white-space:nowrap" class="ft034">https://www.ncbi.nlm.nih.gov/pubmed/38346436</p>
<p style="position:absolute;top:995px;left:503px;white-space:nowrap" class="ft013">.&#160;</p>
<p style="position:absolute;top:1032px;left:108px;white-space:nowrap" class="ft013">23.</p>
<p style="position:absolute;top:1032px;left:130px;white-space:nowrap" class="ft046">&#160;</p>
<p style="position:absolute;top:1032px;left:162px;white-space:nowrap" class="ft032">Rajasingham&#160;R, Wake RM, Beyene T, Katende&#160;A,&#160;Letang E, Boulware DR.&#160;Cryptococcal&#160;<br/>meningitis diagnostics and screening in the&#160;era of point-of-care laboratory testing.&#160;</p>
<p style="position:absolute;top:1052px;left:731px;white-space:nowrap" class="ft019"><i>J Clin&#160;</i></p>
</div>
<!-- Page 141 -->
<a name="141"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page141-div" style="position:relative;width:917px;height:1187px;">
<p style="position:absolute;top:1117px;left:108px;white-space:nowrap" class="ft024"><i>Guidelines for the Prevention and Treatment&#160;of&#160;Opportunistic&#160;Infections in Adults&#160;and Adolescents&#160;With HIV&#160;</i></p>
<p style="position:absolute;top:1117px;left:783px;white-space:nowrap" class="ft024"><i>H-19&#160;</i></p>
<p style="position:absolute;top:109px;left:162px;white-space:nowrap" class="ft019"><i>Microbiol</i></p>
<p style="position:absolute;top:109px;left:231px;white-space:nowrap" class="ft013">. 2019;57(1):</p>
<p style="position:absolute;top:109px;left:321px;white-space:nowrap" class="ft019"><i>In&#160;Press.&#160;</i></p>
<p style="position:absolute;top:109px;left:387px;white-space:nowrap" class="ft013">doi:&#160;10.1128/JCM.01238-01218. Available at:&#160;</p>
<p style="position:absolute;top:129px;left:162px;white-space:nowrap" class="ft034">https://www.pubmed.ncbi.nlm.nih.gov/30257903</p>
<p style="position:absolute;top:129px;left:503px;white-space:nowrap" class="ft013">.&#160;</p>
<p style="position:absolute;top:166px;left:108px;white-space:nowrap" class="ft013">24.</p>
<p style="position:absolute;top:165px;left:130px;white-space:nowrap" class="ft046">&#160;</p>
<p style="position:absolute;top:166px;left:162px;white-space:nowrap" class="ft032">McKinsey DS, Wheat&#160;LJ,&#160;Cloud GA, et al. Itraconazole prophylaxis for fungal&#160;infections in&#160;<br/>patients with advanced human immunodeficiency virus infection: randomized, placebo-<br/>controlled, double-blind study. National&#160;Institute&#160;of Allergy and&#160;Infectious Diseases&#160;Mycoses&#160;<br/>Study Group.&#160;</p>
<p style="position:absolute;top:225px;left:259px;white-space:nowrap" class="ft019"><i>Clin Infect&#160;Dis</i></p>
<p style="position:absolute;top:225px;left:361px;white-space:nowrap" class="ft013">. 1999;28(5):1049-1056. Available at:&#160;</p>
<p style="position:absolute;top:245px;left:162px;white-space:nowrap" class="ft034">https://www.pubmed.ncbi.nlm.nih.gov/10452633</p>
<p style="position:absolute;top:245px;left:503px;white-space:nowrap" class="ft013">.&#160;</p>
<p style="position:absolute;top:282px;left:108px;white-space:nowrap" class="ft013">25.</p>
<p style="position:absolute;top:282px;left:130px;white-space:nowrap" class="ft046">&#160;</p>
<p style="position:absolute;top:282px;left:162px;white-space:nowrap" class="ft032">Powderly&#160;WG, Finkelstein D, Feinberg J, et al. A randomized trial comparing fluconazole&#160;<br/>with clotrimazole troches for the prevention of fungal&#160;infections in patients with advanced&#160;<br/>human immunodeficiency virus infection. NIAID AIDS Clinical&#160;Trials Group.&#160;</p>
<p style="position:absolute;top:322px;left:709px;white-space:nowrap" class="ft019"><i>N Engl&#160;J Med</i></p>
<p style="position:absolute;top:322px;left:804px;white-space:nowrap" class="ft013">.&#160;</p>
<p style="position:absolute;top:342px;left:162px;white-space:nowrap" class="ft013">1995;332(11):700-705.&#160;Available&#160;at:&#160;</p>
<p style="position:absolute;top:342px;left:420px;white-space:nowrap" class="ft034">https://pubmed.ncbi.nlm.nih.gov/7854376</p>
<p style="position:absolute;top:342px;left:710px;white-space:nowrap" class="ft013">.&#160;</p>
<p style="position:absolute;top:379px;left:108px;white-space:nowrap" class="ft013">26.</p>
<p style="position:absolute;top:378px;left:130px;white-space:nowrap" class="ft046">&#160;</p>
<p style="position:absolute;top:379px;left:162px;white-space:nowrap" class="ft032">Awotiwon AA, Johnson&#160;S, Rutherford&#160;GW, Meintjes G, Eshun-Wilson I. Primary antifungal&#160;<br/>prophylaxis for cryptococcal&#160;disease in HIV-positive people.&#160;</p>
<p style="position:absolute;top:399px;left:586px;white-space:nowrap" class="ft019"><i>Cochrane Database Syst Rev</i></p>
<p style="position:absolute;top:399px;left:787px;white-space:nowrap" class="ft013">.&#160;</p>
<p style="position:absolute;top:418px;left:162px;white-space:nowrap" class="ft013">2018;8(8):CD004773. Available&#160;at:&#160;</p>
<p style="position:absolute;top:418px;left:412px;white-space:nowrap" class="ft034">https://www.pubmed.ncbi.nlm.nih.gov/30156270</p>
<p style="position:absolute;top:418px;left:753px;white-space:nowrap" class="ft013">.&#160;</p>
<p style="position:absolute;top:455px;left:108px;white-space:nowrap" class="ft013">27.</p>
<p style="position:absolute;top:455px;left:130px;white-space:nowrap" class="ft046">&#160;</p>
<p style="position:absolute;top:455px;left:162px;white-space:nowrap" class="ft032">van der Horst CM, Saag&#160;MS, Cloud&#160;GA, et&#160;al. Treatment&#160;of cryptococcal&#160;meningitis&#160;<br/>associated with the&#160;acquired immunodeficiency syndrome. National&#160;Institute of Allergy and&#160;<br/>Infectious Diseases&#160;Mycoses Study Group and&#160;AIDS Clinical Trials Group.&#160;</p>
<p style="position:absolute;top:495px;left:688px;white-space:nowrap" class="ft019"><i>N Engl J&#160;Med</i></p>
<p style="position:absolute;top:495px;left:783px;white-space:nowrap" class="ft013">.&#160;</p>
<p style="position:absolute;top:515px;left:162px;white-space:nowrap" class="ft013">1997;337(1):15-21.&#160;Available at:&#160;</p>
<p style="position:absolute;top:515px;left:394px;white-space:nowrap" class="ft034">https://www.pubmed.ncbi.nlm.nih.gov/9203426</p>
<p style="position:absolute;top:515px;left:726px;white-space:nowrap" class="ft013">.&#160;</p>
<p style="position:absolute;top:552px;left:108px;white-space:nowrap" class="ft013">28.</p>
<p style="position:absolute;top:552px;left:130px;white-space:nowrap" class="ft046">&#160;</p>
<p style="position:absolute;top:552px;left:162px;white-space:nowrap" class="ft032">Hamill&#160;RJ, Sobel&#160;JD, El-Sadr W, et&#160;al. Comparison of 2 doses&#160;of liposomal&#160;amphotericin B&#160;<br/>and conventional&#160;amphotericin B deoxycholate&#160;for&#160;treatment&#160;of AIDS-associated acute&#160;<br/>cryptococcal&#160;meningitis: a randomized, double-blind clinical&#160;trial of efficacy and safety.&#160;</p>
<p style="position:absolute;top:592px;left:775px;white-space:nowrap" class="ft019"><i>Clin&#160;</i></p>
<p style="position:absolute;top:612px;left:162px;white-space:nowrap" class="ft019"><i>Infect&#160;Dis</i></p>
<p style="position:absolute;top:612px;left:229px;white-space:nowrap" class="ft013">. 2010;51(2):225-232.&#160;Available&#160;at:&#160;</p>
<p style="position:absolute;top:631px;left:162px;white-space:nowrap" class="ft034">https://www.pubmed.ncbi.nlm.nih.gov/20536366</p>
<p style="position:absolute;top:631px;left:503px;white-space:nowrap" class="ft013">.&#160;</p>
<p style="position:absolute;top:668px;left:108px;white-space:nowrap" class="ft013">29.</p>
<p style="position:absolute;top:668px;left:130px;white-space:nowrap" class="ft046">&#160;</p>
<p style="position:absolute;top:668px;left:162px;white-space:nowrap" class="ft032">Baddour LM, Perfect JR,&#160;Ostrosky-Zeichner L. Successful use&#160;of amphotericin B lipid&#160;<br/>complex in the treatment&#160;of cryptococcosis.&#160;</p>
<p style="position:absolute;top:688px;left:468px;white-space:nowrap" class="ft019"><i>Clin Infect Dis</i></p>
<p style="position:absolute;top:688px;left:569px;white-space:nowrap" class="ft013">. 2005;40 Suppl 6:S409-413.&#160;</p>
<p style="position:absolute;top:708px;left:162px;white-space:nowrap" class="ft013">Available at:&#160;</p>
<p style="position:absolute;top:708px;left:255px;white-space:nowrap" class="ft034">https://www.pubmed.ncbi.nlm.nih.gov/15809927</p>
<p style="position:absolute;top:708px;left:596px;white-space:nowrap" class="ft013">.&#160;</p>
<p style="position:absolute;top:745px;left:108px;white-space:nowrap" class="ft013">30.</p>
<p style="position:absolute;top:745px;left:130px;white-space:nowrap" class="ft046">&#160;</p>
<p style="position:absolute;top:745px;left:162px;white-space:nowrap" class="ft032">Molloy SF,&#160;Kanyama&#160;C,&#160;Heyderman&#160;RS, et al. Antifungal&#160;combinations for&#160;treatment of&#160;<br/>cryptococcal&#160;meningitis in Africa.&#160;</p>
<p style="position:absolute;top:765px;left:402px;white-space:nowrap" class="ft019"><i>N Engl J&#160;Med</i></p>
<p style="position:absolute;top:765px;left:497px;white-space:nowrap" class="ft013">. 2018;378(11):1004-1017.&#160;Available at:&#160;</p>
<p style="position:absolute;top:785px;left:162px;white-space:nowrap" class="ft034">https://www.pubmed.ncbi.nlm.nih.gov/29539274</p>
<p style="position:absolute;top:785px;left:503px;white-space:nowrap" class="ft013">.&#160;</p>
<p style="position:absolute;top:822px;left:108px;white-space:nowrap" class="ft013">31.</p>
<p style="position:absolute;top:822px;left:130px;white-space:nowrap" class="ft046">&#160;</p>
<p style="position:absolute;top:822px;left:162px;white-space:nowrap" class="ft032">Jarvis JN, Leeme TB, Molefi M, et&#160;al. Short-course&#160;high-dose liposomal&#160;amphotericin B for&#160;<br/>human immunodeficiency virus-associated cryptococcal meningitis: a&#160;phase 2 randomized&#160;<br/>controlled trial.&#160;</p>
<p style="position:absolute;top:862px;left:273px;white-space:nowrap" class="ft019"><i>Clin Infect&#160;Dis</i></p>
<p style="position:absolute;top:862px;left:374px;white-space:nowrap" class="ft013">. 2019;68(3):393-401. Available at:&#160;</p>
<p style="position:absolute;top:881px;left:162px;white-space:nowrap" class="ft034">https://www.pubmed.ncbi.nlm.nih.gov/29945252</p>
<p style="position:absolute;top:881px;left:503px;white-space:nowrap" class="ft013">.&#160;</p>
<p style="position:absolute;top:919px;left:108px;white-space:nowrap" class="ft013">32.</p>
<p style="position:absolute;top:918px;left:130px;white-space:nowrap" class="ft046">&#160;</p>
<p style="position:absolute;top:919px;left:162px;white-space:nowrap" class="ft032">Kanyama&#160;C,&#160;Molloy SF,&#160;Chan AK, et&#160;al. One-year&#160;mortality outcomes from the Advancing&#160;<br/>Cryptococcal Meningitis&#160;Treatment&#160;for Africa trial&#160;of cryptococcal&#160;meningitis treatment in&#160;<br/>Malawi.&#160;</p>
<p style="position:absolute;top:958px;left:223px;white-space:nowrap" class="ft019"><i>Clin&#160;Infect&#160;Dis</i></p>
<p style="position:absolute;top:958px;left:325px;white-space:nowrap" class="ft013">. 2020;70(3):521-524.&#160;Available at:&#160;</p>
<p style="position:absolute;top:978px;left:162px;white-space:nowrap" class="ft034">https://www.pubmed.ncbi.nlm.nih.gov/31155650</p>
<p style="position:absolute;top:978px;left:503px;white-space:nowrap" class="ft013">.&#160;</p>
<p style="position:absolute;top:1015px;left:108px;white-space:nowrap" class="ft013">33.</p>
<p style="position:absolute;top:1015px;left:162px;white-space:nowrap" class="ft032">Jarvis JN, Lawrence DS,&#160;Meya DB, et&#160;al. Single-dose liposomal amphotericin B treatment<br/>for cryptococcal&#160;meningitis.&#160;</p>
<p style="position:absolute;top:1035px;left:360px;white-space:nowrap" class="ft019"><i>N Engl&#160;J Med</i></p>
<p style="position:absolute;top:1035px;left:455px;white-space:nowrap" class="ft013">. 2022;386(12):1109-1120. Available at:&#160;</p>
<p style="position:absolute;top:1055px;left:162px;white-space:nowrap" class="ft034">https://www.pubmed.ncbi.nlm.nih.gov/35320642</p>
<p style="position:absolute;top:1055px;left:503px;white-space:nowrap" class="ft013">.&#160;</p>
</div>
<!-- Page 142 -->
<a name="142"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page142-div" style="position:relative;width:917px;height:1187px;">
<p style="position:absolute;top:1117px;left:108px;white-space:nowrap" class="ft024"><i>Guidelines for the Prevention and Treatment&#160;of&#160;Opportunistic&#160;Infections in Adults&#160;and Adolescents&#160;With HIV&#160;</i></p>
<p style="position:absolute;top:1117px;left:783px;white-space:nowrap" class="ft024"><i>H-20&#160;</i></p>
<p style="position:absolute;top:109px;left:108px;white-space:nowrap" class="ft013">34.</p>
<p style="position:absolute;top:108px;left:130px;white-space:nowrap" class="ft046">&#160;</p>
<p style="position:absolute;top:109px;left:162px;white-space:nowrap" class="ft032">Dromer F, Mathoulin-Pelissier S, Launay O, Lortholary O, French Cryptococcosis Study&#160;<br/>Group.&#160;Determinants of disease presentation and outcome&#160;during&#160;cryptococcosis: the&#160;<br/>CryptoA/D study.&#160;</p>
<p style="position:absolute;top:148px;left:290px;white-space:nowrap" class="ft019"><i>PLoS&#160;Med</i></p>
<p style="position:absolute;top:148px;left:362px;white-space:nowrap" class="ft013">. 2007;4(2):e21. Available at:&#160;</p>
<p style="position:absolute;top:168px;left:162px;white-space:nowrap" class="ft034">https://www.pubmed.ncbi.nlm.nih.gov/17284154</p>
<p style="position:absolute;top:168px;left:503px;white-space:nowrap" class="ft013">.&#160;</p>
<p style="position:absolute;top:205px;left:108px;white-space:nowrap" class="ft013">35.</p>
<p style="position:absolute;top:205px;left:130px;white-space:nowrap" class="ft046">&#160;</p>
<p style="position:absolute;top:205px;left:162px;white-space:nowrap" class="ft032">Saag MS, Graybill&#160;RJ, Larsen RA, et al. Practice&#160;guidelines for the management&#160;of&#160;<br/>cryptococcal disease. Infectious Diseases Society of&#160;America.&#160;</p>
<p style="position:absolute;top:225px;left:593px;white-space:nowrap" class="ft019"><i>Clin Infect&#160;Dis</i></p>
<p style="position:absolute;top:225px;left:695px;white-space:nowrap" class="ft013">.&#160;</p>
<p style="position:absolute;top:245px;left:162px;white-space:nowrap" class="ft013">2000;30(4):710-718.&#160;Available&#160;at:&#160;</p>
<p style="position:absolute;top:245px;left:402px;white-space:nowrap" class="ft034">https://pubmed.ncbi.nlm.nih.gov/10770733</p>
<p style="position:absolute;top:245px;left:702px;white-space:nowrap" class="ft013">.&#160;</p>
<p style="position:absolute;top:282px;left:108px;white-space:nowrap" class="ft013">36.</p>
<p style="position:absolute;top:282px;left:130px;white-space:nowrap" class="ft046">&#160;</p>
<p style="position:absolute;top:282px;left:162px;white-space:nowrap" class="ft032">Dromer F, Bernede-Bauduin C, Guillemot&#160;D, Lortholary O, French Cryptococcosis Study&#160;<br/>Group.&#160;Major role&#160;for amphotericin B-flucytosine combination in severe cryptococcosis.&#160;</p>
<p style="position:absolute;top:322px;left:162px;white-space:nowrap" class="ft019"><i>PLoS One</i></p>
<p style="position:absolute;top:322px;left:232px;white-space:nowrap" class="ft013">. 2008;3(8):e2870. Available at:&#160;</p>
<p style="position:absolute;top:322px;left:457px;white-space:nowrap" class="ft034">https://www.pubmed.ncbi.nlm.nih.gov/18682846</p>
<p style="position:absolute;top:322px;left:798px;white-space:nowrap" class="ft013">.&#160;</p>
<p style="position:absolute;top:359px;left:108px;white-space:nowrap" class="ft013">37.</p>
<p style="position:absolute;top:359px;left:130px;white-space:nowrap" class="ft046">&#160;</p>
<p style="position:absolute;top:359px;left:162px;white-space:nowrap" class="ft032">Day JN, Chau TT, Wolbers M, et&#160;al. Combination antifungal therapy for cryptococcal&#160;<br/>meningitis.&#160;</p>
<p style="position:absolute;top:379px;left:243px;white-space:nowrap" class="ft019"><i>N Engl J&#160;Med</i></p>
<p style="position:absolute;top:379px;left:339px;white-space:nowrap" class="ft013">. 2013;368(14):1291-1302. Available at:&#160;</p>
<p style="position:absolute;top:399px;left:162px;white-space:nowrap" class="ft034">https://www.pubmed.ncbi.nlm.nih.gov/23550668</p>
<p style="position:absolute;top:399px;left:503px;white-space:nowrap" class="ft013">.&#160;</p>
<p style="position:absolute;top:436px;left:108px;white-space:nowrap" class="ft013">38.</p>
<p style="position:absolute;top:435px;left:130px;white-space:nowrap" class="ft046">&#160;</p>
<p style="position:absolute;top:436px;left:162px;white-space:nowrap" class="ft032">Larsen RA,&#160;Bozzette SA,&#160;Jones BE,&#160;et&#160;al. Fluconazole combined with flucytosine for&#160;<br/>treatment of cryptococcal meningitis in patients with AIDS.&#160;</p>
<p style="position:absolute;top:455px;left:579px;white-space:nowrap" class="ft019"><i>Clin Infect&#160;Dis</i></p>
<p style="position:absolute;top:455px;left:680px;white-space:nowrap" class="ft013">.&#160;1994;19(4):741-</p>
<p style="position:absolute;top:475px;left:162px;white-space:nowrap" class="ft013">745. Available&#160;at:&#160;</p>
<p style="position:absolute;top:475px;left:289px;white-space:nowrap" class="ft034">https://www.pubmed.ncbi.nlm.nih.gov/7803641</p>
<p style="position:absolute;top:475px;left:622px;white-space:nowrap" class="ft013">.&#160;</p>
<p style="position:absolute;top:512px;left:108px;white-space:nowrap" class="ft013">39.</p>
<p style="position:absolute;top:512px;left:130px;white-space:nowrap" class="ft046">&#160;</p>
<p style="position:absolute;top:512px;left:162px;white-space:nowrap" class="ft032">Bicanic T, Meintjes G, Wood R, et&#160;al.&#160;Fungal burden, early fungicidal activity, and outcome&#160;<br/>in cryptococcal meningitis in antiretroviral-naive&#160;or antiretroviral-experienced patients&#160;<br/>treated with amphotericin B or fluconazole.&#160;</p>
<p style="position:absolute;top:552px;left:467px;white-space:nowrap" class="ft019"><i>Clin Infect&#160;Dis</i></p>
<p style="position:absolute;top:552px;left:568px;white-space:nowrap" class="ft013">. 2007;45(1):76-80.&#160;Available at:&#160;</p>
<p style="position:absolute;top:572px;left:162px;white-space:nowrap" class="ft034">https://pubmed.ncbi.nlm.nih.gov/17554704</p>
<p style="position:absolute;top:572px;left:461px;white-space:nowrap" class="ft013">.&#160;</p>
<p style="position:absolute;top:609px;left:108px;white-space:nowrap" class="ft013">40.</p>
<p style="position:absolute;top:609px;left:130px;white-space:nowrap" class="ft046">&#160;</p>
<p style="position:absolute;top:609px;left:162px;white-space:nowrap" class="ft032">Longley N,&#160;Muzoora C,&#160;Taseera K, et&#160;al. Dose response effect&#160;of high-dose&#160;fluconazole for&#160;<br/>HIV-associated cryptococcal&#160;meningitis&#160;in southwestern Uganda.&#160;</p>
<p style="position:absolute;top:629px;left:618px;white-space:nowrap" class="ft019"><i>Clin Infect&#160;Dis</i></p>
<p style="position:absolute;top:629px;left:720px;white-space:nowrap" class="ft013">.&#160;</p>
<p style="position:absolute;top:649px;left:162px;white-space:nowrap" class="ft013">2008;47(12):1556-1561.&#160;Available at:&#160;</p>
<p style="position:absolute;top:649px;left:428px;white-space:nowrap" class="ft034">https://pubmed.ncbi.nlm.nih.gov/18990067</p>
<p style="position:absolute;top:649px;left:727px;white-space:nowrap" class="ft013">.&#160;</p>
<p style="position:absolute;top:686px;left:108px;white-space:nowrap" class="ft013">41.</p>
<p style="position:absolute;top:685px;left:130px;white-space:nowrap" class="ft046">&#160;</p>
<p style="position:absolute;top:686px;left:162px;white-space:nowrap" class="ft032">Kabanda T,&#160;Siedner MJ,&#160;Klausner&#160;JD,&#160;Muzoora C,&#160;Boulware&#160;DR. Point-of-care&#160;diagnosis&#160;and&#160;<br/>prognostication of cryptococcal&#160;meningitis with the cryptococcal&#160;antigen lateral flow assay&#160;<br/>on cerebrospinal fluid.&#160;</p>
<p style="position:absolute;top:725px;left:322px;white-space:nowrap" class="ft019"><i>Clin Infect&#160;Dis</i></p>
<p style="position:absolute;top:725px;left:423px;white-space:nowrap" class="ft013">.&#160;2014;58(1):113-116.&#160;Available&#160;at:&#160;</p>
<p style="position:absolute;top:745px;left:162px;white-space:nowrap" class="ft034">https://www.pubmed.ncbi.nlm.nih.gov/24065327</p>
<p style="position:absolute;top:745px;left:503px;white-space:nowrap" class="ft013">.&#160;</p>
<p style="position:absolute;top:782px;left:108px;white-space:nowrap" class="ft013">42.</p>
<p style="position:absolute;top:782px;left:130px;white-space:nowrap" class="ft046">&#160;</p>
<p style="position:absolute;top:782px;left:162px;white-space:nowrap" class="ft032">Aberg&#160;JA, Watson J,&#160;Segal M, Chang&#160;LW. Clinical utility of monitoring serum cryptococcal&#160;<br/>antigen (sCRAG) titers in&#160;patients with AIDS-related cryptococcal&#160;disease.&#160;</p>
<p style="position:absolute;top:802px;left:685px;white-space:nowrap" class="ft019"><i>HIV Clin Trials</i></p>
<p style="position:absolute;top:802px;left:793px;white-space:nowrap" class="ft013">.&#160;</p>
<p style="position:absolute;top:822px;left:162px;white-space:nowrap" class="ft013">2000;1(1):1-6. Available at:&#160;</p>
<p style="position:absolute;top:822px;left:359px;white-space:nowrap" class="ft034">https://www.pubmed.ncbi.nlm.nih.gov/11590483</p>
<p style="position:absolute;top:822px;left:700px;white-space:nowrap" class="ft013">.&#160;</p>
<p style="position:absolute;top:859px;left:108px;white-space:nowrap" class="ft013">43.</p>
<p style="position:absolute;top:859px;left:130px;white-space:nowrap" class="ft046">&#160;</p>
<p style="position:absolute;top:859px;left:162px;white-space:nowrap" class="ft032">Pappas&#160;PG,&#160;Chetchotisakd P, Larsen&#160;RA, et al. A&#160;phase II randomized trial&#160;of amphotericin B&#160;<br/>alone or combined with fluconazole&#160;in the treatment&#160;of HIV-associated cryptococcal&#160;<br/>meningitis.&#160;</p>
<p style="position:absolute;top:899px;left:243px;white-space:nowrap" class="ft019"><i>Clin Infect Dis</i></p>
<p style="position:absolute;top:899px;left:345px;white-space:nowrap" class="ft013">. 2009;48(12):1775-1783. Available at:&#160;</p>
<p style="position:absolute;top:919px;left:162px;white-space:nowrap" class="ft034">https://www.pubmed.ncbi.nlm.nih.gov/19441980</p>
<p style="position:absolute;top:919px;left:503px;white-space:nowrap" class="ft013">.&#160;</p>
<p style="position:absolute;top:956px;left:108px;white-space:nowrap" class="ft013">44.</p>
<p style="position:absolute;top:955px;left:130px;white-space:nowrap" class="ft046">&#160;</p>
<p style="position:absolute;top:956px;left:162px;white-space:nowrap" class="ft032">Rolfes MA,&#160;Rhein J, Schutz&#160;C, et&#160;al. Cerebrospinal fluid culture&#160;positivity and clinical&#160;<br/>outcomes after amphotericin-based induction therapy for cryptococcal meningitis.&#160;</p>
<p style="position:absolute;top:976px;left:732px;white-space:nowrap" class="ft019"><i>Open&#160;</i></p>
<p style="position:absolute;top:995px;left:162px;white-space:nowrap" class="ft019"><i>Forum&#160;Infect&#160;Dis</i></p>
<p style="position:absolute;top:995px;left:281px;white-space:nowrap" class="ft013">. 2015;2(4):ofv157.&#160;Available&#160;at:&#160;</p>
<p style="position:absolute;top:1015px;left:162px;white-space:nowrap" class="ft034">https://www.pubmed.ncbi.nlm.nih.gov/26716103</p>
<p style="position:absolute;top:1015px;left:503px;white-space:nowrap" class="ft013">.&#160;</p>
</div>
<!-- Page 143 -->
<a name="143"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page143-div" style="position:relative;width:917px;height:1187px;">
<p style="position:absolute;top:1117px;left:108px;white-space:nowrap" class="ft024"><i>Guidelines for the Prevention and Treatment&#160;of&#160;Opportunistic&#160;Infections in Adults&#160;and Adolescents&#160;With HIV&#160;</i></p>
<p style="position:absolute;top:1117px;left:783px;white-space:nowrap" class="ft024"><i>H-21&#160;</i></p>
<p style="position:absolute;top:109px;left:108px;white-space:nowrap" class="ft013">45.</p>
<p style="position:absolute;top:108px;left:130px;white-space:nowrap" class="ft046">&#160;</p>
<p style="position:absolute;top:109px;left:162px;white-space:nowrap" class="ft032">Saag MS, Cloud GA,&#160;Graybill JR, et&#160;al. A comparison of itraconazole versus&#160;fluconazole&#160;as&#160;<br/>maintenance therapy for&#160;AIDS-associated cryptococcal&#160;meningitis. National&#160;Institute&#160;of&#160;<br/>Allergy and Infectious Diseases Mycoses Study&#160;Group.&#160;</p>
<p style="position:absolute;top:148px;left:549px;white-space:nowrap" class="ft019"><i>Clin Infect&#160;Dis</i></p>
<p style="position:absolute;top:148px;left:650px;white-space:nowrap" class="ft013">. 1999;28(2):291-296.&#160;</p>
<p style="position:absolute;top:168px;left:162px;white-space:nowrap" class="ft013">Available at:&#160;</p>
<p style="position:absolute;top:168px;left:255px;white-space:nowrap" class="ft034">https://pubmed.ncbi.nlm.nih.gov/10064246</p>
<p style="position:absolute;top:168px;left:554px;white-space:nowrap" class="ft013">.&#160;</p>
<p style="position:absolute;top:205px;left:108px;white-space:nowrap" class="ft013">46.</p>
<p style="position:absolute;top:205px;left:130px;white-space:nowrap" class="ft046">&#160;</p>
<p style="position:absolute;top:205px;left:162px;white-space:nowrap" class="ft032">Perfect&#160;JR,&#160;Marr&#160;KA, Walsh TJ, et al. Voriconazole treatment for less-common, emerging, or&#160;<br/>refractory fungal&#160;infections.&#160;</p>
<p style="position:absolute;top:225px;left:359px;white-space:nowrap" class="ft019"><i>Clin Infect&#160;Dis</i></p>
<p style="position:absolute;top:225px;left:461px;white-space:nowrap" class="ft013">. 2003;36(9):1122-1131. Available&#160;at:&#160;</p>
<p style="position:absolute;top:245px;left:162px;white-space:nowrap" class="ft034">https://www.pubmed.ncbi.nlm.nih.gov/12715306</p>
<p style="position:absolute;top:245px;left:503px;white-space:nowrap" class="ft013">.&#160;</p>
<p style="position:absolute;top:282px;left:108px;white-space:nowrap" class="ft013">47.</p>
<p style="position:absolute;top:282px;left:130px;white-space:nowrap" class="ft046">&#160;</p>
<p style="position:absolute;top:282px;left:162px;white-space:nowrap" class="ft032">Pitisuttithum&#160;P, Negroni&#160;R, Graybill JR, et&#160;al. Activity of posaconazole in the&#160;treatment&#160;of&#160;<br/>central&#160;nervous system&#160;fungal&#160;infections.&#160;</p>
<p style="position:absolute;top:302px;left:449px;white-space:nowrap" class="ft019"><i>J Antimicrob Chemother</i></p>
<p style="position:absolute;top:302px;left:619px;white-space:nowrap" class="ft013">. 2005;56(4):745-755.&#160;</p>
<p style="position:absolute;top:322px;left:162px;white-space:nowrap" class="ft013">Available at:&#160;</p>
<p style="position:absolute;top:322px;left:255px;white-space:nowrap" class="ft034">https://www.pubmed.ncbi.nlm.nih.gov/16135526</p>
<p style="position:absolute;top:322px;left:596px;white-space:nowrap" class="ft013">.&#160;</p>
<p style="position:absolute;top:359px;left:108px;white-space:nowrap" class="ft013">48.</p>
<p style="position:absolute;top:359px;left:130px;white-space:nowrap" class="ft046">&#160;</p>
<p style="position:absolute;top:359px;left:162px;white-space:nowrap" class="ft032">Thompson&#160;GR, 3rd, Rendon A, Ribeiro Dos Santos&#160;R, et&#160;al. Isavuconazole&#160;treatment of&#160;<br/>cryptococcosis and dimorphic&#160;mycoses.&#160;</p>
<p style="position:absolute;top:379px;left:441px;white-space:nowrap" class="ft019"><i>Clin Infect&#160;Dis</i></p>
<p style="position:absolute;top:379px;left:543px;white-space:nowrap" class="ft013">. 2016;63(3):356-362. Available at:&#160;</p>
<p style="position:absolute;top:399px;left:162px;white-space:nowrap" class="ft034">https://www.pubmed.ncbi.nlm.nih.gov/27169478</p>
<p style="position:absolute;top:399px;left:503px;white-space:nowrap" class="ft013">.&#160;</p>
<p style="position:absolute;top:436px;left:108px;white-space:nowrap" class="ft013">49.</p>
<p style="position:absolute;top:435px;left:130px;white-space:nowrap" class="ft046">&#160;</p>
<p style="position:absolute;top:436px;left:162px;white-space:nowrap" class="ft032">Powderly&#160;WG, Saag&#160;MS,&#160;Cloud GA, et al. A controlled trial of fluconazole or&#160;amphotericin&#160;<br/>B to prevent&#160;relapse of cryptococcal meningitis in patients with the&#160;acquired&#160;<br/>immunodeficiency syndrome. The&#160;NIAID AIDS Clinical&#160;Trials Group and&#160;Mycoses Study&#160;<br/>Group.&#160;</p>
<p style="position:absolute;top:495px;left:215px;white-space:nowrap" class="ft019"><i>N Engl J&#160;Med</i></p>
<p style="position:absolute;top:495px;left:310px;white-space:nowrap" class="ft013">. 1992;326(12):793-798.&#160;Available&#160;at:&#160;</p>
<p style="position:absolute;top:515px;left:162px;white-space:nowrap" class="ft034">https://pubmed.ncbi.nlm.nih.gov/1538722</p>
<p style="position:absolute;top:515px;left:452px;white-space:nowrap" class="ft013">.&#160;</p>
<p style="position:absolute;top:552px;left:108px;white-space:nowrap" class="ft013">50.</p>
<p style="position:absolute;top:552px;left:130px;white-space:nowrap" class="ft046">&#160;</p>
<p style="position:absolute;top:552px;left:162px;white-space:nowrap" class="ft032">Faini&#160;D, Kalinjuma AV,&#160;Katende&#160;A, et al. Laboratory-reflex cryptococcal&#160;antigen screening&#160;<br/>is associated&#160;with a&#160;survival&#160;benefit in Tanzania.&#160;</p>
<p style="position:absolute;top:572px;left:501px;white-space:nowrap" class="ft019"><i>J Acquir Immune Defic Syndr</i></p>
<p style="position:absolute;top:572px;left:706px;white-space:nowrap" class="ft013">.&#160;</p>
<p style="position:absolute;top:592px;left:162px;white-space:nowrap" class="ft013">2019;80(2):205-213.&#160;Available&#160;at:&#160;</p>
<p style="position:absolute;top:592px;left:402px;white-space:nowrap" class="ft034">https://www.pubmed.ncbi.nlm.nih.gov/30422904</p>
<p style="position:absolute;top:592px;left:743px;white-space:nowrap" class="ft013">.&#160;</p>
<p style="position:absolute;top:629px;left:108px;white-space:nowrap" class="ft013">51.</p>
<p style="position:absolute;top:628px;left:130px;white-space:nowrap" class="ft046">&#160;</p>
<p style="position:absolute;top:629px;left:162px;white-space:nowrap" class="ft013">Meya DB,&#160;Williamson PR. Cryptococcal&#160;disease in diverse hosts.&#160;</p>
<p style="position:absolute;top:629px;left:619px;white-space:nowrap" class="ft019"><i>N Engl&#160;J Med</i></p>
<p style="position:absolute;top:629px;left:714px;white-space:nowrap" class="ft013">.&#160;</p>
<p style="position:absolute;top:649px;left:162px;white-space:nowrap" class="ft013">2024;390(17):1597-1610.&#160;Available at:&#160;</p>
<p style="position:absolute;top:649px;left:437px;white-space:nowrap" class="ft034">https://www.ncbi.nlm.nih.gov/pubmed/38692293</p>
<p style="position:absolute;top:649px;left:778px;white-space:nowrap" class="ft013">.&#160;</p>
<p style="position:absolute;top:686px;left:108px;white-space:nowrap" class="ft013">52.</p>
<p style="position:absolute;top:685px;left:130px;white-space:nowrap" class="ft046">&#160;</p>
<p style="position:absolute;top:686px;left:162px;white-space:nowrap" class="ft032">Boulware&#160;DR, Meya&#160;DB,&#160;Muzoora C,&#160;et&#160;al. Timing&#160;of antiretroviral&#160;therapy after diagnosis&#160;<br/>of cryptococcal meningitis.&#160;</p>
<p style="position:absolute;top:706px;left:354px;white-space:nowrap" class="ft019"><i>N Engl J&#160;Med</i></p>
<p style="position:absolute;top:706px;left:450px;white-space:nowrap" class="ft013">. 2014;370(26):2487-2498. Available at:&#160;</p>
<p style="position:absolute;top:725px;left:162px;white-space:nowrap" class="ft034">https://www.pubmed.ncbi.nlm.nih.gov/24963568</p>
<p style="position:absolute;top:725px;left:503px;white-space:nowrap" class="ft013">.&#160;</p>
<p style="position:absolute;top:762px;left:108px;white-space:nowrap" class="ft013">53.</p>
<p style="position:absolute;top:762px;left:130px;white-space:nowrap" class="ft046">&#160;</p>
<p style="position:absolute;top:762px;left:162px;white-space:nowrap" class="ft032">Scriven JE,&#160;Rhein J, Hullsiek KH, et al. Early ART&#160;after cryptococcal&#160;meningitis is&#160;<br/>associated with cerebrospinal fluid pleocytosis and&#160;macrophage&#160;activation in&#160;a multisite&#160;<br/>randomized trial.&#160;</p>
<p style="position:absolute;top:802px;left:284px;white-space:nowrap" class="ft019"><i>J&#160;Infect Dis</i></p>
<p style="position:absolute;top:802px;left:363px;white-space:nowrap" class="ft013">. 2015;212(5):769-778. Available&#160;at:&#160;</p>
<p style="position:absolute;top:822px;left:162px;white-space:nowrap" class="ft034">https://www.pubmed.ncbi.nlm.nih.gov/25651842</p>
<p style="position:absolute;top:822px;left:503px;white-space:nowrap" class="ft013">.&#160;</p>
<p style="position:absolute;top:859px;left:108px;white-space:nowrap" class="ft013">54.</p>
<p style="position:absolute;top:859px;left:130px;white-space:nowrap" class="ft046">&#160;</p>
<p style="position:absolute;top:859px;left:162px;white-space:nowrap" class="ft032">Zhao H, Zhou M, Zheng&#160;Q, et al. Clinical&#160;features and outcomes of cryptococcemia patients&#160;<br/>with and without HIV infection.&#160;</p>
<p style="position:absolute;top:879px;left:388px;white-space:nowrap" class="ft019"><i>Mycoses</i></p>
<p style="position:absolute;top:879px;left:447px;white-space:nowrap" class="ft013">. 2021;64(6):656-667.&#160;Available at:&#160;</p>
<p style="position:absolute;top:899px;left:162px;white-space:nowrap" class="ft050">https://www.ncbi.nlm.nih.gov/pubmed/33609302</p>
<p style="position:absolute;top:899px;left:488px;white-space:nowrap" class="ft013">.&#160;</p>
<p style="position:absolute;top:936px;left:108px;white-space:nowrap" class="ft013">55.</p>
<p style="position:absolute;top:936px;left:130px;white-space:nowrap" class="ft046">&#160;</p>
<p style="position:absolute;top:936px;left:162px;white-space:nowrap" class="ft032">Ingle&#160;SM,&#160;Miro JM,&#160;May&#160;MT, et&#160;al. Early antiretroviral&#160;therapy not associated with higher&#160;<br/>cryptococcal&#160;meningitis mortality in&#160;people with&#160;human immunodeficiency virus in high-<br/>income&#160;countries: an international collaborative cohort&#160;study.&#160;</p>
<p style="position:absolute;top:976px;left:590px;white-space:nowrap" class="ft019"><i>Clin Infect Dis</i></p>
<p style="position:absolute;top:976px;left:691px;white-space:nowrap" class="ft013">. 2023;77(1):64-</p>
<p style="position:absolute;top:995px;left:162px;white-space:nowrap" class="ft013">73. Available at:&#160;</p>
<p style="position:absolute;top:995px;left:281px;white-space:nowrap" class="ft034">https://www.pubmed.ncbi.nlm.nih.gov/36883578</p>
<p style="position:absolute;top:995px;left:622px;white-space:nowrap" class="ft013">.&#160;</p>
</div>
<!-- Page 144 -->
<a name="144"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page144-div" style="position:relative;width:917px;height:1187px;">
<p style="position:absolute;top:1117px;left:108px;white-space:nowrap" class="ft024"><i>Guidelines for the Prevention and Treatment&#160;of&#160;Opportunistic&#160;Infections in Adults&#160;and Adolescents&#160;With HIV&#160;</i></p>
<p style="position:absolute;top:1117px;left:783px;white-space:nowrap" class="ft024"><i>H-22&#160;</i></p>
<p style="position:absolute;top:109px;left:108px;white-space:nowrap" class="ft013">56.</p>
<p style="position:absolute;top:108px;left:130px;white-space:nowrap" class="ft046">&#160;</p>
<p style="position:absolute;top:109px;left:162px;white-space:nowrap" class="ft032">Boulware&#160;DR, Jarvis&#160;JN.&#160;Timing of antiretroviral&#160;therapy in cryptococcal meningitis: what&#160;<br/>we can (and&#160;cannot) learn from&#160;observational&#160;data.&#160;</p>
<p style="position:absolute;top:129px;left:517px;white-space:nowrap" class="ft019"><i>Clin Infect&#160;Dis</i></p>
<p style="position:absolute;top:129px;left:618px;white-space:nowrap" class="ft013">. 2023;77(1):74-76.&#160;</p>
<p style="position:absolute;top:148px;left:162px;white-space:nowrap" class="ft013">Available at:&#160;</p>
<p style="position:absolute;top:148px;left:255px;white-space:nowrap" class="ft034">https://www.ncbi.nlm.nih.gov/pubmed/36883585</p>
<p style="position:absolute;top:148px;left:596px;white-space:nowrap" class="ft013">.&#160;</p>
<p style="position:absolute;top:185px;left:108px;white-space:nowrap" class="ft013">57.</p>
<p style="position:absolute;top:185px;left:130px;white-space:nowrap" class="ft046">&#160;</p>
<p style="position:absolute;top:185px;left:162px;white-space:nowrap" class="ft032">Chang CC,&#160;Dorasamy&#160;AA, Gosnell BI, et&#160;al. Clinical&#160;and mycological&#160;predictors of&#160;<br/>cryptococcosis-associated&#160;Immune reconstitution inflammatory syndrome&#160;(C-IRIS).&#160;</p>
<p style="position:absolute;top:205px;left:746px;white-space:nowrap" class="ft019"><i>AIDS</i></p>
<p style="position:absolute;top:205px;left:784px;white-space:nowrap" class="ft013">.&#160;</p>
<p style="position:absolute;top:225px;left:162px;white-space:nowrap" class="ft013">2013. Available&#160;at:&#160;</p>
<p style="position:absolute;top:225px;left:298px;white-space:nowrap" class="ft034">https://www.pubmed.ncbi.nlm.nih.gov/23525034</p>
<p style="position:absolute;top:225px;left:639px;white-space:nowrap" class="ft013">.&#160;</p>
<p style="position:absolute;top:262px;left:108px;white-space:nowrap" class="ft013">58.</p>
<p style="position:absolute;top:262px;left:130px;white-space:nowrap" class="ft046">&#160;</p>
<p style="position:absolute;top:262px;left:162px;white-space:nowrap" class="ft032">Rolfes MA,&#160;Hullsiek KH,&#160;Rhein J, et&#160;al. The effect&#160;of therapeutic&#160;lumbar punctures on acute&#160;<br/>mortality from cryptococcal meningitis.&#160;</p>
<p style="position:absolute;top:282px;left:441px;white-space:nowrap" class="ft019"><i>Clin Infect Dis</i></p>
<p style="position:absolute;top:282px;left:543px;white-space:nowrap" class="ft013">. 2014;59(11):1607-1614. Available&#160;</p>
<p style="position:absolute;top:302px;left:162px;white-space:nowrap" class="ft013">at:&#160;</p>
<p style="position:absolute;top:302px;left:184px;white-space:nowrap" class="ft034">https://www.pubmed.ncbi.nlm.nih.gov/25057102</p>
<p style="position:absolute;top:302px;left:524px;white-space:nowrap" class="ft013">.&#160;</p>
<p style="position:absolute;top:339px;left:108px;white-space:nowrap" class="ft013">59.</p>
<p style="position:absolute;top:339px;left:130px;white-space:nowrap" class="ft046">&#160;</p>
<p style="position:absolute;top:339px;left:162px;white-space:nowrap" class="ft032">Fessler RD,&#160;Sobel J,&#160;Guyot L, et&#160;al. Management&#160;of elevated intracranial pressure in patients&#160;<br/>with cryptococcal meningitis.&#160;</p>
<p style="position:absolute;top:359px;left:371px;white-space:nowrap" class="ft019"><i>J Acquir Immune&#160;Defic Syndr Hum Retrovirol</i></p>
<p style="position:absolute;top:359px;left:688px;white-space:nowrap" class="ft013">.&#160;</p>
<p style="position:absolute;top:379px;left:162px;white-space:nowrap" class="ft013">1998;17(2):137-142.&#160;Available&#160;at:&#160;</p>
<p style="position:absolute;top:379px;left:402px;white-space:nowrap" class="ft034">https://www.pubmed.ncbi.nlm.nih.gov/9473014</p>
<p style="position:absolute;top:379px;left:735px;white-space:nowrap" class="ft013">.&#160;</p>
<p style="position:absolute;top:416px;left:108px;white-space:nowrap" class="ft013">60.</p>
<p style="position:absolute;top:415px;left:130px;white-space:nowrap" class="ft046">&#160;</p>
<p style="position:absolute;top:416px;left:162px;white-space:nowrap" class="ft032">Newton&#160;PN,&#160;Thai&#160;le&#160;H, Tip NQ, et&#160;al. A randomized, double-blind, placebo-controlled trial of&#160;<br/>acetazolamide for the treatment of elevated intracranial&#160;pressure&#160;in cryptococcal meningitis.&#160;</p>
<p style="position:absolute;top:455px;left:162px;white-space:nowrap" class="ft019"><i>Clin Infect&#160;Dis</i></p>
<p style="position:absolute;top:455px;left:263px;white-space:nowrap" class="ft013">. 2002;35(6):769-772.&#160;Available at:&#160;</p>
<p style="position:absolute;top:475px;left:162px;white-space:nowrap" class="ft034">https://www.pubmed.ncbi.nlm.nih.gov/12203177</p>
<p style="position:absolute;top:475px;left:503px;white-space:nowrap" class="ft013">.&#160;</p>
<p style="position:absolute;top:512px;left:108px;white-space:nowrap" class="ft013">61.</p>
<p style="position:absolute;top:512px;left:130px;white-space:nowrap" class="ft046">&#160;</p>
<p style="position:absolute;top:512px;left:162px;white-space:nowrap" class="ft032">Beardsley J,&#160;Wolbers M,&#160;Kibengo FM, et&#160;al. Adjunctive&#160;dexamethasone in HIV-associated&#160;<br/>cryptococcal&#160;meningitis.&#160;</p>
<p style="position:absolute;top:532px;left:336px;white-space:nowrap" class="ft019"><i>N Engl J&#160;Med</i></p>
<p style="position:absolute;top:532px;left:431px;white-space:nowrap" class="ft013">. 2016;374(6):542-554.&#160;Available at:&#160;</p>
<p style="position:absolute;top:552px;left:162px;white-space:nowrap" class="ft034">https://www.pubmed.ncbi.nlm.nih.gov/26863355</p>
<p style="position:absolute;top:552px;left:503px;white-space:nowrap" class="ft013">.&#160;</p>
<p style="position:absolute;top:589px;left:108px;white-space:nowrap" class="ft013">62.</p>
<p style="position:absolute;top:589px;left:130px;white-space:nowrap" class="ft046">&#160;</p>
<p style="position:absolute;top:589px;left:162px;white-space:nowrap" class="ft032">Bahr NC,&#160;Rolfes MA, Musubire A, et al. Standardized electrolyte supplementation and fluid&#160;<br/>management&#160;improves survival during&#160;amphotericin therapy for&#160;cryptococcal meningitis in&#160;<br/>resource-limited settings.&#160;</p>
<p style="position:absolute;top:629px;left:341px;white-space:nowrap" class="ft019"><i>Open Forum&#160;Infect&#160;Dis</i></p>
<p style="position:absolute;top:629px;left:501px;white-space:nowrap" class="ft013">. 2014;1(2):ofu070. Available at:&#160;</p>
<p style="position:absolute;top:649px;left:162px;white-space:nowrap" class="ft034">https://www.pubmed.ncbi.nlm.nih.gov/25734140</p>
<p style="position:absolute;top:649px;left:503px;white-space:nowrap" class="ft013">.&#160;</p>
<p style="position:absolute;top:686px;left:108px;white-space:nowrap" class="ft013">63.</p>
<p style="position:absolute;top:685px;left:130px;white-space:nowrap" class="ft046">&#160;</p>
<p style="position:absolute;top:686px;left:162px;white-space:nowrap" class="ft013">Davis&#160;MR,&#160;Nguyen&#160;MH,&#160;Donnelley&#160;MA, Thompson</p>
<p style="position:absolute;top:684px;left:524px;white-space:nowrap" class="ft038">&#160;</p>
<p style="position:absolute;top:686px;left:526px;white-space:nowrap" class="ft013">GR,&#160;III.&#160;Tolerability&#160;of long-term&#160;</p>
<p style="position:absolute;top:706px;left:162px;white-space:nowrap" class="ft013">fluconazole therapy.&#160;</p>
<p style="position:absolute;top:706px;left:307px;white-space:nowrap" class="ft019"><i>J&#160;Antimicrob Chemother</i></p>
<p style="position:absolute;top:706px;left:477px;white-space:nowrap" class="ft013">. 2019;74(3):768-771. Available at:&#160;</p>
<p style="position:absolute;top:725px;left:162px;white-space:nowrap" class="ft034">https://pubmed.ncbi.nlm.nih.gov/30535104</p>
<p style="position:absolute;top:725px;left:461px;white-space:nowrap" class="ft013">.&#160;</p>
<p style="position:absolute;top:762px;left:108px;white-space:nowrap" class="ft013">64.</p>
<p style="position:absolute;top:762px;left:130px;white-space:nowrap" class="ft046">&#160;</p>
<p style="position:absolute;top:762px;left:162px;white-space:nowrap" class="ft032">Shelburne&#160;SA, 3rd,&#160;Darcourt J, White&#160;AC, Jr., et al. The&#160;role&#160;of&#160;immune reconstitution&#160;<br/>inflammatory syndrome&#160;in AIDS-related Cryptococcus neoformans disease&#160;in the era&#160;of&#160;<br/>highly active&#160;antiretroviral therapy.&#160;</p>
<p style="position:absolute;top:802px;left:410px;white-space:nowrap" class="ft019"><i>Clin Infect&#160;Dis</i></p>
<p style="position:absolute;top:802px;left:512px;white-space:nowrap" class="ft013">.&#160;2005;40(7):1049-1052.&#160;Available&#160;at:&#160;</p>
<p style="position:absolute;top:822px;left:162px;white-space:nowrap" class="ft034">https://pubmed.ncbi.nlm.nih.gov/15825000</p>
<p style="position:absolute;top:822px;left:461px;white-space:nowrap" class="ft013">.&#160;</p>
<p style="position:absolute;top:859px;left:108px;white-space:nowrap" class="ft013">65.</p>
<p style="position:absolute;top:859px;left:130px;white-space:nowrap" class="ft046">&#160;</p>
<p style="position:absolute;top:859px;left:162px;white-space:nowrap" class="ft032">Muller M, Wandel&#160;S, Colebunders R,&#160;et&#160;al. Immune reconstitution inflammatory syndrome&#160;in&#160;<br/>patients starting antiretroviral&#160;therapy for HIV infection:&#160;a systematic&#160;review and meta-<br/>analysis.&#160;</p>
<p style="position:absolute;top:899px;left:226px;white-space:nowrap" class="ft019"><i>Lancet&#160;Infect&#160;Dis</i></p>
<p style="position:absolute;top:899px;left:345px;white-space:nowrap" class="ft013">. 2010;10(4):251-261.&#160;Available&#160;at:&#160;</p>
<p style="position:absolute;top:919px;left:162px;white-space:nowrap" class="ft034">https://www.pubmed.ncbi.nlm.nih.gov/20334848</p>
<p style="position:absolute;top:919px;left:503px;white-space:nowrap" class="ft013">.&#160;</p>
<p style="position:absolute;top:956px;left:108px;white-space:nowrap" class="ft013">66.</p>
<p style="position:absolute;top:955px;left:130px;white-space:nowrap" class="ft046">&#160;</p>
<p style="position:absolute;top:956px;left:162px;white-space:nowrap" class="ft032">Boulware&#160;DR, Bonham&#160;SC, Meya&#160;DB, et&#160;al. Paucity of initial&#160;cerebrospinal fluid&#160;<br/>inflammation in cryptococcal&#160;meningitis is associated with subsequent&#160;immune&#160;reconstitution&#160;<br/>inflammatory syndrome.&#160;</p>
<p style="position:absolute;top:995px;left:337px;white-space:nowrap" class="ft019"><i>J Infect&#160;Dis</i></p>
<p style="position:absolute;top:995px;left:416px;white-space:nowrap" class="ft013">.&#160;2010;202(6):962-970.&#160;Available&#160;at:&#160;</p>
<p style="position:absolute;top:1015px;left:162px;white-space:nowrap" class="ft034">https://www.pubmed.ncbi.nlm.nih.gov/20677939</p>
<p style="position:absolute;top:1015px;left:503px;white-space:nowrap" class="ft013">.&#160;</p>
</div>
<!-- Page 145 -->
<a name="145"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page145-div" style="position:relative;width:917px;height:1187px;">
<p style="position:absolute;top:1117px;left:108px;white-space:nowrap" class="ft024"><i>Guidelines for the Prevention and Treatment&#160;of&#160;Opportunistic&#160;Infections in Adults&#160;and Adolescents&#160;With HIV&#160;</i></p>
<p style="position:absolute;top:1117px;left:783px;white-space:nowrap" class="ft024"><i>H-23&#160;</i></p>
<p style="position:absolute;top:109px;left:108px;white-space:nowrap" class="ft013">67.</p>
<p style="position:absolute;top:108px;left:130px;white-space:nowrap" class="ft046">&#160;</p>
<p style="position:absolute;top:109px;left:162px;white-space:nowrap" class="ft032">Chang CC,&#160;Dorasamy&#160;AA, Gosnell BI, et&#160;al. Clinical&#160;and mycological&#160;predictors of&#160;<br/>cryptococcosis-associated&#160;immune&#160;reconstitution inflammatory syndrome.&#160;</p>
<p style="position:absolute;top:129px;left:680px;white-space:nowrap" class="ft019"><i>AIDS</i></p>
<p style="position:absolute;top:129px;left:717px;white-space:nowrap" class="ft013">.&#160;</p>
<p style="position:absolute;top:148px;left:162px;white-space:nowrap" class="ft013">2013;27(13):2089-2099.&#160;Available at:&#160;</p>
<p style="position:absolute;top:148px;left:428px;white-space:nowrap" class="ft034">https://www.pubmed.ncbi.nlm.nih.gov/23525034</p>
<p style="position:absolute;top:148px;left:769px;white-space:nowrap" class="ft013">.&#160;</p>
<p style="position:absolute;top:185px;left:108px;white-space:nowrap" class="ft013">68.</p>
<p style="position:absolute;top:185px;left:130px;white-space:nowrap" class="ft046">&#160;</p>
<p style="position:absolute;top:185px;left:162px;white-space:nowrap" class="ft032">Haddow LJ,&#160;Colebunders&#160;R, Meintjes&#160;G, et al. Cryptococcal immune reconstitution&#160;<br/>inflammatory syndrome&#160;in HIV-1-infected individuals:&#160;proposed&#160;clinical case&#160;definitions.&#160;</p>
<p style="position:absolute;top:225px;left:162px;white-space:nowrap" class="ft019"><i>Lancet&#160;Infect&#160;Dis</i></p>
<p style="position:absolute;top:225px;left:281px;white-space:nowrap" class="ft013">. 2010;10(11):791-802. Available at:&#160;</p>
<p style="position:absolute;top:245px;left:162px;white-space:nowrap" class="ft034">https://www.pubmed.ncbi.nlm.nih.gov/21029993</p>
<p style="position:absolute;top:245px;left:503px;white-space:nowrap" class="ft013">.&#160;</p>
<p style="position:absolute;top:282px;left:108px;white-space:nowrap" class="ft013">69.</p>
<p style="position:absolute;top:282px;left:130px;white-space:nowrap" class="ft046">&#160;</p>
<p style="position:absolute;top:282px;left:162px;white-space:nowrap" class="ft032">Boulware&#160;DR, Meya&#160;DB,&#160;Bergemann&#160;TL, et al. Clinical&#160;features and serum&#160;biomarkers in&#160;<br/>HIV&#160;immune&#160;reconstitution inflammatory syndrome after cryptococcal&#160;meningitis: a&#160;<br/>prospective cohort study.&#160;</p>
<p style="position:absolute;top:322px;left:340px;white-space:nowrap" class="ft019"><i>PLoS Med</i></p>
<p style="position:absolute;top:322px;left:413px;white-space:nowrap" class="ft013">.&#160;2010;7(12):e1000384.&#160;Available at:&#160;</p>
<p style="position:absolute;top:342px;left:162px;white-space:nowrap" class="ft034">https://www.pubmed.ncbi.nlm.nih.gov/21253011</p>
<p style="position:absolute;top:342px;left:503px;white-space:nowrap" class="ft013">.&#160;</p>
<p style="position:absolute;top:379px;left:108px;white-space:nowrap" class="ft013">70.</p>
<p style="position:absolute;top:378px;left:130px;white-space:nowrap" class="ft046">&#160;</p>
<p style="position:absolute;top:379px;left:162px;white-space:nowrap" class="ft032">Kuttiatt V, Sreenivasa P,&#160;Garg I,&#160;Shet&#160;A. Cryptococcal&#160;lymphadenitis and immune&#160;<br/>reconstitution inflammatory syndrome:&#160;current&#160;considerations.&#160;</p>
<p style="position:absolute;top:399px;left:598px;white-space:nowrap" class="ft019"><i>Scand J Infect&#160;Dis</i></p>
<p style="position:absolute;top:399px;left:723px;white-space:nowrap" class="ft013">.&#160;</p>
<p style="position:absolute;top:418px;left:162px;white-space:nowrap" class="ft013">2011;43(8):664-668.&#160;Available&#160;at:&#160;</p>
<p style="position:absolute;top:418px;left:402px;white-space:nowrap" class="ft034">https://www.pubmed.ncbi.nlm.nih.gov/21534892</p>
<p style="position:absolute;top:418px;left:743px;white-space:nowrap" class="ft013">.&#160;</p>
<p style="position:absolute;top:455px;left:108px;white-space:nowrap" class="ft013">71.</p>
<p style="position:absolute;top:455px;left:130px;white-space:nowrap" class="ft046">&#160;</p>
<p style="position:absolute;top:455px;left:162px;white-space:nowrap" class="ft032">Brandt&#160;ME,&#160;Pfaller MA,&#160;Hajjeh RA, et al. Trends in antifungal drug susceptibility of&#160;<br/>Cryptococcus neoformans isolates in the United States: 1992 to&#160;1994 and 1996 to 1998.&#160;</p>
<p style="position:absolute;top:495px;left:162px;white-space:nowrap" class="ft019"><i>Antimicrob&#160;Agents Chemother</i></p>
<p style="position:absolute;top:495px;left:372px;white-space:nowrap" class="ft013">. 2001;45(11):3065-3069. Available&#160;at:&#160;</p>
<p style="position:absolute;top:515px;left:162px;white-space:nowrap" class="ft034">https://www.pubmed.ncbi.nlm.nih.gov/11600357</p>
<p style="position:absolute;top:515px;left:503px;white-space:nowrap" class="ft013">.&#160;</p>
<p style="position:absolute;top:552px;left:108px;white-space:nowrap" class="ft013">72.</p>
<p style="position:absolute;top:552px;left:130px;white-space:nowrap" class="ft046">&#160;</p>
<p style="position:absolute;top:552px;left:162px;white-space:nowrap" class="ft032">Witt&#160;MD, Lewis RJ, Larsen RA, et al.&#160;Identification of patients&#160;with acute AIDS-associated&#160;<br/>cryptococcal&#160;meningitis who can be&#160;effectively treated with fluconazole: the role of&#160;<br/>antifungal susceptibility testing.&#160;</p>
<p style="position:absolute;top:592px;left:387px;white-space:nowrap" class="ft019"><i>Clin Infect&#160;Dis</i></p>
<p style="position:absolute;top:592px;left:488px;white-space:nowrap" class="ft013">. 1996;22(2):322-328. Available&#160;at:&#160;</p>
<p style="position:absolute;top:612px;left:162px;white-space:nowrap" class="ft034">https://www.pubmed.ncbi.nlm.nih.gov/8838190</p>
<p style="position:absolute;top:612px;left:494px;white-space:nowrap" class="ft013">.&#160;</p>
<p style="position:absolute;top:649px;left:108px;white-space:nowrap" class="ft013">73.</p>
<p style="position:absolute;top:648px;left:130px;white-space:nowrap" class="ft046">&#160;</p>
<p style="position:absolute;top:649px;left:162px;white-space:nowrap" class="ft032">Chesdachai&#160;S, Rajasingham&#160;R, Nicol&#160;MR, et al. Minimum&#160;inhibitory concentration&#160;<br/>distribution of fluconazole against Cryptococcus species and the Fluconazole Exposure&#160;<br/>Prediction Model.&#160;</p>
<p style="position:absolute;top:688px;left:291px;white-space:nowrap" class="ft019"><i>Open Forum&#160;Infect&#160;Dis</i></p>
<p style="position:absolute;top:688px;left:451px;white-space:nowrap" class="ft013">. 2019;6(10). Available at:&#160;</p>
<p style="position:absolute;top:708px;left:162px;white-space:nowrap" class="ft034">https://www.pubmed.ncbi.nlm.nih.gov/31420668</p>
<p style="position:absolute;top:708px;left:503px;white-space:nowrap" class="ft013">.&#160;</p>
<p style="position:absolute;top:745px;left:108px;white-space:nowrap" class="ft013">74.</p>
<p style="position:absolute;top:745px;left:130px;white-space:nowrap" class="ft046">&#160;</p>
<p style="position:absolute;top:745px;left:162px;white-space:nowrap" class="ft032">Leenders AC, Reiss&#160;P,&#160;Portegies P, et&#160;al. Liposomal&#160;amphotericin B (AmBisome) compared&#160;<br/>with amphotericin B both followed by&#160;oral&#160;fluconazole in the&#160;treatment of AIDS-associated&#160;<br/>cryptococcal&#160;meningitis.&#160;</p>
<p style="position:absolute;top:785px;left:336px;white-space:nowrap" class="ft019"><i>AIDS</i></p>
<p style="position:absolute;top:785px;left:373px;white-space:nowrap" class="ft013">. 1997;11(12):1463-1471. Available&#160;at:&#160;</p>
<p style="position:absolute;top:805px;left:162px;white-space:nowrap" class="ft034">https://www.pubmed.ncbi.nlm.nih.gov/9342068</p>
<p style="position:absolute;top:805px;left:494px;white-space:nowrap" class="ft013">.&#160;</p>
<p style="position:absolute;top:842px;left:108px;white-space:nowrap" class="ft013">75.</p>
<p style="position:absolute;top:842px;left:130px;white-space:nowrap" class="ft046">&#160;</p>
<p style="position:absolute;top:842px;left:162px;white-space:nowrap" class="ft032">Chen SC,&#160;Australasian Society for Infectious Diseases Mycoses Iterest G. Cryptococcosis in&#160;<br/>Australasia and the&#160;treatment of cryptococcal&#160;and other fungal infections with&#160;liposomal&#160;<br/>amphotericin B.&#160;</p>
<p style="position:absolute;top:881px;left:277px;white-space:nowrap" class="ft019"><i>J&#160;Antimicrob Chemother</i></p>
<p style="position:absolute;top:881px;left:448px;white-space:nowrap" class="ft013">. 2002;49&#160;Suppl 1(Suppl 1):57-61.&#160;Available at:&#160;</p>
<p style="position:absolute;top:901px;left:162px;white-space:nowrap" class="ft034">https://www.pubmed.ncbi.nlm.nih.gov/11801583</p>
<p style="position:absolute;top:901px;left:503px;white-space:nowrap" class="ft013">.&#160;</p>
<p style="position:absolute;top:938px;left:108px;white-space:nowrap" class="ft013">76.</p>
<p style="position:absolute;top:938px;left:130px;white-space:nowrap" class="ft046">&#160;</p>
<p style="position:absolute;top:938px;left:162px;white-space:nowrap" class="ft032">Jarvis JN,&#160;Meintjes G, Williams Z, Rebe K,&#160;Harrison TS. Symptomatic&#160;relapse of HIV-<br/>associated cryptococcal meningitis in South Africa:&#160;the&#160;role&#160;of inadequate secondary&#160;<br/>prophylaxis.&#160;</p>
<p style="position:absolute;top:978px;left:252px;white-space:nowrap" class="ft019"><i>S Afr Med J</i></p>
<p style="position:absolute;top:978px;left:334px;white-space:nowrap" class="ft013">.&#160;2010;100(6):378-382.&#160;Available at:&#160;</p>
<p style="position:absolute;top:998px;left:162px;white-space:nowrap" class="ft034">https://www.pubmed.ncbi.nlm.nih.gov/20526411</p>
<p style="position:absolute;top:998px;left:503px;white-space:nowrap" class="ft013">.&#160;</p>
<p style="position:absolute;top:1035px;left:108px;white-space:nowrap" class="ft013">77.</p>
<p style="position:absolute;top:1035px;left:130px;white-space:nowrap" class="ft046">&#160;</p>
<p style="position:absolute;top:1035px;left:162px;white-space:nowrap" class="ft032">Kirk O,&#160;Reiss P,&#160;Uberti-Foppa C, et&#160;al. Safe interruption of maintenance therapy against&#160;<br/>previous infection with four common&#160;HIV-associated opportunistic&#160;pathogens during potent&#160;</p>
</div>
<!-- Page 146 -->
<a name="146"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page146-div" style="position:relative;width:917px;height:1187px;">
<p style="position:absolute;top:1117px;left:108px;white-space:nowrap" class="ft024"><i>Guidelines for the Prevention and Treatment&#160;of&#160;Opportunistic&#160;Infections in Adults&#160;and Adolescents&#160;With HIV&#160;</i></p>
<p style="position:absolute;top:1117px;left:783px;white-space:nowrap" class="ft024"><i>H-24&#160;</i></p>
<p style="position:absolute;top:109px;left:162px;white-space:nowrap" class="ft013">antiretroviral&#160;therapy.&#160;</p>
<p style="position:absolute;top:109px;left:317px;white-space:nowrap" class="ft019"><i>Ann Intern Med</i></p>
<p style="position:absolute;top:109px;left:426px;white-space:nowrap" class="ft013">. 2002;137(4):239-250.&#160;Available&#160;at:&#160;</p>
<p style="position:absolute;top:129px;left:162px;white-space:nowrap" class="ft034">https://www.pubmed.ncbi.nlm.nih.gov/12186514</p>
<p style="position:absolute;top:129px;left:503px;white-space:nowrap" class="ft013">.&#160;</p>
<p style="position:absolute;top:166px;left:108px;white-space:nowrap" class="ft013">78.</p>
<p style="position:absolute;top:165px;left:130px;white-space:nowrap" class="ft046">&#160;</p>
<p style="position:absolute;top:166px;left:162px;white-space:nowrap" class="ft032">Vibhagool&#160;A, Sungkanuparph S,&#160;Mootsikapun P, et&#160;al. Discontinuation of secondary&#160;<br/>prophylaxis for cryptococcal&#160;meningitis&#160;in human immunodeficiency virus-infected patients&#160;<br/>treated with highly active antiretroviral therapy:&#160;a prospective,&#160;multicenter,&#160;randomized&#160;<br/>study.&#160;</p>
<p style="position:absolute;top:225px;left:208px;white-space:nowrap" class="ft019"><i>Clin Infect&#160;Dis</i></p>
<p style="position:absolute;top:225px;left:309px;white-space:nowrap" class="ft013">. 2003;36(10):1329-1331.&#160;Available at:&#160;</p>
<p style="position:absolute;top:245px;left:162px;white-space:nowrap" class="ft034">https://www.pubmed.ncbi.nlm.nih.gov/12746781</p>
<p style="position:absolute;top:245px;left:503px;white-space:nowrap" class="ft013">.&#160;</p>
<p style="position:absolute;top:282px;left:108px;white-space:nowrap" class="ft013">79.</p>
<p style="position:absolute;top:282px;left:130px;white-space:nowrap" class="ft046">&#160;</p>
<p style="position:absolute;top:282px;left:162px;white-space:nowrap" class="ft032">Mussini&#160;C, Pezzotti P, Miro JM, et&#160;al. Discontinuation of maintenance&#160;therapy for&#160;<br/>cryptococcal&#160;meningitis in patients with AIDS treated with highly active&#160;antiretroviral&#160;<br/>therapy:&#160;an international observational study.&#160;</p>
<p style="position:absolute;top:322px;left:478px;white-space:nowrap" class="ft019"><i>Clin&#160;Infect&#160;Dis</i></p>
<p style="position:absolute;top:322px;left:579px;white-space:nowrap" class="ft013">. 2004;38(4):565-571.&#160;Available&#160;</p>
<p style="position:absolute;top:342px;left:162px;white-space:nowrap" class="ft013">at:&#160;</p>
<p style="position:absolute;top:342px;left:184px;white-space:nowrap" class="ft034">https://www.pubmed.ncbi.nlm.nih.gov/14765351</p>
<p style="position:absolute;top:342px;left:524px;white-space:nowrap" class="ft013">.&#160;</p>
<p style="position:absolute;top:379px;left:108px;white-space:nowrap" class="ft013">80.</p>
<p style="position:absolute;top:378px;left:130px;white-space:nowrap" class="ft046">&#160;</p>
<p style="position:absolute;top:379px;left:162px;white-space:nowrap" class="ft032">Pastick KA,&#160;Nalintya&#160;E, Tugume&#160;L, et&#160;al. Cryptococcosis in pregnancy and&#160;the postpartum&#160;<br/>period: case&#160;series and systematic&#160;review with recommendations for management.&#160;</p>
<p style="position:absolute;top:399px;left:733px;white-space:nowrap" class="ft019"><i>Med&#160;</i></p>
<p style="position:absolute;top:418px;left:162px;white-space:nowrap" class="ft019"><i>Mycol</i></p>
<p style="position:absolute;top:418px;left:205px;white-space:nowrap" class="ft013">. 2020;58(3):282-292. Available at:&#160;</p>
<p style="position:absolute;top:418px;left:454px;white-space:nowrap" class="ft034">https://www.pubmed.ncbi.nlm.nih.gov/31689712</p>
<p style="position:absolute;top:418px;left:795px;white-space:nowrap" class="ft013">.&#160;</p>
<p style="position:absolute;top:455px;left:108px;white-space:nowrap" class="ft013">81.</p>
<p style="position:absolute;top:455px;left:130px;white-space:nowrap" class="ft046">&#160;</p>
<p style="position:absolute;top:455px;left:162px;white-space:nowrap" class="ft032">Miyoshi&#160;S,&#160;Oda N,&#160;Gion&#160;Y, et al. Exacerbation of&#160;pulmonary cryptococcosis associated&#160;with&#160;<br/>enhancement&#160;of Th2 response in the postpartum period.&#160;</p>
<p style="position:absolute;top:475px;left:550px;white-space:nowrap" class="ft019"><i>J&#160;Infect&#160;Chemother</i></p>
<p style="position:absolute;top:475px;left:682px;white-space:nowrap" class="ft013">.&#160;</p>
<p style="position:absolute;top:495px;left:162px;white-space:nowrap" class="ft013">2021;27(8):1248-1250.&#160;Available at:&#160;</p>
<p style="position:absolute;top:495px;left:420px;white-space:nowrap" class="ft034">https://www.ncbi.nlm.nih.gov/pubmed/33840597</p>
<p style="position:absolute;top:495px;left:761px;white-space:nowrap" class="ft013">.&#160;</p>
<p style="position:absolute;top:532px;left:108px;white-space:nowrap" class="ft013">82.</p>
<p style="position:absolute;top:532px;left:130px;white-space:nowrap" class="ft046">&#160;</p>
<p style="position:absolute;top:532px;left:162px;white-space:nowrap" class="ft032">Singh N,&#160;Perfect&#160;JR. Immune reconstitution syndrome&#160;and exacerbation of infections after&#160;<br/>pregnancy.&#160;</p>
<p style="position:absolute;top:552px;left:243px;white-space:nowrap" class="ft019"><i>Clin Infect Dis</i></p>
<p style="position:absolute;top:552px;left:344px;white-space:nowrap" class="ft013">. 2007;45(9):1192-1199.&#160;Available at:&#160;</p>
<p style="position:absolute;top:572px;left:162px;white-space:nowrap" class="ft034">https://www.ncbi.nlm.nih.gov/pubmed/17918082</p>
<p style="position:absolute;top:572px;left:503px;white-space:nowrap" class="ft013">.&#160;</p>
<p style="position:absolute;top:609px;left:108px;white-space:nowrap" class="ft013">83.</p>
<p style="position:absolute;top:609px;left:130px;white-space:nowrap" class="ft046">&#160;</p>
<p style="position:absolute;top:609px;left:162px;white-space:nowrap" class="ft032">O'Grady&#160;N,&#160;McManus D,&#160;Briggs&#160;N, Azar MM, Topal&#160;J, Davis&#160;MW. Dosing&#160;implications for&#160;<br/>liposomal&#160;amphotericin B in pregnancy.&#160;</p>
<p style="position:absolute;top:629px;left:443px;white-space:nowrap" class="ft019"><i>Pharmacotherapy</i></p>
<p style="position:absolute;top:629px;left:568px;white-space:nowrap" class="ft013">. 2023;43(5):452-462. Available&#160;</p>
<p style="position:absolute;top:649px;left:162px;white-space:nowrap" class="ft013">at:&#160;</p>
<p style="position:absolute;top:649px;left:183px;white-space:nowrap" class="ft034">https://www.ncbi.nlm.nih.gov/pubmed/36862037</p>
<p style="position:absolute;top:649px;left:525px;white-space:nowrap" class="ft013">.&#160;</p>
<p style="position:absolute;top:686px;left:108px;white-space:nowrap" class="ft013">84.</p>
<p style="position:absolute;top:685px;left:130px;white-space:nowrap" class="ft046">&#160;</p>
<p style="position:absolute;top:686px;left:162px;white-space:nowrap" class="ft032">AmBisome®&#160;(amphotericin B) liposome&#160;for injection [package&#160;insert]. U.S.&#160;Food and&#160;Drug&#160;<br/>Administration. 2021.&#160;Available&#160;at:&#160;</p>
<p style="position:absolute;top:725px;left:162px;white-space:nowrap" class="ft034">https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/050740Orig1s033lbl.pdf</p>
<p style="position:absolute;top:725px;left:751px;white-space:nowrap" class="ft013">.&#160;</p>
<p style="position:absolute;top:762px;left:108px;white-space:nowrap" class="ft013">85.</p>
<p style="position:absolute;top:762px;left:130px;white-space:nowrap" class="ft046">&#160;</p>
<p style="position:absolute;top:762px;left:162px;white-space:nowrap" class="ft013">Curole&#160;DN.&#160;Cryptococcal meningitis in pregnancy.&#160;</p>
<p style="position:absolute;top:762px;left:518px;white-space:nowrap" class="ft019"><i>J Reprod Med</i></p>
<p style="position:absolute;top:762px;left:616px;white-space:nowrap" class="ft013">. 1981;26(6):317-319.&#160;</p>
<p style="position:absolute;top:782px;left:162px;white-space:nowrap" class="ft013">Available at:&#160;</p>
<p style="position:absolute;top:782px;left:255px;white-space:nowrap" class="ft034">https://www.ncbi.nlm.nih.gov/pubmed/7252951</p>
<p style="position:absolute;top:782px;left:588px;white-space:nowrap" class="ft013">.&#160;</p>
<p style="position:absolute;top:819px;left:108px;white-space:nowrap" class="ft013">86.</p>
<p style="position:absolute;top:819px;left:130px;white-space:nowrap" class="ft046">&#160;</p>
<p style="position:absolute;top:819px;left:162px;white-space:nowrap" class="ft032">Schonebeck&#160;J, Segerbrand E. Candida&#160;albicans septicaemia during first half&#160;of pregnancy&#160;<br/>successfully treated with 5-fluorocytosine.&#160;</p>
<p style="position:absolute;top:839px;left:459px;white-space:nowrap" class="ft019"><i>Br Med&#160;J</i></p>
<p style="position:absolute;top:839px;left:523px;white-space:nowrap" class="ft013">. 1973;4(5888):337-338.&#160;Available at:&#160;</p>
<p style="position:absolute;top:859px;left:162px;white-space:nowrap" class="ft034">https://www.ncbi.nlm.nih.gov/pubmed/4202261</p>
<p style="position:absolute;top:859px;left:495px;white-space:nowrap" class="ft013">.&#160;</p>
<p style="position:absolute;top:896px;left:108px;white-space:nowrap" class="ft013">87.</p>
<p style="position:absolute;top:896px;left:130px;white-space:nowrap" class="ft046">&#160;</p>
<p style="position:absolute;top:896px;left:162px;white-space:nowrap" class="ft013">Philpot&#160;CR,&#160;Lo D. Cryptococcal meningitis in pregnancy.&#160;</p>
<p style="position:absolute;top:896px;left:564px;white-space:nowrap" class="ft019"><i>Med&#160;J Aust</i></p>
<p style="position:absolute;top:896px;left:641px;white-space:nowrap" class="ft013">. 1972;2(18):1005-</p>
<p style="position:absolute;top:916px;left:162px;white-space:nowrap" class="ft013">1007. Available&#160;at:&#160;</p>
<p style="position:absolute;top:916px;left:298px;white-space:nowrap" class="ft034">https://www.ncbi.nlm.nih.gov/pubmed/4578877</p>
<p style="position:absolute;top:916px;left:631px;white-space:nowrap" class="ft013">.&#160;</p>
<p style="position:absolute;top:953px;left:108px;white-space:nowrap" class="ft013">88.</p>
<p style="position:absolute;top:953px;left:130px;white-space:nowrap" class="ft046">&#160;</p>
<p style="position:absolute;top:953px;left:162px;white-space:nowrap" class="ft032">Pursley TJ,&#160;Blomquist IK, Abraham&#160;J, Andersen&#160;HF, Bartley&#160;JA.&#160;Fluconazole-induced&#160;<br/>congenital anomalies in three infants.&#160;</p>
<p style="position:absolute;top:973px;left:424px;white-space:nowrap" class="ft019"><i>Clin Infect&#160;Dis</i></p>
<p style="position:absolute;top:973px;left:526px;white-space:nowrap" class="ft013">. 1996;22(2):336-340.&#160;Available&#160;at:&#160;</p>
<p style="position:absolute;top:993px;left:162px;white-space:nowrap" class="ft034">https://www.pubmed.ncbi.nlm.nih.gov/8838193</p>
<p style="position:absolute;top:993px;left:494px;white-space:nowrap" class="ft013">.&#160;</p>
<p style="position:absolute;top:1030px;left:108px;white-space:nowrap" class="ft013">89.</p>
<p style="position:absolute;top:1030px;left:130px;white-space:nowrap" class="ft046">&#160;</p>
<p style="position:absolute;top:1030px;left:162px;white-space:nowrap" class="ft032">Metruccio F,&#160;Battistoni M, Di Renzo F, Moretto A,&#160;Menegola&#160;E.&#160;Moderate alcohol&#160;<br/>consumption&#160;during pregnancy increases potency&#160;of two different&#160;drugs (the antifungal&#160;</p>
</div>
<!-- Page 147 -->
<a name="147"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page147-div" style="position:relative;width:917px;height:1187px;">
<p style="position:absolute;top:1117px;left:108px;white-space:nowrap" class="ft024"><i>Guidelines for the Prevention and Treatment&#160;of&#160;Opportunistic&#160;Infections in Adults&#160;and Adolescents&#160;With HIV&#160;</i></p>
<p style="position:absolute;top:1117px;left:783px;white-space:nowrap" class="ft024"><i>H-25&#160;</i></p>
<p style="position:absolute;top:109px;left:162px;white-space:nowrap" class="ft032">fluconazole and the antiepileptic valproate) in inducing craniofacial&#160;defects: prediction by the&#160;<br/>in vitro rat whole&#160;embryo&#160;culture.&#160;</p>
<p style="position:absolute;top:129px;left:399px;white-space:nowrap" class="ft019"><i>Arch Toxicol</i></p>
<p style="position:absolute;top:129px;left:488px;white-space:nowrap" class="ft013">. 2023;97(2):619-629. Available&#160;at:&#160;</p>
<p style="position:absolute;top:148px;left:162px;white-space:nowrap" class="ft034">https://www.ncbi.nlm.nih.gov/pubmed/36385218</p>
<p style="position:absolute;top:148px;left:503px;white-space:nowrap" class="ft013">.&#160;</p>
<p style="position:absolute;top:185px;left:108px;white-space:nowrap" class="ft013">90.</p>
<p style="position:absolute;top:185px;left:130px;white-space:nowrap" class="ft046">&#160;</p>
<p style="position:absolute;top:185px;left:162px;white-space:nowrap" class="ft032">Budani&#160;MC,&#160;Fensore&#160;S, Di Marzio M,&#160;Tiboni GM.&#160;Maternal use&#160;of fluconazole&#160;and&#160;<br/>congenital malformations in the progeny: a meta-analysis of the&#160;literature.&#160;</p>
<p style="position:absolute;top:205px;left:677px;white-space:nowrap" class="ft019"><i>Reprod Toxicol</i></p>
<p style="position:absolute;top:205px;left:784px;white-space:nowrap" class="ft013">.&#160;</p>
<p style="position:absolute;top:225px;left:162px;white-space:nowrap" class="ft013">2021;100:42-51. Available at:&#160;</p>
<p style="position:absolute;top:225px;left:374px;white-space:nowrap" class="ft034">https://www.ncbi.nlm.nih.gov/pubmed/33383164</p>
<p style="position:absolute;top:225px;left:715px;white-space:nowrap" class="ft013">.&#160;</p>
<p style="position:absolute;top:262px;left:108px;white-space:nowrap" class="ft013">91.</p>
<p style="position:absolute;top:262px;left:130px;white-space:nowrap" class="ft046">&#160;</p>
<p style="position:absolute;top:262px;left:162px;white-space:nowrap" class="ft032">Zhang Z, Zhang X, Zhou&#160;YY,&#160;Jiang CM, Jiang&#160;HY. The safety&#160;of oral&#160;fluconazole during the&#160;<br/>first trimester of pregnancy: a&#160;systematic review and meta-analysis.&#160;</p>
<p style="position:absolute;top:282px;left:632px;white-space:nowrap" class="ft019"><i>BJOG</i></p>
<p style="position:absolute;top:282px;left:675px;white-space:nowrap" class="ft013">.&#160;</p>
<p style="position:absolute;top:302px;left:162px;white-space:nowrap" class="ft013">2019;126(13):1546-1552.&#160;Available at:&#160;</p>
<p style="position:absolute;top:302px;left:437px;white-space:nowrap" class="ft034">https://www.pubmed.ncbi.nlm.nih.gov/31446677</p>
<p style="position:absolute;top:302px;left:778px;white-space:nowrap" class="ft013">.&#160;</p>
<p style="position:absolute;top:339px;left:108px;white-space:nowrap" class="ft013">92.</p>
<p style="position:absolute;top:339px;left:130px;white-space:nowrap" class="ft046">&#160;</p>
<p style="position:absolute;top:339px;left:162px;white-space:nowrap" class="ft032">Molgaard-Nielsen D, Pasternak B, Hviid A. Use of&#160;oral&#160;fluconazole during pregnancy and&#160;<br/>the&#160;risk of birth defects.&#160;</p>
<p style="position:absolute;top:359px;left:330px;white-space:nowrap" class="ft019"><i>N Engl&#160;J Med</i></p>
<p style="position:absolute;top:359px;left:426px;white-space:nowrap" class="ft013">. 2013;369(9):830-839.&#160;Available at:&#160;</p>
<p style="position:absolute;top:379px;left:162px;white-space:nowrap" class="ft034">https://www.pubmed.ncbi.nlm.nih.gov/23984730</p>
<p style="position:absolute;top:379px;left:503px;white-space:nowrap" class="ft013">.&#160;</p>
<p style="position:absolute;top:416px;left:108px;white-space:nowrap" class="ft013">93.</p>
<p style="position:absolute;top:415px;left:130px;white-space:nowrap" class="ft046">&#160;</p>
<p style="position:absolute;top:416px;left:162px;white-space:nowrap" class="ft032">Howley&#160;MM, Carter TC,&#160;Browne&#160;ML,&#160;Romitti PA,&#160;Cunniff CM,&#160;Druschel&#160;CM. Fluconazole&#160;<br/>use and birth&#160;defects in the National&#160;Birth Defects Prevention Study.&#160;</p>
<p style="position:absolute;top:436px;left:640px;white-space:nowrap" class="ft019"><i>Am J&#160;Obstet&#160;Gynecol</i></p>
<p style="position:absolute;top:436px;left:786px;white-space:nowrap" class="ft013">.&#160;</p>
<p style="position:absolute;top:455px;left:162px;white-space:nowrap" class="ft013">2016;214(5):657 e651-659. Available at:&#160;</p>
<p style="position:absolute;top:455px;left:449px;white-space:nowrap" class="ft034">https://www.pubmed.ncbi.nlm.nih.gov/26640069</p>
<p style="position:absolute;top:455px;left:790px;white-space:nowrap" class="ft013">.&#160;</p>
<p style="position:absolute;top:492px;left:108px;white-space:nowrap" class="ft013">94.</p>
<p style="position:absolute;top:492px;left:130px;white-space:nowrap" class="ft046">&#160;</p>
<p style="position:absolute;top:492px;left:162px;white-space:nowrap" class="ft032">Berard A,&#160;Sheehy O, Zhao JP, et&#160;al. Associations between low-&#160;and high-dose oral&#160;<br/>fluconazole and pregnancy outcomes: 3 nested case-control studies.&#160;</p>
<p style="position:absolute;top:512px;left:633px;white-space:nowrap" class="ft019"><i>CMAJ</i></p>
<p style="position:absolute;top:512px;left:678px;white-space:nowrap" class="ft013">.&#160;</p>
<p style="position:absolute;top:532px;left:162px;white-space:nowrap" class="ft013">2019;191(7):E179-E187.&#160;Available at:&#160;</p>
<p style="position:absolute;top:532px;left:432px;white-space:nowrap" class="ft034">https://www.ncbi.nlm.nih.gov/pubmed/30782643</p>
<p style="position:absolute;top:532px;left:773px;white-space:nowrap" class="ft013">.&#160;</p>
<p style="position:absolute;top:569px;left:108px;white-space:nowrap" class="ft013">95.</p>
<p style="position:absolute;top:569px;left:130px;white-space:nowrap" class="ft046">&#160;</p>
<p style="position:absolute;top:569px;left:162px;white-space:nowrap" class="ft032">Zhu Y, Bateman BT, Gray KJ, et al.&#160;Oral&#160;fluconazole use in the&#160;first trimester and risk of&#160;<br/>congenital malformations: population based cohort&#160;study.&#160;</p>
<p style="position:absolute;top:589px;left:564px;white-space:nowrap" class="ft019"><i>BMJ</i></p>
<p style="position:absolute;top:589px;left:596px;white-space:nowrap" class="ft013">. 2020;369:m1494. Available&#160;</p>
<p style="position:absolute;top:609px;left:162px;white-space:nowrap" class="ft013">at:&#160;</p>
<p style="position:absolute;top:609px;left:184px;white-space:nowrap" class="ft034">https://www.ncbi.nlm.nih.gov/pubmed/32434758</p>
<p style="position:absolute;top:609px;left:525px;white-space:nowrap" class="ft013">.&#160;</p>
<p style="position:absolute;top:646px;left:108px;white-space:nowrap" class="ft013">96.</p>
<p style="position:absolute;top:646px;left:130px;white-space:nowrap" class="ft046">&#160;</p>
<p style="position:absolute;top:646px;left:162px;white-space:nowrap" class="ft032">Mølgaard-Nielsen D, Svanstrom H,&#160;Melbye M, Hviid A, Pasternak B. Association between&#160;<br/>use of oral&#160;fluconazole&#160;during pregnancy and risk of spontaneous abortion and stillbirth.&#160;</p>
<p style="position:absolute;top:686px;left:162px;white-space:nowrap" class="ft019"><i>JAMA</i></p>
<p style="position:absolute;top:686px;left:205px;white-space:nowrap" class="ft013">. 2016;315(1):58-67. Available at:&#160;</p>
<p style="position:absolute;top:686px;left:445px;white-space:nowrap" class="ft034">https://www.pubmed.ncbi.nlm.nih.gov/26746458</p>
<p style="position:absolute;top:686px;left:786px;white-space:nowrap" class="ft013">.&#160;</p>
<p style="position:absolute;top:723px;left:108px;white-space:nowrap" class="ft013">97.</p>
<p style="position:absolute;top:723px;left:130px;white-space:nowrap" class="ft046">&#160;</p>
<p style="position:absolute;top:723px;left:162px;white-space:nowrap" class="ft032">Pasternak B,&#160;Wintzell&#160;V, Furu&#160;K, Engeland A, Neovius M,&#160;Stephansson&#160;O.&#160;Oral fluconazole&#160;<br/>in pregnancy&#160;and risk of&#160;stillbirth and&#160;neonatal death.&#160;</p>
<p style="position:absolute;top:743px;left:534px;white-space:nowrap" class="ft019"><i>JAMA</i></p>
<p style="position:absolute;top:743px;left:577px;white-space:nowrap" class="ft013">. 2018;319(22):2333-2335.&#160;</p>
<p style="position:absolute;top:762px;left:162px;white-space:nowrap" class="ft013">Available at:&#160;</p>
<p style="position:absolute;top:762px;left:255px;white-space:nowrap" class="ft034">https://www.pubmed.ncbi.nlm.nih.gov/29896619</p>
<p style="position:absolute;top:762px;left:596px;white-space:nowrap" class="ft013">.&#160;</p>
<p style="position:absolute;top:800px;left:108px;white-space:nowrap" class="ft013">98.</p>
<p style="position:absolute;top:799px;left:130px;white-space:nowrap" class="ft046">&#160;</p>
<p style="position:absolute;top:800px;left:162px;white-space:nowrap" class="ft032">Liu D, Zhang C, Wu L, Zhang L, Zhang L. Fetal&#160;outcomes after maternal&#160;exposure to oral&#160;<br/>antifungal agents during pregnancy:&#160;a systematic&#160;review and meta-analysis.&#160;</p>
<p style="position:absolute;top:819px;left:687px;white-space:nowrap" class="ft019"><i>Int J Gynaecol&#160;</i></p>
<p style="position:absolute;top:839px;left:162px;white-space:nowrap" class="ft019"><i>Obstet</i></p>
<p style="position:absolute;top:839px;left:207px;white-space:nowrap" class="ft013">. 2020;148(1):6-13.&#160;Available at:&#160;</p>
<p style="position:absolute;top:839px;left:439px;white-space:nowrap" class="ft034">https://www.ncbi.nlm.nih.gov/pubmed/31691277</p>
<p style="position:absolute;top:839px;left:780px;white-space:nowrap" class="ft013">.&#160;</p>
</div>
<!-- Page 148 -->
<a name="148"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page148-div" style="position:relative;width:917px;height:1187px;">
<p style="position:absolute;top:1114px;left:108px;white-space:nowrap" class="ft024"><i>Guidelines for the Prevention and Treatment&#160;of&#160;Opportunistic&#160;Infections in Adults&#160;and Adolescents&#160;With HIV&#160;</i></p>
<p style="position:absolute;top:1114px;left:795px;white-space:nowrap" class="ft024"><i>I-1</i></p>
<p style="position:absolute;top:112px;left:108px;white-space:nowrap" class="ft025"><b>Cryptosporidiosis</b></p>
<p style="position:absolute;top:159px;left:108px;white-space:nowrap" class="ft035"><b>Updated:&#160;</b></p>
<p style="position:absolute;top:159px;left:176px;white-space:nowrap" class="ft036">January 18,&#160;2023&#160;</p>
<p style="position:absolute;top:180px;left:108px;white-space:nowrap" class="ft035"><b>Reviewed:</b></p>
<p style="position:absolute;top:180px;left:181px;white-space:nowrap" class="ft036">&#160;January 8,&#160;2025&#160;</p>
<p style="position:absolute;top:218px;left:108px;white-space:nowrap" class="ft026"><b>Epidemiology</b></p>
<p style="position:absolute;top:260px;left:108px;white-space:nowrap" class="ft013">Cryptosporidiosis is caused by various&#160;species of the protozoan&#160;parasite&#160;</p>
<p style="position:absolute;top:260px;left:608px;white-space:nowrap" class="ft019"><i>Cryptosporidium</i></p>
<p style="position:absolute;top:260px;left:725px;white-space:nowrap" class="ft013">, which&#160;</p>
<p style="position:absolute;top:280px;left:108px;white-space:nowrap" class="ft013">infects the&#160;small&#160;bowel mucosa, and,&#160;if symptomatic, the&#160;infection typically causes diarrhea.&#160;</p>
<p style="position:absolute;top:299px;left:108px;white-space:nowrap" class="ft019"><i>Cryptosporidium</i></p>
<p style="position:absolute;top:299px;left:226px;white-space:nowrap" class="ft013">&#160;can also&#160;infect other gastrointestinal&#160;and extraintestinal sites, especially in&#160;</p>
<p style="position:absolute;top:319px;left:108px;white-space:nowrap" class="ft032">individuals whose immune systems are suppressed. Advanced&#160;immunosuppression—typically CD4 T&#160;<br/>lymphocyte (CD4) cell counts &lt;100 cells/mm</p>
<p style="position:absolute;top:338px;left:424px;white-space:nowrap" class="ft038">3</p>
<p style="position:absolute;top:339px;left:429px;white-space:nowrap" class="ft013">—is&#160;associated with the&#160;greatest risk for&#160;prolonged,&#160;</p>
<p style="position:absolute;top:359px;left:108px;white-space:nowrap" class="ft013">severe, or extraintestinal&#160;cryptosporidiosis.</p>
<p style="position:absolute;top:358px;left:405px;white-space:nowrap" class="ft038">1</p>
<p style="position:absolute;top:359px;left:410px;white-space:nowrap" class="ft013">&#160;The three species that&#160;most commonly infect humans are&#160;</p>
<p style="position:absolute;top:379px;left:108px;white-space:nowrap" class="ft019"><i>C.&#160;hominis</i></p>
<p style="position:absolute;top:379px;left:183px;white-space:nowrap" class="ft013">,&#160;</p>
<p style="position:absolute;top:379px;left:191px;white-space:nowrap" class="ft019"><i>C. parvum</i></p>
<p style="position:absolute;top:379px;left:264px;white-space:nowrap" class="ft013">, and&#160;</p>
<p style="position:absolute;top:379px;left:302px;white-space:nowrap" class="ft019"><i>C. meleagridis</i></p>
<p style="position:absolute;top:379px;left:403px;white-space:nowrap" class="ft013">. Infections are usually caused by&#160;one species,&#160;but a&#160;mixed</p>
<p style="position:absolute;top:399px;left:108px;white-space:nowrap" class="ft013">infection is possible.</p>
<p style="position:absolute;top:397px;left:250px;white-space:nowrap" class="ft038">2,3</p>
<p style="position:absolute;top:436px;left:108px;white-space:nowrap" class="ft032">Cryptosporidiosis remains&#160;a common cause of chronic&#160;diarrhea&#160;in people with HIV and&#160;AIDS&#160;in low-&#160;<br/>and middle-income&#160;countries.</p>
<p style="position:absolute;top:454px;left:314px;white-space:nowrap" class="ft038">4</p>
<p style="position:absolute;top:455px;left:319px;white-space:nowrap" class="ft013">&#160;In&#160;high-income countries with low rates of environmental&#160;</p>
<p style="position:absolute;top:475px;left:108px;white-space:nowrap" class="ft032">contamination and widespread availability of potent antiretroviral therapy (ART), the incidence of&#160;<br/>cryptosporidiosis in people with HIV has decreased.&#160;In the&#160;United States, the&#160;incidence of&#160;<br/>cryptosporidiosis in people with HIV is now &lt;1 case per 1,000 person-years.</p>
<p style="position:absolute;top:514px;left:638px;white-space:nowrap" class="ft038">5</p>
<p style="position:absolute;top:515px;left:643px;white-space:nowrap" class="ft013">&#160;</p>
<p style="position:absolute;top:552px;left:108px;white-space:nowrap" class="ft013">Infection occurs through ingestion of&#160;</p>
<p style="position:absolute;top:552px;left:368px;white-space:nowrap" class="ft019"><i>Cryptosporidium</i></p>
<p style="position:absolute;top:552px;left:486px;white-space:nowrap" class="ft013">&#160;oocysts.&#160;Viable&#160;oocysts in feces can be&#160;</p>
<p style="position:absolute;top:572px;left:108px;white-space:nowrap" class="ft013">transmitted directly through contact with humans or animals infected with&#160;</p>
<p style="position:absolute;top:572px;left:623px;white-space:nowrap" class="ft019"><i>Cryptosporidium</i></p>
<p style="position:absolute;top:572px;left:741px;white-space:nowrap" class="ft013">,&#160;</p>
<p style="position:absolute;top:592px;left:108px;white-space:nowrap" class="ft013">particularly those with diarrhea.&#160;</p>
<p style="position:absolute;top:592px;left:332px;white-space:nowrap" class="ft019"><i>Cryptosporidium</i></p>
<p style="position:absolute;top:592px;left:450px;white-space:nowrap" class="ft013">&#160;oocysts can contaminate public&#160;water supplies and&#160;</p>
<p style="position:absolute;top:612px;left:108px;white-space:nowrap" class="ft032">recreational&#160;water sources—such&#160;as swimming pools and lakes—and may persist despite&#160;standard&#160;<br/>chlorination. Person-to-person transmission of&#160;</p>
<p style="position:absolute;top:631px;left:432px;white-space:nowrap" class="ft019"><i>Cryptosporidium</i></p>
<p style="position:absolute;top:631px;left:550px;white-space:nowrap" class="ft013">&#160;is common,&#160;especially among&#160;</p>
<p style="position:absolute;top:651px;left:108px;white-space:nowrap" class="ft013">sexually active men who&#160;have sex with men.&#160;</p>
<p style="position:absolute;top:688px;left:108px;white-space:nowrap" class="ft026"><b>Clinical Manifestations</b></p>
<p style="position:absolute;top:730px;left:108px;white-space:nowrap" class="ft032">Patients with cryptosporidiosis most&#160;commonly present&#160;with acute or subacute&#160;onset of&#160;watery&#160;<br/>diarrhea, which may be&#160;accompanied by nausea, vomiting, and lower abdominal&#160;cramping. Disease&#160;<br/>severity can&#160;range from&#160;asymptomatic&#160;to profuse,&#160;watery, voluminous diarrhea.</p>
<p style="position:absolute;top:768px;left:657px;white-space:nowrap" class="ft038">6</p>
<p style="position:absolute;top:769px;left:663px;white-space:nowrap" class="ft013">&#160;More severe&#160;</p>
<p style="position:absolute;top:789px;left:108px;white-space:nowrap" class="ft032">symptoms tend to occur in immunosuppressed&#160;people, whereas&#160;transient&#160;diarrhea alone&#160;is&#160;typical&#160;in&#160;<br/>people with&#160;competent immune systems. Fever is&#160;present&#160;in approximately one-third of&#160;patients, and&#160;<br/>malabsorption is common. The&#160;epithelium of the&#160;biliary tract&#160;and the pancreatic&#160;duct can be infected&#160;<br/>with&#160;</p>
<p style="position:absolute;top:849px;left:143px;white-space:nowrap" class="ft019"><i>Cryptosporidium,</i></p>
<p style="position:absolute;top:849px;left:265px;white-space:nowrap" class="ft013">&#160;leading to sclerosing cholangitis and to pancreatitis secondary to papillary&#160;</p>
<p style="position:absolute;top:869px;left:108px;white-space:nowrap" class="ft013">stenosis, particularly among people with prolonged&#160;disease and low CD4 counts.</p>
<p style="position:absolute;top:867px;left:666px;white-space:nowrap" class="ft038">7</p>
<p style="position:absolute;top:869px;left:671px;white-space:nowrap" class="ft013">&#160;Pulmonary&#160;</p>
<p style="position:absolute;top:888px;left:108px;white-space:nowrap" class="ft019"><i>Cryptosporidium</i></p>
<p style="position:absolute;top:888px;left:226px;white-space:nowrap" class="ft013">&#160;infections also have been reported&#160;and may be&#160;under-recognized.</p>
<p style="position:absolute;top:887px;left:679px;white-space:nowrap" class="ft038">8,9</p>
<p style="position:absolute;top:925px;left:108px;white-space:nowrap" class="ft026"><b>Diagnosis&#160;</b></p>
<p style="position:absolute;top:967px;left:108px;white-space:nowrap" class="ft032">Diagnosis&#160;of&#160;cryptosporidiosis was traditionally made by microscopic&#160;identification of the oocysts in&#160;<br/>stool with acid-fast&#160;staining or direct immunofluorescence, which offers higher sensitivity.</p>
<p style="position:absolute;top:985px;left:734px;white-space:nowrap" class="ft038">10</p>
<p style="position:absolute;top:987px;left:745px;white-space:nowrap" class="ft013">&#160;</p>
<p style="position:absolute;top:1006px;left:108px;white-space:nowrap" class="ft032">Concentration methods (e.g., formalin-ethyl acetate) may facilitate diagnosis&#160;of cryptosporidiosis.&#160;<br/>However, these methods&#160;are&#160;insensitive, and other&#160;diagnostic&#160;methods are being increasingly used.&#160;<br/>Antigen detection by enzyme-linked immunosorbent assay or immunochromatographic tests also is&#160;</p>
</div>
<!-- Page 149 -->
<a name="149"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page149-div" style="position:relative;width:917px;height:1187px;">
<p style="position:absolute;top:1114px;left:108px;white-space:nowrap" class="ft024"><i>Guidelines for the Prevention and Treatment&#160;of&#160;Opportunistic&#160;Infections in Adults&#160;and Adolescents&#160;With HIV&#160;</i></p>
<p style="position:absolute;top:1114px;left:795px;white-space:nowrap" class="ft024"><i>I-2&#160;</i></p>
<p style="position:absolute;top:109px;left:108px;white-space:nowrap" class="ft032">useful;&#160;depending on the&#160;specific&#160;test, sensitivities reportedly range from 66%&#160;to 100%.&#160;However,&#160;<br/>some immunochromatographic&#160;tests produce&#160;frequent false-positive&#160;results.</p>
<p style="position:absolute;top:127px;left:631px;white-space:nowrap" class="ft038">11</p>
<p style="position:absolute;top:129px;left:642px;white-space:nowrap" class="ft013">&#160;Polymerase&#160;chain&#160;</p>
<p style="position:absolute;top:148px;left:108px;white-space:nowrap" class="ft032">reaction and multiplex molecular methods are increasingly used for diagnosis and can identify a&#160;<br/>greater number of cases than microscopic&#160;methods.</p>
<p style="position:absolute;top:167px;left:462px;white-space:nowrap" class="ft038">10,12</p>
<p style="position:absolute;top:168px;left:487px;white-space:nowrap" class="ft013">&#160;Cryptosporidial&#160;enteritis also can be&#160;</p>
<p style="position:absolute;top:188px;left:108px;white-space:nowrap" class="ft013">diagnosed from small&#160;sections of tissue from&#160;intestinal&#160;biopsy.&#160;</p>
<p style="position:absolute;top:225px;left:108px;white-space:nowrap" class="ft032">A single stool specimen is usually adequate to diagnose cryptosporidiosis in individuals with profuse&#160;<br/>diarrheal&#160;illness,&#160;whereas&#160;repeat stool&#160;sampling is recommended for those&#160;with milder disease.&#160;</p>
<p style="position:absolute;top:281px;left:108px;white-space:nowrap" class="ft026"><b>Preventing&#160;Exposure&#160;</b></p>
<p style="position:absolute;top:323px;left:108px;white-space:nowrap" class="ft013">People&#160;with&#160;HIV&#160;should&#160;be educated and counseled about how&#160;</p>
<p style="position:absolute;top:323px;left:545px;white-space:nowrap" class="ft019"><i>Cryptosporidium</i></p>
<p style="position:absolute;top:323px;left:662px;white-space:nowrap" class="ft013">&#160;can be&#160;transmitted</p>
<p style="position:absolute;top:323px;left:793px;white-space:nowrap" class="ft012"><b>&#160;</b></p>
<p style="position:absolute;top:343px;left:108px;white-space:nowrap" class="ft012"><b>(BIII).</b></p>
<p style="position:absolute;top:343px;left:156px;white-space:nowrap" class="ft013">&#160;Modes of transmission include&#160;direct&#160;contact&#160;with&#160;animals&#160;and&#160;people,&#160;including&#160;diapered&#160;</p>
<p style="position:absolute;top:363px;left:108px;white-space:nowrap" class="ft013">children,&#160;infected&#160;with&#160;</p>
<p style="position:absolute;top:363px;left:265px;white-space:nowrap" class="ft019"><i>Cryptosporidium</i></p>
<p style="position:absolute;top:363px;left:382px;white-space:nowrap" class="ft013">;&#160;swallowing&#160;contaminated water during recreational&#160;</p>
<p style="position:absolute;top:383px;left:108px;white-space:nowrap" class="ft013">activities;&#160;drinking&#160;contaminated&#160;water;&#160;and&#160;eating&#160;contaminated&#160;food.&#160;</p>
<p style="position:absolute;top:420px;left:108px;white-space:nowrap" class="ft013">Scrupulous handwashing&#160;can reduce&#160;the&#160;risk of diarrhea, including diarrhea caused by&#160;</p>
<p style="position:absolute;top:440px;left:108px;white-space:nowrap" class="ft019"><i>Cryptosporidium,</i></p>
<p style="position:absolute;top:440px;left:230px;white-space:nowrap" class="ft013">&#160;in individuals with&#160;HIV</p>
<p style="position:absolute;top:440px;left:399px;white-space:nowrap" class="ft019"><i>.</i></p>
<p style="position:absolute;top:438px;left:403px;white-space:nowrap" class="ft038">13</p>
<p style="position:absolute;top:440px;left:414px;white-space:nowrap" class="ft019"><i>&#160;</i></p>
<p style="position:absolute;top:440px;left:419px;white-space:nowrap" class="ft013">People with HIV should be advised to wash&#160;their hands&#160;</p>
<p style="position:absolute;top:460px;left:108px;white-space:nowrap" class="ft032">after potential contact&#160;with human feces (including&#160;after diapering small children). Handwashing also&#160;<br/>should be recommended in association&#160;with the following activities: after handling&#160;pets&#160;or&#160;other&#160;<br/>animals,&#160;after&#160;gardening&#160;or&#160;any&#160;other&#160;contact&#160;with&#160;soil,&#160;before&#160;preparing&#160;food&#160;or&#160;eating,&#160;and&#160;before&#160;and&#160;<br/>after&#160;sex</p>
<p style="position:absolute;top:519px;left:165px;white-space:nowrap" class="ft012"><b>&#160;(BIII).&#160;</b></p>
<p style="position:absolute;top:519px;left:219px;white-space:nowrap" class="ft013">Individuals with HIV&#160;should avoid&#160;unprotected sex, especially practices that&#160;could&#160;</p>
<p style="position:absolute;top:539px;left:108px;white-space:nowrap" class="ft032">lead to direct&#160;(e.g., oral-anal&#160;sex) or indirect&#160;(e.g., penile-anal sex) contact&#160;with feces. They should&#160;be&#160;<br/>advised&#160;to&#160;use&#160;prophylactic&#160;barrier&#160;methods—such&#160;as&#160;condoms&#160;and&#160;dental&#160;dams—during&#160;sex&#160;to&#160;reduce&#160;<br/>such&#160;exposures</p>
<p style="position:absolute;top:579px;left:210px;white-space:nowrap" class="ft012"><b>&#160;(BIII).&#160;</b></p>
<p style="position:absolute;top:616px;left:108px;white-space:nowrap" class="ft013">People&#160;with&#160;HIV—particularly those&#160;with CD4 counts &lt;200 cells/mm</p>
<p style="position:absolute;top:614px;left:589px;white-space:nowrap" class="ft038">3</p>
<p style="position:absolute;top:616px;left:595px;white-space:nowrap" class="ft013">—should avoid direct&#160;contact&#160;</p>
<p style="position:absolute;top:636px;left:108px;white-space:nowrap" class="ft013">with diarrhea&#160;or stool from pets&#160;</p>
<p style="position:absolute;top:636px;left:330px;white-space:nowrap" class="ft012"><b>(BIII).&#160;</b></p>
<p style="position:absolute;top:636px;left:382px;white-space:nowrap" class="ft013">They should wear gloves when&#160;handling feces or&#160;cleaning&#160;</p>
<p style="position:absolute;top:655px;left:108px;white-space:nowrap" class="ft013">areas that&#160;might have been contaminated by feces from pets</p>
<p style="position:absolute;top:655px;left:520px;white-space:nowrap" class="ft012"><b>&#160;(BIII).&#160;</b></p>
<p style="position:absolute;top:655px;left:576px;white-space:nowrap" class="ft013">People&#160;with HIV&#160;should also&#160;</p>
<p style="position:absolute;top:675px;left:108px;white-space:nowrap" class="ft013">limit or avoid direct&#160;exposure to calves and lambs</p>
<p style="position:absolute;top:675px;left:452px;white-space:nowrap" class="ft012"><b>&#160;(BII).</b></p>
<p style="position:absolute;top:675px;left:497px;white-space:nowrap" class="ft013">&#160;Paying&#160;attention to hygiene&#160;and avoiding&#160;</p>
<p style="position:absolute;top:695px;left:108px;white-space:nowrap" class="ft032">direct&#160;contact&#160;with stool&#160;are important&#160;when visiting farms or&#160;petting zoos or&#160;other premises where&#160;<br/>animals are housed or exhibited.&#160;</p>
<p style="position:absolute;top:752px;left:108px;white-space:nowrap" class="ft013">People&#160;with&#160;HIV&#160;should&#160;not&#160;drink&#160;water&#160;directly&#160;from&#160;lakes or&#160;rivers</p>
<p style="position:absolute;top:752px;left:566px;white-space:nowrap" class="ft012"><b>&#160;(AIII).</b></p>
<p style="position:absolute;top:752px;left:618px;white-space:nowrap" class="ft013">&#160;Waterborne infection also&#160;</p>
<p style="position:absolute;top:772px;left:108px;white-space:nowrap" class="ft032">can result&#160;from swallowing water during recreational activities. Individuals&#160;with&#160;HIV&#160;should&#160;be&#160;<br/>cautioned&#160;that&#160;lakes,&#160;rivers,&#160;saltwater&#160;beaches,&#160;some&#160;swimming&#160;pools,&#160;recreational&#160;water&#160;parks,&#160;and&#160;<br/>ornamental&#160;water&#160;fountains&#160;may&#160;be&#160;contaminated&#160;with human or animal waste&#160;that contains&#160;</p>
<p style="position:absolute;top:831px;left:108px;white-space:nowrap" class="ft019"><i>Cryptosporidium</i></p>
<p style="position:absolute;top:831px;left:226px;white-space:nowrap" class="ft013">.&#160;</p>
<p style="position:absolute;top:831px;left:234px;white-space:nowrap" class="ft019"><i>Cryptosporidium&#160;</i></p>
<p style="position:absolute;top:831px;left:357px;white-space:nowrap" class="ft013">oocysts are extremely chlorine&#160;resistant and thus may&#160;persist&#160;</p>
<p style="position:absolute;top:851px;left:108px;white-space:nowrap" class="ft013">even in chlorinated recreational water.</p>
<p style="position:absolute;top:850px;left:373px;white-space:nowrap" class="ft038">14,15</p>
<p style="position:absolute;top:851px;left:398px;white-space:nowrap" class="ft013">&#160;They should avoid swimming in water that&#160;is likely&#160;</p>
<p style="position:absolute;top:871px;left:108px;white-space:nowrap" class="ft013">contaminated and should avoid swallowing water&#160;while&#160;swimming&#160;or&#160;playing&#160;in&#160;recreational&#160;water</p>
<p style="position:absolute;top:871px;left:783px;white-space:nowrap" class="ft012"><b>&#160;</b></p>
<p style="position:absolute;top:891px;left:108px;white-space:nowrap" class="ft012"><b>(BIII).&#160;</b></p>
<p style="position:absolute;top:928px;left:108px;white-space:nowrap" class="ft032">Outbreaks&#160;of&#160;cryptosporidiosis have&#160;been linked to drinking water from&#160;municipal&#160;water&#160;supplies.&#160;<br/>During&#160;outbreaks&#160;or&#160;in&#160;other&#160;situations&#160;in&#160;which&#160;a&#160;community&#160;boil&#160;water&#160;advisory&#160;is&#160;issued,&#160;boiling&#160;<br/>water for at least 1 minute&#160;will&#160;eliminate the risk for&#160;cryptosporidiosis</p>
<p style="position:absolute;top:968px;left:591px;white-space:nowrap" class="ft012"><b>&#160;(AIII).&#160;</b></p>
<p style="position:absolute;top:968px;left:648px;white-space:nowrap" class="ft013">Using&#160;submicron&#160;</p>
<p style="position:absolute;top:987px;left:108px;white-space:nowrap" class="ft032">personal-use&#160;water filters&#160;(home&#160;or office types) or&#160;bottled water also may reduce the risk&#160;of&#160;<br/>infection from&#160;water from a&#160;municipal source or&#160;a well&#160;</p>
<p style="position:absolute;top:1007px;left:491px;white-space:nowrap" class="ft012"><b>(BII).</b></p>
<p style="position:absolute;top:1007px;left:532px;white-space:nowrap" class="ft013">&#160;</p>
</div>
<!-- Page 150 -->
<a name="150"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page150-div" style="position:relative;width:917px;height:1187px;">
<p style="position:absolute;top:1114px;left:108px;white-space:nowrap" class="ft024"><i>Guidelines for the Prevention and Treatment&#160;of&#160;Opportunistic&#160;Infections in Adults&#160;and Adolescents&#160;With HIV&#160;</i></p>
<p style="position:absolute;top:1114px;left:795px;white-space:nowrap" class="ft024"><i>I-3&#160;</i></p>
<p style="position:absolute;top:109px;left:108px;white-space:nowrap" class="ft032">For people&#160;with low CD4&#160;counts, the&#160;magnitude of the risk of acquiring cryptosporidiosis from&#160;<br/>drinking water in a non-outbreak setting is uncertain but&#160;is likely small. Available data are&#160;<br/>inadequate to recommend that all&#160;people with HIV&#160;boil&#160;water or avoid drinking tap water in non-<br/>outbreak settings. However, people with HIV may&#160;consider&#160;drinking&#160;only&#160;filtered&#160;water&#160;</p>
<p style="position:absolute;top:168px;left:707px;white-space:nowrap" class="ft012"><b>(CIII),</b></p>
<p style="position:absolute;top:168px;left:754px;white-space:nowrap" class="ft013">&#160;despite&#160;</p>
<p style="position:absolute;top:188px;left:108px;white-space:nowrap" class="ft032">the&#160;complexities involved in selecting appropriate&#160;water&#160;filters,&#160;the&#160;lack&#160;of&#160;enforceable&#160;standards&#160;for&#160;<br/>removal&#160;of&#160;</p>
<p style="position:absolute;top:208px;left:187px;white-space:nowrap" class="ft019"><i>Cryptosporidium</i></p>
<p style="position:absolute;top:208px;left:305px;white-space:nowrap" class="ft013">&#160;oocysts, the costs of the products, and the&#160;difficulty&#160;of&#160;using&#160;the&#160;products&#160;</p>
<p style="position:absolute;top:228px;left:108px;white-space:nowrap" class="ft013">consistently.&#160;Note that&#160;ice&#160;made&#160;from&#160;contaminated&#160;tap&#160;water&#160;also&#160;can&#160;be&#160;a&#160;source&#160;of&#160;infection.&#160;</p>
<p style="position:absolute;top:265px;left:108px;white-space:nowrap" class="ft032">People&#160;with&#160;HIV&#160;with low CD4 counts should&#160;be cautious about eating raw oysters because&#160;<br/>cryptosporidial&#160;oocysts&#160;can&#160;survive&#160;in&#160;oysters&#160;for&#160;&gt;2&#160;months and&#160;have been found in oysters harvested&#160;<br/>from certain commercial&#160;oyster beds</p>
<p style="position:absolute;top:304px;left:361px;white-space:nowrap" class="ft012"><b>&#160;(CIII).</b></p>
<p style="position:absolute;top:304px;left:413px;white-space:nowrap" class="ft013">&#160;In&#160;the&#160;hospital&#160;setting,&#160;standard&#160;precautions&#160;for&#160;use&#160;of&#160;</p>
<p style="position:absolute;top:324px;left:108px;white-space:nowrap" class="ft032">gloves&#160;and&#160;for&#160;handwashing&#160;after&#160;removal&#160;of&#160;gloves&#160;should&#160;be&#160;sufficient&#160;to&#160;prevent transmission of&#160;<br/>cryptosporidiosis from an&#160;infected patient&#160;to&#160;a&#160;susceptible&#160;individual</p>
<p style="position:absolute;top:344px;left:570px;white-space:nowrap" class="ft012"><b>&#160;</b></p>
<p style="position:absolute;top:344px;left:574px;white-space:nowrap" class="ft013">with&#160;HIV</p>
<p style="position:absolute;top:344px;left:638px;white-space:nowrap" class="ft012"><b>&#160;(BIII).&#160;</b></p>
<p style="position:absolute;top:344px;left:691px;white-space:nowrap" class="ft013">Because&#160;of&#160;the&#160;</p>
<p style="position:absolute;top:364px;left:108px;white-space:nowrap" class="ft032">potential&#160;for&#160;fomite&#160;transmission,&#160;some&#160;specialists recommend that people&#160;with&#160;HIV, especially&#160;<br/>individuals who&#160;are&#160;severely&#160;immunocompromised,&#160;not&#160;share&#160;a&#160;room&#160;with&#160;a&#160;patient&#160;with&#160;<br/>cryptosporidiosis</p>
<p style="position:absolute;top:404px;left:224px;white-space:nowrap" class="ft012"><b>&#160;(CIII).</b></p>
<p style="position:absolute;top:404px;left:276px;white-space:nowrap" class="ft013">&#160;</p>
<p style="position:absolute;top:441px;left:108px;white-space:nowrap" class="ft032">People&#160;with&#160;HIV&#160;who travel&#160;to low- and middle-income countries should&#160;be&#160;warned to avoid drinking&#160;<br/>tap water or&#160;using tap water to brush their teeth</p>
<p style="position:absolute;top:461px;left:434px;white-space:nowrap" class="ft012"><b>&#160;(BIII).&#160;</b></p>
<p style="position:absolute;top:461px;left:490px;white-space:nowrap" class="ft013">They should also avoid using ice that&#160;is not&#160;</p>
<p style="position:absolute;top:480px;left:108px;white-space:nowrap" class="ft013">made from&#160;bottled water and consuming</p>
<p style="position:absolute;top:480px;left:387px;white-space:nowrap" class="ft012"><b>&#160;</b></p>
<p style="position:absolute;top:480px;left:391px;white-space:nowrap" class="ft013">raw fruits&#160;or vegetables that may have&#160;been washed in tap&#160;</p>
<p style="position:absolute;top:500px;left:108px;white-space:nowrap" class="ft013">water&#160;</p>
<p style="position:absolute;top:500px;left:151px;white-space:nowrap" class="ft012"><b>(BIII).&#160;</b></p>
<p style="position:absolute;top:537px;left:108px;white-space:nowrap" class="ft013">People&#160;with&#160;HIV&#160;also should avoid other sources&#160;of&#160;</p>
<p style="position:absolute;top:537px;left:468px;white-space:nowrap" class="ft019"><i>Cryptosporidium</i></p>
<p style="position:absolute;top:537px;left:586px;white-space:nowrap" class="ft013">&#160;oocysts&#160;as much as&#160;possible</p>
<p style="position:absolute;top:537px;left:783px;white-space:nowrap" class="ft012"><b>&#160;</b></p>
<p style="position:absolute;top:557px;left:108px;white-space:nowrap" class="ft012"><b>(BIII).</b></p>
<p style="position:absolute;top:557px;left:156px;white-space:nowrap" class="ft013">&#160;This includes avoiding directly working&#160;with people&#160;with diarrhea;&#160;with farm&#160;animals, such&#160;</p>
<p style="position:absolute;top:577px;left:108px;white-space:nowrap" class="ft032">as cattle and sheep; and with domestic&#160;pets that&#160;are very young&#160;or have diarrhea. If exposure is&#160;<br/>unavoidable, gloves should be&#160;worn and good hand&#160;hygiene observed.</p>
<p style="position:absolute;top:597px;left:592px;white-space:nowrap" class="ft012"><b>&#160;</b></p>
<p style="position:absolute;top:633px;left:108px;white-space:nowrap" class="ft026"><b>Preventing&#160;Disease&#160;</b></p>
<p style="position:absolute;top:685px;left:283px;white-space:nowrap" class="ft02"><b>Recommendations for Preventing&#160;Cryptosporidiosis&#160;</b></p>
<p style="position:absolute;top:728px;left:115px;white-space:nowrap" class="ft024"><i>Preventing Chronic&#160;Cryptosporidiosis&#160;</i></p>
<p style="position:absolute;top:754px;left:117px;white-space:nowrap" class="ft030">•</p>
<p style="position:absolute;top:756px;left:124px;white-space:nowrap" class="ft057">&#160;</p>
<p style="position:absolute;top:755px;left:133px;white-space:nowrap" class="ft041">Because&#160;chronic&#160;cryptosporidiosis&#160;occurs&#160;primarily&#160;in people&#160;with&#160;advanced immunodeficiency, initiation of ART&#160;before the&#160;</p>
<p style="position:absolute;top:773px;left:133px;white-space:nowrap" class="ft041">patient&#160;becomes&#160;severely&#160;immunosuppressed&#160;should prevent the&#160;disease&#160;</p>
<p style="position:absolute;top:773px;left:537px;white-space:nowrap" class="ft042"><b>(AII).</b></p>
<p style="position:absolute;top:773px;left:564px;white-space:nowrap" class="ft041">&#160;</p>
<p style="position:absolute;top:803px;left:108px;white-space:nowrap" class="ft042"><b>Key:</b></p>
<p style="position:absolute;top:803px;left:135px;white-space:nowrap" class="ft041">&#160;ART = antiretroviral&#160;therapy&#160;&#160;</p>
<p style="position:absolute;top:838px;left:108px;white-space:nowrap" class="ft032">Because chronic&#160;cryptosporidiosis occurs primarily in people with HIV with advanced&#160;<br/>immunodeficiency, initiation of ART before&#160;they become severely immunosuppressed&#160;should&#160;<br/>prevent&#160;the disease</p>
<p style="position:absolute;top:878px;left:239px;white-space:nowrap" class="ft012"><b>&#160;(AII).</b></p>
<p style="position:absolute;top:878px;left:285px;white-space:nowrap" class="ft013">&#160;Rifabutin and possibly clarithromycin taken for&#160;</p>
<p style="position:absolute;top:878px;left:622px;white-space:nowrap" class="ft019"><i>Mycobacterium avium&#160;</i></p>
<p style="position:absolute;top:898px;left:108px;white-space:nowrap" class="ft013">complex prophylaxis have been found&#160;to protect against cryptosporidiosis.</p>
<p style="position:absolute;top:896px;left:622px;white-space:nowrap" class="ft038">16,17</p>
<p style="position:absolute;top:898px;left:647px;white-space:nowrap" class="ft013">&#160;Rifaximin,&#160;which is&#160;</p>
<p style="position:absolute;top:917px;left:108px;white-space:nowrap" class="ft032">used for&#160;prevention of traveler’s diarrhea, also has&#160;been used to&#160;treat&#160;cryptosporidial diarrhea.&#160;<br/>However, it&#160;is unclear whether rifaximin can protect&#160;against cryptosporidiosis.</p>
<p style="position:absolute;top:936px;left:650px;white-space:nowrap" class="ft038">18</p>
<p style="position:absolute;top:937px;left:661px;white-space:nowrap" class="ft013">&#160;Data are&#160;</p>
<p style="position:absolute;top:957px;left:108px;white-space:nowrap" class="ft032">insufficient, however, to&#160;warrant a&#160;recommendation to use rifaximin, rifabutin, or clarithromycin as&#160;<br/>chemoprophylaxis for cryptosporidiosis.&#160;</p>
</div>
<!-- Page 151 -->
<a name="151"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page151-div" style="position:relative;width:917px;height:1187px;">
<p style="position:absolute;top:1114px;left:108px;white-space:nowrap" class="ft024"><i>Guidelines for the Prevention and Treatment&#160;of&#160;Opportunistic&#160;Infections in Adults&#160;and Adolescents&#160;With HIV&#160;</i></p>
<p style="position:absolute;top:1114px;left:795px;white-space:nowrap" class="ft024"><i>I-4&#160;</i></p>
<p style="position:absolute;top:108px;left:108px;white-space:nowrap" class="ft026"><b>Treating Disease&#160;</b></p>
<p style="position:absolute;top:160px;left:292px;white-space:nowrap" class="ft02"><b>Recommendations for Treating Cryptosporidiosis&#160;</b></p>
<p style="position:absolute;top:194px;left:115px;white-space:nowrap" class="ft024"><i>Managing&#160;Cryptosporidiosis&#160;</i></p>
<p style="position:absolute;top:220px;left:115px;white-space:nowrap" class="ft030">•</p>
<p style="position:absolute;top:222px;left:122px;white-space:nowrap" class="ft057">&#160;</p>
<p style="position:absolute;top:221px;left:131px;white-space:nowrap" class="ft041">Preferred&#160;Management Strategies&#160;</p>
<p style="position:absolute;top:249px;left:131px;white-space:nowrap" class="ft062">o</p>
<p style="position:absolute;top:248px;left:140px;white-space:nowrap" class="ft057">&#160;</p>
<p style="position:absolute;top:247px;left:147px;white-space:nowrap" class="ft041">Aggressive oral&#160;and/or IV&#160;rehydration and replacement of electrolyte&#160;loss&#160;</p>
<p style="position:absolute;top:247px;left:547px;white-space:nowrap" class="ft042"><b>(AIII),</b></p>
<p style="position:absolute;top:247px;left:578px;white-space:nowrap" class="ft041">&#160;</p>
<p style="position:absolute;top:247px;left:581px;white-space:nowrap" class="ft024"><i>and</i></p>
<p style="position:absolute;top:247px;left:602px;white-space:nowrap" class="ft041">&#160;</p>
<p style="position:absolute;top:275px;left:131px;white-space:nowrap" class="ft062">o</p>
<p style="position:absolute;top:274px;left:140px;white-space:nowrap" class="ft057">&#160;</p>
<p style="position:absolute;top:274px;left:147px;white-space:nowrap" class="ft041">Symptomatic treatment of&#160;diarrhea&#160;with&#160;antimotility&#160;agents&#160;</p>
<p style="position:absolute;top:274px;left:466px;white-space:nowrap" class="ft042"><b>(AIII);</b></p>
<p style="position:absolute;top:274px;left:498px;white-space:nowrap" class="ft041">&#160;tincture of&#160;opium&#160;may be more effective than&#160;</p>
<p style="position:absolute;top:291px;left:147px;white-space:nowrap" class="ft041">loperamide&#160;</p>
<p style="position:absolute;top:291px;left:212px;white-space:nowrap" class="ft042"><b>(CIII).</b></p>
<p style="position:absolute;top:291px;left:242px;white-space:nowrap" class="ft041">&#160;</p>
<p style="position:absolute;top:319px;left:131px;white-space:nowrap" class="ft062">o</p>
<p style="position:absolute;top:318px;left:140px;white-space:nowrap" class="ft057">&#160;</p>
<p style="position:absolute;top:317px;left:147px;white-space:nowrap" class="ft041">People with HIV&#160;not&#160;taking ART&#160;should&#160;initiate&#160;ART to achieve immune&#160;restoration to&#160;CD4 count&#160;&gt;100&#160;cells/mm</p>
<p style="position:absolute;top:318px;left:753px;white-space:nowrap" class="ft058">3</p>
<p style="position:absolute;top:317px;left:757px;white-space:nowrap" class="ft041">&#160;</p>
<p style="position:absolute;top:317px;left:761px;white-space:nowrap" class="ft042"><b>(AII).</b></p>
<p style="position:absolute;top:317px;left:788px;white-space:nowrap" class="ft024"><i>&#160;</i></p>
<p style="position:absolute;top:317px;left:791px;white-space:nowrap" class="ft041">&#160;</p>
<p style="position:absolute;top:349px;left:115px;white-space:nowrap" class="ft030">•</p>
<p style="position:absolute;top:351px;left:122px;white-space:nowrap" class="ft057">&#160;</p>
<p style="position:absolute;top:350px;left:131px;white-space:nowrap" class="ft041">General Considerations&#160;</p>
<p style="position:absolute;top:378px;left:131px;white-space:nowrap" class="ft062">o</p>
<p style="position:absolute;top:377px;left:140px;white-space:nowrap" class="ft057">&#160;</p>
<p style="position:absolute;top:376px;left:147px;white-space:nowrap" class="ft041">Nitazoxanide 500 mg&#160;to 1,000&#160;mg&#160;PO twice daily&#160;with food for at least 14 days&#160;</p>
<p style="position:absolute;top:376px;left:576px;white-space:nowrap" class="ft042"><b>(CIII)</b></p>
<p style="position:absolute;top:376px;left:603px;white-space:nowrap" class="ft041">&#160;plus&#160;optimized ART, symptomatic&#160;</p>
<p style="position:absolute;top:394px;left:147px;white-space:nowrap" class="ft041">treatment, and rehydration and electrolyte&#160;replacement,&#160;</p>
<p style="position:absolute;top:394px;left:453px;white-space:nowrap" class="ft024"><i>or</i></p>
<p style="position:absolute;top:394px;left:464px;white-space:nowrap" class="ft041">&#160;&#160;</p>
<p style="position:absolute;top:422px;left:131px;white-space:nowrap" class="ft062">o</p>
<p style="position:absolute;top:420px;left:140px;white-space:nowrap" class="ft057">&#160;</p>
<p style="position:absolute;top:420px;left:147px;white-space:nowrap" class="ft041">Paromomycin 500&#160;mg PO&#160;four&#160;times a day&#160;for&#160;at&#160;least 14 days&#160;to&#160;21&#160;days&#160;</p>
<p style="position:absolute;top:420px;left:550px;white-space:nowrap" class="ft042"><b>(CIII)</b></p>
<p style="position:absolute;top:420px;left:577px;white-space:nowrap" class="ft041">&#160;plus optimized ART, symptomatic&#160;</p>
<p style="position:absolute;top:437px;left:147px;white-space:nowrap" class="ft041">treatment, and rehydration and electrolyte&#160;replacement&#160;</p>
<p style="position:absolute;top:469px;left:115px;white-space:nowrap" class="ft024"><i>Pregnancy</i></p>
<p style="position:absolute;top:469px;left:174px;white-space:nowrap" class="ft041">&#160;</p>
<p style="position:absolute;top:469px;left:177px;white-space:nowrap" class="ft024"><i>Considerations</i></p>
<p style="position:absolute;top:469px;left:259px;white-space:nowrap" class="ft041">&#160;</p>
<p style="position:absolute;top:496px;left:115px;white-space:nowrap" class="ft030">•</p>
<p style="position:absolute;top:497px;left:122px;white-space:nowrap" class="ft057">&#160;</p>
<p style="position:absolute;top:497px;left:142px;white-space:nowrap" class="ft041">During pregnancy, rehydration and initiation of&#160;ART are the&#160;mainstays&#160;of&#160;initial&#160;treatment of cryptosporidiosis&#160;</p>
<p style="position:absolute;top:497px;left:734px;white-space:nowrap" class="ft042"><b>(AII).</b></p>
<p style="position:absolute;top:497px;left:762px;white-space:nowrap" class="ft041">&#160;</p>
<p style="position:absolute;top:523px;left:115px;white-space:nowrap" class="ft030">•</p>
<p style="position:absolute;top:524px;left:122px;white-space:nowrap" class="ft057">&#160;</p>
<p style="position:absolute;top:524px;left:142px;white-space:nowrap" class="ft041">Opiate&#160;exposure&#160;in late pregnancy&#160;has&#160;been associated&#160;with&#160;neonatal&#160;respiratory&#160;depression, and&#160;chronic&#160;exposure&#160;may&#160;</p>
<p style="position:absolute;top:541px;left:142px;white-space:nowrap" class="ft041">result&#160;in neonatal&#160;withdrawal; therefore, tincture of opium</p>
<p style="position:absolute;top:541px;left:451px;white-space:nowrap" class="ft042"><b>&#160;is not recommended&#160;</b></p>
<p style="position:absolute;top:541px;left:578px;white-space:nowrap" class="ft041">in late&#160;pregnancy&#160;</p>
<p style="position:absolute;top:541px;left:675px;white-space:nowrap" class="ft042"><b>(AIII).</b></p>
<p style="position:absolute;top:541px;left:706px;white-space:nowrap" class="ft041">&#160;</p>
<p style="position:absolute;top:567px;left:115px;white-space:nowrap" class="ft030">•</p>
<p style="position:absolute;top:569px;left:122px;white-space:nowrap" class="ft057">&#160;</p>
<p style="position:absolute;top:568px;left:142px;white-space:nowrap" class="ft041">Loperamide is&#160;the preferred antimotility&#160;agent&#160;in&#160;late&#160;pregnancy&#160;</p>
<p style="position:absolute;top:568px;left:489px;white-space:nowrap" class="ft042"><b>(CIII).&#160;</b></p>
<p style="position:absolute;top:568px;left:523px;white-space:nowrap" class="ft041">Loperamide should be&#160;avoided&#160;in the first trimester&#160;</p>
<p style="position:absolute;top:585px;left:142px;white-space:nowrap" class="ft041">unless&#160;benefits&#160;are felt to&#160;outweigh potential&#160;risks&#160;</p>
<p style="position:absolute;top:585px;left:413px;white-space:nowrap" class="ft042"><b>(CIII).</b></p>
<p style="position:absolute;top:585px;left:444px;white-space:nowrap" class="ft041">&#160;</p>
<p style="position:absolute;top:612px;left:115px;white-space:nowrap" class="ft030">•</p>
<p style="position:absolute;top:613px;left:122px;white-space:nowrap" class="ft057">&#160;</p>
<p style="position:absolute;top:613px;left:142px;white-space:nowrap" class="ft041">Nitazoxanide&#160;</p>
<p style="position:absolute;top:613px;left:216px;white-space:nowrap" class="ft042"><b>(CIII)</b></p>
<p style="position:absolute;top:613px;left:244px;white-space:nowrap" class="ft041">&#160;and paromomycin&#160;</p>
<p style="position:absolute;top:613px;left:348px;white-space:nowrap" class="ft042"><b>(CIII)</b></p>
<p style="position:absolute;top:613px;left:376px;white-space:nowrap" class="ft041">&#160;can&#160;be used in pregnancy&#160;after the first&#160;trimester.&#160;</p>
<p style="position:absolute;top:653px;left:387px;white-space:nowrap" class="ft02"><b>Other&#160;Considerations&#160;</b></p>
<p style="position:absolute;top:687px;left:117px;white-space:nowrap" class="ft030">•</p>
<p style="position:absolute;top:688px;left:124px;white-space:nowrap" class="ft057">&#160;</p>
<p style="position:absolute;top:688px;left:133px;white-space:nowrap" class="ft041">Because diarrhea can cause lactase deficiency, people with cryptosporidiosis&#160;should avoid milk&#160;products&#160;</p>
<p style="position:absolute;top:688px;left:705px;white-space:nowrap" class="ft042"><b>(CIII).</b></p>
<p style="position:absolute;top:688px;left:736px;white-space:nowrap" class="ft041">&#160;</p>
<p style="position:absolute;top:718px;left:108px;white-space:nowrap" class="ft042"><b>Key:</b></p>
<p style="position:absolute;top:718px;left:135px;white-space:nowrap" class="ft041">&#160;ART = antiretroviral therapy; CD4&#160;= CD4&#160;T&#160;lymphocyte cell;&#160;IV&#160;= intravenous; PO&#160;= orally&#160;&#160;</p>
<p style="position:absolute;top:753px;left:108px;white-space:nowrap" class="ft032">In the&#160;setting of severe immune&#160;suppression,&#160;ART&#160;with immune restoration to a&#160;CD4 count&#160;<br/>&gt;100 cells/mm</p>
<p style="position:absolute;top:772px;left:211px;white-space:nowrap" class="ft038">3</p>
<p style="position:absolute;top:773px;left:217px;white-space:nowrap" class="ft013">&#160;usually leads to resolution of clinical&#160;cryptosporidiosis</p>
<p style="position:absolute;top:772px;left:599px;white-space:nowrap" class="ft038">19-22</p>
<p style="position:absolute;top:773px;left:625px;white-space:nowrap" class="ft013">&#160;and is the&#160;mainstay of&#160;</p>
<p style="position:absolute;top:793px;left:108px;white-space:nowrap" class="ft032">treatment. People with HIV not already taking antiretrovirals who develop cryptosporidiosis should&#160;<br/>be started on&#160;ART as part of the initial&#160;management&#160;of cryptosporidiosis&#160;</p>
<p style="position:absolute;top:813px;left:612px;white-space:nowrap" class="ft012"><b>(AII).&#160;</b></p>
<p style="position:absolute;top:813px;left:658px;white-space:nowrap" class="ft013">Management&#160;should&#160;</p>
<p style="position:absolute;top:833px;left:108px;white-space:nowrap" class="ft013">also include symptomatic treatment of diarrhea</p>
<p style="position:absolute;top:833px;left:433px;white-space:nowrap" class="ft012"><b>&#160;</b></p>
<p style="position:absolute;top:833px;left:437px;white-space:nowrap" class="ft013">with antimotility agents</p>
<p style="position:absolute;top:833px;left:601px;white-space:nowrap" class="ft012"><b>&#160;(AIII).</b></p>
<p style="position:absolute;top:833px;left:654px;white-space:nowrap" class="ft013">&#160;Tincture&#160;of opium&#160;</p>
<p style="position:absolute;top:852px;left:108px;white-space:nowrap" class="ft013">may be more effective&#160;than loperamide&#160;</p>
<p style="position:absolute;top:852px;left:383px;white-space:nowrap" class="ft012"><b>(CIII).</b></p>
<p style="position:absolute;top:852px;left:431px;white-space:nowrap" class="ft013">&#160;Octreotide, a synthetic&#160;octapeptide&#160;analog of naturally&#160;</p>
<p style="position:absolute;top:872px;left:108px;white-space:nowrap" class="ft032">occurring somatostatin that is approved to treat&#160;secreting tumor–induced diarrhea, is no&#160;more&#160;<br/>effective than other oral&#160;antidiarrheal&#160;agents and&#160;</p>
<p style="position:absolute;top:892px;left:446px;white-space:nowrap" class="ft012"><b>is&#160;usually&#160;not&#160;recommended&#160;(CII).</b></p>
<p style="position:absolute;top:891px;left:698px;white-space:nowrap" class="ft038">23</p>
<p style="position:absolute;top:892px;left:709px;white-space:nowrap" class="ft013">&#160;Because&#160;</p>
<p style="position:absolute;top:912px;left:108px;white-space:nowrap" class="ft032">diarrhea can cause lactase deficiency, people with&#160;HIV&#160;and cryptosporidiosis should avoid milk&#160;<br/>products</p>
<p style="position:absolute;top:932px;left:167px;white-space:nowrap" class="ft012"><b>&#160;(CIII).</b></p>
<p style="position:absolute;top:932px;left:220px;white-space:nowrap" class="ft013">&#160;</p>
<p style="position:absolute;top:969px;left:108px;white-space:nowrap" class="ft032">Rehydration&#160;and repletion of electrolyte losses by either oral&#160;or intravenous route&#160;are important.&#160;<br/>Stool&#160;volume in patients with HIV and AIDS&#160;with severe diarrhea can exceed 10 L/day;&#160;managing&#160;<br/>the&#160;diarrhea often requires intensive support. Oral&#160;rehydration should be&#160;pursued aggressively with&#160;<br/>oral&#160;rehydration solutions</p>
<p style="position:absolute;top:1028px;left:285px;white-space:nowrap" class="ft012"><b>&#160;(AIII).&#160;</b></p>
<p style="position:absolute;top:1028px;left:342px;white-space:nowrap" class="ft013">Most patients can be treated with enteral&#160;nutrition; total&#160;parenteral&#160;</p>
<p style="position:absolute;top:1048px;left:108px;white-space:nowrap" class="ft013">nutrition is rarely indicated</p>
<p style="position:absolute;top:1048px;left:295px;white-space:nowrap" class="ft012"><b>&#160;(CIII).&#160;</b></p>
</div>
<!-- Page 152 -->
<a name="152"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page152-div" style="position:relative;width:917px;height:1187px;">
<p style="position:absolute;top:1114px;left:108px;white-space:nowrap" class="ft024"><i>Guidelines for the Prevention and Treatment&#160;of&#160;Opportunistic&#160;Infections in Adults&#160;and Adolescents&#160;With HIV&#160;</i></p>
<p style="position:absolute;top:1114px;left:795px;white-space:nowrap" class="ft024"><i>I-5&#160;</i></p>
<p style="position:absolute;top:109px;left:108px;white-space:nowrap" class="ft032">Patients with biliary tract&#160;involvement&#160;may require&#160;endoscopic retrograde cholangiopancreatography&#160;<br/>for diagnosis. They may also benefit&#160;from sphincterotomy, stenting, or both.</p>
<p style="position:absolute;top:127px;left:635px;white-space:nowrap" class="ft038">7,24</p>
<p style="position:absolute;top:129px;left:655px;white-space:nowrap" class="ft012"><b>&#160;</b></p>
<p style="position:absolute;top:166px;left:108px;white-space:nowrap" class="ft032">Several&#160;agents—including nitazoxanide, paromomycin, clofazimine, and spiramycin—have&#160;been&#160;<br/>investigated in small, randomized controlled clinical trials of adults with HIV.</p>
<p style="position:absolute;top:184px;left:648px;white-space:nowrap" class="ft038">25</p>
<p style="position:absolute;top:185px;left:659px;white-space:nowrap" class="ft013">&#160;No pharmacologic&#160;or&#160;</p>
<p style="position:absolute;top:205px;left:108px;white-space:nowrap" class="ft013">immunologic&#160;therapy directed specifically against&#160;</p>
<p style="position:absolute;top:205px;left:457px;white-space:nowrap" class="ft019"><i>Cryptosporidium</i></p>
<p style="position:absolute;top:205px;left:575px;white-space:nowrap" class="ft013">&#160;has been&#160;shown to be&#160;</p>
<p style="position:absolute;top:225px;left:108px;white-space:nowrap" class="ft013">consistently effective when used&#160;without&#160;ART.</p>
<p style="position:absolute;top:224px;left:433px;white-space:nowrap" class="ft038">26</p>
<p style="position:absolute;top:225px;left:444px;white-space:nowrap" class="ft013">&#160;</p>
<p style="position:absolute;top:262px;left:108px;white-space:nowrap" class="ft013">Nitazoxanide is an orally&#160;administered nitrothiazole&#160;benzamide with&#160;</p>
<p style="position:absolute;top:262px;left:584px;white-space:nowrap" class="ft019"><i>in vivo</i></p>
<p style="position:absolute;top:262px;left:630px;white-space:nowrap" class="ft013">&#160;activity against a&#160;broad&#160;</p>
<p style="position:absolute;top:282px;left:108px;white-space:nowrap" class="ft032">range of helminths, bacteria, and protozoa. Nitazoxanide is approved by the&#160;U.S.&#160;Food and Drug&#160;<br/>Administration for treatment&#160;of cryptosporidiosis</p>
<p style="position:absolute;top:302px;left:448px;white-space:nowrap" class="ft019"><i>&#160;</i></p>
<p style="position:absolute;top:302px;left:452px;white-space:nowrap" class="ft013">in children over 1 year of age and adults.&#160;</p>
<p style="position:absolute;top:322px;left:108px;white-space:nowrap" class="ft032">Nitazoxanide 500 mg administered twice daily for 3&#160;days to adults without&#160;HIV but with&#160;<br/>cryptosporidiosis resulted in higher rates of diarrhea&#160;resolution and oocyst-free&#160;stools than&#160;<br/>placebo.</p>
<p style="position:absolute;top:360px;left:166px;white-space:nowrap" class="ft038">27,28</p>
<p style="position:absolute;top:361px;left:191px;white-space:nowrap" class="ft013">&#160;In one study,&#160;adults with&#160;HIV&#160;with cryptosporidiosis and CD4 counts &gt;50 cells/mm</p>
<p style="position:absolute;top:360px;left:773px;white-space:nowrap" class="ft038">3</p>
<p style="position:absolute;top:361px;left:779px;white-space:nowrap" class="ft013">&#160;</p>
<p style="position:absolute;top:381px;left:108px;white-space:nowrap" class="ft032">were treated with nitazoxanide&#160;500 mg to 1,000 mg twice daily for 14 days;&#160;the&#160;nitazoxanide&#160;<br/>treatment group had substantially higher rates of parasitological&#160;cure&#160;and resolution of diarrhea&#160;than&#160;<br/>the&#160;placebo group.</p>
<p style="position:absolute;top:420px;left:236px;white-space:nowrap" class="ft038">29</p>
<p style="position:absolute;top:421px;left:247px;white-space:nowrap" class="ft013">&#160;Efficacy of nitazoxanide for the treatment of cryptosporidial&#160;diarrhea in children&#160;</p>
<p style="position:absolute;top:441px;left:108px;white-space:nowrap" class="ft013">with HIV, however,&#160;was not confirmed in two randomized trials in children.</p>
<p style="position:absolute;top:439px;left:634px;white-space:nowrap" class="ft038">30,31</p>
<p style="position:absolute;top:441px;left:660px;white-space:nowrap" class="ft013">&#160;Data from&#160;a&#160;</p>
<p style="position:absolute;top:461px;left:108px;white-space:nowrap" class="ft032">compassionate&#160;use program before the&#160;advent&#160;of potent&#160;ART, which included primarily white male&#160;<br/>adults with&#160;median CD4&#160;counts &lt;50 cells/mm</p>
<p style="position:absolute;top:479px;left:424px;white-space:nowrap" class="ft038">3</p>
<p style="position:absolute;top:480px;left:430px;white-space:nowrap" class="ft013">, reported that&#160;a majority of patients experienced some&#160;</p>
<p style="position:absolute;top:500px;left:108px;white-space:nowrap" class="ft032">degree&#160;of clinical&#160;response (reduction in frequency&#160;of total&#160;stool and of liquid&#160;stools), usually within&#160;<br/>the&#160;first week of treatment.</p>
<p style="position:absolute;top:519px;left:294px;white-space:nowrap" class="ft038">32</p>
<p style="position:absolute;top:520px;left:310px;white-space:nowrap" class="ft013">Adverse&#160;events associated with nitazoxanide&#160;are typically mild, and no&#160;</p>
<p style="position:absolute;top:540px;left:108px;white-space:nowrap" class="ft032">important&#160;drug–drug interactions have&#160;been reported. Because of the&#160;clinical&#160;significance of&#160;<br/>cryptosporidiosis, many experts will institute&#160;a trial&#160;of nitazoxanide or paromomycin in conjunction&#160;<br/>with ART but never instead of ART</p>
<p style="position:absolute;top:580px;left:357px;white-space:nowrap" class="ft012"><b>&#160;(CIII).&#160;</b></p>
<p style="position:absolute;top:617px;left:108px;white-space:nowrap" class="ft032">Paromomycin is a nonabsorbable aminoglycoside indicated for the treatment of intestinal amebiasis&#160;<br/>but not&#160;specifically approved for cryptosporidiosis.&#160;Paromomycin in high doses is effective for the&#160;<br/>treatment of cryptosporidiosis in animal models. A&#160;meta-analysis of 11&#160;published studies&#160;of&#160;<br/>paromomycin in humans&#160;reported a response&#160;rate of 67%;&#160;however, there were few cures,&#160;relapses&#160;<br/>were common, and long-term&#160;success&#160;rates were&#160;only 33%.</p>
<p style="position:absolute;top:695px;left:518px;white-space:nowrap" class="ft038">24</p>
<p style="position:absolute;top:696px;left:529px;white-space:nowrap" class="ft013">&#160;Two randomized trials comparing&#160;</p>
<p style="position:absolute;top:716px;left:108px;white-space:nowrap" class="ft032">paromomycin with placebo demonstrated limited&#160;effectiveness&#160;of the&#160;drug among patients with&#160;<br/>AIDS and cryptosporidiosis.</p>
<p style="position:absolute;top:734px;left:305px;white-space:nowrap" class="ft038">33,34</p>
<p style="position:absolute;top:736px;left:330px;white-space:nowrap" class="ft013">&#160;One&#160;case series suggested a better response&#160;rate&#160;in patients receiving&#160;</p>
<p style="position:absolute;top:756px;left:108px;white-space:nowrap" class="ft013">paromomycin along with&#160;ART.</p>
<p style="position:absolute;top:754px;left:325px;white-space:nowrap" class="ft038">35</p>
<p style="position:absolute;top:756px;left:336px;white-space:nowrap" class="ft013">&#160;Paromomycin may be used instead of nitazoxanide in conjunction&#160;</p>
<p style="position:absolute;top:775px;left:108px;white-space:nowrap" class="ft013">with ART but never instead of ART&#160;</p>
<p style="position:absolute;top:775px;left:361px;white-space:nowrap" class="ft012"><b>(CIII).&#160;</b></p>
<p style="position:absolute;top:813px;left:108px;white-space:nowrap" class="ft029"><i><b>Special Considerations with&#160;Regard to&#160;Starting ART&#160;</b></i></p>
<p style="position:absolute;top:854px;left:108px;white-space:nowrap" class="ft032">As&#160;noted above, patients with cryptosporidiosis should be offered ART as&#160;part&#160;of the&#160;initial&#160;<br/>management&#160;of cryptosporidiosis&#160;</p>
<p style="position:absolute;top:874px;left:342px;white-space:nowrap" class="ft012"><b>(AII).</b></p>
<p style="position:absolute;top:874px;left:384px;white-space:nowrap" class="ft013">&#160;In animal&#160;and&#160;</p>
<p style="position:absolute;top:874px;left:487px;white-space:nowrap" class="ft019"><i>in vitro&#160;</i></p>
<p style="position:absolute;top:874px;left:542px;white-space:nowrap" class="ft013">models, HIV protease inhibitors (PI)&#160;</p>
<p style="position:absolute;top:894px;left:108px;white-space:nowrap" class="ft013">can inhibit&#160;</p>
<p style="position:absolute;top:894px;left:186px;white-space:nowrap" class="ft019"><i>Cryptosporidium</i></p>
<p style="position:absolute;top:894px;left:303px;white-space:nowrap" class="ft013">, but there&#160;is no clinical&#160;evidence&#160;that PI-based&#160;ART is preferable in&#160;</p>
<p style="position:absolute;top:913px;left:108px;white-space:nowrap" class="ft013">patients with documented cryptosporidiosis</p>
<p style="position:absolute;top:913px;left:408px;white-space:nowrap" class="ft012"><b>&#160;(CIII).</b></p>
<p style="position:absolute;top:912px;left:461px;white-space:nowrap" class="ft038">36,37</p>
<p style="position:absolute;top:913px;left:487px;white-space:nowrap" class="ft017"><i><b>&#160;</b></i></p>
<p style="position:absolute;top:951px;left:108px;white-space:nowrap" class="ft029"><i><b>Monitoring of&#160;Response&#160;to&#160;Therapy and&#160;Adverse Events (Including&#160;IRIS)&#160;</b></i></p>
<p style="position:absolute;top:992px;left:108px;white-space:nowrap" class="ft032">Patients should be&#160;monitored closely for signs and&#160;symptoms of&#160;volume depletion, electrolyte&#160;<br/>imbalance, weight&#160;loss, and malnutrition. Immune&#160;reconstitution inflammatory syndrome&#160;(IRIS) has&#160;<br/>been described in association with three cases of extraintestinal&#160;cryptosporidiosis.</p>
<p style="position:absolute;top:1030px;left:672px;white-space:nowrap" class="ft038">38</p>
<p style="position:absolute;top:1031px;left:684px;white-space:nowrap" class="ft071"><i><b>&#160;</b></i></p>
</div>
<!-- Page 153 -->
<a name="153"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}	.ft0131{font-size:16px;font-family:LKZECW+DejaVuSans;color:#000000;}
-->
</style>
<div id="page153-div" style="position:relative;width:917px;height:1187px;">
<p style="position:absolute;top:1114px;left:108px;white-space:nowrap" class="ft024"><i>Guidelines for the Prevention and Treatment&#160;of&#160;Opportunistic&#160;Infections in Adults&#160;and Adolescents&#160;With HIV&#160;</i></p>
<p style="position:absolute;top:1114px;left:795px;white-space:nowrap" class="ft024"><i>I-6&#160;</i></p>
<p style="position:absolute;top:109px;left:108px;white-space:nowrap" class="ft029"><i><b>Managing&#160;Treatment Failure</b></i></p>
<p style="position:absolute;top:112px;left:364px;white-space:nowrap" class="ft0131"><b>&#160;</b></p>
<p style="position:absolute;top:150px;left:108px;white-space:nowrap" class="ft032">Supportive&#160;treatment&#160;and optimization&#160;of ART to achieve full virologic suppression are the main&#160;<br/>approaches to managing treatment failure</p>
<p style="position:absolute;top:170px;left:394px;white-space:nowrap" class="ft012"><b>&#160;(AIII).</b></p>
<p style="position:absolute;top:170px;left:447px;white-space:nowrap" class="ft013">&#160;The clinical&#160;response&#160;rather than results&#160;of stool&#160;</p>
<p style="position:absolute;top:190px;left:108px;white-space:nowrap" class="ft032">tests should&#160;be used to guide&#160;the&#160;response to therapy. Some authorities advocate adding antiparasitic&#160;<br/>drugs&#160;</p>
<p style="position:absolute;top:210px;left:151px;white-space:nowrap" class="ft012"><b>(CIII),</b></p>
<p style="position:absolute;top:210px;left:199px;white-space:nowrap" class="ft013">&#160;such as nitazoxanide or&#160;paromomycin alone or in&#160;combination with azithromycin, as&#160;</p>
<p style="position:absolute;top:229px;left:108px;white-space:nowrap" class="ft013">well&#160;as optimizing ART&#160;in patients with treatment&#160;failure and cryptosporidiosis.</p>
<p style="position:absolute;top:228px;left:660px;white-space:nowrap" class="ft038">39,40</p>
<p style="position:absolute;top:229px;left:686px;white-space:nowrap" class="ft017"><i><b>&#160;</b></i></p>
<p style="position:absolute;top:266px;left:108px;white-space:nowrap" class="ft026"><b>Preventing&#160;Recurrence</b></p>
<p style="position:absolute;top:271px;left:296px;white-space:nowrap" class="ft067"><b>&#160;</b></p>
<p style="position:absolute;top:308px;left:108px;white-space:nowrap" class="ft032">No pharmacologic interventions are&#160;known to be effective in preventing the&#160;recurrence&#160;of&#160;<br/>cryptosporidiosis.&#160;</p>
<p style="position:absolute;top:364px;left:108px;white-space:nowrap" class="ft026"><b>Special&#160;Considerations During&#160;Pregnancy</b></p>
<p style="position:absolute;top:370px;left:451px;white-space:nowrap" class="ft067"><b>&#160;</b></p>
<p style="position:absolute;top:406px;left:108px;white-space:nowrap" class="ft032">During pregnancy, rehydration and initiation of ART are&#160;the&#160;mainstays of initial treatment&#160;of&#160;<br/>cryptosporidiosis&#160;</p>
<p style="position:absolute;top:426px;left:231px;white-space:nowrap" class="ft012"><b>(AII).</b></p>
<p style="position:absolute;top:426px;left:273px;white-space:nowrap" class="ft013">&#160;Pregnancy should not&#160;preclude the use of ART and, in fact, is always an&#160;</p>
<p style="position:absolute;top:446px;left:108px;white-space:nowrap" class="ft032">indication for ART.&#160;Nitazoxanide is not teratogenic in animals, but no data on&#160;use in human&#160;<br/>pregnancy are available. Nitazoxanide&#160;can be&#160;used&#160;in pregnancy&#160;after the first trimester in people&#160;<br/>with severe symptoms&#160;</p>
<p style="position:absolute;top:486px;left:267px;white-space:nowrap" class="ft012"><b>(CIII).</b></p>
<p style="position:absolute;top:486px;left:315px;white-space:nowrap" class="ft013">&#160;Limited information is available about the teratogenic potential of&#160;</p>
<p style="position:absolute;top:505px;left:108px;white-space:nowrap" class="ft032">paromomycin, but&#160;oral&#160;administration is associated&#160;with minimal systemic absorption,&#160;which may&#160;<br/>minimize potential risk. Paromomycin can be&#160;used in pregnancy&#160;after the first trimester in people&#160;<br/>with severe symptoms&#160;</p>
<p style="position:absolute;top:545px;left:267px;white-space:nowrap" class="ft012"><b>(CIII).</b></p>
<p style="position:absolute;top:545px;left:315px;white-space:nowrap" class="ft013">&#160;Loperamide is poorly absorbed and has not been associated&#160;with birth&#160;</p>
<p style="position:absolute;top:565px;left:108px;white-space:nowrap" class="ft032">defects in animal&#160;studies. However, one study identified an increased risk of&#160;congenital&#160;<br/>malformations, and&#160;specifically hypospadias, among 683 women with exposure to loperamide early&#160;<br/>in pregnancy.</p>
<p style="position:absolute;top:603px;left:202px;white-space:nowrap" class="ft038">41</p>
<p style="position:absolute;top:605px;left:213px;white-space:nowrap" class="ft013">&#160;Therefore, loperamide&#160;should be avoided in the first trimester, unless benefits are felt&#160;</p>
<p style="position:absolute;top:624px;left:108px;white-space:nowrap" class="ft013">to outweigh&#160;potential&#160;risks&#160;</p>
<p style="position:absolute;top:624px;left:296px;white-space:nowrap" class="ft012"><b>(CIII).</b></p>
<p style="position:absolute;top:624px;left:344px;white-space:nowrap" class="ft013">&#160;Loperamide&#160;is the&#160;preferred antimotility agent&#160;in late pregnancy&#160;</p>
<p style="position:absolute;top:644px;left:108px;white-space:nowrap" class="ft012"><b>(CIII).</b></p>
<p style="position:absolute;top:644px;left:156px;white-space:nowrap" class="ft013">&#160;Opiate exposure in&#160;late&#160;pregnancy has been&#160;associated with neonatal respiratory depression,&#160;</p>
<p style="position:absolute;top:664px;left:108px;white-space:nowrap" class="ft013">and chronic&#160;exposure may result&#160;in neonatal&#160;withdrawal; therefore, tincture&#160;of opium&#160;</p>
<p style="position:absolute;top:664px;left:698px;white-space:nowrap" class="ft012"><b>is not&#160;</b></p>
<p style="position:absolute;top:684px;left:108px;white-space:nowrap" class="ft012"><b>recommended</b></p>
<p style="position:absolute;top:684px;left:212px;white-space:nowrap" class="ft013">&#160;in late pregnancy&#160;</p>
<p style="position:absolute;top:684px;left:340px;white-space:nowrap" class="ft012"><b>(AIII).</b></p>
<p style="position:absolute;top:682px;left:388px;white-space:nowrap" class="ft038">42</p>
<p style="position:absolute;top:685px;left:400px;white-space:nowrap" class="ft067"><b>&#160;</b></p>
</div>
<!-- Page 154 -->
<a name="154"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page154-div" style="position:relative;width:917px;height:1187px;">
<p style="position:absolute;top:1114px;left:108px;white-space:nowrap" class="ft024"><i>Guidelines for the Prevention and Treatment&#160;of&#160;Opportunistic&#160;Infections in Adults&#160;and Adolescents&#160;With HIV&#160;</i></p>
<p style="position:absolute;top:1114px;left:795px;white-space:nowrap" class="ft024"><i>I-7&#160;</i></p>
<p style="position:absolute;top:108px;left:108px;white-space:nowrap" class="ft026"><b>References&#160;</b></p>
<p style="position:absolute;top:150px;left:102px;white-space:nowrap" class="ft0111">1.&#160;</p>
<p style="position:absolute;top:150px;left:162px;white-space:nowrap" class="ft0111">Flanigan T,&#160;Whalen C,&#160;Turner J, et&#160;al. Cryptosporidium&#160;infection and CD4 counts.&#160;</p>
<p style="position:absolute;top:150px;left:760px;white-space:nowrap" class="ft0112"><i>Ann&#160;</i></p>
<p style="position:absolute;top:171px;left:162px;white-space:nowrap" class="ft0112"><i>Intern&#160;Med</i></p>
<p style="position:absolute;top:171px;left:242px;white-space:nowrap" class="ft0111">.&#160;1992;116(10):840-842.&#160;Available at:&#160;</p>
<p style="position:absolute;top:192px;left:162px;white-space:nowrap" class="ft0113">https://www.ncbi.nlm.nih.gov/pubmed/1348918</p>
<p style="position:absolute;top:192px;left:509px;white-space:nowrap" class="ft0111">.&#160;</p>
<p style="position:absolute;top:229px;left:102px;white-space:nowrap" class="ft0111">2.&#160;</p>
<p style="position:absolute;top:229px;left:162px;white-space:nowrap" class="ft0114">Cama VA, Ross JM, Crawford S, et&#160;al. Differences in clinical manifestations among&#160;<br/>Cryptosporidium&#160;species and subtypes in HIV-infected persons.&#160;</p>
<p style="position:absolute;top:250px;left:627px;white-space:nowrap" class="ft0112"><i>J Infect&#160;Dis</i></p>
<p style="position:absolute;top:250px;left:710px;white-space:nowrap" class="ft0111">.&#160;</p>
<p style="position:absolute;top:271px;left:162px;white-space:nowrap" class="ft0111">2007;196(5):684-691. Available&#160;at:&#160;</p>
<p style="position:absolute;top:271px;left:422px;white-space:nowrap" class="ft0113">https://www.ncbi.nlm.nih.gov/pubmed/17674309</p>
<p style="position:absolute;top:271px;left:778px;white-space:nowrap" class="ft0111">.&#160;</p>
<p style="position:absolute;top:309px;left:102px;white-space:nowrap" class="ft0111">3.&#160;</p>
<p style="position:absolute;top:309px;left:162px;white-space:nowrap" class="ft0114">Wanyiri&#160;JW,&#160;Kanyi&#160;H, Maina&#160;S, et&#160;al.&#160;Cryptosporidiosis&#160;in HIV/AIDS patients in Kenya:&#160;<br/>clinical&#160;features, epidemiology, molecular&#160;characterization and antibody&#160;responses.&#160;</p>
<p style="position:absolute;top:330px;left:766px;white-space:nowrap" class="ft0112"><i>Am J&#160;</i></p>
<p style="position:absolute;top:350px;left:162px;white-space:nowrap" class="ft0112"><i>Trop Med Hyg</i></p>
<p style="position:absolute;top:350px;left:268px;white-space:nowrap" class="ft0111">. 2014;91(2):319-328.&#160;Available at:&#160;</p>
<p style="position:absolute;top:371px;left:162px;white-space:nowrap" class="ft0113">https://www.ncbi.nlm.nih.gov/pubmed/24865675</p>
<p style="position:absolute;top:371px;left:518px;white-space:nowrap" class="ft0111">.&#160;</p>
<p style="position:absolute;top:409px;left:102px;white-space:nowrap" class="ft0111">4.&#160;</p>
<p style="position:absolute;top:409px;left:162px;white-space:nowrap" class="ft0114">Wang RJ, Li&#160;JQ, Chen YC, Zhang LX, Xiao LH.&#160;Widespread&#160;occurrence&#160;of&#160;<br/>Cryptosporidium&#160;infections in patients&#160;with HIV/AIDS: Epidemiology, clinical feature,<br/>diagnosis,&#160;and therapy.&#160;</p>
<p style="position:absolute;top:450px;left:332px;white-space:nowrap" class="ft0112"><i>Acta Trop</i></p>
<p style="position:absolute;top:450px;left:405px;white-space:nowrap" class="ft0111">. 2018;187:257-263. Available&#160;at:&#160;</p>
<p style="position:absolute;top:471px;left:162px;white-space:nowrap" class="ft0113">https://www.ncbi.nlm.nih.gov/pubmed/30118699</p>
<p style="position:absolute;top:471px;left:518px;white-space:nowrap" class="ft0111">.&#160;</p>
<p style="position:absolute;top:509px;left:102px;white-space:nowrap" class="ft0111">5.&#160;</p>
<p style="position:absolute;top:509px;left:162px;white-space:nowrap" class="ft0114">Buchacz&#160;K, Lau B, Jing Y, et&#160;al. Incidence of&#160;AIDS-defining&#160;opportunistic infections&#160;in a&#160;<br/>multicohort&#160;analysis&#160;of&#160;HIV-infected persons in&#160;the&#160;United States and Canada, 2000–<br/>2010.&#160;</p>
<p style="position:absolute;top:550px;left:207px;white-space:nowrap" class="ft0112"><i>J Infect Dis</i></p>
<p style="position:absolute;top:550px;left:290px;white-space:nowrap" class="ft0111">. 2016;214(6):862-872. Available at:&#160;</p>
<p style="position:absolute;top:571px;left:162px;white-space:nowrap" class="ft0113">http://www.ncbi.nlm.nih.gov/pubmed/27559122</p>
<p style="position:absolute;top:571px;left:511px;white-space:nowrap" class="ft0111">.&#160;</p>
<p style="position:absolute;top:609px;left:102px;white-space:nowrap" class="ft0111">6.&#160;</p>
<p style="position:absolute;top:609px;left:162px;white-space:nowrap" class="ft0114">Checkley W, White&#160;AC,&#160;Jr., Jaganath&#160;D, et&#160;al. A review of the&#160;global&#160;burden, novel&#160;<br/>diagnostics,&#160;therapeutics,&#160;and vaccine&#160;targets&#160;for cryptosporidium.&#160;</p>
<p style="position:absolute;top:630px;left:643px;white-space:nowrap" class="ft0112"><i>Lancet&#160;Infect&#160;Dis</i></p>
<p style="position:absolute;top:630px;left:767px;white-space:nowrap" class="ft0111">.&#160;</p>
<p style="position:absolute;top:650px;left:162px;white-space:nowrap" class="ft0111">2015;15(1):85-94. Available at:&#160;</p>
<p style="position:absolute;top:650px;left:395px;white-space:nowrap" class="ft0113">https://www.ncbi.nlm.nih.gov/pubmed/25278220</p>
<p style="position:absolute;top:650px;left:751px;white-space:nowrap" class="ft0111">.&#160;</p>
<p style="position:absolute;top:688px;left:102px;white-space:nowrap" class="ft0111">7.&#160;</p>
<p style="position:absolute;top:688px;left:162px;white-space:nowrap" class="ft0114">Naseer&#160;M,&#160;Dailey FE, Juboori&#160;AA, Samiullah S,&#160;Tahan V. Epidemiology, determinants,&#160;<br/>and management of AIDS cholangiopathy: A review.&#160;</p>
<p style="position:absolute;top:709px;left:551px;white-space:nowrap" class="ft0112"><i>World&#160;J Gastroenterol</i></p>
<p style="position:absolute;top:709px;left:714px;white-space:nowrap" class="ft0111">.&#160;</p>
<p style="position:absolute;top:730px;left:162px;white-space:nowrap" class="ft0111">2018;24(7):767-774. Available&#160;at:&#160;</p>
<p style="position:absolute;top:730px;left:413px;white-space:nowrap" class="ft0113">https://www.ncbi.nlm.nih.gov/pubmed/29467548</p>
<p style="position:absolute;top:730px;left:769px;white-space:nowrap" class="ft0111">.&#160;</p>
<p style="position:absolute;top:768px;left:102px;white-space:nowrap" class="ft0111">8.&#160;</p>
<p style="position:absolute;top:768px;left:162px;white-space:nowrap" class="ft0114">Sponseller JK, Griffiths&#160;JK, Tzipori&#160;S. The evolution of&#160;respiratory Cryptosporidiosis:&#160;<br/>evidence&#160;for transmission by inhalation.&#160;</p>
<p style="position:absolute;top:788px;left:455px;white-space:nowrap" class="ft0112"><i>Clin Microbiol Rev</i></p>
<p style="position:absolute;top:788px;left:594px;white-space:nowrap" class="ft0111">.&#160;2014;27(3):575-586.&#160;</p>
<p style="position:absolute;top:809px;left:162px;white-space:nowrap" class="ft0111">Available at:&#160;</p>
<p style="position:absolute;top:809px;left:259px;white-space:nowrap" class="ft0113">https://www.ncbi.nlm.nih.gov/pubmed/24982322</p>
<p style="position:absolute;top:809px;left:615px;white-space:nowrap" class="ft0111">.&#160;</p>
<p style="position:absolute;top:847px;left:102px;white-space:nowrap" class="ft0111">9.&#160;</p>
<p style="position:absolute;top:847px;left:162px;white-space:nowrap" class="ft0114">Mor&#160;SM, Ascolillo LR, Nakato R, et al. Expectoration of Cryptosporidium Parasites in&#160;<br/>Sputum&#160;of&#160;Human Immunodeficiency Virus-Positive and -Negative&#160;Adults.&#160;</p>
<p style="position:absolute;top:868px;left:711px;white-space:nowrap" class="ft0112"><i>Am&#160;J Trop&#160;</i></p>
<p style="position:absolute;top:888px;left:162px;white-space:nowrap" class="ft0112"><i>Med Hyg</i></p>
<p style="position:absolute;top:888px;left:228px;white-space:nowrap" class="ft0111">. 2018;98(4):1086-1090. Available&#160;at:&#160;</p>
<p style="position:absolute;top:909px;left:162px;white-space:nowrap" class="ft0113">https://www.ncbi.nlm.nih.gov/pubmed/29405104</p>
<p style="position:absolute;top:909px;left:518px;white-space:nowrap" class="ft0111">.&#160;</p>
<p style="position:absolute;top:947px;left:102px;white-space:nowrap" class="ft0111">10.&#160;</p>
<p style="position:absolute;top:947px;left:162px;white-space:nowrap" class="ft0114">Garcia LS,&#160;Arrowood M, Kokoskin E, et&#160;al. Practical&#160;guidance for&#160;clinical&#160;microbiology&#160;<br/>laboratories: laboratory diagnosis of parasites&#160;from the gastrointestinal tract.&#160;</p>
<p style="position:absolute;top:968px;left:715px;white-space:nowrap" class="ft0112"><i>Clin</i></p>
<p style="position:absolute;top:988px;left:162px;white-space:nowrap" class="ft0112"><i>Microbiol&#160;Rev</i></p>
<p style="position:absolute;top:988px;left:265px;white-space:nowrap" class="ft0111">. 2018;31(1). Available at:&#160;</p>
<p style="position:absolute;top:1009px;left:162px;white-space:nowrap" class="ft0113">https://www.ncbi.nlm.nih.gov/pubmed/29142079</p>
<p style="position:absolute;top:1009px;left:518px;white-space:nowrap" class="ft0111">.&#160;</p>
</div>
<!-- Page 155 -->
<a name="155"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page155-div" style="position:relative;width:917px;height:1187px;">
<p style="position:absolute;top:1114px;left:108px;white-space:nowrap" class="ft024"><i>Guidelines for the Prevention and Treatment&#160;of&#160;Opportunistic&#160;Infections in Adults&#160;and Adolescents&#160;With HIV&#160;</i></p>
<p style="position:absolute;top:1114px;left:795px;white-space:nowrap" class="ft024"><i>I-8&#160;</i></p>
<p style="position:absolute;top:109px;left:102px;white-space:nowrap" class="ft0111">11.&#160;</p>
<p style="position:absolute;top:109px;left:162px;white-space:nowrap" class="ft0114">Roellig DM,&#160;Yoder JS, Madison-Antenucci&#160;S, et&#160;al. Community laboratory testing&#160;for&#160;<br/>Cryptosporidium:&#160;multicenter study&#160;retesting public health&#160;surveillance stool&#160;samples&#160;<br/>positive for&#160;Cryptosporidium&#160;by rapid cartridge&#160;assay with direct fluorescent antibody&#160;<br/>testing.&#160;</p>
<p style="position:absolute;top:171px;left:219px;white-space:nowrap" class="ft0112"><i>PLoS One</i></p>
<p style="position:absolute;top:171px;left:292px;white-space:nowrap" class="ft0111">. 2017;12(1):e0169915. Available&#160;at:&#160;</p>
<p style="position:absolute;top:192px;left:162px;white-space:nowrap" class="ft0113">https://www.ncbi.nlm.nih.gov/pubmed/28085927</p>
<p style="position:absolute;top:192px;left:518px;white-space:nowrap" class="ft0111">.&#160;</p>
<p style="position:absolute;top:230px;left:102px;white-space:nowrap" class="ft0111">12.&#160;</p>
<p style="position:absolute;top:230px;left:162px;white-space:nowrap" class="ft0111">Ryan U, Paparini A, Oskam C. New&#160;technologies&#160;for&#160;detection&#160;of enteric&#160;parasites.&#160;</p>
<p style="position:absolute;top:250px;left:162px;white-space:nowrap" class="ft0112"><i>Trends Parasitol</i></p>
<p style="position:absolute;top:250px;left:284px;white-space:nowrap" class="ft0111">. 2017;33(7):532-546. Available&#160;at:&#160;</p>
<p style="position:absolute;top:271px;left:162px;white-space:nowrap" class="ft0113">https://www.ncbi.nlm.nih.gov/pubmed/28385423</p>
<p style="position:absolute;top:271px;left:518px;white-space:nowrap" class="ft0111">.&#160;</p>
<p style="position:absolute;top:309px;left:102px;white-space:nowrap" class="ft0111">13.&#160;</p>
<p style="position:absolute;top:309px;left:162px;white-space:nowrap" class="ft0114">Huang DB,&#160;Zhou J. Effect&#160;of&#160;intensive handwashing in the prevention of&#160;diarrhoeal&#160;<br/>illness among patients&#160;with AIDS: a randomized controlled study.&#160;</p>
<p style="position:absolute;top:330px;left:641px;white-space:nowrap" class="ft0112"><i>J Med Microbiol</i></p>
<p style="position:absolute;top:330px;left:762px;white-space:nowrap" class="ft0111">.&#160;</p>
<p style="position:absolute;top:350px;left:162px;white-space:nowrap" class="ft0111">2007;56(Pt&#160;5):659-663.&#160;Available at:&#160;</p>
<p style="position:absolute;top:350px;left:433px;white-space:nowrap" class="ft0113">https://www.ncbi.nlm.nih.gov/pubmed/17446290</p>
<p style="position:absolute;top:350px;left:788px;white-space:nowrap" class="ft0111">.&#160;</p>
<p style="position:absolute;top:388px;left:102px;white-space:nowrap" class="ft0111">14.&#160;</p>
<p style="position:absolute;top:388px;left:162px;white-space:nowrap" class="ft0114">King BJ, Monis&#160;PT. Critical processes affecting&#160;Cryptosporidium&#160;oocyst&#160;survival in&#160;the&#160;<br/>environment.&#160;</p>
<p style="position:absolute;top:409px;left:262px;white-space:nowrap" class="ft0112"><i>Parasitology</i></p>
<p style="position:absolute;top:409px;left:355px;white-space:nowrap" class="ft0111">. 2007;134(Pt&#160;3):309-323. Available at:&#160;</p>
<p style="position:absolute;top:430px;left:162px;white-space:nowrap" class="ft0113">https://www.ncbi.nlm.nih.gov/pubmed/17096874</p>
<p style="position:absolute;top:430px;left:518px;white-space:nowrap" class="ft0111">.&#160;</p>
<p style="position:absolute;top:468px;left:102px;white-space:nowrap" class="ft0111">15.&#160;</p>
<p style="position:absolute;top:468px;left:162px;white-space:nowrap" class="ft0114">Gharpure R, Perez&#160;A, Miller AD, Wikswo ME, Silver R, Hlavsa&#160;MC. Cryptosporidiosis&#160;<br/>outbreaks—United States, 2009–2017.&#160;</p>
<p style="position:absolute;top:488px;left:445px;white-space:nowrap" class="ft0112"><i>MMWR&#160;Morb Mortal Wkly&#160;Rep</i></p>
<p style="position:absolute;top:488px;left:673px;white-space:nowrap" class="ft0111">.&#160;2019;68(25):568-</p>
<p style="position:absolute;top:509px;left:162px;white-space:nowrap" class="ft0111">572. Available at:&#160;</p>
<p style="position:absolute;top:509px;left:295px;white-space:nowrap" class="ft0113">https://www.ncbi.nlm.nih.gov/pubmed/31246941</p>
<p style="position:absolute;top:509px;left:651px;white-space:nowrap" class="ft0111">.&#160;</p>
<p style="position:absolute;top:547px;left:102px;white-space:nowrap" class="ft0111">16.&#160;</p>
<p style="position:absolute;top:547px;left:162px;white-space:nowrap" class="ft0114">Holmberg SD, Moorman AC, Von&#160;Bargen JC, et al. Possible effectiveness of&#160;<br/>clarithromycin and rifabutin for cryptosporidiosis&#160;chemoprophylaxis&#160;in HIV disease. HIV&#160;<br/>Outpatient Study (HOPS) Investigators.&#160;</p>
<p style="position:absolute;top:588px;left:453px;white-space:nowrap" class="ft0112"><i>JAMA</i></p>
<p style="position:absolute;top:588px;left:498px;white-space:nowrap" class="ft0111">. 1998;279(5):384-386. Available&#160;at:&#160;</p>
<p style="position:absolute;top:609px;left:162px;white-space:nowrap" class="ft0113">https://www.ncbi.nlm.nih.gov/pubmed/9459473</p>
<p style="position:absolute;top:609px;left:509px;white-space:nowrap" class="ft0111">.&#160;</p>
<p style="position:absolute;top:647px;left:102px;white-space:nowrap" class="ft0111">17.&#160;</p>
<p style="position:absolute;top:647px;left:162px;white-space:nowrap" class="ft0114">Fichtenbaum CJ, Zackin R, Feinberg J, Benson C, Griffiths&#160;JK, AIDS Clinical&#160;Trials&#160;<br/>Group New&#160;Works Concept&#160;Sheet&#160;Team&#160;064. Rifabutin but not clarithromycin prevents&#160;<br/>cryptosporidiosis&#160;in persons with advanced HIV infection.&#160;</p>
<p style="position:absolute;top:688px;left:587px;white-space:nowrap" class="ft0112"><i>AIDS</i></p>
<p style="position:absolute;top:688px;left:626px;white-space:nowrap" class="ft0111">. 2000;14(18):2889-</p>
<p style="position:absolute;top:709px;left:162px;white-space:nowrap" class="ft0111">2893. Available&#160;at:&#160;</p>
<p style="position:absolute;top:709px;left:304px;white-space:nowrap" class="ft0113">https://www.ncbi.nlm.nih.gov/pubmed/11153670</p>
<p style="position:absolute;top:709px;left:660px;white-space:nowrap" class="ft0111">.&#160;</p>
<p style="position:absolute;top:747px;left:102px;white-space:nowrap" class="ft0111">18.&#160;</p>
<p style="position:absolute;top:747px;left:162px;white-space:nowrap" class="ft0114">Gathe JC, Jr., Mayberry&#160;C, Clemmons J, Nemecek J. Resolution of severe&#160;cryptosporidial&#160;<br/>diarrhea&#160;with rifaximin in patients with AIDS.&#160;</p>
<p style="position:absolute;top:768px;left:500px;white-space:nowrap" class="ft0112"><i>J Acquir Immune Defic&#160;Syndr</i></p>
<p style="position:absolute;top:768px;left:713px;white-space:nowrap" class="ft0111">.&#160;</p>
<p style="position:absolute;top:788px;left:162px;white-space:nowrap" class="ft0111">2008;48(3):363-364. Available&#160;at:&#160;</p>
<p style="position:absolute;top:788px;left:413px;white-space:nowrap" class="ft0113">https://www.ncbi.nlm.nih.gov/pubmed/18580340</p>
<p style="position:absolute;top:788px;left:769px;white-space:nowrap" class="ft0111">.&#160;</p>
<p style="position:absolute;top:826px;left:102px;white-space:nowrap" class="ft0111">19.&#160;</p>
<p style="position:absolute;top:826px;left:162px;white-space:nowrap" class="ft0114">Maggi&#160;P, Larocca&#160;AM,&#160;Quarto M, et al. Effect of antiretroviral&#160;therapy on&#160;<br/>cryptosporidiosis&#160;and&#160;microsporidiosis in patients infected with human&#160;<br/>immunodeficiency virus&#160;type 1.&#160;</p>
<p style="position:absolute;top:868px;left:395px;white-space:nowrap" class="ft0112"><i>Eur&#160;J Clin Microbiol Infect Dis</i></p>
<p style="position:absolute;top:868px;left:622px;white-space:nowrap" class="ft0111">. 2000;19(3):213-217.&#160;</p>
<p style="position:absolute;top:888px;left:162px;white-space:nowrap" class="ft0111">Available at:</p>
<p style="position:absolute;top:888px;left:259px;white-space:nowrap" class="ft0113">https://www.ncbi.nlm.nih.gov/pubmed/10795595</p>
<p style="position:absolute;top:888px;left:615px;white-space:nowrap" class="ft0111">.&#160;</p>
<p style="position:absolute;top:926px;left:102px;white-space:nowrap" class="ft0111">20.&#160;</p>
<p style="position:absolute;top:926px;left:162px;white-space:nowrap" class="ft0114">Miao YM,&#160;Awad-El-Kariem FM, Franzen C, et&#160;al. Eradication of cryptosporidia and&#160;<br/>microsporidia following&#160;successful antiretroviral&#160;therapy.&#160;</p>
<p style="position:absolute;top:947px;left:580px;white-space:nowrap" class="ft0112"><i>J Acquir Immune Defic Syndr</i></p>
<p style="position:absolute;top:947px;left:794px;white-space:nowrap" class="ft0111">.&#160;</p>
<p style="position:absolute;top:968px;left:162px;white-space:nowrap" class="ft0111">2000;25(2):124-129. Available&#160;at:&#160;</p>
<p style="position:absolute;top:968px;left:413px;white-space:nowrap" class="ft0113">https://www.ncbi.nlm.nih.gov/pubmed/11103042</p>
<p style="position:absolute;top:968px;left:769px;white-space:nowrap" class="ft0111">.&#160;</p>
<p style="position:absolute;top:1006px;left:102px;white-space:nowrap" class="ft0111">21.&#160;</p>
<p style="position:absolute;top:1006px;left:162px;white-space:nowrap" class="ft0114">Schmidt&#160;W,&#160;Wahnschaffe U, Schafer M, et al. Rapid increase&#160;of mucosal&#160;CD4 T cells&#160;<br/>followed by&#160;clearance of&#160;intestinal cryptosporidiosis in an AIDS&#160;patient&#160;receiving highly&#160;</p>
</div>
<!-- Page 156 -->
<a name="156"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page156-div" style="position:relative;width:917px;height:1187px;">
<p style="position:absolute;top:1114px;left:108px;white-space:nowrap" class="ft024"><i>Guidelines for the Prevention and Treatment&#160;of&#160;Opportunistic&#160;Infections in Adults&#160;and Adolescents&#160;With HIV&#160;</i></p>
<p style="position:absolute;top:1114px;left:795px;white-space:nowrap" class="ft024"><i>I-9&#160;</i></p>
<p style="position:absolute;top:109px;left:162px;white-space:nowrap" class="ft0111">active antiretroviral&#160;therapy.&#160;</p>
<p style="position:absolute;top:109px;left:371px;white-space:nowrap" class="ft0112"><i>Gastroenterology</i></p>
<p style="position:absolute;top:109px;left:498px;white-space:nowrap" class="ft0111">.&#160;2001;120(4):984-987. Available&#160;at:&#160;</p>
<p style="position:absolute;top:129px;left:162px;white-space:nowrap" class="ft0113">https://www.ncbi.nlm.nih.gov/pubmed/11231952</p>
<p style="position:absolute;top:129px;left:518px;white-space:nowrap" class="ft0111">.&#160;</p>
<p style="position:absolute;top:167px;left:102px;white-space:nowrap" class="ft0111">22.&#160;</p>
<p style="position:absolute;top:167px;left:162px;white-space:nowrap" class="ft0114">Dillingham&#160;RA, Pinkerton R, Leger&#160;P, et&#160;al. High early&#160;mortality in patients with chronic&#160;<br/>acquired immunodeficiency syndrome&#160;diarrhea&#160;initiating antiretroviral&#160;therapy in Haiti:&#160;a&#160;<br/>case-control&#160;study.&#160;</p>
<p style="position:absolute;top:209px;left:302px;white-space:nowrap" class="ft0112"><i>Am&#160;J Trop Med&#160;Hyg</i></p>
<p style="position:absolute;top:209px;left:449px;white-space:nowrap" class="ft0111">. 2009;80(6):1060-1064. Available&#160;at:&#160;</p>
<p style="position:absolute;top:230px;left:162px;white-space:nowrap" class="ft0113">https://www.ncbi.nlm.nih.gov/pubmed/19478276</p>
<p style="position:absolute;top:230px;left:518px;white-space:nowrap" class="ft0111">.&#160;</p>
<p style="position:absolute;top:267px;left:102px;white-space:nowrap" class="ft0111">23.&#160;</p>
<p style="position:absolute;top:267px;left:162px;white-space:nowrap" class="ft0114">Simon DM, Cello JP, Valenzuela J, et al. Multicenter&#160;trial&#160;of&#160;octreotide&#160;in&#160;patients&#160;with<br/>refractory acquired&#160;immunodeficiency syndrome-associated&#160;diarrhea.&#160;</p>
<p style="position:absolute;top:288px;left:666px;white-space:nowrap" class="ft0112"><i>Gastroenterology</i></p>
<p style="position:absolute;top:288px;left:793px;white-space:nowrap" class="ft0111">.&#160;</p>
<p style="position:absolute;top:309px;left:162px;white-space:nowrap" class="ft0111">1995;108(6):1753-1760.&#160;Available at:&#160;</p>
<p style="position:absolute;top:309px;left:440px;white-space:nowrap" class="ft0113">https://www.ncbi.nlm.nih.gov/pubmed/7768380</p>
<p style="position:absolute;top:309px;left:787px;white-space:nowrap" class="ft0111">.&#160;</p>
<p style="position:absolute;top:347px;left:102px;white-space:nowrap" class="ft0111">24.&#160;</p>
<p style="position:absolute;top:347px;left:162px;white-space:nowrap" class="ft0114">Hashmey R, Smith NH, Cron S, Graviss EA, Chappell CL,&#160;White&#160;AC, Jr.&#160;<br/>Cryptosporidiosis&#160;in Houston, Texas. A report&#160;of&#160;95 cases.&#160;</p>
<p style="position:absolute;top:368px;left:589px;white-space:nowrap" class="ft0112"><i>Medicine (Baltimore)</i></p>
<p style="position:absolute;top:368px;left:744px;white-space:nowrap" class="ft0111">.&#160;</p>
<p style="position:absolute;top:388px;left:162px;white-space:nowrap" class="ft0111">1997;76(2):118-139. Available&#160;at:&#160;</p>
<p style="position:absolute;top:388px;left:413px;white-space:nowrap" class="ft0113">https://www.ncbi.nlm.nih.gov/pubmed/9100739</p>
<p style="position:absolute;top:388px;left:760px;white-space:nowrap" class="ft0111">.&#160;</p>
<p style="position:absolute;top:426px;left:102px;white-space:nowrap" class="ft0111">25.&#160;</p>
<p style="position:absolute;top:426px;left:162px;white-space:nowrap" class="ft0114">Diptyanusa&#160;A, Sari IP. Treatment of&#160;human intestinal cryptosporidiosis: a&#160;review of&#160;<br/>published&#160;clinical trials.&#160;</p>
<p style="position:absolute;top:447px;left:339px;white-space:nowrap" class="ft0112"><i>Int&#160;J Parasitol Drugs Drug Resist</i></p>
<p style="position:absolute;top:447px;left:582px;white-space:nowrap" class="ft0111">. 2021;17:128-138. Available&#160;</p>
<p style="position:absolute;top:468px;left:162px;white-space:nowrap" class="ft0111">at:&#160;</p>
<p style="position:absolute;top:468px;left:185px;white-space:nowrap" class="ft0113">https://www.ncbi.nlm.nih.gov/pubmed/34562754</p>
<p style="position:absolute;top:468px;left:541px;white-space:nowrap" class="ft0111">.&#160;</p>
<p style="position:absolute;top:506px;left:102px;white-space:nowrap" class="ft0111">26.&#160;</p>
<p style="position:absolute;top:506px;left:162px;white-space:nowrap" class="ft0111">White&#160;AC, Jr. Cryptosporidiosis (</p>
<p style="position:absolute;top:506px;left:405px;white-space:nowrap" class="ft0112"><i>Cryptosporidium&#160;</i></p>
<p style="position:absolute;top:506px;left:532px;white-space:nowrap" class="ft0111">Species).&#160;In:&#160;Secondary White&#160;AC,&#160;</p>
<p style="position:absolute;top:526px;left:162px;white-space:nowrap" class="ft0114">Jr., ed^eds.&#160;Subsidiary&#160;White&#160;AC, Jr., trans. Secondary Cryptosporidiosis&#160;<br/>(</p>
<p style="position:absolute;top:547px;left:168px;white-space:nowrap" class="ft0112"><i>Cryptosporidium&#160;</i></p>
<p style="position:absolute;top:547px;left:296px;white-space:nowrap" class="ft0111">Species). Vol. 9th&#160;ed. Philadelphia: Elsevier&#160;Saunders; 2020:3410-</p>
<p style="position:absolute;top:568px;left:162px;white-space:nowrap" class="ft0111">3420.&#160;</p>
<p style="position:absolute;top:606px;left:102px;white-space:nowrap" class="ft0111">27.&#160;</p>
<p style="position:absolute;top:606px;left:162px;white-space:nowrap" class="ft0114">Rossignol&#160;JF, Ayoub A,&#160;Ayers MS. Treatment of diarrhea&#160;caused by Cryptosporidium<br/>parvum: a&#160;prospective&#160;randomized, double-blind,&#160;placebo-controlled study&#160;of&#160;<br/>Nitazoxanide.&#160;</p>
<p style="position:absolute;top:647px;left:267px;white-space:nowrap" class="ft0112"><i>J Infect&#160;Dis</i></p>
<p style="position:absolute;top:647px;left:350px;white-space:nowrap" class="ft0111">. 2001;184(1):103-106.&#160;Available at:&#160;</p>
<p style="position:absolute;top:668px;left:162px;white-space:nowrap" class="ft0113">https://www.ncbi.nlm.nih.gov/pubmed/11398117</p>
<p style="position:absolute;top:668px;left:518px;white-space:nowrap" class="ft0111">.&#160;</p>
<p style="position:absolute;top:706px;left:102px;white-space:nowrap" class="ft0111">28.&#160;</p>
<p style="position:absolute;top:706px;left:162px;white-space:nowrap" class="ft0114">Rossignol&#160;JF, Kabil SM, el-Gohary&#160;Y, Younis&#160;AM. Effect of&#160;nitazoxanide in diarrhea&#160;<br/>and enteritis caused by&#160;Cryptosporidium&#160;species.&#160;</p>
<p style="position:absolute;top:726px;left:519px;white-space:nowrap" class="ft0112"><i>Clin Gastroenterol&#160;Hepatol</i></p>
<p style="position:absolute;top:726px;left:718px;white-space:nowrap" class="ft0111">.&#160;</p>
<p style="position:absolute;top:747px;left:162px;white-space:nowrap" class="ft0111">2006;4(3):320-324. Available&#160;at:&#160;</p>
<p style="position:absolute;top:747px;left:404px;white-space:nowrap" class="ft0113">https://www.ncbi.nlm.nih.gov/pubmed/16527695</p>
<p style="position:absolute;top:747px;left:760px;white-space:nowrap" class="ft0111">.&#160;</p>
<p style="position:absolute;top:785px;left:102px;white-space:nowrap" class="ft0111">29.&#160;</p>
<p style="position:absolute;top:785px;left:162px;white-space:nowrap" class="ft0114">Rossignol&#160;JF, Hidalgo H, Feregrino&#160;M, et&#160;al. A&#160;double-'blind' placebo-controlled study of<br/>nitazoxanide&#160;in the&#160;treatment of cryptosporidial diarrhoea in&#160;AIDS patients&#160;in Mexico.&#160;</p>
<p style="position:absolute;top:826px;left:162px;white-space:nowrap" class="ft0112"><i>Trans R Soc Trop Med&#160;Hyg</i></p>
<p style="position:absolute;top:826px;left:360px;white-space:nowrap" class="ft0111">. 1998;92(6):663-666. Available&#160;at:&#160;</p>
<p style="position:absolute;top:847px;left:162px;white-space:nowrap" class="ft0113">https://www.ncbi.nlm.nih.gov/pubmed/10326116</p>
<p style="position:absolute;top:847px;left:518px;white-space:nowrap" class="ft0111">.&#160;</p>
<p style="position:absolute;top:885px;left:102px;white-space:nowrap" class="ft0111">30.&#160;</p>
<p style="position:absolute;top:885px;left:162px;white-space:nowrap" class="ft0114">Amadi&#160;B, Mwiya&#160;M, Sianongo S, et&#160;al. High dose prolonged&#160;treatment with nitazoxanide&#160;<br/>is&#160;not effective for&#160;cryptosporidiosis&#160;in HIV positive Zambian&#160;children: a&#160;randomised&#160;<br/>controlled&#160;trial.&#160;</p>
<p style="position:absolute;top:926px;left:277px;white-space:nowrap" class="ft0112"><i>BMC Infect&#160;Dis</i></p>
<p style="position:absolute;top:926px;left:390px;white-space:nowrap" class="ft0111">. 2009;9:195. Available&#160;at:&#160;</p>
<p style="position:absolute;top:947px;left:162px;white-space:nowrap" class="ft0113">https://www.ncbi.nlm.nih.gov/pubmed/19954529</p>
<p style="position:absolute;top:947px;left:518px;white-space:nowrap" class="ft0111">.&#160;</p>
<p style="position:absolute;top:985px;left:102px;white-space:nowrap" class="ft0111">31.&#160;</p>
<p style="position:absolute;top:985px;left:162px;white-space:nowrap" class="ft0114">Amadi&#160;B, Mwiya&#160;M, Musuku J, et al.&#160;Effect of nitazoxanide on morbidity&#160;and mortality&#160;<br/>in Zambian&#160;children with cryptosporidiosis: a&#160;randomised&#160;controlled trial.&#160;</p>
<p style="position:absolute;top:1006px;left:698px;white-space:nowrap" class="ft0112"><i>Lancet</i></p>
<p style="position:absolute;top:1006px;left:747px;white-space:nowrap" class="ft0111">.&#160;</p>
<p style="position:absolute;top:1026px;left:162px;white-space:nowrap" class="ft0111">2002;360(9343):1375-1380. Available at:&#160;</p>
<p style="position:absolute;top:1047px;left:162px;white-space:nowrap" class="ft0113">https://www.ncbi.nlm.nih.gov/pubmed/12423984</p>
<p style="position:absolute;top:1047px;left:518px;white-space:nowrap" class="ft0111">.&#160;</p>
</div>
<!-- Page 157 -->
<a name="157"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page157-div" style="position:relative;width:917px;height:1187px;">
<p style="position:absolute;top:1114px;left:108px;white-space:nowrap" class="ft024"><i>Guidelines for the Prevention and Treatment&#160;of&#160;Opportunistic&#160;Infections in Adults&#160;and Adolescents&#160;With HIV&#160;</i></p>
<p style="position:absolute;top:1114px;left:788px;white-space:nowrap" class="ft024"><i>I-10&#160;</i></p>
<p style="position:absolute;top:109px;left:102px;white-space:nowrap" class="ft0111">32.&#160;</p>
<p style="position:absolute;top:109px;left:162px;white-space:nowrap" class="ft0114">Rossignol&#160;JF. Nitazoxanide in&#160;the&#160;treatment of&#160;acquired&#160;immune deficiency syndrome-<br/>related cryptosporidiosis:&#160;results of&#160;the United States&#160;compassionate use&#160;program&#160;in 365&#160;<br/>patients.&#160;</p>
<p style="position:absolute;top:150px;left:227px;white-space:nowrap" class="ft0112"><i>Aliment Pharmacol Ther</i></p>
<p style="position:absolute;top:150px;left:406px;white-space:nowrap" class="ft0111">. 2006;24(5):887-894. Available&#160;at:&#160;</p>
<p style="position:absolute;top:171px;left:162px;white-space:nowrap" class="ft0113">https://www.ncbi.nlm.nih.gov/pubmed/16918894</p>
<p style="position:absolute;top:171px;left:518px;white-space:nowrap" class="ft0111">.&#160;</p>
<p style="position:absolute;top:209px;left:102px;white-space:nowrap" class="ft0111">33.&#160;</p>
<p style="position:absolute;top:209px;left:162px;white-space:nowrap" class="ft0114">White&#160;AC, Jr., Chappell&#160;CL, Hayat CS, Kimball&#160;KT, Flanigan TP, Goodgame RW.&#160;<br/>Paromomycin for&#160;cryptosporidiosis&#160;in&#160;AIDS: a&#160;prospective, double-blind&#160;trial.&#160;</p>
<p style="position:absolute;top:230px;left:730px;white-space:nowrap" class="ft0112"><i>J&#160;Infect&#160;</i></p>
<p style="position:absolute;top:250px;left:162px;white-space:nowrap" class="ft0112"><i>Dis</i></p>
<p style="position:absolute;top:250px;left:187px;white-space:nowrap" class="ft0111">. 1994;170(2):419-424. Available at:&#160;</p>
<p style="position:absolute;top:250px;left:456px;white-space:nowrap" class="ft0113">https://www.ncbi.nlm.nih.gov/pubmed/8035029</p>
<p style="position:absolute;top:250px;left:803px;white-space:nowrap" class="ft0111">.&#160;</p>
<p style="position:absolute;top:288px;left:102px;white-space:nowrap" class="ft0111">34.&#160;</p>
<p style="position:absolute;top:288px;left:162px;white-space:nowrap" class="ft0114">Hewitt RG, Yiannoutsos&#160;CT, Higgs ES, et al. Paromomycin: no more&#160;effective than&#160;<br/>placebo&#160;for&#160;treatment&#160;of&#160;cryptosporidiosis&#160;in patients&#160;with advanced human&#160;<br/>immunodeficiency virus&#160;infection. AIDS&#160;Clinical&#160;Trial&#160;Group.&#160;</p>
<p style="position:absolute;top:330px;left:617px;white-space:nowrap" class="ft0112"><i>Clin Infect&#160;Dis</i></p>
<p style="position:absolute;top:330px;left:723px;white-space:nowrap" class="ft0111">.&#160;</p>
<p style="position:absolute;top:350px;left:162px;white-space:nowrap" class="ft0111">2000;31(4):1084-1092. Available at:&#160;</p>
<p style="position:absolute;top:350px;left:431px;white-space:nowrap" class="ft0113">https://www.ncbi.nlm.nih.gov/pubmed/11049793</p>
<p style="position:absolute;top:350px;left:787px;white-space:nowrap" class="ft0111">.&#160;</p>
<p style="position:absolute;top:388px;left:102px;white-space:nowrap" class="ft0111">35.&#160;</p>
<p style="position:absolute;top:388px;left:162px;white-space:nowrap" class="ft0114">Maggi&#160;P, Larocca&#160;AM,&#160;Ladisa N, et&#160;al. Opportunistic parasitic infections&#160;of the&#160;intestinal&#160;<br/>tract&#160;in&#160;the&#160;era&#160;of highly&#160;active antiretroviral&#160;therapy:&#160;is&#160;the&#160;CD4(+)&#160;count so important?&#160;</p>
<p style="position:absolute;top:430px;left:162px;white-space:nowrap" class="ft0112"><i>Clin Infect&#160;Dis</i></p>
<p style="position:absolute;top:430px;left:268px;white-space:nowrap" class="ft0111">. 2001;33(9):1609-1611. Available&#160;at:&#160;</p>
<p style="position:absolute;top:450px;left:162px;white-space:nowrap" class="ft0113">https://www.ncbi.nlm.nih.gov/pubmed/11588705</p>
<p style="position:absolute;top:450px;left:518px;white-space:nowrap" class="ft0111">.&#160;</p>
<p style="position:absolute;top:488px;left:102px;white-space:nowrap" class="ft0111">36.&#160;</p>
<p style="position:absolute;top:488px;left:162px;white-space:nowrap" class="ft0114">Hommer V,&#160;Eichholz&#160;J,&#160;Petry F. Effect&#160;of&#160;antiretroviral protease&#160;inhibitors alone, and&#160;in&#160;<br/>combination&#160;with paromomycin, on&#160;the excystation, invasion&#160;and in vitro&#160;development of&#160;<br/>Cryptosporidium&#160;parvum.&#160;</p>
<p style="position:absolute;top:530px;left:353px;white-space:nowrap" class="ft0112"><i>J&#160;Antimicrob Chemother</i></p>
<p style="position:absolute;top:530px;left:531px;white-space:nowrap" class="ft0111">. 2003;52(3):359-364.&#160;Available at:&#160;</p>
<p style="position:absolute;top:550px;left:162px;white-space:nowrap" class="ft0113">https://www.ncbi.nlm.nih.gov/pubmed/12888587</p>
<p style="position:absolute;top:550px;left:518px;white-space:nowrap" class="ft0111">.&#160;</p>
<p style="position:absolute;top:588px;left:102px;white-space:nowrap" class="ft0111">37.&#160;</p>
<p style="position:absolute;top:588px;left:162px;white-space:nowrap" class="ft0114">Mele R, Gomez Morales MA, Tosini&#160;F, Pozio E.&#160;Indinavir&#160;reduces&#160;Cryptosporidium&#160;<br/>parvum&#160;infection&#160;in both&#160;in vitro and&#160;in vivo models.&#160;</p>
<p style="position:absolute;top:609px;left:548px;white-space:nowrap" class="ft0112"><i>Int J&#160;Parasitol</i></p>
<p style="position:absolute;top:609px;left:652px;white-space:nowrap" class="ft0111">. 2003;33(7):757-</p>
<p style="position:absolute;top:630px;left:162px;white-space:nowrap" class="ft0111">764. Available at:&#160;</p>
<p style="position:absolute;top:630px;left:295px;white-space:nowrap" class="ft0113">https://www.ncbi.nlm.nih.gov/pubmed/12814654</p>
<p style="position:absolute;top:630px;left:651px;white-space:nowrap" class="ft0111">.&#160;</p>
<p style="position:absolute;top:668px;left:102px;white-space:nowrap" class="ft0111">38.&#160;</p>
<p style="position:absolute;top:668px;left:162px;white-space:nowrap" class="ft0114">Sullivan T,&#160;Reese L, Huprikar&#160;S, Lee M. Pulmonary cryptosporidiosis&#160;and immune<br/>reconstitution inflammatory syndrome:&#160;a case report&#160;and review.&#160;</p>
<p style="position:absolute;top:688px;left:632px;white-space:nowrap" class="ft0112"><i>Int&#160;J STD AIDS</i></p>
<p style="position:absolute;top:688px;left:744px;white-space:nowrap" class="ft0111">.&#160;</p>
<p style="position:absolute;top:709px;left:162px;white-space:nowrap" class="ft0111">2013;24(4):333-334. Available&#160;at:&#160;</p>
<p style="position:absolute;top:709px;left:413px;white-space:nowrap" class="ft0113">https://www.ncbi.nlm.nih.gov/pubmed/23970667</p>
<p style="position:absolute;top:709px;left:769px;white-space:nowrap" class="ft0111">.&#160;</p>
<p style="position:absolute;top:747px;left:102px;white-space:nowrap" class="ft0111">39.&#160;</p>
<p style="position:absolute;top:747px;left:162px;white-space:nowrap" class="ft0114">Smith NH, Cron S, Valdez LM, Chappell CL,&#160;White AC, Jr. Combination drug therapy&#160;<br/>for&#160;cryptosporidiosis in&#160;AIDS.&#160;</p>
<p style="position:absolute;top:768px;left:385px;white-space:nowrap" class="ft0112"><i>J Infect Dis</i></p>
<p style="position:absolute;top:768px;left:468px;white-space:nowrap" class="ft0111">. 1998;178(3):900-903. Available at:&#160;</p>
<p style="position:absolute;top:788px;left:162px;white-space:nowrap" class="ft0113">https://www.ncbi.nlm.nih.gov/pubmed/9728569</p>
<p style="position:absolute;top:788px;left:509px;white-space:nowrap" class="ft0111">.&#160;</p>
<p style="position:absolute;top:826px;left:102px;white-space:nowrap" class="ft0111">40.&#160;</p>
<p style="position:absolute;top:826px;left:162px;white-space:nowrap" class="ft0114">Tomczak E,&#160;McDougal&#160;AN, White&#160;AC, Jr. Resolution of cryptosporidiosis in transplant&#160;<br/>recipients: review of the&#160;literature&#160;and presentation of a renal transplant&#160;patient treated&#160;<br/>with nitazoxanide, azithromycin, and&#160;rifaximin.&#160;</p>
<p style="position:absolute;top:868px;left:510px;white-space:nowrap" class="ft0112"><i>Open Forum&#160;Infect Dis</i></p>
<p style="position:absolute;top:868px;left:677px;white-space:nowrap" class="ft0111">.&#160;</p>
<p style="position:absolute;top:888px;left:162px;white-space:nowrap" class="ft0111">2022;9(1):ofab610. Available&#160;at:</p>
<p style="position:absolute;top:888px;left:403px;white-space:nowrap" class="ft0113">https://www.ncbi.nlm.nih.gov/pubmed/34993260</p>
<p style="position:absolute;top:888px;left:759px;white-space:nowrap" class="ft0111">.&#160;</p>
<p style="position:absolute;top:926px;left:102px;white-space:nowrap" class="ft0111">41.&#160;</p>
<p style="position:absolute;top:926px;left:162px;white-space:nowrap" class="ft0114">Kallen B, Nilsson E, Otterblad Olausson P. Maternal use&#160;of&#160;loperamide in&#160;early&#160;<br/>pregnancy and delivery&#160;outcome.&#160;</p>
<p style="position:absolute;top:947px;left:406px;white-space:nowrap" class="ft0112"><i>Acta Paediatr</i></p>
<p style="position:absolute;top:947px;left:507px;white-space:nowrap" class="ft0111">.&#160;2008;97(5):541-545. Available&#160;at:&#160;</p>
<p style="position:absolute;top:968px;left:162px;white-space:nowrap" class="ft0113">https://www.ncbi.nlm.nih.gov/pubmed/18394096</p>
<p style="position:absolute;top:968px;left:518px;white-space:nowrap" class="ft0111">.&#160;</p>
<p style="position:absolute;top:1006px;left:102px;white-space:nowrap" class="ft0111">42.&#160;</p>
<p style="position:absolute;top:1006px;left:162px;white-space:nowrap" class="ft0114">Esposito DB, Huybrechts&#160;KF, Werler&#160;MM, et al.&#160;Characteristics of&#160;prescription opioid&#160;<br/>analgesics&#160;in pregnancy&#160;and risk of&#160;neonatal opioid withdrawal syndrome&#160;in newborns.&#160;</p>
</div>
<!-- Page 158 -->
<a name="158"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page158-div" style="position:relative;width:917px;height:1187px;">
<p style="position:absolute;top:1114px;left:108px;white-space:nowrap" class="ft024"><i>Guidelines for the Prevention and Treatment&#160;of&#160;Opportunistic&#160;Infections in Adults&#160;and Adolescents&#160;With HIV&#160;</i></p>
<p style="position:absolute;top:1114px;left:788px;white-space:nowrap" class="ft024"><i>I-11&#160;</i></p>
<p style="position:absolute;top:109px;left:162px;white-space:nowrap" class="ft0112"><i>JAMA Netw Open</i></p>
<p style="position:absolute;top:109px;left:292px;white-space:nowrap" class="ft0111">. 2022;5(8):e2228588. Available at:&#160;</p>
<p style="position:absolute;top:129px;left:162px;white-space:nowrap" class="ft0113">https://www.ncbi.nlm.nih.gov/pubmed/36001312</p>
<p style="position:absolute;top:129px;left:518px;white-space:nowrap" class="ft0111">.&#160;</p>
<p style="position:absolute;top:167px;left:102px;white-space:nowrap" class="ft0111">&#160;</p>
</div>
<!-- Page 159 -->
<a name="159"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}	.ft0132{font-size:21px;font-family:BGKYCV+LiberationSansNarrow;color:#005299;}
	.ft0133{font-size:27px;font-family:BTLIFY+Tinos;color:#005299;}
	.ft0134{font-size:10px;font-family:TURBHP+Tinos;color:#000000;}
	.ft0135{font-size:16px;line-height:20px;font-family:TURBHP+Tinos;color:#000000;}
	.ft0136{font-size:16px;line-height:19px;font-family:TURBHP+Tinos;color:#000000;}
-->
</style>
<div id="page159-div" style="position:relative;width:917px;height:1187px;">
<p style="position:absolute;top:1117px;left:108px;white-space:nowrap" class="ft024"><i>Guidelines&#160;for&#160;the&#160;Prevention&#160;and&#160;Treatment&#160;of&#160;Opportunistic&#160;Infections&#160;in&#160;Adults&#160;and&#160;Adolescents&#160;With&#160;HIV&#160;</i></p>
<p style="position:absolute;top:1117px;left:792px;white-space:nowrap" class="ft024"><i>J-1</i></p>
<p style="position:absolute;top:113px;left:108px;white-space:nowrap" class="ft025"><b>Cystoisosporiasis&#160;(Formerly&#160;Isosporiasis)</b></p>
<p style="position:absolute;top:160px;left:108px;white-space:nowrap" class="ft035"><b>Updated:</b></p>
<p style="position:absolute;top:160px;left:174px;white-space:nowrap" class="ft036">&#160;April&#160;23,&#160;2025&#160;</p>
<p style="position:absolute;top:181px;left:108px;white-space:nowrap" class="ft035"><b>Reviewed:</b></p>
<p style="position:absolute;top:181px;left:186px;white-space:nowrap" class="ft036">April&#160;23,&#160;2025</p>
<p style="position:absolute;top:216px;left:108px;white-space:nowrap" class="ft0132"><b>Epidemiology</b></p>
<p style="position:absolute;top:212px;left:223px;white-space:nowrap" class="ft0133"><b>&#160;</b></p>
<p style="position:absolute;top:260px;left:108px;white-space:nowrap" class="ft0136">Cystoisosporiasis,&#160;also&#160;known&#160;as&#160;Isosporiasis,&#160;&#160;is&#160;a&#160;protozoan&#160;gastrointestinal&#160;&#160;infection&#160;that&#160;occurs&#160;<br/>worldwide&#160;but&#160;is&#160;more&#160;common&#160;in&#160;tropical&#160;and&#160;subtropical&#160;regions.&#160;Immunocompromised&#160;&#160;people,&#160;<br/>including&#160;those&#160;who&#160;have&#160;HIV,&#160;are&#160;at&#160;increased&#160;&#160;risk&#160;for&#160;chronic,&#160;debilitating&#160;illness.</p>
<p style="position:absolute;top:300px;left:684px;white-space:nowrap" class="ft0134">1-7</p>
<p style="position:absolute;top:299px;left:700px;white-space:nowrap" class="ft047">&#160;Infection&#160;</p>
<p style="position:absolute;top:320px;left:108px;white-space:nowrap" class="ft0135">results&#160;from&#160;ingestion&#160;of&#160;sporulated&#160;oocysts,&#160;such&#160;as&#160;from&#160;contaminated&#160;food&#160;or&#160;water.&#160;After&#160;<br/>ingestion,&#160;the&#160;parasite&#160;invades&#160;enterocytes&#160;in&#160;the&#160;small&#160;intestine.&#160;Ultimately,&#160;immature&#160;oocysts&#160;are<br/>produced&#160;and&#160;shed&#160;in&#160;stool.</p>
<p style="position:absolute;top:360px;left:296px;white-space:nowrap" class="ft0134">8</p>
<p style="position:absolute;top:359px;left:302px;white-space:nowrap" class="ft047">&#160;Although</p>
<p style="position:absolute;top:359px;left:371px;white-space:nowrap" class="ft049"><i>&#160;Cystoisospora&#160;&#160;(Isospora)&#160;belli&#160;</i></p>
<p style="position:absolute;top:359px;left:590px;white-space:nowrap" class="ft047">completes&#160;&#160;its&#160;life&#160;cycle&#160;in&#160;</p>
<p style="position:absolute;top:380px;left:108px;white-space:nowrap" class="ft0135">humans,&#160;oocysts&#160;&#160;shed&#160;in&#160;the&#160;feces&#160;of&#160;infected&#160;individuals&#160;&#160;must&#160;mature&#160;(sporulate)&#160;outside&#160;&#160;the&#160;host,&#160;in&#160;<br/>the&#160;environment,&#160;to&#160;become&#160;infective&#160;when&#160;ingested.&#160;Available&#160;data&#160;suggest&#160;that&#160;the&#160;maturation&#160;<br/>process&#160;&#160;is&#160;completed&#160;in&#160;approximately&#160;&#160;1&#160;to&#160;2&#160;days&#160;but&#160;might&#160;occur&#160;more&#160;rapidly&#160;in&#160;some&#160;settings.</p>
<p style="position:absolute;top:420px;left:778px;white-space:nowrap" class="ft0134">2</p>
<p style="position:absolute;top:419px;left:784px;white-space:nowrap" class="ft047">&#160;</p>
<p style="position:absolute;top:439px;left:108px;white-space:nowrap" class="ft047">For&#160;complete&#160;lifecycle,&#160;see&#160;the&#160;</p>
<p style="position:absolute;top:439px;left:324px;white-space:nowrap" class="ft050">Centers&#160;for&#160;Disease&#160;&#160;Control&#160;and&#160;Prevention&#160;Cystoisosporiasis</p>
<p style="position:absolute;top:439px;left:744px;white-space:nowrap" class="ft047">&#160;</p>
<p style="position:absolute;top:459px;left:108px;white-space:nowrap" class="ft047">webpage.</p>
<p style="position:absolute;top:496px;left:108px;white-space:nowrap" class="ft049"><i>C.&#160;belli</i></p>
<p style="position:absolute;top:496px;left:158px;white-space:nowrap" class="ft047">&#160;is&#160;frequently&#160;found&#160;in&#160;tropical&#160;and&#160;subtropical&#160;regions&#160;including&#160;the&#160;Caribbean,&#160;Central&#160;and</p>
<p style="position:absolute;top:515px;left:108px;white-space:nowrap" class="ft047">South&#160;America,&#160;Africa,&#160;India,&#160;and&#160;Southeast&#160;Asia.</p>
<p style="position:absolute;top:516px;left:452px;white-space:nowrap" class="ft0134">9</p>
<p style="position:absolute;top:515px;left:458px;white-space:nowrap" class="ft047">&#160;However,&#160;cases&#160;&#160;of&#160;</p>
<p style="position:absolute;top:515px;left:595px;white-space:nowrap" class="ft049"><i>C.&#160;belli</i></p>
<p style="position:absolute;top:515px;left:645px;white-space:nowrap" class="ft047">&#160;can&#160;also&#160;occur&#160;in</p>
<p style="position:absolute;top:536px;left:108px;white-space:nowrap" class="ft0136">resource-rich&#160;countries&#160;&#160;like&#160;the&#160;United&#160;States&#160;due&#160;to&#160;travel&#160;and&#160;immigration,&#160;especially&#160;&#160;when<br/>individuals&#160;are&#160;exposed&#160;to&#160;contaminated&#160;&#160;food&#160;or&#160;water&#160;sources.</p>
<p style="position:absolute;top:556px;left:541px;white-space:nowrap" class="ft0134">10</p>
<p style="position:absolute;top:555px;left:559px;white-space:nowrap" class="ft047">This&#160;parasitic&#160;infection&#160;is&#160;more</p>
<p style="position:absolute;top:575px;left:108px;white-space:nowrap" class="ft0135">commonly&#160;observed&#160;&#160;in&#160;people&#160;with&#160;HIV&#160;(especially,&#160;but&#160;not&#160;exclusively&#160;&#160;in&#160;those&#160;with&#160;low&#160;CD4&#160;T<br/>lymphocyte&#160;[CD4]&#160;cell&#160;counts),&#160;and&#160;outbreaks&#160;among&#160;institutionalized&#160;&#160;groups&#160;have&#160;also&#160;been<br/>reported.</p>
<p style="position:absolute;top:616px;left:169px;white-space:nowrap" class="ft0134">11-13</p>
<p style="position:absolute;top:649px;left:108px;white-space:nowrap" class="ft0132"><b>Clinical&#160;Manifestations</b></p>
<p style="position:absolute;top:653px;left:298px;white-space:nowrap" class="ft035"><b>&#160;</b></p>
<p style="position:absolute;top:693px;left:108px;white-space:nowrap" class="ft0136">The&#160;most&#160;common&#160;manifestation&#160;of&#160;cystoisosporiasis&#160;is&#160;watery,&#160;non-bloody&#160;diarrhea,&#160;which&#160;may&#160;be<br/>associated&#160;&#160;with&#160;abdominal&#160;pain,&#160;cramping,&#160;anorexia,&#160;nausea,&#160;vomiting,&#160;and&#160;low-grade&#160;fever.&#160;The&#160;<br/>diarrhea&#160;can&#160;be&#160;profuse&#160;and&#160;prolonged,&#160;lasting&#160;several&#160;weeks&#160;&#160;or&#160;more,&#160;particularly&#160;in&#160;people&#160;with&#160;<br/>HIV&#160;or&#160;other&#160;immunocompromising&#160;&#160;conditions.&#160;This&#160;&#160;kind&#160;of&#160;diarrhea&#160;often&#160;results&#160;in&#160;severe&#160;<br/>dehydration,&#160;electrolyte&#160;abnormalities&#160;&#160;(e.g.,&#160;hypokalemia),&#160;weight&#160;loss,&#160;and&#160;malabsorption.</p>
<p style="position:absolute;top:773px;left:734px;white-space:nowrap" class="ft0134">6,7,14-18</p>
<p style="position:absolute;top:772px;left:779px;white-space:nowrap" class="ft047">&#160;</p>
<p style="position:absolute;top:793px;left:108px;white-space:nowrap" class="ft0136">Extraintestinal&#160;infection—such&#160;&#160;as&#160;in&#160;the&#160;biliary&#160;tract,&#160;lymph&#160;nodes,&#160;spleen,&#160;and&#160;liver—has&#160;&#160;been&#160;<br/>documented&#160;&#160;in&#160;postmortem&#160;examinations&#160;&#160;of&#160;people&#160;with&#160;HIV.</p>
<p style="position:absolute;top:812px;left:536px;white-space:nowrap" class="ft0134">2,19-21</p>
<p style="position:absolute;top:812px;left:572px;white-space:nowrap" class="ft047">&#160;Acalculous&#160;</p>
<p style="position:absolute;top:832px;left:108px;white-space:nowrap" class="ft047">cholecystitis/cholangiopathy</p>
<p style="position:absolute;top:833px;left:299px;white-space:nowrap" class="ft0134">2&#160;,22-24</p>
<p style="position:absolute;top:832px;left:344px;white-space:nowrap" class="ft047">and&#160;reactive&#160;arthritis</p>
<p style="position:absolute;top:833px;left:485px;white-space:nowrap" class="ft0134">25</p>
<p style="position:absolute;top:832px;left:497px;white-space:nowrap" class="ft047">&#160;also&#160;have&#160;been&#160;reported.&#160;&#160;</p>
<p style="position:absolute;top:867px;left:108px;white-space:nowrap" class="ft0132"><b>Diagnosis</b></p>
<p style="position:absolute;top:910px;left:108px;white-space:nowrap" class="ft047">Typically,&#160;infection&#160;is&#160;diagnosed&#160;&#160;by&#160;detecting&#160;</p>
<p style="position:absolute;top:910px;left:427px;white-space:nowrap" class="ft049"><i>Cystoisospora&#160;&#160;(Isospora)</i></p>
<p style="position:absolute;top:910px;left:600px;white-space:nowrap" class="ft047">&#160;&#160;oocysts&#160;(dimensions,&#160;</p>
<p style="position:absolute;top:931px;left:108px;white-space:nowrap" class="ft047">23–36&#160;</p>
<p style="position:absolute;top:931px;left:156px;white-space:nowrap" class="ft049"><i>µ</i></p>
<p style="position:absolute;top:931px;left:166px;white-space:nowrap" class="ft047">m&#160;by&#160;12–17&#160;</p>
<p style="position:absolute;top:931px;left:252px;white-space:nowrap" class="ft049"><i>µ</i></p>
<p style="position:absolute;top:931px;left:262px;white-space:nowrap" class="ft047">m)&#160;in&#160;fecal&#160;specimens.</p>
<p style="position:absolute;top:931px;left:414px;white-space:nowrap" class="ft0134">2</p>
<p style="position:absolute;top:931px;left:427px;white-space:nowrap" class="ft047">Oocysts&#160;&#160;may&#160;be&#160;shed&#160;intermittently&#160;and&#160;at&#160;low&#160;levels,&#160;</p>
<p style="position:absolute;top:950px;left:108px;white-space:nowrap" class="ft0136">even&#160;by&#160;individuals&#160;with&#160;profuse&#160;diarrhea.&#160;Diagnosis&#160;&#160;can&#160;be&#160;facilitated&#160;by&#160;repeated&#160;stool&#160;<br/>examinations&#160;&#160;with&#160;sensitive&#160;&#160;methods,&#160;such&#160;as&#160;modified&#160;acid-fast&#160;techniques,&#160;&#160;on&#160;which&#160;oocysts&#160;stain&#160;<br/>bright&#160;red,&#160;and&#160;ultraviolet&#160;fluorescence&#160;microscopy,&#160;under&#160;which&#160;there&#160;is&#160;autofluorescence.</p>
<p style="position:absolute;top:990px;left:732px;white-space:nowrap" class="ft0134">2,26</p>
<p style="position:absolute;top:989px;left:752px;white-space:nowrap" class="ft047">&#160;The&#160;</p>
<p style="position:absolute;top:1010px;left:108px;white-space:nowrap" class="ft0136">microbiology/parasitology&#160;&#160;laboratory&#160;should&#160;be&#160;notified&#160;of&#160;the&#160;patient’s&#160;immunodeficiency&#160;&#160;status&#160;&#160;to&#160;<br/>ensure&#160;appropriate&#160;testing&#160;is&#160;done.&#160;Infection&#160;can&#160;also&#160;be&#160;diagnosed&#160;&#160;by&#160;detecting&#160;oocysts&#160;in&#160;duodenal</p>
</div>
<!-- Page 160 -->
<a name="160"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}	.ft0137{font-size:16px;font-family:BTLIFY+Tinos;color:#000000;}
-->
</style>
<div id="page160-div" style="position:relative;width:917px;height:1187px;">
<p style="position:absolute;top:1117px;left:108px;white-space:nowrap" class="ft024"><i>Guidelines&#160;for&#160;the&#160;Prevention&#160;and&#160;Treatment&#160;of&#160;Opportunistic&#160;Infections&#160;in&#160;Adults&#160;and&#160;Adolescents&#160;With&#160;HIV&#160;</i></p>
<p style="position:absolute;top:1117px;left:792px;white-space:nowrap" class="ft024"><i>J-2&#160;</i></p>
<p style="position:absolute;top:110px;left:108px;white-space:nowrap" class="ft0135">aspirates&#160;&#160;or&#160;mucus,&#160;or&#160;by&#160;identifying&#160;developmental&#160;&#160;stages&#160;of&#160;the&#160;parasite&#160;in&#160;intestinal&#160;biopsy&#160;<br/>specimens&#160;&#160;or&#160;using&#160;the&#160;string&#160;test&#160;(Entero-Test).</p>
<p style="position:absolute;top:131px;left:438px;white-space:nowrap" class="ft0134">2,16</p>
<p style="position:absolute;top:130px;left:458px;white-space:nowrap" class="ft047">&#160;&#160;</p>
<p style="position:absolute;top:166px;left:108px;white-space:nowrap" class="ft047">Polymerase&#160;chain&#160;reaction&#160;(PCR)&#160;methods&#160;are&#160;increasingly&#160;&#160;used&#160;to&#160;detect&#160;</p>
<p style="position:absolute;top:166px;left:619px;white-space:nowrap" class="ft049"><i>C.&#160;belli</i></p>
<p style="position:absolute;top:166px;left:669px;white-space:nowrap" class="ft047">&#160;for&#160;diagnosis,&#160;as&#160;</p>
<p style="position:absolute;top:185px;left:108px;white-space:nowrap" class="ft047">supported&#160;by&#160;existing&#160;literature.</p>
<p style="position:absolute;top:186px;left:326px;white-space:nowrap" class="ft0134">10</p>
<p style="position:absolute;top:185px;left:338px;white-space:nowrap" class="ft047">&#160;These&#160;&#160;molecular&#160;quantitative&#160;PCR&#160;or&#160;qPCR&#160;techniques&#160;offer&#160;such&#160;</p>
<p style="position:absolute;top:206px;left:108px;white-space:nowrap" class="ft0135">advantages&#160;&#160;as&#160;faster&#160;detection&#160;and&#160;the&#160;ability&#160;to&#160;detect&#160;multiple&#160;parasites&#160;&#160;simultaneously,&#160;&#160;making&#160;<br/>them&#160;more&#160;efficient&#160;than&#160;traditional&#160;microscopy.</p>
<p style="position:absolute;top:227px;left:440px;white-space:nowrap" class="ft0134">27</p>
<p style="position:absolute;top:226px;left:452px;white-space:nowrap" class="ft047">&#160;PCR&#160;methods&#160;&#160;have&#160;demonstrated&#160;&#160;a&#160;sensitivity&#160;</p>
<p style="position:absolute;top:245px;left:108px;white-space:nowrap" class="ft047">ranging&#160;from&#160;87%&#160;to&#160;100%&#160;and&#160;a&#160;specificity&#160;ranging&#160;from&#160;88%&#160;to&#160;100%&#160;for&#160;detecting&#160;</p>
<p style="position:absolute;top:245px;left:703px;white-space:nowrap" class="ft049"><i>C.&#160;belli</i></p>
<p style="position:absolute;top:245px;left:753px;white-space:nowrap" class="ft047">.</p>
<p style="position:absolute;top:246px;left:758px;white-space:nowrap" class="ft0134">27</p>
<p style="position:absolute;top:245px;left:770px;white-space:nowrap" class="ft047">&#160;</p>
<p style="position:absolute;top:266px;left:108px;white-space:nowrap" class="ft047">However,&#160;it&#160;is&#160;important&#160;to&#160;note&#160;that&#160;the&#160;availability&#160;of&#160;PCR&#160;may&#160;be&#160;limited&#160;in&#160;certain&#160;settings.&#160;</p>
<p style="position:absolute;top:303px;left:108px;white-space:nowrap" class="ft047">A&#160;distinguishing&#160;&#160;feature&#160;of</p>
<p style="position:absolute;top:303px;left:299px;white-space:nowrap" class="ft049"><i>C.&#160;belli</i></p>
<p style="position:absolute;top:303px;left:349px;white-space:nowrap" class="ft047">&#160;is&#160;eosinophilia.</p>
<p style="position:absolute;top:304px;left:456px;white-space:nowrap" class="ft0134">28</p>
<p style="position:absolute;top:303px;left:473px;white-space:nowrap" class="ft047">However,&#160;other&#160;helminths,&#160;certain&#160;fungi</p>
<p style="position:absolute;top:322px;left:108px;white-space:nowrap" class="ft0135">(e.g.,&#160;coccidioidomycosis,&#160;&#160;histoplasmosis,&#160;&#160;cryptococcosis),&#160;&#160;and&#160;certain&#160;protozoan&#160;parasites&#160;<br/>(e.g.,&#160;</p>
<p style="position:absolute;top:343px;left:149px;white-space:nowrap" class="ft049"><i>Dientamoeba&#160;fragilis</i></p>
<p style="position:absolute;top:343px;left:293px;white-space:nowrap" class="ft047">,&#160;</p>
<p style="position:absolute;top:343px;left:302px;white-space:nowrap" class="ft049"><i>Sarcocycstis</i></p>
<p style="position:absolute;top:343px;left:384px;white-space:nowrap" class="ft047">)&#160;&#160;should&#160;be&#160;part&#160;of&#160;the&#160;differential&#160;diagnosis&#160;&#160;as&#160;these&#160;&#160;can&#160;</p>
<p style="position:absolute;top:363px;left:108px;white-space:nowrap" class="ft047">also&#160;cause&#160;eosinophilia&#160;&#160;in&#160;the&#160;blood.&#160;</p>
<p style="position:absolute;top:396px;left:108px;white-space:nowrap" class="ft0132"><b>Preventing&#160;Exposure&#160;</b></p>
<p style="position:absolute;top:440px;left:108px;white-space:nowrap" class="ft049"><i>C</i></p>
<p style="position:absolute;top:440px;left:119px;white-space:nowrap" class="ft047">.</p>
<p style="position:absolute;top:440px;left:124px;white-space:nowrap" class="ft049"><i>&#160;belli&#160;</i></p>
<p style="position:absolute;top:440px;left:163px;white-space:nowrap" class="ft047">is&#160;acquired&#160;by&#160;ingesting&#160;contaminated&#160;&#160;water&#160;or&#160;food.&#160;Hand&#160;washing&#160;with&#160;soap,&#160;avoiding&#160;</p>
<p style="position:absolute;top:460px;left:108px;white-space:nowrap" class="ft047">potentially&#160;contaminated&#160;&#160;food&#160;(e.g.</p>
<p style="position:absolute;top:460px;left:350px;white-space:nowrap" class="ft0137"><b>,</b></p>
<p style="position:absolute;top:460px;left:355px;white-space:nowrap" class="ft047">&#160;salads)&#160;or&#160;water&#160;in&#160;cystoisosporiasis-endemic&#160;&#160;areas,&#160;and&#160;proper&#160;</p>
<p style="position:absolute;top:481px;left:108px;white-space:nowrap" class="ft047">food&#160;preparation&#160;</p>
<p style="position:absolute;top:481px;left:227px;white-space:nowrap" class="ft0137"><b>(</b></p>
<p style="position:absolute;top:481px;left:233px;white-space:nowrap" class="ft047">peeling&#160;fruits&#160;and&#160;cooking&#160;vegetables)&#160;&#160;can&#160;help&#160;prevent&#160;infection.&#160;&#160;</p>
<p style="position:absolute;top:517px;left:108px;white-space:nowrap" class="ft0136">Water&#160;filtration&#160;using&#160;certified&#160;filters&#160;is&#160;effective&#160;(absolute&#160;one&#160;micron&#160;or&#160;less,&#160;National&#160;Sanitation&#160;<br/>Foundation/American&#160;&#160;National&#160;Standards&#160;Institute&#160;[ANSI]&#160;Standard&#160;53&#160;or&#160;Standard&#160;58&#160;for&#160;cyst&#160;<br/>removal&#160;or&#160;cyst&#160;reduction&#160;by&#160;an&#160;ANSI-accredited&#160;&#160;certification&#160;organization).</p>
<p style="position:absolute;top:557px;left:635px;white-space:nowrap" class="ft0134">29</p>
<p style="position:absolute;top:556px;left:647px;white-space:nowrap" class="ft047">&#160;Filters&#160;that&#160;may&#160;</p>
<p style="position:absolute;top:556px;left:764px;white-space:nowrap" class="ft0137"><b>not</b></p>
<p style="position:absolute;top:556px;left:788px;white-space:nowrap" class="ft047">&#160;be&#160;</p>
<p style="position:absolute;top:577px;left:108px;white-space:nowrap" class="ft047">designed&#160;&#160;to&#160;safely&#160;remove&#160;</p>
<p style="position:absolute;top:577px;left:293px;white-space:nowrap" class="ft049"><i>C.&#160;belli&#160;</i></p>
<p style="position:absolute;top:577px;left:348px;white-space:nowrap" class="ft047">and&#160;other&#160;protozoans&#160;&#160;include&#160;those&#160;with&#160;a&#160;nominal&#160;pore&#160;size&#160;of&#160;</p>
<p style="position:absolute;top:597px;left:108px;white-space:nowrap" class="ft0136">one&#160;micron&#160;or&#160;smaller,&#160;filters&#160;labeled&#160;as&#160;“Effective&#160;against&#160;Giardia”&#160;&#160;or&#160;“Effective&#160;against&#160;parasites,”&#160;<br/>carbon&#160;filters,&#160;active&#160;carbon&#160;filters,&#160;chlorinated&#160;filters,&#160;ultraviolet&#160;light&#160;filters,&#160;water&#160;purifiers,&#160;and&#160;<br/>filters&#160;labeled&#160;as&#160;“U.S.&#160;Environmental&#160;Protection&#160;Agency&#160;(EPA)&#160;approved”&#160;or&#160;“EPA&#160;registered”&#160;<br/>(note:&#160;the&#160;EPA&#160;does&#160;not&#160;test,&#160;certify,&#160;or&#160;register&#160;filters&#160;based&#160;on&#160;their&#160;ability&#160;to&#160;remove&#160;</p>
<p style="position:absolute;top:656px;left:705px;white-space:nowrap" class="ft049"><i>Cystoisospora</i></p>
<p style="position:absolute;top:656px;left:799px;white-space:nowrap" class="ft047">&#160;</p>
<p style="position:absolute;top:676px;left:108px;white-space:nowrap" class="ft047">and&#160;other&#160;protozoans).&#160;</p>
<p style="position:absolute;top:711px;left:108px;white-space:nowrap" class="ft0132"><b>Preventing&#160;Disease&#160;</b></p>
<p style="position:absolute;top:764px;left:118px;white-space:nowrap" class="ft056"><b>Recommendations&#160;for&#160;Preventing&#160;&#160;First&#160;Episode&#160;&#160;of</b></p>
<p style="position:absolute;top:764px;left:458px;white-space:nowrap" class="ft068"><i><b>Cystoisospora&#160;&#160;belli</b></i></p>
<p style="position:absolute;top:764px;left:592px;white-space:nowrap" class="ft056"><b>Infection&#160;(Primary&#160;Prophylaxis)</b></p>
<p style="position:absolute;top:792px;left:116px;white-space:nowrap" class="ft042"><b>Indication</b></p>
<p style="position:absolute;top:818px;left:116px;white-space:nowrap" class="ft030">•</p>
<p style="position:absolute;top:819px;left:133px;white-space:nowrap" class="ft041">Individuals&#160;with&#160;CD4&#160;count&#160;&lt;200&#160;cells/mm</p>
<p style="position:absolute;top:821px;left:368px;white-space:nowrap" class="ft058">3</p>
<p style="position:absolute;top:819px;left:377px;white-space:nowrap" class="ft041">living&#160;in&#160;or&#160;traveling&#160;to&#160;regions&#160;endemic&#160;for</p>
<p style="position:absolute;top:819px;left:619px;white-space:nowrap" class="ft024"><i>Cystoisospora&#160;belli</i></p>
<p style="position:absolute;top:819px;left:728px;white-space:nowrap" class="ft042"><b>(CII).</b></p>
<p style="position:absolute;top:852px;left:116px;white-space:nowrap" class="ft042"><b>Preferred&#160;Therapy&#160;</b></p>
<p style="position:absolute;top:878px;left:116px;white-space:nowrap" class="ft030">•</p>
<p style="position:absolute;top:879px;left:133px;white-space:nowrap" class="ft041">TMP-SMX&#160;(160&#160;mg/800&#160;mg)&#160;PO&#160;three&#160;times&#160;weekly</p>
<p style="position:absolute;top:879px;left:431px;white-space:nowrap" class="ft042"><b>(AI),&#160;</b></p>
<p style="position:absolute;top:879px;left:461px;white-space:nowrap" class="ft024"><i>or</i></p>
<p style="position:absolute;top:905px;left:116px;white-space:nowrap" class="ft030">•</p>
<p style="position:absolute;top:906px;left:124px;white-space:nowrap" class="ft057">&#160;</p>
<p style="position:absolute;top:906px;left:133px;white-space:nowrap" class="ft041">TMP-SMX&#160;(160&#160;mg/800&#160;mg)&#160;PO&#160;daily&#160;</p>
<p style="position:absolute;top:906px;left:350px;white-space:nowrap" class="ft042"><b>(AI)</b></p>
<p style="position:absolute;top:906px;left:373px;white-space:nowrap" class="ft041">&#160;</p>
<p style="position:absolute;top:938px;left:116px;white-space:nowrap" class="ft042"><b>Criteria&#160;for&#160;Discontinuation&#160;of&#160;Primary&#160;Prophylaxis&#160;</b></p>
<p style="position:absolute;top:965px;left:116px;white-space:nowrap" class="ft030">•</p>
<p style="position:absolute;top:966px;left:124px;white-space:nowrap" class="ft057">&#160;</p>
<p style="position:absolute;top:966px;left:133px;white-space:nowrap" class="ft041">Sustained&#160;increase&#160;in&#160;CD4&#160;count&#160;to&#160;</p>
<p style="position:absolute;top:966px;left:337px;white-space:nowrap" class="ft064">≥</p>
<p style="position:absolute;top:966px;left:345px;white-space:nowrap" class="ft041">200&#160;cells/mm</p>
<p style="position:absolute;top:968px;left:420px;white-space:nowrap" class="ft058">3</p>
<p style="position:absolute;top:966px;left:425px;white-space:nowrap" class="ft041">&#160;for&#160;&gt;6&#160;months&#160;in&#160;response&#160;to&#160;ART&#160;</p>
<p style="position:absolute;top:966px;left:625px;white-space:nowrap" class="ft042"><b>(BIII).</b></p>
<p style="position:absolute;top:966px;left:659px;white-space:nowrap" class="ft041">&#160;</p>
<p style="position:absolute;top:992px;left:108px;white-space:nowrap" class="ft042"><b>Key:</b></p>
<p style="position:absolute;top:992px;left:137px;white-space:nowrap" class="ft041">&#160;ART&#160;=&#160;antiretroviral&#160;therapy;&#160;CD4&#160;=&#160;CD4&#160;T&#160;lymphocyte;&#160;PO&#160;=&#160;orally;&#160;TMP-SMX&#160;=&#160;trimethoprim-sulfamethoxazole&#160;</p>
<p style="position:absolute;top:1028px;left:108px;white-space:nowrap" class="ft0135">Several&#160;studies&#160;have&#160;found&#160;that&#160;chemoprophylaxis&#160;&#160;with&#160;trimethoprim-sulfamethoxazole&#160;&#160;(TMP-SMX)&#160;<br/>is&#160;associated&#160;&#160;with&#160;a&#160;lower&#160;incidence&#160;&#160;or&#160;prevalence&#160;of&#160;cystoisosporiasis.</p>
<p style="position:absolute;top:1049px;left:593px;white-space:nowrap" class="ft0134">1,3,4,30</p>
<p style="position:absolute;top:1048px;left:638px;white-space:nowrap" class="ft047">In&#160;a&#160;randomized,&#160;</p>
</div>
<!-- Page 161 -->
<a name="161"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}	.ft0138{font-size:16px;font-family:ICIUHX+TimesNewRomanPSMT;color:#000000;}
	.ft0139{font-size:16px;font-family:TURBHP+Tinos;color:#202020;}
	.ft0140{font-size:10px;font-family:BGKYCV+LiberationSansNarrow;color:#000000;}
	.ft0141{font-size:16px;line-height:19px;font-family:TURBHP+Tinos;color:#202020;}
	.ft0142{font-size:16px;line-height:20px;font-family:TURBHP+Tinos;color:#202020;}
	.ft0143{font-size:15px;line-height:18px;font-family:RAJFOH+LiberationSansNarrow;color:#000000;}
-->
</style>
<div id="page161-div" style="position:relative;width:917px;height:1187px;">
<p style="position:absolute;top:1117px;left:108px;white-space:nowrap" class="ft024"><i>Guidelines&#160;for&#160;the&#160;Prevention&#160;and&#160;Treatment&#160;of&#160;Opportunistic&#160;Infections&#160;in&#160;Adults&#160;and&#160;Adolescents&#160;With&#160;HIV&#160;</i></p>
<p style="position:absolute;top:1117px;left:792px;white-space:nowrap" class="ft024"><i>J-3&#160;</i></p>
<p style="position:absolute;top:110px;left:108px;white-space:nowrap" class="ft0135">placebo-controlled&#160;&#160;trial,&#160;daily&#160;TMP-SMX&#160;&#160;(160/800&#160;mg)&#160;was&#160;protective&#160;against&#160;&#160;cystoisosporiasis&#160;&#160;in&#160;<br/>people&#160;with&#160;early-stage&#160;&#160;HIV&#160;infection&#160;(World&#160;Health&#160;Organization&#160;clinical&#160;stage&#160;2&#160;or&#160;3&#160;at<br/>enrollment).</p>
<p style="position:absolute;top:150px;left:192px;white-space:nowrap" class="ft0134">1</p>
<p style="position:absolute;top:149px;left:203px;white-space:nowrap" class="ft047">In&#160;an&#160;observational&#160;&#160;study,</p>
<p style="position:absolute;top:150px;left:380px;white-space:nowrap" class="ft0134">3</p>
<p style="position:absolute;top:149px;left:386px;white-space:nowrap" class="ft047">&#160;the&#160;incidence&#160;&#160;of&#160;cystoisosporiasis&#160;&#160;decreased&#160;&#160;after&#160;</p>
<p style="position:absolute;top:169px;left:108px;white-space:nowrap" class="ft0135">widespread&#160;&#160;introduction&#160;of&#160;antiretroviral&#160;therapy&#160;(ART),&#160;except&#160;in&#160;individuals&#160;&#160;with&#160;CD4&#160;counts&#160;&lt;50&#160;<br/>cells/mm</p>
<p style="position:absolute;top:190px;left:169px;white-space:nowrap" class="ft0134">3</p>
<p style="position:absolute;top:189px;left:175px;white-space:nowrap" class="ft047">.&#160;In&#160;that&#160;study,&#160;multivariable&#160;analysis&#160;found&#160;the&#160;relative&#160;hazard&#160;for</p>
<p style="position:absolute;top:189px;left:638px;white-space:nowrap" class="ft049"><i>C.&#160;belli&#160;</i></p>
<p style="position:absolute;top:189px;left:693px;white-space:nowrap" class="ft047">infection&#160;was&#160;</p>
<p style="position:absolute;top:208px;left:108px;white-space:nowrap" class="ft047">6.2&#160;in&#160;individuals&#160;with&#160;CD4&#160;counts&#160;between&#160;50&#160;and&#160;199&#160;cells/mm</p>
<p style="position:absolute;top:209px;left:558px;white-space:nowrap" class="ft0134">3&#160;</p>
<p style="position:absolute;top:208px;left:569px;white-space:nowrap" class="ft047">and&#160;15.9&#160;for&#160;individuals&#160;with&#160;CD4&#160;</p>
<p style="position:absolute;top:229px;left:108px;white-space:nowrap" class="ft047">counts&#160;&lt;50&#160;cells/mm</p>
<p style="position:absolute;top:229px;left:250px;white-space:nowrap" class="ft0134">3</p>
<p style="position:absolute;top:229px;left:256px;white-space:nowrap" class="ft047">.&#160;After&#160;adjustment&#160;for&#160;the&#160;CD4&#160;count,&#160;the&#160;risk&#160;of&#160;cystoisosporiasis&#160;&#160;was&#160;</p>
<p style="position:absolute;top:248px;left:108px;white-space:nowrap" class="ft0136">substantially&#160;&#160;lower&#160;in&#160;those&#160;receiving&#160;prophylaxis&#160;&#160;with&#160;TMP-SMX,&#160;&#160;sulfadiazine,&#160;or&#160;pyrimethamine&#160;<br/>(unspecified&#160;&#160;regimens).&#160;In&#160;analyses&#160;&#160;of&#160;data&#160;from&#160;a&#160;Los&#160;Angeles&#160;&#160;County&#160;AIDS&#160;surveillance&#160;&#160;registry&#160;<br/>during&#160;the&#160;pre-ART&#160;&#160;era,&#160;the&#160;prevalence&#160;of&#160;cystoisosporiasis&#160;&#160;was&#160;lower&#160;in&#160;people&#160;with&#160;a&#160;history&#160;of&#160;</p>
<p style="position:absolute;top:308px;left:108px;white-space:nowrap" class="ft049"><i>Pneumocystis</i></p>
<p style="position:absolute;top:308px;left:199px;white-space:nowrap" class="ft047">&#160;&#160;pneumonia&#160;(PCP)&#160;compared&#160;to&#160;those&#160;without&#160;PCP;&#160;indirect&#160;evidence&#160;&#160;of&#160;a&#160;protective&#160;</p>
<p style="position:absolute;top:327px;left:108px;white-space:nowrap" class="ft047">effect&#160;from&#160;the&#160;use&#160;of&#160;TMP-SMX&#160;for&#160;PCP&#160;treatment&#160;and&#160;secondary&#160;&#160;prevention.</p>
<p style="position:absolute;top:328px;left:653px;white-space:nowrap" class="ft0134">4</p>
<p style="position:absolute;top:327px;left:664px;white-space:nowrap" class="ft047">Given&#160;the</p>
<p style="position:absolute;top:347px;left:108px;white-space:nowrap" class="ft0136">substantially&#160;&#160;increased&#160;&#160;risk&#160;of&#160;infection&#160;in&#160;individuals&#160;with&#160;low&#160;CD4&#160;counts,&#160;we&#160;recommend&#160;ensuring&#160;<br/>that&#160;individuals&#160;&#160;with&#160;CD4&#160;counts&#160;&lt;200&#160;cells/mm</p>
<p style="position:absolute;top:367px;left:442px;white-space:nowrap" class="ft0134">3&#160;</p>
<p style="position:absolute;top:367px;left:452px;white-space:nowrap" class="ft047">are&#160;started&#160;and&#160;maintained&#160;&#160;on&#160;TMP-SMX&#160;&#160;if&#160;they&#160;</p>
<p style="position:absolute;top:387px;left:108px;white-space:nowrap" class="ft047">are&#160;living&#160;in&#160;or&#160;traveling&#160;to&#160;regions&#160;endemic&#160;for&#160;</p>
<p style="position:absolute;top:387px;left:440px;white-space:nowrap" class="ft049"><i>C.&#160;belli&#160;</i></p>
<p style="position:absolute;top:387px;left:495px;white-space:nowrap" class="ft0137"><b>(CII)</b></p>
<p style="position:absolute;top:387px;left:531px;white-space:nowrap" class="ft047">.&#160;Primary&#160;prophylaxis&#160;can&#160;be</p>
<p style="position:absolute;top:406px;left:108px;white-space:nowrap" class="ft047">discontinued&#160;&#160;for&#160;people&#160;with&#160;a&#160;sustained&#160;&#160;increase&#160;in&#160;CD4&#160;count&#160;to&#160;</p>
<p style="position:absolute;top:406px;left:566px;white-space:nowrap" class="ft0138">≥</p>
<p style="position:absolute;top:406px;left:576px;white-space:nowrap" class="ft047">200&#160;cells/mm</p>
<p style="position:absolute;top:407px;left:667px;white-space:nowrap" class="ft0134">3</p>
<p style="position:absolute;top:406px;left:673px;white-space:nowrap" class="ft047">&#160;for&#160;&gt;6&#160;months&#160;in&#160;</p>
<p style="position:absolute;top:427px;left:108px;white-space:nowrap" class="ft047">response&#160;&#160;to&#160;ART&#160;</p>
<p style="position:absolute;top:427px;left:229px;white-space:nowrap" class="ft0137"><b>(BIII).&#160;</b></p>
<p style="position:absolute;top:427px;left:281px;white-space:nowrap" class="ft0139">Data&#160;on&#160;alternative&#160;medications&#160;&#160;for&#160;primary&#160;prophylaxis&#160;for&#160;people&#160;with&#160;</p>
<p style="position:absolute;top:447px;left:108px;white-space:nowrap" class="ft0142">sulfa&#160;intolerance&#160;are&#160;limited.&#160;The&#160;primary&#160;approach&#160;to&#160;prevention&#160;of&#160;cystoisosporiasis&#160;&#160;is&#160;to&#160;reduce&#160;the&#160;<br/>risk&#160;of&#160;acquisition&#160;by&#160;avoiding&#160;potentially&#160;contaminated&#160;&#160;food&#160;or&#160;water&#160;in&#160;cystoisosporiasis-endemic&#160;<br/>areas&#160;via&#160;regular&#160;hand&#160;washing,&#160;proper&#160;food&#160;preparation&#160;(peeling&#160;fruits,&#160;cooking&#160;vegetables),&#160;&#160;and&#160;use&#160;<br/>of&#160;certified&#160;water&#160;filters&#160;of&#160;1&#160;micron&#160;or&#160;less.</p>
<p style="position:absolute;top:507px;left:409px;white-space:nowrap" class="ft047">&#160;</p>
<p style="position:absolute;top:541px;left:108px;white-space:nowrap" class="ft0132"><b>Treating&#160;Disease&#160;</b></p>
<p style="position:absolute;top:595px;left:257px;white-space:nowrap" class="ft056"><b>Recommendations&#160;&#160;for&#160;Treating&#160;</b></p>
<p style="position:absolute;top:595px;left:469px;white-space:nowrap" class="ft068"><i><b>Cystoisospora&#160;&#160;belli</b></i></p>
<p style="position:absolute;top:595px;left:598px;white-space:nowrap" class="ft056"><b>&#160;&#160;Infection&#160;&#160;&#160;</b></p>
<p style="position:absolute;top:623px;left:116px;white-space:nowrap" class="ft042"><b>General&#160;Management&#160;Considerations&#160;</b></p>
<p style="position:absolute;top:649px;left:116px;white-space:nowrap" class="ft030">•</p>
<p style="position:absolute;top:651px;left:124px;white-space:nowrap" class="ft057">&#160;</p>
<p style="position:absolute;top:650px;left:133px;white-space:nowrap" class="ft041">Fluid&#160;and&#160;electrolyte&#160;support&#160;in&#160;patients&#160;with&#160;dehydration&#160;</p>
<p style="position:absolute;top:650px;left:456px;white-space:nowrap" class="ft042"><b>(AIII)</b></p>
<p style="position:absolute;top:650px;left:486px;white-space:nowrap" class="ft041">&#160;</p>
<p style="position:absolute;top:676px;left:116px;white-space:nowrap" class="ft030">•</p>
<p style="position:absolute;top:677px;left:124px;white-space:nowrap" class="ft057">&#160;</p>
<p style="position:absolute;top:677px;left:133px;white-space:nowrap" class="ft041">Nutritional&#160;supplementation&#160;for&#160;people&#160;who&#160;are&#160;malnourished&#160;</p>
<p style="position:absolute;top:677px;left:483px;white-space:nowrap" class="ft042"><b>(AIII)</b></p>
<p style="position:absolute;top:677px;left:513px;white-space:nowrap" class="ft041">&#160;</p>
<p style="position:absolute;top:709px;left:116px;white-space:nowrap" class="ft042"><b>Preferred&#160;Therapy&#160;for&#160;Acute&#160;Infection&#160;</b></p>
<p style="position:absolute;top:736px;left:116px;white-space:nowrap" class="ft030">•</p>
<p style="position:absolute;top:737px;left:124px;white-space:nowrap" class="ft057">&#160;</p>
<p style="position:absolute;top:737px;left:133px;white-space:nowrap" class="ft041">TMP-SMX</p>
<p style="position:absolute;top:737px;left:193px;white-space:nowrap" class="ft042"><b>&#160;</b></p>
<p style="position:absolute;top:737px;left:197px;white-space:nowrap" class="ft041">(160&#160;mg/800&#160;mg)&#160;PO&#160;(or&#160;IV)&#160;four&#160;times&#160;daily&#160;for&#160;10&#160;days&#160;</p>
<p style="position:absolute;top:737px;left:518px;white-space:nowrap" class="ft042"><b>(AII),</b></p>
<p style="position:absolute;top:737px;left:548px;white-space:nowrap" class="ft041">&#160;</p>
<p style="position:absolute;top:737px;left:552px;white-space:nowrap" class="ft024"><i>or</i></p>
<p style="position:absolute;top:737px;left:564px;white-space:nowrap" class="ft041">&#160;</p>
<p style="position:absolute;top:763px;left:116px;white-space:nowrap" class="ft030">•</p>
<p style="position:absolute;top:765px;left:124px;white-space:nowrap" class="ft057">&#160;</p>
<p style="position:absolute;top:764px;left:133px;white-space:nowrap" class="ft041">TMP-SMX&#160;(160&#160;mg/800&#160;mg)&#160;PO&#160;(or&#160;IV)&#160;twice&#160;daily&#160;for&#160;7&#160;days&#160;</p>
<p style="position:absolute;top:764px;left:483px;white-space:nowrap" class="ft042"><b>(BI),&#160;</b></p>
<p style="position:absolute;top:764px;left:513px;white-space:nowrap" class="ft024"><i>or</i></p>
<p style="position:absolute;top:764px;left:525px;white-space:nowrap" class="ft041">&#160;</p>
<p style="position:absolute;top:791px;left:133px;white-space:nowrap" class="ft062">o</p>
<p style="position:absolute;top:790px;left:143px;white-space:nowrap" class="ft057">&#160;</p>
<p style="position:absolute;top:789px;left:149px;white-space:nowrap" class="ft0143">In&#160;patients&#160;with&#160;persistent&#160;or&#160;worsening&#160;symptoms&#160;while&#160;on&#160;TMP-SMX&#160;(160&#160;mg/800&#160;mg)&#160;twice&#160;daily,&#160;consider&#160;increasing&#160;<br/>the&#160;daily&#160;dose&#160;and/or&#160;extending&#160;the&#160;duration&#160;to&#160;3–4&#160;weeks&#160;</p>
<p style="position:absolute;top:807px;left:481px;white-space:nowrap" class="ft042"><b>(BIII).</b></p>
<p style="position:absolute;top:807px;left:515px;white-space:nowrap" class="ft041">&#160;</p>
<p style="position:absolute;top:833px;left:116px;white-space:nowrap" class="ft042"><b>Note:</b></p>
<p style="position:absolute;top:833px;left:151px;white-space:nowrap" class="ft041">&#160;IV&#160;TMP-SMX&#160;may&#160;be&#160;used&#160;for&#160;patients&#160;with&#160;potential&#160;or&#160;documented&#160;malabsorption.&#160;</p>
<p style="position:absolute;top:865px;left:116px;white-space:nowrap" class="ft042"><b>Alternative&#160;Therapy&#160;for&#160;Acute&#160;Infection&#160;(For&#160;Patients&#160;With&#160;Sulfa&#160;Intolerance&#160;[AIII])&#160;</b></p>
<p style="position:absolute;top:891px;left:116px;white-space:nowrap" class="ft030">•</p>
<p style="position:absolute;top:893px;left:124px;white-space:nowrap" class="ft057">&#160;</p>
<p style="position:absolute;top:893px;left:133px;white-space:nowrap" class="ft041">Pyrimethamine&#160;50–75&#160;mg&#160;PO&#160;daily&#160;plus&#160;leucovorin&#160;10–25&#160;mg&#160;PO&#160;daily&#160;for&#160;4&#160;weeks&#160;</p>
<p style="position:absolute;top:893px;left:602px;white-space:nowrap" class="ft042"><b>(BIII),&#160;</b></p>
<p style="position:absolute;top:893px;left:639px;white-space:nowrap" class="ft024"><i>or</i></p>
<p style="position:absolute;top:893px;left:651px;white-space:nowrap" class="ft041">&#160;</p>
<p style="position:absolute;top:919px;left:116px;white-space:nowrap" class="ft030">•</p>
<p style="position:absolute;top:921px;left:124px;white-space:nowrap" class="ft057">&#160;</p>
<p style="position:absolute;top:920px;left:133px;white-space:nowrap" class="ft041">Ciprofloxacin&#160;500&#160;mg&#160;PO&#160;or&#160;400&#160;mg&#160;IV&#160;(for&#160;those&#160;who&#160;cannot&#160;tolerate&#160;PO)&#160;twice&#160;daily&#160;for&#160;7&#160;days&#160;</p>
<p style="position:absolute;top:920px;left:679px;white-space:nowrap" class="ft042"><b>(CI)</b></p>
<p style="position:absolute;top:920px;left:702px;white-space:nowrap" class="ft041">&#160;</p>
<p style="position:absolute;top:953px;left:116px;white-space:nowrap" class="ft056"><b>Chronic&#160;Maintenance&#160;Therapy&#160;(or&#160;Secondary&#160;Prophylaxis)&#160;</b></p>
<p style="position:absolute;top:972px;left:116px;white-space:nowrap" class="ft056"><b>(In&#160;People&#160;With&#160;HIV&#160;and&#160;CD4&#160;Count&#160;&lt;200&#160;cells/mm</b></p>
<p style="position:absolute;top:973px;left:437px;white-space:nowrap" class="ft0140"><b>3</b></p>
<p style="position:absolute;top:972px;left:442px;white-space:nowrap" class="ft056"><b>)</b></p>
<p style="position:absolute;top:972px;left:446px;white-space:nowrap" class="ft068"><i><b>&#160;</b></i></p>
<p style="position:absolute;top:995px;left:116px;white-space:nowrap" class="ft042"><b>Preferred&#160;Therapy&#160;</b></p>
<p style="position:absolute;top:1021px;left:116px;white-space:nowrap" class="ft030">•</p>
<p style="position:absolute;top:1023px;left:124px;white-space:nowrap" class="ft057">&#160;</p>
<p style="position:absolute;top:1022px;left:133px;white-space:nowrap" class="ft041">TMP-SMX&#160;(160&#160;mg/800&#160;mg)&#160;PO&#160;three&#160;times&#160;weekly&#160;</p>
<p style="position:absolute;top:1022px;left:431px;white-space:nowrap" class="ft042"><b>(AI),&#160;</b></p>
<p style="position:absolute;top:1022px;left:461px;white-space:nowrap" class="ft024"><i>or</i></p>
<p style="position:absolute;top:1022px;left:473px;white-space:nowrap" class="ft042"><b>&#160;</b></p>
<p style="position:absolute;top:1048px;left:116px;white-space:nowrap" class="ft030">•</p>
<p style="position:absolute;top:1049px;left:124px;white-space:nowrap" class="ft057">&#160;</p>
<p style="position:absolute;top:1049px;left:133px;white-space:nowrap" class="ft041">TMP-SMX&#160;(160&#160;mg/800&#160;mg)&#160;PO&#160;daily&#160;</p>
<p style="position:absolute;top:1049px;left:350px;white-space:nowrap" class="ft042"><b>(AIII)</b></p>
<p style="position:absolute;top:1049px;left:380px;white-space:nowrap" class="ft041">&#160;</p>
</div>
<!-- Page 162 -->
<a name="162"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}	.ft0144{font-size:16px;font-family:GGOOQY+Cambria;color:#000000;}
	.ft0145{font-size:15px;line-height:19px;font-family:RAJFOH+LiberationSansNarrow;color:#000000;}
-->
</style>
<div id="page162-div" style="position:relative;width:917px;height:1187px;">
<p style="position:absolute;top:1117px;left:108px;white-space:nowrap" class="ft024"><i>Guidelines&#160;for&#160;the&#160;Prevention&#160;and&#160;Treatment&#160;of&#160;Opportunistic&#160;Infections&#160;in&#160;Adults&#160;and&#160;Adolescents&#160;With&#160;HIV&#160;</i></p>
<p style="position:absolute;top:1117px;left:792px;white-space:nowrap" class="ft024"><i>J-4&#160;</i></p>
<p style="position:absolute;top:109px;left:116px;white-space:nowrap" class="ft042"><b>Alternative&#160;Therapy</b></p>
<p style="position:absolute;top:134px;left:116px;white-space:nowrap" class="ft030">•</p>
<p style="position:absolute;top:135px;left:133px;white-space:nowrap" class="ft041">TMP-SMX&#160;(320&#160;mg/1,600&#160;mg)&#160;PO&#160;three&#160;times&#160;weekly&#160;</p>
<p style="position:absolute;top:135px;left:441px;white-space:nowrap" class="ft042"><b>(BIII),</b></p>
<p style="position:absolute;top:135px;left:479px;white-space:nowrap" class="ft024"><i>or</i></p>
<p style="position:absolute;top:162px;left:116px;white-space:nowrap" class="ft030">•</p>
<p style="position:absolute;top:163px;left:124px;white-space:nowrap" class="ft057">&#160;</p>
<p style="position:absolute;top:163px;left:133px;white-space:nowrap" class="ft041">Pyrimethamine&#160;25&#160;mg&#160;PO&#160;daily&#160;+&#160;leucovorin&#160;5–10&#160;mg&#160;PO&#160;daily&#160;</p>
<p style="position:absolute;top:163px;left:488px;white-space:nowrap" class="ft042"><b>(BIII),&#160;</b></p>
<p style="position:absolute;top:163px;left:525px;white-space:nowrap" class="ft024"><i>or</i></p>
<p style="position:absolute;top:163px;left:537px;white-space:nowrap" class="ft041">&#160;</p>
<p style="position:absolute;top:190px;left:116px;white-space:nowrap" class="ft030">•</p>
<p style="position:absolute;top:191px;left:124px;white-space:nowrap" class="ft057">&#160;</p>
<p style="position:absolute;top:191px;left:133px;white-space:nowrap" class="ft041">Ciprofloxacin&#160;500&#160;mg&#160;PO&#160;three&#160;times&#160;weekly&#160;</p>
<p style="position:absolute;top:191px;left:387px;white-space:nowrap" class="ft042"><b>(CI)</b></p>
<p style="position:absolute;top:191px;left:410px;white-space:nowrap" class="ft041">&#160;as&#160;a&#160;second-line&#160;alternative&#160;</p>
<p style="position:absolute;top:223px;left:116px;white-space:nowrap" class="ft042"><b>Criteria&#160;for&#160;Discontinuation&#160;of&#160;Chronic&#160;Maintenance&#160;Therapy&#160;</b></p>
<p style="position:absolute;top:247px;left:116px;white-space:nowrap" class="ft030">•</p>
<p style="position:absolute;top:249px;left:124px;white-space:nowrap" class="ft057">&#160;</p>
<p style="position:absolute;top:248px;left:133px;white-space:nowrap" class="ft041">Sustained&#160;increase&#160;in&#160;CD4&#160;count&#160;</p>
<p style="position:absolute;top:248px;left:317px;white-space:nowrap" class="ft064">≥</p>
<p style="position:absolute;top:248px;left:325px;white-space:nowrap" class="ft041">200&#160;cells/mm</p>
<p style="position:absolute;top:250px;left:398px;white-space:nowrap" class="ft058">3</p>
<p style="position:absolute;top:248px;left:403px;white-space:nowrap" class="ft041">&#160;for&#160;&gt;6&#160;months&#160;in&#160;response&#160;to&#160;ART&#160;and&#160;without&#160;evidence&#160;of&#160;active&#160;</p>
<p style="position:absolute;top:248px;left:763px;white-space:nowrap" class="ft024"><i>C.&#160;belli</i></p>
<p style="position:absolute;top:248px;left:801px;white-space:nowrap" class="ft041">&#160;</p>
<p style="position:absolute;top:267px;left:133px;white-space:nowrap" class="ft041">infection&#160;</p>
<p style="position:absolute;top:267px;left:184px;white-space:nowrap" class="ft042"><b>(BIII)</b></p>
<p style="position:absolute;top:267px;left:214px;white-space:nowrap" class="ft041">&#160;</p>
<p style="position:absolute;top:300px;left:116px;white-space:nowrap" class="ft056"><b>Other&#160;Considerations&#160;</b></p>
<p style="position:absolute;top:323px;left:116px;white-space:nowrap" class="ft030">•</p>
<p style="position:absolute;top:324px;left:124px;white-space:nowrap" class="ft057">&#160;</p>
<p style="position:absolute;top:324px;left:133px;white-space:nowrap" class="ft041">TMP-SMX&#160;double-strength&#160;tablets&#160;are&#160;(160&#160;mg/800&#160;mg).&#160;</p>
<p style="position:absolute;top:350px;left:116px;white-space:nowrap" class="ft030">•</p>
<p style="position:absolute;top:351px;left:133px;white-space:nowrap" class="ft041">Ciprofloxacin&#160;can&#160;increase&#160;QTc&#160;and&#160;has&#160;been&#160;associated&#160;with&#160;tendon&#160;rupture&#160;and&#160;aortic&#160;aneurysms.</p>
<p style="position:absolute;top:376px;left:116px;white-space:nowrap" class="ft030">•</p>
<p style="position:absolute;top:377px;left:124px;white-space:nowrap" class="ft057">&#160;</p>
<p style="position:absolute;top:377px;left:133px;white-space:nowrap" class="ft0145">Due&#160;to&#160;concerns&#160;about&#160;possible&#160;teratogenicity&#160;associated&#160;with&#160;first-trimester&#160;drug&#160;exposure,&#160;clinicians&#160;may&#160;withhold&#160;<br/>secondary&#160;prophylaxis&#160;during&#160;the&#160;first&#160;trimester&#160;and&#160;treat&#160;only&#160;symptomatic&#160;infection&#160;</p>
<p style="position:absolute;top:396px;left:608px;white-space:nowrap" class="ft042"><b>(CIII),&#160;</b></p>
<p style="position:absolute;top:396px;left:645px;white-space:nowrap" class="ft041">unless&#160;it&#160;is&#160;needed&#160;for&#160;PCP&#160;</p>
<p style="position:absolute;top:413px;left:133px;white-space:nowrap" class="ft041">prophylaxis.&#160;Clinicians&#160;should&#160;consider&#160;giving&#160;supplemental&#160;folic&#160;acid&#160;4&#160;mg/day&#160;to&#160;women&#160;of&#160;childbearing&#160;potential&#160;on&#160;</p>
<p style="position:absolute;top:429px;left:133px;white-space:nowrap" class="ft041">TMP-SMX&#160;prior&#160;to&#160;pregnancy&#160;or&#160;as&#160;soon&#160;as&#160;possible&#160;in&#160;their&#160;first&#160;trimester</p>
<p style="position:absolute;top:429px;left:554px;white-space:nowrap" class="ft042"><b>(BIII).</b></p>
<p style="position:absolute;top:457px;left:108px;white-space:nowrap" class="ft042"><b>Key:</b></p>
<p style="position:absolute;top:457px;left:137px;white-space:nowrap" class="ft041">&#160;ART&#160;=&#160;antiretroviral&#160;therapy;&#160;CD4&#160;=&#160;CD4&#160;T&#160;lymphocyte;&#160;IV&#160;=&#160;intravenously;&#160;PCP&#160;=&#160;</p>
<p style="position:absolute;top:457px;left:588px;white-space:nowrap" class="ft024"><i>Pneumocystis</i></p>
<p style="position:absolute;top:457px;left:666px;white-space:nowrap" class="ft041">&#160;pneumonia;&#160;PO&#160;=&#160;orally;&#160;</p>
<p style="position:absolute;top:475px;left:108px;white-space:nowrap" class="ft041">QTc&#160;=&#160;QT&#160;corrected&#160;for&#160;heart&#160;rate;&#160;TMP-SMX&#160;=&#160;trimethoprim-sulfamethoxazole&#160;</p>
<p style="position:absolute;top:509px;left:108px;white-space:nowrap" class="ft047">Clinical&#160;management&#160;includes&#160;&#160;fluid&#160;and&#160;electrolyte&#160;support&#160;for&#160;people&#160;with&#160;dehydration&#160;</p>
<p style="position:absolute;top:509px;left:716px;white-space:nowrap" class="ft0137"><b>(AIII)&#160;</b></p>
<p style="position:absolute;top:509px;left:765px;white-space:nowrap" class="ft047">and&#160;</p>
<p style="position:absolute;top:530px;left:108px;white-space:nowrap" class="ft047">nutritional&#160;supplementation&#160;&#160;for&#160;people&#160;who&#160;are&#160;malnourished&#160;</p>
<p style="position:absolute;top:530px;left:535px;white-space:nowrap" class="ft0137"><b>(AIII).</b></p>
<p style="position:absolute;top:530px;left:582px;white-space:nowrap" class="ft047">&#160;TMP-SMX&#160;&#160;is&#160;the&#160;antimicrobial&#160;</p>
<p style="position:absolute;top:549px;left:108px;white-space:nowrap" class="ft047">agent&#160;of&#160;choice&#160;for&#160;treatment&#160;of&#160;cystoisosporiasis&#160;</p>
<p style="position:absolute;top:549px;left:451px;white-space:nowrap" class="ft0137"><b>(AII).</b></p>
<p style="position:absolute;top:549px;left:498px;white-space:nowrap" class="ft047">It&#160;is&#160;the&#160;only&#160;agent&#160;whose&#160;use&#160;is&#160;supported&#160;</p>
<p style="position:absolute;top:569px;left:108px;white-space:nowrap" class="ft0135">by&#160;substantial&#160;&#160;published&#160;&#160;data&#160;and&#160;clinical&#160;experience.&#160;&#160;Therefore,&#160;potential&#160;alternative&#160;&#160;therapies&#160;<br/>should&#160;be&#160;reserved&#160;for&#160;people&#160;with&#160;documented&#160;&#160;sulfa&#160;intolerance</p>
<p style="position:absolute;top:590px;left:559px;white-space:nowrap" class="ft0137"><b>(AIII)&#160;</b></p>
<p style="position:absolute;top:590px;left:607px;white-space:nowrap" class="ft047">or&#160;in&#160;whom&#160;treatment&#160;fails&#160;</p>
<p style="position:absolute;top:610px;left:108px;white-space:nowrap" class="ft0137"><b>(BIII).</b></p>
<p style="position:absolute;top:610px;left:154px;white-space:nowrap" class="ft047">&#160;</p>
<p style="position:absolute;top:646px;left:108px;white-space:nowrap" class="ft0135">Three&#160;studies&#160;in&#160;people&#160;with&#160;HIV&#160;in&#160;Haiti&#160;have&#160;demonstrated&#160;&#160;the&#160;effectiveness&#160;&#160;of&#160;various&#160;TMP-SMX&#160;<br/>treatment&#160;regimens.</p>
<p style="position:absolute;top:667px;left:244px;white-space:nowrap" class="ft0134">6,7,31</p>
<p style="position:absolute;top:667px;left:272px;white-space:nowrap" class="ft047">&#160;Participants&#160;&#160;in&#160;these&#160;studies&#160;were&#160;not&#160;receiving&#160;ART,&#160;and&#160;laboratory&#160;</p>
<p style="position:absolute;top:686px;left:108px;white-space:nowrap" class="ft0135">indicators&#160;of&#160;immunodeficiency&#160;&#160;(such&#160;as&#160;CD4&#160;cell&#160;counts)&#160;were&#160;not&#160;reported.&#160;Based&#160;&#160;on&#160;the&#160;initial&#160;<br/>studies,</p>
<p style="position:absolute;top:707px;left:158px;white-space:nowrap" class="ft0134">6,7</p>
<p style="position:absolute;top:705px;left:173px;white-space:nowrap" class="ft0144"><i>&#160;</i></p>
<p style="position:absolute;top:706px;left:178px;white-space:nowrap" class="ft047">the&#160;traditional&#160;treatment&#160;regimen&#160;has&#160;been&#160;a&#160;10-day&#160;course&#160;of&#160;TMP-SMX&#160;&#160;(160/800&#160;mg)&#160;</p>
<p style="position:absolute;top:725px;left:108px;white-space:nowrap" class="ft047">administered&#160;&#160;orally&#160;four&#160;times&#160;daily&#160;</p>
<p style="position:absolute;top:725px;left:360px;white-space:nowrap" class="ft0137"><b>(AII).</b></p>
<p style="position:absolute;top:726px;left:401px;white-space:nowrap" class="ft0134">7,32</p>
<p style="position:absolute;top:725px;left:421px;white-space:nowrap" class="ft047">&#160;In&#160;another&#160;study,&#160;TMP-SMX&#160;&#160;(160/800&#160;mg)&#160;</p>
<p style="position:absolute;top:746px;left:108px;white-space:nowrap" class="ft047">administered&#160;&#160;twice&#160;daily&#160;for&#160;seven&#160;days&#160;was&#160;also&#160;effective&#160;</p>
<p style="position:absolute;top:746px;left:513px;white-space:nowrap" class="ft0137"><b>(BI).</b></p>
<p style="position:absolute;top:746px;left:547px;white-space:nowrap" class="ft0134">31</p>
<p style="position:absolute;top:746px;left:559px;white-space:nowrap" class="ft047">&#160;Although&#160;published&#160;&#160;experience&#160;</p>
<p style="position:absolute;top:765px;left:108px;white-space:nowrap" class="ft0135">using&#160;twice-daily&#160;TMP-SMX&#160;(160/800&#160;mg)&#160;is&#160;limited,&#160;one&#160;approach&#160;would&#160;be&#160;to&#160;start&#160;with&#160;this<br/>regimen&#160;but&#160;increase&#160;the&#160;daily&#160;dose&#160;and/or&#160;the&#160;duration&#160;of&#160;therapy&#160;(up&#160;to&#160;3&#160;to&#160;4&#160;weeks)</p>
<p style="position:absolute;top:786px;left:703px;white-space:nowrap" class="ft0134">6,16</p>
<p style="position:absolute;top:785px;left:724px;white-space:nowrap" class="ft047">&#160;if&#160;</p>
<p style="position:absolute;top:805px;left:108px;white-space:nowrap" class="ft047">symptoms&#160;&#160;worsen&#160;or&#160;persist</p>
<p style="position:absolute;top:805px;left:306px;white-space:nowrap" class="ft0137"><b>(BIII).</b></p>
<p style="position:absolute;top:805px;left:351px;white-space:nowrap" class="ft047">&#160;Intravenous&#160;administration&#160;&#160;of&#160;TMP-SMX&#160;should&#160;be&#160;considered&#160;</p>
<p style="position:absolute;top:825px;left:108px;white-space:nowrap" class="ft0135">for&#160;patients&#160;with&#160;potential&#160;or&#160;documented&#160;malabsorption&#160;or&#160;for&#160;those&#160;who&#160;cannot&#160;tolerate&#160;oral<br/>medications.&#160;</p>
<p style="position:absolute;top:881px;left:108px;white-space:nowrap" class="ft0135">Some&#160;data&#160;suggest&#160;&#160;that&#160;therapy&#160;with&#160;pyrimethamine–sulfadiazine&#160;&#160;and&#160;pyrimethamine–sulfadoxine&#160;<br/>may&#160;be&#160;effective.</p>
<p style="position:absolute;top:902px;left:227px;white-space:nowrap" class="ft0134">2,15,16,33,34</p>
<p style="position:absolute;top:902px;left:290px;white-space:nowrap" class="ft047">&#160;However,&#160;the&#160;combination&#160;of&#160;pyrimethamine&#160;plus&#160;sulfadoxine&#160;</p>
<p style="position:absolute;top:902px;left:726px;white-space:nowrap" class="ft0137"><b>is&#160;not&#160;</b></p>
<p style="position:absolute;top:921px;left:108px;white-space:nowrap" class="ft0137"><b>typically&#160;recommended&#160;(CIII),</b></p>
<p style="position:absolute;top:921px;left:337px;white-space:nowrap" class="ft047">due&#160;to&#160;associations&#160;with&#160;an&#160;increased&#160;&#160;risk&#160;of&#160;severe&#160;cutaneous</p>
<p style="position:absolute;top:941px;left:108px;white-space:nowrap" class="ft047">reactions,&#160;including&#160;Stevens-Johnson&#160;&#160;syndrome,</p>
<p style="position:absolute;top:942px;left:439px;white-space:nowrap" class="ft0134">35&#160;</p>
<p style="position:absolute;top:941px;left:455px;white-space:nowrap" class="ft047">and&#160;slow&#160;clearance&#160;&#160;from&#160;the&#160;body&#160;after&#160;therapy&#160;is&#160;</p>
<p style="position:absolute;top:962px;left:108px;white-space:nowrap" class="ft047">discontinued.</p>
<p style="position:absolute;top:962px;left:198px;white-space:nowrap" class="ft0137"><b>&#160;</b></p>
<p style="position:absolute;top:962px;left:205px;white-space:nowrap" class="ft047">In&#160;addition,&#160;sulfadoxine&#160;is&#160;not&#160;commercially&#160;&#160;available&#160;in&#160;the&#160;United&#160;States.&#160;</p>
<p style="position:absolute;top:998px;left:108px;white-space:nowrap" class="ft0135">Single-agent&#160;therapy&#160;with&#160;pyrimethamine&#160;&#160;has&#160;been&#160;used,&#160;with&#160;anecdotal&#160;&#160;success&#160;&#160;for&#160;treatment&#160;and&#160;<br/>prevention&#160;of&#160;cystoisosporiasis.</p>
<p style="position:absolute;top:1019px;left:322px;white-space:nowrap" class="ft0134">3,36,37</p>
<p style="position:absolute;top:1018px;left:356px;white-space:nowrap" class="ft047">&#160;&#160;Pyrimethamine&#160;&#160;(50–75&#160;mg/day)&#160;plus&#160;leucovorin&#160;</p>
<p style="position:absolute;top:1037px;left:108px;white-space:nowrap" class="ft0135">(10–25&#160;mg/day)&#160;for&#160;4&#160;weeks&#160;may&#160;be&#160;an&#160;effective&#160;treatment&#160;alternative&#160;option&#160;for&#160;sulfa-intolerant&#160;<br/>patients&#160;</p>
<p style="position:absolute;top:1058px;left:166px;white-space:nowrap" class="ft0137"><b>(BIII).&#160;</b></p>
<p style="position:absolute;top:1058px;left:217px;white-space:nowrap" class="ft047">The&#160;leucovorin&#160;is&#160;given</p>
<p style="position:absolute;top:1058px;left:380px;white-space:nowrap" class="ft0137"><b>&#160;</b></p>
<p style="position:absolute;top:1058px;left:385px;white-space:nowrap" class="ft047">to&#160;prevent&#160;myelosuppression&#160;&#160;from&#160;pyrimethamine.</p>
<p style="position:absolute;top:1058px;left:733px;white-space:nowrap" class="ft0137"><b>&#160;</b></p>
</div>
<!-- Page 163 -->
<a name="163"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}	.ft0146{font-size:21px;font-family:QZPFRO+Tinos;color:#000000;}
-->
</style>
<div id="page163-div" style="position:relative;width:917px;height:1187px;">
<p style="position:absolute;top:1117px;left:108px;white-space:nowrap" class="ft024"><i>Guidelines&#160;for&#160;the&#160;Prevention&#160;and&#160;Treatment&#160;of&#160;Opportunistic&#160;Infections&#160;in&#160;Adults&#160;and&#160;Adolescents&#160;With&#160;HIV&#160;</i></p>
<p style="position:absolute;top:1117px;left:792px;white-space:nowrap" class="ft024"><i>J-5&#160;</i></p>
<p style="position:absolute;top:110px;left:108px;white-space:nowrap" class="ft0136">Ciprofloxacin&#160;is&#160;a&#160;second-line&#160;agent&#160;that&#160;can&#160;be&#160;used&#160;for&#160;individuals&#160;with&#160;sulfa&#160;allergy&#160;and&#160;an&#160;<br/>inability&#160;to&#160;obtain&#160;pyrimethamine</p>
<p style="position:absolute;top:129px;left:343px;white-space:nowrap" class="ft0137"><b>(CI).</b></p>
<p style="position:absolute;top:129px;left:383px;white-space:nowrap" class="ft047">In&#160;a&#160;randomized,&#160;controlled&#160;trial&#160;in&#160;Haiti,&#160;ciprofloxacin</p>
<p style="position:absolute;top:149px;left:108px;white-space:nowrap" class="ft0135">500&#160;mg&#160;orally&#160;(PO)&#160;twice&#160;daily&#160;for&#160;7&#160;days&#160;was&#160;less&#160;effective&#160;than&#160;PO&#160;TMP-SMX&#160;&#160;but&#160;may&#160;have&#160;<br/>modest&#160;activity&#160;against&#160;</p>
<p style="position:absolute;top:170px;left:271px;white-space:nowrap" class="ft049"><i>C.&#160;belli</i></p>
<p style="position:absolute;top:170px;left:321px;white-space:nowrap" class="ft047">.</p>
<p style="position:absolute;top:170px;left:326px;white-space:nowrap" class="ft0134">31</p>
<p style="position:absolute;top:170px;left:338px;white-space:nowrap" class="ft047">&#160;&#160;</p>
<p style="position:absolute;top:204px;left:108px;white-space:nowrap" class="ft0146"><i><b>Special&#160;Considerations&#160;With&#160;Regard&#160;to&#160;Starting&#160;ART&#160;</b></i></p>
<p style="position:absolute;top:248px;left:108px;white-space:nowrap" class="ft047">There&#160;are&#160;limited&#160;data&#160;on&#160;the&#160;effectiveness&#160;&#160;of&#160;ART&#160;for&#160;</p>
<p style="position:absolute;top:248px;left:488px;white-space:nowrap" class="ft049"><i>C.&#160;belli</i></p>
<p style="position:absolute;top:248px;left:538px;white-space:nowrap" class="ft047">&#160;infection&#160;in&#160;the&#160;setting&#160;of&#160;HIV&#160;</p>
<p style="position:absolute;top:267px;left:108px;white-space:nowrap" class="ft047">coinfection.</p>
<p style="position:absolute;top:268px;left:188px;white-space:nowrap" class="ft0134">3,23,30</p>
<p style="position:absolute;top:267px;left:228px;white-space:nowrap" class="ft047">Immune&#160;reconstitution&#160;with&#160;ART&#160;may&#160;result&#160;in&#160;fewer&#160;relapses&#160;of&#160;cystoisosporiasis,</p>
<p style="position:absolute;top:287px;left:108px;white-space:nowrap" class="ft0135">and&#160;immune&#160;reconstitution&#160;&#160;inflammatory&#160;syndrome&#160;(IRIS)&#160;has&#160;not&#160;been&#160;reported.&#160;Therefore,&#160;for&#160;<br/>people&#160;with&#160;HIV&#160;and&#160;cystoisosporiasis,&#160;&#160;TMP-SMX&#160;&#160;therapy&#160;and&#160;ART&#160;&#160;should&#160;both&#160;be&#160;started&#160;as&#160;soon&#160;<br/>as&#160;possible,&#160;and&#160;ART&#160;&#160;initiation&#160;should&#160;not&#160;be&#160;deferred</p>
<p style="position:absolute;top:327px;left:480px;white-space:nowrap" class="ft0137"><b>&#160;(AIII).</b></p>
<p style="position:absolute;top:327px;left:533px;white-space:nowrap" class="ft047">&#160;</p>
<p style="position:absolute;top:362px;left:108px;white-space:nowrap" class="ft0146"><i><b>Monitoring&#160;of&#160;Response&#160;to&#160;Therapy&#160;and&#160;Adverse&#160;Events&#160;(Including&#160;IRIS)&#160;</b></i></p>
<p style="position:absolute;top:405px;left:108px;white-space:nowrap" class="ft0135">People&#160;treated&#160;for&#160;cystoisosporiasis&#160;&#160;should&#160;be&#160;monitored&#160;for&#160;clinical&#160;response&#160;and&#160;adverse&#160;events.&#160;In&#160;<br/>people&#160;with&#160;HIV,&#160;TMP-SMX&#160;&#160;therapy&#160;is&#160;commonly&#160;associated&#160;&#160;with&#160;side&#160;effects,&#160;such&#160;as&#160;rash,&#160;fever,&#160;<br/>leukopenia,&#160;thrombocytopenia,&#160;&#160;elevated&#160;&#160;transaminase&#160;&#160;levels,&#160;and&#160;hyperkalemia.&#160;&#160;For&#160;ciprofloxacin,&#160;<br/>side&#160;effects&#160;beyond&#160;gastrointestinal&#160;&#160;issues&#160;&#160;include&#160;prolong&#160;QT&#160;intervals&#160;and&#160;tendonitis&#160;&#160;and&#160;tendon&#160;<br/>rupture.&#160;For&#160;pyrimethamine,&#160;side&#160;effects&#160;include&#160;bone&#160;marrow&#160;suppression.&#160;&#160;As&#160;noted&#160;earlier,&#160;IRIS&#160;has&#160;<br/>not&#160;been&#160;described&#160;in&#160;this&#160;population.</p>
<p style="position:absolute;top:540px;left:108px;white-space:nowrap" class="ft0146"><i><b>Managing&#160;Treatment&#160;Failure&#160;</b></i></p>
<p style="position:absolute;top:583px;left:108px;white-space:nowrap" class="ft0135">If&#160;symptoms&#160;worsen&#160;or&#160;persist&#160;despite&#160;approximately&#160;&#160;5&#160;to&#160;7&#160;days&#160;of&#160;TMP-SMX&#160;&#160;therapy,&#160;the&#160;<br/>possibilities&#160;&#160;of&#160;nonadherence,&#160;&#160;malabsorption,&#160;and&#160;concurrent&#160;other&#160;gastrointestinal&#160;&#160;infections&#160;&#160;or&#160;<br/>enteropathies&#160;&#160;should&#160;be&#160;considered&#160;&#160;and&#160;the&#160;TMP-SMX&#160;&#160;regimen&#160;(daily&#160;dose,&#160;duration,&#160;and&#160;mode&#160;of&#160;<br/>administration)&#160;should&#160;be&#160;reevaluated&#160;</p>
<p style="position:absolute;top:643px;left:372px;white-space:nowrap" class="ft0137"><b>(AIII).</b></p>
<p style="position:absolute;top:643px;left:419px;white-space:nowrap" class="ft0134">38</p>
<p style="position:absolute;top:643px;left:431px;white-space:nowrap" class="ft047">&#160;For&#160;people&#160;with&#160;documented&#160;&#160;sulfa&#160;intolerance&#160;or&#160;in&#160;</p>
<p style="position:absolute;top:662px;left:108px;white-space:nowrap" class="ft0135">whom&#160;treatment&#160;fails,&#160;use&#160;of&#160;a&#160;potential&#160;alternative&#160;agent&#160;(typically&#160;pyrimethamine)&#160;&#160;should&#160;be&#160;<br/>considered&#160;</p>
<p style="position:absolute;top:682px;left:187px;white-space:nowrap" class="ft0137"><b>(BIII).</b></p>
<p style="position:absolute;top:682px;left:233px;white-space:nowrap" class="ft047">&#160;&#160;</p>
<p style="position:absolute;top:719px;left:108px;white-space:nowrap" class="ft047">The&#160;effectiveness&#160;&#160;of&#160;albendazole,</p>
<p style="position:absolute;top:720px;left:337px;white-space:nowrap" class="ft0134">37,39,40</p>
<p style="position:absolute;top:719px;left:383px;white-space:nowrap" class="ft047">nitazoxanide,</p>
<p style="position:absolute;top:720px;left:473px;white-space:nowrap" class="ft0134">41,42</p>
<p style="position:absolute;top:719px;left:499px;white-space:nowrap" class="ft047">&#160;doxycycline,</p>
<p style="position:absolute;top:720px;left:590px;white-space:nowrap" class="ft0134">43</p>
<p style="position:absolute;top:719px;left:602px;white-space:nowrap" class="ft047">&#160;and&#160;the&#160;macrolides&#160;</p>
<p style="position:absolute;top:739px;left:108px;white-space:nowrap" class="ft047">roxithromycin&#160;and&#160;spiramycin,</p>
<p style="position:absolute;top:739px;left:319px;white-space:nowrap" class="ft0134">33,44,45</p>
<p style="position:absolute;top:739px;left:365px;white-space:nowrap" class="ft047">have&#160;not&#160;been&#160;substantiated.&#160;&#160;Metronidazole,&#160;&#160;quinacrine,&#160;</p>
<p style="position:absolute;top:759px;left:108px;white-space:nowrap" class="ft047">iodoquinol,&#160;paromomycin,&#160;&#160;and&#160;furazolidone&#160;appear&#160;to&#160;be&#160;ineffective.</p>
<p style="position:absolute;top:760px;left:582px;white-space:nowrap" class="ft0134">14,33,34,36,44</p>
<p style="position:absolute;top:793px;left:108px;white-space:nowrap" class="ft0132"><b>Preventing&#160;Recurrence</b></p>
<p style="position:absolute;top:797px;left:301px;white-space:nowrap" class="ft035"><b>&#160;</b></p>
<p style="position:absolute;top:837px;left:108px;white-space:nowrap" class="ft047">People&#160;with&#160;HIV&#160;with&#160;CD4&#160;counts&#160;&lt;200&#160;cells/mm</p>
<p style="position:absolute;top:838px;left:451px;white-space:nowrap" class="ft0134">3</p>
<p style="position:absolute;top:837px;left:463px;white-space:nowrap" class="ft047">should&#160;receive&#160;secondary&#160;&#160;prophylaxis&#160;(chronic</p>
<p style="position:absolute;top:857px;left:108px;white-space:nowrap" class="ft047">maintenance&#160;&#160;therapy)&#160;with&#160;TMP-SMX&#160;</p>
<p style="position:absolute;top:857px;left:379px;white-space:nowrap" class="ft0137"><b>(AI),</b></p>
<p style="position:absolute;top:857px;left:414px;white-space:nowrap" class="ft047">&#160;which&#160;is&#160;also&#160;protective&#160;against&#160;</p>
<p style="position:absolute;top:857px;left:639px;white-space:nowrap" class="ft049"><i>Pneumocystis&#160;&#160;jirovecii</i></p>
<p style="position:absolute;top:857px;left:793px;white-space:nowrap" class="ft047">&#160;</p>
<p style="position:absolute;top:877px;left:108px;white-space:nowrap" class="ft047">and&#160;</p>
<p style="position:absolute;top:877px;left:137px;white-space:nowrap" class="ft049"><i>Toxoplasma&#160;&#160;gondii</i></p>
<p style="position:absolute;top:877px;left:269px;white-space:nowrap" class="ft047">&#160;infections.&#160;Based&#160;&#160;on&#160;observational&#160;&#160;studies&#160;&#160;in&#160;Haiti,&#160;approximately&#160;50%&#160;of&#160;</p>
<p style="position:absolute;top:897px;left:108px;white-space:nowrap" class="ft0135">patients&#160;who&#160;did&#160;not&#160;receive&#160;secondary&#160;&#160;prophylaxis&#160;had&#160;symptomatic&#160;&#160;recurrences&#160;&#160;approximately&#160;<br/>2&#160;months&#160;after&#160;completing&#160;a&#160;course&#160;of&#160;TMP-SMX&#160;&#160;therapy.&#160;These&#160;&#160;relapses&#160;&#160;rapidly&#160;responded&#160;&#160;to&#160;<br/>retreatment&#160;and&#160;secondary&#160;&#160;prophylaxis&#160;&#160;decreased&#160;&#160;the&#160;risk&#160;of&#160;another&#160;relapse.</p>
<p style="position:absolute;top:937px;left:635px;white-space:nowrap" class="ft0134">6,7,31</p>
<p style="position:absolute;top:937px;left:664px;white-space:nowrap" class="ft047">&#160;In&#160;a&#160;randomized,&#160;</p>
<p style="position:absolute;top:956px;left:108px;white-space:nowrap" class="ft0135">placebo-controlled&#160;&#160;trial&#160;in&#160;Haiti,&#160;no&#160;symptomatic&#160;&#160;recurrences&#160;were&#160;noted&#160;in&#160;people&#160;who&#160;received&#160;<br/>maintenance&#160;&#160;therapy&#160;with&#160;thrice-weekly&#160;&#160;TMP-SMX&#160;&#160;(160/800&#160;mg)&#160;</p>
<p style="position:absolute;top:976px;left:571px;white-space:nowrap" class="ft0137"><b>(AI).</b></p>
<p style="position:absolute;top:977px;left:606px;white-space:nowrap" class="ft0134">7</p>
<p style="position:absolute;top:976px;left:617px;white-space:nowrap" class="ft047">Daily&#160;TMP-SMX&#160;</p>
<p style="position:absolute;top:995px;left:108px;white-space:nowrap" class="ft047">(160/800&#160;mg)&#160;</p>
<p style="position:absolute;top:995px;left:206px;white-space:nowrap" class="ft0137"><b>(AIII)</b></p>
<p style="position:absolute;top:995px;left:248px;white-space:nowrap" class="ft047">&#160;&#160;and&#160;thrice-weekly&#160;&#160;TMP-SMX&#160;&#160;(320/1600&#160;mg)&#160;have&#160;been&#160;effective&#160;</p>
<p style="position:absolute;top:995px;left:711px;white-space:nowrap" class="ft0137"><b>(BIII)</b></p>
<p style="position:absolute;top:996px;left:752px;white-space:nowrap" class="ft0134">5,16</p>
<p style="position:absolute;top:995px;left:773px;white-space:nowrap" class="ft047">;&#160;</p>
<p style="position:absolute;top:1016px;left:108px;white-space:nowrap" class="ft0136">however,&#160;clinical&#160;and&#160;parasitological&#160;&#160;relapses&#160;&#160;despite&#160;maintenance&#160;&#160;TMP-SMX&#160;&#160;therapy&#160;and&#160;ART&#160;<br/>have&#160;been&#160;reported.</p>
<p style="position:absolute;top:1036px;left:242px;white-space:nowrap" class="ft0134">23</p>
<p style="position:absolute;top:1035px;left:259px;white-space:nowrap" class="ft047">Many&#160;of&#160;these&#160;studies&#160;were&#160;conducted&#160;in&#160;the&#160;pre-ART&#160;era.&#160;It&#160;is&#160;unclear&#160;if</p>
<p style="position:absolute;top:1055px;left:108px;white-space:nowrap" class="ft047">recurrent&#160;</p>
<p style="position:absolute;top:1055px;left:174px;white-space:nowrap" class="ft049"><i>Cystoisospora</i></p>
<p style="position:absolute;top:1055px;left:267px;white-space:nowrap" class="ft047">&#160;&#160;infections&#160;&#160;are&#160;due&#160;to&#160;relapse&#160;or&#160;reinfection.&#160;</p>
</div>
<!-- Page 164 -->
<a name="164"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}	.ft0147{font-size:16px;font-family:KPYRPS+Tinos;color:#005299;}
-->
</style>
<div id="page164-div" style="position:relative;width:917px;height:1187px;">
<p style="position:absolute;top:1117px;left:108px;white-space:nowrap" class="ft024"><i>Guidelines&#160;for&#160;the&#160;Prevention&#160;and&#160;Treatment&#160;of&#160;Opportunistic&#160;Infections&#160;in&#160;Adults&#160;and&#160;Adolescents&#160;With&#160;HIV&#160;</i></p>
<p style="position:absolute;top:1117px;left:792px;white-space:nowrap" class="ft024"><i>J-6&#160;</i></p>
<p style="position:absolute;top:110px;left:108px;white-space:nowrap" class="ft0136">In&#160;sulfa-intolerant&#160;patients,&#160;pyrimethamine&#160;(25&#160;mg/day)&#160;with&#160;leucovorin&#160;(5–10&#160;mg/day)&#160;has&#160;been&#160;<br/>used</p>
<p style="position:absolute;top:129px;left:144px;white-space:nowrap" class="ft0137"><b>(BIII).</b></p>
<p style="position:absolute;top:130px;left:190px;white-space:nowrap" class="ft0134">36</p>
<p style="position:absolute;top:129px;left:206px;white-space:nowrap" class="ft047">Based&#160;&#160;on&#160;limited&#160;data,&#160;ciprofloxacin&#160;&#160;(500&#160;mg&#160;thrice&#160;weekly)&#160;is&#160;considered&#160;a&#160;second-</p>
<p style="position:absolute;top:149px;left:108px;white-space:nowrap" class="ft047">line&#160;alternative,&#160;although&#160;some&#160;data&#160;question&#160;&#160;whether&#160;it&#160;is&#160;efficacious&#160;at&#160;all&#160;</p>
<p style="position:absolute;top:149px;left:628px;white-space:nowrap" class="ft0137"><b>(CI).</b></p>
<p style="position:absolute;top:150px;left:664px;white-space:nowrap" class="ft0134">31</p>
<p style="position:absolute;top:149px;left:676px;white-space:nowrap" class="ft047">&#160;</p>
<p style="position:absolute;top:185px;left:108px;white-space:nowrap" class="ft0146"><i><b>When&#160;To&#160;Stop&#160;Secondary&#160;Prophylaxis</b></i></p>
<p style="position:absolute;top:227px;left:108px;white-space:nowrap" class="ft0135">The&#160;issue&#160;of&#160;discontinuing&#160;&#160;prophylaxis&#160;has&#160;not&#160;been&#160;evaluated&#160;in&#160;a&#160;clinical&#160;trial.&#160;Chemoprophylaxis&#160;<br/>probably&#160;can&#160;be&#160;safely&#160;discontinued&#160;&#160;in&#160;individuals&#160;&#160;without&#160;evidence&#160;&#160;of&#160;active&#160;</p>
<p style="position:absolute;top:248px;left:645px;white-space:nowrap" class="ft049"><i>C.&#160;belli</i></p>
<p style="position:absolute;top:248px;left:695px;white-space:nowrap" class="ft047">&#160;infection&#160;who&#160;</p>
<p style="position:absolute;top:267px;left:108px;white-space:nowrap" class="ft047">have&#160;a&#160;sustained&#160;increase&#160;in&#160;the&#160;CD4&#160;count&#160;to&#160;levels</p>
<p style="position:absolute;top:267px;left:469px;white-space:nowrap" class="ft0138">≥</p>
<p style="position:absolute;top:267px;left:478px;white-space:nowrap" class="ft047">200&#160;cells/mm</p>
<p style="position:absolute;top:268px;left:570px;white-space:nowrap" class="ft0134">3</p>
<p style="position:absolute;top:267px;left:582px;white-space:nowrap" class="ft047">for&#160;&gt;6&#160;months&#160;after&#160;initiation&#160;of</p>
<p style="position:absolute;top:287px;left:108px;white-space:nowrap" class="ft047">ART&#160;</p>
<p style="position:absolute;top:287px;left:146px;white-space:nowrap" class="ft0137"><b>(BIII).</b></p>
<p style="position:absolute;top:287px;left:192px;white-space:nowrap" class="ft047">&#160;</p>
<p style="position:absolute;top:322px;left:108px;white-space:nowrap" class="ft0132"><b>Special&#160;Considerations&#160;During&#160;Pregnancy</b></p>
<p style="position:absolute;top:365px;left:108px;white-space:nowrap" class="ft0135">TMP-SMX&#160;&#160;is&#160;the&#160;agent&#160;of&#160;choice&#160;for&#160;treatment&#160;as&#160;well&#160;as&#160;primary&#160;and&#160;secondary&#160;&#160;prophylaxis&#160;during&#160;<br/>pregnancy.&#160;Although&#160;first-trimester&#160;exposure&#160;to&#160;TMP&#160;has&#160;been&#160;associated&#160;&#160;with&#160;a&#160;small&#160;increase&#160;&#160;in&#160;the&#160;<br/>risk&#160;of&#160;birth&#160;defects,</p>
<p style="position:absolute;top:406px;left:246px;white-space:nowrap" class="ft0134">46-49</p>
<p style="position:absolute;top:405px;left:278px;white-space:nowrap" class="ft047">TMP-SMX&#160;therapy&#160;should&#160;be&#160;provided&#160;in&#160;the&#160;setting&#160;of&#160;maternal</p>
<p style="position:absolute;top:425px;left:108px;white-space:nowrap" class="ft047">symptomatic&#160;</p>
<p style="position:absolute;top:425px;left:201px;white-space:nowrap" class="ft049"><i>C.&#160;belli</i></p>
<p style="position:absolute;top:425px;left:252px;white-space:nowrap" class="ft047">&#160;infection.&#160;Due&#160;to&#160;concerns&#160;about&#160;possible&#160;teratogenicity&#160;&#160;associated&#160;&#160;with&#160;first-</p>
<p style="position:absolute;top:445px;left:108px;white-space:nowrap" class="ft0135">trimester&#160;drug&#160;exposure,&#160;clinicians&#160;may&#160;withhold&#160;secondary&#160;&#160;prophylaxis&#160;&#160;during&#160;the&#160;first&#160;trimester&#160;and&#160;<br/>treat&#160;only&#160;symptomatic&#160;&#160;infection,&#160;unless&#160;&#160;TMP-SMX&#160;&#160;is&#160;needed&#160;&#160;for&#160;PCP&#160;prophylaxis&#160;</p>
<p style="position:absolute;top:465px;left:686px;white-space:nowrap" class="ft0137"><b>(CIII).</b></p>
<p style="position:absolute;top:465px;left:733px;white-space:nowrap" class="ft047">&#160;Most&#160;</p>
<p style="position:absolute;top:484px;left:108px;white-space:nowrap" class="ft0135">members&#160;of&#160;the&#160;Panel&#160;on&#160;Guidelines&#160;for&#160;the&#160;Prevention&#160;and&#160;Treatment&#160;&#160;of&#160;Opportunistic&#160;Infections&#160;in&#160;<br/>Adults&#160;and&#160;Adolescents&#160;&#160;With&#160;HIV&#160;recommend&#160;that&#160;clinicians&#160;&#160;give&#160;supplemental&#160;&#160;folic&#160;acid&#160;4&#160;mg/day&#160;<br/>to&#160;women&#160;who&#160;are&#160;on&#160;TMP-SMX&#160;&#160;if&#160;they&#160;are&#160;capable&#160;&#160;of&#160;becoming&#160;pregnant,&#160;or&#160;as&#160;soon&#160;as&#160;possible&#160;&#160;in&#160;<br/>their&#160;first&#160;trimester&#160;</p>
<p style="position:absolute;top:544px;left:241px;white-space:nowrap" class="ft0137"><b>(BIII).</b></p>
<p style="position:absolute;top:545px;left:287px;white-space:nowrap" class="ft0134">48-50</p>
<p style="position:absolute;top:544px;left:314px;white-space:nowrap" class="ft047">&#160;Additional&#160;details&#160;&#160;regarding&#160;the&#160;use&#160;of&#160;TMP-SMX&#160;&#160;during&#160;pregnancy&#160;</p>
<p style="position:absolute;top:563px;left:108px;white-space:nowrap" class="ft047">are&#160;provided&#160;at&#160;</p>
<p style="position:absolute;top:563px;left:216px;white-space:nowrap" class="ft0147"><i>Pneumocystis</i></p>
<p style="position:absolute;top:563px;left:307px;white-space:nowrap" class="ft050">&#160;&#160;Pneumonia</p>
<p style="position:absolute;top:563px;left:390px;white-space:nowrap" class="ft047">.&#160;Although&#160;pyrimethamine&#160;&#160;has&#160;been&#160;associated&#160;&#160;with&#160;birth&#160;</p>
<p style="position:absolute;top:584px;left:108px;white-space:nowrap" class="ft047">defects&#160;in&#160;animals,&#160;limited&#160;human&#160;data&#160;have&#160;not&#160;suggested&#160;&#160;an&#160;increased&#160;&#160;risk&#160;of&#160;defects.</p>
<p style="position:absolute;top:584px;left:706px;white-space:nowrap" class="ft0134">51</p>
<p style="position:absolute;top:584px;left:718px;white-space:nowrap" class="ft047">&#160;Long-term&#160;</p>
<p style="position:absolute;top:603px;left:108px;white-space:nowrap" class="ft0136">therapy&#160;with&#160;pyrimethamine&#160;should&#160;be&#160;used&#160;only&#160;if&#160;the&#160;potential&#160;benefit&#160;outweighs&#160;the&#160;potential&#160;risk.<br/>Human&#160;data&#160;about&#160;the&#160;use&#160;of&#160;ciprofloxacin&#160;during&#160;several&#160;hundred&#160;pregnancies&#160;&#160;have&#160;not&#160;suggested&#160;&#160;an&#160;<br/>increased&#160;&#160;risk&#160;of&#160;birth&#160;defects&#160;or&#160;cartilage&#160;abnormalities,&#160;&#160;but&#160;efficacy&#160;against&#160;</p>
<p style="position:absolute;top:643px;left:640px;white-space:nowrap" class="ft049"><i>C.&#160;belli</i></p>
<p style="position:absolute;top:643px;left:691px;white-space:nowrap" class="ft047">&#160;has&#160;been&#160;</p>
<p style="position:absolute;top:663px;left:108px;white-space:nowrap" class="ft047">questioned.</p>
<p style="position:absolute;top:664px;left:185px;white-space:nowrap" class="ft0134">52</p>
<p style="position:absolute;top:663px;left:203px;white-space:nowrap" class="ft047">Both&#160;TMP-SMX&#160;and&#160;ciprofloxacin&#160;are&#160;category&#160;C&#160;for&#160;pregnancy.</p>
</div>
<!-- Page 165 -->
<a name="165"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page165-div" style="position:relative;width:917px;height:1187px;">
<p style="position:absolute;top:1117px;left:108px;white-space:nowrap" class="ft024"><i>Guidelines&#160;for&#160;the&#160;Prevention&#160;and&#160;Treatment&#160;of&#160;Opportunistic&#160;Infections&#160;in&#160;Adults&#160;and&#160;Adolescents&#160;With&#160;HIV&#160;</i></p>
<p style="position:absolute;top:1117px;left:792px;white-space:nowrap" class="ft024"><i>J-7&#160;</i></p>
<p style="position:absolute;top:107px;left:108px;white-space:nowrap" class="ft0132"><b>References&#160;</b></p>
<p style="position:absolute;top:151px;left:108px;white-space:nowrap" class="ft047">1.</p>
<p style="position:absolute;top:150px;left:121px;white-space:nowrap" class="ft048">&#160;</p>
<p style="position:absolute;top:151px;left:162px;white-space:nowrap" class="ft0136">Anglaret&#160;X,&#160;Chene&#160;G,&#160;Attia&#160;A,&#160;et&#160;al.&#160;Early&#160;chemoprophylaxis&#160;with&#160;trimethoprim-<br/>sulphamethoxazole&#160;&#160;for&#160;HIV-1-infected&#160;adults&#160;in&#160;Abidjan,&#160;Cote&#160;d’Ivoire:&#160;a&#160;randomised&#160;&#160;trial.&#160;<br/>Cotrimo-CI&#160;Study&#160;Group.&#160;</p>
<p style="position:absolute;top:190px;left:344px;white-space:nowrap" class="ft049"><i>Lancet</i></p>
<p style="position:absolute;top:190px;left:390px;white-space:nowrap" class="ft047">.&#160;1999;353(9163):1463-1468.&#160;&#160;Available&#160;&#160;at:&#160;</p>
<p style="position:absolute;top:211px;left:162px;white-space:nowrap" class="ft050">https://pubmed.ncbi.nlm.nih.gov/10232311</p>
<p style="position:absolute;top:211px;left:456px;white-space:nowrap" class="ft047">.&#160;</p>
<p style="position:absolute;top:247px;left:108px;white-space:nowrap" class="ft047">2.</p>
<p style="position:absolute;top:246px;left:121px;white-space:nowrap" class="ft048">&#160;</p>
<p style="position:absolute;top:247px;left:162px;white-space:nowrap" class="ft0135">Lindsay&#160;&#160;DS,&#160;Dubey&#160;JP,&#160;Blagburn&#160;BL.&#160;Biology&#160;of&#160;Isospora&#160;spp.&#160;from&#160;humans,&#160;nonhuman&#160;<br/>primates,&#160;and&#160;domestic&#160;&#160;animals.&#160;</p>
<p style="position:absolute;top:267px;left:387px;white-space:nowrap" class="ft049"><i>Clin&#160;Microbiol&#160;Rev</i></p>
<p style="position:absolute;top:267px;left:520px;white-space:nowrap" class="ft047">.&#160;1997;10(1):19-34.&#160;Available&#160;&#160;at:&#160;</p>
<p style="position:absolute;top:287px;left:162px;white-space:nowrap" class="ft050">https://pubmed.ncbi.nlm.nih.gov/8993857</p>
<p style="position:absolute;top:287px;left:448px;white-space:nowrap" class="ft047">.&#160;</p>
<p style="position:absolute;top:323px;left:108px;white-space:nowrap" class="ft047">3.</p>
<p style="position:absolute;top:323px;left:121px;white-space:nowrap" class="ft048">&#160;</p>
<p style="position:absolute;top:323px;left:162px;white-space:nowrap" class="ft0135">Guiguet&#160;M,&#160;Furco&#160;A,&#160;Tattevin&#160;P,&#160;Costagliola&#160;D,&#160;Molina&#160;JM,&#160;French&#160;Hospital&#160;Database&#160;&#160;on&#160;<br/>HIVCEG.&#160;HIV-associated&#160;&#160;Isospora&#160;&#160;belli&#160;infection:&#160;incidence&#160;and&#160;risk&#160;factors&#160;in&#160;the&#160;French&#160;<br/>Hospital&#160;Database&#160;&#160;on&#160;HIV.&#160;</p>
<p style="position:absolute;top:364px;left:354px;white-space:nowrap" class="ft049"><i>HIV&#160;Med</i></p>
<p style="position:absolute;top:364px;left:417px;white-space:nowrap" class="ft047">.&#160;2007;8(2):124-130.&#160;Available&#160;at:&#160;</p>
<p style="position:absolute;top:385px;left:162px;white-space:nowrap" class="ft050">https://pubmed.ncbi.nlm.nih.gov/17352769</p>
<p style="position:absolute;top:385px;left:456px;white-space:nowrap" class="ft047">.&#160;</p>
<p style="position:absolute;top:421px;left:108px;white-space:nowrap" class="ft047">4.</p>
<p style="position:absolute;top:420px;left:121px;white-space:nowrap" class="ft048">&#160;</p>
<p style="position:absolute;top:421px;left:162px;white-space:nowrap" class="ft0136">Sorvillo&#160;FJ,&#160;Lieb&#160;LE,&#160;Seidel&#160;J,&#160;Kerndt&#160;P,&#160;Turner&#160;J,&#160;Ash&#160;LR.&#160;Epidemiology&#160;of&#160;isosporiasis&#160;<br/>among&#160;persons&#160;with&#160;acquired&#160;immunodeficiency&#160;&#160;syndrome&#160;in&#160;Los&#160;Angeles&#160;&#160;County.</p>
<p style="position:absolute;top:440px;left:742px;white-space:nowrap" class="ft049"><i>Am&#160;J&#160;</i></p>
<p style="position:absolute;top:460px;left:162px;white-space:nowrap" class="ft049"><i>Trop&#160;Med&#160;Hyg</i></p>
<p style="position:absolute;top:460px;left:263px;white-space:nowrap" class="ft047">.&#160;1995;53(6):656-659.&#160;Available&#160;at:&#160;</p>
<p style="position:absolute;top:460px;left:512px;white-space:nowrap" class="ft050">https://pubmed.ncbi.nlm.nih.gov/8561272</p>
<p style="position:absolute;top:460px;left:798px;white-space:nowrap" class="ft047">.&#160;</p>
<p style="position:absolute;top:497px;left:108px;white-space:nowrap" class="ft047">5.</p>
<p style="position:absolute;top:497px;left:121px;white-space:nowrap" class="ft048">&#160;</p>
<p style="position:absolute;top:497px;left:162px;white-space:nowrap" class="ft0136">Certad&#160;G,&#160;Arenas-Pinto&#160;A,&#160;Pocaterra&#160;L,&#160;et&#160;al.&#160;Isosporiasis&#160;&#160;in&#160;Venezuelan&#160;&#160;adults&#160;infected&#160;with&#160;<br/>human&#160;immunodeficiency&#160;&#160;virus:&#160;clinical&#160;characterization.&#160;</p>
<p style="position:absolute;top:517px;left:564px;white-space:nowrap" class="ft049"><i>Am&#160;J&#160;Trop&#160;Med&#160;Hyg</i></p>
<p style="position:absolute;top:517px;left:704px;white-space:nowrap" class="ft047">.&#160;</p>
<p style="position:absolute;top:537px;left:162px;white-space:nowrap" class="ft047">2003;69(2):217-222.&#160;Available&#160;at:</p>
<p style="position:absolute;top:537px;left:402px;white-space:nowrap" class="ft050">https://pubmed.ncbi.nlm.nih.gov/13677379</p>
<p style="position:absolute;top:537px;left:696px;white-space:nowrap" class="ft047">.</p>
<p style="position:absolute;top:574px;left:108px;white-space:nowrap" class="ft047">6.</p>
<p style="position:absolute;top:574px;left:121px;white-space:nowrap" class="ft048">&#160;</p>
<p style="position:absolute;top:574px;left:162px;white-space:nowrap" class="ft0136">DeHovitz&#160;JA,&#160;Pape&#160;JW,&#160;Boncy&#160;M,&#160;Johnson&#160;WD,&#160;Jr.&#160;Clinical&#160;manifestations&#160;&#160;and&#160;therapy&#160;of&#160;<br/>Isospora&#160;belli&#160;infection&#160;in&#160;patients&#160;with&#160;the&#160;acquired&#160;immunodeficiency&#160;&#160;syndrome.&#160;</p>
<p style="position:absolute;top:593px;left:735px;white-space:nowrap" class="ft049"><i>N&#160;Engl&#160;J&#160;</i></p>
<p style="position:absolute;top:614px;left:162px;white-space:nowrap" class="ft049"><i>Med</i></p>
<p style="position:absolute;top:614px;left:192px;white-space:nowrap" class="ft047">.&#160;1986;315(2):87-90.&#160;Available&#160;at:&#160;</p>
<p style="position:absolute;top:614px;left:433px;white-space:nowrap" class="ft050">https://pubmed.ncbi.nlm.nih.gov/3487730</p>
<p style="position:absolute;top:614px;left:719px;white-space:nowrap" class="ft047">.&#160;</p>
<p style="position:absolute;top:651px;left:108px;white-space:nowrap" class="ft047">7.</p>
<p style="position:absolute;top:651px;left:162px;white-space:nowrap" class="ft0136">Pape&#160;JW,&#160;Verdier&#160;RI,&#160;Johnson&#160;WD,&#160;Jr.&#160;Treatment&#160;and&#160;prophylaxis&#160;of&#160;Isospora&#160;belli&#160;infection&#160;<br/>in&#160;patients&#160;with&#160;the&#160;acquired&#160;immunodeficiency&#160;&#160;syndrome.&#160;</p>
<p style="position:absolute;top:670px;left:572px;white-space:nowrap" class="ft049"><i>N&#160;Engl&#160;J&#160;Med</i></p>
<p style="position:absolute;top:670px;left:667px;white-space:nowrap" class="ft047">.&#160;</p>
<p style="position:absolute;top:691px;left:162px;white-space:nowrap" class="ft047">1989;320(16):1044-1047.&#160;&#160;Available&#160;at:&#160;</p>
<p style="position:absolute;top:691px;left:437px;white-space:nowrap" class="ft050">https://pubmed.ncbi.nlm.nih.gov/2927483</p>
<p style="position:absolute;top:691px;left:722px;white-space:nowrap" class="ft047">.&#160;</p>
<p style="position:absolute;top:728px;left:108px;white-space:nowrap" class="ft047">8.</p>
<p style="position:absolute;top:728px;left:121px;white-space:nowrap" class="ft048">&#160;</p>
<p style="position:absolute;top:728px;left:162px;white-space:nowrap" class="ft047">Centers&#160;&#160;for&#160;Disease&#160;Control&#160;and&#160;Prevention.&#160;Cystoisosporiasis.&#160;&#160;2024.&#160;Available&#160;&#160;at:&#160;</p>
<p style="position:absolute;top:748px;left:162px;white-space:nowrap" class="ft050">https://www.cdc.gov/dpdx/cystoisosporiasis/index.html</p>
<p style="position:absolute;top:748px;left:540px;white-space:nowrap" class="ft047">.&#160;</p>
<p style="position:absolute;top:784px;left:108px;white-space:nowrap" class="ft047">9.</p>
<p style="position:absolute;top:784px;left:121px;white-space:nowrap" class="ft048">&#160;</p>
<p style="position:absolute;top:784px;left:162px;white-space:nowrap" class="ft047">Hechenbleikner&#160;&#160;EM,&#160;McQuade&#160;&#160;JA.&#160;Parasitic&#160;colitis.&#160;</p>
<p style="position:absolute;top:784px;left:524px;white-space:nowrap" class="ft049"><i>Clin&#160;Colon&#160;Rectal&#160;Surg</i></p>
<p style="position:absolute;top:784px;left:685px;white-space:nowrap" class="ft047">.&#160;2015;28(2):79-</p>
<p style="position:absolute;top:805px;left:162px;white-space:nowrap" class="ft047">86.&#160;Available&#160;at:&#160;</p>
<p style="position:absolute;top:805px;left:281px;white-space:nowrap" class="ft050">https://pubmed.ncbi.nlm.nih.gov/26034403</p>
<p style="position:absolute;top:805px;left:575px;white-space:nowrap" class="ft047">.&#160;</p>
<p style="position:absolute;top:842px;left:108px;white-space:nowrap" class="ft047">10.</p>
<p style="position:absolute;top:842px;left:130px;white-space:nowrap" class="ft048">&#160;</p>
<p style="position:absolute;top:842px;left:162px;white-space:nowrap" class="ft047">Legua&#160;&#160;P,&#160;Seas&#160;C.&#160;Cystoisospora&#160;&#160;and&#160;cyclospora.&#160;</p>
<p style="position:absolute;top:842px;left:498px;white-space:nowrap" class="ft049"><i>Curr&#160;&#160;Opin&#160;Infect&#160;Dis</i></p>
<p style="position:absolute;top:842px;left:640px;white-space:nowrap" class="ft047">.&#160;2013;26(5):479-483.&#160;</p>
<p style="position:absolute;top:862px;left:162px;white-space:nowrap" class="ft047">Available&#160;at:&#160;</p>
<p style="position:absolute;top:862px;left:254px;white-space:nowrap" class="ft050">https://pubmed.ncbi.nlm.nih.gov/23982239</p>
<p style="position:absolute;top:862px;left:548px;white-space:nowrap" class="ft047">.&#160;</p>
<p style="position:absolute;top:898px;left:108px;white-space:nowrap" class="ft047">11.</p>
<p style="position:absolute;top:898px;left:130px;white-space:nowrap" class="ft048">&#160;</p>
<p style="position:absolute;top:898px;left:162px;white-space:nowrap" class="ft0136">Johnstone&#160;SL,&#160;Erasmus&#160;L,&#160;Thomas&#160;&#160;J,&#160;et&#160;al.&#160;Epidemiology&#160;and&#160;aetiology&#160;of&#160;moderate&#160;to&#160;severe&#160;<br/>diarrhoea&#160;in&#160;hospitalised&#160;&#160;patients&#160;&gt;/=5&#160;years&#160;old&#160;living&#160;with&#160;HIV&#160;in&#160;South&#160;Africa,&#160;2018–<br/>2021:&#160;a&#160;case-control&#160;&#160;analysis.&#160;</p>
<p style="position:absolute;top:938px;left:371px;white-space:nowrap" class="ft049"><i>PLOS&#160;Glob&#160;Public&#160;Health</i></p>
<p style="position:absolute;top:938px;left:549px;white-space:nowrap" class="ft047">.&#160;2023;3(9):e0001718.&#160;&#160;Available&#160;at:&#160;</p>
<p style="position:absolute;top:958px;left:162px;white-space:nowrap" class="ft050">https://pubmed.ncbi.nlm.nih.gov/37682831</p>
<p style="position:absolute;top:958px;left:456px;white-space:nowrap" class="ft047">.&#160;</p>
<p style="position:absolute;top:995px;left:108px;white-space:nowrap" class="ft047">12.</p>
<p style="position:absolute;top:995px;left:130px;white-space:nowrap" class="ft048">&#160;</p>
<p style="position:absolute;top:995px;left:162px;white-space:nowrap" class="ft0135">Nsagha&#160;&#160;DS,&#160;Njunda&#160;AL,&#160;Assob&#160;NJC,&#160;et&#160;al.&#160;Intestinal&#160;parasitic&#160;&#160;infections&#160;in&#160;relation&#160;to&#160;CD4(+)&#160;<br/>T&#160;cell&#160;counts&#160;and&#160;diarrhea&#160;in&#160;HIV/AIDS&#160;patients&#160;&#160;with&#160;or&#160;without&#160;antiretroviral&#160;therapy&#160;in&#160;<br/>Cameroon.</p>
<p style="position:absolute;top:1035px;left:242px;white-space:nowrap" class="ft049"><i>BMC&#160;Infect&#160;Dis</i></p>
<p style="position:absolute;top:1035px;left:349px;white-space:nowrap" class="ft047">.&#160;2016;16:9.&#160;Available&#160;at:</p>
<p style="position:absolute;top:1055px;left:162px;white-space:nowrap" class="ft050">https://pubmed.ncbi.nlm.nih.gov/26754404</p>
<p style="position:absolute;top:1055px;left:456px;white-space:nowrap" class="ft047">.&#160;</p>
</div>
<!-- Page 166 -->
<a name="166"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page166-div" style="position:relative;width:917px;height:1187px;">
<p style="position:absolute;top:1117px;left:108px;white-space:nowrap" class="ft024"><i>Guidelines&#160;for&#160;the&#160;Prevention&#160;and&#160;Treatment&#160;of&#160;Opportunistic&#160;Infections&#160;in&#160;Adults&#160;and&#160;Adolescents&#160;With&#160;HIV&#160;</i></p>
<p style="position:absolute;top:1117px;left:792px;white-space:nowrap" class="ft024"><i>J-8&#160;</i></p>
<p style="position:absolute;top:110px;left:108px;white-space:nowrap" class="ft047">13.</p>
<p style="position:absolute;top:110px;left:130px;white-space:nowrap" class="ft048">&#160;</p>
<p style="position:absolute;top:110px;left:162px;white-space:nowrap" class="ft0136">Assefa&#160;&#160;S,&#160;Erko&#160;B,&#160;Medhin&#160;G,&#160;Assefa&#160;Z,&#160;Shimelis&#160;T.&#160;Intestinal&#160;parasitic&#160;infections&#160;in&#160;relation&#160;<br/>to&#160;HIV/AIDS&#160;status,&#160;diarrhea&#160;and&#160;CD4&#160;T-cell&#160;count.</p>
<p style="position:absolute;top:129px;left:527px;white-space:nowrap" class="ft049"><i>BMC&#160;Infect&#160;Dis</i></p>
<p style="position:absolute;top:129px;left:633px;white-space:nowrap" class="ft047">.&#160;2009;9:155.&#160;Available</p>
<p style="position:absolute;top:149px;left:162px;white-space:nowrap" class="ft047">at:&#160;</p>
<p style="position:absolute;top:149px;left:184px;white-space:nowrap" class="ft050">https://pubmed.ncbi.nlm.nih.gov/19765310</p>
<p style="position:absolute;top:149px;left:478px;white-space:nowrap" class="ft047">.&#160;</p>
<p style="position:absolute;top:185px;left:108px;white-space:nowrap" class="ft047">14.</p>
<p style="position:absolute;top:185px;left:130px;white-space:nowrap" class="ft048">&#160;</p>
<p style="position:absolute;top:185px;left:162px;white-space:nowrap" class="ft047">Forthal&#160;DN,&#160;Guest&#160;SS.&#160;Isospora&#160;belli&#160;enteritis&#160;in&#160;three&#160;homosexual&#160;&#160;men.&#160;</p>
<p style="position:absolute;top:185px;left:662px;white-space:nowrap" class="ft049"><i>Am&#160;J&#160;Trop&#160;Med&#160;Hyg</i></p>
<p style="position:absolute;top:185px;left:801px;white-space:nowrap" class="ft047">.&#160;</p>
<p style="position:absolute;top:206px;left:162px;white-space:nowrap" class="ft047">1984;33(6):1060-1064.&#160;Available&#160;&#160;at:&#160;</p>
<p style="position:absolute;top:206px;left:420px;white-space:nowrap" class="ft050">https://pubmed.ncbi.nlm.nih.gov/6507724</p>
<p style="position:absolute;top:206px;left:706px;white-space:nowrap" class="ft047">.&#160;</p>
<p style="position:absolute;top:243px;left:108px;white-space:nowrap" class="ft047">15.</p>
<p style="position:absolute;top:243px;left:162px;white-space:nowrap" class="ft0135">Modigliani&#160;R,&#160;Bories&#160;C,&#160;Le&#160;Charpentier&#160;Y,&#160;et&#160;al.&#160;Diarrhoea&#160;and&#160;malabsorption&#160;&#160;in&#160;acquired&#160;<br/>immune&#160;deficiency&#160;syndrome:&#160;a&#160;study&#160;of&#160;four&#160;cases&#160;with&#160;special&#160;&#160;emphasis&#160;&#160;on&#160;opportunistic&#160;<br/>protozoan&#160;infestations.&#160;</p>
<p style="position:absolute;top:283px;left:324px;white-space:nowrap" class="ft049"><i>Gut</i></p>
<p style="position:absolute;top:283px;left:349px;white-space:nowrap" class="ft047">.&#160;1985;26(2):179-187.&#160;Available&#160;&#160;at:&#160;</p>
<p style="position:absolute;top:303px;left:162px;white-space:nowrap" class="ft050">https://pubmed.ncbi.nlm.nih.gov/4038492</p>
<p style="position:absolute;top:303px;left:448px;white-space:nowrap" class="ft047">.&#160;</p>
<p style="position:absolute;top:339px;left:108px;white-space:nowrap" class="ft047">16.</p>
<p style="position:absolute;top:339px;left:162px;white-space:nowrap" class="ft0135">Whiteside&#160;&#160;ME,&#160;Barkin&#160;JS,&#160;May&#160;RG,&#160;Weiss&#160;SD,&#160;Fischl&#160;MA,&#160;MacLeod&#160;CL.&#160;Enteric&#160;coccidiosis<br/>among&#160;patients&#160;with&#160;the&#160;acquired&#160;immunodeficiency&#160;&#160;syndrome.&#160;</p>
<p style="position:absolute;top:359px;left:606px;white-space:nowrap" class="ft049"><i>Am&#160;J&#160;Trop&#160;Med&#160;Hyg</i></p>
<p style="position:absolute;top:359px;left:745px;white-space:nowrap" class="ft047">.&#160;</p>
<p style="position:absolute;top:380px;left:162px;white-space:nowrap" class="ft047">1984;33(6):1065-1072.&#160;Available&#160;&#160;at:&#160;</p>
<p style="position:absolute;top:380px;left:420px;white-space:nowrap" class="ft050">https://pubmed.ncbi.nlm.nih.gov/6334448</p>
<p style="position:absolute;top:380px;left:706px;white-space:nowrap" class="ft047">.&#160;</p>
<p style="position:absolute;top:416px;left:108px;white-space:nowrap" class="ft047">17.</p>
<p style="position:absolute;top:416px;left:130px;white-space:nowrap" class="ft048">&#160;</p>
<p style="position:absolute;top:416px;left:162px;white-space:nowrap" class="ft0135">Bialek&#160;R,&#160;Overkamp&#160;D,&#160;Rettig&#160;I,&#160;Knobloch&#160;J.&#160;Case&#160;report:&#160;nitazoxanide&#160;&#160;treatment&#160;failure&#160;in&#160;<br/>chronic&#160;isosporiasis.&#160;</p>
<p style="position:absolute;top:436px;left:307px;white-space:nowrap" class="ft049"><i>Am&#160;J&#160;Trop&#160;Med&#160;Hyg</i></p>
<p style="position:absolute;top:436px;left:446px;white-space:nowrap" class="ft047">.&#160;2001;65(2):94-95.&#160;Available&#160;&#160;at:&#160;</p>
<p style="position:absolute;top:457px;left:162px;white-space:nowrap" class="ft050">https://pubmed.ncbi.nlm.nih.gov/11508398</p>
<p style="position:absolute;top:457px;left:456px;white-space:nowrap" class="ft047">.&#160;</p>
<p style="position:absolute;top:493px;left:108px;white-space:nowrap" class="ft047">18.</p>
<p style="position:absolute;top:492px;left:130px;white-space:nowrap" class="ft048">&#160;</p>
<p style="position:absolute;top:493px;left:162px;white-space:nowrap" class="ft0135">Williams&#160;DT,&#160;Smith&#160;RS,&#160;Mallon&#160;WK.&#160;Severe&#160;hypokalemia,&#160;&#160;paralysis,&#160;and&#160;AIDS-associated&#160;<br/>isospora&#160;&#160;belli&#160;diarrhea.&#160;</p>
<p style="position:absolute;top:513px;left:324px;white-space:nowrap" class="ft049"><i>J&#160;Emerg&#160;Med</i></p>
<p style="position:absolute;top:513px;left:416px;white-space:nowrap" class="ft047">.&#160;2011;41(6):e129-132.&#160;Available&#160;at:&#160;</p>
<p style="position:absolute;top:533px;left:162px;white-space:nowrap" class="ft050">https://pubmed.ncbi.nlm.nih.gov/18993015</p>
<p style="position:absolute;top:533px;left:456px;white-space:nowrap" class="ft047">.&#160;</p>
<p style="position:absolute;top:569px;left:108px;white-space:nowrap" class="ft047">19.</p>
<p style="position:absolute;top:569px;left:130px;white-space:nowrap" class="ft048">&#160;</p>
<p style="position:absolute;top:569px;left:162px;white-space:nowrap" class="ft0135">Frenkel&#160;JK,&#160;Silva&#160;MB,&#160;Saldanha&#160;J,&#160;et&#160;al.&#160;Isospora&#160;belli&#160;infection:&#160;observation&#160;&#160;of&#160;unicellular&#160;<br/>cysts&#160;in&#160;mesenteric&#160;&#160;lymphoid&#160;tissues&#160;&#160;of&#160;a&#160;Brazilian&#160;patient&#160;with&#160;AIDS&#160;and&#160;animal&#160;inoculation.&#160;</p>
<p style="position:absolute;top:609px;left:162px;white-space:nowrap" class="ft049"><i>J&#160;Eukaryot&#160;Microbiol</i></p>
<p style="position:absolute;top:609px;left:308px;white-space:nowrap" class="ft047">.&#160;2003;50&#160;Suppl:682-684.&#160;Available&#160;at:</p>
<p style="position:absolute;top:629px;left:162px;white-space:nowrap" class="ft050">https://pubmed.ncbi.nlm.nih.gov/14736218</p>
<p style="position:absolute;top:629px;left:456px;white-space:nowrap" class="ft047">.&#160;</p>
<p style="position:absolute;top:667px;left:108px;white-space:nowrap" class="ft047">20.</p>
<p style="position:absolute;top:666px;left:130px;white-space:nowrap" class="ft048">&#160;</p>
<p style="position:absolute;top:667px;left:162px;white-space:nowrap" class="ft0136">Restrepo&#160;&#160;C,&#160;Macher&#160;AM,&#160;Radany&#160;&#160;EH.&#160;Disseminated&#160;&#160;extraintestinal&#160;&#160;isosporiasis&#160;&#160;in&#160;a&#160;patient&#160;<br/>with&#160;acquired&#160;immune&#160;deficiency&#160;syndrome.&#160;</p>
<p style="position:absolute;top:686px;left:474px;white-space:nowrap" class="ft049"><i>Am&#160;J&#160;Clin&#160;Pathol</i></p>
<p style="position:absolute;top:686px;left:592px;white-space:nowrap" class="ft047">.&#160;1987;87(4):536-542.&#160;</p>
<p style="position:absolute;top:706px;left:162px;white-space:nowrap" class="ft047">Available&#160;at:&#160;</p>
<p style="position:absolute;top:706px;left:254px;white-space:nowrap" class="ft050">https://pubmed.ncbi.nlm.nih.gov/3826017</p>
<p style="position:absolute;top:706px;left:540px;white-space:nowrap" class="ft047">.&#160;</p>
<p style="position:absolute;top:743px;left:108px;white-space:nowrap" class="ft047">21.</p>
<p style="position:absolute;top:743px;left:130px;white-space:nowrap" class="ft048">&#160;</p>
<p style="position:absolute;top:743px;left:162px;white-space:nowrap" class="ft047">Bernard&#160;E,&#160;Delgiudice&#160;P,&#160;Carles&#160;M,&#160;et&#160;al.&#160;Disseminated&#160;&#160;isosporiasis&#160;&#160;in&#160;an&#160;AIDS&#160;patient.&#160;</p>
<p style="position:absolute;top:743px;left:770px;white-space:nowrap" class="ft049"><i>Eur&#160;J&#160;</i></p>
<p style="position:absolute;top:763px;left:162px;white-space:nowrap" class="ft049"><i>Clin&#160;Microbiol&#160;Infect&#160;Dis</i></p>
<p style="position:absolute;top:763px;left:336px;white-space:nowrap" class="ft047">.&#160;1997;16(9):699-701.&#160;Available&#160;at:&#160;</p>
<p style="position:absolute;top:783px;left:162px;white-space:nowrap" class="ft050">https://pubmed.ncbi.nlm.nih.gov/9352268</p>
<p style="position:absolute;top:783px;left:448px;white-space:nowrap" class="ft047">.</p>
<p style="position:absolute;top:820px;left:108px;white-space:nowrap" class="ft047">22.</p>
<p style="position:absolute;top:820px;left:130px;white-space:nowrap" class="ft048">&#160;</p>
<p style="position:absolute;top:820px;left:162px;white-space:nowrap" class="ft0136">Benator&#160;DA,&#160;French&#160;AL,&#160;Beaudet&#160;&#160;LM,&#160;Levy&#160;CS,&#160;Orenstein&#160;&#160;JM.&#160;Isospora&#160;belli&#160;infection&#160;<br/>associated&#160;&#160;with&#160;acalculous&#160;&#160;cholecystitis&#160;&#160;in&#160;a&#160;patient&#160;with&#160;AIDS.&#160;</p>
<p style="position:absolute;top:839px;left:604px;white-space:nowrap" class="ft049"><i>Ann&#160;Intern&#160;Med</i></p>
<p style="position:absolute;top:839px;left:712px;white-space:nowrap" class="ft047">.&#160;</p>
<p style="position:absolute;top:860px;left:162px;white-space:nowrap" class="ft047">1994;121(9):663-664.&#160;Available&#160;&#160;at:&#160;</p>
<p style="position:absolute;top:860px;left:412px;white-space:nowrap" class="ft050">https://pubmed.ncbi.nlm.nih.gov/7944075</p>
<p style="position:absolute;top:860px;left:697px;white-space:nowrap" class="ft047">.&#160;</p>
<p style="position:absolute;top:897px;left:108px;white-space:nowrap" class="ft047">23.</p>
<p style="position:absolute;top:897px;left:162px;white-space:nowrap" class="ft0136">Lagrange-Xelot&#160;&#160;M,&#160;Porcher&#160;R,&#160;Sarfati&#160;C,&#160;et&#160;al.&#160;Isosporiasis&#160;in&#160;patients&#160;with&#160;HIV&#160;infection&#160;in<br/>the&#160;highly&#160;active&#160;antiretroviral&#160;therapy&#160;era&#160;in&#160;France.&#160;</p>
<p style="position:absolute;top:916px;left:530px;white-space:nowrap" class="ft049"><i>HIV&#160;Med</i></p>
<p style="position:absolute;top:916px;left:594px;white-space:nowrap" class="ft047">.&#160;2008;9(2):126-130.&#160;Available&#160;</p>
<p style="position:absolute;top:937px;left:162px;white-space:nowrap" class="ft047">at:&#160;</p>
<p style="position:absolute;top:937px;left:184px;white-space:nowrap" class="ft050">https://pubmed.ncbi.nlm.nih.gov/18257775</p>
<p style="position:absolute;top:937px;left:478px;white-space:nowrap" class="ft047">.&#160;</p>
<p style="position:absolute;top:974px;left:108px;white-space:nowrap" class="ft047">24.</p>
<p style="position:absolute;top:974px;left:130px;white-space:nowrap" class="ft048">&#160;</p>
<p style="position:absolute;top:974px;left:162px;white-space:nowrap" class="ft0136">Walther&#160;Z,&#160;Topazian&#160;&#160;MD.&#160;Isospora&#160;&#160;cholangiopathy:&#160;&#160;case&#160;study&#160;with&#160;histologic&#160;<br/>characterization&#160;and&#160;molecular&#160;confirmation.</p>
<p style="position:absolute;top:993px;left:476px;white-space:nowrap" class="ft049"><i>Hum&#160;Pathol</i></p>
<p style="position:absolute;top:993px;left:560px;white-space:nowrap" class="ft047">.&#160;2009;40(9):1342-1346.&#160;Available</p>
<p style="position:absolute;top:1013px;left:162px;white-space:nowrap" class="ft047">at:&#160;</p>
<p style="position:absolute;top:1013px;left:184px;white-space:nowrap" class="ft050">https://pubmed.ncbi.nlm.nih.gov/19447468</p>
<p style="position:absolute;top:1013px;left:478px;white-space:nowrap" class="ft047">.&#160;</p>
</div>
<!-- Page 167 -->
<a name="167"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page167-div" style="position:relative;width:917px;height:1187px;">
<p style="position:absolute;top:1117px;left:108px;white-space:nowrap" class="ft024"><i>Guidelines&#160;for&#160;the&#160;Prevention&#160;and&#160;Treatment&#160;of&#160;Opportunistic&#160;Infections&#160;in&#160;Adults&#160;and&#160;Adolescents&#160;With&#160;HIV&#160;</i></p>
<p style="position:absolute;top:1117px;left:792px;white-space:nowrap" class="ft024"><i>J-9&#160;</i></p>
<p style="position:absolute;top:110px;left:108px;white-space:nowrap" class="ft047">25.</p>
<p style="position:absolute;top:110px;left:130px;white-space:nowrap" class="ft048">&#160;</p>
<p style="position:absolute;top:110px;left:162px;white-space:nowrap" class="ft0136">Gonzalez-Dominguez&#160;&#160;J,&#160;Roldan&#160;R,&#160;Villanueva&#160;JL,&#160;Kindelan&#160;JM,&#160;Jurado&#160;R,&#160;Torre-Cisneros&#160;&#160;J.&#160;<br/>Isospora&#160;belli&#160;reactive&#160;arthritis&#160;in&#160;a&#160;patient&#160;with&#160;AIDS.</p>
<p style="position:absolute;top:129px;left:541px;white-space:nowrap" class="ft049"><i>Ann&#160;Rheum&#160;Dis</i></p>
<p style="position:absolute;top:129px;left:648px;white-space:nowrap" class="ft047">.&#160;1994;53(9):618-619.</p>
<p style="position:absolute;top:149px;left:162px;white-space:nowrap" class="ft047">Available&#160;at:&#160;</p>
<p style="position:absolute;top:149px;left:254px;white-space:nowrap" class="ft050">https://pubmed.ncbi.nlm.nih.gov/7979603</p>
<p style="position:absolute;top:149px;left:540px;white-space:nowrap" class="ft047">.&#160;</p>
<p style="position:absolute;top:185px;left:108px;white-space:nowrap" class="ft047">26.</p>
<p style="position:absolute;top:185px;left:130px;white-space:nowrap" class="ft048">&#160;</p>
<p style="position:absolute;top:185px;left:162px;white-space:nowrap" class="ft0135">Bialek&#160;R,&#160;Binder&#160;N,&#160;Dietz&#160;K,&#160;Knobloch&#160;J,&#160;Zelck&#160;UE.&#160;Comparison&#160;of&#160;autofluorescence&#160;&#160;and&#160;<br/>iodine&#160;staining&#160;for&#160;detection&#160;of&#160;Isospora&#160;belli&#160;in&#160;feces.&#160;</p>
<p style="position:absolute;top:206px;left:538px;white-space:nowrap" class="ft049"><i>Am&#160;J&#160;Trop&#160;Med&#160;Hyg</i></p>
<p style="position:absolute;top:206px;left:678px;white-space:nowrap" class="ft047">.&#160;2002;67(3):304-</p>
<p style="position:absolute;top:226px;left:162px;white-space:nowrap" class="ft047">305.&#160;Available&#160;at:&#160;</p>
<p style="position:absolute;top:226px;left:289px;white-space:nowrap" class="ft050">https://pubmed.ncbi.nlm.nih.gov/12408672</p>
<p style="position:absolute;top:226px;left:583px;white-space:nowrap" class="ft047">.&#160;</p>
<p style="position:absolute;top:262px;left:108px;white-space:nowrap" class="ft047">27.</p>
<p style="position:absolute;top:262px;left:130px;white-space:nowrap" class="ft048">&#160;</p>
<p style="position:absolute;top:262px;left:162px;white-space:nowrap" class="ft0135">Taniuchi&#160;&#160;M,&#160;Verweij&#160;JJ,&#160;Sethabutr&#160;O,&#160;et&#160;al.&#160;Multiplex&#160;polymerase&#160;chain&#160;reaction&#160;method&#160;to&#160;<br/>detect&#160;Cyclospora,&#160;&#160;Cystoisospora,&#160;&#160;and&#160;Microsporidia&#160;&#160;in&#160;stool&#160;samples.&#160;</p>
<p style="position:absolute;top:283px;left:651px;white-space:nowrap" class="ft049"><i>Diagn&#160;Microbiol&#160;</i></p>
<p style="position:absolute;top:303px;left:162px;white-space:nowrap" class="ft049"><i>Infect&#160;Dis</i></p>
<p style="position:absolute;top:303px;left:228px;white-space:nowrap" class="ft047">.&#160;2011;71(4):386-390.&#160;Available&#160;&#160;at:&#160;</p>
<p style="position:absolute;top:303px;left:479px;white-space:nowrap" class="ft050">https://pubmed.ncbi.nlm.nih.gov/21982218</p>
<p style="position:absolute;top:303px;left:773px;white-space:nowrap" class="ft047">.&#160;</p>
<p style="position:absolute;top:339px;left:108px;white-space:nowrap" class="ft047">28.</p>
<p style="position:absolute;top:339px;left:162px;white-space:nowrap" class="ft047">Dubey&#160;JP,&#160;Almeria&#160;S.&#160;Cystoisospora&#160;belli&#160;infections&#160;in&#160;humans:&#160;the&#160;past&#160;100&#160;years.</p>
<p style="position:absolute;top:359px;left:162px;white-space:nowrap" class="ft049"><i>Parasitology</i></p>
<p style="position:absolute;top:359px;left:248px;white-space:nowrap" class="ft047">.&#160;2019;146(12):1490-1527.&#160;&#160;Available&#160;&#160;at:&#160;</p>
<p style="position:absolute;top:380px;left:162px;white-space:nowrap" class="ft050">https://pubmed.ncbi.nlm.nih.gov/31303182</p>
<p style="position:absolute;top:380px;left:456px;white-space:nowrap" class="ft047">.&#160;</p>
<p style="position:absolute;top:416px;left:108px;white-space:nowrap" class="ft047">29.</p>
<p style="position:absolute;top:416px;left:130px;white-space:nowrap" class="ft048">&#160;</p>
<p style="position:absolute;top:416px;left:162px;white-space:nowrap" class="ft0135">Centers&#160;&#160;for&#160;Disease&#160;Control&#160;and&#160;Prevention.&#160;About&#160;choosing&#160;&#160;home&#160;water&#160;filters.&#160;2024.&#160;<br/>Available&#160;at:&#160;</p>
<p style="position:absolute;top:436px;left:254px;white-space:nowrap" class="ft050">https://www.cdc.gov/drinking-water/prevention/about-choosing-home-water-</p>
<p style="position:absolute;top:457px;left:162px;white-space:nowrap" class="ft050">filters.html</p>
<p style="position:absolute;top:457px;left:238px;white-space:nowrap" class="ft047">.&#160;</p>
<p style="position:absolute;top:493px;left:108px;white-space:nowrap" class="ft047">30.</p>
<p style="position:absolute;top:492px;left:130px;white-space:nowrap" class="ft048">&#160;</p>
<p style="position:absolute;top:493px;left:162px;white-space:nowrap" class="ft0136">Dillingham&#160;RA,&#160;Pinkerton&#160;R,&#160;Leger&#160;P,&#160;et&#160;al.&#160;High&#160;early&#160;mortality&#160;in&#160;patients&#160;with&#160;chronic&#160;<br/>acquired&#160;immunodeficiency&#160;&#160;syndrome&#160;&#160;diarrhea&#160;initiating&#160;antiretroviral&#160;therapy&#160;in&#160;Haiti:&#160;a&#160;<br/>case-control&#160;&#160;study.&#160;</p>
<p style="position:absolute;top:532px;left:296px;white-space:nowrap" class="ft049"><i>Am&#160;J&#160;Trop&#160;Med&#160;Hyg</i></p>
<p style="position:absolute;top:532px;left:437px;white-space:nowrap" class="ft047">.&#160;2009;80(6):1060-1064.&#160;Available&#160;&#160;at:&#160;</p>
<p style="position:absolute;top:553px;left:162px;white-space:nowrap" class="ft050">https://pubmed.ncbi.nlm.nih.gov/19478276</p>
<p style="position:absolute;top:553px;left:456px;white-space:nowrap" class="ft047">.&#160;</p>
<p style="position:absolute;top:590px;left:108px;white-space:nowrap" class="ft047">31.</p>
<p style="position:absolute;top:590px;left:130px;white-space:nowrap" class="ft048">&#160;</p>
<p style="position:absolute;top:590px;left:162px;white-space:nowrap" class="ft0135">Verdier&#160;RI,&#160;Fitzgerald&#160;DW,&#160;Johnson&#160;WD,&#160;Jr.,&#160;Pape&#160;JW.&#160;Trimethoprim-sulfamethoxazole&#160;<br/>compared&#160;with&#160;ciprofloxacin&#160;&#160;for&#160;treatment&#160;and&#160;prophylaxis&#160;of&#160;Isospora&#160;belli&#160;and&#160;Cyclospora<br/>cayetanensis&#160;&#160;infection&#160;in&#160;HIV-infected&#160;patients.&#160;A&#160;randomized,&#160;controlled&#160;trial.&#160;</p>
<p style="position:absolute;top:629px;left:713px;white-space:nowrap" class="ft049"><i>Ann&#160;Intern&#160;</i></p>
<p style="position:absolute;top:650px;left:162px;white-space:nowrap" class="ft049"><i>Med</i></p>
<p style="position:absolute;top:650px;left:192px;white-space:nowrap" class="ft047">.&#160;2000;132(11):885-888.&#160;Available&#160;&#160;at:&#160;</p>
<p style="position:absolute;top:650px;left:460px;white-space:nowrap" class="ft050">http://www.ncbi.nlm.nih.gov/pubmed/10836915</p>
<p style="position:absolute;top:650px;left:788px;white-space:nowrap" class="ft047">.&#160;</p>
<p style="position:absolute;top:686px;left:108px;white-space:nowrap" class="ft047">32.</p>
<p style="position:absolute;top:686px;left:130px;white-space:nowrap" class="ft048">&#160;</p>
<p style="position:absolute;top:686px;left:162px;white-space:nowrap" class="ft0135">Shane&#160;AL,&#160;Mody&#160;RK,&#160;Crump&#160;JA,&#160;et&#160;al.&#160;2017&#160;Infectious&#160;Diseases&#160;&#160;Society&#160;of&#160;America&#160;clinical&#160;<br/>practice&#160;guidelines&#160;&#160;for&#160;the&#160;diagnosis&#160;and&#160;management&#160;&#160;of&#160;infectious&#160;diarrhea.&#160;</p>
<p style="position:absolute;top:706px;left:693px;white-space:nowrap" class="ft049"><i>Clin&#160;Infect&#160;Dis</i></p>
<p style="position:absolute;top:706px;left:793px;white-space:nowrap" class="ft047">.&#160;</p>
<p style="position:absolute;top:727px;left:162px;white-space:nowrap" class="ft047">2017;65(12):e45-e80.&#160;&#160;Available&#160;at:&#160;</p>
<p style="position:absolute;top:727px;left:409px;white-space:nowrap" class="ft050">https://pubmed.ncbi.nlm.nih.gov/29053792</p>
<p style="position:absolute;top:727px;left:703px;white-space:nowrap" class="ft047">.&#160;</p>
<p style="position:absolute;top:763px;left:108px;white-space:nowrap" class="ft047">33.</p>
<p style="position:absolute;top:762px;left:130px;white-space:nowrap" class="ft048">&#160;</p>
<p style="position:absolute;top:763px;left:162px;white-space:nowrap" class="ft0135">Ebrahimzadeh&#160;&#160;A,&#160;Bottone&#160;EJ.&#160;Persistent&#160;diarrhea&#160;caused&#160;&#160;by&#160;Isospora&#160;belli:&#160;therapeutic&#160;<br/>response&#160;&#160;to&#160;pyrimethamine&#160;and&#160;sulfadiazine.&#160;</p>
<p style="position:absolute;top:783px;left:474px;white-space:nowrap" class="ft049"><i>Diagn&#160;Microbiol&#160;Infect&#160;Dis</i></p>
<p style="position:absolute;top:783px;left:661px;white-space:nowrap" class="ft047">.&#160;1996;26(2):87-89.&#160;</p>
<p style="position:absolute;top:803px;left:162px;white-space:nowrap" class="ft047">Available&#160;at:&#160;</p>
<p style="position:absolute;top:803px;left:254px;white-space:nowrap" class="ft050">https://pubmed.ncbi.nlm.nih.gov/8985661</p>
<p style="position:absolute;top:803px;left:540px;white-space:nowrap" class="ft047">.&#160;</p>
<p style="position:absolute;top:839px;left:108px;white-space:nowrap" class="ft047">34.</p>
<p style="position:absolute;top:839px;left:130px;white-space:nowrap" class="ft048">&#160;</p>
<p style="position:absolute;top:839px;left:162px;white-space:nowrap" class="ft0135">Trier&#160;JS,&#160;Moxey&#160;PC,&#160;Schimmel&#160;EM,&#160;Robles&#160;E.&#160;Chronic&#160;intestinal&#160;&#160;coccidiosis&#160;&#160;in&#160;man:&#160;<br/>intestinal&#160;morphology&#160;and&#160;response&#160;to&#160;treatment.&#160;</p>
<p style="position:absolute;top:860px;left:504px;white-space:nowrap" class="ft049"><i>Gastroenterology</i></p>
<p style="position:absolute;top:860px;left:620px;white-space:nowrap" class="ft047">.&#160;&#160;1974;66(5):923-935.&#160;</p>
<p style="position:absolute;top:880px;left:162px;white-space:nowrap" class="ft047">Available&#160;at:&#160;</p>
<p style="position:absolute;top:880px;left:254px;white-space:nowrap" class="ft050">https://pubmed.ncbi.nlm.nih.gov/4826994</p>
<p style="position:absolute;top:880px;left:540px;white-space:nowrap" class="ft047">.&#160;</p>
<p style="position:absolute;top:916px;left:108px;white-space:nowrap" class="ft047">35.</p>
<p style="position:absolute;top:916px;left:130px;white-space:nowrap" class="ft048">&#160;</p>
<p style="position:absolute;top:916px;left:162px;white-space:nowrap" class="ft0135">Navin&#160;TR,&#160;Miller&#160;KD,&#160;Satriale&#160;RF,&#160;Lobel&#160;HO.&#160;Adverse&#160;&#160;reactions&#160;associated&#160;&#160;with&#160;<br/>pyrimethamine-sulfadoxine&#160;&#160;prophylaxis&#160;&#160;for&#160;Pneumocystis&#160;&#160;carinii&#160;infections&#160;in&#160;AIDS.&#160;</p>
<p style="position:absolute;top:937px;left:754px;white-space:nowrap" class="ft049"><i>Lancet</i></p>
<p style="position:absolute;top:937px;left:800px;white-space:nowrap" class="ft047">.&#160;</p>
<p style="position:absolute;top:957px;left:162px;white-space:nowrap" class="ft047">1985;1(8441):1332.&#160;Available&#160;&#160;at:&#160;</p>
<p style="position:absolute;top:957px;left:397px;white-space:nowrap" class="ft050">https://pubmed.ncbi.nlm.nih.gov/2860516</p>
<p style="position:absolute;top:957px;left:683px;white-space:nowrap" class="ft047">.&#160;</p>
<p style="position:absolute;top:993px;left:108px;white-space:nowrap" class="ft047">36.</p>
<p style="position:absolute;top:993px;left:162px;white-space:nowrap" class="ft0135">Weiss&#160;LM,&#160;Perlman&#160;DC,&#160;Sherman&#160;J,&#160;Tanowitz&#160;H,&#160;Wittner&#160;M.&#160;Isospora&#160;belli&#160;infection:&#160;<br/>treatment&#160;with&#160;pyrimethamine.&#160;</p>
<p style="position:absolute;top:1013px;left:379px;white-space:nowrap" class="ft049"><i>Ann&#160;Intern&#160;Med</i></p>
<p style="position:absolute;top:1013px;left:488px;white-space:nowrap" class="ft047">.&#160;1988;109(6):474-475.&#160;Available&#160;at:&#160;</p>
<p style="position:absolute;top:1034px;left:162px;white-space:nowrap" class="ft050">https://pubmed.ncbi.nlm.nih.gov/3261956</p>
<p style="position:absolute;top:1034px;left:448px;white-space:nowrap" class="ft047">.&#160;</p>
</div>
<!-- Page 168 -->
<a name="168"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page168-div" style="position:relative;width:917px;height:1187px;">
<p style="position:absolute;top:1117px;left:108px;white-space:nowrap" class="ft024"><i>Guidelines&#160;for&#160;the&#160;Prevention&#160;and&#160;Treatment&#160;of&#160;Opportunistic&#160;Infections&#160;in&#160;Adults&#160;and&#160;Adolescents&#160;With&#160;HIV&#160;</i></p>
<p style="position:absolute;top:1117px;left:785px;white-space:nowrap" class="ft024"><i>J-10&#160;</i></p>
<p style="position:absolute;top:110px;left:108px;white-space:nowrap" class="ft047">37.</p>
<p style="position:absolute;top:110px;left:130px;white-space:nowrap" class="ft048">&#160;</p>
<p style="position:absolute;top:110px;left:162px;white-space:nowrap" class="ft0136">Jongwutiwes&#160;&#160;S,&#160;Sampatanukul&#160;P,&#160;Putaporntip&#160;C.&#160;Recurrent&#160;isosporiasis&#160;&#160;over&#160;a&#160;decade&#160;&#160;in&#160;an&#160;<br/>immunocompetent&#160;&#160;host&#160;successfully&#160;treated&#160;with&#160;pyrimethamine.</p>
<p style="position:absolute;top:129px;left:616px;white-space:nowrap" class="ft049"><i>Scand&#160;J&#160;Infect&#160;Dis</i></p>
<p style="position:absolute;top:129px;left:741px;white-space:nowrap" class="ft047">.&#160;</p>
<p style="position:absolute;top:149px;left:162px;white-space:nowrap" class="ft047">2002;34(11):859-862.&#160;Available&#160;&#160;at:&#160;</p>
<p style="position:absolute;top:149px;left:412px;white-space:nowrap" class="ft050">https://pubmed.ncbi.nlm.nih.gov/12578164</p>
<p style="position:absolute;top:149px;left:706px;white-space:nowrap" class="ft047">.&#160;</p>
<p style="position:absolute;top:185px;left:108px;white-space:nowrap" class="ft047">38.</p>
<p style="position:absolute;top:185px;left:130px;white-space:nowrap" class="ft048">&#160;</p>
<p style="position:absolute;top:185px;left:162px;white-space:nowrap" class="ft0135">Iordanov&#160;RB,&#160;Leining&#160;LM,&#160;Wu&#160;M,&#160;Chan&#160;G,&#160;DiNardo&#160;AR,&#160;Mejia&#160;R.&#160;Case&#160;report:&#160;molecular&#160;<br/>diagnosis&#160;&#160;of&#160;Cystoisospora&#160;&#160;belli&#160;in&#160;a&#160;severely&#160;immunocompromised&#160;&#160;patient&#160;with&#160;HIV&#160;and&#160;<br/>Kaposi&#160;sarcoma.&#160;</p>
<p style="position:absolute;top:226px;left:281px;white-space:nowrap" class="ft049"><i>Am&#160;J&#160;Trop&#160;Med&#160;Hyg</i></p>
<p style="position:absolute;top:226px;left:421px;white-space:nowrap" class="ft047">.&#160;2021;106(2):678-680.&#160;Available&#160;&#160;at:&#160;</p>
<p style="position:absolute;top:247px;left:162px;white-space:nowrap" class="ft050">https://pubmed.ncbi.nlm.nih.gov/34844211</p>
<p style="position:absolute;top:247px;left:456px;white-space:nowrap" class="ft047">.&#160;</p>
<p style="position:absolute;top:283px;left:108px;white-space:nowrap" class="ft047">39.</p>
<p style="position:absolute;top:282px;left:130px;white-space:nowrap" class="ft048">&#160;</p>
<p style="position:absolute;top:283px;left:162px;white-space:nowrap" class="ft0135">Dionisio&#160;D,&#160;Sterrantino&#160;G,&#160;Meli&#160;M,&#160;Leoncini&#160;&#160;F,&#160;Orsi&#160;A,&#160;Nicoletti&#160;P.&#160;Treatment&#160;of&#160;isosporiasis&#160;<br/>with&#160;combined&#160;albendazole&#160;&#160;and&#160;ornidazole&#160;in&#160;patients&#160;with&#160;AIDS.</p>
<p style="position:absolute;top:303px;left:622px;white-space:nowrap" class="ft049"><i>AIDS</i></p>
<p style="position:absolute;top:303px;left:660px;white-space:nowrap" class="ft047">.&#160;1996;10(11):1301-</p>
<p style="position:absolute;top:323px;left:162px;white-space:nowrap" class="ft047">1302.&#160;Available&#160;at:&#160;</p>
<p style="position:absolute;top:323px;left:298px;white-space:nowrap" class="ft050">https://pubmed.ncbi.nlm.nih.gov/8883600</p>
<p style="position:absolute;top:323px;left:583px;white-space:nowrap" class="ft047">.&#160;</p>
<p style="position:absolute;top:359px;left:108px;white-space:nowrap" class="ft047">40.</p>
<p style="position:absolute;top:359px;left:130px;white-space:nowrap" class="ft048">&#160;</p>
<p style="position:absolute;top:359px;left:162px;white-space:nowrap" class="ft0136">Zulu&#160;I,&#160;Veitch&#160;A,&#160;Sianongo&#160;S,&#160;et&#160;al.&#160;Albendazole&#160;chemotherapy&#160;&#160;for&#160;AIDS-related&#160;diarrhoea&#160;in&#160;<br/>Zambia--clinical,&#160;&#160;parasitological&#160;&#160;and&#160;mucosal&#160;responses.&#160;</p>
<p style="position:absolute;top:379px;left:558px;white-space:nowrap" class="ft049"><i>Aliment&#160;Pharmacol&#160;&#160;Ther</i></p>
<p style="position:absolute;top:379px;left:728px;white-space:nowrap" class="ft047">.&#160;2002;&#160;</p>
<p style="position:absolute;top:399px;left:162px;white-space:nowrap" class="ft047">16(3):595-601.&#160;Available&#160;at:</p>
<p style="position:absolute;top:399px;left:364px;white-space:nowrap" class="ft050">https://pubmed.ncbi.nlm.nih.gov/11876715</p>
<p style="position:absolute;top:399px;left:658px;white-space:nowrap" class="ft047">.</p>
<p style="position:absolute;top:436px;left:108px;white-space:nowrap" class="ft047">41.</p>
<p style="position:absolute;top:436px;left:130px;white-space:nowrap" class="ft048">&#160;</p>
<p style="position:absolute;top:436px;left:162px;white-space:nowrap" class="ft0136">Romero&#160;Cabello&#160;R,&#160;Guerrero&#160;LR,&#160;Munoz&#160;Garcia&#160;MR,&#160;Geyne&#160;Cruz&#160;A.&#160;Nitazoxanide&#160;&#160;for&#160;the&#160;<br/>treatment&#160;of&#160;intestinal&#160;protozoan&#160;and&#160;helminthic&#160;infections&#160;in&#160;Mexico.&#160;</p>
<p style="position:absolute;top:455px;left:649px;white-space:nowrap" class="ft049"><i>Trans&#160;&#160;R&#160;Soc&#160;Trop&#160;Med&#160;</i></p>
<p style="position:absolute;top:476px;left:162px;white-space:nowrap" class="ft049"><i>Hyg</i></p>
<p style="position:absolute;top:476px;left:190px;white-space:nowrap" class="ft047">.&#160;1997;91(6):701-703.&#160;Available&#160;&#160;at:&#160;</p>
<p style="position:absolute;top:476px;left:440px;white-space:nowrap" class="ft050">https://pubmed.ncbi.nlm.nih.gov/9580117</p>
<p style="position:absolute;top:476px;left:726px;white-space:nowrap" class="ft047">.&#160;</p>
<p style="position:absolute;top:513px;left:108px;white-space:nowrap" class="ft047">42.</p>
<p style="position:absolute;top:513px;left:162px;white-space:nowrap" class="ft0135">Doumbo&#160;O,&#160;Rossignol&#160;JF,&#160;Pichard&#160;E,&#160;et&#160;al.&#160;Nitazoxanide&#160;in&#160;the&#160;treatment&#160;of&#160;cryptosporidial<br/>diarrhea&#160;and&#160;other&#160;intestinal&#160;parasitic&#160;&#160;infections&#160;associated&#160;&#160;with&#160;acquired&#160;immunodeficiency&#160;<br/>syndrome&#160;in&#160;tropical&#160;Africa.&#160;</p>
<p style="position:absolute;top:553px;left:362px;white-space:nowrap" class="ft049"><i>Am&#160;J&#160;Trop&#160;Med&#160;Hyg</i></p>
<p style="position:absolute;top:553px;left:501px;white-space:nowrap" class="ft047">.&#160;1997;56(6):637-639.&#160;Available&#160;at:&#160;</p>
<p style="position:absolute;top:573px;left:162px;white-space:nowrap" class="ft050">https://pubmed.ncbi.nlm.nih.gov/9230795</p>
<p style="position:absolute;top:573px;left:448px;white-space:nowrap" class="ft047">.&#160;</p>
<p style="position:absolute;top:609px;left:108px;white-space:nowrap" class="ft047">43.</p>
<p style="position:absolute;top:609px;left:162px;white-space:nowrap" class="ft0135">Meyohas&#160;MC,&#160;Capella&#160;F,&#160;Poirot&#160;JL,&#160;et&#160;al.&#160;[Treatment&#160;with&#160;doxycycline&#160;and&#160;nifuroxazide&#160;of<br/>Isospora&#160;belli&#160;infection&#160;in&#160;AIDS].&#160;</p>
<p style="position:absolute;top:629px;left:398px;white-space:nowrap" class="ft049"><i>Pathol&#160;Biol&#160;(Paris)</i></p>
<p style="position:absolute;top:629px;left:530px;white-space:nowrap" class="ft047">.&#160;1990;38(5&#160;(&#160;Pt&#160;2)):589-591.&#160;Available&#160;</p>
<p style="position:absolute;top:650px;left:162px;white-space:nowrap" class="ft047">at:&#160;</p>
<p style="position:absolute;top:650px;left:184px;white-space:nowrap" class="ft050">https://pubmed.ncbi.nlm.nih.gov/2385457</p>
<p style="position:absolute;top:650px;left:469px;white-space:nowrap" class="ft047">.&#160;</p>
<p style="position:absolute;top:686px;left:108px;white-space:nowrap" class="ft047">44.</p>
<p style="position:absolute;top:686px;left:130px;white-space:nowrap" class="ft048">&#160;</p>
<p style="position:absolute;top:686px;left:162px;white-space:nowrap" class="ft0135">Gaska&#160;&#160;JA,&#160;Tietze&#160;KJ,&#160;Cosgrove&#160;EM.&#160;Unsuccessful&#160;&#160;treatment&#160;of&#160;enteritis&#160;due&#160;to&#160;Isospora&#160;belli&#160;<br/>with&#160;spiramycin:&#160;&#160;a&#160;case&#160;report.&#160;</p>
<p style="position:absolute;top:706px;left:379px;white-space:nowrap" class="ft049"><i>J&#160;Infect&#160;Dis</i></p>
<p style="position:absolute;top:706px;left:457px;white-space:nowrap" class="ft047">.&#160;1985;152(6):1336-1338.&#160;Available&#160;&#160;at:&#160;</p>
<p style="position:absolute;top:727px;left:162px;white-space:nowrap" class="ft050">https://pubmed.ncbi.nlm.nih.gov/4067332</p>
<p style="position:absolute;top:727px;left:448px;white-space:nowrap" class="ft047">.&#160;</p>
<p style="position:absolute;top:763px;left:108px;white-space:nowrap" class="ft047">45.</p>
<p style="position:absolute;top:762px;left:130px;white-space:nowrap" class="ft048">&#160;</p>
<p style="position:absolute;top:763px;left:162px;white-space:nowrap" class="ft0135">Musey&#160;&#160;KL,&#160;Chidiac&#160;C,&#160;Beaucaire&#160;&#160;G,&#160;Houriez&#160;S,&#160;Fourrier&#160;A.&#160;Effectiveness&#160;of&#160;roxithromycin&#160;<br/>for&#160;treating&#160;Isospora&#160;belli&#160;infection.&#160;</p>
<p style="position:absolute;top:783px;left:411px;white-space:nowrap" class="ft049"><i>J&#160;Infect&#160;Dis</i></p>
<p style="position:absolute;top:783px;left:489px;white-space:nowrap" class="ft047">.&#160;1988;158(3):646.&#160;Available&#160;at:&#160;</p>
<p style="position:absolute;top:803px;left:162px;white-space:nowrap" class="ft050">https://pubmed.ncbi.nlm.nih.gov/3411149</p>
<p style="position:absolute;top:803px;left:448px;white-space:nowrap" class="ft047">.&#160;</p>
<p style="position:absolute;top:839px;left:108px;white-space:nowrap" class="ft047">46.</p>
<p style="position:absolute;top:839px;left:130px;white-space:nowrap" class="ft048">&#160;</p>
<p style="position:absolute;top:839px;left:162px;white-space:nowrap" class="ft0135">Hernandez-Diaz&#160;&#160;S,&#160;Werler&#160;MM,&#160;Walker&#160;AM,&#160;Mitchell&#160;&#160;AA.&#160;Neural&#160;tube&#160;defects&#160;in&#160;relation&#160;to&#160;<br/>use&#160;of&#160;folic&#160;acid&#160;antagonists&#160;&#160;during&#160;pregnancy.&#160;</p>
<p style="position:absolute;top:860px;left:488px;white-space:nowrap" class="ft049"><i>Am&#160;J&#160;Epidemiol</i></p>
<p style="position:absolute;top:860px;left:597px;white-space:nowrap" class="ft047">.&#160;2001;153(10):961-968.&#160;</p>
<p style="position:absolute;top:880px;left:162px;white-space:nowrap" class="ft047">Available&#160;at:&#160;</p>
<p style="position:absolute;top:880px;left:254px;white-space:nowrap" class="ft050">https://pubmed.ncbi.nlm.nih.gov/11384952</p>
<p style="position:absolute;top:880px;left:548px;white-space:nowrap" class="ft047">.&#160;</p>
<p style="position:absolute;top:916px;left:108px;white-space:nowrap" class="ft047">47.</p>
<p style="position:absolute;top:916px;left:130px;white-space:nowrap" class="ft048">&#160;</p>
<p style="position:absolute;top:916px;left:162px;white-space:nowrap" class="ft0135">Jungmann&#160;EM,&#160;Mercey&#160;D,&#160;DeRuiter&#160;A,&#160;et&#160;al.&#160;Is&#160;first&#160;trimester&#160;exposure&#160;to&#160;the&#160;combination&#160;of&#160;<br/>antiretroviral&#160;therapy&#160;and&#160;folate&#160;antagonists&#160;&#160;a&#160;risk&#160;factor&#160;for&#160;congenital&#160;abnormalities?&#160;</p>
<p style="position:absolute;top:937px;left:760px;white-space:nowrap" class="ft049"><i>Sex&#160;</i></p>
<p style="position:absolute;top:956px;left:162px;white-space:nowrap" class="ft049"><i>Transm&#160;&#160;Infect</i></p>
<p style="position:absolute;top:956px;left:258px;white-space:nowrap" class="ft047">.&#160;2001;77(6):441-443.&#160;Available&#160;&#160;at:&#160;</p>
<p style="position:absolute;top:976px;left:162px;white-space:nowrap" class="ft050">https://pubmed.ncbi.nlm.nih.gov/11714944</p>
<p style="position:absolute;top:976px;left:456px;white-space:nowrap" class="ft047">.&#160;</p>
<p style="position:absolute;top:1013px;left:108px;white-space:nowrap" class="ft047">48.</p>
<p style="position:absolute;top:1013px;left:130px;white-space:nowrap" class="ft048">&#160;</p>
<p style="position:absolute;top:1013px;left:162px;white-space:nowrap" class="ft0136">Czeizel&#160;&#160;AE,&#160;Rockenbauer&#160;M,&#160;Sorensen&#160;&#160;HT,&#160;Olsen&#160;J.&#160;The&#160;teratogenic&#160;risk&#160;of&#160;trimethoprim-<br/>sulfonamides:&#160;&#160;a&#160;population&#160;based&#160;&#160;case-control&#160;study.&#160;</p>
<p style="position:absolute;top:1033px;left:531px;white-space:nowrap" class="ft049"><i>Reprod&#160;Toxicol</i></p>
<p style="position:absolute;top:1033px;left:637px;white-space:nowrap" class="ft047">.&#160;2001;15(6):637-646.&#160;</p>
<p style="position:absolute;top:1053px;left:162px;white-space:nowrap" class="ft047">Available&#160;at:&#160;</p>
<p style="position:absolute;top:1053px;left:254px;white-space:nowrap" class="ft050">https://pubmed.ncbi.nlm.nih.gov/11738517</p>
<p style="position:absolute;top:1053px;left:548px;white-space:nowrap" class="ft047">.</p>
</div>
<!-- Page 169 -->
<a name="169"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page169-div" style="position:relative;width:917px;height:1187px;">
<p style="position:absolute;top:1117px;left:108px;white-space:nowrap" class="ft024"><i>Guidelines&#160;for&#160;the&#160;Prevention&#160;and&#160;Treatment&#160;of&#160;Opportunistic&#160;Infections&#160;in&#160;Adults&#160;and&#160;Adolescents&#160;With&#160;HIV&#160;</i></p>
<p style="position:absolute;top:1117px;left:785px;white-space:nowrap" class="ft024"><i>J-11&#160;</i></p>
<p style="position:absolute;top:110px;left:108px;white-space:nowrap" class="ft047">49.</p>
<p style="position:absolute;top:110px;left:130px;white-space:nowrap" class="ft048">&#160;</p>
<p style="position:absolute;top:110px;left:162px;white-space:nowrap" class="ft0136">Hernandez-Diaz&#160;&#160;S,&#160;Werler&#160;MM,&#160;Walker&#160;AM,&#160;Mitchell&#160;&#160;AA.&#160;Folic&#160;acid&#160;antagonists&#160;&#160;during&#160;<br/>pregnancy&#160;and&#160;the&#160;risk&#160;of&#160;birth&#160;defects.</p>
<p style="position:absolute;top:129px;left:435px;white-space:nowrap" class="ft049"><i>N&#160;Engl&#160;J&#160;Med</i></p>
<p style="position:absolute;top:129px;left:531px;white-space:nowrap" class="ft047">.&#160;2000;343(22):1608-1614.&#160;Available</p>
<p style="position:absolute;top:149px;left:162px;white-space:nowrap" class="ft047">at:&#160;</p>
<p style="position:absolute;top:149px;left:184px;white-space:nowrap" class="ft050">https://pubmed.ncbi.nlm.nih.gov/11096168</p>
<p style="position:absolute;top:149px;left:478px;white-space:nowrap" class="ft047">.&#160;</p>
<p style="position:absolute;top:185px;left:108px;white-space:nowrap" class="ft047">50.</p>
<p style="position:absolute;top:185px;left:130px;white-space:nowrap" class="ft048">&#160;</p>
<p style="position:absolute;top:185px;left:162px;white-space:nowrap" class="ft0135">Bortolus&#160;R,&#160;Filippini&#160;F,&#160;Cipriani&#160;S,&#160;et&#160;al.&#160;Efficacy&#160;of&#160;4.0&#160;mg&#160;versus&#160;0.4&#160;mg&#160;folic&#160;acid&#160;<br/>supplementation&#160;&#160;on&#160;the&#160;reproductive&#160;outcomes:&#160;&#160;a&#160;randomized&#160;controlled&#160;trial.&#160;</p>
<p style="position:absolute;top:206px;left:703px;white-space:nowrap" class="ft049"><i>Nutrients</i></p>
<p style="position:absolute;top:206px;left:764px;white-space:nowrap" class="ft047">.&#160;</p>
<p style="position:absolute;top:226px;left:162px;white-space:nowrap" class="ft047">2021;13(12).&#160;Available&#160;&#160;at:&#160;</p>
<p style="position:absolute;top:226px;left:349px;white-space:nowrap" class="ft050">https://pubmed.ncbi.nlm.nih.gov/34959975</p>
<p style="position:absolute;top:226px;left:643px;white-space:nowrap" class="ft047">.&#160;</p>
<p style="position:absolute;top:262px;left:108px;white-space:nowrap" class="ft047">51.</p>
<p style="position:absolute;top:262px;left:130px;white-space:nowrap" class="ft048">&#160;</p>
<p style="position:absolute;top:262px;left:162px;white-space:nowrap" class="ft0135">Deen&#160;JL,&#160;von&#160;Seidlein&#160;L,&#160;Pinder&#160;M,&#160;Walraven&#160;&#160;GE,&#160;Greenwood&#160;BM.&#160;The&#160;safety&#160;of&#160;the&#160;<br/>combination&#160;artesunate&#160;&#160;and&#160;pyrimethamine-sulfadoxine&#160;&#160;given&#160;during&#160;pregnancy.&#160;</p>
<p style="position:absolute;top:283px;left:723px;white-space:nowrap" class="ft049"><i>Trans&#160;R&#160;Soc&#160;</i></p>
<p style="position:absolute;top:303px;left:162px;white-space:nowrap" class="ft049"><i>Trop&#160;Med&#160;Hyg</i></p>
<p style="position:absolute;top:303px;left:263px;white-space:nowrap" class="ft047">.&#160;2001;95(4):424-428.&#160;Available&#160;at:&#160;</p>
<p style="position:absolute;top:323px;left:162px;white-space:nowrap" class="ft050">https://pubmed.ncbi.nlm.nih.gov/11579889</p>
<p style="position:absolute;top:323px;left:456px;white-space:nowrap" class="ft047">.&#160;</p>
<p style="position:absolute;top:359px;left:108px;white-space:nowrap" class="ft047">52.</p>
<p style="position:absolute;top:359px;left:130px;white-space:nowrap" class="ft048">&#160;</p>
<p style="position:absolute;top:359px;left:162px;white-space:nowrap" class="ft0136">Nahum&#160;GG,&#160;Uhl&#160;K,&#160;Kennedy&#160;DL.&#160;Antibiotic&#160;use&#160;in&#160;pregnancy&#160;and&#160;lactation:&#160;what&#160;is&#160;and&#160;is&#160;<br/>not&#160;known&#160;about&#160;teratogenic&#160;&#160;and&#160;toxic&#160;risks.&#160;</p>
<p style="position:absolute;top:379px;left:473px;white-space:nowrap" class="ft049"><i>Obstet&#160;Gynecol</i></p>
<p style="position:absolute;top:379px;left:577px;white-space:nowrap" class="ft047">.&#160;2006;107(5):1120-1138.&#160;</p>
<p style="position:absolute;top:399px;left:162px;white-space:nowrap" class="ft047">Available&#160;at:&#160;</p>
<p style="position:absolute;top:399px;left:254px;white-space:nowrap" class="ft050">https://pubmed.ncbi.nlm.nih.gov/16648419</p>
<p style="position:absolute;top:399px;left:548px;white-space:nowrap" class="ft047">.</p>
</div>
<!-- Page 170 -->
<a name="170"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page170-div" style="position:relative;width:917px;height:1187px;">
<p style="position:absolute;top:1121px;left:108px;white-space:nowrap" class="ft024"><i>Guidelines for the Prevention and Treatment&#160;of&#160;Opportunistic&#160;Infections in Adults&#160;and Adolescents&#160;With HIV&#160;</i></p>
<p style="position:absolute;top:1121px;left:791px;white-space:nowrap" class="ft024"><i>K-1</i></p>
<p style="position:absolute;top:112px;left:108px;white-space:nowrap" class="ft025"><b>Cytomegalovirus&#160;Disease&#160;</b></p>
<p style="position:absolute;top:159px;left:108px;white-space:nowrap" class="ft035"><b>Updated:</b></p>
<p style="position:absolute;top:159px;left:172px;white-space:nowrap" class="ft036">&#160;July 1</p>
<p style="position:absolute;top:159px;left:214px;white-space:nowrap" class="ft037">4</p>
<p style="position:absolute;top:159px;left:223px;white-space:nowrap" class="ft036">,&#160;2025&#160;</p>
<p style="position:absolute;top:180px;left:108px;white-space:nowrap" class="ft035"><b>Reviewed:</b></p>
<p style="position:absolute;top:180px;left:181px;white-space:nowrap" class="ft036">&#160;July&#160;1</p>
<p style="position:absolute;top:180px;left:223px;white-space:nowrap" class="ft037">4</p>
<p style="position:absolute;top:180px;left:232px;white-space:nowrap" class="ft036">,&#160;2025</p>
<p style="position:absolute;top:180px;left:273px;white-space:nowrap" class="ft035"><b>&#160;</b></p>
<p style="position:absolute;top:218px;left:108px;white-space:nowrap" class="ft026"><b>Epidemiology&#160;</b></p>
<p style="position:absolute;top:260px;left:108px;white-space:nowrap" class="ft032">Cytomegalovirus (CMV)&#160;is a double-stranded DNA virus in the herpesvirus&#160;family that can cause&#160;<br/>disseminated or localized end-organ disease in people&#160;with HIV.&#160;CMV&#160;infection is common in the&#160;<br/>general&#160;population, but CMV prevalence differs by&#160;geography,&#160;socioeconomic&#160;status, and&#160;race or&#160;<br/>ethnicity.</p>
<p style="position:absolute;top:318px;left:173px;white-space:nowrap" class="ft038">1</p>
<p style="position:absolute;top:319px;left:178px;white-space:nowrap" class="ft013">&#160;In the&#160;U.S.&#160;National Health and Nutrition Examination Survey&#160;1999–2004,&#160;overall CMV&#160;</p>
<p style="position:absolute;top:339px;left:108px;white-space:nowrap" class="ft032">seroprevalence for individuals aged 6&#160;to 49 years in the&#160;United&#160;States was 50.4%.&#160;Higher CMV&#160;<br/>seropositivity was associated with older age;&#160;being female;&#160;foreign birthplace;&#160;and markers of lower&#160;<br/>socioeconomic&#160;status, such as low household income, low education, and high household crowding.</p>
<p style="position:absolute;top:377px;left:798px;white-space:nowrap" class="ft038">1</p>
<p style="position:absolute;top:379px;left:803px;white-space:nowrap" class="ft013">&#160;</p>
<p style="position:absolute;top:399px;left:108px;white-space:nowrap" class="ft032">CMV seroprevalence&#160;is generally higher among developing countries, with seroprevalence between&#160;<br/>40% to 70%&#160;of adults in&#160;most high-income countries,</p>
<p style="position:absolute;top:417px;left:476px;white-space:nowrap" class="ft038">2</p>
<p style="position:absolute;top:418px;left:482px;white-space:nowrap" class="ft013">&#160;compared with 80% to 100% in&#160;several&#160;low-</p>
<p style="position:absolute;top:438px;left:108px;white-space:nowrap" class="ft013">income&#160;countries.</p>
<p style="position:absolute;top:437px;left:231px;white-space:nowrap" class="ft038">2-4</p>
<p style="position:absolute;top:438px;left:246px;white-space:nowrap" class="ft013">&#160;Few&#160;studies have&#160;evaluated CMV&#160;seroprevalence among people with HIV, but&#160;</p>
<p style="position:absolute;top:458px;left:108px;white-space:nowrap" class="ft032">data reported from Africa suggests&#160;CMV seroprevalence is similar or slightly&#160;higher among adults&#160;<br/>with HIV versus&#160;adults&#160;without&#160;HIV.</p>
<p style="position:absolute;top:477px;left:364px;white-space:nowrap" class="ft038">3,5,6</p>
<p style="position:absolute;top:478px;left:386px;white-space:nowrap" class="ft013">&#160;</p>
<p style="position:absolute;top:515px;left:108px;white-space:nowrap" class="ft032">CMV&#160;is acquired through&#160;contact with CMV-infected body fluids. CMV can&#160;be transmitted&#160;in&#160;<br/>several&#160;ways, including through breastfeeding, perinatally, sexually, viral&#160;shedding in bodily fluids&#160;<br/>(saliva, urine, or tears), and through blood products&#160;(transfusions, transplantation).</p>
<p style="position:absolute;top:553px;left:677px;white-space:nowrap" class="ft038">7,8</p>
<p style="position:absolute;top:555px;left:691px;white-space:nowrap" class="ft013">&#160;After&#160;primary&#160;</p>
<p style="position:absolute;top:574px;left:108px;white-space:nowrap" class="ft032">infection, CMV&#160;establishes a lifelong latent&#160;infection that&#160;can reactivate and cause clinical&#160;disease,&#160;<br/>particularly in persons with compromised&#160;immune systems.</p>
<p style="position:absolute;top:593px;left:519px;white-space:nowrap" class="ft038">9</p>
<p style="position:absolute;top:594px;left:525px;white-space:nowrap" class="ft013">&#160;End-organ disease caused by&#160;CMV&#160;</p>
<p style="position:absolute;top:614px;left:108px;white-space:nowrap" class="ft032">occurs in people&#160;with&#160;HIV— especially those with advanced disease and typically among those with&#160;<br/>CD4 T lymphocyte (CD4) cell counts&#160;&lt;50 cells/mm</p>
<p style="position:absolute;top:633px;left:467px;white-space:nowrap" class="ft038">3</p>
<p style="position:absolute;top:634px;left:473px;white-space:nowrap" class="ft013">—who are&#160;not receiving, adherent to, or&#160;</p>
<p style="position:absolute;top:654px;left:108px;white-space:nowrap" class="ft013">responding to antiretroviral&#160;therapy (ART).</p>
<p style="position:absolute;top:652px;left:407px;white-space:nowrap" class="ft038">10-12</p>
<p style="position:absolute;top:654px;left:434px;white-space:nowrap" class="ft013">&#160;Among those treated with ART who have&#160;achieved&#160;</p>
<p style="position:absolute;top:674px;left:108px;white-space:nowrap" class="ft013">virologic&#160;suppression, a&#160;new diagnosis&#160;of CMV end-organ disease is exceedingly rare.&#160;&#160;</p>
<p style="position:absolute;top:711px;left:108px;white-space:nowrap" class="ft032">Before&#160;potent ART, an estimated 30% of people with&#160;advanced&#160;HIV&#160;experienced CMV retinitis, the&#160;<br/>most common CMV end-organ disease in people with HIV.</p>
<p style="position:absolute;top:729px;left:521px;white-space:nowrap" class="ft038">10-12</p>
<p style="position:absolute;top:731px;left:547px;white-space:nowrap" class="ft013">&#160;The incidence of new cases of CMV&#160;</p>
<p style="position:absolute;top:750px;left:108px;white-space:nowrap" class="ft013">end-</p>
<p style="position:absolute;top:750px;left:139px;white-space:nowrap" class="ft018">organ disease has declined by&#160;</p>
<p style="position:absolute;top:750px;left:348px;white-space:nowrap" class="ft069">≥</p>
<p style="position:absolute;top:750px;left:357px;white-space:nowrap" class="ft018">95% with the advent&#160;of potent ART.</p>
<p style="position:absolute;top:749px;left:609px;white-space:nowrap" class="ft038">13,14</p>
<p style="position:absolute;top:750px;left:634px;white-space:nowrap" class="ft013">&#160;The incidence rate of&#160;</p>
<p style="position:absolute;top:770px;left:108px;white-space:nowrap" class="ft032">CMV retinitis in individuals with HIV&#160;since&#160;the&#160;introduction of&#160;effective&#160;ART has been reported to&#160;<br/>be 0.36 per&#160;100 person-years, with&#160;those with a CD4&#160;count&#160;</p>
<p style="position:absolute;top:790px;left:519px;white-space:nowrap" class="ft091">below&#160;50 cells/mm</p>
<p style="position:absolute;top:789px;left:650px;white-space:nowrap" class="ft0108">3</p>
<p style="position:absolute;top:790px;left:655px;white-space:nowrap" class="ft091">&#160;</p>
<p style="position:absolute;top:790px;left:660px;white-space:nowrap" class="ft013">accounting for the&#160;</p>
<p style="position:absolute;top:810px;left:108px;white-space:nowrap" class="ft013">majority of cases.</p>
<p style="position:absolute;top:809px;left:230px;white-space:nowrap" class="ft038">15</p>
<p style="position:absolute;top:810px;left:241px;white-space:nowrap" class="ft013">&#160;For people with established CMV&#160;retinitis,&#160;recurrence of active lesions occurs&#160;at&#160;</p>
<p style="position:absolute;top:830px;left:108px;white-space:nowrap" class="ft032">a rate&#160;substantially lower than that seen in the era&#160;before potent&#160;ART. Nevertheless, even&#160;for those&#160;<br/>with&#160;retinitis whose immune&#160;recovery is&#160;sufficient&#160;to warrant discontinuation of anti-CMV&#160;therapy&#160;<br/>(i.e., CD4 counts&#160;</p>
<p style="position:absolute;top:869px;left:230px;white-space:nowrap" class="ft069">≥</p>
<p style="position:absolute;top:869px;left:239px;white-space:nowrap" class="ft013">100 cells/mm</p>
<p style="position:absolute;top:868px;left:333px;white-space:nowrap" class="ft038">3</p>
<p style="position:absolute;top:869px;left:338px;white-space:nowrap" class="ft013">), relapse at a&#160;rate of 0.03 per&#160;person-year&#160;has been documented.</p>
<p style="position:absolute;top:868px;left:783px;white-space:nowrap" class="ft038">16</p>
<p style="position:absolute;top:869px;left:794px;white-space:nowrap" class="ft013">&#160;</p>
<p style="position:absolute;top:889px;left:108px;white-space:nowrap" class="ft032">CMV&#160;is the&#160;most common cause of vision loss in&#160;people with&#160;HIV, even in the era of effective&#160;ART;&#160;<br/>therefore, regular ophthalmologic follow-up is needed regardless&#160;of&#160;whether&#160;anti-CMV therapy is&#160;<br/>continued.</p>
<p style="position:absolute;top:928px;left:180px;white-space:nowrap" class="ft038">15</p>
<p style="position:absolute;top:929px;left:192px;white-space:nowrap" class="ft013">&#160;See CMV Retinitis Monitoring below&#160;for more&#160;information.&#160;</p>
</div>
<!-- Page 171 -->
<a name="171"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page171-div" style="position:relative;width:917px;height:1187px;">
<p style="position:absolute;top:1121px;left:108px;white-space:nowrap" class="ft024"><i>Guidelines for the Prevention and Treatment&#160;of&#160;Opportunistic&#160;Infections in Adults&#160;and Adolescents&#160;With HIV&#160;</i></p>
<p style="position:absolute;top:1121px;left:791px;white-space:nowrap" class="ft024"><i>K-2&#160;</i></p>
<p style="position:absolute;top:108px;left:108px;white-space:nowrap" class="ft026"><b>Clinical Manifestations&#160;</b></p>
<p style="position:absolute;top:150px;left:108px;white-space:nowrap" class="ft029"><i><b>CMV&#160;Retinitis&#160;</b></i></p>
<p style="position:absolute;top:191px;left:108px;white-space:nowrap" class="ft032">Retinitis is the most common clinical&#160;manifestation of CMV end-organ disease in people&#160;with HIV.&#160;<br/>It presents as&#160;unilateral&#160;disease in two-thirds of cases, but ultimately progresses to bilateral&#160;in most&#160;<br/>affected people&#160;in the absence of therapy or immune recovery.</p>
<p style="position:absolute;top:230px;left:539px;white-space:nowrap" class="ft038">16</p>
<p style="position:absolute;top:231px;left:550px;white-space:nowrap" class="ft013">&#160;&#160;</p>
<p style="position:absolute;top:268px;left:108px;white-space:nowrap" class="ft032">Peripheral retinitis (i.e., outside&#160;the major vascular&#160;arcades, not involving the&#160;macula&#160;or optic disc)&#160;<br/>may be asymptomatic&#160;or present&#160;with floaters, scotomata, or peripheral&#160;visual&#160;field defects. Posterior&#160;<br/>retinal lesions, especially those impinging on the macula or optic&#160;disc, are associated with decreased&#160;<br/>visual&#160;acuity or central&#160;visual&#160;field defects. &#160;</p>
<p style="position:absolute;top:365px;left:108px;white-space:nowrap" class="ft034">CMV&#160;retinitis</p>
<p style="position:absolute;top:365px;left:204px;white-space:nowrap" class="ft013">&#160;is a full-thickness necrotizing retinal&#160;infection that typically produces fluffy,&#160;yellow-</p>
<p style="position:absolute;top:385px;left:108px;white-space:nowrap" class="ft013">white&#160;</p>
<p style="position:absolute;top:385px;left:151px;white-space:nowrap" class="ft034">retinal lesions</p>
<p style="position:absolute;top:385px;left:247px;white-space:nowrap" class="ft013">, with&#160;or without&#160;intraretinal&#160;hemorrhage.</p>
<p style="position:absolute;top:383px;left:533px;white-space:nowrap" class="ft038">17,18</p>
<p style="position:absolute;top:385px;left:558px;white-space:nowrap" class="ft013">&#160;The most typical&#160;feature is the&#160;</p>
<p style="position:absolute;top:404px;left:108px;white-space:nowrap" class="ft032">lesion border, which has tiny, dry-appearing, granular, dot-like “satellites” at&#160;the interface between&#160;<br/>infected and normal&#160;retina. Vitreous humor inflammation is unlikely unless immune recovery with&#160;<br/>ART occurs.</p>
<p style="position:absolute;top:443px;left:196px;white-space:nowrap" class="ft038">10</p>
<p style="position:absolute;top:444px;left:207px;white-space:nowrap" class="ft013">&#160;Blood vessels near the&#160;lesions may appear to be&#160;sheathed. Occasionally, CMV&#160;retinitis&#160;</p>
<p style="position:absolute;top:464px;left:108px;white-space:nowrap" class="ft013">lesions, particularly peripheral&#160;lesions,&#160;may have only a&#160;granular appearance&#160;throughout&#160;the lesion.&#160;</p>
<p style="position:absolute;top:501px;left:108px;white-space:nowrap" class="ft032">In the&#160;absence of effective ART or&#160;specific&#160;anti-CMV&#160;therapy,&#160;retinitis lesions invariably enlarge.&#160;<br/>Untreated lesions in severely immunodeficient individuals will&#160;involve the entire&#160;retina&#160;within&#160;<br/>6 months.&#160;Movement of lesion borders occurs at variable rates in different directions,</p>
<p style="position:absolute;top:539px;left:696px;white-space:nowrap" class="ft038">19</p>
<p style="position:absolute;top:541px;left:708px;white-space:nowrap" class="ft013">&#160;causing a&#160;</p>
<p style="position:absolute;top:561px;left:108px;white-space:nowrap" class="ft013">characteristic&#160;</p>
<p style="position:absolute;top:561px;left:204px;white-space:nowrap" class="ft034">“brushfire”&#160;pattern</p>
<p style="position:absolute;top:561px;left:334px;white-space:nowrap" class="ft013">, with the granular,&#160;leading edges advancing&#160;before an atrophic</p>
<p style="position:absolute;top:580px;left:108px;white-space:nowrap" class="ft013">gliotic scar.</p>
<p style="position:absolute;top:579px;left:188px;white-space:nowrap" class="ft038">20</p>
<p style="position:absolute;top:580px;left:200px;white-space:nowrap" class="ft013">&#160;</p>
<p style="position:absolute;top:618px;left:108px;white-space:nowrap" class="ft029"><i><b>CMV&#160;Colitis&#160;and Esophagitis&#160;</b></i></p>
<p style="position:absolute;top:659px;left:108px;white-space:nowrap" class="ft013">Colitis occurs in 5% to 10% of people&#160;with advanced HIV.</p>
<p style="position:absolute;top:658px;left:515px;white-space:nowrap" class="ft038">11</p>
<p style="position:absolute;top:659px;left:526px;white-space:nowrap" class="ft013">&#160;The&#160;most frequent clinical&#160;</p>
<p style="position:absolute;top:679px;left:108px;white-space:nowrap" class="ft032">manifestations are&#160;weight&#160;loss, fever,&#160;anorexia, abdominal&#160;pain, diarrhea (often bloody), and malaise.&#160;<br/>In the&#160;colon,&#160;and especially in the cecum, CMV can&#160;cause perforation and present&#160;as an acute&#160;<br/>abdomen. Computed tomography (CT)&#160;may show colonic thickening or a colonic&#160;mass&#160;that&#160;may be&#160;<br/>mistaken for&#160;malignancy or other opportunistic&#160;infections (OIs). Hemorrhage and perforation can be&#160;<br/>life-threatening complications.&#160;</p>
<p style="position:absolute;top:795px;left:108px;white-space:nowrap" class="ft032">Esophagitis&#160;and occasional oral ulcers occur in a&#160;small&#160;percentage of people with advanced HIV,&#160;<br/>leading to odynophagia, nausea, mid-epigastric&#160;or retrosternal&#160;discomfort, and fever.&#160;&#160;</p>
<p style="position:absolute;top:852px;left:108px;white-space:nowrap" class="ft029"><i><b>CMV&#160;Pneumonia&#160;</b></i></p>
<p style="position:absolute;top:894px;left:108px;white-space:nowrap" class="ft032">In contrast to&#160;other severely immunosuppressing conditions, CMV pneumonitis is uncommon in&#160;<br/>people with&#160;advanced HIV. CMV&#160;is&#160;detected frequently in the bronchoalveolar lavage (BAL) using&#160;<br/>DNA–specific polymerase&#160;chain reaction (PCR), but it is usually a&#160;bystander&#160;and should trigger a&#160;<br/>search for a&#160;more&#160;likely causative&#160;pathogen.&#160;</p>
<p style="position:absolute;top:990px;left:108px;white-space:nowrap" class="ft029"><i><b>CMV of the Central Nervous&#160;System&#160;</b></i></p>
<p style="position:absolute;top:1031px;left:108px;white-space:nowrap" class="ft032">CMV&#160;neurologic&#160;disease&#160;includes dementia, ventriculoencephalitis, central&#160;nervous&#160;system&#160;<br/>vasculitis, and polyradiculomyelopathies.</p>
<p style="position:absolute;top:1050px;left:395px;white-space:nowrap" class="ft038">21</p>
<p style="position:absolute;top:1051px;left:406px;white-space:nowrap" class="ft013">&#160;People&#160;with dementia caused by&#160;CMV&#160;encephalitis&#160;</p>
</div>
<!-- Page 172 -->
<a name="172"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page172-div" style="position:relative;width:917px;height:1187px;">
<p style="position:absolute;top:1121px;left:108px;white-space:nowrap" class="ft024"><i>Guidelines for the Prevention and Treatment&#160;of&#160;Opportunistic&#160;Infections in Adults&#160;and Adolescents&#160;With HIV&#160;</i></p>
<p style="position:absolute;top:1121px;left:791px;white-space:nowrap" class="ft024"><i>K-3&#160;</i></p>
<p style="position:absolute;top:109px;left:108px;white-space:nowrap" class="ft032">typically are&#160;lethargic&#160;or confused,&#160;with or without&#160;fever. People&#160;with ventriculoencephalitis have a&#160;<br/>more&#160;acute course,&#160;with focal&#160;neurologic&#160;signs, often including cranial nerve palsies or nystagmus,&#160;<br/>and rapid progression to death. Periventricular enhancement&#160;on imaging (CT&#160;or magnetic&#160;resonance)&#160;<br/>highly suggests CMV ventriculoencephalitis rather than HIV-associated neurocognitive disorder.&#160;<br/>CMV&#160;polyradiculomyelopathy and transverse myelitis cause a Guillain-Barré–like&#160;syndrome&#160;<br/>characterized by radicular&#160;back pain, urinary retention, and progressive bilateral&#160;weakness&#160;in the&#160;<br/>lower extremities. Clinical symptoms usually progress&#160;over&#160;several&#160;weeks to include loss&#160;of bowel&#160;<br/>and bladder&#160;control and flaccid paraplegia. Additionally, spastic&#160;myelopathy and sacral paresthesia&#160;<br/>may occur.&#160;&#160;</p>
<p style="position:absolute;top:304px;left:108px;white-space:nowrap" class="ft026"><b>Diagnosis&#160;</b></p>
<p style="position:absolute;top:346px;left:108px;white-space:nowrap" class="ft032">The&#160;diagnosis of CMV&#160;end-organ disease is typically based on the clinical&#160;presentation and, when&#160;<br/>possible, evidence&#160;of the&#160;virus in tissue. CMV&#160;is often present in end-organ&#160;disease and can be&#160;<br/>detected by PCR, antigen&#160;assays,&#160;or culture. Detection of CMV&#160;in blood has limited utility&#160;in&#160;<br/>diagnosing CMV&#160;end-organ disease in&#160;people with&#160;HIV.&#160;A negative serum&#160;or&#160;plasma PCR&#160;assay&#160;<br/>does not rule&#160;out CMV end-organ disease, and CMV viremia&#160;may be present&#160;in the absence of end-<br/>organ disease, particularly in those with low CD4&#160;cell counts.</p>
<p style="position:absolute;top:444px;left:533px;white-space:nowrap" class="ft038">21-26</p>
<p style="position:absolute;top:445px;left:559px;white-space:nowrap" class="ft013">&#160;&#160;</p>
<p style="position:absolute;top:482px;left:108px;white-space:nowrap" class="ft032">The&#160;presence&#160;of CMV serum antibodies&#160;does not establish the presence of CMV&#160;disease,&#160;because a&#160;<br/>large proportion of the general population has been&#160;exposed to CMV&#160;and is seropositive. However, a&#160;<br/>negative&#160;immunoglobulin G antibody&#160;level&#160;indicates that CMV&#160;is unlikely to be&#160;the&#160;cause of the&#160;<br/>disease process.&#160;</p>
<p style="position:absolute;top:579px;left:108px;white-space:nowrap" class="ft029"><i><b>CMV&#160;Retinitis&#160;</b></i></p>
<p style="position:absolute;top:620px;left:108px;white-space:nowrap" class="ft032">CMV&#160;retinitis&#160;is usually diagnosed based on recognition of characteristic retinal&#160;changes observed&#160;<br/>through a&#160;dilated pupil during an ophthalmoscopic examination performed by&#160;an experienced&#160;<br/>ophthalmologist. Nearly&#160;all cases can be diagnosed&#160;clinically. In&#160;rare cases, the diagnosis&#160;may be&#160;<br/>unclear, and&#160;PCR of aqueous or vitreous humor&#160;specimens for CMV&#160;and other pathogens—<br/>especially herpes simplex&#160;virus, varicella-zoster virus, and&#160;</p>
<p style="position:absolute;top:699px;left:515px;white-space:nowrap" class="ft019"><i>Toxoplasma gondii</i></p>
<p style="position:absolute;top:699px;left:648px;white-space:nowrap" class="ft013">—can be&#160;useful for&#160;</p>
<p style="position:absolute;top:719px;left:108px;white-space:nowrap" class="ft032">establishing the&#160;diagnosis.&#160;Detection of CMV&#160;DNA&#160;in cerebrospinal&#160;fluid (CSF) or vitreous or&#160;<br/>aqueous humor specimens&#160;is highly suggestive that&#160;CMV&#160;is the&#160;cause of ocular disease. In&#160;one study,&#160;<br/>CMV&#160;DNA&#160;was detected&#160;in 82% of vitreous specimens collected at&#160;diagnosis of CMV retinitis, 77%&#160;<br/>of relapsed retinitis, and 23% of quiescent retinitis.</p>
<p style="position:absolute;top:777px;left:460px;white-space:nowrap" class="ft038">27</p>
<p style="position:absolute;top:779px;left:471px;white-space:nowrap" class="ft013">&#160;Therefore,&#160;failure&#160;to detect&#160;CMV&#160;DNA&#160;in&#160;</p>
<p style="position:absolute;top:799px;left:108px;white-space:nowrap" class="ft032">vitreous specimens does not rule out&#160;the&#160;presence&#160;of&#160;CMV retinitis. A response&#160;to empiric&#160;anti-CMV&#160;<br/>therapy also&#160;can be an important&#160;diagnostic&#160;indicator.&#160;&#160;</p>
<p style="position:absolute;top:856px;left:108px;white-space:nowrap" class="ft029"><i><b>CMV&#160;Colitis&#160;and Esophagitis&#160;</b></i></p>
<p style="position:absolute;top:897px;left:108px;white-space:nowrap" class="ft032">CMV&#160;colitis is usually diagnosed based on demonstration of mucosal ulcerations on endoscopic&#160;<br/>examination, combined with histopathologic&#160;demonstration of characteristic intranuclear and&#160;<br/>intracytoplasmic inclusions on hematoxylin and eosin stains.</p>
<p style="position:absolute;top:935px;left:527px;white-space:nowrap" class="ft038">11,28</p>
<p style="position:absolute;top:937px;left:553px;white-space:nowrap" class="ft013">&#160;Similarly, CMV&#160;esophagitis is&#160;</p>
<p style="position:absolute;top:956px;left:108px;white-space:nowrap" class="ft032">diagnosed by&#160;the&#160;presence&#160;of ulcers of the distal&#160;esophagus together with biopsy evidence&#160;of&#160;<br/>intranuclear inclusion bodies in the&#160;endothelial cells&#160;with an inflammatory reaction at&#160;the&#160;edge of the&#160;<br/>ulcer.</p>
<p style="position:absolute;top:995px;left:147px;white-space:nowrap" class="ft038">11</p>
<p style="position:absolute;top:996px;left:158px;white-space:nowrap" class="ft013">&#160;The&#160;number of inclusion bodies in specimens can vary&#160;widely and&#160;may be rare.&#160;</p>
<p style="position:absolute;top:1016px;left:108px;white-space:nowrap" class="ft032">Immunohistochemistry can also be used to detect&#160;CMV&#160;in tissue. In the&#160;absence of histopathologic&#160;<br/>changes, culturing CMV and detection of CMV DNA by&#160;PCR from a&#160;biopsy&#160;or cells brushed from&#160;<br/>the&#160;colon or the&#160;esophagus are insufficient to diagnose of CMV&#160;colitis or esophagitis, because a&#160;</p>
</div>
<!-- Page 173 -->
<a name="173"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}	.ft0148{font-size:20px;font-family:RAJFOH+LiberationSansNarrow;color:#1f487c;}
-->
</style>
<div id="page173-div" style="position:relative;width:917px;height:1187px;">
<p style="position:absolute;top:1121px;left:108px;white-space:nowrap" class="ft024"><i>Guidelines for the Prevention and Treatment&#160;of&#160;Opportunistic&#160;Infections in Adults&#160;and Adolescents&#160;With HIV&#160;</i></p>
<p style="position:absolute;top:1121px;left:791px;white-space:nowrap" class="ft024"><i>K-4&#160;</i></p>
<p style="position:absolute;top:109px;left:108px;white-space:nowrap" class="ft032">substantial&#160;number of patients with low CD4 cell counts may shed CMV in in the gastrointestinal&#160;<br/>tract in the&#160;absence of clinical disease.</p>
<p style="position:absolute;top:127px;left:373px;white-space:nowrap" class="ft038">26</p>
<p style="position:absolute;top:129px;left:384px;white-space:nowrap" class="ft013">&#160;&#160;</p>
<p style="position:absolute;top:166px;left:108px;white-space:nowrap" class="ft029"><i><b>CMV&#160;Pneumonia</b></i></p>
<p style="position:absolute;top:207px;left:108px;white-space:nowrap" class="ft032">The&#160;diagnosis of CMV&#160;pneumonitis, a rare&#160;entity in people&#160;with&#160;HIV,&#160;requires consistent&#160;clinical&#160;and&#160;<br/>radiological findings (e.g., diffuse pulmonary interstitial&#160;infiltrates, fever, and cough or&#160;dyspnea),&#160;<br/>identification&#160;of multiple&#160;CMV&#160;inclusion bodies in&#160;lung tissue or cytology, and the&#160;absence&#160;of any&#160;<br/>other pathogens that are more commonly associated with pneumonitis.</p>
<p style="position:absolute;top:265px;left:595px;white-space:nowrap" class="ft038">24,29,30</p>
<p style="position:absolute;top:267px;left:635px;white-space:nowrap" class="ft013">&#160;CMV PCR&#160;from the&#160;</p>
<p style="position:absolute;top:286px;left:108px;white-space:nowrap" class="ft032">BAL has&#160;not been shown&#160;to have diagnostic value in people with HIV. Detection of CMV in the&#160;<br/>lungs in the&#160;absence&#160;of these criteria&#160;typically represents viral shedding, rather than clinical&#160;disease. &#160;</p>
<p style="position:absolute;top:343px;left:108px;white-space:nowrap" class="ft029"><i><b>CMV of the Central Nervous&#160;System&#160;</b></i></p>
<p style="position:absolute;top:385px;left:108px;white-space:nowrap" class="ft032">CMV&#160;neurologic&#160;disease&#160;is diagnosed&#160;based on a&#160;compatible&#160;clinical&#160;syndrome&#160;and the presence of&#160;<br/>CMV&#160;in&#160;CSF&#160;or brain tissue, most often evaluated with PCR.</p>
<p style="position:absolute;top:403px;left:531px;white-space:nowrap" class="ft038">12,22,25</p>
<p style="position:absolute;top:405px;left:570px;white-space:nowrap" class="ft013">&#160;The&#160;CSF&#160;in CMV encephalitis&#160;</p>
<p style="position:absolute;top:424px;left:108px;white-space:nowrap" class="ft032">typically demonstrates lymphocytic pleocytosis, low-to-normal glucose levels, and normal-to-<br/>elevated protein levels, although normal CSF findings do not rule&#160;out the diagnosis of CMV&#160;<br/>encephalitis. The CSF in&#160;CMV&#160;polyradiculopathy usually demonstrates neutrophilic pleocytosis&#160;<br/>(usually 100–200 neutrophils/µL and some erythrocytes) accompanied by low&#160;glucose levels and&#160;<br/>elevated protein levels.&#160;</p>
<p style="position:absolute;top:540px;left:108px;white-space:nowrap" class="ft026"><b>Preventing&#160;Exposure</b></p>
<p style="position:absolute;top:540px;left:280px;white-space:nowrap" class="ft0122"><b>&#160;</b></p>
<p style="position:absolute;top:582px;left:108px;white-space:nowrap" class="ft032">CMV&#160;infection is common in the general&#160;U.S. population, with higher seroprevalence among older&#160;<br/>individuals, women, people&#160;born outside&#160;of the&#160;United States, and people&#160;with lower socioeconomic&#160;<br/>status.</p>
<p style="position:absolute;top:620px;left:152px;white-space:nowrap" class="ft038">1</p>
<p style="position:absolute;top:622px;left:157px;white-space:nowrap" class="ft013">&#160;However, in people&#160;with HIV,&#160;CMV&#160;seropositivity cannot&#160;be assumed. Limited options exist&#160;</p>
<p style="position:absolute;top:642px;left:108px;white-space:nowrap" class="ft032">to prevent&#160;exposure to CMV&#160;among adults with HIV, but condoms may reduce sexual transmission&#160;<br/>of CMV.</p>
<p style="position:absolute;top:660px;left:170px;white-space:nowrap" class="ft038">31,32</p>
<p style="position:absolute;top:661px;left:196px;white-space:nowrap" class="ft013">&#160;&#160;</p>
<p style="position:absolute;top:698px;left:108px;white-space:nowrap" class="ft026"><b>Preventing&#160;Disease&#160;&#160;</b></p>
<p style="position:absolute;top:747px;left:299px;white-space:nowrap" class="ft02"><b>Recommendations for Preventing&#160;CMV&#160;Disease&#160;</b></p>
<p style="position:absolute;top:775px;left:116px;white-space:nowrap" class="ft030">•</p>
<p style="position:absolute;top:776px;left:123px;white-space:nowrap" class="ft057">&#160;</p>
<p style="position:absolute;top:776px;left:133px;white-space:nowrap" class="ft041">To prevent&#160;CMV&#160;end-organ&#160;disease, administer&#160;ART to maintain the CD4 count&#160;</p>
<p style="position:absolute;top:776px;left:568px;white-space:nowrap" class="ft064">≥</p>
<p style="position:absolute;top:776px;left:576px;white-space:nowrap" class="ft041">100 cells/mm</p>
<p style="position:absolute;top:777px;left:649px;white-space:nowrap" class="ft058">3&#160;</p>
<p style="position:absolute;top:776px;left:656px;white-space:nowrap" class="ft042"><b>(AI).</b></p>
<p style="position:absolute;top:770px;left:679px;white-space:nowrap" class="ft0148">&#160;</p>
<p style="position:absolute;top:803px;left:108px;white-space:nowrap" class="ft042"><b>Key:&#160;</b></p>
<p style="position:absolute;top:803px;left:138px;white-space:nowrap" class="ft041">ART =&#160;antiretroviral&#160;therapy; CD4&#160;= CD4&#160;T&#160;lymphocyte;&#160;CMV&#160;= cytomegalovirus&#160;</p>
<p style="position:absolute;top:838px;left:108px;white-space:nowrap" class="ft013">CMV&#160;end-organ disease is best prevented using ART to maintain a CD4 count&#160;</p>
<p style="position:absolute;top:838px;left:654px;white-space:nowrap" class="ft069">≥</p>
<p style="position:absolute;top:838px;left:664px;white-space:nowrap" class="ft013">100 cells/mm</p>
<p style="position:absolute;top:837px;left:758px;white-space:nowrap" class="ft038">3&#160;</p>
<p style="position:absolute;top:838px;left:766px;white-space:nowrap" class="ft012"><b>(AI).</b></p>
<p style="position:absolute;top:838px;left:801px;white-space:nowrap" class="ft013">&#160;</p>
<p style="position:absolute;top:858px;left:108px;white-space:nowrap" class="ft032">A randomized, placebo-controlled trial&#160;failed to show&#160;benefit for the&#160;use of valganciclovir&#160;<br/>prophylaxis (the current&#160;standard oral agent&#160;for treatment of CMV disease) combined with ART as&#160;<br/>preventive&#160;therapy for CMV&#160;end-organ disease in&#160;people at high risk (CD4&#160;count&#160;&lt;100&#160;cells/mm</p>
<p style="position:absolute;top:896px;left:776px;white-space:nowrap" class="ft038">3</p>
<p style="position:absolute;top:897px;left:782px;white-space:nowrap" class="ft013">&#160;</p>
<p style="position:absolute;top:917px;left:108px;white-space:nowrap" class="ft013">and CMV viremia&#160;detected by plasma&#160;CMV&#160;DNA&#160;PCR assay).</p>
<p style="position:absolute;top:916px;left:544px;white-space:nowrap" class="ft038">33</p>
<p style="position:absolute;top:917px;left:555px;white-space:nowrap" class="ft013">&#160;Therefore,&#160;valganciclovir primary&#160;</p>
<p style="position:absolute;top:937px;left:108px;white-space:nowrap" class="ft013">prophylaxis&#160;</p>
<p style="position:absolute;top:937px;left:194px;white-space:nowrap" class="ft012"><b>is</b></p>
<p style="position:absolute;top:937px;left:205px;white-space:nowrap" class="ft013">&#160;</p>
<p style="position:absolute;top:937px;left:210px;white-space:nowrap" class="ft012"><b>not&#160;recommended</b></p>
<p style="position:absolute;top:937px;left:342px;white-space:nowrap" class="ft013">&#160;to prevent&#160;CMV&#160;end-organ disease in people with HIV,&#160;even&#160;</p>
<p style="position:absolute;top:957px;left:108px;white-space:nowrap" class="ft013">among patients who&#160;have&#160;CMV viremia&#160;</p>
<p style="position:absolute;top:957px;left:389px;white-space:nowrap" class="ft012"><b>(AI),</b></p>
<p style="position:absolute;top:957px;left:424px;white-space:nowrap" class="ft013">&#160;and&#160;monitoring of CMV viremia&#160;</p>
<p style="position:absolute;top:957px;left:657px;white-space:nowrap" class="ft012"><b>is</b></p>
<p style="position:absolute;top:957px;left:669px;white-space:nowrap" class="ft013">&#160;</p>
<p style="position:absolute;top:957px;left:673px;white-space:nowrap" class="ft012"><b>not&#160;</b></p>
<p style="position:absolute;top:977px;left:108px;white-space:nowrap" class="ft012"><b>recommended</b></p>
<p style="position:absolute;top:977px;left:212px;white-space:nowrap" class="ft013">.&#160;</p>
<p style="position:absolute;top:1014px;left:108px;white-space:nowrap" class="ft032">The&#160;primary method for preventing severe CMV disease is recognizing the early manifestations of&#160;<br/>the&#160;disease and instituting proper therapy. People&#160;who have a&#160;low CD4 cell count (&lt;100 cells/mm</p>
<p style="position:absolute;top:1032px;left:782px;white-space:nowrap" class="ft038">3</p>
<p style="position:absolute;top:1034px;left:788px;white-space:nowrap" class="ft013">)&#160;</p>
<p style="position:absolute;top:1054px;left:108px;white-space:nowrap" class="ft013">and are&#160;not on ART should be made aware of how&#160;to recognize floaters in the eye and their&#160;</p>
</div>
<!-- Page 174 -->
<a name="174"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page174-div" style="position:relative;width:917px;height:1187px;">
<p style="position:absolute;top:1121px;left:108px;white-space:nowrap" class="ft024"><i>Guidelines for the Prevention and Treatment&#160;of&#160;Opportunistic&#160;Infections in Adults&#160;and Adolescents&#160;With HIV&#160;</i></p>
<p style="position:absolute;top:1121px;left:791px;white-space:nowrap" class="ft024"><i>K-5&#160;</i></p>
<p style="position:absolute;top:109px;left:108px;white-space:nowrap" class="ft032">implication.&#160;Development of floaters&#160;or changes in&#160;visual&#160;acuity should prompt&#160;an urgent&#160;referral to&#160;<br/>ophthalmology&#160;</p>
<p style="position:absolute;top:129px;left:217px;white-space:nowrap" class="ft012"><b>(AIII).</b></p>
<p style="position:absolute;top:129px;left:265px;white-space:nowrap" class="ft013">&#160;The Panel&#160;on&#160;Guidelines for the&#160;Prevention and Treatment of Opportunistic&#160;</p>
<p style="position:absolute;top:148px;left:108px;white-space:nowrap" class="ft032">Infections in&#160;Adults and&#160;Adolescents&#160;With HIV (the Panel) recommends a baseline&#160;ophthalmologic&#160;<br/>examination for people with HIV and&#160;CD4 counts&#160;&lt;100 cells/mm</p>
<p style="position:absolute;top:167px;left:561px;white-space:nowrap" class="ft038">3</p>
<p style="position:absolute;top:168px;left:566px;white-space:nowrap" class="ft013">, with counseling about the&#160;</p>
<p style="position:absolute;top:188px;left:108px;white-space:nowrap" class="ft013">potential&#160;symptoms of CMV&#160;retinitis&#160;</p>
<p style="position:absolute;top:188px;left:367px;white-space:nowrap" class="ft012"><b>(CIII).</b></p>
<p style="position:absolute;top:188px;left:415px;white-space:nowrap" class="ft013">&#160;In the premodern&#160;ART era, it&#160;was common&#160;for follow-</p>
<p style="position:absolute;top:208px;left:108px;white-space:nowrap" class="ft032">up ophthalmologic examinations to be&#160;performed every 3 to 4 months for&#160;persons&#160;with CD4 counts&#160;<br/>&lt;50 cells/mm</p>
<p style="position:absolute;top:226px;left:202px;white-space:nowrap" class="ft038">3</p>
<p style="position:absolute;top:228px;left:208px;white-space:nowrap" class="ft013">&#160;(the&#160;range associated&#160;with most cases of CMV&#160;retinitis), because early CMV&#160;retinitis&#160;</p>
<p style="position:absolute;top:248px;left:108px;white-space:nowrap" class="ft032">may be asymptomatic. The&#160;same follow-up&#160;schedule&#160;is appropriate in the&#160;era of effective ART if&#160;<br/>CD4 counts fall below 50&#160;cells/mm</p>
<p style="position:absolute;top:266px;left:353px;white-space:nowrap" class="ft038">3&#160;</p>
<p style="position:absolute;top:267px;left:361px;white-space:nowrap" class="ft013">for any reason, including treatment&#160;failure&#160;</p>
<p style="position:absolute;top:267px;left:656px;white-space:nowrap" class="ft012"><b>(CIII).</b></p>
<p style="position:absolute;top:267px;left:705px;white-space:nowrap" class="ft013">&#160;Individuals&#160;</p>
<p style="position:absolute;top:287px;left:108px;white-space:nowrap" class="ft032">with CMV retinitis and ART failure are more likely to be asymptomatic&#160;than&#160;were individuals in the&#160;<br/>premodern ART era.</p>
<p style="position:absolute;top:306px;left:251px;white-space:nowrap" class="ft038">18</p>
<p style="position:absolute;top:307px;left:263px;white-space:nowrap" class="ft013">&#160;&#160;</p>
<p style="position:absolute;top:344px;left:108px;white-space:nowrap" class="ft026"><b>Treating Disease&#160;</b></p>
<p style="position:absolute;top:395px;left:260px;white-space:nowrap" class="ft02"><b>Recommendations for Treating Cytomegalovirus&#160;Infections&#160;</b></p>
<p style="position:absolute;top:429px;left:116px;white-space:nowrap" class="ft056"><b>Treating&#160;CMV&#160;Retinitis&#160;</b></p>
<p style="position:absolute;top:453px;left:116px;white-space:nowrap" class="ft042"><b>General Considerations&#160;</b></p>
<p style="position:absolute;top:479px;left:116px;white-space:nowrap" class="ft030">•</p>
<p style="position:absolute;top:480px;left:123px;white-space:nowrap" class="ft057">&#160;</p>
<p style="position:absolute;top:480px;left:133px;white-space:nowrap" class="ft041">CMV retinitis&#160;should be&#160;treated with the active participation&#160;of an ophthalmologist who&#160;is familiar with CMV&#160;retinitis&#160;</p>
<p style="position:absolute;top:497px;left:133px;white-space:nowrap" class="ft041">diagnosis&#160;and&#160;management.</p>
<p style="position:absolute;top:497px;left:287px;white-space:nowrap" class="ft042"><b>&#160;</b></p>
<p style="position:absolute;top:523px;left:116px;white-space:nowrap" class="ft030">•</p>
<p style="position:absolute;top:525px;left:123px;white-space:nowrap" class="ft057">&#160;</p>
<p style="position:absolute;top:525px;left:133px;white-space:nowrap" class="ft041">See CMV Retinitis Monitoring&#160;below for ophthalmic&#160;monitoring recommendations for people on&#160;treatment&#160;for CMV&#160;retinitis&#160;</p>
<p style="position:absolute;top:542px;left:133px;white-space:nowrap" class="ft041">and&#160;after discontinuation of maintenance therapy.</p>
<p style="position:absolute;top:542px;left:402px;white-space:nowrap" class="ft042"><b>&#160;</b></p>
<p style="position:absolute;top:574px;left:116px;white-space:nowrap" class="ft042"><b>Induction&#160;Therapy Followed&#160;by Maintenance&#160;Therapy&#160;</b></p>
<p style="position:absolute;top:600px;left:116px;white-space:nowrap" class="ft024"><i>Preferred&#160;Therapy&#160;</i></p>
<p style="position:absolute;top:626px;left:116px;white-space:nowrap" class="ft030">•</p>
<p style="position:absolute;top:628px;left:123px;white-space:nowrap" class="ft057">&#160;</p>
<p style="position:absolute;top:627px;left:133px;white-space:nowrap" class="ft041">Valganciclovir</p>
<p style="position:absolute;top:629px;left:209px;white-space:nowrap" class="ft058">a</p>
<p style="position:absolute;top:627px;left:213px;white-space:nowrap" class="ft041">&#160;900&#160;mg&#160;PO every&#160;12&#160;hours&#160;for 14–21 days, then&#160;maintenance therapy&#160;with&#160;valganciclovir 900&#160;mg PO&#160;once&#160;</p>
<p style="position:absolute;top:645px;left:133px;white-space:nowrap" class="ft041">daily&#160;</p>
<p style="position:absolute;top:645px;left:161px;white-space:nowrap" class="ft042"><b>(AI),</b></p>
<p style="position:absolute;top:645px;left:185px;white-space:nowrap" class="ft041">&#160;</p>
<p style="position:absolute;top:645px;left:189px;white-space:nowrap" class="ft024"><i>or</i></p>
<p style="position:absolute;top:645px;left:200px;white-space:nowrap" class="ft041">&#160;</p>
<p style="position:absolute;top:671px;left:116px;white-space:nowrap" class="ft030">•</p>
<p style="position:absolute;top:672px;left:123px;white-space:nowrap" class="ft057">&#160;</p>
<p style="position:absolute;top:672px;left:133px;white-space:nowrap" class="ft041">Ganciclovir</p>
<p style="position:absolute;top:673px;left:194px;white-space:nowrap" class="ft058">a</p>
<p style="position:absolute;top:672px;left:201px;white-space:nowrap" class="ft041">5 mg/kg IV every&#160;12&#160;hours&#160;for&#160;14–21&#160;days, then maintenance therapy&#160;with&#160;valganciclovir&#160;900 mg&#160;PO once&#160;</p>
<p style="position:absolute;top:689px;left:133px;white-space:nowrap" class="ft041">daily&#160;</p>
<p style="position:absolute;top:689px;left:161px;white-space:nowrap" class="ft042"><b>(AI),&#160;</b></p>
<p style="position:absolute;top:689px;left:189px;white-space:nowrap" class="ft024"><i>or</i></p>
<p style="position:absolute;top:689px;left:200px;white-space:nowrap" class="ft041">&#160;</p>
<p style="position:absolute;top:715px;left:116px;white-space:nowrap" class="ft030">•</p>
<p style="position:absolute;top:717px;left:123px;white-space:nowrap" class="ft057">&#160;</p>
<p style="position:absolute;top:716px;left:133px;white-space:nowrap" class="ft041">Ganciclovir</p>
<p style="position:absolute;top:717px;left:194px;white-space:nowrap" class="ft058">a</p>
<p style="position:absolute;top:716px;left:201px;white-space:nowrap" class="ft041">5 mg/kg IV every&#160;12&#160;hours&#160;for&#160;14–21&#160;days, then maintenance therapy&#160;with&#160;ganciclovir&#160;5 mg/kg IV daily&#160;</p>
<p style="position:absolute;top:716px;left:760px;white-space:nowrap" class="ft042"><b>(AI)</b></p>
<p style="position:absolute;top:716px;left:780px;white-space:nowrap" class="ft024"><i>&#160;</i></p>
<p style="position:absolute;top:748px;left:116px;white-space:nowrap" class="ft042"><b>Notes</b></p>
<p style="position:absolute;top:748px;left:151px;white-space:nowrap" class="ft041">&#160;&#160;</p>
<p style="position:absolute;top:775px;left:116px;white-space:nowrap" class="ft030">•</p>
<p style="position:absolute;top:775px;left:123px;white-space:nowrap" class="ft057">&#160;</p>
<p style="position:absolute;top:775px;left:135px;white-space:nowrap" class="ft044">Many&#160;clinicians&#160;prefer the IV formulation when retinitis&#160;is more central and sight-threatening or when&#160;adequate GI&#160;<br/>absorption is&#160;a&#160;concern; transition to&#160;oral valganciclovir can be&#160;considered&#160;when there is&#160;evidence&#160;of clinical&#160;response.&#160;</p>
<p style="position:absolute;top:819px;left:116px;white-space:nowrap" class="ft030">•</p>
<p style="position:absolute;top:819px;left:123px;white-space:nowrap" class="ft057">&#160;</p>
<p style="position:absolute;top:819px;left:135px;white-space:nowrap" class="ft041">PO valganciclovir is the preferred&#160;maintenance regimen&#160;as it is&#160;the&#160;easiest and least toxic&#160;to&#160;administer to an outpatient&#160;</p>
<p style="position:absolute;top:836px;left:135px;white-space:nowrap" class="ft041">population,&#160;provided&#160;that GI absorption is&#160;adequate.&#160;&#160;</p>
<p style="position:absolute;top:868px;left:116px;white-space:nowrap" class="ft024"><i>Alternative Therapy&#160;&#160;</i></p>
<p style="position:absolute;top:895px;left:116px;white-space:nowrap" class="ft030">•</p>
<p style="position:absolute;top:896px;left:123px;white-space:nowrap" class="ft057">&#160;</p>
<p style="position:absolute;top:896px;left:133px;white-space:nowrap" class="ft041">Foscarnet</p>
<p style="position:absolute;top:897px;left:187px;white-space:nowrap" class="ft058">a</p>
<p style="position:absolute;top:896px;left:192px;white-space:nowrap" class="ft041">&#160;60&#160;mg/kg IV&#160;every&#160;8&#160;hours&#160;or&#160;90&#160;mg/kg IV every&#160;12&#160;hours&#160;for 14–21&#160;days, then maintenance therapy&#160;with&#160;</p>
<p style="position:absolute;top:913px;left:133px;white-space:nowrap" class="ft041">foscarnet 90&#160;mg/kg or 120&#160;mg/kg&#160;IV&#160;every&#160;24 hours&#160;</p>
<p style="position:absolute;top:913px;left:416px;white-space:nowrap" class="ft042"><b>(BI)</b></p>
<p style="position:absolute;top:913px;left:436px;white-space:nowrap" class="ft041">&#160;</p>
<p style="position:absolute;top:913px;left:440px;white-space:nowrap" class="ft024"><i>or</i></p>
<p style="position:absolute;top:913px;left:450px;white-space:nowrap" class="ft041">&#160;</p>
<p style="position:absolute;top:939px;left:116px;white-space:nowrap" class="ft030">•</p>
<p style="position:absolute;top:941px;left:123px;white-space:nowrap" class="ft057">&#160;</p>
<p style="position:absolute;top:940px;left:133px;white-space:nowrap" class="ft041">Cidofovir</p>
<p style="position:absolute;top:941px;left:181px;white-space:nowrap" class="ft058">a,b</p>
<p style="position:absolute;top:940px;left:192px;white-space:nowrap" class="ft041">&#160;5 mg/kg IV every&#160;week for&#160;2 weeks, then maintenance therapy with&#160;cidofovir&#160;5 mg/kg IV&#160;every other week.&#160;</p>
<p style="position:absolute;top:957px;left:133px;white-space:nowrap" class="ft041">Administer 1 L of&#160;normal&#160;saline before and, if additional&#160;fluid&#160;load&#160;can be tolerated,&#160;administer another 1 L of&#160;normal&#160;saline&#160;</p>
<p style="position:absolute;top:975px;left:133px;white-space:nowrap" class="ft044">after each&#160;cidofovir&#160;infusion. Administer probenecid 2 g&#160;PO 3 hours&#160;before each cidofovir dose followed&#160;by 1 g PO&#160;2 hours&#160;<br/>after the dose, and 1&#160;g PO&#160;8 hours&#160;after&#160;the&#160;dose&#160;(total&#160;of&#160;4 g)&#160;</p>
<p style="position:absolute;top:992px;left:473px;white-space:nowrap" class="ft042"><b>(CI).&#160;</b></p>
<p style="position:absolute;top:992px;left:500px;white-space:nowrap" class="ft041">&#160;</p>
<p style="position:absolute;top:1020px;left:133px;white-space:nowrap" class="ft062">o</p>
<p style="position:absolute;top:1018px;left:142px;white-space:nowrap" class="ft057">&#160;</p>
<p style="position:absolute;top:1018px;left:149px;white-space:nowrap" class="ft042"><b>Note:&#160;</b></p>
<p style="position:absolute;top:1018px;left:184px;white-space:nowrap" class="ft041">Cidofovir&#160;should be&#160;avoided in patients&#160;with sulfonamide allergy because of&#160;cross-hypersensitivity&#160;with&#160;</p>
<p style="position:absolute;top:1035px;left:149px;white-space:nowrap" class="ft041">probenecid.&#160;&#160;</p>
</div>
<!-- Page 175 -->
<a name="175"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page175-div" style="position:relative;width:917px;height:1187px;">
<p style="position:absolute;top:1121px;left:108px;white-space:nowrap" class="ft024"><i>Guidelines for the Prevention and Treatment&#160;of&#160;Opportunistic&#160;Infections in Adults&#160;and Adolescents&#160;With HIV&#160;</i></p>
<p style="position:absolute;top:1121px;left:791px;white-space:nowrap" class="ft024"><i>K-6&#160;</i></p>
<p style="position:absolute;top:109px;left:116px;white-space:nowrap" class="ft042"><b>If Immediate Sight-Threatening Lesions&#160;(within 1,500&#160;microns of&#160;the&#160;fovea&#160;or optic&#160;disc)&#160;</b></p>
<p style="position:absolute;top:135px;left:116px;white-space:nowrap" class="ft030">•</p>
<p style="position:absolute;top:136px;left:123px;white-space:nowrap" class="ft057">&#160;</p>
<p style="position:absolute;top:136px;left:133px;white-space:nowrap" class="ft041">Add intravitreal&#160;injections&#160;of ganciclovir&#160;(2 mg/injection) or&#160;foscarnet&#160;(2.4 mg/injection), repeated weekly&#160;during the&#160;</p>
<p style="position:absolute;top:153px;left:133px;white-space:nowrap" class="ft041">induction period&#160;until&#160;lesion&#160;inactivity is achieved&#160;</p>
<p style="position:absolute;top:153px;left:400px;white-space:nowrap" class="ft042"><b>(BIII),</b></p>
<p style="position:absolute;top:153px;left:431px;white-space:nowrap" class="ft041">&#160;then systemic&#160;treatment alone is&#160;considered to&#160;be adequate for&#160;</p>
<p style="position:absolute;top:170px;left:133px;white-space:nowrap" class="ft041">maintenance therapy.&#160;</p>
<p style="position:absolute;top:171px;left:254px;white-space:nowrap" class="ft057">&#160;</p>
<p style="position:absolute;top:198px;left:133px;white-space:nowrap" class="ft062">o</p>
<p style="position:absolute;top:197px;left:142px;white-space:nowrap" class="ft057">&#160;</p>
<p style="position:absolute;top:197px;left:149px;white-space:nowrap" class="ft042"><b>Note:</b></p>
<p style="position:absolute;top:197px;left:180px;white-space:nowrap" class="ft041">&#160;Intravitreal&#160;administration&#160;of cidofovir&#160;</p>
<p style="position:absolute;top:197px;left:387px;white-space:nowrap" class="ft042"><b>is contraindicated,</b></p>
<p style="position:absolute;top:197px;left:496px;white-space:nowrap" class="ft041">&#160;as&#160;it has&#160;been associated with uveitis&#160;and&#160;marked&#160;</p>
<p style="position:absolute;top:214px;left:149px;white-space:nowrap" class="ft041">hypotony&#160;of&#160;the&#160;injected eye&#160;</p>
<p style="position:absolute;top:214px;left:306px;white-space:nowrap" class="ft042"><b>(AIII).</b></p>
<p style="position:absolute;top:214px;left:336px;white-space:nowrap" class="ft041">&#160;</p>
<p style="position:absolute;top:246px;left:116px;white-space:nowrap" class="ft042"><b>Peripheral&#160;Lesions&#160;</b></p>
<p style="position:absolute;top:272px;left:116px;white-space:nowrap" class="ft030">•</p>
<p style="position:absolute;top:274px;left:123px;white-space:nowrap" class="ft057">&#160;</p>
<p style="position:absolute;top:273px;left:133px;white-space:nowrap" class="ft041">Valganciclovir</p>
<p style="position:absolute;top:275px;left:209px;white-space:nowrap" class="ft058">a</p>
<p style="position:absolute;top:273px;left:213px;white-space:nowrap" class="ft041">&#160;900&#160;mg&#160;PO every&#160;12&#160;hours&#160;for 14–21 days, then&#160;maintenance therapy&#160;with&#160;valganciclovir&#160;900&#160;mg PO&#160;once&#160;</p>
<p style="position:absolute;top:291px;left:133px;white-space:nowrap" class="ft041">daily&#160;</p>
<p style="position:absolute;top:291px;left:161px;white-space:nowrap" class="ft042"><b>(AI)</b></p>
<p style="position:absolute;top:291px;left:182px;white-space:nowrap" class="ft041">&#160;</p>
<p style="position:absolute;top:323px;left:116px;white-space:nowrap" class="ft042"><b>Duration&#160;of&#160;Induction&#160;Therapy&#160;for CMV&#160;Retinitis&#160;</b></p>
<p style="position:absolute;top:349px;left:117px;white-space:nowrap" class="ft030">•</p>
<p style="position:absolute;top:350px;left:123px;white-space:nowrap" class="ft057">&#160;</p>
<p style="position:absolute;top:349px;left:135px;white-space:nowrap" class="ft041">Minimum 14–21 days; duration determined&#160;by&#160;clinical&#160;response based on&#160;retinal&#160;examination&#160;</p>
<p style="position:absolute;top:376px;left:116px;white-space:nowrap" class="ft030">•</p>
<p style="position:absolute;top:376px;left:123px;white-space:nowrap" class="ft057">&#160;</p>
<p style="position:absolute;top:376px;left:135px;white-space:nowrap" class="ft042"><b>Note:</b></p>
<p style="position:absolute;top:376px;left:167px;white-space:nowrap" class="ft041">&#160;Many&#160;clinicians&#160;continue&#160;induction-level&#160;treatment until&#160;retinal&#160;lesion&#160;opacity is&#160;resolved or markedly&#160;reduced,&#160;</p>
<p style="position:absolute;top:393px;left:135px;white-space:nowrap" class="ft041">indicating virus&#160;inactivity&#160;</p>
<p style="position:absolute;top:393px;left:271px;white-space:nowrap" class="ft042"><b>(BIII).</b></p>
<p style="position:absolute;top:393px;left:301px;white-space:nowrap" class="ft041">&#160;</p>
<p style="position:absolute;top:426px;left:116px;white-space:nowrap" class="ft042"><b>Starting Maintenance&#160;Therapy&#160;for CMV&#160;Retinitis&#160;</b></p>
<p style="position:absolute;top:452px;left:117px;white-space:nowrap" class="ft030">•</p>
<p style="position:absolute;top:453px;left:123px;white-space:nowrap" class="ft057">&#160;</p>
<p style="position:absolute;top:452px;left:135px;white-space:nowrap" class="ft041">Maintenance therapy is&#160;started after induction has&#160;achieved&#160;control&#160;of retinitis. Regimens are as detailed above.&#160;</p>
<p style="position:absolute;top:452px;left:747px;white-space:nowrap" class="ft042"><b>&#160;</b></p>
<p style="position:absolute;top:485px;left:117px;white-space:nowrap" class="ft042"><b>Immune Recovery Uveitis&#160;</b></p>
<p style="position:absolute;top:511px;left:117px;white-space:nowrap" class="ft030">•</p>
<p style="position:absolute;top:512px;left:123px;white-space:nowrap" class="ft057">&#160;</p>
<p style="position:absolute;top:512px;left:133px;white-space:nowrap" class="ft041">The Panel&#160;favors&#160;the use of both&#160;corticosteroids&#160;and&#160;anti-CMV therapy&#160;for&#160;active intraocular inflammation at the&#160;onset of&#160;</p>
<p style="position:absolute;top:529px;left:133px;white-space:nowrap" class="ft041">IRU and&#160;the&#160;use&#160;of corticosteroids for&#160;cystoid macular edemas, a&#160;late&#160;complication&#160;of IRU&#160;</p>
<p style="position:absolute;top:529px;left:622px;white-space:nowrap" class="ft042"><b>(CIII).</b></p>
<p style="position:absolute;top:529px;left:653px;white-space:nowrap" class="ft041">&#160;</p>
<p style="position:absolute;top:555px;left:117px;white-space:nowrap" class="ft030">•</p>
<p style="position:absolute;top:557px;left:123px;white-space:nowrap" class="ft057">&#160;</p>
<p style="position:absolute;top:556px;left:133px;white-space:nowrap" class="ft041">Corticosteroids&#160;can be administered by&#160;oral,&#160;periocular, or intravitreal routes.&#160;&#160;</p>
<p style="position:absolute;top:584px;left:133px;white-space:nowrap" class="ft062">o</p>
<p style="position:absolute;top:583px;left:142px;white-space:nowrap" class="ft057">&#160;</p>
<p style="position:absolute;top:582px;left:149px;white-space:nowrap" class="ft041">Prednisone&#160;1 mg/kg PO daily&#160;(maximum&#160;dose of&#160;60–80 mg/day)&#160;until&#160;clinical&#160;response, but&#160;for&#160;no&#160;longer than&#160;1 month,&#160;</p>
<p style="position:absolute;top:600px;left:149px;white-space:nowrap" class="ft041">followed by&#160;tapering&#160;and discontinuation over 2 to&#160;3 months&#160;</p>
<p style="position:absolute;top:600px;left:476px;white-space:nowrap" class="ft042"><b>(BIII)</b></p>
<p style="position:absolute;top:600px;left:504px;white-space:nowrap" class="ft041">&#160;</p>
<p style="position:absolute;top:627px;left:133px;white-space:nowrap" class="ft062">o</p>
<p style="position:absolute;top:626px;left:142px;white-space:nowrap" class="ft057">&#160;</p>
<p style="position:absolute;top:626px;left:149px;white-space:nowrap" class="ft041">Periocular or intravitreal corticosteroid&#160;injections can be repeated&#160;after the expected duration of&#160;effect if there is&#160;</p>
<p style="position:absolute;top:643px;left:149px;white-space:nowrap" class="ft041">evidence of incomplete&#160;clinical&#160;response and no treatment&#160;complications&#160;</p>
<p style="position:absolute;top:643px;left:547px;white-space:nowrap" class="ft042"><b>(BIII).</b></p>
<p style="position:absolute;top:643px;left:577px;white-space:nowrap" class="ft041">&#160;</p>
<p style="position:absolute;top:675px;left:117px;white-space:nowrap" class="ft042"><b>Stopping Maintenance Therapy for CMV&#160;Retinitis&#160;</b></p>
<p style="position:absolute;top:701px;left:117px;white-space:nowrap" class="ft030">•</p>
<p style="position:absolute;top:703px;left:123px;white-space:nowrap" class="ft057">&#160;</p>
<p style="position:absolute;top:703px;left:133px;white-space:nowrap" class="ft041">CMV treatment&#160;for at least 3 months,&#160;</p>
<p style="position:absolute;top:703px;left:337px;white-space:nowrap" class="ft042"><b>and</b></p>
<p style="position:absolute;top:703px;left:359px;white-space:nowrap" class="ft041">&#160;lesions&#160;are inactive,&#160;</p>
<p style="position:absolute;top:703px;left:474px;white-space:nowrap" class="ft042"><b>and</b></p>
<p style="position:absolute;top:703px;left:496px;white-space:nowrap" class="ft041">&#160;CD4 count&#160;</p>
<p style="position:absolute;top:703px;left:561px;white-space:nowrap" class="ft064">≥</p>
<p style="position:absolute;top:703px;left:569px;white-space:nowrap" class="ft041">100 cells/mm</p>
<p style="position:absolute;top:704px;left:641px;white-space:nowrap" class="ft058">3&#160;</p>
<p style="position:absolute;top:703px;left:648px;white-space:nowrap" class="ft041">for at least 3 months&#160;in&#160;</p>
<p style="position:absolute;top:720px;left:133px;white-space:nowrap" class="ft041">response to ART&#160;</p>
<p style="position:absolute;top:720px;left:228px;white-space:nowrap" class="ft042"><b>(AII)</b></p>
<p style="position:absolute;top:720px;left:252px;white-space:nowrap" class="ft041">&#160;</p>
<p style="position:absolute;top:720px;left:256px;white-space:nowrap" class="ft042"><b>&#160;</b></p>
<p style="position:absolute;top:747px;left:133px;white-space:nowrap" class="ft062">o</p>
<p style="position:absolute;top:746px;left:142px;white-space:nowrap" class="ft057">&#160;</p>
<p style="position:absolute;top:746px;left:149px;white-space:nowrap" class="ft042"><b>Note:</b></p>
<p style="position:absolute;top:746px;left:180px;white-space:nowrap" class="ft041">&#160;In all&#160;people&#160;for&#160;whom&#160;anti-CMV&#160;maintenance therapy&#160;has&#160;been&#160;discontinued,&#160;ophthalmologic&#160;monitoring&#160;for&#160;early&#160;</p>
<p style="position:absolute;top:763px;left:149px;white-space:nowrap" class="ft041">detection&#160;of&#160;CMV&#160;relapse&#160;and&#160;IRU&#160;should be&#160;performed&#160;at least every&#160;3 months&#160;and&#160;then yearly&#160;after&#160;immune&#160;</p>
<p style="position:absolute;top:780px;left:149px;white-space:nowrap" class="ft041">reconstitution&#160;</p>
<p style="position:absolute;top:780px;left:225px;white-space:nowrap" class="ft042"><b>(AIII).</b></p>
<p style="position:absolute;top:780px;left:256px;white-space:nowrap" class="ft041">&#160;Monitoring CMV&#160;viral&#160;load&#160;in blood has&#160;poor positive predictive&#160;value&#160;for&#160;relapse of&#160;retinitis&#160;and,&#160;</p>
<p style="position:absolute;top:798px;left:149px;white-space:nowrap" class="ft041">therefore, is&#160;not&#160;recommended for people&#160;with&#160;HIV&#160;</p>
<p style="position:absolute;top:798px;left:427px;white-space:nowrap" class="ft042"><b>(AII).&#160;</b></p>
<p style="position:absolute;top:830px;left:116px;white-space:nowrap" class="ft042"><b>Restarting&#160;Maintenance&#160;Therapy for CMV Retinitis&#160;</b></p>
<p style="position:absolute;top:856px;left:116px;white-space:nowrap" class="ft030">•</p>
<p style="position:absolute;top:858px;left:123px;white-space:nowrap" class="ft057">&#160;</p>
<p style="position:absolute;top:857px;left:133px;white-space:nowrap" class="ft041">CD4 count&#160;&lt;100&#160;cells/mm</p>
<p style="position:absolute;top:858px;left:274px;white-space:nowrap" class="ft058">3&#160;</p>
<p style="position:absolute;top:857px;left:281px;white-space:nowrap" class="ft042"><b>(AIII)</b></p>
<p style="position:absolute;top:857px;left:308px;white-space:nowrap" class="ft041">&#160;</p>
<p style="position:absolute;top:888px;left:116px;white-space:nowrap" class="ft056"><b>Treating&#160;CMV&#160;Colitis or Esophagitis&#160;</b></p>
<p style="position:absolute;top:913px;left:116px;white-space:nowrap" class="ft024"><i>Preferred&#160;Therapy&#160;</i></p>
<p style="position:absolute;top:939px;left:116px;white-space:nowrap" class="ft030">•</p>
<p style="position:absolute;top:940px;left:133px;white-space:nowrap" class="ft041">Ganciclovir</p>
<p style="position:absolute;top:941px;left:194px;white-space:nowrap" class="ft058">a</p>
<p style="position:absolute;top:940px;left:201px;white-space:nowrap" class="ft041">5 mg/kg IV every&#160;12&#160;hours</p>
<p style="position:absolute;top:940px;left:348px;white-space:nowrap" class="ft042"><b>(AI);</b></p>
<p style="position:absolute;top:940px;left:376px;white-space:nowrap" class="ft041">may&#160;switch to&#160;valganciclovir&#160;900&#160;mg PO&#160;every&#160;12 hours&#160;once the patient&#160;can&#160;</p>
<p style="position:absolute;top:957px;left:133px;white-space:nowrap" class="ft041">absorb and tolerate&#160;PO therapy&#160;</p>
<p style="position:absolute;top:957px;left:308px;white-space:nowrap" class="ft042"><b>(AIII)</b></p>
<p style="position:absolute;top:957px;left:335px;white-space:nowrap" class="ft041">&#160;</p>
<p style="position:absolute;top:983px;left:116px;white-space:nowrap" class="ft030">•</p>
<p style="position:absolute;top:985px;left:123px;white-space:nowrap" class="ft057">&#160;</p>
<p style="position:absolute;top:984px;left:133px;white-space:nowrap" class="ft041">Valganciclovir</p>
<p style="position:absolute;top:986px;left:209px;white-space:nowrap" class="ft058">a</p>
<p style="position:absolute;top:984px;left:213px;white-space:nowrap" class="ft041">&#160;900&#160;mg PO&#160;every 12&#160;hours&#160;can&#160;be&#160;used in&#160;patients&#160;with&#160;mild&#160;disease&#160;</p>
<p style="position:absolute;top:984px;left:594px;white-space:nowrap" class="ft042"><b>(AIII).</b></p>
<p style="position:absolute;top:984px;left:625px;white-space:nowrap" class="ft041">&#160;</p>
</div>
<!-- Page 176 -->
<a name="176"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page176-div" style="position:relative;width:917px;height:1187px;">
<p style="position:absolute;top:1121px;left:108px;white-space:nowrap" class="ft024"><i>Guidelines for the Prevention and Treatment&#160;of&#160;Opportunistic&#160;Infections in Adults&#160;and Adolescents&#160;With HIV&#160;</i></p>
<p style="position:absolute;top:1121px;left:791px;white-space:nowrap" class="ft024"><i>K-7&#160;</i></p>
<p style="position:absolute;top:109px;left:116px;white-space:nowrap" class="ft024"><i>Alternative Therapy&#160;</i></p>
<p style="position:absolute;top:135px;left:116px;white-space:nowrap" class="ft030">•</p>
<p style="position:absolute;top:136px;left:123px;white-space:nowrap" class="ft057">&#160;</p>
<p style="position:absolute;top:136px;left:133px;white-space:nowrap" class="ft041">Foscarnet</p>
<p style="position:absolute;top:137px;left:187px;white-space:nowrap" class="ft058">a</p>
<p style="position:absolute;top:136px;left:192px;white-space:nowrap" class="ft041">&#160;60&#160;mg/kg IV&#160;every&#160;8&#160;hours&#160;or&#160;90&#160;mg/kg IV every&#160;12&#160;hours&#160;</p>
<p style="position:absolute;top:136px;left:510px;white-space:nowrap" class="ft042"><b>(BIII)</b></p>
<p style="position:absolute;top:136px;left:538px;white-space:nowrap" class="ft041">—for patients&#160;with treatment-limiting toxicities to&#160;</p>
<p style="position:absolute;top:153px;left:133px;white-space:nowrap" class="ft041">ganciclovir&#160;or with ganciclovir&#160;resistance;&#160;</p>
<p style="position:absolute;top:153px;left:358px;white-space:nowrap" class="ft024"><i>or</i></p>
<p style="position:absolute;top:153px;left:369px;white-space:nowrap" class="ft041">&#160;</p>
<p style="position:absolute;top:179px;left:116px;white-space:nowrap" class="ft030">•</p>
<p style="position:absolute;top:181px;left:123px;white-space:nowrap" class="ft057">&#160;</p>
<p style="position:absolute;top:180px;left:133px;white-space:nowrap" class="ft041">Cidofovir</p>
<p style="position:absolute;top:182px;left:181px;white-space:nowrap" class="ft058">a,b</p>
<p style="position:absolute;top:180px;left:192px;white-space:nowrap" class="ft041">&#160;5 mg/kg/week&#160;IV&#160;for 2&#160;weeks, then 5&#160;mg/kg IV every&#160;other week. Administer 1 L of normal&#160;saline before and,&#160;if&#160;</p>
<p style="position:absolute;top:198px;left:133px;white-space:nowrap" class="ft041">additional&#160;fluid&#160;load can be&#160;tolerated, administer another&#160;1 L&#160;of normal&#160;saline after cidofovir infusion. Administer probenecid&#160;</p>
<p style="position:absolute;top:215px;left:133px;white-space:nowrap" class="ft044">2 g&#160;PO 3 hours&#160;before each&#160;cidofovir&#160;dose followed&#160;by 1 g PO 2&#160;hours&#160;after the dose and&#160;1 g PO&#160;8 hours&#160;after the&#160;dose&#160;<br/>(total&#160;of 4&#160;g)&#160;</p>
<p style="position:absolute;top:232px;left:202px;white-space:nowrap" class="ft042"><b>(CI).&#160;</b></p>
<p style="position:absolute;top:232px;left:229px;white-space:nowrap" class="ft041">&#160;</p>
<p style="position:absolute;top:260px;left:133px;white-space:nowrap" class="ft062">o</p>
<p style="position:absolute;top:259px;left:142px;white-space:nowrap" class="ft057">&#160;</p>
<p style="position:absolute;top:258px;left:149px;white-space:nowrap" class="ft042"><b>Note:&#160;</b></p>
<p style="position:absolute;top:258px;left:184px;white-space:nowrap" class="ft041">Cidofovir&#160;should be&#160;avoided in patients with&#160;sulfonamide allergy&#160;because of&#160;cross-hypersensitivity&#160;with&#160;</p>
<p style="position:absolute;top:276px;left:149px;white-space:nowrap" class="ft041">probenecid.&#160;</p>
<p style="position:absolute;top:276px;left:217px;white-space:nowrap" class="ft024"><i>&#160;</i></p>
<p style="position:absolute;top:308px;left:116px;white-space:nowrap" class="ft024"><i>Duration of Anti-CMV Therapy&#160;</i></p>
<p style="position:absolute;top:334px;left:116px;white-space:nowrap" class="ft030">•</p>
<p style="position:absolute;top:335px;left:123px;white-space:nowrap" class="ft057">&#160;</p>
<p style="position:absolute;top:335px;left:133px;white-space:nowrap" class="ft041">21–42&#160;days&#160;or until&#160;signs and symptoms&#160;have resolved&#160;</p>
<p style="position:absolute;top:335px;left:436px;white-space:nowrap" class="ft042"><b>(AIII)&#160;</b></p>
<p style="position:absolute;top:367px;left:116px;white-space:nowrap" class="ft042"><b>Note:&#160;</b></p>
<p style="position:absolute;top:367px;left:151px;white-space:nowrap" class="ft041">After&#160;resolution of acute disease, maintenance therapy&#160;is&#160;not routinely&#160;recommended&#160;for CMV GI disease unless&#160;there&#160;</p>
<p style="position:absolute;top:385px;left:116px;white-space:nowrap" class="ft041">is&#160;concurrent&#160;retinitis, there have&#160;already been&#160;recurrent&#160;infections,&#160;or severe disease was&#160;present&#160;initially.</p>
<p style="position:absolute;top:385px;left:694px;white-space:nowrap" class="ft042"><b>&#160;&#160;</b></p>
<p style="position:absolute;top:416px;left:116px;white-space:nowrap" class="ft056"><b>Treating&#160;CMV&#160;Pneumonia&#160;&#160;</b></p>
<p style="position:absolute;top:440px;left:116px;white-space:nowrap" class="ft024"><i>Preferred&#160;Therapy&#160;</i></p>
<p style="position:absolute;top:466px;left:116px;white-space:nowrap" class="ft030">•</p>
<p style="position:absolute;top:468px;left:123px;white-space:nowrap" class="ft057">&#160;</p>
<p style="position:absolute;top:467px;left:133px;white-space:nowrap" class="ft041">Ganciclovir</p>
<p style="position:absolute;top:469px;left:194px;white-space:nowrap" class="ft058">a</p>
<p style="position:absolute;top:467px;left:201px;white-space:nowrap" class="ft041">5 mg/kg IV every&#160;12&#160;hours&#160;</p>
<p style="position:absolute;top:467px;left:348px;white-space:nowrap" class="ft042"><b>(BIII)&#160;</b></p>
<p style="position:absolute;top:467px;left:379px;white-space:nowrap" class="ft041">&#160;</p>
<p style="position:absolute;top:500px;left:116px;white-space:nowrap" class="ft024"><i>Alternative Therapy&#160;</i></p>
<p style="position:absolute;top:526px;left:116px;white-space:nowrap" class="ft030">•</p>
<p style="position:absolute;top:527px;left:123px;white-space:nowrap" class="ft057">&#160;</p>
<p style="position:absolute;top:527px;left:133px;white-space:nowrap" class="ft041">Foscarnet</p>
<p style="position:absolute;top:528px;left:187px;white-space:nowrap" class="ft058">a</p>
<p style="position:absolute;top:527px;left:192px;white-space:nowrap" class="ft041">&#160;60&#160;mg/kg IV&#160;every&#160;8&#160;hours&#160;or&#160;90&#160;mg/kg IV every&#160;12&#160;hours&#160;</p>
<p style="position:absolute;top:527px;left:510px;white-space:nowrap" class="ft042"><b>(BIII)</b></p>
<p style="position:absolute;top:527px;left:538px;white-space:nowrap" class="ft041">&#160;</p>
<p style="position:absolute;top:559px;left:116px;white-space:nowrap" class="ft042"><b>Note:</b></p>
<p style="position:absolute;top:559px;left:148px;white-space:nowrap" class="ft041">&#160;Transition to valganciclovir&#160;900&#160;mg PO&#160;twice daily can be considered if CMV pneumonia is&#160;not&#160;life-threatening&#160;and&#160;oral&#160;</p>
<p style="position:absolute;top:576px;left:116px;white-space:nowrap" class="ft041">medications can&#160;be&#160;absorbed</p>
<p style="position:absolute;top:576px;left:277px;white-space:nowrap" class="ft042"><b>&#160;(BIII).</b></p>
<p style="position:absolute;top:576px;left:311px;white-space:nowrap" class="ft041">&#160;</p>
<p style="position:absolute;top:609px;left:116px;white-space:nowrap" class="ft024"><i>Duration of Anti-CMV Therapy&#160;</i></p>
<p style="position:absolute;top:635px;left:116px;white-space:nowrap" class="ft030">•</p>
<p style="position:absolute;top:636px;left:123px;white-space:nowrap" class="ft057">&#160;</p>
<p style="position:absolute;top:636px;left:133px;white-space:nowrap" class="ft064">≥</p>
<p style="position:absolute;top:636px;left:141px;white-space:nowrap" class="ft065">21 days&#160;</p>
<p style="position:absolute;top:636px;left:187px;white-space:nowrap" class="ft041">or until&#160;signs and&#160;symptoms have&#160;resolved&#160;</p>
<p style="position:absolute;top:636px;left:423px;white-space:nowrap" class="ft042"><b>(CII)</b></p>
<p style="position:absolute;top:636px;left:447px;white-space:nowrap" class="ft041">&#160;</p>
<p style="position:absolute;top:668px;left:116px;white-space:nowrap" class="ft042"><b>Note:&#160;</b></p>
<p style="position:absolute;top:668px;left:151px;white-space:nowrap" class="ft041">After&#160;resolution of acute disease, maintenance therapy&#160;is&#160;not routinely recommended for&#160;CMV&#160;pneumonia unless&#160;there&#160;</p>
<p style="position:absolute;top:685px;left:116px;white-space:nowrap" class="ft041">is&#160;concurrent&#160;retinitis, there have&#160;already been&#160;recurrent&#160;infections,&#160;or severe disease was&#160;present&#160;initially.</p>
<p style="position:absolute;top:685px;left:694px;white-space:nowrap" class="ft042"><b>&#160;&#160;</b></p>
<p style="position:absolute;top:717px;left:116px;white-space:nowrap" class="ft056"><b>Treating&#160;CMV&#160;Neurological&#160;Disease&#160;&#160;</b></p>
<p style="position:absolute;top:741px;left:116px;white-space:nowrap" class="ft024"><i>Preferred&#160;Therapy&#160;</i></p>
<p style="position:absolute;top:767px;left:116px;white-space:nowrap" class="ft030">•</p>
<p style="position:absolute;top:769px;left:123px;white-space:nowrap" class="ft057">&#160;</p>
<p style="position:absolute;top:768px;left:133px;white-space:nowrap" class="ft041">Ganciclovir</p>
<p style="position:absolute;top:769px;left:194px;white-space:nowrap" class="ft058">a</p>
<p style="position:absolute;top:768px;left:201px;white-space:nowrap" class="ft041">5 mg/kg IV every&#160;12&#160;hours&#160;plus foscarnet</p>
<p style="position:absolute;top:769px;left:425px;white-space:nowrap" class="ft058">a</p>
<p style="position:absolute;top:768px;left:429px;white-space:nowrap" class="ft041">&#160;(60 mg/kg&#160;IV&#160;every&#160;8 hours&#160;or 90 mg/kg IV&#160;every&#160;12 hours)&#160;</p>
<p style="position:absolute;top:768px;left:756px;white-space:nowrap" class="ft042"><b>(BIII)</b></p>
<p style="position:absolute;top:768px;left:783px;white-space:nowrap" class="ft041">&#160;</p>
<p style="position:absolute;top:794px;left:116px;white-space:nowrap" class="ft030">•</p>
<p style="position:absolute;top:796px;left:123px;white-space:nowrap" class="ft057">&#160;</p>
<p style="position:absolute;top:795px;left:133px;white-space:nowrap" class="ft041">The role&#160;of oral&#160;valganciclovir has&#160;not&#160;been established.&#160;</p>
<p style="position:absolute;top:828px;left:116px;white-space:nowrap" class="ft024"><i>Duration of Anti-CMV Therapy&#160;</i></p>
<p style="position:absolute;top:854px;left:116px;white-space:nowrap" class="ft030">•</p>
<p style="position:absolute;top:855px;left:123px;white-space:nowrap" class="ft057">&#160;</p>
<p style="position:absolute;top:855px;left:133px;white-space:nowrap" class="ft064">≥</p>
<p style="position:absolute;top:855px;left:141px;white-space:nowrap" class="ft041">21 days&#160;based&#160;on&#160;clinical&#160;response&#160;</p>
<p style="position:absolute;top:855px;left:336px;white-space:nowrap" class="ft042"><b>(AIII)</b></p>
<p style="position:absolute;top:855px;left:363px;white-space:nowrap" class="ft041">&#160;</p>
<p style="position:absolute;top:887px;left:116px;white-space:nowrap" class="ft042"><b>Note:&#160;</b></p>
<p style="position:absolute;top:887px;left:151px;white-space:nowrap" class="ft041">After&#160;resolution of acute disease, maintenance therapy&#160;is&#160;not routinely&#160;recommended&#160;for CMV CNS disease unless&#160;</p>
<p style="position:absolute;top:904px;left:116px;white-space:nowrap" class="ft041">there is&#160;concurrent retinitis, there&#160;have already&#160;been recurrent&#160;infections, or&#160;severe&#160;disease was&#160;present initially.</p>
<p style="position:absolute;top:904px;left:725px;white-space:nowrap" class="ft042"><b>&#160;&#160;</b></p>
<p style="position:absolute;top:936px;left:116px;white-space:nowrap" class="ft056"><b>Pregnancy Considerations&#160;</b></p>
<p style="position:absolute;top:960px;left:116px;white-space:nowrap" class="ft030">•</p>
<p style="position:absolute;top:962px;left:123px;white-space:nowrap" class="ft057">&#160;</p>
<p style="position:absolute;top:961px;left:133px;white-space:nowrap" class="ft041">During pregnancy, indications for&#160;treatment of CMV infection are the&#160;same&#160;as for other&#160;people with HIV&#160;</p>
<p style="position:absolute;top:961px;left:695px;white-space:nowrap" class="ft042"><b>(AIII).</b></p>
<p style="position:absolute;top:961px;left:726px;white-space:nowrap" class="ft041">&#160;</p>
<p style="position:absolute;top:987px;left:116px;white-space:nowrap" class="ft030">•</p>
<p style="position:absolute;top:989px;left:123px;white-space:nowrap" class="ft057">&#160;</p>
<p style="position:absolute;top:988px;left:133px;white-space:nowrap" class="ft041">Valganciclovir&#160;is&#160;the&#160;preferred treatment for&#160;maternal&#160;CMV disease during&#160;pregnancy&#160;</p>
<p style="position:absolute;top:988px;left:597px;white-space:nowrap" class="ft042"><b>(BIII).</b></p>
<p style="position:absolute;top:988px;left:628px;white-space:nowrap" class="ft041">&#160;</p>
<p style="position:absolute;top:1014px;left:116px;white-space:nowrap" class="ft030">•</p>
<p style="position:absolute;top:1016px;left:123px;white-space:nowrap" class="ft057">&#160;</p>
<p style="position:absolute;top:1016px;left:133px;white-space:nowrap" class="ft041">Foscarnet&#160;and&#160;cidofovir&#160;</p>
<p style="position:absolute;top:1016px;left:264px;white-space:nowrap" class="ft042"><b>are not&#160;recommended</b></p>
<p style="position:absolute;top:1016px;left:392px;white-space:nowrap" class="ft041">&#160;in the&#160;absence of&#160;resistance or&#160;toxicity&#160;with&#160;ganciclovir/valganciclovir</p>
<p style="position:absolute;top:1016px;left:768px;white-space:nowrap" class="ft042"><b>&#160;</b></p>
<p style="position:absolute;top:1033px;left:133px;white-space:nowrap" class="ft042"><b>(AIII);&#160;</b></p>
<p style="position:absolute;top:1033px;left:168px;white-space:nowrap" class="ft041">use of&#160;foscarnet and&#160;cidofovir should only&#160;be done in consultation with a&#160;maternal–fetal&#160;medicine specialist,&#160;and&#160;</p>
<p style="position:absolute;top:1050px;left:133px;white-space:nowrap" class="ft041">additional&#160;fetal&#160;surveillance may&#160;be&#160;recommended in the setting of maternal&#160;renal&#160;insufficiency&#160;</p>
<p style="position:absolute;top:1050px;left:649px;white-space:nowrap" class="ft042"><b>(BIII).</b></p>
<p style="position:absolute;top:1050px;left:679px;white-space:nowrap" class="ft041">&#160;</p>
</div>
<!-- Page 177 -->
<a name="177"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page177-div" style="position:relative;width:917px;height:1187px;">
<p style="position:absolute;top:1121px;left:108px;white-space:nowrap" class="ft024"><i>Guidelines for the Prevention and Treatment&#160;of&#160;Opportunistic&#160;Infections in Adults&#160;and Adolescents&#160;With HIV&#160;</i></p>
<p style="position:absolute;top:1121px;left:791px;white-space:nowrap" class="ft024"><i>K-8&#160;</i></p>
<p style="position:absolute;top:109px;left:116px;white-space:nowrap" class="ft030">•</p>
<p style="position:absolute;top:110px;left:123px;white-space:nowrap" class="ft057">&#160;</p>
<p style="position:absolute;top:110px;left:133px;white-space:nowrap" class="ft041">In pregnant women diagnosed with&#160;primary&#160;CMV infection,&#160;the&#160;fetus should be&#160;monitored by periodic&#160;ultrasound after&#160;</p>
<p style="position:absolute;top:127px;left:133px;white-space:nowrap" class="ft041">20 weeks&#160;gestation&#160;</p>
<p style="position:absolute;top:127px;left:241px;white-space:nowrap" class="ft042"><b>(CIII).</b></p>
<p style="position:absolute;top:127px;left:272px;white-space:nowrap" class="ft041">&#160;</p>
<p style="position:absolute;top:154px;left:108px;white-space:nowrap" class="ft042"><b>Key:&#160;</b></p>
<p style="position:absolute;top:154px;left:138px;white-space:nowrap" class="ft041">ART =&#160;antiretroviral&#160;therapy; CD4&#160;= CD4&#160;T&#160;lymphocyte;&#160;CMV&#160;= cytomegalovirus; CNS = central&#160;nervous&#160;system;&#160;</p>
<p style="position:absolute;top:171px;left:108px;white-space:nowrap" class="ft041">GI = gastrointestinal; IRU = immune&#160;recovery&#160;uveitis; IV&#160;= intravenously; the&#160;Panel = the&#160;Panel&#160;on&#160;Guidelines for the Prevention&#160;</p>
<p style="position:absolute;top:189px;left:108px;white-space:nowrap" class="ft041">and&#160;Treatment of Opportunistic&#160;Infections in Adults&#160;and Adolescents With HIV; PO = orally&#160;</p>
<p style="position:absolute;top:216px;left:108px;white-space:nowrap" class="ft058">a</p>
<p style="position:absolute;top:215px;left:112px;white-space:nowrap" class="ft041">&#160;Renal&#160;dose adjustment required in patients&#160;with&#160;chronic&#160;renal&#160;insufficiency&#160;and/or&#160;acute&#160;renal&#160;failure&#160;</p>
<p style="position:absolute;top:242px;left:108px;white-space:nowrap" class="ft058">b</p>
<p style="position:absolute;top:241px;left:112px;white-space:nowrap" class="ft041">&#160;Contraindicated for&#160;serum creatinine &gt;1.5 mg/dL or creatinine&#160;clearance &lt;55 mL/min&#160;</p>
<p style="position:absolute;top:276px;left:108px;white-space:nowrap" class="ft029"><i><b>CMV&#160;Retinitis&#160;</b></i></p>
<p style="position:absolute;top:317px;left:108px;white-space:nowrap" class="ft032">The&#160;therapeutic&#160;approach to CMV&#160;retinitis should&#160;be individualized based on tolerance of systemic&#160;<br/>medications, prior exposure to anti-CMV&#160;drugs,&#160;and the&#160;location of lesions. CMV retinitis should be&#160;<br/>treated with the&#160;active&#160;participation of an ophthalmologist who is familiar with the&#160;diagnosis and&#160;<br/>management&#160;of this retinal&#160;disease.&#160;&#160;</p>
<p style="position:absolute;top:414px;left:108px;white-space:nowrap" class="ft032">The&#160;Panel&#160;recommends the following&#160;as first-line&#160;therapies for treating CMV&#160;retinitis: oral&#160;<br/>valganciclovir&#160;</p>
<p style="position:absolute;top:434px;left:211px;white-space:nowrap" class="ft012"><b>(AI),</b></p>
<p style="position:absolute;top:434px;left:246px;white-space:nowrap" class="ft013">&#160;intravenous (IV)&#160;ganciclovir&#160;</p>
<p style="position:absolute;top:434px;left:451px;white-space:nowrap" class="ft012"><b>(AI),</b></p>
<p style="position:absolute;top:434px;left:486px;white-space:nowrap" class="ft013">&#160;or IV ganciclovir induction followed by oral&#160;</p>
<p style="position:absolute;top:454px;left:108px;white-space:nowrap" class="ft013">valganciclovir maintenance&#160;</p>
<p style="position:absolute;top:454px;left:302px;white-space:nowrap" class="ft012"><b>(AI);&#160;</b></p>
<p style="position:absolute;top:454px;left:343px;white-space:nowrap" class="ft013">other effective treatments, such as IV&#160;foscarnet&#160;</p>
<p style="position:absolute;top:454px;left:672px;white-space:nowrap" class="ft012"><b>(BI)</b></p>
<p style="position:absolute;top:454px;left:702px;white-space:nowrap" class="ft013">&#160;and IV&#160;</p>
<p style="position:absolute;top:474px;left:108px;white-space:nowrap" class="ft013">cidofovir&#160;</p>
<p style="position:absolute;top:474px;left:176px;white-space:nowrap" class="ft012"><b>(CI),</b></p>
<p style="position:absolute;top:474px;left:211px;white-space:nowrap" class="ft013">&#160;are not routinely recommended due to substantial&#160;toxicities,&#160;including&#160;</p>
<p style="position:absolute;top:493px;left:108px;white-space:nowrap" class="ft013">nephrotoxicity.</p>
<p style="position:absolute;top:492px;left:213px;white-space:nowrap" class="ft038">20,34-41</p>
<p style="position:absolute;top:493px;left:253px;white-space:nowrap" class="ft013">&#160;Systemic&#160;therapy has been documented to reduce CMV&#160;involvement in the&#160;</p>
<p style="position:absolute;top:513px;left:108px;white-space:nowrap" class="ft013">contralateral&#160;eye,</p>
<p style="position:absolute;top:512px;left:227px;white-space:nowrap" class="ft038">34</p>
<p style="position:absolute;top:513px;left:238px;white-space:nowrap" class="ft013">&#160;reduce&#160;CMV visceral&#160;disease, and improve survival.</p>
<p style="position:absolute;top:512px;left:603px;white-space:nowrap" class="ft038">35,42</p>
<p style="position:absolute;top:513px;left:629px;white-space:nowrap" class="ft013">&#160;Given the evident&#160;</p>
<p style="position:absolute;top:533px;left:108px;white-space:nowrap" class="ft032">benefits of systemic&#160;anti-CMV therapy, treatment regimens for&#160;CMV&#160;retinitis&#160;should include a&#160;<br/>systemic component&#160;as recommended in the table above. Few&#160;trials have compared regimen efficacy&#160;<br/>during the past 15 years.&#160;None of the&#160;listed regimens have been&#160;proven in clinical&#160;trials to&#160;be more&#160;<br/>effective in protecting vision.</p>
<p style="position:absolute;top:591px;left:311px;white-space:nowrap" class="ft038">36-40</p>
<p style="position:absolute;top:593px;left:337px;white-space:nowrap" class="ft013">&#160;&#160;</p>
<p style="position:absolute;top:630px;left:108px;white-space:nowrap" class="ft013">The&#160;Panel&#160;recommends IV ganciclovir&#160;</p>
<p style="position:absolute;top:630px;left:378px;white-space:nowrap" class="ft012"><b>(AI)</b></p>
<p style="position:absolute;top:630px;left:409px;white-space:nowrap" class="ft013">&#160;or oral&#160;valganciclovir&#160;</p>
<p style="position:absolute;top:630px;left:566px;white-space:nowrap" class="ft012"><b>(AI)</b></p>
<p style="position:absolute;top:630px;left:597px;white-space:nowrap" class="ft013">&#160;for an induction period&#160;</p>
<p style="position:absolute;top:650px;left:108px;white-space:nowrap" class="ft032">lasting at least 14 to 21 days, with the&#160;duration determined by clinical&#160;response based on retinal&#160;<br/>examination. Many clinicians continue&#160;induction-level&#160;treatment&#160;until retinal lesion opacity is&#160;<br/>resolved or&#160;markedly reduced, indicating virus inactivity&#160;</p>
<p style="position:absolute;top:689px;left:503px;white-space:nowrap" class="ft012"><b>(BIII).</b></p>
<p style="position:absolute;top:688px;left:551px;white-space:nowrap" class="ft038">20</p>
<p style="position:absolute;top:689px;left:562px;white-space:nowrap" class="ft013">&#160;Many clinicians prefer&#160;the&#160;IV&#160;</p>
<p style="position:absolute;top:709px;left:108px;white-space:nowrap" class="ft032">formulation for induction&#160;when retinitis is more central and sight-threatening or when adequate&#160;<br/>gastrointestinal (GI) absorption is a concern. In such cases, transition to oral valganciclovir can be&#160;<br/>considered when there is evidence of clinical&#160;response. In cases&#160;where toxicity of ganciclovir and&#160;<br/>valganciclovir (e.g., severe cytopenias)&#160;is a concern&#160;or there is concern for ganciclovir-resistant&#160;<br/>CMV,&#160;IV&#160;foscarnet should be used&#160;</p>
<p style="position:absolute;top:788px;left:353px;white-space:nowrap" class="ft012"><b>(BI).</b></p>
<p style="position:absolute;top:788px;left:387px;white-space:nowrap" class="ft013">&#160;If both ganciclovir and foscarnet&#160;should be&#160;avoided or&#160;</p>
<p style="position:absolute;top:808px;left:108px;white-space:nowrap" class="ft013">cannot&#160;be used, IV cidofovir should be&#160;used&#160;</p>
<p style="position:absolute;top:808px;left:416px;white-space:nowrap" class="ft012"><b>(CI).</b></p>
<p style="position:absolute;top:808px;left:451px;white-space:nowrap" class="ft013">&#160;Cidofovir administration is complicated by the&#160;</p>
<p style="position:absolute;top:828px;left:108px;white-space:nowrap" class="ft032">need to coadminister IV saline hydration and probenecid with each dose to counter the&#160;<br/>nephrotoxicity of the&#160;drug. In addition,&#160;IV cidofovir&#160;is associated&#160;with an increased risk of&#160;<br/>intraocular inflammation, hypotony, and neutropenia.</p>
<p style="position:absolute;top:866px;left:477px;white-space:nowrap" class="ft038">43-46</p>
<p style="position:absolute;top:868px;left:504px;white-space:nowrap" class="ft013">&#160;&#160;</p>
<p style="position:absolute;top:905px;left:108px;white-space:nowrap" class="ft032">In the&#160;presence of&#160;immediately sight-threatening retinal lesions (those within&#160;1,500 microns of the&#160;<br/>fovea or optic disc) at&#160;presentation, the&#160;Panel recommends supplementing systemic&#160;therapy with&#160;<br/>intravitreal&#160;injections of&#160;ganciclovir or foscarnet, at least initially, to provide&#160;immediate, high&#160;<br/>intraocular levels of the drug and presumably faster control&#160;of the retinitis&#160;</p>
<p style="position:absolute;top:964px;left:622px;white-space:nowrap" class="ft012"><b>(BIII).</b></p>
<p style="position:absolute;top:964px;left:669px;white-space:nowrap" class="ft013">&#160;Injections are&#160;</p>
<p style="position:absolute;top:984px;left:108px;white-space:nowrap" class="ft032">continued on&#160;a weekly basis during induction therapy until&#160;lesion inactivity is&#160;achieved, at which&#160;<br/>time&#160;systemic treatment alone is adequate for maintenance&#160;therapy. The recommendation to&#160;<br/>supplement&#160;systemic&#160;therapy with intravitreal&#160;injections is based both on the&#160;experience&#160;of&#160;<br/>ophthalmologists who saw considerable&#160;disease early in the HIV epidemic, and pharmacokinetic&#160;</p>
</div>
<!-- Page 178 -->
<a name="178"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page178-div" style="position:relative;width:917px;height:1187px;">
<p style="position:absolute;top:1121px;left:108px;white-space:nowrap" class="ft024"><i>Guidelines for the Prevention and Treatment&#160;of&#160;Opportunistic&#160;Infections in Adults&#160;and Adolescents&#160;With HIV&#160;</i></p>
<p style="position:absolute;top:1121px;left:791px;white-space:nowrap" class="ft024"><i>K-9&#160;</i></p>
<p style="position:absolute;top:109px;left:108px;white-space:nowrap" class="ft032">considerations, but the&#160;clinical benefit of such&#160;supplementation&#160;has not been&#160;confirmed in clinical&#160;<br/>trials. Although intravitreal injections deliver high concentrations of the&#160;drug to the target&#160;organ&#160;<br/>immediately&#160;while&#160;steady-state concentrations in the&#160;eye&#160;are being achieved&#160;over time&#160;with&#160;<br/>systemically delivered medications,</p>
<p style="position:absolute;top:167px;left:355px;white-space:nowrap" class="ft038">34</p>
<p style="position:absolute;top:168px;left:366px;white-space:nowrap" class="ft013">&#160;such injections can be complicated by bacterial or fungal&#160;</p>
<p style="position:absolute;top:188px;left:108px;white-space:nowrap" class="ft013">infections, hemorrhage, or retinal detachment. &#160;</p>
<p style="position:absolute;top:225px;left:108px;white-space:nowrap" class="ft032">Intravitreal cidofovir is associated with hypotony and uveitis—and a substantially increased risk of&#160;<br/>immune&#160;recovery uveitis—and&#160;</p>
<p style="position:absolute;top:245px;left:326px;white-space:nowrap" class="ft012"><b>is not&#160;recommended</b></p>
<p style="position:absolute;top:245px;left:474px;white-space:nowrap" class="ft013">&#160;</p>
<p style="position:absolute;top:245px;left:479px;white-space:nowrap" class="ft012"><b>(AIII).</b></p>
<p style="position:absolute;top:244px;left:527px;white-space:nowrap" class="ft038">39,47</p>
<p style="position:absolute;top:245px;left:553px;white-space:nowrap" class="ft013">&#160;The&#160;ganciclovir implant, a reservoir&#160;</p>
<p style="position:absolute;top:265px;left:108px;white-space:nowrap" class="ft032">device for the slow release of drug into the&#160;eye, previously used for local&#160;therapy, is no longer&#160;<br/>manufactured. Intravitreal&#160;drug injections are&#160;not necessary for&#160;people with&#160;peripheral&#160;retinal lesions;&#160;<br/>oral valganciclovir alone&#160;will&#160;be adequate&#160;</p>
<p style="position:absolute;top:304px;left:401px;white-space:nowrap" class="ft012"><b>(AI).&#160;</b></p>
<p style="position:absolute;top:342px;left:108px;white-space:nowrap" class="ft032">After completing induction therapy, patients should&#160;be transitioned to a&#160;maintenance regimen. See&#160;<br/>When to Start Maintenance Therapy below.&#160;</p>
<p style="position:absolute;top:399px;left:108px;white-space:nowrap" class="ft029"><i><b>CMV&#160;Disease Other&#160;Than&#160;Retinitis&#160;</b></i></p>
<p style="position:absolute;top:440px;left:108px;white-space:nowrap" class="ft070"><b>CMV Colitis and Esophagitis&#160;</b></p>
<p style="position:absolute;top:478px;left:108px;white-space:nowrap" class="ft032">For patients&#160;who have colitis or esophagitis, anti-CMV&#160;therapy&#160;for 21 to 42&#160;days is recommended&#160;<br/>until resolution of signs and symptoms&#160;</p>
<p style="position:absolute;top:498px;left:380px;white-space:nowrap" class="ft012"><b>(AIII),</b></p>
<p style="position:absolute;top:498px;left:428px;white-space:nowrap" class="ft013">&#160;based on data&#160;that CMV persists with only 14 days&#160;of&#160;</p>
<p style="position:absolute;top:517px;left:108px;white-space:nowrap" class="ft013">treatment for CMV&#160;colitis in people with HIV.</p>
<p style="position:absolute;top:516px;left:430px;white-space:nowrap" class="ft038">48</p>
<p style="position:absolute;top:517px;left:441px;white-space:nowrap" class="ft013">&#160;IV&#160;ganciclovir is the therapy&#160;of choice&#160;</p>
<p style="position:absolute;top:517px;left:715px;white-space:nowrap" class="ft012"><b>(AI)</b></p>
<p style="position:absolute;top:517px;left:746px;white-space:nowrap" class="ft013">&#160;and can&#160;</p>
<p style="position:absolute;top:537px;left:108px;white-space:nowrap" class="ft032">be switched to oral&#160;valganciclovir once the person can tolerate and absorb&#160;oral&#160;medications,&#160;<br/>extrapolated from&#160;randomized, clinical&#160;trial&#160;data showing non-inferiority of&#160;oral&#160;valganciclovir for&#160;<br/>treatment of CMV&#160;disease in people receiving a&#160;solid organ transplant (SOT)&#160;</p>
<p style="position:absolute;top:577px;left:644px;white-space:nowrap" class="ft012"><b>(AIII).</b></p>
<p style="position:absolute;top:576px;left:693px;white-space:nowrap" class="ft038">49</p>
<p style="position:absolute;top:577px;left:704px;white-space:nowrap" class="ft013">&#160;Oral&#160;</p>
<p style="position:absolute;top:597px;left:108px;white-space:nowrap" class="ft013">valganciclovir can be used in patients with mild disease&#160;</p>
<p style="position:absolute;top:597px;left:496px;white-space:nowrap" class="ft012"><b>(AIII).&#160;</b></p>
<p style="position:absolute;top:597px;left:549px;white-space:nowrap" class="ft013">Foscarnet&#160;with IV hydration should&#160;</p>
<p style="position:absolute;top:617px;left:108px;white-space:nowrap" class="ft032">be used as an&#160;alternative&#160;if&#160;ganciclovir-related toxicity is treatment-limiting or in cases of&#160;<br/>ganciclovir-resistant&#160;virus&#160;</p>
<p style="position:absolute;top:637px;left:292px;white-space:nowrap" class="ft012"><b>(BIII).</b></p>
<p style="position:absolute;top:637px;left:339px;white-space:nowrap" class="ft013">&#160;Cidofovir, administered with saline&#160;hydration before and after&#160;</p>
<p style="position:absolute;top:656px;left:108px;white-space:nowrap" class="ft013">therapy, can&#160;be used as an&#160;alternative&#160;</p>
<p style="position:absolute;top:656px;left:369px;white-space:nowrap" class="ft012"><b>(CI).</b></p>
<p style="position:absolute;top:656px;left:404px;white-space:nowrap" class="ft013">&#160;&#160;</p>
<p style="position:absolute;top:694px;left:108px;white-space:nowrap" class="ft070"><b>CMV Pneumonia&#160;</b></p>
<p style="position:absolute;top:731px;left:108px;white-space:nowrap" class="ft032">Experience treating well-documented CMV&#160;pneumonia&#160;in people&#160;with HIV is limited and anecdotal.&#160;<br/>Treatment&#160;with IV ganciclovir or, alternatively, with foscarnet, is recommended&#160;</p>
<p style="position:absolute;top:751px;left:665px;white-space:nowrap" class="ft012"><b>(BIII).&#160;</b></p>
<p style="position:absolute;top:751px;left:716px;white-space:nowrap" class="ft013">The optimal&#160;</p>
<p style="position:absolute;top:771px;left:108px;white-space:nowrap" class="ft013">duration of therapy is a&#160;minimum of 21 days (extrapolated from&#160;SOT data)&#160;</p>
<p style="position:absolute;top:771px;left:628px;white-space:nowrap" class="ft012"><b>(CII).</b></p>
<p style="position:absolute;top:771px;left:670px;white-space:nowrap" class="ft013">&#160;The&#160;role&#160;of oral&#160;</p>
<p style="position:absolute;top:791px;left:108px;white-space:nowrap" class="ft032">valganciclovir has not been established, but based&#160;on clinical&#160;experience with&#160;SOT, transition to oral&#160;<br/>valganciclovir can be considered if CMV&#160;pneumonia is not life-threatening and oral&#160;medications can&#160;<br/>be absorbed&#160;</p>
<p style="position:absolute;top:831px;left:195px;white-space:nowrap" class="ft012"><b>(BIII).&#160;</b></p>
<p style="position:absolute;top:831px;left:247px;white-space:nowrap" class="ft013">&#160;</p>
<p style="position:absolute;top:868px;left:108px;white-space:nowrap" class="ft070"><b>CMV of&#160;the&#160;Central&#160;Nervous System&#160;</b></p>
<p style="position:absolute;top:906px;left:108px;white-space:nowrap" class="ft032">Therapy for&#160;neurologic&#160;disease has not been extensively studied.&#160;Given the poor outcomes in many&#160;<br/>patients with CMV-related neurologic&#160;disease, the&#160;Panel&#160;recommends initiating therapy&#160;with both IV&#160;<br/>ganciclovir and IV foscarnet, despite the substantial toxicities associated with such an approach&#160;</p>
<p style="position:absolute;top:965px;left:108px;white-space:nowrap" class="ft012"><b>(BIII).</b></p>
<p style="position:absolute;top:964px;left:156px;white-space:nowrap" class="ft038">50</p>
<p style="position:absolute;top:965px;left:167px;white-space:nowrap" class="ft013">&#160;The&#160;role&#160;of oral&#160;valganciclovir has not been established. The optimal&#160;duration of therapy has&#160;</p>
<p style="position:absolute;top:985px;left:108px;white-space:nowrap" class="ft032">not been established, but&#160;a minimum&#160;duration of 21&#160;days is recommended, with extension based on&#160;<br/>clinical&#160;response&#160;</p>
<p style="position:absolute;top:1005px;left:228px;white-space:nowrap" class="ft012"><b>(AIII).&#160;&#160;</b></p>
</div>
<!-- Page 179 -->
<a name="179"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}	.ft0149{font-size:17px;font-family:BTLIFY+Tinos;color:#202020;}
-->
</style>
<div id="page179-div" style="position:relative;width:917px;height:1187px;">
<p style="position:absolute;top:1121px;left:108px;white-space:nowrap" class="ft024"><i>Guidelines for the Prevention and Treatment&#160;of&#160;Opportunistic&#160;Infections in Adults&#160;and Adolescents&#160;With HIV&#160;</i></p>
<p style="position:absolute;top:1121px;left:784px;white-space:nowrap" class="ft024"><i>K-10&#160;</i></p>
<p style="position:absolute;top:109px;left:108px;white-space:nowrap" class="ft032">After resolution of acute disease, chronic maintenance&#160;therapy is not&#160;routinely recommended for&#160;<br/>CMV&#160;GI disease, pneumonia, or central&#160;nervous system&#160;disease.&#160;See When to Start&#160;Maintenance&#160;<br/>Therapy for&#160;exceptions.&#160;</p>
<p style="position:absolute;top:186px;left:108px;white-space:nowrap" class="ft029"><i><b>Special Considerations Regarding IRIS and&#160;Antiretroviral&#160;Therapy&#160;Initiation&#160;</b></i></p>
<p style="position:absolute;top:227px;left:108px;white-space:nowrap" class="ft032">Immune recovery uveitis (IRU) is an ocular form&#160;of&#160;immune&#160;reconstitution inflammatory&#160;<br/>syndrome (IRIS) characterized by inflammation in the anterior chamber&#160;or vitreous body.&#160;It is&#160;<br/>presumed to&#160;be prompted&#160;by immune&#160;recovery with&#160;ART. IRU can occur both in the context of&#160;<br/>active&#160;CMV&#160;retinitis and in persons who have previously had CMV&#160;retinitis.&#160;IRU is&#160;usually observed&#160;<br/>in patients with a substantial rise in CD4 cell count in the&#160;first 4 to 12 weeks after ART initiation.</p>
<p style="position:absolute;top:305px;left:780px;white-space:nowrap" class="ft038">51-55</p>
<p style="position:absolute;top:306px;left:807px;white-space:nowrap" class="ft013">&#160;</p>
<p style="position:absolute;top:326px;left:108px;white-space:nowrap" class="ft013">The&#160;estimated incidence of IRU is&#160;0.02&#160;per person-year after immune&#160;recovery.</p>
<p style="position:absolute;top:325px;left:656px;white-space:nowrap" class="ft038">56</p>
<p style="position:absolute;top:326px;left:668px;white-space:nowrap" class="ft013">&#160;Ocular&#160;</p>
<p style="position:absolute;top:346px;left:108px;white-space:nowrap" class="ft032">complications of IRU include macular edema and the development&#160;of epiretinal&#160;membranes, which&#160;<br/>can cause loss of vision.&#160;Although the&#160;inflammatory reactions seen at the onset&#160;of IRU can be&#160;<br/>transient&#160;as immune reconstitution occurs, the&#160;complications may persist,&#160;permanently compromising&#160;<br/>vision.&#160;&#160;</p>
<p style="position:absolute;top:442px;left:108px;white-space:nowrap" class="ft032">Treatment&#160;of IRU usually consists of corticosteroid therapy, but&#160;the&#160;benefit of&#160;anti-CMV therapy is&#160;<br/>unclear.</p>
<p style="position:absolute;top:461px;left:163px;white-space:nowrap" class="ft038">51,57</p>
<p style="position:absolute;top:462px;left:188px;white-space:nowrap" class="ft013">&#160;The&#160;Panel&#160;favors the use&#160;of both corticosteroids and anti-CMV&#160;therapy for active&#160;</p>
<p style="position:absolute;top:482px;left:108px;white-space:nowrap" class="ft032">intraocular inflammation at&#160;the&#160;onset of IRU and the use of corticosteroids for cystoid macular&#160;<br/>edemas, a late&#160;complication of IRU&#160;</p>
<p style="position:absolute;top:502px;left:356px;white-space:nowrap" class="ft012"><b>(CIII).</b></p>
<p style="position:absolute;top:502px;left:405px;white-space:nowrap" class="ft013">&#160;Data are insufficient upon which&#160;to base a&#160;</p>
<p style="position:absolute;top:522px;left:108px;white-space:nowrap" class="ft032">recommendation regarding the&#160;preferred route of corticosteroid administration;&#160;periocular,&#160;<br/>intravitreal, and oral&#160;administration all&#160;have been reported to be&#160;potentially successful.</p>
<p style="position:absolute;top:540px;left:705px;white-space:nowrap" class="ft038">52,58-61</p>
<p style="position:absolute;top:542px;left:746px;white-space:nowrap" class="ft013">&#160;</p>
<p style="position:absolute;top:562px;left:108px;white-space:nowrap" class="ft032">Although specific&#160;oral&#160;corticosteroid regimens for the treatment of CMV as a&#160;complication of IRU&#160;<br/>have not&#160;been studied in&#160;prospective clinical&#160;trials, it&#160;is reasonable&#160;to follow guidelines for use of oral&#160;<br/>prednisone in other inflammatory eye diseases.</p>
<p style="position:absolute;top:600px;left:433px;white-space:nowrap" class="ft038">62</p>
<p style="position:absolute;top:601px;left:444px;white-space:nowrap" class="ft013">&#160;In general, prednisone 1 mg/kg/day, with a&#160;</p>
<p style="position:absolute;top:621px;left:108px;white-space:nowrap" class="ft032">maximum adult oral dose&#160;of 60 mg/day&#160;to 80 mg/day, should be&#160;administered until&#160;there is a clinical&#160;<br/>response,&#160;but&#160;for no longer than 1 month, followed&#160;by a tapering regimen and discontinuation over&#160;<br/>2 to 3 months</p>
<p style="position:absolute;top:661px;left:202px;white-space:nowrap" class="ft012"><b>&#160;(BIII).</b></p>
<p style="position:absolute;top:661px;left:254px;white-space:nowrap" class="ft013">&#160;</p>
<p style="position:absolute;top:661px;left:258px;white-space:nowrap" class="ft091">Periocular or intravitreal corticosteroid injections can be&#160;repeated after the&#160;</p>
<p style="position:absolute;top:680px;left:108px;white-space:nowrap" class="ft0127">injection’s expected duration of effect if there&#160;has&#160;been an incomplete&#160;clinical&#160;response and there&#160;<br/>have been no&#160;treatment&#160;complications&#160;</p>
<p style="position:absolute;top:700px;left:374px;white-space:nowrap" class="ft0149"><b>(BIII).</b></p>
<p style="position:absolute;top:700px;left:421px;white-space:nowrap" class="ft019"><i>&#160;</i></p>
<p style="position:absolute;top:737px;left:108px;white-space:nowrap" class="ft032">One study&#160;demonstrated a substantial&#160;increase in IRU associated with immediate, as opposed to&#160;<br/>deferred initiation, of ART (71% vs. 31%).</p>
<p style="position:absolute;top:756px;left:406px;white-space:nowrap" class="ft038">63</p>
<p style="position:absolute;top:757px;left:417px;white-space:nowrap" class="ft013">&#160;However, in the&#160;current&#160;era, the rate of clinically&#160;</p>
<p style="position:absolute;top:777px;left:108px;white-space:nowrap" class="ft032">significant&#160;IRU following initiation of ART appears to be low&#160;(approximately 0.02 per person-<br/>year).</p>
<p style="position:absolute;top:796px;left:148px;white-space:nowrap" class="ft038">56</p>
<p style="position:absolute;top:797px;left:159px;white-space:nowrap" class="ft013">&#160;Delaying ART until retinitis is controlled may reduce&#160;the&#160;likelihood or severity of&#160;IRU;&#160;</p>
<p style="position:absolute;top:817px;left:108px;white-space:nowrap" class="ft032">however, this strategy must be weighed against the&#160;potential&#160;for a worsened immunocompromised&#160;<br/>state and the occurrence of other OIs. &#160;</p>
<p style="position:absolute;top:874px;left:108px;white-space:nowrap" class="ft032">As&#160;CMV replication usually declines within 1 to 2&#160;weeks after anti-CMV therapy is initiated, ART&#160;<br/>should be initiated no later than 1 to 2&#160;weeks after&#160;starting anti-CMV therapy for retinitis,&#160;<br/>esophagitis,&#160;colitis, or other end-organ&#160;diseases caused by CMV&#160;</p>
<p style="position:absolute;top:913px;left:555px;white-space:nowrap" class="ft012"><b>(BIII).&#160;</b></p>
<p style="position:absolute;top:913px;left:606px;white-space:nowrap" class="ft013">IRIS is a particular concern&#160;</p>
<p style="position:absolute;top:933px;left:108px;white-space:nowrap" class="ft032">with any neurologic disease, including&#160;CMV encephalitis, ventriculitis, and radiculitis. In these cases,&#160;<br/>however, the&#160;Panel recommends initiating ART&#160;within 2 weeks,&#160;although clinical&#160;judgment&#160;based on&#160;<br/>the&#160;individual case is needed&#160;</p>
<p style="position:absolute;top:973px;left:310px;white-space:nowrap" class="ft012"><b>(BIII).&#160;</b></p>
</div>
<!-- Page 180 -->
<a name="180"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page180-div" style="position:relative;width:917px;height:1187px;">
<p style="position:absolute;top:1121px;left:108px;white-space:nowrap" class="ft024"><i>Guidelines for the Prevention and Treatment&#160;of&#160;Opportunistic&#160;Infections in Adults&#160;and Adolescents&#160;With HIV&#160;</i></p>
<p style="position:absolute;top:1121px;left:784px;white-space:nowrap" class="ft024"><i>K-11&#160;</i></p>
<p style="position:absolute;top:109px;left:108px;white-space:nowrap" class="ft029"><i><b>Monitoring of&#160;Response&#160;to&#160;Therapy and&#160;Adverse Events&#160;&#160;</b></i></p>
<p style="position:absolute;top:150px;left:108px;white-space:nowrap" class="ft070"><b>CMV Retinitis&#160;Monitoring&#160;</b></p>
<p style="position:absolute;top:188px;left:108px;white-space:nowrap" class="ft032">Indirect&#160;ophthalmoscopy&#160;of both eyes&#160;through dilated pupils should be&#160;performed at&#160;the&#160;time of&#160;<br/>diagnosis of&#160;CMV&#160;retinitis,</p>
<p style="position:absolute;top:208px;left:297px;white-space:nowrap" class="ft039">&#160;</p>
<p style="position:absolute;top:208px;left:301px;white-space:nowrap" class="ft013">2 weeks after initiating&#160;therapy, and&#160;monthly thereafter while&#160;the&#160;patient&#160;</p>
<p style="position:absolute;top:228px;left:108px;white-space:nowrap" class="ft013">is on anti-CMV&#160;treatment&#160;</p>
<p style="position:absolute;top:228px;left:290px;white-space:nowrap" class="ft012"><b>(BIII).</b></p>
<p style="position:absolute;top:228px;left:337px;white-space:nowrap" class="ft013">&#160;The purpose of&#160;such examinations is to evaluate treatment&#160;efficacy,&#160;</p>
<p style="position:absolute;top:248px;left:108px;white-space:nowrap" class="ft032">identify second eye&#160;involvement&#160;in cases of unilateral disease, and detect&#160;IRU or complications such&#160;<br/>as retinal detachment. Monthly fundus&#160;photographs,&#160;using a standardized technique&#160;that&#160;documents&#160;<br/>the&#160;appearance of the retina, provide&#160;the optimum method for following patients and detecting early&#160;<br/>lesion reactivation.</p>
<p style="position:absolute;top:307px;left:239px;white-space:nowrap" class="ft012"><b>&#160;&#160;</b></p>
<p style="position:absolute;top:344px;left:108px;white-space:nowrap" class="ft013">For people&#160;who have experienced immune recovery&#160;(CD4 count&#160;</p>
<p style="position:absolute;top:344px;left:555px;white-space:nowrap" class="ft069">≥</p>
<p style="position:absolute;top:344px;left:565px;white-space:nowrap" class="ft013">100 cells/mm</p>
<p style="position:absolute;top:343px;left:659px;white-space:nowrap" class="ft038">3</p>
<p style="position:absolute;top:344px;left:664px;white-space:nowrap" class="ft013">&#160;</p>
<p style="position:absolute;top:344px;left:669px;white-space:nowrap" class="ft018">for&#160;</p>
<p style="position:absolute;top:344px;left:693px;white-space:nowrap" class="ft069">≥</p>
<p style="position:absolute;top:344px;left:703px;white-space:nowrap" class="ft018">3 months)</p>
<p style="position:absolute;top:344px;left:772px;white-space:nowrap" class="ft013">, the&#160;</p>
<p style="position:absolute;top:364px;left:108px;white-space:nowrap" class="ft032">frequency of&#160;ophthalmologic follow-up can be decreased to every 3 months. Individuals should be&#160;<br/>examined at&#160;least yearly when CD4 counts stabilize&#160;and remain above&#160;100 cells/mm</p>
<p style="position:absolute;top:382px;left:689px;white-space:nowrap" class="ft038">3</p>
<p style="position:absolute;top:384px;left:695px;white-space:nowrap" class="ft013">, HIV RNA&#160;</p>
<p style="position:absolute;top:404px;left:108px;white-space:nowrap" class="ft032">blood levels&#160;remain undetectable, and existing CMV retinitis lesions have remained clinically&#160;<br/>inactive&#160;for an extended period; however, examinations should be repeated if laboratory values&#160;<br/>suggest loss&#160;of immune&#160;reconstitution (CD4 count&#160;&lt;100 cells/mm</p>
<p style="position:absolute;top:442px;left:562px;white-space:nowrap" class="ft038">3</p>
<p style="position:absolute;top:443px;left:568px;white-space:nowrap" class="ft013">)&#160;</p>
<p style="position:absolute;top:443px;left:578px;white-space:nowrap" class="ft012"><b>(AIII).</b></p>
<p style="position:absolute;top:443px;left:626px;white-space:nowrap" class="ft013">&#160;Clinicians should be&#160;</p>
<p style="position:absolute;top:463px;left:108px;white-space:nowrap" class="ft032">aware that lesion reactivation and retinal&#160;complications still&#160;occasionally occur in patients with&#160;<br/>immune&#160;reconstitution, and regular ophthalmologic follow-up as&#160;noted above&#160;is needed whether anti-<br/>CMV&#160;therapy is continued.</p>
<p style="position:absolute;top:501px;left:296px;white-space:nowrap" class="ft038">15</p>
<p style="position:absolute;top:503px;left:307px;white-space:nowrap" class="ft013">&#160;&#160;</p>
<p style="position:absolute;top:540px;left:108px;white-space:nowrap" class="ft032">Monitoring&#160;CMV&#160;viral load in blood&#160;has poor&#160;positive predictive value for detecting relapse of&#160;<br/>retinitis and&#160;</p>
<p style="position:absolute;top:560px;left:194px;white-space:nowrap" class="ft012"><b>is not recommended</b></p>
<p style="position:absolute;top:560px;left:343px;white-space:nowrap" class="ft013">&#160;for&#160;people with&#160;HIV&#160;</p>
<p style="position:absolute;top:560px;left:491px;white-space:nowrap" class="ft012"><b>(AII).</b></p>
<p style="position:absolute;top:558px;left:533px;white-space:nowrap" class="ft038">64</p>
<p style="position:absolute;top:560px;left:545px;white-space:nowrap" class="ft013">&#160;</p>
<p style="position:absolute;top:560px;left:549px;white-space:nowrap" class="ft012"><b>&#160;</b></p>
<p style="position:absolute;top:597px;left:108px;white-space:nowrap" class="ft013">People&#160;with&#160;CD4 counts&#160;below 100 cells/mm</p>
<p style="position:absolute;top:595px;left:420px;white-space:nowrap" class="ft038">3</p>
<p style="position:absolute;top:597px;left:426px;white-space:nowrap" class="ft013">&#160;who&#160;have&#160;no visual&#160;changes or&#160;evident&#160;CMV-related&#160;</p>
<p style="position:absolute;top:617px;left:108px;white-space:nowrap" class="ft032">retinal pathology remain at&#160;risk for CMV retinitis prior to immune&#160;reconstitution after initiation of&#160;<br/>ART.</p>
<p style="position:absolute;top:635px;left:147px;white-space:nowrap" class="ft038">65,66</p>
<p style="position:absolute;top:637px;left:172px;white-space:nowrap" class="ft013">&#160;Development&#160;of CMV retinitis in the&#160;setting of recent&#160;ART initiation is not IRIS and&#160;</p>
<p style="position:absolute;top:656px;left:108px;white-space:nowrap" class="ft032">should be treated with systemic anti-CMV&#160;therapy,&#160;similar to any person&#160;with CMV retinitis, and the&#160;<br/>ART regimen should be continued&#160;</p>
<p style="position:absolute;top:676px;left:351px;white-space:nowrap" class="ft012"><b>(AII).</b></p>
<p style="position:absolute;top:676px;left:392px;white-space:nowrap" class="ft013">&#160;Corticosteroids are&#160;not&#160;recommended in people with initial&#160;</p>
<p style="position:absolute;top:696px;left:108px;white-space:nowrap" class="ft013">CMV&#160;retinitis&#160;after initiating effective&#160;ART&#160;</p>
<p style="position:absolute;top:696px;left:414px;white-space:nowrap" class="ft012"><b>(AIII).</b></p>
<p style="position:absolute;top:696px;left:463px;white-space:nowrap" class="ft013">&#160;&#160;</p>
<p style="position:absolute;top:733px;left:108px;white-space:nowrap" class="ft032">In addition, in the absence of IRU,&#160;corticosteroids should not&#160;be&#160;used in people undergoing&#160;treatment&#160;<br/>for CMV retinitis who have worsening retinitis upon ART initiation; however, anti-CMV therapy&#160;<br/>and ART regimens should&#160;be continued&#160;</p>
<p style="position:absolute;top:773px;left:387px;white-space:nowrap" class="ft012"><b>(AIII).&#160;</b></p>
<p style="position:absolute;top:773px;left:439px;white-space:nowrap" class="ft013">IRU can occur&#160;months or years after successful&#160;</p>
<p style="position:absolute;top:793px;left:108px;white-space:nowrap" class="ft032">treatment of CMV&#160;retinitis&#160;in a&#160;person&#160;with a&#160;history of CMV retinitis whose&#160;immune&#160;function is&#160;<br/>deteriorating and who&#160;subsequently starts taking ART or has&#160;such therapy optimized. &#160;</p>
<p style="position:absolute;top:850px;left:108px;white-space:nowrap" class="ft070"><b>Drug Adverse&#160;Effects&#160;</b></p>
<p style="position:absolute;top:887px;left:108px;white-space:nowrap" class="ft032">Adverse effects of ganciclovir/valganciclovir include anemia, neutropenia, thrombocytopenia,&#160;<br/>nausea, diarrhea, and renal dysfunction. Ganciclovir-related neutropenia&#160;can&#160;often be reversed with&#160;<br/>granulocyte colony-stimulating factor.</p>
<p style="position:absolute;top:926px;left:373px;white-space:nowrap" class="ft038">67,68</p>
<p style="position:absolute;top:927px;left:398px;white-space:nowrap" class="ft013">&#160;In people&#160;receiving ganciclovir or valganciclovir,&#160;</p>
<p style="position:absolute;top:947px;left:108px;white-space:nowrap" class="ft032">complete&#160;blood counts (CBC) and renal function should be&#160;monitored twice weekly during induction&#160;<br/>and at&#160;least once weekly during maintenance&#160;therapy, or more frequently if indicated&#160;</p>
<p style="position:absolute;top:967px;left:698px;white-space:nowrap" class="ft012"><b>(AIII).&#160;</b></p>
<p style="position:absolute;top:967px;left:750px;white-space:nowrap" class="ft013">&#160;</p>
<p style="position:absolute;top:1004px;left:108px;white-space:nowrap" class="ft032">Adverse effects of foscarnet&#160;include&#160;nephrotoxicity and electrolyte abnormalities, seizures that&#160;occur&#160;<br/>characteristically in the&#160;context&#160;of renal&#160;insufficiency, and anemia. Foscarnet&#160;should be administered&#160;<br/>with intravenous hydration. Genital ulcers also can&#160;occur during&#160;foscarnet&#160;administration in people&#160;</p>
</div>
<!-- Page 181 -->
<a name="181"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page181-div" style="position:relative;width:917px;height:1187px;">
<p style="position:absolute;top:1121px;left:108px;white-space:nowrap" class="ft024"><i>Guidelines for the Prevention and Treatment&#160;of&#160;Opportunistic&#160;Infections in Adults&#160;and Adolescents&#160;With HIV&#160;</i></p>
<p style="position:absolute;top:1121px;left:784px;white-space:nowrap" class="ft024"><i>K-12&#160;</i></p>
<p style="position:absolute;top:109px;left:108px;white-space:nowrap" class="ft032">with urinary&#160;incontinence&#160;due to the&#160;toxic effects of&#160;excreted drug on exposed&#160;skin. Foscarnet&#160;is&#160;<br/>typically given in the&#160;inpatient&#160;setting&#160;because of the intensity of monitoring and need for hydration.&#160;<br/>Serum electrolytes (including potassium, magnesium, calcium, and phosphorus), renal function tests&#160;<br/>and CBC should be&#160;closely monitored&#160;</p>
<p style="position:absolute;top:168px;left:375px;white-space:nowrap" class="ft012"><b>(AIII).&#160;</b></p>
<p style="position:absolute;top:168px;left:428px;white-space:nowrap" class="ft013">In people who receive foscarnet as maintenance&#160;</p>
<p style="position:absolute;top:188px;left:108px;white-space:nowrap" class="ft032">therapy in the&#160;outpatient&#160;setting, serum&#160;electrolytes, renal&#160;function tests, and&#160;CBC should&#160;be&#160;<br/>performed at&#160;least weekly, if stable&#160;</p>
<p style="position:absolute;top:208px;left:354px;white-space:nowrap" class="ft012"><b>(AIII).</b></p>
<p style="position:absolute;top:208px;left:403px;white-space:nowrap" class="ft013">&#160;Foscarnet&#160;treatment&#160;should be&#160;stopped if the&#160;treating&#160;</p>
<p style="position:absolute;top:228px;left:108px;white-space:nowrap" class="ft032">physician determines that&#160;there has been a substantial worsening&#160;of renal function or there is a severe&#160;<br/>electrolyte imbalance when compared&#160;to pre-treatment values&#160;</p>
<p style="position:absolute;top:248px;left:537px;white-space:nowrap" class="ft012"><b>(AIII);</b></p>
<p style="position:absolute;top:248px;left:587px;white-space:nowrap" class="ft013">&#160;no definitive laboratory profile&#160;</p>
<p style="position:absolute;top:267px;left:108px;white-space:nowrap" class="ft013">exists to prompt&#160;treatment discontinuation. &#160;</p>
<p style="position:absolute;top:304px;left:108px;white-space:nowrap" class="ft032">Adverse effects of cidofovir include dose-related nephrotoxicity, neutropenia, uveitis, and&#160;hypotony&#160;<br/>(low intraocular pressure). The risk of&#160;severe renal&#160;injury from IV cidofovir can be reduced by pre-&#160;<br/>and post-hydration and oral&#160;probenecid before cidofovir administration. Serum creatinine, urinalysis,&#160;<br/>and CBC should be&#160;analyzed within 48&#160;hours of each IV cidofovir infusion.&#160;Drug administration is&#160;<br/>contraindicated if renal&#160;dysfunction or&#160;substantial&#160;proteinuria is detected (see&#160;</p>
<p style="position:absolute;top:384px;left:644px;white-space:nowrap" class="ft034">Table 6</p>
<p style="position:absolute;top:384px;left:697px;white-space:nowrap" class="ft013">&#160;for renal&#160;</p>
<p style="position:absolute;top:404px;left:108px;white-space:nowrap" class="ft032">dosing information). Particular attention is needed&#160;for patients receiving other potentially&#160;<br/>nephrotoxic&#160;medications, including tenofovir disoproxil&#160;fumarate. Periodic&#160;ophthalmologic&#160;<br/>examinations are needed to monitor for&#160;cidofovir-associated uveitis or hypotony, even when CMV&#160;<br/>disease does&#160;not include retinitis.&#160;&#160;</p>
<p style="position:absolute;top:500px;left:108px;white-space:nowrap" class="ft029"><i><b>Managing&#160;Treatment Failure&#160;&#160;</b></i></p>
<p style="position:absolute;top:542px;left:108px;white-space:nowrap" class="ft032">Failure of therapy for CMV&#160;retinitis&#160;or reactivation of lesions is most likely in patients who do&#160;not&#160;<br/>experience&#160;substantial immune reconstitution after&#160;initiation or&#160;optimization&#160;of ART.</p>
<p style="position:absolute;top:560px;left:695px;white-space:nowrap" class="ft038">18</p>
<p style="position:absolute;top:562px;left:707px;white-space:nowrap" class="ft013">&#160;Treatment&#160;</p>
<p style="position:absolute;top:581px;left:108px;white-space:nowrap" class="ft032">failure may also result from inadequate anti-CMV&#160;intraocular drug levels, CMV&#160;drug resistance, or&#160;<br/>nonadherence to CMV treatment or ART. Many experts believe that&#160;early progression of disease&#160;<br/>(enlargement&#160;of lesions or&#160;new lesions)&#160;is most&#160;often caused by the limited intraocular penetration of&#160;<br/>systemically administered drugs.</p>
<p style="position:absolute;top:639px;left:335px;white-space:nowrap" class="ft038">57,69,70</p>
<p style="position:absolute;top:641px;left:374px;white-space:nowrap" class="ft013">&#160;Data are limited on treatment failure for CMV disease other&#160;</p>
<p style="position:absolute;top:661px;left:108px;white-space:nowrap" class="ft032">than retinitis, but the&#160;potential&#160;mechanisms and management strategies for treatment&#160;failure are likely&#160;<br/>similar to those seen in the setting of retinitis.</p>
<p style="position:absolute;top:680px;left:422px;white-space:nowrap" class="ft017"><i><b>&#160;</b></i></p>
<p style="position:absolute;top:718px;left:108px;white-space:nowrap" class="ft032">When lesions reactivate in patients receiving maintenance therapy, a&#160;round&#160;of treatment induction&#160;<br/>with the current&#160;maintenance therapy is recommended, followed by reinstitution of maintenance&#160;<br/>therapy&#160;</p>
<p style="position:absolute;top:757px;left:164px;white-space:nowrap" class="ft012"><b>(BIII).</b></p>
<p style="position:absolute;top:756px;left:211px;white-space:nowrap" class="ft038">71</p>
<p style="position:absolute;top:757px;left:223px;white-space:nowrap" class="ft013">&#160;Ganciclovir and foscarnet in combination appear to provide superior efficacy than&#160;</p>
<p style="position:absolute;top:777px;left:108px;white-space:nowrap" class="ft032">either agent&#160;alone, and their combination is recommended for people&#160;whose&#160;disease does&#160;not respond&#160;<br/>to single-drug therapy or&#160;if there is continued progression or&#160;multiple&#160;reactivations of retinitis&#160;</p>
<p style="position:absolute;top:817px;left:108px;white-space:nowrap" class="ft012"><b>(CIII).</b></p>
<p style="position:absolute;top:815px;left:156px;white-space:nowrap" class="ft038">71</p>
<p style="position:absolute;top:817px;left:168px;white-space:nowrap" class="ft013">&#160;Notably, this drug combination is associated with substantial toxicity.&#160;&#160;</p>
<p style="position:absolute;top:854px;left:108px;white-space:nowrap" class="ft013">Drug resistance&#160;can occur in patients receiving long-term anti-CMV&#160;therapy.</p>
<p style="position:absolute;top:852px;left:639px;white-space:nowrap" class="ft038">72-75</p>
<p style="position:absolute;top:854px;left:665px;white-space:nowrap" class="ft013">&#160;Drug resistance&#160;</p>
<p style="position:absolute;top:874px;left:108px;white-space:nowrap" class="ft013">developed at&#160;a rate of approximately 25% per person-year in the pre-ART era</p>
<p style="position:absolute;top:872px;left:643px;white-space:nowrap" class="ft038">72,76,77</p>
<p style="position:absolute;top:874px;left:683px;white-space:nowrap" class="ft013">&#160;for ganciclovir,&#160;</p>
<p style="position:absolute;top:894px;left:108px;white-space:nowrap" class="ft013">foscarnet, and cidofovir.</p>
<p style="position:absolute;top:892px;left:277px;white-space:nowrap" class="ft038">72,73</p>
<p style="position:absolute;top:894px;left:302px;white-space:nowrap" class="ft013">&#160;In the&#160;ART era, the 1-year incidence of resistance appears to&#160;be lower&#160;</p>
<p style="position:absolute;top:913px;left:108px;white-space:nowrap" class="ft013">(approximately 5% per person-year).</p>
<p style="position:absolute;top:912px;left:363px;white-space:nowrap" class="ft038">78</p>
<p style="position:absolute;top:913px;left:374px;white-space:nowrap" class="ft013">&#160;Low-level&#160;resistance to ganciclovir occurs through&#160;mutations&#160;</p>
<p style="position:absolute;top:933px;left:108px;white-space:nowrap" class="ft032">in the CMV&#160;UL97 (phosphotransferase) gene, and high-level resistance&#160;to ganciclovir typically&#160;<br/>occurs because of mutations in both the CMV&#160;UL97 and UL54&#160;(DNA polymerase) genes.</p>
<p style="position:absolute;top:952px;left:728px;white-space:nowrap" class="ft038">74,79-83</p>
<p style="position:absolute;top:953px;left:768px;white-space:nowrap" class="ft013">&#160;</p>
<p style="position:absolute;top:973px;left:108px;white-space:nowrap" class="ft032">Resistance to foscarnet&#160;or&#160;cidofovir occurs because&#160;of mutations&#160;in the CMV&#160;UL54 gene.&#160;High-level&#160;<br/>resistance to ganciclovir often is associated with cross-resistance to cidofovir</p>
<p style="position:absolute;top:991px;left:640px;white-space:nowrap" class="ft038">81</p>
<p style="position:absolute;top:993px;left:652px;white-space:nowrap" class="ft013">&#160;and occasionally to&#160;</p>
<p style="position:absolute;top:1013px;left:108px;white-space:nowrap" class="ft013">foscarnet.</p>
<p style="position:absolute;top:1011px;left:176px;white-space:nowrap" class="ft038">82</p>
<p style="position:absolute;top:1013px;left:187px;white-space:nowrap" class="ft013">&#160;Although early progression of CMV disease (within&#160;2 months) in&#160;patients who&#160;recently&#160;</p>
<p style="position:absolute;top:1032px;left:108px;white-space:nowrap" class="ft032">started anti-CMV&#160;drug treatment is typically not&#160;a result&#160;of drug resistance,&#160;late&#160;CMV&#160;reactivation&#160;<br/>after many months of treatment may be due&#160;to resistance.</p>
<p style="position:absolute;top:1051px;left:504px;white-space:nowrap" class="ft038">40</p>
<p style="position:absolute;top:1052px;left:515px;white-space:nowrap" class="ft013">&#160;By&#160;themselves, peripheral&#160;blood CMV&#160;</p>
</div>
<!-- Page 182 -->
<a name="182"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page182-div" style="position:relative;width:917px;height:1187px;">
<p style="position:absolute;top:1121px;left:108px;white-space:nowrap" class="ft024"><i>Guidelines for the Prevention and Treatment&#160;of&#160;Opportunistic&#160;Infections in Adults&#160;and Adolescents&#160;With HIV&#160;</i></p>
<p style="position:absolute;top:1121px;left:784px;white-space:nowrap" class="ft024"><i>K-13&#160;</i></p>
<p style="position:absolute;top:109px;left:108px;white-space:nowrap" class="ft013">viral load measurements have poor positive&#160;predictive value for treatment&#160;failure.</p>
<p style="position:absolute;top:107px;left:671px;white-space:nowrap" class="ft038">64</p>
<p style="position:absolute;top:109px;left:682px;white-space:nowrap" class="ft013">&#160;Maribavir has&#160;</p>
<p style="position:absolute;top:129px;left:108px;white-space:nowrap" class="ft032">recently been approved by the&#160;U.S.&#160;Food and Drug&#160;Administration for treatment&#160;of posttransplant&#160;<br/>refractory CMV&#160;but has&#160;not been studied extensively in people&#160;with HIV.&#160;</p>
<p style="position:absolute;top:185px;left:108px;white-space:nowrap" class="ft032">Ganciclovir resistance in patients who&#160;fail therapy can be&#160;detected by CMV&#160;DNA&#160;PCR of&#160;blood&#160;<br/>specimens followed by detection of UL97 mutations by&#160;DNA sequencing or&#160;by a point mutation&#160;<br/>assay.</p>
<p style="position:absolute;top:224px;left:150px;white-space:nowrap" class="ft038">84,85–86</p>
<p style="position:absolute;top:225px;left:192px;white-space:nowrap" class="ft013">&#160;Sequencing the UL97 gene from&#160;PCR-amplified specimens from blood can&#160;be&#160;</p>
<p style="position:absolute;top:245px;left:108px;white-space:nowrap" class="ft032">accomplished in less&#160;than&#160;48 hours and correlates&#160;well with conventional&#160;drug susceptibility testing&#160;<br/>and clinical&#160;outcomes.</p>
<p style="position:absolute;top:263px;left:263px;white-space:nowrap" class="ft038">86</p>
<p style="position:absolute;top:265px;left:274px;white-space:nowrap" class="ft013">&#160;A comparison of circulating CMV&#160;in blood and vitreous fluid showed&#160;</p>
<p style="position:absolute;top:285px;left:108px;white-space:nowrap" class="ft013">identical&#160;UL97 sequences&#160;in more than 90% of cases;</p>
<p style="position:absolute;top:283px;left:478px;white-space:nowrap" class="ft038">27</p>
<p style="position:absolute;top:285px;left:489px;white-space:nowrap" class="ft013">&#160;therefore, evaluating the&#160;blood for&#160;resistance&#160;</p>
<p style="position:absolute;top:304px;left:108px;white-space:nowrap" class="ft032">is reasonable, and detection of resistance in the blood or urine&#160;correlates with the clinical behavior of&#160;<br/>retinitis in most cases.</p>
<p style="position:absolute;top:323px;left:261px;white-space:nowrap" class="ft038">87</p>
<p style="position:absolute;top:324px;left:273px;white-space:nowrap" class="ft013">&#160;Viral&#160;culture&#160;and susceptibility testing&#160;and viral&#160;DNA sequencing often are&#160;</p>
<p style="position:absolute;top:344px;left:108px;white-space:nowrap" class="ft032">not available&#160;in clinical&#160;laboratories because they are too time-consuming or costly. UL97&#160;mutants&#160;<br/>usually respond to foscarnet, as do some UL54 mutants.</p>
<p style="position:absolute;top:363px;left:495px;white-space:nowrap" class="ft038">88</p>
<p style="position:absolute;top:364px;left:506px;white-space:nowrap" class="ft013">&#160;The Panel&#160;recommends treating&#160;</p>
<p style="position:absolute;top:384px;left:108px;white-space:nowrap" class="ft032">ganciclovir-resistant&#160;CMV with a series of intravitreal injections of foscarnet and/or IV foscarnet&#160;or&#160;<br/>IV cidofovir&#160;</p>
<p style="position:absolute;top:404px;left:198px;white-space:nowrap" class="ft012"><b>(CIII).</b></p>
<p style="position:absolute;top:404px;left:247px;white-space:nowrap" class="ft013">&#160;Intravitreal&#160;administration of cidofovir&#160;</p>
<p style="position:absolute;top:404px;left:522px;white-space:nowrap" class="ft012"><b>is&#160;not recommended,</b></p>
<p style="position:absolute;top:404px;left:674px;white-space:nowrap" class="ft013">&#160;as it&#160;has&#160;been&#160;</p>
<p style="position:absolute;top:424px;left:108px;white-space:nowrap" class="ft013">associated with uveitis and marked hypotony of the&#160;injected eye&#160;</p>
<p style="position:absolute;top:424px;left:554px;white-space:nowrap" class="ft012"><b>(AIII).</b></p>
<p style="position:absolute;top:422px;left:603px;white-space:nowrap" class="ft038">55,89</p>
<p style="position:absolute;top:424px;left:628px;white-space:nowrap" class="ft013">&#160;&#160;</p>
<p style="position:absolute;top:460px;left:108px;white-space:nowrap" class="ft026"><b>Preventing&#160;Recurrence</b></p>
<p style="position:absolute;top:460px;left:296px;white-space:nowrap" class="ft0122"><b>&#160;</b></p>
<p style="position:absolute;top:502px;left:108px;white-space:nowrap" class="ft029"><i><b>When to&#160;Start&#160;Maintenance&#160;Therapy &#160;</b></i></p>
<p style="position:absolute;top:543px;left:108px;white-space:nowrap" class="ft032">After induction therapy for CMV retinitis is completed, chronic&#160;maintenance therapy should be&#160;<br/>started&#160;</p>
<p style="position:absolute;top:563px;left:158px;white-space:nowrap" class="ft012"><b>(AI).</b></p>
<p style="position:absolute;top:562px;left:193px;white-space:nowrap" class="ft038">21,25,34,37,90</p>
<p style="position:absolute;top:563px;left:261px;white-space:nowrap" class="ft013">&#160;Maintenance therapy is started after induction has achieved control&#160;of retinitis,&#160;</p>
<p style="position:absolute;top:583px;left:108px;white-space:nowrap" class="ft032">as evidenced&#160;by resolved&#160;or markedly&#160;reduced retinal lesion opacity. Oral&#160;valganciclovir is the&#160;<br/>preferred regimen as it is&#160;the easiest and least&#160;toxic to administer to an outpatient&#160;population,&#160;<br/>provided that GI absorption is adequate. Alternative&#160;regimens for&#160;chronic suppression include&#160;<br/>parenteral&#160;ganciclovir, parenteral&#160;foscarnet, and parenteral&#160;cidofovir. Systemic therapy must be&#160;<br/>administered to prevent&#160;disease in the&#160;contralateral&#160;eye until&#160;immune reconstitution has occurred.&#160;<br/>Repeated intravitreal injections of ganciclovir or foscarnet&#160;alone have&#160;appeared to be effective&#160;for&#160;<br/>maintenance therapy of CMV&#160;retinitis&#160;in uncontrolled case series,</p>
<p style="position:absolute;top:701px;left:562px;white-space:nowrap" class="ft038">91</p>
<p style="position:absolute;top:702px;left:573px;white-space:nowrap" class="ft013">&#160;but this strategy should be&#160;</p>
<p style="position:absolute;top:722px;left:108px;white-space:nowrap" class="ft013">reserved for those individuals who cannot be&#160;treated with systemic&#160;therapy.&#160;</p>
<p style="position:absolute;top:759px;left:108px;white-space:nowrap" class="ft032">The choice of regimen—including drug type&#160;and administration route—should be&#160;made in&#160;<br/>consultation with an ophthalmologist. Considerations should include the anatomic&#160;location of the&#160;<br/>retinal lesion, vision in the contralateral&#160;eye, and the&#160;individual’s immunologic&#160;and virologic status,&#160;<br/>comorbidities, concomitant&#160;medications, and response to ART.&#160;Ocular complications, such as IRU&#160;<br/>and retinal detachment, are related to lesion size; therefore, the retinitis should be&#160;controlled with&#160;<br/>anti-CMV therapy to minimize&#160;lesion size&#160;until immune recovery&#160;is sufficient.&#160;Furthermore,&#160;<br/>evidence&#160;from both the&#160;pre-ART and&#160;ART eras demonstrates that&#160;specific&#160;anti-CMV therapy&#160;<br/>decreases mortality among immune-compromised&#160;patients with CMV&#160;retinitis.</p>
<p style="position:absolute;top:896px;left:651px;white-space:nowrap" class="ft038">26,35,41,92</p>
<p style="position:absolute;top:898px;left:705px;white-space:nowrap" class="ft013">&#160;</p>
<p style="position:absolute;top:935px;left:108px;white-space:nowrap" class="ft032">After resolution of the acute non-ocular CMV disease and initiation of effective ART, chronic&#160;<br/>maintenance therapy is not routinely recommended for CMV&#160;GI&#160;disease, pneumonia, and central&#160;<br/>nervous&#160;system&#160;disease unless&#160;there is&#160;concurrent retinitis, there have already been recurrent&#160;<br/>infections, or&#160;severe disease was&#160;present initially.&#160;&#160;</p>
</div>
<!-- Page 183 -->
<a name="183"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page183-div" style="position:relative;width:917px;height:1187px;">
<p style="position:absolute;top:1121px;left:108px;white-space:nowrap" class="ft024"><i>Guidelines for the Prevention and Treatment&#160;of&#160;Opportunistic&#160;Infections in Adults&#160;and Adolescents&#160;With HIV&#160;</i></p>
<p style="position:absolute;top:1121px;left:784px;white-space:nowrap" class="ft024"><i>K-14&#160;</i></p>
<p style="position:absolute;top:109px;left:108px;white-space:nowrap" class="ft029"><i><b>When to&#160;Stop Maintenance Therapy&#160;&#160;</b></i></p>
<p style="position:absolute;top:150px;left:108px;white-space:nowrap" class="ft032">Based on the&#160;experience&#160;of multiple&#160;investigators and following&#160;guidelines published by the U.S&#160;<br/>Public&#160;Health Service&#160;and the&#160;Infectious Diseases&#160;Society of America, the Panel recommends&#160;<br/>treatment with systemic&#160;anti-CMV&#160;therapy for at&#160;least 3 months,&#160;maintaining a&#160;sustained (at&#160;least&#160;<br/>3 months) increase in CD4 count&#160;</p>
<p style="position:absolute;top:210px;left:340px;white-space:nowrap" class="ft069">≥</p>
<p style="position:absolute;top:210px;left:349px;white-space:nowrap" class="ft013">100&#160;cells/mm</p>
<p style="position:absolute;top:208px;left:443px;white-space:nowrap" class="ft038">3</p>
<p style="position:absolute;top:210px;left:448px;white-space:nowrap" class="ft013">&#160;while on ART,&#160;and ensuring CMV retinitis lesions</p>
<p style="position:absolute;top:229px;left:108px;white-space:nowrap" class="ft013">are inactive before stopping maintenance therapy&#160;</p>
<p style="position:absolute;top:229px;left:452px;white-space:nowrap" class="ft012"><b>(AII).</b></p>
<p style="position:absolute;top:228px;left:494px;white-space:nowrap" class="ft038">13,93-101</p>
<p style="position:absolute;top:229px;left:540px;white-space:nowrap" class="ft013">&#160;Such decisions should be&#160;made in&#160;</p>
<p style="position:absolute;top:249px;left:108px;white-space:nowrap" class="ft013">consultation with an ophthalmologist. &#160;</p>
<p style="position:absolute;top:286px;left:108px;white-space:nowrap" class="ft013">Retinitis relapse</p>
<p style="position:absolute;top:285px;left:220px;white-space:nowrap" class="ft038">102,103</p>
<p style="position:absolute;top:286px;left:256px;white-space:nowrap" class="ft013">&#160;occurs at&#160;a rate&#160;of 0.03/person-years in people&#160;with CD4 counts&#160;</p>
<p style="position:absolute;top:306px;left:108px;white-space:nowrap" class="ft069">≥</p>
<p style="position:absolute;top:306px;left:117px;white-space:nowrap" class="ft018">100</p>
<p style="position:absolute;top:306px;left:143px;white-space:nowrap" class="ft013">&#160;cells/mm</p>
<p style="position:absolute;top:305px;left:211px;white-space:nowrap" class="ft038">3</p>
<p style="position:absolute;top:306px;left:217px;white-space:nowrap" class="ft013">&#160;and has&#160;been documented in people&#160;with CD4 counts &gt;750 cells/mm</p>
<p style="position:absolute;top:305px;left:695px;white-space:nowrap" class="ft038">3</p>
<p style="position:absolute;top:306px;left:701px;white-space:nowrap" class="ft013">. Therefore,&#160;in&#160;</p>
<p style="position:absolute;top:326px;left:108px;white-space:nowrap" class="ft032">all&#160;people&#160;for&#160;whom&#160;anti-CMV&#160;maintenance&#160;therapy&#160;has&#160;been discontinued,&#160;ophthalmologic&#160;<br/>monitoring&#160;for&#160;early&#160;detection&#160;of&#160;CMV&#160;relapse&#160;and&#160;IRU&#160;should&#160;be&#160;performed&#160;at&#160;least&#160;every&#160;3&#160;months&#160;<br/>and&#160;then&#160;yearly&#160;after&#160;immune&#160;reconstitution&#160;</p>
<p style="position:absolute;top:366px;left:411px;white-space:nowrap" class="ft012"><b>(AIII).</b></p>
<p style="position:absolute;top:366px;left:459px;white-space:nowrap" class="ft013">&#160;Monitoring&#160;CMV&#160;viral&#160;load&#160;in&#160;blood&#160;has&#160;poor&#160;</p>
<p style="position:absolute;top:386px;left:108px;white-space:nowrap" class="ft013">positive&#160;predictive&#160;value&#160;for&#160;relapse&#160;of&#160;retinitis&#160;and, therefore,&#160;</p>
<p style="position:absolute;top:386px;left:534px;white-space:nowrap" class="ft012"><b>is&#160;not&#160;recommended</b></p>
<p style="position:absolute;top:386px;left:681px;white-space:nowrap" class="ft013">&#160;for&#160;people&#160;with&#160;</p>
<p style="position:absolute;top:405px;left:108px;white-space:nowrap" class="ft013">HIV&#160;</p>
<p style="position:absolute;top:405px;left:143px;white-space:nowrap" class="ft012"><b>(AII).</b></p>
<p style="position:absolute;top:404px;left:184px;white-space:nowrap" class="ft038">64</p>
<p style="position:absolute;top:405px;left:195px;white-space:nowrap" class="ft013">&#160;</p>
<p style="position:absolute;top:442px;left:108px;white-space:nowrap" class="ft032">Reactivation&#160;of CMV retinitis occurs frequently in people whose CD4 cell counts have decreased to&#160;<br/>&lt;50 cells/mm</p>
<p style="position:absolute;top:461px;left:202px;white-space:nowrap" class="ft038">3</p>
<p style="position:absolute;top:462px;left:208px;white-space:nowrap" class="ft013">&#160;and whose anti-CMV&#160;maintenance therapies have been discontinued.</p>
<p style="position:absolute;top:461px;left:689px;white-space:nowrap" class="ft038">104</p>
<p style="position:absolute;top:462px;left:706px;white-space:nowrap" class="ft013">&#160;Therefore, for&#160;</p>
<p style="position:absolute;top:482px;left:108px;white-space:nowrap" class="ft032">people with&#160;CMV&#160;retinitis, reinstitution of maintenance therapy should occur&#160;if the CD4 cell count&#160;<br/>has decreased to &lt;100 cells/mm</p>
<p style="position:absolute;top:501px;left:328px;white-space:nowrap" class="ft038">3</p>
<p style="position:absolute;top:502px;left:334px;white-space:nowrap" class="ft013">&#160;after prior successful immune reconstitution&#160;</p>
<p style="position:absolute;top:502px;left:647px;white-space:nowrap" class="ft012"><b>(AIII).&#160;</b></p>
<p style="position:absolute;top:538px;left:108px;white-space:nowrap" class="ft026"><b>Special&#160;Considerations During&#160;Pregnancy</b></p>
<p style="position:absolute;top:538px;left:451px;white-space:nowrap" class="ft0122"><b>&#160;</b></p>
<p style="position:absolute;top:580px;left:108px;white-space:nowrap" class="ft032">During pregnancy, diagnostic&#160;considerations and indications for treatment are&#160;the same as for other&#160;<br/>people with&#160;HIV&#160;</p>
<p style="position:absolute;top:600px;left:228px;white-space:nowrap" class="ft012"><b>(AIII).</b></p>
<p style="position:absolute;top:600px;left:277px;white-space:nowrap" class="ft013">&#160;Active CMV&#160;retinitis or other end-organ CMV disease during pregnancy is&#160;</p>
<p style="position:absolute;top:620px;left:108px;white-space:nowrap" class="ft032">uncommon in the ART era. Suspected&#160;or confirmed&#160;fetal&#160;CMV&#160;infection is not an indication for the&#160;<br/>treatment of the mother in the absence&#160;of maternal&#160;disease (see below).</p>
<p style="position:absolute;top:639px;left:598px;white-space:nowrap" class="ft038">105</p>
<p style="position:absolute;top:640px;left:615px;white-space:nowrap" class="ft013">&#160;If anti-CMV&#160;treatment is&#160;</p>
<p style="position:absolute;top:660px;left:108px;white-space:nowrap" class="ft032">required during pregnancy because of&#160;active&#160;maternal&#160;CMV&#160;disease, ART&#160;should be given as soon as&#160;<br/>possible and&#160;no longer than 2 weeks after initiating anti-CMV&#160;therapy to prevent transmission to the&#160;<br/>fetus and to limit&#160;other complications of immune&#160;compromise,&#160;balancing concerns about&#160;the possible<br/>development of IRIS. Duration of anti-CMV therapy should follow guidance&#160;for nonpregnant&#160;adults. &#160;</p>
<p style="position:absolute;top:756px;left:108px;white-space:nowrap" class="ft032">Based on limited data (case reports only), toxicity reports, and ease of use&#160;of&#160;the&#160;various drugs,&#160;<br/>valganciclovir is considered the best choice of treatment for maternal CMV&#160;disease requiring&#160;<br/>treatment during pregnancy&#160;</p>
<p style="position:absolute;top:796px;left:303px;white-space:nowrap" class="ft012"><b>(BIII).</b></p>
<p style="position:absolute;top:796px;left:350px;white-space:nowrap" class="ft013">&#160;Ganciclovir is embryotoxic&#160;among rabbits and mice and&#160;</p>
<p style="position:absolute;top:816px;left:108px;white-space:nowrap" class="ft032">teratogenic (e.g., cleft&#160;palate, anophthalmia, aplastic&#160;kidney and&#160;pancreas, and hydrocephalus) in&#160;<br/>rabbits.</p>
<p style="position:absolute;top:834px;left:159px;white-space:nowrap" class="ft038">106-108</p>
<p style="position:absolute;top:836px;left:197px;white-space:nowrap" class="ft013">&#160;As&#160;a prodrug with conversion to ganciclovir for activity, valganciclovir is expected to&#160;</p>
<p style="position:absolute;top:856px;left:108px;white-space:nowrap" class="ft032">have similar reproductive&#160;toxicity. However, safe&#160;use of valganciclovir in all&#160;trimesters of&#160;human&#160;<br/>pregnancy after organ transplantation and in other&#160;patient populations has been reported.</p>
<p style="position:absolute;top:874px;left:719px;white-space:nowrap" class="ft038">106,107,109,110</p>
<p style="position:absolute;top:875px;left:795px;white-space:nowrap" class="ft013">&#160;</p>
<p style="position:absolute;top:895px;left:108px;white-space:nowrap" class="ft032">Valganciclovir use during&#160;pregnancy may result in fetal anemia.&#160;Additional&#160;fetal&#160;surveillance may be&#160;<br/>considered if&#160;maternal&#160;CMV&#160;treatment is required. &#160;</p>
<p style="position:absolute;top:952px;left:108px;white-space:nowrap" class="ft032">For retinal&#160;disease in pregnancy, the use of intravitreal ganciclovir injections as local&#160;therapy that&#160;is&#160;<br/>not systemically absorbed should pose no risk to the fetus.</p>
<p style="position:absolute;top:971px;left:510px;white-space:nowrap" class="ft038">111</p>
<p style="position:absolute;top:972px;left:527px;white-space:nowrap" class="ft013">&#160;People with inactive retinal&#160;disease who&#160;</p>
<p style="position:absolute;top:992px;left:108px;white-space:nowrap" class="ft013">achieved immune reconstitution before pregnancy&#160;do not require treatment&#160;with an anti-CMV&#160;agent.&#160;</p>
<p style="position:absolute;top:1029px;left:108px;white-space:nowrap" class="ft013">Foscarnet&#160;is&#160;associated with an increase in skeletal&#160;anomalies or variants in rats and rabbits.</p>
<p style="position:absolute;top:1027px;left:741px;white-space:nowrap" class="ft038">112,113</p>
<p style="position:absolute;top:1029px;left:777px;white-space:nowrap" class="ft013">&#160;No&#160;</p>
<p style="position:absolute;top:1049px;left:108px;white-space:nowrap" class="ft013">experience&#160;with use early in human pregnancy has been reported.&#160;A single case report of use in the&#160;</p>
</div>
<!-- Page 184 -->
<a name="184"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page184-div" style="position:relative;width:917px;height:1187px;">
<p style="position:absolute;top:1121px;left:108px;white-space:nowrap" class="ft024"><i>Guidelines for the Prevention and Treatment&#160;of&#160;Opportunistic&#160;Infections in Adults&#160;and Adolescents&#160;With HIV&#160;</i></p>
<p style="position:absolute;top:1121px;left:784px;white-space:nowrap" class="ft024"><i>K-15&#160;</i></p>
<p style="position:absolute;top:109px;left:108px;white-space:nowrap" class="ft013">third trimester described&#160;a normal infant&#160;outcome.</p>
<p style="position:absolute;top:107px;left:454px;white-space:nowrap" class="ft038">114</p>
<p style="position:absolute;top:109px;left:471px;white-space:nowrap" class="ft013">&#160;Cidofovir is embryotoxic and teratogenic&#160;</p>
<p style="position:absolute;top:129px;left:108px;white-space:nowrap" class="ft013">(e.g., meningomyelocele and skeletal abnormalities) in rats and rabbits.</p>
<p style="position:absolute;top:127px;left:600px;white-space:nowrap" class="ft038">115</p>
<p style="position:absolute;top:129px;left:617px;white-space:nowrap" class="ft013">&#160;No&#160;experience&#160;with use of&#160;</p>
<p style="position:absolute;top:148px;left:108px;white-space:nowrap" class="ft032">cidofovir in&#160;human pregnancy has been reported. Based on these&#160;concerns, foscarnet&#160;or cidofovir use&#160;<br/>in pregnancy&#160;</p>
<p style="position:absolute;top:168px;left:202px;white-space:nowrap" class="ft012"><b>is not recommended</b></p>
<p style="position:absolute;top:168px;left:350px;white-space:nowrap" class="ft013">&#160;in&#160;the&#160;absence&#160;of resistance&#160;or toxicity with&#160;</p>
<p style="position:absolute;top:188px;left:108px;white-space:nowrap" class="ft013">ganciclovir/valganciclovir&#160;</p>
<p style="position:absolute;top:188px;left:293px;white-space:nowrap" class="ft012"><b>(AIII);</b></p>
<p style="position:absolute;top:188px;left:343px;white-space:nowrap" class="ft013">&#160;if either agent is&#160;used, this should be&#160;done&#160;in consultation with a&#160;</p>
<p style="position:absolute;top:208px;left:108px;white-space:nowrap" class="ft032">maternal–fetal medicine specialist. Use of either drug may result in maternal&#160;renal&#160;toxicity&#160;and/or&#160;<br/>insufficiency. Additional fetal&#160;surveillance may be recommended in the&#160;setting of maternal&#160;renal&#160;<br/>insufficiency&#160;</p>
<p style="position:absolute;top:248px;left:202px;white-space:nowrap" class="ft012"><b>(BIII).</b></p>
<p style="position:absolute;top:246px;left:250px;white-space:nowrap" class="ft038">105,116-120</p>
<p style="position:absolute;top:248px;left:307px;white-space:nowrap" class="ft013">&#160;</p>
<p style="position:absolute;top:247px;left:311px;white-space:nowrap" class="ft0111">&#160;</p>
<p style="position:absolute;top:285px;left:108px;white-space:nowrap" class="ft029"><i><b>Suspected or Confirmed&#160;Fetal&#160;CMV&#160;</b></i></p>
<p style="position:absolute;top:326px;left:108px;white-space:nowrap" class="ft013">Primary infection, reactivation, or reinfection with CMV&#160;during&#160;pregnancy (non-primary&#160;infection)</p>
<p style="position:absolute;top:325px;left:793px;white-space:nowrap" class="ft038">121</p>
<p style="position:absolute;top:326px;left:810px;white-space:nowrap" class="ft013">&#160;</p>
<p style="position:absolute;top:346px;left:108px;white-space:nowrap" class="ft013">can lead to&#160;</p>
<p style="position:absolute;top:346px;left:187px;white-space:nowrap" class="ft019"><i>in-utero</i></p>
<p style="position:absolute;top:346px;left:242px;white-space:nowrap" class="ft013">&#160;transmission and&#160;congenital&#160;CMV&#160;disease.&#160;Maternal CMV infection and fetal&#160;</p>
<p style="position:absolute;top:366px;left:108px;white-space:nowrap" class="ft032">congenital CMV infection have&#160;been&#160;associated with an increased risk of perinatal HIV transmission&#160;<br/>among pregnant&#160;women&#160;who have not received ART.</p>
<p style="position:absolute;top:384px;left:478px;white-space:nowrap" class="ft038">122</p>
<p style="position:absolute;top:386px;left:495px;white-space:nowrap" class="ft013">&#160;Maternal&#160;ART to prevent&#160;perinatal&#160;HIV&#160;has&#160;</p>
<p style="position:absolute;top:405px;left:108px;white-space:nowrap" class="ft032">been associated with decreased rates of perinatal/early postnatal CMV and decreased CMV-related&#160;<br/>clinical&#160;symptoms among infants exposed to or infected with HIV.</p>
<p style="position:absolute;top:424px;left:568px;white-space:nowrap" class="ft038">123</p>
<p style="position:absolute;top:425px;left:585px;white-space:nowrap" class="ft013">&#160;Studies indicate&#160;the&#160;prevalence&#160;</p>
<p style="position:absolute;top:445px;left:108px;white-space:nowrap" class="ft032">of congenital CMV&#160;disease among infants in the United States who are exposed to HIV is&#160;1.2% to&#160;<br/>1.3%.</p>
<p style="position:absolute;top:464px;left:148px;white-space:nowrap" class="ft038">124</p>
<p style="position:absolute;top:465px;left:165px;white-space:nowrap" class="ft013">&#160;Risk factors for&#160;congenital&#160;CMV&#160;include&#160;mothers with&#160;CD4 &lt;200 cells/mm</p>
<p style="position:absolute;top:464px;left:691px;white-space:nowrap" class="ft038">3</p>
<p style="position:absolute;top:465px;left:696px;white-space:nowrap" class="ft013">, mothers with&#160;</p>
<p style="position:absolute;top:485px;left:108px;white-space:nowrap" class="ft013">urinary CMV shedding,</p>
<p style="position:absolute;top:483px;left:272px;white-space:nowrap" class="ft038">125</p>
<p style="position:absolute;top:485px;left:289px;white-space:nowrap" class="ft013">&#160;and&#160;perinatal HIV infection.</p>
<p style="position:absolute;top:483px;left:488px;white-space:nowrap" class="ft038">90</p>
<p style="position:absolute;top:485px;left:499px;white-space:nowrap" class="ft013">&#160;&#160;</p>
<p style="position:absolute;top:522px;left:108px;white-space:nowrap" class="ft032">In women diagnosed&#160;with primary CMV infection in pregnancy,&#160;the&#160;fetus should be&#160;monitored by&#160;<br/>periodic&#160;ultrasound after&#160;20 weeks&#160;gestation&#160;</p>
<p style="position:absolute;top:542px;left:417px;white-space:nowrap" class="ft012"><b>(CIII).</b></p>
<p style="position:absolute;top:540px;left:466px;white-space:nowrap" class="ft038">126</p>
<p style="position:absolute;top:542px;left:483px;white-space:nowrap" class="ft013">&#160;In studies&#160;in populations without&#160;HIV, about&#160;</p>
<p style="position:absolute;top:562px;left:108px;white-space:nowrap" class="ft032">5% to 25%&#160;of newborns infected with CMV&#160;had ultrasound evidence of congenital infection&#160;<br/>(e.g., cerebral calcifications, abdominal and liver calcifications, hydrops, microcephaly,&#160;<br/>ventriculomegaly, ascites, and echogenic&#160;fetal&#160;bowel).</p>
<p style="position:absolute;top:600px;left:483px;white-space:nowrap" class="ft038">126</p>
<p style="position:absolute;top:601px;left:499px;white-space:nowrap" class="ft013">&#160;Any ultrasound findings suspicious of&#160;</p>
<p style="position:absolute;top:621px;left:108px;white-space:nowrap" class="ft032">congenital CMV infection should prompt&#160;consideration of invasive testing (i.e., amniocentesis) for&#160;<br/>definitive&#160;diagnosis.</p>
<p style="position:absolute;top:639px;left:248px;white-space:nowrap" class="ft038">118</p>
<p style="position:absolute;top:641px;left:265px;white-space:nowrap" class="ft013">&#160;Referral to a maternal–fetal&#160;medicine&#160;specialist for evaluation, counseling,&#160;</p>
<p style="position:absolute;top:661px;left:108px;white-space:nowrap" class="ft032">and potential further testing is recommended. Potential noninvasive biomarkers for&#160;predicting&#160;<br/>congenital CMV infection are&#160;under&#160;study.</p>
<p style="position:absolute;top:679px;left:404px;white-space:nowrap" class="ft038">127</p>
<p style="position:absolute;top:680px;left:421px;white-space:nowrap" class="ft013">&#160;</p>
<p style="position:absolute;top:718px;left:108px;white-space:nowrap" class="ft032">If fetal&#160;CMV infection is confirmed, there is no standard maternal&#160;or fetal&#160;therapy that&#160;can prevent&#160;<br/>congenital CMV.</p>
<p style="position:absolute;top:736px;left:228px;white-space:nowrap" class="ft038">105,126</p>
<p style="position:absolute;top:737px;left:264px;white-space:nowrap" class="ft013">&#160;Although several&#160;observational studies reported the&#160;possible effectiveness and&#160;</p>
<p style="position:absolute;top:757px;left:108px;white-space:nowrap" class="ft013">safety of hyperimmune globulin (HIG)&#160;in pregnancy for the&#160;treatment&#160;of congenital&#160;CMV,</p>
<p style="position:absolute;top:756px;left:732px;white-space:nowrap" class="ft038">128-131</p>
<p style="position:absolute;top:757px;left:770px;white-space:nowrap" class="ft013">&#160;two&#160;</p>
<p style="position:absolute;top:777px;left:108px;white-space:nowrap" class="ft032">large, randomized, placebo-controlled trials demonstrated that&#160;HIG&#160;is not effective&#160;at&#160;decreasing the&#160;<br/>risk of congenital&#160;CMV&#160;in&#160;the&#160;setting of maternal&#160;primary infection.</p>
<p style="position:absolute;top:796px;left:578px;white-space:nowrap" class="ft038">132-134</p>
<p style="position:absolute;top:797px;left:616px;white-space:nowrap" class="ft013">&#160;Thus, HIG administration&#160;</p>
<p style="position:absolute;top:817px;left:108px;white-space:nowrap" class="ft012"><b>is not recommended</b></p>
<p style="position:absolute;top:817px;left:256px;white-space:nowrap" class="ft013">&#160;during pregnancy&#160;</p>
<p style="position:absolute;top:817px;left:386px;white-space:nowrap" class="ft012"><b>(AI).&#160;</b></p>
<p style="position:absolute;top:817px;left:426px;white-space:nowrap" class="ft013">Limited recent data&#160;exist for use of oral&#160;valacyclovir in&#160;</p>
<p style="position:absolute;top:837px;left:108px;white-space:nowrap" class="ft032">the&#160;setting of maternal primary CMV infection that occurs close&#160;to the time of conception or in the&#160;<br/>first trimester of pregnancy to reduce neonatal&#160;CMV&#160;infection.</p>
<p style="position:absolute;top:855px;left:541px;white-space:nowrap" class="ft038">135-139</p>
<p style="position:absolute;top:856px;left:578px;white-space:nowrap" class="ft013">&#160;Additional&#160;studies are needed to&#160;</p>
<p style="position:absolute;top:876px;left:108px;white-space:nowrap" class="ft032">validate&#160;this strategy and&#160;it&#160;has not been endorsed&#160;by the&#160;Society of Maternal-Fetal&#160;Medicine nor the&#160;<br/>American College&#160;of Obstetricians and Gynecologists.</p>
</div>
<!-- Page 185 -->
<a name="185"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page185-div" style="position:relative;width:917px;height:1187px;">
<p style="position:absolute;top:1132px;left:108px;white-space:nowrap" class="ft024"><i>Guidelines for the Prevention and Treatment&#160;of&#160;Opportunistic&#160;Infections in Adults&#160;and Adolescents&#160;With HIV&#160;</i></p>
<p style="position:absolute;top:1132px;left:784px;white-space:nowrap" class="ft024"><i>K-16&#160;</i></p>
<p style="position:absolute;top:108px;left:108px;white-space:nowrap" class="ft026"><b>References&#160;</b></p>
<p style="position:absolute;top:150px;left:108px;white-space:nowrap" class="ft047">1.</p>
<p style="position:absolute;top:150px;left:120px;white-space:nowrap" class="ft048">&#160;</p>
<p style="position:absolute;top:150px;left:162px;white-space:nowrap" class="ft051">Bate SL,&#160;Dollard&#160;SC,&#160;Cannon&#160;MJ.&#160;Cytomegalovirus Seroprevalence in&#160;the United&#160;States: The&#160;<br/>National Health&#160;and&#160;Nutrition&#160;Examination&#160;Surveys,&#160;1988–2004.&#160;</p>
<p style="position:absolute;top:169px;left:596px;white-space:nowrap" class="ft049"><i>Clinical Infectious Diseases</i></p>
<p style="position:absolute;top:169px;left:781px;white-space:nowrap" class="ft047">.&#160;</p>
<p style="position:absolute;top:188px;left:162px;white-space:nowrap" class="ft047">2010;50(11):1439-1447. Available at:&#160;</p>
<p style="position:absolute;top:188px;left:417px;white-space:nowrap" class="ft050">https://doi.org/10.1086/652438</p>
<p style="position:absolute;top:188px;left:622px;white-space:nowrap" class="ft047">.&#160;</p>
<p style="position:absolute;top:225px;left:108px;white-space:nowrap" class="ft047">2.</p>
<p style="position:absolute;top:225px;left:120px;white-space:nowrap" class="ft048">&#160;</p>
<p style="position:absolute;top:225px;left:162px;white-space:nowrap" class="ft051">Fowler K, Mucha J,&#160;Neumann&#160;M, et&#160;al.&#160;A systematic&#160;literature review of the global&#160;<br/>seroprevalence of cytomegalovirus: possible implications for&#160;treatment,&#160;screening,&#160;and&#160;vaccine&#160;<br/>development.&#160;</p>
<p style="position:absolute;top:263px;left:255px;white-space:nowrap" class="ft049"><i>BMC Public Health</i></p>
<p style="position:absolute;top:263px;left:386px;white-space:nowrap" class="ft047">. 2022;22(1):1659.&#160;Available at:&#160;</p>
<p style="position:absolute;top:282px;left:162px;white-space:nowrap" class="ft050">https://www.ncbi.nlm.nih.gov/pubmed/36050659</p>
<p style="position:absolute;top:282px;left:488px;white-space:nowrap" class="ft047">.&#160;</p>
<p style="position:absolute;top:319px;left:108px;white-space:nowrap" class="ft047">3.</p>
<p style="position:absolute;top:319px;left:120px;white-space:nowrap" class="ft048">&#160;</p>
<p style="position:absolute;top:319px;left:162px;white-space:nowrap" class="ft051">Bates M,&#160;Brantsaeter AB. Human cytomegalovirus (CMV) in&#160;Africa: a neglected&#160;but&#160;important&#160;<br/>pathogen.&#160;</p>
<p style="position:absolute;top:338px;left:231px;white-space:nowrap" class="ft049"><i>J Virus Erad</i></p>
<p style="position:absolute;top:338px;left:315px;white-space:nowrap" class="ft047">. 2016;2(3):136-142. Available at:&#160;</p>
<p style="position:absolute;top:357px;left:162px;white-space:nowrap" class="ft050">https://www.ncbi.nlm.nih.gov/pubmed/27482452</p>
<p style="position:absolute;top:357px;left:488px;white-space:nowrap" class="ft047">.&#160;</p>
<p style="position:absolute;top:394px;left:108px;white-space:nowrap" class="ft047">4.</p>
<p style="position:absolute;top:394px;left:120px;white-space:nowrap" class="ft048">&#160;</p>
<p style="position:absolute;top:394px;left:162px;white-space:nowrap" class="ft051">Zuhair M, Smit GSA,&#160;Wallis G, et&#160;al. Estimation&#160;of the worldwide seroprevalence of&#160;<br/>cytomegalovirus: A systematic review and&#160;meta-analysis.&#160;</p>
<p style="position:absolute;top:413px;left:546px;white-space:nowrap" class="ft049"><i>Rev Med&#160;Virol</i></p>
<p style="position:absolute;top:413px;left:642px;white-space:nowrap" class="ft047">.&#160;2019;29(3):e2034.&#160;</p>
<p style="position:absolute;top:432px;left:162px;white-space:nowrap" class="ft047">Available at:&#160;</p>
<p style="position:absolute;top:432px;left:251px;white-space:nowrap" class="ft050">https://www.ncbi.nlm.nih.gov/pubmed/30706584</p>
<p style="position:absolute;top:432px;left:577px;white-space:nowrap" class="ft047">.&#160;</p>
<p style="position:absolute;top:469px;left:108px;white-space:nowrap" class="ft047">5.</p>
<p style="position:absolute;top:468px;left:120px;white-space:nowrap" class="ft048">&#160;</p>
<p style="position:absolute;top:469px;left:162px;white-space:nowrap" class="ft051">Mhandire D,&#160;Duri&#160;K, Kaba&#160;M,&#160;et al.&#160;Seroprevalence of&#160;Cytomegalovirus infection&#160;Among&#160;HIV-<br/>infected and&#160;HIV-uninfected pregnant&#160;women attending&#160;antenatal clinic in&#160;Harare, Zimbabwe.&#160;</p>
<p style="position:absolute;top:507px;left:162px;white-space:nowrap" class="ft049"><i>Viral Immunol</i></p>
<p style="position:absolute;top:507px;left:259px;white-space:nowrap" class="ft047">. 2019;32(7):289-295.&#160;Available at:&#160;</p>
<p style="position:absolute;top:526px;left:162px;white-space:nowrap" class="ft050">https://www.ncbi.nlm.nih.gov/pubmed/31347990</p>
<p style="position:absolute;top:526px;left:488px;white-space:nowrap" class="ft047">.&#160;</p>
<p style="position:absolute;top:563px;left:108px;white-space:nowrap" class="ft047">6.</p>
<p style="position:absolute;top:562px;left:120px;white-space:nowrap" class="ft048">&#160;</p>
<p style="position:absolute;top:563px;left:162px;white-space:nowrap" class="ft051">Hoehl S, Berger A, Ciesek&#160;S,&#160;Rabenau&#160;HF.&#160;Thirty&#160;years of&#160;CMV seroprevalence-a longitudinal&#160;<br/>analysis in&#160;a German&#160;university&#160;hospital.&#160;</p>
<p style="position:absolute;top:582px;left:435px;white-space:nowrap" class="ft049"><i>Eur J Clin&#160;Microbiol Infect Dis</i></p>
<p style="position:absolute;top:582px;left:643px;white-space:nowrap" class="ft047">. 2020;39(6):1095-1102.&#160;</p>
<p style="position:absolute;top:601px;left:162px;white-space:nowrap" class="ft047">Available at:&#160;</p>
<p style="position:absolute;top:601px;left:251px;white-space:nowrap" class="ft050">https://www.ncbi.nlm.nih.gov/pubmed/31989374</p>
<p style="position:absolute;top:601px;left:577px;white-space:nowrap" class="ft047">.&#160;</p>
<p style="position:absolute;top:638px;left:108px;white-space:nowrap" class="ft047">7.</p>
<p style="position:absolute;top:637px;left:120px;white-space:nowrap" class="ft048">&#160;</p>
<p style="position:absolute;top:638px;left:162px;white-space:nowrap" class="ft051">Centers for&#160;Disease Control and&#160;Prevention. Clinical overview of&#160;CMV and&#160;congenital CMV.&#160;<br/>2024. Available at:&#160;</p>
<p style="position:absolute;top:657px;left:292px;white-space:nowrap" class="ft050">https://www.cdc.gov/cytomegalovirus/hcp/clinical-overview/index.html</p>
<p style="position:absolute;top:657px;left:768px;white-space:nowrap" class="ft047">&#160;&#160;</p>
<p style="position:absolute;top:693px;left:108px;white-space:nowrap" class="ft047">8.</p>
<p style="position:absolute;top:693px;left:120px;white-space:nowrap" class="ft048">&#160;</p>
<p style="position:absolute;top:693px;left:162px;white-space:nowrap" class="ft051">Gupta M, Shorman M.&#160;Cytomegalovirus infections. StatPearls. Treasure Island&#160;(FL). StatPearls&#160;<br/>Publishing.&#160;2025.&#160;Accessed: July&#160;2,2025.&#160;</p>
<p style="position:absolute;top:712px;left:438px;white-space:nowrap" class="ft050">https://pubmed.ncbi.nlm.nih.gov/29083720/</p>
<p style="position:absolute;top:712px;left:729px;white-space:nowrap" class="ft047">.&#160;</p>
<p style="position:absolute;top:749px;left:108px;white-space:nowrap" class="ft047">9.</p>
<p style="position:absolute;top:749px;left:120px;white-space:nowrap" class="ft048">&#160;</p>
<p style="position:absolute;top:749px;left:162px;white-space:nowrap" class="ft047">Griffiths P,&#160;Baraniak&#160;I,&#160;Reeves M.&#160;The pathogenesis of human&#160;cytomegalovirus.&#160;</p>
<p style="position:absolute;top:749px;left:696px;white-space:nowrap" class="ft049"><i>J Pathol</i></p>
<p style="position:absolute;top:749px;left:752px;white-space:nowrap" class="ft047">.&#160;</p>
<p style="position:absolute;top:768px;left:162px;white-space:nowrap" class="ft047">2015;235(2):288-297. Available at:&#160;</p>
<p style="position:absolute;top:768px;left:400px;white-space:nowrap" class="ft050">https://www.ncbi.nlm.nih.gov/pubmed/25205255</p>
<p style="position:absolute;top:768px;left:727px;white-space:nowrap" class="ft047">.&#160;</p>
<p style="position:absolute;top:805px;left:108px;white-space:nowrap" class="ft047">10.</p>
<p style="position:absolute;top:805px;left:129px;white-space:nowrap" class="ft048">&#160;</p>
<p style="position:absolute;top:805px;left:162px;white-space:nowrap" class="ft051">Jabs DA, Van&#160;Natta ML, Kempen&#160;JH,&#160;et&#160;al. Characteristics of&#160;patients with&#160;cytomegalovirus&#160;<br/>retinitis in&#160;the&#160;era of highly active antiretroviral therapy.&#160;</p>
<p style="position:absolute;top:824px;left:537px;white-space:nowrap" class="ft049"><i>Am J Ophthalmol</i></p>
<p style="position:absolute;top:824px;left:654px;white-space:nowrap" class="ft047">. 2002;133(1):48-61.&#160;</p>
<p style="position:absolute;top:843px;left:162px;white-space:nowrap" class="ft047">Available at:&#160;</p>
<p style="position:absolute;top:843px;left:251px;white-space:nowrap" class="ft050">http://www.ncbi.nlm.nih.gov/pubmed/11755839</p>
<p style="position:absolute;top:843px;left:571px;white-space:nowrap" class="ft047">.&#160;</p>
<p style="position:absolute;top:880px;left:108px;white-space:nowrap" class="ft047">11.</p>
<p style="position:absolute;top:880px;left:129px;white-space:nowrap" class="ft048">&#160;</p>
<p style="position:absolute;top:880px;left:162px;white-space:nowrap" class="ft051">Dieterich&#160;DT,&#160;Rahmin&#160;M. Cytomegalovirus colitis in&#160;AIDS: presentation&#160;in&#160;44&#160;patients and&#160;a&#160;<br/>review of&#160;the literature.&#160;</p>
<p style="position:absolute;top:899px;left:321px;white-space:nowrap" class="ft049"><i>J Acquir Immune Defic Syndr</i></p>
<p style="position:absolute;top:899px;left:517px;white-space:nowrap" class="ft047">. 1991;4&#160;Suppl&#160;1:S29-35. Available at:&#160;</p>
<p style="position:absolute;top:918px;left:162px;white-space:nowrap" class="ft050">http://www.ncbi.nlm.nih.gov/pubmed/1848619</p>
<p style="position:absolute;top:918px;left:474px;white-space:nowrap" class="ft047">.&#160;</p>
<p style="position:absolute;top:955px;left:108px;white-space:nowrap" class="ft047">12.</p>
<p style="position:absolute;top:955px;left:129px;white-space:nowrap" class="ft048">&#160;</p>
<p style="position:absolute;top:955px;left:162px;white-space:nowrap" class="ft047">Arribas JR, Storch&#160;GA,&#160;Clifford&#160;DB, Tselis AC. Cytomegalovirus encephalitis.&#160;</p>
<p style="position:absolute;top:955px;left:688px;white-space:nowrap" class="ft049"><i>Ann&#160;Intern Med</i></p>
<p style="position:absolute;top:955px;left:792px;white-space:nowrap" class="ft047">.&#160;</p>
<p style="position:absolute;top:974px;left:162px;white-space:nowrap" class="ft047">1996;125(7):577-587. Available at:&#160;</p>
<p style="position:absolute;top:974px;left:400px;white-space:nowrap" class="ft050">http://www.ncbi.nlm.nih.gov/pubmed/8815757</p>
<p style="position:absolute;top:974px;left:712px;white-space:nowrap" class="ft047">.&#160;</p>
<p style="position:absolute;top:1011px;left:108px;white-space:nowrap" class="ft047">13.</p>
<p style="position:absolute;top:1011px;left:129px;white-space:nowrap" class="ft048">&#160;</p>
<p style="position:absolute;top:1011px;left:162px;white-space:nowrap" class="ft051">Jabs DA, Van&#160;Natta ML,&#160;Holbrook&#160;JT,&#160;et&#160;al.&#160;Longitudinal study&#160;of&#160;the ocular complications of&#160;<br/>AIDS: 1. Ocular diagnoses at enrollment.&#160;</p>
<p style="position:absolute;top:1030px;left:439px;white-space:nowrap" class="ft049"><i>Ophthalmology</i></p>
<p style="position:absolute;top:1030px;left:542px;white-space:nowrap" class="ft047">. 2007;114(4):780-786.&#160;Available&#160;at:&#160;</p>
<p style="position:absolute;top:1049px;left:162px;white-space:nowrap" class="ft050">http://www.ncbi.nlm.nih.gov/pubmed/17258320</p>
<p style="position:absolute;top:1049px;left:482px;white-space:nowrap" class="ft047">.&#160;</p>
</div>
<!-- Page 186 -->
<a name="186"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page186-div" style="position:relative;width:917px;height:1187px;">
<p style="position:absolute;top:1132px;left:108px;white-space:nowrap" class="ft024"><i>Guidelines for the Prevention and Treatment&#160;of&#160;Opportunistic&#160;Infections in Adults&#160;and Adolescents&#160;With HIV&#160;</i></p>
<p style="position:absolute;top:1132px;left:784px;white-space:nowrap" class="ft024"><i>K-17&#160;</i></p>
<p style="position:absolute;top:109px;left:108px;white-space:nowrap" class="ft047">14.</p>
<p style="position:absolute;top:108px;left:129px;white-space:nowrap" class="ft048">&#160;</p>
<p style="position:absolute;top:109px;left:162px;white-space:nowrap" class="ft051">Schwarcz L,&#160;Chen&#160;MJ, Vittinghoff&#160;E,&#160;Hsu&#160;L,&#160;Schwarcz&#160;S.&#160;Declining&#160;incidence&#160;of AIDS-defining&#160;<br/>opportunistic&#160;illnesses: results from 16&#160;years of&#160;population-based&#160;AIDS surveillance.&#160;</p>
<p style="position:absolute;top:128px;left:726px;white-space:nowrap" class="ft049"><i>AIDS</i></p>
<p style="position:absolute;top:128px;left:762px;white-space:nowrap" class="ft047">.&#160;</p>
<p style="position:absolute;top:147px;left:162px;white-space:nowrap" class="ft047">2013;27(4):597-605.&#160;Available at:&#160;</p>
<p style="position:absolute;top:147px;left:392px;white-space:nowrap" class="ft050">http://www.ncbi.nlm.nih.gov/pubmed/23079812</p>
<p style="position:absolute;top:147px;left:712px;white-space:nowrap" class="ft047">.&#160;</p>
<p style="position:absolute;top:184px;left:108px;white-space:nowrap" class="ft047">15.</p>
<p style="position:absolute;top:183px;left:129px;white-space:nowrap" class="ft048">&#160;</p>
<p style="position:absolute;top:184px;left:162px;white-space:nowrap" class="ft051">Sugar EA,&#160;Jabs DA, Ahuja A,&#160;et al.&#160;Incidence of cytomegalovirus retinitis in&#160;the&#160;era of highly&#160;<br/>active antiretroviral therapy.&#160;</p>
<p style="position:absolute;top:203px;left:353px;white-space:nowrap" class="ft049"><i>Am J Ophthalmol</i></p>
<p style="position:absolute;top:203px;left:470px;white-space:nowrap" class="ft047">.&#160;2012;153(6):1016-1024&#160;e1015. Available at:&#160;</p>
<p style="position:absolute;top:222px;left:162px;white-space:nowrap" class="ft050">https://www.ncbi.nlm.nih.gov/pubmed/22310076</p>
<p style="position:absolute;top:222px;left:488px;white-space:nowrap" class="ft047">.&#160;</p>
<p style="position:absolute;top:259px;left:108px;white-space:nowrap" class="ft047">16.</p>
<p style="position:absolute;top:258px;left:129px;white-space:nowrap" class="ft048">&#160;</p>
<p style="position:absolute;top:259px;left:162px;white-space:nowrap" class="ft051">Jabs DA, Van&#160;Natta ML, Thorne JE,&#160;et al.&#160;Course of&#160;cytomegalovirus retinitis in&#160;the era of&#160;highly&#160;<br/>active antiretroviral therapy: 2. Second&#160;eye involvement and&#160;retinal&#160;detachment.&#160;</p>
<p style="position:absolute;top:278px;left:695px;white-space:nowrap" class="ft049"><i>Ophthalmology</i></p>
<p style="position:absolute;top:278px;left:797px;white-space:nowrap" class="ft047">.&#160;</p>
<p style="position:absolute;top:297px;left:162px;white-space:nowrap" class="ft047">2004;111(12):2232-2239.&#160;Available at:&#160;</p>
<p style="position:absolute;top:297px;left:425px;white-space:nowrap" class="ft050">http://www.ncbi.nlm.nih.gov/pubmed/15582079</p>
<p style="position:absolute;top:297px;left:745px;white-space:nowrap" class="ft047">.&#160;</p>
<p style="position:absolute;top:333px;left:108px;white-space:nowrap" class="ft047">17.</p>
<p style="position:absolute;top:333px;left:129px;white-space:nowrap" class="ft048">&#160;</p>
<p style="position:absolute;top:333px;left:162px;white-space:nowrap" class="ft051">Holland&#160;GN, Vaudaux&#160;JD, Jeng&#160;SM, et&#160;al. Characteristics of untreated&#160;AIDS-related&#160;<br/>cytomegalovirus retinitis.&#160;I.&#160;Findings before the era of&#160;highly active antiretroviral therapy&#160;(1988&#160;<br/>to&#160;1994).&#160;</p>
<p style="position:absolute;top:371px;left:226px;white-space:nowrap" class="ft049"><i>Am&#160;J Ophthalmol</i></p>
<p style="position:absolute;top:371px;left:342px;white-space:nowrap" class="ft047">.&#160;2008;145(1):5-11. Available at:&#160;</p>
<p style="position:absolute;top:390px;left:162px;white-space:nowrap" class="ft050">https://www.ncbi.nlm.nih.gov/pubmed/18154750</p>
<p style="position:absolute;top:390px;left:488px;white-space:nowrap" class="ft047">.&#160;</p>
<p style="position:absolute;top:427px;left:108px;white-space:nowrap" class="ft047">18.</p>
<p style="position:absolute;top:427px;left:129px;white-space:nowrap" class="ft048">&#160;</p>
<p style="position:absolute;top:427px;left:162px;white-space:nowrap" class="ft051">Holland&#160;GN, Vaudaux&#160;JD, Shiramizu KM,&#160;et al.&#160;Characteristics of&#160;untreated&#160;AIDS-related&#160;<br/>cytomegalovirus retinitis. II.&#160;Findings in the era of&#160;highly&#160;active antiretroviral therapy&#160;(1997&#160;to&#160;<br/>2000).&#160;</p>
<p style="position:absolute;top:465px;left:209px;white-space:nowrap" class="ft049"><i>Am J Ophthalmol</i></p>
<p style="position:absolute;top:465px;left:325px;white-space:nowrap" class="ft047">. 2008;145(1):12-22.&#160;Available at:&#160;</p>
<p style="position:absolute;top:484px;left:162px;white-space:nowrap" class="ft050">http://www.ncbi.nlm.nih.gov/pubmed/18154751</p>
<p style="position:absolute;top:484px;left:482px;white-space:nowrap" class="ft047">.&#160;</p>
<p style="position:absolute;top:521px;left:108px;white-space:nowrap" class="ft047">19.</p>
<p style="position:absolute;top:521px;left:129px;white-space:nowrap" class="ft048">&#160;</p>
<p style="position:absolute;top:521px;left:162px;white-space:nowrap" class="ft051">Holland&#160;GN, Shuler JD. Progression&#160;rates of&#160;cytomegalovirus retinopathy&#160;in&#160;ganciclovir-treated&#160;<br/>and&#160;untreated&#160;patients.&#160;</p>
<p style="position:absolute;top:540px;left:315px;white-space:nowrap" class="ft049"><i>Arch Ophthalmol</i></p>
<p style="position:absolute;top:540px;left:430px;white-space:nowrap" class="ft047">. 1992;110(10):1435-1442. Available at:&#160;</p>
<p style="position:absolute;top:559px;left:162px;white-space:nowrap" class="ft050">https://www.ncbi.nlm.nih.gov/pubmed/1329703</p>
<p style="position:absolute;top:559px;left:480px;white-space:nowrap" class="ft047">.&#160;</p>
<p style="position:absolute;top:596px;left:108px;white-space:nowrap" class="ft047">20.</p>
<p style="position:absolute;top:596px;left:129px;white-space:nowrap" class="ft048">&#160;</p>
<p style="position:absolute;top:596px;left:162px;white-space:nowrap" class="ft047">Holland&#160;GN. AIDS and&#160;ophthalmology:&#160;the first quarter century.&#160;</p>
<p style="position:absolute;top:596px;left:594px;white-space:nowrap" class="ft049"><i>Am J Ophthalmol</i></p>
<p style="position:absolute;top:596px;left:710px;white-space:nowrap" class="ft047">.&#160;</p>
<p style="position:absolute;top:615px;left:162px;white-space:nowrap" class="ft047">2008;145(3):397-408. Available at:&#160;</p>
<p style="position:absolute;top:615px;left:400px;white-space:nowrap" class="ft050">http://www.ncbi.nlm.nih.gov/pubmed/18282490</p>
<p style="position:absolute;top:615px;left:720px;white-space:nowrap" class="ft047">.&#160;</p>
<p style="position:absolute;top:652px;left:108px;white-space:nowrap" class="ft047">21.</p>
<p style="position:absolute;top:652px;left:129px;white-space:nowrap" class="ft048">&#160;</p>
<p style="position:absolute;top:652px;left:162px;white-space:nowrap" class="ft051">Arribas JR, Clifford&#160;DB, Fichtenbaum CJ, Commins&#160;DL, Powderly&#160;WG,&#160;Storch&#160;GA. Level of&#160;<br/>cytomegalovirus (CMV) DNA in&#160;cerebrospinal fluid&#160;of&#160;subjects with&#160;AIDS and&#160;CMV infection&#160;<br/>of the central&#160;nervous system.&#160;</p>
<p style="position:absolute;top:690px;left:363px;white-space:nowrap" class="ft049"><i>J Infect Dis</i></p>
<p style="position:absolute;top:690px;left:439px;white-space:nowrap" class="ft047">. 1995;172(2):527-531.&#160;Available at:&#160;</p>
<p style="position:absolute;top:709px;left:162px;white-space:nowrap" class="ft050">http://www.ncbi.nlm.nih.gov/pubmed/7622897</p>
<p style="position:absolute;top:709px;left:474px;white-space:nowrap" class="ft047">.&#160;</p>
<p style="position:absolute;top:746px;left:108px;white-space:nowrap" class="ft047">22.</p>
<p style="position:absolute;top:746px;left:129px;white-space:nowrap" class="ft048">&#160;</p>
<p style="position:absolute;top:746px;left:162px;white-space:nowrap" class="ft051">Dodt KK, Jacobsen PH, Hofmann&#160;B,&#160;et al.&#160;Development&#160;of cytomegalovirus (CMV) disease&#160;may&#160;<br/>be predicted&#160;in&#160;HIV-infected&#160;patients by&#160;CMV polymerase chain&#160;reaction&#160;and&#160;the&#160;antigenemia&#160;<br/>test.&#160;</p>
<p style="position:absolute;top:784px;left:193px;white-space:nowrap" class="ft049"><i>AIDS</i></p>
<p style="position:absolute;top:784px;left:229px;white-space:nowrap" class="ft047">.&#160;1997;11(3):F21-28. Available at:&#160;</p>
<p style="position:absolute;top:784px;left:460px;white-space:nowrap" class="ft050">http://www.ncbi.nlm.nih.gov/pubmed/9147416</p>
<p style="position:absolute;top:784px;left:771px;white-space:nowrap" class="ft047">.&#160;</p>
<p style="position:absolute;top:821px;left:108px;white-space:nowrap" class="ft047">23.</p>
<p style="position:absolute;top:821px;left:129px;white-space:nowrap" class="ft048">&#160;</p>
<p style="position:absolute;top:821px;left:162px;white-space:nowrap" class="ft051">Zurlo&#160;JJ, O'Neill&#160;D, Polis MA, et al.&#160;Lack of clinical utility&#160;of cytomegalovirus blood&#160;and&#160;urine&#160;<br/>cultures in&#160;patients with&#160;HIV infection.&#160;</p>
<p style="position:absolute;top:840px;left:424px;white-space:nowrap" class="ft049"><i>Ann&#160;Intern&#160;Med</i></p>
<p style="position:absolute;top:840px;left:529px;white-space:nowrap" class="ft047">.&#160;1993;118(1):12-17. Available at:&#160;</p>
<p style="position:absolute;top:859px;left:162px;white-space:nowrap" class="ft050">http://www.ncbi.nlm.nih.gov/pubmed/8093214</p>
<p style="position:absolute;top:859px;left:474px;white-space:nowrap" class="ft047">.&#160;</p>
<p style="position:absolute;top:896px;left:108px;white-space:nowrap" class="ft047">24.</p>
<p style="position:absolute;top:896px;left:129px;white-space:nowrap" class="ft048">&#160;</p>
<p style="position:absolute;top:896px;left:162px;white-space:nowrap" class="ft051">Rodriguez-Barradas MC,&#160;Stool E, Musher DM,&#160;et al.&#160;Diagnosing&#160;and&#160;treating&#160;cytomegalovirus&#160;<br/>pneumonia in patients with&#160;AIDS.&#160;</p>
<p style="position:absolute;top:915px;left:392px;white-space:nowrap" class="ft049"><i>Clin&#160;Infect Dis</i></p>
<p style="position:absolute;top:915px;left:489px;white-space:nowrap" class="ft047">. 1996;23(1):76-81. Available at:&#160;</p>
<p style="position:absolute;top:934px;left:162px;white-space:nowrap" class="ft050">http://www.ncbi.nlm.nih.gov/pubmed/8816133</p>
<p style="position:absolute;top:934px;left:474px;white-space:nowrap" class="ft047">.&#160;</p>
<p style="position:absolute;top:971px;left:108px;white-space:nowrap" class="ft047">25.</p>
<p style="position:absolute;top:971px;left:129px;white-space:nowrap" class="ft048">&#160;</p>
<p style="position:absolute;top:971px;left:162px;white-space:nowrap" class="ft051">Wolf&#160;DG,&#160;Spector&#160;SA.&#160;Diagnosis of human&#160;cytomegalovirus central&#160;nervous system disease&#160;in&#160;<br/>AIDS patients by&#160;DNA amplification&#160;from&#160;cerebrospinal fluid.&#160;</p>
<p style="position:absolute;top:990px;left:581px;white-space:nowrap" class="ft049"><i>J Infect Dis</i></p>
<p style="position:absolute;top:990px;left:657px;white-space:nowrap" class="ft047">.&#160;1992;166(6):1412-</p>
<p style="position:absolute;top:1009px;left:162px;white-space:nowrap" class="ft047">1415. Available at:&#160;</p>
<p style="position:absolute;top:1009px;left:292px;white-space:nowrap" class="ft050">http://www.ncbi.nlm.nih.gov/pubmed/1331254</p>
<p style="position:absolute;top:1009px;left:604px;white-space:nowrap" class="ft047">.&#160;</p>
</div>
<!-- Page 187 -->
<a name="187"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}	.ft0150{font-size:16px;line-height:18px;font-family:TURBHP+Tinos;color:#005299;}
-->
</style>
<div id="page187-div" style="position:relative;width:917px;height:1187px;">
<p style="position:absolute;top:1132px;left:108px;white-space:nowrap" class="ft024"><i>Guidelines for the Prevention and Treatment&#160;of&#160;Opportunistic&#160;Infections in Adults&#160;and Adolescents&#160;With HIV&#160;</i></p>
<p style="position:absolute;top:1132px;left:784px;white-space:nowrap" class="ft024"><i>K-18&#160;</i></p>
<p style="position:absolute;top:109px;left:108px;white-space:nowrap" class="ft047">26.</p>
<p style="position:absolute;top:108px;left:129px;white-space:nowrap" class="ft048">&#160;</p>
<p style="position:absolute;top:109px;left:162px;white-space:nowrap" class="ft051">Deayton&#160;JR, Prof Sabin&#160;CA, Johnson&#160;MA, Emery&#160;VC, Wilson&#160;P,&#160;Griffiths PD. Importance&#160;of&#160;<br/>cytomegalovirus viraemia in&#160;risk of disease&#160;progression&#160;and&#160;death&#160;in&#160;HIV-infected&#160;patients&#160;<br/>receiving&#160;highly&#160;active antiretroviral therapy.&#160;</p>
<p style="position:absolute;top:147px;left:465px;white-space:nowrap" class="ft049"><i>Lancet</i></p>
<p style="position:absolute;top:147px;left:510px;white-space:nowrap" class="ft047">.&#160;2004;363(9427):2116-2121. Available at:&#160;</p>
<p style="position:absolute;top:166px;left:162px;white-space:nowrap" class="ft050">http://www.ncbi.nlm.nih.gov/pubmed/15220032</p>
<p style="position:absolute;top:166px;left:482px;white-space:nowrap" class="ft047">.&#160;</p>
<p style="position:absolute;top:203px;left:108px;white-space:nowrap" class="ft047">27.</p>
<p style="position:absolute;top:202px;left:129px;white-space:nowrap" class="ft048">&#160;</p>
<p style="position:absolute;top:203px;left:162px;white-space:nowrap" class="ft051">Hu&#160;H, Jabs DA, Forman MS,&#160;et al.&#160;Comparison&#160;of cytomegalovirus (CMV) UL97&#160;gene sequences&#160;<br/>in&#160;the blood&#160;and&#160;vitreous of&#160;patients with&#160;acquired&#160;immunodeficiency&#160;syndrome&#160;and&#160;CMV&#160;<br/>retinitis.&#160;</p>
<p style="position:absolute;top:241px;left:221px;white-space:nowrap" class="ft049"><i>J Infect Dis</i></p>
<p style="position:absolute;top:241px;left:296px;white-space:nowrap" class="ft047">. 2002;185(7):861-867.&#160;Available at:&#160;</p>
<p style="position:absolute;top:260px;left:162px;white-space:nowrap" class="ft050">http://www.ncbi.nlm.nih.gov/pubmed/11920309</p>
<p style="position:absolute;top:260px;left:482px;white-space:nowrap" class="ft047">.&#160;</p>
<p style="position:absolute;top:296px;left:108px;white-space:nowrap" class="ft047">28.</p>
<p style="position:absolute;top:296px;left:129px;white-space:nowrap" class="ft048">&#160;</p>
<p style="position:absolute;top:296px;left:162px;white-space:nowrap" class="ft051">Laine L,&#160;Bonacini&#160;M,&#160;Sattler F,&#160;Young&#160;T,&#160;Sherrod&#160;A.&#160;Cytomegalovirus and&#160;Candida esophagitis&#160;<br/>in&#160;patients with&#160;AIDS.&#160;</p>
<p style="position:absolute;top:315px;left:315px;white-space:nowrap" class="ft049"><i>J Acquir Immune Defic Syndr</i></p>
<p style="position:absolute;top:315px;left:510px;white-space:nowrap" class="ft047">. 1992;5(6):605-609.&#160;Available at:&#160;</p>
<p style="position:absolute;top:334px;left:162px;white-space:nowrap" class="ft050">http://www.ncbi.nlm.nih.gov/pubmed/1316961</p>
<p style="position:absolute;top:334px;left:474px;white-space:nowrap" class="ft047">.&#160;</p>
<p style="position:absolute;top:371px;left:108px;white-space:nowrap" class="ft047">29.</p>
<p style="position:absolute;top:371px;left:129px;white-space:nowrap" class="ft048">&#160;</p>
<p style="position:absolute;top:371px;left:162px;white-space:nowrap" class="ft047">Poh&#160;KC, Zheng&#160;S.&#160;A rare case&#160;of CMV&#160;pneumonia in HIV-infection.&#160;</p>
<p style="position:absolute;top:371px;left:620px;white-space:nowrap" class="ft049"><i>Respir Med&#160;Case Rep</i></p>
<p style="position:absolute;top:371px;left:764px;white-space:nowrap" class="ft047">.&#160;</p>
<p style="position:absolute;top:390px;left:162px;white-space:nowrap" class="ft047">2019;28:100945. Available at:&#160;</p>
<p style="position:absolute;top:390px;left:367px;white-space:nowrap" class="ft050">https://www.ncbi.nlm.nih.gov/pubmed/31709138</p>
<p style="position:absolute;top:390px;left:694px;white-space:nowrap" class="ft047">.&#160;</p>
<p style="position:absolute;top:427px;left:108px;white-space:nowrap" class="ft047">30.</p>
<p style="position:absolute;top:427px;left:129px;white-space:nowrap" class="ft048">&#160;</p>
<p style="position:absolute;top:427px;left:162px;white-space:nowrap" class="ft051">Jabbehdari S,&#160;Marjani&#160;M,&#160;Moniri&#160;A, et&#160;al. Cytomegalovirus pneumonia in&#160;HIV-infected patients:&#160;<br/>case&#160;series from Iran.&#160;</p>
<p style="position:absolute;top:446px;left:307px;white-space:nowrap" class="ft049"><i>HIV &amp; AIDS&#160;Review</i></p>
<p style="position:absolute;top:446px;left:443px;white-space:nowrap" class="ft047">. 2022;21(4):327-331.&#160;Available at:&#160;</p>
<p style="position:absolute;top:465px;left:162px;white-space:nowrap" class="ft0150">https://hivaids.termedia.pl/Cytomegalovirus-pneumonia-in-HIV-infected-patients-case-series-<br/>from-Iran,146650,0,2.html</p>
<p style="position:absolute;top:484px;left:339px;white-space:nowrap" class="ft047">.&#160;</p>
<p style="position:absolute;top:521px;left:108px;white-space:nowrap" class="ft047">31.</p>
<p style="position:absolute;top:521px;left:129px;white-space:nowrap" class="ft048">&#160;</p>
<p style="position:absolute;top:521px;left:162px;white-space:nowrap" class="ft047">Drew LW.&#160;Condoms&#160;and&#160;the transmission&#160;of cytomegalovirus.&#160;</p>
<p style="position:absolute;top:521px;left:580px;white-space:nowrap" class="ft049"><i>Sexually Transmitted&#160;Diseases</i></p>
<p style="position:absolute;top:521px;left:782px;white-space:nowrap" class="ft047">.&#160;</p>
<p style="position:absolute;top:540px;left:162px;white-space:nowrap" class="ft047">1998;25(9):481-482.&#160;Available at:&#160;</p>
<p style="position:absolute;top:559px;left:162px;white-space:nowrap" class="ft0150">https://journals.lww.com/stdjournal/fulltext/1998/10000/condoms_and_the_transmission_of_cyto<br/>megalovirus.7.aspx</p>
<p style="position:absolute;top:578px;left:290px;white-space:nowrap" class="ft047">.&#160;</p>
<p style="position:absolute;top:615px;left:108px;white-space:nowrap" class="ft047">32.</p>
<p style="position:absolute;top:615px;left:129px;white-space:nowrap" class="ft048">&#160;</p>
<p style="position:absolute;top:615px;left:162px;white-space:nowrap" class="ft051">Katznelson&#160;S,&#160;Drew WL,&#160;Mintz L.&#160;Efficacy of the condom as&#160;a barrier to&#160;the transmission&#160;of&#160;<br/>cytomegalovirus.&#160;</p>
<p style="position:absolute;top:634px;left:280px;white-space:nowrap" class="ft049"><i>J Infect Dis</i></p>
<p style="position:absolute;top:634px;left:356px;white-space:nowrap" class="ft047">. 1984;150(1):155-157.&#160;Available at:&#160;</p>
<p style="position:absolute;top:653px;left:162px;white-space:nowrap" class="ft050">https://www.ncbi.nlm.nih.gov/pubmed/6086770</p>
<p style="position:absolute;top:653px;left:480px;white-space:nowrap" class="ft047">.&#160;</p>
<p style="position:absolute;top:690px;left:108px;white-space:nowrap" class="ft047">33.</p>
<p style="position:absolute;top:690px;left:129px;white-space:nowrap" class="ft048">&#160;</p>
<p style="position:absolute;top:690px;left:162px;white-space:nowrap" class="ft051">Wohl DA, Kendall&#160;MA, Andersen&#160;J, et&#160;al. Low rate of CMV end-organ&#160;disease in&#160;HIV-infected&#160;<br/>patients despite&#160;low CD4+&#160;cell counts and&#160;CMV viremia: results of ACTG protocol&#160;A5030.&#160;</p>
<p style="position:absolute;top:709px;left:772px;white-space:nowrap" class="ft049"><i>HIV&#160;</i></p>
<p style="position:absolute;top:728px;left:162px;white-space:nowrap" class="ft049"><i>Clin&#160;Trials</i></p>
<p style="position:absolute;top:728px;left:234px;white-space:nowrap" class="ft047">.&#160;2009;10(3):143-152. Available at:&#160;</p>
<p style="position:absolute;top:728px;left:472px;white-space:nowrap" class="ft050">http://www.ncbi.nlm.nih.gov/pubmed/19632953</p>
<p style="position:absolute;top:728px;left:792px;white-space:nowrap" class="ft047">.&#160;</p>
<p style="position:absolute;top:765px;left:108px;white-space:nowrap" class="ft047">34.</p>
<p style="position:absolute;top:765px;left:129px;white-space:nowrap" class="ft048">&#160;</p>
<p style="position:absolute;top:765px;left:162px;white-space:nowrap" class="ft051">Martin&#160;DF,&#160;Kuppermann&#160;BD, Wolitz RA, Palestine AG, Li&#160;H, Robinson&#160;CA. Oral ganciclovir&#160;for&#160;<br/>patients with&#160;cytomegalovirus retinitis treated with&#160;a ganciclovir implant.&#160;Roche&#160;Ganciclovir&#160;<br/>Study&#160;Group.&#160;</p>
<p style="position:absolute;top:803px;left:255px;white-space:nowrap" class="ft049"><i>N Engl J Med</i></p>
<p style="position:absolute;top:803px;left:346px;white-space:nowrap" class="ft047">.&#160;1999;340(14):1063-1070. Available at:&#160;</p>
<p style="position:absolute;top:822px;left:162px;white-space:nowrap" class="ft050">http://www.ncbi.nlm.nih.gov/pubmed/10194235</p>
<p style="position:absolute;top:822px;left:482px;white-space:nowrap" class="ft047">.&#160;</p>
<p style="position:absolute;top:859px;left:108px;white-space:nowrap" class="ft047">35.</p>
<p style="position:absolute;top:859px;left:129px;white-space:nowrap" class="ft048">&#160;</p>
<p style="position:absolute;top:859px;left:162px;white-space:nowrap" class="ft051">Kempen&#160;JH, Jabs DA, Wilson&#160;LA,&#160;Dunn&#160;JP, West SK, Tonascia J.&#160;Mortality&#160;risk&#160;for patients&#160;with&#160;<br/>cytomegalovirus retinitis and&#160;acquired&#160;immune deficiency&#160;syndrome.&#160;</p>
<p style="position:absolute;top:878px;left:623px;white-space:nowrap" class="ft049"><i>Clin&#160;Infect Dis</i></p>
<p style="position:absolute;top:878px;left:720px;white-space:nowrap" class="ft047">.&#160;</p>
<p style="position:absolute;top:897px;left:162px;white-space:nowrap" class="ft047">2003;37(10):1365-1373. Available at:&#160;</p>
<p style="position:absolute;top:897px;left:417px;white-space:nowrap" class="ft050">http://www.ncbi.nlm.nih.gov/pubmed/14583871</p>
<p style="position:absolute;top:897px;left:737px;white-space:nowrap" class="ft047">.&#160;</p>
<p style="position:absolute;top:934px;left:108px;white-space:nowrap" class="ft047">36.</p>
<p style="position:absolute;top:934px;left:129px;white-space:nowrap" class="ft048">&#160;</p>
<p style="position:absolute;top:934px;left:162px;white-space:nowrap" class="ft051">Studies of Ocular Complications of ARGTACTG. The ganciclovir implant plus&#160;oral ganciclovir&#160;<br/>versus parenteral cidofovir for the treatment&#160;of cytomegalovirus retinitis in&#160;patients with&#160;acquired&#160;<br/>immunodeficiency&#160;syndrome: The Ganciclovir Cidofovir Cytomegalovirus Retinitis Trial.&#160;</p>
<p style="position:absolute;top:972px;left:761px;white-space:nowrap" class="ft049"><i>Am J&#160;</i></p>
<p style="position:absolute;top:991px;left:162px;white-space:nowrap" class="ft049"><i>Ophthalmol</i></p>
<p style="position:absolute;top:991px;left:241px;white-space:nowrap" class="ft047">.&#160;2001;131(4):457-467. Available at:&#160;</p>
<p style="position:absolute;top:1010px;left:162px;white-space:nowrap" class="ft050">http://www.ncbi.nlm.nih.gov/pubmed/11292409</p>
<p style="position:absolute;top:1010px;left:482px;white-space:nowrap" class="ft047">.&#160;</p>
</div>
<!-- Page 188 -->
<a name="188"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page188-div" style="position:relative;width:917px;height:1187px;">
<p style="position:absolute;top:1132px;left:108px;white-space:nowrap" class="ft024"><i>Guidelines for the Prevention and Treatment&#160;of&#160;Opportunistic&#160;Infections in Adults&#160;and Adolescents&#160;With HIV&#160;</i></p>
<p style="position:absolute;top:1132px;left:784px;white-space:nowrap" class="ft024"><i>K-19&#160;</i></p>
<p style="position:absolute;top:109px;left:108px;white-space:nowrap" class="ft047">37.</p>
<p style="position:absolute;top:108px;left:129px;white-space:nowrap" class="ft048">&#160;</p>
<p style="position:absolute;top:109px;left:162px;white-space:nowrap" class="ft051">Musch DC,&#160;Martin&#160;DF,&#160;Gordon&#160;JF,&#160;Davis MD, Kuppermann&#160;BD.&#160;Treatment&#160;of cytomegalovirus&#160;<br/>retinitis with&#160;a sustained-release ganciclovir implant.&#160;The Ganciclovir Implant Study&#160;Group.&#160;</p>
<p style="position:absolute;top:128px;left:775px;white-space:nowrap" class="ft049"><i>N&#160;</i></p>
<p style="position:absolute;top:147px;left:162px;white-space:nowrap" class="ft049"><i>Engl J Med</i></p>
<p style="position:absolute;top:147px;left:238px;white-space:nowrap" class="ft047">.&#160;1997;337(2):83-90. Available at:&#160;</p>
<p style="position:absolute;top:147px;left:468px;white-space:nowrap" class="ft050">http://www.ncbi.nlm.nih.gov/pubmed/9211677</p>
<p style="position:absolute;top:147px;left:780px;white-space:nowrap" class="ft047">.&#160;</p>
<p style="position:absolute;top:184px;left:108px;white-space:nowrap" class="ft047">38.</p>
<p style="position:absolute;top:183px;left:129px;white-space:nowrap" class="ft048">&#160;</p>
<p style="position:absolute;top:184px;left:162px;white-space:nowrap" class="ft051">Martin&#160;DF,&#160;Sierra-Madero&#160;J, Walmsley&#160;S,&#160;et al.&#160;A controlled&#160;trial&#160;of valganciclovir as induction&#160;<br/>therapy&#160;for cytomegalovirus retinitis.&#160;</p>
<p style="position:absolute;top:203px;left:412px;white-space:nowrap" class="ft049"><i>N Engl&#160;J Med</i></p>
<p style="position:absolute;top:203px;left:503px;white-space:nowrap" class="ft047">. 2002;346(15):1119-1126.&#160;Available at:&#160;</p>
<p style="position:absolute;top:222px;left:162px;white-space:nowrap" class="ft050">http://www.ncbi.nlm.nih.gov/pubmed/11948271</p>
<p style="position:absolute;top:222px;left:482px;white-space:nowrap" class="ft047">.&#160;</p>
<p style="position:absolute;top:259px;left:108px;white-space:nowrap" class="ft047">39.</p>
<p style="position:absolute;top:258px;left:129px;white-space:nowrap" class="ft048">&#160;</p>
<p style="position:absolute;top:259px;left:162px;white-space:nowrap" class="ft051">Kempen&#160;JH, Jabs DA, Wilson&#160;LA,&#160;Dunn&#160;JP, West SK, Tonascia JA. Risk&#160;of vision&#160;loss in&#160;<br/>patients with&#160;cytomegalovirus retinitis and&#160;the acquired&#160;immunodeficiency&#160;syndrome.&#160;</p>
<p style="position:absolute;top:278px;left:733px;white-space:nowrap" class="ft049"><i>Arch&#160;</i></p>
<p style="position:absolute;top:296px;left:162px;white-space:nowrap" class="ft049"><i>Ophthalmol</i></p>
<p style="position:absolute;top:296px;left:241px;white-space:nowrap" class="ft047">.&#160;2003;121(4):466-476. Available at:&#160;</p>
<p style="position:absolute;top:315px;left:162px;white-space:nowrap" class="ft050">http://www.ncbi.nlm.nih.gov/pubmed/12695243</p>
<p style="position:absolute;top:315px;left:482px;white-space:nowrap" class="ft047">.&#160;</p>
<p style="position:absolute;top:352px;left:108px;white-space:nowrap" class="ft047">40.</p>
<p style="position:absolute;top:352px;left:129px;white-space:nowrap" class="ft048">&#160;</p>
<p style="position:absolute;top:352px;left:162px;white-space:nowrap" class="ft051">Studies of&#160;Ocular&#160;Complications of AIDS Research&#160;Group&#160;in&#160;collaboration&#160;with&#160;the AIDS&#160;<br/>Clinical Trials Group.&#160;Foscarnet-Ganciclovir&#160;Cytomegalovirus Retinitis Trial. 4. Visual&#160;<br/>outcomes. Studies of&#160;Ocular Complications of AIDS Research&#160;Group&#160;in&#160;collaboration&#160;with&#160;the&#160;<br/>AIDS Clinical Trials Group.&#160;</p>
<p style="position:absolute;top:409px;left:354px;white-space:nowrap" class="ft049"><i>Ophthalmology</i></p>
<p style="position:absolute;top:409px;left:456px;white-space:nowrap" class="ft047">. 1994;101(7):1250-1261. Available at:&#160;</p>
<p style="position:absolute;top:428px;left:162px;white-space:nowrap" class="ft050">http://www.ncbi.nlm.nih.gov/pubmed/8035989</p>
<p style="position:absolute;top:428px;left:474px;white-space:nowrap" class="ft047">.&#160;</p>
<p style="position:absolute;top:465px;left:108px;white-space:nowrap" class="ft047">41.</p>
<p style="position:absolute;top:465px;left:129px;white-space:nowrap" class="ft048">&#160;</p>
<p style="position:absolute;top:465px;left:162px;white-space:nowrap" class="ft051">Bowen&#160;EF, Wilson&#160;P,&#160;Cope A, et al.&#160;Cytomegalovirus retinitis in&#160;AIDS patients: influence of&#160;<br/>cytomegaloviral load on&#160;response&#160;to&#160;ganciclovir,&#160;time&#160;to&#160;recurrence&#160;and&#160;survival.&#160;</p>
<p style="position:absolute;top:484px;left:701px;white-space:nowrap" class="ft049"><i>AIDS</i></p>
<p style="position:absolute;top:484px;left:736px;white-space:nowrap" class="ft047">.&#160;</p>
<p style="position:absolute;top:503px;left:162px;white-space:nowrap" class="ft047">1996;10(13):1515-1520. Available at:&#160;</p>
<p style="position:absolute;top:503px;left:417px;white-space:nowrap" class="ft050">http://www.ncbi.nlm.nih.gov/pubmed/8931786</p>
<p style="position:absolute;top:503px;left:728px;white-space:nowrap" class="ft047">.&#160;</p>
<p style="position:absolute;top:540px;left:108px;white-space:nowrap" class="ft047">42.</p>
<p style="position:absolute;top:540px;left:129px;white-space:nowrap" class="ft048">&#160;</p>
<p style="position:absolute;top:540px;left:162px;white-space:nowrap" class="ft051">Jabs DA, Ahuja A, Van&#160;Natta M, Dunn&#160;JP, Yeh&#160;S,&#160;Studies of the&#160;Ocular Complications of&#160;ARG.&#160;<br/>Comparison&#160;of treatment&#160;regimens for cytomegalovirus retinitis in&#160;patients with&#160;AIDS in&#160;the era&#160;<br/>of highly&#160;active antiretroviral therapy.&#160;</p>
<p style="position:absolute;top:578px;left:417px;white-space:nowrap" class="ft049"><i>Ophthalmology</i></p>
<p style="position:absolute;top:578px;left:520px;white-space:nowrap" class="ft047">. 2013;120(6):1262-1270.&#160;Available&#160;at:&#160;</p>
<p style="position:absolute;top:597px;left:162px;white-space:nowrap" class="ft050">http://www.ncbi.nlm.nih.gov/pubmed/23419804</p>
<p style="position:absolute;top:597px;left:482px;white-space:nowrap" class="ft047">.&#160;</p>
<p style="position:absolute;top:634px;left:108px;white-space:nowrap" class="ft047">43.</p>
<p style="position:absolute;top:634px;left:129px;white-space:nowrap" class="ft048">&#160;</p>
<p style="position:absolute;top:634px;left:162px;white-space:nowrap" class="ft051">Davis JL,&#160;Taskintuna I,&#160;Freeman&#160;WR,&#160;Weinberg&#160;DV, Feuer WJ,&#160;Leonard&#160;RE.&#160;Iritis and&#160;hypotony&#160;<br/>after treatment with&#160;intravenous cidofovir for cytomegalovirus retinitis.&#160;</p>
<p style="position:absolute;top:653px;left:638px;white-space:nowrap" class="ft049"><i>Arch&#160;Ophthalmol</i></p>
<p style="position:absolute;top:653px;left:753px;white-space:nowrap" class="ft047">.&#160;</p>
<p style="position:absolute;top:672px;left:162px;white-space:nowrap" class="ft047">1997;115(6):733-737. Available at:&#160;</p>
<p style="position:absolute;top:672px;left:400px;white-space:nowrap" class="ft050">https://www.ncbi.nlm.nih.gov/pubmed/9194724</p>
<p style="position:absolute;top:672px;left:718px;white-space:nowrap" class="ft047">.&#160;</p>
<p style="position:absolute;top:709px;left:108px;white-space:nowrap" class="ft047">44.</p>
<p style="position:absolute;top:709px;left:129px;white-space:nowrap" class="ft048">&#160;</p>
<p style="position:absolute;top:709px;left:162px;white-space:nowrap" class="ft051">Long-term follow-up&#160;of&#160;patients with&#160;AIDS treated&#160;with&#160;parenteral cidofovir for&#160;cytomegalovirus&#160;<br/>retinitis: the HPMPC&#160;Peripheral Cytomegalovirus Retinitis Trial. The Studies&#160;of&#160;Ocular&#160;<br/>Complications of&#160;AIDS Research&#160;Group&#160;in&#160;collaboration&#160;with&#160;the AIDS Clinical Trials Group.&#160;</p>
<p style="position:absolute;top:766px;left:162px;white-space:nowrap" class="ft049"><i>AIDS</i></p>
<p style="position:absolute;top:766px;left:198px;white-space:nowrap" class="ft047">. 2000;14(11):1571-1581. Available at:&#160;</p>
<p style="position:absolute;top:766px;left:461px;white-space:nowrap" class="ft050">https://www.ncbi.nlm.nih.gov/pubmed/10983644</p>
<p style="position:absolute;top:766px;left:787px;white-space:nowrap" class="ft047">.&#160;</p>
<p style="position:absolute;top:803px;left:108px;white-space:nowrap" class="ft047">45.</p>
<p style="position:absolute;top:803px;left:129px;white-space:nowrap" class="ft048">&#160;</p>
<p style="position:absolute;top:803px;left:162px;white-space:nowrap" class="ft051">Labetoulle M, Goujard&#160;C,&#160;Frau&#160;E,&#160;Offret H,&#160;Delfraissy&#160;JF,&#160;Gasnault&#160;J. Cidofovir&#160;ocular toxicity&#160;is&#160;<br/>related to&#160;previous ocular&#160;history.&#160;</p>
<p style="position:absolute;top:822px;left:388px;white-space:nowrap" class="ft049"><i>AIDS</i></p>
<p style="position:absolute;top:822px;left:424px;white-space:nowrap" class="ft047">. 2000;14(5):622-623.&#160;Available at:&#160;</p>
<p style="position:absolute;top:841px;left:162px;white-space:nowrap" class="ft050">https://www.ncbi.nlm.nih.gov/pubmed/10780729</p>
<p style="position:absolute;top:841px;left:488px;white-space:nowrap" class="ft047">.&#160;</p>
<p style="position:absolute;top:878px;left:108px;white-space:nowrap" class="ft047">46.</p>
<p style="position:absolute;top:878px;left:129px;white-space:nowrap" class="ft048">&#160;</p>
<p style="position:absolute;top:878px;left:162px;white-space:nowrap" class="ft051">Lampinen TM,&#160;Critchlow CW,&#160;Kuypers JM, et al.&#160;Association&#160;of antiretroviral therapy&#160;with&#160;<br/>detection&#160;of&#160;HIV-1 RNA&#160;and&#160;DNA in&#160;the anorectal mucosa of&#160;homosexual men.&#160;</p>
<p style="position:absolute;top:897px;left:697px;white-space:nowrap" class="ft049"><i>AIDS</i></p>
<p style="position:absolute;top:897px;left:732px;white-space:nowrap" class="ft047">.&#160;</p>
<p style="position:absolute;top:916px;left:162px;white-space:nowrap" class="ft047">2000;14(5):F69-75.&#160;Available at:&#160;</p>
<p style="position:absolute;top:916px;left:385px;white-space:nowrap" class="ft050">https://www.ncbi.nlm.nih.gov/pubmed/10780708</p>
<p style="position:absolute;top:916px;left:711px;white-space:nowrap" class="ft047">.&#160;</p>
<p style="position:absolute;top:953px;left:108px;white-space:nowrap" class="ft047">47.</p>
<p style="position:absolute;top:953px;left:129px;white-space:nowrap" class="ft048">&#160;</p>
<p style="position:absolute;top:953px;left:162px;white-space:nowrap" class="ft051">Taskintuna I, Rahhal FM, Rao&#160;NA, et al.&#160;Adverse events and&#160;autopsy&#160;findings after intravitreous&#160;<br/>cidofovir (HPMPC) therapy&#160;in&#160;patients&#160;with&#160;acquired&#160;immune deficiency&#160;syndrome&#160;(AIDS).&#160;</p>
<p style="position:absolute;top:991px;left:162px;white-space:nowrap" class="ft049"><i>Ophthalmology</i></p>
<p style="position:absolute;top:991px;left:265px;white-space:nowrap" class="ft047">. 1997;104(11):1827-1836;&#160;discussion&#160;1836-1827.&#160;Available at:&#160;</p>
<p style="position:absolute;top:1010px;left:162px;white-space:nowrap" class="ft050">http://www.ncbi.nlm.nih.gov/pubmed/9373113</p>
<p style="position:absolute;top:1010px;left:474px;white-space:nowrap" class="ft047">.&#160;</p>
</div>
<!-- Page 189 -->
<a name="189"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page189-div" style="position:relative;width:917px;height:1187px;">
<p style="position:absolute;top:1132px;left:108px;white-space:nowrap" class="ft024"><i>Guidelines for the Prevention and Treatment&#160;of&#160;Opportunistic&#160;Infections in Adults&#160;and Adolescents&#160;With HIV&#160;</i></p>
<p style="position:absolute;top:1132px;left:784px;white-space:nowrap" class="ft024"><i>K-20&#160;</i></p>
<p style="position:absolute;top:109px;left:108px;white-space:nowrap" class="ft047">48.</p>
<p style="position:absolute;top:108px;left:129px;white-space:nowrap" class="ft048">&#160;</p>
<p style="position:absolute;top:109px;left:162px;white-space:nowrap" class="ft051">Dieterich&#160;DT,&#160;Kotler DP,&#160;Busch&#160;DF,&#160;et al.&#160;Ganciclovir&#160;treatment&#160;of cytomegalovirus colitis in&#160;<br/>AIDS: a randomized, double-blind, placebo-controlled&#160;multicenter study.&#160;</p>
<p style="position:absolute;top:128px;left:650px;white-space:nowrap" class="ft049"><i>J Infect Dis</i></p>
<p style="position:absolute;top:128px;left:726px;white-space:nowrap" class="ft047">.&#160;</p>
<p style="position:absolute;top:147px;left:162px;white-space:nowrap" class="ft047">1993;167(2):278-282. Available at:&#160;</p>
<p style="position:absolute;top:147px;left:400px;white-space:nowrap" class="ft050">https://www.ncbi.nlm.nih.gov/pubmed/8380610</p>
<p style="position:absolute;top:147px;left:718px;white-space:nowrap" class="ft047">.&#160;</p>
<p style="position:absolute;top:184px;left:108px;white-space:nowrap" class="ft047">49.</p>
<p style="position:absolute;top:183px;left:129px;white-space:nowrap" class="ft048">&#160;</p>
<p style="position:absolute;top:184px;left:162px;white-space:nowrap" class="ft051">Asberg&#160;A, Humar A, Rollag&#160;H, et&#160;al. Oral valganciclovir is noninferior to&#160;intravenous ganciclovir&#160;<br/>for the treatment&#160;of cytomegalovirus disease&#160;in&#160;solid&#160;organ transplant recipients.&#160;</p>
<p style="position:absolute;top:203px;left:696px;white-space:nowrap" class="ft049"><i>Am J&#160;</i></p>
<p style="position:absolute;top:222px;left:162px;white-space:nowrap" class="ft049"><i>Transplant</i></p>
<p style="position:absolute;top:222px;left:235px;white-space:nowrap" class="ft047">.&#160;2007;7(9):2106-2113. Available at:&#160;</p>
<p style="position:absolute;top:241px;left:162px;white-space:nowrap" class="ft050">https://www.ncbi.nlm.nih.gov/pubmed/17640310</p>
<p style="position:absolute;top:241px;left:488px;white-space:nowrap" class="ft047">.&#160;</p>
<p style="position:absolute;top:278px;left:108px;white-space:nowrap" class="ft047">50.</p>
<p style="position:absolute;top:277px;left:129px;white-space:nowrap" class="ft048">&#160;</p>
<p style="position:absolute;top:278px;left:162px;white-space:nowrap" class="ft051">Anduze-Faris&#160;BM,&#160;Fillet&#160;AM,&#160;Gozlan&#160;J, et&#160;al. Induction and&#160;maintenance&#160;therapy&#160;of&#160;<br/>cytomegalovirus central nervous system infection&#160;in&#160;HIV-infected&#160;patients.&#160;</p>
<p style="position:absolute;top:296px;left:662px;white-space:nowrap" class="ft049"><i>AIDS</i></p>
<p style="position:absolute;top:296px;left:698px;white-space:nowrap" class="ft047">.&#160;</p>
<p style="position:absolute;top:315px;left:162px;white-space:nowrap" class="ft047">2000;14(5):517-524.&#160;Available at:&#160;</p>
<p style="position:absolute;top:315px;left:392px;white-space:nowrap" class="ft050">https://www.ncbi.nlm.nih.gov/pubmed/10780714</p>
<p style="position:absolute;top:315px;left:718px;white-space:nowrap" class="ft047">.&#160;</p>
<p style="position:absolute;top:352px;left:108px;white-space:nowrap" class="ft047">51.</p>
<p style="position:absolute;top:352px;left:129px;white-space:nowrap" class="ft048">&#160;</p>
<p style="position:absolute;top:352px;left:162px;white-space:nowrap" class="ft051">Nguyen&#160;QD, Kempen&#160;JH, Bolton&#160;SG,&#160;Dunn&#160;JP,&#160;Jabs&#160;DA. Immune recovery&#160;uveitis in&#160;patients&#160;<br/>with&#160;AIDS and&#160;cytomegalovirus retinitis&#160;after highly&#160;active antiretroviral therapy.&#160;</p>
<p style="position:absolute;top:371px;left:706px;white-space:nowrap" class="ft049"><i>Am J&#160;</i></p>
<p style="position:absolute;top:390px;left:162px;white-space:nowrap" class="ft049"><i>Ophthalmol</i></p>
<p style="position:absolute;top:390px;left:241px;white-space:nowrap" class="ft047">.&#160;2000;129(5):634-639. Available at:&#160;</p>
<p style="position:absolute;top:409px;left:162px;white-space:nowrap" class="ft050">http://www.ncbi.nlm.nih.gov/pubmed/10844056</p>
<p style="position:absolute;top:409px;left:482px;white-space:nowrap" class="ft047">.&#160;</p>
<p style="position:absolute;top:446px;left:108px;white-space:nowrap" class="ft047">52.</p>
<p style="position:absolute;top:446px;left:129px;white-space:nowrap" class="ft048">&#160;</p>
<p style="position:absolute;top:446px;left:162px;white-space:nowrap" class="ft051">Karavellas MP,&#160;Plummer&#160;DJ,&#160;Macdonald&#160;JC, et&#160;al. Incidence of immune recovery&#160;vitritis in&#160;<br/>cytomegalovirus retinitis patients following&#160;institution&#160;of successful highly&#160;active antiretroviral&#160;<br/>therapy.&#160;</p>
<p style="position:absolute;top:484px;left:220px;white-space:nowrap" class="ft049"><i>J Infect Dis</i></p>
<p style="position:absolute;top:484px;left:296px;white-space:nowrap" class="ft047">. 1999;179(3):697-700. Available at:&#160;</p>
<p style="position:absolute;top:503px;left:162px;white-space:nowrap" class="ft050">http://www.ncbi.nlm.nih.gov/pubmed/9952380</p>
<p style="position:absolute;top:503px;left:474px;white-space:nowrap" class="ft047">.&#160;</p>
<p style="position:absolute;top:540px;left:108px;white-space:nowrap" class="ft047">53.</p>
<p style="position:absolute;top:540px;left:129px;white-space:nowrap" class="ft048">&#160;</p>
<p style="position:absolute;top:540px;left:162px;white-space:nowrap" class="ft051">Robinson&#160;MR, Reed&#160;G, Csaky&#160;KG, Polis MA, Whitcup&#160;SM.&#160;Immune-recovery&#160;uveitis in&#160;patients&#160;<br/>with&#160;cytomegalovirus retinitis taking&#160;highly&#160;active antiretroviral therapy.&#160;</p>
<p style="position:absolute;top:559px;left:647px;white-space:nowrap" class="ft049"><i>Am J Ophthalmol</i></p>
<p style="position:absolute;top:559px;left:763px;white-space:nowrap" class="ft047">.&#160;</p>
<p style="position:absolute;top:578px;left:162px;white-space:nowrap" class="ft047">2000;130(1):49-56. Available at:&#160;</p>
<p style="position:absolute;top:578px;left:384px;white-space:nowrap" class="ft050">http://www.ncbi.nlm.nih.gov/pubmed/11004259</p>
<p style="position:absolute;top:578px;left:704px;white-space:nowrap" class="ft047">.&#160;</p>
<p style="position:absolute;top:615px;left:108px;white-space:nowrap" class="ft047">54.</p>
<p style="position:absolute;top:615px;left:129px;white-space:nowrap" class="ft048">&#160;</p>
<p style="position:absolute;top:615px;left:162px;white-space:nowrap" class="ft051">Karavellas MP,&#160;Song&#160;M,&#160;Macdonald&#160;JC, Freeman&#160;WR.&#160;Long-term posterior&#160;and&#160;anterior segment&#160;<br/>complications of immune recovery&#160;uveitis associated&#160;with&#160;cytomegalovirus retinitis.&#160;</p>
<p style="position:absolute;top:634px;left:722px;white-space:nowrap" class="ft049"><i>Am J&#160;</i></p>
<p style="position:absolute;top:653px;left:162px;white-space:nowrap" class="ft049"><i>Ophthalmol</i></p>
<p style="position:absolute;top:653px;left:241px;white-space:nowrap" class="ft047">.&#160;2000;130(1):57-64.&#160;Available at:&#160;</p>
<p style="position:absolute;top:653px;left:471px;white-space:nowrap" class="ft050">http://www.ncbi.nlm.nih.gov/pubmed/11004260</p>
<p style="position:absolute;top:653px;left:791px;white-space:nowrap" class="ft047">.&#160;</p>
<p style="position:absolute;top:690px;left:108px;white-space:nowrap" class="ft047">55.</p>
<p style="position:absolute;top:690px;left:129px;white-space:nowrap" class="ft048">&#160;</p>
<p style="position:absolute;top:690px;left:162px;white-space:nowrap" class="ft051">Kempen&#160;JH, Min&#160;YI, Freeman&#160;WR,&#160;et al.&#160;Risk&#160;of immune recovery&#160;uveitis in&#160;patients with&#160;AIDS&#160;<br/>and&#160;cytomegalovirus retinitis.&#160;</p>
<p style="position:absolute;top:709px;left:362px;white-space:nowrap" class="ft049"><i>Ophthalmology</i></p>
<p style="position:absolute;top:709px;left:465px;white-space:nowrap" class="ft047">.&#160;2006;113(4):684-694. Available at:&#160;</p>
<p style="position:absolute;top:728px;left:162px;white-space:nowrap" class="ft050">http://www.ncbi.nlm.nih.gov/pubmed/16581429</p>
<p style="position:absolute;top:728px;left:482px;white-space:nowrap" class="ft047">.&#160;</p>
<p style="position:absolute;top:765px;left:108px;white-space:nowrap" class="ft047">56.</p>
<p style="position:absolute;top:765px;left:129px;white-space:nowrap" class="ft048">&#160;</p>
<p style="position:absolute;top:765px;left:162px;white-space:nowrap" class="ft051">Jabs DA, Ahuja A, Van&#160;Natta ML,&#160;et al. Long-term outcomes of&#160;cytomegalovirus retinitis in&#160;the&#160;<br/>era of&#160;modern&#160;antiretroviral therapy: results from a United&#160;States&#160;cohort.&#160;</p>
<p style="position:absolute;top:784px;left:645px;white-space:nowrap" class="ft049"><i>Ophthalmology</i></p>
<p style="position:absolute;top:784px;left:747px;white-space:nowrap" class="ft047">.&#160;</p>
<p style="position:absolute;top:803px;left:162px;white-space:nowrap" class="ft047">2015;122(7):1452-1463. Available at:&#160;</p>
<p style="position:absolute;top:803px;left:417px;white-space:nowrap" class="ft050">http://www.ncbi.nlm.nih.gov/pubmed/25892019</p>
<p style="position:absolute;top:803px;left:737px;white-space:nowrap" class="ft047">.&#160;</p>
<p style="position:absolute;top:840px;left:108px;white-space:nowrap" class="ft047">57.</p>
<p style="position:absolute;top:840px;left:129px;white-space:nowrap" class="ft048">&#160;</p>
<p style="position:absolute;top:840px;left:162px;white-space:nowrap" class="ft051">Jabs DA, Wingard&#160;JR, de&#160;Bustros S,&#160;de Miranda P,&#160;Saral R,&#160;Santos GW. BW&#160;B759U for&#160;<br/>cytomegalovirus retinitis: intraocular drug&#160;penetration.&#160;</p>
<p style="position:absolute;top:859px;left:527px;white-space:nowrap" class="ft049"><i>Arch&#160;Ophthalmol</i></p>
<p style="position:absolute;top:859px;left:642px;white-space:nowrap" class="ft047">. 1986;104(10):1436-</p>
<p style="position:absolute;top:878px;left:162px;white-space:nowrap" class="ft047">1437. Available at:&#160;</p>
<p style="position:absolute;top:878px;left:292px;white-space:nowrap" class="ft050">http://www.ncbi.nlm.nih.gov/pubmed/3021090</p>
<p style="position:absolute;top:878px;left:604px;white-space:nowrap" class="ft047">.&#160;</p>
<p style="position:absolute;top:915px;left:108px;white-space:nowrap" class="ft047">58.</p>
<p style="position:absolute;top:915px;left:129px;white-space:nowrap" class="ft048">&#160;</p>
<p style="position:absolute;top:915px;left:162px;white-space:nowrap" class="ft051">Rodrigues Alves N, Barao&#160;C,&#160;Mota C,&#160;Costa L,&#160;Proenca RP. Immune recovery&#160;uveitis: a focus&#160;<br/>review.&#160;</p>
<p style="position:absolute;top:934px;left:215px;white-space:nowrap" class="ft049"><i>Graefes Arch Clin&#160;Exp&#160;Ophthalmol</i></p>
<p style="position:absolute;top:934px;left:449px;white-space:nowrap" class="ft047">.&#160;2024;262(8):2703-2712. Available at:&#160;</p>
<p style="position:absolute;top:953px;left:162px;white-space:nowrap" class="ft050">https://www.ncbi.nlm.nih.gov/pubmed/38381160</p>
<p style="position:absolute;top:953px;left:488px;white-space:nowrap" class="ft047">.</p>
<p style="position:absolute;top:990px;left:108px;white-space:nowrap" class="ft047">59.</p>
<p style="position:absolute;top:989px;left:129px;white-space:nowrap" class="ft048">&#160;</p>
<p style="position:absolute;top:990px;left:162px;white-space:nowrap" class="ft051">El-Bradey&#160;MH,&#160;Cheng&#160;L,&#160;Song&#160;MK, Torriani FJ, Freeman&#160;WR.&#160;Long-term results of treatment of&#160;<br/>macular&#160;complications in&#160;eyes with&#160;immune recovery&#160;uveitis using&#160;a graded&#160;treatment&#160;approach.&#160;</p>
<p style="position:absolute;top:1028px;left:162px;white-space:nowrap" class="ft049"><i>Retina</i></p>
<p style="position:absolute;top:1028px;left:205px;white-space:nowrap" class="ft047">.&#160;2004;24(3):376-382. Available at:&#160;</p>
<p style="position:absolute;top:1028px;left:443px;white-space:nowrap" class="ft050">https://www.ncbi.nlm.nih.gov/pubmed/15187659</p>
<p style="position:absolute;top:1028px;left:770px;white-space:nowrap" class="ft047">.&#160;</p>
</div>
<!-- Page 190 -->
<a name="190"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page190-div" style="position:relative;width:917px;height:1187px;">
<p style="position:absolute;top:1132px;left:108px;white-space:nowrap" class="ft024"><i>Guidelines for the Prevention and Treatment&#160;of&#160;Opportunistic&#160;Infections in Adults&#160;and Adolescents&#160;With HIV&#160;</i></p>
<p style="position:absolute;top:1132px;left:784px;white-space:nowrap" class="ft024"><i>K-21&#160;</i></p>
<p style="position:absolute;top:109px;left:108px;white-space:nowrap" class="ft047">60.</p>
<p style="position:absolute;top:108px;left:129px;white-space:nowrap" class="ft048">&#160;</p>
<p style="position:absolute;top:109px;left:162px;white-space:nowrap" class="ft047">Kuppermann&#160;BD, Holland&#160;GN. Immune recovery&#160;uveitis.&#160;</p>
<p style="position:absolute;top:109px;left:546px;white-space:nowrap" class="ft049"><i>Am J Ophthalmol</i></p>
<p style="position:absolute;top:109px;left:662px;white-space:nowrap" class="ft047">. 2000;130(1):103-</p>
<p style="position:absolute;top:128px;left:162px;white-space:nowrap" class="ft047">106.&#160;Available at:&#160;</p>
<p style="position:absolute;top:128px;left:284px;white-space:nowrap" class="ft050">https://www.ncbi.nlm.nih.gov/pubmed/11004267</p>
<p style="position:absolute;top:128px;left:610px;white-space:nowrap" class="ft047">.&#160;</p>
<p style="position:absolute;top:165px;left:108px;white-space:nowrap" class="ft047">61.</p>
<p style="position:absolute;top:164px;left:129px;white-space:nowrap" class="ft048">&#160;</p>
<p style="position:absolute;top:165px;left:162px;white-space:nowrap" class="ft047">Holland&#160;GN. Immune recovery&#160;uveitis.&#160;</p>
<p style="position:absolute;top:165px;left:424px;white-space:nowrap" class="ft049"><i>Ocul Immunol Inflamm</i></p>
<p style="position:absolute;top:165px;left:578px;white-space:nowrap" class="ft047">. 1999;7(3-4):215-221. Available&#160;</p>
<p style="position:absolute;top:184px;left:162px;white-space:nowrap" class="ft047">at:&#160;</p>
<p style="position:absolute;top:184px;left:183px;white-space:nowrap" class="ft050">https://www.ncbi.nlm.nih.gov/pubmed/10611730</p>
<p style="position:absolute;top:184px;left:509px;white-space:nowrap" class="ft047">.</p>
<p style="position:absolute;top:221px;left:108px;white-space:nowrap" class="ft047">62.</p>
<p style="position:absolute;top:220px;left:129px;white-space:nowrap" class="ft048">&#160;</p>
<p style="position:absolute;top:221px;left:162px;white-space:nowrap" class="ft051">Jabs DA, Rosenbaum JT,&#160;Foster CS,&#160;et al.&#160;Guidelines for&#160;the use of immunosuppressive drugs in&#160;<br/>patients with&#160;ocular inflammatory&#160;disorders: recommendations of an&#160;expert panel.&#160;</p>
<p style="position:absolute;top:240px;left:707px;white-space:nowrap" class="ft049"><i>Am J&#160;</i></p>
<p style="position:absolute;top:259px;left:162px;white-space:nowrap" class="ft049"><i>Ophthalmol</i></p>
<p style="position:absolute;top:259px;left:241px;white-space:nowrap" class="ft047">.&#160;2000;130(4):492-513. Available at:&#160;</p>
<p style="position:absolute;top:278px;left:162px;white-space:nowrap" class="ft050">https://www.ncbi.nlm.nih.gov/pubmed/11024423</p>
<p style="position:absolute;top:278px;left:488px;white-space:nowrap" class="ft047">.&#160;</p>
<p style="position:absolute;top:314px;left:108px;white-space:nowrap" class="ft047">63.</p>
<p style="position:absolute;top:314px;left:129px;white-space:nowrap" class="ft048">&#160;</p>
<p style="position:absolute;top:314px;left:162px;white-space:nowrap" class="ft051">Ortega-Larrocea G, Espinosa E,&#160;Reyes-Teran G.&#160;Lower incidence and&#160;severity&#160;of&#160;<br/>cytomegalovirus-associated&#160;immune recovery&#160;uveitis&#160;in&#160;HIV-infected patients with&#160;delayed&#160;<br/>highly active antiretroviral&#160;therapy.&#160;</p>
<p style="position:absolute;top:352px;left:400px;white-space:nowrap" class="ft049"><i>AIDS</i></p>
<p style="position:absolute;top:352px;left:435px;white-space:nowrap" class="ft047">.&#160;2005;19(7):735-738.&#160;Available at:&#160;</p>
<p style="position:absolute;top:371px;left:162px;white-space:nowrap" class="ft050">http://www.ncbi.nlm.nih.gov/pubmed/15821403</p>
<p style="position:absolute;top:371px;left:482px;white-space:nowrap" class="ft047">.&#160;</p>
<p style="position:absolute;top:408px;left:108px;white-space:nowrap" class="ft047">64.</p>
<p style="position:absolute;top:408px;left:129px;white-space:nowrap" class="ft048">&#160;</p>
<p style="position:absolute;top:408px;left:162px;white-space:nowrap" class="ft051">Jabs DA, Martin&#160;BK, Forman&#160;MS, Ricks MO. Cytomegalovirus (CMV) blood&#160;DNA load,&#160;CMV&#160;<br/>retinitis progression, and&#160;occurrence of resistant CMV&#160;in&#160;patients with&#160;CMV retinitis.&#160;</p>
<p style="position:absolute;top:427px;left:731px;white-space:nowrap" class="ft049"><i>The&#160;</i></p>
<p style="position:absolute;top:446px;left:162px;white-space:nowrap" class="ft049"><i>Journal of Infectious Diseases</i></p>
<p style="position:absolute;top:446px;left:362px;white-space:nowrap" class="ft047">.&#160;2005;192(4):640-649.&#160;Available&#160;at:&#160;</p>
<p style="position:absolute;top:465px;left:162px;white-space:nowrap" class="ft050">https://doi.org/10.1086/432012</p>
<p style="position:absolute;top:465px;left:367px;white-space:nowrap" class="ft047">.&#160;</p>
<p style="position:absolute;top:502px;left:108px;white-space:nowrap" class="ft047">65.</p>
<p style="position:absolute;top:502px;left:129px;white-space:nowrap" class="ft048">&#160;</p>
<p style="position:absolute;top:502px;left:162px;white-space:nowrap" class="ft051">Ruiz-Cruz M, Alvarado-de la Barrera C, Ablanedo-Terrazas Y, Reyes-Teran&#160;G. Proposed clinical&#160;<br/>case definition&#160;for cytomegalovirus-immune recovery&#160;retinitis.&#160;</p>
<p style="position:absolute;top:521px;left:580px;white-space:nowrap" class="ft049"><i>Clin&#160;Infect Dis</i></p>
<p style="position:absolute;top:521px;left:677px;white-space:nowrap" class="ft047">. 2014;59(2):298-</p>
<p style="position:absolute;top:540px;left:162px;white-space:nowrap" class="ft047">303.&#160;Available at:&#160;</p>
<p style="position:absolute;top:540px;left:284px;white-space:nowrap" class="ft050">http://www.ncbi.nlm.nih.gov/pubmed/24771331</p>
<p style="position:absolute;top:540px;left:604px;white-space:nowrap" class="ft047">.&#160;</p>
<p style="position:absolute;top:577px;left:108px;white-space:nowrap" class="ft047">66.</p>
<p style="position:absolute;top:577px;left:129px;white-space:nowrap" class="ft048">&#160;</p>
<p style="position:absolute;top:577px;left:162px;white-space:nowrap" class="ft051">Jabs DA, Van&#160;Natta ML, Holland&#160;GN, Danis R, Studies of&#160;the Ocular Complications of ARG.&#160;<br/>Cytomegalovirus retinitis in&#160;patients with&#160;acquired&#160;immunodeficiency&#160;syndrome&#160;after initiating&#160;<br/>antiretroviral therapy.&#160;</p>
<p style="position:absolute;top:615px;left:310px;white-space:nowrap" class="ft049"><i>Am J Ophthalmol</i></p>
<p style="position:absolute;top:615px;left:426px;white-space:nowrap" class="ft047">.&#160;2017;174:23-32. Available at:&#160;</p>
<p style="position:absolute;top:634px;left:162px;white-space:nowrap" class="ft050">https://www.ncbi.nlm.nih.gov/pubmed/27984023</p>
<p style="position:absolute;top:634px;left:488px;white-space:nowrap" class="ft047">.&#160;</p>
<p style="position:absolute;top:671px;left:108px;white-space:nowrap" class="ft047">67.</p>
<p style="position:absolute;top:671px;left:129px;white-space:nowrap" class="ft048">&#160;</p>
<p style="position:absolute;top:671px;left:162px;white-space:nowrap" class="ft051">Dubreuil-Lemaire ML,&#160;Gori A,&#160;Vittecoq&#160;D, et&#160;al. Lenograstim for&#160;the treatment&#160;of neutropenia in&#160;<br/>patients receiving&#160;ganciclovir for cytomegalovirus infection: a randomised,&#160;placebo-controlled&#160;<br/>trial in&#160;AIDS patients.&#160;</p>
<p style="position:absolute;top:709px;left:312px;white-space:nowrap" class="ft049"><i>Eur J Haematol</i></p>
<p style="position:absolute;top:709px;left:417px;white-space:nowrap" class="ft047">.&#160;2000;65(5):337-343. Available at:&#160;</p>
<p style="position:absolute;top:728px;left:162px;white-space:nowrap" class="ft050">http://www.ncbi.nlm.nih.gov/pubmed/11092465</p>
<p style="position:absolute;top:728px;left:482px;white-space:nowrap" class="ft047">.&#160;</p>
<p style="position:absolute;top:765px;left:108px;white-space:nowrap" class="ft047">68.</p>
<p style="position:absolute;top:765px;left:129px;white-space:nowrap" class="ft048">&#160;</p>
<p style="position:absolute;top:765px;left:162px;white-space:nowrap" class="ft051">Kuritzkes DR, Parenti D,&#160;Ward&#160;DJ, et al.&#160;Filgrastim prevents severe neutropenia and&#160;reduces&#160;<br/>infective morbidity&#160;in&#160;patients with&#160;advanced&#160;HIV&#160;infection: results of a randomized,&#160;multicenter,&#160;<br/>controlled&#160;trial. G-CSF&#160;930101 Study&#160;Group.&#160;</p>
<p style="position:absolute;top:803px;left:465px;white-space:nowrap" class="ft049"><i>AIDS</i></p>
<p style="position:absolute;top:803px;left:501px;white-space:nowrap" class="ft047">.&#160;1998;12(1):65-74. Available at:&#160;</p>
<p style="position:absolute;top:822px;left:162px;white-space:nowrap" class="ft050">http://www.ncbi.nlm.nih.gov/pubmed/9456256</p>
<p style="position:absolute;top:822px;left:474px;white-space:nowrap" class="ft047">.&#160;</p>
<p style="position:absolute;top:859px;left:108px;white-space:nowrap" class="ft047">69.</p>
<p style="position:absolute;top:859px;left:129px;white-space:nowrap" class="ft048">&#160;</p>
<p style="position:absolute;top:859px;left:162px;white-space:nowrap" class="ft051">Kuppermann&#160;BD, Quiceno&#160;JI, Flores-Aguilar&#160;M,&#160;et al.&#160;Intravitreal ganciclovir concentration&#160;after&#160;<br/>intravenous administration&#160;in&#160;AIDS patients with&#160;cytomegalovirus retinitis: implications for&#160;<br/>therapy.&#160;</p>
<p style="position:absolute;top:897px;left:220px;white-space:nowrap" class="ft049"><i>J Infect Dis</i></p>
<p style="position:absolute;top:897px;left:296px;white-space:nowrap" class="ft047">. 1993;168(6):1506-1509. Available at:&#160;</p>
<p style="position:absolute;top:916px;left:162px;white-space:nowrap" class="ft050">http://www.ncbi.nlm.nih.gov/pubmed/8245536</p>
<p style="position:absolute;top:916px;left:474px;white-space:nowrap" class="ft047">.&#160;</p>
<p style="position:absolute;top:953px;left:108px;white-space:nowrap" class="ft047">70.</p>
<p style="position:absolute;top:953px;left:129px;white-space:nowrap" class="ft048">&#160;</p>
<p style="position:absolute;top:953px;left:162px;white-space:nowrap" class="ft051">Arevalo&#160;JF,&#160;Gonzalez&#160;C,&#160;Capparelli EV, et al.&#160;Intravitreous and&#160;plasma concentrations of&#160;<br/>ganciclovir and&#160;foscarnet after intravenous therapy&#160;in&#160;patients with&#160;AIDS and&#160;cytomegalovirus&#160;<br/>retinitis.&#160;</p>
<p style="position:absolute;top:991px;left:221px;white-space:nowrap" class="ft049"><i>J Infect Dis</i></p>
<p style="position:absolute;top:991px;left:296px;white-space:nowrap" class="ft047">. 1995;172(4):951-956.&#160;Available at:&#160;</p>
<p style="position:absolute;top:1010px;left:162px;white-space:nowrap" class="ft050">http://www.ncbi.nlm.nih.gov/pubmed/7561215</p>
<p style="position:absolute;top:1010px;left:474px;white-space:nowrap" class="ft047">.&#160;</p>
</div>
<!-- Page 191 -->
<a name="191"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page191-div" style="position:relative;width:917px;height:1187px;">
<p style="position:absolute;top:1132px;left:108px;white-space:nowrap" class="ft024"><i>Guidelines for the Prevention and Treatment&#160;of&#160;Opportunistic&#160;Infections in Adults&#160;and Adolescents&#160;With HIV&#160;</i></p>
<p style="position:absolute;top:1132px;left:784px;white-space:nowrap" class="ft024"><i>K-22&#160;</i></p>
<p style="position:absolute;top:109px;left:108px;white-space:nowrap" class="ft047">71.</p>
<p style="position:absolute;top:108px;left:129px;white-space:nowrap" class="ft048">&#160;</p>
<p style="position:absolute;top:109px;left:162px;white-space:nowrap" class="ft051">Combination&#160;foscarnet and&#160;ganciclovir&#160;therapy&#160;vs monotherapy&#160;for&#160;the treatment&#160;of relapsed&#160;<br/>cytomegalovirus retinitis in patients with&#160;AIDS. The Cytomegalovirus Retreatment Trial.&#160;The&#160;<br/>Studies of Ocular Complications of AIDS Research&#160;Group&#160;in&#160;Collaboration&#160;with the AIDS&#160;<br/>Clinical Trials Group.&#160;</p>
<p style="position:absolute;top:166px;left:311px;white-space:nowrap" class="ft049"><i>Arch Ophthalmol</i></p>
<p style="position:absolute;top:166px;left:426px;white-space:nowrap" class="ft047">. 1996;114(1):23-33. Available at:&#160;</p>
<p style="position:absolute;top:185px;left:162px;white-space:nowrap" class="ft050">http://www.ncbi.nlm.nih.gov/pubmed/8540847</p>
<p style="position:absolute;top:185px;left:474px;white-space:nowrap" class="ft047">.&#160;</p>
<p style="position:absolute;top:222px;left:108px;white-space:nowrap" class="ft047">72.</p>
<p style="position:absolute;top:221px;left:129px;white-space:nowrap" class="ft048">&#160;</p>
<p style="position:absolute;top:222px;left:162px;white-space:nowrap" class="ft051">Jabs DA, Enger&#160;C, Dunn&#160;JP,&#160;Forman M.&#160;Cytomegalovirus retinitis&#160;and&#160;viral resistance:&#160;<br/>ganciclovir resistance. CMV Retinitis and&#160;Viral Resistance Study&#160;Group.&#160;</p>
<p style="position:absolute;top:241px;left:649px;white-space:nowrap" class="ft049"><i>J Infect&#160;Dis</i></p>
<p style="position:absolute;top:241px;left:725px;white-space:nowrap" class="ft047">.&#160;</p>
<p style="position:absolute;top:260px;left:162px;white-space:nowrap" class="ft047">1998;177(3):770-773. Available at:&#160;</p>
<p style="position:absolute;top:260px;left:400px;white-space:nowrap" class="ft050">http://www.ncbi.nlm.nih.gov/pubmed/9498461</p>
<p style="position:absolute;top:260px;left:712px;white-space:nowrap" class="ft047">.&#160;</p>
<p style="position:absolute;top:296px;left:108px;white-space:nowrap" class="ft047">73.</p>
<p style="position:absolute;top:296px;left:129px;white-space:nowrap" class="ft048">&#160;</p>
<p style="position:absolute;top:296px;left:162px;white-space:nowrap" class="ft051">Jabs DA, Enger&#160;C, Forman M, Dunn&#160;JP. Incidence of foscarnet resistance and&#160;cidofovir resistance&#160;<br/>in&#160;patients treated&#160;for cytomegalovirus retinitis. The Cytomegalovirus Retinitis and&#160;Viral&#160;<br/>Resistance Study&#160;Group.&#160;</p>
<p style="position:absolute;top:334px;left:330px;white-space:nowrap" class="ft049"><i>Antimicrob&#160;Agents Chemother</i></p>
<p style="position:absolute;top:334px;left:530px;white-space:nowrap" class="ft047">. 1998;42(9):2240-2244.&#160;Available at:&#160;</p>
<p style="position:absolute;top:353px;left:162px;white-space:nowrap" class="ft050">http://www.ncbi.nlm.nih.gov/pubmed/9736542</p>
<p style="position:absolute;top:353px;left:474px;white-space:nowrap" class="ft047">.&#160;</p>
<p style="position:absolute;top:390px;left:108px;white-space:nowrap" class="ft047">74.</p>
<p style="position:absolute;top:390px;left:129px;white-space:nowrap" class="ft048">&#160;</p>
<p style="position:absolute;top:390px;left:162px;white-space:nowrap" class="ft051">Jabs DA, Martin&#160;BK, Forman&#160;MS, et&#160;al. Mutations conferring&#160;ganciclovir resistance in&#160;a cohort&#160;<br/>of patients with&#160;acquired&#160;immunodeficiency&#160;syndrome&#160;and&#160;cytomegalovirus retinitis.&#160;</p>
<p style="position:absolute;top:409px;left:727px;white-space:nowrap" class="ft049"><i>J Infect Dis</i></p>
<p style="position:absolute;top:409px;left:803px;white-space:nowrap" class="ft047">.&#160;</p>
<p style="position:absolute;top:428px;left:162px;white-space:nowrap" class="ft047">2001;183(2):333-337. Available at:&#160;</p>
<p style="position:absolute;top:428px;left:400px;white-space:nowrap" class="ft050">http://www.ncbi.nlm.nih.gov/pubmed/11120934</p>
<p style="position:absolute;top:428px;left:720px;white-space:nowrap" class="ft047">.&#160;</p>
<p style="position:absolute;top:465px;left:108px;white-space:nowrap" class="ft047">75.</p>
<p style="position:absolute;top:465px;left:129px;white-space:nowrap" class="ft048">&#160;</p>
<p style="position:absolute;top:465px;left:162px;white-space:nowrap" class="ft051">Emery&#160;VC, Griffiths PD.&#160;Prediction&#160;of cytomegalovirus load&#160;and&#160;resistance patterns after&#160;<br/>antiviral chemotherapy.&#160;</p>
<p style="position:absolute;top:484px;left:323px;white-space:nowrap" class="ft049"><i>Proc Natl&#160;Acad&#160;Sci U S&#160;A</i></p>
<p style="position:absolute;top:484px;left:492px;white-space:nowrap" class="ft047">.&#160;2000;97(14):8039-8044.&#160;Available at:&#160;</p>
<p style="position:absolute;top:503px;left:162px;white-space:nowrap" class="ft050">http://www.ncbi.nlm.nih.gov/pubmed/10859361</p>
<p style="position:absolute;top:503px;left:482px;white-space:nowrap" class="ft047">.&#160;</p>
<p style="position:absolute;top:540px;left:108px;white-space:nowrap" class="ft047">76.</p>
<p style="position:absolute;top:540px;left:129px;white-space:nowrap" class="ft048">&#160;</p>
<p style="position:absolute;top:540px;left:162px;white-space:nowrap" class="ft051">Jabs DA, Enger C,&#160;Dunn&#160;JP,&#160;Forman M, Hubbard&#160;L. Cytomegalovirus retinitis and&#160;viral&#160;<br/>resistance: 3. Culture results. CMV Retinitis and&#160;Viral Resistance&#160;Study&#160;Group.&#160;</p>
<p style="position:absolute;top:559px;left:692px;white-space:nowrap" class="ft049"><i>Am J&#160;</i></p>
<p style="position:absolute;top:578px;left:162px;white-space:nowrap" class="ft049"><i>Ophthalmol</i></p>
<p style="position:absolute;top:578px;left:241px;white-space:nowrap" class="ft047">.&#160;1998;126(4):543-549. Available at:&#160;</p>
<p style="position:absolute;top:578px;left:487px;white-space:nowrap" class="ft050">http://www.ncbi.nlm.nih.gov/pubmed/9780099</p>
<p style="position:absolute;top:578px;left:799px;white-space:nowrap" class="ft047">.&#160;</p>
<p style="position:absolute;top:615px;left:108px;white-space:nowrap" class="ft047">77.</p>
<p style="position:absolute;top:615px;left:129px;white-space:nowrap" class="ft048">&#160;</p>
<p style="position:absolute;top:615px;left:162px;white-space:nowrap" class="ft051">Weinberg&#160;A, Jabs DA, Chou&#160;S,&#160;et al.&#160;Mutations conferring&#160;foscarnet resistance in&#160;a cohort of&#160;<br/>patients with&#160;acquired&#160;immunodeficiency&#160;syndrome&#160;and&#160;cytomegalovirus retinitis.&#160;</p>
<p style="position:absolute;top:634px;left:709px;white-space:nowrap" class="ft049"><i>J Infect Dis</i></p>
<p style="position:absolute;top:634px;left:785px;white-space:nowrap" class="ft047">.&#160;</p>
<p style="position:absolute;top:653px;left:162px;white-space:nowrap" class="ft047">2003;187(5):777-784. Available at:&#160;</p>
<p style="position:absolute;top:653px;left:400px;white-space:nowrap" class="ft050">http://www.ncbi.nlm.nih.gov/pubmed/12599051</p>
<p style="position:absolute;top:653px;left:720px;white-space:nowrap" class="ft047">.&#160;</p>
<p style="position:absolute;top:690px;left:108px;white-space:nowrap" class="ft047">78.</p>
<p style="position:absolute;top:690px;left:129px;white-space:nowrap" class="ft048">&#160;</p>
<p style="position:absolute;top:690px;left:162px;white-space:nowrap" class="ft051">Martin&#160;BK, Ricks MO,&#160;Forman&#160;MS, Jabs DA,&#160;Cytomegalovirus Ra, Group&#160;VRS.&#160;Change over&#160;<br/>time in&#160;incidence of ganciclovir resistance in&#160;patients with&#160;cytomegalovirus retinitis.&#160;</p>
<p style="position:absolute;top:709px;left:723px;white-space:nowrap" class="ft049"><i>Clin&#160;Infect&#160;</i></p>
<p style="position:absolute;top:728px;left:162px;white-space:nowrap" class="ft049"><i>Dis</i></p>
<p style="position:absolute;top:728px;left:185px;white-space:nowrap" class="ft047">. 2007;44(7):1001-1008. Available at:&#160;</p>
<p style="position:absolute;top:728px;left:440px;white-space:nowrap" class="ft050">http://www.ncbi.nlm.nih.gov/pubmed/17342657</p>
<p style="position:absolute;top:728px;left:760px;white-space:nowrap" class="ft047">.&#160;</p>
<p style="position:absolute;top:765px;left:108px;white-space:nowrap" class="ft047">79.</p>
<p style="position:absolute;top:765px;left:129px;white-space:nowrap" class="ft048">&#160;</p>
<p style="position:absolute;top:765px;left:162px;white-space:nowrap" class="ft051">Chou&#160;S,&#160;Erice&#160;A, Jordan&#160;MC, et&#160;al. Analysis of&#160;the UL97&#160;phosphotransferase&#160;coding&#160;sequence in&#160;<br/>clinical cytomegalovirus isolates and&#160;identification&#160;of mutations conferring&#160;ganciclovir resistance.&#160;</p>
<p style="position:absolute;top:803px;left:162px;white-space:nowrap" class="ft049"><i>J Infect Dis</i></p>
<p style="position:absolute;top:803px;left:238px;white-space:nowrap" class="ft047">.&#160;1995;171(3):576-583. Available at:&#160;</p>
<p style="position:absolute;top:803px;left:485px;white-space:nowrap" class="ft050">http://www.ncbi.nlm.nih.gov/pubmed/7876604</p>
<p style="position:absolute;top:803px;left:796px;white-space:nowrap" class="ft047">.&#160;</p>
<p style="position:absolute;top:840px;left:108px;white-space:nowrap" class="ft047">80.</p>
<p style="position:absolute;top:840px;left:129px;white-space:nowrap" class="ft048">&#160;</p>
<p style="position:absolute;top:840px;left:162px;white-space:nowrap" class="ft051">Chou&#160;S,&#160;Guentzel S,&#160;Michels KR,&#160;Miner RC,&#160;Drew&#160;WL. Frequency of UL97&#160;phosphotransferase&#160;<br/>mutations related&#160;to&#160;ganciclovir resistance in&#160;clinical cytomegalovirus isolates.&#160;</p>
<p style="position:absolute;top:859px;left:686px;white-space:nowrap" class="ft049"><i>J&#160;Infect Dis</i></p>
<p style="position:absolute;top:859px;left:761px;white-space:nowrap" class="ft047">.&#160;</p>
<p style="position:absolute;top:878px;left:162px;white-space:nowrap" class="ft047">1995;172(1):239-242. Available at:&#160;</p>
<p style="position:absolute;top:878px;left:400px;white-space:nowrap" class="ft050">http://www.ncbi.nlm.nih.gov/pubmed/7797920</p>
<p style="position:absolute;top:878px;left:712px;white-space:nowrap" class="ft047">.&#160;</p>
<p style="position:absolute;top:915px;left:108px;white-space:nowrap" class="ft047">81.</p>
<p style="position:absolute;top:915px;left:129px;white-space:nowrap" class="ft048">&#160;</p>
<p style="position:absolute;top:915px;left:162px;white-space:nowrap" class="ft051">Smith&#160;IL, Cherrington&#160;JM,&#160;Jiles RE,&#160;Fuller MD, Freeman&#160;WR,&#160;Spector&#160;SA. High-level&#160;resistance&#160;<br/>of cytomegalovirus to&#160;ganciclovir&#160;is associated with&#160;alterations in&#160;both&#160;the UL97&#160;and&#160;DNA&#160;<br/>polymerase genes.&#160;</p>
<p style="position:absolute;top:953px;left:288px;white-space:nowrap" class="ft049"><i>J Infect&#160;Dis</i></p>
<p style="position:absolute;top:953px;left:364px;white-space:nowrap" class="ft047">. 1997;176(1):69-77. Available at:&#160;</p>
<p style="position:absolute;top:972px;left:162px;white-space:nowrap" class="ft050">http://www.ncbi.nlm.nih.gov/pubmed/9207351</p>
<p style="position:absolute;top:972px;left:474px;white-space:nowrap" class="ft047">.&#160;</p>
<p style="position:absolute;top:1009px;left:108px;white-space:nowrap" class="ft047">82.</p>
<p style="position:absolute;top:1008px;left:129px;white-space:nowrap" class="ft048">&#160;</p>
<p style="position:absolute;top:1009px;left:162px;white-space:nowrap" class="ft051">Chou&#160;S,&#160;Lurain&#160;NS,&#160;Thompson&#160;KD, Miner RC, Drew&#160;WL.&#160;Viral DNA polymerase mutations&#160;<br/>associated&#160;with&#160;drug resistance in&#160;human&#160;cytomegalovirus.&#160;</p>
<p style="position:absolute;top:1028px;left:555px;white-space:nowrap" class="ft049"><i>J Infect Dis</i></p>
<p style="position:absolute;top:1028px;left:631px;white-space:nowrap" class="ft047">. 2003;188(1):32-39.&#160;</p>
<p style="position:absolute;top:1047px;left:162px;white-space:nowrap" class="ft047">Available at:&#160;</p>
<p style="position:absolute;top:1047px;left:251px;white-space:nowrap" class="ft050">http://www.ncbi.nlm.nih.gov/pubmed/12825168</p>
<p style="position:absolute;top:1047px;left:571px;white-space:nowrap" class="ft047">.&#160;</p>
</div>
<!-- Page 192 -->
<a name="192"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page192-div" style="position:relative;width:917px;height:1187px;">
<p style="position:absolute;top:1132px;left:108px;white-space:nowrap" class="ft024"><i>Guidelines for the Prevention and Treatment&#160;of&#160;Opportunistic&#160;Infections in Adults&#160;and Adolescents&#160;With HIV&#160;</i></p>
<p style="position:absolute;top:1132px;left:784px;white-space:nowrap" class="ft024"><i>K-23&#160;</i></p>
<p style="position:absolute;top:109px;left:108px;white-space:nowrap" class="ft047">83.</p>
<p style="position:absolute;top:108px;left:129px;white-space:nowrap" class="ft048">&#160;</p>
<p style="position:absolute;top:109px;left:162px;white-space:nowrap" class="ft051">Chou&#160;S,&#160;Van Wechel LC,&#160;Lichy&#160;HM,&#160;Marousek&#160;GI.&#160;Phenotyping&#160;of cytomegalovirus drug&#160;<br/>resistance mutations by&#160;using&#160;recombinant&#160;viruses incorporating&#160;a reporter gene.&#160;</p>
<p style="position:absolute;top:128px;left:698px;white-space:nowrap" class="ft049"><i>Antimicrob&#160;</i></p>
<p style="position:absolute;top:147px;left:162px;white-space:nowrap" class="ft049"><i>Agents Chemother</i></p>
<p style="position:absolute;top:147px;left:284px;white-space:nowrap" class="ft047">. 2005;49(7):2710-2715. Available at:&#160;</p>
<p style="position:absolute;top:166px;left:162px;white-space:nowrap" class="ft050">http://www.ncbi.nlm.nih.gov/pubmed/15980340</p>
<p style="position:absolute;top:166px;left:482px;white-space:nowrap" class="ft047">.&#160;</p>
<p style="position:absolute;top:203px;left:108px;white-space:nowrap" class="ft047">84.</p>
<p style="position:absolute;top:202px;left:129px;white-space:nowrap" class="ft048">&#160;</p>
<p style="position:absolute;top:203px;left:162px;white-space:nowrap" class="ft051">Wolf&#160;DG, Smith&#160;IL, Lee&#160;DJ, Freeman&#160;WR,&#160;Flores-Aguilar&#160;M,&#160;Spector SA.&#160;Mutations in&#160;human&#160;<br/>cytomegalovirus UL97&#160;gene confer clinical resistance&#160;to&#160;ganciclovir and&#160;can be detected directly&#160;<br/>in&#160;patient&#160;plasma.&#160;</p>
<p style="position:absolute;top:241px;left:283px;white-space:nowrap" class="ft049"><i>J Clin&#160;Invest</i></p>
<p style="position:absolute;top:241px;left:366px;white-space:nowrap" class="ft047">.&#160;1995;95(1):257-263.&#160;Available at:&#160;</p>
<p style="position:absolute;top:260px;left:162px;white-space:nowrap" class="ft050">http://www.ncbi.nlm.nih.gov/pubmed/7814623</p>
<p style="position:absolute;top:260px;left:474px;white-space:nowrap" class="ft047">.&#160;</p>
<p style="position:absolute;top:296px;left:108px;white-space:nowrap" class="ft047">85.</p>
<p style="position:absolute;top:296px;left:129px;white-space:nowrap" class="ft048">&#160;</p>
<p style="position:absolute;top:296px;left:162px;white-space:nowrap" class="ft051">Vitravene Study&#160;G. Randomized dose-comparison&#160;studies of intravitreous fomivirsen for&#160;<br/>treatment&#160;of cytomegalovirus retinitis that has reactivated&#160;or&#160;is persistently&#160;active despite other&#160;<br/>therapies in&#160;patients with&#160;AIDS.&#160;</p>
<p style="position:absolute;top:334px;left:378px;white-space:nowrap" class="ft049"><i>Am J&#160;Ophthalmol</i></p>
<p style="position:absolute;top:334px;left:495px;white-space:nowrap" class="ft047">.&#160;2002;133(4):475-483.&#160;Available at:&#160;</p>
<p style="position:absolute;top:353px;left:162px;white-space:nowrap" class="ft050">http://www.ncbi.nlm.nih.gov/pubmed/11931781</p>
<p style="position:absolute;top:353px;left:482px;white-space:nowrap" class="ft047">.&#160;</p>
<p style="position:absolute;top:390px;left:108px;white-space:nowrap" class="ft047">86.</p>
<p style="position:absolute;top:390px;left:129px;white-space:nowrap" class="ft048">&#160;</p>
<p style="position:absolute;top:390px;left:162px;white-space:nowrap" class="ft051">Jabs DA, Martin&#160;BK, Ricks MO,&#160;Forman&#160;MS,&#160;Cytomegalovirus Ra,&#160;Group&#160;VRS.&#160;Detection&#160;of&#160;<br/>ganciclovir resistance in&#160;patients with&#160;AIDS and&#160;cytomegalovirus retinitis:&#160;correlation&#160;of&#160;<br/>genotypic methods with&#160;viral phenotype and&#160;clinical outcome.&#160;</p>
<p style="position:absolute;top:428px;left:577px;white-space:nowrap" class="ft049"><i>J Infect Dis</i></p>
<p style="position:absolute;top:428px;left:653px;white-space:nowrap" class="ft047">. 2006;193(12):1728-</p>
<p style="position:absolute;top:447px;left:162px;white-space:nowrap" class="ft047">1737. Available at:&#160;</p>
<p style="position:absolute;top:447px;left:292px;white-space:nowrap" class="ft050">http://www.ncbi.nlm.nih.gov/pubmed/16703517</p>
<p style="position:absolute;top:447px;left:612px;white-space:nowrap" class="ft047">.&#160;</p>
<p style="position:absolute;top:484px;left:108px;white-space:nowrap" class="ft047">87.</p>
<p style="position:absolute;top:484px;left:129px;white-space:nowrap" class="ft048">&#160;</p>
<p style="position:absolute;top:484px;left:162px;white-space:nowrap" class="ft051">Jabs DA, Martin&#160;BK, Forman&#160;MS, et&#160;al. Cytomegalovirus resistance to&#160;ganciclovir and&#160;clinical&#160;<br/>outcomes&#160;of patients with&#160;cytomegalovirus retinitis.&#160;</p>
<p style="position:absolute;top:503px;left:509px;white-space:nowrap" class="ft049"><i>Am&#160;J Ophthalmol</i></p>
<p style="position:absolute;top:503px;left:625px;white-space:nowrap" class="ft047">.&#160;2003;135(1):26-34.&#160;</p>
<p style="position:absolute;top:522px;left:162px;white-space:nowrap" class="ft047">Available at:&#160;</p>
<p style="position:absolute;top:522px;left:251px;white-space:nowrap" class="ft050">http://www.ncbi.nlm.nih.gov/pubmed/12504693</p>
<p style="position:absolute;top:522px;left:571px;white-space:nowrap" class="ft047">.&#160;</p>
<p style="position:absolute;top:559px;left:108px;white-space:nowrap" class="ft047">88.</p>
<p style="position:absolute;top:559px;left:129px;white-space:nowrap" class="ft048">&#160;</p>
<p style="position:absolute;top:559px;left:162px;white-space:nowrap" class="ft051">Jabs DA, Martin&#160;BK, Forman&#160;MS, Cytomegalovirus Ra, Group&#160;VRR. Mortality&#160;associated&#160;with&#160;<br/>resistant&#160;cytomegalovirus among&#160;patients with&#160;cytomegalovirus retinitis and&#160;AIDS.&#160;</p>
<p style="position:absolute;top:597px;left:162px;white-space:nowrap" class="ft049"><i>Ophthalmology</i></p>
<p style="position:absolute;top:597px;left:265px;white-space:nowrap" class="ft047">. 2010;117(1):128-132&#160;e122. Available at:&#160;</p>
<p style="position:absolute;top:616px;left:162px;white-space:nowrap" class="ft050">http://www.ncbi.nlm.nih.gov/pubmed/19818505</p>
<p style="position:absolute;top:616px;left:482px;white-space:nowrap" class="ft047">.&#160;</p>
<p style="position:absolute;top:653px;left:108px;white-space:nowrap" class="ft047">89.</p>
<p style="position:absolute;top:653px;left:129px;white-space:nowrap" class="ft048">&#160;</p>
<p style="position:absolute;top:653px;left:162px;white-space:nowrap" class="ft051">Banker AS, Arevalo&#160;JF,&#160;Munguia D, et al.&#160;Intraocular pressure and&#160;aqueous humor dynamics in&#160;<br/>patients with&#160;AIDS treated&#160;with&#160;intravitreal&#160;cidofovir&#160;(HPMPC) for cytomegalovirus retinitis.&#160;</p>
<p style="position:absolute;top:672px;left:784px;white-space:nowrap" class="ft049"><i>Am&#160;</i></p>
<p style="position:absolute;top:691px;left:162px;white-space:nowrap" class="ft049"><i>J Ophthalmol</i></p>
<p style="position:absolute;top:691px;left:252px;white-space:nowrap" class="ft047">.&#160;1997;124(2):168-180. Available at:&#160;</p>
<p style="position:absolute;top:710px;left:162px;white-space:nowrap" class="ft050">https://www.ncbi.nlm.nih.gov/pubmed/9262540</p>
<p style="position:absolute;top:710px;left:480px;white-space:nowrap" class="ft047">.&#160;</p>
<p style="position:absolute;top:747px;left:108px;white-space:nowrap" class="ft047">90.</p>
<p style="position:absolute;top:747px;left:129px;white-space:nowrap" class="ft048">&#160;</p>
<p style="position:absolute;top:747px;left:162px;white-space:nowrap" class="ft051">(ACTG) ACTG. Studies of ocular complications of&#160;AIDS Foscarnet-Ganciclovir&#160;<br/>Cytomegalovirus Retinitis Trial: 1. Rationale, design,&#160;and&#160;methods.&#160;AIDS Clinical Trials Group&#160;<br/>(ACTG).&#160;</p>
<p style="position:absolute;top:785px;left:226px;white-space:nowrap" class="ft049"><i>Control Clin&#160;Trials</i></p>
<p style="position:absolute;top:785px;left:353px;white-space:nowrap" class="ft047">. 1992;13(1):22-39. Available at:&#160;</p>
<p style="position:absolute;top:804px;left:162px;white-space:nowrap" class="ft050">http://www.ncbi.nlm.nih.gov/pubmed/1315661</p>
<p style="position:absolute;top:804px;left:474px;white-space:nowrap" class="ft047">.&#160;</p>
<p style="position:absolute;top:841px;left:108px;white-space:nowrap" class="ft047">91.</p>
<p style="position:absolute;top:841px;left:129px;white-space:nowrap" class="ft048">&#160;</p>
<p style="position:absolute;top:841px;left:162px;white-space:nowrap" class="ft051">Young&#160;S, Morlet N, Besen&#160;G, et&#160;al. High-dose&#160;(2000-microgram) intravitreous ganciclovir&#160;in&#160;the&#160;<br/>treatment&#160;of cytomegalovirus retinitis.&#160;</p>
<p style="position:absolute;top:860px;left:419px;white-space:nowrap" class="ft049"><i>Ophthalmology</i></p>
<p style="position:absolute;top:860px;left:521px;white-space:nowrap" class="ft047">.&#160;1998;105(8):1404-1410.&#160;Available&#160;at:&#160;</p>
<p style="position:absolute;top:879px;left:162px;white-space:nowrap" class="ft050">https://www.ncbi.nlm.nih.gov/pubmed/9709750</p>
<p style="position:absolute;top:879px;left:480px;white-space:nowrap" class="ft047">.&#160;</p>
<p style="position:absolute;top:916px;left:108px;white-space:nowrap" class="ft047">92.</p>
<p style="position:absolute;top:916px;left:129px;white-space:nowrap" class="ft048">&#160;</p>
<p style="position:absolute;top:916px;left:162px;white-space:nowrap" class="ft051">Spector&#160;SA,&#160;Wong&#160;R,&#160;Hsia K, Pilcher M,&#160;Stempien&#160;MJ. Plasma cytomegalovirus (CMV) DNA&#160;<br/>load predicts CMV disease&#160;and&#160;survival&#160;in&#160;AIDS patients.&#160;</p>
<p style="position:absolute;top:935px;left:548px;white-space:nowrap" class="ft049"><i>J Clin&#160;Invest</i></p>
<p style="position:absolute;top:935px;left:632px;white-space:nowrap" class="ft047">. 1998;101(2):497-502.&#160;</p>
<p style="position:absolute;top:954px;left:162px;white-space:nowrap" class="ft047">Available at:&#160;</p>
<p style="position:absolute;top:954px;left:251px;white-space:nowrap" class="ft050">http://www.ncbi.nlm.nih.gov/pubmed/9435323</p>
<p style="position:absolute;top:954px;left:563px;white-space:nowrap" class="ft047">.&#160;</p>
<p style="position:absolute;top:991px;left:108px;white-space:nowrap" class="ft047">93.</p>
<p style="position:absolute;top:990px;left:129px;white-space:nowrap" class="ft048">&#160;</p>
<p style="position:absolute;top:991px;left:162px;white-space:nowrap" class="ft051">Tural C,&#160;Romeu&#160;J, Sirera G, et&#160;al. Long-lasting&#160;remission&#160;of cytomegalovirus retinitis without&#160;<br/>maintenance therapy&#160;in&#160;human&#160;immunodeficiency&#160;virus-infected&#160;patients.&#160;</p>
<p style="position:absolute;top:1010px;left:652px;white-space:nowrap" class="ft049"><i>J Infect Dis</i></p>
<p style="position:absolute;top:1010px;left:728px;white-space:nowrap" class="ft047">.&#160;</p>
<p style="position:absolute;top:1029px;left:162px;white-space:nowrap" class="ft047">1998;177(4):1080-1083. Available at:&#160;</p>
<p style="position:absolute;top:1029px;left:417px;white-space:nowrap" class="ft050">http://www.ncbi.nlm.nih.gov/pubmed/9534987</p>
<p style="position:absolute;top:1029px;left:728px;white-space:nowrap" class="ft047">.&#160;</p>
</div>
<!-- Page 193 -->
<a name="193"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page193-div" style="position:relative;width:917px;height:1187px;">
<p style="position:absolute;top:1132px;left:108px;white-space:nowrap" class="ft024"><i>Guidelines for the Prevention and Treatment&#160;of&#160;Opportunistic&#160;Infections in Adults&#160;and Adolescents&#160;With HIV&#160;</i></p>
<p style="position:absolute;top:1132px;left:784px;white-space:nowrap" class="ft024"><i>K-24&#160;</i></p>
<p style="position:absolute;top:109px;left:108px;white-space:nowrap" class="ft047">94.</p>
<p style="position:absolute;top:108px;left:129px;white-space:nowrap" class="ft048">&#160;</p>
<p style="position:absolute;top:109px;left:162px;white-space:nowrap" class="ft051">Vrabec TR,&#160;Baldassano&#160;VF,&#160;Whitcup&#160;SM.&#160;Discontinuation&#160;of maintenance therapy&#160;in&#160;patients&#160;<br/>with&#160;quiescent cytomegalovirus retinitis&#160;and&#160;elevated&#160;CD4+ counts.&#160;</p>
<p style="position:absolute;top:128px;left:613px;white-space:nowrap" class="ft049"><i>Ophthalmology</i></p>
<p style="position:absolute;top:128px;left:716px;white-space:nowrap" class="ft047">.&#160;</p>
<p style="position:absolute;top:147px;left:162px;white-space:nowrap" class="ft047">1998;105(7):1259-1264. Available at:&#160;</p>
<p style="position:absolute;top:147px;left:417px;white-space:nowrap" class="ft050">http://www.ncbi.nlm.nih.gov/pubmed/9663231</p>
<p style="position:absolute;top:147px;left:728px;white-space:nowrap" class="ft047">.&#160;</p>
<p style="position:absolute;top:184px;left:108px;white-space:nowrap" class="ft047">95.</p>
<p style="position:absolute;top:183px;left:129px;white-space:nowrap" class="ft048">&#160;</p>
<p style="position:absolute;top:184px;left:162px;white-space:nowrap" class="ft051">Macdonald&#160;JC, Torriani FJ, Morse LS,&#160;Karavellas MP,&#160;Reed JB,&#160;Freeman&#160;WR.&#160;Lack&#160;of&#160;<br/>reactivation&#160;of cytomegalovirus (CMV) retinitis after&#160;stopping&#160;CMV maintenance therapy&#160;in&#160;<br/>AIDS patients with&#160;sustained&#160;elevations in&#160;CD4&#160;T cells in&#160;response to&#160;highly&#160;active antiretroviral&#160;<br/>therapy.&#160;</p>
<p style="position:absolute;top:241px;left:220px;white-space:nowrap" class="ft049"><i>J Infect Dis</i></p>
<p style="position:absolute;top:241px;left:296px;white-space:nowrap" class="ft047">. 1998;177(5):1182-1187. Available at:&#160;</p>
<p style="position:absolute;top:260px;left:162px;white-space:nowrap" class="ft050">http://www.ncbi.nlm.nih.gov/pubmed/9593001</p>
<p style="position:absolute;top:260px;left:474px;white-space:nowrap" class="ft047">.&#160;</p>
<p style="position:absolute;top:296px;left:108px;white-space:nowrap" class="ft047">96.</p>
<p style="position:absolute;top:296px;left:129px;white-space:nowrap" class="ft048">&#160;</p>
<p style="position:absolute;top:296px;left:162px;white-space:nowrap" class="ft051">Whitcup&#160;SM,&#160;Fortin&#160;E,&#160;Lindblad&#160;AS,&#160;et&#160;al. Discontinuation&#160;of anticytomegalovirus therapy&#160;in&#160;<br/>patients with&#160;HIV infection&#160;and&#160;cytomegalovirus retinitis.&#160;</p>
<p style="position:absolute;top:315px;left:547px;white-space:nowrap" class="ft049"><i>JAMA</i></p>
<p style="position:absolute;top:315px;left:589px;white-space:nowrap" class="ft047">.&#160;1999;282(17):1633-1637.&#160;</p>
<p style="position:absolute;top:334px;left:162px;white-space:nowrap" class="ft047">Available at:&#160;</p>
<p style="position:absolute;top:334px;left:251px;white-space:nowrap" class="ft050">http://www.ncbi.nlm.nih.gov/pubmed/10553789</p>
<p style="position:absolute;top:334px;left:571px;white-space:nowrap" class="ft047">.&#160;</p>
<p style="position:absolute;top:371px;left:108px;white-space:nowrap" class="ft047">97.</p>
<p style="position:absolute;top:371px;left:129px;white-space:nowrap" class="ft048">&#160;</p>
<p style="position:absolute;top:371px;left:162px;white-space:nowrap" class="ft051">Jabs DA, Bolton&#160;SG,&#160;Dunn&#160;JP,&#160;Palestine AG.&#160;Discontinuing anticytomegalovirus therapy&#160;in&#160;<br/>patients with&#160;immune reconstitution&#160;after combination&#160;antiretroviral therapy.&#160;</p>
<p style="position:absolute;top:390px;left:672px;white-space:nowrap" class="ft049"><i>Am&#160;J Ophthalmol</i></p>
<p style="position:absolute;top:390px;left:789px;white-space:nowrap" class="ft047">.&#160;</p>
<p style="position:absolute;top:409px;left:162px;white-space:nowrap" class="ft047">1998;126(6):817-822. Available at:&#160;</p>
<p style="position:absolute;top:409px;left:400px;white-space:nowrap" class="ft050">http://www.ncbi.nlm.nih.gov/pubmed/9860006</p>
<p style="position:absolute;top:409px;left:712px;white-space:nowrap" class="ft047">.&#160;</p>
<p style="position:absolute;top:446px;left:108px;white-space:nowrap" class="ft047">98.</p>
<p style="position:absolute;top:446px;left:129px;white-space:nowrap" class="ft048">&#160;</p>
<p style="position:absolute;top:446px;left:162px;white-space:nowrap" class="ft051">Jouan&#160;M,&#160;Saves M,&#160;Tubiana R, et al.&#160;Discontinuation&#160;of maintenance&#160;therapy&#160;for cytomegalovirus&#160;<br/>retinitis in&#160;HIV-infected&#160;patients receiving&#160;highly&#160;active antiretroviral therapy.&#160;</p>
<p style="position:absolute;top:465px;left:684px;white-space:nowrap" class="ft049"><i>AIDS</i></p>
<p style="position:absolute;top:465px;left:719px;white-space:nowrap" class="ft047">.&#160;</p>
<p style="position:absolute;top:484px;left:162px;white-space:nowrap" class="ft047">2001;15(1):23-31. Available at:&#160;</p>
<p style="position:absolute;top:484px;left:375px;white-space:nowrap" class="ft050">http://www.ncbi.nlm.nih.gov/pubmed/11192865</p>
<p style="position:absolute;top:484px;left:695px;white-space:nowrap" class="ft047">.&#160;</p>
<p style="position:absolute;top:521px;left:108px;white-space:nowrap" class="ft047">99.</p>
<p style="position:absolute;top:521px;left:129px;white-space:nowrap" class="ft048">&#160;</p>
<p style="position:absolute;top:521px;left:162px;white-space:nowrap" class="ft051">Walmsley SL,&#160;Raboud&#160;J, Angel&#160;JB, et al.&#160;Long-term follow-up&#160;of a cohort of HIV-infected&#160;<br/>patients who&#160;discontinued maintenance&#160;therapy&#160;for cytomegalovirus retinitis.&#160;</p>
<p style="position:absolute;top:540px;left:675px;white-space:nowrap" class="ft049"><i>HIV Clin&#160;Trials</i></p>
<p style="position:absolute;top:540px;left:779px;white-space:nowrap" class="ft047">.&#160;</p>
<p style="position:absolute;top:559px;left:162px;white-space:nowrap" class="ft047">2006;7(1):1-9. Available at:&#160;</p>
<p style="position:absolute;top:559px;left:351px;white-space:nowrap" class="ft050">http://www.ncbi.nlm.nih.gov/pubmed/16632459</p>
<p style="position:absolute;top:559px;left:671px;white-space:nowrap" class="ft047">.&#160;</p>
<p style="position:absolute;top:596px;left:108px;white-space:nowrap" class="ft047">100.</p>
<p style="position:absolute;top:596px;left:137px;white-space:nowrap" class="ft048">&#160;</p>
<p style="position:absolute;top:596px;left:162px;white-space:nowrap" class="ft051">Holbrook&#160;JT,&#160;Colvin&#160;R, van&#160;Natta ML, et&#160;al. Evaluation&#160;of the United&#160;States Public Health&#160;<br/>Service guidelines for&#160;discontinuation&#160;of anticytomegalovirus therapy&#160;after immune recovery&#160;in&#160;<br/>patients with&#160;cytomegalovirus retinitis.&#160;</p>
<p style="position:absolute;top:634px;left:423px;white-space:nowrap" class="ft049"><i>Am J Ophthalmol</i></p>
<p style="position:absolute;top:634px;left:540px;white-space:nowrap" class="ft047">. 2011;152(4):628-637&#160;e621.&#160;Available&#160;</p>
<p style="position:absolute;top:653px;left:162px;white-space:nowrap" class="ft047">at:&#160;</p>
<p style="position:absolute;top:653px;left:183px;white-space:nowrap" class="ft050">https://www.ncbi.nlm.nih.gov/pubmed/21742304</p>
<p style="position:absolute;top:653px;left:509px;white-space:nowrap" class="ft047">.</p>
<p style="position:absolute;top:690px;left:108px;white-space:nowrap" class="ft047">101.</p>
<p style="position:absolute;top:690px;left:137px;white-space:nowrap" class="ft048">&#160;</p>
<p style="position:absolute;top:690px;left:162px;white-space:nowrap" class="ft051">1999&#160;USPHS/IDSA guidelines for&#160;the prevention&#160;of&#160;opportunistic infections in&#160;persons infected&#160;<br/>with&#160;human&#160;immunodeficiency&#160;virus. U.S.&#160;Public Health&#160;Service (USPHS)&#160;and&#160;Infectious&#160;<br/>Diseases Society&#160;of America (IDSA).&#160;</p>
<p style="position:absolute;top:728px;left:414px;white-space:nowrap" class="ft049"><i>MMWR Recomm Rep</i></p>
<p style="position:absolute;top:728px;left:556px;white-space:nowrap" class="ft047">.&#160;1999;48(RR-10):1-59,&#160;61-56.&#160;</p>
<p style="position:absolute;top:747px;left:162px;white-space:nowrap" class="ft047">Available at:&#160;</p>
<p style="position:absolute;top:747px;left:251px;white-space:nowrap" class="ft050">https://www.ncbi.nlm.nih.gov/pubmed/10499670</p>
<p style="position:absolute;top:747px;left:577px;white-space:nowrap" class="ft047">.&#160;</p>
<p style="position:absolute;top:784px;left:108px;white-space:nowrap" class="ft047">102.</p>
<p style="position:absolute;top:784px;left:137px;white-space:nowrap" class="ft048">&#160;</p>
<p style="position:absolute;top:784px;left:162px;white-space:nowrap" class="ft051">Jabs DA, Ahuja A, Van&#160;Natta M, Lyon A, Srivastava&#160;S,&#160;Gangaputra S.&#160;Course of&#160;<br/>cytomegalovirus retinitis in the era of&#160;highly&#160;active antiretroviral&#160;therapy: five-year outcomes.&#160;</p>
<p style="position:absolute;top:822px;left:162px;white-space:nowrap" class="ft049"><i>Ophthalmology</i></p>
<p style="position:absolute;top:822px;left:265px;white-space:nowrap" class="ft047">. 2010;117(11):2152-2161.e2151-2152. Available at:&#160;</p>
<p style="position:absolute;top:841px;left:162px;white-space:nowrap" class="ft050">https://pubmed.ncbi.nlm.nih.gov/20673591/</p>
<p style="position:absolute;top:841px;left:453px;white-space:nowrap" class="ft047">.&#160;</p>
<p style="position:absolute;top:878px;left:108px;white-space:nowrap" class="ft047">103.</p>
<p style="position:absolute;top:878px;left:137px;white-space:nowrap" class="ft048">&#160;</p>
<p style="position:absolute;top:878px;left:162px;white-space:nowrap" class="ft051">Komanduri KV, Feinberg&#160;J, Hutchins RK, et al.&#160;Loss&#160;of cytomegalovirus-specific CD4+ T cell&#160;<br/>responses in&#160;human&#160;immunodeficiency&#160;virus type 1-infected patients with&#160;high&#160;CD4+ T&#160;cell&#160;<br/>counts and&#160;recurrent&#160;retinitis.&#160;</p>
<p style="position:absolute;top:916px;left:359px;white-space:nowrap" class="ft049"><i>J Infect Dis</i></p>
<p style="position:absolute;top:916px;left:435px;white-space:nowrap" class="ft047">. 2001;183(8):1285-1289.&#160;Available at:&#160;</p>
<p style="position:absolute;top:935px;left:162px;white-space:nowrap" class="ft050">https://pubmed.ncbi.nlm.nih.gov/11262214/</p>
<p style="position:absolute;top:935px;left:453px;white-space:nowrap" class="ft047">.</p>
<p style="position:absolute;top:972px;left:108px;white-space:nowrap" class="ft047">104.</p>
<p style="position:absolute;top:971px;left:137px;white-space:nowrap" class="ft048">&#160;</p>
<p style="position:absolute;top:972px;left:162px;white-space:nowrap" class="ft051">Torriani&#160;FJ, Freeman&#160;WR,&#160;Macdonald&#160;JC, et al.&#160;CMV retinitis recurs after stopping&#160;treatment&#160;in&#160;<br/>virological and&#160;immunological failures of potent&#160;antiretroviral therapy.&#160;</p>
<p style="position:absolute;top:991px;left:634px;white-space:nowrap" class="ft049"><i>AIDS</i></p>
<p style="position:absolute;top:991px;left:670px;white-space:nowrap" class="ft047">.&#160;2000;14(2):173-</p>
<p style="position:absolute;top:1010px;left:162px;white-space:nowrap" class="ft047">180.&#160;Available at:&#160;</p>
<p style="position:absolute;top:1010px;left:284px;white-space:nowrap" class="ft050">http://www.ncbi.nlm.nih.gov/pubmed/10708288</p>
<p style="position:absolute;top:1010px;left:604px;white-space:nowrap" class="ft047">.&#160;</p>
</div>
<!-- Page 194 -->
<a name="194"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page194-div" style="position:relative;width:917px;height:1187px;">
<p style="position:absolute;top:1132px;left:108px;white-space:nowrap" class="ft024"><i>Guidelines for the Prevention and Treatment&#160;of&#160;Opportunistic&#160;Infections in Adults&#160;and Adolescents&#160;With HIV&#160;</i></p>
<p style="position:absolute;top:1132px;left:784px;white-space:nowrap" class="ft024"><i>K-25&#160;</i></p>
<p style="position:absolute;top:109px;left:108px;white-space:nowrap" class="ft047">105.</p>
<p style="position:absolute;top:108px;left:137px;white-space:nowrap" class="ft048">&#160;</p>
<p style="position:absolute;top:109px;left:162px;white-space:nowrap" class="ft051">Practice bulletin&#160;no.&#160;151: Cytomegalovirus, parvovirus B19,&#160;varicella zoster, and&#160;toxoplasmosis&#160;<br/>in&#160;pregnancy.&#160;</p>
<p style="position:absolute;top:128px;left:256px;white-space:nowrap" class="ft049"><i>Obstet Gynecol</i></p>
<p style="position:absolute;top:128px;left:358px;white-space:nowrap" class="ft047">.&#160;2015;125(6):1510-1525. Available at:&#160;</p>
<p style="position:absolute;top:147px;left:162px;white-space:nowrap" class="ft050">https://pubmed.ncbi.nlm.nih.gov/26000539</p>
<p style="position:absolute;top:147px;left:448px;white-space:nowrap" class="ft047">.&#160;</p>
<p style="position:absolute;top:184px;left:108px;white-space:nowrap" class="ft047">106.</p>
<p style="position:absolute;top:183px;left:137px;white-space:nowrap" class="ft048">&#160;</p>
<p style="position:absolute;top:184px;left:162px;white-space:nowrap" class="ft051">Faqi AS,&#160;Klug&#160;A, Merker HJ, Chahoud&#160;I. Ganciclovir induces&#160;reproductive hazards in&#160;male rats&#160;<br/>after short-term exposure.&#160;</p>
<p style="position:absolute;top:203px;left:337px;white-space:nowrap" class="ft049"><i>Hum Exp&#160;Toxicol</i></p>
<p style="position:absolute;top:203px;left:452px;white-space:nowrap" class="ft047">. 1997;16(9):505-511.&#160;Available at:&#160;</p>
<p style="position:absolute;top:222px;left:162px;white-space:nowrap" class="ft050">http://www.ncbi.nlm.nih.gov/pubmed/9306137</p>
<p style="position:absolute;top:222px;left:474px;white-space:nowrap" class="ft047">.&#160;</p>
<p style="position:absolute;top:259px;left:108px;white-space:nowrap" class="ft047">107.</p>
<p style="position:absolute;top:258px;left:137px;white-space:nowrap" class="ft048">&#160;</p>
<p style="position:absolute;top:259px;left:162px;white-space:nowrap" class="ft051">Miller BW, Howard TK, Goss JA, Mostello&#160;DJ, Holcomb&#160;WL, Jr.,&#160;Brennan DC.&#160;Renal&#160;<br/>transplantation&#160;one week&#160;after conception.&#160;</p>
<p style="position:absolute;top:278px;left:446px;white-space:nowrap" class="ft049"><i>Transplantation</i></p>
<p style="position:absolute;top:278px;left:552px;white-space:nowrap" class="ft047">. 1995;60(11):1353-1354.&#160;Available&#160;</p>
<p style="position:absolute;top:297px;left:162px;white-space:nowrap" class="ft047">at:&#160;</p>
<p style="position:absolute;top:297px;left:183px;white-space:nowrap" class="ft050">http://www.ncbi.nlm.nih.gov/pubmed/8525535</p>
<p style="position:absolute;top:297px;left:494px;white-space:nowrap" class="ft047">.&#160;</p>
<p style="position:absolute;top:333px;left:108px;white-space:nowrap" class="ft047">108.</p>
<p style="position:absolute;top:333px;left:137px;white-space:nowrap" class="ft048">&#160;</p>
<p style="position:absolute;top:333px;left:162px;white-space:nowrap" class="ft051">Pescovitz MD. Absence of teratogenicity&#160;of oral ganciclovir used&#160;during&#160;early&#160;pregnancy&#160;in&#160;a&#160;<br/>liver transplant&#160;recipient.&#160;</p>
<p style="position:absolute;top:352px;left:331px;white-space:nowrap" class="ft049"><i>Transplantation</i></p>
<p style="position:absolute;top:352px;left:438px;white-space:nowrap" class="ft047">.&#160;1999;67(5):758-759. Available at:&#160;</p>
<p style="position:absolute;top:371px;left:162px;white-space:nowrap" class="ft050">http://www.ncbi.nlm.nih.gov/pubmed/10096536</p>
<p style="position:absolute;top:371px;left:482px;white-space:nowrap" class="ft047">.&#160;</p>
<p style="position:absolute;top:408px;left:108px;white-space:nowrap" class="ft047">109.</p>
<p style="position:absolute;top:408px;left:137px;white-space:nowrap" class="ft048">&#160;</p>
<p style="position:absolute;top:408px;left:162px;white-space:nowrap" class="ft051">Adler SP, Nigro&#160;G,&#160;Pereira L.&#160;Recent&#160;advances in&#160;the prevention&#160;and&#160;treatment&#160;of congenital&#160;<br/>cytomegalovirus infections.&#160;</p>
<p style="position:absolute;top:427px;left:349px;white-space:nowrap" class="ft049"><i>Semin&#160;Perinatol</i></p>
<p style="position:absolute;top:427px;left:456px;white-space:nowrap" class="ft047">. 2007;31(1):10-18. Available at:&#160;</p>
<p style="position:absolute;top:446px;left:162px;white-space:nowrap" class="ft050">http://www.ncbi.nlm.nih.gov/pubmed/17317422</p>
<p style="position:absolute;top:446px;left:482px;white-space:nowrap" class="ft047">.&#160;</p>
<p style="position:absolute;top:483px;left:108px;white-space:nowrap" class="ft047">110.</p>
<p style="position:absolute;top:483px;left:137px;white-space:nowrap" class="ft048">&#160;</p>
<p style="position:absolute;top:483px;left:162px;white-space:nowrap" class="ft051">Seidel V, Feiterna-Sperling&#160;C, Siedentopf JP,&#160;et al.&#160;Intrauterine therapy&#160;of cytomegalovirus&#160;<br/>infection&#160;with valganciclovir:&#160;review of&#160;the literature.&#160;</p>
<p style="position:absolute;top:502px;left:520px;white-space:nowrap" class="ft049"><i>Med&#160;Microbiol Immunol</i></p>
<p style="position:absolute;top:502px;left:682px;white-space:nowrap" class="ft047">.&#160;2017;206(5):347-</p>
<p style="position:absolute;top:521px;left:162px;white-space:nowrap" class="ft047">354.&#160;Available at:&#160;</p>
<p style="position:absolute;top:521px;left:284px;white-space:nowrap" class="ft050">https://www.ncbi.nlm.nih.gov/pubmed/28733760</p>
<p style="position:absolute;top:521px;left:610px;white-space:nowrap" class="ft047">.&#160;</p>
<p style="position:absolute;top:558px;left:108px;white-space:nowrap" class="ft047">111.</p>
<p style="position:absolute;top:558px;left:137px;white-space:nowrap" class="ft048">&#160;</p>
<p style="position:absolute;top:558px;left:162px;white-space:nowrap" class="ft051">Henry&#160;K, Cantrill&#160;H, Fletcher C,&#160;Chinnock&#160;BJ, Balfour HH, Jr.&#160;Use&#160;of intravitreal&#160;ganciclovir&#160;<br/>(dihydroxy&#160;propoxymethyl&#160;guanine) for&#160;cytomegalovirus retinitis in&#160;a patient&#160;with&#160;AIDS.&#160;</p>
<p style="position:absolute;top:577px;left:755px;white-space:nowrap" class="ft049"><i>Am J&#160;</i></p>
<p style="position:absolute;top:596px;left:162px;white-space:nowrap" class="ft049"><i>Ophthalmol</i></p>
<p style="position:absolute;top:596px;left:241px;white-space:nowrap" class="ft047">.&#160;1987;103(1):17-23.&#160;Available at:&#160;</p>
<p style="position:absolute;top:596px;left:471px;white-space:nowrap" class="ft050">https://www.ncbi.nlm.nih.gov/pubmed/3026186</p>
<p style="position:absolute;top:596px;left:789px;white-space:nowrap" class="ft047">.&#160;</p>
<p style="position:absolute;top:633px;left:108px;white-space:nowrap" class="ft047">112.</p>
<p style="position:absolute;top:633px;left:137px;white-space:nowrap" class="ft048">&#160;</p>
<p style="position:absolute;top:633px;left:162px;white-space:nowrap" class="ft047">FOSCAVIR&#160;® (foscarnet&#160;sodium) injection&#160;2011.&#160;</p>
<p style="position:absolute;top:670px;left:108px;white-space:nowrap" class="ft047">113.</p>
<p style="position:absolute;top:670px;left:137px;white-space:nowrap" class="ft048">&#160;</p>
<p style="position:absolute;top:670px;left:162px;white-space:nowrap" class="ft047">Mathias CV,&#160;Simões MJ,&#160;Amed AM, et&#160;al.&#160;Foscarnet&#160;effects on&#160;the rat pregnancy&#160;outcome.&#160;</p>
<p style="position:absolute;top:670px;left:768px;white-space:nowrap" class="ft049"><i>Int J&#160;</i></p>
<p style="position:absolute;top:689px;left:162px;white-space:nowrap" class="ft049"><i>Morphol</i></p>
<p style="position:absolute;top:689px;left:220px;white-space:nowrap" class="ft047">. 2005;23(2):137-140. Available at:&#160;</p>
<p style="position:absolute;top:689px;left:458px;white-space:nowrap" class="ft050">https://www.scielo.cl/pdf/ijmorphol/v23n2/art08.pdf</p>
<p style="position:absolute;top:689px;left:805px;white-space:nowrap" class="ft047">.&#160;</p>
<p style="position:absolute;top:726px;left:108px;white-space:nowrap" class="ft047">114.</p>
<p style="position:absolute;top:726px;left:137px;white-space:nowrap" class="ft048">&#160;</p>
<p style="position:absolute;top:726px;left:162px;white-space:nowrap" class="ft051">Alvarez-McLeod&#160;A, Havlik&#160;J,&#160;Drew&#160;KE.&#160;Foscarnet treatment&#160;of genital infection&#160;due&#160;to&#160;<br/>acyclovir-resistant&#160;herpes&#160;simplex&#160;virus type 2&#160;in a pregnant&#160;patient&#160;with&#160;AIDS: case&#160;report.&#160;</p>
<p style="position:absolute;top:745px;left:773px;white-space:nowrap" class="ft049"><i>Clin&#160;</i></p>
<p style="position:absolute;top:764px;left:162px;white-space:nowrap" class="ft049"><i>Infect Dis</i></p>
<p style="position:absolute;top:764px;left:226px;white-space:nowrap" class="ft047">. 1999;29(4):937-938. Available at:&#160;</p>
<p style="position:absolute;top:764px;left:465px;white-space:nowrap" class="ft050">http://www.ncbi.nlm.nih.gov/pubmed/10589917</p>
<p style="position:absolute;top:764px;left:785px;white-space:nowrap" class="ft047">.&#160;</p>
<p style="position:absolute;top:801px;left:108px;white-space:nowrap" class="ft047">115.</p>
<p style="position:absolute;top:801px;left:137px;white-space:nowrap" class="ft048">&#160;</p>
<p style="position:absolute;top:801px;left:162px;white-space:nowrap" class="ft051">De Clercq&#160;E.&#160;Therapeutic potential of Cidofovir (HPMPC, Vistide) for the treatment of DNA&#160;<br/>virus (i.e.&#160;herpes-, papova-, pox- and adenovirus) infections.&#160;</p>
<p style="position:absolute;top:820px;left:565px;white-space:nowrap" class="ft049"><i>Verh&#160;K Acad&#160;Geneeskd Belg</i></p>
<p style="position:absolute;top:820px;left:752px;white-space:nowrap" class="ft047">.&#160;</p>
<p style="position:absolute;top:839px;left:162px;white-space:nowrap" class="ft047">1996;58(1):19-47;&#160;discussion&#160;47-19.&#160;Available at:&#160;</p>
<p style="position:absolute;top:858px;left:162px;white-space:nowrap" class="ft050">https://www.ncbi.nlm.nih.gov/pubmed/8701600</p>
<p style="position:absolute;top:858px;left:480px;white-space:nowrap" class="ft047">.&#160;</p>
<p style="position:absolute;top:895px;left:108px;white-space:nowrap" class="ft047">116.</p>
<p style="position:absolute;top:895px;left:137px;white-space:nowrap" class="ft048">&#160;</p>
<p style="position:absolute;top:895px;left:162px;white-space:nowrap" class="ft051">Indications for Outpatient Antenatal&#160;Fetal Surveillance: ACOG Committee Opinion,&#160;Number&#160;<br/>828.&#160;</p>
<p style="position:absolute;top:914px;left:195px;white-space:nowrap" class="ft049"><i>Obstet&#160;Gynecol</i></p>
<p style="position:absolute;top:914px;left:297px;white-space:nowrap" class="ft047">.&#160;2021;137(6):e177-e197.&#160;Available at:&#160;</p>
<p style="position:absolute;top:933px;left:162px;white-space:nowrap" class="ft050">https://www.ncbi.nlm.nih.gov/pubmed/34011892</p>
<p style="position:absolute;top:933px;left:488px;white-space:nowrap" class="ft047">.&#160;</p>
<p style="position:absolute;top:970px;left:108px;white-space:nowrap" class="ft047">117.</p>
<p style="position:absolute;top:970px;left:137px;white-space:nowrap" class="ft048">&#160;</p>
<p style="position:absolute;top:970px;left:162px;white-space:nowrap" class="ft051">Khalil A,&#160;Sotiriadis A, Chaoui R,&#160;et al.&#160;ISUOG Practice&#160;Guidelines: role of ultrasound&#160;in&#160;<br/>congenital infection.&#160;</p>
<p style="position:absolute;top:989px;left:302px;white-space:nowrap" class="ft049"><i>Ultrasound&#160;Obstet Gynecol</i></p>
<p style="position:absolute;top:989px;left:483px;white-space:nowrap" class="ft047">.&#160;2020;56(1):128-151.&#160;Available at:&#160;</p>
<p style="position:absolute;top:1008px;left:162px;white-space:nowrap" class="ft050">https://www.ncbi.nlm.nih.gov/pubmed/32400006</p>
<p style="position:absolute;top:1008px;left:488px;white-space:nowrap" class="ft047">.&#160;</p>
</div>
<!-- Page 195 -->
<a name="195"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page195-div" style="position:relative;width:917px;height:1187px;">
<p style="position:absolute;top:1132px;left:108px;white-space:nowrap" class="ft024"><i>Guidelines for the Prevention and Treatment&#160;of&#160;Opportunistic&#160;Infections in Adults&#160;and Adolescents&#160;With HIV&#160;</i></p>
<p style="position:absolute;top:1132px;left:784px;white-space:nowrap" class="ft024"><i>K-26&#160;</i></p>
<p style="position:absolute;top:109px;left:108px;white-space:nowrap" class="ft047">118.</p>
<p style="position:absolute;top:108px;left:137px;white-space:nowrap" class="ft048">&#160;</p>
<p style="position:absolute;top:109px;left:162px;white-space:nowrap" class="ft051">Enders M, Daiminger A, Exler S,&#160;Ertan K, Enders G, Bald&#160;R. Prenatal diagnosis&#160;of congenital&#160;<br/>cytomegalovirus infection&#160;in&#160;115&#160;cases: a&#160;5&#160;years' single center experience.&#160;</p>
<p style="position:absolute;top:128px;left:661px;white-space:nowrap" class="ft049"><i>Prenat Diagn</i></p>
<p style="position:absolute;top:128px;left:751px;white-space:nowrap" class="ft047">.&#160;</p>
<p style="position:absolute;top:147px;left:162px;white-space:nowrap" class="ft047">2017;37(4):389-398.&#160;Available at:&#160;</p>
<p style="position:absolute;top:147px;left:392px;white-space:nowrap" class="ft050">https://www.ncbi.nlm.nih.gov/pubmed/28207161</p>
<p style="position:absolute;top:147px;left:718px;white-space:nowrap" class="ft047">.&#160;</p>
<p style="position:absolute;top:184px;left:108px;white-space:nowrap" class="ft047">119.</p>
<p style="position:absolute;top:183px;left:137px;white-space:nowrap" class="ft048">&#160;</p>
<p style="position:absolute;top:184px;left:162px;white-space:nowrap" class="ft051">Hughes BL,&#160;Gyamfi-Bannerman&#160;C.&#160;Diagnosis and&#160;antenatal management&#160;of congenital&#160;<br/>cytomegalovirus infection.&#160;</p>
<p style="position:absolute;top:203px;left:343px;white-space:nowrap" class="ft049"><i>Am J Obstet&#160;Gynecol</i></p>
<p style="position:absolute;top:203px;left:482px;white-space:nowrap" class="ft047">. 2016;214(6):B5-b11. Available at:&#160;</p>
<p style="position:absolute;top:222px;left:162px;white-space:nowrap" class="ft050">https://pubmed.ncbi.nlm.nih.gov/26902990/</p>
<p style="position:absolute;top:222px;left:453px;white-space:nowrap" class="ft047">.&#160;</p>
<p style="position:absolute;top:259px;left:108px;white-space:nowrap" class="ft047">120.</p>
<p style="position:absolute;top:258px;left:137px;white-space:nowrap" class="ft048">&#160;</p>
<p style="position:absolute;top:259px;left:162px;white-space:nowrap" class="ft047">Boppana SB,&#160;Hui&#160;L.&#160;Cytomegalovirus infection&#160;in&#160;pregnancy. 2024.&#160;Available at:&#160;</p>
<p style="position:absolute;top:278px;left:162px;white-space:nowrap" class="ft050">https://www.uptodate.com/contents/cytomegalovirus-infection-in-pregnancy</p>
<p style="position:absolute;top:278px;left:668px;white-space:nowrap" class="ft047">&#160;&#160;</p>
<p style="position:absolute;top:314px;left:108px;white-space:nowrap" class="ft047">121.</p>
<p style="position:absolute;top:314px;left:137px;white-space:nowrap" class="ft048">&#160;</p>
<p style="position:absolute;top:314px;left:162px;white-space:nowrap" class="ft051">Yamamoto&#160;AY, Mussi-Pinhata MM, Boppana SB,&#160;et al.&#160;Human&#160;cytomegalovirus reinfection&#160;is&#160;<br/>associated&#160;with&#160;intrauterine&#160;transmission&#160;in&#160;a highly&#160;cytomegalovirus-immune&#160;maternal&#160;<br/>population.&#160;</p>
<p style="position:absolute;top:352px;left:241px;white-space:nowrap" class="ft049"><i>Am J Obstet&#160;Gynecol</i></p>
<p style="position:absolute;top:352px;left:380px;white-space:nowrap" class="ft047">.&#160;2010;202(3):297&#160;e291-298. Available at:&#160;</p>
<p style="position:absolute;top:371px;left:162px;white-space:nowrap" class="ft050">http://www.ncbi.nlm.nih.gov/pubmed/20060091</p>
<p style="position:absolute;top:371px;left:482px;white-space:nowrap" class="ft047">.&#160;</p>
<p style="position:absolute;top:408px;left:108px;white-space:nowrap" class="ft047">122.</p>
<p style="position:absolute;top:408px;left:137px;white-space:nowrap" class="ft048">&#160;</p>
<p style="position:absolute;top:408px;left:162px;white-space:nowrap" class="ft047">Adachi K,&#160;Xu J,&#160;Ank&#160;B,&#160;et&#160;al. Congenital cytomegalovirus and&#160;HIV perinatal transmission.&#160;</p>
<p style="position:absolute;top:427px;left:162px;white-space:nowrap" class="ft049"><i>Pediatr Infect Dis J</i></p>
<p style="position:absolute;top:427px;left:291px;white-space:nowrap" class="ft047">.&#160;2018;37(10):1016-1021. Available at:&#160;</p>
<p style="position:absolute;top:446px;left:162px;white-space:nowrap" class="ft050">https://pubmed.ncbi.nlm.nih.gov/30216294/</p>
<p style="position:absolute;top:446px;left:453px;white-space:nowrap" class="ft047">.&#160;</p>
<p style="position:absolute;top:483px;left:108px;white-space:nowrap" class="ft047">123.</p>
<p style="position:absolute;top:483px;left:137px;white-space:nowrap" class="ft048">&#160;</p>
<p style="position:absolute;top:483px;left:162px;white-space:nowrap" class="ft051">Frederick&#160;T,&#160;Homans J,&#160;Spencer L, et&#160;al.&#160;The effect of prenatal&#160;highly&#160;active antiretroviral therapy&#160;<br/>on&#160;the transmission&#160;of congenital and&#160;perinatal/early&#160;postnatal&#160;cytomegalovirus among&#160;HIV-<br/>infected and&#160;HIV-exposed&#160;infants.&#160;</p>
<p style="position:absolute;top:521px;left:393px;white-space:nowrap" class="ft049"><i>Clin&#160;Infect Dis</i></p>
<p style="position:absolute;top:521px;left:490px;white-space:nowrap" class="ft047">. 2012;55(6):877-884.&#160;Available at:&#160;</p>
<p style="position:absolute;top:540px;left:162px;white-space:nowrap" class="ft050">http://www.ncbi.nlm.nih.gov/pubmed/22675157</p>
<p style="position:absolute;top:540px;left:482px;white-space:nowrap" class="ft047">.&#160;</p>
<p style="position:absolute;top:577px;left:108px;white-space:nowrap" class="ft047">124.</p>
<p style="position:absolute;top:577px;left:137px;white-space:nowrap" class="ft048">&#160;</p>
<p style="position:absolute;top:577px;left:162px;white-space:nowrap" class="ft051">Purswani MU, Russell&#160;JS,&#160;Dietrich&#160;M,&#160;et al.&#160;Birth&#160;prevalence of&#160;congenital cytomegalovirus&#160;<br/>nfection&#160;in&#160;HIV-exposed uninfected&#160;children&#160;in&#160;the era of&#160;combination&#160;antiretroviral therapy.&#160;</p>
<p style="position:absolute;top:596px;left:780px;white-space:nowrap" class="ft049"><i>The&#160;</i></p>
<p style="position:absolute;top:615px;left:162px;white-space:nowrap" class="ft049"><i>Journal of Pediatrics</i></p>
<p style="position:absolute;top:615px;left:302px;white-space:nowrap" class="ft047">. 2020;216:82-87.e82. Available at:&#160;</p>
<p style="position:absolute;top:634px;left:162px;white-space:nowrap" class="ft050">https://www.sciencedirect.com/science/article/pii/S0022347619311618?via%3Dihub</p>
<p style="position:absolute;top:634px;left:724px;white-space:nowrap" class="ft047">.&#160;</p>
<p style="position:absolute;top:671px;left:108px;white-space:nowrap" class="ft047">125.</p>
<p style="position:absolute;top:671px;left:137px;white-space:nowrap" class="ft048">&#160;</p>
<p style="position:absolute;top:671px;left:162px;white-space:nowrap" class="ft051">Adachi K,&#160;Xu&#160;J, Ank&#160;B,&#160;et&#160;al. Cytomegalovirus urinary&#160;shedding in&#160;HIV-infected&#160;pregnant&#160;<br/>women&#160;and&#160;congenital cytomegalovirus infection.&#160;</p>
<p style="position:absolute;top:690px;left:496px;white-space:nowrap" class="ft049"><i>Clin&#160;Infect Dis</i></p>
<p style="position:absolute;top:690px;left:593px;white-space:nowrap" class="ft047">. 2017;65(3):405-413. Available&#160;</p>
<p style="position:absolute;top:709px;left:162px;white-space:nowrap" class="ft047">at:&#160;</p>
<p style="position:absolute;top:709px;left:183px;white-space:nowrap" class="ft050">https://pubmed.ncbi.nlm.nih.gov/28369278/</p>
<p style="position:absolute;top:709px;left:473px;white-space:nowrap" class="ft047">.&#160;</p>
<p style="position:absolute;top:746px;left:108px;white-space:nowrap" class="ft047">126.</p>
<p style="position:absolute;top:746px;left:137px;white-space:nowrap" class="ft048">&#160;</p>
<p style="position:absolute;top:746px;left:162px;white-space:nowrap" class="ft051">Society-for-Maternal-Fetal-Medicine, Hughes BL,&#160;Gyamfi-Bannerman&#160;C. Diagnosis and&#160;<br/>antenatal management of congenital cytomegalovirus infection.&#160;</p>
<p style="position:absolute;top:765px;left:585px;white-space:nowrap" class="ft049"><i>Am&#160;J Obstet Gynecol</i></p>
<p style="position:absolute;top:765px;left:725px;white-space:nowrap" class="ft047">.&#160;</p>
<p style="position:absolute;top:784px;left:162px;white-space:nowrap" class="ft047">2016;214(6):B5-B11. Available at:&#160;</p>
<p style="position:absolute;top:784px;left:398px;white-space:nowrap" class="ft050">https://www.ncbi.nlm.nih.gov/pubmed/26902990</p>
<p style="position:absolute;top:784px;left:724px;white-space:nowrap" class="ft047">.&#160;</p>
<p style="position:absolute;top:821px;left:108px;white-space:nowrap" class="ft047">127.</p>
<p style="position:absolute;top:821px;left:137px;white-space:nowrap" class="ft048">&#160;</p>
<p style="position:absolute;top:821px;left:162px;white-space:nowrap" class="ft051">Tanimura K,&#160;Yamada H. Potential biomarkers for predicting&#160;congenital&#160;cytomegalovirus&#160;<br/>infection.&#160;</p>
<p style="position:absolute;top:840px;left:229px;white-space:nowrap" class="ft049"><i>Int&#160;J Mol Sci</i></p>
<p style="position:absolute;top:840px;left:314px;white-space:nowrap" class="ft047">. 2018;19(12):3760. Available at:&#160;</p>
<p style="position:absolute;top:840px;left:538px;white-space:nowrap" class="ft050">https://www.mdpi.com/1422-</p>
<p style="position:absolute;top:859px;left:162px;white-space:nowrap" class="ft050">0067/19/12/3760/htm#</p>
<p style="position:absolute;top:859px;left:313px;white-space:nowrap" class="ft047">.&#160;</p>
<p style="position:absolute;top:896px;left:108px;white-space:nowrap" class="ft047">128.</p>
<p style="position:absolute;top:896px;left:137px;white-space:nowrap" class="ft048">&#160;</p>
<p style="position:absolute;top:896px;left:162px;white-space:nowrap" class="ft051">Kagan&#160;KO, Enders M,&#160;Schampera MS, et al.&#160;Prevention of maternal-fetal&#160;transmission&#160;of&#160;<br/>cytomegalovirus after primary&#160;maternal infection&#160;in&#160;the first trimester by&#160;biweekly&#160;<br/>hyperimmunoglobulin&#160;administration.&#160;</p>
<p style="position:absolute;top:934px;left:417px;white-space:nowrap" class="ft049"><i>Ultrasound&#160;Obstet Gynecol</i></p>
<p style="position:absolute;top:934px;left:598px;white-space:nowrap" class="ft047">. 2019;53(3):383-389.&#160;</p>
<p style="position:absolute;top:953px;left:162px;white-space:nowrap" class="ft047">Available at:</p>
<p style="position:absolute;top:953px;left:251px;white-space:nowrap" class="ft050">https://pubmed.ncbi.nlm.nih.gov/29947159/</p>
<p style="position:absolute;top:953px;left:542px;white-space:nowrap" class="ft047">.</p>
<p style="position:absolute;top:990px;left:108px;white-space:nowrap" class="ft047">129.</p>
<p style="position:absolute;top:989px;left:137px;white-space:nowrap" class="ft048">&#160;</p>
<p style="position:absolute;top:990px;left:162px;white-space:nowrap" class="ft051">Nigro&#160;G, Adler SP, La Torre R, Best AM,&#160;Congenital-Cytomegalovirus-Collaborating-Group.&#160;<br/>Passive immunization&#160;during&#160;pregnancy for&#160;congenital cytomegalovirus infection.&#160;</p>
<p style="position:absolute;top:1009px;left:708px;white-space:nowrap" class="ft049"><i>N Engl J Med</i></p>
<p style="position:absolute;top:1009px;left:799px;white-space:nowrap" class="ft047">.&#160;</p>
<p style="position:absolute;top:1028px;left:162px;white-space:nowrap" class="ft047">2005;353(13):1350-1362.&#160;Available at:&#160;</p>
<p style="position:absolute;top:1028px;left:425px;white-space:nowrap" class="ft050">http://www.ncbi.nlm.nih.gov/pubmed/16192480</p>
<p style="position:absolute;top:1028px;left:745px;white-space:nowrap" class="ft047">.&#160;</p>
</div>
<!-- Page 196 -->
<a name="196"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page196-div" style="position:relative;width:917px;height:1187px;">
<p style="position:absolute;top:1132px;left:108px;white-space:nowrap" class="ft024"><i>Guidelines for the Prevention and Treatment&#160;of&#160;Opportunistic&#160;Infections in Adults&#160;and Adolescents&#160;With HIV&#160;</i></p>
<p style="position:absolute;top:1132px;left:784px;white-space:nowrap" class="ft024"><i>K-27&#160;</i></p>
<p style="position:absolute;top:109px;left:108px;white-space:nowrap" class="ft047">130.</p>
<p style="position:absolute;top:108px;left:137px;white-space:nowrap" class="ft048">&#160;</p>
<p style="position:absolute;top:109px;left:162px;white-space:nowrap" class="ft051">Nigro&#160;G, Torre RL,&#160;Pentimalli&#160;H, et al.&#160;Regression&#160;of fetal cerebral abnormalities by&#160;primary&#160;<br/>cytomegalovirus infection&#160;following&#160;hyperimmunoglobulin therapy.&#160;</p>
<p style="position:absolute;top:128px;left:616px;white-space:nowrap" class="ft049"><i>Prenat Diagn</i></p>
<p style="position:absolute;top:128px;left:706px;white-space:nowrap" class="ft047">.&#160;</p>
<p style="position:absolute;top:147px;left:162px;white-space:nowrap" class="ft047">2008;28(6):512-517.&#160;Available at:&#160;</p>
<p style="position:absolute;top:147px;left:392px;white-space:nowrap" class="ft050">http://www.ncbi.nlm.nih.gov/pubmed/18509871</p>
<p style="position:absolute;top:147px;left:712px;white-space:nowrap" class="ft047">.&#160;</p>
<p style="position:absolute;top:184px;left:108px;white-space:nowrap" class="ft047">131.</p>
<p style="position:absolute;top:183px;left:137px;white-space:nowrap" class="ft048">&#160;</p>
<p style="position:absolute;top:184px;left:162px;white-space:nowrap" class="ft051">Nigro&#160;G, Adler SP, Congenital-Cytomegalic-Disease-Collaborating-Group.&#160;High-dose&#160;<br/>cytomegalovirus (CMV) hyperimmune globulin&#160;and&#160;maternal CMV DNAemia&#160;independently&#160;<br/>predict infant&#160;outcome in&#160;pregnant&#160;women&#160;with&#160;a primary&#160;CMV infection.&#160;</p>
<p style="position:absolute;top:222px;left:656px;white-space:nowrap" class="ft049"><i>Clin Infect Dis</i></p>
<p style="position:absolute;top:222px;left:753px;white-space:nowrap" class="ft047">.&#160;</p>
<p style="position:absolute;top:241px;left:162px;white-space:nowrap" class="ft047">2020;71(6):1491-1498.&#160;Available at:&#160;</p>
<p style="position:absolute;top:241px;left:408px;white-space:nowrap" class="ft050">https://pubmed.ncbi.nlm.nih.gov/31628849/</p>
<p style="position:absolute;top:241px;left:699px;white-space:nowrap" class="ft047">.&#160;</p>
<p style="position:absolute;top:278px;left:108px;white-space:nowrap" class="ft047">132.</p>
<p style="position:absolute;top:277px;left:137px;white-space:nowrap" class="ft048">&#160;</p>
<p style="position:absolute;top:278px;left:162px;white-space:nowrap" class="ft047">Hughes B. LB17. Randomized&#160;trial to&#160;prevent&#160;congenital cytomegalovirus (CMV).&#160;</p>
<p style="position:absolute;top:278px;left:714px;white-space:nowrap" class="ft049"><i>Open&#160;Forum&#160;</i></p>
<p style="position:absolute;top:296px;left:162px;white-space:nowrap" class="ft049"><i>Infectious Diseases&#160;</i></p>
<p style="position:absolute;top:296px;left:294px;white-space:nowrap" class="ft047">2019;6:S1000-S1001. Available at:&#160;</p>
<p style="position:absolute;top:315px;left:162px;white-space:nowrap" class="ft050">https://academic.oup.com/ofid/article/6/Supplement_2/S1000/5603805</p>
<p style="position:absolute;top:315px;left:630px;white-space:nowrap" class="ft047">.&#160;</p>
<p style="position:absolute;top:352px;left:108px;white-space:nowrap" class="ft047">133.</p>
<p style="position:absolute;top:352px;left:137px;white-space:nowrap" class="ft048">&#160;</p>
<p style="position:absolute;top:352px;left:162px;white-space:nowrap" class="ft051">Revello&#160;MG, Lazzarotto&#160;T, Guerra B, et&#160;al. A randomized&#160;trial of hyperimmune globulin to&#160;<br/>prevent congenital cytomegalovirus.&#160;</p>
<p style="position:absolute;top:371px;left:407px;white-space:nowrap" class="ft049"><i>N&#160;Engl J Med</i></p>
<p style="position:absolute;top:371px;left:498px;white-space:nowrap" class="ft047">. 2014;370(14):1316-1326.&#160;Available at:&#160;</p>
<p style="position:absolute;top:390px;left:162px;white-space:nowrap" class="ft050">http://www.ncbi.nlm.nih.gov/pubmed/24693891</p>
<p style="position:absolute;top:390px;left:482px;white-space:nowrap" class="ft047">.&#160;</p>
<p style="position:absolute;top:427px;left:108px;white-space:nowrap" class="ft047">134.</p>
<p style="position:absolute;top:427px;left:137px;white-space:nowrap" class="ft048">&#160;</p>
<p style="position:absolute;top:427px;left:162px;white-space:nowrap" class="ft051">Hughes BL, Clifton&#160;RG, Rouse&#160;DJ, et&#160;al. A trial of hyperimmune globulin&#160;to&#160;prevent&#160;congenital&#160;<br/>cytomegalovirus infection.&#160;</p>
<p style="position:absolute;top:446px;left:343px;white-space:nowrap" class="ft049"><i>N Engl J Med</i></p>
<p style="position:absolute;top:446px;left:434px;white-space:nowrap" class="ft047">.&#160;2021;385(5):436-444. Available at:&#160;</p>
<p style="position:absolute;top:465px;left:162px;white-space:nowrap" class="ft050">https://www.ncbi.nlm.nih.gov/pubmed/34320288</p>
<p style="position:absolute;top:465px;left:488px;white-space:nowrap" class="ft047">.&#160;</p>
<p style="position:absolute;top:502px;left:108px;white-space:nowrap" class="ft047">135.</p>
<p style="position:absolute;top:502px;left:137px;white-space:nowrap" class="ft048">&#160;</p>
<p style="position:absolute;top:502px;left:162px;white-space:nowrap" class="ft051">Egloff C,&#160;Sibiude J, Vauloup-Fellous C, et al. New data on&#160;efficacy of valacyclovir in&#160;secondary&#160;<br/>prevention&#160;of maternal-fetal transmission&#160;of cytomegalovirus.&#160;</p>
<p style="position:absolute;top:521px;left:575px;white-space:nowrap" class="ft049"><i>Ultrasound&#160;Obstet Gynecol</i></p>
<p style="position:absolute;top:521px;left:756px;white-space:nowrap" class="ft047">.&#160;</p>
<p style="position:absolute;top:540px;left:162px;white-space:nowrap" class="ft047">2023;61(1):59-66. Available at:&#160;</p>
<p style="position:absolute;top:540px;left:376px;white-space:nowrap" class="ft050">https://www.ncbi.nlm.nih.gov/pubmed/35900718</p>
<p style="position:absolute;top:540px;left:702px;white-space:nowrap" class="ft047">.&#160;</p>
<p style="position:absolute;top:577px;left:108px;white-space:nowrap" class="ft047">136.</p>
<p style="position:absolute;top:577px;left:137px;white-space:nowrap" class="ft048">&#160;</p>
<p style="position:absolute;top:577px;left:162px;white-space:nowrap" class="ft051">Shahar-Nissan&#160;K, Pardo&#160;J,&#160;Peled&#160;O, et&#160;al.&#160;Valaciclovir&#160;to&#160;prevent&#160;vertical transmission&#160;of&#160;<br/>cytomegalovirus after maternal primary&#160;infection&#160;during&#160;pregnancy: a randomised, double-blind,&#160;<br/>placebo-controlled&#160;trial.&#160;</p>
<p style="position:absolute;top:615px;left:325px;white-space:nowrap" class="ft049"><i>Lancet</i></p>
<p style="position:absolute;top:615px;left:369px;white-space:nowrap" class="ft047">. 2020;396(10253):779-785. Available at:&#160;</p>
<p style="position:absolute;top:634px;left:162px;white-space:nowrap" class="ft050">https://www.ncbi.nlm.nih.gov/pubmed/32919517</p>
<p style="position:absolute;top:634px;left:488px;white-space:nowrap" class="ft047">.&#160;</p>
<p style="position:absolute;top:671px;left:108px;white-space:nowrap" class="ft047">137.</p>
<p style="position:absolute;top:671px;left:137px;white-space:nowrap" class="ft048">&#160;</p>
<p style="position:absolute;top:671px;left:162px;white-space:nowrap" class="ft051">Chatzakis C,&#160;Sotiriadis A, Dinas K, Ville Y. Neonatal&#160;and&#160;long-term outcomes&#160;of infants with&#160;<br/>congenital&#160;cytomegalovirus infection&#160;and&#160;negative amniocentesis:&#160;systematic review and&#160;meta-<br/>analysis.&#160;</p>
<p style="position:absolute;top:709px;left:223px;white-space:nowrap" class="ft049"><i>Ultrasound&#160;Obstet Gynecol</i></p>
<p style="position:absolute;top:709px;left:405px;white-space:nowrap" class="ft047">. 2023;61(2):158-167.&#160;Available at:&#160;</p>
<p style="position:absolute;top:728px;left:162px;white-space:nowrap" class="ft050">https://www.ncbi.nlm.nih.gov/pubmed/36412976</p>
<p style="position:absolute;top:728px;left:488px;white-space:nowrap" class="ft047">.&#160;</p>
<p style="position:absolute;top:765px;left:108px;white-space:nowrap" class="ft047">138.</p>
<p style="position:absolute;top:765px;left:137px;white-space:nowrap" class="ft048">&#160;</p>
<p style="position:absolute;top:765px;left:162px;white-space:nowrap" class="ft051">Faure-Bardon&#160;V, Fourgeaud J,&#160;Stirnemann&#160;J,&#160;Leruez-Ville M,&#160;Ville Y. Secondary&#160;prevention of&#160;<br/>congenital cytomegalovirus infection&#160;with&#160;valacyclovir&#160;following&#160;maternal primary&#160;infection&#160;in&#160;<br/>early&#160;pregnancy.&#160;</p>
<p style="position:absolute;top:803px;left:276px;white-space:nowrap" class="ft049"><i>Ultrasound&#160;Obstet Gynecol</i></p>
<p style="position:absolute;top:803px;left:457px;white-space:nowrap" class="ft047">.&#160;2021;58(4):576-581.&#160;Available at:&#160;</p>
<p style="position:absolute;top:822px;left:162px;white-space:nowrap" class="ft050">https://www.ncbi.nlm.nih.gov/pubmed/33998084</p>
<p style="position:absolute;top:822px;left:488px;white-space:nowrap" class="ft047">.&#160;</p>
<p style="position:absolute;top:859px;left:108px;white-space:nowrap" class="ft047">139.</p>
<p style="position:absolute;top:859px;left:137px;white-space:nowrap" class="ft048">&#160;</p>
<p style="position:absolute;top:859px;left:162px;white-space:nowrap" class="ft051">Zammarchi&#160;L, Tomasoni LR, Liuzzi G,&#160;et al.&#160;Treatment with&#160;valacyclovir during&#160;pregnancy&#160;for&#160;<br/>prevention&#160;of congenital cytomegalovirus infection:&#160;a real-life&#160;multicenter Italian&#160;observational&#160;<br/>study.&#160;</p>
<p style="position:absolute;top:897px;left:206px;white-space:nowrap" class="ft049"><i>Am J&#160;Obstet Gynecol</i></p>
<p style="position:absolute;top:897px;left:346px;white-space:nowrap" class="ft047">. 2023;5(10):1-10. Available at:&#160;</p>
<p style="position:absolute;top:916px;left:162px;white-space:nowrap" class="ft050">https://www.ajogmfm.org/article/S2589-9333(23)00243-4/fulltext</p>
<p style="position:absolute;top:916px;left:599px;white-space:nowrap" class="ft047">.&#160;</p>
</div>
<!-- Page 197 -->
<a name="197"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}	.ft0151{font-size:14px;font-family:DLWLNJ+HelveticaLTStd-LightObl;color:#231f1f;}
	.ft0152{font-size:14px;font-family:SSXFYJ+Arial,Italic;color:#231f1f;}
	.ft0153{font-size:24px;font-family:SNNOPR+HelveticaLTStd;color:#244f9e;}
	.ft0154{font-size:18px;font-family:SNNOPR+HelveticaLTStd;color:#244f9e;}
	.ft0155{font-size:18px;font-family:PQNALN+MinionPro;color:#244f9e;}
	.ft0156{font-size:18px;font-family:MLWKWG+Arial,Bold;color:#244f9e;}
	.ft0157{font-size:18px;font-family:UPHQDT+Arial;color:#244f9e;}
	.ft0158{font-size:18px;font-family:OZDTOK+Arial;color:#244f9e;}
	.ft0159{font-size:17px;font-family:BTLIFY+Tinos;color:#231f1f;}
	.ft0160{font-size:17px;font-family:TURBHP+Tinos;color:#231f1f;}
	.ft0161{font-size:14px;font-family:TURBHP+Tinos;color:#231f1f;}
	.ft0162{font-size:17px;font-family:PKKETS+TimesNewRomanPSMT;color:#231f1f;}
	.ft0163{font-size:17px;font-family:KPYRPS+Tinos;color:#231f1f;}
	.ft0164{font-size:17px;line-height:25px;font-family:TURBHP+Tinos;color:#231f1f;}
-->
</style>
<div id="page197-div" style="position:relative;width:917px;height:1187px;">
<p style="position:absolute;top:1117px;left:81px;white-space:nowrap" class="ft0151">Guidelines for the Prevention and Treatment of Opportunistic Infections in Adults and Adolescents with HIV&#160;</p>
<p style="position:absolute;top:1118px;left:808px;white-space:nowrap" class="ft0152"><i>KK</i></p>
<p style="position:absolute;top:1117px;left:827px;white-space:nowrap" class="ft0151">-1</p>
<p style="position:absolute;top:75px;left:81px;white-space:nowrap" class="ft0153"><b>Appendix&#160;A.&#160;List of&#160;Abbreviations &#160;</b></p>
<p style="position:absolute;top:81px;left:476px;white-space:nowrap" class="ft0154"><b>(Last updated May 7,&#160;2013;&#160;last reviewed</b></p>
<p style="position:absolute;top:80px;left:819px;white-space:nowrap" class="ft0155">&#160;</p>
<p style="position:absolute;top:111px;left:81px;white-space:nowrap" class="ft0156"><b>January</b></p>
<p style="position:absolute;top:111px;left:150px;white-space:nowrap" class="ft0157"><b>&#160;</b></p>
<p style="position:absolute;top:111px;left:155px;white-space:nowrap" class="ft0158"><b>8</b></p>
<p style="position:absolute;top:111px;left:165px;white-space:nowrap" class="ft0157"><b>, 202</b></p>
<p style="position:absolute;top:111px;left:205px;white-space:nowrap" class="ft0158"><b>5</b></p>
<p style="position:absolute;top:110px;left:215px;white-space:nowrap" class="ft0154"><b>)</b></p>
<p style="position:absolute;top:148px;left:81px;white-space:nowrap" class="ft0159"><b>Acronym/Abbreviation</b></p>
<p style="position:absolute;top:179px;left:81px;white-space:nowrap" class="ft0164">ABGs &#160;<br/>ACTG &#160;<br/>AFB&#160;<br/>AIN &#160;<br/>ALT&#160;&#160;<br/>anti-HBc&#160;<br/>anti-HBs&#160;<br/>ART&#160;&#160;<br/>ARV&#160;&#160;<br/>ASCCP&#160;&#160;<br/>ASC-H &#160;</p>
<p style="position:absolute;top:482px;left:81px;white-space:nowrap" class="ft0164">ASC-US&#160;<br/>AST&#160;<br/>AUC&#160;<br/>BA&#160;<br/>BAL&#160;<br/>BID&#160;<br/>BIW&#160;<br/>CAP&#160;<br/>CAPD&#160;<br/>CD4&#160;<br/>CDC&#160;<br/>CDI&#160;<br/>CES-D&#160;<br/>CFU&#160;<br/>CIA&#160;<br/>CIN&#160;<br/>C</p>
<p style="position:absolute;top:899px;left:93px;white-space:nowrap" class="ft0161">max</p>
<p style="position:absolute;top:892px;left:117px;white-space:nowrap" class="ft0160">&#160;</p>
<p style="position:absolute;top:918px;left:81px;white-space:nowrap" class="ft0160">C</p>
<p style="position:absolute;top:925px;left:93px;white-space:nowrap" class="ft0161">min</p>
<p style="position:absolute;top:918px;left:115px;white-space:nowrap" class="ft0160">&#160;</p>
<p style="position:absolute;top:943px;left:81px;white-space:nowrap" class="ft0164">CMV&#160;<br/>CNS&#160;<br/>CPE&#160;<br/>CrCl&#160;<br/>CSF&#160;<br/>CT&#160;</p>
<p style="position:absolute;top:148px;left:351px;white-space:nowrap" class="ft0159"><b>Definition</b></p>
<p style="position:absolute;top:179px;left:351px;white-space:nowrap" class="ft0164">arterial blood gases<br/>AIDS Clinical&#160;Trials Group<br/>acid-fact bacilli<br/>anal intraepithelial neoplasia<br/>alanine aminotransferase<br/>hepatitis B core antibody<br/>hepatitis B surface antibody<br/>antiretroviral therapy<br/>antiretroviral<br/>American Society for Colposcopy and Cervical Pathology</p>
<p style="position:absolute;top:409px;left:752px;white-space:nowrap" class="ft0162">&#160;</p>
<p style="position:absolute;top:434px;left:351px;white-space:nowrap" class="ft0164">&#160;atypical squamous cells—cannot exclude high grade cervical&#160;<br/>squamous intraepithelial lesion<br/>atypical squamous cells of uncertain significance<br/>serum aspartate aminotransferase<br/>area under the curve<br/>bacillary angiomatosis<br/>bronchoalveolar lavage<br/>twice a day<br/>twice a week<br/>community-acquired pneumonia<br/>continuous ambulatory peritoneal dialysis<br/>CD4&#160;T&#160;lymphocyte cell<br/>Centers for Disease Control and Prevention</p>
<p style="position:absolute;top:766px;left:351px;white-space:nowrap" class="ft0163"><i>Clostridium difficile</i></p>
<p style="position:absolute;top:766px;left:490px;white-space:nowrap" class="ft0160">-associated infection</p>
<p style="position:absolute;top:791px;left:351px;white-space:nowrap" class="ft0160">Center for Epidemiologic Studies Depression Scale</p>
<p style="position:absolute;top:791px;left:706px;white-space:nowrap" class="ft0162">&#160;</p>
<p style="position:absolute;top:817px;left:351px;white-space:nowrap" class="ft0164">colony-forming unit<br/>chemiluminescence immunoassays&#160;<br/>cervical intraepithelial neoplasia<br/>maximum concentration<br/>minimum concentration<br/>cytomegalovirus<br/>central nervous system<br/>central nervous system penetration effectiveness<br/>creatinine clearance<br/>cerebrospinal fluid<br/>computed tomography</p>
</div>
<!-- Page 198 -->
<a name="198"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page198-div" style="position:relative;width:917px;height:1187px;">
<p style="position:absolute;top:1117px;left:81px;white-space:nowrap" class="ft0151">Guidelines for the Prevention and Treatment of Opportunistic Infections in Adults and Adolescents with HIV&#160;</p>
<p style="position:absolute;top:1118px;left:808px;white-space:nowrap" class="ft0152"><i>KK</i></p>
<p style="position:absolute;top:1117px;left:827px;white-space:nowrap" class="ft0151">-2</p>
<p style="position:absolute;top:78px;left:81px;white-space:nowrap" class="ft0160">CYP3A4&#160;</p>
<p style="position:absolute;top:78px;left:351px;white-space:nowrap" class="ft0160">Cytochrome P450 3A4</p>
<p style="position:absolute;top:103px;left:81px;white-space:nowrap" class="ft0160">DAAs&#160;</p>
<p style="position:absolute;top:103px;left:351px;white-space:nowrap" class="ft0160">direct acting antiviral agents</p>
<p style="position:absolute;top:129px;left:81px;white-space:nowrap" class="ft0160">DOT&#160;</p>
<p style="position:absolute;top:129px;left:351px;white-space:nowrap" class="ft0160">directly observed therapy</p>
<p style="position:absolute;top:155px;left:81px;white-space:nowrap" class="ft0160">DS&#160;</p>
<p style="position:absolute;top:155px;left:351px;white-space:nowrap" class="ft0160">double strength</p>
<p style="position:absolute;top:180px;left:81px;white-space:nowrap" class="ft0160">EDTA&#160;</p>
<p style="position:absolute;top:180px;left:351px;white-space:nowrap" class="ft0160">ethylenediaminetetraacetic acid</p>
<p style="position:absolute;top:206px;left:81px;white-space:nowrap" class="ft0160">EIAs&#160;</p>
<p style="position:absolute;top:206px;left:351px;white-space:nowrap" class="ft0160">enzyme immunoassays&#160;</p>
<p style="position:absolute;top:231px;left:81px;white-space:nowrap" class="ft0160">EM&#160;</p>
<p style="position:absolute;top:231px;left:351px;white-space:nowrap" class="ft0160">erythema multiforme</p>
<p style="position:absolute;top:257px;left:81px;white-space:nowrap" class="ft0160">FDA&#160;</p>
<p style="position:absolute;top:257px;left:351px;white-space:nowrap" class="ft0160">Food and Drug&#160;Administration</p>
<p style="position:absolute;top:283px;left:81px;white-space:nowrap" class="ft0160">FTA-ABS&#160;</p>
<p style="position:absolute;top:283px;left:351px;white-space:nowrap" class="ft0160">fluorescent treponemal antibody absorbed&#160;</p>
<p style="position:absolute;top:308px;left:81px;white-space:nowrap" class="ft0160">g&#160;</p>
<p style="position:absolute;top:308px;left:351px;white-space:nowrap" class="ft0160">gram</p>
<p style="position:absolute;top:334px;left:81px;white-space:nowrap" class="ft0160">G6PD&#160;</p>
<p style="position:absolute;top:334px;left:351px;white-space:nowrap" class="ft0160">Glucose-6-phosphate dehydrogenase</p>
<p style="position:absolute;top:360px;left:81px;white-space:nowrap" class="ft0160">GFR&#160;</p>
<p style="position:absolute;top:360px;left:351px;white-space:nowrap" class="ft0160">glomerular filtration rate</p>
<p style="position:absolute;top:385px;left:81px;white-space:nowrap" class="ft0160">GI&#160;</p>
<p style="position:absolute;top:385px;left:351px;white-space:nowrap" class="ft0160">gastrointestinal</p>
<p style="position:absolute;top:411px;left:81px;white-space:nowrap" class="ft0160">HAV&#160;</p>
<p style="position:absolute;top:411px;left:351px;white-space:nowrap" class="ft0160">hepatitis&#160;A&#160;virus</p>
<p style="position:absolute;top:437px;left:81px;white-space:nowrap" class="ft0160">HBV&#160;</p>
<p style="position:absolute;top:437px;left:351px;white-space:nowrap" class="ft0160">hepatitis B virus</p>
<p style="position:absolute;top:462px;left:81px;white-space:nowrap" class="ft0160">HCV&#160;</p>
<p style="position:absolute;top:462px;left:351px;white-space:nowrap" class="ft0160">hepatitis C virus</p>
<p style="position:absolute;top:488px;left:81px;white-space:nowrap" class="ft0160">HHV-8&#160;</p>
<p style="position:absolute;top:488px;left:351px;white-space:nowrap" class="ft0160">human herpesvirus-8</p>
<p style="position:absolute;top:514px;left:81px;white-space:nowrap" class="ft0160">HPA&#160;</p>
<p style="position:absolute;top:514px;left:351px;white-space:nowrap" class="ft0160">hypothalamic-pituitary-adrenal</p>
<p style="position:absolute;top:539px;left:81px;white-space:nowrap" class="ft0160">HPV&#160;</p>
<p style="position:absolute;top:539px;left:351px;white-space:nowrap" class="ft0160">human papillomavirus</p>
<p style="position:absolute;top:565px;left:81px;white-space:nowrap" class="ft0160">HSIL&#160;</p>
<p style="position:absolute;top:565px;left:351px;white-space:nowrap" class="ft0160">high grade cervical squamous intraepithelial lesion</p>
<p style="position:absolute;top:591px;left:81px;white-space:nowrap" class="ft0160">HSV&#160;</p>
<p style="position:absolute;top:591px;left:351px;white-space:nowrap" class="ft0160">herpes simplex virus</p>
<p style="position:absolute;top:616px;left:81px;white-space:nowrap" class="ft0160">HSV-1&#160;</p>
<p style="position:absolute;top:616px;left:351px;white-space:nowrap" class="ft0160">herpes simplex virus 1</p>
<p style="position:absolute;top:642px;left:81px;white-space:nowrap" class="ft0160">HSV-2&#160;</p>
<p style="position:absolute;top:642px;left:351px;white-space:nowrap" class="ft0160">herpes simplex virus 2</p>
<p style="position:absolute;top:668px;left:81px;white-space:nowrap" class="ft0160">ICP&#160;</p>
<p style="position:absolute;top:668px;left:351px;white-space:nowrap" class="ft0160">intracranial pressure</p>
<p style="position:absolute;top:693px;left:81px;white-space:nowrap" class="ft0160">ICU&#160;</p>
<p style="position:absolute;top:693px;left:351px;white-space:nowrap" class="ft0160">intensive care unit</p>
<p style="position:absolute;top:719px;left:81px;white-space:nowrap" class="ft0160">IFN&#160;</p>
<p style="position:absolute;top:719px;left:351px;white-space:nowrap" class="ft0160">interferon</p>
<p style="position:absolute;top:744px;left:81px;white-space:nowrap" class="ft0160">IgG&#160;</p>
<p style="position:absolute;top:744px;left:351px;white-space:nowrap" class="ft0160">immunoglobulin G</p>
<p style="position:absolute;top:770px;left:81px;white-space:nowrap" class="ft0160">IgM&#160;</p>
<p style="position:absolute;top:770px;left:351px;white-space:nowrap" class="ft0160">immunoglobulin M</p>
<p style="position:absolute;top:796px;left:81px;white-space:nowrap" class="ft0160">IGRA&#160;</p>
<p style="position:absolute;top:796px;left:351px;white-space:nowrap" class="ft0160">interferon-gamma release assays</p>
<p style="position:absolute;top:821px;left:81px;white-space:nowrap" class="ft0160">IM&#160;</p>
<p style="position:absolute;top:821px;left:351px;white-space:nowrap" class="ft0160">intramuscular</p>
<p style="position:absolute;top:847px;left:81px;white-space:nowrap" class="ft0160">IND&#160;</p>
<p style="position:absolute;top:847px;left:351px;white-space:nowrap" class="ft0160">investigational new drug</p>
<p style="position:absolute;top:873px;left:81px;white-space:nowrap" class="ft0160">IRIS&#160;</p>
<p style="position:absolute;top:873px;left:351px;white-space:nowrap" class="ft0160">immune reconstitution inflammatory syndrome</p>
<p style="position:absolute;top:898px;left:81px;white-space:nowrap" class="ft0160">IRU&#160;</p>
<p style="position:absolute;top:898px;left:351px;white-space:nowrap" class="ft0160">immune recovery uveitis</p>
<p style="position:absolute;top:924px;left:81px;white-space:nowrap" class="ft0160">IV</p>
<p style="position:absolute;top:924px;left:351px;white-space:nowrap" class="ft0160">intravenous</p>
<p style="position:absolute;top:950px;left:81px;white-space:nowrap" class="ft0160">IVIG&#160;</p>
<p style="position:absolute;top:950px;left:351px;white-space:nowrap" class="ft0160">intravenous immunoglobulin</p>
<p style="position:absolute;top:975px;left:81px;white-space:nowrap" class="ft0160">JCV&#160;</p>
<p style="position:absolute;top:975px;left:351px;white-space:nowrap" class="ft0160">JC virus</p>
<p style="position:absolute;top:1001px;left:81px;white-space:nowrap" class="ft0160">KS&#160;</p>
<p style="position:absolute;top:1001px;left:351px;white-space:nowrap" class="ft0160">Kaposi Sarcoma</p>
<p style="position:absolute;top:1027px;left:81px;white-space:nowrap" class="ft0160">LEEP&#160;</p>
<p style="position:absolute;top:1027px;left:351px;white-space:nowrap" class="ft0160">loop electrosurgical excision procedure</p>
<p style="position:absolute;top:1052px;left:81px;white-space:nowrap" class="ft0160">LP&#160;</p>
<p style="position:absolute;top:1052px;left:351px;white-space:nowrap" class="ft0160">lumbar puncture</p>
<p style="position:absolute;top:1078px;left:81px;white-space:nowrap" class="ft0160">LSIL&#160;</p>
<p style="position:absolute;top:1078px;left:351px;white-space:nowrap" class="ft0160">low grade squamous intraepithelial lesion</p>
</div>
<!-- Page 199 -->
<a name="199"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page199-div" style="position:relative;width:917px;height:1187px;">
<p style="position:absolute;top:1117px;left:81px;white-space:nowrap" class="ft0151">Guidelines for the Prevention and Treatment of Opportunistic Infections in Adults and Adolescents with HIV&#160;</p>
<p style="position:absolute;top:1118px;left:808px;white-space:nowrap" class="ft0152"><i>KK</i></p>
<p style="position:absolute;top:1117px;left:827px;white-space:nowrap" class="ft0151">-3</p>
<p style="position:absolute;top:78px;left:81px;white-space:nowrap" class="ft0160">LTBI&#160;</p>
<p style="position:absolute;top:78px;left:351px;white-space:nowrap" class="ft0160">latent tuberculosis infection</p>
<p style="position:absolute;top:103px;left:81px;white-space:nowrap" class="ft0160">MAC&#160;</p>
<p style="position:absolute;top:103px;left:351px;white-space:nowrap" class="ft0163"><i>Mycobacterium avium</i></p>
<p style="position:absolute;top:103px;left:506px;white-space:nowrap" class="ft0160">&#160;complex</p>
<p style="position:absolute;top:129px;left:81px;white-space:nowrap" class="ft0160">MAI&#160;</p>
<p style="position:absolute;top:129px;left:351px;white-space:nowrap" class="ft0163"><i>Mycobacterium avium intracellulare</i></p>
<p style="position:absolute;top:155px;left:81px;white-space:nowrap" class="ft0160">MCD&#160;</p>
<p style="position:absolute;top:155px;left:351px;white-space:nowrap" class="ft0160">multicentric Castleman’s disease</p>
<p style="position:absolute;top:180px;left:81px;white-space:nowrap" class="ft0160">MDR&#160;TB&#160;</p>
<p style="position:absolute;top:180px;left:351px;white-space:nowrap" class="ft0160">multi-drug-resistant tuberculosis</p>
<p style="position:absolute;top:206px;left:81px;white-space:nowrap" class="ft0160">mg&#160;</p>
<p style="position:absolute;top:206px;left:351px;white-space:nowrap" class="ft0160">milligram</p>
<p style="position:absolute;top:231px;left:81px;white-space:nowrap" class="ft0160">mmHg&#160;</p>
<p style="position:absolute;top:231px;left:351px;white-space:nowrap" class="ft0160">millimeters of mercury</p>
<p style="position:absolute;top:257px;left:81px;white-space:nowrap" class="ft0160">MSM&#160;</p>
<p style="position:absolute;top:257px;left:351px;white-space:nowrap" class="ft0160">men who have sex with men</p>
<p style="position:absolute;top:283px;left:81px;white-space:nowrap" class="ft0160">MTB&#160;</p>
<p style="position:absolute;top:283px;left:351px;white-space:nowrap" class="ft0163"><i>Mycobacterium tuberculosis</i></p>
<p style="position:absolute;top:308px;left:81px;white-space:nowrap" class="ft0160">NAA&#160;</p>
<p style="position:absolute;top:308px;left:351px;white-space:nowrap" class="ft0160">nucleic acid amplification</p>
<p style="position:absolute;top:334px;left:81px;white-space:nowrap" class="ft0160">NNRTI&#160;</p>
<p style="position:absolute;top:334px;left:351px;white-space:nowrap" class="ft0160">non-nucleoside reverse transcriptase inhibitor</p>
<p style="position:absolute;top:360px;left:81px;white-space:nowrap" class="ft0160">NRTI&#160;</p>
<p style="position:absolute;top:360px;left:351px;white-space:nowrap" class="ft0160">nucleoside reverse transcriptase inhibitors</p>
<p style="position:absolute;top:385px;left:81px;white-space:nowrap" class="ft0160">NSAID&#160;</p>
<p style="position:absolute;top:385px;left:351px;white-space:nowrap" class="ft0160">non-steroidal anti-inflammatory drugs</p>
<p style="position:absolute;top:411px;left:81px;white-space:nowrap" class="ft0160">NVP&#160;</p>
<p style="position:absolute;top:411px;left:351px;white-space:nowrap" class="ft0160">nevirapine</p>
<p style="position:absolute;top:437px;left:81px;white-space:nowrap" class="ft0160">OI&#160;</p>
<p style="position:absolute;top:437px;left:351px;white-space:nowrap" class="ft0160">opportunistic infection</p>
<p style="position:absolute;top:462px;left:81px;white-space:nowrap" class="ft0160">PCP&#160;</p>
<p style="position:absolute;top:462px;left:351px;white-space:nowrap" class="ft0163"><i>Pneumocystis</i></p>
<p style="position:absolute;top:462px;left:446px;white-space:nowrap" class="ft0160">&#160;pneumonia</p>
<p style="position:absolute;top:488px;left:81px;white-space:nowrap" class="ft0160">PCR&#160;</p>
<p style="position:absolute;top:488px;left:351px;white-space:nowrap" class="ft0160">polymerase chain reaction</p>
<p style="position:absolute;top:514px;left:81px;white-space:nowrap" class="ft0160">PEL&#160;</p>
<p style="position:absolute;top:514px;left:351px;white-space:nowrap" class="ft0160">primary effusion lymphoma</p>
<p style="position:absolute;top:539px;left:81px;white-space:nowrap" class="ft0160">PK&#160;</p>
<p style="position:absolute;top:539px;left:351px;white-space:nowrap" class="ft0160">pharmacokinetic</p>
<p style="position:absolute;top:565px;left:81px;white-space:nowrap" class="ft0160">PML&#160;</p>
<p style="position:absolute;top:565px;left:351px;white-space:nowrap" class="ft0160">progressive multifocal leukoencephalopathy</p>
<p style="position:absolute;top:591px;left:81px;white-space:nowrap" class="ft0160">PO&#160;</p>
<p style="position:absolute;top:591px;left:351px;white-space:nowrap" class="ft0160">orally</p>
<p style="position:absolute;top:616px;left:81px;white-space:nowrap" class="ft0160">PORN&#160;</p>
<p style="position:absolute;top:616px;left:351px;white-space:nowrap" class="ft0160">Progressive Outer Retinal Necrosis</p>
<p style="position:absolute;top:642px;left:81px;white-space:nowrap" class="ft0160">PPV&#160;</p>
<p style="position:absolute;top:642px;left:351px;white-space:nowrap" class="ft0160">polysaccharide vaccine</p>
<p style="position:absolute;top:668px;left:81px;white-space:nowrap" class="ft0160">PSI&#160;</p>
<p style="position:absolute;top:668px;left:351px;white-space:nowrap" class="ft0160">pneumonia severity index</p>
<p style="position:absolute;top:693px;left:81px;white-space:nowrap" class="ft0160">q(n)h&#160;</p>
<p style="position:absolute;top:693px;left:351px;white-space:nowrap" class="ft0160">every ”n” hours</p>
<p style="position:absolute;top:719px;left:81px;white-space:nowrap" class="ft0160">qAM&#160;</p>
<p style="position:absolute;top:719px;left:351px;white-space:nowrap" class="ft0160">every morning</p>
<p style="position:absolute;top:744px;left:81px;white-space:nowrap" class="ft0160">QID&#160;</p>
<p style="position:absolute;top:744px;left:351px;white-space:nowrap" class="ft0160">four times a day</p>
<p style="position:absolute;top:770px;left:81px;white-space:nowrap" class="ft0160">qPM&#160;</p>
<p style="position:absolute;top:770px;left:351px;white-space:nowrap" class="ft0160">every evening</p>
<p style="position:absolute;top:796px;left:81px;white-space:nowrap" class="ft0160">RPR&#160;</p>
<p style="position:absolute;top:796px;left:351px;white-space:nowrap" class="ft0160">rapid plasma reagin&#160;</p>
<p style="position:absolute;top:821px;left:81px;white-space:nowrap" class="ft0160">RVR&#160;</p>
<p style="position:absolute;top:821px;left:351px;white-space:nowrap" class="ft0160">rapid virological response</p>
<p style="position:absolute;top:847px;left:81px;white-space:nowrap" class="ft0160">SCr&#160;</p>
<p style="position:absolute;top:847px;left:351px;white-space:nowrap" class="ft0160">serum creatinine</p>
<p style="position:absolute;top:873px;left:81px;white-space:nowrap" class="ft0160">SJS&#160;</p>
<p style="position:absolute;top:873px;left:351px;white-space:nowrap" class="ft0160">Stevens-Johnson syndrome</p>
<p style="position:absolute;top:898px;left:81px;white-space:nowrap" class="ft0160">SLE&#160;</p>
<p style="position:absolute;top:898px;left:351px;white-space:nowrap" class="ft0160">systemic lupus erythematosus</p>
<p style="position:absolute;top:924px;left:81px;white-space:nowrap" class="ft0160">SQ&#160;</p>
<p style="position:absolute;top:924px;left:351px;white-space:nowrap" class="ft0160">subcutaneous</p>
<p style="position:absolute;top:950px;left:81px;white-space:nowrap" class="ft0160">SS&#160;</p>
<p style="position:absolute;top:950px;left:351px;white-space:nowrap" class="ft0160">single strength</p>
<p style="position:absolute;top:975px;left:81px;white-space:nowrap" class="ft0160">STD&#160;</p>
<p style="position:absolute;top:975px;left:351px;white-space:nowrap" class="ft0160">sexually transmitted disease</p>
<p style="position:absolute;top:1001px;left:81px;white-space:nowrap" class="ft0160">SVR&#160;</p>
<p style="position:absolute;top:1001px;left:351px;white-space:nowrap" class="ft0160">sustained virologic response</p>
<p style="position:absolute;top:1027px;left:81px;white-space:nowrap" class="ft0160">TB&#160;</p>
<p style="position:absolute;top:1027px;left:351px;white-space:nowrap" class="ft0160">tuberculosis</p>
<p style="position:absolute;top:1052px;left:81px;white-space:nowrap" class="ft0160">TDM&#160;</p>
<p style="position:absolute;top:1052px;left:351px;white-space:nowrap" class="ft0160">therapeutic drug monitoring</p>
<p style="position:absolute;top:1078px;left:81px;white-space:nowrap" class="ft0160">TE&#160;</p>
<p style="position:absolute;top:1078px;left:351px;white-space:nowrap" class="ft0163"><i>Toxoplasma</i></p>
<p style="position:absolute;top:1078px;left:435px;white-space:nowrap" class="ft0160">&#160;encephalitis</p>
</div>
<!-- Page 200 -->
<a name="200"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page200-div" style="position:relative;width:917px;height:1187px;">
<p style="position:absolute;top:1117px;left:81px;white-space:nowrap" class="ft0151">Guidelines for the Prevention and Treatment of Opportunistic Infections in Adults and Adolescents with HIV&#160;</p>
<p style="position:absolute;top:1118px;left:808px;white-space:nowrap" class="ft0152"><i>KK</i></p>
<p style="position:absolute;top:1117px;left:827px;white-space:nowrap" class="ft0151">-4</p>
<p style="position:absolute;top:78px;left:81px;white-space:nowrap" class="ft0160">TEN&#160;</p>
<p style="position:absolute;top:78px;left:351px;white-space:nowrap" class="ft0160">toxic epidermal necrolysis</p>
<p style="position:absolute;top:103px;left:81px;white-space:nowrap" class="ft0160">TID&#160;</p>
<p style="position:absolute;top:103px;left:351px;white-space:nowrap" class="ft0160">three times daily</p>
<p style="position:absolute;top:129px;left:81px;white-space:nowrap" class="ft0160">TIW&#160;</p>
<p style="position:absolute;top:129px;left:351px;white-space:nowrap" class="ft0160">three times weekly</p>
<p style="position:absolute;top:155px;left:81px;white-space:nowrap" class="ft0160">TP-PA&#160;</p>
<p style="position:absolute;top:155px;left:351px;white-space:nowrap" class="ft0163"><i>T.&#160;pallidum</i></p>
<p style="position:absolute;top:155px;left:431px;white-space:nowrap" class="ft0160">&#160;particle agglutination</p>
<p style="position:absolute;top:180px;left:81px;white-space:nowrap" class="ft0160">TST&#160;</p>
<p style="position:absolute;top:180px;left:351px;white-space:nowrap" class="ft0160">tuberculin skin test</p>
<p style="position:absolute;top:206px;left:81px;white-space:nowrap" class="ft0160">ULN&#160;</p>
<p style="position:absolute;top:206px;left:351px;white-space:nowrap" class="ft0160">upper limit of normal</p>
<p style="position:absolute;top:231px;left:81px;white-space:nowrap" class="ft0160">VAIN&#160;</p>
<p style="position:absolute;top:231px;left:351px;white-space:nowrap" class="ft0160">vaginal intra-epithelial neoplasia</p>
<p style="position:absolute;top:257px;left:81px;white-space:nowrap" class="ft0160">VDRL&#160;</p>
<p style="position:absolute;top:257px;left:351px;white-space:nowrap" class="ft0160">Venereal Disease Research Laboratory</p>
<p style="position:absolute;top:283px;left:81px;white-space:nowrap" class="ft0160">VIII&#160;</p>
<p style="position:absolute;top:283px;left:351px;white-space:nowrap" class="ft0160">vestibulocochlear</p>
<p style="position:absolute;top:308px;left:81px;white-space:nowrap" class="ft0160">VIN&#160;</p>
<p style="position:absolute;top:308px;left:351px;white-space:nowrap" class="ft0160">vulvar intraepithelial neoplasia</p>
<p style="position:absolute;top:334px;left:81px;white-space:nowrap" class="ft0160">VZV&#160;</p>
<p style="position:absolute;top:334px;left:351px;white-space:nowrap" class="ft0160">varicella zoster virus</p>
<p style="position:absolute;top:360px;left:81px;white-space:nowrap" class="ft0160">WBC&#160;</p>
<p style="position:absolute;top:360px;left:351px;white-space:nowrap" class="ft0160">white blood cell</p>
<p style="position:absolute;top:385px;left:81px;white-space:nowrap" class="ft0160">WHO&#160;</p>
<p style="position:absolute;top:385px;left:351px;white-space:nowrap" class="ft0160">World Health Organization</p>
<p style="position:absolute;top:411px;left:81px;white-space:nowrap" class="ft0160">XDR&#160;TB&#160;</p>
<p style="position:absolute;top:411px;left:351px;white-space:nowrap" class="ft0160">extensively drug-resistant tuberculosis</p>
<p style="position:absolute;top:453px;left:81px;white-space:nowrap" class="ft0159"><b>Abbreviation&#160;</b></p>
<p style="position:absolute;top:453px;left:351px;white-space:nowrap" class="ft0159"><b>Drug Name</b></p>
<p style="position:absolute;top:484px;left:81px;white-space:nowrap" class="ft0160">3TC &#160;</p>
<p style="position:absolute;top:484px;left:351px;white-space:nowrap" class="ft0160">lamivudine</p>
<p style="position:absolute;top:510px;left:81px;white-space:nowrap" class="ft0160">5-FU</p>
<p style="position:absolute;top:510px;left:351px;white-space:nowrap" class="ft0160">fluorouracil</p>
<p style="position:absolute;top:535px;left:81px;white-space:nowrap" class="ft0160">ATV/r</p>
<p style="position:absolute;top:535px;left:351px;white-space:nowrap" class="ft0160">ritonavir-boosted atazanavir</p>
<p style="position:absolute;top:561px;left:81px;white-space:nowrap" class="ft0160">BCA</p>
<p style="position:absolute;top:561px;left:351px;white-space:nowrap" class="ft0160">bichloroacetic acid</p>
<p style="position:absolute;top:587px;left:81px;white-space:nowrap" class="ft0160">BOC</p>
<p style="position:absolute;top:587px;left:351px;white-space:nowrap" class="ft0160">boceprevir</p>
<p style="position:absolute;top:612px;left:81px;white-space:nowrap" class="ft0160">COBI</p>
<p style="position:absolute;top:612px;left:351px;white-space:nowrap" class="ft0160">cobicistat</p>
<p style="position:absolute;top:638px;left:81px;white-space:nowrap" class="ft0160">ddA-TP</p>
<p style="position:absolute;top:638px;left:351px;white-space:nowrap" class="ft0160">dideoxyadenosine triphosphate</p>
<p style="position:absolute;top:663px;left:81px;white-space:nowrap" class="ft0160">ddI</p>
<p style="position:absolute;top:663px;left:351px;white-space:nowrap" class="ft0160">didanosine</p>
<p style="position:absolute;top:689px;left:81px;white-space:nowrap" class="ft0160">DHA</p>
<p style="position:absolute;top:689px;left:351px;white-space:nowrap" class="ft0160">dihydroartemisinin</p>
<p style="position:absolute;top:715px;left:81px;white-space:nowrap" class="ft0160">EFV</p>
<p style="position:absolute;top:715px;left:351px;white-space:nowrap" class="ft0160">efavirenz</p>
<p style="position:absolute;top:740px;left:81px;white-space:nowrap" class="ft0160">EMB</p>
<p style="position:absolute;top:740px;left:351px;white-space:nowrap" class="ft0160">ethambutol</p>
<p style="position:absolute;top:766px;left:81px;white-space:nowrap" class="ft0160">EVG</p>
<p style="position:absolute;top:766px;left:351px;white-space:nowrap" class="ft0160">elvitegravir</p>
<p style="position:absolute;top:792px;left:81px;white-space:nowrap" class="ft0160">FTC</p>
<p style="position:absolute;top:792px;left:351px;white-space:nowrap" class="ft0160">emtricitabine</p>
<p style="position:absolute;top:817px;left:81px;white-space:nowrap" class="ft0160">INH</p>
<p style="position:absolute;top:817px;left:351px;white-space:nowrap" class="ft0160">isoniazid</p>
<p style="position:absolute;top:843px;left:81px;white-space:nowrap" class="ft0160">MVC</p>
<p style="position:absolute;top:843px;left:351px;white-space:nowrap" class="ft0160">maraviroc</p>
<p style="position:absolute;top:869px;left:81px;white-space:nowrap" class="ft0160">PCV13</p>
<p style="position:absolute;top:869px;left:351px;white-space:nowrap" class="ft0160">13-valent pneumococcal conjugate vaccine</p>
<p style="position:absolute;top:894px;left:81px;white-space:nowrap" class="ft0160">PegIFN</p>
<p style="position:absolute;top:894px;left:351px;white-space:nowrap" class="ft0160">peginterferon alfa</p>
<p style="position:absolute;top:920px;left:81px;white-space:nowrap" class="ft0160">PI</p>
<p style="position:absolute;top:920px;left:351px;white-space:nowrap" class="ft0160">protease inhibitor</p>
<p style="position:absolute;top:946px;left:81px;white-space:nowrap" class="ft0160">PPV23</p>
<p style="position:absolute;top:946px;left:351px;white-space:nowrap" class="ft0160">23-valent pneumococcal polysaccharides vaccine</p>
<p style="position:absolute;top:971px;left:81px;white-space:nowrap" class="ft0160">PZA</p>
<p style="position:absolute;top:971px;left:351px;white-space:nowrap" class="ft0160">pyrazinamide</p>
<p style="position:absolute;top:997px;left:81px;white-space:nowrap" class="ft0160">RAL</p>
<p style="position:absolute;top:997px;left:351px;white-space:nowrap" class="ft0160">raltegravir</p>
<p style="position:absolute;top:1023px;left:81px;white-space:nowrap" class="ft0160">RBV</p>
<p style="position:absolute;top:1023px;left:351px;white-space:nowrap" class="ft0160">ribavirin</p>
<p style="position:absolute;top:1048px;left:81px;white-space:nowrap" class="ft0160">RFB</p>
<p style="position:absolute;top:1048px;left:351px;white-space:nowrap" class="ft0160">rifabutin</p>
<p style="position:absolute;top:1074px;left:81px;white-space:nowrap" class="ft0160">RIF</p>
<p style="position:absolute;top:1074px;left:351px;white-space:nowrap" class="ft0160">rifampin</p>
</div>
<!-- Page 201 -->
<a name="201"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page201-div" style="position:relative;width:917px;height:1187px;">
<p style="position:absolute;top:1117px;left:81px;white-space:nowrap" class="ft0151">Guidelines for the Prevention and Treatment of Opportunistic Infections in Adults and Adolescents with HIV&#160;</p>
<p style="position:absolute;top:1118px;left:808px;white-space:nowrap" class="ft0152"><i>KK</i></p>
<p style="position:absolute;top:1117px;left:827px;white-space:nowrap" class="ft0151">-5</p>
<p style="position:absolute;top:78px;left:81px;white-space:nowrap" class="ft0160">RPT&#160;</p>
<p style="position:absolute;top:78px;left:351px;white-space:nowrap" class="ft0160">rifapentine</p>
<p style="position:absolute;top:103px;left:81px;white-space:nowrap" class="ft0160">SMX&#160;</p>
<p style="position:absolute;top:103px;left:351px;white-space:nowrap" class="ft0160">sulfamethoxazole</p>
<p style="position:absolute;top:129px;left:81px;white-space:nowrap" class="ft0160">TCA&#160;</p>
<p style="position:absolute;top:129px;left:351px;white-space:nowrap" class="ft0160">trichloroacetic acid</p>
<p style="position:absolute;top:155px;left:81px;white-space:nowrap" class="ft0160">TDF&#160;</p>
<p style="position:absolute;top:155px;left:351px;white-space:nowrap" class="ft0160">tenofovir disoproxil fumarate</p>
<p style="position:absolute;top:180px;left:81px;white-space:nowrap" class="ft0160">TMP&#160;</p>
<p style="position:absolute;top:180px;left:351px;white-space:nowrap" class="ft0160">trimethoprim</p>
<p style="position:absolute;top:206px;left:81px;white-space:nowrap" class="ft0160">TMP-SMX&#160;</p>
<p style="position:absolute;top:206px;left:351px;white-space:nowrap" class="ft0160">trimethoprim-sulfamethoxazole</p>
<p style="position:absolute;top:231px;left:81px;white-space:nowrap" class="ft0160">TVR&#160;</p>
<p style="position:absolute;top:231px;left:351px;white-space:nowrap" class="ft0160">telaprevir</p>
<p style="position:absolute;top:257px;left:81px;white-space:nowrap" class="ft0160">ZDV&#160;</p>
<p style="position:absolute;top:257px;left:351px;white-space:nowrap" class="ft0160">zidovudine</p>
</div>
<!-- Page 202 -->
<a name="202"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}	.ft0165{font-size:15px;line-height:17px;font-family:QZSKMX+LiberationSansNarrow;color:#000000;}
-->
</style>
<div id="page202-div" style="position:relative;width:917px;height:1187px;">
<p style="position:absolute;top:1117px;left:81px;white-space:nowrap" class="ft024"><i>Guidelines for the Prevention and Treatment&#160;of&#160;Opportunistic&#160;Infections in Adults&#160;and Adolescents&#160;With HIV&#160;</i></p>
<p style="position:absolute;top:1117px;left:812px;white-space:nowrap" class="ft024"><i>LL-1</i></p>
<p style="position:absolute;top:112px;left:81px;white-space:nowrap" class="ft025"><b>Appendix&#160;B.&#160;Panel&#160;Roster&#160;and&#160;Financial&#160;Disclosures&#160;</b></p>
<p style="position:absolute;top:159px;left:81px;white-space:nowrap" class="ft026"><b>Leadership&#160;</b></p>
<p style="position:absolute;top:234px;left:135px;white-space:nowrap" class="ft02"><b>Member&#160;</b></p>
<p style="position:absolute;top:234px;left:290px;white-space:nowrap" class="ft02"><b>Institution&#160;</b></p>
<p style="position:absolute;top:224px;left:440px;white-space:nowrap" class="ft02"><b>Panel Section&#160;</b></p>
<p style="position:absolute;top:244px;left:456px;white-space:nowrap" class="ft02"><b>Group(s)&#160;</b></p>
<p style="position:absolute;top:212px;left:633px;white-space:nowrap" class="ft02"><b>Financial Disclosure&#160;</b></p>
<p style="position:absolute;top:256px;left:602px;white-space:nowrap" class="ft02"><b>Company&#160;</b></p>
<p style="position:absolute;top:256px;left:727px;white-space:nowrap" class="ft02"><b>Relationship&#160;</b></p>
<p style="position:absolute;top:288px;left:88px;white-space:nowrap" class="ft041">Constance Benson&#160;</p>
<p style="position:absolute;top:288px;left:249px;white-space:nowrap" class="ft0165"><i>University&#160;of&#160;California,&#160;<br/>San Diego&#160;School&#160;of&#160;</i></p>
<p style="position:absolute;top:322px;left:249px;white-space:nowrap" class="ft024"><i>Medicine &#160;</i></p>
<p style="position:absolute;top:288px;left:411px;white-space:nowrap" class="ft041">Leadership&#160;</p>
<p style="position:absolute;top:320px;left:411px;white-space:nowrap" class="ft024"><i>Mycobacterium avium</i></p>
<p style="position:absolute;top:320px;left:531px;white-space:nowrap" class="ft041">&#160;</p>
<p style="position:absolute;top:337px;left:411px;white-space:nowrap" class="ft041">Complex&#160;</p>
<p style="position:absolute;top:288px;left:573px;white-space:nowrap" class="ft041">Gilead&#160;Sciences&#160;</p>
<p style="position:absolute;top:314px;left:573px;white-space:nowrap" class="ft041">BioMerieux&#160;</p>
<p style="position:absolute;top:288px;left:708px;white-space:nowrap" class="ft041">Research Support&#160;</p>
<p style="position:absolute;top:341px;left:573px;white-space:nowrap" class="ft041">ViiV&#160;</p>
<p style="position:absolute;top:341px;left:708px;white-space:nowrap" class="ft044">Data and Safety&#160;<br/>Monitoring Board&#160;</p>
<p style="position:absolute;top:393px;left:88px;white-space:nowrap" class="ft041">John&#160;Brooks&#160;</p>
<p style="position:absolute;top:393px;left:249px;white-space:nowrap" class="ft024"><i>Atlanta, GA&#160;</i></p>
<p style="position:absolute;top:393px;left:411px;white-space:nowrap" class="ft041">Leadership&#160;</p>
<p style="position:absolute;top:425px;left:411px;white-space:nowrap" class="ft041">Mpox&#160;</p>
<p style="position:absolute;top:393px;left:573px;white-space:nowrap" class="ft041">None&#160;</p>
<p style="position:absolute;top:393px;left:708px;white-space:nowrap" class="ft041">N/A&#160;</p>
<p style="position:absolute;top:452px;left:88px;white-space:nowrap" class="ft041">Shireesha Dhanireddy&#160;</p>
<p style="position:absolute;top:452px;left:249px;white-space:nowrap" class="ft024"><i>University&#160;of&#160;Washington&#160;</i></p>
<p style="position:absolute;top:469px;left:249px;white-space:nowrap" class="ft024"><i>School&#160;of Medicine &#160;</i></p>
<p style="position:absolute;top:452px;left:411px;white-space:nowrap" class="ft041">Immunizations&#160;</p>
<p style="position:absolute;top:484px;left:411px;white-space:nowrap" class="ft041">Leadership&#160;</p>
<p style="position:absolute;top:452px;left:573px;white-space:nowrap" class="ft041">None&#160;</p>
<p style="position:absolute;top:452px;left:708px;white-space:nowrap" class="ft041">N/A&#160;</p>
<p style="position:absolute;top:511px;left:88px;white-space:nowrap" class="ft041">Henry&#160;Masur&#160;</p>
<p style="position:absolute;top:511px;left:249px;white-space:nowrap" class="ft024"><i>National&#160;Institutes of&#160;</i></p>
<p style="position:absolute;top:528px;left:249px;white-space:nowrap" class="ft024"><i>Health &#160;</i></p>
<p style="position:absolute;top:511px;left:411px;white-space:nowrap" class="ft041">Leadership&#160;</p>
<p style="position:absolute;top:511px;left:573px;white-space:nowrap" class="ft041">None&#160;</p>
<p style="position:absolute;top:511px;left:708px;white-space:nowrap" class="ft041">N/A&#160;</p>
<p style="position:absolute;top:555px;left:88px;white-space:nowrap" class="ft041">Alice Pau&#160;</p>
<p style="position:absolute;top:555px;left:249px;white-space:nowrap" class="ft0165"><i>National&#160;Institutes of&#160;<br/>Health &#160;</i></p>
<p style="position:absolute;top:555px;left:411px;white-space:nowrap" class="ft041">Leadership&#160;</p>
<p style="position:absolute;top:588px;left:411px;white-space:nowrap" class="ft041">Pharmacology&#160;</p>
<p style="position:absolute;top:555px;left:573px;white-space:nowrap" class="ft041">None&#160;</p>
<p style="position:absolute;top:555px;left:708px;white-space:nowrap" class="ft041">N/A&#160;</p>
<p style="position:absolute;top:615px;left:81px;white-space:nowrap" class="ft042"><b>Note:</b></p>
<p style="position:absolute;top:615px;left:116px;white-space:nowrap" class="ft041">Members&#160;are required to update disclosures&#160;annually&#160;and&#160;to notify&#160;guideline staff of any&#160;relevant changes&#160;in status during&#160;the&#160;</p>
<p style="position:absolute;top:632px;left:81px;white-space:nowrap" class="ft041">interim.&#160;</p>
</div>
<!-- Page 203 -->
<a name="203"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page203-div" style="position:relative;width:917px;height:1187px;">
<p style="position:absolute;top:1117px;left:81px;white-space:nowrap" class="ft024"><i>Guidelines for the Prevention and Treatment&#160;of&#160;Opportunistic&#160;Infections in Adults&#160;and Adolescents&#160;With HIV&#160;</i></p>
<p style="position:absolute;top:1117px;left:812px;white-space:nowrap" class="ft024"><i>LL-2&#160;</i></p>
<p style="position:absolute;top:112px;left:81px;white-space:nowrap" class="ft025"><b>Appendix&#160;B.&#160;Panel&#160;Roster&#160;and&#160;Financial&#160;Disclosures&#160;</b></p>
<p style="position:absolute;top:159px;left:81px;white-space:nowrap" class="ft026"><b>Section Review Group&#160;</b></p>
<p style="position:absolute;top:1020px;left:81px;white-space:nowrap" class="ft041">* Section Group&#160;Lead&#160;</p>
<p style="position:absolute;top:1044px;left:81px;white-space:nowrap" class="ft042"><b>Note:</b></p>
<p style="position:absolute;top:1044px;left:112px;white-space:nowrap" class="ft041">&#160;Members&#160;are required to update&#160;disclosures&#160;annually&#160;and&#160;to notify guideline staff of any&#160;relevant changes&#160;in status during the&#160;</p>
<p style="position:absolute;top:1062px;left:81px;white-space:nowrap" class="ft041">interim.&#160;</p>
<p style="position:absolute;top:230px;left:122px;white-space:nowrap" class="ft02"><b>Member&#160;</b></p>
<p style="position:absolute;top:230px;left:277px;white-space:nowrap" class="ft02"><b>Institution&#160;</b></p>
<p style="position:absolute;top:221px;left:433px;white-space:nowrap" class="ft02"><b>Panel Section&#160;</b></p>
<p style="position:absolute;top:240px;left:449px;white-space:nowrap" class="ft02"><b>Group(s)</b></p>
<p style="position:absolute;top:211px;left:626px;white-space:nowrap" class="ft02"><b>Financial Disclosure&#160;</b></p>
<p style="position:absolute;top:251px;left:595px;white-space:nowrap" class="ft02"><b>Company&#160;</b></p>
<p style="position:absolute;top:251px;left:726px;white-space:nowrap" class="ft02"><b>Relationship&#160;</b></p>
<p style="position:absolute;top:280px;left:89px;white-space:nowrap" class="ft041">Lydia&#160;Aoun-Barakat&#160;</p>
<p style="position:absolute;top:280px;left:225px;white-space:nowrap" class="ft024"><i>Yale&#160;University&#160;School&#160;of&#160;</i></p>
<p style="position:absolute;top:298px;left:225px;white-space:nowrap" class="ft024"><i>Medicine&#160;</i></p>
<p style="position:absolute;top:280px;left:413px;white-space:nowrap" class="ft041">Section&#160;Review&#160;Group&#160;&#160;</p>
<p style="position:absolute;top:280px;left:562px;white-space:nowrap" class="ft041">None&#160;</p>
<p style="position:absolute;top:280px;left:709px;white-space:nowrap" class="ft041">N/A&#160;</p>
<p style="position:absolute;top:325px;left:89px;white-space:nowrap" class="ft041">Rodrigo&#160;Burgos&#160;</p>
<p style="position:absolute;top:325px;left:225px;white-space:nowrap" class="ft0165"><i>University&#160;of&#160;Illinois&#160;Chicago,<br/>Retzky&#160;College&#160;of Pharmacy&#160;</i></p>
<p style="position:absolute;top:325px;left:413px;white-space:nowrap" class="ft041">Section&#160;Review&#160;Group</p>
<p style="position:absolute;top:357px;left:413px;white-space:nowrap" class="ft041">Pharmacology&#160;</p>
<p style="position:absolute;top:325px;left:562px;white-space:nowrap" class="ft041">ViiV&#160;Healthcare/GSK&#160;</p>
<p style="position:absolute;top:325px;left:709px;white-space:nowrap" class="ft041">Advisory&#160;Board&#160;</p>
<p style="position:absolute;top:352px;left:562px;white-space:nowrap" class="ft041">Gilead&#160;Sciences&#160;</p>
<p style="position:absolute;top:381px;left:562px;white-space:nowrap" class="ft044">Janssen Vaccines &amp;&#160;<br/>Prevention&#160;</p>
<p style="position:absolute;top:427px;left:562px;white-space:nowrap" class="ft041">Merck&#160;</p>
<p style="position:absolute;top:456px;left:562px;white-space:nowrap" class="ft041">Shionogi,&#160;Inc.&#160;</p>
<p style="position:absolute;top:486px;left:562px;white-space:nowrap" class="ft041">ViiV&#160;Healthcare/GSK&#160;</p>
<p style="position:absolute;top:352px;left:709px;white-space:nowrap" class="ft041">Research Support&#160;</p>
<p style="position:absolute;top:513px;left:562px;white-space:nowrap" class="ft041">OptumRx, Inc.&#160;</p>
<p style="position:absolute;top:513px;left:709px;white-space:nowrap" class="ft041">Consultant&#160;</p>
<p style="position:absolute;top:540px;left:89px;white-space:nowrap" class="ft041">Thomas&#160;Campbell*&#160;</p>
<p style="position:absolute;top:540px;left:225px;white-space:nowrap" class="ft024"><i>University&#160;of Colorado School&#160;</i></p>
<p style="position:absolute;top:557px;left:225px;white-space:nowrap" class="ft024"><i>of Medicine&#160;</i></p>
<p style="position:absolute;top:540px;left:413px;white-space:nowrap" class="ft041">Section&#160;Review&#160;Group</p>
<p style="position:absolute;top:540px;left:562px;white-space:nowrap" class="ft041">None&#160;</p>
<p style="position:absolute;top:540px;left:709px;white-space:nowrap" class="ft041">N/A&#160;</p>
<p style="position:absolute;top:584px;left:89px;white-space:nowrap" class="ft041">Catherine Decker&#160;</p>
<p style="position:absolute;top:584px;left:225px;white-space:nowrap" class="ft0165"><i>Walter Reed National&#160;Military&#160;<br/>Medical&#160;Center;&#160;Uniformed&#160;</i></p>
<p style="position:absolute;top:618px;left:225px;white-space:nowrap" class="ft024"><i>Services&#160;University</i></p>
<p style="position:absolute;top:617px;left:330px;white-space:nowrap" class="ft013">&#160;</p>
<p style="position:absolute;top:584px;left:413px;white-space:nowrap" class="ft041">Section&#160;Review&#160;Group</p>
<p style="position:absolute;top:584px;left:562px;white-space:nowrap" class="ft041">None&#160;&#160;</p>
<p style="position:absolute;top:584px;left:709px;white-space:nowrap" class="ft041">N/A&#160;</p>
<p style="position:absolute;top:645px;left:89px;white-space:nowrap" class="ft041">Ellen Kitchell&#160;</p>
<p style="position:absolute;top:645px;left:225px;white-space:nowrap" class="ft024"><i>The University&#160;of Texas&#160;</i></p>
<p style="position:absolute;top:662px;left:225px;white-space:nowrap" class="ft024"><i>Southwestern Medical&#160;Center&#160;</i></p>
<p style="position:absolute;top:645px;left:413px;white-space:nowrap" class="ft041">Section&#160;Review&#160;Group</p>
<p style="position:absolute;top:645px;left:562px;white-space:nowrap" class="ft041">None&#160;</p>
<p style="position:absolute;top:645px;left:709px;white-space:nowrap" class="ft041">N/A&#160;</p>
<p style="position:absolute;top:689px;left:89px;white-space:nowrap" class="ft041">Susana&#160;Lazarte&#160;</p>
<p style="position:absolute;top:689px;left:225px;white-space:nowrap" class="ft0165"><i>The University of Texas&#160;<br/>Southwestern Medical&#160;Center&#160;</i></p>
<p style="position:absolute;top:689px;left:413px;white-space:nowrap" class="ft041">Section&#160;Review&#160;Group</p>
<p style="position:absolute;top:689px;left:562px;white-space:nowrap" class="ft041">None&#160;&#160;</p>
<p style="position:absolute;top:689px;left:709px;white-space:nowrap" class="ft041">N/A&#160;</p>
<p style="position:absolute;top:733px;left:89px;white-space:nowrap" class="ft041">Paul&#160;Pham&#160;</p>
<p style="position:absolute;top:733px;left:225px;white-space:nowrap" class="ft024"><i>The Johns&#160;Hopkins University&#160;</i></p>
<p style="position:absolute;top:751px;left:225px;white-space:nowrap" class="ft0165"><i>School&#160;of Medicine; Westview&#160;<br/>Urgent Care Medi&#160;Center&#160;</i></p>
<p style="position:absolute;top:733px;left:413px;white-space:nowrap" class="ft041">Section Review&#160;Group</p>
<p style="position:absolute;top:766px;left:413px;white-space:nowrap" class="ft041">Bacteria&#160;Enteric&#160;</p>
<p style="position:absolute;top:783px;left:413px;white-space:nowrap" class="ft041">Infections&#160;</p>
<p style="position:absolute;top:733px;left:562px;white-space:nowrap" class="ft041">Novo Nordisk&#160;</p>
<p style="position:absolute;top:733px;left:709px;white-space:nowrap" class="ft041">Stockholder</p>
<p style="position:absolute;top:816px;left:89px;white-space:nowrap" class="ft041">Gregory&#160;Robbins&#160;</p>
<p style="position:absolute;top:816px;left:225px;white-space:nowrap" class="ft024"><i>Massachusetts&#160;General&#160;</i></p>
<p style="position:absolute;top:833px;left:225px;white-space:nowrap" class="ft024"><i>Hospital&#160;</i></p>
<p style="position:absolute;top:816px;left:413px;white-space:nowrap" class="ft041">Section&#160;Review&#160;Group</p>
<p style="position:absolute;top:816px;left:562px;white-space:nowrap" class="ft041">Leonard-Meron&#160;</p>
<p style="position:absolute;top:833px;left:562px;white-space:nowrap" class="ft041">Biosciences&#160;</p>
<p style="position:absolute;top:816px;left:709px;white-space:nowrap" class="ft041">Consultant&#160;</p>
<p style="position:absolute;top:860px;left:89px;white-space:nowrap" class="ft041">Anandi&#160;Sheth&#160;</p>
<p style="position:absolute;top:860px;left:225px;white-space:nowrap" class="ft0165"><i>Emory&#160;University&#160;School&#160;of&#160;<br/>Medicine&#160;</i></p>
<p style="position:absolute;top:860px;left:413px;white-space:nowrap" class="ft041">Section&#160;Review&#160;Group</p>
<p style="position:absolute;top:860px;left:562px;white-space:nowrap" class="ft041">None&#160;</p>
<p style="position:absolute;top:860px;left:709px;white-space:nowrap" class="ft041">N/A&#160;</p>
<p style="position:absolute;top:904px;left:89px;white-space:nowrap" class="ft041">William Short&#160;</p>
<p style="position:absolute;top:904px;left:225px;white-space:nowrap" class="ft024"><i>Perelman&#160;School of Medicine&#160;</i></p>
<p style="position:absolute;top:921px;left:225px;white-space:nowrap" class="ft0165"><i>at the University&#160;of&#160;<br/>Pennsylvania&#160;</i></p>
<p style="position:absolute;top:904px;left:413px;white-space:nowrap" class="ft041">Section&#160;Review&#160;Group</p>
<p style="position:absolute;top:904px;left:562px;white-space:nowrap" class="ft041">ViiV Healthcare&#160;</p>
<p style="position:absolute;top:936px;left:562px;white-space:nowrap" class="ft041">Gilead&#160;Sciences&#160;</p>
<p style="position:absolute;top:904px;left:709px;white-space:nowrap" class="ft041">Advisory&#160;Board&#160;</p>
<p style="position:absolute;top:963px;left:562px;white-space:nowrap" class="ft041">ViiV&#160;Healthcare&#160;</p>
<p style="position:absolute;top:993px;left:562px;white-space:nowrap" class="ft041">Gilead&#160;Sciences&#160;</p>
<p style="position:absolute;top:963px;left:709px;white-space:nowrap" class="ft041">Research Support&#160;</p>
</div>
<!-- Page 204 -->
<a name="204"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page204-div" style="position:relative;width:917px;height:1187px;">
<p style="position:absolute;top:1117px;left:81px;white-space:nowrap" class="ft024"><i>Guidelines for the Prevention and Treatment&#160;of&#160;Opportunistic&#160;Infections in Adults&#160;and Adolescents&#160;With HIV&#160;</i></p>
<p style="position:absolute;top:1117px;left:812px;white-space:nowrap" class="ft024"><i>LL-3&#160;</i></p>
<p style="position:absolute;top:112px;left:81px;white-space:nowrap" class="ft025"><b>Appendix&#160;B.&#160;Panel&#160;Roster&#160;and&#160;Financial&#160;Disclosures&#160;</b></p>
<p style="position:absolute;top:159px;left:81px;white-space:nowrap" class="ft026"><b>Bacterial&#160;Enteric&#160;Infections&#160;</b></p>
<p style="position:absolute;top:229px;left:122px;white-space:nowrap" class="ft02"><b>Member&#160;</b></p>
<p style="position:absolute;top:229px;left:263px;white-space:nowrap" class="ft02"><b>Institution&#160;</b></p>
<p style="position:absolute;top:220px;left:403px;white-space:nowrap" class="ft02"><b>Panel Section&#160;</b></p>
<p style="position:absolute;top:239px;left:420px;white-space:nowrap" class="ft02"><b>Group(s)&#160;</b></p>
<p style="position:absolute;top:210px;left:610px;white-space:nowrap" class="ft02"><b>Financial Disclosure&#160;</b></p>
<p style="position:absolute;top:249px;left:566px;white-space:nowrap" class="ft02"><b>Company&#160;</b></p>
<p style="position:absolute;top:249px;left:713px;white-space:nowrap" class="ft02"><b>Relationship&#160;</b></p>
<p style="position:absolute;top:278px;left:88px;white-space:nowrap" class="ft041">Carolyn Alonso&#160;&#160;</p>
<p style="position:absolute;top:278px;left:224px;white-space:nowrap" class="ft024"><i>Harvard Medical&#160;School;&#160;</i></p>
<p style="position:absolute;top:296px;left:224px;white-space:nowrap" class="ft024"><i>Beth Israel&#160;Deaconess&#160;</i></p>
<p style="position:absolute;top:313px;left:224px;white-space:nowrap" class="ft024"><i>Medical&#160;Center&#160;&#160;</i></p>
<p style="position:absolute;top:278px;left:384px;white-space:nowrap" class="ft041">Bacterial&#160;Enteric&#160;</p>
<p style="position:absolute;top:296px;left:384px;white-space:nowrap" class="ft041">Infections&#160;</p>
<p style="position:absolute;top:278px;left:528px;white-space:nowrap" class="ft041">Clinical&#160;Care Options&#160;</p>
<p style="position:absolute;top:278px;left:681px;white-space:nowrap" class="ft041">Honoraria&#160;&#160;</p>
<p style="position:absolute;top:311px;left:528px;white-space:nowrap" class="ft041">DSM&#160;</p>
<p style="position:absolute;top:344px;left:528px;white-space:nowrap" class="ft041">Pfizer&#160;</p>
<p style="position:absolute;top:311px;left:681px;white-space:nowrap" class="ft041">Advisory&#160;Board&#160;</p>
<p style="position:absolute;top:376px;left:528px;white-space:nowrap" class="ft041">Merck&#160;</p>
<p style="position:absolute;top:376px;left:681px;white-space:nowrap" class="ft041">Research Support&#160;</p>
<p style="position:absolute;top:403px;left:528px;white-space:nowrap" class="ft041">Ferring&#160;</p>
<p style="position:absolute;top:403px;left:681px;white-space:nowrap" class="ft041">Travel&#160;Support&#160;</p>
<p style="position:absolute;top:436px;left:88px;white-space:nowrap" class="ft041">Anna&#160;Bowen &#160;</p>
<p style="position:absolute;top:436px;left:224px;white-space:nowrap" class="ft024"><i>Centers&#160;for Disease&#160;</i></p>
<p style="position:absolute;top:454px;left:224px;white-space:nowrap" class="ft024"><i>Control&#160;and&#160;Prevention &#160;</i></p>
<p style="position:absolute;top:436px;left:384px;white-space:nowrap" class="ft041">Bacterial&#160;Enteric&#160;</p>
<p style="position:absolute;top:454px;left:384px;white-space:nowrap" class="ft041">Infections&#160;</p>
<p style="position:absolute;top:436px;left:528px;white-space:nowrap" class="ft041">None &#160;</p>
<p style="position:absolute;top:436px;left:681px;white-space:nowrap" class="ft041">N/A &#160;</p>
<p style="position:absolute;top:481px;left:88px;white-space:nowrap" class="ft041">Paul&#160;Pham&#160;&#160;</p>
<p style="position:absolute;top:481px;left:224px;white-space:nowrap" class="ft024"><i>The Johns&#160;Hopkins&#160;</i></p>
<p style="position:absolute;top:498px;left:224px;white-space:nowrap" class="ft0165"><i>University&#160;School&#160;of&#160;<br/>Medicine: Westview&#160;</i></p>
<p style="position:absolute;top:532px;left:224px;white-space:nowrap" class="ft024"><i>Urgent Care Medi&#160;Center&#160;</i></p>
<p style="position:absolute;top:481px;left:384px;white-space:nowrap" class="ft041">Section&#160;Review&#160;Group&#160;</p>
<p style="position:absolute;top:513px;left:384px;white-space:nowrap" class="ft041">Bacterial&#160;Enteric&#160;</p>
<p style="position:absolute;top:530px;left:384px;white-space:nowrap" class="ft041">Infections&#160;</p>
<p style="position:absolute;top:481px;left:528px;white-space:nowrap" class="ft041">Novo Nordisk&#160;&#160;</p>
<p style="position:absolute;top:481px;left:681px;white-space:nowrap" class="ft041">Stockholder&#160;&#160;</p>
<p style="position:absolute;top:559px;left:88px;white-space:nowrap" class="ft041">Jennifer Spicer&#160;&#160;</p>
<p style="position:absolute;top:559px;left:224px;white-space:nowrap" class="ft0165"><i>Emory&#160;University&#160;School&#160;<br/>of Medicine &#160;</i></p>
<p style="position:absolute;top:559px;left:384px;white-space:nowrap" class="ft044">Bacterial&#160;Enteric&#160;<br/>Infections&#160;</p>
<p style="position:absolute;top:559px;left:528px;white-space:nowrap" class="ft041">None &#160;</p>
<p style="position:absolute;top:559px;left:681px;white-space:nowrap" class="ft041">N/A &#160;</p>
<p style="position:absolute;top:603px;left:88px;white-space:nowrap" class="ft041">Brian Zanoni* &#160;</p>
<p style="position:absolute;top:603px;left:224px;white-space:nowrap" class="ft024"><i>Emory&#160;University&#160;School&#160;</i></p>
<p style="position:absolute;top:621px;left:224px;white-space:nowrap" class="ft024"><i>of Medicine &#160;</i></p>
<p style="position:absolute;top:603px;left:384px;white-space:nowrap" class="ft041">Bacterial&#160;Enteric&#160;</p>
<p style="position:absolute;top:621px;left:384px;white-space:nowrap" class="ft041">Infections&#160;</p>
<p style="position:absolute;top:603px;left:528px;white-space:nowrap" class="ft041">Accordant Health&#160;</p>
<p style="position:absolute;top:621px;left:528px;white-space:nowrap" class="ft041">Services&#160;&#160;</p>
<p style="position:absolute;top:603px;left:681px;white-space:nowrap" class="ft041">Consultant&#160;&#160;</p>
<p style="position:absolute;top:648px;left:81px;white-space:nowrap" class="ft041">* Section&#160;Group&#160;Lead&#160;</p>
<p style="position:absolute;top:674px;left:81px;white-space:nowrap" class="ft042"><b>Note:</b></p>
<p style="position:absolute;top:674px;left:116px;white-space:nowrap" class="ft041">Members&#160;are required to update&#160;disclosures&#160;annually and to notify guideline staff of&#160;any&#160;relevant changes&#160;in status during the&#160;</p>
<p style="position:absolute;top:691px;left:81px;white-space:nowrap" class="ft041">interim.&#160;</p>
</div>
<!-- Page 205 -->
<a name="205"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page205-div" style="position:relative;width:917px;height:1187px;">
<p style="position:absolute;top:1117px;left:81px;white-space:nowrap" class="ft024"><i>Guidelines for the Prevention and Treatment&#160;of&#160;Opportunistic&#160;Infections&#160;in Adults&#160;and Adolescents&#160;With HIV&#160;</i></p>
<p style="position:absolute;top:1117px;left:812px;white-space:nowrap" class="ft024"><i>LL-4&#160;</i></p>
<p style="position:absolute;top:112px;left:81px;white-space:nowrap" class="ft025"><b>Appendix&#160;B.&#160;Panel&#160;Roster&#160;and&#160;Financial&#160;Disclosures&#160;</b></p>
<p style="position:absolute;top:159px;left:81px;white-space:nowrap" class="ft026"><b>Bartonellosis&#160;</b></p>
<p style="position:absolute;top:909px;left:81px;white-space:nowrap" class="ft041">* Section&#160;Group&#160;Lead&#160;</p>
<p style="position:absolute;top:935px;left:81px;white-space:nowrap" class="ft042"><b>Note:</b></p>
<p style="position:absolute;top:935px;left:116px;white-space:nowrap" class="ft041">Members&#160;are required to update&#160;disclosures&#160;annually and to notify guideline staff of&#160;any&#160;relevant changes&#160;in status during the&#160;</p>
<p style="position:absolute;top:952px;left:81px;white-space:nowrap" class="ft041">interim.&#160;</p>
<p style="position:absolute;top:229px;left:124px;white-space:nowrap" class="ft02"><b>Member&#160;</b></p>
<p style="position:absolute;top:229px;left:258px;white-space:nowrap" class="ft02"><b>Institution&#160;</b></p>
<p style="position:absolute;top:220px;left:396px;white-space:nowrap" class="ft02"><b>Panel Section&#160;</b></p>
<p style="position:absolute;top:239px;left:413px;white-space:nowrap" class="ft02"><b>Group(s)&#160;</b></p>
<p style="position:absolute;top:210px;left:609px;white-space:nowrap" class="ft02"><b>Financial Disclosure&#160;</b></p>
<p style="position:absolute;top:249px;left:565px;white-space:nowrap" class="ft02"><b>Company&#160;</b></p>
<p style="position:absolute;top:249px;left:713px;white-space:nowrap" class="ft02"><b>Relationship&#160;</b></p>
<p style="position:absolute;top:278px;left:88px;white-space:nowrap" class="ft041">Nesli&#160;Basgoz</p>
<p style="position:absolute;top:278px;left:227px;white-space:nowrap" class="ft024"><i>Harvard Medical</i></p>
<p style="position:absolute;top:296px;left:227px;white-space:nowrap" class="ft024"><i>School&#160;</i></p>
<p style="position:absolute;top:278px;left:371px;white-space:nowrap" class="ft041">Bartonellosis</p>
<p style="position:absolute;top:278px;left:526px;white-space:nowrap" class="ft041">None&#160;</p>
<p style="position:absolute;top:278px;left:682px;white-space:nowrap" class="ft041">N/A</p>
<p style="position:absolute;top:323px;left:88px;white-space:nowrap" class="ft041">Carl Boodman</p>
<p style="position:absolute;top:323px;left:227px;white-space:nowrap" class="ft024"><i>University&#160;of Manitoba,&#160;</i></p>
<p style="position:absolute;top:340px;left:227px;white-space:nowrap" class="ft024"><i>Canada&#160;</i></p>
<p style="position:absolute;top:323px;left:371px;white-space:nowrap" class="ft041">Bartonellosis&#160;</p>
<p style="position:absolute;top:323px;left:526px;white-space:nowrap" class="ft041">Research&#160;Foundation&#160;</p>
<p style="position:absolute;top:340px;left:526px;white-space:nowrap" class="ft041">Flanders-Fonds&#160;de&#160;</p>
<p style="position:absolute;top:357px;left:526px;white-space:nowrap" class="ft041">Recherche du&#160;Québec&#160;</p>
<p style="position:absolute;top:389px;left:526px;white-space:nowrap" class="ft041">European&#160;Society of&#160;</p>
<p style="position:absolute;top:406px;left:526px;white-space:nowrap" class="ft044">Clinical&#160;Microbiology and&#160;<br/>Infectious Diseases&#160;</p>
<p style="position:absolute;top:456px;left:526px;white-space:nowrap" class="ft044">Canadian Institute of&#160;<br/>Health Research&#160;</p>
<p style="position:absolute;top:490px;left:526px;white-space:nowrap" class="ft041">fellowship</p>
<p style="position:absolute;top:523px;left:526px;white-space:nowrap" class="ft041">Clinical&#160;Investigator&#160;</p>
<p style="position:absolute;top:540px;left:526px;white-space:nowrap" class="ft041">Program&#160;(University&#160;of&#160;</p>
<p style="position:absolute;top:557px;left:526px;white-space:nowrap" class="ft041">Manitoba)&#160;</p>
<p style="position:absolute;top:323px;left:682px;white-space:nowrap" class="ft041">Research Support&#160;</p>
<p style="position:absolute;top:584px;left:526px;white-space:nowrap" class="ft041">European&#160;Union&#160;</p>
<p style="position:absolute;top:601px;left:526px;white-space:nowrap" class="ft041">(doctoral&#160;mobility&#160;grant)&#160;</p>
<p style="position:absolute;top:584px;left:682px;white-space:nowrap" class="ft041">Travel&#160;Support&#160;</p>
<p style="position:absolute;top:628px;left:526px;white-space:nowrap" class="ft041">International&#160;Diagnostics&#160;</p>
<p style="position:absolute;top:645px;left:526px;white-space:nowrap" class="ft041">Network/Global Health&#160;</p>
<p style="position:absolute;top:662px;left:526px;white-space:nowrap" class="ft041">CPD&#160;</p>
<p style="position:absolute;top:628px;left:682px;white-space:nowrap" class="ft041">Consultant&#160;</p>
<p style="position:absolute;top:689px;left:88px;white-space:nowrap" class="ft041">James&#160;Kirby&#160;</p>
<p style="position:absolute;top:689px;left:227px;white-space:nowrap" class="ft024"><i>Harvard Medical&#160;</i></p>
<p style="position:absolute;top:707px;left:227px;white-space:nowrap" class="ft024"><i>School; Beth Israel&#160;</i></p>
<p style="position:absolute;top:724px;left:227px;white-space:nowrap" class="ft0165"><i>Deaconess&#160;Medical&#160;<br/>Center&#160;</i></p>
<p style="position:absolute;top:689px;left:371px;white-space:nowrap" class="ft041">Bartonellosis&#160;</p>
<p style="position:absolute;top:689px;left:526px;white-space:nowrap" class="ft041">None&#160;</p>
<p style="position:absolute;top:689px;left:682px;white-space:nowrap" class="ft041">N/A&#160;</p>
<p style="position:absolute;top:768px;left:88px;white-space:nowrap" class="ft041">Jane&#160;Koehler&#160;</p>
<p style="position:absolute;top:768px;left:227px;white-space:nowrap" class="ft024"><i>University&#160;of&#160;California,&#160;</i></p>
<p style="position:absolute;top:785px;left:227px;white-space:nowrap" class="ft0165"><i>San Francisco School&#160;<br/>of Medicine&#160;</i></p>
<p style="position:absolute;top:768px;left:371px;white-space:nowrap" class="ft041">Bartonellosis&#160;</p>
<p style="position:absolute;top:768px;left:526px;white-space:nowrap" class="ft041">None&#160;</p>
<p style="position:absolute;top:768px;left:682px;white-space:nowrap" class="ft041">N/A&#160;</p>
<p style="position:absolute;top:829px;left:88px;white-space:nowrap" class="ft041">Grace Marx&#160;</p>
<p style="position:absolute;top:829px;left:227px;white-space:nowrap" class="ft024"><i>Centers&#160;for Disease&#160;</i></p>
<p style="position:absolute;top:847px;left:227px;white-space:nowrap" class="ft024"><i>Control&#160;and&#160;Prevention&#160;</i></p>
<p style="position:absolute;top:829px;left:371px;white-space:nowrap" class="ft041">Bartonellosis&#160;</p>
<p style="position:absolute;top:829px;left:526px;white-space:nowrap" class="ft041">None&#160;</p>
<p style="position:absolute;top:829px;left:682px;white-space:nowrap" class="ft041">N/A&#160;</p>
<p style="position:absolute;top:865px;left:88px;white-space:nowrap" class="ft041">Stacey&#160;Rose*&#160;</p>
<p style="position:absolute;top:865px;left:227px;white-space:nowrap" class="ft024"><i>Baylor College of&#160;</i></p>
<p style="position:absolute;top:882px;left:227px;white-space:nowrap" class="ft024"><i>Medicine&#160;</i></p>
<p style="position:absolute;top:865px;left:371px;white-space:nowrap" class="ft041">Bartonellosis&#160;</p>
<p style="position:absolute;top:865px;left:526px;white-space:nowrap" class="ft041">None&#160;</p>
<p style="position:absolute;top:865px;left:682px;white-space:nowrap" class="ft041">N/A&#160;</p>
</div>
<!-- Page 206 -->
<a name="206"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page206-div" style="position:relative;width:917px;height:1187px;">
<p style="position:absolute;top:1117px;left:81px;white-space:nowrap" class="ft024"><i>Guidelines for the Prevention and Treatment&#160;of&#160;Opportunistic&#160;Infections in Adults&#160;and Adolescents&#160;With HIV&#160;</i></p>
<p style="position:absolute;top:1117px;left:812px;white-space:nowrap" class="ft024"><i>LL-5&#160;</i></p>
<p style="position:absolute;top:112px;left:81px;white-space:nowrap" class="ft025"><b>Appendix&#160;B.&#160;Panel&#160;Roster&#160;and&#160;Financial&#160;Disclosures&#160;</b></p>
<p style="position:absolute;top:159px;left:81px;white-space:nowrap" class="ft026"><b>Candidiasis&#160;</b></p>
<p style="position:absolute;top:229px;left:122px;white-space:nowrap" class="ft02"><b>Member&#160;</b></p>
<p style="position:absolute;top:229px;left:270px;white-space:nowrap" class="ft02"><b>Institution&#160;</b></p>
<p style="position:absolute;top:220px;left:423px;white-space:nowrap" class="ft02"><b>Panel Section&#160;</b></p>
<p style="position:absolute;top:239px;left:439px;white-space:nowrap" class="ft02"><b>Group(s)&#160;</b></p>
<p style="position:absolute;top:210px;left:623px;white-space:nowrap" class="ft02"><b>Financial Disclosure&#160;</b></p>
<p style="position:absolute;top:249px;left:592px;white-space:nowrap" class="ft02"><b>Company&#160;</b></p>
<p style="position:absolute;top:249px;left:727px;white-space:nowrap" class="ft02"><b>Relationship&#160;</b></p>
<p style="position:absolute;top:278px;left:88px;white-space:nowrap" class="ft041">Melissa Johnson&#160;&#160;</p>
<p style="position:absolute;top:278px;left:222px;white-space:nowrap" class="ft024"><i>Duke University&#160;School&#160;of&#160;</i></p>
<p style="position:absolute;top:296px;left:222px;white-space:nowrap" class="ft024"><i>Medicine &#160;</i></p>
<p style="position:absolute;top:278px;left:398px;white-space:nowrap" class="ft041">Candidiasis&#160;</p>
<p style="position:absolute;top:278px;left:553px;white-space:nowrap" class="ft041">Scynexis&#160;&#160;</p>
<p style="position:absolute;top:278px;left:708px;white-space:nowrap" class="ft041">Research Support&#160;</p>
<p style="position:absolute;top:305px;left:553px;white-space:nowrap" class="ft041">Biomeme&#160;</p>
<p style="position:absolute;top:305px;left:708px;white-space:nowrap" class="ft041">Patent&#160;</p>
<p style="position:absolute;top:332px;left:88px;white-space:nowrap" class="ft041">Michail Lionakis &#160;</p>
<p style="position:absolute;top:332px;left:222px;white-space:nowrap" class="ft024"><i>National&#160;Institutes&#160;of Health&#160;&#160;</i></p>
<p style="position:absolute;top:332px;left:398px;white-space:nowrap" class="ft041">Candidiasis&#160;</p>
<p style="position:absolute;top:332px;left:553px;white-space:nowrap" class="ft041">None&#160;</p>
<p style="position:absolute;top:332px;left:708px;white-space:nowrap" class="ft041">N/A</p>
<p style="position:absolute;top:359px;left:88px;white-space:nowrap" class="ft041">Jeniel&#160;Nett*&#160;&#160;</p>
<p style="position:absolute;top:359px;left:222px;white-space:nowrap" class="ft024"><i>University&#160;of&#160;Wisconsin–</i></p>
<p style="position:absolute;top:376px;left:222px;white-space:nowrap" class="ft024"><i>Madison School&#160;of Medicine&#160;</i></p>
<p style="position:absolute;top:394px;left:222px;white-space:nowrap" class="ft024"><i>and&#160;Public&#160;Health &#160;</i></p>
<p style="position:absolute;top:359px;left:398px;white-space:nowrap" class="ft041">Candidiasis&#160;</p>
<p style="position:absolute;top:359px;left:553px;white-space:nowrap" class="ft041">None&#160;</p>
<p style="position:absolute;top:359px;left:708px;white-space:nowrap" class="ft041">N/A</p>
<p style="position:absolute;top:421px;left:88px;white-space:nowrap" class="ft041">Jack&#160;Sobel &#160;</p>
<p style="position:absolute;top:421px;left:222px;white-space:nowrap" class="ft024"><i>Wayne State&#160;University&#160;</i></p>
<p style="position:absolute;top:438px;left:222px;white-space:nowrap" class="ft024"><i>School&#160;of Medicine &#160;</i></p>
<p style="position:absolute;top:421px;left:398px;white-space:nowrap" class="ft041">Candidiasis&#160;</p>
<p style="position:absolute;top:421px;left:553px;white-space:nowrap" class="ft041">Mycovia&#160;</p>
<p style="position:absolute;top:438px;left:553px;white-space:nowrap" class="ft041">Pharmaceuticals&#160;&#160;</p>
<p style="position:absolute;top:421px;left:708px;white-space:nowrap" class="ft041">Consultant&#160;&#160;</p>
<p style="position:absolute;top:465px;left:81px;white-space:nowrap" class="ft041">* Section&#160;Group&#160;Lead &#160;</p>
<p style="position:absolute;top:491px;left:81px;white-space:nowrap" class="ft042"><b>Note:</b></p>
<p style="position:absolute;top:491px;left:116px;white-space:nowrap" class="ft041">Members&#160;are required to update&#160;disclosures&#160;annually and to notify guideline staff of&#160;any&#160;relevant changes&#160;in status during the&#160;</p>
<p style="position:absolute;top:508px;left:81px;white-space:nowrap" class="ft041">interim. &#160;</p>
</div>
<!-- Page 207 -->
<a name="207"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page207-div" style="position:relative;width:917px;height:1187px;">
<p style="position:absolute;top:1117px;left:81px;white-space:nowrap" class="ft024"><i>Guidelines for the Prevention and Treatment&#160;of&#160;Opportunistic&#160;Infections in Adults&#160;and Adolescents&#160;With HIV&#160;</i></p>
<p style="position:absolute;top:1117px;left:812px;white-space:nowrap" class="ft024"><i>LL-6&#160;</i></p>
<p style="position:absolute;top:112px;left:81px;white-space:nowrap" class="ft025"><b>Appendix&#160;B.&#160;Panel&#160;Roster&#160;and&#160;Financial&#160;Disclosures&#160;</b></p>
<p style="position:absolute;top:159px;left:81px;white-space:nowrap" class="ft026"><b>Community-Acquired&#160;Pneumonia&#160;</b></p>
<p style="position:absolute;top:229px;left:128px;white-space:nowrap" class="ft02"><b>Member&#160;</b></p>
<p style="position:absolute;top:229px;left:276px;white-space:nowrap" class="ft02"><b>Institution&#160;</b></p>
<p style="position:absolute;top:220px;left:419px;white-space:nowrap" class="ft02"><b>Panel Section&#160;</b></p>
<p style="position:absolute;top:239px;left:436px;white-space:nowrap" class="ft02"><b>Group(s)&#160;</b></p>
<p style="position:absolute;top:210px;left:619px;white-space:nowrap" class="ft02"><b>Financial Disclosure&#160;</b></p>
<p style="position:absolute;top:249px;left:582px;white-space:nowrap" class="ft02"><b>Company&#160;</b></p>
<p style="position:absolute;top:249px;left:721px;white-space:nowrap" class="ft02"><b>Relationship&#160;</b></p>
<p style="position:absolute;top:278px;left:88px;white-space:nowrap" class="ft041">Engi&#160;Attia&#160;</p>
<p style="position:absolute;top:278px;left:235px;white-space:nowrap" class="ft024"><i>University&#160;of&#160;</i></p>
<p style="position:absolute;top:296px;left:235px;white-space:nowrap" class="ft024"><i>Washington School&#160;of&#160;</i></p>
<p style="position:absolute;top:313px;left:235px;white-space:nowrap" class="ft024"><i>Medicine&#160;</i></p>
<p style="position:absolute;top:278px;left:398px;white-space:nowrap" class="ft041">Community-Acquired&#160;</p>
<p style="position:absolute;top:296px;left:398px;white-space:nowrap" class="ft041">Pneumonia&#160;</p>
<p style="position:absolute;top:278px;left:546px;white-space:nowrap" class="ft041">None&#160;</p>
<p style="position:absolute;top:278px;left:696px;white-space:nowrap" class="ft041">N/A&#160;</p>
<p style="position:absolute;top:340px;left:88px;white-space:nowrap" class="ft041">Kristina Crothers &#160;</p>
<p style="position:absolute;top:340px;left:235px;white-space:nowrap" class="ft024"><i>University&#160;of&#160;Washington&#160;</i></p>
<p style="position:absolute;top:357px;left:235px;white-space:nowrap" class="ft024"><i>School&#160;of Medicine&#160;</i></p>
<p style="position:absolute;top:340px;left:398px;white-space:nowrap" class="ft041">Community-Acquired&#160;</p>
<p style="position:absolute;top:357px;left:398px;white-space:nowrap" class="ft041">Pneumonia&#160;</p>
<p style="position:absolute;top:389px;left:398px;white-space:nowrap" class="ft024"><i>Pneumocystis</i></p>
<p style="position:absolute;top:389px;left:475px;white-space:nowrap" class="ft041">&#160;</p>
<p style="position:absolute;top:406px;left:398px;white-space:nowrap" class="ft041">Pneumonia&#160;</p>
<p style="position:absolute;top:340px;left:546px;white-space:nowrap" class="ft041">None&#160;</p>
<p style="position:absolute;top:340px;left:696px;white-space:nowrap" class="ft041">N/A&#160;</p>
<p style="position:absolute;top:433px;left:88px;white-space:nowrap" class="ft041">Miwako Kobayashi&#160;&#160;</p>
<p style="position:absolute;top:433px;left:235px;white-space:nowrap" class="ft024"><i>Centers&#160;for Disease&#160;</i></p>
<p style="position:absolute;top:451px;left:235px;white-space:nowrap" class="ft024"><i>Control&#160;and&#160;Prevention&#160;</i></p>
<p style="position:absolute;top:433px;left:398px;white-space:nowrap" class="ft041">Community-Acquired&#160;</p>
<p style="position:absolute;top:451px;left:398px;white-space:nowrap" class="ft041">Pneumonia&#160;</p>
<p style="position:absolute;top:433px;left:546px;white-space:nowrap" class="ft041">None&#160;</p>
<p style="position:absolute;top:433px;left:696px;white-space:nowrap" class="ft041">N/A&#160;</p>
<p style="position:absolute;top:478px;left:88px;white-space:nowrap" class="ft041">Ioannis&#160;Konstantinidis&#160;</p>
<p style="position:absolute;top:478px;left:235px;white-space:nowrap" class="ft041">University&#160;of&#160;Pittsburgh&#160;</p>
<p style="position:absolute;top:495px;left:235px;white-space:nowrap" class="ft041">Medical&#160;Center&#160;</p>
<p style="position:absolute;top:478px;left:398px;white-space:nowrap" class="ft041">Community-Acquired&#160;</p>
<p style="position:absolute;top:495px;left:398px;white-space:nowrap" class="ft041">Pneumonia&#160;</p>
<p style="position:absolute;top:478px;left:546px;white-space:nowrap" class="ft041">None&#160;</p>
<p style="position:absolute;top:478px;left:696px;white-space:nowrap" class="ft041">N/A&#160;</p>
<p style="position:absolute;top:522px;left:88px;white-space:nowrap" class="ft041">Michael&#160;Niederman&#160;&#160;</p>
<p style="position:absolute;top:522px;left:235px;white-space:nowrap" class="ft024"><i>NewYork-Presbyterian/&#160;</i></p>
<p style="position:absolute;top:539px;left:235px;white-space:nowrap" class="ft024"><i>Weill&#160;Cornell&#160;Medicine&#160;</i></p>
<p style="position:absolute;top:556px;left:235px;white-space:nowrap" class="ft024"><i>Medical&#160;Center&#160;</i></p>
<p style="position:absolute;top:522px;left:398px;white-space:nowrap" class="ft041">Community-Acquired&#160;</p>
<p style="position:absolute;top:539px;left:398px;white-space:nowrap" class="ft041">Pneumonia&#160;</p>
<p style="position:absolute;top:522px;left:546px;white-space:nowrap" class="ft041">Merck&#160;</p>
<p style="position:absolute;top:522px;left:696px;white-space:nowrap" class="ft041">Scientific&#160;Advisory&#160;</p>
<p style="position:absolute;top:539px;left:696px;white-space:nowrap" class="ft041">Board&#160;</p>
<p style="position:absolute;top:566px;left:546px;white-space:nowrap" class="ft041">GSK&#160;</p>
<p style="position:absolute;top:566px;left:696px;white-space:nowrap" class="ft044">Data and Safety&#160;<br/>Monitoring&#160;Board&#160;</p>
<p style="position:absolute;top:610px;left:546px;white-space:nowrap" class="ft041">Boehringer-Ingelheim&#160;</p>
<p style="position:absolute;top:610px;left:696px;white-space:nowrap" class="ft044">Research Support (paid&#160;<br/>to institution)&#160;</p>
<p style="position:absolute;top:654px;left:546px;white-space:nowrap" class="ft041">Merck&#160;</p>
<p style="position:absolute;top:654px;left:696px;white-space:nowrap" class="ft041">Consultant&#160;</p>
<p style="position:absolute;top:681px;left:88px;white-space:nowrap" class="ft041">Maria&#160;Rodriguez-</p>
<p style="position:absolute;top:698px;left:88px;white-space:nowrap" class="ft041">Barradas *&#160;</p>
<p style="position:absolute;top:681px;left:235px;white-space:nowrap" class="ft024"><i>Michael&#160;E.&#160;DeBakey&#160;</i></p>
<p style="position:absolute;top:698px;left:235px;white-space:nowrap" class="ft024"><i>Department of&#160;Veterans&#160;</i></p>
<p style="position:absolute;top:716px;left:235px;white-space:nowrap" class="ft024"><i>Affairs&#160;Medical&#160;Center;&#160;</i></p>
<p style="position:absolute;top:733px;left:235px;white-space:nowrap" class="ft0165"><i>Baylor College&#160;of&#160;<br/>Medicine&#160;</i></p>
<p style="position:absolute;top:681px;left:398px;white-space:nowrap" class="ft041">Community-Acquired&#160;</p>
<p style="position:absolute;top:698px;left:398px;white-space:nowrap" class="ft041">Pneumonia&#160;</p>
<p style="position:absolute;top:681px;left:546px;white-space:nowrap" class="ft041">None&#160;</p>
<p style="position:absolute;top:681px;left:696px;white-space:nowrap" class="ft041">N/A&#160;</p>
<p style="position:absolute;top:777px;left:88px;white-space:nowrap" class="ft041">Jerry&#160;Zifodya&#160;</p>
<p style="position:absolute;top:777px;left:235px;white-space:nowrap" class="ft024"><i>Tulane School&#160;of Medicine&#160;</i></p>
<p style="position:absolute;top:777px;left:398px;white-space:nowrap" class="ft041">Community-Acquired&#160;</p>
<p style="position:absolute;top:794px;left:398px;white-space:nowrap" class="ft041">Pneumonia&#160;</p>
<p style="position:absolute;top:777px;left:546px;white-space:nowrap" class="ft041">Firland&#160;Foundation&#160;</p>
<p style="position:absolute;top:809px;left:546px;white-space:nowrap" class="ft041">Wetmore Foundation&#160;</p>
<p style="position:absolute;top:777px;left:696px;white-space:nowrap" class="ft041">Research Support&#160;&#160;</p>
<p style="position:absolute;top:836px;left:81px;white-space:nowrap" class="ft041">* Section&#160;Group&#160;Lead &#160;</p>
<p style="position:absolute;top:862px;left:81px;white-space:nowrap" class="ft042"><b>Note:</b></p>
<p style="position:absolute;top:862px;left:116px;white-space:nowrap" class="ft041">Members&#160;are required to update&#160;disclosures&#160;annually and to notify guideline staff of&#160;any&#160;relevant changes&#160;in status during the&#160;</p>
<p style="position:absolute;top:880px;left:81px;white-space:nowrap" class="ft041">interim. &#160;</p>
</div>
<!-- Page 208 -->
<a name="208"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page208-div" style="position:relative;width:917px;height:1187px;">
<p style="position:absolute;top:1117px;left:81px;white-space:nowrap" class="ft024"><i>Guidelines for the Prevention and Treatment&#160;of&#160;Opportunistic&#160;Infections in Adults&#160;and Adolescents&#160;With HIV&#160;</i></p>
<p style="position:absolute;top:1117px;left:812px;white-space:nowrap" class="ft024"><i>LL-7&#160;</i></p>
<p style="position:absolute;top:112px;left:81px;white-space:nowrap" class="ft025"><b>Appendix&#160;B.&#160;Panel&#160;Roster&#160;and&#160;Financial&#160;Disclosures&#160;</b></p>
<p style="position:absolute;top:159px;left:81px;white-space:nowrap" class="ft026"><b>Cryptosporidiosis/Microsporidiosis&#160;</b></p>
<p style="position:absolute;top:231px;left:129px;white-space:nowrap" class="ft02"><b>Member&#160;</b></p>
<p style="position:absolute;top:231px;left:283px;white-space:nowrap" class="ft02"><b>Institution&#160;</b></p>
<p style="position:absolute;top:221px;left:440px;white-space:nowrap" class="ft02"><b>Panel Section&#160;</b></p>
<p style="position:absolute;top:241px;left:457px;white-space:nowrap" class="ft02"><b>Group(s)&#160;</b></p>
<p style="position:absolute;top:211px;left:634px;white-space:nowrap" class="ft02"><b>Financial Disclosure&#160;</b></p>
<p style="position:absolute;top:251px;left:600px;white-space:nowrap" class="ft02"><b>Company&#160;</b></p>
<p style="position:absolute;top:251px;left:725px;white-space:nowrap" class="ft02"><b>Relationship&#160;</b></p>
<p style="position:absolute;top:281px;left:88px;white-space:nowrap" class="ft041">Mahalia Desruisseaux&#160;&#160;</p>
<p style="position:absolute;top:281px;left:236px;white-space:nowrap" class="ft024"><i>Yale School&#160;of Medicine &#160;</i></p>
<p style="position:absolute;top:281px;left:411px;white-space:nowrap" class="ft041">Cryptosporidiosis/</p>
<p style="position:absolute;top:299px;left:411px;white-space:nowrap" class="ft041">Microsporidiosis&#160;</p>
<p style="position:absolute;top:331px;left:411px;white-space:nowrap" class="ft041">Geographic&#160;Opportunistic&#160;</p>
<p style="position:absolute;top:348px;left:411px;white-space:nowrap" class="ft041">Infections&#160;</p>
<p style="position:absolute;top:281px;left:574px;white-space:nowrap" class="ft041">None &#160;</p>
<p style="position:absolute;top:281px;left:704px;white-space:nowrap" class="ft041">N/A &#160;</p>
<p style="position:absolute;top:381px;left:88px;white-space:nowrap" class="ft041">Timothy Hatlen&#160;&#160;</p>
<p style="position:absolute;top:381px;left:236px;white-space:nowrap" class="ft024"><i>University&#160;of&#160;California, Los&#160;</i></p>
<p style="position:absolute;top:398px;left:236px;white-space:nowrap" class="ft0165"><i>Angeles David&#160;Geffen&#160;<br/>School&#160;of Medicine &#160;</i></p>
<p style="position:absolute;top:381px;left:411px;white-space:nowrap" class="ft041">Cryptosporidiosis/</p>
<p style="position:absolute;top:398px;left:411px;white-space:nowrap" class="ft041">Microsporidiosis&#160;</p>
<p style="position:absolute;top:381px;left:574px;white-space:nowrap" class="ft041">None &#160;</p>
<p style="position:absolute;top:381px;left:704px;white-space:nowrap" class="ft041">N/A &#160;</p>
<p style="position:absolute;top:483px;left:88px;white-space:nowrap" class="ft041">Michele Hlavsa&#160;&#160;</p>
<p style="position:absolute;top:483px;left:236px;white-space:nowrap" class="ft024"><i>Centers&#160;for Disease Control&#160;</i></p>
<p style="position:absolute;top:501px;left:236px;white-space:nowrap" class="ft024"><i>and&#160;Prevention&#160;&#160;</i></p>
<p style="position:absolute;top:483px;left:411px;white-space:nowrap" class="ft041">Cryptosporidiosis/</p>
<p style="position:absolute;top:501px;left:411px;white-space:nowrap" class="ft041">Microsporidiosis&#160;</p>
<p style="position:absolute;top:483px;left:574px;white-space:nowrap" class="ft041">None &#160;</p>
<p style="position:absolute;top:483px;left:704px;white-space:nowrap" class="ft041">N/A &#160;</p>
<p style="position:absolute;top:529px;left:88px;white-space:nowrap" class="ft041">Nagalingeswaran&#160;</p>
<p style="position:absolute;top:547px;left:88px;white-space:nowrap" class="ft041">Kumarasamy&#160;&#160;</p>
<p style="position:absolute;top:529px;left:236px;white-space:nowrap" class="ft024"><i>The Warren Alpert Medical&#160;</i></p>
<p style="position:absolute;top:547px;left:236px;white-space:nowrap" class="ft024"><i>School&#160;of Brown&#160;University&#160;&#160;</i></p>
<p style="position:absolute;top:529px;left:411px;white-space:nowrap" class="ft041">Cryptosporidiosis/</p>
<p style="position:absolute;top:547px;left:411px;white-space:nowrap" class="ft041">Microsporidiosis&#160;</p>
<p style="position:absolute;top:529px;left:574px;white-space:nowrap" class="ft041">Indian Council&#160;of&#160;</p>
<p style="position:absolute;top:547px;left:574px;white-space:nowrap" class="ft041">Medical&#160;Research&#160;</p>
<p style="position:absolute;top:579px;left:574px;white-space:nowrap" class="ft044">World&#160;Health&#160;<br/>Organization&#160;</p>
<p style="position:absolute;top:628px;left:574px;white-space:nowrap" class="ft041">Unitaid&#160;</p>
<p style="position:absolute;top:660px;left:574px;white-space:nowrap" class="ft041">amfAR&#160;</p>
<p style="position:absolute;top:529px;left:704px;white-space:nowrap" class="ft041">Research Support&#160;&#160;</p>
<p style="position:absolute;top:687px;left:88px;white-space:nowrap" class="ft041">Honorine Ward&#160;&#160;</p>
<p style="position:absolute;top:687px;left:236px;white-space:nowrap" class="ft024"><i>Tufts&#160;University&#160;School&#160;of&#160;</i></p>
<p style="position:absolute;top:705px;left:236px;white-space:nowrap" class="ft024"><i>Medicine &#160;</i></p>
<p style="position:absolute;top:687px;left:411px;white-space:nowrap" class="ft041">Cryptosporidiosis/</p>
<p style="position:absolute;top:705px;left:411px;white-space:nowrap" class="ft041">Microsporidiosis&#160;</p>
<p style="position:absolute;top:687px;left:574px;white-space:nowrap" class="ft041">None &#160;</p>
<p style="position:absolute;top:687px;left:704px;white-space:nowrap" class="ft041">N/A &#160;</p>
<p style="position:absolute;top:733px;left:88px;white-space:nowrap" class="ft041">Louis&#160;Weiss*&#160;&#160;</p>
<p style="position:absolute;top:733px;left:236px;white-space:nowrap" class="ft024"><i>Albert Einstein&#160;College&#160;of&#160;</i></p>
<p style="position:absolute;top:750px;left:236px;white-space:nowrap" class="ft024"><i>Medicine &#160;</i></p>
<p style="position:absolute;top:733px;left:411px;white-space:nowrap" class="ft041">Cryptosporidiosis/</p>
<p style="position:absolute;top:750px;left:411px;white-space:nowrap" class="ft041">Microsporidiosis&#160;</p>
<p style="position:absolute;top:733px;left:574px;white-space:nowrap" class="ft041">None&#160;</p>
<p style="position:absolute;top:733px;left:704px;white-space:nowrap" class="ft041">N/A&#160;</p>
<p style="position:absolute;top:792px;left:88px;white-space:nowrap" class="ft041">Clinton&#160;White&#160;&#160;</p>
<p style="position:absolute;top:792px;left:236px;white-space:nowrap" class="ft024"><i>The University&#160;of Texas&#160;</i></p>
<p style="position:absolute;top:809px;left:236px;white-space:nowrap" class="ft024"><i>Medical&#160;Branch&#160;&#160;</i></p>
<p style="position:absolute;top:792px;left:411px;white-space:nowrap" class="ft041">Cryptosporidiosis/</p>
<p style="position:absolute;top:809px;left:411px;white-space:nowrap" class="ft041">Microsporidiosis&#160;</p>
<p style="position:absolute;top:792px;left:574px;white-space:nowrap" class="ft041">None &#160;</p>
<p style="position:absolute;top:792px;left:704px;white-space:nowrap" class="ft041">N/A &#160;</p>
<p style="position:absolute;top:838px;left:88px;white-space:nowrap" class="ft041">Lihua&#160;Xiao&#160;&#160;</p>
<p style="position:absolute;top:838px;left:236px;white-space:nowrap" class="ft024"><i>Centers&#160;for Disease Control&#160;</i></p>
<p style="position:absolute;top:855px;left:236px;white-space:nowrap" class="ft024"><i>and&#160;Prevention&#160;&#160;</i></p>
<p style="position:absolute;top:838px;left:411px;white-space:nowrap" class="ft041">Cryptosporidiosis/</p>
<p style="position:absolute;top:855px;left:411px;white-space:nowrap" class="ft041">Microsporidiosis&#160;</p>
<p style="position:absolute;top:838px;left:574px;white-space:nowrap" class="ft041">None &#160;</p>
<p style="position:absolute;top:838px;left:704px;white-space:nowrap" class="ft041">N/A &#160;</p>
<p style="position:absolute;top:884px;left:81px;white-space:nowrap" class="ft041">* Section&#160;Group&#160;Lead&#160;</p>
<p style="position:absolute;top:910px;left:81px;white-space:nowrap" class="ft042"><b>Note:</b></p>
<p style="position:absolute;top:910px;left:116px;white-space:nowrap" class="ft041">Members&#160;are required to update&#160;disclosures&#160;annually and to notify guideline staff of&#160;any&#160;relevant changes&#160;in status during the&#160;</p>
<p style="position:absolute;top:927px;left:81px;white-space:nowrap" class="ft041">interim.&#160;</p>
</div>
<!-- Page 209 -->
<a name="209"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}	.ft0166{font-size:20px;line-height:24px;font-family:BGKYCV+LiberationSansNarrow;color:#005299;}
-->
</style>
<div id="page209-div" style="position:relative;width:917px;height:1187px;">
<p style="position:absolute;top:1117px;left:81px;white-space:nowrap" class="ft024"><i>Guidelines for the Prevention and Treatment&#160;of&#160;Opportunistic&#160;Infections in Adults&#160;and Adolescents&#160;With HIV&#160;&#160;</i></p>
<p style="position:absolute;top:1117px;left:758px;white-space:nowrap" class="ft024"><i>LL-8&#160;</i></p>
<p style="position:absolute;top:112px;left:81px;white-space:nowrap" class="ft025"><b>Appendix&#160;B.&#160;Panel&#160;Roster&#160;and&#160;Financial&#160;Disclosures&#160;</b></p>
<p style="position:absolute;top:159px;left:81px;white-space:nowrap" class="ft0166"><b>Geographic Opportunistic Infections&#160;(Chagas Disease,&#160;Cystoisosporiasis,&#160;Leishmaniasis,&#160;<br/>Malaria, Talaromycosis)&#160;</b></p>
<p style="position:absolute;top:905px;left:81px;white-space:nowrap" class="ft041">* Section&#160;Group&#160;Lead&#160;</p>
<p style="position:absolute;top:931px;left:81px;white-space:nowrap" class="ft042"><b>Note:</b></p>
<p style="position:absolute;top:931px;left:116px;white-space:nowrap" class="ft041">Members&#160;are required to update&#160;disclosures&#160;annually and to notify guideline staff of&#160;any&#160;relevant changes&#160;in status during the&#160;</p>
<p style="position:absolute;top:949px;left:81px;white-space:nowrap" class="ft041">interim.&#160;</p>
<p style="position:absolute;top:254px;left:128px;white-space:nowrap" class="ft02"><b>Member&#160;</b></p>
<p style="position:absolute;top:254px;left:293px;white-space:nowrap" class="ft02"><b>Institution&#160;</b></p>
<p style="position:absolute;top:244px;left:460px;white-space:nowrap" class="ft02"><b>Panel Section&#160;</b></p>
<p style="position:absolute;top:263px;left:476px;white-space:nowrap" class="ft02"><b>Group(s)&#160;</b></p>
<p style="position:absolute;top:234px;left:643px;white-space:nowrap" class="ft02"><b>Financial Disclosure&#160;</b></p>
<p style="position:absolute;top:273px;left:619px;white-space:nowrap" class="ft02"><b>Company&#160;</b></p>
<p style="position:absolute;top:273px;left:734px;white-space:nowrap" class="ft02"><b>Relationship&#160;</b></p>
<p style="position:absolute;top:303px;left:89px;white-space:nowrap" class="ft041">Naomi&#160;Aronson&#160;</p>
<p style="position:absolute;top:303px;left:238px;white-space:nowrap" class="ft024"><i>F. Edward&#160;Hébert School&#160;of&#160;</i></p>
<p style="position:absolute;top:320px;left:238px;white-space:nowrap" class="ft024"><i>Medicine at&#160;Uniformed Services&#160;</i></p>
<p style="position:absolute;top:337px;left:238px;white-space:nowrap" class="ft024"><i>University&#160;</i></p>
<p style="position:absolute;top:303px;left:433px;white-space:nowrap" class="ft041">Geographic&#160;Opportunistic&#160;</p>
<p style="position:absolute;top:320px;left:433px;white-space:nowrap" class="ft041">Infections&#160;</p>
<p style="position:absolute;top:303px;left:595px;white-space:nowrap" class="ft041">None&#160;</p>
<p style="position:absolute;top:303px;left:724px;white-space:nowrap" class="ft041">N/A&#160;</p>
<p style="position:absolute;top:364px;left:89px;white-space:nowrap" class="ft041">Johanna&#160;Daily</p>
<p style="position:absolute;top:364px;left:238px;white-space:nowrap" class="ft024"><i>Albert&#160;Einstein&#160;College&#160;of</i></p>
<p style="position:absolute;top:381px;left:238px;white-space:nowrap" class="ft024"><i>Medicine, Weiler Hospital&#160;</i></p>
<p style="position:absolute;top:364px;left:433px;white-space:nowrap" class="ft041">Geographic&#160;Opportunistic</p>
<p style="position:absolute;top:381px;left:433px;white-space:nowrap" class="ft041">Infections&#160;</p>
<p style="position:absolute;top:364px;left:595px;white-space:nowrap" class="ft041">None</p>
<p style="position:absolute;top:364px;left:724px;white-space:nowrap" class="ft041">N/A</p>
<p style="position:absolute;top:408px;left:89px;white-space:nowrap" class="ft041">Mahalia Desruisseaux&#160;</p>
<p style="position:absolute;top:408px;left:238px;white-space:nowrap" class="ft024"><i>Yale&#160;School&#160;of Medicine&#160;</i></p>
<p style="position:absolute;top:408px;left:433px;white-space:nowrap" class="ft044">Cryptosporidiosis/&#160;<br/>Microsporidiosis&#160;</p>
<p style="position:absolute;top:458px;left:433px;white-space:nowrap" class="ft041">Geographic&#160;Opportunistic&#160;</p>
<p style="position:absolute;top:475px;left:433px;white-space:nowrap" class="ft041">Infections&#160;</p>
<p style="position:absolute;top:408px;left:595px;white-space:nowrap" class="ft041">None&#160;</p>
<p style="position:absolute;top:408px;left:724px;white-space:nowrap" class="ft041">N/A&#160;</p>
<p style="position:absolute;top:508px;left:89px;white-space:nowrap" class="ft041">Thuy&#160;Le&#160;</p>
<p style="position:absolute;top:508px;left:238px;white-space:nowrap" class="ft024"><i>Duke University&#160;School&#160;of&#160;</i></p>
<p style="position:absolute;top:525px;left:238px;white-space:nowrap" class="ft024"><i>Medicine&#160;</i></p>
<p style="position:absolute;top:508px;left:433px;white-space:nowrap" class="ft041">Geographic&#160;Opportunistic&#160;</p>
<p style="position:absolute;top:525px;left:433px;white-space:nowrap" class="ft041">Infections&#160;</p>
<p style="position:absolute;top:508px;left:595px;white-space:nowrap" class="ft041">Gilead&#160;Sciences&#160;</p>
<p style="position:absolute;top:508px;left:724px;white-space:nowrap" class="ft041">Research Support&#160;</p>
<p style="position:absolute;top:525px;left:724px;white-space:nowrap" class="ft044">(paid&#160;to&#160;<br/>institution)&#160;</p>
<p style="position:absolute;top:569px;left:89px;white-space:nowrap" class="ft041">Rogelio&#160;López-Vélez&#160;</p>
<p style="position:absolute;top:569px;left:238px;white-space:nowrap" class="ft024"><i>Ramón&#160;y&#160;Cajal&#160;Health Research&#160;</i></p>
<p style="position:absolute;top:586px;left:238px;white-space:nowrap" class="ft0165"><i>Institute, Ramón&#160;y Cajal&#160;<br/>University&#160;Hospital&#160;</i></p>
<p style="position:absolute;top:569px;left:433px;white-space:nowrap" class="ft041">Geographic&#160;Opportunistic&#160;</p>
<p style="position:absolute;top:586px;left:433px;white-space:nowrap" class="ft041">Infections&#160;</p>
<p style="position:absolute;top:569px;left:595px;white-space:nowrap" class="ft041">None&#160;</p>
<p style="position:absolute;top:569px;left:724px;white-space:nowrap" class="ft041">N/A&#160;</p>
<p style="position:absolute;top:630px;left:89px;white-space:nowrap" class="ft041">Rojelio Mejia&#160;</p>
<p style="position:absolute;top:630px;left:238px;white-space:nowrap" class="ft024"><i>Baylor College of Medicine&#160;</i></p>
<p style="position:absolute;top:630px;left:433px;white-space:nowrap" class="ft041">Geographic&#160;Opportunistic&#160;</p>
<p style="position:absolute;top:648px;left:433px;white-space:nowrap" class="ft041">Infections&#160;</p>
<p style="position:absolute;top:630px;left:595px;white-space:nowrap" class="ft041">IC-Medtech&#160;</p>
<p style="position:absolute;top:630px;left:724px;white-space:nowrap" class="ft041">Research Support&#160;&#160;</p>
<p style="position:absolute;top:657px;left:595px;white-space:nowrap" class="ft041">Roche/GenMark&#160;</p>
<p style="position:absolute;top:657px;left:724px;white-space:nowrap" class="ft041">Advisory&#160;Board&#160;</p>
<p style="position:absolute;top:684px;left:89px;white-space:nowrap" class="ft041">Edward Mitre*&#160;</p>
<p style="position:absolute;top:684px;left:238px;white-space:nowrap" class="ft0165"><i>F. Edward&#160;Hébert School&#160;of&#160;<br/>Medicine at Uniformed&#160;Services&#160;</i></p>
<p style="position:absolute;top:719px;left:238px;white-space:nowrap" class="ft024"><i>University&#160;</i></p>
<p style="position:absolute;top:684px;left:433px;white-space:nowrap" class="ft044">Geographic&#160;Opportunistic&#160;<br/>Infections&#160;</p>
<p style="position:absolute;top:684px;left:595px;white-space:nowrap" class="ft041">None&#160;</p>
<p style="position:absolute;top:684px;left:724px;white-space:nowrap" class="ft041">N/A&#160;</p>
<p style="position:absolute;top:746px;left:89px;white-space:nowrap" class="ft041">Susan&#160;Montgomery&#160;</p>
<p style="position:absolute;top:746px;left:238px;white-space:nowrap" class="ft0165"><i>Centers&#160;for Disease Control and&#160;<br/>Prevention&#160;</i></p>
<p style="position:absolute;top:746px;left:433px;white-space:nowrap" class="ft044">Geographic&#160;Opportunistic&#160;<br/>Infections&#160;</p>
<p style="position:absolute;top:746px;left:595px;white-space:nowrap" class="ft041">None&#160;</p>
<p style="position:absolute;top:746px;left:724px;white-space:nowrap" class="ft041">N/A&#160;</p>
<p style="position:absolute;top:790px;left:89px;white-space:nowrap" class="ft041">Sunil&#160;Parikh&#160;</p>
<p style="position:absolute;top:790px;left:238px;white-space:nowrap" class="ft024"><i>Yale School&#160;of Public Health&#160;</i></p>
<p style="position:absolute;top:790px;left:433px;white-space:nowrap" class="ft041">Geographic&#160;Opportunistic&#160;</p>
<p style="position:absolute;top:807px;left:433px;white-space:nowrap" class="ft041">Infections&#160;</p>
<p style="position:absolute;top:790px;left:595px;white-space:nowrap" class="ft041">Medincell&#160;</p>
<p style="position:absolute;top:790px;left:724px;white-space:nowrap" class="ft041">Scientific Advisory&#160;</p>
<p style="position:absolute;top:807px;left:724px;white-space:nowrap" class="ft041">Board&#160;</p>
<p style="position:absolute;top:834px;left:595px;white-space:nowrap" class="ft041">Kainomyx&#160;</p>
<p style="position:absolute;top:834px;left:724px;white-space:nowrap" class="ft041">Consultant&#160;</p>
<p style="position:absolute;top:861px;left:89px;white-space:nowrap" class="ft041">Adrienne Showler&#160;</p>
<p style="position:absolute;top:861px;left:238px;white-space:nowrap" class="ft024"><i>National&#160;Institute of Allergy&#160;and&#160;</i></p>
<p style="position:absolute;top:878px;left:238px;white-space:nowrap" class="ft024"><i>Infectious&#160;Diseases&#160;</i></p>
<p style="position:absolute;top:861px;left:433px;white-space:nowrap" class="ft041">Geographic&#160;Opportunistic&#160;</p>
<p style="position:absolute;top:878px;left:433px;white-space:nowrap" class="ft041">Infections&#160;</p>
<p style="position:absolute;top:861px;left:595px;white-space:nowrap" class="ft041">None&#160;</p>
<p style="position:absolute;top:861px;left:724px;white-space:nowrap" class="ft041">N/A&#160;</p>
</div>
<!-- Page 210 -->
<a name="210"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page210-div" style="position:relative;width:917px;height:1187px;">
<p style="position:absolute;top:1117px;left:81px;white-space:nowrap" class="ft024"><i>Guidelines for the Prevention and Treatment&#160;of&#160;Opportunistic&#160;Infections in Adults&#160;and Adolescents&#160;With HIV&#160;</i></p>
<p style="position:absolute;top:1117px;left:812px;white-space:nowrap" class="ft024"><i>LL-9&#160;</i></p>
<p style="position:absolute;top:112px;left:81px;white-space:nowrap" class="ft025"><b>Appendix&#160;B.&#160;Panel&#160;Roster&#160;and&#160;Financial&#160;Disclosures&#160;</b></p>
<p style="position:absolute;top:159px;left:81px;white-space:nowrap" class="ft026"><b>Hepatitis B&#160;Virus&#160;</b></p>
<p style="position:absolute;top:232px;left:135px;white-space:nowrap" class="ft02"><b>Member&#160;</b></p>
<p style="position:absolute;top:232px;left:289px;white-space:nowrap" class="ft02"><b>Institution&#160;</b></p>
<p style="position:absolute;top:223px;left:439px;white-space:nowrap" class="ft02"><b>Panel Section&#160;</b></p>
<p style="position:absolute;top:242px;left:456px;white-space:nowrap" class="ft02"><b>Group(s)&#160;</b></p>
<p style="position:absolute;top:212px;left:633px;white-space:nowrap" class="ft02"><b>Financial Disclosure&#160;</b></p>
<p style="position:absolute;top:253px;left:609px;white-space:nowrap" class="ft02"><b>Company&#160;</b></p>
<p style="position:absolute;top:253px;left:733px;white-space:nowrap" class="ft02"><b>Relationship&#160;</b></p>
<p style="position:absolute;top:284px;left:90px;white-space:nowrap" class="ft041">Debika Bhattacharya&#160;&#160;</p>
<p style="position:absolute;top:284px;left:251px;white-space:nowrap" class="ft024"><i>University&#160;of&#160;California,&#160;</i></p>
<p style="position:absolute;top:302px;left:251px;white-space:nowrap" class="ft024"><i>Los Angeles David&#160;</i></p>
<p style="position:absolute;top:319px;left:251px;white-space:nowrap" class="ft024"><i>Geffen School&#160;of&#160;</i></p>
<p style="position:absolute;top:336px;left:251px;white-space:nowrap" class="ft024"><i>Medicine &#160;</i></p>
<p style="position:absolute;top:284px;left:413px;white-space:nowrap" class="ft041">Hepatitis B Virus</p>
<p style="position:absolute;top:285px;left:504px;white-space:nowrap" class="ft057">&#160;</p>
<p style="position:absolute;top:284px;left:575px;white-space:nowrap" class="ft041">Gilead&#160;Sciences&#160;&#160;</p>
<p style="position:absolute;top:284px;left:723px;white-space:nowrap" class="ft041">Research Support&#160;</p>
<p style="position:absolute;top:302px;left:724px;white-space:nowrap" class="ft041">(paid&#160;to&#160;institution)&#160;&#160;</p>
<p style="position:absolute;top:363px;left:90px;white-space:nowrap" class="ft041">Claudia Hawkins&#160;&#160;</p>
<p style="position:absolute;top:363px;left:251px;white-space:nowrap" class="ft024"><i>Northwestern&#160;University&#160;</i></p>
<p style="position:absolute;top:380px;left:251px;white-space:nowrap" class="ft024"><i>Feinberg School&#160;of&#160;</i></p>
<p style="position:absolute;top:397px;left:251px;white-space:nowrap" class="ft024"><i>Medicine &#160;</i></p>
<p style="position:absolute;top:363px;left:413px;white-space:nowrap" class="ft041">Hepatitis B Virus</p>
<p style="position:absolute;top:363px;left:504px;white-space:nowrap" class="ft057">&#160;</p>
<p style="position:absolute;top:363px;left:575px;white-space:nowrap" class="ft041">None &#160;</p>
<p style="position:absolute;top:363px;left:723px;white-space:nowrap" class="ft041">N/A &#160;</p>
<p style="position:absolute;top:424px;left:90px;white-space:nowrap" class="ft041">Min Kim&#160;&#160;</p>
<p style="position:absolute;top:424px;left:251px;white-space:nowrap" class="ft024"><i>Centers&#160;for Disease&#160;</i></p>
<p style="position:absolute;top:442px;left:251px;white-space:nowrap" class="ft024"><i>Control&#160;and&#160;Prevention &#160;</i></p>
<p style="position:absolute;top:424px;left:413px;white-space:nowrap" class="ft041">Hepatitis B Virus</p>
<p style="position:absolute;top:425px;left:504px;white-space:nowrap" class="ft057">&#160;</p>
<p style="position:absolute;top:424px;left:575px;white-space:nowrap" class="ft041">None &#160;</p>
<p style="position:absolute;top:424px;left:723px;white-space:nowrap" class="ft041">N/A &#160;</p>
<p style="position:absolute;top:472px;left:90px;white-space:nowrap" class="ft041">Kristen Marks&#160;&#160;</p>
<p style="position:absolute;top:472px;left:251px;white-space:nowrap" class="ft024"><i>Weill Cornell&#160;Medicine &#160;</i></p>
<p style="position:absolute;top:472px;left:413px;white-space:nowrap" class="ft041">Hepatitis B Virus</p>
<p style="position:absolute;top:472px;left:504px;white-space:nowrap" class="ft057">&#160;</p>
<p style="position:absolute;top:472px;left:575px;white-space:nowrap" class="ft041">Gilead&#160;Sciences&#160;&#160;</p>
<p style="position:absolute;top:472px;left:723px;white-space:nowrap" class="ft041">Consultant&#160;&#160;</p>
<p style="position:absolute;top:502px;left:575px;white-space:nowrap" class="ft041">Immorna&#160;&#160;</p>
<p style="position:absolute;top:534px;left:575px;white-space:nowrap" class="ft041">Novo Nordisk&#160;</p>
<p style="position:absolute;top:502px;left:724px;white-space:nowrap" class="ft044">Data and Safety&#160;<br/>Monitoring&#160;Board &#160;</p>
<p style="position:absolute;top:561px;left:575px;white-space:nowrap" class="ft041">Viiv&#160;Healthcare&#160;&#160;</p>
<p style="position:absolute;top:561px;left:723px;white-space:nowrap" class="ft041">Research Support&#160;</p>
<p style="position:absolute;top:578px;left:724px;white-space:nowrap" class="ft041">(paid&#160;to&#160;institution)&#160;&#160;</p>
<p style="position:absolute;top:608px;left:90px;white-space:nowrap" class="ft041">Chloe Thio*&#160;</p>
<p style="position:absolute;top:608px;left:251px;white-space:nowrap" class="ft024"><i>The Johns&#160;Hopkins&#160;</i></p>
<p style="position:absolute;top:626px;left:251px;white-space:nowrap" class="ft024"><i>University&#160;School&#160;of&#160;</i></p>
<p style="position:absolute;top:643px;left:251px;white-space:nowrap" class="ft024"><i>Medicine &#160;</i></p>
<p style="position:absolute;top:608px;left:413px;white-space:nowrap" class="ft041">Hepatitis B Virus</p>
<p style="position:absolute;top:609px;left:504px;white-space:nowrap" class="ft057">&#160;</p>
<p style="position:absolute;top:608px;left:575px;white-space:nowrap" class="ft041">None &#160;</p>
<p style="position:absolute;top:608px;left:723px;white-space:nowrap" class="ft041">N/A &#160;</p>
<p style="position:absolute;top:670px;left:81px;white-space:nowrap" class="ft041">* Section&#160;Group&#160;Lead &#160;</p>
<p style="position:absolute;top:696px;left:81px;white-space:nowrap" class="ft042"><b>Note:</b></p>
<p style="position:absolute;top:696px;left:116px;white-space:nowrap" class="ft041">Members&#160;are required to update&#160;disclosures&#160;annually and to notify guideline staff of&#160;any&#160;relevant changes&#160;in status during the&#160;</p>
<p style="position:absolute;top:713px;left:81px;white-space:nowrap" class="ft041">interim. &#160;</p>
</div>
<!-- Page 211 -->
<a name="211"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page211-div" style="position:relative;width:917px;height:1187px;">
<p style="position:absolute;top:1117px;left:81px;white-space:nowrap" class="ft024"><i>Guidelines for the Prevention and Treatment&#160;of&#160;Opportunistic&#160;Infections in Adults&#160;and Adolescents&#160;With HIV&#160;</i></p>
<p style="position:absolute;top:1117px;left:805px;white-space:nowrap" class="ft024"><i>LL-10&#160;</i></p>
<p style="position:absolute;top:112px;left:81px;white-space:nowrap" class="ft025"><b>Appendix&#160;B.&#160;Panel&#160;Roster&#160;and&#160;Financial&#160;Disclosures&#160;</b></p>
<p style="position:absolute;top:159px;left:81px;white-space:nowrap" class="ft026"><b>Hepatitis C&#160;Virus&#160;</b></p>
<p style="position:absolute;top:230px;left:124px;white-space:nowrap" class="ft02"><b>Member&#160;</b></p>
<p style="position:absolute;top:230px;left:264px;white-space:nowrap" class="ft02"><b>Institution&#160;</b></p>
<p style="position:absolute;top:220px;left:411px;white-space:nowrap" class="ft02"><b>Panel Section&#160;</b></p>
<p style="position:absolute;top:240px;left:427px;white-space:nowrap" class="ft02"><b>Group(s)&#160;</b></p>
<p style="position:absolute;top:210px;left:619px;white-space:nowrap" class="ft02"><b>Financial Disclosure&#160;</b></p>
<p style="position:absolute;top:250px;left:581px;white-space:nowrap" class="ft02"><b>Company&#160;</b></p>
<p style="position:absolute;top:250px;left:719px;white-space:nowrap" class="ft02"><b>Relationship&#160;</b></p>
<p style="position:absolute;top:280px;left:90px;white-space:nowrap" class="ft041">Meena Bansal&#160;&#160;</p>
<p style="position:absolute;top:280px;left:230px;white-space:nowrap" class="ft024"><i>Icahn School of&#160;</i></p>
<p style="position:absolute;top:297px;left:230px;white-space:nowrap" class="ft024"><i>Medicine at&#160;Mount Sinai&#160;&#160;</i></p>
<p style="position:absolute;top:280px;left:384px;white-space:nowrap" class="ft041">Hepatitis C Virus&#160;</p>
<p style="position:absolute;top:280px;left:548px;white-space:nowrap" class="ft041">Pfizer&#160;</p>
<p style="position:absolute;top:312px;left:548px;white-space:nowrap" class="ft041">Histoindex&#160;</p>
<p style="position:absolute;top:344px;left:548px;white-space:nowrap" class="ft041">Siemens&#160;&#160;</p>
<p style="position:absolute;top:280px;left:697px;white-space:nowrap" class="ft041">Travel&#160;Support&#160;</p>
<p style="position:absolute;top:371px;left:548px;white-space:nowrap" class="ft041">The Kinetix Group&#160;&#160;</p>
<p style="position:absolute;top:403px;left:548px;white-space:nowrap" class="ft041">Madrigal&#160;&#160;</p>
<p style="position:absolute;top:436px;left:548px;white-space:nowrap" class="ft041">Pfizer&#160;&#160;</p>
<p style="position:absolute;top:468px;left:548px;white-space:nowrap" class="ft041">mBIOTA&#160;</p>
<p style="position:absolute;top:500px;left:548px;white-space:nowrap" class="ft041">CurveBio&#160;</p>
<p style="position:absolute;top:532px;left:548px;white-space:nowrap" class="ft041">GSK&#160;</p>
<p style="position:absolute;top:564px;left:548px;white-space:nowrap" class="ft041">Fibrinostics&#160;</p>
<p style="position:absolute;top:597px;left:548px;white-space:nowrap" class="ft041">Boeheringer-Ingelheim&#160;</p>
<p style="position:absolute;top:629px;left:548px;white-space:nowrap" class="ft041">Merck&#160;&#160;</p>
<p style="position:absolute;top:661px;left:548px;white-space:nowrap" class="ft041">NOVO&#160;Nordisk&#160;</p>
<p style="position:absolute;top:693px;left:548px;white-space:nowrap" class="ft041">Boston&#160;Pharma&#160;</p>
<p style="position:absolute;top:371px;left:697px;white-space:nowrap" class="ft041">Consultant&#160;</p>
<p style="position:absolute;top:720px;left:90px;white-space:nowrap" class="ft041">Greer&#160;Burkholder&#160;&#160;</p>
<p style="position:absolute;top:720px;left:230px;white-space:nowrap" class="ft024"><i>The University&#160;of&#160;</i></p>
<p style="position:absolute;top:737px;left:230px;white-space:nowrap" class="ft0165"><i>Alabama&#160;at Birmingham&#160;<br/>Marnix E. Heersink&#160;</i></p>
<p style="position:absolute;top:772px;left:230px;white-space:nowrap" class="ft024"><i>School&#160;of Medicine&#160;</i></p>
<p style="position:absolute;top:720px;left:384px;white-space:nowrap" class="ft041">Hepatitis C Virus&#160;</p>
<p style="position:absolute;top:720px;left:548px;white-space:nowrap" class="ft041">Merck Foundation &#160;</p>
<p style="position:absolute;top:752px;left:548px;white-space:nowrap" class="ft041">Cepheid &#160;</p>
<p style="position:absolute;top:720px;left:697px;white-space:nowrap" class="ft041">Research Support&#160;&#160;</p>
<p style="position:absolute;top:799px;left:90px;white-space:nowrap" class="ft041">Emily Cartwright&#160;&#160;</p>
<p style="position:absolute;top:799px;left:230px;white-space:nowrap" class="ft0165"><i>Centers&#160;for Disease&#160;<br/>Control&#160;and&#160;Prevention &#160;</i></p>
<p style="position:absolute;top:799px;left:384px;white-space:nowrap" class="ft041">Hepatitis C Virus&#160;</p>
<p style="position:absolute;top:799px;left:548px;white-space:nowrap" class="ft041">None&#160;&#160;</p>
<p style="position:absolute;top:799px;left:697px;white-space:nowrap" class="ft041">N/A &#160;</p>
<p style="position:absolute;top:844px;left:90px;white-space:nowrap" class="ft041">Arthur Kim&#160;&#160;</p>
<p style="position:absolute;top:844px;left:230px;white-space:nowrap" class="ft024"><i>Harvard Medical&#160;School&#160;&#160;</i></p>
<p style="position:absolute;top:844px;left:383px;white-space:nowrap" class="ft041">Hepatitis C Virus&#160;</p>
<p style="position:absolute;top:844px;left:548px;white-space:nowrap" class="ft041">Shionogi, Inc&#160;</p>
<p style="position:absolute;top:844px;left:697px;white-space:nowrap" class="ft041">Data and Safety&#160;</p>
<p style="position:absolute;top:861px;left:697px;white-space:nowrap" class="ft041">Monitoring&#160;Board &#160;</p>
<p style="position:absolute;top:889px;left:90px;white-space:nowrap" class="ft041">Nina&#160;Kim &#160;</p>
<p style="position:absolute;top:889px;left:230px;white-space:nowrap" class="ft024"><i>University&#160;of&#160;</i></p>
<p style="position:absolute;top:906px;left:230px;white-space:nowrap" class="ft024"><i>Washington School&#160;of&#160;</i></p>
<p style="position:absolute;top:923px;left:230px;white-space:nowrap" class="ft0165"><i>Medicine and School&#160;of&#160;<br/>Public Health &#160;</i></p>
<p style="position:absolute;top:889px;left:384px;white-space:nowrap" class="ft041">Hepatitis C Virus&#160;</p>
<p style="position:absolute;top:889px;left:548px;white-space:nowrap" class="ft041">Gilead&#160;Sciences&#160;</p>
<p style="position:absolute;top:906px;left:548px;white-space:nowrap" class="ft041">(FOCUS&#160;Grant)&#160;&#160;</p>
<p style="position:absolute;top:889px;left:697px;white-space:nowrap" class="ft041">Research Support&#160;</p>
<p style="position:absolute;top:906px;left:697px;white-space:nowrap" class="ft041">(paid&#160;to&#160;institution)&#160;&#160;</p>
<p style="position:absolute;top:967px;left:90px;white-space:nowrap" class="ft041">Kristen Marks&#160;&#160;</p>
<p style="position:absolute;top:967px;left:230px;white-space:nowrap" class="ft024"><i>Weill Cornell Medicine &#160;</i></p>
<p style="position:absolute;top:967px;left:383px;white-space:nowrap" class="ft041">Hepatitis C Virus&#160;</p>
<p style="position:absolute;top:967px;left:548px;white-space:nowrap" class="ft041">Gilead&#160;Sciences &#160;</p>
<p style="position:absolute;top:967px;left:696px;white-space:nowrap" class="ft041">Consultant&#160;&#160;</p>
<p style="position:absolute;top:995px;left:548px;white-space:nowrap" class="ft041">Immorna&#160;&#160;</p>
<p style="position:absolute;top:1027px;left:548px;white-space:nowrap" class="ft041">Novo Norodisk&#160;</p>
<p style="position:absolute;top:995px;left:697px;white-space:nowrap" class="ft041">Data and Safety&#160;</p>
<p style="position:absolute;top:1012px;left:697px;white-space:nowrap" class="ft041">Monitoring&#160;Board &#160;</p>
</div>
<!-- Page 212 -->
<a name="212"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page212-div" style="position:relative;width:917px;height:1187px;">
<p style="position:absolute;top:1117px;left:81px;white-space:nowrap" class="ft024"><i>Guidelines for the Prevention and Treatment&#160;of&#160;Opportunistic&#160;Infections in Adults&#160;and Adolescents&#160;With HIV&#160;</i></p>
<p style="position:absolute;top:1117px;left:805px;white-space:nowrap" class="ft024"><i>LL-11&#160;</i></p>
<p style="position:absolute;top:109px;left:548px;white-space:nowrap" class="ft041">Viiv &#160;</p>
<p style="position:absolute;top:109px;left:696px;white-space:nowrap" class="ft044">Research Support&#160;<br/>(paid&#160;to&#160;institution)&#160;&#160;</p>
<p style="position:absolute;top:154px;left:90px;white-space:nowrap" class="ft041">Susanna Naggie &#160;</p>
<p style="position:absolute;top:154px;left:230px;white-space:nowrap" class="ft0165"><i>Duke University&#160;School&#160;<br/>of Medicine &#160;</i></p>
<p style="position:absolute;top:154px;left:384px;white-space:nowrap" class="ft041">Hepatitis C Virus&#160;</p>
<p style="position:absolute;top:154px;left:548px;white-space:nowrap" class="ft044">Bristol&#160;Myers&#160;<br/>Squibb/PRA 9&#160;</p>
<p style="position:absolute;top:154px;left:697px;white-space:nowrap" class="ft044">Event Adjudication&#160;<br/>Committee&#160;&#160;</p>
<p style="position:absolute;top:198px;left:548px;white-space:nowrap" class="ft041">Vir Biotechnology&#160;&#160;</p>
<p style="position:absolute;top:198px;left:696px;white-space:nowrap" class="ft041">Advisory&#160;Board&#160;&#160;</p>
<p style="position:absolute;top:226px;left:548px;white-space:nowrap" class="ft041">Vir Biotechnology&#160;&#160;</p>
<p style="position:absolute;top:226px;left:696px;white-space:nowrap" class="ft041">Stockholder&#160;</p>
<p style="position:absolute;top:268px;left:548px;white-space:nowrap" class="ft044">Clinical&#160;Infectious&#160;<br/>Diseases&#160;&#160;</p>
<p style="position:absolute;top:268px;left:697px;white-space:nowrap" class="ft041">Deputy&#160;Editor &#160;&#160;</p>
<p style="position:absolute;top:312px;left:90px;white-space:nowrap" class="ft041">Merceditas&#160;</p>
<p style="position:absolute;top:329px;left:90px;white-space:nowrap" class="ft041">Villanueva*&#160;&#160;</p>
<p style="position:absolute;top:312px;left:230px;white-space:nowrap" class="ft024"><i>Yale&#160;School&#160;of Medicine &#160;</i></p>
<p style="position:absolute;top:312px;left:384px;white-space:nowrap" class="ft041">Hepatitis&#160;C Virus&#160;</p>
<p style="position:absolute;top:312px;left:548px;white-space:nowrap" class="ft041">None&#160;</p>
<p style="position:absolute;top:312px;left:697px;white-space:nowrap" class="ft041">N/A&#160;</p>
<p style="position:absolute;top:356px;left:81px;white-space:nowrap" class="ft041">* Section&#160;Group&#160;Lead &#160;</p>
<p style="position:absolute;top:382px;left:81px;white-space:nowrap" class="ft042"><b>Note:</b></p>
<p style="position:absolute;top:382px;left:116px;white-space:nowrap" class="ft041">Members&#160;are required to update&#160;disclosures&#160;annually and to notify guideline staff of&#160;any&#160;relevant changes&#160;in status during the&#160;</p>
<p style="position:absolute;top:400px;left:81px;white-space:nowrap" class="ft041">interim. &#160;</p>
</div>
<!-- Page 213 -->
<a name="213"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}	.ft0167{font-size:15px;font-family:RAJFOH+LiberationSansNarrow;color:#1b1b1b;}
-->
</style>
<div id="page213-div" style="position:relative;width:917px;height:1187px;">
<p style="position:absolute;top:1117px;left:81px;white-space:nowrap" class="ft024"><i>Guidelines for the Prevention and Treatment&#160;of&#160;Opportunistic&#160;Infections in Adults&#160;and Adolescents&#160;With HIV&#160;</i></p>
<p style="position:absolute;top:1117px;left:805px;white-space:nowrap" class="ft024"><i>LL-1</i></p>
<p style="position:absolute;top:1116px;left:830px;white-space:nowrap" class="ft065">2</p>
<p style="position:absolute;top:112px;left:81px;white-space:nowrap" class="ft025"><b>Appendix&#160;B.&#160;Panel&#160;Roster&#160;and&#160;Financial&#160;Disclosures&#160;</b></p>
<p style="position:absolute;top:159px;left:81px;white-space:nowrap" class="ft026"><b>Herpes (HHV-8/CMV)&#160;</b></p>
<p style="position:absolute;top:235px;left:125px;white-space:nowrap" class="ft02"><b>Member&#160;</b></p>
<p style="position:absolute;top:235px;left:276px;white-space:nowrap" class="ft02"><b>Institution&#160;</b></p>
<p style="position:absolute;top:225px;left:429px;white-space:nowrap" class="ft02"><b>Panel Section&#160;</b></p>
<p style="position:absolute;top:245px;left:446px;white-space:nowrap" class="ft02"><b>Group(s)&#160;</b></p>
<p style="position:absolute;top:214px;left:626px;white-space:nowrap" class="ft02"><b>Financial Disclosure&#160;</b></p>
<p style="position:absolute;top:257px;left:588px;white-space:nowrap" class="ft02"><b>Company&#160;</b></p>
<p style="position:absolute;top:257px;left:720px;white-space:nowrap" class="ft02"><b>Relationship&#160;</b></p>
<p style="position:absolute;top:290px;left:90px;white-space:nowrap" class="ft041">Gary&#160;Holland&#160;</p>
<p style="position:absolute;top:290px;left:230px;white-space:nowrap" class="ft0165"><i>University&#160;of&#160;California, Los&#160;<br/>Angeles David&#160;Geffen&#160;</i></p>
<p style="position:absolute;top:325px;left:230px;white-space:nowrap" class="ft024"><i>School&#160;of Medicine&#160;</i></p>
<p style="position:absolute;top:290px;left:406px;white-space:nowrap" class="ft041">Herpes&#160;(HHV-8/CMV)&#160;</p>
<p style="position:absolute;top:323px;left:406px;white-space:nowrap" class="ft041">Herpes&#160;(HSV/VZV)&#160;</p>
<p style="position:absolute;top:290px;left:562px;white-space:nowrap" class="ft041">None&#160;</p>
<p style="position:absolute;top:290px;left:696px;white-space:nowrap" class="ft041">N/A&#160;</p>
<p style="position:absolute;top:355px;left:90px;white-space:nowrap" class="ft041">Christine&#160;Johnston&#160;</p>
<p style="position:absolute;top:355px;left:230px;white-space:nowrap" class="ft024"><i>University&#160;of Washington&#160;</i></p>
<p style="position:absolute;top:372px;left:230px;white-space:nowrap" class="ft024"><i>School&#160;of Medicine &#160;</i></p>
<p style="position:absolute;top:355px;left:406px;white-space:nowrap" class="ft041">Herpes (HHV-8/CMV)&#160;</p>
<p style="position:absolute;top:388px;left:406px;white-space:nowrap" class="ft041">Herpes&#160;(HSV/VZV)&#160;</p>
<p style="position:absolute;top:355px;left:562px;white-space:nowrap" class="ft041">GSK&#160;</p>
<p style="position:absolute;top:388px;left:562px;white-space:nowrap" class="ft041">Pfizer&#160;</p>
<p style="position:absolute;top:420px;left:562px;white-space:nowrap" class="ft041">Assembly&#160;</p>
<p style="position:absolute;top:437px;left:562px;white-space:nowrap" class="ft041">Biosciences&#160;</p>
<p style="position:absolute;top:469px;left:562px;white-space:nowrap" class="ft041">Oxymo&#160;</p>
<p style="position:absolute;top:501px;left:562px;white-space:nowrap" class="ft041">Aicuris&#160;</p>
<p style="position:absolute;top:355px;left:697px;white-space:nowrap" class="ft041">Consultant&#160;</p>
<p style="position:absolute;top:532px;left:562px;white-space:nowrap" class="ft041">GSK&#160;</p>
<p style="position:absolute;top:564px;left:562px;white-space:nowrap" class="ft041">Moderna&#160;</p>
<p style="position:absolute;top:596px;left:562px;white-space:nowrap" class="ft041">Gilead&#160;</p>
<p style="position:absolute;top:532px;left:697px;white-space:nowrap" class="ft041">Research Support&#160;</p>
<p style="position:absolute;top:627px;left:562px;white-space:nowrap" class="ft041">HIV Vaccine Trials&#160;</p>
<p style="position:absolute;top:627px;left:696px;white-space:nowrap" class="ft041">Data and Safety&#160;</p>
<p style="position:absolute;top:644px;left:697px;white-space:nowrap" class="ft041">Monitoring&#160;Board&#160;</p>
<p style="position:absolute;top:674px;left:90px;white-space:nowrap" class="ft041">Warren&#160;Phipps*</p>
<p style="position:absolute;top:674px;left:230px;white-space:nowrap" class="ft024"><i>University&#160;of&#160;Washington&#160;</i></p>
<p style="position:absolute;top:692px;left:230px;white-space:nowrap" class="ft024"><i>School&#160;of Medicine &#160;</i></p>
<p style="position:absolute;top:674px;left:406px;white-space:nowrap" class="ft041">Herpes (HHV-8/CMV)</p>
<p style="position:absolute;top:674px;left:561px;white-space:nowrap" class="ft041">None&#160;</p>
<p style="position:absolute;top:674px;left:696px;white-space:nowrap" class="ft041">N/A&#160;</p>
<p style="position:absolute;top:722px;left:90px;white-space:nowrap" class="ft041">Ramya&#160;Ramaswami&#160;</p>
<p style="position:absolute;top:722px;left:230px;white-space:nowrap" class="ft024"><i>National&#160;Institutes of Health&#160;</i></p>
<p style="position:absolute;top:722px;left:406px;white-space:nowrap" class="ft041">Herpes (HHV-8/CMV)&#160;</p>
<p style="position:absolute;top:722px;left:561px;white-space:nowrap" class="ft041">Celgene/Bristol&#160;</p>
<p style="position:absolute;top:739px;left:562px;white-space:nowrap" class="ft041">Myers&#160;Squibb&#160;</p>
<p style="position:absolute;top:772px;left:562px;white-space:nowrap" class="ft041">EMD Serono&#160;</p>
<p style="position:absolute;top:804px;left:562px;white-space:nowrap" class="ft041">Merck&#160;</p>
<p style="position:absolute;top:836px;left:562px;white-space:nowrap" class="ft041">Sobi/CTI BioPharma&#160;</p>
<p style="position:absolute;top:868px;left:562px;white-space:nowrap" class="ft041">PDS&#160;Biotech&#160;</p>
<p style="position:absolute;top:900px;left:562px;white-space:nowrap" class="ft041">Eli&#160;Lilly&#160;</p>
<p style="position:absolute;top:722px;left:697px;white-space:nowrap" class="ft0167">Research Support</p>
<p style="position:absolute;top:722px;left:796px;white-space:nowrap" class="ft042"><b>&#160;</b></p>
<p style="position:absolute;top:931px;left:90px;white-space:nowrap" class="ft041">Shannon&#160;Ross&#160;</p>
<p style="position:absolute;top:931px;left:230px;white-space:nowrap" class="ft0165"><i>The University&#160;of Alabama&#160;<br/>at Birmingham Marnix E.&#160;</i></p>
<p style="position:absolute;top:965px;left:230px;white-space:nowrap" class="ft024"><i>Heersink&#160;School&#160;of&#160;</i></p>
<p style="position:absolute;top:983px;left:230px;white-space:nowrap" class="ft024"><i>Medicine &#160;</i></p>
<p style="position:absolute;top:931px;left:406px;white-space:nowrap" class="ft041">Herpes (HHV-8/CMV)&#160;</p>
<p style="position:absolute;top:963px;left:406px;white-space:nowrap" class="ft041">Herpes&#160;(HSV/VZV)&#160;</p>
<p style="position:absolute;top:931px;left:562px;white-space:nowrap" class="ft041">None&#160;</p>
<p style="position:absolute;top:931px;left:696px;white-space:nowrap" class="ft041">N/A&#160;</p>
<p style="position:absolute;top:1010px;left:81px;white-space:nowrap" class="ft041">*&#160;Section Group&#160;Lead</p>
<p style="position:absolute;top:1036px;left:81px;white-space:nowrap" class="ft042"><b>Note:</b></p>
<p style="position:absolute;top:1036px;left:116px;white-space:nowrap" class="ft041">Members&#160;are required to update&#160;disclosures&#160;annually and to notify guideline staff of&#160;any&#160;relevant changes&#160;in status during the&#160;</p>
<p style="position:absolute;top:1053px;left:81px;white-space:nowrap" class="ft041">interim. &#160;</p>
</div>
<!-- Page 214 -->
<a name="214"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page214-div" style="position:relative;width:917px;height:1187px;">
<p style="position:absolute;top:1117px;left:81px;white-space:nowrap" class="ft024"><i>Guidelines for the Prevention and Treatment&#160;of&#160;Opportunistic&#160;Infections in Adults&#160;and Adolescents&#160;With HIV&#160;</i></p>
<p style="position:absolute;top:1117px;left:805px;white-space:nowrap" class="ft024"><i>LL-1</i></p>
<p style="position:absolute;top:1116px;left:830px;white-space:nowrap" class="ft065">3</p>
<p style="position:absolute;top:112px;left:81px;white-space:nowrap" class="ft025"><b>Appendix&#160;B.&#160;Panel&#160;Roster&#160;and&#160;Financial&#160;Disclosures&#160;</b></p>
<p style="position:absolute;top:159px;left:81px;white-space:nowrap" class="ft026"><b>Herpes (HSV/VZV)&#160;</b></p>
<p style="position:absolute;top:229px;left:120px;white-space:nowrap" class="ft02"><b>Member&#160;</b></p>
<p style="position:absolute;top:229px;left:261px;white-space:nowrap" class="ft02"><b>Institution&#160;</b></p>
<p style="position:absolute;top:220px;left:415px;white-space:nowrap" class="ft02"><b>Panel Section&#160;</b></p>
<p style="position:absolute;top:239px;left:432px;white-space:nowrap" class="ft02"><b>Group(s)&#160;</b></p>
<p style="position:absolute;top:210px;left:622px;white-space:nowrap" class="ft02"><b>Financial Disclosure&#160;</b></p>
<p style="position:absolute;top:249px;left:585px;white-space:nowrap" class="ft02"><b>Company&#160;</b></p>
<p style="position:absolute;top:249px;left:720px;white-space:nowrap" class="ft02"><b>Relationship&#160;</b></p>
<p style="position:absolute;top:278px;left:90px;white-space:nowrap" class="ft041">Gary&#160;Holland&#160;</p>
<p style="position:absolute;top:278px;left:220px;white-space:nowrap" class="ft024"><i>University&#160;of&#160;California,&#160;</i></p>
<p style="position:absolute;top:296px;left:220px;white-space:nowrap" class="ft024"><i>Los Angeles David&#160;Geffen&#160;</i></p>
<p style="position:absolute;top:313px;left:220px;white-space:nowrap" class="ft024"><i>School&#160;of Medicine&#160;</i></p>
<p style="position:absolute;top:278px;left:386px;white-space:nowrap" class="ft041">Herpes&#160;(HHV-8/CMV)&#160;</p>
<p style="position:absolute;top:311px;left:386px;white-space:nowrap" class="ft041">Herpes&#160;(HSV/VZV)&#160;</p>
<p style="position:absolute;top:278px;left:554px;white-space:nowrap" class="ft041">None&#160;</p>
<p style="position:absolute;top:278px;left:696px;white-space:nowrap" class="ft041">N/A&#160;</p>
<p style="position:absolute;top:340px;left:90px;white-space:nowrap" class="ft041">Christine&#160;Johnston&#160;</p>
<p style="position:absolute;top:340px;left:220px;white-space:nowrap" class="ft024"><i>University&#160;of&#160;Washington&#160;</i></p>
<p style="position:absolute;top:357px;left:220px;white-space:nowrap" class="ft024"><i>School&#160;of Medicine&#160;</i></p>
<p style="position:absolute;top:340px;left:386px;white-space:nowrap" class="ft041">Herpes (HHV-8/CMV)&#160;</p>
<p style="position:absolute;top:372px;left:386px;white-space:nowrap" class="ft041">Herpes&#160;(HSV/VZV)&#160;</p>
<p style="position:absolute;top:340px;left:554px;white-space:nowrap" class="ft041">GSK&#160;</p>
<p style="position:absolute;top:372px;left:554px;white-space:nowrap" class="ft041">Pfizer&#160;</p>
<p style="position:absolute;top:404px;left:554px;white-space:nowrap" class="ft041">Assembly&#160;Biosciences&#160;</p>
<p style="position:absolute;top:436px;left:554px;white-space:nowrap" class="ft041">Oxymo&#160;</p>
<p style="position:absolute;top:469px;left:554px;white-space:nowrap" class="ft041">Aicuris&#160;</p>
<p style="position:absolute;top:340px;left:697px;white-space:nowrap" class="ft041">Consultant&#160;</p>
<p style="position:absolute;top:496px;left:554px;white-space:nowrap" class="ft041">GSK&#160;</p>
<p style="position:absolute;top:528px;left:554px;white-space:nowrap" class="ft041">Moderna&#160;</p>
<p style="position:absolute;top:496px;left:697px;white-space:nowrap" class="ft041">Research Support&#160;</p>
<p style="position:absolute;top:555px;left:554px;white-space:nowrap" class="ft041">HIV Vaccine Trials&#160;</p>
<p style="position:absolute;top:555px;left:696px;white-space:nowrap" class="ft041">Data and Safety&#160;</p>
<p style="position:absolute;top:572px;left:697px;white-space:nowrap" class="ft041">Monitoring&#160;Board&#160;</p>
<p style="position:absolute;top:599px;left:90px;white-space:nowrap" class="ft041">Andrew Karaba&#160;</p>
<p style="position:absolute;top:599px;left:220px;white-space:nowrap" class="ft024"><i>The Johns&#160;Hopkins&#160;</i></p>
<p style="position:absolute;top:616px;left:220px;white-space:nowrap" class="ft024"><i>University&#160;School&#160;of&#160;</i></p>
<p style="position:absolute;top:633px;left:220px;white-space:nowrap" class="ft024"><i>Medicine &#160;</i></p>
<p style="position:absolute;top:599px;left:386px;white-space:nowrap" class="ft041">Herpes&#160;(HSV/VZV)&#160;</p>
<p style="position:absolute;top:599px;left:554px;white-space:nowrap" class="ft041">Hologic, Inc.&#160;</p>
<p style="position:absolute;top:599px;left:696px;white-space:nowrap" class="ft041">Consultant&#160;</p>
<p style="position:absolute;top:660px;left:90px;white-space:nowrap" class="ft041">Poonam Mathur&#160;</p>
<p style="position:absolute;top:660px;left:220px;white-space:nowrap" class="ft024"><i>University&#160;of Washington&#160;</i></p>
<p style="position:absolute;top:678px;left:220px;white-space:nowrap" class="ft024"><i>School&#160;of Medicine &#160;</i></p>
<p style="position:absolute;top:660px;left:386px;white-space:nowrap" class="ft041">Herpes&#160;(HSV/VZV)&#160;</p>
<p style="position:absolute;top:660px;left:554px;white-space:nowrap" class="ft041">None&#160;</p>
<p style="position:absolute;top:660px;left:697px;white-space:nowrap" class="ft041">N/A&#160;</p>
<p style="position:absolute;top:704px;left:90px;white-space:nowrap" class="ft041">Shannon&#160;Ross&#160;</p>
<p style="position:absolute;top:704px;left:220px;white-space:nowrap" class="ft0165"><i>The University&#160;of Alabama&#160;<br/>at Birmingham Marnix E.&#160;</i></p>
<p style="position:absolute;top:739px;left:220px;white-space:nowrap" class="ft024"><i>Heersink&#160;School&#160;of&#160;</i></p>
<p style="position:absolute;top:756px;left:220px;white-space:nowrap" class="ft024"><i>Medicine &#160;</i></p>
<p style="position:absolute;top:704px;left:386px;white-space:nowrap" class="ft041">Herpes (HHV-8/CMV)&#160;</p>
<p style="position:absolute;top:737px;left:386px;white-space:nowrap" class="ft041">Herpes&#160;(HSV/VZV)&#160;</p>
<p style="position:absolute;top:704px;left:554px;white-space:nowrap" class="ft041">None&#160;</p>
<p style="position:absolute;top:704px;left:696px;white-space:nowrap" class="ft041">N/A&#160;</p>
<p style="position:absolute;top:783px;left:90px;white-space:nowrap" class="ft041">Sarah&#160;Schmalzle*&#160;</p>
<p style="position:absolute;top:783px;left:220px;white-space:nowrap" class="ft024"><i>Baltimore County&#160;</i></p>
<p style="position:absolute;top:800px;left:220px;white-space:nowrap" class="ft024"><i>Department of&#160;Health&#160;</i></p>
<p style="position:absolute;top:783px;left:386px;white-space:nowrap" class="ft041">Herpes&#160;(HSV/VZV)&#160;</p>
<p style="position:absolute;top:783px;left:554px;white-space:nowrap" class="ft041">None&#160;</p>
<p style="position:absolute;top:783px;left:697px;white-space:nowrap" class="ft041">N/A&#160;</p>
<p style="position:absolute;top:836px;left:81px;white-space:nowrap" class="ft041">*&#160;Section Group&#160;Lead</p>
<p style="position:absolute;top:862px;left:81px;white-space:nowrap" class="ft042"><b>Note:</b></p>
<p style="position:absolute;top:862px;left:116px;white-space:nowrap" class="ft041">Members&#160;are required to update&#160;disclosures&#160;annually and to notify guideline staff of&#160;any&#160;relevant changes&#160;in status during the&#160;</p>
<p style="position:absolute;top:879px;left:81px;white-space:nowrap" class="ft041">interim.&#160;</p>
</div>
<!-- Page 215 -->
<a name="215"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page215-div" style="position:relative;width:917px;height:1187px;">
<p style="position:absolute;top:1117px;left:81px;white-space:nowrap" class="ft024"><i>Guidelines for the Prevention and Treatment&#160;of&#160;Opportunistic&#160;Infections in Adults&#160;and Adolescents&#160;With HIV&#160;</i></p>
<p style="position:absolute;top:1117px;left:805px;white-space:nowrap" class="ft024"><i>LL-1</i></p>
<p style="position:absolute;top:1116px;left:830px;white-space:nowrap" class="ft065">4</p>
<p style="position:absolute;top:112px;left:81px;white-space:nowrap" class="ft025"><b>Appendix&#160;B.&#160;Panel&#160;Roster&#160;and&#160;Financial&#160;Disclosures&#160;</b></p>
<p style="position:absolute;top:159px;left:81px;white-space:nowrap" class="ft026"><b>Human Papillomavirus&#160;</b></p>
<p style="position:absolute;top:229px;left:129px;white-space:nowrap" class="ft02"><b>Member&#160;</b></p>
<p style="position:absolute;top:229px;left:276px;white-space:nowrap" class="ft02"><b>Institution&#160;</b></p>
<p style="position:absolute;top:220px;left:423px;white-space:nowrap" class="ft02"><b>Panel Section&#160;</b></p>
<p style="position:absolute;top:239px;left:439px;white-space:nowrap" class="ft02"><b>Group(s)&#160;</b></p>
<p style="position:absolute;top:210px;left:623px;white-space:nowrap" class="ft02"><b>Financial Disclosure&#160;</b></p>
<p style="position:absolute;top:249px;left:585px;white-space:nowrap" class="ft02"><b>Company&#160;</b></p>
<p style="position:absolute;top:249px;left:720px;white-space:nowrap" class="ft02"><b>Relationship&#160;</b></p>
<p style="position:absolute;top:278px;left:88px;white-space:nowrap" class="ft041">Susan&#160;Cu-Uvin&#160;</p>
<p style="position:absolute;top:278px;left:236px;white-space:nowrap" class="ft024"><i>The Warren Alpert&#160;</i></p>
<p style="position:absolute;top:296px;left:236px;white-space:nowrap" class="ft024"><i>Medical&#160;School&#160;of Brown&#160;</i></p>
<p style="position:absolute;top:313px;left:236px;white-space:nowrap" class="ft024"><i>University&#160;&#160;</i></p>
<p style="position:absolute;top:278px;left:398px;white-space:nowrap" class="ft041">Human&#160;Papillomavirus</p>
<p style="position:absolute;top:279px;left:521px;white-space:nowrap" class="ft057">&#160;</p>
<p style="position:absolute;top:278px;left:553px;white-space:nowrap" class="ft041">AIDS&#160;Malignancy&#160;</p>
<p style="position:absolute;top:296px;left:553px;white-space:nowrap" class="ft041">Consortium &#160;</p>
<p style="position:absolute;top:278px;left:695px;white-space:nowrap" class="ft041">Data and Safety&#160;</p>
<p style="position:absolute;top:296px;left:695px;white-space:nowrap" class="ft041">Monitoring&#160;Board&#160;</p>
<p style="position:absolute;top:340px;left:88px;white-space:nowrap" class="ft041">Grant Ellsworth*&#160;</p>
<p style="position:absolute;top:340px;left:236px;white-space:nowrap" class="ft024"><i>Weill&#160;Cornell&#160;Medical&#160;</i></p>
<p style="position:absolute;top:357px;left:236px;white-space:nowrap" class="ft024"><i>College&#160;&#160;</i></p>
<p style="position:absolute;top:340px;left:398px;white-space:nowrap" class="ft041">Human&#160;Papillomavirus</p>
<p style="position:absolute;top:340px;left:521px;white-space:nowrap" class="ft057">&#160;</p>
<p style="position:absolute;top:340px;left:553px;white-space:nowrap" class="ft041">Merck&#160;</p>
<p style="position:absolute;top:340px;left:695px;white-space:nowrap" class="ft041">Research Support (paid&#160;</p>
<p style="position:absolute;top:357px;left:695px;white-space:nowrap" class="ft041">to institution) &#160;</p>
<p style="position:absolute;top:384px;left:88px;white-space:nowrap" class="ft041">Andrea Lisco&#160;</p>
<p style="position:absolute;top:384px;left:236px;white-space:nowrap" class="ft024"><i>National&#160;Institutes of&#160;</i></p>
<p style="position:absolute;top:401px;left:236px;white-space:nowrap" class="ft024"><i>Health &#160;</i></p>
<p style="position:absolute;top:384px;left:398px;white-space:nowrap" class="ft041">Human&#160;Papillomavirus</p>
<p style="position:absolute;top:384px;left:521px;white-space:nowrap" class="ft057">&#160;</p>
<p style="position:absolute;top:384px;left:553px;white-space:nowrap" class="ft041">Merck&#160;</p>
<p style="position:absolute;top:384px;left:695px;white-space:nowrap" class="ft041">Other—Support&#160;under&#160;</p>
<p style="position:absolute;top:401px;left:695px;white-space:nowrap" class="ft041">Merck Investigator&#160;</p>
<p style="position:absolute;top:418px;left:695px;white-space:nowrap" class="ft041">Studies for&#160;clinical&#160;trial&#160;</p>
<p style="position:absolute;top:445px;left:553px;white-space:nowrap" class="ft041">NeoImmuneTech&#160;</p>
<p style="position:absolute;top:445px;left:695px;white-space:nowrap" class="ft041">Research Support&#160;</p>
<p style="position:absolute;top:472px;left:88px;white-space:nowrap" class="ft041">Lauri Markowitz&#160;</p>
<p style="position:absolute;top:472px;left:236px;white-space:nowrap" class="ft024"><i>Centers&#160;for&#160;Disease&#160;</i></p>
<p style="position:absolute;top:489px;left:236px;white-space:nowrap" class="ft024"><i>Control&#160;and&#160;Prevention&#160;</i></p>
<p style="position:absolute;top:472px;left:398px;white-space:nowrap" class="ft041">Human&#160;Papillomavirus</p>
<p style="position:absolute;top:472px;left:521px;white-space:nowrap" class="ft057">&#160;</p>
<p style="position:absolute;top:472px;left:553px;white-space:nowrap" class="ft041">None&#160;</p>
<p style="position:absolute;top:472px;left:695px;white-space:nowrap" class="ft041">N/A&#160;</p>
<p style="position:absolute;top:516px;left:88px;white-space:nowrap" class="ft041">L.&#160;Stewart Massad</p>
<p style="position:absolute;top:516px;left:236px;white-space:nowrap" class="ft0165"><i>Washington University&#160;<br/>School&#160;of Medicine in&#160;</i></p>
<p style="position:absolute;top:551px;left:236px;white-space:nowrap" class="ft024"><i>St.&#160;Louis&#160;&#160;</i></p>
<p style="position:absolute;top:516px;left:398px;white-space:nowrap" class="ft041">Human&#160;Papillomavirus</p>
<p style="position:absolute;top:517px;left:521px;white-space:nowrap" class="ft057">&#160;</p>
<p style="position:absolute;top:516px;left:553px;white-space:nowrap" class="ft041">Merck&#160;</p>
<p style="position:absolute;top:516px;left:695px;white-space:nowrap" class="ft041">Consultant&#160;</p>
<p style="position:absolute;top:578px;left:88px;white-space:nowrap" class="ft041">Anna-Barbara Moscicki&#160;</p>
<p style="position:absolute;top:578px;left:236px;white-space:nowrap" class="ft0165"><i>University&#160;of California,&#160;<br/>Los Angeles David&#160;Geffen&#160;</i></p>
<p style="position:absolute;top:612px;left:236px;white-space:nowrap" class="ft024"><i>School&#160;of Medicine&#160;</i></p>
<p style="position:absolute;top:578px;left:398px;white-space:nowrap" class="ft041">Human&#160;Papillomavirus</p>
<p style="position:absolute;top:578px;left:521px;white-space:nowrap" class="ft057">&#160;</p>
<p style="position:absolute;top:578px;left:553px;white-space:nowrap" class="ft041">Merck&#160;</p>
<p style="position:absolute;top:578px;left:695px;white-space:nowrap" class="ft041">Advisory&#160;Board&#160;</p>
<p style="position:absolute;top:639px;left:88px;white-space:nowrap" class="ft041">Joel&#160;Palefsky&#160;</p>
<p style="position:absolute;top:639px;left:236px;white-space:nowrap" class="ft0165"><i>University&#160;of California,&#160;<br/>San Francisco School of</i></p>
<p style="position:absolute;top:674px;left:236px;white-space:nowrap" class="ft024"><i>Medicine &#160;</i></p>
<p style="position:absolute;top:639px;left:398px;white-space:nowrap" class="ft041">Human&#160;Papillomavirus</p>
<p style="position:absolute;top:639px;left:521px;white-space:nowrap" class="ft057">&#160;</p>
<p style="position:absolute;top:639px;left:553px;white-space:nowrap" class="ft041">Merck&#160;</p>
<p style="position:absolute;top:671px;left:553px;white-space:nowrap" class="ft041">GSK&#160;</p>
<p style="position:absolute;top:704px;left:553px;white-space:nowrap" class="ft041">Abbott&#160;</p>
<p style="position:absolute;top:639px;left:695px;white-space:nowrap" class="ft041">Consultant&#160;</p>
<p style="position:absolute;top:731px;left:553px;white-space:nowrap" class="ft041">Roche&#160;Molecular&#160;</p>
<p style="position:absolute;top:748px;left:553px;white-space:nowrap" class="ft041">Diagnostics&#160;&#160;</p>
<p style="position:absolute;top:780px;left:553px;white-space:nowrap" class="ft041">Merck&#160;</p>
<p style="position:absolute;top:812px;left:553px;white-space:nowrap" class="ft041">GSK&#160;</p>
<p style="position:absolute;top:844px;left:553px;white-space:nowrap" class="ft041">Abbott&#160;</p>
<p style="position:absolute;top:731px;left:695px;white-space:nowrap" class="ft041">Honoraria&#160;</p>
<p style="position:absolute;top:871px;left:553px;white-space:nowrap" class="ft044">Roche&#160;Molecular&#160;<br/>Diagnostics&#160;&#160;</p>
<p style="position:absolute;top:921px;left:553px;white-space:nowrap" class="ft041">Atila&#160;Biosystems</p>
<p style="position:absolute;top:953px;left:553px;white-space:nowrap" class="ft041">Hologic&#160;</p>
<p style="position:absolute;top:871px;left:695px;white-space:nowrap" class="ft041">Research Support&#160;</p>
<p style="position:absolute;top:980px;left:88px;white-space:nowrap" class="ft041">Elizabeth&#160;Stier&#160;</p>
<p style="position:absolute;top:980px;left:236px;white-space:nowrap" class="ft024"><i>Boston&#160;University&#160;Medical&#160;</i></p>
<p style="position:absolute;top:997px;left:236px;white-space:nowrap" class="ft024"><i>Campus&#160;&#160;</i></p>
<p style="position:absolute;top:980px;left:398px;white-space:nowrap" class="ft041">Human&#160;Papillomavirus</p>
<p style="position:absolute;top:980px;left:521px;white-space:nowrap" class="ft057">&#160;</p>
<p style="position:absolute;top:980px;left:553px;white-space:nowrap" class="ft041">None&#160;</p>
<p style="position:absolute;top:980px;left:695px;white-space:nowrap" class="ft041">N/A&#160;</p>
<p style="position:absolute;top:1024px;left:88px;white-space:nowrap" class="ft041">John&#160;Weiser&#160;</p>
<p style="position:absolute;top:1024px;left:236px;white-space:nowrap" class="ft024"><i>Centers&#160;for&#160;Disease&#160;</i></p>
<p style="position:absolute;top:1041px;left:236px;white-space:nowrap" class="ft024"><i>Control&#160;and&#160;Prevention&#160;</i></p>
<p style="position:absolute;top:1024px;left:398px;white-space:nowrap" class="ft041">Human&#160;Papillomavirus</p>
<p style="position:absolute;top:1024px;left:521px;white-space:nowrap" class="ft057">&#160;</p>
<p style="position:absolute;top:1024px;left:553px;white-space:nowrap" class="ft041">None&#160;</p>
<p style="position:absolute;top:1024px;left:695px;white-space:nowrap" class="ft041">N/A&#160;</p>
</div>
<!-- Page 216 -->
<a name="216"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page216-div" style="position:relative;width:917px;height:1187px;">
<p style="position:absolute;top:1117px;left:81px;white-space:nowrap" class="ft024"><i>Guidelines for the Prevention and Treatment&#160;of&#160;Opportunistic&#160;Infections in Adults&#160;and Adolescents&#160;With HIV&#160;</i></p>
<p style="position:absolute;top:1117px;left:805px;white-space:nowrap" class="ft024"><i>LL-1</i></p>
<p style="position:absolute;top:1116px;left:830px;white-space:nowrap" class="ft065">5</p>
<p style="position:absolute;top:137px;left:129px;white-space:nowrap" class="ft02"><b>Member&#160;</b></p>
<p style="position:absolute;top:137px;left:276px;white-space:nowrap" class="ft02"><b>Institution&#160;</b></p>
<p style="position:absolute;top:127px;left:423px;white-space:nowrap" class="ft02"><b>Panel Section&#160;</b></p>
<p style="position:absolute;top:147px;left:439px;white-space:nowrap" class="ft02"><b>Group(s)&#160;</b></p>
<p style="position:absolute;top:118px;left:623px;white-space:nowrap" class="ft02"><b>Financial Disclosure&#160;</b></p>
<p style="position:absolute;top:156px;left:585px;white-space:nowrap" class="ft02"><b>Company&#160;</b></p>
<p style="position:absolute;top:156px;left:720px;white-space:nowrap" class="ft02"><b>Relationship&#160;</b></p>
<p style="position:absolute;top:186px;left:88px;white-space:nowrap" class="ft041">John&#160;Winters&#160;</p>
<p style="position:absolute;top:186px;left:236px;white-space:nowrap" class="ft024"><i>Icahn School&#160;of&#160;Medicine&#160;</i></p>
<p style="position:absolute;top:203px;left:236px;white-space:nowrap" class="ft024"><i>at Mount Sinai&#160;&#160;</i></p>
<p style="position:absolute;top:186px;left:398px;white-space:nowrap" class="ft041">Human&#160;Papillomavirus</p>
<p style="position:absolute;top:186px;left:521px;white-space:nowrap" class="ft057">&#160;</p>
<p style="position:absolute;top:186px;left:553px;white-space:nowrap" class="ft041">None&#160;</p>
<p style="position:absolute;top:186px;left:695px;white-space:nowrap" class="ft041">N/A&#160;</p>
<p style="position:absolute;top:230px;left:81px;white-space:nowrap" class="ft041">*&#160;Section Group&#160;Lead</p>
<p style="position:absolute;top:256px;left:81px;white-space:nowrap" class="ft042"><b>Note:</b></p>
<p style="position:absolute;top:256px;left:116px;white-space:nowrap" class="ft041">Members&#160;are required to update&#160;disclosures&#160;annually and to notify guideline staff of&#160;any&#160;relevant changes&#160;in status during the&#160;</p>
<p style="position:absolute;top:274px;left:81px;white-space:nowrap" class="ft041">interim. &#160;</p>
</div>
<!-- Page 217 -->
<a name="217"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page217-div" style="position:relative;width:917px;height:1187px;">
<p style="position:absolute;top:1117px;left:81px;white-space:nowrap" class="ft024"><i>Guidelines for the Prevention and Treatment&#160;of&#160;Opportunistic&#160;Infections in Adults&#160;and Adolescents&#160;With HIV&#160;</i></p>
<p style="position:absolute;top:1117px;left:805px;white-space:nowrap" class="ft024"><i>LL-1</i></p>
<p style="position:absolute;top:1116px;left:830px;white-space:nowrap" class="ft065">6</p>
<p style="position:absolute;top:112px;left:81px;white-space:nowrap" class="ft025"><b>Appendix&#160;B.&#160;Panel&#160;Roster&#160;and&#160;Financial&#160;Disclosures&#160;</b></p>
<p style="position:absolute;top:159px;left:81px;white-space:nowrap" class="ft026"><b>Immunizations&#160;</b></p>
<p style="position:absolute;top:232px;left:135px;white-space:nowrap" class="ft02"><b>Member&#160;</b></p>
<p style="position:absolute;top:232px;left:297px;white-space:nowrap" class="ft02"><b>Institution&#160;</b></p>
<p style="position:absolute;top:222px;left:452px;white-space:nowrap" class="ft02"><b>Panel Section&#160;</b></p>
<p style="position:absolute;top:242px;left:469px;white-space:nowrap" class="ft02"><b>Group(s)&#160;</b></p>
<p style="position:absolute;top:211px;left:639px;white-space:nowrap" class="ft02"><b>Financial Disclosure&#160;</b></p>
<p style="position:absolute;top:252px;left:608px;white-space:nowrap" class="ft02"><b>Company&#160;</b></p>
<p style="position:absolute;top:252px;left:727px;white-space:nowrap" class="ft02"><b>Relationship&#160;</b></p>
<p style="position:absolute;top:283px;left:88px;white-space:nowrap" class="ft041">Meagan&#160;Deming&#160;</p>
<p style="position:absolute;top:283px;left:249px;white-space:nowrap" class="ft024"><i>University&#160;of&#160;Maryland&#160;</i></p>
<p style="position:absolute;top:300px;left:249px;white-space:nowrap" class="ft024"><i>School&#160;of Medicine &#160;</i></p>
<p style="position:absolute;top:283px;left:425px;white-space:nowrap" class="ft041">Immunizations</p>
<p style="position:absolute;top:283px;left:504px;white-space:nowrap" class="ft057">&#160;</p>
<p style="position:absolute;top:283px;left:586px;white-space:nowrap" class="ft041">CEPI&#160;</p>
<p style="position:absolute;top:283px;left:708px;white-space:nowrap" class="ft041">Research Support&#160;</p>
<p style="position:absolute;top:327px;left:88px;white-space:nowrap" class="ft041">Shireesha Dhanireddy&#160;</p>
<p style="position:absolute;top:327px;left:249px;white-space:nowrap" class="ft0165"><i>University&#160;of&#160;Washington&#160;<br/>School&#160;of Medicine &#160;</i></p>
<p style="position:absolute;top:327px;left:425px;white-space:nowrap" class="ft041">Leadership&#160;</p>
<p style="position:absolute;top:354px;left:425px;white-space:nowrap" class="ft041">Immunizations&#160;</p>
<p style="position:absolute;top:327px;left:586px;white-space:nowrap" class="ft041">None&#160;</p>
<p style="position:absolute;top:327px;left:708px;white-space:nowrap" class="ft041">N/A&#160;</p>
<p style="position:absolute;top:386px;left:88px;white-space:nowrap" class="ft041">Philip&#160;Peters</p>
<p style="position:absolute;top:386px;left:249px;white-space:nowrap" class="ft024"><i>Centers&#160;for&#160;Disease Control</i></p>
<p style="position:absolute;top:404px;left:249px;white-space:nowrap" class="ft024"><i>and&#160;Prevention&#160;&#160;</i></p>
<p style="position:absolute;top:386px;left:425px;white-space:nowrap" class="ft041">Immunizations</p>
<p style="position:absolute;top:387px;left:504px;white-space:nowrap" class="ft057">&#160;</p>
<p style="position:absolute;top:386px;left:586px;white-space:nowrap" class="ft041">None&#160;</p>
<p style="position:absolute;top:386px;left:708px;white-space:nowrap" class="ft041">N/A&#160;</p>
<p style="position:absolute;top:431px;left:88px;white-space:nowrap" class="ft041">Daniel&#160;Solomon*&#160;</p>
<p style="position:absolute;top:431px;left:249px;white-space:nowrap" class="ft024"><i>Harvard Medical&#160;School&#160;</i></p>
<p style="position:absolute;top:431px;left:425px;white-space:nowrap" class="ft041">Immunizations</p>
<p style="position:absolute;top:431px;left:504px;white-space:nowrap" class="ft057">&#160;</p>
<p style="position:absolute;top:431px;left:586px;white-space:nowrap" class="ft041">None&#160;</p>
<p style="position:absolute;top:431px;left:708px;white-space:nowrap" class="ft041">N/A&#160;</p>
<p style="position:absolute;top:458px;left:88px;white-space:nowrap" class="ft041">Jennifer Whitaker&#160;</p>
<p style="position:absolute;top:458px;left:249px;white-space:nowrap" class="ft024"><i>Baylor College&#160;of Medicine&#160;</i></p>
<p style="position:absolute;top:458px;left:425px;white-space:nowrap" class="ft041">Immunizations</p>
<p style="position:absolute;top:458px;left:504px;white-space:nowrap" class="ft057">&#160;</p>
<p style="position:absolute;top:458px;left:586px;white-space:nowrap" class="ft041">Pfizer&#160;</p>
<p style="position:absolute;top:458px;left:708px;white-space:nowrap" class="ft041">Research Support&#160;</p>
<p style="position:absolute;top:485px;left:81px;white-space:nowrap" class="ft041">*&#160;Section Group&#160;Lead</p>
<p style="position:absolute;top:511px;left:81px;white-space:nowrap" class="ft042"><b>Note:</b></p>
<p style="position:absolute;top:511px;left:116px;white-space:nowrap" class="ft041">Members&#160;are required to update&#160;disclosures&#160;annually and to notify guideline staff of&#160;any&#160;relevant changes&#160;in status during the&#160;</p>
<p style="position:absolute;top:528px;left:81px;white-space:nowrap" class="ft041">interim. &#160;</p>
</div>
<!-- Page 218 -->
<a name="218"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page218-div" style="position:relative;width:917px;height:1187px;">
<p style="position:absolute;top:1117px;left:81px;white-space:nowrap" class="ft024"><i>Guidelines for the Prevention and Treatment&#160;of&#160;Opportunistic&#160;Infections in Adults&#160;and Adolescents&#160;With HIV&#160;</i></p>
<p style="position:absolute;top:1117px;left:805px;white-space:nowrap" class="ft024"><i>LL-1</i></p>
<p style="position:absolute;top:1116px;left:830px;white-space:nowrap" class="ft065">7</p>
<p style="position:absolute;top:112px;left:81px;white-space:nowrap" class="ft025"><b>Appendix&#160;B.&#160;Panel&#160;Roster&#160;and&#160;Financial&#160;Disclosures&#160;</b></p>
<p style="position:absolute;top:159px;left:81px;white-space:nowrap" class="ft026"><b>Invasive Mycoses&#160;</b></p>
<p style="position:absolute;top:229px;left:125px;white-space:nowrap" class="ft02"><b>Member&#160;</b></p>
<p style="position:absolute;top:229px;left:270px;white-space:nowrap" class="ft02"><b>Institution&#160;</b></p>
<p style="position:absolute;top:220px;left:409px;white-space:nowrap" class="ft02"><b>Panel Section&#160;</b></p>
<p style="position:absolute;top:239px;left:426px;white-space:nowrap" class="ft02"><b>Group(s)&#160;</b></p>
<p style="position:absolute;top:210px;left:613px;white-space:nowrap" class="ft02"><b>Financial Disclosure&#160;</b></p>
<p style="position:absolute;top:249px;left:572px;white-space:nowrap" class="ft02"><b>Company&#160;</b></p>
<p style="position:absolute;top:249px;left:717px;white-space:nowrap" class="ft02"><b>Relationship&#160;</b></p>
<p style="position:absolute;top:278px;left:88px;white-space:nowrap" class="ft041">John&#160;Baddley&#160;</p>
<p style="position:absolute;top:278px;left:229px;white-space:nowrap" class="ft024"><i>University&#160;of Maryland&#160;</i></p>
<p style="position:absolute;top:296px;left:229px;white-space:nowrap" class="ft024"><i>School&#160;of Medicine &#160;</i></p>
<p style="position:absolute;top:278px;left:391px;white-space:nowrap" class="ft041">Invasive Mycoses&#160;</p>
<p style="position:absolute;top:278px;left:533px;white-space:nowrap" class="ft041">None&#160;</p>
<p style="position:absolute;top:278px;left:688px;white-space:nowrap" class="ft041">N/A&#160;</p>
<p style="position:absolute;top:323px;left:88px;white-space:nowrap" class="ft041">David&#160;Boulware&#160;</p>
<p style="position:absolute;top:323px;left:229px;white-space:nowrap" class="ft024"><i>University&#160;of&#160;Minnesota&#160;</i></p>
<p style="position:absolute;top:340px;left:229px;white-space:nowrap" class="ft024"><i>Medical&#160;School&#160;&#160;</i></p>
<p style="position:absolute;top:323px;left:391px;white-space:nowrap" class="ft041">Invasive Mycoses&#160;</p>
<p style="position:absolute;top:323px;left:533px;white-space:nowrap" class="ft041">None&#160;</p>
<p style="position:absolute;top:323px;left:688px;white-space:nowrap" class="ft041">N/A&#160;</p>
<p style="position:absolute;top:367px;left:88px;white-space:nowrap" class="ft041">Marisa Miceli&#160;</p>
<p style="position:absolute;top:367px;left:229px;white-space:nowrap" class="ft024"><i>University&#160;of&#160;Michigan&#160;</i></p>
<p style="position:absolute;top:384px;left:229px;white-space:nowrap" class="ft024"><i>Medical&#160;School&#160;&#160;</i></p>
<p style="position:absolute;top:367px;left:391px;white-space:nowrap" class="ft041">Invasive Mycoses&#160;</p>
<p style="position:absolute;top:367px;left:533px;white-space:nowrap" class="ft041">Scynexis&#160;</p>
<p style="position:absolute;top:396px;left:533px;white-space:nowrap" class="ft041">F2G&#160;</p>
<p style="position:absolute;top:425px;left:533px;white-space:nowrap" class="ft041">AN2 Therapeutics&#160;</p>
<p style="position:absolute;top:454px;left:533px;white-space:nowrap" class="ft041">Pulmocide&#160;</p>
<p style="position:absolute;top:367px;left:688px;white-space:nowrap" class="ft041">Research Support (paid&#160;</p>
<p style="position:absolute;top:384px;left:688px;white-space:nowrap" class="ft041">to institution) &#160;</p>
<p style="position:absolute;top:481px;left:533px;white-space:nowrap" class="ft041">Scynexis&#160;</p>
<p style="position:absolute;top:481px;left:688px;white-space:nowrap" class="ft041">Data and&#160;Safety&#160;</p>
<p style="position:absolute;top:498px;left:688px;white-space:nowrap" class="ft041">Monitoring&#160;Board&#160;</p>
<p style="position:absolute;top:525px;left:88px;white-space:nowrap" class="ft041">John&#160;Perfect*&#160;</p>
<p style="position:absolute;top:525px;left:229px;white-space:nowrap" class="ft024"><i>Duke University&#160;School&#160;of&#160;</i></p>
<p style="position:absolute;top:543px;left:229px;white-space:nowrap" class="ft024"><i>Medicine &#160;</i></p>
<p style="position:absolute;top:525px;left:391px;white-space:nowrap" class="ft041">Invasive Mycoses&#160;</p>
<p style="position:absolute;top:525px;left:533px;white-space:nowrap" class="ft041">None&#160;</p>
<p style="position:absolute;top:525px;left:688px;white-space:nowrap" class="ft041">N/A&#160;</p>
<p style="position:absolute;top:570px;left:88px;white-space:nowrap" class="ft041">George&#160;R.&#160;Thompson&#160;</p>
<p style="position:absolute;top:570px;left:229px;white-space:nowrap" class="ft024"><i>University&#160;of California,&#160;</i></p>
<p style="position:absolute;top:587px;left:229px;white-space:nowrap" class="ft024"><i>Davis Medical&#160;Center &#160;</i></p>
<p style="position:absolute;top:570px;left:391px;white-space:nowrap" class="ft041">Invasive Mycoses&#160;</p>
<p style="position:absolute;top:570px;left:533px;white-space:nowrap" class="ft041">Astellas Pharma&#160;</p>
<p style="position:absolute;top:599px;left:533px;white-space:nowrap" class="ft041">Basilea &#160;</p>
<p style="position:absolute;top:628px;left:533px;white-space:nowrap" class="ft041">GSK&#160;</p>
<p style="position:absolute;top:657px;left:533px;white-space:nowrap" class="ft041">Melinta&#160;</p>
<p style="position:absolute;top:687px;left:533px;white-space:nowrap" class="ft041">Mundipharma &#160;</p>
<p style="position:absolute;top:716px;left:533px;white-space:nowrap" class="ft041">Cidara Therapeutics&#160;</p>
<p style="position:absolute;top:745px;left:533px;white-space:nowrap" class="ft041">F2G&#160;</p>
<p style="position:absolute;top:570px;left:688px;white-space:nowrap" class="ft041">Scientific Advisory&#160;Board&#160;</p>
<p style="position:absolute;top:772px;left:533px;white-space:nowrap" class="ft041">Pfizer&#160;</p>
<p style="position:absolute;top:772px;left:688px;white-space:nowrap" class="ft041">Data and Safety&#160;</p>
<p style="position:absolute;top:789px;left:688px;white-space:nowrap" class="ft041">Management&#160;Board&#160;</p>
<p style="position:absolute;top:816px;left:533px;white-space:nowrap" class="ft041">Astellas Pharma&#160;</p>
<p style="position:absolute;top:845px;left:533px;white-space:nowrap" class="ft041">Basilea &#160;</p>
<p style="position:absolute;top:875px;left:533px;white-space:nowrap" class="ft041">GSK&#160;</p>
<p style="position:absolute;top:904px;left:533px;white-space:nowrap" class="ft041">Melinta&#160;</p>
<p style="position:absolute;top:933px;left:533px;white-space:nowrap" class="ft041">Mundipharma &#160;</p>
<p style="position:absolute;top:962px;left:533px;white-space:nowrap" class="ft041">Cidara Therapeutics&#160;</p>
<p style="position:absolute;top:991px;left:533px;white-space:nowrap" class="ft041">F2G&#160;&#160;&#160;</p>
<p style="position:absolute;top:816px;left:688px;white-space:nowrap" class="ft041">Research Support&#160;</p>
<p style="position:absolute;top:1018px;left:81px;white-space:nowrap" class="ft041">*&#160;Section Group&#160;Lead</p>
<p style="position:absolute;top:1045px;left:81px;white-space:nowrap" class="ft042"><b>Note:</b></p>
<p style="position:absolute;top:1045px;left:116px;white-space:nowrap" class="ft041">Members&#160;are required to update&#160;disclosures&#160;annually and to notify guideline staff of&#160;any&#160;relevant changes&#160;in status during the&#160;</p>
<p style="position:absolute;top:1062px;left:81px;white-space:nowrap" class="ft041">interim. &#160;</p>
</div>
<!-- Page 219 -->
<a name="219"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page219-div" style="position:relative;width:917px;height:1187px;">
<p style="position:absolute;top:1117px;left:81px;white-space:nowrap" class="ft024"><i>Guidelines for the Prevention and Treatment&#160;of&#160;Opportunistic&#160;Infections in Adults&#160;and Adolescents&#160;With HIV&#160;</i></p>
<p style="position:absolute;top:1117px;left:805px;white-space:nowrap" class="ft024"><i>LL-1</i></p>
<p style="position:absolute;top:1116px;left:830px;white-space:nowrap" class="ft065">8</p>
<p style="position:absolute;top:112px;left:81px;white-space:nowrap" class="ft025"><b>Appendix&#160;B.&#160;Panel&#160;Roster&#160;and&#160;Financial&#160;Disclosures&#160;</b></p>
<p style="position:absolute;top:159px;left:81px;white-space:nowrap" class="ft026"><b>Mpox</b></p>
<p style="position:absolute;top:231px;left:135px;white-space:nowrap" class="ft02"><b>Member&#160;</b></p>
<p style="position:absolute;top:231px;left:297px;white-space:nowrap" class="ft02"><b>Institution&#160;</b></p>
<p style="position:absolute;top:221px;left:452px;white-space:nowrap" class="ft02"><b>Panel Section&#160;</b></p>
<p style="position:absolute;top:240px;left:469px;white-space:nowrap" class="ft02"><b>Group(s)&#160;</b></p>
<p style="position:absolute;top:211px;left:639px;white-space:nowrap" class="ft02"><b>Financial Disclosure&#160;</b></p>
<p style="position:absolute;top:250px;left:615px;white-space:nowrap" class="ft02"><b>Company&#160;</b></p>
<p style="position:absolute;top:250px;left:734px;white-space:nowrap" class="ft02"><b>Relationship&#160;</b></p>
<p style="position:absolute;top:281px;left:88px;white-space:nowrap" class="ft041">John&#160;Brooks&#160;</p>
<p style="position:absolute;top:281px;left:249px;white-space:nowrap" class="ft024"><i>Atlanta, GA&#160;</i></p>
<p style="position:absolute;top:281px;left:425px;white-space:nowrap" class="ft041">Leadership&#160;</p>
<p style="position:absolute;top:313px;left:425px;white-space:nowrap" class="ft041">Mpox</p>
<p style="position:absolute;top:313px;left:455px;white-space:nowrap" class="ft057">&#160;</p>
<p style="position:absolute;top:281px;left:585px;white-space:nowrap" class="ft041">None&#160;</p>
<p style="position:absolute;top:281px;left:722px;white-space:nowrap" class="ft041">N/A&#160;</p>
<p style="position:absolute;top:340px;left:88px;white-space:nowrap" class="ft041">Chase Cannon&#160;</p>
<p style="position:absolute;top:340px;left:249px;white-space:nowrap" class="ft024"><i>University&#160;of Washington&#160;</i></p>
<p style="position:absolute;top:340px;left:425px;white-space:nowrap" class="ft041">Mpox</p>
<p style="position:absolute;top:340px;left:455px;white-space:nowrap" class="ft057">&#160;</p>
<p style="position:absolute;top:340px;left:585px;white-space:nowrap" class="ft041">Roche&#160;Diagnostics&#160;</p>
<p style="position:absolute;top:340px;left:722px;white-space:nowrap" class="ft041">Consultant&#160;</p>
<p style="position:absolute;top:367px;left:585px;white-space:nowrap" class="ft041">Hologic&#160;</p>
<p style="position:absolute;top:367px;left:722px;white-space:nowrap" class="ft041">Research Support&#160;</p>
<p style="position:absolute;top:394px;left:88px;white-space:nowrap" class="ft041">Emily Heil&#160;</p>
<p style="position:absolute;top:394px;left:249px;white-space:nowrap" class="ft024"><i>University&#160;of&#160;Maryland&#160;</i></p>
<p style="position:absolute;top:411px;left:249px;white-space:nowrap" class="ft024"><i>School&#160;of Pharmacy&#160;&#160;</i></p>
<p style="position:absolute;top:394px;left:425px;white-space:nowrap" class="ft041">Mpox&#160;</p>
<p style="position:absolute;top:426px;left:425px;white-space:nowrap" class="ft041">Pharmacology</p>
<p style="position:absolute;top:426px;left:504px;white-space:nowrap" class="ft057">&#160;</p>
<p style="position:absolute;top:394px;left:585px;white-space:nowrap" class="ft041">Wolters&#160;Kluwer&#160;</p>
<p style="position:absolute;top:394px;left:722px;white-space:nowrap" class="ft041">Consultant&#160;</p>
<p style="position:absolute;top:459px;left:88px;white-space:nowrap" class="ft041">Jesse&#160;O’Shea*&#160;</p>
<p style="position:absolute;top:459px;left:249px;white-space:nowrap" class="ft024"><i>Centers&#160;for Disease Control&#160;</i></p>
<p style="position:absolute;top:476px;left:249px;white-space:nowrap" class="ft024"><i>and&#160;Prevention&#160;&#160;</i></p>
<p style="position:absolute;top:459px;left:425px;white-space:nowrap" class="ft041">Mpox</p>
<p style="position:absolute;top:459px;left:455px;white-space:nowrap" class="ft057">&#160;</p>
<p style="position:absolute;top:459px;left:585px;white-space:nowrap" class="ft041">None&#160;</p>
<p style="position:absolute;top:459px;left:722px;white-space:nowrap" class="ft041">N/A&#160;</p>
<p style="position:absolute;top:503px;left:88px;white-space:nowrap" class="ft041">Agam Rao&#160;</p>
<p style="position:absolute;top:503px;left:249px;white-space:nowrap" class="ft024"><i>Centers&#160;for Disease Control&#160;</i></p>
<p style="position:absolute;top:520px;left:249px;white-space:nowrap" class="ft024"><i>and&#160;Prevention&#160;&#160;</i></p>
<p style="position:absolute;top:503px;left:425px;white-space:nowrap" class="ft041">Mpox</p>
<p style="position:absolute;top:503px;left:455px;white-space:nowrap" class="ft057">&#160;</p>
<p style="position:absolute;top:503px;left:585px;white-space:nowrap" class="ft041">None&#160;</p>
<p style="position:absolute;top:503px;left:722px;white-space:nowrap" class="ft041">N/A&#160;</p>
<p style="position:absolute;top:547px;left:88px;white-space:nowrap" class="ft041">Boghuma Kabisen Titanji</p>
<p style="position:absolute;top:547px;left:249px;white-space:nowrap" class="ft024"><i>Emory&#160;University&#160;School&#160;of&#160;</i></p>
<p style="position:absolute;top:564px;left:249px;white-space:nowrap" class="ft024"><i>Medicine &#160;</i></p>
<p style="position:absolute;top:547px;left:425px;white-space:nowrap" class="ft041">Mpox</p>
<p style="position:absolute;top:547px;left:455px;white-space:nowrap" class="ft057">&#160;</p>
<p style="position:absolute;top:547px;left:585px;white-space:nowrap" class="ft041">None&#160;</p>
<p style="position:absolute;top:547px;left:722px;white-space:nowrap" class="ft041">N/A</p>
<p style="position:absolute;top:591px;left:88px;white-space:nowrap" class="ft041">Jason&#160;Zucker&#160;</p>
<p style="position:absolute;top:591px;left:249px;white-space:nowrap" class="ft024"><i>Columbia University&#160;Vagelos&#160;</i></p>
<p style="position:absolute;top:609px;left:249px;white-space:nowrap" class="ft024"><i>College&#160;of&#160;Physicians and&#160;</i></p>
<p style="position:absolute;top:626px;left:249px;white-space:nowrap" class="ft024"><i>Surgeons&#160;&#160;</i></p>
<p style="position:absolute;top:591px;left:425px;white-space:nowrap" class="ft041">Mpox</p>
<p style="position:absolute;top:592px;left:455px;white-space:nowrap" class="ft057">&#160;</p>
<p style="position:absolute;top:591px;left:585px;white-space:nowrap" class="ft041">None&#160;</p>
<p style="position:absolute;top:591px;left:722px;white-space:nowrap" class="ft041">N/A&#160;</p>
<p style="position:absolute;top:653px;left:81px;white-space:nowrap" class="ft041">*&#160;Section Group&#160;Lead</p>
<p style="position:absolute;top:679px;left:81px;white-space:nowrap" class="ft042"><b>Note:</b></p>
<p style="position:absolute;top:679px;left:116px;white-space:nowrap" class="ft041">Members&#160;are required to update&#160;disclosures&#160;annually and to notify guideline staff of&#160;any&#160;relevant changes&#160;in status during the&#160;</p>
<p style="position:absolute;top:696px;left:81px;white-space:nowrap" class="ft041">interim. &#160;</p>
</div>
<!-- Page 220 -->
<a name="220"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page220-div" style="position:relative;width:917px;height:1187px;">
<p style="position:absolute;top:1117px;left:81px;white-space:nowrap" class="ft024"><i>Guidelines for the Prevention and Treatment&#160;of&#160;Opportunistic&#160;Infections in Adults&#160;and Adolescents&#160;With HIV&#160;</i></p>
<p style="position:absolute;top:1117px;left:805px;white-space:nowrap" class="ft024"><i>LL-1</i></p>
<p style="position:absolute;top:1116px;left:830px;white-space:nowrap" class="ft065">9</p>
<p style="position:absolute;top:112px;left:81px;white-space:nowrap" class="ft025"><b>Appendix&#160;B.&#160;Panel&#160;Roster&#160;and&#160;Financial&#160;Disclosures&#160;</b></p>
<p style="position:absolute;top:159px;left:81px;white-space:nowrap" class="ft0118"><i><b>Mycobacterium avium</b></i></p>
<p style="position:absolute;top:159px;left:262px;white-space:nowrap" class="ft026"><b>&#160;Complex&#160;</b></p>
<p style="position:absolute;top:564px;left:81px;white-space:nowrap" class="ft041">*&#160;Section Group&#160;Lead</p>
<p style="position:absolute;top:590px;left:81px;white-space:nowrap" class="ft042"><b>Note:</b></p>
<p style="position:absolute;top:590px;left:116px;white-space:nowrap" class="ft041">Members&#160;are required to update&#160;disclosures&#160;annually&#160;and&#160;to notify guideline staff of&#160;any&#160;relevant changes&#160;in status&#160;during&#160;the&#160;</p>
<p style="position:absolute;top:607px;left:81px;white-space:nowrap" class="ft041">interim.&#160;</p>
<p style="position:absolute;top:230px;left:128px;white-space:nowrap" class="ft02"><b>Member&#160;</b></p>
<p style="position:absolute;top:230px;left:290px;white-space:nowrap" class="ft02"><b>Institution&#160;</b></p>
<p style="position:absolute;top:220px;left:455px;white-space:nowrap" class="ft02"><b>Panel Section&#160;</b></p>
<p style="position:absolute;top:239px;left:472px;white-space:nowrap" class="ft02"><b>Group(s)&#160;</b></p>
<p style="position:absolute;top:210px;left:642px;white-space:nowrap" class="ft02"><b>Financial Disclosure&#160;</b></p>
<p style="position:absolute;top:249px;left:618px;white-space:nowrap" class="ft02"><b>Company&#160;</b></p>
<p style="position:absolute;top:249px;left:734px;white-space:nowrap" class="ft02"><b>Relationship&#160;</b></p>
<p style="position:absolute;top:278px;left:88px;white-space:nowrap" class="ft041">Constance Benson*</p>
<p style="position:absolute;top:278px;left:236px;white-space:nowrap" class="ft024"><i>University&#160;of&#160;California, San&#160;</i></p>
<p style="position:absolute;top:296px;left:236px;white-space:nowrap" class="ft024"><i>Diego School&#160;of Medicine&#160;</i></p>
<p style="position:absolute;top:278px;left:425px;white-space:nowrap" class="ft041">Leadership&#160;</p>
<p style="position:absolute;top:311px;left:425px;white-space:nowrap" class="ft024"><i>Mycobacterium avium</i></p>
<p style="position:absolute;top:311px;left:545px;white-space:nowrap" class="ft041">&#160;</p>
<p style="position:absolute;top:328px;left:425px;white-space:nowrap" class="ft041">Complex&#160;</p>
<p style="position:absolute;top:278px;left:591px;white-space:nowrap" class="ft041">Gilead&#160;Sciences</p>
<p style="position:absolute;top:311px;left:591px;white-space:nowrap" class="ft041">BioMerieux&#160;</p>
<p style="position:absolute;top:278px;left:722px;white-space:nowrap" class="ft041">Research Support&#160;</p>
<p style="position:absolute;top:296px;left:722px;white-space:nowrap" class="ft041">(paid&#160;to&#160;institution)&#160;</p>
<p style="position:absolute;top:338px;left:591px;white-space:nowrap" class="ft041">ViiV&#160;</p>
<p style="position:absolute;top:338px;left:722px;white-space:nowrap" class="ft041">Data and&#160;Safety&#160;</p>
<p style="position:absolute;top:355px;left:722px;white-space:nowrap" class="ft041">Monitoring&#160;Board</p>
<p style="position:absolute;top:353px;left:816px;white-space:nowrap" class="ft013">&#160;</p>
<p style="position:absolute;top:382px;left:88px;white-space:nowrap" class="ft041">Lauren Collins</p>
<p style="position:absolute;top:382px;left:236px;white-space:nowrap" class="ft0165"><i>Emory&#160;University&#160;School&#160;of&#160;<br/>Medicine&#160;</i></p>
<p style="position:absolute;top:382px;left:425px;white-space:nowrap" class="ft024"><i>Mycobacterium avium</i></p>
<p style="position:absolute;top:382px;left:545px;white-space:nowrap" class="ft041">&#160;</p>
<p style="position:absolute;top:399px;left:425px;white-space:nowrap" class="ft041">Complex&#160;</p>
<p style="position:absolute;top:382px;left:591px;white-space:nowrap" class="ft041">None&#160;</p>
<p style="position:absolute;top:382px;left:722px;white-space:nowrap" class="ft041">N/A</p>
<p style="position:absolute;top:426px;left:88px;white-space:nowrap" class="ft041">Timothy Hatlen&#160;</p>
<p style="position:absolute;top:426px;left:236px;white-space:nowrap" class="ft0165"><i>University&#160;of&#160;California, Los&#160;<br/>Angeles David&#160;Geffen School&#160;</i></p>
<p style="position:absolute;top:460px;left:236px;white-space:nowrap" class="ft024"><i>of Medicine&#160;</i></p>
<p style="position:absolute;top:493px;left:236px;white-space:nowrap" class="ft024"><i>Harbor-UCLA Medical&#160;Center&#160;</i></p>
<p style="position:absolute;top:426px;left:425px;white-space:nowrap" class="ft044">Cryptosporidiosis/<br/>Microsporidiosis&#160;&#160;</p>
<p style="position:absolute;top:475px;left:425px;white-space:nowrap" class="ft024"><i>Mycobacterium avium</i></p>
<p style="position:absolute;top:475px;left:545px;white-space:nowrap" class="ft041">&#160;</p>
<p style="position:absolute;top:493px;left:425px;white-space:nowrap" class="ft041">Complex&#160;</p>
<p style="position:absolute;top:426px;left:591px;white-space:nowrap" class="ft041">None&#160;</p>
<p style="position:absolute;top:426px;left:722px;white-space:nowrap" class="ft041">N/A</p>
<p style="position:absolute;top:520px;left:88px;white-space:nowrap" class="ft041">Maura Manion</p>
<p style="position:absolute;top:520px;left:236px;white-space:nowrap" class="ft024"><i>National&#160;Institutes of Health&#160;</i></p>
<p style="position:absolute;top:520px;left:425px;white-space:nowrap" class="ft024"><i>Mycobacterium avium</i></p>
<p style="position:absolute;top:520px;left:545px;white-space:nowrap" class="ft041">&#160;</p>
<p style="position:absolute;top:537px;left:425px;white-space:nowrap" class="ft041">Complex&#160;</p>
<p style="position:absolute;top:520px;left:591px;white-space:nowrap" class="ft041">None&#160;</p>
<p style="position:absolute;top:520px;left:722px;white-space:nowrap" class="ft041">N/A</p>
</div>
<!-- Page 221 -->
<a name="221"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}	.ft0168{font-size:15px;font-family:KXOVXL+Arimo;color:#000000;}
-->
</style>
<div id="page221-div" style="position:relative;width:917px;height:1187px;">
<p style="position:absolute;top:1117px;left:81px;white-space:nowrap" class="ft024"><i>Guidelines for the Prevention and Treatment&#160;of&#160;Opportunistic&#160;Infections in Adults&#160;and Adolescents&#160;With HIV&#160;</i></p>
<p style="position:absolute;top:1117px;left:805px;white-space:nowrap" class="ft024"><i>LL-</i></p>
<p style="position:absolute;top:1116px;left:823px;white-space:nowrap" class="ft065">20</p>
<p style="position:absolute;top:112px;left:81px;white-space:nowrap" class="ft025"><b>Appendix&#160;B.&#160;Panel&#160;Roster&#160;and&#160;Financial&#160;Disclosures&#160;</b></p>
<p style="position:absolute;top:159px;left:81px;white-space:nowrap" class="ft0118"><i><b>Mycobacterium tuberculosis&#160;</b></i></p>
<p style="position:absolute;top:230px;left:125px;white-space:nowrap" class="ft02"><b>Member&#160;</b></p>
<p style="position:absolute;top:230px;left:280px;white-space:nowrap" class="ft02"><b>Institution&#160;</b></p>
<p style="position:absolute;top:230px;left:421px;white-space:nowrap" class="ft02"><b>Panel Section Group(s)&#160;</b></p>
<p style="position:absolute;top:210px;left:647px;white-space:nowrap" class="ft02"><b>Financial Disclosure&#160;</b></p>
<p style="position:absolute;top:250px;left:622px;white-space:nowrap" class="ft02"><b>Company&#160;</b></p>
<p style="position:absolute;top:250px;left:734px;white-space:nowrap" class="ft02"><b>Relationship&#160;</b></p>
<p style="position:absolute;top:280px;left:88px;white-space:nowrap" class="ft041">James&#160;Brust*&#160;</p>
<p style="position:absolute;top:280px;left:229px;white-space:nowrap" class="ft0165"><i>Albert Einstein&#160;College&#160;of&#160;<br/>Medicine &#160;</i></p>
<p style="position:absolute;top:280px;left:411px;white-space:nowrap" class="ft024"><i>Mycobacterium tuberculosis</i></p>
<p style="position:absolute;top:280px;left:564px;white-space:nowrap" class="ft0168"><i>&#160;</i></p>
<p style="position:absolute;top:280px;left:600px;white-space:nowrap" class="ft041">None&#160;</p>
<p style="position:absolute;top:280px;left:722px;white-space:nowrap" class="ft041">N/A&#160;</p>
<p style="position:absolute;top:324px;left:88px;white-space:nowrap" class="ft041">Kelly&#160;Dooley&#160;</p>
<p style="position:absolute;top:324px;left:229px;white-space:nowrap" class="ft024"><i>Vanderbilt University School&#160;</i></p>
<p style="position:absolute;top:341px;left:229px;white-space:nowrap" class="ft024"><i>of Medicine &#160;</i></p>
<p style="position:absolute;top:324px;left:411px;white-space:nowrap" class="ft024"><i>Mycobacterium tuberculosis</i></p>
<p style="position:absolute;top:324px;left:564px;white-space:nowrap" class="ft0168"><i>&#160;</i></p>
<p style="position:absolute;top:324px;left:600px;white-space:nowrap" class="ft041">None&#160;</p>
<p style="position:absolute;top:324px;left:722px;white-space:nowrap" class="ft041">N/A&#160;</p>
<p style="position:absolute;top:368px;left:88px;white-space:nowrap" class="ft041">Neela Goswami&#160;</p>
<p style="position:absolute;top:368px;left:229px;white-space:nowrap" class="ft024"><i>Centers&#160;for&#160;Disease Control&#160;</i></p>
<p style="position:absolute;top:385px;left:229px;white-space:nowrap" class="ft024"><i>and&#160;Prevention&#160;&#160;</i></p>
<p style="position:absolute;top:368px;left:411px;white-space:nowrap" class="ft024"><i>Mycobacterium tuberculosis</i></p>
<p style="position:absolute;top:368px;left:564px;white-space:nowrap" class="ft0168"><i>&#160;</i></p>
<p style="position:absolute;top:368px;left:600px;white-space:nowrap" class="ft041">None&#160;</p>
<p style="position:absolute;top:368px;left:722px;white-space:nowrap" class="ft041">N/A&#160;</p>
<p style="position:absolute;top:412px;left:88px;white-space:nowrap" class="ft041">Scott Heysell&#160;</p>
<p style="position:absolute;top:412px;left:229px;white-space:nowrap" class="ft024"><i>University of Virginia School&#160;</i></p>
<p style="position:absolute;top:429px;left:229px;white-space:nowrap" class="ft024"><i>of Medicine &#160;</i></p>
<p style="position:absolute;top:412px;left:411px;white-space:nowrap" class="ft024"><i>Mycobacterium tuberculosis</i></p>
<p style="position:absolute;top:412px;left:564px;white-space:nowrap" class="ft0168"><i>&#160;</i></p>
<p style="position:absolute;top:412px;left:600px;white-space:nowrap" class="ft041">None&#160;</p>
<p style="position:absolute;top:412px;left:722px;white-space:nowrap" class="ft041">N/A&#160;</p>
<p style="position:absolute;top:456px;left:88px;white-space:nowrap" class="ft041">Jyoti&#160;Mathad&#160;</p>
<p style="position:absolute;top:456px;left:229px;white-space:nowrap" class="ft024"><i>NewYork-Presbyterian/Weill&#160;</i></p>
<p style="position:absolute;top:474px;left:229px;white-space:nowrap" class="ft024"><i>Cornell&#160;Medicine &#160;</i></p>
<p style="position:absolute;top:456px;left:411px;white-space:nowrap" class="ft024"><i>Mycobacterium tuberculosis</i></p>
<p style="position:absolute;top:457px;left:564px;white-space:nowrap" class="ft0168"><i>&#160;</i></p>
<p style="position:absolute;top:456px;left:600px;white-space:nowrap" class="ft041">None&#160;</p>
<p style="position:absolute;top:456px;left:722px;white-space:nowrap" class="ft041">N/A&#160;</p>
<p style="position:absolute;top:500px;left:88px;white-space:nowrap" class="ft041">Graeme Meintjes&#160;</p>
<p style="position:absolute;top:500px;left:229px;white-space:nowrap" class="ft0165"><i>University&#160;of Cape&#160;Town,&#160;<br/>South&#160;Africa, Faculty of&#160;</i></p>
<p style="position:absolute;top:535px;left:229px;white-space:nowrap" class="ft024"><i>Health Sciences &#160;</i></p>
<p style="position:absolute;top:500px;left:411px;white-space:nowrap" class="ft024"><i>Mycobacterium tuberculosis</i></p>
<p style="position:absolute;top:501px;left:564px;white-space:nowrap" class="ft0168"><i>&#160;</i></p>
<p style="position:absolute;top:500px;left:600px;white-space:nowrap" class="ft044">Otsuka&#160;<br/>Pharmaceutical&#160;</p>
<p style="position:absolute;top:500px;left:722px;white-space:nowrap" class="ft044">Data and Safety&#160;<br/>Monitoring&#160;Board&#160;</p>
<p style="position:absolute;top:562px;left:88px;white-space:nowrap" class="ft041">Sarita Shah&#160;</p>
<p style="position:absolute;top:562px;left:229px;white-space:nowrap" class="ft0165"><i>Emory&#160;University&#160;School&#160;of&#160;<br/>Medicine &#160;</i></p>
<p style="position:absolute;top:562px;left:411px;white-space:nowrap" class="ft024"><i>Mycobacterium tuberculosis</i></p>
<p style="position:absolute;top:562px;left:564px;white-space:nowrap" class="ft0168"><i>&#160;</i></p>
<p style="position:absolute;top:562px;left:600px;white-space:nowrap" class="ft041">None&#160;</p>
<p style="position:absolute;top:562px;left:722px;white-space:nowrap" class="ft041">N/A&#160;</p>
<p style="position:absolute;top:606px;left:88px;white-space:nowrap" class="ft041">Timothy&#160;Sterling&#160;</p>
<p style="position:absolute;top:606px;left:229px;white-space:nowrap" class="ft0165"><i>Vanderbilt&#160;University&#160;Medical&#160;<br/>Center&#160;&#160;</i></p>
<p style="position:absolute;top:606px;left:411px;white-space:nowrap" class="ft024"><i>Mycobacterium tuberculosis</i></p>
<p style="position:absolute;top:606px;left:564px;white-space:nowrap" class="ft0168"><i>&#160;</i></p>
<p style="position:absolute;top:606px;left:600px;white-space:nowrap" class="ft041">None&#160;</p>
<p style="position:absolute;top:606px;left:722px;white-space:nowrap" class="ft041">N/A&#160;</p>
<p style="position:absolute;top:650px;left:81px;white-space:nowrap" class="ft041">*&#160;Section Group&#160;Lead</p>
<p style="position:absolute;top:676px;left:81px;white-space:nowrap" class="ft042"><b>Note:</b></p>
<p style="position:absolute;top:676px;left:116px;white-space:nowrap" class="ft041">Members&#160;are required to update&#160;disclosures&#160;annually and to notify guideline staff of&#160;any&#160;relevant changes&#160;in status during the&#160;</p>
<p style="position:absolute;top:694px;left:81px;white-space:nowrap" class="ft041">interim.&#160;</p>
</div>
<!-- Page 222 -->
<a name="222"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}	.ft0169{font-size:15px;font-family:TURBHP+Tinos;color:#000000;}
-->
</style>
<div id="page222-div" style="position:relative;width:917px;height:1187px;">
<p style="position:absolute;top:1117px;left:81px;white-space:nowrap" class="ft024"><i>Guidelines for the Prevention and Treatment&#160;of&#160;Opportunistic&#160;Infections in Adults&#160;and Adolescents&#160;With HIV&#160;</i></p>
<p style="position:absolute;top:1117px;left:805px;white-space:nowrap" class="ft024"><i>LL-</i></p>
<p style="position:absolute;top:1116px;left:823px;white-space:nowrap" class="ft065">21</p>
<p style="position:absolute;top:112px;left:81px;white-space:nowrap" class="ft025"><b>Appendix&#160;B.&#160;Panel&#160;Roster&#160;and&#160;Financial&#160;Disclosures&#160;</b></p>
<p style="position:absolute;top:159px;left:81px;white-space:nowrap" class="ft0118"><i><b>Pneumocystis</b></i></p>
<p style="position:absolute;top:159px;left:198px;white-space:nowrap" class="ft026"><b>&#160;Pneumonia&#160;</b></p>
<p style="position:absolute;top:230px;left:128px;white-space:nowrap" class="ft02"><b>Member&#160;</b></p>
<p style="position:absolute;top:230px;left:276px;white-space:nowrap" class="ft02"><b>Institution&#160;</b></p>
<p style="position:absolute;top:220px;left:431px;white-space:nowrap" class="ft02"><b>Panel Section&#160;</b></p>
<p style="position:absolute;top:240px;left:447px;white-space:nowrap" class="ft02"><b>Group(s)&#160;</b></p>
<p style="position:absolute;top:211px;left:631px;white-space:nowrap" class="ft02"><b>Financial Disclosure&#160;</b></p>
<p style="position:absolute;top:250px;left:597px;white-space:nowrap" class="ft02"><b>Company&#160;</b></p>
<p style="position:absolute;top:250px;left:723px;white-space:nowrap" class="ft02"><b>Relationship&#160;</b></p>
<p style="position:absolute;top:280px;left:90px;white-space:nowrap" class="ft041">Kristina Crothers&#160;</p>
<p style="position:absolute;top:280px;left:237px;white-space:nowrap" class="ft024"><i>University&#160;of&#160;Washington&#160;</i></p>
<p style="position:absolute;top:297px;left:238px;white-space:nowrap" class="ft024"><i>School&#160;of Medicine &#160;</i></p>
<p style="position:absolute;top:280px;left:400px;white-space:nowrap" class="ft041">Community-Acquired&#160;</p>
<p style="position:absolute;top:297px;left:400px;white-space:nowrap" class="ft041">Pneumonia &#160;</p>
<p style="position:absolute;top:329px;left:400px;white-space:nowrap" class="ft024"><i>Pneumocystis</i></p>
<p style="position:absolute;top:329px;left:476px;white-space:nowrap" class="ft041">&#160;Pneumonia&#160;</p>
<p style="position:absolute;top:280px;left:572px;white-space:nowrap" class="ft041">None&#160;</p>
<p style="position:absolute;top:280px;left:703px;white-space:nowrap" class="ft041">N/A&#160;</p>
<p style="position:absolute;top:356px;left:90px;white-space:nowrap" class="ft041">Jannik&#160;Helweg-Larsen&#160;</p>
<p style="position:absolute;top:356px;left:237px;white-space:nowrap" class="ft024"><i>Rigshospitalet,&#160;</i></p>
<p style="position:absolute;top:373px;left:238px;white-space:nowrap" class="ft024"><i>Copenhagen&#160;University,&#160;</i></p>
<p style="position:absolute;top:391px;left:238px;white-space:nowrap" class="ft024"><i>Denmark&#160;&#160;</i></p>
<p style="position:absolute;top:356px;left:400px;white-space:nowrap" class="ft024"><i>Pneumocystis</i></p>
<p style="position:absolute;top:356px;left:476px;white-space:nowrap" class="ft041">&#160;Pneumonia&#160;</p>
<p style="position:absolute;top:356px;left:572px;white-space:nowrap" class="ft041">None&#160;</p>
<p style="position:absolute;top:356px;left:703px;white-space:nowrap" class="ft041">N/A&#160;</p>
<p style="position:absolute;top:417px;left:90px;white-space:nowrap" class="ft041">Aley Kalapila&#160;</p>
<p style="position:absolute;top:417px;left:237px;white-space:nowrap" class="ft024"><i>Emory&#160;University&#160;School&#160;</i></p>
<p style="position:absolute;top:435px;left:238px;white-space:nowrap" class="ft024"><i>of Medicine &#160;</i></p>
<p style="position:absolute;top:418px;left:400px;white-space:nowrap" class="ft024"><i>Pneumocystis</i></p>
<p style="position:absolute;top:418px;left:476px;white-space:nowrap" class="ft041">&#160;Pneumonia&#160;</p>
<p style="position:absolute;top:417px;left:572px;white-space:nowrap" class="ft041">The Body Pro&#160;</p>
<p style="position:absolute;top:417px;left:703px;white-space:nowrap" class="ft041">Honoraria&#160;</p>
<p style="position:absolute;top:462px;left:90px;white-space:nowrap" class="ft041">Joseph Kovacs*&#160;</p>
<p style="position:absolute;top:462px;left:237px;white-space:nowrap" class="ft024"><i>National&#160;Institutes of&#160;</i></p>
<p style="position:absolute;top:479px;left:238px;white-space:nowrap" class="ft024"><i>Health &#160;</i></p>
<p style="position:absolute;top:462px;left:400px;white-space:nowrap" class="ft024"><i>Pneumocystis</i></p>
<p style="position:absolute;top:462px;left:476px;white-space:nowrap" class="ft041">&#160;Pneumonia&#160;</p>
<p style="position:absolute;top:494px;left:400px;white-space:nowrap" class="ft024"><i>Toxoplasma gondii</i></p>
<p style="position:absolute;top:494px;left:503px;white-space:nowrap" class="ft0169">&#160;</p>
<p style="position:absolute;top:462px;left:572px;white-space:nowrap" class="ft041">Matinas&#160;</p>
<p style="position:absolute;top:494px;left:572px;white-space:nowrap" class="ft041">Merck&#160;</p>
<p style="position:absolute;top:462px;left:703px;white-space:nowrap" class="ft041">Research Support&#160;</p>
<p style="position:absolute;top:521px;left:90px;white-space:nowrap" class="ft041">Alison Morris&#160;</p>
<p style="position:absolute;top:521px;left:237px;white-space:nowrap" class="ft024"><i>University&#160;of&#160;Pittsburgh&#160;</i></p>
<p style="position:absolute;top:538px;left:238px;white-space:nowrap" class="ft024"><i>School&#160;of Medicine &#160;</i></p>
<p style="position:absolute;top:521px;left:400px;white-space:nowrap" class="ft024"><i>Pneumocystis</i></p>
<p style="position:absolute;top:521px;left:476px;white-space:nowrap" class="ft041">&#160;Pneumonia&#160;</p>
<p style="position:absolute;top:521px;left:572px;white-space:nowrap" class="ft041">Pfitzer&#160;</p>
<p style="position:absolute;top:521px;left:703px;white-space:nowrap" class="ft041">Research Support&#160;</p>
<p style="position:absolute;top:548px;left:572px;white-space:nowrap" class="ft041">AstraZeneca&#160;</p>
<p style="position:absolute;top:548px;left:703px;white-space:nowrap" class="ft041">Travel Support&#160;</p>
<p style="position:absolute;top:575px;left:90px;white-space:nowrap" class="ft041">Sean&#160;Wasserman&#160;</p>
<p style="position:absolute;top:575px;left:237px;white-space:nowrap" class="ft024"><i>University&#160;of&#160;Cape Town,&#160;</i></p>
<p style="position:absolute;top:592px;left:238px;white-space:nowrap" class="ft0165"><i>South&#160;Africa, Faculty of&#160;<br/>Health Sciences &#160;</i></p>
<p style="position:absolute;top:575px;left:400px;white-space:nowrap" class="ft024"><i>Pneumocystis</i></p>
<p style="position:absolute;top:575px;left:476px;white-space:nowrap" class="ft041">&#160;Pneumonia&#160;</p>
<p style="position:absolute;top:575px;left:572px;white-space:nowrap" class="ft041">None&#160;</p>
<p style="position:absolute;top:575px;left:703px;white-space:nowrap" class="ft041">N/A&#160;</p>
<p style="position:absolute;top:636px;left:81px;white-space:nowrap" class="ft041">*&#160;Section Group&#160;Lead</p>
<p style="position:absolute;top:662px;left:81px;white-space:nowrap" class="ft042"><b>Note:</b></p>
<p style="position:absolute;top:662px;left:116px;white-space:nowrap" class="ft041">Members&#160;are required to update&#160;disclosures&#160;annually and to notify guideline staff of&#160;any&#160;relevant changes&#160;in status during the&#160;</p>
<p style="position:absolute;top:680px;left:81px;white-space:nowrap" class="ft041">interim.&#160;</p>
</div>
<!-- Page 223 -->
<a name="223"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page223-div" style="position:relative;width:917px;height:1187px;">
<p style="position:absolute;top:1117px;left:81px;white-space:nowrap" class="ft024"><i>Guidelines for the Prevention and Treatment&#160;of&#160;Opportunistic&#160;Infections in Adults&#160;and Adolescents&#160;With HIV&#160;</i></p>
<p style="position:absolute;top:1117px;left:805px;white-space:nowrap" class="ft024"><i>LL-</i></p>
<p style="position:absolute;top:1116px;left:823px;white-space:nowrap" class="ft065">22</p>
<p style="position:absolute;top:112px;left:81px;white-space:nowrap" class="ft025"><b>Appendix&#160;B.&#160;Panel&#160;Roster&#160;and&#160;Financial&#160;Disclosures&#160;</b></p>
<p style="position:absolute;top:159px;left:81px;white-space:nowrap" class="ft026"><b>Pregnancy&#160;</b></p>
<p style="position:absolute;top:229px;left:128px;white-space:nowrap" class="ft02"><b>Member&#160;</b></p>
<p style="position:absolute;top:229px;left:286px;white-space:nowrap" class="ft02"><b>Institution&#160;</b></p>
<p style="position:absolute;top:220px;left:446px;white-space:nowrap" class="ft02"><b>Panel Section&#160;</b></p>
<p style="position:absolute;top:239px;left:463px;white-space:nowrap" class="ft02"><b>Group(s)&#160;</b></p>
<p style="position:absolute;top:210px;left:637px;white-space:nowrap" class="ft02"><b>Financial Disclosure&#160;</b></p>
<p style="position:absolute;top:249px;left:606px;white-space:nowrap" class="ft02"><b>Company&#160;</b></p>
<p style="position:absolute;top:249px;left:727px;white-space:nowrap" class="ft02"><b>Relationship&#160;</b></p>
<p style="position:absolute;top:278px;left:90px;white-space:nowrap" class="ft041">Jean&#160;Anderson&#160;</p>
<p style="position:absolute;top:278px;left:236px;white-space:nowrap" class="ft024"><i>The Johns&#160;Hopkins&#160;University&#160;</i></p>
<p style="position:absolute;top:296px;left:236px;white-space:nowrap" class="ft024"><i>School&#160;of Medicine &#160;</i></p>
<p style="position:absolute;top:278px;left:420px;white-space:nowrap" class="ft041">Pregnancy&#160;</p>
<p style="position:absolute;top:278px;left:582px;white-space:nowrap" class="ft041">None&#160;</p>
<p style="position:absolute;top:278px;left:710px;white-space:nowrap" class="ft041">N/A&#160;</p>
<p style="position:absolute;top:323px;left:90px;white-space:nowrap" class="ft041">Katherine Bunge&#160;</p>
<p style="position:absolute;top:323px;left:236px;white-space:nowrap" class="ft024"><i>UPMC Magee-Womens&#160;</i></p>
<p style="position:absolute;top:340px;left:236px;white-space:nowrap" class="ft024"><i>Hospital &#160;</i></p>
<p style="position:absolute;top:323px;left:420px;white-space:nowrap" class="ft041">Pregnancy&#160;</p>
<p style="position:absolute;top:323px;left:582px;white-space:nowrap" class="ft041">None&#160;</p>
<p style="position:absolute;top:323px;left:710px;white-space:nowrap" class="ft041">N/A&#160;</p>
<p style="position:absolute;top:367px;left:90px;white-space:nowrap" class="ft041">Karley Dutra&#160;</p>
<p style="position:absolute;top:367px;left:236px;white-space:nowrap" class="ft024"><i>Medical&#160;University of South&#160;</i></p>
<p style="position:absolute;top:384px;left:236px;white-space:nowrap" class="ft024"><i>Carolina &#160;</i></p>
<p style="position:absolute;top:367px;left:420px;white-space:nowrap" class="ft041">Pregnancy&#160;</p>
<p style="position:absolute;top:367px;left:582px;white-space:nowrap" class="ft041">None&#160;</p>
<p style="position:absolute;top:367px;left:710px;white-space:nowrap" class="ft041">N/A&#160;</p>
<p style="position:absolute;top:411px;left:90px;white-space:nowrap" class="ft041">Oluwatosin&#160;Goje&#160;</p>
<p style="position:absolute;top:411px;left:236px;white-space:nowrap" class="ft0165"><i>Cleveland&#160;Clinic&#160;Lerner&#160;<br/>College&#160;of&#160;Medicine &#160;</i></p>
<p style="position:absolute;top:411px;left:420px;white-space:nowrap" class="ft041">Pregnancy&#160;</p>
<p style="position:absolute;top:411px;left:582px;white-space:nowrap" class="ft041">Elsevier&#160;</p>
<p style="position:absolute;top:443px;left:582px;white-space:nowrap" class="ft041">Merck&#160;</p>
<p style="position:absolute;top:411px;left:710px;white-space:nowrap" class="ft041">Editorial&#160;Board&#160;</p>
<p style="position:absolute;top:470px;left:90px;white-space:nowrap" class="ft041">Erica Hardy&#160;</p>
<p style="position:absolute;top:470px;left:236px;white-space:nowrap" class="ft024"><i>Warren&#160;Alpert Medical&#160;School&#160;</i></p>
<p style="position:absolute;top:487px;left:236px;white-space:nowrap" class="ft024"><i>of Brown University&#160;&#160;</i></p>
<p style="position:absolute;top:470px;left:420px;white-space:nowrap" class="ft041">Pregnancy&#160;</p>
<p style="position:absolute;top:470px;left:582px;white-space:nowrap" class="ft041">None&#160;</p>
<p style="position:absolute;top:470px;left:710px;white-space:nowrap" class="ft041">N/A&#160;</p>
<p style="position:absolute;top:514px;left:90px;white-space:nowrap" class="ft041">Sylvia LaCourse*&#160;</p>
<p style="position:absolute;top:514px;left:236px;white-space:nowrap" class="ft024"><i>University&#160;of&#160;Washington&#160;</i></p>
<p style="position:absolute;top:531px;left:236px;white-space:nowrap" class="ft024"><i>School&#160;of Medicine and&#160;</i></p>
<p style="position:absolute;top:549px;left:236px;white-space:nowrap" class="ft024"><i>School&#160;of Public&#160;Health &#160;</i></p>
<p style="position:absolute;top:514px;left:420px;white-space:nowrap" class="ft041">Pregnancy&#160;</p>
<p style="position:absolute;top:514px;left:582px;white-space:nowrap" class="ft041">Merck&#160;</p>
<p style="position:absolute;top:514px;left:710px;white-space:nowrap" class="ft041">Research Support&#160;</p>
<p style="position:absolute;top:531px;left:710px;white-space:nowrap" class="ft041">(paid&#160;to&#160;institution)&#160;</p>
<p style="position:absolute;top:558px;left:582px;white-space:nowrap" class="ft041">Merck&#160;</p>
<p style="position:absolute;top:558px;left:710px;white-space:nowrap" class="ft041">Travel&#160;Support&#160;</p>
<p style="position:absolute;top:585px;left:90px;white-space:nowrap" class="ft041">Gweneth Lazenby&#160;</p>
<p style="position:absolute;top:585px;left:236px;white-space:nowrap" class="ft024"><i>Medical&#160;University&#160;of South&#160;</i></p>
<p style="position:absolute;top:603px;left:236px;white-space:nowrap" class="ft024"><i>Carolina &#160;</i></p>
<p style="position:absolute;top:585px;left:420px;white-space:nowrap" class="ft041">Pregnancy&#160;</p>
<p style="position:absolute;top:585px;left:582px;white-space:nowrap" class="ft041">None&#160;</p>
<p style="position:absolute;top:585px;left:710px;white-space:nowrap" class="ft041">N/A&#160;</p>
<p style="position:absolute;top:630px;left:90px;white-space:nowrap" class="ft041">Anna&#160;Powell&#160;</p>
<p style="position:absolute;top:630px;left:236px;white-space:nowrap" class="ft024"><i>The Johns&#160;Hopkins University&#160;</i></p>
<p style="position:absolute;top:647px;left:236px;white-space:nowrap" class="ft024"><i>School&#160;of Medicine &#160;</i></p>
<p style="position:absolute;top:630px;left:420px;white-space:nowrap" class="ft041">Pregnancy&#160;</p>
<p style="position:absolute;top:630px;left:582px;white-space:nowrap" class="ft041">Cepheid&#160;</p>
<p style="position:absolute;top:630px;left:710px;white-space:nowrap" class="ft041">Consultant&#160;</p>
<p style="position:absolute;top:674px;left:90px;white-space:nowrap" class="ft041">Rodney&#160;Wright&#160;</p>
<p style="position:absolute;top:674px;left:236px;white-space:nowrap" class="ft024"><i>Albert Einstein College&#160;of&#160;</i></p>
<p style="position:absolute;top:691px;left:236px;white-space:nowrap" class="ft024"><i>Medicine &#160;</i></p>
<p style="position:absolute;top:674px;left:420px;white-space:nowrap" class="ft041">Pregnancy&#160;</p>
<p style="position:absolute;top:674px;left:582px;white-space:nowrap" class="ft041">None&#160;</p>
<p style="position:absolute;top:674px;left:710px;white-space:nowrap" class="ft041">N/A&#160;</p>
<p style="position:absolute;top:718px;left:81px;white-space:nowrap" class="ft041">*&#160;Section Group&#160;Lead</p>
<p style="position:absolute;top:744px;left:81px;white-space:nowrap" class="ft042"><b>Note:</b></p>
<p style="position:absolute;top:744px;left:116px;white-space:nowrap" class="ft041">Members&#160;are required to update&#160;disclosures&#160;annually and to notify guideline staff of&#160;any&#160;relevant changes&#160;in status during the&#160;</p>
<p style="position:absolute;top:761px;left:81px;white-space:nowrap" class="ft041">interim.&#160;</p>
</div>
<!-- Page 224 -->
<a name="224"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page224-div" style="position:relative;width:917px;height:1187px;">
<p style="position:absolute;top:1117px;left:81px;white-space:nowrap" class="ft024"><i>Guidelines for the Prevention and Treatment&#160;of&#160;Opportunistic&#160;Infections in Adults&#160;and Adolescents&#160;With HIV&#160;</i></p>
<p style="position:absolute;top:1117px;left:805px;white-space:nowrap" class="ft024"><i>LL-</i></p>
<p style="position:absolute;top:1116px;left:823px;white-space:nowrap" class="ft065">23</p>
<p style="position:absolute;top:112px;left:81px;white-space:nowrap" class="ft025"><b>Appendix&#160;B.&#160;Panel&#160;Roster&#160;and&#160;Financial&#160;Disclosures&#160;</b></p>
<p style="position:absolute;top:159px;left:81px;white-space:nowrap" class="ft026"><b>Syphilis&#160;</b></p>
<p style="position:absolute;top:230px;left:122px;white-space:nowrap" class="ft02"><b>Member&#160;</b></p>
<p style="position:absolute;top:230px;left:276px;white-space:nowrap" class="ft02"><b>Institution&#160;</b></p>
<p style="position:absolute;top:220px;left:426px;white-space:nowrap" class="ft02"><b>Panel Section&#160;</b></p>
<p style="position:absolute;top:239px;left:442px;white-space:nowrap" class="ft02"><b>Group(s)&#160;</b></p>
<p style="position:absolute;top:210px;left:619px;white-space:nowrap" class="ft02"><b>Financial Disclosure&#160;</b></p>
<p style="position:absolute;top:249px;left:592px;white-space:nowrap" class="ft02"><b>Company&#160;</b></p>
<p style="position:absolute;top:249px;left:730px;white-space:nowrap" class="ft02"><b>Relationship&#160;</b></p>
<p style="position:absolute;top:279px;left:90px;white-space:nowrap" class="ft041">Laura Bachmann&#160;</p>
<p style="position:absolute;top:279px;left:224px;white-space:nowrap" class="ft024"><i>Centers&#160;for Disease Control&#160;</i></p>
<p style="position:absolute;top:296px;left:224px;white-space:nowrap" class="ft024"><i>and&#160;Prevention&#160;&#160;</i></p>
<p style="position:absolute;top:279px;left:413px;white-space:nowrap" class="ft041">Syphilis</p>
<p style="position:absolute;top:279px;left:455px;white-space:nowrap" class="ft057">&#160;</p>
<p style="position:absolute;top:279px;left:548px;white-space:nowrap" class="ft041">None&#160;</p>
<p style="position:absolute;top:279px;left:717px;white-space:nowrap" class="ft041">N/A&#160;</p>
<p style="position:absolute;top:323px;left:90px;white-space:nowrap" class="ft041">Khalil&#160;Ghanem&#160;</p>
<p style="position:absolute;top:323px;left:224px;white-space:nowrap" class="ft0165"><i>The Johns&#160;Hopkins University&#160;<br/>School&#160;of Medicine &#160;</i></p>
<p style="position:absolute;top:323px;left:413px;white-space:nowrap" class="ft041">Syphilis</p>
<p style="position:absolute;top:323px;left:455px;white-space:nowrap" class="ft057">&#160;</p>
<p style="position:absolute;top:323px;left:548px;white-space:nowrap" class="ft041">None&#160;</p>
<p style="position:absolute;top:323px;left:717px;white-space:nowrap" class="ft041">N/A&#160;</p>
<p style="position:absolute;top:367px;left:90px;white-space:nowrap" class="ft041">Matthew Hamill&#160;</p>
<p style="position:absolute;top:367px;left:224px;white-space:nowrap" class="ft0165"><i>The Johns&#160;Hopkins&#160;University&#160;<br/>School&#160;of Medicine &#160;</i></p>
<p style="position:absolute;top:367px;left:413px;white-space:nowrap" class="ft041">Syphilis</p>
<p style="position:absolute;top:367px;left:455px;white-space:nowrap" class="ft057">&#160;</p>
<p style="position:absolute;top:367px;left:548px;white-space:nowrap" class="ft041">Chembio&#160;Diagnostics, Inc.&#160;</p>
<p style="position:absolute;top:367px;left:717px;white-space:nowrap" class="ft041">Honoraria&#160;</p>
<p style="position:absolute;top:394px;left:548px;white-space:nowrap" class="ft041">Cepheid &#160;</p>
<p style="position:absolute;top:426px;left:548px;white-space:nowrap" class="ft041">Chembio&#160;Diagnostics, Inc.&#160;</p>
<p style="position:absolute;top:458px;left:548px;white-space:nowrap" class="ft041">Roche&#160;Diagnostics&#160;&#160;</p>
<p style="position:absolute;top:394px;left:717px;white-space:nowrap" class="ft041">Other&#160;</p>
<p style="position:absolute;top:485px;left:90px;white-space:nowrap" class="ft041">Edward W. Hook&#160;</p>
<p style="position:absolute;top:485px;left:224px;white-space:nowrap" class="ft024"><i>The University&#160;of Alabama at&#160;</i></p>
<p style="position:absolute;top:502px;left:224px;white-space:nowrap" class="ft0165"><i>Birmingham&#160;Marnix&#160;E.&#160;<br/>Heersink&#160;School&#160;of&#160;Medicine &#160;</i></p>
<p style="position:absolute;top:485px;left:413px;white-space:nowrap" class="ft041">Syphilis</p>
<p style="position:absolute;top:485px;left:455px;white-space:nowrap" class="ft057">&#160;</p>
<p style="position:absolute;top:485px;left:548px;white-space:nowrap" class="ft041">Visby Diagnostics&#160;</p>
<p style="position:absolute;top:517px;left:548px;white-space:nowrap" class="ft041">Global&#160;Antibiotic&#160;Research&#160;</p>
<p style="position:absolute;top:535px;left:548px;white-space:nowrap" class="ft041">and&#160;Development Program&#160;</p>
<p style="position:absolute;top:567px;left:548px;white-space:nowrap" class="ft041">INNOVIA&#160;Therapeutics&#160;</p>
<p style="position:absolute;top:485px;left:717px;white-space:nowrap" class="ft041">Scientific Advisory&#160;</p>
<p style="position:absolute;top:502px;left:717px;white-space:nowrap" class="ft041">Board &#160;</p>
<p style="position:absolute;top:594px;left:548px;white-space:nowrap" class="ft041">Global&#160;Antibiotic&#160;Research&#160;</p>
<p style="position:absolute;top:611px;left:548px;white-space:nowrap" class="ft041">and&#160;Development Program&#160;</p>
<p style="position:absolute;top:594px;left:717px;white-space:nowrap" class="ft041">Research Support&#160;</p>
<p style="position:absolute;top:638px;left:548px;white-space:nowrap" class="ft041">Global&#160;Antibiotic&#160;Research&#160;</p>
<p style="position:absolute;top:655px;left:548px;white-space:nowrap" class="ft041">and&#160;Development Program&#160;</p>
<p style="position:absolute;top:638px;left:717px;white-space:nowrap" class="ft041">Consultant&#160;</p>
<p style="position:absolute;top:682px;left:90px;white-space:nowrap" class="ft041">Arlene Sena&#160;</p>
<p style="position:absolute;top:682px;left:224px;white-space:nowrap" class="ft024"><i>The University&#160;of North&#160;</i></p>
<p style="position:absolute;top:699px;left:224px;white-space:nowrap" class="ft024"><i>Carolina at Chapel&#160;Hill&#160;School&#160;</i></p>
<p style="position:absolute;top:717px;left:224px;white-space:nowrap" class="ft024"><i>of Medicine &#160;</i></p>
<p style="position:absolute;top:682px;left:413px;white-space:nowrap" class="ft041">Syphilis</p>
<p style="position:absolute;top:682px;left:455px;white-space:nowrap" class="ft057">&#160;</p>
<p style="position:absolute;top:682px;left:548px;white-space:nowrap" class="ft041">Hologic&#160;</p>
<p style="position:absolute;top:682px;left:717px;white-space:nowrap" class="ft041">Speakers Bureau&#160;</p>
<p style="position:absolute;top:709px;left:548px;white-space:nowrap" class="ft041">Entasis&#160;</p>
<p style="position:absolute;top:709px;left:717px;white-space:nowrap" class="ft041">Advisory&#160;Board&#160;</p>
<p style="position:absolute;top:744px;left:90px;white-space:nowrap" class="ft041">Irene Stafford&#160;</p>
<p style="position:absolute;top:744px;left:224px;white-space:nowrap" class="ft024"><i>The University&#160;of Texas&#160;Health&#160;</i></p>
<p style="position:absolute;top:761px;left:224px;white-space:nowrap" class="ft024"><i>Science Center&#160;at Houston,&#160;</i></p>
<p style="position:absolute;top:778px;left:224px;white-space:nowrap" class="ft024"><i>McGovern Medical&#160;School &#160;</i></p>
<p style="position:absolute;top:744px;left:413px;white-space:nowrap" class="ft041">Syphilis</p>
<p style="position:absolute;top:744px;left:455px;white-space:nowrap" class="ft057">&#160;</p>
<p style="position:absolute;top:744px;left:548px;white-space:nowrap" class="ft041">None&#160;</p>
<p style="position:absolute;top:744px;left:717px;white-space:nowrap" class="ft041">N/A&#160;</p>
<p style="position:absolute;top:805px;left:90px;white-space:nowrap" class="ft041">Susan&#160;Tuddenham*&#160;</p>
<p style="position:absolute;top:805px;left:224px;white-space:nowrap" class="ft024"><i>The Johns&#160;Hopkins University&#160;</i></p>
<p style="position:absolute;top:822px;left:224px;white-space:nowrap" class="ft024"><i>School&#160;of Medicine &#160;</i></p>
<p style="position:absolute;top:805px;left:413px;white-space:nowrap" class="ft041">Syphilis</p>
<p style="position:absolute;top:805px;left:455px;white-space:nowrap" class="ft057">&#160;</p>
<p style="position:absolute;top:805px;left:548px;white-space:nowrap" class="ft041">None&#160;</p>
<p style="position:absolute;top:805px;left:717px;white-space:nowrap" class="ft041">N/A&#160;</p>
<p style="position:absolute;top:849px;left:90px;white-space:nowrap" class="ft041">Kimberly Workowski&#160;</p>
<p style="position:absolute;top:849px;left:224px;white-space:nowrap" class="ft0165"><i>Emory&#160;University&#160;School&#160;of&#160;<br/>Medicine &#160;</i></p>
<p style="position:absolute;top:849px;left:413px;white-space:nowrap" class="ft041">Syphilis</p>
<p style="position:absolute;top:849px;left:455px;white-space:nowrap" class="ft057">&#160;</p>
<p style="position:absolute;top:849px;left:548px;white-space:nowrap" class="ft041">Gilead&#160;</p>
<p style="position:absolute;top:881px;left:548px;white-space:nowrap" class="ft041">Abbvie&#160;</p>
<p style="position:absolute;top:914px;left:548px;white-space:nowrap" class="ft041">Acuris&#160;</p>
<p style="position:absolute;top:849px;left:717px;white-space:nowrap" class="ft041">Research Support&#160;</p>
<p style="position:absolute;top:941px;left:81px;white-space:nowrap" class="ft041">*&#160;Section Group&#160;Lead</p>
<p style="position:absolute;top:967px;left:81px;white-space:nowrap" class="ft042"><b>Note:</b></p>
<p style="position:absolute;top:967px;left:116px;white-space:nowrap" class="ft041">Members&#160;are required to update&#160;disclosures&#160;annually and to notify guideline staff of&#160;any&#160;relevant changes&#160;in status during the&#160;</p>
<p style="position:absolute;top:984px;left:81px;white-space:nowrap" class="ft041">interim.&#160;</p>
</div>
<!-- Page 225 -->
<a name="225"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page225-div" style="position:relative;width:917px;height:1187px;">
<p style="position:absolute;top:1117px;left:81px;white-space:nowrap" class="ft024"><i>Guidelines for the Prevention and Treatment&#160;of&#160;Opportunistic&#160;Infections in Adults&#160;and Adolescents&#160;With HIV&#160;</i></p>
<p style="position:absolute;top:1117px;left:805px;white-space:nowrap" class="ft024"><i>LL-</i></p>
<p style="position:absolute;top:1116px;left:823px;white-space:nowrap" class="ft065">24</p>
<p style="position:absolute;top:112px;left:81px;white-space:nowrap" class="ft025"><b>Appendix&#160;B.&#160;Panel&#160;Roster&#160;and&#160;Financial&#160;Disclosures&#160;</b></p>
<p style="position:absolute;top:159px;left:81px;white-space:nowrap" class="ft0118"><i><b>Toxoplasma gondii&#160;</b></i></p>
<p style="position:absolute;top:689px;left:81px;white-space:nowrap" class="ft041">*&#160;Section Group&#160;Lead</p>
<p style="position:absolute;top:715px;left:81px;white-space:nowrap" class="ft042"><b>Note:</b></p>
<p style="position:absolute;top:715px;left:116px;white-space:nowrap" class="ft041">Members&#160;are required to update disclosures&#160;annually and&#160;to notify guideline staff of any&#160;relevant changes&#160;in status&#160;during the&#160;</p>
<p style="position:absolute;top:732px;left:81px;white-space:nowrap" class="ft041">interim.&#160;</p>
<p style="position:absolute;top:229px;left:128px;white-space:nowrap" class="ft02"><b>Member&#160;</b></p>
<p style="position:absolute;top:229px;left:280px;white-space:nowrap" class="ft02"><b>Institution&#160;</b></p>
<p style="position:absolute;top:220px;left:433px;white-space:nowrap" class="ft02"><b>Panel Section&#160;</b></p>
<p style="position:absolute;top:239px;left:449px;white-space:nowrap" class="ft02"><b>Group(s)&#160;</b></p>
<p style="position:absolute;top:210px;left:630px;white-space:nowrap" class="ft02"><b>Financial Disclosure&#160;</b></p>
<p style="position:absolute;top:249px;left:595px;white-space:nowrap" class="ft02"><b>Company&#160;</b></p>
<p style="position:absolute;top:249px;left:724px;white-space:nowrap" class="ft02"><b>Relationship&#160;</b></p>
<p style="position:absolute;top:278px;left:89px;white-space:nowrap" class="ft041">Sarita Boyd</p>
<p style="position:absolute;top:278px;left:238px;white-space:nowrap" class="ft024"><i>U.S. Food and Drug&#160;</i></p>
<p style="position:absolute;top:296px;left:238px;white-space:nowrap" class="ft024"><i>Administration&#160;</i></p>
<p style="position:absolute;top:278px;left:406px;white-space:nowrap" class="ft024"><i>Toxoplasma gondii</i></p>
<p style="position:absolute;top:278px;left:568px;white-space:nowrap" class="ft041">None</p>
<p style="position:absolute;top:278px;left:703px;white-space:nowrap" class="ft041">N/A</p>
<p style="position:absolute;top:323px;left:89px;white-space:nowrap" class="ft041">Joseph Kovacs*&#160;</p>
<p style="position:absolute;top:323px;left:238px;white-space:nowrap" class="ft024"><i>National&#160;Institutes of&#160;</i></p>
<p style="position:absolute;top:340px;left:238px;white-space:nowrap" class="ft024"><i>Health&#160;</i></p>
<p style="position:absolute;top:323px;left:406px;white-space:nowrap" class="ft024"><i>Pneumocystis</i></p>
<p style="position:absolute;top:323px;left:483px;white-space:nowrap" class="ft041">&#160;</p>
<p style="position:absolute;top:340px;left:406px;white-space:nowrap" class="ft041">Pneumonia&#160;</p>
<p style="position:absolute;top:372px;left:406px;white-space:nowrap" class="ft024"><i>Toxoplasma gondii&#160;</i></p>
<p style="position:absolute;top:323px;left:568px;white-space:nowrap" class="ft041">Martinas&#160;</p>
<p style="position:absolute;top:355px;left:568px;white-space:nowrap" class="ft041">Merck&#160;</p>
<p style="position:absolute;top:323px;left:703px;white-space:nowrap" class="ft041">Research Support&#160;</p>
<p style="position:absolute;top:399px;left:89px;white-space:nowrap" class="ft041">Janaki&#160;Kuruppu&#160;</p>
<p style="position:absolute;top:399px;left:238px;white-space:nowrap" class="ft0165"><i>National&#160;Institutes&#160;of&#160;<br/>Health&#160;</i></p>
<p style="position:absolute;top:399px;left:406px;white-space:nowrap" class="ft024"><i>Toxoplasma gondii&#160;</i></p>
<p style="position:absolute;top:399px;left:568px;white-space:nowrap" class="ft041">None&#160;</p>
<p style="position:absolute;top:399px;left:703px;white-space:nowrap" class="ft041">N/A&#160;</p>
<p style="position:absolute;top:443px;left:89px;white-space:nowrap" class="ft041">Leon Lai&#160;</p>
<p style="position:absolute;top:443px;left:238px;white-space:nowrap" class="ft024"><i>MedStar Washington&#160;</i></p>
<p style="position:absolute;top:460px;left:238px;white-space:nowrap" class="ft024"><i>Hospital Center&#160;</i></p>
<p style="position:absolute;top:443px;left:406px;white-space:nowrap" class="ft024"><i>Toxoplasma gondii&#160;</i></p>
<p style="position:absolute;top:443px;left:568px;white-space:nowrap" class="ft041">None&#160;</p>
<p style="position:absolute;top:443px;left:703px;white-space:nowrap" class="ft041">N/A&#160;</p>
<p style="position:absolute;top:487px;left:89px;white-space:nowrap" class="ft041">Jose M.&#160;Miro&#160;</p>
<p style="position:absolute;top:487px;left:238px;white-space:nowrap" class="ft024"><i>Hospital&#160;Clinic&#160;de&#160;</i></p>
<p style="position:absolute;top:505px;left:238px;white-space:nowrap" class="ft024"><i>Barcelona–IDIBAPS,&#160;</i></p>
<p style="position:absolute;top:522px;left:238px;white-space:nowrap" class="ft0165"><i>University&#160;of&#160;Barcelona,&#160;<br/>Spain&#160;</i></p>
<p style="position:absolute;top:487px;left:406px;white-space:nowrap" class="ft024"><i>Toxoplasma gondii&#160;</i></p>
<p style="position:absolute;top:487px;left:568px;white-space:nowrap" class="ft041">None&#160;</p>
<p style="position:absolute;top:487px;left:703px;white-space:nowrap" class="ft041">N/A&#160;</p>
<p style="position:absolute;top:566px;left:89px;white-space:nowrap" class="ft041">Daniel&#160;Podzamczer&#160;</p>
<p style="position:absolute;top:566px;left:238px;white-space:nowrap" class="ft0165"><i>Fight&#160;AIDS and Infectious&#160;<br/>Diseases&#160;Foundation,&#160;</i></p>
<p style="position:absolute;top:600px;left:238px;white-space:nowrap" class="ft024"><i>Hospital Germans Trias&#160;i&#160;</i></p>
<p style="position:absolute;top:618px;left:238px;white-space:nowrap" class="ft024"><i>Pujol,&#160;Badalona,&#160;Spain&#160;</i></p>
<p style="position:absolute;top:566px;left:406px;white-space:nowrap" class="ft024"><i>Toxoplasma gondii&#160;</i></p>
<p style="position:absolute;top:566px;left:568px;white-space:nowrap" class="ft041">ViiV&#160;Healthcare&#160;</p>
<p style="position:absolute;top:566px;left:703px;white-space:nowrap" class="ft041">Research Support&#160;</p>
<p style="position:absolute;top:645px;left:89px;white-space:nowrap" class="ft041">Bryan&#160;R. Smith&#160;</p>
<p style="position:absolute;top:645px;left:238px;white-space:nowrap" class="ft024"><i>National&#160;Institutes of&#160;</i></p>
<p style="position:absolute;top:662px;left:238px;white-space:nowrap" class="ft024"><i>Health&#160;</i></p>
<p style="position:absolute;top:645px;left:406px;white-space:nowrap" class="ft024"><i>Toxoplasma gondii&#160;</i></p>
<p style="position:absolute;top:645px;left:568px;white-space:nowrap" class="ft041">None&#160;</p>
<p style="position:absolute;top:645px;left:703px;white-space:nowrap" class="ft041">N/A&#160;</p>
</div>
</body>
</html>
